﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Yorgun, MA
   Toklu, Y
   Altinkaynak, H
   Tanriverdi, B
   Ergin, M
   Bicer, C
AF Yorgun, Mucella Arikan
   Toklu, Yasin
   Altinkaynak, Hasan
   Tanriverdi, Burak
   Ergin, Merve
   Bicer, Cemile
TI A Novel Tool for the Assessment Oxidative Stress in Age-Related Macular
   Degeneration: Thiol/Disulfide Homeostasis Revisited
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; choroidal neovascular membrane;
   oxidative stress; thiol; thiol; disulfide ratio
ID PLASMA; ASSOCIATION; GLUTATHIONE; DEFENSE
AB Purpose: To investigate thiol/disulfide status using a novel automated assay in patients with age-related macular degeneration (AMD) compared to age-matched healthy controls.Methods: A total of 64 AMD patients [51 (79%) non-exudative, 13 (21%) exudative AMD] and 21 age-matched healthy control subjects were enrolled in this study. Plasma total thiol, native thiol, disulfide levels were measured and native thiol/disulfide ratio (TDR) was calculated using a novel spectrophotometric assay.Results: Patients with AMD had significantly lower levels of total thiol (434.8 7.0 mol/L vs. 472.2 +/- 7.9 mol/L, p < 0.001), native thiol (393.6 +/- 6.5 mol/L vs. 437.5 +/- 7.1 mol/L, p = 0.004) compared to healthy controls. However, plasma disulfide levels were higher in AMD patients (20.6 +/- 0.9 mol/L vs. 17.3 +/- 1.3 mol/L, p = 0.113) compared to healthy controls. The TDR was not statistically different between the early AMD group and healthy controls (24.2 +/- 2.3 vs. 29.5 +/- 3.1, p = 0.345). However, intermediate and advanced stage AMD groups had significantly lower levels of TDR compared to healthy controls (21.6 +/- 2.6 vs. 29.5 +/- 3.1, p = 0.023 and 20.3 +/- 1.2 vs. 29.5 +/- 3.1, p = 0.005, respectively). Native TDR was significantly lower in patients with exudative and non-exudative AMD (19.9 +/- 2.3 vs. 29.5 +/- 3.1, p = 0.024 and 21.8 +/- 1.14 vs. 29.47 +/- 3.1 respectively, p = 0.011).Conclusion: A greater extent of thiol consumption occurred in AMD patients compared to age-matched healthy controls. However, despite the similar levels of total thiol levels between several grades of AMD, the plasma native TDR value was decreased in accordance with the severity of the disease, which reflected the disease grade better.
C1 [Yorgun, Mucella Arikan; Toklu, Yasin; Altinkaynak, Hasan; Tanriverdi, Burak] Yildirim Beyazit Univ, Ankara Ataturk Educ & Res Hosp, Dept Ophthalmol, Ankara, Turkey.
   [Ergin, Merve; Bicer, Cemile] Yildirim Beyazit Univ, Ankara Ataturk Educ & Res Hosp, Dept Biochem, Ankara, Turkey.
C3 Ankara Ataturk Training & Research Hospital; Yildirim Beyazit
   University; Ankara Ataturk Training & Research Hospital; Yildirim
   Beyazit University
RP Yorgun, MA (通讯作者)，Ankara Ataturk Educ & Res Hosp, Dept Ophthalmol, Ankara, Turkey.
EM mcllarkn@yahoo.com
RI Tanrıverdi, Burak/AAH-8760-2021; Altinkaynak, Hasan/V-6058-2017
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Atmaca G, 2004, YONSEI MED J, V45, P776, DOI 10.3349/ymj.2004.45.5.776
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   DI MASCIO P, 1991, AM J CLIN NUTR, V53, pS194, DOI 10.1093/ajcn/53.1.194S
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Erel O, 2014, CLIN BIOCHEM, V47, P326, DOI 10.1016/j.clinbiochem.2014.09.026
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Go YM, 2011, FREE RADICAL BIO MED, V50, P495, DOI 10.1016/j.freeradbiomed.2010.11.029
   HU ML, 1994, METHOD ENZYMOL, V233, P380
   Jiang SN, 2005, INVEST OPHTH VIS SCI, V46, P1054, DOI 10.1167/iovs.04-0949
   Jones DP, 2009, FREE RADICAL BIO MED, V47, P1329, DOI 10.1016/j.freeradbiomed.2009.08.021
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kundi H, 2015, SCAND CARDIOVASC J, V49, P95, DOI 10.3109/14017431.2015.1013153
   Prabhu A, 2014, CANCER RES, V74, P787, DOI 10.1158/0008-5472.CAN-13-1423
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Tetik S, 2010, INDIAN J BIOCHEM BIO, V47, P353
   Ugurlu N, 2013, CURR EYE RES, V38, P497, DOI 10.3109/02713683.2013.774023
   Winkler BS, 1999, MOL VIS, V5
NR 28
TC 7
Z9 7
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD DEC
PY 2016
VL 41
IS 12
BP 1584
EP 1589
DI 10.3109/02713683.2016.1141965
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EF8UD
UT WOS:000390604500012
PM 27261249
DA 2022-11-30
ER

PT J
AU Nunes, RP
   Rosa, PR
   Giani, A
   Goldhardt, R
   Thomas, B
   Garcia, CA
   Gregori, G
   Feuer, W
   Lam, BL
   Staurenghi, G
   Rosenfeld, PJ
AF Nunes, Renata Portella
   Rosa, Potyra R.
   Giani, Andrea
   Goldhardt, Raquel
   Thomas, Benjamin
   Garcia Filho, Carlos Alexandre
   Gregori, Giovanni
   Feuer, William
   Lam, Byron L.
   Staurenghi, Giovanni
   Rosenfeld, Philip J.
TI Choroidal Thickness in Eyes With Central Geographic Atrophy Secondary to
   Stargardt Disease and Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; PSEUDODRUSEN; MACULOPATHY; PREVALENCE;
   LIPOFUSCIN; MUTATIONS
AB BACKGROUND AND OBJECTIVE: Choroidal thickness (CT) measurements from eyes with similar areas of macular geographic atrophy (GA) secondary to age-related macular degeneration (AMD) and Stargardt disease (STGD) were compared to determine whether GA from different diseases had a similar or different effect on the underlying subfoveal choroid.
   PATIENTS AND METHODS: Eyes with the diagnosis of central GA secondary to STGD and AMD were matched, with subfoveal CT measurements obtained from the central B-scan using an enhanced depth imaging protocol. The area of GA was measured using fundus autofluorescence (FAF) imaging. AMD eyes were divided into those with and without reticular pseudodrusen.
   RESULTS: A total of 22 eyes of 22 patients were included in the STGD and AMD groups and were matched with respect to the area of GA. The mean age of the STGD patients was 48.9 years (standard deviation [SD] = 17.1), and the mean age was 81.8 years (SD = 6.2) for the AMD patients. Mean area measurements of GA for the STGD and AMD groups were 5.4 mm(2) (SD = 4.1) and 5.1 mm(2) (SD = 4.0), respectively (P = .83). After adjusting for age and axial length, eyes with STGD had a mean CT measurement greater than the AMD eyes (336.1 mu m vs. 198.1 mu m, respectively; P = .039). However, this difference was driven by AMD eyes with reticular pseudodrusen (RPD) and by a single Stargardt case with a very thick choroid. Eyes with RPD had statistically thinner subfoveal CT measurements when compared with all other groups.
   CONCLUSION: A small but statistically significant increase in the CT of STGD eyes was observed when compared with normal controls and AMD eyes without RPD. However, this small increase in CT was driven by a single case with a markedly thicker choroid within the STGD group, so it is unlikely that a clinically significant difference exists. However, AMD eyes with GA and RPD had significantly thinner subfoveal CT measurements.
C1 [Nunes, Renata Portella; Rosa, Potyra R.; Goldhardt, Raquel; Thomas, Benjamin; Garcia Filho, Carlos Alexandre; Gregori, Giovanni; Feuer, William; Lam, Byron L.; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
   [Nunes, Renata Portella] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Giani, Andrea; Staurenghi, Giovanni] Univ Milan, Luigi Sacco Hosp, Dept Clin Sci Luigi Sacco, Eye Clin, I-20122 Milan, Italy.
C3 Bascom Palmer Eye Institute; University of Miami; Universidade Federal
   de Sao Paulo (UNIFESP); University of Milan; Luigi Sacco Hospital
RP Rosenfeld, PJ (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@med.miami.edu
RI Staurenghi, Giovanni/K-4388-2017; Giani, Andrea/L-5926-2017
OI Staurenghi, Giovanni/0000-0002-2299-5251; Giani,
   Andrea/0000-0003-0682-1945
FU Macula Vision Research Foundation; Carl Zeiss Meditec; Research to
   Prevent Blindness; NEI [P30 EY014801]; Feig Family Foundation; Emma
   Clyde Hodge Memorial Foundation; Macular Vision Research Foundation;
   GlaxoSmithKline; Alexion Pharmaceuticals; Ocata Therapeutics; Optovue;
   Novartis; NATIONAL EYE INSTITUTE [P30EY014801] Funding Source: NIH
   RePORTER
FX This research was supported by a grant from the Macula Vision Research
   Foundation; Carl Zeiss Meditec; an unrestricted grant from Research to
   Prevent Blindness; NEI core center grant P30 EY014801 to the University
   of Miami; the Feig Family Foundation; and the Emma Clyde Hodge Memorial
   Foundation.; Drs. Portella Nunes, Garcia, and Gregori received research
   support from Carl Zeiss Meditec. Dr. Gregori co-owns a patent that is
   licensed to Carl Zeiss Meditec. Dr. Rosenfeld has received research
   support from the Macular Vision Research Foundation, Carl Zeiss Meditec,
   GlaxoSmithKline, Alexion Pharmaceuticals, Ocata Therapeutics, and
   Acucela Pharmaceuticals and is a consultant for Acucela, Alcon Research,
   Allergan, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim,
   Chengdu Kanghong Biotech, Digisight, F. Hoffmann-La Roche Ltd, Merck
   Pharmaceuticals, Genentech/Roche, Healios K. K., Oraya, Tyrogenex, and
   Vision Medicines. Dr. Giani is a consultant for Novartis
   Pharmaceuticals. Dr. Staurenghi is a consultant for Alcon Laboratories,
   Allergan, Bayer, Boehringer, GlaxoSmithKline, Heidelberg Engineering,
   Novartis Pharmaceuticals, Optos, QLT Phototherapeutics, Roche, and Carl
   Zeiss Meditec and receives research support from Optovue, Novartis and
   Carl Zeiss Meditec. Dr. Staurenghi also co-owns a patent that is
   licensed to Ocular Instruments. The remaining authors report no relevant
   financial disclosures.
CR Abbey AM, 2015, OSLI RETINA, V46, P18, DOI 10.3928/23258160-20150101-03
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Cideciyan AV, 2004, HUM MOL GENET, V13, P525, DOI 10.1093/hmg/ddh048
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Fein JG, 2014, OPHTHAL SURG LAS IM, V45, P32, DOI 10.3928/23258160-20131220-04
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Giani A, 2012, INVEST OPHTH VIS SCI, V53, P3999, DOI 10.1167/iovs.11-9258
   Goldhardt R, 2012, INVEST OPHTHALMOL  S, V53, P2048
   Gomes NL, 2009, INVEST OPHTH VIS SCI, V50, P3953, DOI 10.1167/iovs.08-2657
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klevering BJ, 2005, GRAEF ARCH CLIN EXP, V243, P90, DOI 10.1007/s00417-004-1079-4
   LOPEZ PF, 1990, OPHTHALMOLOGY, V97, P798
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2014, RETINA-J RET VIT DIS, V34, P2336, DOI 10.1097/IAE.0000000000000377
   Stone EM, 2007, AM J OPHTHALMOL, V144, P791, DOI 10.1016/j.ajo.2007.08.022
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Thorell MR, 2015, OSLI RETINA, V46, P513, DOI 10.3928/23258160-20150521-02
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
NR 26
TC 13
Z9 13
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD SEP
PY 2015
VL 46
IS 8
BP 814
EP 822
DI 10.3928/23258160-20150909-05
PG 9
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA DP9UD
UT WOS:000378842000006
PM 26431296
DA 2022-11-30
ER

PT J
AU Kim, KM
   Kim, JH
   Chang, YS
   Kim, JW
   Kim, CG
AF Kim, Kyung Min
   Kim, Jae Hui
   Chang, Young Suk
   Kim, Jong Woo
   Kim, Chul Gu
TI Long-Term Outcomes in Patients with Neovascular Age-Related Macular
   Degeneration Who Maintain Dry Macula after Three Monthly Ranibizumab
   Injections
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; anti-vascular endothelial growth
   factor; ellipsoid zone; long-term; ranibizumab
ID GROWTH-FACTOR THERAPY; DOSING REGIMEN; HEMORRHAGE; EFFICACY; SAFETY
AB Purpose: To evaluate long-term changes in visual acuity and retinal microstructure in patients with neovascular age-related macular degeneration (AMD) who had maintained dry macula after initial treatment. Methods: This retrospective observational study included 55 eyes that were diagnosed with neovascular AMD, were treated with three monthly ranibizumab injections, and maintained dry macula during a two-year follow-up. Best-corrected visual acuity (BCVA) at three months and at the final follow-up were compared, and the degree of visual improvement was compared between eyes with and without improvement of the ellipsoid zone. In addition, the incidence of improvement of the ellipsoid zone was compared between eyes with different extents of disruption. Results: The mean follow-up period was 30.3 +/- 4.1 months. BCVA at three months and at the final follow-up was 0.51 +/- 0.46 and 0.45 +/- 0.49 (P<0.001). Among 35 eyes that exhibited >200 m of disruption of the ellipsoid zone, 15 (42.9%) showed improvement of the ellipsoid zone, and the improvement in BCVA was greater in these eyes than that in the remaining 20 eyes (P=0.021). A higher incidence of improvement of the ellipsoid zone was noted in eyes with 200 to 800 m of disruption than in eyes with >800 m of disruption (P<0.001). Conclusions: Long-term improvement in visual acuity was noted in eyes that had maintained dry macula after three ranibizumab injections. The status of the ellipsoid zone at three months was closely associated with visual improvement.
C1 [Kim, Kyung Min; Kim, Jae Hui; Kim, Jong Woo; Kim, Chul Gu] Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, Seoul, South Korea.
   [Chang, Young Suk] Konyang Univ, Dept Ophthalmol, Coll Med, Daejeon, South Korea.
C3 Konyang University; Konyang University Hospital; Konyang University;
   Konyang University Hospital
RP Kim, JH (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
FU Kim's Eye Hospital Research Center
FX This study was supported by Kim's Eye Hospital Research Center.
CR Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kim YM, 2012, AM J OPHTHALMOL, V154, P164, DOI 10.1016/j.ajo.2012.01.030
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P435, DOI 10.1007/s00417-012-2034-4
   Patel RD, 2011, SEMIN OPHTHALMOL, V26, P372, DOI 10.3109/08820538.2011.570845
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shin HJ, 2013, RETINA-J RET VIT DIS, V33, P964, DOI 10.1097/IAE.0b013e3182835f70
   Tano Y, 2011, ACTA OPHTHALMOL, V89, P208, DOI 10.1111/j.1755-3768.2010.02065.x
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Vaze A, 2014, RETINA-J RET VIT DIS, V34, P1774, DOI 10.1097/IAE.0000000000000173
NR 20
TC 2
Z9 2
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PY 2018
VL 33
IS 3
BP 371
EP 376
DI 10.1080/08820538.2016.1247179
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GF8JW
UT WOS:000432217800015
PM 27960586
DA 2022-11-30
ER

PT J
AU Petrovski, G
   Berenyi, E
   Moe, MC
   Vajas, A
   Fesus, L
   Berta, A
   Facsko, A
AF Petrovski, Goran
   Berenyi, Erika
   Moe, Morten C.
   Vajas, Attila
   Fesues, Laszlo
   Berta, Andras
   Facsko, Andrea
TI Clearance of dying ARPE-19 cells by professional and nonprofessional
   phagocytes in vitro - implications for age-related macular degeneration
   (AMD)
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE AMD; Anoikis; macrophages; nonprofessional phagocytes; phagocytosis;
   triamcinolone
ID RETINAL-PIGMENT EPITHELIUM; INTRAVITREAL TRIAMCINOLONE ACETONIDE;
   APOPTOTIC CELLS; MACROPHAGES; TOXICITY; BINDING; ARPE19
AB Purpose: Failure of retinal pigment epithelial (RPE) cells and macrophages to engulf different dying cells in the retina may result in accumulation of debris and development of age-related macular degeneration (AMD). The dynamics and influence of different treatments on this clearance process can be studied in vitro using human ARPE-19 cells and macrophages as phagocytes modelling dry and wet type of AMD, respectively.
   Methods: Death through extracellular matrix detachment using polyHEMA-coated surfaces (anoikis) and UV irradiation (apoptosis) was induced in ARPE-19 cells. Two-coloured phagocytic assays were performed to quantify the amount of dying cells phagocytes engulfed (flow cytometry) and for visualization (fluorescent and scanning electron microscopy). The effect of phosphatidylserine inhibition with recombinant annexin-V and glucocorticoid (triamcinolone) treatment on the phagocytic process was tested.
   Results: The clearance of anoikic and apoptotic cells by nondying ARPE-19 cells over 8 hr of co-incubation increased over time (at 8 hr, over 53% and 35% of the phagocytes contained engulfed dying cells, respectively). The human macrophages engulfed the anoikic and apoptotic ARPE-19 cells with seven and four times lower capacity, respectively. Phosphatidylserine appearance on the dying cells did not affect, but triamcinolone treatment enhanced the phagocytosis of the dying cells by macrophages.
   Conclusions: ARPE-19 cells are more efficient in clearing anoikic than UV-induced apoptotic cells. Macrophages are less efficient in the clearance process than ARPE-19 cells. The present model can be used for studying both dry and wet type of AMD in vitro and for testing different pharmacological aspects affecting this disease.
C1 [Petrovski, Goran; Vajas, Attila; Berta, Andras; Facsko, Andrea] Univ Debrecen, Med & Hlth Sci Ctr, Dept Ophthalmol, H-4012 Debrecen, Hungary.
   [Petrovski, Goran; Berenyi, Erika; Fesues, Laszlo] Univ Debrecen, Med & Hlth Sci Ctr, Dept Biochem, H-4012 Debrecen, Hungary.
C3 University of Debrecen; University of Debrecen
RP Petrovski, G (通讯作者)，Univ Debrecen, Med & Hlth Sci Ctr, Dept Ophthalmol, H-4012 Debrecen, Hungary.
EM gokip@indi.dote.hu
RI Petrovski, Goran/A-8983-2012; Vajas, Attila/AAA-3014-2021
OI Petrovski, Goran/0000-0003-2905-9252
FU University of Debrecen, Medical and Health Science Center; Research
   Council of Norway
FX The authors acknowledge the financial support from the MECENATURA Grant
   (University of Debrecen, Medical and Health Science Center) and The
   Research Council of Norway.
CR Dini L, 2000, EUR J HISTOCHEM, V44, P217
   EDWARDS RB, 1977, SCIENCE, V197, P1001, DOI 10.1126/science.560718
   Fadok VA, 1998, CURR BIOL, V8, pR693, DOI 10.1016/S0960-9822(98)70438-5
   Finnemann SC, 1999, J EXP MED, V190, P861, DOI 10.1084/jem.190.6.861
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hafezi F, 1997, EXP EYE RES, V64, P963, DOI 10.1006/exer.1997.0288
   Irschick EU, 2004, OPHTHALMIC RES, V36, P200, DOI 10.1159/000078778
   Jonas JB, 2005, PROG RETIN EYE RES, V24, P587, DOI 10.1016/j.preteyeres.2005.01.004
   Jonas JB, 2006, OPHTHALMIC RES, V38, P218, DOI 10.1159/000093796
   Kawahara S, 2000, Nippon Ganka Gakkai Zasshi, V104, P86
   KIRCHHOF B, 1989, GRAEF ARCH CLIN EXP, V227, P60, DOI 10.1007/BF02169828
   MULLEN RJ, 1976, SCIENCE, V192, P799, DOI 10.1126/science.1265483
   Narayanan R, 2006, INVEST OPHTH VIS SCI, V47, P722, DOI 10.1167/iovs.05-0772
   Palaniyar N, 2004, J BIOL CHEM, V279, P32728, DOI 10.1074/jbc.M403763200
   Petrovski G, 2007, CELL DEATH DIFFER, V14, P1117, DOI 10.1038/sj.cdd.4402112
   Roduit R, 2008, APOPTOSIS, V13, P343, DOI 10.1007/s10495-008-0179-8
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Savill J, 2003, SCIENCE, V302, P1516, DOI 10.1126/science.1092533
   Turowski P, 2004, INVEST OPHTH VIS SCI, V45, P2786, DOI 10.1167/iovs.03-0943
   Valamanesh F, 2007, MOL VIS, V13, P1746
   van der Goes A, 2000, J LEUKOCYTE BIOL, V67, P801, DOI 10.1002/jlb.67.6.801
   Wilt SD, 1999, EXP EYE RES, V69, P405, DOI 10.1006/exer.1999.0714
   Yeung CK, 2003, INVEST OPHTH VIS SCI, V44, P5293, DOI 10.1167/iovs.03-0490
NR 27
TC 13
Z9 13
U1 0
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2011
VL 89
IS 1
BP E30
EP E34
DI 10.1111/j.1755-3768.2010.02047.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 711YL
UT WOS:000286628100004
PM 21091941
DA 2022-11-30
ER

PT J
AU Wakabayashi, T
   Naito, H
   Takara, K
   Kidoya, H
   Sakimoto, S
   Oshima, Y
   Nishida, K
   Takakura, N
AF Wakabayashi, Taku
   Naito, Hisamichi
   Takara, Kazuhiro
   Kidoya, Hiroyasu
   Sakimoto, Susumu
   Oshima, Yusuke
   Nishida, Kohji
   Takakura, Nobuyuki
TI Identification of Vascular Endothelial Side Population Cells in the
   Choroidal Vessels and Their Potential Role in Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE angiogenesis; endothelial cell; stem cell; side population; choroid
ID HEMATOPOIETIC STEM-CELLS; PROGENITOR CELLS; APELIN/APJ SYSTEM;
   BLOOD-VESSELS; UNITED-STATES; NEOVASCULARIZATION; MOUSE; ANGIOGENESIS;
   RETINOPATHY; PREVALENCE
AB PURPOSE. The neovascular form of age-related macular degeneration (AMD) is characterized by the growth of abnormal new blood vessels from the choroid, termed choroidal neovascularization (CNV). The origin of the new vessels in CNV, however, has not been elucidated fully to our knowledge. The purpose of this study is to identify vascular endothelial side population (SP) cells in the preexisting choroidal vessels, and investigate their potential role in AMD.
   METHODS. We made single cell suspensions of freshly isolated mouse choroidal, retinal, and brain tissue by enzymatic digestion. Vascular endothelial SP cells were isolated using flow cytometry based on the ability to efflux the DNA-binding dye, Hoechst 33342, via ATP-binding cassette (ABC) transporters.
   RESULTS. In the choroid, 2.8% of CD31(+)CD45 vascular endothelial cells (ECs) showed a typical SP staining pattern. They were not bone marrow-derived and possessed high colony-forming capacity in vitro. They proliferated during laser-induced CNV in vivo. In contrast, stereotypic SP staining pattern was not observed in retinal and brain ECs. Retinal and brain EC-SP cells included increased SP populations with less colony-forming capacity within the SP compartment, because they contained cells with and without proliferative potential. The latter still could efflux the dye due to high levels of ABC transporters, such as ABCB1a, ABCC4, and ABCC6.
   CONCLUSIONS. The EC-SP cells in the choroid may represent vessel-residing endothelial stem/progenitor cells contributing mainly to angiogenesis, and may be useful for augmenting vascular regeneration or for developing new antiangiogenic therapy in AMD.
C1 [Wakabayashi, Taku; Naito, Hisamichi; Takara, Kazuhiro; Kidoya, Hiroyasu; Sakimoto, Susumu; Takakura, Nobuyuki] Osaka Univ, Dept Signal Transduct, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan.
   [Wakabayashi, Taku; Sakimoto, Susumu; Oshima, Yusuke; Nishida, Kohji] Osaka Univ, Dept Ophthalmol, Grad Sch Med, Suita, Osaka 5650871, Japan.
   [Takakura, Nobuyuki] CREST, JST, Chiyoda Ku, Tokyo, Japan.
C3 Osaka University; Osaka University; Japan Science & Technology Agency
   (JST)
RP Takakura, N (通讯作者)，Osaka Univ, Dept Signal Transduct, Microbial Dis Res Inst, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.
EM ntakaku@biken.osaka-u.ac.jp
OI Nishida, Kohji/0000-0001-9069-3610; Naito, Hisamichi/0000-0002-0750-1743
FU Banyu Life Science Foundation International; Ministry of Education,
   Culture, Sports, Science, and Technology; Japan Society for the
   Promotion of Science of Japan
FX Supported by Banyu Life Science Foundation International (HN),
   Grant-in-Aid for Scientific Research from the Ministry of Education,
   Culture, Sports, Science, and Technology, and Japan Society for the
   Promotion of Science of Japan (NT). The authors alone are responsible
   for the content and writing of the paper.
CR Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Challen GA, 2006, STEM CELLS, V24, P3, DOI 10.1634/stemcells.2005-0116
   Chan-Ling T, 2006, AM J PATHOL, V168, P1031, DOI 10.2353/ajpath.2006.050697
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Golebiewska A, 2011, CELL STEM CELL, V8, P136, DOI 10.1016/j.stem.2011.01.007
   Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797
   Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607
   Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Kidoya H, 2012, ONCOGENE, V31, P3254, DOI 10.1038/onc.2011.489
   Kidoya H, 2008, EMBO J, V27, P522, DOI 10.1038/sj.emboj.7601982
   Naito H, 2012, EMBO J, V31, P842, DOI 10.1038/emboj.2011.465
   Naito H, 2012, CANCER SCI, V103, P433, DOI 10.1111/j.1349-7006.2011.02157.x
   Okuno Y, 2011, BLOOD, V117, P5264, DOI 10.1182/blood-2011-01-330720
   Purhonen S, 2008, P NATL ACAD SCI USA, V105, P6620, DOI 10.1073/pnas.0710516105
   Rinkevich Y, 2011, NATURE, V476, P409, DOI 10.1038/nature10346
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   Ryan SJ, 1982, ARCH OPHTHALMOL-CHIC, V125, P71
   Sakimoto S, 2012, DEVELOPMENT, V139, P1327, DOI 10.1242/dev.072330
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Tachikawa M, 2008, MICROVASC RES, V75, P68, DOI 10.1016/j.mvr.2007.05.002
   Tagami M, 2009, BRAIN RES, V1283, P186, DOI 10.1016/j.brainres.2009.05.095
   Takakura N, 1998, IMMUNITY, V9, P677, DOI 10.1016/S1074-7613(00)80665-2
   Tomita M, 2004, STEM CELLS, V22, P21, DOI 10.1634/stemcells.22-1-21
   Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460
NR 29
TC 14
Z9 16
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2013
VL 54
IS 10
BP 6686
EP 6693
DI 10.1167/iovs.13-12342
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 246VI
UT WOS:000326567700027
PM 24022013
DA 2022-11-30
ER

PT J
AU Lindsley, KB
   Hutfless, S
   Hawkins, BS
   Blim, JF
   Roberts, D
   Olsen, TW
   Lum, F
   Dickersin, K
AF Lindsley, Kristina B.
   Hutfless, Susan
   Hawkins, Barbara S.
   Blim, Jill F.
   Roberts, Dan
   Olsen, Timothy W.
   Lum, Flora
   Dickersin, Kay
TI Evaluation of Clinical Questions and Patient-Important Outcomes
   Associated With the Treatment of Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; SETTING PRIORITIES; SYSTEMATIC-REVIEWS; GUIDELINES;
   GAPS; EYE
AB IMPORTANCE Identifying and prioritizing unanswered clinical questions may help to best allocate limited resources for research associated with the treatment of age-related macular degeneration (AMD).
   OBJECTIVE To identify and prioritize clinical questions and outcomes for research associated with the treatment of AMD through engagement with professional and patient stakeholders.
   DESIGN, SETTING, AND PARTICIPANTS Multiple cross-sectional survey questions were used in a modified Delphi process for panel members of US and international organizations, the American Academy of Ophthalmology (MO) Retina/Vitreous Panel (n=7), health care professionals from the American Society of Retinal Specialists (ASRS) (n=90), Atlantic Coast Retina Conference (ACRC) and Macula 2017 meeting (n=34); and patients from MD (Macular Degeneration) Support (n=46). Data were collected from January 20, 2015, to January 9. 2017.
   MAIN OUTCOMES AND MEASURES The prioritizing of clinical questions and patient-important outcomes for AMD.
   RESULTS Seventy clinical questions were derived from the AAO Preferred Practice Patterns for AMD and suggestions by the MO Retina/Vitreous Panel. The MO Retina/Vitreous Panel assessed all 70 clinical questions and rated 17 of 70 questions (24%) as highly important. Health care professionals assessed the 17 highly important dinical questions and rated 12 of 17 questions (71%) as high priority for research to answer; 9 of 12 high-priority clinical questions were associated with aspects of anti-vascular endothelial growth factor agents. Patients assessed the 17 highly important clinical questions and rated all as high priority. Additionally, patients identified 6 of 33 outcomes (18%) as most important to them (choroidal neovascularization, development of advanced AMD, retinal hemorrhage, gain of vision, slowing vision loss, and serious ocular events).
   CONCLUSIONS AND RELEVANCE Input from 4 stakeholder groups suggests good agreement on which 12 priority clinical questions can be used to underpin research related to the treatment of AMD. The 6 most important outcomes identified by patients were balanced between intended effects of AMD treatment (eg, slowing vision loss) and adverse events. Consideration of these patient-important outcomes may help to guide clinical care and future areas of research.
C1 [Lindsley, Kristina B.; Dickersin, Kay] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Lindsley, Kristina B.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
   [Hutfless, Susan] Johns Hopkins Sch Med, Gastroenterol & Hepatol, Baltimore, MD USA.
   [Hawkins, Barbara S.] Johns Hopkins Sch Med, Dept Ophthalmol, Baltimore, MD USA.
   [Blim, Jill F.] Amer Soc Retina Specialists, Chicago, IL USA.
   [Roberts, Dan] MD Macular Degenerat Support, Grandview, MO USA.
   [Olsen, Timothy W.] Mayo Clin, Dept Ophthalmol, Rochester, MN USA.
   [Olsen, Timothy W.] Amer Acad Ophthalmol, Preferred Practice Pattern Retina Vitreous Panel, San Francisco, CA USA.
   [Lum, Flora] Amer Acad Ophthalmol, Qual & Data Sci, San Francisco, CA USA.
C3 Johns Hopkins University; Johns Hopkins Bloomberg School of Public
   Health; Utrecht University; Utrecht University Medical Center; Johns
   Hopkins University; Johns Hopkins Medicine; Johns Hopkins University;
   Johns Hopkins Medicine; Mayo Clinic
RP Lindsley, KB (通讯作者)，Univ Med Ctr Utrecht, Dept Epidemiol, Huispost Str 6-131, NL-3508 GA Utrecht, Netherlands.
EM k.b.lindsley@umcutrecht.nl
FU National Eye Institute, National Institutes of Health, Department of
   Health and Human Services [1 U01 EY020522]; NATIONAL EYE INSTITUTE
   [U01EY020522] Funding Source: NIH RePORTER
FX This research was funded by National Eye Institute grant 1 U01 EY020522,
   National Institutes of Health, Department of Health and Human Services.
CR American Academy of Ophthalmology Retina, 2015, PREF PRACT PATT GUID
   (American Academy of Ophthalmology Retina/Vitreous Panel San Francisco, 2014, PREF PRACT PATT GUID
   Custer RL, 1999, J CAREER TECH ED, V15, DOI DOI 10.21061/JCTE.V15I2.702
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Guyatt GH, 2000, JAMA-J AM MED ASSOC, V284, P1290, DOI 10.1001/jama.284.10.1290
   Institute of Medicine, 2011, LEARN WHAT WORKS BES
   Krezel AK, 2015, BRIT J OPHTHALMOL, V99, P1560, DOI 10.1136/bjophthalmol-2014-306544
   Le JT, 2017, OPHTHALMOL RETINA, V1, P94, DOI 10.1016/j.oret.2016.10.003
   Li TJ, 2012, ANN INTERN MED, V156, P367, DOI 10.7326/0003-4819-156-5-201203060-00009
   Li TJ, 2010, OPHTHALMOLOGY, V117, P1937, DOI 10.1016/j.ophtha.2010.07.004
   Lindsley K, 2016, OPHTHALMOLOGY, V123, P884, DOI 10.1016/j.ophtha.2015.12.004
   Mayo-Wilson Evan, 2018, Pilot Feasibility Stud, V4, P95, DOI 10.1186/s40814-018-0284-6
   Paulus YM, 2017, QUAL LIFE RES, V26, P2139, DOI 10.1007/s11136-017-1547-z
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rowe F, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004905
   Sackett DL., 2000, EVIDENCE BASED MED P
   Saldanha IJ, 2017, CORNEA, V36, P1584, DOI 10.1097/ICO.0000000000001350
   Saldanha IJ, 2017, JAMA OPHTHALMOL, V135, P933, DOI 10.1001/jamaophthalmol.2017.2583
   Saldanha IJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109400
   Williamson PR, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-132
   WILLIAMSON PR, 2017, TRIALS S3, V18, DOI DOI 10.1186/S13063-017-1978-4
   Yu T, 2015, J GLAUCOMA, V24, P348, DOI 10.1097/IJG.0b013e31829e5616
NR 22
TC 8
Z9 8
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD NOV
PY 2018
VL 136
IS 11
BP 1217
EP 1225
DI 10.1001/jamaophthalmol.2018.3456
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GZ6OF
UT WOS:000449557200006
PM 30128539
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Ahn, SM
   Lee, SY
   Hwang, SY
   Kim, SW
   Oh, J
   Yun, C
AF Ahn, So Min
   Lee, Suk Yeon
   Hwang, Soon-Young
   Kim, Seong-Woo
   Oh, Jaeryung
   Yun, Cheolmin
TI Retinal vascular flow and choroidal thickness in eyes with early
   age-related macular degeneration with reticular pseudodrusen
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Early age-related macular degeneration; Reticular pseudodrusen; Retinal
   atrophy; Optical coherence tomography angiography
ID OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL DRUSENOID DEPOSITS; OCULAR
   PERFUSION-PRESSURE; GEOGRAPHIC-ATROPHY; HEALTHY-SUBJECTS;
   CLINICAL-TRIAL; FELLOW-EYES; RISK-FACTOR; ANGIOGRAPHY; DISEASE
AB Background: To investigate the characteristics of retinal vessels and retinal thickness in eyes with early age-related macular degeneration (AMD) with or without reticular pseudodrusen.
   Methods: We retrospectively evaluated the clinical history and optical coherence tomography (OCT) and OCT angiography images of consecutive patients with early AMD. We calculated the retinal vessel densities of the superficial and deep capillary plexus with the ImageJ software (National Institutes of Health, Bethesda, MD, USA) and investigated the relationship with mean retinal thickness and subfoveal choroidal thickness.
   Results: We included 135 early AMD eyes and classified 60 of them into a reticular pseudodrusen group and 75 into a non-reticular pseudodrusen group. The vascular densities of the superficial and deep capillary plexus in the reticular pseudodrusen group (32.35% +/- 3.67 and 26.71% +/- 2.88%) were not different from those of the non-reticular pseudodrusen group (33.18% +/- 2.2% and % 27.43 +/- 1.79%; P = 0.546 and P = 0.318, respectively). The retinal thickness of the reticular pseudodrusen group (28731 mu m +/- 24.36 mu m) did not differ from that of the non-reticular pseudodrusen group (294.27 mu m +/- 20.71 mu m; P = 0.493), while subfoveal choroidal thickness in the reticular pseudodrusen group (158. 13 mu m +/- 42.53 mu m) was lower than that in the non-reticular pseudodrusen group (237.89 mu m +/- 60.94 mu m; P < 0.001). Multivariate analysis revealed that lower vascular density of the superficial capillary plexus and subfoveal choroidal thickness were associated with retinal thinning in reticular pseudodrusen group (P = 0.003 and P = 0.036) and older age was associated with retinal thickness in the non-reticular pseudodrusen group (P = 0.005).
   Conclusions: Retinal thinning in early AMD patients with reticular pseudodrusen was accompanied by choroidal and retinal vascular loss, which suggests a possible linkage of retinal thinning with vascular alterations.
C1 [Ahn, So Min; Lee, Suk Yeon; Kim, Seong-Woo; Oh, Jaeryung; Yun, Cheolmin] Korea Univ, Coll Med, Dept Ophthalmol, 123 Jeokgeum Ro, Seoul, South Korea.
   [Hwang, Soon-Young] Korea Univ, Coll Med, Dept Biostat, Seoul, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine); Korea
   University; Korea University Medicine (KU Medicine)
RP Yun, C (通讯作者)，Korea Univ, Coll Med, Dept Ophthalmol, 123 Jeokgeum Ro, Seoul, South Korea.
EM yuncheolmin@gmail.com
RI Oh, Jaeryung/ABD-3090-2021; Lee, Suk Yeon/AAH-4959-2021
OI Oh, Jaeryung/0000-0002-1036-6562; Hwang, Soon Young/0000-0001-7474-1803
FU Korea University [K1723451]
FX This research was supported by grants from Korea University (K1723451).
   However, the funding organization had no role in the design or conduct
   of this research.
CR A Martillo Miguel, 2012, Med Hypothesis Discov Innov Ophthalmol, V1, P37
   Al-Sheikh M, 2017, INVEST OPHTH VIS SCI, V58, P2063, DOI 10.1167/iovs.16-21289
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Cicinelli MV, 2018, BR J OPHTHALMOL
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Costa VP, 2014, ACTA OPHTHALMOL, V92, pe252, DOI 10.1111/aos.12298
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Cymerman RM, 2016, CURR EYE RES, V41, P1482, DOI 10.3109/02713683.2015.1128552
   Duan XR, 2010, OPHTHALMOLOGY, V117, P1585, DOI 10.1016/j.ophtha.2009.12.036
   Falsini B, 2011, INVEST OPHTH VIS SCI, V52, P1064, DOI 10.1167/iovs.10-5964
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Gupta P, 2013, INVEST OPHTH VIS SCI, V54, P7968, DOI 10.1167/iovs.13-12436
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Hamel CP, 2009, AM J OPHTHALMOL, V147, P609, DOI 10.1016/j.ajo.2008.10.022
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mitchell P, 2005, NEUROLOGY, V65, P1005, DOI 10.1212/01.wnl.0000179177.15900.ca
   Mones J, 2018, BRIT J OPHTHALMOL, V102, P388, DOI 10.1136/bjophthalmol-2017-310268
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Myers CE, 2015, AM J OPHTHALMOL, V159, P445, DOI 10.1016/j.ajo.2014.11.025
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2015, INVEST OPHTH VIS SCI, V56, P5914, DOI 10.1167/iovs.15-17133
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Song WK, 2010, INVEST OPHTH VIS SCI, V51, P3913, DOI 10.1167/iovs.09-4189
   Spaide RF, 2017, JAMA OPHTHALMOL, V135, P259, DOI 10.1001/jamaophthalmol.2016.5327
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Toto L, 2017, BRIT J OPHTHALMOL, V101, P774, DOI 10.1136/bjophthalmol-2016-309160
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Waheed NK, 2016, DEV OPHTHALMOL, V56, P91, DOI 10.1159/000442784
   Wang JJ, 2006, HEART, V92, P1583, DOI 10.1136/hrt.2006.090522
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yu J, 2016, INVEST OPHTH VIS SCI, V57, pOCT204, DOI 10.1167/iovs.15-18630
   Yun C, 2016, INVEST OPHTH VIS SCI, V57, P6604, DOI 10.1167/iovs.16-19989
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 58
TC 13
Z9 13
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUL 28
PY 2018
VL 18
AR 184
DI 10.1186/s12886-018-0866-3
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GO4QW
UT WOS:000439998600001
PM 30055588
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Dietzel, M
   Pauleikhoff, D
   Arning, A
   Heimes, B
   Lommatzsch, A
   Stoll, M
   Hense, HW
AF Dietzel, Martha
   Pauleikhoff, Daniel
   Arning, Astrid
   Heimes, Britta
   Lommatzsch, Albrecht
   Stoll, Monika
   Hense, Hans-Werner
TI The contribution of genetic factors to phenotype and progression of
   drusen in early age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Genetics; CFH; ARMS2; ABCA1; Drusen; Phenotype; Early age-related
   macular degeneration
ID COMPLEMENT FACTOR-H; GRADING SYSTEM; MACULOPATHY; RISK; ASSOCIATIONS;
   DISEASE; MODELS
AB Genetic factors contribute to the development and progression of age-related macular degeneration (AMD). We aimed to assess the association of drusen as phenotypic characteristics of early AMD and their progression with polymorphisms in the CFH, ABCA1, and ARMS2 genes.
   In the Munster Aging and Retina Study (MARS), drusen were detected in 406 patients with early AMD and 170 healthy controls according to the International Classification using fundus photographs, with a follow-up examination after 2.6 years (median). Six drusen features were assessed: drusen number (</a parts per thousand yen20); confluence of drusen (</a parts per thousand yen50 %), largest drusen size (</a parts per thousand yen175 mu m); area occupied by drusen (</a parts per thousand yen10 %); most frequent drusen size (</a parts per thousand yen175 mu m), and presence of soft, indistinct drusen (no/yes). Based on these features, an unweighted summary drusen severity score (DSS; categorized in "low", "intermediate" and "high") was calculated. The relationship of each drusen feature and the DSS with CFH rs1061170, ABCA1 rs1883025, and ARMS2 rs10490924 at baseline and after 2.6 years was analyzed using multivariate logistic regression models.
   Cross-sectionally, each drusen feature was associated with a higher frequency of the CFH and ARMS2 risk variants. Compared to healthy eyes, the CFH risk variant was more common in eyes with early as well as advanced drusen features, while the ARMS2 variant was only associated with advanced drusen. After 2.6 years, 43 % of the eyes showed a progression of at least 1 unit in the DSS. The progression from low to higher DSS was inversely associated with ABCA1 (OR = 0.54), and the progression from intermediate to high DSS was positively related to CFH rs1061170 (OR = 2.3; p < 0.05 for each).
   Variants in CFH, ABCA1, and ARMS2 genes are related to the presence and progression of drusen in early AMD. CFH and, inversely, ABCA1 seem to be involved in early drusen development, while the role of ARMS2 is more pronounced in advanced stages of early AMD.
C1 [Dietzel, Martha; Hense, Hans-Werner] Univ Munster, Inst Epidemiol & Social Med, D-48129 Munster, Germany.
   [Dietzel, Martha; Pauleikhoff, Daniel; Heimes, Britta; Lommatzsch, Albrecht] St Franziskus Hosp Munster, Dept Ophthalmol, Hohenzollernring 74, D-48129 Munster, Germany.
   [Arning, Astrid; Stoll, Monika] Univ Munster, D-48149 Munster, Germany.
C3 University of Munster; St. Franziskus-Hospital; University of Munster
RP Dietzel, M (通讯作者)，St Franziskus Hosp Munster, Dept Ophthalmol, Hohenzollernring 74, D-48129 Munster, Germany.
EM martha.dietzel@uni-muenster.de
OI Heimes-Bussmann, Britta/0000-0003-3898-1679
FU Deutsche Forschungsgemeinschaft [HE 2293/5-1, 5-2, 5-3, PA 357/7-1];
   Intramural Fund (IMF) of the Medical Faculty of the University of
   Munster; Pro Retina Foundation; Jackstaedt Foundation
FX The study was supported by grants from Deutsche Forschungsgemeinschaft
   HE 2293/5-1, 5-2, 5-3 and PA 357/7-1; the Intramural Fund (IMF) of the
   Medical Faculty of the University of Munster; the Pro Retina Foundation;
   and the Jackstaedt Foundation.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Farwick A, 2010, INVEST OPHTH VIS SCI, V51, P731, DOI 10.1167/iovs.09-3953
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
NR 20
TC 19
Z9 19
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2014
VL 252
IS 8
BP 1273
EP 1281
DI 10.1007/s00417-014-2690-7
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AM4MX
UT WOS:000339829900012
PM 24970616
DA 2022-11-30
ER

PT J
AU Chen, HY
   Liu, B
   Lukas, TJ
   Neufeld, AH
AF Chen, Huiyi
   Liu, Bin
   Lukas, Thomas J.
   Neufeld, Arthur H.
TI The Aged Retinal Pigment Epithelium/Choroid: A Potential Substratum for
   the Pathogenesis of Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT FACTOR-H; GENOME SCAN; SUSCEPTIBILITY; GENE; DRUSEN;
   POLYMORPHISM; EXPRESSION; COMMON; MODEL; CFH
AB Background: Although the statement that age is the greatest risk factor for Age-related macular degeneration (AMD) is widely accepted, the cellular and molecular explanations for that clinical statement are not generally known. A major focus of AMD research is the retinal pigment epithelium (RPE)/choroid. The purpose of this study was to characterize the changes in the RPE/choroid with age that may provide a background for the development of AMD.
   Methodology/Principal Findings: We compared the transcriptional profiles, key protein levels and histology of the RPE/choroid from young and old mice. Using three statistical methods, microarray data demonstrated marked changes in the old mouse. There were 315 genes differentially expressed with age; most of these genes were related to immune responses and inflammatory activity. Canonical pathways having significant numbers of upregulated genes in aged RPE/choroid included leukocyte extravasation, complement cascades, natural killer cell signaling and IL-10 signaling. By contrast, the adjacent neural retina showed completely different age-related changes. The levels of proteins that participate in leukocyte extravasation and complement pathways were consistently increased in the normal, aged RPE/choroid. Furthermore, there was increased gene expression and protein levels of leukocyte attracting signal, chemokine ligand 2 (Ccl2) in aged RPE/choroid. In old animals, there was marked extravasation and accumulation of leukocytes from the choroidal circulation onto Bruch's membrane and into the RPE.
   Conclusions/Significance: These phenotypic changes indicate that the RPE/choroid in the normal, old mouse has become an immunologically active tissue. There are signals from the normal, aged RPE/choroid which recruit leukocytes from the circulation and activate the complement cascade. These age-related changes that occur in the RPE/choroid with age, to the extent that they occur in the human retina, may provide the background for an error in regulation of immunological activity to cause AMD to appear in an elderly individual.
C1 [Chen, Huiyi; Liu, Bin; Lukas, Thomas J.; Neufeld, Arthur H.] Northwestern Univ, Sch Med, Dept Ophthalmol, Lab Invest Aging Retina, Chicago, IL 60611 USA.
C3 Northwestern University
RP Chen, HY (通讯作者)，Northwestern Univ, Sch Med, Dept Ophthalmol, Lab Invest Aging Retina, Chicago, IL 60611 USA.
EM a-neufeld@northwestern.edu
FU NIH [EY12017]; Research to Prevent Blindness; NATIONAL EYE INSTITUTE
   [R01EY012017] Funding Source: NIH RePORTER
FX This work was supported by NIH grant EY12017, a generous gift from the
   Forsythe Foundation and an unrestricted grant from Research to Prevent
   Blindness. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Burke D, 2007, BRIT J PSYCHIAT, V190, P371, DOI 10.1192/bjp.bp.106.033407
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Drachman DA, 2006, NEUROLOGY, V67, P1340, DOI 10.1212/01.wnl.0000240127.89601.83
   Dreier R, 2004, EXP CELL RES, V297, P303, DOI 10.1016/j.yexcr.2004.02.027
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fiotti N, 2005, GENET MED, V7, P272, DOI 10.1097/01.GIM.0000159903.69597.73
   Frick C, 2005, EUR J IMMUNOL, V35, P3610, DOI 10.1002/eji.200425914
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Ida H, 2003, PHYSIOL GENOMICS, V15, P258, DOI 10.1152/physiolgenomics.00126.2003
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lanier LL, 2003, CURR OPIN IMMUNOL, V15, P308, DOI 10.1016/S0952-7915(03)00039-6
   Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098
   Liu WM, 2002, BIOINFORMATICS, V18, P1593, DOI 10.1093/bioinformatics/18.12.1593
   Luckow B, 2004, EUR J IMMUNOL, V34, P2568, DOI 10.1002/eji.200324776
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murray J, 2006, J AAPOS, V10, P6, DOI 10.1016/j.jaapos.2006.01.010
   Radeke MJ, 2007, EXP EYE RES, V85, P366, DOI 10.1016/j.exer.2007.05.006
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Smyth, 2004, STAT APPL GENET MOL, V3, P1, DOI DOI 10.2202/1544-6115.1027
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Van Coillie E, 1999, CYTOKINE GROWTH F R, V10, P61, DOI 10.1016/S1359-6101(99)00005-2
   Zen K, 2003, CURR OPIN CELL BIOL, V15, P557, DOI 10.1016/S0955-0674(03)00103-0
   Zen K, 2004, J BIOL CHEM, V279, P44924, DOI 10.1074/jbc.M402115200
   Zen K, 2005, MOL BIOL CELL, V16, P2694, DOI 10.1091/mbc.E05-01-0036
NR 50
TC 93
Z9 97
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 4
PY 2008
VL 3
IS 6
AR e2339
DI 10.1371/journal.pone.0002339
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 396TO
UT WOS:000262614300032
PM 18523633
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Kozlowski, MR
AF Kozlowski, Michael R.
TI Senescent Retinal Pigment Epithelial Cells Are More Sensitive to
   Vascular Endothelial Growth Factor: Implications for "Wet" Age-Related
   Macular Degeneration
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID BETA-GALACTOSIDASE ACTIVITY; SOLUBLE VEGF; EXPRESSION; ARPE-19;
   DYSFUNCTION; SECRETION; CULTURE; MODELS; MARKER
AB Purpose: Senescence of the retinal pigment epithelial (RPE) cell layer has been implicated in the occurrence of age-related macular degeneration (AMD). The present study examines whether the ability of vascular endothelial growth factor (VEGF) to decrease the barrier function of RPE cells is enhanced in senescent RPE cells, which could contribute to the pathology of "wet" AMD.
   Methods: Low or high population doubling level (PDL) range ARPE-19 human RPE cells were cultured in 6-well plates on membrane-containing inserts. After 2 weeks, the cells were treated with either VEGF or its vehicle and their transepithelial electrical resistance (TEER) was measured. One week later, the cells were stained for senescence-associated beta-galactosidase (SABG) activity.
   Results: VEGF was significantly more effective in reducing the TEER of the high PDL ARPE-19 cell layers than the low PDL layers (25% decrease vs. 6% decrease; t-test, P=0.0013). The low PDL cell layers had a modest uniform level of SABG staining. In contrast, the high PDL layers displayed darker and more mottled SABG staining indicative of the presence of senescent cells.
   Conclusions: The present results show that the ability of VEGF to reduce the barrier function of RPE cell layers is greater in high PDL layers, which display signs of senescence, than in low PDL layers. Senescence-induced changes in the responsiveness of RPE cell layers to VEGF could contribute to the pathology of AMD. Agents that strengthen the barrier properties of RPE cells or reduce their responsiveness to VEGF could be effective in treating "wet" AMD.
C1 Midwestern Univ, Arizona Coll Optometry, Glendale, AZ 8530 USA.
C3 Midwestern University; Midwestern University - Arizona College of
   Optometry
RP Kozlowski, MR (通讯作者)，Midwestern Univ, Arizona Coll Optometry, Glendale Hall,Suite 127,19555 N 59th Ave, Glendale, AZ 8530 USA.
EM mkozlo@midwestern.edu
OI Kozlowski, Michael/0000-0003-1213-7015
CR Ablonczy Z, 2007, EXP EYE RES, V85, P762, DOI 10.1016/j.exer.2007.08.010
   Ablonczy Z, 2014, FASEB J, V28, P2369, DOI 10.1096/fj.13-248021
   Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Chang CW, 1997, INVEST OPHTH VIS SCI, V38, P1082
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Coppe JP, 2006, J BIOL CHEM, V281, P29568, DOI 10.1074/jbc.M603307200
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ford KM, 2012, INVEST OPHTH VIS SCI, V53, P7520, DOI 10.1167/iovs.12-10098
   Geisen P, 2006, CURR EYE RES, V31, P739, DOI 10.1080/02713680600837408
   Gilbert C., 2007, GLOBAL INITIATIVE EL, V2007, P32
   Glotin AL, 2008, FREE RADICAL BIO MED, V44, P1348, DOI 10.1016/j.freeradbiomed.2007.12.023
   Hartnett ME, 2003, EXP EYE RES, V77, P593, DOI 10.1016/S0014-4835(03)00189-1
   Honda S, 2002, BRIT J OPHTHALMOL, V86, P159, DOI 10.1136/bjo.86.2.159
   Jang DH, 2015, J GERONTOL A-BIOL, V70, P20, DOI 10.1093/gerona/glt212
   Jin ML, 2002, INVEST OPHTH VIS SCI, V43, P2782
   Kanski J. J., 2007, CLIN OPHTHALMOLOGY S, P629
   Kozlowski M. R., 2013, ARVO ANN M
   Kozlowski MR, 2015, CURR EYE RES, V40, P501, DOI 10.3109/02713683.2014.935440
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Lara-Castillo N, 2009, AM J PATHOL, V175, P2343, DOI 10.2353/ajpath.2009.090439
   Luo Y, 2006, INVEST OPHTH VIS SCI, V47, P3644, DOI 10.1167/iovs.06-0166
   Marchiando AM, 2010, ANNU REV PATHOL-MECH, V5, P119, DOI 10.1146/annurev.pathol.4.110807.092135
   Mishima K, 1999, INVEST OPHTH VIS SCI, V40, P1590
   Nakamura K, 2006, CANCER RES, V66, P9134, DOI 10.1158/0008-5472.CAN-05-4290
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   Peng SM, 2010, INVEST OPHTH VIS SCI, V51, P3216, DOI 10.1167/iovs.09-4162
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   QUINN RH, 1992, INVEST OPHTH VIS SCI, V33, P3513
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Severino J, 2000, EXP CELL RES, V257, P162, DOI 10.1006/excr.2000.4875
   Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5
   Shlush LI, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-16
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Spaide RF, 2006, AGE RELATED MACULAR
   Thompson W., 2006, AGE RELATED MACULAR
   Yang NC, 2005, EXP GERONTOL, V40, P813, DOI 10.1016/j.exger.2005.07.011
NR 40
TC 5
Z9 5
U1 0
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD MAR 1
PY 2015
VL 31
IS 2
BP 87
EP 92
DI 10.1089/jop.2014.0071
PG 6
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA CB8QR
UT WOS:000349896300004
PM 25453983
DA 2022-11-30
ER

PT J
AU Mursch-Edlmayr, AS
   Luft, N
   Podkowinski, D
   Ring, M
   Schmetterer, L
   Bolz, M
AF Mursch-Edlmayr, Anna Sophie
   Luft, Nikolaus
   Podkowinski, Dominika
   Ring, Michael
   Schmetterer, Leopold
   Bolz, Matthias
TI Effects of three intravitreal injections of aflibercept on the ocular
   circulation in eyes with age-related maculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE macula; clinical trial; optic nerve; pharmacology; retina
ID LASER SPECKLE FLOWGRAPHY; ENDOTHELIAL GROWTH-FACTOR; BLOOD-FLOW; MACULAR
   DEGENERATION; RETINAL CIRCULATION; GEOGRAPHIC ATROPHY; BEVACIZUMAB;
   VEGF; RANIBIZUMAB
AB Aims To investigate changes in ocular perfusion following three consecutive intravitreal injections with aflibercept for treatment of neovascular age-related macular degeneration (nAMD). Methods The study included 20 eyes from 20 Caucasian patients with unilateral nAMD and 20 fellow eyes. All nAMD eyes were treated with standard intravitreal injection of aflibercept (IVA; 2 mg). Measurements of ocular perfusion at the optic nerve head (ONH) and the choroid were performed with laser speckle flowgraphy (LSFG). Measurements were conducted at baseline, 1 week after the first injection, at the time point of the second and third injection as well as 1 month after the third injection. Results In treated eyes, mean blur rate (the main output parameter of LSFG) in the ONH microvasculature and in the choroid was significantly reduced 1 week after the first IVA treatment. The effect persisted throughout the entire follow-up period (p<0.001). No change in ocular perfusion was observed in fellow eyes. Conclusions IVA for treatment of nAMD leads to a reduction in perfusion of the ONH and the choroid in the treated eye with no apparent effect on the fellow eye.
C1 [Mursch-Edlmayr, Anna Sophie; Podkowinski, Dominika] Kepler Univ Klinikum GmbH, Ophthalmol, Linz, Austria.
   [Luft, Nikolaus] Ludwig Maximilians Univ Munchen, Ophthalmol, Munich, Germany.
   [Ring, Michael] Johannes Kepler Univ Linz, Med Res Ctr, Ophthalmol, Linz, Austria.
   [Schmetterer, Leopold] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Ocular Imaging, Singapore, Singapore.
   [Bolz, Matthias] Kepler Univ Hosp, Dept Ophthalmol, A-4020 Linz, Austria.
C3 University of Munich; Johannes Kepler University Linz; National
   University of Singapore; Singapore National Eye Center; Kepler
   University Hospital
RP Bolz, M (通讯作者)，Kepler Univ Hosp, Dept Ophthalmol, A-4020 Linz, Austria.
EM matthias.bolz@kepleruniklinikum.at
RI Bolz, Matthias/HCI-0622-2022
OI Schmetterer, Leopold/0000-0002-7189-1707; Reisinger, Anna
   Sophie/0000-0003-2218-5897
FU Nidek
FX Unrestricted research grant from Nidek.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Aizawa N, 2011, CLIN OPHTHALMOL, V5, P1171, DOI 10.2147/OPTH.S22093
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Costa VP, 2014, ACTA OPHTHALMOL, V92, pe252, DOI 10.1111/aos.12298
   Enaida Hiroshi, 2010, Ophthalmic Surg Lasers Imaging, V41 Online, pe1, DOI 10.3928/15428877-20101124-11
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Forstermann U, 2012, EUR HEART J, V33, P829, DOI 10.1093/eurheartj/ehr304
   Fontaine O, 2011, INVEST OPHTH VIS SCI, V52, P7400, DOI 10.1167/iovs.10-6646
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gupta P, 2017, RETINA-J RET VIT DIS, V37, P2269, DOI 10.1097/IAE.0000000000001481
   Kunikata H, 2014, CLIN OPHTHALMOL, V1119
   Luft N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168190
   Luft N, 2016, INVEST OPHTH VIS SCI, V57, P5417, DOI 10.1167/iovs.16-19896
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mekjavic PJ, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00125
   Nagasato D, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0211-7
   Okamoto M, 2018, GRAEF ARCH CLIN EXP, V256, P885, DOI 10.1007/s00417-018-3939-3
   Okamoto M, 2015, OSLI RETINA, V46, P25, DOI 10.3928/23258160-20150101-04
   Okuno T, 2002, JPN J OPHTHALMOL, V46, P170, DOI 10.1016/S0021-5155(01)00498-1
   Riva CE, 2010, ACTA OPHTHALMOL, V88, P622, DOI 10.1111/j.1755-3768.2009.01621.x
   Sacu S, 2011, INVEST OPHTH VIS SCI, V52, P3046, DOI 10.1167/iovs.10-5842
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Selid PD, 2014, OSLI RETINA, V45, P275, DOI 10.3928/23258160-20140709-03
   Shimomura Y, 2009, GRAEF ARCH CLIN EXP, V247, P1089, DOI 10.1007/s00417-009-1054-1
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Sugimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1543, DOI 10.1007/s00417-017-3692-z
   Sugiyama T, 2010, ACTA OPHTHALMOL, V88, P723, DOI 10.1111/j.1755-3768.2009.01586.x
   Wang YM, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2772871
   Werkmeister RM, 2012, INVEST OPHTH VIS SCI, V53, P6062, DOI 10.1167/iovs.12-9514
NR 31
TC 3
Z9 3
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2020
VL 104
IS 1
BP 53
EP 57
DI 10.1136/bjophthalmol-2019-313919
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KA1YB
UT WOS:000505593600011
PM 30979731
OA Green Published
DA 2022-11-30
ER

PT J
AU Zivkovic, M
   Jaksic, V
   Zlatanovic, M
   Sefic-Kasumovic, S
   Radosavljevic, A
   Zlatanovic, N
   Zlatanovic, G
   Dordevic-Jocic, J
   Jovanovic, P
   Radenkovic, M
   Jovanovic, S
AF Zivkovic, Maja
   Jaksic, Vesna
   Zlatanovic, Marko
   Sefic-Kasumovic, Sanja
   Radosavljevic, Aleksandra
   Zlatanovic, Nevena
   Zlatanovic, Gordana
   Dordevic-Jocic, Jasmina
   Jovanovic, Predrag
   Radenkovic, Marija
   Jovanovic, Svetlana
TI Abnormalities in the thickness of the retinal ganglion cell / inner
   plexiform layer in age-related macular degeneration
SO SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO
LA English
DT Article
DE dry AMD; wet AMD; ganglion cell layer; ganglion cell complex
ID OPTICAL COHERENCE TOMOGRAPHY; RANIBIZUMAB; BEVACIZUMAB; DEFINITION; AMD
AB Introduction/Objective The study aims to analyze the thickness of both the ganglion cell layer and the inner plexiform layer (GCL + IPL) among patients suffering from dry and wet form of age-related macular degeneration (AMD).
   Methods One hundred ninety-five patients with AMD participated in the study, along with 94 healthy individuals (mean age 75.2 +/- 7.8 years; range 55-86). They were divided into three groups: the first group, or group I, included 100 patients suffering from wet AMD; the second group, or group II, included 95 patients afflicted with dry AMD; the final 94 patients made up the control group, group Ill, of healthy individuals without systemic or ocular diseases. Measurements such as the average macular thickness, the average and minimum GCL + IPL thickness, and the GCL + IPL thickness in all six sectors were obtained by Cirrus spectral-domain optical coherence tomography (SD-OCT, Carl Zeiss Meditec, Inc., Dublin, CA, USA). SPSS version 20.0 was used to analyze the data, while the level of statistical significance was set at p < 0.05.
   Results In the case of patients with wet AMD, the average value for GCL + IPL thickness was 43.13 mu m, for patients with dry AMD the value was 66.73 mu m, and the average thickness measured for the control group was 86.23 mu m. There was a statistically significant difference between the average GCL + IPL and minimum GCL + IPL thicknesses between the groups (p <0.001). Lower values were noted for patients with wet AMD (p < 0.001) than those with dry AMD. In the latter, the average GCL + IPL and the minimum GCL + IPLthicknesses were lower than those of the healthy participants, at a level of statistical significance (p <0.001).
   Conclusion Participants with AMD exhibited thinner GCL + IPL than the healthy participants, as did the participants with wet AMD when compared to the participants with dry AMD.
C1 [Zivkovic, Maja; Dordevic-Jocic, Jasmina; Jovanovic, Predrag] Univ Nis, Fac Med, Dept Ophthalmol, Nish, Serbia.
   [Zivkovic, Maja; Zlatanovic, Marko; Dordevic-Jocic, Jasmina; Jovanovic, Predrag; Radenkovic, Marija] Nis Clin Ctr, Ophthalmol Clin, Nish, Serbia.
   [Jaksic, Vesna; Radosavljevic, Aleksandra] Univ Belgrade, Fac Med, Dept Ophthalmol, Belgrade, Serbia.
   [Sefic-Kasumovic, Sanja] Federat Bosnia & Herzegovina, Dr Sefic Eye Cin, Sarajevo, Bosnia & Herceg.
   [Zlatanovic, Nevena] Community Hlth Ctr Nis, Nish, Serbia.
   [Zlatanovic, Gordana] Clin Maja Eye Hosp, Nish, Serbia.
   [Jovanovic, Svetlana] Univ Kragujevac, Fac Med Sci, Clin Dept Ophthalmol, POB 109, Kragujevac 34000, Serbia.
C3 University of Nis; University of Belgrade; University of Kragujevac
RP Jovanovic, S (通讯作者)，Univ Kragujevac, Fac Med Sci, Clin Dept Ophthalmol, POB 109, Kragujevac 34000, Serbia.
EM drsvetlanajovanovic@yahoo.com
RI Radosavljevic, Aleksandra/K-3730-2014
OI Radosavljevic, Aleksandra/0000-0002-8859-5103; Jaksic,
   Vesna/0000-0001-9941-7305
CR Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Cachulo L, 2011, OPHTHALMOLOGICA, V225, P144, DOI 10.1159/000321064
   Cheng CK, 2009, RETINA-J RET VIT DIS, V29, P306, DOI 10.1097/IAE.0b013e3181909404
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103
   DeBuc DC, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3268773
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Johnson JG, 2012, EPIDEMIOLOGY EYE DIS, P571
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Koh VT, 2012, INVEST OPHTH VIS SCI, V53, P5853, DOI 10.1167/iovs.12-10414
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Padnick-Silver L, 2012, RETINA-J RET VIT DIS, V32, P1045, DOI 10.1097/IAE.0b03e31823fb82b
   Park SS, 2010, INVEST OPHTH VIS SCI, V51, P4200, DOI 10.1167/iovs.09-4256
   Parlak M, 2015, INT OPHTHALMOL, V35, P473, DOI 10.1007/s10792-014-9972-2
   Ramkumar HL, 2018, RETINA-J RET VIT DIS, V38, P2159, DOI 10.1097/IAE.0000000000001867
   Rimayanti U, 2014, GRAEF ARCH CLIN EXP, V252, P563, DOI 10.1007/s00417-013-2496-z
   Savastano MC, 2014, INVEST OPHTH VIS SCI, V55, P560, DOI 10.1167/iovs.13-12172
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Tan O, 2009, OPHTHALMOLOGY, V116, P2305, DOI 10.1016/j.ophtha.2009.05.025
   Velez-Montoya R, 2013, RETINA-J RET VIT DIS, V33, P1487, DOI 10.1097/IAE.0b013e318271f265
   Wang M, 2009, ARCH OPHTHALMOL-CHIC, V127, P875, DOI 10.1001/archophthalmol.2009.145
   Yehoshua Z, 2011, SEMIN OPHTHALMOL, V26, P167, DOI 10.3109/08820538.2011.577132
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 32
TC 0
Z9 0
U1 0
U2 0
PU SRPSKO LEKARSKO DRUSTVO
PI BEOGRAD
PA UREDNISTVO CASOPISA SRPSKI ARHIV, UL DZORDZA VASINGTONA 19, BEOGRAD,
   11000, SERBIA
SN 0370-8179
J9 SRP ARK CELOK LEK
JI Srp. Ark. Celok. Lek.
PD NOV-DEC
PY 2020
VL 148
IS 11-12
BP 727
EP 731
DI 10.2298/SARH181226097Z
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA PN4GQ
UT WOS:000604439300012
OA gold
DA 2022-11-30
ER

PT J
AU Colak, E
   Zoric, L
   Radosavljevic, A
   Ignjatovic, S
AF Colak, Emina
   Zoric, Lepsa
   Radosavljevic, Aleksandra
   Ignjatovic, Svetlana
TI The Association of Serum Iron-Binding Proteins and the Antioxidant
   Parameter Levels in Age-Related Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Oxidative stress; antioxidant defense parameters; iron; iron-binding
   proteins
ID HOMEOSTASIS; PEROXIDASE; ESTROGEN; DISEASE; GENDER; DRUSEN; COHORT;
   DAMAGE; BRAIN; MICE
AB Purpose: Age-related macular degeneration (AMD) is the leading cause of the irreversible central visual loss among the elderly in the developed countries. Iron is considered a potent generator of the oxidative damage whose levels increase with age, potentially exacerbating the age-related diseases. The aim of this study was to assess the serum values of iron, and iron-binding proteins (transferrin, ferritin, and haptoglobin) in patients with AMD along with the parameters of the antioxidant defense: superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione reductase, and total antioxidant status (TAS), in order to analyze the possible impact of iron and iron-binding proteins to the development of oxidative stress in AMD patients, and the association of the selected parameters with the AMD. In addition, the aim was to examine the gender differences and calculate the cutoff points of tested parameters that could be associated with AMD.Material and methods: A cross-sectional study included 55 AMD patients aged 71.77.36 years and 65 aged-matched control subjects aged 70.256.46years.Results: Significantly lower ferritin (P=0.025), SOD (P=0.026), GPx (P=0.019), and TAS (P<0.004) values were found in patients with AMD compared to the controls (P<0.05). Significant association of GPx < 27U/gHb (odds ratio [OR]: 1.13; 95% confidence interval [CI] 0.78-2.10; P=0.049), TAS < 1.25mmol/L (OR: 5.77; 95% CI 0.98-367.0; P<0.000), ferritin < 84.8pg/mL (OR: 2.52; 95% CI 1.37-4.62; P=0.002), and haptoglobin<1.51g/L (OR: 1.94; 95% CI 1.05-3.56; P=0.031) was found with the AMD. According to receiver operating characteristic curve analysis, ferritin concentration <84.8pg/L, GPx < 27U/gHb, and TAS < 1.25mmol/L have sufficient predictive ability for AMD.Conclusion: Significantly reduced capacity of the antioxidant defense system and iron-binding storage proteins (ferritin) found in AMD could have an important role in the development of increase oxidative stress in AMD patients.
C1 [Colak, Emina; Ignjatovic, Svetlana] Clin Ctr Serbia, Inst Med Biochem, Visegradska 26, Belgrade 11000, Serbia.
   [Colak, Emina; Ignjatovic, Svetlana] Univ Belgrade, Sch Pharm, Belgrade, Serbia.
   [Zoric, Lepsa] Univ Pristina, Clin Eye Dis, Ctr Clin, Fac Med, Settlement Kosovska Mitr, Serbia.
   [Radosavljevic, Aleksandra] Clin Ctr Serbia, Inst Ophthalmol, Med Retina Dept, Belgrade, Serbia.
   [Radosavljevic, Aleksandra] Univ Belgrade, Sch Med, Belgrade, Serbia.
C3 Clinical Centre of Serbia; University of Belgrade; Universiteti i
   Prishtines; Clinical Centre of Serbia; University of Belgrade
RP Colak, E (通讯作者)，Clin Ctr Serbia, Inst Med Biochem, Visegradska 26, Belgrade 11000, Serbia.
EM eminacolak@sbb.rs
RI Radosavljevic, Aleksandra/K-3730-2014; Radosavljevic,
   Aleksandra/AAK-2407-2020; Čolak, Emina/AAQ-1969-2021
OI Radosavljevic, Aleksandra/0000-0002-8859-5103; Radosavljevic,
   Aleksandra/0000-0002-8859-5103; Čolak, Emina/0000-0003-1901-3146
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Behndig A, 2001, INVEST OPHTH VIS SCI, V42, P2293
   Bu WM, 2012, FASEB J, V26, P2394, DOI 10.1096/fj.11-198853
   Bulvik BE, 2012, AGE, V34, P693, DOI 10.1007/s11357-011-9268-7
   Burdo JR, 2003, BIOMETALS, V16, P63, DOI 10.1023/A:1020718718550
   Cascio C, 2015, STEROIDS, V103, P31, DOI 10.1016/j.steroids.2015.08.002
   CHEVION M, 1988, FREE RADICAL BIO MED, V5, P27, DOI 10.1016/0891-5849(88)90059-7
   COHEN SM, 1994, BRIT J OPHTHALMOL, V78, P791, DOI 10.1136/bjo.78.10.791
   Colak E, 2017, J CLIN BIOCHEM NUTR, V60, P100, DOI 10.3164/jcbn.16-30
   Colak E, 2012, BIOCHEM MEDICA, V22, P39
   Colak E, 2011, OPHTHALMIC RES, V46, P125, DOI 10.1159/000323815
   Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, P1221, DOI 10.1167/iovs.02-0285
   Cuji D, 2010, J MED BIOCHEM, V30, P33
   Doulias PT, 2008, FREE RADICAL RES, V42, P253, DOI 10.1080/10715760801911649
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Elliot SJ, 2010, EXP EYE RES, V90, P10, DOI 10.1016/j.exer.2009.09.001
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Fleming DJ, 2002, AM J CLIN NUTR, V76, P1375, DOI 10.1093/ajcn/76.6.1375
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   GOLDBERG DM, 1983, METHOD ENZYMAT AN, P258
   GOLDSTEIN S, 1988, FREE RADICAL BIO MED, V4, P295, DOI 10.1016/0891-5849(88)90050-0
   Haan MN, 2006, ARCH OPHTHALMOL-CHIC, V124, P988, DOI 10.1001/archopht.124.7.988
   HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1
   Harris ZL, 1998, AM J CLIN NUTR, V67, p972S, DOI 10.1093/ajcn/67.5.972S
   Ii H O, 2016, PLOS ONE, V11
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Killilea DW, 2003, ANTIOXID REDOX SIGN, V5, P507, DOI 10.1089/152308603770310158
   Mahad DH, 2015, LANCET NEUROL, V14, P183, DOI 10.1016/S1474-4422(14)70256-X
   MILLER NJ, 1993, CLIN SCI, V84, P407, DOI 10.1042/cs0840407
   Milton NGN, 2004, DRUG AGING, V21, P81, DOI 10.2165/00002512-200421020-00002
   olak E, 2013, AGING CLIN EXP RES, V24, P588
   PAGLIA DE, 1967, J LAB CLIN MED, V70, P158
   Plestina-Borjan I, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/804054
   Ritchie RF, 2002, J CLIN LAB ANAL, V16, P237, DOI 10.1002/jcla.10048
   Rouault TA, 2001, NAT GENET, V28, P299, DOI 10.1038/91036
   Sergejeva O, 2016, MEDICINA-LITHUANIA, V52, P79, DOI 10.1016/j.medici.2016.02.004
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Song D, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00024
   Thomson AM, 1993, INT J BIOCHEM CELL B, V31, P1139
   Wysokinski D, 2015, ACTA BIOCHIM POL, V62, P177, DOI 10.18388/abp.2014_843
NR 41
TC 9
Z9 9
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2018
VL 43
IS 5
BP 659
EP 665
DI 10.1080/02713683.2018.1437452
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GC9BP
UT WOS:000430092800013
PM 29448841
DA 2022-11-30
ER

PT J
AU Freeman, SR
   Kozak, I
   Cheng, LY
   Bartsch, DU
   Mojana, F
   Nigam, N
   Brar, M
   Yuson, R
   Freeman, WR
AF Freeman, Samuel R.
   Kozak, Igor
   Cheng, Lingyun
   Bartsch, Dirk-Uwe
   Mojana, Francesca
   Nigam, Nitin
   Brar, Manpreet
   Yuson, Ritchie
   Freeman, William R.
TI OPTICAL COHERENCE TOMOGRAPHY-RASTER SCANNING AND MANUAL SEGMENTATION IN
   DETERMINING DRUSEN VOLUME IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE imaging; OCT; drusen; macular degeneration
ID COMPLEMENT FACTOR-H; VISUAL IMPAIRMENT; EYE DISEASE; RISK; POLYMORPHISM;
   VARIANT; GENES
AB Purpose: Drusen are the hallmark of age-related macular degeneration (AMD), and substantial evidence exists that the amount of drusen and their effect on retinal pigment epithelium is a strong predictor of progression of AMD and vision loss. Until recently, it was not possible to quantitate the volume of the drusen. However, the use of image-stabilized scanning laser ophthalmoscope or spectral domain-optical coherence tomography (OCT) has enabled determination of drusen volume of this abnormal material. The purpose of this study was to assess the correlation of drusen volume with Age-Related Eye Disease Study (AREDS) grade and drusen area in dry AMD.
   Methods: Thirty-six eyes from 18 patients with nonexudative AMD with visual acuity between 20/16 and 20/160 were studied. Spectral domain-OCT or simultaneous OCT scans were taken as color fundus photographs (35) of each eye. Early Treatment Diabetic Retinopathy Study visions were also recorded. The full AREDS score excluding late-stage AMD was determined by agreement between two trained observers. Drusen volume was determined by examination of a series of 96 spectral domain-OCT scans taken from arcade to arcade for a length of 6 mm. The volume was determined by calculating the drusen area in each scan and determining the drusen volume by calculating the effective volume of each cut using National Institutes of Health Image J. Drusen were identified and outlined manually, not using an automated algorithm.
   Results: There was a strong and significant correlation between drusen volume and AREDS-determined drusen area (P < 0.0001, r = 0.78). In addition, there was a correlation between AREDS classification and drusen volume (P = 0.023, r = 0.43) as determined by pairwise correlation.
   Conclusion: Drusen volume as determined by spectral domain-OCT correlates with AREDS-determined drusen area and AREDS grade in nonexudative AMD. The correlation is not perfect, however, because drusen area and volume average 40% and 82% of the variation, respectively. Drusen volume can provide additional information in grading the severity of eyes with dry AMD. RETINA 30: 431-435, 2010
C1 [Kozak, Igor] Univ Calif San Diego, Jacobs Retina Ctr, Shiley Eye Ctr, Dept Ophthalmol, La Jolla, CA 92037 USA.
   Univ Calif San Diego, Sch Med, Shiley Eye Ctr, La Jolla, CA 92037 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego
RP Kozak, I (通讯作者)，Univ Calif San Diego, Jacobs Retina Ctr, Shiley Eye Ctr, Dept Ophthalmol, 9415 Campus Point Dr, La Jolla, CA 92037 USA.
EM ikozak@eyecenter.ucsd.edu
RI Kozak, Igor/AAC-4645-2019
FU National Institutes of Health [EYO 7366]; RPB Inc.; Fight for Blindness,
   Inc.
FX Supported by National Institutes of Health EYO 7366 ( W. R. F.) and an
   unrestricted grant from RPB Inc. and Fight for Blindness, Inc.
CR Alam S, 2006, OPHTHALMOLOGY, V113, P1425, DOI 10.1016/j.ophtha.2006.03.020
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Leitgeb RA, 2004, OPT LETT, V29, P171, DOI 10.1364/OL.29.000171
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
NR 22
TC 50
Z9 51
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2010
VL 30
IS 3
BP 431
EP 435
DI 10.1097/IAE.0b013e3181bd2f94
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 608AD
UT WOS:000278548800008
PM 19952989
DA 2022-11-30
ER

PT J
AU Lee, SW
   Sim, H
   Park, JY
   Kim, JS
   Chang, IB
   Park, YS
   Hwang, JH
AF Lee, Seong Woo
   Sim, Ha Eun
   Park, Jae Yong
   Kim, Jae Suk
   Chang, In Beom
   Park, Young Soon
   Hwang, Je Hyung
TI Changes in inner retinal layer thickness in patients with exudative
   age-related macular degeneration during treatment with anti-vascular
   endothelial growth factor
SO MEDICINE
LA English
DT Article
DE age-related macular degeneration; ganglion cell-inner plexiform layer;
   inner retinal layer thickness; intravitreal anti-VEGF antibody
   injection; retinal nerve fiber layer
ID PLEXIFORM LAYER; INTRAVITREAL RANIBIZUMAB; INTRAOCULAR-PRESSURE; 10-YEAR
   INCIDENCE; PROGRESSION; SURVIVAL; VEGF
AB The aim of this study was to identify any changes that occur in the retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GC-IPL) in patients with exudative age-related macular degeneration (AMD) during treatment with anti-vascular endothelial growth factor (VEGF) injections. Patients were enrolled in this retrospective study if they had exudative AMD, had received at least 3 injections of ranibizumab or aflibercept, and had a minimum of 12 months of follow-up. We analyzed the changes in the RNFL and GC-IPL using spectral-domain optical coherence tomography in rescan mode. Fifty-two eyes of 52 patients who had been treated with repeated anti-VEGF injections for exudative AMD were included. At the final visit, there was no significant between-group difference in best-corrected visual acuity or intraocular pressure. There was a significant decrease in central macular thickness in all groups (P < .05). There was a decrease in RNFL thickness that was only statistically significant in the ranibizumab group and when the ranibizumab or aflibercept groups were combined (P = .036 and .044, respectively). The thickness of the GC-IPL layer was significantly decreased in the aflibercept and total group (P = .035 andP = .048, respectively). The thicknesses of the RNFL and GC-IPL decreased in patients with exudative AMD who underwent repeated anti-VEGF injections.
C1 [Lee, Seong Woo; Sim, Ha Eun; Park, Jae Yong; Kim, Jae Suk; Hwang, Je Hyung] Inje Univ, Sanggye Paik Hosp, Dept Ophthalmol, 1342 Dongil Ro, Seoul 139707, South Korea.
   [Chang, In Beom] Inje Univ, Busan Paik Hosp, Dept Ophthalmol, Busan, South Korea.
   [Park, Young Soon] Eye Love Eye Clin, Seoul, South Korea.
C3 Inje University; Inje University
RP Hwang, JH (通讯作者)，Inje Univ, Sanggye Paik Hosp, Dept Ophthalmol, 1342 Dongil Ro, Seoul 139707, South Korea.
EM violentviolet15@daum.net
OI Hwang, Jehyung/0000-0001-8081-7771
CR Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P1044, DOI 10.1097/IAE.0b013e3180592ba6
   Gunther JB, 2009, SURV OPHTHALMOL, V54, P372, DOI 10.1016/j.survophthal.2009.02.004
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Jo Young-Joon, 2016, Korean J Ophthalmol, V30, P114, DOI 10.3341/kjo.2016.30.2.114
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Kim Se Young, 2020, Korean J Ophthalmol, V34, P11, DOI 10.3341/kjo.2019.0081
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Lee HJ, 2015, AM J OPHTHALMOL, V160, P283, DOI 10.1016/j.ajo.2015.05.015
   Lee WJ, 2017, J GLAUCOMA, V26, P980, DOI 10.1097/IJG.0000000000000776
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P1478, DOI 10.1097/IAE.0000000000001759
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Parlak M, 2015, INT OPHTHALMOL, V35, P473, DOI 10.1007/s10792-014-9972-2
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saha S, 2016, NEUROSCIENCE, V329, P1, DOI 10.1016/j.neuroscience.2016.04.032
   Saleh R, 2017, GRAEF ARCH CLIN EXP, V255, P817, DOI 10.1007/s00417-017-3590-4
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999
   Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Zachary I, 2005, NEUROSIGNALS, V14, P207, DOI 10.1159/000088637
   Zinkernagel MS, 2015, INVEST OPHTH VIS SCI, V56, P1894, DOI 10.1167/iovs.14-16204
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 27
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD APR
PY 2020
VL 99
IS 17
AR e19955
DI 10.1097/MD.0000000000019955
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA ME5SP
UT WOS:000544715800091
PM 32332680
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tedeschi-Blok, N
   Buckley, J
   Varma, R
   Triche, TJ
   Hinton, DR
AF Tedeschi-Blok, Nicole
   Buckley, Jonathan
   Varma, Rohit
   Triche, Timothy J.
   Hinton, David R.
TI Population-based study of early age-related macular degeneration - Role
   of the complement factor HY402H polymorphism in bilateral but not
   unilateral disease
SO OPHTHALMOLOGY
LA English
DT Article
ID FACTOR-H POLYMORPHISM; FAMILIAL AGGREGATION; Y402H VARIANT; MACULOPATHY;
   RISK; ASSOCIATION; PREVALENCE
AB Objective: Recently, a strong association has been observed for the complement factor H (CFH) Tyr402His polymorphism with early and advanced age-related macular degeneration (AMD) in independent non-Hispanic White, clinic-based, case-control studies. These studies suggest the CFH His402 allele is a major risk allele in early and advanced AMD, explaining 43% to 70% of all AMD in older adults. We utilized a population-based study design of early AMD among Latinos/Hispanics to evaluate the CFH Tyr402His polymorphism for an association with early AMD phenotypes.
   Design: Retrospective population-based case-control study.
   Participants: This study cohort consists of 285 early AMD cases and 570 controls matched on age, birthplace, and smoking status.
   Methods: Genotype determination was performed by allele-specific digestion of polymerase chain reaction products.
   Main Outcome Measures: Complement factor H Tyr402His polymorphism.
   Results: We observed no overall statistically significant association with early AMD among Latinos. However, a subset of early AMD cases that have bilateral, not unilateral, intermediate-to-large soft macular drusen were 1.7 times more likely to carry either the homozygous or heterozygous His402 genotype.
   Conclusions: Our data suggest that the CFH Tyr402His is not a major risk factor for overall early AMD in this Latino population, but may play a role in susceptibility to phenotypes of early AMD likely to progress to late AMD.
C1 Univ So Calif, Keck Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90033 USA.
   Univ So Calif, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   Univ So Calif, Keck Sch Med, Dept Opthalmol, Los Angeles, CA 90033 USA.
   Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
   Childrens Hosp Los Angeles, Dept Pathol, Los Angeles, CA 90027 USA.
C3 University of Southern California; Doheny Eye Institute; University of
   Southern California; University of Southern California; University of
   Southern California; Children's Hospital Los Angeles
RP Hinton, DR (通讯作者)，Univ So Calif, Keck Sch Med, Dept Pathol & Lab Med, 2011 Zonal Ave,HMR 209, Los Angeles, CA 90033 USA.
EM dhinton@usc.edu
FU NATIONAL EYE INSTITUTE [P30EY003040] Funding Source: NIH RePORTER; NEI
   NIH HHS [U10 EY011753, EY-03040, EY-11753, P30 EY003040] Funding Source:
   Medline
CR [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   DeJong PTVM, 1997, AM J OPHTHALMOL, V124, P862, DOI 10.1016/S0002-9394(14)71715-5
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Varma R, 2004, OPHTHALMOLOGY, V111, P1121, DOI 10.1016/j.ophtha.2004.02.001
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 27
TC 34
Z9 43
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2007
VL 114
IS 1
BP 99
EP 103
DI 10.1016/j.ophtha.2006.07.043
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 123DA
UT WOS:000243275300016
PM 17198853
DA 2022-11-30
ER

PT J
AU Lupidi, M
   Schiavon, S
   Cerquaglia, A
   Fruttini, D
   Gujar, R
   Muzi, A
   Fiore, T
   Reibaldi, M
   Chhablani, J
   Cagini, C
AF Lupidi, Marco
   Schiavon, Stefano
   Cerquaglia, Alessio
   Fruttini, Daniela
   Gujar, Ramkailash
   Muzi, Alessio
   Fiore, Tito
   Reibaldi, Michele
   Chhablani, Jay
   Cagini, Carlo
TI Real-world outcomes of anti-VEGF therapy in treatment-naive neovascular
   age-related macular degeneration diagnosed on OCT angiography: the
   REVEAL study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; anti-VEGF therapy; optical coherence
   tomography; optical coherence tomography angiography; neovascular AMD
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB;
   VERTEPORFIN; DISEASE
AB Purpose To compare the 12 months visual and anatomical outcomes of treatment-naive neovascular age-related macular degeneration (nAMD) patients diagnosed by optical coherence tomography angiography (OCT-A) compared with fluorescein angiography (FA)/indocyanine green angiography (ICGA), after anti-VEGF treatment in a real-world setting. Methods Monocentric, observational, parallel-group study of nAMD patients diagnosed with either FA/ICGA or non-invasive OCT-A methods. Patients were treated with a fixed dosing regimen of intravitreal ranibizumab or aflibercept and followed up for 12 months. Primary outcomes were the 12 months functional (BCVA) and anatomical (CST reduction) gains between the two groups. The stratification of BCVA and CST gains by type of neovascular lesion and by anti-VEGF treatment was also assessed. Results Seventy-two patients received FA/ICGA for the initial diagnosis of nAMD, while 73 received OCT-A. Overall, the mean BCVA gain at 12 months was 11.5 +/- 9.6 letters. There were no statistically significant differences between the invasive and non-invasive imaging groups in BCVA gain (p = 0.87) or CST reduction (p = 0.76). No statistically significant outcome differences between different lesion types and the two drugs were observed. Conclusion In a real-world setting, nAMD patients diagnosed with OCT-A showed meaningful improvements in visual and anatomical parameters during 12 months of treatment, without significant differences with those diagnosed by invasive modalities.
C1 [Lupidi, Marco; Schiavon, Stefano; Cerquaglia, Alessio; Gujar, Ramkailash; Muzi, Alessio; Fiore, Tito; Cagini, Carlo] Univ Perugia, S Maria Misericordia Hosp, Sect Ophthalmol, Dept Med & Surg, Perugia, Italy.
   [Lupidi, Marco] Univ Eye Clin, DiNOGMi, Fdn Macula Onlus, Genoa, Italy.
   [Lupidi, Marco] Ctr Odeon, Paris, France.
   [Fruttini, Daniela] Univ Perugia, S Maria Misericordia Hosp, Sect Internal Med, Dept Med & Surg, Perugia, Italy.
   [Reibaldi, Michele] Univ Turin, Dept Surg Sci, Eye Clin Sect, Turin, Italy.
   [Chhablani, Jay] Univ Pittsburgh, UPMC Eye Ctr, Pittsburgh, PA USA.
C3 University of Perugia; University of Perugia; University of Turin;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Chhablani, J (通讯作者)，Univ Pittsburgh, Dept Ophthalmol, Med Ctr, Pittsburgh, PA 15260 USA.
EM jay.chhablani@gmail.com
RI Cagini, Carlo/H-3431-2019; Cagini, Carlo/L-2914-2016
OI Cagini, Carlo/0000-0002-3812-9219; Cagini, Carlo/0000-0002-3812-9219
CR Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chalam K V, 2016, J Ophthalmic Vis Res, V11, P84, DOI 10.4103/2008-322X.180709
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Cohen SY, 2017, RETINA-J RET VIT DIS, V37, P1625, DOI 10.1097/IAE.0000000000001695
   Cole ED, 2016, RETINA-J RET VIT DIS, V36, pS83, DOI 10.1097/IAE.0000000000001338
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   European Medicines Agency (EMA)-Eylea, 2018, EYL SUMM PROD
   European Medicines Agency (EMA)-Lucentis, 2018, LUC SUMM PROD
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Gillies MC, 2020, OPHTHALMOLOGY, V127, P198, DOI 10.1016/j.ophtha.2019.08.023
   Giocanti-Auregan A, 2020, GRAEF ARCH CLIN EXP, V258, P537, DOI 10.1007/s00417-019-04581-y
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kaiser PK, 2017, OPHTHALMOL RETINA, V1, P304, DOI 10.1016/j.oret.2017.01.004
   Lupidi M, 2018, EUR J OPHTHALMOL, V28, P349, DOI 10.1177/1120672118766807
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mones J, 2020, OPHTHALMOLOGICA, V243, P1, DOI 10.1159/000502747
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Perrott-Reynolds R, 2019, EYE, V33, P274, DOI 10.1038/s41433-018-0229-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Talks J, 2019, SURV OPHTHALMOL, V64, P707, DOI 10.1016/j.survophthal.2019.02.008
   Tick S, 2018, J FR OPHTALMOL, V41, P862, DOI 10.1016/j.jfo.2018.06.002
NR 33
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2022
VL 100
IS 4
BP E936
EP E942
DI 10.1111/aos.15005
EA AUG 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1A9ZF
UT WOS:000685686500001
PM 34407298
DA 2022-11-30
ER

PT J
AU Wenkstern, AR
   Valmaggia, C
AF Wenkstern, Andrea R.
   Valmaggia, Christophe
TI Visual Outcomes after Anti-VEGF Therapy for Exudative Age-Related
   Macular Degeneration in a Real-Life Setting
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE anti-vascular endothelial growth factor; age-related macular
   degeneration; real-life results
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB
AB Background To report visual outcomes of anti-vascular endothelial growth factor (anti-VEGF) therapy for exudative age-related macular degeneration (AMD) in a real-life setting.
   Patients and Methods Retrospective case series of consecutive patients treated with either ranibizumab and/or aflibercept for monolateral or bilateral exudative AMD. A physician established the indication for treatment and administered the injections. An independent physician confirmed the indication for primary treatment. A Pro Re Nata and a Treat and Extend regimen were used. Assessment of subretinal and/or intraretinal fluid, retinal hemorrhage and increase in pigment epithelial detachment served as criteria for further treatment decisions. Visual acuity (VA) was measured in ETDRS letters at each examination and then analyzed using a specialized software. Evolution of mean VA was considered for all study eyes and subgroups of eyes with an initial VA >= 70 ETDRS letters (subgroup 1) and <= 69 ETDRS letters (subgroup 2).
   Results A total of 102 eyes of 76 patients (30 men, mean age 75.9 years; 46 women, mean age 81.5 years) were included. Subgroup 1 consisted of 47 eyes, and subgroup 2 of 55 eyes. Mean follow-up was 55 months (range 6 to 150 months). For the entire collective as for subgroups 1 and 2, the mean VA was 64, 77, or 51 ETDRS letters at baseline. Mean VA improved at month 12 (68, 80, or 58 ETDRES letters) and then slowly decreased over time until month 150 (62, 72, or 54 ETDRS letters). Maximum improvement of + 5, + 3, or, + 9 ETDRS letters occurred after 9, 8, or 10 months of followup. Atrophy and fibrosis were mainly responsible for VA decrease. Ten serious adverse events were reported to Swissmedic: two cases of cardiovascular events and eight cases of intraocular inflammation.
   Conclusions Anti-VEGF therapy carried out in a real-life setting shows good VA outcomes with a favorable safety profile.
C1 [Wenkstern, Andrea R.] Eye Care Ctr Uzwil, Bahnhofstr 83b, CH-9240 Uzwil, Switzerland.
   [Valmaggia, Christophe] Cantonal Hosp St Gallen, Dept Ophthalmol, St Gallen, Switzerland.
C3 Kantonsspital St. Gallen
RP Wenkstern, AR (通讯作者)，Eye Care Ctr Uzwil, Bahnhofstr 83b, CH-9240 Uzwil, Switzerland.
EM awk@augenzentrum-uzwil.ch
RI Wenkstern, Andrea/AAV-5035-2021; Wenkstern, Andrea/DWZ-6625-2022
OI Wenkstern, Andrea/0000-0003-0008-3363
CR Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Chandra S, 2021, EYE, V35, P409, DOI 10.1038/s41433-020-0851-y
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Ebneter A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76354-1
   Emerson GG., 2017, J VITREORETIN DIS, V1, P401, DOI [10.1177/2474126417735963, DOI 10.1177/2474126417735963]
   Gerding H, 2016, KLIN MONATSBL AUGENH, V233, P471, DOI 10.1055/s-0041-111835
   Greenberg JP, 2019, OPHTHALMOL RETINA, V3, P753, DOI 10.1016/j.oret.2019.04.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kung FF, 2020, OPHTHALMOL RETINA, V4, P1047, DOI 10.1016/j.oret.2020.05.005
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Melo GB, 2021, PROG RETIN EYE RES, V80, DOI 10.1016/j.preteyeres.2020.100862
   Nguyen CL, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0785-3
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
NR 17
TC 1
Z9 1
U1 0
U2 1
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD APR
PY 2021
VL 238
IS 04
BP 396
EP 402
DI 10.1055/a-1403-3224
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RV2QZ
UT WOS:000645685300019
PM 33930919
DA 2022-11-30
ER

PT J
AU Abokyi, S
   To, CH
   Lam, TT
   Tse, DY
AF Abokyi, Samuel
   To, Chi-Ho
   Lam, Tim T.
   Tse, Dennis Y.
TI Central Role of Oxidative Stress in Age-Related Macular Degeneration:
   Evidence from a Review of the Molecular Mechanisms and Animal Models
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT FACTOR-H; RETINAL-PIGMENT
   EPITHELIUM; APOLIPOPROTEIN-E GENE; LIGHT-INDUCED DAMAGE; CHOROIDAL
   NEOVASCULARIZATION; BRUCHS MEMBRANE; TRANSGENIC MICE;
   SUPEROXIDE-DISMUTASE; CIGARETTE-SMOKE
AB Age-related macular degeneration (AMD) is a common cause of visual impairment in the elderly. There are very limited therapeutic options for AMD with the predominant therapies targeting vascular endothelial growth factor (VEGF) in the retina of patients afflicted with wet AMD. Hence, it is important to remind readers, especially those interested in AMD, about current studies that may help to develop novel therapies for other stages of AMD. This study, therefore, provides a comprehensive review of studies on human specimens as well as rodent models of the disease, to identify and analyze the molecular mechanisms behind AMD development and progression. The evaluation of this information highlights the central role that oxidative damage in the retina plays in contributing to major pathways, including inflammation and angiogenesis, found in the AMD phenotype. Following on the debate of oxidative stress as the earliest injury in the AMD pathogenesis, we demonstrated how the targeting of oxidative stress-associated pathways, such as autophagy and nuclear factor erythroid 2-related factor 2 (Nrf2) signaling, might be the futuristic direction to explore in the search of an effective treatment for AMD, as the dysregulation of these mechanisms is crucial to oxidative injury in the retina. In addition, animal models of AMD have been discussed in great detail, with their strengths and pitfalls included, to assist inform in the selection of suitable models for investigating any of the molecular mechanisms.
C1 [Abokyi, Samuel; To, Chi-Ho; Lam, Tim T.; Tse, Dennis Y.] Hong Kong Polytech Univ, Sch Optometry, Hong Kong, Peoples R China.
   [Abokyi, Samuel] Univ Cape Coast, Dept Optometry, Cape Coast, Ghana.
C3 Hong Kong Polytechnic University; University of Cape Coast
RP Tse, DY (通讯作者)，Hong Kong Polytech Univ, Sch Optometry, Hong Kong, Peoples R China.
EM dennis.tse@polyu.edu.hk
RI TSE, Dennis Yan-yin/B-9949-2011
OI TSE, Dennis Yan-yin/0000-0001-7561-9121; ABOKYI,
   SAMUEL/0000-0001-8808-1340
FU Henry G Leong Endowed Professorship in Elderly Vision; PolyU Central
   Research Grant [1ZE6H]; GYBQT; Hong Kong PH.D. Fellowship
   [UGC/GEN/456/08, UGC/456/09]
FX This work was supported by grants from the Henry G Leong Endowed
   Professorship in Elderly Vision awarded to Professor Chi-Ho To, the
   PolyU Central Research Grant 1ZE6H, GYBQT, and the Hong Kong PH.D.
   Fellowship UGC/GEN/456/08, UGC/456/09.
CR Albert DM, 2010, ARCH OPHTHALMOL-CHIC, V128, P212, DOI 10.1001/archophthalmol.2009.395
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049905
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Baatout S, 1996, Rom J Intern Med, V34, P263
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Behndig A, 1998, INVEST OPHTH VIS SCI, V39, P471
   Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Bonen A, 2004, P NUTR SOC, V63, P245, DOI 10.1079/PNS2004331
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   BROWN MS, 1983, J CLIN INVEST, V72, P743, DOI 10.1172/JCI111044
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Campa C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/546826
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Cankova Z, 2011, EXP EYE RES, V93, P947, DOI 10.1016/j.exer.2011.10.016
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Cashman SM, 2011, INVEST OPHTH VIS SCI, V52, P3436, DOI 10.1167/iovs.10-6002
   Catala A, 2006, INT J BIOCHEM CELL B, V38, P1482, DOI 10.1016/j.biocel.2006.02.010
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Chou CF, 2013, AM J PREV MED, V45, P29, DOI 10.1016/j.amepre.2013.02.018
   Christen WG, 2010, OPHTHALMOLOGY, V117, P1163, DOI 10.1016/j.ophtha.2009.10.043
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   de Vries HE, 2008, FREE RADICAL BIO MED, V45, P1375, DOI 10.1016/j.freeradbiomed.2008.09.001
   Demontis GC, 2002, INVEST OPHTH VIS SCI, V43, P2421
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Ding JD, 2015, AM J PATHOL, V185, P29, DOI 10.1016/j.ajpath.2014.08.026
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Ethen CM, 2007, INVEST OPHTH VIS SCI, V48, P3469, DOI 10.1167/iovs.06-1058
   Evans JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub2
   Falk MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112473
   Fang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep21018
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Fritsche LG, 2009, HUM MUTAT, V30, P1048, DOI 10.1002/humu.20957
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Gemenetzi M, 2016, EYE, V30, P1, DOI 10.1038/eye.2015.203
   Gijbels MJJ, 1999, ATHEROSCLEROSIS, V143, P15, DOI 10.1016/S0021-9150(98)00263-9
   Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200
   Giordano S, 2014, REDOX BIOL, V2, P82, DOI 10.1016/j.redox.2013.12.013
   Glickman RD, 1999, P SOC PHOTO-OPT INS, V3863, P428, DOI 10.1117/12.364425
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Hafezi F, 2000, BRIT J OPHTHALMOL, V84, P922, DOI 10.1136/bjo.84.8.922
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   He Y, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14696
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hohn A, 2013, REDOX BIOL, V1, P140, DOI 10.1016/j.redox.2013.01.006
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Horinouchi T, 2016, BIOL PHARM BULL, V39, P909, DOI 10.1248/bpb.b16-00025
   Hosaka S, 2005, LUMINESCENCE, V20, P419, DOI 10.1002/bio.867
   Hu WZ, 2008, INVEST OPHTH VIS SCI, V49, P407, DOI 10.1167/iovs.07-0870
   Hughes AE, 2011, MOL VIS, V17, P983
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Ibrahimi A, 2002, CURR OPIN CLIN NUTR, V5, P139, DOI 10.1097/00075197-200203000-00004
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jain A, 2015, J BIOL CHEM, V290, P14945, DOI 10.1074/jbc.M115.656116
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jeffrey BG, 2001, LIPIDS, V36, P859, DOI 10.1007/s11745-001-0796-3
   Jensen SK, 2006, BRIT J NUTR, V95, P477, DOI 10.1079/BJN20051667
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kan MY, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-73
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kawa MP, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/483960
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kim GH, 2016, GRAEF ARCH CLIN EXP, V254, P705, DOI 10.1007/s00417-015-3258-x
   Kim YH, 2009, GRAEF ARCH CLIN EXP, V247, P651, DOI 10.1007/s00417-009-1049-y
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Kono N, 2013, SCIENCE, V340, P1106, DOI 10.1126/science.1233508
   Krause TA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094313
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Laing KJ, 2004, DEV COMP IMMUNOL, V28, P443, DOI 10.1016/j.dci.2003.09.006
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   LANUM J, 1978, SURV OPHTHALMOL, V22, P221, DOI 10.1016/0039-6257(78)90070-X
   LAW A, 1990, J LIPID RES, V31, P1109
   LEANDERSON P, 1990, CHEM-BIOL INTERACT, V75, P71, DOI 10.1016/0009-2797(90)90023-G
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P1416, DOI 10.1097/IAE.0b013e318184661d
   Lira SA, 2012, IMMUNOL RES, V54, P111, DOI 10.1007/s12026-012-8313-7
   Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20639
   Liu Q, 2003, GENE THER, V10, P935, DOI 10.1038/sj.gt.3302036
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P2636, DOI 10.1167/iovs.09-4397
   Loskutova E, 2013, NUTRIENTS, V5, P1962, DOI 10.3390/nu5061962
   Lowenstein PR, 2007, CURR GENE THER, V7, P347, DOI 10.2174/156652307782151498
   Lu L, 2009, BIOORGAN MED CHEM, V17, P7548, DOI 10.1016/j.bmc.2009.09.009
   Luhmann UFO, 2013, EXP EYE RES, V107, P80, DOI 10.1016/j.exer.2012.11.015
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   MALINOW MR, 1980, INVEST OPHTH VIS SCI, V19, P857
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manor D, 2007, VITAM HORM, V76, P45, DOI 10.1016/S0083-6729(07)76003-X
   Mates JM, 1999, CLIN BIOCHEM, V32, P595, DOI 10.1016/S0009-9120(99)00075-2
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Michikawa T, 2009, ASIA PAC J CLIN NUTR, V18, P1
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   MULLER DPR, 1983, LANCET, V1, P225
   Natoli R, 2017, INVEST OPHTH VIS SCI, V58, P2977, DOI 10.1167/iovs.17-21672
   Niki E, 2014, FREE RADICAL BIO MED, V66, P3, DOI 10.1016/j.freeradbiomed.2013.03.022
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nyska A, 2002, TOXICOL PATHOL, V30, P620, DOI 10.1080/01926230290166724
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Olchawa MM, 2017, FREE RADICAL RES, V51, P799, DOI 10.1080/10715762.2017.1380307
   Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   OUAHCHI K, 1995, NAT GENET, V9, P141, DOI 10.1038/ng0295-141
   PASANTESMORALES H, 1985, BRAIN RES, V330, P154, DOI 10.1016/0006-8993(85)90018-6
   PASSANITI A, 1992, LAB INVEST, V67, P519
   Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group, 1990, J OCCUP ENVIRON MED, V33, P841
   Paulus YM, 2015, OSLI RETINA, V46, P362, DOI 10.3928/23258160-20150323-11
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Qi XP, 2003, INVEST OPHTH VIS SCI, V44, P1088, DOI 10.1167/iovs.02-0864
   Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Reme, 2012, METHOD MOL BIOL, V935, P87
   Renganathan K, 2008, ADV EXP MED BIOL, V613, P261, DOI 10.1007/978-0-387-74904-4_30
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   Rogue RS, 1999, BRAIN RES, V836, P110, DOI 10.1016/S0006-8993(99)01625-X
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Rozanowska M, 2005, PHOTOCHEM PHOTOBIOL, V81, P1305, DOI 10.1562/2004-11-13-IR-371
   Rozanowska MB, 2012, PHOTOCHEM PHOTOBIOL, V88, P1303, DOI 10.1111/j.1751-1097.2012.01240.x
   Rudolf M, 2005, BRIT J OPHTHALMOL, V89, P1627, DOI 10.1136/bjo.2005.071183
   Rudolf M., OPHTHALMOLOGE, V101, P715
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Ryeom SW, 1996, J CELL SCI, V109, P387
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Sallo FB, 2009, EXP EYE RES, V89, P178, DOI 10.1016/j.exer.2009.03.006
   Sandbach JM, 2001, INVEST OPHTH VIS SCI, V42, P2173
   Schaumberg DA, 2014, JAMA OPHTHALMOL, V132, P84, DOI 10.1001/jamaophthalmol.2013.5506
   Schmack I, 2009, MOL VIS, V15, P146
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Shen DF, 2006, OPHTHALMIC RES, V38, P71, DOI 10.1159/000090266
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   STEELE F, 1990, NEURON, V4, P883, DOI 10.1016/0896-6273(90)90141-2
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Szade A, 2015, IUBMB LIFE, V67, P145, DOI 10.1002/iub.1358
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomita H, 2005, INVEST OPHTH VIS SCI, V46, P427, DOI 10.1167/iovs.04-0946
   Tong HP, 2006, CLIN BIOCHEM, V39, P267, DOI 10.1016/j.clinbiochem.2005.11.013
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Viiri LE, 2008, CIRC-CARDIOVASC GENE, V1, P107, DOI 10.1161/CIRCGENETICS.108.791764
   Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   Wang F, 2003, INVEST OPHTH VIS SCI, V44, P781, DOI 10.1167/iovs.02-0281
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Witmer AN, 2002, J HISTOCHEM CYTOCHEM, V50, P767, DOI 10.1177/002215540205000603
   Witmer AN, 2001, J PATHOL, V195, P490, DOI 10.1002/path.969
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yin LL, 2012, AM J PATHOL, V180, P541, DOI 10.1016/j.ajpath.2011.10.015
   Yokota T, 2001, P NATL ACAD SCI USA, V98, P15185, DOI 10.1073/pnas.261456098
   Zandi S, 2015, CELL REP, V10, P1173, DOI 10.1016/j.celrep.2015.01.050
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200
   Zhang Y, 2017, MOL VIS, V23, P228
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhong X, 2016, INVEST OPHTH VIS SCI, V57, P5558, DOI 10.1167/iovs.16-19965
NR 225
TC 62
Z9 63
U1 9
U2 11
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD FEB 10
PY 2020
VL 2020
AR 7901270
DI 10.1155/2020/7901270
PG 19
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA QJ7FC
UT WOS:000619851200001
PM 32104539
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Thakkinstian, A
   McEvoy, M
   Chakravarthy, U
   Chakrabarti, S
   McKay, GJ
   Ryu, E
   Silvestri, G
   Kaur, I
   Francis, P
   Iwata, T
   Akahori, M
   Arning, A
   Edwards, AO
   Seddon, JM
   Attia, J
AF Thakkinstian, Ammarin
   McEvoy, Mark
   Chakravarthy, Usha
   Chakrabarti, Subhabrata
   McKay, Gareth J.
   Ryu, Euijung
   Silvestri, Giuliana
   Kaur, Inderjeet
   Francis, Peter
   Iwata, Takeshi
   Akahori, Masakazu
   Arning, Astrid
   Edwards, Albert O.
   Seddon, Johanna M.
   Attia, John
TI The Association Between Complement Component 2/Complement Factor B
   Polymorphisms and Age-related Macular Degeneration: A HuGE Review and
   Meta-Analysis
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Review
DE complement component factor 2; complement factor B; genetic association
   studies; genetics; genome; human; macular degeneration; meta-analysis;
   molecular epidemiology
ID FACTOR-H; ASSESSING SUSCEPTIBILITY; NONCODING VARIANT; PUBLICATION BIAS;
   FUNNEL PLOTS; RISK-FACTOR; FLIP-FLOP; 3 GENES; 2 C2; C3
AB The authors performed a systematic review of the association of complement component 2(C2)/complement factor B (CFB) gene polymorphisms with age-related macular degeneration (AMD). In total, data from 19 studies published between 2006 and 2011 were pooled for 4 polymorphisms: rs9332739 and rs547154 in the C2 gene and rs4151667 and rs641153 in the CFB gene. Data extraction and assessments for risk of bias were independently performed by 2 reviewers. Allele frequencies and allele and genotypic effects were pooled. Heterogeneity and publication bias were explored. Pooled minor allele frequencies for all 4 SNPs were between 4.7 and 9.6 for all polymorphisms, except for an Indian population in which the C allele at rs9332739 was the major allele. For the C2 polymorphisms, the minor C allele at rs9332739 and the minor T allele at rs547154 carried estimated relative risks (odds ratios) of 0.55 (95 confidence interval (CI): 0.46, 0.65) and 0.47 (95 CI: 0.39, 0.57), respectively. For the CFB polymorphisms, the minor A alleles at rs4151667 and rs614153 carried estimated risks of 0.54 (95 CI: 0.45, 0.64) and 0.41 (95 CI: 0.34, 0.51), respectively. These allele effects contributed to an absolute lowering of the risk of all AMD in Caucasian populations by 2.06.0. This meta-analysis provides a robust estimate of the protective association of C2/CFB with AMD.
C1 [Thakkinstian, Ammarin] Mahidol Univ, Ramathibodi Hosp, Fac Med, Sect Clin Epidemiol & Biostat, Bangkok 10400, Thailand.
   [McEvoy, Mark; Attia, John] Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2300, Australia.
   [Chakravarthy, Usha; McKay, Gareth J.; Silvestri, Giuliana] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Chakrabarti, Subhabrata; Kaur, Inderjeet] LV Prasad Eye Inst, Brien Holden Eye Res Ctr, Hyderabad, Andhra Pradesh, India.
   [Ryu, Euijung] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA.
   [Francis, Peter] Oregon Hlth & Sci Univ, Macular Degenerat Ctr, Casey Eye Inst, Portland, OR 97201 USA.
   [Iwata, Takeshi; Akahori, Masakazu] Natl Hosp Org Tokyo Med Ctr, Div Mol & Cellular Biol, Natl Inst Sensory Organs, Tokyo, Japan.
   [Arning, Astrid] Leibniz Inst Arteriosclerosis Res, Munster, Germany.
   [Edwards, Albert O.] Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Ophthalm Epidemiol & Genet Serv, Dept Ophthalmol, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Med Ctr, Boston, MA USA.
   [Attia, John] John Hunter Hosp, Newcastle, NSW, Australia.
   [Attia, John] Hunter Med Res Inst, Newcastle, NSW, Australia.
C3 Mahidol University; University of Newcastle; Queens University Belfast;
   L. V. Prasad Eye Institute; Mayo Clinic; Oregon Health & Science
   University; University of Oregon; Tufts University; Tufts Medical
   Center; John Hunter Hospital; Hunter Medical Research Institute;
   University of Newcastle
RP Thakkinstian, A (通讯作者)，Mahidol Univ, Ramathibodi Hosp, Fac Med, Sect Clin Epidemiol & Biostat, Bangkok 10400, Thailand.
EM ammarin.tha@mahidol.ac.th
RI Chakrabarti, Subhabrata/F-2468-2015; Thakkinstian, Ammarin/J-4788-2019;
   McKay, Gareth/AAZ-2601-2020; Kaur, Inderjeet/ABD-1833-2021; Attia, John
   R/F-5376-2013
OI Chakrabarti, Subhabrata/0000-0003-3717-4963; McKay,
   Gareth/0000-0001-8197-6280; Attia, John R/0000-0001-9800-1308;
   Chakravarthy, Usha/0000-0002-2606-3734; Silvestri,
   Giuliana/0000-0001-5662-5374; McEvoy, Mark/0000-0002-5505-5557
FU NEI NIH HHS [R01 EY011309] Funding Source: Medline
CR Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Clarke GM, 2010, GENET EPIDEMIOL, V34, P266, DOI 10.1002/gepi.20458
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Cui L, 2010, INVEST OPHTH VIS SCI, V51, P1116, DOI 10.1167/iovs.09-4265
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Hayden KM, 2005, J AM GERIATR SOC, V53, P935, DOI 10.1111/j.1532-5415.2005.53301.x
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Ioannidis JPA, 2004, NAT GENET, V36, P1312, DOI 10.1038/ng1474
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Lin PI, 2007, AM J HUM GENET, V80, P531, DOI 10.1086/512133
   Little J, 2006, HUGENET HUGE REV HDB
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Minelli C, 2005, INT J EPIDEMIOL, V34, P1319, DOI 10.1093/ije/dyi169
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Palmer TM, 2008, STATA J, V8, P242, DOI 10.1177/1536867X0800800206
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Peters JL, 2008, J CLIN EPIDEMIOL, V61, P991, DOI 10.1016/j.jclinepi.2007.11.010
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rossman MD, 2003, AM J HUM GENET, V73, P720, DOI 10.1086/378097
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Spiegelhalter D., 2007, WINBUGS USER MANUAL
   StataCorp, 2009, STAT STAT SOFTW REL
   Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Thakkinstian A, 2009, J APPL STAT, V36, P633, DOI 10.1080/02664760802484990
   Thompson JR, 2005, STAT MED, V24, P2241, DOI 10.1002/sim.2100
   Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V
   Thompson SG, 1997, STAT MED, V16, P2741, DOI 10.1002/(SICI)1097-0258(19971215)16:23<2741::AID-SIM703>3.0.CO;2-0
   THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zaykin DV, 2008, AM J HUM GENET, V82, P794, DOI 10.1016/j.ajhg.2008.02.001
NR 65
TC 48
Z9 50
U1 0
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD SEP 1
PY 2012
VL 176
IS 5
BP 361
EP 372
DI 10.1093/aje/kws031
PG 12
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 998GX
UT WOS:000308226600001
PM 22869612
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Liu, QY
   Pan, YC
   Shu, HY
   Zhang, LJ
   Li, QY
   Ge, QM
   Shao, Y
   Zhou, Q
AF Liu, Qi-Ying
   Pan, Yi-Cong
   Shu, Hui-Ye
   Zhang, Li-Juan
   Li, Qiu-Yu
   Ge, Qian-Min
   Shao, Yi
   Zhou, Qiong
TI Brain Activity in Age-Related Macular Degeneration Patients From the
   Perspective of Regional Homogeneity: A Resting-State Functional Magnetic
   Resonance Imaging Study
SO FRONTIERS IN AGING NEUROSCIENCE
LA English
DT Article
DE neural regional homogeneity; resting state; functional magnetic
   resonance imaging; age-related macular degeneration (AMD); pathogenesis
ID OPEN-GLOBE INJURY; COMITANT STRABISMUS; ACTIVITY PATTERN; VISUAL
   PATHWAY; CORTEX; MEMORY; CONNECTIVITY; STIMULATION; PREVALENCE;
   AMPLITUDE
AB ObjectiveIn this study, the regional homogeneity (ReHo) method was used to investigate levels of cerebral homogeneity in individuals with age-related macular degeneration (AMD), with the aim of exploring whether these measures are associated with clinical characteristics. Materials and MethodsPatients with AMD and healthy controls attending the First Affiliated Hospital of Nanchang University were invited to participate. Resting state functional magnetic resonance images were recorded in each participant and levels of synchronous neural activity were evaluated using ReHo. Receiver operating characteristic (ROC) curves were used to evaluate the sensitivity and specificity of this method. ResultsEighteen patients with AMD (9 males and 9 females) and 15 healthy controls (HCs) were recruited. The two groups were approximately matched in age, gender and weight. Compared with controls, the ReHo values were significantly higher in the AMD group at the limbic lobe and parahippocampal gyrus, and were significantly reduced at the cingulate gyrus, superior frontal gyrus, middle frontal gyrus, inferior parietal lobule, and precentral gyrus. Mean ReHo values at the cingulate gyrus and the superior frontal gyrus were negatively correlated with clinical symptoms. ConclusionBrain neural homogeneity dysfunction is a manifestation of visual pathways in AMD patients, and may be one of the pathological mechanisms of chronic vision loss, anxiety and depression in AMD patients. In addition, the ReHo data may be useful for early screening for AMD.
C1 [Liu, Qi-Ying; Pan, Yi-Cong; Shu, Hui-Ye; Zhang, Li-Juan; Li, Qiu-Yu; Ge, Qian-Min; Shao, Yi; Zhou, Qiong] Nanchang Univ, Jiangxi Ctr Natl Ocular Dis Clin Res Ctr, Dept Ophthalmol, Affiliated Hosp 1, Nanchang, Peoples R China.
C3 Nanchang University
RP Shao, Y; Zhou, Q (通讯作者)，Nanchang Univ, Jiangxi Ctr Natl Ocular Dis Clin Res Ctr, Dept Ophthalmol, Affiliated Hosp 1, Nanchang, Peoples R China.
EM freebee99@163.com; qiongzD06@126.com
FU Central Government Guides Local Science and Technology Development
   Foundation [20211ZDG02003]; Key Research Foundation of Jiangxi Province
   [20181BBG70004, 20203BBG73059]; Excellent Talents Development Project of
   Jiangxi Province [20192BCBL23020]; Natural Science Foundation of Jiangxi
   Province [20181BAB205034]; Grassroots Health Appropriate Technology
   Spark Promotion Plan Project of Jiangxi Province [20188003]; Health
   Development Planning Commission Science Foundation of Jiangxi Province
   [20201032, 202130210]; Health Development Planning Commission Science
   TCM Foundation of Jiangxi Province [2018A060, 2020A0087]; Education
   Department Foundation of Jiangxi Province [GJJ200157, GJJ200159,
   GJJ200169]
FX Funding This work was supported by the Central Government Guides Local
   Science and Technology Development Foundation (No. 20211ZDG02003), the
   Key Research Foundation of Jiangxi Province (Nos. 20181BBG70004 and
   20203BBG73059), the Excellent Talents Development Project of Jiangxi
   Province (No. 20192BCBL23020), the Natural Science Foundation of Jiangxi
   Province (No. 20181BAB205034), the Grassroots Health Appropriate
   Technology "Spark Promotion Plan" Project of Jiangxi Province (No.
   20188003), the Health Development Planning Commission Science Foundation
   of Jiangxi Province (Nos. 20201032 and 202130210), the Health
   Development Planning Commission Science TCM Foundation of Jiangxi
   Province (Nos. 2018A060 and 2020A0087), and the Education Department
   Foundation of Jiangxi Province (Nos. GJJ200157, GJJ200159, and
   GJJ200169).
CR Aminoff EM, 2013, TRENDS COGN SCI, V17, P379, DOI 10.1016/j.tics.2013.06.009
   Amunts K, 2005, ANAT EMBRYOL, V210, P343, DOI 10.1007/s00429-005-0025-5
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Burger C, 2017, NEUROPSYCHOPHARMACOL, V42, P1399, DOI 10.1038/npp.2017.36
   Dai XJ, 2012, SLEEP MED, V13, P720, DOI 10.1016/j.sleep.2011.09.019
   Fischer M, 2021, WIRES COGN SCI, V12, DOI 10.1002/wcs.1546
   Giesbrecht B, 2013, VISION RES, V85, P80, DOI 10.1016/j.visres.2012.10.006
   Huang X, 2017, NEUROPSYCH DIS TREAT, V13, P2849, DOI 10.2147/NDT.S147645
   Huang X, 2017, NEUROREPORT, V28, P1085, DOI 10.1097/WNR.0000000000000855
   Huang X, 2016, NEUROPSYCH DIS TREAT, V12, P1901, DOI 10.2147/NDT.S110541
   Huang X, 2016, NEUROPSYCH DIS TREAT, V12, P1303, DOI 10.2147/NDT.S105478
   Krishnan V, 2020, CURR NEUROL NEUROSCI, V20, DOI 10.1007/s11910-020-01065-z
   Li C, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00317
   Li HJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164031
   Li MG, 2020, NEURORADIOLOGY, V62, P327, DOI 10.1007/s00234-019-02333-7
   Li R, 2015, SCI REP-UK, V5, DOI 10.1038/srep11635
   Liao XL, 2019, ENDOCR PRACT, V25, P320, DOI 10.4158/EP-2018-0517
   Mankin EA, 2020, NEURON, V106, P218, DOI 10.1016/j.neuron.2020.02.024
   Nebel MB, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00080
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Rusbridge C, 2020, VET CLIN N AM-SMALL, V50, P1157, DOI 10.1016/j.cvsm.2020.06.009
   Shang CY, 2018, PSYCHOL MED, V48, P2530, DOI 10.1017/S0033291718000144
   Shao Y, 2019, MOL MED REP, V19, P4832, DOI 10.3892/mmr.2019.10147
   Shao Y, 2015, NEUROPSYCH DIS TREAT, V11, P3065, DOI 10.2147/NDT.S92968
   Song YW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089493
   Spencer KM, 2004, P NATL ACAD SCI USA, V101, P17288, DOI 10.1073/pnas.0406074101
   Suthana N, 2012, NEW ENGL J MED, V366, P502, DOI 10.1056/NEJMoa1107212
   Tan G, 2016, NEUROPSYCH DIS TREAT, V12, P2015, DOI 10.2147/NDT.S110539
   Tan G, 2016, NEUROPSYCH DIS TREAT, V12, P1243, DOI 10.2147/NDT.S104756
   Tang LY, 2018, J PAIN RES, V11, P843, DOI 10.2147/JPR.S156634
   Tononi G, 1998, NEUROIMAGE, V7, P133, DOI 10.1006/nimg.1997.0313
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Ward LM, 2003, TRENDS COGN SCI, V7, P553, DOI 10.1016/j.tics.2003.10.012
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xiang CQ, 2019, PAIN PRACT, V19, P397, DOI 10.1111/papr.12753
   Xu MW, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00743
   Ye L, 2018, INT J OPHTHALMOL-CHI, V11, P1056, DOI 10.18240/ijo.2018.06.26
   Zang YF, 2004, NEUROIMAGE, V22, P394, DOI 10.1016/j.neuroimage.2003.12.030
   Zhang B, 2020, INT J OPHTHALMOL-CHI, V13, P263, DOI 10.18240/ijo.2020.02.10
   Zhu PW, 2018, INT J OPHTHALMOL-CHI, V11, P668, DOI 10.18240/ijo.2018.04.22
NR 40
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-4365
J9 FRONT AGING NEUROSCI
JI Front. Aging Neurosci.
PD MAY 9
PY 2022
VL 14
AR 865430
DI 10.3389/fnagi.2022.865430
PG 9
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 1P8KR
UT WOS:000802253200001
PM 35615597
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ross, RJ
   Zhou, M
   Shen, D
   Fariss, RN
   Ding, XY
   Bojanowski, CM
   Tuo, J
   Chan, CC
AF Ross, Robert J.
   Zhou, Min
   Shen, Defen
   Fariss, Robert N.
   Ding, Xiaoyan
   Bojanowski, Christine M.
   Tuo, Jingsheng
   Chan, Chi-Chao
TI Immunological protein expression profile in Ccl2/Cx3cr1 deficient mice
   with lesions similar to age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; animal model; chemokine; cytokine;
   complement factor; toll-like receptor 4; microglia; macrophage
ID COMPLEMENT FACTOR-H; ENDOTOXIN-INDUCED UVEITIS; TOLL-LIKE RECEPTOR-4;
   VISUAL IMPAIRMENT; EPITHELIAL-CELLS; BRUCHS MEMBRANE; UNITED-STATES;
   VARIANT; SUSCEPTIBILITY; POLYMORPHISM
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the United States. Cel2 knock-out (KO) mice sporadically develop the cardinal features of AMD in their senescent stage. Humans bearing a loss of function variant or single nucleotide polymorphism (SNP) in CX3CR1 are at increased risk of developing AMD. We recently developed Ccl2(-/-)/Cx3cr(-/-) mice, which consistently develop retinal degeneration with many AMD features. Since there is strong evidence for an immunological role in AMD pathogenesis, we examined ocular immune protein expression levels in Ccl2(-/-)/Cx3cr1(-/-), Ccl2(-/-), Cx3crl(-/-), and age-matched wild-type (WT) mice. Immunohistochemistry revealed increased complement C3d in Bruch's membrane, retinal pigment epithelium (RPE), choroidal capillaries, and particularly drusen of the Ccl2(-/-) Cx3cr1(-/-) mice relative to the WT controls. No change was detected in single KO mice. Real-time RT-PCR revealed a 2.5-fold increase in C3 expression in the Ccl2(-/-)/Cx3cl(-/-). While the retinas of four month old WT and Ccl2(-/-) showed minimal immunoreactivity for markers of macrophages and microglia, infiltrates of these mononuclear phagocytic cells were detected in the Ccl2(-/-)/Cx3cr(-/-) retinal lesions and a few foci in the Cx3c1(-/-) retina. The Ccl2(-/-)/Cx3cr1(-/-) had reduced toll-like receptor 4 (TLR4) expression in the RPE. Following LPS injection, the Ccl2(-/-)/Cx3cr1(-/-) had significantly reduced endotoxin-induced uveitis scores and showed a diminished increase in Tlr4 mRNA expression. No changes in TLR4 expression were detected in either single KO. Autoantibodies against the retina and photoreceptors were also detected in the Ccl2(-/-) /Cx3cr1(-/-) serum. Real-time RT-PCR revealed significant increases in Ccl5 transcript in the Ccl2(-/-)/Cx3cr1(-/-) relative to the WT. These results suggest that innate immunity and possibly adaptive immunity play an important role in Ccl2(-/-)/Cx3cr1(-/-) retinal degeneration. Moreover, since human AMD patients show similar immunopathological profiles, these results support the Ccl2(-/-)/Cx3Cr1(-/-) as a suitable model for human AMD. Published by Elsevier Ltd.
C1 [Ross, Robert J.; Zhou, Min; Shen, Defen; Ding, Xiaoyan; Bojanowski, Christine M.; Tuo, Jingsheng; Chan, Chi-Chao] NEI, NIH, Immunol Lab, Immunopathol Sect, Bethesda, MD 20892 USA.
   [Fariss, Robert N.] NICHHD, NIH, NEI, Bethesda, MD 20892 USA.
   [Ding, Xiaoyan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD);
   NIH National Eye Institute (NEI); Sun Yat Sen University
RP Chan, CC (通讯作者)，NEI, NIH, Immunol Lab, Immunopathol Sect, 10 Ctr Dr Bldg 10,Room 10N103, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
RI Fariss, Robert/ABI-1771-2020
OI Tuo, Jingsheng/0000-0002-1372-7810; Fariss, Robert/0000-0003-3227-7170
FU Intramural NIH HHS [Z01 EY000222-22, Z01 EY000418-04] Funding Source:
   Medline; NATIONAL EYE INSTITUTE [Z01EY000459, Z01EY000222, ZICEY000461,
   ZIAEY000418] Funding Source: NIH RePORTER
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048
   Augustin Albert J, 2006, Expert Opin Emerg Drugs, V11, P725, DOI 10.1517/14728214.11.4.725
   BAUDOUIN C, 1992, JPN J OPHTHALMOL, V36, P443
   Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715
   CHAN CC, 1985, OPHTHALMOLOGY, V92, P1025
   Combadiere C, 2003, CIRCULATION, V107, P1009, DOI 10.1161/01.CIR.0000057548.68243.42
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Edfeldt K, 2002, CIRCULATION, V105, P1158, DOI 10.1161/circ.105.10.1158
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fan HK, 2006, BBA-MOL CELL RES, V1763, P1051, DOI 10.1016/j.bbamcr.2006.08.003
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kindzelskii AL, 2004, J GEN PHYSIOL, V124, P139, DOI 10.1085/jgp.200409062
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   LI Q, 1995, EXP EYE RES, V61, P629, DOI 10.1016/S0014-4835(05)80056-9
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Negi VS, 2000, J RHEUMATOL, V27, P380
   Nielsen CH, 2002, J LEUKOCYTE BIOL, V72, P249
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Riedemann NC, 2002, J IMMUNOL, V168, P1919, DOI 10.4049/jimmunol.168.4.1919
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Shen DF, 2000, OCUL IMMUNOL INFLAMM, V8, P221, DOI 10.1076/ocii.8.4.221.6461
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Soames CJ, 1997, BIOCHEM J, V326, P553, DOI 10.1042/bj3260553
   Tuaillon N, 2002, INVEST OPHTH VIS SCI, V43, P1493
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Vogt SD, 2006, EXP EYE RES, V83, P834, DOI 10.1016/j.exer.2006.04.002
   Wang LS, 2004, J VIROL, V78, P1616, DOI 10.1128/JVI.78.4.1616-1622.2004
   Xu XH, 2001, CIRCULATION, V104, P3103, DOI 10.1161/hc5001.100631
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 46
TC 56
Z9 62
U1 0
U2 11
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD APR
PY 2008
VL 86
IS 4
BP 675
EP 683
DI 10.1016/j.exer.2008.01.014
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 295DB
UT WOS:000255454100015
PM 18308304
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Alis, A
   Alis, MG
AF Alis, Abdulkadir
   Alis, Meryem Guler
TI Long-term effect of intravitreal aflibercept treatment on choroidal
   vascularity index in neovascular age-related macular degeneration
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Age-related macular degeneration; Anti-VEGF treatment, Binarization;
   Choroidal vascularity index; Optical Coherence Tomography
ID ENDOTHELIAL GROWTH-FACTOR; PHOTODYNAMIC THERAPY; LASER PHOTOCOAGULATION;
   THICKNESS CHANGES; BLOOD-FLOW; RANIBIZUMAB; SUBFOVEAL; EYES; INJECTION;
   BINARIZATION
AB Background: Our aim is to examine the effect of intravitreal aflibercept treatment on the choroidal vascularity index in eyes with neovascular age-related macular degeneration (nARMD) using the binarization method.
   Methods: Included in the study were the 38 eyes of 38 patients diagnosed with nARMD and treated with intravitreal aflibercept at our clinic. The patients' 12-month records were reviewed retrospectively. Patients' choroidal thickness (CT) was measured at baseline, 3rd month, 6th month, and 12th month on EDI-OCT images. We calculated luminal area (LA), stromal area (SA), total choroidal area (TCA), and choroid vascular index (CVI) values using binarization.
   Results: The mean age of the patients was 70,1 +/- 8 years. The mean of injections over 12 months was 5.6 +/- 2. Baseline values were CT 224 mu m, LA 0,214 mm(2), SA 0,119mm(2), TCA 0,333 mm(2), and CVI 64% respectively. At the 3rd month, values were CT 223 mu m, LA 0,212 mm(2), SA 0,121 mm(2), TCA 0,332 mm(2), and CVI 64%, respectively. The 6th-month values were CT 221 mu m, LA 0,204 mm(2), SA 0,116 mm(2), TCA 0,320 mm(2), and CVI 64%, respectively, and 12-month values were CT 218 mu m, LA 0,204 mm(2), SA 0,112 mm(2), TCA 0,318 mm(2), and CVI 64%, respectively. According to LogMAR, BCVA was 0.59 at baseline, 0.56 at 3 months, 0.52 at 6 months, and 0.51 at 12 months. At the end of month 12, we observed a statistically significant decrease in CT. No significant changes were observed in other parameters. When the number of injections was correlated with CVI, CT, and BCVA, a significant negative correlation was observed with CVI
   Conclusions: Aflibercept treatment reduces CT by affecting not only luminal but also stromal areas of the choroid in the long term but does not change the CVI. However, as the number of injections increases, CVI decreases.
C1 [Alis, Abdulkadir; Alis, Meryem Guler] Fatih Sultan Mehmet Training & Res Hosp, Istanbul, Turkey.
C3 Fatih Sultan Mehmet Training & Research Hospital
RP Alis, A (通讯作者)，Fatih Sultan Mehmet Training & Res Hosp, Istanbul, Turkey.
EM gozdrkadir@gmail.com
RI guler alis, meryem/AAD-2701-2022
CR Agrawal R, 2017, ACTA OPHTHALMOL, V95, pe770, DOI 10.1111/aos.13442
   Ayoub T, 2009, J ROY SOC MED, V102, P56, DOI 10.1258/jrsm.2009.080298
   Bakthavatsalam M, 2017, GRAEF ARCH CLIN EXP, V255, P935, DOI 10.1007/s00417-017-3591-3
   Chen HS, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0749-7
   Demirel S, 2020, GRAEF ARCH CLIN EXP, V258, P1649, DOI 10.1007/s00417-020-04740-6
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gharbiya M, 2018, CURR EYE RES, V43, P391, DOI 10.1080/02713683.2017.1405045
   Gharbiya M, 2015, J OCUL PHARMACOL TH, V31, P357, DOI 10.1089/jop.2014.0160
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Itagaki K, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01542-6
   Kallitsis A, 2007, IN VIVO, V21, P1049
   Kaya F, 2017, J FR OPHTALMOL, V40, P832, DOI 10.1016/j.jfo.2017.04.014
   Koh LHL, 2017, ACTA OPHTHALMOL, V95, pE597, DOI 10.1111/aos.13399
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Kourlas H, 2007, CLIN THER, V29, P1850, DOI 10.1016/j.clinthera.2007.09.008
   Kurzinger GR, 2010, KLIN MONATSBL AUGENH, V227, P501, DOI 10.1055/s-0028-1110015
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Majji AB, 2000, INVEST OPHTH VIS SCI, V41, P3936
   Minnella AM, 2016, BIODRUGS, V30, P353, DOI 10.1007/s40259-016-0179-0
   Mottet B, 2018, ACTA OPHTHALMOL, V96, pE783, DOI 10.1111/aos.13763
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nishi T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164672
   ODwyer A., 2015, GOZ TEMEL HASTALIKLA, V3th, P677
   Okamoto M, 2018, GRAEF ARCH CLIN EXP, V256, P885, DOI 10.1007/s00417-018-3939-3
   Pellegrini M, 2021, GRAEF ARCH CLIN EXP, V259, P911, DOI 10.1007/s00417-020-04957-5
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Sobaci G, 2006, EUR J OPHTHALMOL, V16, P119, DOI 10.5301/EJO.2008.1371
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Takahashi Y, 2018, JPN J OPHTHALMOL, V62, P576, DOI 10.1007/s10384-018-0615-4
   Ting DSW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08276-4
   Wei X, 2017, RETINA-J RET VIT DIS, V37, P1120, DOI 10.1097/IAE.0000000000001312
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P1693, DOI 10.1007/s00417-015-3260-3
NR 35
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD DEC
PY 2021
VL 36
AR 102582
DI 10.1016/j.pdpdt.2021.102582
EA OCT 2021
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA WL6EE
UT WOS:000710495700008
PM 34648995
DA 2022-11-30
ER

PT J
AU Ishibashi, T
AF Ishibashi, Tatsuro
CA LEVEL-J Study Grp
TI Maintenance therapy with pegaptanib sodium for neovascular age-related
   macular degeneration: an exploratory study in Japanese patients (LEVEL-J
   study)
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Neovascular age-related macular degeneration; Maintenance therapy;
   Pegaptanib sodium; Japanese patients; Exploratory study
ID VISUAL IMPAIRMENT; CASE SERIES; PREVALENCE; RANIBIZUMAB; SAFETY;
   BEVACIZUMAB; MACULOPATHY; POPULATION; ROTTERDAM; BLINDNESS
AB To explore the efficacy and safety of pegaptanib sodium as maintenance therapy in Japanese patients with neovascular, age-related macular degeneration (AMD) after induction therapy (LEVEL-J study).
   A multi-center, prospective study was conducted at 21 medical institutions between 2009 and 2011. Of Japanese neovascular AMD patients with choroidal neovascularization who showed improvement in visual acuity (VA) with induction therapy, those who were scheduled for intravitreal injections of pegaptanib as maintenance therapy were recruited. LogMAR VA was assessed. Booster treatment (unscheduled treatment with other agents) was allowed during the study period if symptoms were judged to have worsened. Safety was assessed by monitoring adverse events and intraocular pressure (IOP).
   Of 75 patients included in the analysis, 80 % completed the 54-week study period. Their mean age was 74.7 +/- A 6.9 years, and 54 patients (72.0 %) were men. The mean number of pegaptanib injections was 5.7 +/- A 2.6. Booster treatment was not required in 40 eyes (53.3 %). Mean logMAR VA was 0.61 +/- A 0.31 before induction therapy, 0.26 +/- A 0.24 before maintenance therapy, and 0.29 +/- A 0.28 at 54 weeks. No notable change in VA was observed during maintenance therapy. Adverse events were reported in 4 patients (5.3 %), including increased intraocular pressure, cancer, gallstones and recurrence of breast cancer, but mean IOP remained stable during maintenance therapy.
   The results of this exploratory study suggest that maintenance therapy with pegaptanib is potentially an effective and well-tolerated option in Japanese patients with neovascular AMD in whom induction therapy has been successful.
C1 [Ishibashi, Tatsuro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, Fukuoka 8128582, Japan.
C3 Kyushu University
RP Ishibashi, T (通讯作者)，Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM ishi@eye.med.kyushu-u.ac.jp
FU HEART (Ishikawa, Japan)
FX The LEVEL-J Study Group was organized and sponsored by the nonprofit
   organization HEART (Ishikawa, Japan). The Office of the Study Group,
   managed by Clinical Study Support, Inc. (Aichi, Japan), was responsible
   for site initiation, study management, data collection, and analysis.
   Professional medical English editing was done by K. K. FORTE (FORTE,
   Inc.).
CR Albrecht J, 2005, J CLIN EPIDEMIOL, V58, P1227, DOI 10.1016/j.jclinepi.2005.04.003
   Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Farah SE, 2008, OPHTHAL SURG LAS IM, V39, P294, DOI 10.3928/15428877-20080701-05
   Friberg TR, 2010, BRIT J OPHTHALMOL, V94, P1611, DOI 10.1136/bjo.2009.174946
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hughes MS, 2006, OPHTHAL SURG LAS IM, V37, P446, DOI 10.3928/15428877-20061101-01
   Ishibashi Tatsuro, 2011, Nippon Ganka Gakkai Zasshi, V115, P122
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Kooistra B, 2009, J BONE JOINT SURG AM, V91A, P21, DOI 10.2106/JBJS.H.01573
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Marcus DM, 2008, INVEST OPHTHALMOL VI, V49
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pfizer PRO, INT REP MAC PMS
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Tano Yasuo, 2008, Nippon Ganka Gakkai Zasshi, V112, P590
   Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
NR 27
TC 5
Z9 6
U1 0
U2 4
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD SEP
PY 2013
VL 57
IS 5
BP 417
EP 423
DI 10.1007/s10384-013-0255-7
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 214IV
UT WOS:000324126900001
PM 23860781
DA 2022-11-30
ER

PT J
AU Haensli, C
   Pfister, IB
   Garweg, JG
AF Haensli, Christof
   Pfister, Isabel B.
   Garweg, Justus G.
TI Switching to Brolucizumab in Neovascular Age-Related Macular
   Degeneration Incompletely Responsive to Ranibizumab or Aflibercept:
   Real-Life 6 Month Outcomes
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE brolucizumab; ranibizumab; aflibercept; anti-VEGF; neovascular
   age-related macular degeneration; visual acuity; reading acuity; disease
   activity; treatment change; treat and extend
ID CONTRAST SENSITIVITY; READING SPEED; INJECTION; SAFETY; VEGF
AB Purpose: The aim of this study was to evaluate the effect of switching treatment in eyes with neovascular age-related macular degeneration (nAMD) and treatment intervals of <= 6 weeks to brolucizumab. Methods: In this prospective series, eyes with persisting retinal fluid under aflibercept or ranibizumab every 4-6 weeks were switched to brolucizumab. Visual acuity (BCVA), reading acuity (RA), treatment intervals, central subfield thickness (CST), and the presence of intra- and subretinal fluid were recorded over 6 months. Results: Seven of 12 eyes completed the 6 month follow-up and received 4.4 +/- 0.5 brolucizumab injections within 28.0 +/- 2.8 weeks. Treatment intervals increased from 5.3 +/- 0.9 weeks to 9.0 +/- 2.8 weeks (95% confidence interval of extension (CI): 1.6 to 5.9). BCVA improved from 67.8 +/- 7.2 to 72.2 +/- 7.5 (95% CI: -0.3 to 9.1) ETDRS letters, RA improved from 0.48 +/- 0.15 to 0.31 +/- 0.17 LogRAD (95% CI: 0.03 to 0.25), and CST improved from 422.1 +/- 97.3 to 353.6 +/- 100.9 mu m (95% CI: -19.9 to 157.1). Treatment was terminated early in five eyes (two intraocular inflammations with vascular occlusion without vision loss, one stroke, and two changes in the treatment plan). Conclusions: Improvement in visual performance and longer treatment intervals in our series over 6 months indicate the potential of brolucizumab to reduce the treatment burden in nAMD, while two instances of intraocular inflammation were encountered.
C1 [Haensli, Christof; Pfister, Isabel B.; Garweg, Justus G.] Berner Augenklin Lindenhofspital, CH-3012 Bern, Switzerland.
   [Garweg, Justus G.] Univ Bern, Dept Ophthalmol, Inselspital, CH-3012 Bern, Switzerland.
C3 University of Bern
RP Haensli, C (通讯作者)，Berner Augenklin Lindenhofspital, CH-3012 Bern, Switzerland.
EM christof.haensli@augenklinik-bern.ch;
   isabel.pfister@augenklinik-bern.ch; justus.garweg@augenklinik-bern.ch
OI Hansli, Christof/0000-0002-2615-197X; Garweg, Justus
   G./0000-0003-3973-5082
CR Altinbay D, 2021, CURR EYE RES, V46, P1581, DOI 10.1080/02713683.2021.1896740
   [Anonymous], NOVARTIS REPORTS 1 Y
   Aslam T, 2014, GRAEF ARCH CLIN EXP, V252, P201, DOI 10.1007/s00417-013-2421-5
   Avaylon J, 2020, INT MED CASE REP J, V13, P145, DOI 10.2147/IMCRJ.S252260
   Azuma K, 2018, CLIN OPHTHALMOL, V12, P1589, DOI 10.2147/OPTH.S172115
   Baumal C.R., 2020, OPHTHALMOL RETIN, DOI [10.1016/j.ophtha.2020.04.017, DOI 10.1016/J.OPHTHA.2020.04.017]
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Bulirsch LM, 2022, BRIT J OPHTHALMOL, V106, P1288, DOI 10.1136/bjophthalmol-2020-318672
   Curry B, 2017, ASIA-PAC J OPHTHALMO, V6, P481, DOI 10.22608/APO.2017364
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Garweg JG, 2021, GRAEF ARCH CLIN EXP, V259, P2181, DOI 10.1007/s00417-020-05048-1
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Haug Sara J, 2020, Am J Ophthalmol Case Rep, V18, P100680, DOI 10.1016/j.ajoc.2020.100680
   Holz FG, 2021, OPHTHALMOLOGE, V118, P248, DOI 10.1007/s00347-021-01321-8
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kaya C, 2019, CLIN OPHTHALMOL, V13, P2403, DOI 10.2147/OPTH.S224456
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   Kitchens JW, 2016, OPHTHALMOLOGY, V123, P1511, DOI 10.1016/j.ophtha.2016.02.046
   Koike N, 2019, CLIN OPHTHALMOL, V13, P1247, DOI 10.2147/OPTH.S206910
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Mieno H, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01364-6
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Nixon DR, 2017, CLIN OPHTHALMOL, V11, P715, DOI 10.2147/OPTH.S131343
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Puell MC, 2021, EUR J OPHTHALMOL, V31, P3149, DOI 10.1177/1120672121990624
   Rossouw P, 2020, OPHTHAL PHYSL OPT, V40, P760, DOI 10.1111/opo.12736
   Sabour-Pickett S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/268438
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   Sharma A, 2021, EYE, V35, P1045, DOI 10.1038/s41433-020-1111-x
   Varadaraj V, 2018, AM J OPHTHALMOL, V186, P138, DOI 10.1016/j.ajo.2017.11.026
   Witkin Andre J, 2020, J Vitreoretin Dis, V4, P269, DOI 10.1177/2474126420930863
NR 32
TC 12
Z9 12
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUN
PY 2021
VL 10
IS 12
AR 2666
DI 10.3390/jcm10122666
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA SZ3PF
UT WOS:000666480700001
PM 34204266
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sakurada, Y
   Kikushima, W
   Sugiyama, A
   Yoneyama, S
   Tanabe, N
   Matsubara, M
   Iijima, H
AF Sakurada, Yoichi
   Kikushima, Wataru
   Sugiyama, Atsushi
   Yoneyama, Seigo
   Tanabe, Naohiko
   Matsubara, Mio
   Iijima, Hiroyuki
TI AREDS simplified severity scale as a predictive factor for response to
   aflibercept therapy for typical neovascular age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Fellow-eye severity; Aflibercept;
   Retreatment-free period; Visual improvement; ARMS2 A69S
ID PACHYCHOROID NEOVASCULOPATHY; RISK-FACTORS; RANIBIZUMAB; EYE; ARMS2
AB To investigate whether the severity of the condition in the untreated fellow eye is a predictive factor for the response to intravitreal aflibercept injection (IAI) for exudative age-related macular degeneration (AMD).
   A retrospective medical chart review was conducted for 88 patients with treatment-na < ve neovascular AMD, who were initially treated with three monthly IAIs, followed by monthly monitoring and re-injection as needed for at least 12 months. Subjects were classified into three groups according to the severity of the condition in their untreated eye, based on the severity scale in the Age-Related Eye Disease Study (AREDS): group 0, AREDS severity level 1 (no drusen); group 1, AREDS severity level 2 or 3 (any drusen); group 2, AREDS severity level 4 (advanced AMD). Genotyping was performed in all cases for ARMS2 A69S and CFH I62V.
   Fellow-eye severity was associated with age and the risk variant of ARMS2 A69S (P = 0.005 and 0.001, respectively). Although best-corrected visual acuity (BCVA) had improved significantly after 12 months in all groups, this improvement was significantly greater in group 0 than in the other groups (P = 0.008). The retreatment-free period was also significantly longer for group 0 than for the other groups (P = 0.016), and the number of additional injections was significantly associated with fellow-eye severity (P = 0.007).
   Fellow-eye severity was associated with treatment response in terms of visual improvement and retreatment and may be a predictive factor for response to IAI for neovascular AMD.
C1 [Sakurada, Yoichi; Kikushima, Wataru; Sugiyama, Atsushi; Yoneyama, Seigo; Tanabe, Naohiko; Matsubara, Mio; Iijima, Hiroyuki] Univ Yamanashi, Fac Med, Dept Ophthalmol, Kofu, Yamanashi, Japan.
C3 University of Yamanashi
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, Kofu, Yamanashi, Japan.
EM sakurada@yamanashi.ac.jp
FU JSPS (Japan Society for the promotion of Science) KAKENHI [26861441]
FX This study was supported in part by JSPS (Japan Society for the
   promotion of Science) KAKENHI grant number 26861441.
CR [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Ferrara N, 2009, EUR CYTOKINE NETW, V20, P158, DOI 10.1684/ecn.2009.0170
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/srep44020
   Kikushima W, 2016, J OCUL PHARMACOL TH, V32, P376, DOI 10.1089/jop.2015.0125
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   Kume A, 2016, OPHTHALMOLOGY, V123, P1263, DOI 10.1016/j.ophtha.2016.01.042
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Miyake M, 2015, INVEST OPHTH VIS SCI, V56, P5353, DOI 10.1167/iovs.14-16020
   Nakata I, 2015, SCI REP-UK, V5, DOI 10.1038/srep09345
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sundaresan P, 2012, INVEST OPHTH VIS SCI, V53, P7492, DOI 10.1167/iovs.12-10073
   Tateno Y, 2016, OPHTHALMIC GENET, V37, P177, DOI 10.3109/13816810.2015.1020557
NR 22
TC 4
Z9 4
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2018
VL 256
IS 1
BP 99
EP 104
DI 10.1007/s00417-017-3847-y
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FR5WO
UT WOS:000419137400011
PM 29177890
DA 2022-11-30
ER

PT J
AU Gupta, D
   Gupta, V
   Singh, V
   Chawla, S
   Parveen, F
   Agrawal, S
   Phadke, SR
AF Gupta, Divya
   Gupta, Vani
   Singh, Vinita
   Chawla, Shobhit
   Parveen, Farah
   Agrawal, Suraksha
   Phadke, Shubha R.
TI Study of Polymorphisms in CX3CR1, PLEKHA1 and VEGF Genes as Risk Factors
   for Age-related Macular Degeneration in Indian Patients
SO ARCHIVES OF MEDICAL RESEARCH
LA English
DT Article
DE AMD; CX3CR1; PLEKHA1; VEGF; Indian; PCR-RFLP
ID ENDOTHELIAL GROWTH-FACTOR; DIABETIC-RETINOPATHY; COMMON VARIANTS;
   POOLED-ANALYSIS; SUSCEPTIBILITY; ASSOCIATION; DISEASE; MACULOPATHY;
   LOC387715; CANCER
AB Background and Aims. Age-related macular degeneration (AMD) is an important cause of visual impaiiinent in elderly persons. AMD is a multifactorial disease in which both environmental and genetic factors have been implicated. Various single nucleotide polymorphisms (SNPs) have been found to be associated with AMD. This study aimed to investigate the association of polymorphisms in CX3CR1, PLEKHA1 and VEGF genes with AMD in Indian patients. Methods. Genotyping for the CX3CR1 T280M (C > T) and V249I (G > A), PLEKHAl A320T (G > A) & VEGF +674 (C > T) and +936 (C > T) was performed in 121 AMD patients and 100 controls by polymerase chain reaction, restriction fragment length polymorphism (PCR-RFLP) and sequencing method. Results. The genotype analysis of VEGF gene polymorphisms (+674 and +936) showed a significant association with AMD. Odds ratios for VEGF (+674) and VEGF (+936) were 2.37 and 2.50 with a p value 0.0029 and 0.0358 for the autosomal dominant model. CX3CR1 (T280M and V249I) and PLEKHA1 (A320T) polymorphisms were not found to be associated with AMD. Odds ratios for mutant alleles of T280M and V249I polymorphisms in CX3CR1 gene were 0.95 and 0.83, respectively, compared to the wild-type alleles. Odds ratio for the polymorphism in the PLEKHA1 gene was 0.63. Conclusions. The present study suggests that both polymorphisms in VEGF gene are risk factors for AMD in the Indian population. Detection of individuals at risk could lead to strategies for prevention, early diagnosis and management of AMD. (C) 2014 IMSS. Published by Elsevier Inc.
C1 [Gupta, Divya; Parveen, Farah; Agrawal, Suraksha; Phadke, Shubha R.] Sanjay Gandhi Postgrad Inst Med Sci, Dept Med Genet, Lucknow 226014, Uttar Pradesh, India.
   [Gupta, Vani] Kings Georges Med Univ, Dept Physiol, Lucknow, Uttar Pradesh, India.
   [Singh, Vinita] Kings Georges Med Univ, Dept Ophthalmol, Lucknow, Uttar Pradesh, India.
   [Chawla, Shobhit] Prakash Netra Kendra, Lucknow, Uttar Pradesh, India.
C3 Sanjay Gandhi Postgraduate Institute of Medical Sciences; King George's
   Medical University; King George's Medical University
RP Phadke, SR (通讯作者)，Sanjay Gandhi Postgrad Inst Med Sci, Dept Med Genet, Lucknow 226014, Uttar Pradesh, India.
EM shubharaophadke@gmail.com
OI Phadke, Shubha/0000-0002-6624-082X
FU Indian Council of Medical Research (ICMR) [45/20/2010/CMB/BMS,
   63/8/2010-BMS New Delhi]
FX I would like to express my greatest appreciation to all the participants
   in the study. This work was supported by the Indian Council of Medical
   Research (ICMR) 45/20/2010/CMB/BMS and 63/8/2010-BMS New Delhi.
CR Almeida LN, 2012, GRAEF ARCH CLIN EXP, V250, P185, DOI 10.1007/s00417-011-1807-5
   Balkwill F, 2003, SEMIN IMMUNOL, V15, P49, DOI 10.1016/S1044-5323(02)00127-6
   Belo VA, 2011, DNA CELL BIOL, V30, P709, DOI 10.1089/dna.2011.1260
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Churchill AJ, 2008, INVEST OPHTH VIS SCI, V49, P3611, DOI 10.1167/iovs.07-1383
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Darrington E, 2012, ASIAN J ANDROL, V14, P745, DOI 10.1038/aja.2011.197
   Faure S, 2000, SCIENCE, V287, P2274, DOI 10.1126/science.287.5461.2274
   He Y, 2010, DNA CELL BIOL, V29, P393, DOI 10.1089/dna.2009.1015
   Howard OMZ, 1996, TRENDS BIOTECHNOL, V14, P46, DOI 10.1016/0167-7799(96)80920-6
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2006, HUM MOL GENET, V15, P3206
   Jiang YM, 2013, J INT MED RES, V41, P317, DOI 10.1177/0300060513475570
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Lu Y, 2012, MOL BIOL REP, V39, P6547, DOI 10.1007/s11033-012-1483-5
   McDermott D H, 2000, Science, V290, P2031
   McDermott DH, 2003, J CLIN INVEST, V111, P1241, DOI 10.1172/JCI200316790
   Mittal RD, 2011, DNA CELL BIOL, V30, P309, DOI 10.1089/dna.2010.1138
   Perrin RM, 2005, DIABETOLOGIA, V48, P2422, DOI 10.1007/s00125-005-1951-8
   Popp N, 2013, J CLIN EXP OPHTHALMO, V4
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ryu E, 2010, MOL VIS, V16, P2811
   Schaumberg DA, 2014, JAMA OPHTHALMOL, V132, P84, DOI 10.1001/jamaophthalmol.2013.5506
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Zerbib J, 2011, EXP EYE RES, V93, P382, DOI 10.1016/j.exer.2011.05.005
NR 26
TC 7
Z9 8
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0188-4409
EI 1873-5487
J9 ARCH MED RES
JI Arch. Med. Res.
PD AUG
PY 2014
VL 45
IS 6
BP 489
EP 494
DI 10.1016/j.arcmed.2014.07.005
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AQ1NN
UT WOS:000342548200007
PM 25050486
DA 2022-11-30
ER

PT J
AU Shin, JY
   Lee, J
   Park, J
   Kim, M
   Chung, H
   Byeon, SH
AF Shin, Joo Youn
   Lee, Jonghyun
   Park, Jinkyu
   Kim, Min
   Chung, Hyewon
   Byeon, Suk Ho
TI Association of Keratin 8 Level in Aqueous Humor With Outcomes of
   Intravitreal Ranibizumab Treatment for Neovascular Age-Related Macular
   Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; aqueous humor; keratin 8; retinal
   pigment epithelium; anti-vascular endothelial growth factor
ID PIGMENT EPITHELIAL-CELLS; ANTI-VEGF THERAPY; PROTEOMIC ANALYSIS;
   RESISTANCE; PROGRESSION; EXPRESSION; AMD
AB Purpose: To investigate keratin 8 (KRT8) level in the aqueous humor (AH) of patients with neovascular age-related macular degeneration (nAMD) and elucidate its association with intravitreal ranibizumab (IVR) treatment outcomes.
   Methods: This prospective study involved 58 eyes of treatment-naive nAMD patients treated with three IVR doses monthly and whose AH samples were collected at baseline and two months after the initial treatment. KRT8 level was determined using the enzyme-linked immunosorbent assay and compared with that of the control group, which comprised patients who underwent cataract surgery during the same period. The nAMD-affected eyes were classified into responder (dry) and poor responder (persistent fluid) groups, according to optical coherence tomography (OCT) findings atmonth three. Additionally, associations between the KRT8 level and IVR treatment outcomes were analyzed.
   Results: The baseline KRT8 level was significantly higher in the AMD group than in the control group. In the AMD group, responders demonstrated significant differences between the KRT8 level at the baseline and month two, whereas poor responders exhibited no significant change. Regression analysis revealed that a higher KRT8 level at month two was significantly associated with persistent fluid upon OCT at months three and six.
   Conclusions: Monitoring aqueous KRT8 level may facilitate early determination of the therapeutic effects of IVR in nAMD patients and reflect the conditions of retinal pigment epithelium during the disease course.
   Translational Relevance: Monitoring aqueous KRT8 may aid early determination of therapeutic effects of IVR in neovascular AMD patients and reflect the health conditions of retinal pigment epithelium.
C1 [Shin, Joo Youn; Park, Jinkyu; Byeon, Suk Ho] Yonsei Univ, Inst Vision Res, Severance Hosp, Dept Ophthalmol,Coll Med, 50 Yonsei ro, Seoul 03722, South Korea.
   [Lee, Jonghyun] Inje Univ, Ilsan Paik Hosp, Dept Ophthalmol, Coll Med, Goyang, South Korea.
   [Kim, Min] Yonsei Univ, Inst Vision Res, Gangnam Severance Hosp, Dept Ophthalmol,Coll Med, Seoul, South Korea.
   [Chung, Hyewon] Konkuk Univ, Med Ctr, Dept Ophthalmol, Sch Med, 120-1 Neungdong ro, Seoul 05030, South Korea.
C3 Yonsei University; Yonsei University Health System; Inje University;
   Yonsei University; Yonsei University Health System; Konkuk University;
   Konkuk University Medical Center
RP Byeon, SH (通讯作者)，Yonsei Univ, Inst Vision Res, Severance Hosp, Dept Ophthalmol,Coll Med, 50 Yonsei ro, Seoul 03722, South Korea.; Chung, H (通讯作者)，Konkuk Univ, Med Ctr, Dept Ophthalmol, Sch Med, 120-1 Neungdong ro, Seoul 05030, South Korea.
EM hchung@kuh.ac.kr; shbyeon@yuhs.ac
OI Shin, Joo Youn/0000-0003-4543-477X; Kim, Min/0000-0003-1873-6959; Byeon,
   suk ho/0000-0001-8101-0830
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Science and ICT [2017R1A2B4011045,
   2019R1A2C2086729]; Yonsei University College of Medicine [6-2015-0045];
   Novartis, Korea
FX Supported by grants for the Basic Science Research Program through the
   National Research Foundation of Korea (NRF), funded by the Ministry of
   Science and ICT (grant numbers: 2017R1A2B4011045 and 2019R1A2C2086729),
   and a faculty research grant of Yonsei University College of Medicine
   (grant number: 6-2015-0045) and Novartis, Korea.
CR Baek A, 2017, AUTOPHAGY, V13, P248, DOI 10.1080/15548627.2016.1256932
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Busch T, 2012, J CELL SCI, V125, P2148, DOI 10.1242/jcs.080127
   Carbone C, 2011, CLIN CANCER RES, V17, P5822, DOI 10.1158/1078-0432.CCR-11-1185
   Caulin C, 2000, J CELL BIOL, V149, P17, DOI 10.1083/jcb.149.1.17
   Dikmetas O, 2013, MOL VIS, V19, P2571
   Fang J, 2017, CANCER SCI, V108, P178, DOI 10.1111/cas.13120
   Girouard MP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168641
   GRISANTI S, 1995, INVEST OPHTH VIS SCI, V36, P391
   Hammers H, 2012, J CLIN ONCOL, V30, DOI 10.1200/jco.2012.30.5_suppl.390
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hu DN, 2017, J CLIN OPHTHALMOL EY, V1, P1002
   HUNT RC, 1990, J CELL PHYSIOL, V145, P187, DOI 10.1002/jcp.1041450202
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Kang GY, 2014, J PROTEOME RES, V13, P581, DOI 10.1021/pr400751k
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kim TW, 2012, J PROTEOME RES, V11, P4034, DOI 10.1021/pr300080s
   Ku NO, 2006, J CELL BIOL, V174, P115, DOI 10.1083/jcb.200602146
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Lee H, 2014, BMB REP, V47, P292, DOI 10.5483/BMBRep.2014.47.5.193
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Piao Y, 2013, CLIN CANCER RES, V19, P4392, DOI 10.1158/1078-0432.CCR-12-1557
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Tao GZ, 2009, J CELL SCI, V122, P3851, DOI 10.1242/jcs.051862
   Wu S, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0606-0
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yao JQ, 2013, PROTEOM CLIN APPL, V7, P550, DOI 10.1002/prca.201200012
   Zatloukal K, 2000, AM J PATHOL, V156, P1263, DOI 10.1016/S0002-9440(10)64997-8
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
NR 31
TC 1
Z9 1
U1 1
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JAN
PY 2022
VL 11
IS 1
AR 26
DI 10.1167/tvst.11.1.26
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1L9DR
UT WOS:000799581700025
PM 35040914
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Thomas, DS
   Lee, AY
   Muller, PL
   Schwartz, R
   Olvera-Barrios, A
   Warwick, AN
   Patel, PJ
   Heeren, TFC
   Egan, C
   Taylor, P
   Tufail, A
AF Thomas, Darren S.
   Lee, Aaron Y.
   Mueller, Philipp L.
   Schwartz, Roy
   Olvera-Barrios, Abraham
   Warwick, Alasdair N.
   Patel, Praven J.
   Heeren, Tjebo F. C.
   Egan, Catherine
   Taylor, Paul
   Tufail, Adnan
CA UK AMD EMR Users Grp
TI Contextualizing single-arm trials with real-world data: An emulated
   target trial comparing therapies for neovascular age-related macular
   degeneration
SO CTS-CLINICAL AND TRANSLATIONAL SCIENCE
LA English
DT Article
ID EFFICACY
AB One-in-four ophthalmology trials are single-armed, which poses challenges to their interpretation. We demonstrate how real-world cohorts used as external/synthetic control arms can contextualize such trials. We herein emulated a target trial on the intention-to-treat efficacy of off-label bevacizumab (q6w) pro re nata relative to fixed-interval aflibercept (q8w) for improving week 54 visual acuity of eyes affected by neovascular age-related macular degeneration. The bevacizumab arm (n = 65) was taken from the ABC randomized controlled trial. A total of 4,471 aflibercept-treated eyes aligning with the ABC trial eligibility were identified from electronic health records and synthetic control arms were created by emulating randomization conditional on age, sex, and baseline visual read via exact matching and propensity score methods. We undertook an inferiority analysis on mean difference at 54 weeks; outcomes regression on achieving a change in visual acuity of greater than or equal to 15, greater than or equal to 10, and less than or equal to -15 Early Treatment Diabetic Retinopathy (ETDRS) letters at week 54; and a time-to-event analysis on achieving a change in visual acuity of greater than or equal to 15, greater than or equal to 10, and less than or equal to -15 ETDRS letters by week 54. The findings suggest off-label bevacizumab to be neither inferior nor superior to licensed aflibercept. Our study highlights how real-world cohorts representing the counterfactual intervention could aid the interpretation of single-armed trials when analyzed in accord to the target trial framework.
C1 [Thomas, Darren S.; Taylor, Paul] Univ Coll London UCL, Inst Hlth Informat, London, England.
   [Lee, Aaron Y.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.
   [Mueller, Philipp L.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Mueller, Philipp L.; Schwartz, Roy; Olvera-Barrios, Abraham; Warwick, Alasdair N.; Heeren, Tjebo F. C.; Egan, Catherine; Tufail, Adnan] Moorfields Eye Hosp NHS Fdn Trust, 162 City Rd, London EC1V 2PD, England.
   [Mueller, Philipp L.; Schwartz, Roy; Olvera-Barrios, Abraham; Heeren, Tjebo F. C.; Egan, Catherine; Tufail, Adnan] UCL, Inst Ophthalmol, London, England.
   [Schwartz, Roy; Patel, Praven J.; Egan, Catherine; Tufail, Adnan] Moorfields Eye Hosp, Biomed Res Ctr, Natl Inst Hlth Res, London, England.
   [Schwartz, Roy; Patel, Praven J.; Egan, Catherine; Tufail, Adnan] UCL Inst Ophthalmol, London, England.
   [Warwick, Alasdair N.; UK AMD EMR Users Grp] Univ Coll London UCL, Inst Cardiovasc Sci, London, England.
C3 University of London; University College London; University of
   Washington; University of Washington Seattle; University of Bonn;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   University of London; University College London
RP Tufail, A (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, 162 City Rd, London EC1V 2PD, England.
EM adnan.tufail@nhs.net
RI Olvera-Barrios, Abraham/GQH-4711-2022; Heeren, Tjebo/R-5055-2019;
   Olvera-Barrios, Abraham/AAG-1197-2020
OI Olvera-Barrios, Abraham/0000-0002-3305-4465; Heeren,
   Tjebo/0000-0001-5297-2301; Olvera-Barrios, Abraham/0000-0002-3305-4465;
   Tufail, Adnan/0000-0001-6131-7640; Lee, Aaron/0000-0002-7452-1648
FU Moorfields Eye Hospital; Novartis Pharmaceuticals
FX The ABC trial was funded by the Special Trustees of Moorfields Eye
   Hospital. Novartis Pharmaceuticals awarded a grant to cover the costs
   for extracting and storing electronic health records but were not
   involved in the study.
CR Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786
   Carrigan G, 2020, CLIN PHARMACOL THER, V107, P369, DOI 10.1002/cpt.1586
   Davies J, 2018, J COMP EFFECT RES, V7, P855, DOI 10.2217/cer-2018-0032
   Dickerman BA, 2019, NAT MED, V25, P1601, DOI 10.1038/s41591-019-0597-x
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Franklin JM, 2020, CLIN PHARMACOL THER, V107, P817, DOI 10.1002/cpt.1633
   Gokbuget N, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.84
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hernan MA., 2020, CAUSAL INFERENCE WHA
   Hernan MA, 2016, J CLIN EPIDEMIOL, V79, P70, DOI 10.1016/j.jclinepi.2016.04.014
   Hernan MA, 2016, AM J EPIDEMIOL, V183, P758, DOI 10.1093/aje/kwv254
   Lodi S, 2019, AM J EPIDEMIOL, V188, P1569, DOI 10.1093/aje/kwz100
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Murray EJ, 2016, CLIN TRIALS, V13, P372, DOI 10.1177/1740774516634335
   Patel PJ., RETINA-J RET VIT DIS, DOI [10.1097/IAE.0b013e31823f0ba3, DOI 10.1097/IAE.0B013E31823F0BA3]
   Patel PJ, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-56
   Patel S, 2018, OPHTHALMOL RETINA, V2, P785, DOI 10.1016/j.oret.2017.12.006
   R Development Core Team R, 2019, R LANG ENV STAT COMP
   Robinson D., 2020, fuzzyjoin: Join Tables Together on Inexact Matching ,
   Schmidli H, 2020, CLIN PHARMACOL THER, V107, P806, DOI 10.1002/cpt.1723
   Tan DSW, 2016, J THORAC ONCOL, V11, P1550, DOI 10.1016/j.jtho.2016.05.029
   Bui TC, 2018, IEEE GLOBE WORK
   Therneau T, 2021, PACKAGE SURVIVAL ANA
   Tufail A, 2020, BRIT J OPHTHALMOL, V104, P672, DOI 10.1136/bjophthalmol-2018-313682
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Turner B, 2020, AM J OPHTHALMOL, V211, P132, DOI 10.1016/j.ajo.2019.11.004
   U.S. Food & Drug Administration, 2018, FRAMEWORK FDAS REAL
   van Asten F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197670
   Wickham H., 2019, J OPEN SOURCE SOFTW, V4, P1686, DOI [10.21105/joss.01686, DOI 10.21105/JOSS.01686]
NR 30
TC 1
Z9 1
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1752-8054
EI 1752-8062
J9 CTS-CLIN TRANSL SCI
JI CTS-Clin. Transl. Sci.
PD MAY
PY 2021
VL 14
IS 3
BP 1166
EP 1175
DI 10.1111/cts.12974
EA MAR 2021
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA SU3GZ
UT WOS:000624267900001
PM 33421321
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Falkenstein, IA
   Cheng, L
   Morrison, VL
   Kozak, I
   Tammewar, AM
   Freeman, WR
AF Falkenstein, Iryna A.
   Cheng, Lingyun
   Morrison, Victoria L.
   Kozak, Igor
   Tammewar, Ajay M.
   Freeman, William R.
TI Standardized visual acuity results associated with primary versus
   secondary bevacizumab (avastin) treatment for choroidal
   neovascularization in age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; bevacizurnab (Avastin); choroidal
   neovascularization; intravitreal treatment; pegaptanib sodium (Macugen)
ID INTRAVITREAL BEVACIZUMAB; RANIBIZUMAB; INJECTION; SAFETY
AB Purpose: To compare standardized visual outcomes and macular thickness changes associated with primary and secondary bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) therapy for choroidal neovascularization (CNV) in age-related macular degeneration (AMD).
   Methods: Eighteen eyes received primary bevacizumab treatment; 20 eyes received pegaptanib (Macugen; Eyetech/OSI Pharmaceuticals, New York, NY) as initial treatment followed by bevacizumab therapy. Both medications were injected at 6-week intervals. Best-corrected visual acuity was measured with the ETDRS chart. Three- and 6-month data were analyzed for all eyes.
   Results: Mean visual acuity improvement in the primary bevacizumab treatment cohort was 1.5 ETDRS lines at 3 months (P = 0.0009) and 2.2 ETDRS lines at 6 months (P = 0.0004) compared with -0.4 ETDRS line at 3 months (P = 0.27) and 0.2 ETDRS line at 6 months (P = 0.70) in the secondary bevacizumab treatment group. Mean decrease in retinal thickness was also higher in the primary bevacizumab treatment group (90.9 mu m [P = 0.0037] vs 43.8 mu m [P 0.13], respectively) than in the secondary bevacizumab treatment group (73.72 mu m [P = 0.051] vs 33.0 mu m [P = 0.21], respectively) at 3 months and 6 months.
   Conclusion: Primary bevacizumab therapy resulted in significantly greater visual improvement than secondary bevacizumab treatment at 3 months or 6 months. To our knowledge, this is the first report comparing primary bevacizumab treatment of CNV in AMD with secondary bevacizumab treatment after multiple pegaptanib injections.
C1 Univ Calif San Diego, Shiley Eye Ctr, Joan & Irwin Jacobs Retina Ctr, Dept Ophthalmol, La Jolla, CA 92037 USA.
C3 University of California System; University of California San Diego
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Shiley Eye Ctr, Joan & Irwin Jacobs Retina Ctr, Dept Ophthalmol, 9415 Campus Point Dr, La Jolla, CA 92037 USA.
EM freeman@eyecenter.ucsd.edu
RI Kozak, Igor/AAC-4645-2019
FU NATIONAL EYE INSTITUTE [R01EY007366] Funding Source: NIH RePORTER; NEI
   NIH HHS [R01 EY007366, R01 EY007366-21] Funding Source: Medline
CR AISENBREY S, 2006, GRAEFES ARCH CL 1221
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Bakri SJ, 2006, AM J OPHTHALMOL, V142, P162, DOI 10.1016/j.ajo.2006.03.058
   BLACKHURST DW, 1989, RETINA-J RET VIT DIS, V9, P163, DOI 10.1097/00006982-198909030-00001
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Feiner L, 2006, RETINA-J RET VIT DIS, V26, P882, DOI 10.1097/01.iae.0000230717.85319.f5
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Freeman WR, 2006, RETINA-J RET VIT DIS, V26, P853, DOI 10.1097/01.iae.0000244722.35073.7c
   Friedlander SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1363
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Kahook MY, 2006, OPHTHAL SURG LAS IM, V37, P144, DOI 10.3928/1542-8877-20060301-11
   Kiss C, 2006, RETINA-J RET VIT DIS, V26, P877, DOI 10.1097/01.iae.0000237080.10627.b7
   Kozak I, 2005, RETINA-J RET VIT DIS, V25, P994, DOI 10.1097/00006982-200512000-00007
   Laud K, 2006, RETINA-J RET VIT DIS, V26, P960, DOI 10.1097/01.iae.0000240121.28034.c3
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   LOVIEKITCHIN JE, 1988, OPHTHAL PHYSL OPT, V8, P363, DOI 10.1111/j.1475-1313.1988.tb01170.x
   Mason JO, 2006, RETINA-J RET VIT DIS, V26, P839, DOI 10.1097/01.iae.0000230425.31296.3b
   Paula JS, 2006, ACTA OPHTHALMOL SCAN, V84, P556, DOI 10.1111/j.1600-0420.2006.00721.x
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sakaguchi H, 2007, BRIT J OPHTHALMOL, V91, P161, DOI 10.1136/bjo.2006.099887
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Yamamoto I, 2007, BRIT J OPHTHALMOL, V91, P157, DOI 10.1136/bjo.2006.096776
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 31
TC 34
Z9 35
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL-AUG
PY 2007
VL 27
IS 6
BP 701
EP 706
DI 10.1097/IAE.0b013e3180654240
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 189NT
UT WOS:000247996400006
PM 17621178
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Memarzadeh, E
   Heidari-Soureshjani, S
AF Memarzadeh, Ezatollah
   Heidari-Soureshjani, Saeid
TI The Relationship between Statin and Risk of Age-Related Macular
   Degeneration: A Systematic Review and Meta-Analysis
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID CHOLESTEROL-LOWERING MEDICATIONS; CONVERTING ENZYME-INHIBITORS; A
   REDUCTASE INHIBITORS; PROGRESSION; COHORT; HEALTH; ASSOCIATION;
   MACULOPATHY; PREVENTION
AB Introduction and Aim. Age-related macular degeneration (AMD) is one of the leading causes of blindness and visual defect, particularly in elderly people across the world. This meta-analysis aimed at investigating the relationship between statin and the risk of AMD. Methods. Web of Science, PubMed, and Scopus databases were searched for articles that addressed the relationship between statin consumption and risk of AMD. The pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using a random-effects model. Subgroup analyses and sensitivity analyses were also conducted. Cochran's Q test and the I-2 statistic were used to evaluate the heterogeneity. To assess potential publication bias, Begg's test was used. Results. In total, 22 studies were reviewed in the meta-analysis that included 2063195 participants and 313702 (15.20%) AMD patients compared to individuals not receiving statins. The OR of AMD in statin-receiving participants was 0.93 (95% CI; 0.83-1.05, P=0.225). The OR of AMD in those that received statins was 0.92 (95% CI; 0.75-1.13, P=0.440) in case-control studies, 0.95 (95% CI; 0.82-1.09, P=0.458) in cohort studies, 0.951 (95% CI; 0.59-1.53, P=0.831) in cross-sectional studies, 0.94 (95% CI; 0.80-1.10, P=0.468) in North America, 0.81 (95% CI; 0.54-1.21, P=0.308) in Europe, 1.05 (95% CI; 0.94-1.18, P=0.362) in Asia, and 0.52 (95% CI; 0.26-1.04, P=0.125) in Australia. No publication bias was observed in this study (P=0.114). Conclusion. According to the results of this study, taking statins does not increase or decrease the risk of AMD development. Therefore, this drug group cannot be considered a protective or risk factor for the occurrence of AMD.
C1 [Memarzadeh, Ezatollah] Shahrekord Univ Med Sci, Kashani Hosp, Sch Med, Dept Ophthalmol, Shahrekord, Iran.
   [Heidari-Soureshjani, Saeid] Shahrekord Univ Med Sci, Modeling Hlth Res Ctr, Shahrekord, Iran.
C3 Shahrekord University Medical Sciences; Shahrekord University Medical
   Sciences
RP Heidari-Soureshjani, S (通讯作者)，Shahrekord Univ Med Sci, Modeling Hlth Res Ctr, Shahrekord, Iran.
EM e_memarzadeh@yahoo.com; heidari_62@yahoo.com
RI Heidari-Soureshjani, Saeid/HDK-6386-2022
OI Heidari-Soureshjani, Saeid/0000-0002-7592-3868
CR Al Moujahed A., 2020, INVESTIGATIVE OPHTHA, V61, P3
   Al-Holou SN, 2015, OPHTHALMOLOGY, V122, P2490, DOI 10.1016/j.ophtha.2015.08.028
   Barbosa DTQ, 2014, EYE, V28, P472, DOI 10.1038/eye.2014.8
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chuo JY, 2007, OPHTHAL EPIDEMIOL, V14, P367, DOI 10.1080/09286580701421684
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Cruickshanks KJ, 2017, JAMA OPHTHALMOL, V135, P1417, DOI 10.1001/jamaophthalmol.2017.5001
   Etminan M, 2008, CURR DRUG SAF, V3, P24, DOI 10.2174/157488608783333952
   Fong DS, 2010, AM J OPHTHALMOL, V149, P955, DOI 10.1016/j.ajo.2009.12.037
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Kaiserman N, 2009, CURR EYE RES, V34, P304, DOI 10.1080/02713680902741670
   Kananen F, 2021, ACTA OPHTHALMOL, V99, pE1063, DOI 10.1111/aos.14774
   Klein R, 2004, AM J OPHTHALMOL, V137, P747, DOI 10.1016/j.ajo.2004.01.037
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Lee H, 2019, YONSEI MED J, V60, P679, DOI 10.3349/ymj.2019.60.7.679
   Ludwig CA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0252878
   Ma L, 2015, SCI REP-UK, V5, DOI 10.1038/srep18280
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   MARTINI E, 1991, Annali di Ottalmologia e Clinica Oculistica, V117, P1121
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Ooi K, 2019, CLIN EXP OPHTHALMOL, V47, P105
   Peterson J., 2011, NEWCASTLE OTTAWA SCA, P1
   Rajeshuni N, 2019, EYE, V33, P163, DOI 10.1038/s41433-018-0195-z
   Ruiz-Moreno JM, 2021, INT OPHTHALMOL, V41, P3427, DOI 10.1007/s10792-021-01906-x
   Shalev V, 2011, OPHTHAL EPIDEMIOL, V18, P83, DOI 10.3109/09286586.2011.560746
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Smeeth L, 2009, BRIT J CLIN PHARMACO, V67, P99, DOI 10.1111/j.1365-2125.2008.03308.x
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Stahl A, 2020, DTSCH ARZTEBL INT, V117, P513, DOI 10.3238/arztebl.2020.0513
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Tsao SW, 2013, DRUG AGING, V30, P205, DOI 10.1007/s40266-013-0061-4
   Tzotzas T, 2006, ATHEROSCLEROSIS SUPP, V7, P568, DOI 10.1016/S1567-5688(06)82299-3
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   VanderBeek BL, 2013, RETINA-J RET VIT DIS, V33, P414, DOI 10.1097/IAE.0b013e318276e0cf
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Wei CX, 2016, ADV EXP MED BIOL, V854, P103, DOI 10.1007/978-3-319-17121-0_15
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
NR 42
TC 0
Z9 0
U1 1
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD MAY 9
PY 2022
VL 2022
AR 8564818
DI 10.1155/2022/8564818
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1Q5GE
UT WOS:000802714800002
PM 35586594
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Thomas, A
   Harikrishnan, PM
   Ramachandran, R
   Ramachandran, S
   Manoj, R
   Palanisamy, P
   Gopi, VP
AF Thomas, Anju
   Harikrishnan, P. M.
   Ramachandran, Rajiv
   Ramachandran, Srikkanth
   Manoj, Rigved
   Palanisamy, P.
   Gopi, Varun P.
TI A novel multiscale and multipath convolutional neural network based
   age-related macular degeneration detection using OCT images
SO COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
LA English
DT Article
DE Age-related macular degeneration; Multiscale and multipath CNN;
   Classification; Ten-fold cross-validation
ID COHERENCE TOMOGRAPHY IMAGES; CLASSIFICATION; DISEASE; EDEMA; PREVALENCE;
   BURDEN
AB Background and Objective: One of the significant retinal diseases that affected older people is called Age related Macular Degeneration (AMD). The first stage creates a blur effect on vision and later leads to central vision loss. Most people overlooked the primary stage blurring and converted it into an advanced stage. There is no proper treatment to cure the disease. So the early detection of AMD is essential to prevent its extension into the advanced stage. This paper proposes a novel deep Convolutional Neural Network (CNN) architecture to automate AMD diagnosis early from Optical Coherence Tomographic (OCT) images. Methods: The proposed architecture is a multiscale and multipath CNN with six convolutional layers. The multiscale convolution layer permits the network to produce many local structures with various filter dimensions. The multipath feature extraction permits CNN to merge more features regarding the sparse local and fine global structures. The performance of the proposed architecture is evaluated through ten-fold cross-validation methods using different classifiers like support vector machine, multi-layer perceptron, and random forest. Results: The proposed CNN with the random forest classifier gives the best classification accuracy results. The proposed method is tested on data set 1, data set 2, data set 3, data set 4, and achieved an accuracy of 0.9666, 0.9897, 0.9974, and 0.9978 respectively, with random forest classifier. Also, we tested the combination of first three data sets and achieved an accuracy of 0.9902. Conclusions: An efficient algorithm for detecting AMD from OCT images is proposed based on a multiscale and multipath CNN architecture. Comparison with other approaches produced results that exhibit the efficiency of the proposed algorithm in the detection of AMD. The proposed architecture can be applied in rapid screening of the eye for the early detection of AMD. Due to less complexity and fewer learnable parameters. (c) 2021 Elsevier B.V. All rights reserved.
C1 [Thomas, Anju; Harikrishnan, P. M.; Ramachandran, Rajiv; Ramachandran, Srikkanth; Manoj, Rigved; Palanisamy, P.; Gopi, Varun P.] Natl Inst Technol Tiruchirappalli, Dept Elect & Commun Engn, Tiruchirappalli 620015, Tamil Nadu, India.
C3 National Institute of Technology (NIT System); National Institute of
   Technology Tiruchirappalli
RP Palanisamy, P (通讯作者)，Natl Inst Technol Tiruchirappalli, Dept Elect & Commun Engn, Tiruchirappalli 620015, Tamil Nadu, India.
EM anjukandathil.thomas@gmail.com; haripm033@gmail.com;
   rrajiv9802@gmail.com; supersri04@gmail.com; rigvedmanoj1998@gmail.com;
   palan@nitt.edu; varun@nitt.edu
RI Thomas, Anju/ABF-6145-2021; PONNUSAMY, PALANISAMY/AAM-5285-2020; Gopi,
   Varun P/S-3943-2019
OI Thomas, Anju/0000-0002-2178-0531; PONNUSAMY,
   PALANISAMY/0000-0003-3687-5944; Gopi, Varun P/0000-0001-5593-3949;
   Ramachandran, Rajiv/0000-0003-2774-7975
CR Akbar B, 2015, 2015 2ND INTERNATIONAL CONFERENCE ON ELECTRONICS AND COMMUNICATION SYSTEMS (ICECS), P1735, DOI 10.1109/ECS.2015.7124883
   Alqudah AM, 2020, MED BIOL ENG COMPUT, V58, P41, DOI 10.1007/s11517-019-02066-y
   Bhatia KK, 2020, RETINA-J RET VIT DIS, V40, P1549, DOI 10.1097/IAE.0000000000002640
   Bouvrie J., 2006, NEURAL NETS
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Daqi G, 2007, 2007 INT JOINT C NEU, P2971, DOI DOI 10.1109/IJCNN.2007.4371433
   Das V, 2019, BIOMED SIGNAL PROCES, V54, DOI 10.1016/j.bspc.2019.101605
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Fang LY, 2019, J VIS COMMUN IMAGE R, V59, P327, DOI 10.1016/j.jvcir.2019.01.022
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Gayathri S, 2021, PHYS ENG SCI MED, V44, P639, DOI 10.1007/s13246-021-01012-3
   Gayathri S, 2020, BIOMED SIGNAL PROCES, V62, DOI 10.1016/j.bspc.2020.102115
   Gayathri S, 2020, IEEE ACCESS, V8, P57497, DOI 10.1109/ACCESS.2020.2979753
   Huang GB, 2000, IEEE T NEURAL NETWOR, V11, P799, DOI 10.1109/72.846750
   Huang LF, 2019, IEEE SIGNAL PROC LET, V26, P1026, DOI 10.1109/LSP.2019.2917779
   Hussain MA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198281
   Hwang DK, 2019, THERANOSTICS, V9, P232, DOI 10.7150/thno.28447
   Jemshi KM, 2018, INT J COMPUT ASS RAD, V13, P1369, DOI 10.1007/s11548-018-1795-6
   Kandhasamy JP, 2020, MULTIMED TOOLS APPL, V79, P10581, DOI 10.1007/s11042-019-7485-8
   Karri SPK, 2017, BIOMED OPT EXPRESS, V8, P579, DOI 10.1364/BOE.8.000579
   Kaymak S, 2018, INT C INTELL COMP CO, P265, DOI 10.1109/ICCP.2018.8516635
   Kermany D, 2018, MENDELEY DATA, V2, DOI 10.17632/rscbjbr9sj.2
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Khalid S., 2017, INTERVIEW BASED ITER
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   Kuwayama S, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/6319581
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Meng TQ, 2018, CHIN CONTR CONF, P9362, DOI 10.23919/ChiCC.2018.8483036
   Motozawa N, 2019, OPHTHALMOL THER, V8, P527, DOI 10.1007/s40123-019-00207-y
   Naz S., 2016, 2016 6 INT C IMAGE P, P1
   Raju M, 2021, 2021 SIXTH INTERNATIONAL CONFERENCE ON WIRELESS COMMUNICATIONS, SIGNAL PROCESSING AND NETWORKING (WISPNET), P368, DOI [10.1109/WiSPNET51692.2021.9419393, 10.1109/WISPNET51692.2021.9419393]
   Raju M, 2020, PHYS ENG SCI MED, V43, P1219, DOI 10.1007/s13246-020-00924-w
   Rasti R, 2018, IEEE T MED IMAGING, V37, P1024, DOI 10.1109/TMI.2017.2780115
   Rong YB, 2019, IEEE J BIOMED HEALTH, V23, P253, DOI 10.1109/JBHI.2018.2795545
   Roychowdhury A, 2018, LECT NOTES ELECTR EN, V475, P168, DOI 10.1007/978-981-10-8240-5_19
   Saha S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47390-3
   Selvaraju RR, 2017, IEEE I CONF COMP VIS, P618, DOI 10.1109/ICCV.2017.74
   Serener A, 2019, 2019 SCIENTIFIC MEETING ON ELECTRICAL-ELECTRONICS & BIOMEDICAL ENGINEERING AND COMPUTER SCIENCE (EBBT)
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Srivastava N, 2014, J MACH LEARN RES, V15, P1929
   Sugmk J, 2014, 7 2014 BIOM ENG INT, P1, DOI DOI 10.1109/BMEICON.2014.7017441
   Sun YK, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.1.016012
   Tan JH, 2018, FUTURE GENER COMP SY, V87, P127, DOI 10.1016/j.future.2018.05.001
   Thomas A, 2021, COMPUT METH PROG BIO, V200, DOI 10.1016/j.cmpb.2020.105822
   Varun P.G., 2017, 3 INT C RES COMP INT
   Visa S., 2011, MAICS, V710, P120
   Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4
   Wang Y, 2016, BIOMED OPT EXPRESS, V7, P4928, DOI 10.1364/BOE.7.004928
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu Z., 2020, BRIT J OPHTHALMOL
   Yadav S, 2016, INT CONF ADV COMPU, P78, DOI 10.1109/IACC.2016.25
   Yaqoob Z, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2360525
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
   Yoo TK, 2019, MED BIOL ENG COMPUT, V57, P677, DOI 10.1007/s11517-018-1915-z
NR 54
TC 9
Z9 9
U1 1
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-2607
EI 1872-7565
J9 COMPUT METH PROG BIO
JI Comput. Meth. Programs Biomed.
PD SEP
PY 2021
VL 209
AR 106294
DI 10.1016/j.cmpb.2021.106294
EA AUG 2021
PG 11
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Theory & Methods; Engineering, Biomedical; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Medical Informatics
GA UP2KV
UT WOS:000695214600011
PM 34364184
DA 2022-11-30
ER

PT J
AU Li, ML
   Dolz-Marco, R
   Messinger, JD
   Wang, L
   Feist, RM
   Girkin, CA
   Gattoussi, S
   Ferrara, D
   Curcio, CA
   Freund, KB
AF Li, Miaoling
   Dolz-Marco, Rosa
   Messinger, Jeffrey D.
   Wang, Lan
   Feist, Richard M.
   Girkin, Christopher A.
   Gattoussi, Sarra
   Ferrara, Daniela
   Curcio, Christine A.
   Freund, K. Bailey
TI Clinicopathologic Correlation of Anti-Vascular Endothelial Growth
   Factore-Treated Type 3 Neovascularization in Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID RETINAL ANGIOMATOUS PROLIFERATION; OPTICAL COHERENCE TOMOGRAPHY; OCCULT
   CHOROIDAL NEOVASCULARIZATION; INDOCYANINE GREEN VIDEOANGIOGRAPHY;
   ACQUIRED VITELLIFORM LESIONS; PIGMENT-EPITHELIUM; SUBRETINAL
   NEOVASCULARIZATION; CLINICAL CHARACTERISTICS; BRUCHS MEMBRANE; MOUSE
   MODEL
AB Purpose: To correlate histologic results with previously recorded multimodal imaging results from a patient with type 3 neovascularization secondary to age-related macular degeneration (AMD).
   Design: Case study, clinical imaging, laboratory imaging, and eye-tracked clinicopathologic correlation.
   Participant: An 86-year-old white woman with type 3 neovascularization secondary to AMD treated with 6 intravitreal injections of bevacizumab.
   Methods: Multimodal retinal imaging at each clinic visit was correlated with ex vivo and high-resolution histologic images of the preserved donor eye. Clinical imaging included serial near-infrared reflectance and eye-tracked spectral-domain OCT. Eye tracking, applied to the donor eye, enabled identification of histologic features corresponding to clinical OCT signatures.
   Main Outcome Measures: Histologic correlates for clinical OCT signatures were sought, including reflectivity of the vascular complex, intraretinal hyperreflective foci and intraretinal cellularity, analysis of the topography of pathologic features, and evaluation of the suberetinal pigment epithelium (RPE) plus basal lamina (BL) space.
   Results: Clinical imaging showed a deep neovascular lesion in close relationship with a mixed serous and drusenoid pigment epithelium detachment (PED), characteristic of type 3 neovascularization. Antiangiogenic therapy achieved a complete resolution of exudation. The PED progressively flattened with each treatment, leaving a persistent triangular hyperreflectivity in the outer retina. This persistent deep lesion histologically correlated with a vascular complex implanted into sub-RPE basal laminar deposit. No connection between the choriocapillaris and the sub-RPE plus BL space was observed. Both RPE-derived and lipid-filled cells were correlated with clinical intraretinal hyperreflective foci. The sub-RPE plus BL space contained macrophages, lymphocytes, Muller cell processes, and subducted RPE.
   Conclusions: Clinicopathologic correlation of type 3 neovascularization showed vascular elements of retinal origin accompanied by collagenous material and Muller cell processes implanting into thick sub-RPE basal laminar deposit, which may simulate the appearance of chorioretinal anastomosis. Surrounding RPEderived and lipid-filled cells thought to be microglia correlated with clinical intraretinal hyperreflective foci. (C) 2017 by the American Academy of Ophthalmology
C1 [Li, Miaoling; Messinger, Jeffrey D.; Wang, Lan; Feist, Richard M.; Girkin, Christopher A.; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL USA.
   [Li, Miaoling] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China.
   [Dolz-Marco, Rosa; Gattoussi, Sarra; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA.
   [Dolz-Marco, Rosa; Gattoussi, Sarra; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Dolz-Marco, Rosa] FISABIO Ophthalmol Med, Valencia, Spain.
   [Feist, Richard M.] Retina Consultants Alabama, Birmingham, AL USA.
   [Ferrara, Daniela] Genentech Inc, San Francisco, CA 94080 USA.
   [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
C3 University of Alabama System; University of Alabama Birmingham; Sun Yat
   Sen University; Vitreous Retina Macula Consultants of New York;
   Manhattan Eye Ear & Throat Hospital; Roche Holding; Genentech; New York
   University
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI ; Freund, K. Bailey/V-7488-2018
OI Girkin, Christopher/0000-0002-5781-7682; Gattoussi,
   Sarra/0000-0002-8905-7112; Dolz-Marco, Rosa/0000-0002-2963-2541; Freund,
   K. Bailey/0000-0002-7888-9773; Ferrara, Daniela/0000-0002-1380-7562
FU Alcon; Genentech; Heidelberg Engineering; Novartis; Roche; Thea; Hoffman
   LaRoche; Genentech/Roche; Hoffman-LaRoche
FX The author(s) have made the following disclosure(s): R.D.-M.: Financial
   support - Alcon, Genentech, Heidelberg Engineering, Novartis, Roche,
   Thea; C.A.C.: Financial support - Hoffman LaRoche; Heidelberg
   Engineering; K.B.F.: Consultant - Opotvue; Optos; Heidelberg
   Engineering; Genentech; GrayBug Vision; Financial support -
   Genentech/Roche; Supported by Hoffman-LaRoche. The Funding Organization
   had no role in the design and conduct of this study.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Augustin M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164419
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Balaratnasingam C, 2016, AM J OPHTHALMOL, V172, P28, DOI 10.1016/j.ajo.2016.09.008
   Bringmann A, 2009, PROG RETIN EYE RES, V28, P423, DOI 10.1016/j.preteyeres.2009.07.001
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Chen KC, 2016, AM J OPHTHALMOL, V164, P89, DOI 10.1016/j.ajo.2016.02.002
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Dorrell MI, 2009, J CLIN INVEST, V119, P611, DOI 10.1172/JCI35977
   Edwards MM, 2017, INVEST OPHTH VIS SCI, V58, P1352, DOI 10.1167/iovs.16-21229
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Gass JDM, 1987, STEREOSCOPIC ATLAS M, P64
   Girkin CA, 2017, INVEST OPHTH VIS SCI, V58, P3759, DOI 10.1167/iovs.17-21842
   GREEN WR, 1971, ARCH OPHTHALMOL-CHIC, V86, P487, DOI 10.1001/archopht.1971.01000010489001
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Hata M, 2017, RETINA
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Hu WZ, 2008, INVEST OPHTH VIS SCI, V49, P407, DOI 10.1167/iovs.07-0870
   Hua J, 2011, INVEST OPHTH VIS SCI, V52, P2809, DOI 10.1167/iovs.10-6496
   Inoue Y, 2007, BRIT J OPHTHALMOL, V91, P1720, DOI 10.1136/bjo.2006.111583
   Johnson V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132013
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein ML, 2011, AM J OPHTHALMOL, V151, P161, DOI 10.1016/j.ajo.2010.07.020
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Lane-Donovan C, 2017, J LIPID RES, V58, P1036, DOI 10.1194/jlr.R075507
   Li C, 2007, ARCH OPHTHALMOL-CHIC, V125, P795, DOI 10.1001/archopht.125.6.795
   Linsenmeier RA, 2017, PROG RETIN EYE RES, V58, P115, DOI 10.1016/j.preteyeres.2017.01.003
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Ma WX, 2016, ADV EXP MED BIOL, V854, P73, DOI 10.1007/978-3-319-17121-0_11
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Marsiglia M, 2015, RETINA-J RET VIT DIS, V35, P966, DOI 10.1097/IAE.0000000000000460
   Miere A, 2017, RETINA
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Monson DM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1664, DOI 10.1001/archopht.126.12.1664
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Oeller JN, 1903, ATLAS RARE OPHTHALMO, V2
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Oishi A, 2017, INVEST OPHTH VIS SCI, V58, P2198, DOI 10.1167/iovs.16-20781
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Pang CE, 2014, AM J OPHTHALMOL, V158, P171, DOI 10.1016/j.ajo.2014.03.003
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   Phasukkijwatana N, 2017, BRIT J OPHTHALMOL, V101, P597, DOI 10.1136/bjophthalmol-2016-308815
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1241, DOI 10.1097/IAE.0b013e31827b639e
   Rodriguez IR, 2014, EXP EYE RES, V128, P151, DOI 10.1016/j.exer.2014.09.009
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Shijo T, 2017, GRAEF ARCH CLIN EXP, V255, P1125, DOI 10.1007/s00417-017-3622-0
   Shimada H, 2007, GRAEF ARCH CLIN EXP, V245, P295, DOI 10.1007/s00417-006-0367-6
   Skalet AH, 2017, RETINA-J RET VIT DIS, V37, P1620, DOI 10.1097/IAE.0000000000001672
   SLAKTER JS, 1994, ARCH OPHTHALMOL-CHIC, V112, P465, DOI 10.1001/archopht.1994.01090160041020
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Spaide R. F., 2017, RETINA
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Tan ACS, 2017, RETINA-J RET VIT DIS, V37, P234, DOI 10.1097/IAE.0000000000001343
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Vujosevic S, 2017, RETINA-J RET VIT DIS, V37, P1092, DOI 10.1097/IAE.0000000000001304
   Wright WS, 2011, EXP EYE RES, V93, P437, DOI 10.1016/j.exer.2011.06.003
   YAMAGISHI K, 1988, Nippon Ganka Gakkai Zasshi, V92, P1629
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
NR 82
TC 57
Z9 59
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2018
VL 125
IS 2
BP 276
EP 287
DI 10.1016/j.ophtha.2017.08.019
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FT0FN
UT WOS:000422797600028
PM 28964579
DA 2022-11-30
ER

PT J
AU Hall, JB
   Bailey, JNC
   Hoffman, JD
   Pericak-Vance, MA
   Scott, WK
   Kovach, JL
   Schwartz, SG
   Agarwal, A
   Brantley, MA
   Haines, JL
   Bush, WS
AF Hall, Jacob B.
   Bailey, Jessica N. Cooke
   Hoffman, Joshua D.
   Pericak-Vance, Margaret A.
   Scott, William K.
   Kovach, Jaclyn L.
   Schwartz, Stephen G.
   Agarwal, Anita
   Brantley, Milam A., Jr.
   Haines, Jonathan L.
   Bush, William S.
TI Estimating cumulative pathway effects on risk for age-related macular
   degeneration using mixed linear models
SO BMC BIOINFORMATICS
LA English
DT Article
DE Age-related macular degeneration (AMD); Heritability; Pathway analysis;
   Mixed linear model (MLM); Proportion of variance explained (PVE)
ID FACTOR-H POLYMORPHISM; COMPLEMENT; GENE; SUSCEPTIBILITY; PREVALENCE;
   DISEASE
AB Background: Age-related macular degeneration (AMD) is the leading cause of irreversible visual loss in the elderly in developed countries and typically affects more than 10 % of individuals over age 80. AMD has a large genetic component, with heritability estimated to be between 45 % and 70 %. Numerous variants have been identified and implicate various molecular mechanisms and pathways for AMD pathogenesis but those variants only explain a portion of AMD's heritability. The goal of our study was to estimate the cumulative genetic contribution of common variants on AMD risk for multiple pathways related to the etiology of AMD, including angiogenesis, antioxidant activity, apoptotic signaling, complement activation, inflammatory response, response to nicotine, oxidative phosphorylation, and the tricarboxylic acid cycle. While these mechanisms have been associated with AMD in literature, the overall extent of the contribution to AMD risk for each is unknown.
   Methods: In a case-control dataset with 1,813 individuals genotyped for over 600,000 SNPs we used Genome-wide Complex Trait Analysis (GCTA) to estimate the proportion of AMD risk explained by SNPs in genes associated with each pathway. SNPs within a 50 kb region flanking each gene were also assessed, as well as more distant, putatively regulatory SNPs, based on DNaseI hypersensitivity data from ocular tissue in the ENCODE project.
   Results: We found that 19 previously associated AMD risk SNPs contributed to 13.3 % of the risk for AMD in our dataset, while the remaining genotyped SNPs contributed to 36.7 % of AMD risk. Adjusting for the 19 risk SNPs, the complement activation and inflammatory response pathways still explained a statistically significant proportion of additional risk for AMD (9.8 % and 17.9 %, respectively), with other pathways showing no significant effects (0.3 % - 4.4 %).
   Discussion: Our results show that SNPs associated with complement activation and inflammation significantly contribute to AMD risk, separately from the risk explained by the 19 known risk SNPs. We found that SNPs within 50 kb regions flanking genes explained additional risk beyond genic SNPs, suggesting a potential regulatory role, but that more distant SNPs explained less than 0.5 % additional risk for each pathway.
   Conclusions: From these analyses we find that the impact of complement SNPs on risk for AMD extends beyond the established genome-wide significant SNPs.
C1 [Hall, Jacob B.; Hoffman, Joshua D.] Vanderbilt Univ, Grad Program Human Genet, Nashville, TN 37235 USA.
   [Bailey, Jessica N. Cooke] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Pericak-Vance, Margaret A.; Scott, William K.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Kovach, Jaclyn L.; Schwartz, Stephen G.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
   [Agarwal, Anita; Brantley, Milam A., Jr.] Vanderbilt Univ, Dept Ophthalmol & Visual Sci, Nashville, TN 37235 USA.
   [Haines, Jonathan L.; Bush, William S.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Inst Computat Biol, Cleveland, OH 44106 USA.
C3 Vanderbilt University; Case Western Reserve University; University of
   Miami; Bascom Palmer Eye Institute; University of Miami; Vanderbilt
   University; Case Western Reserve University
RP Bush, WS (通讯作者)，Case Western Reserve Univ, Dept Epidemiol & Biostat, Inst Computat Biol, Cleveland, OH 44106 USA.
EM wsb36@case.edu
RI Cooke Bailey, Jessica Nicole/AFQ-5925-2022; Haines,
   Jonathan/C-3374-2012; Bush, William/N-1369-2019; Bailey, Jessica
   Cooke/Q-5062-2019
OI Cooke Bailey, Jessica Nicole/0000-0002-4001-8702; Haines,
   Jonathan/0000-0002-4351-4728; Bush, William/0000-0002-9729-6519; Bailey,
   Jessica Cooke/0000-0002-4001-8702; Scott, William/0000-0001-9336-6404
FU ocular genomics training grant, from the National Institutes of Health
   [1T32EY021453-01]; PhRMA; NATIONAL EYE INSTITUTE [T32EY021453] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
   [T32GM080178] Funding Source: NIH RePORTER
FX This work was supported by an ocular genomics training grant,
   1T32EY021453-01, from the National Institutes of Health. JNCB is
   supported by a PhRMA postdoctoral fellowship in informatics. The funder
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bhosale P, 2004, J APPL MICROBIOL, V96, P623, DOI 10.1111/j.1365-2672.2004.02197.x
   BRALEY AE, 1966, AM J OPHTHALMOL, V61, P1
   Bush WS, 2010, AM J HUM GENET, V86, P621, DOI 10.1016/j.ajhg.2010.02.027
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heier JS, 2013, OPHTHALMOLOGY, V120, pS23, DOI 10.1016/j.ophtha.2013.01.059
   Hinrichs AS, 2006, NUCLEIC ACIDS RES, V34, pD590, DOI 10.1093/nar/gkj144
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Joshi-Tope G, 2005, NUCLEIC ACIDS RES, V33, pD428, DOI 10.1093/nar/gki072
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Naj AC, 2013, ANN HUM GENET, V77, P215, DOI 10.1111/ahg.12011
   Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29
   Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185
   Ramanan VK, 2012, TRENDS GENET, V28, P323, DOI 10.1016/j.tig.2012.03.004
   Sabo PJ, 2006, NAT METHODS, V3, P511, DOI 10.1038/NMETH890
   Schmidt S, 2000, MOL VIS, V6, P287
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang JA, 2011, AM J HUM GENET, V88, P76, DOI 10.1016/j.ajhg.2010.11.011
   Zhao C, 2011, AGING-US, V3, P346, DOI 10.18632/aging.100303
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 34
TC 6
Z9 6
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD OCT 14
PY 2015
VL 16
AR 329
DI 10.1186/s12859-015-0760-4
PG 9
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA CT3JX
UT WOS:000362704100001
PM 26467978
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ibuki, M
   Lee, D
   Shinojima, A
   Miwa, Y
   Tsubota, K
   Kurihara, T
AF Ibuki, Mari
   Lee, Deokho
   Shinojima, Ari
   Miwa, Yukihiro
   Tsubota, Kazuo
   Kurihara, Toshihide
TI Rice Bran and Vitamin B6 Suppress Pathological Neovascularization in a
   Murine Model of Age-Related Macular Degeneration as Novel HIF Inhibitors
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE hypoxia-inducible factor; age-related macular degeneration; vascular
   endothelial growth factor; food ingredients; rice bran; vitamin B6;
   retinal pigment epithelium
ID RETINAL-PIGMENT EPITHELIUM; VEGF; EXPRESSION; RETINOPATHY; THERAPY;
   CELLS
AB Pathological neovascularization in the eye is a leading cause of blindness in all age groups from retinopathy of prematurity (ROP) in children to age-related macular degeneration (AMD) in the elderly. Inhibiting neovascularization via antivascular endothelial growth factor (VEGF) drugs has been used for the effective treatment. However, anti-VEGF therapies may cause development of chorioretinal atrophy as they affect a physiological amount of VEGF essential for retinal homeostasis. Furthermore, anti-VEGF therapies are still ineffective in some cases, especially in patients with AMD. Hypoxia-inducible factor (HIF) is a strong regulator of VEGF induction under hypoxic and other stress conditions. Our previous reports have indicated that HIF is associated with pathological retinal neovascularization in murine models of ROP and AMD, and HIF inhibition suppresses neovascularization by reducing an abnormal increase in VEGF expression. Along with this, we attempted to find novel effective HIF inhibitors from natural foods of our daily lives. Food ingredients were screened for prospective HIF inhibitors in ocular cell lines of 661W and ARPE-19, and a murine AMD model was utilized for examining suppressive effects of the ingredients on retinal neovascularization. As a result, rice bran and its component, vitamin B6 showed inhibitory effects on HIF activation and suppressed VEGF mRNA induction under a CoCl2-induced pseudo-hypoxic condition. Dietary supplement of these significantly suppressed retinal neovascularization in the AMD model. These data suggest that rice bran could have promising therapeutic values in the management of pathological ocular neovascularization.
C1 [Ibuki, Mari; Lee, Deokho; Shinojima, Ari; Miwa, Yukihiro; Kurihara, Toshihide] Keio Univ, Lab Photobiol, Sch Med, Tokyo 1608582, Japan.
   [Ibuki, Mari; Lee, Deokho; Shinojima, Ari; Miwa, Yukihiro; Tsubota, Kazuo; Kurihara, Toshihide] Keio Univ, Dept Ophthalmol, Sch Med, Tokyo 1608582, Japan.
   [Miwa, Yukihiro] Tokyo Anim Eye Clin, Anim Eye Care, Tokyo 1580093, Japan.
   [Tsubota, Kazuo] Tsubota Lab Inc, Tokyo 1600016, Japan.
C3 Keio University; Keio University
RP Kurihara, T (通讯作者)，Keio Univ, Lab Photobiol, Sch Med, Tokyo 1608582, Japan.; Tsubota, K (通讯作者)，Tsubota Lab Inc, Tokyo 1600016, Japan.
EM shirayuki0727@yahoo.co.jp; deokholee@keio.jp; ari.shinojima@keio.jp;
   yukihiro226@gmail.com; tsubota@tsubota-lab.com; kurihara@z8.keio.jp
RI Shinojima, Ari/AAR-4442-2021; Tsubota, Kazuo/M-1915-2013
OI Shinojima, Ari/0000-0003-2322-0332; Tsubota, Kazuo/0000-0002-8874-7111;
   Kurihara, Toshihide/0000-0002-5457-2720; Miwa,
   Yukihiro/0000-0002-5377-6772; Lee, Deokho/0000-0002-5992-9039
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT)
   [18K09424]
FX This work was supported by Grants-in-Aid for Scientific Research
   (KAKENHI) (18K09424 to Toshihide Kurihara) from the Ministry of
   Education, Culture, Sports, Science and Technology (MEXT).
CR Ablonczy Z, 2014, FASEB J, V28, P2369, DOI 10.1096/fj.13-248021
   Bahrami B, 2019, CLIN EXP OPHTHALMOL, V47, P1074, DOI 10.1111/ceo.13579
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Cabral Thiago, 2017, Int J Retina Vitreous, V3, P31, DOI 10.1186/s40942-017-0084-9
   Chew EY, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12914
   Chu CY, 2016, INT J ONCOL, V48, P271, DOI 10.3892/ijo.2015.3253
   Ding J, 2012, CURR DIABETES REP, V12, P346, DOI 10.1007/s11892-012-0283-6
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Fogli S, 2018, EYE, V32, P1010, DOI 10.1038/s41433-018-0021-7
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Forooghian F, 2007, BRIT J OPHTHALMOL, V91, DOI 10.1136/bjo.2007.123125
   Giovannitti J A, 1991, Anesth Prog, V38, P154
   Gomez-Pinilla F, 2008, NAT REV NEUROSCI, V9, P568, DOI 10.1038/nrn2421
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gul K., 2015, BIOACT CARBOHYDR DIE, V6, P24, DOI [10.1016/j.bcdf.2015.06.002, DOI 10.1016/J.BCDF.2015.06.002]
   Hanyuda A, 2020, EYE, V34, P1465, DOI 10.1038/s41433-020-0820-5
   Hellinen L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50324-8
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Ibuki M, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00174
   Ibuki M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205049
   Inoue Y, 2007, BRIT J OPHTHALMOL, V91, P1720, DOI 10.1136/bjo.2006.111583
   Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009
   Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654
   Kunimi H, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133171
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Kurihara T, 2009, MOL VIS, V15
   Lawrenson JG, 2019, NUTRIENTS, V11, DOI 10.3390/nu11092123
   Lee D, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10101405
   Lehmann GL, 2014, EXP EYE RES, V126, P5, DOI 10.1016/j.exer.2014.04.021
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022
   Malek G, 2018, EXPERT OPIN DRUG DIS, V13, P359, DOI 10.1080/17460441.2018.1430136
   Mansour SE, 2020, CLIN OPHTHALMOL, V14, P653, DOI 10.2147/OPTH.S236637
   McCann JC, 2005, AM J CLIN NUTR, V82, P281, DOI 10.1093/ajcn/82.2.281
   Miwa Y, 2019, NEUROCHEM INT, V128, P21, DOI 10.1016/j.neuint.2019.03.008
   Mohamed Q, 2007, JAMA-J AM MED ASSOC, V298, P902, DOI 10.1001/jama.298.8.902
   Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200
   Noel A, 2007, TRENDS MOL MED, V13, P345, DOI 10.1016/j.molmed.2007.06.005
   Ohno H., 2012, J PHYS FITNESS SPORT, V1, P5, DOI [10.7600/jpfsm.1.5, DOI 10.7600/JPFSM.1.5]
   Okamoto T, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.20
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   Park HY, 2017, FOOD FUNCT, V8, P935, DOI 10.1039/c6fo01763k
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sasaki M, 2012, J NUTR BIOCHEM, V23, P423, DOI 10.1016/j.jnutbio.2011.01.006
   Sayyad Z, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17241-0
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Shoda C, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041055
   Simo R, 2009, DIABETES CARE, V32, P1556, DOI 10.2337/dc09-0565
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Takei A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42546
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
NR 54
TC 13
Z9 12
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2020
VL 21
IS 23
AR 8940
DI 10.3390/ijms21238940
PG 25
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA PD2EJ
UT WOS:000597504400001
PM 33255657
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wolf, S
   Holz, FG
   Midena, E
   Souied, EH
   Lambrou, G
   Machewitz, T
   Allmeier, H
   Mitchell, P
AF Wolf, Sebastian
   Holz, Frank G.
   Midena, Edoardo
   Souied, Eric H.
   Lambrou, George
   Machewitz, Tobias
   Allmeier, Helmut
   Mitchell, Paul
CA ARIES Study Investigators
TI Patients with Neovascular Age-Related Macular Degeneration Requiring
   Intensive Intravitreal Aflibercept Treatment: An ARIES Post Hoc Analysis
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Injection-intensive; Intravitreal aflibercept; Neovascular age-related
   macular degeneration; Treat-and-extend; Treatment intervals; Treatment
   outcomes
ID ENDOTHELIAL GROWTH-FACTOR; REGIMENS; EFFICACY; SAFETY
AB Introduction The aim of this post hoc analysis of the ARIES study is to explore the requirement for intravitreal aflibercept (IVT-AFL) treatment intervals of < 8 weeks (w) in patients with neovascular age-related macular degeneration (nAMD), and to assess vision and anatomic outcomes in such patients who require more intensive treatment. Methods ARIES was a multicenter, randomized, phase 3b/4 study that investigated the efficacy of two IVT-AFL proactive, individualized, treat-and-extend regimens over 2 years in treatment-naive patients with nAMD. Patients were determined as injection-intensive if the study investigator identified that a treatment interval of < 8 w was needed and if they had >= 1 interval of < 8 w after three initial monthly doses. Treatment intervals could be extended subsequently if extension criteria were met. This is a post hoc analysis of patients enrolled in ARIES and statistical analysis is descriptive. Results Of 269 patients in the combined treatment arms, 23.0% (n = 62) were injection-intensive (Year 1: 13.8% [n = 37]; Year 2: 9.3% [n = 25]). Time from IVT-AFL initiation to injection-intensive determination varied (range, 16-100 w; median: 43.2 w). Mean treatment interval was 8.4 w before and 6.1 w after injection-intensive determination. Overall, 59.7% achieved treatment intervals of >= 8 w following injection-intensive determination. Vision improvements from baseline to Week 104 were smaller for injection-intensive patients than non-injection-intensive patients (mean [SD] best-corrected visual acuity change: + 2.3 [15.6] vs. + 5.9 [12.3] letters). Anatomic outcomes were similar between injection-intensive and non-injection-intensive patients (central retinal thickness change from baseline to Week 104: - 160 [154] vs. - 167 [136] mu m). Conclusions In ARIES, 23% of treatment-naive patients with nAMD experienced at least one treatment interval of < 8 w. Injection-intensive patients showed improved vision and anatomic outcomes. For most, treatment intervals could be extended to >= 8 w following injection-intensive determination. ClinicalTrials.gov Identifier: NCT02581891.
C1 [Wolf, Sebastian] Univ Bern, Univ Hosp, Inselspital, Reading Ctr, Freiburgstr, CH-3010 Bern, Switzerland.
   [Wolf, Sebastian] Univ Bern, Univ Hosp, Inselspital, Dept Ophthalmol, Freiburgstr, CH-3010 Bern, Switzerland.
   [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Midena, Edoardo] Univ Padua, Dept Ophthalmol, Padua, Italy.
   [Souied, Eric H.] Univ Paris Est Creteil, Hop Intercommunal Creteil, Dept Ophtalmol, Creteil, France.
   [Lambrou, George; Allmeier, Helmut] Bayer Consumer Care AG, Pharmaceut, Basel, Switzerland.
   [Machewitz, Tobias] Bayer AG, Berlin, Germany.
   [Mitchell, Paul] Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
C3 University of Bern; University Hospital of Bern; University of Bern;
   University Hospital of Bern; University of Bonn; University of Padua;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Bayer AG;
   Bayer AG; University of Sydney; Westmead Institute for Medical Research
RP Wolf, S (通讯作者)，Univ Bern, Univ Hosp, Inselspital, Reading Ctr, Freiburgstr, CH-3010 Bern, Switzerland.; Wolf, S (通讯作者)，Univ Bern, Univ Hosp, Inselspital, Dept Ophthalmol, Freiburgstr, CH-3010 Bern, Switzerland.
EM sebastian.wolf@insel.ch
RI Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028
FU Bayer AG, Leverkusen, Germany - Bayer Consumer Care AG, Basel,
   Switzerland
FX The ARIES study was sponsored by Bayer AG, Leverkusen, Germany. This
   post hoc analysis and the journal's Rapid Service Fees were funded by
   Bayer Consumer Care AG, Basel, Switzerland.
CR [Anonymous], 2021, EYLEA PRESCRIBING IN
   [Anonymous], 2021, AFLIBERCEPT EYLEA SU
   Brown DM, 2022, EVALUATION 8 MG INTR
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Mitchell P, 2021, RETINA-J RET VIT DIS, V41, P1911, DOI 10.1097/IAE.0000000000003128
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Ross AH, 2020, EYE, V34, P1825, DOI 10.1038/s41433-019-0747-x
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
NR 10
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD OCT
PY 2022
VL 11
IS 5
BP 1793
EP 1803
DI 10.1007/s40123-022-00541-8
EA JUL 2022
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4I0YA
UT WOS:000823335800001
PM 35821380
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Qiu, FF
   Meng, T
   Chen, Q
   Zhou, KL
   Shao, Y
   Matlock, G
   Ma, X
   Wu, WJ
   Du, YH
   Wang, X
   Deng, GT
   Ma, JX
   Xu, QG
AF Qiu, Fangfang
   Meng, Tuo
   Chen, Qian
   Zhou, Kelu
   Shao, Yan
   Matlock, Greg
   Ma, Xiang
   Wu, Wenjing
   Du, Yanhong
   Wang, Xiang
   Deng, Guotao
   Ma, Jian-xing
   Xu, Qingguo
TI Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of
   Experimental Diabetic Retinopathy and Neovascular Age-Related Macular
   Degeneration
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE nanoparticle; PLGA; ocular neovascularization; age-related macular
   degeneration; diabetic retinopathy; PPAR alpha
ID ENDOTHELIAL GROWTH-FACTOR; INTERCELLULAR-ADHESION MOLECULE-1; PPAR-ALPHA
   AGONIST; INTRAVITREAL INJECTIONS; TERM COMPLICATIONS; DOWN-REGULATION;
   DRUG-DELIVERY; PHARMACOKINETICS; BIOAVAILABILITY; ANGIOGENESIS
AB Fenofibrate is a peroxisome proliferatoractivated receptor alpha (PPAR alpha) agonist and has been shown to have therapeutic effects on diabetic retinopathy (DR). However, the effects of fenofibrate through systemic administration are not as potent as desired due to inefficient drug delivery to the retina. The present study aimed to explore the sustained therapeutic effects of fenofibrate-loaded biodegradable nanoparticles (NP) on both DR and neovascular age-related macular degeneration (AMD). Fenofibrate was successfully encapsulated into poly(lactic-co-glycolic acid) (PLGA) NP (Feno-NP), and Feno-NP were optimized by varying polymer composition to achieve high drug loading and prolonged drug release. The Feno-NP made of PLGA 34 kDa demonstrated a drug content of 6% w/w and a sustained drug release up to 60 days in vitro. Feno-NP (PLGA 34 kDa) was selected for following in vivo studies, and one single intravitreal (IVT) injection of Feno-NP into rat eyes with a 30G fine needle maintained sustained fenofibric acid drug level in the eye for more than 60 days. The efficacy of Feno-NP in DR and neovascular AMD was investigated using streptozotocin (STZ)-induced diabetic rats, laser-induced choroidal neovascularization (CNV) rats, and very low-density lipoprotein receptor knockout (Vldlr(-/-)) mice. Therapeutic effects of Feno-NP were evaluated by measuring electroretinogram (ERG), retinal vascular leakage, leukostasis, CNV size, and retinal levels of vascular endothelial growth factor (VEGF) and intracellular adhesion molecule-1 (ICAM-1). In diabetic rats, Feno-NP ameliorated retinal dysfunctions, reduced retinal vascular leakage, inhibited retinal leukostasis, and downregulated the overexpression of VEGF and ICAM-1 at 8 weeks after one IVT injection. In addition, Feno-NP reduced retinal vascular leakage and CNV formation in both CNV rats and Vldlr(-/-) mice. Moreover, no toxicity of Feno-NP or Blank-NP to retinal structure and function was detected. Feno-NP exhibited good physiochemical characteristics and controlled drug release profile, conferring prolonged beneficial effects on DR and neovascular AMD.
C1 [Qiu, Fangfang; Chen, Qian; Zhou, Kelu; Shao, Yan; Matlock, Greg; Ma, Xiang; Wu, Wenjing; Du, Yanhong; Deng, Guotao; Ma, Jian-xing] Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK 73104 USA.
   [Qiu, Fangfang] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Sect Endocrinol & Diabet, Oklahoma City, OK 73104 USA.
   [Wang, Xiang] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA.
   [Meng, Tuo; Xu, Qingguo] Virginia Commonwealth Univ, Dept Pharmaceut, Richmond, VA 23298 USA.
   [Xu, Qingguo] Virginia Commonwealth Univ, Dept Ophthalmol, Richmond, VA 23298 USA.
   [Xu, Qingguo] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA.
   [Chen, Qian] Xiamen Univ, Eye Inst, Xiamen 361000, Fujian, Peoples R China.
   [Shao, Yan] Tianjin Med Univ, Eye Hosp, Tianjin 300384, Peoples R China.
   [Deng, Guotao] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center; University of Oklahoma System; University of Oklahoma
   Health Sciences Center; Virginia Commonwealth University; Virginia
   Commonwealth University; Virginia Commonwealth University; Xiamen
   University; Tianjin Medical University; Sun Yat Sen University
RP Ma, JX (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK 73104 USA.; Xu, QG (通讯作者)，Virginia Commonwealth Univ, Dept Pharmaceut, Richmond, VA 23298 USA.; Xu, QG (通讯作者)，Virginia Commonwealth Univ, Dept Ophthalmol, Richmond, VA 23298 USA.; Xu, QG (通讯作者)，Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA.
EM Jian-xing-Ma@ouhsc.edu; qxu@vcu.edu
RI Meng, Tuo/AGD-5727-2022; Qiu, Fangfang/GLT-3181-2022; Qiu,
   Fangfang/GLT-3151-2022
OI Meng, Tuo/0000-0003-4190-2521; Qiu, Fangfang/0000-0002-3584-0275; Qiu,
   Fangfang/0000-0002-3584-0275; Wang, Xiang/0000-0003-3304-5996
FU National Institutes of Health (NIH) [EY027827, EY018659, EY019309,
   GM122744]; Juvenile Diabetes Research Foundation Innovative (JDRF)
   [2-SRA-2014-147-QR]; Oklahoma Center for the Advancement of Science and
   Technology (OCAST) [HR16-041]; Ralph E. Powe Junior Faculty Enhancement
   Award; NATIONAL EYE INSTITUTE [R01EY027827, R01EY019309, R01EY018659]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCES [P30GM122744] Funding Source: NIH RePORTER
FX This study was supported by grants from National Institutes of Health
   (NIH) (EY027827, EY018659, EY019309, GM122744), a Juvenile Diabetes
   Research Foundation Innovative (JDRF) grant (2-SRA-2014-147-QR), an
   Oklahoma Center for the Advancement of Science and Technology (OCAST)
   grant (HR16-041), and a Ralph E. Powe Junior Faculty Enhancement Award.
   The funding organization had no role in the design or conduct of this
   research. The authors acknowledge Drew Wassel in Charlesson LLC,
   Oklahoma City, Oklahoma State, for the assistance with LC-MS/MS
   analysis.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Ashton S, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad2355
   Attridge RL, 2013, AM J HEALTH-SYST PH, V70, P1219, DOI 10.2146/ajhp120131
   BALFOUR JA, 1990, DRUGS, V40, P260, DOI 10.2165/00003495-199040020-00007
   Boyer DS, 2014, OPHTHALMOLOGY, V121, P1904, DOI 10.1016/j.ophtha.2014.04.024
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216
   Chen Y, 2013, DIABETES, V62, P261, DOI 10.2337/db11-0413
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Chew EY, 2010, NEW ENGL J MED, V363, P233, DOI 10.1056/NEJMoa1001288
   Chibber R, 2007, CURR DIABETES REV, V3, P3, DOI 10.2174/157339907779802139
   Clermont A, 2011, DIABETES, V60, P1590, DOI 10.2337/db10-1260
   Deng GT, 2017, INVEST OPHTH VIS SCI, V58, P5030, DOI 10.1167/iovs.16-21402
   Deng YP, 2017, CELL PHYSIOL BIOCHEM, V42, P2255, DOI 10.1159/000479999
   Esmaeili MA, 2016, HUM MOL GENET, V25, P317, DOI 10.1093/hmg/ddv477
   Galvao J, 2014, FASEB J, V28, P1317, DOI 10.1096/fj.13-235440
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gong Y, 2016, EBIOMEDICINE, V13, P201, DOI 10.1016/j.ebiom.2016.09.025
   Guay DRP, 1999, ANN PHARMACOTHER, V33, P1083, DOI 10.1345/aph.18432
   Heikkinen EM, 2018, EUR J PHARM SCI, V123, P106, DOI 10.1016/j.ejps.2018.07.034
   Hu Y, 2013, P NATL ACAD SCI USA, V110, P15401, DOI 10.1073/pnas.1307211110
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jiang C, 2007, MOL VIS, V13, P1783
   Jin J, 2011, INVEST OPHTH VIS SCI, V52, P6230, DOI 10.1167/iovs.10-6229
   Jonas JB, 2008, EYE, V22, P590, DOI 10.1038/eye.2008.10
   Joussen AM, 2002, AM J PATHOL, V160, P501, DOI 10.1016/S0002-9440(10)64869-9
   Keating GM, 2011, AM J CARDIOVASC DRUG, V11, P227, DOI 10.2165/11207690-000000000-00000
   Keech AC, 2007, LANCET, V370, P1687, DOI 10.1016/S0140-6736(07)61607-9
   Klose D, 2009, EUR J PHARM SCI, V37, P43, DOI 10.1016/j.ejps.2008.12.016
   Kompella UB, 2013, PROG RETIN EYE RES, V36, P172, DOI 10.1016/j.preteyeres.2013.04.001
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Lecleire-Collet A, 2011, INVEST OPHTH VIS SCI, V52, P2861, DOI 10.1167/iovs.10-5960
   Lee SS, 2010, PHARM RES-DORDR, V27, P2043, DOI 10.1007/s11095-010-0159-x
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Losey P, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0295-7
   Luo LX, 2019, J CONTROL RELEASE, V296, P68, DOI 10.1016/j.jconrel.2019.01.018
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836
   Moran EP, 2015, PPAR RES, V2015, DOI 10.1155/2015/595426
   Nguyen DH, 2013, DISCOV MED, V15, P343
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Pan Q, 2015, J CONTROL RELEASE, V201, P32, DOI 10.1016/j.jconrel.2015.01.009
   Park K, 2009, DIABETES, V58, P1902, DOI 10.2337/db08-1327
   Patel CM, 2014, ULTRASON SONOCHEM, V21, P1100, DOI 10.1016/j.ultsonch.2013.12.001
   Patil H, 2015, AAPS J, V17, P194, DOI 10.1208/s12248-014-9674-8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Shen Y.G.W., 2014, J CLIN EXP OPHTHALMO, V5, P5, DOI [10.4172/2155-9570.1000347, DOI 10.4172/2155-9570.1000347]
   Tien T, 2014, MOL VIS, V20, P732
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Tranos P, 2013, DRUG DES DEV THER, V7, P485, DOI 10.2147/DDDT.S43470
   Tsai TI, 2009, DOC OPHTHALMOL, V119, P199, DOI 10.1007/s10633-009-9191-8
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   Varet J, 2003, CELL MOL LIFE SCI, V60, P810, DOI 10.1007/s00018-003-2322-6
   Vlase L, 2010, ARZNEIMITTEL-FORSCH, V60, P560, DOI 10.1055/s-0031-1296325
   Wang B, 2019, NANOMED-NANOTECHNOL, V17, P119, DOI 10.1016/j.nano.2019.01.001
   Xu QG, 2013, J CONTROL RELEASE, V170, P279, DOI 10.1016/j.jconrel.2013.05.035
   Xu Qingguo, 2013, Middle East Afr J Ophthalmol, V20, P26, DOI 10.4103/0974-9233.106384
   Yerramothu P, 2018, EYE, V32, P491, DOI 10.1038/eye.2017.241
   Yousaf AM, 2015, INT J NANOMED, V10, P1819, DOI 10.2147/IJN.S78895
   2017, INVEST OPHTHALMOL VI, V58, P5065
   2018, MOL CELL BIOCH, V445, P105
   2016, ASIAN J PHARM SCI, V11, P507
NR 63
TC 37
Z9 38
U1 4
U2 41
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD MAY
PY 2019
VL 16
IS 5
BP 1958
EP 1970
DI 10.1021/acs.molpharmaceut.8b01319
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA HX4FV
UT WOS:000467351300016
PM 30912953
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Sun, C
   Zhao, M
   Li, XX
AF Sun, Chuan
   Zhao, Min
   Li, Xiaoxin
TI CFB/C2 Gene Polymorphisms and Risk of Age-Related Macular Degeneration:
   A Systematic Review and Meta-Analysis
SO CURRENT EYE RESEARCH
LA English
DT Review
DE CFB/C2 gene; Polymorphisms; Age-related macular degeneration; Systematic
   review; Meta-analysis
ID COMPLEMENT-FACTOR-H; GENOME-WIDE ASSOCIATION; HARDY-WEINBERG
   EQUILIBRIUM; COMPONENT 2 C2; FACTOR-B BF; EYE DISEASE; CHINESE
   POPULATION; CUMULATIVE METAANALYSIS; INCREASES RISK; EXACT TESTS
AB Purpose: To investigate whether the polymorphisms of CFB/C2 gene are associated with age-related macular degeneration (AMD), and to evaluate the magnitude of gene effect.
   Methods: We performed a meta-analysis of the association between four SNPs in CFB/C2 gene (rs9332739, rs547154, rs4151667, and rs641153) and risk of AMD using data from 15 case-control studies involving 8905 subjects. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using fixed-and random-effects models. The Q and I-2 statistics were used to evaluate between-study heterogeneity. Harbord's modified test was used to detect small study effects. Sensitivity analysis, cumulative meta-analysis, and meta-regression were also performed.
   Results: For rs9332739, rs547154, rs4151667, and rs641153, the pooled ORs in a dominant genetic model were 0.474 (fixed effects, P < 0.001, 95% CI 0.378-0.596), 0.399 (random effects, 95% CI 0.289-0.551, P < 0.001), 0.496 (fixed effects, 95% CI 0.390-0.632, P < 0.001), and 0.557 (random effects, P = 0.008, 95% CI 0.362-0.856), respectively. These results suggested that variant alleles of all the four SNPs has significant protective effect against AMD. Contour-enhanced funnel plots and Harbord's test showed moderate small study effects for rs9332739 and rs4151667. Heterogeneity were found for rs547154 and rs641153, subgroup analysis suggested that ethnicity was the main source for heterogeneity. Stratification by ethnicity indicated stronger protective effects of rare alleles in Caucasians. Genotype distribution analysis also suggested that frequencies of rare homozygous genotype were higher in Caucasian group.
   Conclusions: Our meta-analysis indicated strong protective effects of the variant alleles of four SNPs in CFB/C2 gene (rs9332739, rs547154, rs4151667, and rs641153) against AMD. The disease risk descended to nearly one half for individuals carrying at least one copy of the rare alleles. The protective effects seemed to be stronger in Caucasians, of which the genotype frequencies were also higher.
C1 [Sun, Chuan; Zhao, Min; Li, Xiaoxin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China.
   Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China.
C3 Peking University
RP Li, XX (通讯作者)，Peking Univ, Peoples Hosp, Dept Ophthalmol, Xizhimen S St 11, Beijing 100044, Peoples R China.
EM drlixiaoxin@163.com
OI Zhao, Min/0000-0003-0521-9186
FU National Basic Research Program of China (973 program) [2011 CB 510200]
FX This research is supported by grants from the National Basic Research
   Program of China (973 program, No. 2011 CB 510200). The authors thank
   Dr. Zhenglin Yang, who kindly provided them allele and genotype counts
   data for this meta-analysis.
CR Altman DG, 2001, BMJ-BRIT MED J, V323, P224, DOI 10.1136/bmj.323.7306.224
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Attia J, 2003, J CLIN EPIDEMIOL, V56, P297, DOI 10.1016/S0895-4356(03)00011-8
   Baatz H, 2009, KLIN MONATSBL AUGENH, V226, P654, DOI 10.1055/s-0028-1109318
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Doney ASF, 2009, DIABETIC MED, V26, P460, DOI 10.1111/j.1464-5491.2009.02719.x
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Ioannidis JPA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000841
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406
   LAU J, 1995, J CLIN EPIDEMIOL, V48, P45, DOI 10.1016/0895-4356(94)00106-Z
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   LOKKI ML, 1991, IMMUNOGENETICS, V34, P242, DOI 10.1007/BF00215259
   Mckay GJ, 2010, MOL VIS, V16, P194
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Moreno SG, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2981
   Muckersie E, 2008, EXP EYE RES, V87, P543
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Peters JL, 2008, J CLIN EPIDEMIOL, V61, P991, DOI 10.1016/j.jclinepi.2007.11.010
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Rama D. J., 2008, NEW ENGL J MED, V358, P2606
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Rucker G, 2011, BIOMETRICAL J, V53, P351, DOI 10.1002/bimj.201000151
   Ryu E, 2010, MOL VIS, V16, P2811
   Schaid DJ, 2006, AM J HUM GENET, V79, P1071, DOI 10.1086/510257
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864
NR 57
TC 20
Z9 21
U1 0
U2 7
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0271-3683
J9 CURR EYE RES
JI Curr. Eye Res.
PD APR
PY 2012
VL 37
IS 4
BP 259
EP 271
DI 10.3109/02713683.2011.635401
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 915UK
UT WOS:000302052700001
PM 22440158
DA 2022-11-30
ER

PT J
AU Lujan, LML
   McCarty, MF
   Di Nicolantonio, JJ
   Ruiz, JCG
   Rosas-Burgos, EC
   Plascencia-Jatomea, M
   Assanga, SBI
AF Lewis Lujan, Lidianys Maria
   McCarty, Mark F.
   Di Nicolantonio, James J.
   Galvez Ruiz, Juan Carlos
   Rosas-Burgos, Ema Carina
   Plascencia-Jatomea, Maribel
   Iloki Assanga, Simon Bernard
TI Nutraceuticals/Drugs Promoting Mitophagy and Mitochondrial Biogenesis
   May Combat the Mitochondrial Dysfunction Driving Progression of Dry
   Age-Related Macular Degeneration
SO NUTRIENTS
LA English
DT Review
DE nutraceuticals; age-related macular degeneration; mitochondrial
   biogenesis; Sirt1; AMPK; Nrf2; ferulic acid; melatonin; berberine;
   astaxanthin
ID ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; GLYCINE INHIBITS ANGIOGENESIS;
   OXIDATIVE STRESS; FERULIC ACID; SKELETAL-MUSCLE; PPAR-ALPHA; ALU RNA;
   INFLAMMASOME ACTIVATION; MEDIATED REGULATION
AB In patients with age-related macular degeneration (AMD), the crucial retinal pigment epithelial (RPE) cells are characterized by mitochondria that are structurally and functionally defective. Moreover, deficient expression of the mRNA-editing enzyme Dicer is noted specifically in these cells. This Dicer deficit up-regulates expression of Alu RNA, which in turn damages mitochondria-inducing the loss of membrane potential, boosting oxidant generation, and causing mitochondrial DNA to translocate to the cytoplasmic region. The cytoplasmic mtDNA, in conjunction with induced oxidative stress, triggers a non-canonical pathway of NLRP3 inflammasome activation, leading to the production of interleukin-18 that acts in an autocrine manner to induce apoptotic death of RPE cells, thereby driving progression of dry AMD. It is proposed that measures which jointly up-regulate mitophagy and mitochondrial biogenesis (MB), by replacing damaged mitochondria with "healthy" new ones, may lessen the adverse impact of Alu RNA on RPE cells, enabling the prevention or control of dry AMD. An analysis of the molecular biology underlying mitophagy/MB and inflammasome activation suggests that nutraceuticals or drugs that can activate Sirt1, AMPK, Nrf2, and PPAR alpha may be useful in this regard. These include ferulic acid, melatonin urolithin A and glucosamine (Sirt1), metformin and berberine (AMPK), lipoic acid and broccoli sprout extract (Nrf2), and fibrate drugs and astaxanthin (PPAR alpha). Hence, nutraceutical regimens providing physiologically meaningful doses of several or all of the: ferulic acid, melatonin, glucosamine, berberine, lipoic acid, and astaxanthin, may have potential for control of dry AMD.
C1 [Lewis Lujan, Lidianys Maria; Rosas-Burgos, Ema Carina; Plascencia-Jatomea, Maribel] Univ Sonora, Dept Res & Postgrad Food, Blvd Luis Encinas & Rosales S-N, Hermosillo 83000, Sonora, Mexico.
   [McCarty, Mark F.] Catalyt Longev Fdn, San Diego, CA 92109 USA.
   [Di Nicolantonio, James J.] St Lukes Mid Amer Heart Inst, Kansas City, MO 64111 USA.
   [Galvez Ruiz, Juan Carlos; Iloki Assanga, Simon Bernard] Sonora Univ, Dept Biol Chem Sci, Blvd Luis Encinas & Rosales, Hermosillo 83000, Sonora, Mexico.
C3 Universidad de Sonora; Saint Luke's Mid America Heart Institute;
   Universidad de Sonora
RP Assanga, SBI (通讯作者)，Sonora Univ, Dept Biol Chem Sci, Blvd Luis Encinas & Rosales, Hermosillo 83000, Sonora, Mexico.
EM lidianys1@yahoo.es; markfmccarty@gmail.com; jjdinicol@gmail.com;
   juan.galvez@unison.mx; carina.rosas@unison.mx;
   maribel.plascencia@unison.mx; ilokiassanga@gmail.com
RI Iloki Assanga, Simon Bernard/GNP-3218-2022; Plascencia-Jatomea,
   Maribel/G-2019-2018
OI Iloki Assanga, Simon Bernard/0000-0002-2058-5881; DiNicolantonio,
   James/0000-0002-7888-1528; Plascencia-Jatomea,
   Maribel/0000-0003-0339-3658; Rosas-Burgos, Ema
   Carina/0000-0002-2836-0898; Galvez-Ruiz, Juan Carlos/0000-0002-4035-313X
CR Alvarez-Guardia D, 2010, CARDIOVASC RES, V87, P449, DOI 10.1093/cvr/cvq080
   Amin K, 2003, CANCER BIOL THER, V2, P173, DOI 10.4161/cbt.2.2.280
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Blitzer AL, 2021, JAMA OPHTHALMOL, V139, P302, DOI 10.1001/jamaophthalmol.2020.6331
   Botta M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041197
   Brandstetter C, 2015, J BIOL CHEM, V290, P31189, DOI 10.1074/jbc.M115.671180
   Brown EE, 2019, INVEST OPHTH VIS SCI, V60, P1470, DOI 10.1167/iovs.18-26422
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Bruns H, 2016, AMINO ACIDS, V48, P2549, DOI 10.1007/s00726-016-2278-0
   Bumrungpert A, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060713
   Campagna R, 2021, BBA-MOL CELL RES, V1868, DOI 10.1016/j.bbamcr.2021.119082
   Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Chai TF, 2012, CELL SIGNAL, V24, P1700, DOI 10.1016/j.cellsig.2012.04.017
   Chan EC, 2015, CURR PHARM DESIGN, V21, P5988, DOI 10.2174/1381612821666151029111127
   Chan EC, 2013, INVEST OPHTH VIS SCI, V54, P7061, DOI 10.1167/iovs.13-12883
   Chen Y, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2021.11909
   Chen YY, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/1649156
   Chimento A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061381
   Choi HD, 2011, PLANT FOOD HUM NUTR, V66, P363, DOI 10.1007/s11130-011-0258-9
   Costford SR, 2010, AM J PHYSIOL-ENDOC M, V298, pE117, DOI 10.1152/ajpendo.00318.2009
   Das S, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/345105
   de la Rosa A, 2022, MED SCI SPORT EXER, V54, P466, DOI 10.1249/MSS.0000000000002821
   Di Virgilio F, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00039
   Dieguez HH, 2020, J PINEAL RES, V68, DOI 10.1111/jpi.12643
   Ding D, 2021, J CELL PHYSIOL, V236, P2740, DOI 10.1002/jcp.30040
   Ding YW, 2016, INT J MOL MED, V37, P1049, DOI 10.3892/ijmm.2016.2503
   Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899
   Du KW, 2021, IMMUN INFLAMM DIS, V9, P710, DOI 10.1002/iid3.424
   Duncan JG, 2007, CIRCULATION, V115, P909, DOI 10.1161/CIRCULATIONAHA.106.662296
   Ebeling MC, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101552
   EL-Mesallamy HO, 2018, ENVIRON SCI POLLUT R, V25, P6218, DOI 10.1007/s11356-017-0873-6
   Fang J, 2018, AGING-US, V10, P2954, DOI 10.18632/aging.101602
   Fang R, 2017, J IMMUNOL, V199, P3222, DOI 10.4049/jimmunol.1700699
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Feng KM, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251925
   Fruchart JC, 2006, DRUGS TODAY, V42, P39, DOI 10.1358/dot.2006.42.1.963528
   Fukuda S, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2022751118
   Fulco M, 2008, DEV CELL, V14, P661, DOI 10.1016/j.devcel.2008.02.004
   Gerding H, 2009, KLIN MONATSBL AUGENH, V226, P216, DOI 10.1055/s-0028-1109326
   Ghosh N, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76564-7
   Giralt A, 2011, J BIOL CHEM, V286, P16958, DOI 10.1074/jbc.M110.202390
   Gleyzer N, 2005, MOL CELL BIOL, V25, P1354, DOI 10.1128/MCB.25.4.1354-1366.2005
   Gupta P, 2022, J LEUKOCYTE BIOL, V111, P611, DOI 10.1002/JLB.3A0620-348RR
   Han CF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01654-6
   Han L, 2020, FOOD FUNCT, V11, P3073, DOI [10.1039/c9fo02334h, 10.1039/C9FO02334H]
   Hariharan N, 2010, CIRC RES, V107, P1470, DOI 10.1161/CIRCRESAHA.110.227371
   Hawley SA, 2010, CELL METAB, V11, P554, DOI 10.1016/j.cmet.2010.04.001
   Hong SY, 2015, NAT MED, V21, P887, DOI 10.1038/nm.3882
   Hou TT, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109205
   Jacobs KM, 2008, INT J BIOL SCI, V4, P291
   Jeffrey S, 2021, CURR DIABETES REV, V17, DOI 10.2174/1573399817666210118145550
   Jia Y, 2016, J NUTR BIOCHEM, V28, P9, DOI [10.1016/j.jnutbio.2015.09.015, 10.20463/jenb.2016.0055]
   Jia Y, 2012, MOL NUTR FOOD RES, V56, P878, DOI 10.1002/mnfr.201100798
   Jiang QX, 2016, MOL CELL BIOCHEM, V420, P171, DOI 10.1007/s11010-016-2787-x
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kensler TW, 2013, TOP CURR CHEM, V329, P163, DOI 10.1007/128_2012_339
   Kersten S, 2014, MOL METAB, V3, P354, DOI 10.1016/j.molmet.2014.02.002
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Khoo HE, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8040085
   Kim J, 2011, CELL CYCLE, V10, P1337, DOI 10.4161/cc.10.9.15291
   Kim SH, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091137
   Kim YM, 2017, AM J PHYSIOL-CELL PH, V312, pC749, DOI 10.1152/ajpcell.00346.2016
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Koczor CA, 2015, PHYSIOL GENOMICS, V47, P447, DOI 10.1152/physiolgenomics.00045.2015
   Kong XX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011707
   Koriyama Y, 2013, BRAIN RES, V1499, P145, DOI 10.1016/j.brainres.2012.12.041
   Krestinina O, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22157964
   Krestinina O, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9030262
   Kyung S, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102524
   Lan F, 2008, J BIOL CHEM, V283, P27628, DOI 10.1074/jbc.M805711200
   Lee YS, 2006, DIABETES, V55, P2256, DOI 10.2337/db06-0006
   Lem DW, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10081255
   Liang YP, 2019, ENDOCR J, V66, P51, DOI 10.1507/endocrj.EJ18-0109
   Lim S, 2022, PHARMACOL RES, V176, DOI 10.1016/j.phrs.2021.106052
   Liu XH, 2017, CELL CYCLE, V16, P1302, DOI 10.1080/15384101.2017.1320004
   Mao XY, 2016, DISCOV MED, V22, P337
   Mashhadi NS, 2018, ASIA PAC J CLIN NUTR, V27, P341, DOI 10.6133/apjcn.052017.11
   McCarty MF, 2007, J MED FOOD, V10, P566, DOI 10.1089/jmf.2007.621
   McCarty MF, 2019, MED HYPOTHESES, V123, P125, DOI 10.1016/j.mehy.2019.01.012
   McCarty MF, 2018, MED HYPOTHESES, V118, P114, DOI 10.1016/j.mehy.2018.06.032
   McCarty MF, 2019, J DIET SUPPL, V16, P179, DOI 10.1080/19390211.2018.1448920
   Moghadam FH, 2018, EUR J PHARMACOL, V841, P104, DOI 10.1016/j.ejphar.2018.10.003
   Musi N, 2002, DIABETES, V51, P2074, DOI 10.2337/diabetes.51.7.2074
   NikoliA N., 2012, BIOCHEM RES INT, V2012
   Oslowski CM, 2012, CELL METAB, V16, P265, DOI 10.1016/j.cmet.2012.07.005
   Pacholec M, 2010, J BIOL CHEM, V285, P8340, DOI 10.1074/jbc.M109.088682
   Piantadosi CA, 2008, CIRC RES, V103, P1232, DOI 10.1161/01.RES.0000338597.71702.ad
   Pinelli R, 2020, ARCH ITAL BIOL, V158, P24, DOI 10.12871/00039829202013
   Remels AHV, 2013, BBA-MOL BASIS DIS, V1832, P1313, DOI 10.1016/j.bbadis.2013.03.018
   Ren YF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040705
   Revollo JR, 2004, J BIOL CHEM, V279, P50754, DOI 10.1074/jbc.M408388200
   Romdhoniyyah DF, 2021, OPHTHALMOL THER, V10, P245, DOI 10.1007/s40123-021-00344-3
   Rose ML, 1999, CARCINOGENESIS, V20, P793, DOI 10.1093/carcin/20.5.793
   Russell RC, 2014, CELL RES, V24, P42, DOI 10.1038/cr.2013.166
   Sacitharan PK, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-0277-0
   Sakurai A, 2005, J CELL PHYSIOL, V203, P529, DOI 10.1002/jcp.20246
   Salminen A, 2008, BIOESSAYS, V30, P939, DOI 10.1002/bies.20799
   Scarpulla RC, 2011, BBA-MOL CELL RES, V1813, P1269, DOI 10.1016/j.bbamcr.2010.09.019
   Selen ES, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.100884
   Shaked M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028804
   Skokowa J, 2009, NAT MED, V15, P151, DOI 10.1038/nm.1913
   Stefanova N A, 2013, Adv Gerontol, V26, P122
   Sundaresan NR, 2009, J CLIN INVEST, V119, P2758, DOI 10.1172/JCI39162
   Tang XX, 2021, ANGIOGENESIS, V24, P363, DOI 10.1007/s10456-020-09757-3
   Tanito M, 2007, FREE RADICAL BIO MED, V42, P1838, DOI 10.1016/j.freeradbiomed.2007.03.018
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tossberg JT, 2020, J IMMUNOL, V205, P2606, DOI 10.4049/jimmunol.2000384
   Turner N, 2008, DIABETES, V57, P1414, DOI 10.2337/db07-1552
   Velagapudi R, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201801237
   Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101
   Wang K, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21887
   Wang YX, 2021, J SCI FOOD AGR, V101, P5116, DOI 10.1002/jsfa.11157
   Wang Z, 2012, J PINEAL RES, V53, P129, DOI 10.1111/j.1600-079X.2012.00978.x
   Wright CB, 2020, P NATL ACAD SCI USA, V117, P2579, DOI 10.1073/pnas.1909761117
   Wu N, 2013, MOL CELL, V49, P1167, DOI 10.1016/j.molcel.2013.01.035
   Xu TT, 2021, NUTR METAB, V18, DOI 10.1186/s12986-021-00540-9
   Yamashina S, 2007, J GASTROEN HEPATOL, V22, pS62, DOI 10.1111/j.1440-1746.2006.04655.x
   Yang YY, 2019, MOL MED REP, V19, P2245, DOI 10.3892/mmr.2019.9875
   Ye Y, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.653887
   Yi CX, 2005, ANN NY ACAD SCI, V1057, P384, DOI 10.1196/annals.1356.029
   Yoshida H, 2010, ATHEROSCLEROSIS, V209, P520, DOI 10.1016/j.atherosclerosis.2009.10.012
   Yu LM, 2014, J PINEAL RES, V57, P228, DOI 10.1111/jpi.12161
   Zhang XX, 2021, PHARMAZIE, V76, P55, DOI 10.1691/ph.2021.0958
   Zhao MT, 2011, CELL METAB, V13, P119, DOI 10.1016/j.cmet.2011.01.009
   Zheng J, 2013, AM J PHYSIOL-REG I, V304, pR110, DOI 10.1152/ajpregu.00648.2011
   Zhou B, 2014, HEPATOLOGY, V59, P2196, DOI 10.1002/hep.26992
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505
   Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831
NR 131
TC 1
Z9 1
U1 18
U2 18
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD MAY
PY 2022
VL 14
IS 9
AR 1985
DI 10.3390/nu14091985
PG 13
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 1G8UB
UT WOS:000796123800001
PM 35565950
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Jin, I
   Tang, DN
   Gengaroli, J
   Perry, KN
   Burlutsky, G
   Craig, A
   Liew, G
   Mitchell, P
   Gopinath, B
AF Jin, Ivan
   Tang, Diana
   Gengaroli, Jessica
   Perry, Kathryn Nicholson
   Burlutsky, George
   Craig, Ashley
   Liew, Gerald
   Mitchell, Paul
   Gopinath, Bamini
TI Cross-sectional study evaluating burden and depressive symptoms in
   family carers of persons with age-related macular degeneration in
   Australia
SO BMJ OPEN
LA English
DT Article
DE epidemiology; mental health; medical retina; public health
ID QUALITY-OF-LIFE; CAREGIVER BURDEN; OLDER PERSONS; OVARIAN-CANCER;
   PREVALENCE; DISEASE; HEALTH; IMPACT; PREDICTORS; INTERVIEW
AB Objectives We aimed to analyse the degree of carer burden and depressive symptoms in family carers of persons with age-related macular degeneration (AMD) and explore the factors independently associated with carer burden and depressive symptoms. Methods Cross-sectional study using self-administered and interviewer-administered surveys, involving 96 family carer-care recipient pairs. Participants were identified from tertiary ophthalmology clinics in Sydney, Australia, as well as the Macular Disease Foundation of Australia database. Logistic regression, Pearson and Spearman correlation analyses were used to investigate associations of explanatory factors (family caregiving experience, carer fatigue, carer quality of life and care-recipient level of dependency) with study outcomes-carer burden and depressive symptoms. Results Over one in two family carers reported experiencing mild or moderate-severe burden. More than one in five and more than one in three family carers experienced depressive symptoms and substantial fatigue, respectively. High level of care-recipient dependency was associated with greater odds of moderate-severe and mild carer burden, multivariable-adjusted OR 8.42 (95% CI 1.88 to 37.60) and OR 4.26 (95% CI 1.35 to 13.43), respectively. High levels of fatigue were associated with threefold greater odds of the carer experiencing depressive symptoms, multivariable-adjusted OR 3.47 (95% CI 1.00 to 12.05). Conclusions A substantial degree of morbidity is observed in family carers during the caregiving experience for patients with AMD. Level of dependency on the family carer and fatigue were independently associated with family carer burden and depressive symptoms.
C1 [Jin, Ivan; Liew, Gerald; Mitchell, Paul] Univ Sydney, Ctr Vis Res, Sydney, NSW, Australia.
   [Tang, Diana; Burlutsky, George; Gopinath, Bamini] Macquarie Univ, Macquarie Univ Hearing, Sydney, NSW, Australia.
   [Gengaroli, Jessica; Perry, Kathryn Nicholson] Australian Coll Appl Psychol, Discipline Psychol Sci, Sydney, NSW, Australia.
   [Craig, Ashley] Univ Sydney, Northern Clin Sch, St Leonards, NSW, Australia.
C3 University of Sydney; Macquarie University; University of Sydney
RP Gopinath, B (通讯作者)，Macquarie Univ, Macquarie Univ Hearing, Sydney, NSW, Australia.
EM bamini.gopinath@mq.edu.au
RI jin, ivan/GXH-4042-2022; Liew, Gerald/AAB-6870-2022; Nicholson Perry,
   Kathryn/J-4468-2012
OI Nicholson Perry, Kathryn/0000-0003-0609-9219; Craig,
   Ashley/0000-0001-7647-7604; Tang, Diana/0000-0003-2007-9054
FU Australian National Health and Medical Research Council [APP1115729];
   Macular Disease Foundation Australia
FX This work was supported by the Australian National Health and Medical
   Research Council under a Partnership Project Grant (APP1115729); and the
   Macular Disease Foundation Australia.
CR ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6
   Bambara JK, 2009, INVEST OPHTH VIS SCI, V50, P1585, DOI 10.1167/iovs.08-2744
   Bedard M, 2001, GERONTOLOGIST, V41, P652, DOI 10.1093/geront/41.5.652
   Berman K, 2006, INT PSYCHOGERIATR, V18, P415, DOI 10.1017/S1041610205002905
   Bialon LN, 2012, AM J HOSP PALLIAT ME, V29, P210, DOI 10.1177/1049909111416494
   Braich PS, 2012, OPHTHALMOLOGY, V119, P221, DOI 10.1016/j.ophtha.2011.07.038
   Butow PN, 2014, GYNECOL ONCOL, V132, P690, DOI 10.1016/j.ygyno.2014.01.002
   Cain C.J., 2000, J FAMILY NURSING, V6, P46, DOI DOI 10.1177/107484070000600104
   Corfield EC, 2016, COMPR PSYCHIAT, V71, P1, DOI 10.1016/j.comppsych.2016.08.004
   Economics DA, 2011, EYES FUTURE CLEAR, P144
   Elkin E, 2012, BEYONG BINARY OUTCOM
   Evans S, 2007, QUAL LIFE RES, V16, P17, DOI 10.1007/s11136-006-9002-6
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Genc F, 2019, PSYCHIAT INVEST, V16, P285, DOI 10.30773/pi.2019.02.20
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Goldberg Arnold, 2011, Med Health R I, V94, P41
   Gopinath B, 2015, AGING MENT HEALTH, V19, P239, DOI 10.1080/13607863.2014.924477
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   Hebert R, 2000, CAN J AGING, V19, P494, DOI 10.1017/S0714980800012484
   Hirschfeld M, 2003, INT J NURS STUD, V40, P463, DOI 10.1016/S0020-7489(03)00063-4
   Hu P, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012638
   Irwin M, 1999, ARCH INTERN MED, V159, P1701, DOI 10.1001/archinte.159.15.1701
   Khare S, 2016, INDIAN J OPHTHALMOL, V64, P572, DOI 10.4103/0301-4738.191493
   KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022
   Kuriakose RK, 2017, INT OPHTHALMOL, V37, P767, DOI 10.1007/s10792-016-0296-2
   Lindt N, 2020, BMC GERIATR, V20, DOI 10.1186/s12877-020-01708-3
   Liu S, 2017, J CLIN NURS, V26, P1291, DOI 10.1111/jocn.13601
   Malhi GS, 2018, LANCET, V392, P2299, DOI 10.1016/S0140-6736(18)31948-2
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mausbach BT, 2013, AM J GERIAT PSYCHIAT, V21, P5, DOI 10.1016/j.jagp.2012.10.001
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Pinquart M, 2003, PSYCHOL AGING, V18, P250, DOI 10.1037/0882-7974.18.2.250
   Price MA, 2010, MED J AUSTRALIA, V193, pS52
   Ranmuthugala G, 2009, AUST FAM PHYSICIAN, V38, P618
   Reid CE, 2005, AUST J PSYCHOL, V57, P186, DOI 10.1080/00049530500141022
   Riffin C, 2019, J AM GERIATR SOC, V67, P277, DOI 10.1111/jgs.15664
   Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215
   Schwarzer R., 1995, MEASURES HLTH PSYCHO, P35
   Shumye S, 2019, HEALTH QUAL LIFE OUT, V17, DOI 10.1186/s12955-019-1233-7
   Sivertsen H, 2015, DEMENT GERIATR COGN, V40, P311, DOI 10.1159/000437299
   Song JI, 2011, SUPPORT CARE CANCER, V19, P1519, DOI 10.1007/s00520-010-0977-8
   Vitaliano PP, 1997, ANN BEHAV MED, V19, P117, DOI 10.1007/BF02883328
   Vukicevic M, 2016, EYE, V30, P413, DOI 10.1038/eye.2015.235
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649
NR 46
TC 2
Z9 2
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD SEP
PY 2021
VL 11
IS 9
AR e048658
DI 10.1136/bmjopen-2021-048658
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA UT0YP
UT WOS:000697851300032
PM 34497082
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Hahn, P
   Milam, AH
   Dunaief, JL
AF Hahn, P
   Milam, AH
   Dunaief, JL
TI Maculas affected by age-related macular degeneration contain increased
   chelatable iron in the retinal pigment epithelium and Bruch's membrane
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID OXIDATIVE STRESS; A-BETA; CERULOPLASMIN; DEFICIENCY; TOXICITY; DISEASE
AB Objective: To investigate whether iron is involved in the pathogenesis of age-related macular degeneration (AMD).
   Methods: Postmortem AMD-affected (nonexudative or exudative) and healthy maculas were studied using the 3,3'-diaminobenzidine-enhanced Perls Prussian blue stain. The Perls Prussian blue stain was quantified by computer-assisted analysis of digital images. To determine whether the iron was chelatable, sections treated with the iron chelator deferoxamine were compared with adjacent, nonchelated sections.
   Results: Compared with healthy maculas, AMD-affected maculas had statistically significant increases in the total iron level. Some of this iron was chelatable. The iron was present in retinal pigment epithelium and Bruch's membrane in maculas from patients who had drusen only, geographic atrophy, and exudative AMD in pathologic areas and, occasionally, in relatively healthy areas.
   Conclusions: Oxidative stress has been implicated in the pathogenesis of AMD by the Age-Related Eye Disease Study. Increased concentrations of iron, which generate highly reactive hydroxyl radicals via the Fenton reaction, may induce oxidative stress in the macula and lead to AMD. As the increased iron concentrations in AMD-affected eyes consist in part of a chelatable iron pool, treatment of patients who have AMD with iron chelators might be considered a potential therapy. While there are, as yet, no clinical data indicating that the treatment of patients who have AMD with iron chelators is beneficial, data presented herein indicate that further investigation of iron concentrations in postmortem tissues and the mechanisms of iron transport in the retina is warranted.
C1 Univ Penn, Kirby Ctr Mol Ophtalmol, Scheie Eye Inst, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine
RP Dunaief, JL (通讯作者)，Univ Penn, Kirby Ctr Mol Ophtalmol, Scheie Eye Inst, 305 Stellar Chance Labs, Philadelphia, PA 19104 USA.
OI Hahn, Paul/0000-0002-6574-388X
FU NEI NIH HHS [EY00417] Funding Source: Medline
CR Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   DOLY M, 1986, OPHTHALMIC RES, V18, P21, DOI 10.1159/000265409
   Frank R N, 1998, Trans Am Ophthalmol Soc, V96, P635
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812
   HUNT RC, 1992, J CELL PHYSIOL, V152, P102, DOI 10.1002/jcp.1041520114
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Kontoghiorghes GJ, 2000, TRANSFUS SCI, V23, P211, DOI 10.1016/S0955-3886(00)00089-8
   Milam AH, 2001, METH MOLEC MED, V47, P71, DOI 10.1385/1-59259-085-3:71
   MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761
   MORITA H, 1995, ANN NEUROL, V37, P646, DOI 10.1002/ana.410370515
   Rottkamp CA, 2001, FREE RADICAL BIO MED, V30, P447, DOI 10.1016/S0891-5849(00)00494-9
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5
   Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866
   TAWARA A, 1986, INVEST OPHTH VIS SCI, V27, P226
   VERGARA O, 1989, EXP EYE RES, V49, P1115, DOI 10.1016/S0014-4835(89)80030-2
   Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979
   Yefimova MG, 2002, INVEST OPHTH VIS SCI, V43, P537
NR 23
TC 203
Z9 222
U1 1
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD AUG
PY 2003
VL 121
IS 8
BP 1099
EP 1105
DI 10.1001/archopht.121.8.1099
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 709HR
UT WOS:000184620200003
PM 12912686
DA 2022-11-30
ER

PT J
AU Gorgun, E
   Guven, M
   Unal, M
   Batar, B
   Guven, GS
   Yenerel, M
   Tatlipinar, S
   Seven, M
   Yuksel, A
AF Gorgun, Ebru
   Guven, Mehmet
   Unal, Mustafa
   Batar, Bahadir
   Guven, Gulgun S.
   Yenerel, Melda
   Tatlipinar, Sinan
   Seven, Mehmet
   Yuksel, Adnan
TI Polymorphisms of the DNA Repair Genes XPD and XRCC1 and the Risk of
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; RETINAL-PIGMENT EPITHELIUM;
   CHROMOSOMAL-ABERRATIONS; OXIDATIVE STRESS; CELL CARCINOMA; DAMAGE;
   CANCER; FREQUENCY; VARIANT; PREDISPOSITION
AB PURPOSE. Oxidative stress seems to be an important factor in the development of age-related macular degeneration (AMD). The role of DNA repair mechanisms has also received attention recently in AMD pathogenesis. This case-control study was conducted to determine the frequency of polymorphisms in two DNA repair enzyme genes, xeroderma pigmentosum complementation group D (XPD), codons 312 and 751, and x-ray cross-complementing group 1 (XRCC1), codons 194 and 399, in patients with AMD and in disease-free control subjects.
   METHODS. Polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) were used to analyze XPD Asp312Asn and Lys751Gln and XRCC1 Arg194Trp and Arg399Gln in 120 patients with AMD (65 with dry type and 55 with wet type) and in age-matched 205 disease-free control subjects.
   RESULTS. Genotypic and allelic distributions of the polymorphisms were detected. For the XPD polymorphism, although the allele frequencies were not different between the patients and healthy control subjects, there was a significant difference between frequencies for the XPD751 Gln/Gln genotype in AMD patients (9%) and healthy control subjects (19%; P = 0.02). The XPD751 Gln/Gln genotype seemed to have a protective effect against development of AMD (odds ratio, 0.41; 95% confidence interval, 0.19-0.88). Stratification by subtype of AMD revealed that the XPD751 Gln/Gln genotype was significantly lower only in the patients with dry type (P = 0.02). These interactions remained nearly significant after Bonferroni correction (P < 0.0125). Haplotype analysis for the two XPD polymorphisms revealed that the haplotype GC ((312)Asp-(751)Gln) was a protective haplotype against AMD. No statistically significant difference was found for the genotypic and allelic distributions of the polymorphisms in the XRCC1 gene between the patients and the control subjects.
   CONCLUSIONS. Polymorphism in XPD codon 751 may be associated with the development of AMD. (Invest Ophthalmol Vis Sci. 2010; 51: 4732-4737) DOI:10.1167/iovs.09-4842
C1 [Gorgun, Ebru; Yenerel, Melda; Tatlipinar, Sinan] Yeditepe Univ, Fac Med, Dept Ophthalmol, Istanbul, Turkey.
   [Guven, Mehmet; Batar, Bahadir] Istanbul Univ, Dept Med Biol, Cerrahpasa Fac Med, Istanbul, Turkey.
   [Unal, Mustafa] Akdeniz Univ, Fac Med, Dept Ophthalmol, TR-07058 Antalya, Turkey.
   [Guven, Gulgun S.; Seven, Mehmet; Yuksel, Adnan] Istanbul Univ, Dept Med Genet, Cerrahpasa Med Sch, Istanbul, Turkey.
C3 Yeditepe University; Istanbul University; Istanbul University -
   Cerrahpasa; Akdeniz University; Istanbul University; Istanbul University
   - Cerrahpasa
RP Unal, M (通讯作者)，Pinarbasi Mah 758 Sokak Nazlibahce Evleri,C Blok, Istanbul, Turkey.
EM mustafaunalmd@gmail.com
RI Seven, Mehmet/E-1017-2019; Batar, Bahadir/F-4724-2018; GUVEN,
   MEHMET/C-9833-2019; ÜNAL, MUSTAFA/C-7426-2016
OI Seven, Mehmet/0000-0001-7878-2039; Yuksel, Adnan/0000-0002-7275-8254;
   GUVEN, MEHMET/0000-0002-8749-1708
FU University of Istanbul [1153]; Akdeniz University Scientific Research
   Projects Unit
FX Supported by the Research Fund of The University of Istanbul, Project
   1153. MU was supported by Akdeniz University Scientific Research
   Projects Unit.
CR AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benhamou S, 2002, MUTAGENESIS, V17, P463, DOI 10.1093/mutage/17.6.463
   Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773
   Bojanowski Christine M, 2005, Trans Am Ophthalmol Soc, V103, P37
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Caldecott KW, 2003, DNA REPAIR, V2, P955, DOI 10.1016/S1568-7864(03)00118-6
   Chen JZ, 2003, AM J MED, V114, P697, DOI 10.1016/S0002-9343(03)00199-2
   Clarkson SG, 2005, DNA REPAIR, V4, P1068, DOI 10.1016/j.dnarep.2005.07.001
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dybdahl M, 1999, CANCER EPIDEM BIOMAR, V8, P77
   Ethen CM, 2007, INVEST OPHTH VIS SCI, V48, P3469, DOI 10.1167/iovs.06-1058
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Frosina G, 2000, EUR J BIOCHEM, V267, P2135, DOI 10.1046/j.1432-1327.2000.01266.x
   Guven M, 2007, HEART VESSELS, V22, P355, DOI 10.1007/s00380-007-0986-9
   Guven M, 2007, MOL VIS, V13, P12
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Izzotti A, 2003, AM J MED, V114, P638, DOI 10.1016/S0002-9343(03)00114-1
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Johnson AB, 2007, MUTAT RES-FUND MOL M, V618, P149, DOI 10.1016/j.mrfmmm.2006.10.007
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kazimirova A, 2009, MUTAT RES-FUND MOL M, V661, P35, DOI 10.1016/j.mrfmmm.2008.10.017
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Ladiges W, 2003, MECH AGEING DEV, V124, P27, DOI 10.1016/S0047-6374(02)00166-5
   Lunn RM, 1999, CANCER RES, V59, P2557
   Lunn RM, 2000, CARCINOGENESIS, V21, P551, DOI 10.1093/carcin/21.4.551
   McCall MR, 1999, FREE RADICAL BIO MED, V26, P1034, DOI 10.1016/S0891-5849(98)00302-5
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Ohia SE, 2005, MUTAT RES-FUND MOL M, V579, P22, DOI 10.1016/j.mrfmmm.2005.03.025
   Polosak J, 2010, BIOGERONTOLOGY, V11, P287, DOI 10.1007/s10522-009-9246-y
   Sacca SC, 2009, MUTAT RES-FUND MOL M, V667, P98, DOI 10.1016/j.mrfmmm.2008.11.002
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Shen MR, 1998, CANCER RES, V58, P604
   Sickel W, 1972, Adv Exp Med Biol, V24, P101
   Spitz MR, 2001, CANCER RES, V61, P1354
   Szaflik JP, 2009, MUTAT RES-FUND MOL M, V669, P169, DOI 10.1016/j.mrfmmm.2009.06.008
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Tolppanen AM, 2009, MOL VIS, V15, P762
   Tomescu D, 2001, CARCINOGENESIS, V22, P403, DOI 10.1093/carcin/22.3.403
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Unal M, 2007, EXP EYE RES, V85, P328, DOI 10.1016/j.exer.2007.06.003
   van der Pluijm I, 2008, PLOS BIOL, V6, P2614, DOI 10.1371/journal.pbio.0060304
   Vodicka P, 2004, CARCINOGENESIS, V25, P757, DOI 10.1093/carcin/bgh064
   Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154
   Yu HP, 2004, CANCER GENET CYTOGEN, V154, P10, DOI 10.1016/j.cancergencyto.2004.01.027
NR 48
TC 29
Z9 30
U1 0
U2 13
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2010
VL 51
IS 9
BP 4732
EP 4737
DI 10.1167/iovs.09-4842
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 645YS
UT WOS:000281502700051
PM 20375340
DA 2022-11-30
ER

PT J
AU Chiu, CJ
   Milton, RC
   Klein, R
   Gensler, G
   Taylor, A
AF Chiu, Chung-Jung
   Milton, Roy C.
   Klein, Ronald
   Gensler, Gary
   Taylor, Allen
TI Dietary Compound Score and Risk of Age-Related Macular Degeneration in
   the Age-Related Eye Disease Study
SO OPHTHALMOLOGY
LA English
DT Article
ID GLYCEMIC INDEX; CARBOHYDRATE; ANTIOXIDANTS
AB Purpose: Because foods provide many nutrients that may interact to modify risk for multifactorial diseases such as age-related macular degeneration (AMD), we sought to develop a composite scoring system to summarize the combined effect of multiple dietary nutrients on AMD risk. This has not been done previously.
   Design: Cross-sectional study.
   Participants: From the 4003 participants in the Age-Related Eye Disease Study (AREDS), there were 7,934 eyes included in this study.
   Methods: Considering dietary intakes of vitamins C and E, zinc, lutein/zeaxanthin, docosahexaenoic acid, eicosapentaenoic acid, and low-dietary glycemic index (dGI) from AREDS baseline information, we assigned each nutrient a percentile rank score then summed them into a compound score for each participant. Using eye as the unit of analysis, we evaluated the association between the compound score and risk of prevalent AMD. Validation, fitness, and performance of the model were evaluated using bootstrapping techniques, adjusted quasi-likelihood under the independence model criterion, and the c-index, respectively.
   Main Outcome Measures: Stereoscopic fundus photographs of the macula were taken and graded at baseline using the AREDS protocol and AMD Classification System.
   Results: Our results showed that higher compound scores were associated with lower risk for early AMD, indicated by drusen, and advanced AMD. Validation analyses indicated that these relationships are robust (the average 50-time bootstrapping per quartile odds ratios = 0.727, 0.827, and 0.753, respectively, for drusen, and 0.616, 0.536, and 0.572, respectively, for advanced AMD). Model selection analyses suggested that the compound score should be included, but that measures of dietary beta-carotene should not be included.
   Conclusions: We found that consuming diets that provide low dGI and higher intakes of these nutrients were associated with the greatest reduction in risk for prevalent drusen and advanced AMD, whereas dietary beta-carotene did not affect these relationships. These findings warrant further prospective studies.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2009;116:939-946 (C) 2009 by the American Academy of Ophthalmology.
C1 [Chiu, Chung-Jung; Taylor, Allen] Tufts Univ, Jean Mayer USDA, Human Nutr Res Ctr Aging, Dept Ophthalmol,Sch Med, Boston, MA 02111 USA.
   [Milton, Roy C.; Gensler, Gary] EMMES Corp, AREDS Coordinating Ctr, Rockville, MD USA.
   [Klein, Ronald] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI USA.
C3 Tufts University; United States Department of Agriculture (USDA); Emmes
   Corporation; University of Wisconsin System; University of Wisconsin
   Madison
RP Chiu, CJ (通讯作者)，Tufts Univ, Jean Mayer USDA, Human Nutr Res Ctr Aging, Dept Ophthalmol,Sch Med, 711 Washington St, Boston, MA 02111 USA.
EM cj.chiu@tufts.edu
OI Klein, Ronald/0000-0002-4428-6237
FU U. S. Department of Agriculture, National Institutes of Health
   [1950-5100-060-01A, R01-13250, R03-EY014183-01A2]; Johnson and Johnson
   Focused Giving Program; American Health Assistance Foundation; NATIONAL
   EYE INSTITUTE [R01EY013250, R03EY014183] Funding Source: NIH RePORTER
FX Financial support for this project has been provided by the U. S.
   Department of Agriculture under agreements, 1950-5100-060-01A (C-JC, AT)
   and R01-13250 and R03-EY014183-01A2 from the National Institutes of
   Health (AT); grants (AT) from the Johnson and Johnson Focused Giving
   Program and American Health Assistance Foundation, and to C-JC from the
   Ross Aging Initiative. Any opinions, findings, conclusions, or
   recommendations expressed in this publication are those of the authors
   and do not necessarily reflect the views or policies of the US
   Department of Agriculture, nor does mention of trade names, commercial
   products, or organizations imply endorsement by the US Government.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, EXP EYE RES, V84, P229, DOI 10.1016/j.exer.2006.05.015
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Chiu CJ, 2002, J PUBLIC HEALTH DENT, V62, P28, DOI 10.1111/j.1752-7325.2002.tb03417.x
   Coleman H, 2007, CURR OPIN OPHTHALMOL, V18, P220, DOI 10.1097/ICU.0b013e32814a586b
   Cook NR, 2007, CIRCULATION, V115, P928, DOI 10.1161/CIRCULATIONAHA.106.672402
   EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552
   Foster-Powell K, 2002, AM J CLIN NUTR, V76, P5, DOI 10.1093/ajcn/76.1.5
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Hayes DP, 2008, AM J CLIN NUTR, V88, p578S, DOI 10.1093/ajcn/88.2.578S
   JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   McCarty CA, 1996, B WORLD HEALTH ORGAN, V74, P353
   Pan W, 2001, BIOMETRICS, V57, P120, DOI 10.1111/j.0006-341X.2001.00120.x
   Pepe MS, 2004, AM J EPIDEMIOL, V159, P882, DOI 10.1093/aje/kwh101
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Waijers PMCM, 2007, BRIT J NUTR, V97, P219, DOI 10.1017/S0007114507250421
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   WOLEVER TMS, 1994, AM J CLIN NUTR, V59, P1265, DOI 10.1093/ajcn/59.6.1265
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 29
TC 44
Z9 46
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2009
VL 116
IS 5
BP 939
EP 946
DI 10.1016/j.ophtha.2008.12.025
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 508DI
UT WOS:000270907500019
PM 19410952
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Funk, M
   Karl, D
   Georgopoulos, M
   Benesch, T
   Sacu, S
   Polak, K
   Zlabinger, GJ
   Schmidt-Erfurth, U
AF Funk, Marion
   Karl, David
   Georgopoulos, Michael
   Benesch, Thomas
   Sacu, Stefan
   Polak, Kaija
   Zlabinger, Gerhard J.
   Schmidt-Erfurth, Ursula
TI Neovascular Age-related Macular Degeneration: Intraocular Cytokines and
   Growth Factors and the Influence of Therapy with Ranibizumab
SO OPHTHALMOLOGY
LA English
DT Article
ID INDUCED CHOROIDAL NEOVASCULARIZATION; RETINAL-PIGMENT EPITHELIUM;
   AQUEOUS-HUMOR LEVELS; ISCHEMIC RETINOPATHY; FACTOR RECEPTORS; PERICYTE
   LOSS; EXPRESSION; ANGIOGENESIS; INHIBITION; CELLS
AB Purpose: To investigate concentrations of growth factors and inflammatory cytokines in eyes with neovascular age-related macular degeneration (AMD) before and during therapy with intravitreal ranibizumab and to identify associations with disease activity.
   Design: Prospective clinical trial.
   Participants and Controls: Twenty-eight eyes of patients with neovascular AMD were compared with 28 eyes of age-matched patients with cataract as control.
   Methods: Ranibizumab was administered intravitreously once at baseline, and retreatments were given at monthly visits if optical coherence tomography (OCT) revealed macular edema or vision loss had occurred. Aqueous humor samples were taken each time intravitreal interventions were performed. Follow-up was 12 months. Luminex (Luminex Inc., Austin, TX) multiplex assays were used for measurement of 29 different growth factors and cytokines, including vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF).
   Main Outcome Measures: Differences in the concentrations of growth factors and inflammatory cytokines in eyes with neovascular AMD compared with control eyes and the influence of therapy with intravitreal ranibizumab.
   Results: A significantly increased expression of VEGF (P = 0.033) and a significantly decreased expression of PDGF (P = 0.038) were measured in the aqueous humor of eyes with neovascular AMD. Furthermore, a significant decrease of VEGF (P<0.001) was observed after intravitreal injection of ranibizumb along with significant changes in visual acuity and central retinal thickness (P = 0.039 and P<0.001). During follow-up with a flexible regimen, a correlation was identified between increased VEGF levels and persistent or recurrent macular edema. Changes in PDGF levels were strongly associated with alterations in VEGF concentration.
   Conclusions: Vascular endothelial growth factor and PDGF-AA seemed to be associated with disease activity of neovascular AMD. Intravitreal anti-angiogenic treatment with ranibizumab resulted in significantly decreased intraocular VEGF expression below physiologic levels compared with controls. This effect was measurable as long as 4 weeks after each injection and was prolonged by consecutive retreatment. With recurrence after discontinuation of treatment, VEGF levels increased again.
C1 [Funk, Marion; Karl, David; Georgopoulos, Michael; Sacu, Stefan; Polak, Kaija; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Vienna, Austria.
   [Benesch, Thomas] Med Univ Vienna, Inst Med Stat, Vienna, Austria.
   [Zlabinger, Gerhard J.] Med Univ Vienna, Inst Immunol, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna; Medical
   University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Univ Vienna, Dept Ophthalmol, Wahringer Gurtel 18-20-8I, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Funk, Marion/0000-0002-4099-6995; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311; Zlabinger, Gerhard/0000-0002-7478-4173
CR AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Browning AC, 2008, BRIT J OPHTHALMOL, V92, P1003, DOI 10.1136/bjo.2007.127670
   Chun DW, 2006, OPHTHALMOLOGY, V113, P1706, DOI 10.1016/j.ophtha.2006.04.033
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Gaudry M, 1997, BLOOD, V90, P4153, DOI 10.1182/blood.V90.10.4153
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Ooi KGJ, 2006, INVEST OPHTH VIS SCI, V47, P272, DOI 10.1167/iovs.05-0790
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Takase H, 2006, INVEST OPHTH VIS SCI, V47, P1557, DOI 10.1167/iovs.05-0836
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wartiovaara U, 1998, THROMB HAEMOSTASIS, V80, P171, DOI 10.1055/s-0037-1615158
   Wilkinson-Berka JL, 2004, AM J PATHOL, V164, P1263, DOI 10.1016/S0002-9440(10)63214-2
   Yamada H, 2000, AM J PATHOL, V156, P477, DOI 10.1016/S0002-9440(10)64752-9
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Yi XJ, 1998, EXP BRAIN RES, V118, P155, DOI 10.1007/s002210050267
   YOSHIDA M, 1992, BIOCHEM BIOPH RES CO, V189, P66, DOI 10.1016/0006-291X(92)91526-V
NR 30
TC 130
Z9 142
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2009
VL 116
IS 12
BP 2393
EP 2399
DI 10.1016/j.ophtha.2009.05.039
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 530HE
UT WOS:000272579200020
PM 19815292
DA 2022-11-30
ER

PT J
AU Farsiu, S
   Chiu, SJ
   O'Connell, RV
   Folgar, FA
   Yuan, E
   Izatt, JA
   Toth, CA
AF Farsiu, Sina
   Chiu, Stephanie J.
   O'Connell, Rachelle V.
   Folgar, Francisco A.
   Yuan, Eric
   Izatt, Joseph A.
   Toth, Cynthia A.
CA Age-Related Eye Dis Study 2 Ancill
TI Quantitative Classification of Eyes with and without Intermediate
   Age-related Macular Degeneration Using Optical Coherence Tomography
SO OPHTHALMOLOGY
LA English
DT Article
ID AUTOMATIC SEGMENTATION; CHOROIDAL THICKNESS; GEOGRAPHIC ATROPHY; RETINAL
   LAYERS; NATURAL COURSE; SD-OCT; DRUSEN; RISK; PROGRESSION; DISEASE
AB Objective: To define quantitative indicators for the presence of intermediate age-related macular degeneration (AMD) via spectral-domain optical coherence tomography (SD-OCT) imaging of older adults.
   Design: Evaluation of diagnostic test and technology.
   Participants and Controls: One eye from 115 elderly subjects without AMD and 269 subjects with intermediate AMD from the Age-Related Eye Disease Study 2 (AREDS2) Ancillary SD-OCT Study.
   Methods: We semiautomatically delineated the retinal pigment epithelium (RPE) and RPE drusen complex (RPEDC, the axial distance from the apex of the drusen and RPE layer to Bruch's membrane) and total retina (TR, the axial distance between the inner limiting and Bruch's membranes) boundaries. We registered and averaged the thickness maps from control subjects to generate a map of "normal" non-AMD thickness. We considered RPEDC thicknesses larger or smaller than 3 standard deviations from the mean as abnormal, indicating drusen or geographic atrophy (GA), respectively. We measured TR volumes, RPEDC volumes, and abnormal RPEDC thickening and thinning volumes for each subject. By using different combinations of these 4 disease indicators, we designed 5 automated classifiers for the presence of AMD on the basis of the generalized linear model regression framework. We trained and evaluated the performance of these classifiers using the leave-one-out method.
   Main Outcome Measures: The range and topographic distribution of the RPEDC and TR thicknesses in a 5-mm diameter cylinder centered at the fovea.
   Results: The most efficient method for separating AMD and control eyes required all 4 disease indicators. The area under the curve (AUC) of the receiver operating characteristic (ROC) for this classifier was >0.99. Overall neurosensory retinal thickening in eyes with AMD versus control eyes in our study contrasts with previous smaller studies.
   Conclusions: We identified and validated efficient biometrics to distinguish AMD from normal eyes by analyzing the topographic distribution of normal and abnormal RPEDC thicknesses across a large atlas of eyes. We created an online atlas to share the 38 400 SD-OCT images in this study, their corresponding segmentations, and quantitative measurements. (C) 2014 by the American Academy of Ophthalmology.
C1 [Farsiu, Sina; O'Connell, Rachelle V.; Folgar, Francisco A.; Yuan, Eric; Izatt, Joseph A.; Toth, Cynthia A.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Farsiu, Sina; Chiu, Stephanie J.; Izatt, Joseph A.; Toth, Cynthia A.] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA.
   [Farsiu, Sina] Duke Univ, Dept Elect & Comp Engn, Durham, NC USA.
C3 Duke University; Duke University; Duke University
RP Farsiu, S (通讯作者)，DUMC, Box 3802, Durham, NC 27710 USA.
EM sina.farsiu@duke.edu
RI Izatt, Joseph/C-9067-2014; Toth, Cynthia/L-5534-2019
OI Izatt, Joseph/0000-0003-1993-2249; Toth, Cynthia/0000-0002-2324-0854;
   Farsiu, Sina/0000-0003-4872-2902
FU American Health Assistance Foundation [IST-4400S]; National Institutes
   of Health [R01-EY022691, P30-EY-005722]; Genentech [IST-4400S]; Alcon
   Laboratories; NATIONAL EYE INSTITUTE [R01EY022691, P30EY005722] Funding
   Source: NIH RePORTER
FX This project was funded in part by the American Health Assistance
   Foundation, Genentech Grant IST-4400S, and National Institutes of Health
   Grants R01-EY022691 and P30-EY-005722. The AREDS2 Ancillary SD-OCT Study
   (ClinicalTrials.gov identifier: NCT00734487) was funded by the Genentech
   Grant IST-4400S, with clinical imaging equipment support from Bioptigen
   and a startup donation from Alcon Laboratories. The sponsor or funding
   organization had no role in the design or conduct of this research.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Burke TR, 2011, INVEST OPHTH VIS SCI, V52, P8006, DOI 10.1167/iovs.11-7693
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   de Kinkelder R, 2013, J BIOPHOTONICS, V6, P314, DOI 10.1002/jbio.201200018
   Dobson AJ, 1990, INTRO GENERALIZED LI, P21
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hartmann KI, 2012, RETINA-J RET VIT DIS, V32, P1492, DOI 10.1097/IAE.0b013e318242b949
   Hastie T., 2008, ELEMENTS STAT LEARNI, P241
   Hood DC, 2009, INVEST OPHTH VIS SCI, V50, P2328, DOI 10.1167/iovs.08-2936
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kay SM, 1998, FUNDAMENTALS STAT SI, V2, P74
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Lee BR, 2009, RETINA-J RET VIT DIS, V29, P1328, DOI 10.1097/IAE.0b013e3181ac7d30
   Leng T, 2009, RETINA-J RET VIT DIS, V29, P988, DOI 10.1097/IAE.0b013e3181ae7113
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Lin P, 2012, INVEST OPHTH VIS SCI, V53, P1874, DOI 10.1167/iovs.11-9290
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Metz Charles E, 2006, J Am Coll Radiol, V3, P413, DOI 10.1016/j.jacr.2006.02.021
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Pappuru RR, 2011, INVEST OPHTH VIS SCI, V52, P6743, DOI 10.1167/iovs.10-6723
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Sadda SR, 2010, RETINA-J RET VIT DIS, V30, P1390, DOI 10.1097/IAE.0b013e3181e44599
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Tatrai E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030922
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 44
TC 186
Z9 193
U1 2
U2 31
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2014
VL 121
IS 1
BP 162
EP 172
DI 10.1016/j.ophtha.2013.07.013
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 282KG
UT WOS:000329169500030
PM 23993787
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Keenan, TDL
   Goldacre, R
   Goldacre, MJ
AF Keenan, Tiarnan D. L.
   Goldacre, Raph
   Goldacre, Michael J.
TI Associations Between Age-Related Macular Degeneration, Alzheimer
   Disease, and Dementia: Record Linkage Study of Hospital Admissions
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID COGNITIVE IMPAIRMENT; DIABETES-MELLITUS; TRENDS; RATES; RISK; CARE
AB IMPORTANCE The potential association between age-related macular degeneration (AMD) and Alzheimer disease (AD) is uncertain and has implications for understanding disease pathogenesis, referral, and treatments.
   OBJECTIVES To determine whether individuals admitted to the hospital with AMD were significantly more or less likely to develop AD or dementia in the following years, as well as to assess whether people with AD or dementia were significantly more or less likely to be admitted to the hospital for AMD treatment in the years following diagnosis of dementia.
   DESIGN, SETTING, AND PARTICIPANTS An AMD cohort of 65 894 people was constructed from English National Health Service, linked hospital episode statistics from January 1, 1999, through February 28, 2011, by identifying computerized record abstracts for all people with an admission or day case care for AMD. A dementia cohort (168 092 people) and a reference cohort (>7.7 million people) were constructed in similar ways.
   MAIN OUTCOMES AND MEASURES Risk of AD or dementia following AMD and risk of AMD following AD or dementia. Rate ratios were calculated based on standardized rates of AD and dementia in the AMD cohort, as well as standardized rates of AMD in the AD and dementia cohort, relative to those in the reference cohort.
   RESULTS The risk of AD or dementia following AMD was not elevated. The rate ratio was 0.86 (95% Cl, 0.67-1.08) for AD and 0.91 (0.79-1.04) for dementia. The likelihood of being admitted for AMD following AD or dementia was very low: the rate ratio was 0.04(0.01-0.10) for people with AD and 0.07(0.04-0.11) for those with dementia.
   CONCLUSIONS AND RELEVANCE These neurodegenerative conditions may share environmental risk factors and histopathologic features. However, considering AD and other dementia after AMD, their coexistence at the individual level is no different from that expected by chance. Our data also suggest that patients in England with dementia may be substantially less likely to receive AMD treatment. Further research is required to determine whether people with dementia receive appropriate investigation and treatment for AMD, as well as identify and address potential barriers.
C1 [Keenan, Tiarnan D. L.] Univ Manchester, Inst Human Dev, Ctr Hearing & Vis Res, Manchester, Lancs, England.
   [Goldacre, Raph; Goldacre, Michael J.] Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford, England.
C3 University of Manchester; University of Oxford
RP Keenan, TDL (通讯作者)，Manchester Royal Eye Hosp, Oxford Rd, Manchester M13 9WH, Lancs, England.
EM tiarnan.keenan@doctors.org.uk
OI Goldacre, Raphael/0000-0002-7393-1880
FU English National Institute for Health Research; Fight for Sight
   [1865/66] Funding Source: researchfish
FX This study was supported by the English National Institute for Health
   Research to analyze the linked data and by Fight For Sight through a
   clinical fellowship (Dr Keenan). No other disclosures were reported.
CR Abel GA, 2004, UK INDICES OF MULTIP
   Al Hazzouri AZ, 2011, AM J EPIDEMIOL, V173, P1148, DOI 10.1093/aje/kwq483
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Breslow NE, 1987, IARC SCIENTIFIC PUBL, VII, P103
   Cai J, 2012, EMBO MOL MED, V4, P980, DOI 10.1002/emmm.201101084
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Doyle Y, 2000, BRIT MED J, V321, P563, DOI 10.1136/bmj.321.7260.563
   Fois AF, 2010, J NEUROL NEUROSUR PS, V81, P215, DOI 10.1136/jnnp.2009.175463
   Goldacre MJ, 2012, BRIT J OPHTHALMOL, V96, P872, DOI 10.1136/bjophthalmol-2012-301519
   Health and Social Care Information Centre, HOSPITAL EPISODE STA
   Jin HX, 2010, J MED CHEM, V53, P1117, DOI 10.1021/jm901381j
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Keenan TDL, 2012, BRIT J OPHTHALMOL, V96, P413, DOI 10.1136/bjophthalmol-2011-300338
   Keenan TDL, 2009, J GLAUCOMA, V18, P201, DOI 10.1097/IJG.0b013e318181540a
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Kim SJ, 2012, EXP EYE RES, V96, P42, DOI 10.1016/j.exer.2012.01.005
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Koch James M, 2005, J Am Med Dir Assoc, V6, P233, DOI 10.1016/j.jamda.2005.04.001
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Proitsi P, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.12.036
   Shah R, 2007, OPHTHAL PHYSL OPT, V27, P473, DOI 10.1111/j.1475-1313.2007.00506.x
   Thorpe CT, 2012, J AM GERIATR SOC, V60, P644, DOI 10.1111/j.1532-5415.2012.03907.x
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
NR 28
TC 61
Z9 64
U1 0
U2 11
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JAN
PY 2014
VL 132
IS 1
BP 63
EP 68
DI 10.1001/jamaophthalmol.2013.5696
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 291TI
UT WOS:000329852300010
PM 24232933
OA Bronze
DA 2022-11-30
ER

PT J
AU Mrak, B
   Caljkusic-Mance, T
   Mrak, B
   Cerovski, B
   Trobonjaca, Z
AF Mrak, Bernard
   Caljkusic-Mance, Tea
   Mrak, Bernarda
   Cerovski, Branimir
   Trobonjaca, Zlatko
TI The Role of the Spectral Domain Ocular Coherence Tomography in Detection
   of Age-Related Macular Degeneration
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE dry form macular degeneration; SD OCT; non ionizing radiation; gender
   conditioned prevalence
ID RETINAL THICKNESS
AB Age-related macular degeneration (ARMD) is one of the most common causes of the vision loss and blindness in developed countries. Among other harmful effects, exposure to the UV radiation is the most prominent factor for the development of the disorder Using the method of SD OCT (Spectral Domain Ocular Coherence Tomography) we performed measurement of the neurosensory retinal thickness of 19 eyes of low vision patients from the population of Primorsko-Goranska County of Republic of Croatia, with dry form of the terminal macular degeneration. These results we compared with control measurements performed on 28 eyes of healthy, normal vision subjects from same County. We determined following parameters: central foveal thickness (CFT), macular volume (MV) and mean foveal thickness (MFT) in the both groups. Results showed statistically significant reduction of CFT in the group of normal vision female patients when compared to males, while any significant difference of CFT between total groups of normal vision individuals and low vision patients was not detected. Furthermore, we noticed statistically significant (p<0.000001) decrease of the MV in the group of the low vision patients in comparison to healthy subjects and statistically significant (p<0.000001) reduction of the MFT of the low vision patients when compared to normal vision individuals. In our study we detected the absence of any significant difference of the CFT between healthy and low vision population, what looks like controversial finding, because neurosensory retina in the ARMD is thin and atrophic, but on the other side it is known that fixation point in low vision patients is translocated from the damaged fovea to extrafoveal region, usually above the fovea, where neurosensory retina is of the normal thickness, but with the less sensitivity. Furthermore, our results suggest possible connection of higher incidence of ARMD with lower CFT in females. Owing to the thicker neurosensory retina in males and better protection, damaging effect of the UV irradiation, which is the proven factor of ARMD development, is smaller. From the evolutionary point of view it is possible that males in all vertebrates have more resistant macula because during the evolutionary process they have spent much more time outside in the sunlight than females.
C1 [Mrak, Bernard; Caljkusic-Mance, Tea] Univ Rijeka, Rijeka Univ Hosp Ctr, Dept Ophthalmol, Rijeka, Croatia.
   [Trobonjaca, Zlatko] Univ Rijeka, Sch Med, Dept Physiol & Immunol, Rijeka, Croatia.
   [Cerovski, Branimir] Univ Zagreb, Ctr Hosp, Dept Ophthalmol, Zagreb 41000, Croatia.
C3 University of Rijeka; University of Rijeka; University of Zagreb;
   University of Zagreb, School of Dental Medicine
RP Mrak, B (通讯作者)，Univ Rijeka, Rijeka Univ Hosp Ctr, Dept Ophthalmol, Rijeka, Croatia.
EM bernard.mrak2@ri.t-com.hr; bernard.mrak2@ri.t-com.hr
RI Trobonjaca, Zlatko/S-7635-2018; Čaljkušić-Mance, Tea/O-8908-2019
OI Trobonjaca, Zlatko/0000-0001-7548-5717; 
CR Al-Karmi R, 2006, CAN J OPHTHALMOL, V41, P313, DOI 10.1139/I06-016
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Caljkusic-Mance T, 2010, COLLEGIUM ANTROPOL, V34, P109
   GODARA P, 2010, OPHTHAL SURG LAS IM, V41, P104
   Kelliher C, 2006, BRIT J OPHTHALMOL, V90, P367, DOI 10.1136/bjo.2005.075861
   Ooto S, 2010, INVEST OPHTH VIS SCI, V51, P465, DOI 10.1167/iovs.09-4047
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Vojnikovic B, 2010, COLLEGIUM ANTROPOL, V34, P5
   Wagner-Schuman M, 2011, INVEST OPHTH VIS SCI, V52, P625, DOI 10.1167/iovs.10-5886
NR 9
TC 1
Z9 1
U1 0
U2 4
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RES, P O BOX 290, ULICA GRADA VUKOVARA 72/IV, 10000
   ZAGREB, CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD SEP
PY 2011
VL 35
SU 2
BP 157
EP 160
PG 4
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 828MG
UT WOS:000295504500033
PM 22220425
DA 2022-11-30
ER

PT J
AU Jo, YJ
   Sonoda, KH
   Oshima, Y
   Takeda, A
   Kohno, R
   Yamada, J
   Hamuro, J
   Yang, Y
   Notomi, S
   Hisatomi, T
   Ishibashi, T
AF Jo, Young-Joon
   Sonoda, Koh-Hei
   Oshima, Yuji
   Takeda, Atsunobu
   Kohno, Ri-ichiro
   Yamada, Jun
   Hamuro, Junji
   Yang, Yang
   Notomi, Shoji
   Hisatomi, Toshio
   Ishibashi, Tatsuro
TI Establishment of a New Animal Model of Focal Subretinal Fibrosis That
   Resembles Disciform Lesion in Advanced Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; IN-VITRO; OXIDATIVE STRESS; REDOX STATUS;
   MACROPHAGES; MICE; NEOVASCULARIZATION; DEPLETION; DISEASE; DAMAGE
AB PURPOSE. Subretinal fibrosis causes damage to visual acuity, especially if the lesion is in the macula, as is frequently observed in advanced age-related macular degeneration. Exudate leukocytes form abnormal vessels that initiate regional inflammation accompanied with local glial proliferation and matrix production. The purpose of this study was to establish an animal model of focal subretinal fibrosis.
   METHODS. Macrophage-rich peritoneal exudate cells (PECs) were injected into the subretinal space of C57BL/6 or MCP-1 knockout (KO) mice. Seven days later, the size of the subretinal fibrotic tissue was evaluated by the adherent area of glial fibrillary acidic protein (GFAP)-positive retinal glial cells on choroidal flat mounts. Myofibroblastic changes and collagen synthesis were detected by alpha-smooth muscle actin (alpha-SMA) and Masson trichrome staining of the histologic section, respectively. alpha-SMA expression was also examined on retinal pigment epithelium (RPE) cells during co-culture with activated macrophages.
   RESULTS. Subretinal fibrous tissue was observed by funduscopy in PEC-injected mice after 7 days. The tissue consisted of a monotonous, low-cell-density area that expressed alpha-SMA with collagen synthesis. Both steroid and antioxidant treatment can reduce residual glia. Because PEC-injected MCP-1 KO mice showed less residual glia, not only exogenous macrophages, but also intrinsic macrophages were activated. The macrophages directly induced myofibrotic changes in RPE cells in vitro.
   CONCLUSIONS. Activated macrophages form subretinal fibrosis when they are placed in the subretinal space and induce myofibrotic changes in RPE cells. (Invest Ophthalmol Vis Sci. 2011; 52: 6089-6095) DOI:10.1167/iovs.10-5189
C1 [Sonoda, Koh-Hei] Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan.
   [Jo, Young-Joon] Chungnam Natl Univ, Dept Ophthalmol, Sch Med, Taejon, South Korea.
   [Yamada, Jun; Hamuro, Junji] Kyoto Prefectural Univ, Dept Ophthalmol, Sch Med, Kyoto 606, Japan.
C3 Kyushu University; Chungnam National University; Kyoto Prefectural
   University
RP Sonoda, KH (通讯作者)，Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM sonodak@med.kyushu-u.ac.jp
OI Hisatomi, Toshio/0000-0003-2552-9595
FU Japanese Ministry of Education, Science, Sports and Culture [B2
   14770962, B2 13470369]; Hiroki Sanui; Grants-in-Aid for Scientific
   Research [23689071] Funding Source: KAKEN
FX Supported by Japanese Ministry of Education, Science, Sports and Culture
   Grants B2 14770962 (K-HS) and B2 13470369 (TI) and by a contribution
   from Hiroki Sanui.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson MF, 2004, NEUROCHEM INT, V44, P153, DOI 10.1016/S0197-0186(03)00133-5
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Delair E, 2009, INVEST OPHTH VIS SCI, V50, P1754, DOI 10.1167/iovs.07-1376
   DIAMOND JR, 1995, AM J KIDNEY DIS, V26, P133, DOI 10.1016/0272-6386(95)90166-3
   Duffield JS, 2005, J CLIN INVEST, V115, P56, DOI 10.1172/JCI200522675
   Ebert R, 2006, STEM CELLS, V24, P1226, DOI 10.1634/stemcells.2005-0117
   Fallowfield JA, 2007, J IMMUNOL, V178, P5288, DOI 10.4049/jimmunol.178.8.5288
   GRISANTI S, 1995, INVEST OPHTH VIS SCI, V36, P391
   ISHIBASHI T, 1987, INVEST OPHTH VIS SCI, V28, P1116
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lim WK, 2004, AM J OPHTHALMOL, V138, P475, DOI 10.1016/j.ajo.2004.04.013
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   MEISTER A, 1994, J BIOL CHEM, V269, P9397
   Murata Y, 2002, INT IMMUNOL, V14, P201, DOI 10.1093/intimm/14.2.201
   Murata Y, 2002, INT IMMUNOL, V14, P627, DOI 10.1093/intimm/dxf031
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   PALESTINE AG, 1985, OPHTHALMOLOGY, V92, P838
   Peterson JD, 1998, P NATL ACAD SCI USA, V95, P3071, DOI 10.1073/pnas.95.6.3071
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Sugita S, 2003, J EXP MED, V198, P161, DOI 10.1084/jem.20030097
   van der Veer WM, 2009, BURNS, V35, P15, DOI 10.1016/j.burns.2008.06.020
   WALLYN RH, 1979, ARCH OPHTHALMOL-CHIC, V97, P2128
   Wickham L, 2009, DEV OPHTHALMOL, V44, P37, DOI 10.1159/000223944
   Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277
   Yamamoto T, 1999, J RHEUMATOL, V26, P609
   Zheng YP, 2004, INVEST OPHTH VIS SCI, V45, P668, DOI 10.1167/iovs.02-0808
NR 27
TC 36
Z9 40
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2011
VL 52
IS 9
BP 6089
EP 6095
DI 10.1167/iovs.10-5189
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 806XC
UT WOS:000293849400005
PM 21051730
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Hyttinen, J
   Blasiak, J
   Tavi, P
   Kaarniranta, K
AF Hyttinen, Juha
   Blasiak, Janusz
   Tavi, Pasi
   Kaarniranta, Kai
TI Therapeutic potential of PGC-1 alpha in age-related macular degeneration
   (AMD) - the involvement of mitochondrial quality control, autophagy, and
   antioxidant response
SO EXPERT OPINION ON THERAPEUTIC TARGETS
LA English
DT Article
DE Age-related macular degeneration; antioxidant response; autophagy;
   mitochondria; pgc-1 alpha; retinal pigment epithelium
ID PIGMENT EPITHELIAL-CELLS; FATTY-ACID OXIDATION; SKELETAL-MUSCLE;
   TRANSCRIPTIONAL COACTIVATOR; RETINAL INFLAMMATION; ENDOTHELIAL-CELLS;
   GENE-EXPRESSION; PROCYANIDIN B2; RECEPTOR-ALPHA; CANCER-CELLS
AB Introduction: Age-related macular degeneration (AMD) is the leading, cause of sight loss in the elderly in the Western world. Most patients remain still without any treatment options. The targeting of Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 alpha), a transcription co-factor, is a putative therapy against AMD.
   Areas covered: The characteristics of AMD and their possible connection with PGC-1 alpha as well as the transcriptional and post-transcriptional control of PGC-1 alpha are discussed. The PGC-1 alpha-driven control of mitochondrial functions, and its involvement in autophagy and antioxidant responses are also examined. Therapeutic possibilities via drugs and epigenetic approaches to enhance PGC-1 alpha expression are discussed. Authors conducted a search of literature mainly from the recent decade from the PubMed database.
   Expert opinion: Therapy options in AMD could include PGC-1 alpha activation or stabilization. This could be achieved by a direct elevation of PGC-1 alpha activity, a stabilization or modification of its upstream activators and inhibitors by chemical compounds, like 5-Aminoimidazole-4-carboxamide riboside, metformin, and resveratrol. Furthermore, manipulations with epigenetic modifiers of PGC-1 alpha expression, including miRNAs, e.g. miR-204, are considered. A therapy aimed at PGC-1 alpha up-regulation may be possible in other disorders besides AMD, if they are associated with disturbances in the mitochondria-antioxidant response-autophagy axis.
C1 [Hyttinen, Juha; Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio, Finland.
   [Blasiak, Janusz] Univ Lodz, Fac Biol & Environm Sci, Dept Mol Genet, Lodz, Poland.
   [Tavi, Pasi] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio, Finland.
C3 University of Eastern Finland; University of Lodz; University of Eastern
   Finland; Kuopio University Hospital; University of Eastern Finland
RP Hyttinen, J (通讯作者)，Univ Eastern Finland, Inst Clin Med, POB 1627, FI-70211 Kuopio, Finland.
EM Juha.hyttinen@uef.fi
OI Hyttinen, Juha/0000-0002-3414-4032; Blasiak, Janusz/0000-0001-9539-9584
FU European Union [722717]; Kuopio University Hospital VTR grant [5503770];
   Sigrid Juselius Foundation; Paivikki and Sakari Sohlberg Foundation;
   Finnish Eye Foundation; National Science Centre, Poland
   [2017/27/B/NZ3/0087];  [296840];  [333302]
FX We are grateful to our supporters: the European Union's Horizon 2020
   research and innovation programme under the Marie Sklodowska-Curie grant
   agreement No. 722717, the of Finland (296840, 333302), the Kuopio
   University Hospital VTR grant (5503770), the Sigrid Juselius Foundation,
   the Paivikki and Sakari Sohlberg Foundation, the University of Eastern
   Finland strategical support, the Finnish Eye Foundation and National
   Science Centre, Poland (2017/27/B/NZ3/00872).
CR Adijanto J, 2014, J BIOL CHEM, V289, P20570, DOI 10.1074/jbc.M114.565457
   Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   Anderson RM, 2008, AGING CELL, V7, P101, DOI 10.1111/j.1474-9726.2007.00357.x
   Domenech EB, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040347
   Baldelli S, 2013, BBA-GEN SUBJECTS, V1830, P4137, DOI 10.1016/j.bbagen.2013.04.006
   Barzilai N, 2016, CELL METAB, V23, P1060, DOI 10.1016/j.cmet.2016.05.011
   Bhattarai N, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10010067
   Blattler SM, 2012, MOL CELL BIOL, V32, P3333, DOI 10.1128/MCB.00337-12
   Blasiak J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041684
   Blasiak J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228840
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Blasiak J, 2019, J CELL MOL MED, V23, P8464, DOI 10.1111/jcmm.14731
   Blitzer AL, 2021, JAMA OPHTHALMOL, V139, P302, DOI 10.1001/jamaophthalmol.2020.6331
   Booth FW, 2015, PROG MOL BIOL TRANSL, V135, P129, DOI 10.1016/bs.pmbts.2015.07.016
   Bost F, 2019, AM J CANCER RES, V9, P198
   Brown EE, 2019, INVEST OPHTH VIS SCI, V60, P1470, DOI 10.1167/iovs.18-26422
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Cai R, 2012, J BIOL CHEM, V287, P44464, DOI 10.1074/jbc.M112.422626
   Cam H, 2004, MOL CELL, V16, P399, DOI 10.1016/j.molcel.2004.09.037
   Canto C, 2010, CELL METAB, V11, P213, DOI 10.1016/j.cmet.2010.02.006
   Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4
   Chen FY, 2019, EMBO J, V38, DOI 10.15252/embj.201899727
   Cherry AD, 2015, ANTIOXID REDOX SIGN, V22, P965, DOI 10.1089/ars.2014.6200
   Choi HI, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04593-w
   Chu-Tan JA, 2018, INVEST OPHTH VIS SCI, V59, P4094, DOI 10.1167/iovs.18-24623
   Cunningham JT, 2007, NATURE, V450, P736, DOI 10.1038/nature06322
   Di WC, 2018, CURR ISSUES MOL BIOL, V28, P29, DOI 10.21775/cimb.028.029
   Dillon LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044335
   Farghali H, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8765954
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Fernandez-Marcos PJ, 2011, AM J CLIN NUTR, V93, p884S, DOI 10.3945/ajcn.110.001917
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Fierro-Fernandez M, 2020, FASEB J, V34, P410, DOI 10.1096/fj.201901599RR
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Gerhart-Hines Z, 2007, EMBO J, V26, P1913, DOI 10.1038/sj.emboj.7601633
   Gong X, 2016, AM J TRANSL RES, V8, P2127
   Gureev AP, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00435
   Gurubaran IS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061976
   Hall DP, 2014, CANCER CELL, V26, P738, DOI 10.1016/j.ccell.2014.09.015
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Herzig RP, 2000, J BIOL CHEM, V275, P13134, DOI 10.1074/jbc.275.17.13134
   Hikichi T, 2001, AM J OPHTHALMOL, V132, P587, DOI 10.1016/S0002-9394(01)01139-4
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Hong Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082311
   Housley MP, 2009, J BIOL CHEM, V284, P5148, DOI 10.1074/jbc.M808890200
   Houzelle A, 2020, J CELL PHYSIOL, V235, P9851, DOI 10.1002/jcp.29797
   Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200
   Hwang JT, 2007, ANN NY ACAD SCI, V1095, P441, DOI 10.1196/annals.1397.047
   Hyttinen JMT, 2021, AGEING RES REV, V67, DOI 10.1016/j.arr.2021.101260
   Hyttinen JMT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225800
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Irrcher I, 2009, AM J PHYSIOL-CELL PH, V296, pC116, DOI 10.1152/ajpcell.00267.2007
   Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Joo MS, 2016, MOL CELL BIOL, V36, P1931, DOI 10.1128/MCB.00118-16
   Josifovska N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030813
   Justin A, 2020, NEUROTOX RES, V37, P508, DOI 10.1007/s12640-019-00132-9
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kaarniranta K, 2018, ADV DRUG DELIVER REV, V126, P177, DOI 10.1016/j.addr.2018.04.016
   Karthikeyan B, 2017, APOPTOSIS, V22, P72, DOI 10.1007/s10495-016-1318-2
   Kim J, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.16
   Kinoshita S, 2014, J NUTR BIOCHEM, V25, P1177, DOI 10.1016/j.jnutbio.2014.06.004
   Klionsky DJ, 2011, AUTOPHAGY, V7, P1273, DOI 10.4161/auto.7.11.17661
   Koskela A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050284
   Bervejillo ML, 2019, ADV EXP MED BIOL, V1127, P39, DOI 10.1007/978-3-030-11488-6_3
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039
   Li CP, 2013, BIOCHEM BIOPH RES CO, V438, P739, DOI 10.1016/j.bbrc.2013.07.097
   Li S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061736
   Li Y, 2021, EXP EYE RES, V207, DOI 10.1016/j.exer.2021.108586
   Li Y, 2014, CAN J PHYSIOL PHARM, V92, P765, DOI 10.1139/cjpp-2014-0018
   Little K, 2018, EBIOMEDICINE, V38, P283, DOI 10.1016/j.ebiom.2018.11.029
   Loftsson T, 2022, ACTA OPHTHALMOL, V100, P7, DOI 10.1111/aos.14861
   Luu J, 2018, P NATL ACAD SCI USA, V115, P2866, DOI 10.1073/pnas.1721033115
   Lyons CL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103092
   Marcelo KL, 2016, TRENDS ENDOCRIN MET, V27, P706, DOI 10.1016/j.tem.2016.06.001
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Naidu SD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11262-5
   Nita M, 2020, EXCLI J, V19, P1353, DOI 10.17179/excli2020-2915
   Ohira A, 2015, ACTA OPHTHALMOL, V93, P610, DOI 10.1111/aos.12803
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Olson BL, 2008, GENE DEV, V22, P252, DOI 10.1101/gad.1624208
   Palmieri M, 2011, HUM MOL GENET, V20, P3852, DOI 10.1093/hmg/ddr306
   Paterno JJ, 2020, GENES-BASEL, V11, DOI 10.3390/genes11111318
   Peng KG, 2017, MOL NEUROBIOL, V54, P3783, DOI 10.1007/s12035-016-9944-9
   Pershadsingh HA, 2008, PPAR RES, V2008, DOI 10.1155/2008/164273
   Pettersson-Klein AT, 2018, MOL METAB, V9, P28, DOI 10.1016/j.molmet.2018.01.017
   Piantadosi CA, 2008, CIRC RES, V103, P1232, DOI 10.1161/01.RES.0000338597.71702.ad
   Ping Z, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/876825
   Potthoff MJ, 2007, J CLIN INVEST, V117, P2459, DOI 10.1172/JCI31960
   Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2
   Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667
   Qiu FF, 2019, MOL PHARMACEUT, V16, P1958, DOI 10.1021/acs.molpharmaceut.8b01319
   Rodgers JT, 2010, CELL METAB, V11, P23, DOI 10.1016/j.cmet.2009.11.006
   Romdhoniyyah DF, 2021, OPHTHALMOL THER, V10, P245, DOI 10.1007/s40123-021-00344-3
   Rosales MAB, 2019, LIFE SCI ALLIANCE, V2, DOI [10.26508/lsa.201800212, 10.26508/lsa.201900436]
   Ruan HB, 2012, CELL METAB, V16, P226, DOI 10.1016/j.cmet.2012.07.006
   Ruderman NB, 2010, AM J PHYSIOL-ENDOC M, V298, pE751, DOI 10.1152/ajpendo.00745.2009
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Rytinki MM, 2009, J BIOL CHEM, V284, P26184, DOI 10.1074/jbc.M109.038943
   Salazar G, 2020, AUTOPHAGY, V16, P1092, DOI 10.1080/15548627.2019.1659612
   Salma N, 2015, J CELL PHYSIOL, V230, P2330, DOI 10.1002/jcp.24978
   Sano M, 2004, CIRC RES, V95, P867, DOI 10.1161/01.RES.0000146675.88354.04
   Scarpulla RC, 2012, TRENDS ENDOCRIN MET, V23, P459, DOI 10.1016/j.tem.2012.06.006
   Scarpulla RC, 2012, BBA-GENE REGUL MECH, V1819, P1088, DOI 10.1016/j.bbagrm.2011.10.011
   Shu DY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124271
   Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101
   Summer R, 2019, AM J PHYSIOL-LUNG C, V316, pL1049, DOI 10.1152/ajplung.00244.2018
   Sun CK, 2007, INT HEART J, V48, P533, DOI 10.1536/ihj.48.533
   Suntar I, 2020, ACTA PHARMACOL SIN B, V10, P734, DOI 10.1016/j.apsb.2020.01.001
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Teyssier C, 2005, GENE DEV, V19, P1466, DOI 10.1101/gad.1295005
   Timm KN, 2020, CARDIOVASC DRUG THER, V34, P255, DOI 10.1007/s10557-020-06941-x
   Timon-Gomez A, 2018, SEMIN CELL DEV BIOL, V76, P163, DOI 10.1016/j.semcdb.2017.08.055
   Trausch-Azar J, 2010, J BIOL CHEM, V285, P40192, DOI 10.1074/jbc.M110.131615
   Usui-Ouchi A, 2017, INT IMMUNOPHARMACOL, V52, P70, DOI 10.1016/j.intimp.2017.08.027
   Vainshtein A, 2015, AM J PHYSIOL-CELL PH, V308, pC710, DOI 10.1152/ajpcell.00380.2014
   Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Waldman M, 2018, CARDIOVASC DIABETOL, V17, DOI 10.1186/s12933-018-0754-4
   Wang GM, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.622665
   Wang J, 2018, ONCOTARGETS THER, V11, P7777, DOI 10.2147/OTT.S159095
   Wang ZG, 2019, FEBS OPEN BIO, V9, P859, DOI 10.1002/2211-5463.12614
   Whittington HJ, 2013, CARDIOVASC RES, V99, P694, DOI 10.1093/cvr/cvt140
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu JW, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109606
   Xu M, 2020, J AGR FOOD CHEM, V68, P1306, DOI 10.1021/acs.jafc.9b07489
   Yang CC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101717
   Yin Y, 2018, EXP THER MED, V16, P2363, DOI 10.3892/etm.2018.6494
   Yu B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16312-7
   Zhang LW, 2018, MOL MED REP, V17, P4490, DOI 10.3892/mmr.2018.8433
   Zhang W, 2019, INVEST OPHTH VIS SCI, V60, P294, DOI 10.1167/iovs.18-25617
   Zhao HS, 2017, NEUROSCIENCE, V348, P241, DOI 10.1016/j.neuroscience.2017.02.027
NR 139
TC 2
Z9 2
U1 2
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1472-8222
EI 1744-7631
J9 EXPERT OPIN THER TAR
JI Expert Opin. Ther. Targets
PD SEP 2
PY 2021
VL 25
IS 9
BP 773
EP 785
DI 10.1080/14728222.2021.1991913
EA OCT 2021
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA WZ6WK
UT WOS:000710765900001
PM 34637373
DA 2022-11-30
ER

PT J
AU Griffin, DR
   Richmond, PP
   Olson, JC
AF Griffin, David R.
   Richmond, Preston P.
   Olson, John C.
TI Intravitreal Aflibercept Outcomes in Patients with Persistent Macular
   Exudate Previously Treated with Bevacizumab and/or Ranibizumab for
   Neovascular Age-Related Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VEGF-TRAP; BINDING; FLUID
AB Purpose. To assess whether intravitreal aflibercept (2.0mg) can effectively reduce persistent macular exudate and enhance visual acuity in ranibizumab (0.5mg) and/or bevacizumab (1.25 mg) treatment resistant patients with neovascular age-related macular degeneration. Methods. This retrospective study included 47 treatment resistant eyes from 47 patients switched to intravitreal aflibercept injections after receiving a minimum of 3 injections with either ranibizumab or bevacizumab. Snellen visual acuity and optical coherence tomography were assessed just prior to the first injection (baseline) and prior to the fourth injection (final). Additionally, anatomical regions of persistent macular exudate were tracked to determine if these areas yielded varying responses to aflibercept. Results. At baseline, patients had received an average of 11.3 injections with any prior anti-VEGF drug (SD 5.96). For whole group analysis, baseline and final central retinal thickness were 370.57 mu m and 295.7 mu m (P <=.001), respectively. Baseline and final retinal fluid volumes were 4.81 mm(3) and 4.37 mm(3) (P <=.001), respectively. Baseline and final logMAR were 0.56 and 0.53 (P = 0.301), respectively. Anatomic location of persistent exudate did not appreciably alter treatment outcome. Conclusion. Central retinal thickness and total retinal fluid volume were reduced in ranibizumab and/or bevacizumab treatment resistant patients following three aflibercept injections. No appreciable change in visual acuity was noted.
C1 [Griffin, David R.] Univ Cent Florida, Coll Med, Orlando, FL 32827 USA.
   [Richmond, Preston P.; Olson, John C.] Cent Florida Retina & Macular Degenerat Ctr, Orlando, FL 32806 USA.
C3 State University System of Florida; University of Central Florida
RP Griffin, DR (通讯作者)，Univ Cent Florida, Coll Med, 6850 Lake Nona Blvd, Orlando, FL 32827 USA.
EM david.griffin@knights.ucf.edu
CR Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Carneiro AM, 2012, CLIN OPHTHALMOL, V6, P1149, DOI 10.2147/OPTH.S33017
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   De Bats F, 2012, J FR OPHTALMOL, V35, P661, DOI 10.1016/j.jfo.2012.01.015
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Frampton JE, 2013, DRUG AGING, V30, P331, DOI 10.1007/s40266-013-0077-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
NR 24
TC 12
Z9 13
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2014
VL 2014
AR 497178
DI 10.1155/2014/497178
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX1NA
UT WOS:000346712400001
PM 25505976
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Cheng, CK
   Chen, SJ
   Chen, JT
   Chen, LJ
   Chen, SN
   Chen, WL
   Hsu, SM
   Lai, CH
   Sheu, SJ
   Wu, PC
   Wu, WC
   Wu, WC
   Yang, CM
   Yeung, L
   Chen, TC
   Yang, CH
AF Cheng, Cheng-Kuo
   Chen, Shih-Jen
   Chen, Jiann-Torng
   Chen, Lee-Jen
   Chen, San-Ni
   Chen, Wen-Lu
   Hsu, Sheng-Min
   Lai, Chien-Hsiung
   Sheu, Shwu-Jiuan
   Wu, Pei-Chang
   Wu, Wei-Chi
   Wu, Wen-Chuan
   Yang, Chung-May
   Yeung, Ling
   Chen, Ta-Ching
   Yang, Chang-Hao
TI Optimal approaches and criteria to treat-and-extend regimen
   implementation for Neovascular age-related macular degeneration: experts
   consensus in Taiwan
SO BMC OPHTHALMOLOGY
LA English
DT Review
DE Anti-vascular endothelial growth factors; Expert opinion; Neovascular
   age-related macular degeneration; Treat-and-extend
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; GROWTH-FACTOR THERAPY; INTRAVITREAL
   AFLIBERCEPT; VISUAL-ACUITY; MANAGEMENT; OUTCOMES; RANIBIZUMAB;
   PREVALENCE; FLUID
AB The management of neovascular age-related macular degeneration (nAMD) has taken a major stride forward with the advent of anti-VEGF agents. The treat-and-extend (T&E) approach is a refined management strategy, tailoring to the individual patient's disease course and treatment outcome. To provide guidance to implementing anti-VEGF T&E regimens for nAMD in resource-limited health care systems, an advisory board was held to discuss and generate expert consensus, based on local and international guidelines, current evidence, as well as local experience and reimbursement policies. In the experts' opinion, treatment of nAMD should aim to maximize and maintain visual acuity benefits while minimizing treatment burden. Based on current evidence, treatment could be initiated with 3 consecutive monthly injections. After the initial period, treatment interval may be extended by 2 or 4 weeks each time for the qualified patients (i.e. no BCVA loss >= 5 ETDRS letters and dry retina), and a maximum interval of 16 weeks is permitted. For patients meeting the shortening criteria (i.e. any increased fluid with BCVA loss >= 5 ETDRS letters, or presence of new macular hemorrhage or new neovascularization), the treatment interval should be reduced by 2 or 4 weeks each time, with a minimal interval of 4 weeks. Discontinuation of anti-VEGF may be considered for those who have received 2-3 consecutive injections spaced 16 weeks apart and present with stable disease. For these individuals, regular monitoring (e.g. 3-4 months) is recommended and monthly injections should be reinstated upon signs of disease recurrence.
C1 [Cheng, Cheng-Kuo] Shin Kong Wu Ho Su Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Cheng, Cheng-Kuo] Natl Taiwan Univ, Sch Med, Dept Ophthalmol, Taipei, Taiwan.
   [Cheng, Cheng-Kuo] Fu Jen Catholic Univ, Sch Med, Dept Ophthalmol, New Taipei, Taiwan.
   [Chen, Shih-Jen] Natl Yang Ming Univ, Sch Med, Dept Ophthalmol, Taipei, Taiwan.
   [Chen, Shih-Jen] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chen, Jiann-Torng] Tri Serv Gen Hosp, Natl Def Med Ctr, Dept Ophthalmol, Taipei, Taiwan.
   [Chen, Lee-Jen] Mackay Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chen, San-Ni] Changhua Christian Hosp, Dept Ophthalmol, Changhua, Taiwan.
   [Chen, San-Ni; Chen, Wen-Lu] China Med Univ Hosp, Dept Ophthalmol, Taichung, Taiwan.
   [Hsu, Sheng-Min] Natl Cheng Kung Univ, Dept Ophthalmol, Coll Med, Tainan, Taiwan.
   [Hsu, Sheng-Min] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Ophthalmol, Tainan, Taiwan.
   [Lai, Chien-Hsiung; Yeung, Ling] Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
   [Lai, Chien-Hsiung] Chang Gung Mem Hosp, Dept Ophthalmol, Chiayi, Taiwan.
   [Lai, Chien-Hsiung] Chang Gung Univ Sci & Technol, Dept Nursing, Chiayi, Taiwan.
   [Sheu, Shwu-Jiuan; Wu, Wen-Chuan] Kaohsiung Med Univ, Chung Ho Mem Hosp, Dept Ophthalmol, Kaohsiung, Taiwan.
   [Sheu, Shwu-Jiuan; Wu, Wen-Chuan] Kaohsiung Med Univ, Sch Med, Dept Ophthalmol, Kaohsiung, Taiwan.
   [Wu, Pei-Chang] Chang Gung Univ, Chang Gung Mem Hosp, Kaohsiung Med Ctr, Coll Med,Dept Ophthalmol, Kaohsiung, Taiwan.
   [Wu, Wei-Chi] Chang Gung Univ, Chang Gung Mem Hosp, Linkou Med Ctr, Coll Med,Dept Ophthalmol, Taoyuan, Taiwan.
   [Yang, Chung-May; Chen, Ta-Ching; Yang, Chang-Hao] Natl Taiwan Univ Hosp, Dept Ophthalmol, 8 Chung Shan S Rd,Zhongshan S Rd, Taipei 100226, Taiwan.
   [Yeung, Ling] Chang Gung Mem Hosp, Dept Ophthalmol, Keelung, Taiwan.
C3 Shin Kong Wu Ho Su Memorial Hospital; National Taiwan University; Fu Jen
   Catholic University; National Yang Ming Chiao Tung University; Taipei
   Veterans General Hospital; National Defense Medical Center; Tri-Service
   General Hospital; Mackay Memorial Hospital; Changhua Christian Hospital;
   China Medical University Taiwan; China Medical University Hospital -
   Taiwan; National Cheng Kung University; National Cheng Kung University;
   National Cheng Kung University Hospital; Chang Gung University; Chang
   Gung Memorial Hospital; Chang Gung University of Science & Technology;
   Kaohsiung Medical University; Kaohsiung Medical University Hospital;
   Kaohsiung Medical University; Chang Gung Memorial Hospital; Chang Gung
   University; Chang Gung Memorial Hospital; Chang Gung University;
   National Taiwan University; National Taiwan University Hospital; Chang
   Gung Memorial Hospital
RP Yang, CH (通讯作者)，Natl Taiwan Univ Hosp, Dept Ophthalmol, 8 Chung Shan S Rd,Zhongshan S Rd, Taipei 100226, Taiwan.
EM chyangoph@ntu.edu.tw
OI YANG, CHUNG-MAY/0000-0003-4082-420X; YANG, CHANG-HAO/0000-0002-4328-8716
CR Adrean SD, 2018, OPHTHALMOL RETINA, V2, P225, DOI 10.1016/j.oret.2017.07.009
   Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   Arendt P, 2019, RETINA-J RET VIT DIS, V39, P27, DOI 10.1097/IAE.0000000000001923
   Baek J, 2019, INVEST OPHTH VIS SCI, V60, P590, DOI 10.1167/iovs.18-24244
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Chen LJ, 2020, J FORMOS MED ASSOC, V119, P569, DOI 10.1016/j.jfma.2019.04.012
   Eichenbaum D, 2019, ASS RES VIS OPHTH AR
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Garcia-Layana A, 2015, DRUG AGING, V32, P797, DOI 10.1007/s40266-015-0300-y
   Gillies M., 2017, 17 C EUR RET MAC VIT
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Hosokawa M., 2018, ASS RES VIS OPHTH AR
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Joko T, 2020, PATIENT PREFER ADHER, V14, P553, DOI 10.2147/PPA.S228890
   Kertes PJ, 2020, JAMA OPHTHALMOL, V138, P244, DOI 10.1001/jamaophthalmol.2019.5540
   Koh A, 2017, ASIA-PAC J OPHTHALMO, V6, P296, DOI 10.22608/APO.2016125
   Korobelnik JF, 2020, GRAEF ARCH CLIN EXP, V258, P1149, DOI 10.1007/s00417-020-04703-x
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Lo KJ, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/4538135
   Mantel I, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.6
   Mitchell P, 2018, 18 EUR SOC RET SPEC
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Palkar AH, 2019, TAIWAN J OPHTHALMOL, V9, P72, DOI 10.4103/tjo.tjo_35_18
   Patel PJ, 2017, CLIN OPHTHALMOL, V11, P1957, DOI 10.2147/OPTH.S145732
   Reiter GS, 2021, RETINA-J RET VIT DIS, V41, P1318, DOI 10.1097/IAE.0000000000003023
   Riaz M, 2017, ESSENT OPHTHALMOL, P169, DOI 10.1007/978-4-431-56511-6_14
   Ross AH, 2020, EYE, V34, P1825, DOI 10.1038/s41433-019-0747-x
   Schmidt-Erfurth U, 2020, OPHTHALMOLOGY, V127, P1211, DOI 10.1016/j.ophtha.2020.03.010
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Takayama K, 2017, OPHTHALMOLOGICA, V237, P105, DOI 10.1159/000461785
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Wang FH, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/7530458
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Yang BCL, 2019, TAIWAN J OPHTHALMOL, V9, P249, DOI 10.4103/tjo.tjo_34_19
   Zhou HY, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-019-1278-8
NR 41
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JAN 15
PY 2022
VL 22
IS 1
AR 25
DI 10.1186/s12886-021-02231-8
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YH1HF
UT WOS:000742924900002
PM 35033037
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lee, JS
   Kang, HG
   Lee, CS
   Woo, SJ
AF Lee, Jong Suk
   Kang, Hyun Goo
   Lee, Christopher Seungkyu
   Woo, Se Joon
TI Short-Term Outcomes following "Switching" to Monthly Ranibizumab in
   Neovascular Age-Related Macular Degeneration Showing Insufficient
   Response to Bimonthly Aflibercept
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY; INTRAVITREAL
   AFLIBERCEPT; VISUAL-ACUITY; TACHYPHYLAXIS; THERAPY; BEVACIZUMAB; TREAT;
   EYES
AB Background/Objectives. To evaluate the efficacy of switching to monthly ranibizumab in neovascular age-related macular degeneration (nAMD) showing an insufficient response to bimonthly aflibercept. Subjects/Methods. A total of 13 nAMD eyes showing an insufficient treatment response to three successive aflibercept injections were enrolled through a retrospective chart review. After switching, three consecutive monthly intravitreal ranibizumab injections were performed. The main outcome measurements included the best-corrected visual acuity (BCVA), central retinal thickness (CRT), presence of intraretinal fluid (IRF), and subretinal fluid (SRF) using optical coherence tomography (OCT) and were measured every month. Results. CRT and logMAR VA were 349.62 +/- 223.51 mu m and 0.50 +/- 0.23 at the baseline and 274.69 +/- 148.77 mu m and 0.46 +/- 0.24, 311.54 +/- 192.90 mu m and 0.45 +/- 0.20 at 1 month after the first and third ranibizumab injections, respectively. The CRT decrease during three ranibizumab injections was statistically significant (38.08 +/- 69.52 mu m, p=0.033). Change in VA was not statistically significant. The percentage of eyes with SRF was 100% at baseline and 53.8%, 76.9%, and 69.2% one month after each ranibizumab injections. The percentage of eyes with IRF was 38.5% at baseline and 23.1%, 23.1%, and 15.4%, respectively, after switching. Conclusion. Switching to monthly ranibizumab in nAMD showing an insufficient response to bimonthly aflibercept led to immediate anatomical improvement. It can be considered in countries where the healthcare insurance system limits the minimum injection interval of aflibercept.
C1 [Lee, Jong Suk; Woo, Se Joon] Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Coll Med, Seongnam, South Korea.
   [Lee, Jong Suk] Nune Eye Hosp, Seoul, South Korea.
   [Kang, Hyun Goo] Yonsei Univ, Gangnam Severance Hosp, Inst Vis Res, Dept Ophthalmol,Coll Med, Seoul, South Korea.
   [Lee, Christopher Seungkyu] Yonsei Univ, Severance Eye Hosp, Inst Vis Res, Dept Ophthalmol,Coll Med, Seoul, South Korea.
C3 Seoul National University (SNU); Yonsei University; Yonsei University
   Health System; Yonsei University; Yonsei University Health System
RP Woo, SJ (通讯作者)，Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Coll Med, Seongnam, South Korea.; Lee, CS (通讯作者)，Yonsei Univ, Severance Eye Hosp, Inst Vis Res, Dept Ophthalmol,Coll Med, Seoul, South Korea.
EM sklee219@yuhs.ac; sejoon1@snu.ac.kr
RI ; Woo, Se Joon/I-7357-2013; Kang, Hyun Goo/C-5569-2018
OI Lee, Jong Suk/0000-0003-4101-6490; Lee, Christopher/0000-0001-5054-9470;
   Woo, Se Joon/0000-0003-3692-7169; Kang, Hyun Goo/0000-0001-8359-9618
FU National Research Foundation (NRF) of Korea - Korea Government (MSIT)
   [2020R1F1A1072795]
FX This work was supported by the National Research Foundation (NRF) of
   Korea grant funded by the Korea Government (MSIT) (2020R1F1A1072795).
CR Abou-Ltaif S, 2016, SAUDI J OPHTHALMOL, V30, P227, DOI 10.1016/j.sjopt.2016.10.008
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Bohni SC, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0101-4
   Bulirsch LM, 2022, BRIT J OPHTHALMOL, V106, P1288, DOI 10.1136/bjophthalmol-2020-318672
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gale RP, 2020, BRIT J OPHTHALMOL, V104, P493, DOI 10.1136/bjophthalmol-2019-314251
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hirakata T, 2016, CLIN OPHTHALMOL, V10, P969, DOI 10.2147/OPTH.S101596
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Inoue M, 2016, AM J OPHTHALMOL, V169, P95, DOI 10.1016/j.ajo.2016.06.021
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Mantel I, 2016, RETINA-J RET VIT DIS, V36, P53, DOI 10.1097/IAE.0000000000000664
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Slean Geraldine R, 2016, Int J Retina Vitreous, V2, P2, DOI 10.1186/s40942-016-0028-9
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Waibel S, 2018, KLIN MONATSBL AUGENH, V235, P616, DOI 10.1055/s-0043-106308
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
NR 27
TC 1
Z9 1
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD AUG 12
PY 2021
VL 2021
AR 5547686
DI 10.1155/2021/5547686
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UD8DD
UT WOS:000687432700001
PM 34422404
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hu, CC
   Lin, HC
   Sheu, JJ
   Kao, LT
AF Hu, Chao-Chien
   Lin, Herng-Ching
   Sheu, Jau-Jiuan
   Kao, Li-Ting
TI Neovascular age-related macular degeneration is not associated with
   coronary heart disease in a Chinese Population: a population-based study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; coronary heart disease; neovascular
   age-related macular degeneration
ID CARDIOVASCULAR RISK-FACTORS; BLUE-MOUNTAINS-EYE; ARTERY-DISEASE; POOLED
   FINDINGS; 3 CONTINENTS; ATHEROSCLEROSIS; MACULOPATHY
AB Purpose: This case-control study aimed to explore the association between prior coronary heart disease (CHD) and neovascular age-related macular degeneration (AMD) using a population-based data set in Taiwan.
   Methods: We analysed data sourced from the Taiwan Longitudinal Health Insurance Database 2005. The study consisted of 1970 patients with neovascular AMD as cases and 5910 age- and sex-matched controls. We performed a conditional logistic regression to examine the odds ratio (OR) and its corresponding 95% confidence interval (CI) for previously diagnosed CHD between cases and controls.
   Results: Of the 7880 sampled patients, 24.5% had a prior history of CHD; CHD was found in 25.7% of cases and in 22.7% of controls (p = 0.008). The conditional logistic regression analysis indicated that the OR for prior CHD for cases was 1.17 [95% confidence interval (CI): 1.04-1.32] compared to the controls. However, after adjusting for patient's monthly income, geographic location, urbanization level, age, hyperlipidaemia, diabetes and hypertension, we failed to observe an association between prior CHD and AMD (OR = 1.03, 95% CI = 0.91-1.17). Additionally, the medical comorbidities of hyperlipidaemia (adjusted OR = 1.29, 95% CI = 1.15-1.45), hypertension (adjusted OR = 1.20, 95% CI = 1.05-1.37) and diabetes (adjusted OR = 1.47, 95% CI = 1.32-1.65) were significantly associated with AMD.
   Conclusions: This study presented no significant difference in the odds of prior CHD between patients with AMD and those without AMD after adjusting for comorbidities and sociodemographic characteristics in a Chinese population.
C1 [Hu, Chao-Chien] Taipei Med Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Hu, Chao-Chien] Shin Kong Wu Ho Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Hu, Chao-Chien] Fu Jen Catholic Univ, Sch Med, Hsingchuang, Taiwan.
   [Lin, Herng-Ching; Kao, Li-Ting] Taipei Med Univ Hosp, Sleep Res Ctr, Taipei, Taiwan.
   [Lin, Herng-Ching] Taipei Med Univ, Sch Hlth Care Adm, Taipei, Taiwan.
   [Sheu, Jau-Jiuan] Taipei Med Univ Hosp, Dept Neurol, Taipei, Taiwan.
   [Sheu, Jau-Jiuan] Taipei Med Univ, Dept Neurol, Sch Med, Coll Med, Taipei, Taiwan.
   [Kao, Li-Ting] Natl Def Med Ctr, Grad Inst Life Sci, Taipei 110, Taiwan.
C3 Taipei Medical University; Taipei Medical University Hospital; Shin Kong
   Wu Ho Su Memorial Hospital; Fu Jen Catholic University; Taipei Medical
   University; Taipei Medical University Hospital; Taipei Medical
   University; Taipei Medical University; Taipei Medical University
   Hospital; Taipei Medical University; National Defense Medical Center
RP Kao, LT (通讯作者)，Natl Def Med Ctr, Grad Inst Life Sci, Taipei 110, Taiwan.
EM kaoliting@gmail.com
RI Kao, Li-Ting/W-9287-2018
OI Kao, Li-Ting/0000-0003-0692-7408
FU Shin Kong Wu-Ho-Su Memorial Hospital [SKH-TMU-10302]
FX Herng-Ching Lin, Jau-Jiuan Sheu and Li-Ting Kao have equal contributions
   to this study. This research was supported by a grant from Shin Kong
   Wu-Ho-Su Memorial Hospital (SKH-TMU-10302).
CR Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cachulo MD, 2016, ACTA OPHTHALMOL
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Chung SD, 2015, ACTA OPHTHALMOL, V93, pE176, DOI 10.1111/aos.12478
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   La TY, 2014, CURR EYE RES, V39, P1232, DOI 10.3109/02713683.2014.907431
   Libby P, 2005, CIRCULATION, V111, P3481, DOI 10.1161/CIRCULATIONAHA.105.537878
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mack M, 2014, CARDIOL CLIN, V32, P323, DOI 10.1016/j.ccl.2014.04.003
   McCullough PA, 2007, CLIN J AM SOC NEPHRO, V2, P611, DOI 10.2215/CJN.03871106
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Thomas J, 2015, SOUTH MED J, V108, P502, DOI 10.14423/SMJ.0000000000000329
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   Yang K, 2014, RETINA-J RET VIT DIS, V34, P1539, DOI 10.1097/IAE.0000000000000118
   Yip JLY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132565
NR 32
TC 3
Z9 3
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2017
VL 95
IS 7
BP E587
EP E591
DI 10.1111/aos.13204
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FM0JE
UT WOS:000414648500009
PM 27543376
OA Bronze
DA 2022-11-30
ER

PT J
AU Mattes, D
   Haas, A
   Renner, W
   Steinbrugger, I
   El-Shabrawi, Y
   Wedrich, A
   Werner, C
   Schmut, O
   Weger, M
AF Mattes, Dietmar
   Haas, Anton
   Renner, Wilfried
   Steinbrugger, Iris
   El-Shabrawi, Yosuf
   Wedrich, Andreas
   Werner, Christoph
   Schmut, Otto
   Weger, Martin
TI Analysis of three pigment epithelium-derived factor gene polymorphisms
   in patients with exudative age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; MET72THR
   POLYMORPHISM; FACTOR PEDF; FACTOR-B; RISK; EYE; SUSCEPTIBILITY;
   ANGIOGENESIS; VARIANT
AB Purpose: Exudative age-related macular degeneration (exudative AMD) is a common vision-threatening disease, with both environmental and genetic factors contributing to its development. Recently, homozygosity for the 72Met variant of the pigment epithelium-derived factor (PEDF) Met72Thr gene polymorphism (rs1136287) was identified as a novel risk factor for exudative AMD in Chinese patients from Taiwan. The role of this polymorphism, however, has not yet been determined in a white European population. In addition, two other PEDF gene polymorphisms, -5736T > C (rs12150053) and -5304C > T (rs12948385), have been associated with increased risk of diabetic retinopathy, but have not yet been studied among patients with exudative AMD. The purpose of the present study was thus to investigate a hypothesized association between these PEDF polymorphisms and the presence of exudative AMD in a white European population.
   Methods: The present case-control study comprised 269 patients with exudative AMD and 155 control subjects. Genotypes of the PEDF polymorphisms were determined by 5'-exonuclease assays (TaqMan).
   Results: PEDF genotype and allele frequencies were not significantly different between AMD patients and control subjects. The two promoter polymorphisms, -5736T > C (rs12150053) and -5304C > T (rs12948385), were in complete association. Presence of the homozygous PEDF 72 Met/Met genotype was associated with a nonsignificant odds ratio of 1.00 (95% confidence interval: 0.67-1.49, p=0.99). Similarly, presence of the homozygous PEDF-5736 TT genotype or -5304 CC genotype was associated with a nonsignificant odds ratio of 0.99 (95% confidence interval: 0.56-1.75, p=0.97). Both promoter polymorphisms were in linkage disequilibrium with the Met72Thr (rs1136287) polymorphism (D'=0.83) and formed three common and one rare haplotype. Haplotype frequencies were similar between AMD patients and control subjects (p > 0.05).
   Conclusions: Our data suggest that none of the investigated PEDF polymorphisms is likely a major risk factor for exudative AMD in a white European population.
C1 [Mattes, Dietmar; Haas, Anton; Steinbrugger, Iris; El-Shabrawi, Yosuf; Wedrich, Andreas; Werner, Christoph; Schmut, Otto; Weger, Martin] Med Univ Graz, Dept Ophthalmol, A-8036 Graz, Austria.
   [Renner, Wilfried] Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, A-8036 Graz, Austria.
C3 Medical University of Graz; Medical University of Graz
RP Mattes, D (通讯作者)，Med Univ Graz, Dept Ophthalmol, Auenbruggerpl 4, A-8036 Graz, Austria.
EM di.mattes@meduni-graz.at
RI Wedrich, Andreas/AAE-9171-2020
CR Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Iizuka H, 2007, BIOCHEM BIOPH RES CO, V361, P421, DOI 10.1016/j.bbrc.2007.07.025
   Karakousis PC, 2001, MOL VIS, V7, P154
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koenekoop R, 1999, MOL VIS, V5
   Lin JM, 2008, AM J OPHTHALMOL, V145, P716, DOI 10.1016/j.ajo.2007.11.006
   Liu H, 2004, P NATL ACAD SCI USA, V101, P6605, DOI 10.1073/pnas.0308342101
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   *NAT ADV EYE COUNC, 1993, PUBL NIH
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Okamoto H, 2006, MOL VIS, V12, P156
   Renno RZ, 2002, INVEST OPHTH VIS SCI, V43, P1574
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
   Simonovic M, 2001, P NATL ACAD SCI USA, V98, P11131, DOI 10.1073/pnas.211268598
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176
   Tombran-Tink J, 1996, Mol Vis, V2, P11
   TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700
   Weger M, 2007, MOL VIS, V13, P1274
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Yamagishi S, 2005, MED HYPOTHESES, V64, P1202, DOI 10.1016/j.mehy.2005.01.017
   Yamagishi S, 2002, INT J CLIN PHARM RES, V22, P67
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
NR 40
TC 10
Z9 13
U1 0
U2 0
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD FEB 16
PY 2009
VL 15
IS 34-35
BP 343
EP 348
PG 6
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 427NL
UT WOS:000264785900002
PM 19223990
DA 2022-11-30
ER

PT J
AU Fliney, GD
   Zukin, LM
   Hagedorn, C
AF Fliney, Greg D.
   Zukin, Leonid M.
   Hagedorn, Curtis
TI Neovascular Age-Related Macular Degeneration Disease Quiescence with
   Visual Acuity Stability in a Subgroup of Patients Following PRN
   Treatment
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE macular degeneration; VEGF; disease quiescence; PRN; visual acuity
ID RANIBIZUMAB; BEVACIZUMAB; THERAPY; EYE
AB Purpose: This study evaluates long-term visual acuity (VA) outcomes in patients with prolonged clinically quiescent neovascular age-related macular degeneration (AMD) after treatment with a pro re nata (PRN) regimen of anti-vascular endothelial growth factor agents (bevacizumab, ranibizumab, and/or aflibercept).
   Methods: This retrospective study analyzes VA changes in 105 eyes from 72 patients with a period of AMD disease quiescence (determined by retinal examination) not requiring treatment for at least 180 days. All patients were seen at Colorado Retina Associates between October 31, 2005 and December 31, 2015. VA was measured at the time of first treatment, last treatment, and final clinic visit showing changes in VA during the treatment and quiescent periods. The sample was stratified to compare those with VA gain throughout the study to those with VA loss.
   Results: The aggregate group showed VA stability during the treatment period (20/117 to 20/116) with a significant decline during the quiescent period (to 20/235; P<0.001). The VA gainers had a significant increase in VA during the treatment period (20/187 to 20/88; P<0.001) and VA stability during the quiescent period (to 20/93). VA losers had a significant decline in VA during both the treatment and quiescent periods (P<0.001).
   Conclusion: Overall, PRN treatment resulted in a decline in VA during a period of apparent disease quiescence. There is a group of patients that does not lose VA during this period, and if patients like these can be identified, their treatment could be optimized to include a period of clinically justified nontreatment.
C1 [Fliney, Greg D.; Zukin, Leonid M.] Univ Colorado, Sch Med, Aurora, CO USA.
   [Hagedorn, Curtis] Colorado Retina Associates, Denver, CO USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus
RP Hagedorn, C (通讯作者)，Colorado Retina Associates, 400 Indiana St 310, Golden, CO 80401 USA.
EM chagedorn@retinacolorado.com
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Pauleikhoff D, 2011, GRAEF ARCH CLIN EXP, V249, P631, DOI 10.1007/s00417-011-1639-3
   RAY WA, 1985, INVEST OPHTH VIS SCI, V26, P1186
   Roberts MF, 2002, BRIT J OPHTHALMOL, V86, P658, DOI 10.1136/bjo.86.6.658
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarwar S, 2016, COCHRANE DB SYST REV, V2
   Schmucker CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137866
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
NR 22
TC 3
Z9 3
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD OCT
PY 2017
VL 33
IS 8
BP 604
EP 609
DI 10.1089/jop.2017.0013
PG 6
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA FI5HW
UT WOS:000412014100006
PM 28829220
DA 2022-11-30
ER

PT J
AU Buitendijk, GHS
   Rochtchina, E
   Myers, C
   van Duijn, CM
   Lee, KE
   Klein, BEK
   Meuer, SM
   de Jong, PTVM
   Holliday, EG
   Tan, AG
   Uitterlinden, AG
   Sivakumaran, TS
   Attia, J
   Hofman, A
   Mitchell, P
   Vingerling, JR
   Iyengar, SK
   Janssens, ACJW
   Wang, JJ
   Klein, R
   Klaver, CCW
AF Buitendijk, Gabrielle H. S.
   Rochtchina, Elena
   Myers, Chelsea
   van Duijn, Cornelia M.
   Lee, Kristine E.
   Klein, Barbara E. K.
   Meuer, Stacy M.
   de Jong, Paulus T. V. M.
   Holliday, Elizabeth G.
   Tan, Ava G.
   Uitterlinden, Andre G.
   Sivakumaran, Theru S.
   Attia, John
   Hofman, Albert
   Mitchell, Paul
   Vingerling, Johannes R.
   Iyengar, Sudha K.
   Janssens, A. Cecile J. W.
   Wang, Jie Jin
   Klein, Ronald
   Klaver, Caroline C. W.
TI Prediction of Age-related Macular Degeneration in the General Population
   The Three Continent AMD Consortium
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; DIETARY ANTIOXIDANTS; RISK ALLELES; GENETIC RISK;
   MACULOPATHY; PREVALENCE; MODEL; OLDER; EYE; CFH
AB Purpose: Prediction models for age-related macular degeneration (AMD) based on case-control studies have a tendency to overestimate risks. The aim of this study is to develop a prediction model for late AMD based on data from population-based studies.
   Design: Three population-based studies: the Rotterdam Study (RS), the Beaver Dam Eye Study (BDES), and the Blue Mountains Eye Study (BMES) from the Three Continent AMD Consortium (3CC).
   Participants: People (n = 10 106) with gradable fundus photographs, genotype data, and follow-up data without late AMD at baseline.
   Methods: Features of AMD were graded on fundus photographs using the 3CC AMD severity scale. Associations with known genetic and environmental AMD risk factors were tested using Cox proportional hazard analysis. In the RS, the prediction of AMD was estimated for multivariate models by area under receiver operating characteristic curves (AUCs). The best model was validated in the BDES and BMES, and associations of variables were re-estimated in the pooled data set. Beta coefficients were used to construct a risk score, and risk of incident late AMD was calculated using Cox proportional hazard analysis. Cumulative incident risks were estimated using Kaplan-Meier product-limit analysis.
   Main Outcome Measures: Incident late AMD determined per visit during a median follow-up period of 11.1 years with a total of 4 to 5 visits.
   Results: Overall, 363 participants developed incident late AMD, 3378 participants developed early AMD, and 6365 participants remained free of any AMD. The highest AUC was achieved with a model including age, sex, 26 single nucleotide polymorphisms in AMD risk genes, smoking, body mass index, and baseline AMD phenotype. The AUC of this model was 0.88 in the RS, 0.85 in the BDES and BMES at validation, and 0.87 in the pooled analysis. Individuals with low-risk scores had a hazard ratio (HR) of 0.02 (95% confidence interval [CI], 0.01-0.04) to develop late AMD, and individuals with high-risk scores had an HR of 22.0 (95% CI, 15.2-31.8). Cumulative risk of incident late AMD ranged from virtually 0 to more than 65% for those with the highest risk scores.
   Conclusions: Our prediction model is robust and distinguishes well between those who will develop late AMD and those who will not. Estimated risks were lower in these population-based studies than in previous case-control studies. (C) 2013 by the American Academy of Ophthalmology.
C1 [Buitendijk, Gabrielle H. S.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, NL-3000 CA Rotterdam, Netherlands.
   [Buitendijk, Gabrielle H. S.; van Duijn, Cornelia M.; Uitterlinden, Andre G.; Hofman, Albert; Vingerling, Johannes R.; Janssens, A. Cecile J. W.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Rochtchina, Elena; Tan, Ava G.; Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Rochtchina, Elena; Tan, Ava G.; Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   [Myers, Chelsea; Lee, Kristine E.; Klein, Barbara E. K.; Meuer, Stacy M.; Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [de Jong, Paulus T. V. M.] Netherlands Inst Neurosci, Dept Ophthalmogenet, Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Leiden Univ, Med Ctr, Dept Ophthalmol, Leiden, Netherlands.
   [Holliday, Elizabeth G.; Attia, John] Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2300, Australia.
   [Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
   [Uitterlinden, Andre G.; Hofman, Albert] Netherlands Genom Initiat, Netherlands Consortium Hlth Aging, The Hague, Netherlands.
   [Sivakumaran, Theru S.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA.
   [Sivakumaran, Theru S.; Iyengar, Sudha K.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Attia, John] John Hunter Hosp, Dept Med, Newcastle, NSW, Australia.
   [Attia, John] Hunter Med Res Inst, Newcastle, NSW, Australia.
   [Janssens, A. Cecile J. W.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA.
   [Wang, Jie Jin] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; University of Sydney; University of Sydney; Westmead
   Institute for Medical Research; University of Wisconsin System;
   University of Wisconsin Madison; Royal Netherlands Academy of Arts &
   Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University
   of Amsterdam; Academic Medical Center Amsterdam; Leiden University;
   Leiden University Medical Center (LUMC); Leiden University - Excl LUMC;
   University of Newcastle; Erasmus University Rotterdam; Erasmus MC;
   Cincinnati Children's Hospital Medical Center; Case Western Reserve
   University; John Hunter Hospital; Hunter Medical Research Institute;
   University of Newcastle; Emory University; Rollins School Public Health;
   Centre for Eye Research Australia; University of Melbourne
RP Klaver, CCW (通讯作者)，Erasmus MC, Dept Ophthalmol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM c.c.w.klaver@erasmusmc.nl
RI Mitchell, Paul/P-1498-2014; wang, jie/GRS-0942-2022; Klaver, Caroline
   C.W./A-2013-2016; Attia, John R/F-5376-2013; Wang, Jie Jin/P-1499-2014;
   /S-1190-2019
OI Attia, John R/0000-0001-9800-1308; Wang, Jie Jin/0000-0001-9491-4898;
   /0000-0001-7488-250X; Klein, Ronald/0000-0002-4428-6237; Van Duijn,
   Cornelia/0000-0002-2374-9204; Klaver, Caroline/0000-0002-2355-5258;
   Janssens, A Cecile/0000-0002-6153-4976; Tan, Ava
   Grace/0000-0003-3344-0339
FU Netherlands Organization for Scientific Research, the Hague; Swart van
   Essen, Rotterdam; Bevordering van Volkskracht, Rotterdam; Rotterdamse
   Blindenbelangen Association, Rotterdam; Algemene Nederlandse Vereniging
   ter Voorkoming van Blindheid, Doorn, The Netherlands; Oogfonds
   Nederland, Utrecht; MDFonds, Utrecht; Vereniging Trustfonds Erasmus
   Universiteit Rotterdam, Rotterdam, The Netherlands; Lijf en Leven,
   Krimpen aan de IJssel, The Netherlands; Topcon Europe BV, Capelle aan
   den IJssel, The Netherlands; National Institutes of Health [EY06594];
   Research to Prevent Blindness (RPB), New York, New York; National Eye
   Institute; Australian National Health & Medical Research Council
   (NHMRC), Canberra, Australia (NHMRC) [974159, 211069, 302068]; Centre
   for Clinical Research Excellence in Translational Clinical Research in
   Eye Diseases [529923]; Australian NHMRC, Canberra Australia (NHMRC)
   [512423, 475604, 529912]; Wellcome Trust, United Kingdom, as part of the
   Wellcome Trust Case Control Consortium 2 [085475/B/08/Z, 085475/08/Z];
   National Health & Medical Research Council Senior Research Fellowship
   [358702, 632909]; NATIONAL EYE INSTITUTE [U10EY006594] Funding Source:
   NIH RePORTER
FX The RS was supported by the Netherlands Organization for Scientific
   Research, the Hague; Swart van Essen, Rotterdam; Bevordering van
   Volkskracht, Rotterdam; Rotterdamse Blindenbelangen Association,
   Rotterdam; Algemene Nederlandse Vereniging ter Voorkoming van Blindheid,
   Doorn, The Netherlands; Oogfonds Nederland, Utrecht; MDFonds, Utrecht;
   Vereniging Trustfonds Erasmus Universiteit Rotterdam, Rotterdam, The
   Netherlands; and Lijf en Leven, Krimpen aan de IJssel, The Netherlands.
   An unrestricted grant was obtained from Topcon Europe BV, Capelle aan
   den IJssel, The Netherlands. The BDES was supported by National
   Institutes of Health Grant EY06594 (B. E. K. K. and R. K.) and, in part,
   by Research to Prevent Blindness (RPB) (B. E. K. K. and R. K., Senior
   Scientific Investigator Awards), New York, New York. The National Eye
   Institute provided funding for the entire study, including collection
   and analyses of data; RPB provided additional support for data analyses.
   The content of this report is solely the responsibility of the authors
   and does not necessarily reflect the official views of the National Eye
   Institute or the National Institutes of Health. The BMES was supported
   by the Australian National Health & Medical Research Council (NHMRC),
   Canberra, Australia (NHMRC project Grant IDs 974159, 211069, 302068),
   and Centre for Clinical Research Excellence in Translational Clinical
   Research in Eye Diseases (grant ID 529923). The BMES Genome-Wide
   Association Study and genotyping costs were supported by the Australian
   NHMRC, Canberra Australia (NHMRC project Grant IDs 512423, 475604, and
   529912), and the Wellcome Trust, United Kingdom, as part of the Wellcome
   Trust Case Control Consortium 2 (A. Viswanathan, P. McGuffin, P.
   Mitchell, F. Topouzis, P. Foster, grant IDs 085475/B/08/Z and
   085475/08/Z). J.J.W. is funded by a National Health & Medical Research
   Council Senior Research Fellowship (Grant ID 358702, 2005-2009, and ID
   632909, 2010-2014). The funding organizations had no role in the design
   and conduct of the study; the collection, management, analysis, and
   interpretation of the data; or the preparation, review, or approval of
   the manuscript.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boltz A, 2012, OPHTHALMOLOGY, V119, P1615, DOI 10.1016/j.ophtha.2012.02.001
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gibson J, 2010, BRIT J OPHTHALMOL, V94, P1382, DOI 10.1136/bjo.2010.182568
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007
   Hofman A, 2011, EUR J EPIDEMIOL, V26, P657, DOI 10.1007/s10654-011-9610-5
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Janssens ACJW, 2011, EUR J EPIDEMIOL, V26, P313, DOI 10.1007/s10654-011-9551-z
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 1997, ARCH OPHTHALMOL-CHIC, V115, P945, DOI 10.1001/archopht.1997.01100160115033
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, OPHTHALMIC EPIDEMIOL
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Mckay GJ, 2010, MOL VIS, V16, P194
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rothman KJ, 2008, MODERN EPIDEMIOLOGY, P33
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Szklo M, 1998, EPIDEMIOL REV, V20, P81, DOI 10.1093/oxfordjournals.epirev.a017974
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   World Health Organization, 2004, VISION 2020 RIGHT SI
   Ying GS, 2011, OPHTHALMOLOGY, V118, P332, DOI 10.1016/j.ophtha.2010.06.030
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zanke B, 2010, CAN J OPHTHALMOL, V45, P22, DOI 10.3129/i09-209
NR 49
TC 72
Z9 73
U1 0
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2013
VL 120
IS 12
BP 2644
EP 2655
DI 10.1016/j.ophtha.2013.07.053
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 255OL
UT WOS:000327249600051
PM 24120328
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Hanumunthadu, D
   Ilginis, T
   Restori, M
   Sagoo, M
   Tufail, A
   Balaggan, KS
   Patel, PJ
AF Hanumunthadu, Daren
   Ilginis, Tomas
   Restori, Marie
   Sagoo, Mandeep
   Tufail, Adnan
   Balaggan, Kamaljit S.
   Patel, Praveen J.
TI Spectral-domain Optical Coherence Tomography Retinal and Choroidal
   Thickness Metric Repeatability in Age-related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL AFLIBERCEPT; SEGMENTATION ERROR; BLOOD-FLOW; THERAPY;
   REPRODUCIBILITY; BEVACIZUMAB; PARAMETERS; VOLUME; EYES; OCT
AB PURPOSE: To determine the intrasession repeatability of spectral-domain OCT (SDOCT)-derived macular retinal and choroidal metrics in patients with neovascular age-related macular degeneration (nAMD) in the Distance of Choroid Study (DOCS).
   DESIGN: Validity and reliability analysis.
   METHODS: Enrolled patients underwent repeated SDOCT imaging using the Spectralis OCT (Heidelberg Engineering, Heidelberg, Germany). A single technician certified for clinical trials took 3 macular volume scans. Retinal thicknesses were calculated for each of the 9 Early Treatment Diabetic Retinopathy Study (ETDRS) macular subfields. Center point thickness and total macular volume were also included in the analysis. Manual subfoveal choroidal thickness measurements were made by a masked observer.
   RESULTS: A total of 40 eyes of 40 patients were included in this analysis (mean [+/- standard deviation] age: 74.1 [+/- 7.2] years, 60% male). The coefficient of repeatability (CR) of the central macular subfield was 30.6 mu m (95% confidence interval [CI] 29.8-1.4 mu m). The CR for the other macular subfields ranged from 7.0 mu m to 38.2 mu m. The CR for the total macular volume was 0.212 mm(3) (95% CI 0.206-0.217 mm(3)) and the CR for the center point was 47.5 mu m (95% CI 46.2-48.7 mu m). Images were also reviewed for the presence of segmentation error in the central macular subfield, and after exclusion of these eyes the revised CR for this subfield was 13.7 mu m (95% CI 13.3-14.1 mu m). The intrasession CR of subfoveal choroidal thickness was 34.7 mu m (95% CI 33.7-35.7 mu m).
   CONCLUSIONS: This study suggests that a change of greater than 31 mu m in Spectralis SDOCT-derived retinal thickness measurement of the central macular subfield and 35 mu m in subfoveal choroidal thickness is necessary to detect true clinical change associated with disease progression or improvement in nAMD with a revised figure of 14 mu m for central macular retinal subfield thickness in the absence of segmentation error. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Hanumunthadu, Daren; Ilginis, Tomas; Restori, Marie; Sagoo, Mandeep; Tufail, Adnan; Balaggan, Kamaljit S.; Patel, Praveen J.] Moorfields Eye Hosp Natl Hlth Serv Fdn Trust, Natl Inst Hlth Res, Biomed Res Ctr, London, England.
   [Hanumunthadu, Daren; Ilginis, Tomas; Restori, Marie; Sagoo, Mandeep; Tufail, Adnan; Balaggan, Kamaljit S.; Patel, Praveen J.] UCL, Inst Ophthalmol, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London
RP Patel, PJ (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, 162 City Rd, London EC1V 2PD, England.
EM praveen.patel@moorfields.nhs.uk
OI Sagoo, Mandeep/0000-0003-1530-3824; Tufail, Adnan/0000-0001-6131-7640
FU NIHR BIOMEDICAL RESEARCH Centre at Moorfields Eye Hospital NHS
   Foundation Trust; NIHR Moorfields Clinical Research Facility;
   SALUTARISMD; UCL Institute of Ophthalmology
FX THE RESEARCH WAS FUNDED BY SALUTARISMD AND SUPPORTED BY THE NIHR
   BIOMEDICAL RESEARCH Centre at Moorfields Eye Hospital NHS Foundation
   Trust and UCL Institute of Ophthalmology and the NIHR Moorfields
   Clinical Research Facility. The views expressed are those of the
   author(s) and not necessarily those of the NHS, the NIHR or the
   Department of Health.
CR BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Comyn O, 2012, INVEST OPHTH VIS SCI, V53, P7754, DOI 10.1167/iovs.12-10895
   de Boer JF, 2003, OPT LETT, V28, P2067, DOI 10.1364/OL.28.002067
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Kafieh Raheleh, 2013, J Med Signals Sens, V3, P45
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Keane PA, 2009, INVEST OPHTH VIS SCI, V50, P3378, DOI 10.1167/iovs.08-2728
   Kim M, 2013, INDIAN J OPHTHALMOL, V61, P213, DOI 10.4103/0301-4738.97075
   Krebs I, 2011, INVEST OPHTH VIS SCI, V52, P6925, DOI 10.1167/iovs.10-6612
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mimouni M, 2014, CAN J OPHTHALMOL, V49, P183, DOI 10.1016/j.jcjo.2013.11.004
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Parravano M, 2010, INVEST OPHTH VIS SCI, V51, P4788, DOI 10.1167/iovs.09-4976
   Patel PJ, 2011, ACTA OPHTHALMOL, V89, P526, DOI 10.1111/j.1755-3768.2009.01761.x
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P399, DOI 10.1167/iovs.08-1697
   Rahman W, 2013, GRAEF ARCH CLIN EXP, V251, P1483, DOI 10.1007/s00417-012-2199-x
   Razavi S, 2015, AM J OPHTHALMOL, V160, P1006, DOI 10.1016/j.ajo.2015.08.009
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Shin JY, 2015, ACTA OPHTHALMOL, V93, P524, DOI 10.1111/aos.12653
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tah V, 2014, INDIAN J OPHTHALMOL, V62, P941, DOI 10.4103/0301-4738.143936
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Unlu C, 2015, INT J OPHTHALMOL-CHI, V8, P849, DOI 10.3980/j.issn.2222-3959.2015.04.38
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
NR 32
TC 13
Z9 13
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2016
VL 166
BP 154
EP 161
DI 10.1016/j.ajo.2016.03.052
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DO2QD
UT WOS:000377624000023
PM 27066726
DA 2022-11-30
ER

PT J
AU Wang, JJ
   Buitendijk, GHS
   Rochtchina, E
   Lee, KE
   Klein, BEK
   van Duijn, CM
   Flood, VM
   Meuer, SM
   Attia, J
   Myers, C
   Holliday, EG
   Tan, AG
   Smith, WT
   Iyengar, SK
   de Jong, PTVM
   Hofman, A
   Vingerling, JR
   Mitchell, P
   Klein, R
   Klaver, CCW
AF Wang, Jie Jin
   Buitendijk, Gabrielle H. S.
   Rochtchina, Elena
   Lee, Kristine E.
   Klein, Barbara E. K.
   van Duijn, Cornelia M.
   Flood, Victoria M.
   Meuer, Stacy M.
   Attia, John
   Myers, Chelsea
   Holliday, Elizabeth G.
   Tan, Ava G.
   Smith, Wayne T.
   Iyengar, Sudha K.
   de Jong, Paulus T. V. M.
   Hofman, Albert
   Vingerling, Johannes R.
   Mitchell, Paul
   Klein, Ronald
   Klaver, Caroline C. W.
TI Genetic Susceptibility, Dietary Antioxidants, and Long-Term Incidence of
   Age-Related Macular Degeneration in Two Populations
SO OPHTHALMOLOGY
LA English
DT Article
ID POLYUNSATURATED FATTY-ACIDS; INFLAMMATORY MARKERS; CFH GENE; RISK;
   SMOKING; LUTEIN; PROGRESSION; ZEAXANTHIN; OMEGA-3-FATTY-ACIDS;
   SUPPLEMENTATION
AB Objective: To examine effect modification between genetic susceptibility to age-related macular degeneration (AMD) and dietary antioxidant or fish consumption on AMD risk.
   Design: Pooled data analysis of population-based cohorts.
   Participants: Participants from the Blue Mountains Eye Study (BMES) and Rotterdam Study (RS).
   Methods: Dietary intakes of antioxidants (lutein/zeaxanthin [LZ], beta-carotene, and vitamin C), long-chain omega-3 polyunsaturated fatty acids, and zinc were estimated from food frequency questionnaires. The AMD genetic risk was classified according to the number of risk alleles of CFH (rs1061170) or ARMS2 (rs10490924) as low (no or 1 risk allele) or high (>= 2 risk alleles). Interactions between dietary intake and genetic risk levels were assessed. Associations between dietary intake and AMD risk were assessed comparing the highest with the 2 lower intake tertiles by genetic risk subgroups using discrete logistic regression, conducted in each study separately and then using pooled data. Participants without AMD lesions at any visit were controls. We adjusted for age and sex in analyses of each cohort sample and for smoking status and study site in pooled-data analyses.
   Main Outcome Measures: All 15-year incident late AMD cases were confirmed by chief investigators of the Beaver Dam Eye Study, BMES, and RS. Intergrader reproducibility was assessed in an early AMD subsample, with 86.4% agreement between BMES and RS graders, allowing for a 1-step difference on a 5-step AMD severity scale.
   Results: In pooled data analyses, we found significant interaction between AMD genetic risk status and LZ intake (P = 0.0009) but nonsignificant interactions between genetic risk status and weekly fish consumption (P = 0.05) for risk of any AMD. Among participants with high genetic risk, the highest intake tertile of LZ was associated with a >20% reduced risk of early AMD, and weekly consumption of fish was associated with a 40% reduced risk of late AMD. No similar association was evident among participants with low genetic risk. No interaction was detected between beta-carotene or vitamin C and genetic risk status.
   Conclusions: Protection against AMD from greater LZ and fish consumption in persons with high genetic risk based on 2 major AMD genes raises the possibility of personalized preventive interventions. (C) 2014 by the American Academy of Ophthalmology.
C1 [Wang, Jie Jin; Rochtchina, Elena; Tan, Ava G.; Mitchell, Paul] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Wang, Jie Jin; Rochtchina, Elena; Tan, Ava G.; Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   [Wang, Jie Jin] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Buitendijk, Gabrielle H. S.; Lee, Kristine E.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Buitendijk, Gabrielle H. S.; van Duijn, Cornelia M.; Hofman, Albert; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Klein, Barbara E. K.; Meuer, Stacy M.; Myers, Chelsea; Klein, Ronald] Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Flood, Victoria M.] Univ Wollongong, Fac Hlth & Behav Sci, Wollongong, NSW, Australia.
   [Attia, John; Holliday, Elizabeth G.] Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2300, Australia.
   [Attia, John; Holliday, Elizabeth G.; Smith, Wayne T.] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW 2300, Australia.
   [Attia, John] John Hunter Hosp, Dept Med, Newcastle, NSW, Australia.
   [Attia, John] Hunter Med Res Inst, Newcastle, NSW, Australia.
   [Smith, Wayne T.] Univ Sydney, Sydney Med Sch, Sch Publ Hlth, Sydney, NSW 2006, Australia.
   [Iyengar, Sudha K.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [de Jong, Paulus T. V. M.] AMC, Netherlands Inst Neurosci, Inst Royal Netherlands Acad Arts & Sci, Dept Ophthalmol, Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.] LUMC, Dept Ophthalmol, Leiden, Netherlands.
   [Hofman, Albert] Netherlands Genom Initiat, Netherlands Consortium Hlth Aging, The Hague, Netherlands.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; Centre for Eye Research Australia; Royal Victorian Eye
   & Ear Hospital; University of Melbourne; Erasmus University Rotterdam;
   Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of
   Wisconsin System; University of Wisconsin Madison; University of
   Wollongong; University of Newcastle; University of Newcastle; John
   Hunter Hospital; Hunter Medical Research Institute; University of
   Newcastle; University of Sydney; Case Western Reserve University; Royal
   Netherlands Academy of Arts & Sciences; Netherlands Institute for
   Neuroscience (NIN-KNAW); University of Amsterdam; Academic Medical
   Center Amsterdam; Leiden University; Leiden University Medical Center
   (LUMC)
RP Wang, JJ (通讯作者)，Univ Sydney, Westmead Hosp, Dept Ophthalmol, Ctr Vis Res, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin.wang@sydney.edu.au
RI Mitchell, Paul/P-1498-2014; Wang, Jie Jin/P-1499-2014; Klaver, Caroline
   C.W./A-2013-2016; wang, jie/GRS-0942-2022; Flood, Victoria
   M/A-8732-2016; Attia, John R/F-5376-2013; /S-1190-2019
OI Wang, Jie Jin/0000-0001-9491-4898; Flood, Victoria
   M/0000-0001-5310-7221; Attia, John R/0000-0001-9800-1308;
   /0000-0001-7488-250X; Klein, Ronald/0000-0002-4428-6237; Klaver,
   Caroline/0000-0002-2355-5258; Tan, Ava Grace/0000-0003-3344-0339; Van
   Duijn, Cornelia/0000-0002-2374-9204
FU National Health and Medical Research Council (Canberra, Australia)
   [512423, 590204]; National Health and Medical Research Council (NHMRC),
   Canberra, Australia [974159, 211069, 302068]; Centre for Clinical
   Research Excellence in Translational Clinical Research in Eye Diseases
   [529923]; NHMRC, Canberra, Australia [512423, 475604, 529912]; Wellcome
   Trust, United Kingdom, Wellcome Trust Case Control Consortium 2
   [085475/B/08/Z, 085475/08/Z]; Netherlands Organization for Scientific
   Research, the Hague; Swart van Essen, Rotterdam; Rotterdamse
   Blindenbelangen Association, Rotterdam; Algemene Nederlandse Vereniging
   ter Voorkoming van Blindheid, Doorn, The Netherlands; Oogfonds
   Nederland, Utrecht; MDFonds, Utrecht; Vereniging Trustfonds Erasmus
   Universiteit Rotterdam, Rotterdam, The Netherlands; Lijf en Leven,
   Krimpen aan de IJssel, The Netherlands; Topcon Europe BV, Capelle aan de
   IJssel, The Netherlands; NHMRC (Canberra, Australia) Senior Research
   Fellowship [358702, 632909]; Bevordering van Volkskracht, Rotterdam
FX This work was supported by the National Health and Medical Research
   Council (Canberra, Australia) (Project Grant IDs 512423 and 590204 to
   J.J.W). The BMES was supported by the National Health and Medical
   Research Council (NHMRC), Canberra, Australia (NHMRC Project Grant IDs
   974159, 211069, 302068, and Centre for Clinical Research Excellence in
   Translational Clinical Research in Eye Diseases Grant ID 529923). The
   BMES Genome-Wide Association Study and genotyping costs were supported
   by the NHMRC, Canberra, Australia (NHMRC Project Grant IDs 512423,
   475604, and 529912), and the Wellcome Trust, United Kingdom, as part of
   Wellcome Trust Case Control Consortium 2 (A. Viswanathan, P. McGuffin,
   P. Mitchell, F. Topouzis, P. Foster, Grant IDs 085475/B/08/Z and
   085475/08/Z). The RS was supported by the Netherlands Organization for
   Scientific Research, the Hague; Swart van Essen, Rotterdam; Bevordering
   van Volkskracht, Rotterdam; Rotterdamse Blindenbelangen Association,
   Rotterdam; Algemene Nederlandse Vereniging ter Voorkoming van Blindheid,
   Doorn, The Netherlands; Oogfonds Nederland, Utrecht; MDFonds, Utrecht;
   Vereniging Trustfonds Erasmus Universiteit Rotterdam, Rotterdam, The
   Netherlands; and Lijf en Leven, Krimpen aan de IJssel, The Netherlands.
   An unrestricted grant was obtained from Topcon Europe BV, Capelle aan de
   IJssel, The Netherlands. J.J.W. is funded by an NHMRC (Canberra,
   Australia) Senior Research Fellowship (Grant IDs 358702, 2005-2009 and
   632909, 2010-2014). The sponsor or funding organization had no role in
   the design or conduct of this research.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   *AUSTR BUR STAND, 1998, 48050 NAT NUTR SURV
   *AUSTR BUR STAND, 1999, 4804 0 NAT NUTR SURV
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 2013, OPHTHALMIC IN PRESS
   Klipstein-Grobusch K, 1999, AM J CLIN NUTR, V69, P261
   Klipstein-Grobusch K, 1998, EUR J CLIN NUTR, V52, P588, DOI 10.1038/sj.ejcn.1600611
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Lewis J, 1990, NUTTAB 90 NUTR DATA
   Li SY, 2012, INVEST OPHTH VIS SCI, V53, P5976, DOI 10.1167/iovs.12-10007
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Ramkumar HL, 2013, J NUTR, V143, P1129, DOI 10.3945/jn.112.169649
   Rangel-Huerta OD, 2012, BRIT J NUTR, V107, pS159, DOI 10.1017/S0007114512001559
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Smith W, 1998, AUST NZ J PUBL HEAL, V22, P456, DOI 10.1111/j.1467-842X.1998.tb01414.x
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   van Poppel G., 1998, Journal of Food Composition and Analysis, V11, P112, DOI 10.1006/jfca.1998.0568
   VANROSSUM CTM, 2011, 3500500062011 RIVM
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
   Winkler BS, 1999, MOL VIS, V5
NR 40
TC 50
Z9 50
U1 1
U2 28
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2014
VL 121
IS 3
BP 667
EP 675
DI 10.1016/j.ophtha.2013.10.017
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AC3FT
UT WOS:000332401800016
PM 24290803
DA 2022-11-30
ER

PT J
AU Dieguez, HH
   Romeo, HE
   Alaimo, A
   Fleitas, MFG
   Aranda, ML
   Rosenstein, RE
   Dorfman, D
AF Dieguez, Hernan H.
   Romeo, Horacio E.
   Alaimo, Agustina
   Gonzalez Fleitas, Maria F.
   Aranda, Marcos L.
   Rosenstein, Ruth E.
   Dorfman, Damian
TI Oxidative stress damage circumscribed to the central temporal retinal
   pigment epithelium in early experimental non-exudative age-related
   macular degeneration
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Non-exudative age-related macular degeneration; Superior cervical
   ganglion; Retinal pigment epithelium; Oxidative stress; Mitochondria;
   Antioxidant system
ID MITOCHONDRIA; RPE; PROTECTION; MELANIN
AB Non-exudative age-related macular degeneration (NE-AMD) represents the leading cause of blindness in the elderly. The macular retinal pigment epithelium (RPE) lies in a high oxidative environment because its high metabolic demand, mitochondria concentration, reactive oxygen species levels, and macular blood flow. It has been suggested that oxidative stress-induced damage to the RPE plays a key role in NE-AMD pathogenesis. The fact that the disease limits to the macular region raises the question as to why this area is particularly susceptible. We have developed a NE-AMD model induced by superior cervical ganglionectomy (SCGx) in C57BL/6J mice, which reproduces the disease hallmarks exclusively circumscribed to the temporal region of the RPE/outer retina. The aim of this work was analyzing RPE regional differences that could explain AMD localized susceptibility. Lower melanin content, thicker basal infoldings, higher mitochondrial mass, and higher levels of antioxidant enzymes, were found in the temporal RPE compared with the nasal region. Moreover, SCGx induced a decrease in the antioxidant system, and in mitochondria mass, as well as an increase in mitochondria superoxide, lipid peroxidation products, nuclear Nrf2 and heme oxygenase-1 levels, and in the occurrence of damaged mitochondria exclusively at the temporal RPE. These findings suggest that despite the well-known differences between the human and mouse retina, it might not be NE-AMD pathophysiology which conditions the localization of the disease, but the macular RPE histologic and metabolic specific attributes that make it more susceptible to choroid alterations leading initially to a localized RPE dysfunction/damage, and secondarily to macular degeneration.
C1 [Dieguez, Hernan H.; Gonzalez Fleitas, Maria F.; Aranda, Marcos L.; Rosenstein, Ruth E.; Dorfman, Damian] Univ Buenos Aires, Sch Med, Lab Retinal Neurochem & Expt Ophthalmol, Dept Human Biochem,CONICET,CEFyBO, Buenos Aires, DF, Argentina.
   [Romeo, Horacio E.] Pontifical Catholic Univ Argentina, Sch Engn & Agr Sci, CONICET, BIOMED,UCA, Buenos Aires, DF, Argentina.
   [Alaimo, Agustina] Univ Buenos Aires, Fac Exact & Nat Sci, Interdisciplinary Lab Cellular Dynam & Nanotools, Dept Biol Chem,CONICET,IQUIBICEN, Buenos Aires, DF, Argentina.
C3 Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   University of Buenos Aires; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET); Pontifical Catholic University of
   Argentina; Consejo Nacional de Investigaciones Cientificas y Tecnicas
   (CONICET); University of Buenos Aires
RP Dorfman, D (通讯作者)，UBA, Dept Bioquim Humana, Fac Med, CEFyBO,CONICET, Paraguay 2155,5 P, RA-1121 Buenos Aires, DF, Argentina.
EM ddorfman@fmed.uba.ar
OI Aranda, Marcos/0000-0003-1891-3476; Gonzalez Fleitas, Maria
   Florencia/0000-0001-5795-8365
FU National Scientific and Technical Research Council (CONICET) [PIP 0707];
   National Agency for Scientific and Technical Promotion (ANPCYT) [PICT
   1563, PICT 0356, PICT 2731]; University of Buenos Aires (UBA)
   [20020100100678]
FX This work was funded by the National Scientific and Technical Research
   Council (CONICET) PIP 0707, the National Agency for Scientific and
   Technical Promotion (ANPCYT) PICT 1563, PICT 0356, and PICT 2731, the
   University of Buenos Aires (UBA) 20020100100678.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dieguez HH, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.031641
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Durairaj C, 2012, EXP EYE RES, V98, P23, DOI 10.1016/j.exer.2012.03.004
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lambros ML, 2016, ADV EXP MED BIOL, V854, P67, DOI 10.1007/978-3-319-17121-0_10
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018-016-2223-0
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   McCord JM, 2005, BIOMED PHARMACOTHER, V59, P139, DOI 10.1016/j.biopha.2005.03.005
   Rickman C. Bowes, 2013, INVEST OPHTHALMOL VI, V54
   ROMEO HE, 1991, J AUTONOM NERV SYST, V32, P159, DOI 10.1016/0165-1838(91)90066-C
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   SCHMIDT SY, 1986, INVEST OPHTH VIS SCI, V27, P1063
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Van Remmen H, 2001, EXP GERONTOL, V36, P957
   Volland S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125631
   Winkler BS, 1999, MOL VIS, V5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
NR 32
TC 20
Z9 21
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD FEB 1
PY 2019
VL 131
BP 72
EP 80
DI 10.1016/j.freeradbiomed.2018.11.035
PG 9
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA HG7TX
UT WOS:000455199300008
PM 30502459
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Roller, AB
   Amaro, MH
AF Roller, Aaron Brock
   Amaro, Miguel Hage
TI Intravitreal ranibizumab and bevacizumab for the treatment of
   nonsubfoveal choroidal neovascularization in age-related macular
   degeneration
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Choroidal neovascularization/drug therapy; Macular degeneration/drug
   therapy; Antibodies, monoclonal; Angiogenesis inhibitors; Visual acuity
ID PHOTODYNAMIC THERAPY; VERTEPORFIN; JUXTAFOVEAL; SECONDARY
AB Purpose: To investigate the efficacy of vascular endothelial growth factor-specific (VEGF) monoclonal antibodies in the treatment of choroidal neovascularization secondary to age-related macular degeneration (AMD) that does not extend beneath the foveal center (nonsubfoveal CNV). Methods: The study design was a retrospective chart review of consecutive patients over a two-month period under active treatment with bevacizumab and/or ranibizumab for neovascular AMD. Patients with neovascularization within the macula that did not extend beneath the center of the foveal avascular zone, along with at least one large drusen (>= 125 mu) or many intermediate size (63-124 mu) drusen were included. Best corrected Snellen visual acuity and optical coherence tomography (OCT) analysis of the central macular thickness was recorded for each visit. Serial injections of bevacizumab and/or ranibizumab were administered until there was resolution of subretinal fluid clinically or by OCT. Data over the entire follow-up period were analyzed for overall visual acuity and OCT changes. All patients had follow-up since diagnosis of at least 6 months (mean=9.6 months). Results: Of the thirteen included patients, eleven had reduction of retinal thickening in the area involved by the CNV. The remaining two patients did not have OCT data available but had no fluid or activity on clinical examination at last follow-up. One patient (8%) lost one line of vision; one (8%) remained stable, and eleven (84%) gained one or more lines of visual acuity. Three patients (23%) gained three or more lines. The average treatment outcome for all patients was a gain of 1.7 +/- 1.3 lines of Snellen acuity. Both therapeutic agents were effective, with an average gain of 1.6 +/- 0.6 lines for patients treated with bevacizumab, 1.5 +/- 1.9 lines gained for patients treated with ranibizumab and 2.5 +/- 0.7 lines gained in the two patients who received both agents over the course of their treatment. Conclusions: The use of intravitreal anti-VEGF agents for nonsubfoveal CNV in AMD is effective. Our results are comparable to published results from large-scale trials of anti-VEGF therapy for subfoveal CNV. Our data support the idea that bevacizumab or ranibizumab appear to be the treatment of choice for AMD patients with nonsubfoveal CNV.
C1 [Roller, Aaron Brock; Amaro, Miguel Hage] Univ Iowa Hosp & Clin, Dept Ophthalmol, Iowa City, IA 52242 USA.
C3 University of Iowa
RP Roller, AB (通讯作者)，Univ Iowa, Dept Ophthalmol, 200 Hawkins Dr, Iowa City, IA 52242 USA.
EM aaron-roller@uiowa.edu
CR Bashshur ZF, 2008, ARCH OPHTHALMOL-CHIC, V126, P1315, DOI 10.1001/archopht.126.9.1315
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P938, DOI 10.1016/j.ajo.2008.02.020
   Blair MP, 2004, RETINA-J RET VIT DIS, V24, P501, DOI 10.1097/00006982-200408000-00001
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Frennesson CI, 2004, ACTA OPHTHALMOL SCAN, V82, P651, DOI 10.1111/j.1600-0420.2004.00382.x
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Macular Photocoagulation Study Group, 1991, ARCH OPHTHALMOL-CHIC, V109, P614
   Mones JM, 2007, OPHTHAL SURG LAS IM, V38, P226, DOI 10.3928/15428877-20070501-07
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Voelker M, 2005, GRAEF ARCH CLIN EXP, V243, P1241, DOI 10.1007/s00417-005-0021-8
   Wachtlin J, 2005, GRAEF ARCH CLIN EXP, V243, P438, DOI 10.1007/s00417-004-1071-z
   1996, ARCH OPHTHALMOL, V114, P1023
NR 17
TC 3
Z9 3
U1 0
U2 0
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD SEP-OCT
PY 2009
VL 72
IS 5
BP 677
EP 681
DI 10.1590/S0004-27492009000500016
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 558OT
UT WOS:000274754600016
PM 20027409
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Anastasopoulos, E
   Haidich, AB
   Coleman, AL
   Wilson, MR
   Harris, A
   Yu, F
   Koskosas, A
   Pappas, T
   Keskini, C
   Kalouda, P
   Karkamanis, G
   Topouzis, F
AF Anastasopoulos, Eleftherios
   Haidich, Anna Bettina
   Coleman, Anne Louise
   Wilson, M. Roy
   Harris, Alon
   Yu, Fei
   Koskosas, Archimides
   Pappas, Theofanis
   Keskini, Christina
   Kalouda, Pelagia
   Karkamanis, Georgia
   Topouzis, Fotis
TI Risk factors for Age-related Macular Degeneration in a Greek population:
   The Thessaloniki Eye Study
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Age-related macular degeneration; risk factors; Thessaloniki Eye study;
   Greek population; afternoon nap
ID LONG-TERM INCIDENCE; OPEN-ANGLE GLAUCOMA; ANGELES LATINO EYE; BLUE
   MOUNTAINS EYE; MARITAL-STATUS; CATARACT-SURGERY; BLOOD-PRESSURE;
   SUNLIGHT EXPOSURE; POOLED FINDINGS; SLEEP DURATION
AB Purpose: To assess the association of potential risk factors with early and late age-related macular degeneration (AMD) in the Thessaloniki Eye Study (TES) population
   Design: Population-based, cross-sectional study of subjects over age of 60 living in Thessaloniki, Greece
   Methods: Subjects without any AMD features and subjects with early and late AMD (neovascular AMD or geographic atrophy) were identified in the TES cohort using standardized procedures and masked grading of stereo color fundus photos. Demographic, lifestyle, systemic and other ophthalmic covariates were also collected during a detailed examination process. Their association with AMD was investigated using univariate and multivariate adjusted logistic regression models.
   Results: Among the 2108 participants with gradable photos, the grading process identified 1204 subjects with no AMD, 848 subjects with early AMD, and 56 subjects with late AMD (24 with geographic atrophy and 32 with neovascular AMD). In multivariate analysis, compared to no AMD, late AMD was positively associated with older age (OR:1.16; 95%CI:1.10-1.22 per year of age), current smoking (smoking vs. never smoking, OR:2.34; 95%CI:1.12-4.90), prior cataract surgery (cataract surgery vs. no cataract surgery OR:2.06; 95%CI:0.96-4.40), marital status (divorced/separated vs. married, OR:3.10; 95%CI:1.08-8.93) and with 60% lower odds when sleeping in the afternoon (yes vs. no, OR:0.40; 95%CI:0.22-0.72). Early AMD was positively associated with older age (OR: 1.03; 95%CI:1.01-1.05 per year of age) and negatively with higher pulse pressure (OR:0.99; 95%CI:0.98-0.99 per mmHg).
   Conclusions: In TES, apart for well-known risk factors for AMD like age, smoking, and cataract surgery, two novel behavioral risk factors for prevalent late AMD were suggested. Sleeping in the afternoon was associated with 60% decreased odds for late AMD and 67% decreased odds for neovascular AMD. Being divorced/separated compared to married was associated with 3-fold higher odds for late AMD. Large longitudinal population-based studies will be necessary to further establish the potential late AMD risk effects of these two novel factors, to demonstrate potential implications of underlying pathogenetic mechanisms, and to explore preventive measures and therapeutic targets.
C1 [Anastasopoulos, Eleftherios; Koskosas, Archimides; Pappas, Theofanis; Keskini, Christina; Kalouda, Pelagia; Karkamanis, Georgia; Topouzis, Fotis] Aristotle Univ Thessaloniki, Sch Med, Dept Ophthalmol, Lab Res & Clin Applicat Ophthalmol LARCAO, Thessaloniki, Greece.
   [Haidich, Anna Bettina] Aristotle Univ Thessaloniki, Sch Med, Dept Epidemiol, Thessaloniki, Greece.
   [Coleman, Anne Louise] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA.
   [Wilson, M. Roy] Wayne State Univ, Detroit, MI USA.
   [Harris, Alon] Indiana Univ Sch Med, Dept Ophthalmol, Eugene & Marilyn Glick Eye Inst, Indianapolis, IN 46202 USA.
   [Yu, Fei] UCLA, Fielding Sch Publ Hlth, Dept Biostat, Los Angeles, CA USA.
C3 Aristotle University of Thessaloniki; Aristotle University of
   Thessaloniki; University of California System; University of California
   Los Angeles; University of California Los Angeles Medical Center; David
   Geffen School of Medicine at UCLA; Wayne State University; Indiana
   University System; Indiana University Bloomington; University of
   California System; University of California Los Angeles
RP Topouzis, F (通讯作者)，Aristotle Univ Thessaloniki, AHEPA Hosp, Dept Ophthalmol A, St Kiriakidi 1, Thessaloniki 54636, Greece.
EM ftopouzis@otenet.gr
RI Haidich, Anna Bettina/L-9426-2019
OI Haidich, Anna Bettina/0000-0001-5100-8799; Topouzis,
   Fotis/0000-0002-8966-537X
FU Pfizer; Novartis; Alcon; Thea
FX Fotis Topouzis: Receipts of Grants/Research support: Pfizer, Novartis,
   Alcon, Thea. Receipts of Honoraria or consultation fees: Alcon,
   Novartis, Thea, Bayer, Allergan, Pfizer, Merck, Santen
CR Anastasopoulos E, 2011, J GLAUCOMA, V20, P160, DOI 10.1097/IJG.0b013e3181d9d8bd
   Atzema CL, 2011, CAN MED ASSOC J, V183, P1482, DOI 10.1503/cmaj.110170
   Barnett Elizabeth, 2006, BMC Cardiovasc Disord, V6, P45, DOI 10.1186/1471-2261-6-45
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Burgess HJ, 2013, J SLEEP RES, V22, P83, DOI 10.1111/j.1365-2869.2012.01042.x
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Campos Costa Ines, 2013, Am J Neurodegener Dis, V2, P228
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chakravarthy U, 2006, BMJ-BRIT MED J, V333, P869, DOI 10.1136/bmj.39009.366736.80
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   Damiani G, 2015, CLIN INTERV AGING, V10, P237, DOI 10.2147/CIA.S71165
   DiMatteo MR, 2004, HEALTH PSYCHOL, V23, P207, DOI 10.1037/0278-6133.23.2.207
   Empana JP, 2008, EUR J CARDIOV PREV R, V15, P577, DOI 10.1097/HJR.0b013e3283083e04
   Engstrom M, 2006, ARTERIOSCL THROM VAS, V26, P643, DOI 10.1161/01.ATV.0000200100.14612.bb
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Franklin SS, 2001, CIRCULATION, V103, P1245
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Fraser-Bell S, 2010, AM J OPHTHALMOL, V149, P735, DOI 10.1016/j.ajo.2009.11.013
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Harvard School of Public Health, 2011, GREEK TOB EP
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Inaba A, 2005, SOC SCI MED, V61, P2280, DOI 10.1016/j.socscimed.2005.07.014
   Kamon Y, 2008, J OCCUP HEALTH, V50, P348, DOI 10.1539/joh.L7158
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Keenan TDL, 2017, BRIT J OPHTHALMOL, V101, P155, DOI 10.1136/bjophthalmol-2015-308278
   Kerkhof GA, 2010, PROG BRAIN RES, V185, P155, DOI 10.1016/B978-0-444-53702-7.00009-9
   Khurana RN, 2016, RETINA-J RET VIT DIS, V36, P255, DOI 10.1097/IAE.0000000000000706
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2014, OPHTHALMOLOGY, V121, P1604, DOI 10.1016/j.ophtha.2014.03.005
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kozobolis VP, 1999, ARCH OPHTHALMOL-CHIC, V117, P664
   Lau EYY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125752
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Manzoli L, 2007, SOC SCI MED, V64, P77, DOI 10.1016/j.socscimed.2006.08.031
   Marchiafava PL, 1999, J PINEAL RES, V26, P184, DOI 10.1111/j.1600-079X.1999.tb00582.x
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Naska A, 2007, ARCH INTERN MED, V167, P296, DOI 10.1001/archinte.167.3.296
   Nesmith BLW, 2014, RETINA-J RET VIT DIS, V34, P2423, DOI 10.1097/IAE.0000000000000247
   Pagliarini S, 1997, ARCH OPHTHALMOL-CHIC, V115, P616, DOI 10.1001/archopht.1997.01100150618007
   Perez-Canales JL, 2016, OPHTHAL EPIDEMIOL, V23, P20, DOI 10.3109/09286586.2015.1119288
   Robles TF, 2014, PSYCHOL BULL, V140, P140, DOI 10.1037/a0031859
   Roman MJ, 2009, J AM COLL CARDIOL, V54, P1730, DOI 10.1016/j.jacc.2009.05.070
   Rosen R, 2009, MOL VIS, V15, P1673
   Sbarra DA, 2009, PSYCHOSOM MED, V71, P828, DOI 10.1097/PSY.0b013e3181b4c4f2
   Skene DJ, 2003, EXP GERONTOL, V38, P199, DOI 10.1016/S0531-5565(02)00198-5
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Topouzis F, 2007, AM J OPHTHALMOL, V144, P511, DOI 10.1016/j.ajo.2007.06.029
   Topouzis F, 2006, AM J OPHTHALMOL, V142, P1076, DOI 10.1016/j.ajo.2006.07.042
   Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   WHO, BMI CLASSIFICATION
   World Health Organization, GLOB STAT REP GREEC
   World Health Organization, PROF HLTH WELL BEING
   WYKE S, 1992, SOC SCI MED, V34, P523, DOI 10.1016/0277-9536(92)90208-8
   Yamada T, 2015, SLEEP, V38, P1945, DOI 10.5665/sleep.5246
NR 64
TC 4
Z9 5
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PY 2018
VL 25
IS 5-6
BP 457
EP 469
DI 10.1080/09286586.2018.1512634
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA GV1XS
UT WOS:000445876500018
PM 30265203
DA 2022-11-30
ER

PT J
AU Klein, R
   Knudtson, MD
   Klein, BEK
   Wong, TY
   Cotch, MF
   Liu, K
   Cheng, CY
   Burke, GL
   Saad, MF
   Jacobs, DR
   Sharrett, AR
AF Klein, Ronald
   Knudtson, Michael D.
   Klein, Barbara E. K.
   Wong, Tien Y.
   Cotch, Mary Frances
   Liu, Kiang
   Cheng, Ching Y.
   Burke, Gregory L.
   Saad, Mohammed F.
   Jacobs, David R., Jr.
   Sharrett, A. Richey
TI Inflammation, complement factor H, and age-related macular degeneration
   - The Multi-Ethnic Study of Atherosclerosis
SO OPHTHALMOLOGY
LA English
DT Article
ID CHLAMYDIA-PNEUMONIAE INFECTION; C-REACTIVE PROTEIN; RISK-FACTORS;
   CARDIOVASCULAR-DISEASE; 5-YEAR INCIDENCE; MEDICATION USE; MACULOPATHY;
   MARKERS; ASSOCIATION; PATHOGENESIS
AB Objective: To describe the relationship of systemic inflammatory disease, complement factor H (CFH) Y402H (1277T -> C) genotype status and age-related macular degeneration (AMD) prevalence in a multiethnic population of whites, blacks, Hispanics, and Chinese.
   Design: Population-based, cross-sectional study.
   Participants: We included 5887 persons aged 45 to 84 years with gradable AMD.
   Methods: Digital fundus photographs were used to measure AMD. Two years earlier, biomarkers of inflammation were measured and history of inflammatory disease and use of anti inflammatory agents obtained. Main Outcome Measure: Prevalence of AMD.
   Results: While controlling for age, gender, race/ethnicity, and study site, there were no associations between systemic inflammatory factors and AMD severity. Higher levels of high-sensitivity C-reactive protein (odds ratio [OR] per standard deviation [SD] increase in natural log [In] units, 2.34; 95% confidence interval [CI], 1.33-4.13) and interleukin-6 (OR per SD in In, 2.06; 95% CI, 1.21-3.49) were associated with geographic atrophy but not other AMD end points. History of periodontal disease (OR, 1.68; 95% CI, 1.14-2.47) was related to increased retinal pigment. A history of arthritis was associated with soft distinct drusen (OR, 1.24; 95% CI, 1.06-1.46). A history of oral steroid use was related to large drusen (OR, 2.13; 95% CI, 1.14-3.97) and soft distinct drusen (OR, 1.76; 95% CI, 1.00-3.10) and history of cyclooxygenase 2 inhibitor use were associated with large drusen (OR, 1.50; 95% CI, 1.10-2.04), soft indistinct drusen (OR, 1.84; 95% CI, 1.09-3.10), and large drusen area (OR, 1.66; 95% CI, 1.02-2.71). Whites, blacks, and Hispanics with CFH Y402H CC variant genotype had the highest frequency of early AMD compared with those with wild TT genotype. The frequency of CFH did explain some of the difference in AMD prevalence between Chinese and Hispanics compared with whites, but did not explain the difference in prevalence between whites and blacks.
   Conclusions: This study confirmed associations of the Y402H CFH gene variant with AMD in nonwhite populations, but neither explained the lack of association between inflammatory factors and AMD in the cohort nor the basis for the observed differences in AMD prevalence across ethnic groups.
C1 [Klein, Ronald; Knudtson, Michael D.; Klein, Barbara E. K.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Health, Madison, WI 53726 USA.
   [Wong, Tien Y.] Univ Melbourne, Ctr Eye Res, Melbourne, Vic, Australia.
   [Wong, Tien Y.] Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore.
   [Cotch, Mary Frances] NEI, Div Epidemiol & Clin Res, NIH, Bethesda, MD 20892 USA.
   [Liu, Kiang] Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL USA.
   [Cheng, Ching Y.; Sharrett, A. Richey] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Cheng, Ching Y.] NHGRI, Inherited Dis Res Branch, NIH, Baltimore, MD USA.
   [Cheng, Ching Y.] Taipei Vet Gen Hosp, Taipei, Taiwan.
   [Cheng, Ching Y.] Natl Yang Ming Univ, Dept Ophthalmol, Taipei 112, Taiwan.
   [Burke, Gregory L.] Wake Forest Univ, Dept Publ Hlth Sci, Wake Forest, NC USA.
   [Saad, Mohammed F.] Stony Brook Med Sch, Dept Prevent Med, Stony Brook, NY USA.
   [Jacobs, David R., Jr.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
   [Jacobs, David R., Jr.] Univ Oslo, Dept Nutr, Oslo, Norway.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Melbourne; National University of Singapore; Singapore
   National Eye Center; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); Northwestern University; Johns Hopkins
   University; Johns Hopkins Bloomberg School of Public Health; National
   Institutes of Health (NIH) - USA; NIH National Human Genome Research
   Institute (NHGRI); NIH National Institute on Aging (NIA); Taipei
   Veterans General Hospital; National Yang Ming Chiao Tung University;
   Wake Forest University; University of Minnesota System; University of
   Minnesota Twin Cities; University of Oslo
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Health, 610 N Walnut Street,450 WARE, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
RI Cheng, Ching-Yu/K-7017-2013; Wong, Tien Yin/AAC-9724-2020; Cheng,
   Ching-Yu/Y-2229-2019
OI Cheng, Ching-Yu/0000-0003-0655-885X; Wong, Tien Yin/0000-0002-8448-1264;
   Cheng, Ching-Yu/0000-0003-0655-885X; Klein, Ronald/0000-0002-4428-6237;
   Cotch, Mary Frances/0000-0002-2046-4350; Jacobs,
   David/0000-0002-7232-0543
FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95165,
   N01-HC-95169]; NIH [HL69979-03]; DIVISION OF EPIDEMIOLOGY AND CLINICAL
   APPLICATIONS [N01HC095159, N01HC095165, N01HC095169] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [ZIAEY000403] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL095165,
   R43HL095169, R01HL069979, R44HL095169] Funding Source: NIH RePORTER;
   NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG200327] Funding Source:
   NIH RePORTER
FX The authors do not have any conflicts of interest related to the
   article.; Supported by contracts N01-HC-95159 through N01-HC-95165 and
   N01-HC-95169 from the National Heart, Lung, and Blood Institute.
   Additional support was provided by NIH grant HL69979-03 (Klein R and
   Won, TY). A full list of participating MESA investigators and
   institutions can be found at http://www.mesa-nhlbi.org.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 1991, Ophthalmology, V98, P786
   Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Douglas IJ, 2007, OPHTHALMOLOGY, V114, P1164, DOI 10.1016/j.ophtha.2006.09.018
   ERNST E, 1987, JAMA-J AM MED ASSOC, V257, P2318, DOI 10.1001/jama.257.17.2318
   Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Ishida O, 2003, BRIT J OPHTHALMOL, V87, P523, DOI 10.1136/bjo.87.5.523
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   KANNEL WB, 1992, JAMA-J AM MED ASSOC, V267, P1253, DOI 10.1001/jama.267.9.1253
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   KLEIN R, AGE RELATED MACULAR
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Robman L, 2007, INVEST OPHTH VIS SCI, V48, P4007, DOI 10.1167/iovs.06-1434
   Sarks S., 1985, RETINAL DIS, P87
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   *U WASH, 2007, MULT STUD ATH FIELD
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   Wong TY, 2006, AM J OPHTHALMOL, V141, P446, DOI 10.1016/j.ajo.2005.08.063
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 54
TC 74
Z9 79
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2008
VL 115
IS 10
BP 1742
EP 1749
DI 10.1016/j.ophtha.2008.03.021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 357NJ
UT WOS:000259852200015
PM 18538409
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Osterman, MD
   Song, YE
   Nittala, M
   Sadda, SR
   Scott, WK
   Stambolian, D
   Pericak-Vance, MA
   Haines, JL
AF Osterman, Michael D.
   Song, Yeunjoo E.
   Nittala, Muneeswar
   Sadda, SriniVas R.
   Scott, William K.
   Stambolian, Dwight
   Pericak-Vance, Margaret A.
   Haines, Jonathan L.
TI Genomewide Association Study of Retinal Traits in the Amish Reveals Loci
   Influencing Drusen Development and Link to Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE drusen; age-related macular degeneration (AMD); genetics
ID COMPLEMENT FACTOR-H; VITAMIN-C; GENETIC-VARIATION; WIDE ASSOCIATION;
   RISK; SLC23A2; VISION; POLYMORPHISM; TRANSPORTER; EXPRESSION
AB PURPOSE. The purpose of this study was to identify genetic risk loci for retinal traits, including drusen, in an Amish study population and compare these risk loci to known risk loci of age-related macular degeneration (AMD). METHODS. Participants were recruited from Amish communities in Ohio, Indiana, and Pennsylvania. Each participant underwent a basic health history, ophthalmologic examination, and genotyping. A genomewide association analysis (GWAS) was conducted for the presence and quantity of each of three retinal traits: geographic atrophy, drusen area, and drusen volume. The findings were compared to results from a prior large GWAS of predominantly European-ancestry individuals. Further, a genetic risk score for AMD was used to predict the presence and quantity of the retinal traits.RESULTS. After quality control, 1074 participants were included in analyses. Six single nucleotide polymorphisms (SNPs) met criteria for genomewide significance and 48 were suggestively associated across three retinal traits. The significant SNPs were not highly correlated with known risk SNPs for AMD. A genetic risk score for AMD provided significant predictive value of the retinal traits. CONCLUSIONS. We identified potential novel genetic risk loci for AMD in a midwestern Amish study population. Additionally, we determined that there is a clear link between the genetic risk of AMD and drusen. Further study, including longitudinal data collection, may improve our ability to define this connection and improve understanding of the biological risk factors underlying drusen development.
C1 [Osterman, Michael D.; Song, Yeunjoo E.; Haines, Jonathan L.] Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH USA.
   [Osterman, Michael D.; Haines, Jonathan L.] Case Western Reserve Univ, Cleveland Inst Computat Biol, Cleveland, OH USA.
   [Nittala, Muneeswar; Sadda, SriniVas R.] Doheny Eye Inst, Doheny Imaging Reading Ctr, Los Angeles, CA USA.
   [Scott, William K.; Pericak-Vance, Margaret A.] Univ Miami, John P Hussman Inst Human Genom, Miller Sch Med, Miami, FL USA.
   [Scott, William K.; Pericak-Vance, Margaret A.] Univ Miami, Dr John T Macdonald Fdn Dept Human Genet, Miller Sch Med, Miami, FL USA.
   [Stambolian, Dwight] Univ Penn, Ophthalmol & Genet, Philadelphia, PA USA.
   [Osterman, Michael D.] Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, 10900 Euclid Ave, Cleveland, OH 44106 USA.
C3 Case Western Reserve University; Case Western Reserve University; Doheny
   Eye Institute; University of Miami; University of Miami; University of
   Pennsylvania; Case Western Reserve University
RP Osterman, MD (通讯作者)，Case Western Reserve Univ, Cleveland Inst Computat Biol, Cleveland, OH USA.; Osterman, MD (通讯作者)，Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, 10900 Euclid Ave, Cleveland, OH 44106 USA.
EM michael.osterman@case.edu
FU National Institutes of Health/National Eye Institute (NEI);  [EY023164];
    [EY022310];  [EY012118]
FX The authors thank the Amish families for their willing partici-pation in
   our study. The authors used the Anabaptist Genealogy Database68 and
   information from the Swiss Anabaptist Geneal-ogy Association to help
   determine relationships. Supported by National Institutes of
   Health/National Eye Institute (NEI), grants EY023164, EY022310, and
   EY012118. The authors acknowledge the resources provided by the
   Depart-ment of Population and Quantitative Health Sciences, School of
   Medicine at Case Western Reserve University, the Doheny Imaging Reading
   Center at the Doheny Eye Institute, the Departments of Ophthalmology and
   Genetics at the Univer-sity of Pennsylvania, and the John P. Hussman
   Institute for Human Genomics at University of Miami, Miller School of
   Medicine.
CR Agarwala R, 2003, AM J MED GENET C, V121C, P32, DOI 10.1002/ajmg.c.20004
   Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Andreeva K, 2014, OPHTHALMOL EYE DIS, V6, P43, DOI 10.4137/OED.S17671
   [Anonymous], 2020, R FDN STAT COMP
   [Anonymous], MULTIETHNIC GENOTYPI
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen AA, 2009, CARCINOGENESIS, V30, P977, DOI 10.1093/carcin/bgp076
   Cheng Q, 2017, OPHTHAL EPIDEMIOL, V24, P413, DOI 10.1080/09286586.2017.1337911
   Chintala S, 2005, P NATL ACAD SCI USA, V102, P10964, DOI 10.1073/pnas.0502856102
   Corvi F, 2021, EYE, V35, P2594, DOI 10.1038/s41433-020-01293-0
   de Jong EK, 2020, GENETICS AND GENOMICS OF EYE DISEASE: ADVANCING TO PRECISION MEDICINE, P155, DOI 10.1016/B978-0-12-816222-4.00010-1
   De Jong PTVM, 2018, EYE, V32, P904, DOI 10.1038/eye.2017.298
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Erichsen HC, 2006, AM J EPIDEMIOL, V163, P245, DOI 10.1093/aje/kwj035
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gavin DP, 2012, NEUROPSYCHOPHARMACOL, V37, P531, DOI 10.1038/npp.2011.221
   Gogarten SM, 2019, BIOINFORMATICS, V35, P5346, DOI 10.1093/bioinformatics/btz567
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hoffman JD, 2016, INVEST OPHTH VIS SCI, V57, P2225, DOI 10.1167/iovs.15-18571
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Hostetler J. A., 1993, AMISH SOC, DOI 10.2307/539066
   Huang Y, 2005, CANCER RES, V65, P7446, DOI 10.1158/0008-5472.CAN-04-4267
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lamoureux EL, 2011, BRIT J OPHTHALMOL, V95, P666, DOI 10.1136/bjo.2010.185207
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu B, 2007, INVEST OPHTHALMOL VI, V48, P46
   Liu B, 2013, INVEST OPHTH VIS SCI, V54, P1061, DOI 10.1167/iovs.12-10142
   Liu B, 2009, NEUROBIOL DIS, V33, P104, DOI 10.1016/j.nbd.2008.09.020
   Liu G, 2021, AGING-US, V13, P9748, DOI 10.18632/aging.202729
   Machiela MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/bioinformatics/btv402
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Manichaikul A, 2010, BIOINFORMATICS, V26, P2867, DOI 10.1093/bioinformatics/btq559
   Marmor DJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P117, DOI 10.1001/archophthalmol.2009.366
   Merle BMJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.17
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Nittala MG, 2019, OSLI RETINA, V50, pE236, DOI 10.3928/23258160-20190905-15
   Ong MS, 2019, RNA DIS, V9, P6
   Or C, 2019, INTJ RETIN VITR, V5, P9
   Pollack S, 2019, DIABETES, V68, P441, DOI 10.2337/db18-0567
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Reid CA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29726-7
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   S.A.G.E, 2016, STAT AN GEN EP
   Sardell RJ, 2016, OPHTHALMOLOGY, V123, P2537, DOI 10.1016/j.ophtha.2016.09.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Stanton CM, 2014, ADV EXP MED BIOL, V801, P251, DOI 10.1007/978-1-4614-3209-8_32
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Thee EF, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.26
   Tian H, SSRN ELECT J
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zanon-Moreno V, 2011, MOL VIS, V17, P2997
   Zhou Y, 2020, INT J ONCOL, V57, P314, DOI 10.3892/ijo.2020.5036
NR 69
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2022
VL 63
IS 8
AR 17
DI 10.1167/iovs.63.8.17
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4N7UB
UT WOS:000854220600005
PM 35857289
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Phadke, G
   Hanna, RM
   Ferrey, A
   Torres, EA
   Singla, A
   Kaushal, A
   Kalantar-Zadeh, K
   Kurtz, I
   Jhaveri, KD
AF Phadke, Gautam
   Hanna, Ramy M.
   Ferrey, Antoney
   Torres, Everardo Arias
   Singla, Anjali
   Kaushal, Amit
   Kalantar-Zadeh, Kamyar
   Kurtz, Ira
   Jhaveri, Kenar D.
TI Review of intravitreal VEGF inhibitor toxicity and report of collapsing
   FSGS with TMA in a patient with age-related macular degeneration
SO CLINICAL KIDNEY JOURNAL
LA English
DT Review
DE aflibercept; age-related macular degeneration; collapsing focal and
   segmental glomerulosclerosis; diabetic macular edema; diabetic
   retinopathy; intravitreal VEGF nephrotoxicity; nephrotic syndrome;
   thrombotic microangiopathy; vascular endothelial growth factor (VEGF)
   blockade
ID ENDOTHELIAL GROWTH-FACTOR; THROMBOTIC MICROANGIOPATHY; NEPHROTIC
   SYNDROME; SEGMENTAL GLOMERULOSCLEROSIS; PRESSURE CHANGES;
   BLOOD-PRESSURE; FACTOR THERAPY; BEVACIZUMAB; INJECTION; DISEASE
AB Intravitreal vascular endothelial growth factor (VEGF) receptor blockade is used for a variety of retinal pathologies. These include age-related macular degeneration (AMD), diabetic macular edema (DME) and central retinal vein obstruction. Reports of absorption of intravitreal agents into systemic circulation have increased in number and confirmation of depletion of VEGF has been confirmed. Increasingly there are studies and case reports showing worsening hypertension, proteinuria, renal dysfunction and glomerular disease. The pathognomonic findings of systemic VEGF blockade, thrombotic microangiopathies (TMA5), are also being increasingly reported. One lesion that occurs in conjunction with TMA5 that has been described is collapsing focal segmental glomerulosclerosis (cFSGS). cFSGS has been postulated to occur due to TMAinduced chronic glomerular hypoxia. In this updated review we discuss the mechanistic, pharmacological, epidemiological and clinical evidence of intravitreal VEGF toxicity. We review cases of biopsy-proven toxicity presented by our group and other investigators. We also present the third reported case of cFSGS in the setting of intravitreal VEGF blockade with a chronic TMA component that was crucially found on biopsy. This patient is a 74-year-old nondiabetic male receiving aflibercept for AMD. Of the two prior cases of cFSGS in the setting of VEGF blockade, one had AMD and the other had DME. This case solidifies the finding of cFSGS and its association with chronic TMA as a lesion that may be frequently encountered in patients receiving intravitreal VEGF inhibitors.
C1 [Phadke, Gautam; Singla, Anjali] Metrolina Nephrol Associates, Charlotte, NC USA.
   [Phadke, Gautam] Univ North Dakota, Fargo Sch Med, Div Nephrol, Dept Med, Grand Forks, ND USA.
   [Hanna, Ramy M.; Ferrey, Antoney; Kalantar-Zadeh, Kamyar] Univ Calif Irvine, Div Nephrol, Dept Med, Orange, CA 92668 USA.
   [Torres, Everardo Arias] Univ Calif Irvine, Dept Med, Orange, CA 92668 USA.
   [Kaushal, Amit] Sanford Hlth, Fargo, ND USA.
   [Kaushal, Amit] Univ North Dakota, Fargo Sch Med, Dept Med, Grand Forks, ND USA.
   [Kurtz, Ira] Univ Calif Los Angeles, Div Nephrol, Dept Med, Los Angeles, CA USA.
   [Kurtz, Ira] Brain Res Inst, Westwood, CA USA.
   [Jhaveri, Kenar D.] Hofstra Sch Med, Northwell Hlth, New York, NY USA.
C3 University of North Dakota Grand Forks; University of California System;
   University of California Irvine; University of California System;
   University of California Irvine; Sanford Health; University of North
   Dakota Grand Forks; University of California System; University of
   California Los Angeles; Hofstra University; Northwell Health
RP Hanna, RM (通讯作者)，Univ Calif Irvine, Div Nephrol, Dept Med, Orange, CA 92668 USA.
EM rhannamd81@yahoo.com
RI Kalantar-Zadeh, Kamyar/Q-4734-2018
OI Kalantar-Zadeh, Kamyar/0000-0002-8666-0725
CR Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Avery RL, 2016, JAMA OPHTHALMOL, V134, P21, DOI 10.1001/jamaophthalmol.2015.4070
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Bagheri S, 2018, GALEN MED J, V7, DOI 10.22086/gmj.v0i0.1299
   Buob D, 2016, KIDNEY INT, V90, P1321, DOI 10.1016/j.kint.2016.07.021
   Cheungpasitporn W, 2015, TRANSPLANTATION, V99, P2382, DOI 10.1097/TP.0000000000000750
   Chung YR, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.4.4
   Dalvin LA, 2019, JAMA OPHTHALMOL, V137, P483, DOI 10.1001/jamaophthalmol.2018.6891
   Eylea, FDA PACK INS
   Georgalas I, 2014, CURR DRUG SAF, V9, P156, DOI 10.2174/1574886309666140211113635
   Glassman AR, 2018, INVEST OPHTH VIS SCI, V59, P1199, DOI 10.1167/iovs.17-22853
   Hanhart J, 2018, ACTA OPHTHALMOL, V96, pE732, DOI 10.1111/aos.13731
   Hanhart J, 2018, GRAEF ARCH CLIN EXP, V256, P651, DOI 10.1007/s00417-018-3917-9
   Hanhart J, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0586-0
   Hanna RM, 2018, TRANSPL P, V50, P4033, DOI 10.1016/j.transproceed.2018.07.020
   Hanna RM, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.579603
   Hanna RM, 2020, SAGE OPEN MED CASE R, V8, DOI 10.1177/2050313X20952650
   Hanna RM, 2020, SAGE OPEN MED CASE R, V8, DOI 10.1177/2050313X20907033
   Hanna RM, 2019, KIDNEY INT, V96, P572, DOI 10.1016/j.kint.2019.02.042
   Hanna RM, 2019, CLIN KIDNEY J, V12, P92, DOI 10.1093/ckj/sfy060
   Hanna RM, 2016, CLIN KIDNEY J, V9, P239, DOI 10.1093/ckj/sfv139
   Hirano T, 2018, RETINA-J RET VIT DIS, V38, P1801, DOI 10.1097/IAE.0000000000002004
   Izzedine H, 2011, ANN ONCOL, V22, P487, DOI 10.1093/annonc/mdq743
   Izzedine H, 2014, INT J NEPHROL, V2014, DOI 10.1155/2014/143426
   Izzedine H, 2007, NEPHROL DIAL TRANSPL, V22, P1481, DOI 10.1093/ndt/gfl565
   Jampol LM, 2018, OPHTHALMOLOGY, V125, P1054, DOI 10.1016/j.ophtha.2018.01.019
   Jamrozy-Witkowska Agnieszka, 2011, Klin Oczna, V113, P127
   Kameda Y, 2018, J DIABETES INVEST, V9, P937, DOI 10.1111/jdi.12771
   Kenworthy JA., 2019, J VITREORETIN DIS, V3, P54, DOI [10.1177/2474126418815823, DOI 10.1177/2474126418815823]
   Khneizer Gebran, 2017, J Nephropathol, V6, P134, DOI 10.15171/jnp.2017.23
   Kumasaka R, 2004, J CLIN ONCOL, V22, P2504, DOI 10.1200/jco.2004.09.064
   Lee K, 2009, RETINA-J RET VIT DIS, V29, P1409, DOI 10.1097/IAE.0b013e3181b21056
   Lucentis, FDA PACK INS
   Maisarah J, 2020, NEPHROL DIAL TRANSPL, V35
   Morales E, 2017, NEFROLOGIA, V37, P653, DOI [10.1016/j.nefro.2016.10.011, 10.1016/j.nefroe.2017.10.007]
   Nobakht N, 2019, KIDNEY INT REP, V4, P1508, DOI 10.1016/j.ekir.2019.07.019
   O'Neill RA, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1650-1
   Pelle G, 2011, AM J KIDNEY DIS, V57, P756, DOI 10.1053/j.ajkd.2010.11.030
   Perez-Valdivia MA, 2014, NEFROLOGIA, V34, P421, DOI 10.3265/Nefrologia.pre2014.Mar.12388
   Rasier R, 2009, EYE, V23, P1714, DOI 10.1038/eye.2008.360
   Risimic D, 2013, HELL J CARDIOL, V54, P435
   Rogers CA, 2018, OPHTHALMOL RETINA, V2, P118, DOI 10.1016/j.oret.2017.05.015
   Sato T, 2013, PEDIATR INT, V55, pe46, DOI 10.1111/ped.12017
   Scott IU, 2007, OPHTHALMOLOGY, V114, P1860, DOI 10.1016/j.ophtha.2007.05.062
   Shah AR, 2019, OPHTHALMOL RETINA, V3, P410, DOI 10.1016/j.oret.2019.01.019
   Shye M, 2020, CLIN KIDNEY J, V13, P969, DOI 10.1093/ckj/sfaa049
   Starr Matthew R, 2019, Ophthalmic Surg Lasers Imaging Retina, V50, pe140, DOI 10.3928/23258160-20190503-14
   Touzani F, 2019, Case Rep Nephrol, V2019, P2919080, DOI 10.1155/2019/2919080
   Tschulakow A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113701
   Usui-Ouchi A, 2019, J CLIN INVEST, V129, P3032, DOI 10.1172/JCI129862
   Valsan D, 2017, AM J KIDNEY DIS, V69, pA99
   Yen W, 2019, ASN KIDN WEEK
   Yoon MH, 2016, J KOR OPHTHALMOL SOC, V57, P429, DOI 10.3341/jkos.2016.57.3.429
   Yoshimoto M, 2020, AUTHOREA, DOI [10.22541/au. 159986309.90198834, DOI 10.22541/AU.159986309.90198834]
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
NR 55
TC 1
Z9 1
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2048-8505
EI 2048-8513
J9 CLIN KIDNEY J
JI Clin. Kidney J.
PD OCT
PY 2021
VL 14
IS 10
BP 2158
EP 2165
DI 10.1093/ckj/sfab066
EA MAR 2021
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Urology & Nephrology
GA WE2GT
UT WOS:000705444500004
PM 34603693
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Elbay, A
   Ozer, OF
   Akkan, JCU
   Celik, U
   Kutluturk, I
   Koytak, A
   Ozdemir, H
AF Elbay, Ahmet
   Ozer, Omer Faruk
   Akkan, Julide Canan Umurhan
   Celik, Ugur
   Kutluturk, Isil
   Koytak, Arif
   Ozdemir, Hakan
TI Comparison of serum thiol-disulphide homeostasis and total
   antioxidant-oxidant levels between exudative age-related macular
   degeneration patients and healthy subjects
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Native thiol; Thiol-disulphide
   homeostasis; Total antioxidant status; Total oxidant status
ID OXIDATIVE STRESS; LIPID-PEROXIDATION; HUMAN PLASMA; MACULOPATHY;
   ASSOCIATION; PENTOSIDINE; ENZYMES; DAMAGE; RISK; DNA
AB The purpose of the study was to calculate serum total oxidant status (TOS), total antioxidant status (TAS), and dynamic thiol-disulphide (T-D) homeostasis in patients with age-related macular degeneration (AMD), and compare the results with healthy individuals.
   Thirty-three exudative AMD patients and 33 healthy controls were included in this case-control study. Participants' serum TAS and TOS levels were measured. In addition, total thiol (TT), native thiol (NT), and disulphide (DS) concentrations were assessed using a novel automated method of measurement.
   In comparison with the control group, serum TAS, TT, and NT levels were found to be significantly lower (p < 0.0001, p = 0.004, p = 0.003, respectively) and TOS levels were detected higher (p = 0.032) in AMD patients. Serum DS levels were elevated in the AMD patient group, but the difference was not statistically significant (p = 0.219). DS/TT and DS/NT ratios were significantly higher (p = 0.012, p = 0.013, respectively) in AMD patients. A positive correlation was found between TT and NT (p < 0.0001) in AMD group.
   Serum TOS levels are higher, TAS levels are lower, and the T-D balance is shifted to the DS bond side in AMD patients. These results suggest that increased oxidative stress and decreased antioxidant levels may play a role in AMD progression. Further studies are needed to confirm the pathophysiologic role of T-D homeostasis in AMD.
C1 [Elbay, Ahmet; Akkan, Julide Canan Umurhan; Koytak, Arif; Ozdemir, Hakan] Bezmialem Univ, Sch Med, Dept Ophthalmol, Zumrutevler Mh Yol 6 Sk 2 Seyrantepe Konutlari A4, Istanbul, Turkey.
   [Ozer, Omer Faruk] Bezmialem Univ, Sch Med, Dept Biochem, Istanbul, Turkey.
   [Celik, Ugur] Istanbul Medeniyet Univ, Sch Med, Dept Ophthalmol, Istanbul, Turkey.
   [Kutluturk, Isil] Umraniye Training & Res Hosp, Dept Ophthalmol, Istanbul, Turkey.
C3 Bezmialem Vakif University; Bezmialem Vakif University; Istanbul
   Medeniyet University; Istanbul Umraniye Training & Research Hospital
RP Elbay, A (通讯作者)，Bezmialem Univ, Sch Med, Dept Ophthalmol, Zumrutevler Mh Yol 6 Sk 2 Seyrantepe Konutlari A4, Istanbul, Turkey.
EM elbayamd@gmail.com
RI Celik, Ugur/M-6521-2013; Ozer, Omer Faruk/Y-2516-2018
OI Ozer, Omer Faruk/0000-0002-9034-4805
CR Brantley MA, 2012, AM J OPHTHALMOL, V153, P460, DOI 10.1016/j.ajo.2011.08.033
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Delcourt C, 1999, OPHTHALMOLOGY, V106, P215, DOI 10.1016/S0161-6420(99)90059-3
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Erel O, 2004, CLIN BIOCHEM, V37, P277, DOI 10.1016/j.clinbiochem.2003.11.015
   Erel O, 2005, CLIN BIOCHEM, V38, P1103, DOI 10.1016/j.clinbiochem.2005.08.008
   Erel O, 2014, CLIN BIOCHEM, V47, P326, DOI 10.1016/j.clinbiochem.2014.09.026
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Handa JT, 1998, EXP EYE RES, V66, P411, DOI 10.1006/exer.1997.0442
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Javadzadeh A, 2010, MOL VIS, V16, P2578
   Jones DP, 2009, FREE RADICAL BIO MED, V47, P1329, DOI 10.1016/j.freeradbiomed.2009.08.021
   Krohne TU, 2010, INVEST OPHTH VIS SCI, V51, P553, DOI 10.1167/iovs.09-3755
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Ng WT, 2006, CLIN EXP OPHTHALMOL, V34, P9, DOI 10.1111/j.1442-9071.2006.01141.x
   Ohia SE, 2005, MUTAT RES-FUND MOL M, V579, P22, DOI 10.1016/j.mrfmmm.2005.03.025
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Plestina-Borjan I, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/804054
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Sen CK, 2000, AM J CLIN NUTR, V72, p653S, DOI 10.1093/ajcn/72.2.653S
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sung CC, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/301982
   Turell L, 2013, FREE RADICAL BIO MED, V65, P244, DOI 10.1016/j.freeradbiomed.2013.05.050
   Ugurlu N, 2013, CURR EYE RES, V38, P497, DOI 10.3109/02713683.2013.774023
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
NR 35
TC 3
Z9 3
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD OCT
PY 2017
VL 37
IS 5
BP 1095
EP 1101
DI 10.1007/s10792-016-0367-4
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FJ3WG
UT WOS:000412662600003
PM 27734243
DA 2022-11-30
ER

PT J
AU Bindewald, A
   Schmitz-Valckenberg, S
   Jorzik, JJ
   Dolar-Szczasny, J
   Sieber, H
   Keilhauer, C
   Weinberger, AWA
   Dithmar, S
   Pauleikhoff, D
   Mansmann, U
   Wolf, S
   Holz, FG
AF Bindewald, A
   Schmitz-Valckenberg, S
   Jorzik, JJ
   Dolar-Szczasny, J
   Sieber, H
   Keilhauer, C
   Weinberger, AWA
   Dithmar, S
   Pauleikhoff, D
   Mansmann, U
   Wolf, S
   Holz, FG
CA FAM Study Grp
TI Classification of abnormal fundus autofluorescence patterns in the
   junctional zone of geographic atrophy in patients with age related
   macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; SCANNING LASER OPHTHALMOSCOPE; IN-VIVO;
   LIPOFUSCIN ACCUMULATION; RPE CELLS; MACULOPATHY; TOPOGRAPHY; COMPONENT;
   MICE
AB Aim: To describe and classify patterns of abnormal fundus autofluorescence (FAF) in the junctional zone of geographic atrophy (GA) in patients with age related macular degeneration.
   Methods: Digital FAF images were recorded in 164 eyes of 107 patients using a confocal scanning laser ophthalmoscope (cSLO; excitation 488 nm, detection above 500 nm) as part of a prospective multicentre natural history study (FAM Study). FAF images were obtained in accordance with a standardised protocol for digital image acquisition and generation of mean images after automated alignment.
   Results: Image quality was sufficient for classification of FAF patterns in 149 eyes (90.9%) with lens opacities being the most common reason for insufficient image quality. Abnormal FAF outside GA in 149 eyes was classified into four patterns: focal (12.1%), banded (12.8%), patchy (2.0%), and diffuse (57.0%), whereby 12.1% had normal background FAF in the junctional zone. In 4% there was no predominant pattern. The diffuse pattern was subdivided into four groups including reticular (4.7%), branching (27.5%), fine granular (18.1%), and fine granular with peripheral punctate spots (6.7%).
   Conclusions: Different phenotypic patterns of abnormal FAF in the junctional zone of GA can be identified with cSLO FAF imaging. These distinct patterns may reflect heterogeneity at a cellular and molecular level in contrast with a non-specific ageing process. A refined phenotypic classification may be helpful to identify prognostic determinants for the spread of atrophy and visual loss, for identification of genetic risk factors as well as for the design of future interventional trials.
C1 Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   Heidelberg Univ, Dept Ophthalmol, D-69120 Heidelberg, Germany.
   Med Univ Lublin, Eye Hosp 1, PL-20079 Lublin, Poland.
   Univ Wurzburg, Dept Ophthalmol, D-97080 Wurzburg, Germany.
   Univ Aachen, Dept Ophthalmol, D-52074 Aachen, Germany.
   St Franziskus Hosp, Dept Ophthalmol, D-48149 Munster, Germany.
   Univ Munich, Inst Med Biometr & Epidemiol, D-81377 Munich, Germany.
   Univ Bern, Inselspital, Dept Ophthalmol, CH-3010 Bern, Switzerland.
C3 University of Bonn; Ruprecht Karls University Heidelberg; Medical
   University of Lublin; University of Wurzburg; RWTH Aachen University;
   St. Franziskus-Hospital; University of Munich; University of Bern;
   University Hospital of Bern
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM frank.holz@ukb.uni-bonn.de
RI Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028; Bindewald-Wittich,
   Almut/0000-0002-8151-3953; Dolar-Szczasny, Joanna/0000-0003-4206-4371
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Bellmann C, 2002, ARCH OPHTHALMOL-CHIC, V120, P579, DOI 10.1001/archopht.120.5.579
   Bellmann C, 1997, OPHTHALMOLOGE, V94, P385, DOI 10.1007/s003470050130
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bindewald A, 2004, AM J OPHTHALMOL, V137, P556, DOI 10.1016/j.ajo.2003.08.004
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Elkin PL, 2003, MAYO CLIN PROC, V78, P57, DOI 10.4065/78.1.57
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gerlai R, 2002, TRENDS NEUROSCI, V25, P506, DOI 10.1016/S0166-2236(02)02250-6
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   von Ruckmann A, 1999, GRAEF ARCH CLIN EXP, V237, P1, DOI 10.1007/s004170050186
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
NR 37
TC 129
Z9 138
U1 0
U2 14
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2005
VL 89
IS 7
BP 874
EP 878
DI 10.1136/bjo.2004.057794
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 936UM
UT WOS:000229880900023
PM 15965170
OA Bronze, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Bennion, AE
   Shaw, RL
   Gibson, JM
AF Bennion, Amy E.
   Shaw, Rachel L.
   Gibson, Jonathan M.
TI What do we know about the experience of age related macular
   degeneration? A systematic review and meta-synthesis of qualitative
   research
SO SOCIAL SCIENCE & MEDICINE
LA English
DT Review
DE Ageing; Vision loss; Meta-synthesis; Age related macular degeneration
ID OLDER-ADULTS; FOCUS GROUPS; OF-LIFE; VISION; METASYNTHESIS;
   QUESTIONNAIRE; ETHNOGRAPHY; PERCEPTIONS; DISABILITY; ADJUSTMENT
AB Age Related Macular Degeneration (AMD) is the leading cause of registerable blindness with a high medical and societal cost burden. Much of the research examining experiences of living with AMD has been conducted independently with small sample sizes and has failed to impact on practice. Metasynthesis of qualitative research can improve the understanding of the experience of living with AMD by drawing together findings of qualitative studies. This article presents a systematic review and metasynthesis of qualitative studies investigating the experience of AMD (literature searched up to April 2012; published studies identified range from 1996 to 2009). The review highlights themes relating to: functional limitations, adaptation and independence; feelings about the future with vision impairment; interaction with the health service; social engagement; disclosure; and the emotional impacts of living with AMD. Attention to the experience of living with AMD can help us to better understand the needs of patients. This meta-synthesis aimed to bring together the findings of qualitative research studies and highlights important areas for consideration when caring for patients with AMD. Our findings suggest that a holistic approach to service provision and support for AMD is needed which takes into account individuals' needs and experiences when coping with and adjusting to living with AMD. This support should aim to reduce stigma, increase social engagement, and develop the psychological resources of patients with AMD. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Bennion, Amy E.; Shaw, Rachel L.; Gibson, Jonathan M.] Aston Univ, Aston Res Ctr Hlth Ageing, Birmingham B4 7ET, W Midlands, England.
C3 Aston University
RP Bennion, AE (通讯作者)，Aston Univ, Aston Res Ctr Hlth Ageing, Birmingham B4 7ET, W Midlands, England.
EM bennioae@aston.ac.uk
OI Gibson, Jonathan M/0000-0002-9281-5244; Shaw, Rachel/0000-0002-0438-7666
CR Bambara JK, 2009, J VISUAL IMPAIR BLIN, V103, P137, DOI 10.1177/0145482X0910300303
   Bambara JK, 2009, INVEST OPHTH VIS SCI, V50, P1585, DOI 10.1167/iovs.08-2744
   Baumgartner LM, 2007, QUAL HEALTH RES, V17, P919, DOI 10.1177/1049732307305881
   Bonastre J, 2002, Eur J Health Econ, V3, P94, DOI 10.1007/s10198-002-0104-y
   Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brouwer D.M., 2005, INT C SER, V1282, P474, DOI [10.1016/j.ics.2005.05.100, DOI 10.1016/J.ICS.2005.05.100]
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Campbell R, 2003, SOC SCI MED, V56, P671, DOI 10.1016/S0277-9536(02)00064-3
   Cartwright T, 2007, SOC SCI MED, V64, P1692, DOI 10.1016/j.socscimed.2006.11.034
   Crossland M. D., 2007, VISUAL IMPAIRMENT RE, V9, P39
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Dixon-Woods M, 2004, QUAL SAF HEALTH CARE, V13, P223, DOI 10.1136/qshc.2003.008714
   Dixon-Woods Mary, 2006, BMC Med Res Methodol, V6, P35, DOI 10.1186/1471-2288-6-35
   Dixon-Woods Mary, 2007, J Health Serv Res Policy, V12, P42, DOI 10.1258/135581907779497486
   Feely M, 2007, J VISUAL IMPAIR BLIN, V101, P44, DOI 10.1177/0145482X0710100106
   Finfgeld DL, 2003, QUAL HEALTH RES, V13, P893, DOI 10.1177/1049732303253462
   GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196
   Ivanoff SD, 1996, DISABIL REHABIL, V18, P515, DOI 10.3109/09638289609166038
   Jarrar Z., 2011, BRIT J OPHTHALMOLOGY
   Kelly M., 2009, PUBLIC HLTH, V123, P14
   Kempen GIJM, 1999, SOC SCI MED, V48, P1161, DOI 10.1016/S0277-9536(98)00427-4
   Larkin M., 2006, QUAL RES PSYCHOL, V3, P102, DOI [10.1191/1478088706qp062oa, DOI 10.1191/1478088706QP062OA]
   Lawton J, 2008, SOC SCI MED, V67, P47, DOI 10.1016/j.socscimed.2008.03.028
   Lawton J, 2009, HEALTH EXPECT, V12, P138, DOI 10.1111/j.1369-7625.2009.00537.x
   Malpass A, 2009, SOC SCI MED, V68, P154, DOI 10.1016/j.socscimed.2008.09.068
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Mitchell J, 2008, AM J OPHTHALMOL, V146, P447, DOI 10.1016/j.ajo.2008.04.031
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Mitchell Jan, 2005, Health Qual Life Outcomes, V3, P25, DOI 10.1186/1477-7525-3-25
   Mogk M, 2008, J VISUAL IMPAIR BLIN, V102, P581, DOI 10.1177/0145482X0810201002
   Moore LW, 2000, WESTERN J NURS RES, V22, P571, DOI 10.1177/01939450022044601
   Moore LW, 2005, APPL NURS RES, V18, P110, DOI 10.1016/j.apnr.2004.06.014
   Moore LW, 2003, J ADV NURS, V43, P10
   Mulrow C, 1997, ANN INTERN MED, V127, P989, DOI 10.7326/0003-4819-127-11-199712010-00008
   Murray J, 2006, SOC SCI MED, V63, P1363, DOI 10.1016/j.socscimed.2006.03.037
   Nyman S. R., 2011, DISABILITY REHABILIT, P1
   Owsley C, 2006, REHABIL PSYCHOL, V51, P23, DOI 10.1037/0090-5550.51.1.23
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Peel E, 2007, BMJ-BRIT MED J, V335, P493, DOI 10.1136/bmj.39302.444572.DE
   Penninx BWJH, 1997, SOC SCI MED, V44, P393, DOI 10.1016/S0277-9536(96)00156-6
   Rudman DL, 2010, OTJR-OCCUP PART HEAL, V30, P87, DOI 10.3928/15394492-20100325-04
   Rycroft-Malone J, 2004, J ADV NURS, V47, P81, DOI 10.1111/j.1365-2648.2004.03068.x
   Sandelowski M, 1997, RES NURS HEALTH, V20, P365, DOI 10.1002/(SICI)1098-240X(199708)20:4<365::AID-NUR9>3.0.CO;2-E
   Smith JA, 2011, HEALTH PSYCHOL REV, V5, P9, DOI 10.1080/17437199.2010.510659
   Spencer L., QUALITATIVE RES METH, P227
   Stanford P, 2009, BRIT J VISUAL IMPA, V27, P129, DOI 10.1177/0264619609102216
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   Walsh D, 2005, J ADV NURS, V50, P204, DOI 10.1111/j.1365-2648.2005.03380.x
   Whitehead L, 2006, INT J NURS STUD, V43, P1023, DOI 10.1016/j.ijnurstu.2006.01.003
   Wong EYH, 2004, J VISUAL IMPAIR BLIN, V98, P629, DOI 10.1177/0145482X0409801007
   Yardley L, 2000, PSYCHOL HEALTH, V15, P215, DOI 10.1080/08870440008400302
   Yardley L., 2008, SAGE HDB QUALITATIVE, P352
NR 56
TC 55
Z9 55
U1 0
U2 47
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0277-9536
J9 SOC SCI MED
JI Soc. Sci. Med.
PD SEP
PY 2012
VL 75
IS 6
BP 976
EP 985
DI 10.1016/j.socscimed.2012.04.023
PG 10
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA 979LQ
UT WOS:000306821900003
PM 22709445
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Nuthmann, A
   Thibaut, M
   Tran, TH
   Boucart, M
AF Nuthmann, Antje
   Thibaut, Miguel
   Tran, Thi Ha Chau
   Boucart, Muriel
TI Impact of neovascular age-related macular degeneration on eye-movement
   control during scene viewing: Viewing biases and guidance by visual
   salience
SO VISION RESEARCH
LA English
DT Article
DE Macular degeneration; Eye movements; Naturalistic scenes; Saliency;
   Individual differences
ID PREFERRED RETINAL LOCUS; FIXATION STABILITY; PERCEPTION; SELECTION;
   IDENTIFICATION; VARIABILITY; ALLOCATION; LOCATIONS; DIRECTION; FEATURES
AB Human vision requires us to analyze the visual periphery to decide where to fixate next. In the present study, we investigated this process in people with age-related macular degeneration (AMD). In particular, we examined viewing biases and the extent to which visual salience guides fixation selection during free-viewing of naturalistic scenes. We used an approach combining generalized linear mixed modeling (GLMM) with a-priori scene parcellation. This method allows one to investigate group differences in terms of scene coverage and observers' well-known tendency to look at the center of scene images. Moreover, it allows for testing whether image salience influences fixation probability above and beyond what can be accounted for by the central bias. Compared with age-matched normally sighted control subjects (and young subjects), AMD patients' viewing behavior was less exploratory, with a stronger central fixation bias. All three subject groups showed a salience effect on fixation selection-higher-salience scene patches were more likely to be fixated. Importantly, the salience effect for the AMD group was of similar size as the salience effect for the control group, suggesting that guidance by visual salience was still intact. The variances for by-subject random effects in the GLMM indicated substantial individual differences. A separate model exclusively considered the AMD data and included fixation stability as a covariate, with the results suggesting that reduced fixation stability was associated with a reduced impact of visual salience on fixation selection.
C1 [Nuthmann, Antje] Univ Kiel, Inst Psychol, Kiel, Germany.
   [Thibaut, Miguel; Tran, Thi Ha Chau; Boucart, Muriel] Univ Lille, Lille Neurosci & Cognit, INSERM, Lille, France.
   [Tran, Thi Ha Chau] Catholic Univ Lille, Lille Catholic Hosp, Ophthalmol Dept, Lille, France.
   [Nuthmann, Antje] Univ Kiel, Inst Psychol, Olshausenstr 62, D-24118 Kiel, Germany.
   [Boucart, Muriel] Fac Med, Pole Rech, 1 Pl Verdun, F-59000 Lille, France.
C3 University of Kiel; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille;
   University of Kiel; Universite de Franche-Comte; Universite de Lille -
   ISITE; Universite de Lille
RP Nuthmann, A (通讯作者)，Univ Kiel, Inst Psychol, Olshausenstr 62, D-24118 Kiel, Germany.; Boucart, M (通讯作者)，Fac Med, Pole Rech, 1 Pl Verdun, F-59000 Lille, France.
EM nuthmann@psychologie.uni-kiel.de; muriel.boucart@chru-lille.fr
OI Nuthmann, Antje/0000-0003-3338-3434
CR Acik A, 2010, FRONT PSYCHOL, V1, DOI 10.3389/fpsyg.2010.00207
   AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   Altemir I, 2022, BRAIN SCI, V12, DOI 10.3390/brainsci12010019
   Anderson NC, 2020, J VISION, V20, DOI 10.1167/jov.20.8.21
   Baayen RH, 2008, J MEM LANG, V59, P390, DOI 10.1016/j.jml.2007.12.005
   Baddeley RJ, 2006, VISION RES, V46, P2824, DOI 10.1016/j.visres.2006.02.024
   Barr DJ, 2013, J MEM LANG, V68, P255, DOI 10.1016/j.jml.2012.11.001
   Barthelme S, 2013, J VISION, V13, DOI 10.1167/13.12.1
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Bolker BM, 2009, TRENDS ECOL EVOL, V24, P127, DOI 10.1016/j.tree.2008.10.008
   Borji A, 2013, IEEE T PATTERN ANAL, V35, P185, DOI 10.1109/TPAMI.2012.89
   Boucart M, 2013, INVEST OPHTH VIS SCI, V54, P1950, DOI 10.1167/iovs.12-9680
   Boucart M, 2008, VISUAL NEUROSCI, V25, P685, DOI 10.1017/S0952523808080826
   Brown VA, 2021, ADV METH PRACT PSYCH, V4, DOI 10.1177/2515245920960351
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Clarke ADF, 2014, VISION RES, V102, P41, DOI 10.1016/j.visres.2014.06.016
   Costela FM, 2017, INVEST OPHTH VIS SCI, V58, P6073, DOI 10.1167/iovs.17-21839
   CRONBACH LJ, 1957, AM PSYCHOL, V12, P671, DOI 10.1037/h0043943
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2004, VISION RES, V44, P1537, DOI 10.1016/j.visres.2004.01.006
   Crossland MD, 2011, RETINA-J RET VIT DIS, V31, P2109, DOI 10.1097/IAE.0b013e31820d3fba
   Crossland MD, 2011, INVEST OPHTH VIS SCI, V52, P411, DOI 10.1167/iovs.10-5473
   CUMMINGS RW, 1985, AM J OPTOM PHYS OPT, V62, P833
   David EJ, 2019, J VISION, V19, DOI 10.1167/19.14.22
   Demidenko E., 2013, MIXED MODELS THEORY
   EFRON B, 1977, SCI AM, V236, P119, DOI 10.1038/scientificamerican0577-119
   Foulsham T, 2008, VISION RES, V48, P1777, DOI 10.1016/j.visres.2008.05.018
   Foulsham T, 2010, VISION RES, V50, P779, DOI 10.1016/j.visres.2010.01.019
   Frintrop S, 2010, ACM T APPL PERCEPT, V7, DOI 10.1145/1658349.1658355
   Garcia-Diaz A, 2012, J VISION, V12, DOI 10.1167/12.6.17
   Gelman A., 2007, DATA ANAL USING REGR, DOI 10.1017/CBO9780511790942
   Gonzalez EG, 2006, CAN J OPHTHALMOL, V41, P333, DOI 10.1139/I06-019
   Gupta A, 2018, INVEST OPHTH VIS SCI, V59, P1105, DOI 10.1167/iovs.16-21404
   Hohenstein S., 2020, REMEF REMOVE PARTIAL
   Itti L, 1998, IEEE T PATTERN ANAL, V20, P1254, DOI 10.1109/34.730558
   Jaeger TF, 2008, J MEM LANG, V59, P434, DOI 10.1016/j.jml.2007.11.007
   Kliegl R, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2010.00238
   Kumar G, 2014, INVEST OPHTH VIS SCI, V55, P5125, DOI 10.1167/iovs.14-14608
   Kuznetsova A, 2017, J STAT SOFTW, V82, P1, DOI 10.18637/jss.v082.i13
   Zhaoping L, 2019, CURR OPIN NEUROBIOL, V58, P1, DOI 10.1016/j.conb.2019.06.001
   Loschky LC, 2019, J VISION, V19, DOI 10.1167/19.5.15
   Ludwig CJH, 2014, P NATL ACAD SCI USA, V111, pE291, DOI 10.1073/pnas.1313553111
   Makowski S., 2014, SHRINKAGE APPL TUTOR, DOI [10.5281/zenodo.11172, DOI 10.5281/ZENODO.11172]
   Malcolm GL, 2016, TRENDS COGN SCI, V20, P843, DOI 10.1016/j.tics.2016.09.003
   Malcolm GL, 2009, J VISION, V9, DOI 10.1167/9.11.8
   Mannan SK, 1996, SPATIAL VISION, V10, P165, DOI 10.1163/156856896X00123
   Nuthmann A, 2021, J VISION, V21, DOI 10.1167/jov.21.4.2
   Nuthmann A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78203-7
   Nuthmann A, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00491
   Nuthmann A, 2017, PSYCHON B REV, V24, P370, DOI 10.3758/s13423-016-1124-4
   Nuthmann A, 2015, ANN NY ACAD SCI, V1339, P82, DOI 10.1111/nyas.12705
   Nuthmann A, 2014, J EXP PSYCHOL HUMAN, V40, P342, DOI 10.1037/a0033854
   Nuthmann A, 2010, J VISION, V10, DOI 10.1167/10.8.20
   Parkhurst D, 2002, VISION RES, V42, P107, DOI 10.1016/S0042-6989(01)00250-4
   Peters RJ, 2005, VISION RES, V45, P2397, DOI 10.1016/j.visres.2005.03.019
   Querques G, 2012, GRAEF ARCH CLIN EXP, V250, P479, DOI 10.1007/s00417-011-1831-5
   RABBITT P, 1993, Q J EXP PSYCHOL-A, V46, P385, DOI 10.1080/14640749308401055
   Rohrschneider K, 1995, Ger J Ophthalmol, V4, P197
   Rothkegel LOM, 2017, J VISION, V17, DOI 10.1167/17.13.3
   Rouder JN, 2019, PSYCHON B REV, V26, P452, DOI 10.3758/s13423-018-1558-y
   Rubin GS, 2013, VISION RES, V90, P43, DOI 10.1016/j.visres.2013.02.015
   Rubin GS, 2009, NEURO-OPHTHALMOLOGY, V33, P120, DOI 10.1080/01658100902998732
   Salvucci D.D., 2000, P EYE TRACK RES APPL, P71, DOI DOI 10.1145/355017.355028
   Schielzeth H, 2009, BEHAV ECOL, V20, P416, DOI 10.1093/beheco/arn145
   SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136
   Seghier ML, 2018, TRENDS COGN SCI, V22, P517, DOI 10.1016/j.tics.2018.03.003
   Shammi P, 1998, AGING NEUROPSYCHOL C, V5, P1, DOI 10.1076/anec.5.1.1.23
   Staub A, 2020, J EXP PSYCHOL HUMAN, V46, P1235, DOI 10.1037/xhp0000853
   STEINMAN RM, 1965, J OPT SOC AM, V55, P1158, DOI 10.1364/JOSA.55.001158
   Sullivan B, 2015, VISION RES, V116, P68, DOI 10.1016/j.visres.2015.07.007
   Tarita-Nistor L, 2015, OPTOMETRY VISION SCI, V92, P863, DOI 10.1097/OPX.0000000000000641
   Tatler BW, 2007, J VISION, V7, DOI 10.1167/7.14.4
   Tatler BW, 2005, VISION RES, V45, P643, DOI 10.1016/j.visres.2004.09.017
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Thi HCT, 2012, OPTOMETRY VISION SCI, V89, P419, DOI 10.1097/OPX.0b013e31824c3a21
   Thi HCT, 2010, INVEST OPHTH VIS SCI, V51, P6868, DOI 10.1167/iovs.10-5517
   Thibaut M, 2016, J FR OPHTALMOL, V39, P82, DOI 10.1016/j.jfo.2015.08.010
   Thibaut M, 2020, CLIN EXP OPTOM, V103, P648, DOI 10.1111/cxo.12982
   Thibaut M, 2015, OPHTHAL PHYSL OPT, V35, P336, DOI 10.1111/opo.12201
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   Van Renswoude DR, 2016, INFANT BEHAV DEV, V44, P38, DOI 10.1016/j.infbeh.2016.05.005
   Verghese P, 2021, ANNU REV VIS SCI, V7, P773, DOI 10.1146/annurev-vision-100119-125555
   Vogel EK, 2008, CURR DIR PSYCHOL SCI, V17, P171, DOI 10.1111/j.1467-8721.2008.00569.x
   Vullings C, 2021, J VISION, V21, DOI 10.1167/jov.21.3.9
   Wickham H, 2016, GGPLOT2 ELEGANT GRAP, DOI 10.1007/978-3-319-24277-4
   Wiecek E, 2012, INVEST OPHTH VIS SCI, V53, P6600, DOI 10.1167/iovs.12-10012
   Wilke C.O., 2017, cowplot: Streamlined plot theme and plot annotations for ``ggplot2''. R package version 0.8.0
   WILKINSON GN, 1973, ROY STAT SOC C-APP, V22, P392
   Wloka C., 2018, ARXIV, DOI [10.48550/arXiv.1812.08848, DOI 10.48550/ARXIV.1812.08848]
   Wolfers T, 2020, PSYCHOL MED, V50, P314, DOI 10.1017/S0033291719000084
NR 90
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-6989
EI 1878-5646
J9 VISION RES
JI Vision Res.
PD DEC
PY 2022
VL 201
AR 108105
DI 10.1016/j.visres.2022.108105
PG 13
WC Neurosciences; Ophthalmology; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology; Psychology
GA 4Q5UB
UT WOS:000856146900002
PM 36081228
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Chou, YB
   Chen, MJ
   Lin, TC
   Chen, SJ
   Hwang, DK
AF Chou, Yu-Bai
   Chen, Meng-Jou
   Lin, Tai-Chi
   Chen, Shih-Jen
   Hwang, De-Kuang
TI Priority options of anti-vascular endothelial growth factor agents in
   wet age-related macular degeneration under the National Health Insurance
   Program
SO JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
LA English
DT Article
DE Aflibercept; Age-related macular degeneration; National Health
   Insurance; Ranibizumab
ID INTRAVITREAL AFLIBERCEPT; ANTI-VEGF; ANATOMICAL OUTCOMES; TREATMENT
   PATTERNS; RANIBIZUMAB; EYES; THERAPY; DETACHMENT; RESISTANT; FLUID
AB Background: Age-related macular degeneration (AMD) is a leading cause of blindness worldwide, for which intravitreal injection of anti-vascular endothelial growth factor (VEGF) is the primary treatment option. The purpose of the current study was to investigate the prioritization of anti-VEGF agents for wet AMD under the National Health Insurance (NHI) Program, and their clinical outcomes. Methods: Patients who were diagnosed with active choroidal neovascularization caused by AMD, and who met the criteria for reimbursement for anti-VEGF therapy by the NHI program in Taiwan between August 1, 2014 and May 31, 2015, were included in the study. Factors potentially influencing the choice of treatment agent were analyzed, and clinical outcomes were compared between the two different agents and their protocols. Results: A total of 166 treatment applications in 166 eyes from 159 patients were enrolled in the study. Age, laterality, presence of retinal pigment epithelial detachment, history of hypertension, coronary artery disease, and cerebral vascular accidents were significantly associated with the selection of the anti-VEGF agent. Treatment patterns and clinical outcomes were similar between the patients treated with ranibizumab and those treated with aflibercept. Significantly fewer injections were given during the follow-up period in those treated with aflibercept. Conclusion: Under the restrictive insurance program in Taiwan, more patients and ophthalmologists chose to treat wet AMD using aflibercept. However, in clinical practice, no significant differences in efficacy or clinical outcomes were found between the patients treated with ranibizumab and those treated with aflibercept.
C1 [Chou, Yu-Bai; Chen, Meng-Jou; Lin, Tai-Chi; Chen, Shih-Jen; Hwang, De-Kuang] Taipei Vet Gen Hosp, Dept Ophthalmol, 201,Sect 2,Shi Pai Rd, Taipei 112, Taiwan.
   [Chou, Yu-Bai] Natl Yang Ming Univ, Dept Publ Hlth, Taipei, Taiwan.
   [Chou, Yu-Bai] Natl Yang Ming Univ, Inst Publ Hlth, Taipei, Taiwan.
   [Lin, Tai-Chi] Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan.
   [Chen, Shih-Jen; Hwang, De-Kuang] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
C3 Taipei Veterans General Hospital; National Yang Ming Chiao Tung
   University; National Yang Ming Chiao Tung University; National Yang Ming
   Chiao Tung University; National Yang Ming Chiao Tung University
RP Hwang, DK (通讯作者)，Taipei Vet Gen Hosp, Dept Ophthalmol, 201,Sect 2,Shi Pai Rd, Taipei 112, Taiwan.
EM m95gbk@gmail.com
RI Hwang, DK De-Kuang/J-3931-2016
OI Hwang, DK De-Kuang/0000-0001-6346-8485
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Johnston SS, 2013, ADV THER, V30, P1111, DOI 10.1007/s12325-013-0078-4
   Kaiser PK, 2012, GRAEF ARCH CLIN EXP, V250, P1563, DOI 10.1007/s00417-012-2123-4
   Kalouda P, 2015, SEMIN OPHTHALMOL, V30, P6, DOI 10.3109/08820538.2013.807852
   Kim H, 2009, MOL VIS, V15
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Pepple K, 2011, SEMIN OPHTHALMOL, V26, P198, DOI 10.3109/08820538.2011.570850
   Reich O, 2015, RISK MANAG HEALTHC P, V8, P55, DOI 10.2147/RMHP.S80536
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 25
TC 5
Z9 5
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1726-4901
EI 1728-7731
J9 J CHIN MED ASSOC
JI J. Chin. Med. Assoc.
PD AUG
PY 2019
VL 82
IS 8
BP 659
EP 664
DI 10.1097/JCMA.0000000000000138
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA JI6DQ
UT WOS:000493557700012
PM 31259835
OA hybrid
DA 2022-11-30
ER

PT J
AU Ferrington, DA
   Ebeling, MC
   Kapphahn, RJ
   Terluk, MR
   Fisher, CR
   Polanco, JR
   Roehrich, H
   Leary, MM
   Geng, ZH
   Dutton, JR
   Montezuma, SR
AF Ferrington, Deborah A.
   Ebeling, Mara C.
   Kapphahn, Rebecca J.
   Terluk, Marcia R.
   Fisher, Cody R.
   Polanco, Jorge R.
   Roehrich, Heidi
   Leary, Michaela M.
   Geng, Zhaohui
   Dutton, James R.
   Montezuma, Sandra R.
TI Altered bioenergetics and enhanced resistance to oxidative stress in
   human retinal pigment epithelial cells from donors with age-related
   macular degeneration
SO REDOX BIOLOGY
LA English
DT Article
DE 6 max) Age-related macular degeneration; Retinal pigment epithelium;
   Mitochondrial function; Glycolytic function; Antioxidants; Oxidative
   stress
ID SUSCEPTIBILITY
AB Age-related macular degeneration (AMD) is the leading cause of blindness among older adults. It has been suggested that mitochondrial defects in the retinal pigment epithelium (RPE) underlies AMD pathology. To test this idea, we developed primary cultures of RPE to ask whether RPE from donors with AMD differ in their metabolic profile compared with healthy age-matched donors. Analysis of gene expression, protein content, and RPE function showed that these cultured cells replicated many of the cardinal features of RPE in vivo. Using the Seahorse Extracellular Flux Analyzer to measure bioenergetics, we observed RPE from donors with AMD exhibited reduced mitochondrial and glycolytic function compared with healthy donors. RPE from AMD donors were also more resistant to oxidative inactivation of these two energy-producing pathways and were less susceptible to oxidation-induced cell death compared with cells from healthy donors. Investigation of the potential mechanism responsible for differences in bioenergetics and resistance to oxidative stress showed RPE from AMD donors had increased PGC1 alpha protein as well as differential expression of multiple genes in response to an oxidative challenge. Based on our data, we propose that cultured RPE from donors phenotyped for the presence or absence of AMD provides an excellent model system for studying "AMD in a dish". Our results are consistent with the ideas that (i) a bioenergetics crisis in the RPE contributes to AMD pathology, and (ii) the diseased environment in vivo causes changes in the cellular profile that are retained in vitro.
C1 [Ferrington, Deborah A.; Ebeling, Mara C.; Kapphahn, Rebecca J.; Terluk, Marcia R.; Fisher, Cody R.; Polanco, Jorge R.; Leary, Michaela M.; Montezuma, Sandra R.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.
   [Ferrington, Deborah A.; Fisher, Cody R.] Univ Minnesota, Grad Program Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.
   [Roehrich, Heidi] Univ Minnesota, Histol Core Vis Res, Minneapolis, MN 55455 USA.
   [Geng, Zhaohui; Dutton, James R.] Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA.
   [Geng, Zhaohui; Dutton, James R.] Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities
RP Ferrington, DA (通讯作者)，380 Lions Res Bldg,2001 6th St SE, Minneapolis, MN 55455 USA.
EM Ferri013@umn.edu; ebeli017@umn.edu; kapph001@umn.edu; mrterluk@umn.edu;
   fishe765@umn.edu; polan070@umn.edu; rohri002@umn.edu; leary070@umn.edu;
   gengx027@umn.edu; dutto015@umn.edu; smontezu@umn.edu
OI Ferrington, Deborah/0000-0003-2561-7464
FU NEI NIH HHS [R01 EY026012] Funding Source: Medline; NIA NIH HHS [T32
   AG029796] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY026012]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG029796]
   Funding Source: NIH RePORTER
CR Alliance for Eye and Vision Research, 2013, 20 ANN SPEC REP
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhattacharya S, 2012, INVEST OPHTH VIS SCI, V53, P8350, DOI 10.1167/iovs.12-10495
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Blenkinsop T. A., 2016, METHOD MOL BIOL, V945, P45
   Carver KA, 2016, INVEST OPHTH VIS SCI, V57, P360, DOI 10.1167/iovs.15-17117
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Kumar S, 2016, MOL CELL ENDOCRINOL, V422, P233, DOI 10.1016/j.mce.2015.12.019
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Liang HY, 2006, ADV PHYSIOL EDUC, V30, P145, DOI 10.1152/advan.00052.2006
   Maldonado M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056187
   Noh YH, 2009, J BIOL CHEM, V284, P8470, DOI 10.1074/jbc.M808981200
   Nordgaard C. L., 2008, INVEST OPHTHALMOL VI, V49
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Parinot C, 2014, JOVE-J VIS EXP, DOI 10.3791/52100
   Poynton RA, 2014, BBA-GEN SUBJECTS, V1840, P906, DOI 10.1016/j.bbagen.2013.08.001
   Quiros PM, 2016, NAT REV MOL CELL BIO, V17, P213, DOI 10.1038/nrm.2016.23
   Reddy MA, 2016, ARTERIOSCL THROM VAS, V36, P864, DOI 10.1161/ATVBAHA.115.306770
   Rohrer B, 2016, ADV EXP MED BIOL, V854, P793, DOI 10.1007/978-3-319-17121-0_106
   Setn R., 2011, US OPHTHALMIC REV, V4, P96
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024
   Strauss O., 2005, PHYSIOL REV, V85, P525
   Teduk KR., 2015, J NEUROSCI, V35, P7304
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu XY, 2012, MOL BIOL REP, V39, P8891, DOI 10.1007/s11033-012-1756-z
NR 28
TC 86
Z9 87
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2317
J9 REDOX BIOL
JI Redox Biol.
PD OCT
PY 2017
VL 13
BP 255
EP 265
DI 10.1016/j.redox.2017.05.015
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA FG6GK
UT WOS:000410470000019
PM 28600982
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Demirok, G
   Ozturk, S
   Muslehiddinoglu, I
   Topalak, Y
   Yenice, E
   Tabakci, B
   Altay, Y
   Sengun, A
   Turacli, E
AF Demirok, Gulizar
   Ozturk, Sertac
   Muslehiddinoglu, Ilknur
   Topalak, Yasemin
   Yenice, Esay
   Tabakci, Burcu
   Altay, Yesim
   Sengun, Ahmet
   Turacli, Erol
TI THE CORRELATION OF CHOROIDAL THICKNESS AND OCULAR PULSE AMPLITUDE IN
   NON-EXUDATIVE AGE-RELATED MACULAR DEGENERATION
SO TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI
LA English
DT Article
DE Choroidal Thickness; Ocular Pulse Amplitude; Dynamic Contour Tonometry;
   EDI Mode Optical Coherence Tomography
ID OPTICAL COHERENCE TOMOGRAPHY; EYES
AB Introduction: The choroid is involved in the pathogenesis of various retinal diseases, including age-related macular degeneration (AMD). The ocular pulse amplitude (OPA) gives useful information about intraocular blood flow and is an indirect indicator of choroidal perfusion. In this study, we aimed to assess the correlation between the OPA and choroidal thickness (CT) in the eyes of healthy individuals and of individuals with non-exudative early stage AMD.
   Materials and Method: Fourty-four eyes of 44 non-exudative AMD patients and 41 age-matched eyes of 41 healthy individuals were included in the study. All eyes underwent a detailed ophthalmic evaluation, including axial length (AL) and ocular pulse amplitude (OPA) measurements. The CT was measured using optical coherence tomography. Parameters were compared between the two groups and correlation between OPA and CT was assessed.
   Results: The mean subfoveal, foveal, and parafoveal CT were 245.82 +/- 24.29 mu m, 230.66 +/- 23.44 mu m, 219.55 +/- 25.39 mu m in AMD group, respectively. The corresponding values were 278.44 +/- 34.18 mu m, 263.76 +/- 32.45 mu m, and 253.79 +/- 34.81 mu m in control group, respectively. The mean ages of groups were 69.6 +/- 8.97 years, and 65.0 +/- 5.89 years, respectively. The mean OPA was 3.43 +/- 1.14mmHg and 3.49 +/- 1.12mmHg, respectively. The average CT in AMD patients were significantly lower than the control group in all three regions (subfoveal- foveal- parafoveal) (all p<0,001). In controls, there was a moderate positive correlation between the OPA and CT in the three segments (p=0.002, 0.009, and 0.003; respectively). However only the foveal CT showed significant positive correlation with the OPA in AMD group (p=0.047).
   Conclusion: Our results showed a considerable correlation between ocular pulse amplitude and choroidal thickness in healthy subject. In non-exudative AMD group, there was a weak correlation between them. It can be hypothesized that; in patients with AMD, degeneration and/or thinning of choroidal pattern is a reason for this result.
C1 [Demirok, Gulizar; Ozturk, Sertac; Muslehiddinoglu, Ilknur; Topalak, Yasemin; Yenice, Esay; Sengun, Ahmet; Turacli, Erol] Ufuk Univ, Fac Med, Dept Opthalmol, Ankara, Turkey.
   [Tabakci, Burcu] Agri State Hosp, Opthalmol Clin, Agri, Turkey.
   [Altay, Yesim] Ankara Numune Training & Res Hosp, Opthalmolgy Clin, Ankara, Turkey.
C3 Ufuk University; Agri State Hospital; Ankara Numune Training & Research
   Hospital
RP Demirok, G (通讯作者)，Ufuk Univ, Fac Med, Dept Opthalmol, Ankara, Turkey.
EM gsoyugelen@yahoo.com
RI Ozturk, Sertac/AGO-2476-2022
OI Ozturk, Sertac/0000-0001-6533-6144
CR Alm A., 1992, ADLERS PHYSL EYE, P198
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Ben Zion I, 2007, BRIT J OPHTHALMOL, V91, P882, DOI 10.1136/bjo.2006.108340
   Cao JT, 1998, ARCH OPHTHALMOL-CHIC, V116, P589, DOI 10.1001/archopht.116.5.589
   Dervisogullari MS, EYE LOND, V29, P371
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maul EA, 2011, OPHTHALMOLOGY, V118, P1571, DOI 10.1016/j.ophtha.2011.01.016
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Schmidt KG, 2000, BRIT J OPHTHALMOL, V84, P1282, DOI 10.1136/bjo.84.11.1282
   Schmidt KG, 2001, BRIT J OPHTHALMOL, V85, P678, DOI 10.1136/bjo.85.6.678
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Wojtkowski M, 2002, J BIOMED OPT, V7, P457, DOI 10.1117/1.1482379
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
NR 19
TC 0
Z9 0
U1 0
U2 0
PU GUNES KITABEVI LTD STI
PI ANKARA
PA M RAUF INAN SOK NO 3, ANKARA, SIHHIYE 06410, TURKEY
SN 1304-2947
EI 1307-9948
J9 TURK J GERIATR
JI Turk. J. Geriatr.
PY 2015
VL 18
IS 3
BP 211
EP 216
PG 6
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA DB1GY
UT WOS:000368257500005
DA 2022-11-30
ER

PT J
AU Balaratnasingam, C
   Messinger, JD
   Sloan, KR
   Yannuzzi, LA
   Freund, KB
   Curcio, CA
AF Balaratnasingam, Chandrakumar
   Messinger, Jeffrey D.
   Sloan, Kenneth R.
   Yannuzzi, Lawrence A.
   Freund, K. Bailey
   Curcio, Christine A.
TI Histologic and Optical Coherence Tomographic Correlates in Drusenoid
   Pigment Epithelium Detachment in Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID ACQUIRED VITELLIFORM LESIONS; GEOGRAPHIC ATROPHY; CHOROIDAL
   NEOVASCULARIZATION; HYPERREFLECTIVE FOCI; INTRAVITREAL RANIBIZUMAB;
   RETINITIS-PIGMENTOSA; NATURAL-HISTORY; GRADING SYSTEM; EYES; PROGRESSION
AB Purpose: Drusenoid pigment epithelium detachment (DPED) is a known precursor to geographic atrophy in age-related macular degeneration (AMD). We sought histologic correlates for spectral-domain (SD) optical coherence tomography (OCT) signatures in DPED and determined the frequency and origin of these OCT signatures in a clinical cohort of DPED eyes.
   Design: Laboratory imaging and histologic comparison, and retrospective, observational cohort study.
   Participants: Four donor eyes with histopathologic diagnosis of AMD (2 with nonneovascular DPED and 2 with neovascular pigment epithelium detachment [PED]) and 49 eyes of 33 clinic patients with nonneovascular DPED more than 2 mm in diameter.
   Methods: Donor eyes underwent multimodal ex vivo imaging, including SD OCT, then processing for highresolution histologic analysis. All clinic patients underwent SD OCT, near-infrared reflectance, and color photography.
   Main Outcome Measures: Histologic correlates for SD OCT signatures in DPED, estimate of coverage by different retinal pigment epithelium (RPE) phenotypes in the DPED surface; frequency and origin of histologically verified SD OCT signatures in a clinical cohort of DPED eyes, and comparisons of histologic features between neovascular PED and DPED resulting from AMD.
   Results: Intraretinal and subretinal hyperreflective foci as seen on SD OCT correlated to RPE cells on histologic examination. Hypertransmission of light below the RPE-basal lamina band correlated with dissociated RPE. Subretinal hyperreflective material resulting from acquired vitelliform lesions corresponded to regions of apically expelled RPE organelles. In the clinical cohort, all histologically verified reflectivity signatures were visible and quantifiable. The appearance of intraretinal hyperreflective foci was preceded by thickening of the RPE-basal lamina band. Compared with PEDs associated with neovascular AMD, DPEDs had different crystallization patterns, no lipid-filled cells, and thinner basal laminar deposits.
   Conclusions: Multiple RPE fates in AMD, including intraretinal cells that are highly prognostic for progression, can be followed and quantified reliably using eye-tracked serial SD OCT. This information may be particularly useful for obtaining an accurate timeline of incipient geographic atrophy in clinic populations and for quantifying anatomic end points and response to therapy in AMD clinical trials. (C) 2017 by the American Academy of Ophthalmology
C1 [Balaratnasingam, Chandrakumar; Yannuzzi, Lawrence A.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Balaratnasingam, Chandrakumar; Yannuzzi, Lawrence A.; Freund, K. Bailey] Manhattan Eye Ear & Throat Inst, LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
   [Balaratnasingam, Chandrakumar; Freund, K. Bailey] NYU, Dept Ophthalmol, Langone Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Balaratnasingam, Chandrakumar] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Perth, WA, Australia.
   [Sloan, Kenneth R.] Univ Alabama Birmingham, Dept Comp & Informat Sci, Birmingham, AL 35294 USA.
   [Messinger, Jeffrey D.; Sloan, Kenneth R.; Yannuzzi, Lawrence A.; Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol, Sch Med, Birmingham, AL 35294 USA.
C3 Vitreous Retina Macula Consultants of New York; New York University; NYU
   Langone Medical Center; University of Western Australia; University of
   Alabama System; University of Alabama Birmingham; University of Alabama
   System; University of Alabama Birmingham
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol, Sch Med, EyeSight Fdn,Alabama Vis Res Labs, 1670 Univ Blvd,Room 360, Birmingham, AL 35294 USA.
EM curcio@uab.edu
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Macula Foundation in New York, NY; LuEsther T. Mertz Retinal Research
   Center in New York, NY; National Institutes of Health, Bethesda,
   Maryland [R01 EY06109]; Research to Prevent Blindness, Inc., New York,
   New York; EyeSight Foundation of Alabama, Birmingham AL; National Eye
   Institute, National Institutes of Health [P30 EY003039]; Edward N. and
   Della L. Thome Memorial Foundation, Boston MA.; NATIONAL EYE INSTITUTE
   [R01EY006109, P30EY003039] Funding Source: NIH RePORTER
FX Supported by the Macula Foundation and the LuEsther T. Mertz Retinal
   Research Center, both in New York, NY. The funding organizations had no
   role in the design and conduct of this study. Histopathologic analysis
   was supported by the National Institutes of Health, Bethesda, Maryland
   (grant no.: R01 EY06109); Research to Prevent Blindness, Inc., New York,
   New York; and the EyeSight Foundation of Alabama, Birmingham AL.
   Acquisition of donor eyes received additional support from the
   International Retinal Research Foundation, Birmingham, AL; the National
   Eye Institute, National Institutes of Health (grant no.: P30 EY003039);
   and the Arnold and Mabel Beckman Initiative for Macular Research, Los
   Angeles CA. Creation of Project MACULA received additional support from
   the Edward N. and Della L. Thome Memorial Foundation, Boston MA.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Arora S, 2011, EYE, V25, P1034, DOI 10.1038/eye.2011.115
   Balaratnasingam C, 2016, AM J OPHTHALMOL, V172, P28, DOI 10.1016/j.ajo.2016.09.008
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chen KC, 2016, AM J OPHTHALMOL, V164, P89, DOI 10.1016/j.ajo.2016.02.002
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Clemens CR, 2015, RETINA-J RET VIT DIS, V35, P1351, DOI 10.1097/IAE.0000000000000473
   Collin GB, 2015, HUM MOL GENET, V24, P6958, DOI 10.1093/hmg/ddv399
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Curcio CA, 2015, AM J OPHTHALMOL, V160, P1024, DOI 10.1016/j.ajo.2015.08.001
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Joachim NDL, 2015, JAMA OPHTHALMOL, V133, P698, DOI 10.1001/jamaophthalmol.2015.0498
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   KLIEN BA, 1950, AM J OPHTHALMOL, V33, P371, DOI 10.1016/0002-9394(50)90335-7
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   LI ZY, 1995, OPHTHALMOLOGY, V102, P805, DOI 10.1016/S0161-6420(95)30953-0
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   PRAKASH YS, 1994, NEUROIMAGE, V1, P325, DOI 10.1006/nimg.1994.1017
   Ritter M, 2010, EYE, V24, P962, DOI 10.1038/eye.2009.265
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schlanitz FG, 2015, AM J OPHTHALMOL, V160, P335, DOI 10.1016/j.ajo.2015.05.008
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Shields CL, 2012, ARCH OPHTHALMOL-CHIC, V130, P850, DOI 10.1001/archophthalmol.2012.1135
   Starnes AC, 2016, VISUAL NEUROSCI, V33, DOI 10.1017/S0952523815000310
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Suzuki M, 2015, RETINA-J RET VIT DIS, V35, P859, DOI 10.1097/IAE.0000000000000503
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Zacks DN, 2004, ARCH OPHTHALMOL-CHIC, V122, P406, DOI 10.1001/archopht.122.3.406
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 67
TC 83
Z9 85
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2017
VL 124
IS 5
BP 644
EP 656
DI 10.1016/j.ophtha.2016.12.034
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW3MT
UT WOS:000402402400017
PM 28153442
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Jakobsdottir, J
   Conley, YP
   Weeks, DE
   Mah, TS
   Ferrell, RE
   Gorin, MB
AF Jakobsdottir, J
   Conley, YP
   Weeks, DE
   Mah, TS
   Ferrell, RE
   Gorin, MB
TI Susceptibility genes for age-related maculopathy on chromosome 10q26
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; MACULAR DEGENERATION; GENOMEWIDE-SCAN; LINKAGE
   ANALYSIS; ASSOCIATION; PROTEINS; DRUSEN; IDENTIFICATION; EXPRESSION;
   HAPLOTYPE
AB On the basis of genomewide linkage studies of families affected with age-related maculopathy ( ARM), we previously identified a significant linkage peak on 10q26, which has been independently replicated by several groups. We performed a focused SNP genotyping study of our families and an additional control cohort. We identified a strong association signal overlying three genes, PLEKHA1, LOC387715, and PRSS11. All nonsynonymous SNPs in this critical region were genotyped, yielding a highly significant association (P <.00001) between PLEKHA1/LOC387715 and ARM. Although it is difficult to determine statistically which of these two genes is most important, SNPs in PLEKHA1 are more likely to account for the linkage signal in this region than are SNPs in LOC387715; thus, this gene and its alleles are implicated as an important risk factor for ARM. We also found weaker evidence supporting the possible involvement of the GRK5/RGS10 locus in ARM. These associations appear to be independent of the association of ARM with the Y402H allele of complement factor H, which has previously been reported as a major susceptibility factor for ARM. The combination of our analyses strongly implicates PLEKHA1/LOC387715 as primarily responsible for the evidence of linkage of ARM to the 10q26 locus and as a major contributor to ARM susceptibility. The association of either a single or a double copy of the high-risk allele within the PLEKHA1/LOC387715 locus accounts for an odds ratio of 5.0 (95% confidence interval 3.2-7.9) for ARM and a population attributable risk as high as 57%.
C1 Univ Pittsburgh, Sch Med, Dept Ophthalmol, UPMC,Eye Ctr, Pittsburgh, PA USA.
   Univ Pittsburgh, Sch Med, Dept Biostat, Pittsburgh, PA USA.
   Univ Pittsburgh, Sch Med, Dept Human Genet, Grad Sch Publ Hlth, Pittsburgh, PA USA.
   Univ Pittsburgh, Sch Med, Dept Hlth Promot & Dev, Sch Nursing, Pittsburgh, PA USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh
RP Gorin, MB (通讯作者)，Eye & Ear Inst Pittsburgh, Dept Ophthalmol, Bldg 203 Lothrop St,Room 1027, Pittsburgh, PA 15213 USA.
EM gorinmb@upmc.edu
RI Weeks, Daniel E/B-2995-2012
OI Weeks, Daniel E/0000-0001-9410-7228; Mah-Fraser,
   Tammy/0000-0003-1795-8031; Jakobsdottir, Johanna/0000-0002-8019-9683
FU NEI NIH HHS [R01EY009859, R01 EY009859] Funding Source: Medline; NHGRI
   NIH HHS [N01HG65403] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R01EY009859] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME
   RESEARCH INSTITUTE [N01HG065403] Funding Source: NIH RePORTER
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Browning SR, 2005, GENET EPIDEMIOL, V28, P110, DOI 10.1002/gepi.20051
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   De Luca A, 2004, J HISTOCHEM CYTOCHEM, V52, P1609, DOI 10.1369/jhc.4A6330.2004
   Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Fan J, 2003, NAT MED, V9, P315, DOI 10.1038/nm832
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Gudbjartsson DF, 2000, NAT GENET, V25, P12, DOI 10.1038/75514
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HARIBABU B, 1993, P NATL ACAD SCI USA, V90, P9398, DOI 10.1073/pnas.90.20.9398
   Hollborn M, 2004, CURR EYE RES, V28, P215, DOI 10.1076/ceyr.28.3.215.26250
   Huang QQ, 2004, AM J HUM GENET, V75, P1106, DOI 10.1086/426000
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kong X, 2004, AM J HUM GENET, V75, P1143, DOI 10.1086/426405
   Lange K., 2001, AM J HUM GENET S, V69, pA1886
   Li C, 2004, AM J HUM GENET, V74, P418, DOI 10.1086/381712
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Moratz C, 2004, METHOD ENZYMOL, V389, P15
   Mukhopadhyay N, 2005, BIOINFORMATICS, V21, P2556, DOI 10.1093/bioinformatics/bti364
   Mukhopadhyay N, 2004, HUM HERED, V58, P175, DOI 10.1159/000083545
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murwantoko, 2004, BIOCHEM J, V381, P895, DOI 10.1042/BJ20040435
   North BV, 2005, HUM HERED, V59, P79, DOI 10.1159/000085222
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   R Development Core Team, 2004, R LANG ENV STAT COMP
   Rinaldo A, 2005, GENET EPIDEMIOL, V28, P193, DOI 10.1002/gepi.20056
   Santangelo Susan L, 2005, Ophthalmic Genet, V26, P61, DOI 10.1080/13816810490967944
   Schaid DJ, 2002, AM J HUM GENET, V71, P992, DOI 10.1086/342666
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-18
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Shi GX, 2004, J IMMUNOL, V172, P5175, DOI 10.4049/jimmunol.172.9.5175
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 49
TC 440
Z9 470
U1 0
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD SEP
PY 2005
VL 77
IS 3
BP 389
EP 407
DI 10.1086/444437
PG 19
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 956QE
UT WOS:000231314100006
PM 16080115
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Stattin, M
   Ahmed, D
   Graf, A
   Haas, AM
   Kickinger, S
   Jacob, M
   Krepler, K
   Ansari-Shahrezaei, S
AF Stattin, Martin
   Ahmed, Daniel
   Graf, Alexandra
   Haas, Anna-Maria
   Kickinger, Stefan
   Jacob, Michael
   Krepler, Katharina
   Ansari-Shahrezaei, Siamak
TI The Effect of Treatment Discontinuation During the COVID-19 Pandemic on
   Visual Acuity in Exudative Neovascular Age-Related Macular Degeneration:
   1-Year Results
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Age-related macular degeneration; Anti-vascular endothelial growth
   factor; Coronavirus disease 2019; Intravitreal injection; Lockdown;
   Pandemic
ID EXTEND REGIMEN; RANIBIZUMAB
AB Introduction To evaluate the effect of a 9-week treatment deferral due to healthcare restrictions caused by Austria's first governmental lockdown associated with the coronavirus disease 2019 (COVID-19) pandemic on visual acuity (VA) in eyes compromised by exudative neovascular age-related macular degeneration (nAMD) after 1 year. Methods Retrospective data collection of 98 eyes (98 patients) with a treatment discontinuation at a tertiary eye care center (Clinic Landstrasse, Vienna Healthcare Group, Austria) between March 16 and May 4, 2020. Prior to the lockdown, patients received multiple intravitreal injections (IVI) of anti-vascular endothelial growth factor with a personalized treatment interval for 3 years on average and at least three IVI after the lockdown. Results When the treatment interval doubled to 117.6 +/- 31.4 days in spring 2020, patients lost 2.2 +/- 4.6 ETDRS letters (p = 0.002) on average before reinitiating therapy. In total, 4.1 +/- 8.1 letters (p < 0.0001) were lost despite continuous individual re-treatment over the course of the next year. In a univariate analysis, the extended interval time remained statistically significant (p < 0.0001), indicating a larger VA reduction within intervals with increasing interval time in days. Conclusion The short-term treatment interruption had a persistent negative impact on the VA course of eyes under therapy after 1 year. Continuous therapy independent of the underlying treatment regimen remains of utmost importance in exudative nAMD. Our data should create awareness to regulators regarding future decisions despite the global pandemic.
   Plain Language Summary Age-related macular degeneration (AMD) is the leading cause of legal blindness in developed countries. Wet AMD refers to the existence of new vessel growth in the macular, the part of the retina with the highest concentration of photoreceptors and hence the best visual acuity. The gold standard therapy of wet AMD consists of repeated injections of an antibody against new vessel formation into the eye to stabilize the disease. The sudden break of a treatment regimen for an individual person has never been investigated as it is ethically not acceptable. The coronavirus disease 2019 (COVID-19) pandemic and its associated lockdown led to an emerging situation in spring, 2020. We were forced by governmental restrictions to minimize contact with the most vulnerable patient cohort-the elderly. As an initial consequence, the Medical Retina Unit of Department of Ophthalmology (Clinic Landstrasse, Vienna Healthcare Group, Austria) postponed appointments of patients with only one eye afflicted by wet AMD. This study examined the effect of a short-term treatment deferral caused by the first national COVID-19 lockdown in eyes of patients with ongoing therapy of wet AMD in Austria. The break led to a persistent visual loss despite re-treatment, which was still evident after 1 year. Our findings provide further support for an adequate and permanent therapy of wet AMD and regard intravitreal injections as urgent standard of care. It should be taken into consideration by authorities in future pandemic planning.
C1 [Stattin, Martin; Ahmed, Daniel; Haas, Anna-Maria; Kickinger, Stefan; Jacob, Michael; Krepler, Katharina; Ansari-Shahrezaei, Siamak] Karl Landsteiner Inst Retinal Res & Imaging, Vienna, Austria.
   [Stattin, Martin; Ahmed, Daniel; Haas, Anna-Maria; Kickinger, Stefan; Krepler, Katharina; Ansari-Shahrezaei, Siamak] Vienna Healthcare Grp, Dept Ophthalmol, Clin Landstr, Med Retina Unit, Juchgasse 25, A-1030 Vienna, Austria.
   [Graf, Alexandra] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Spitalgasse 23, A-1090 Vienna, Austria.
   [Ansari-Shahrezaei, Siamak] Sigmund Freud Univ Vienna, Med Sch, Campus Prater Freudpl 3, A-1020 Vienna, Austria.
   [Ansari-Shahrezaei, Siamak] Med Univ Graz, Dept Ophthalmol, Auenbruggerpl 1, A-8036 Graz, Austria.
C3 Medical University of Vienna; Medical University of Graz
RP Ansari-Shahrezaei, S (通讯作者)，Vienna Healthcare Grp, Dept Ophthalmol, Clin Landstr, Med Retina Unit, Juchgasse 25, A-1030 Vienna, Austria.
EM martin.stattin@gesundheitsverbund.at;
   daniel.ahmed@gesundheitsverbund.at; alexandra.graf@meduniwien.ac.at;
   anna-maria.haas@gesundheitsverbund.at;
   stefan.kickinger@gesundheitsverbund.at;
   michael.jacob@gesundheitsverbund.at;
   katharina.krepler@gesundheitsverbund.at;
   siamak.ansarishahrezaei@gesundheitsverbund.at
OI Ansari Shahrezaei, Siamak/0000-0001-8032-4686; Graf,
   Alexandra/0000-0003-0035-2658
CR [Anonymous], 2020, LANCET, V395, P922, DOI 10.1016/S0140-6736(20)30644-9
   [Anonymous], IVT EP COVID 19
   [Anonymous], NEW REC URG NON PAT
   Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2621, DOI 10.1007/s00417-020-04955-7
   Borrelli E, 2020, EYE, V34, P1175, DOI 10.1038/s41433-020-0880-6
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Danyliv A, 2017, ADV THER, V34, P611, DOI 10.1007/s12325-017-0484-0
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kim JH, 2017, RETINA-J RET VIT DIS, V37, P2254, DOI 10.1097/IAE.0000000000001494
   Korobelnik JF, 2020, GRAEF ARCH CLIN EXP, V258, P1149, DOI 10.1007/s00417-020-04703-x
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Pedrosa AC, 2016, CLIN OPHTHALMOL, V10, P541, DOI 10.2147/OPTH.S90913
   Rahimzadeh M., 2021, PHYS, V6, P1, DOI [10.38192/1.6.3.10, DOI 10.38192/1.6.3.10]
   Seitzman GD, 2020, OPHTHALMOLOGY, V127, P980, DOI 10.1016/j.ophtha.2020.03.030
   Sekeroglu MA, 2022, EUR J OPHTHALMOL, V32, P1064, DOI 10.1177/11206721211010613
   Soares RR, 2020, OPHTHALMOL RETINA, V4, P134, DOI 10.1016/j.oret.2019.07.010
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Stattin M, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/8345850
   Stattin M, 2019, ACTA OPHTHALMOL, V97, pE131, DOI 10.1111/aos.13840
   Teo KYC, 2021, EYE, V35, P2793, DOI 10.1038/s41433-020-01315-x
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Viola F, 2021, RETINA-J RET VIT DIS, V41, P701, DOI 10.1097/IAE.0000000000002941
   Yang KB, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.576275
   Yeter DY, 2021, J FR OPHTALMOL, V44, P299, DOI 10.1016/j.jfo.2021.02.001
NR 29
TC 8
Z9 8
U1 2
U2 10
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD DEC
PY 2021
VL 10
IS 4
BP 935
EP 945
DI 10.1007/s40123-021-00381-y
EA AUG 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WW6GA
UT WOS:000683283900001
PM 34374028
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Huang, Q
   Xiang, Y
AF Huang, Qing
   Xiang, Yi
TI Polymorphisms in Selected Genes and Their Association with Age-Related
   Macular Degeneration in a Chinese Population
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Genetic Predisposition to Disease; Genotyping Techniques; Macular
   Degeneration; Odds Ratio; Polymorphism, Genetic
ID ENDOTHELIAL GROWTH-FACTOR; RISK-FACTORS; CX3CR1; DISEASE
AB Background: Increasing evidence shows that polymorphisms in a number of genes can influence age-related macular degeneration (AMD) risk. This study aimed to investigate the association of CX3CR1 839C/T, CX3CR1 745G/A, PLEKHA1 958A/G, VEGFA +674C/T, and VEGFA +936C/T polymorphisms with AMD risk among Chinese.
   Material/Methods: The polymorphisms were genotyped on 827 AMD patients and 827 controls, and the odds ratios (ORs) were calculated under allele, additive, recessive, and dominant genetic models. Logistic regression analysis was performed to control for potential confounders (age, sex, and smoking status).
   Results: We showed that all the 5 polymorphisms showed a significant association with AMD risk under the additive model (for homozygous mutant genotype) and at least 1 other genetic model, both before and after adjustment for the potential confounders. PLEKHA1 958A/G polymorphism was associated with a decreased AMD risk (additive model: aOR=0.722, 95% CI=0.450-0.979, P=0.019; allele model: aOR=0.883, 95% CI=0.736-0.992, P=0.014), while all other polymorphisms were associated with an increased AMD risk (CX3CR1 839C/T, additive model: aOR=2.682, 95% CI=1.119-5.709, P=0.022, recessive model: aOR=2.729, 95% CI=1.141-6.048, P=0.010; CX3CR1 745G/A, additive model: aOR=2.614, 95% CI=1.231-6.012, P=0.020, recessive model: aOR=2.340, 95% CI=1.227-5.993, P=0.011; VEGFA +674C/T, additive model: aOR=1.601, 95% CI=1.253-2.179, P<0.001, dominant model: aOR=1.287, 95% CI=1.058-1.570, P<0.001, allele model: OR=1.220, 95% CI=1.118-1.427, P<0.001; VEGFA +936C/T, additive model: aOR=1.509, 95% CI=1.105-2.311, P<0.001, recessive model: aOR=1.432, 95% CI=1.027-2.192, P=0.009, dominant model: aOR=1.207, 95% CI=1.031-1.514, P0.001, allele model: aOR=1.216, 95% CI=1.062-1.408, P<0.001).
   Conclusions: We conclude that the 5 polymorphisms could serve as biomarkers for AMD susceptibility.
C1 [Huang, Qing; Xiang, Yi] Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Dept Ophthalmol, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology
RP Xiang, Y (通讯作者)，Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Dept Ophthalmol, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
EM xiangyi145@hotmail.com
CR Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Gaunt TR, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-428
   Gupta D, 2014, ARCH MED RES, V45, P489, DOI 10.1016/j.arcmed.2014.07.005
   Horie-Inoue K, 2014, BIOCHEM BIOPH RES CO, V452, P263, DOI 10.1016/j.bbrc.2014.08.013
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jiang YM, 2013, J INT MED RES, V41, P317, DOI 10.1177/0300060513475570
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Leveziel N, 2007, MOL VIS, V13, P2153
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Ma BF, 2015, INT J CLIN EXP PATHO, V8, P9592
   Moatti D, 2001, BLOOD, V97, P1925, DOI 10.1182/blood.V97.7.1925
   Qu Y, 2011, OPHTHALMIC RES, V45, P142, DOI 10.1159/000319543
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
   Yu WH, 2013, MOL BIOL REP, V40, P5551, DOI 10.1007/s11033-013-2656-6
   Zampros I, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/319728
NR 20
TC 3
Z9 3
U1 0
U2 5
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD MAR 22
PY 2018
VL 24
BP 1693
EP 1700
DI 10.12659/MSM.906298
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GA2WR
UT WOS:000428188000002
PM 29565837
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Liutkeviciene, R
   Vilkeviciute, A
   Streleckiene, G
   Kriauciuniene, L
   Chaleckis, R
   Deltuva, VP
AF Liutkeviciene, Rasa
   Vilkeviciute, Alvita
   Streleckiene, Greta
   Kriauciuniene, Loresa
   Chaleckis, Romanas
   Deltuva, Vytenis Pranas
TI Associations of cholesteryl ester transfer protein (CETP) gene variants
   with predisposition to age-related macular degeneration
SO GENE
LA English
DT Article
DE Age-related macular degeneration; CETP (rs5882 rs708272 rs3764261
   rs1800775 rs2303790); Gene polymorphism
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; RISK-FACTORS; CARDIOVASCULAR-DISEASE;
   POLYMORPHISMS; PREVALENCE; EYE; METAANALYSIS; HYPERTENSION; MACULOPATHY;
   POPULATION
AB Purpose: To determine the frequency of the genotypes of single nucleotide polymorphisms (SNPs) in the gene encoding cholesteryl ester transfer protein (CETP) and their associations with age-related macular degeneration (AMD) in the Lithuanian population.
   Study design: A total of 1264 subjects were examined: 251 patients with early AMD, 206 patients with exudative AMD, and 807 healthy controls.
   Methods: The genotyping of CETP (rs5882, rs708272, rs3764261, rs1800775, rs2303790) was carried out using the RT-PCR.
   Results: Binomial logistic regression analysis revealed that each copy of rs5882 allele A was associated with a 1.3-fold increased risk of exudative AMD (p = 0.046). The G/A and A/A genotypes of the rs708272 polymorphism were associated with 1.5-fold and 1.7-fold increased risks of exudative AMD (p = 0.049 and p = 0.021, respectively). Combination of two genotypes (G/A + A/A) under the dominant model were associated with a 1.5-fold increased risk of exudative AMD (p = 0.021).
   Analysis of rs708272 revealed that the G/A and A/A genotypes under the co-dominant model were associated with 1.5-fold and 1.7-fold increased risks of exudative AMD, respectively (OR = 1.450, 95% CI = 1.002-2.098; p = 0.049 and OR = 1.710, 95% CI = 1.064-2.156; p = 0.021, respectively). Both genotypes (G/A + A/A) under the dominant model were associated with the 1.5-fold increased risk of exudative AMD, as well (OR = 1.514, 95% CI = 1.064-2.156; p = 0.021) and each additional copy A allele was associated with a 1.3 fold increased risk of exudative AMD (OR = 1.316, 95% CI = 1.051-1.646; p = 0.016). The rs3764261 polymorphism was identified to be protective: the C/A genotype and the combination of two genotypes (C/A + A/A) were associated with 1.8-fold and 1.5-fold decreased risks of exudative AMD (p = 0.001 and p = 0.015, respectively).
   Conclusion: Our study identified two polymorphisms with a higher risk of AMD development (rs5882 and rs708272) and a protective polymorphism for AMD (rs3764261).
C1 [Liutkeviciene, Rasa; Kriauciuniene, Loresa] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, LT-50161 Kaunas, Lithuania.
   [Liutkeviciene, Rasa; Vilkeviciute, Alvita; Streleckiene, Greta; Kriauciuniene, Loresa; Deltuva, Vytenis Pranas] Lithuanian Univ Hlth Sci, Neurosci Inst, Med Acad, Eiveniu 2, LT-50161 Kaunas, Lithuania.
   [Chaleckis, Romanas] Gunma Univ, Initiat Adv Res, Maebashi, Gunma 3718512, Japan.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences; Gunma University
RP Liutkeviciene, R (通讯作者)，Dept Ophthalmol, Eiveniu 2, Kaunas, Lithuania.
EM rasa.liutkeviciene@kaunoklinikos.lt
RI Chaleckis, Romanas/K-2629-2014
OI Chaleckis, Romanas/0000-0001-8042-1005; Varkalaite,
   Greta/0000-0003-3488-2171
FU Research Council of Lithuania [SEN-11/2015]
FX This work was funded by a grant (No. SEN-11/2015) from the Research
   Council of Lithuania.
CR [Anonymous], 2011, AM J OPHTHALMOL, V132, P668
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P400, DOI [10.1111/j.1600-0420.2005.00474.x, 10.1111/j.1600-0420.2005.thesis.x]
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Cerman E, 2015, TURK J MED SCI, V45, P1004, DOI 10.3906/sag-1406-146
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen JJ, 2014, DNA CELL BIOL, V33, P807, DOI 10.1089/dna.2013.2265
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cougnard-Gregoire A., 2015, PLOS ONE, V9
   Cougnard-Gregoire A., 2015, SCI REP, V5
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Meng QY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143924
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Neverauskiene J., 2003, INT J OPHTHALMOL-CHI, V3, P225
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Ulas F, 2013, INT OPHTHALMOL, V33, P485, DOI 10.1007/s10792-013-9728-4
   Wang D, 2015, OPHTHALMIC GENET, V36, P303, DOI 10.3109/13816810.2014.881506
   Wang JH, 2011, HEART, V97, P1542, DOI 10.1136/heartjnl-2011-300342
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep15711
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 32
TC 14
Z9 15
U1 0
U2 22
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD DEC 15
PY 2017
VL 636
BP 30
EP 35
DI 10.1016/j.gene.2017.09.022
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA FL3HP
UT WOS:000414113800004
PM 28918250
DA 2022-11-30
ER

PT J
AU Shah, N
   Maguire, MG
   Martin, DF
   Shaffer, J
   Ying, GS
   Grunwald, JE
   Toth, CA
   Jaffe, GJ
   Daniel, E
AF Shah, Neepa
   Maguire, Maureen G.
   Martin, Daniel F.
   Shaffer, James
   Ying, Gui-Shuang
   Grunwald, Juan E.
   Toth, Cynthia A.
   Jaffe, Glenn J.
   Daniel, Ebenezer
CA Comparison Age-Related Macular Deg
TI Angiographic Cystoid Macular Edema and Outcomes in the Comparison of
   Age-Related Macular Degeneration Treatments Trials
SO OPHTHALMOLOGY
LA English
DT Article
AB Purpose: To describe morphologic and visual outcomes in eyes with angiographic cystoid macular edema (CME) treated with ranibizumab or bevacizumab for neovascular age-related macular degeneration (nAMD).
   Design: Prospective cohort study within a randomized clinical trial.
   Participants: A total of 1185 CATT study subjects.
   Methods: Baseline fluorescein angiography (FA) images of all CATT study eyes were evaluated for CME. Grading of other characteristics on optical coherence tomography (OCT) and photographic images at baseline and during 2-year follow-up was completed by readers at the CATT Reading Centers. Three groups were created on the basis of baseline CME and intraretinal fluid (IRF) status: (1) CME, (2) IRF without CME, (3) neither CME nor IRF.
   Main Outcome Measures: Visual acuity (VA) and total central retinal thickness (CRT) on OCT at baseline, year 1, and 2.
   Results: Among 1131 participants with images of sufficient quality for determining CME and IRF at baseline, 92 (8.1%) had CME, 766 (67.7%) had IRF without CME, and 273 (24.1%) had neither. At baseline, eyes with CME had worse mean VA (letters) than eyes with IRF without CME and eyes with neither CME nor IRF (52 vs. 60 vs. 66 letters, P < 0.001); higher mean total CRT (mm) on OCT (514 vs. 472 vs. 404, P < 0.001); and greater hemorrhage, retinal angiomatous proliferation (RAP) lesions, and classic choroidal neovascularization (CNV). All groups showed improvement in VA at follow-up; however, the CME group started and ended with the worst VA among the 3 groups. Central retinal thickness, although higher at baseline for the CME group, was similar at 1 and 2 years follow-up for all groups. More eyes with CME (65.3%) developed scarring during 2 years of follow-up compared with eyes with IRF without CME (43.8%) and eyes with neither CME nor IRF (32.5%; P < 0.001).
   Conclusions: In CATT, eyes with CME had worse baseline and follow-up VA, although all groups showed similar rates of improvement in VA during 2 years of follow-up. Cystoid macular edema seems to be a marker for poorer visual outcomes in nAMD because of underlying baseline retinal dysfunction and subsequent scarring. (C) 2016 by the American Academy of Ophthalmology.
C1 [Shah, Neepa; Maguire, Maureen G.; Shaffer, James; Ying, Gui-Shuang; Grunwald, Juan E.; Daniel, Ebenezer] Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Toth, Cynthia A.; Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Cleveland Clinic
   Foundation; Duke University
RP Shah, N (通讯作者)，Presbyterian Med Ctr, Scheie Eye Inst, 51 N 39th St, Philadelphia, PA 19104 USA.
EM neepa.shah@uphs.upenn.edu
RI Toth, Cynthia/L-5534-2019; Ciulla, Thomas/AAA-1299-2020
OI Toth, Cynthia/0000-0002-2324-0854; Ciulla, Thomas/0000-0001-5557-6777;
   Vavvas, Demetrios/0000-0002-8622-6478; Folk, James/0000-0002-6271-2906;
   Losordo, Douglas/0000-0002-6857-7506
FU Genentech; Bioptigen; National Eye Institute, National Institutes of
   Health, Department of Health and Human Services [R21EY023689,
   U10EY017823, U10EY017825, U10EY017826, U10EY017828]; NATIONAL EYE
   INSTITUTE [U10EY017825, U10EY017826, U10EY017823, U10EY017828,
   R21EY023689] Funding Source: NIH RePORTER
FX Supported by grants R21EY023689, U10EY017823, U10EY017825, U10EY017826,
   and U10EY017828 from the National Eye Institute, National Institutes of
   Health, Department of Health and Human Services.
CR BRESSLER SB, 1983, RETINA-J RET VIT DIS, V3, P7, DOI 10.1097/00006982-198300310-00002
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   GASS JDM, 1993, RETINA AND VITREOUS, P295
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Jaffe G, 2006, RETINAL IMAGING, V18, P206
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Jampol LM, 1994, RETINA, V2, P999
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Quinn C J, 1996, Optom Clin, V5, P111
   Ritter M, 2014, BR J OPHTHALMOL, V0, P1
   WILLIAMS TD, 1992, OPTOMETRY VISION SCI, V69, P369, DOI 10.1097/00006324-199205000-00006
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 14
TC 11
Z9 11
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2016
VL 123
IS 4
BP 858
EP 864
DI 10.1016/j.ophtha.2015.11.030
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DH3WU
UT WOS:000372718300030
PM 26778329
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Liisborg, C
   Nielsen, MK
   Hasselbalch, HC
   Sorensen, TL
AF Liisborg, Charlotte
   Nielsen, Marie Krogh
   Hasselbalch, Hans Carl
   Sorensen, Torben Lykke
TI Patients with myeloproliferative neoplasms and high levels of systemic
   inflammation develop age-related macular degeneration
SO ECLINICALMEDICINE
LA English
DT Article
DE Age-related macular degeneration; Myeloproliferative neoplasms; Drusen;
   Inflammation; Neutrophil-to-lymphocyte ratio
ID ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; OXIDATIVE STRESS; POOLED
   FINDINGS; RISK-FACTORS; PREVALENCE; DISEASE; MACULOPATHY; DRUSEN;
   PERSPECTIVES
AB Background: Epidemiological data show that myeloproliferative neoplasms (MPNs) are associated with increased risk of neovascular age-related macular degeneration (AMD). However, knowledge about the retinal findings in these patients is lacking. This study was conducted to examine retinal ageing and the prevalence of a hallmark of AMD; drusen, in patients with MPNs. Further, we examine the role of chronic systemic inflammation, considered central in both AMD and MPNs.
   Methods: In this single-centre cross-sectional study, we consecutively enrolled 200 patients with MPNs. The study was divided into three substudies. Firstly, we obtained colour fundus photographs from all patients to evaluate and compare the prevalence of drusen with the published estimates from three large population-based studies. Secondly, to evaluate age-related changes in the various retinal layers, optical coherence tomography images were obtained from 150 of the patients and compared to a healthy control group, from a previous study. Thirdly, venous blood was sampled from 63 patients to determine the JAK2V617F allele burden and neutrophil-to-lymphocyte ratio (NLR), a marker of systemic inflammation, in MPN patients with and without drusen.
   Findings: Patients with MPNs had an increased risk of having large drusen compared to the three population-based studies OR 5.7 (95%CI, 41-8.0), OR 6.0 (95%CI, 42-8.4) and OR 7.0 (95%CI, 5.0-9.7). Also, we found that the retinal site of drusen accumulation - the Bruch's-membrane-retinal-pigment-epithelium-complex was thicker compared to healthy controls, 0.43 mu m (95%CI 0.17-0.71, p = 0.0014), but there was no sign of accelerated retinal ageing in terms of thinning of the neuroretina. Further, we found that MPN patients with drusen had a higher level of systemic inflammation than MPN patients with no drusen (p = 0.0383).
   Interpretation: Patients with MPNs suffer from accelerated accumulation of subretinal drusen and therefore AMD from an earlier age than healthy individuals. We find that the retinal changes are located only between the neuroretina and the choroidal bloodstream. Further, we find that the drusen accumulation is associated with a higher JAK2V617F allele burden and a higher NLR, suggesting that low-grade chronic inflammation is a part of the pathogenesis of drusen formation and AMD. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Liisborg, Charlotte; Nielsen, Marie Krogh; Sorensen, Torben Lykke] Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Liisborg, Charlotte; Hasselbalch, Hans Carl; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark.
   [Hasselbalch, Hans Carl] Zealand Univ Hosp, Dept Haematol, Vestermarksvej 15-17, DK-4000 Roskilde, Denmark.
C3 University of Copenhagen
RP Liisborg, C (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM liisborg@c.dk
OI Liisborg, Charlotte/0000-0002-6353-6027
FU Fight for Sight, Denmark; Region Zealand
FX The first author would like to thank "Fight for Sight, Denmark" and
   Region Zealand for funding her PhD. Further, we thank Grace Hambelton,
   Bowdoin College, Brunswick, Maine, United States for assistance in OCT
   image evaluation.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Andersen M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183620
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Bak M, 2017, JAMA OPHTHALMOL, V135, P835, DOI 10.1001/jamaophthalmol.2017.2011
   Barbui T, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0054-y
   Brady T., REV QUICK GUIDE COMM
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108196
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Curcio CA, 2017, JAMA OPHTHALMOL, V135, P843, DOI 10.1001/jamaophthalmol.2017.2008
   Ellis-Behnke Rutledge G, 2013, J Glaucoma, V22 Suppl 5, pS32, DOI 10.1097/IJG.0b013e3182934aca
   Fernandez-Robredo P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01862
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Geyer HL, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/284706
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Harris J, 2017, PATHOBIOL AGING AGE, V7, DOI 10.1080/20010001.2017.1398016
   Hasselbalch HC, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/102476
   Hasselbalch HC, 2015, EUR J HAEMATOL, V94, P96, DOI 10.1111/ejh.12437
   Hasselbalch HC, 2012, BLOOD, V119, P3219, DOI 10.1182/blood-2011-11-394775
   Hermouet S, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/145293
   Hultcrantz M, 2012, J CLIN ONCOL, V30, P2995, DOI 10.1200/JCO.2012.42.1925
   Jabs DA, 2015, AM J OPHTHALMOL, V159, P1115, DOI 10.1016/j.ajo.2015.01.037
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Lussana F, 2017, J AUTOIMMUN, V85, P58, DOI 10.1016/j.jaut.2017.06.010
   Lussana F, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0425-z
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Niazi S, 2019, ACTA OPHTHALMOL, V97, P558, DOI 10.1111/aos.14072
   Nielsen MK, 2019, CLIN EXP OPHTHALMOL, V47, P69, DOI 10.1111/ceo.13362
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Qin BD, 2016, MOD RHEUMATOL, V26, P372, DOI 10.3109/14397595.2015.1091136
   Rashid K, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00176
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Schnabolk G, 2019, ADV EXP MED BIOL, V1185, P27, DOI 10.1007/978-3-030-27378-1_5
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spivak JL, 2017, NEW ENGL J MED, V376, P2168, DOI 10.1056/NEJMra1406186
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118086
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 62
TC 5
Z9 5
U1 1
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2589-5370
J9 ECLINICALMEDICINE
JI EClinicalMedicine
PD SEP
PY 2020
VL 26
AR 100526
DI 10.1016/j.eclinm.2020.100526
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA RV5ZK
UT WOS:000645910400032
PM 33089124
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lee, KY
   Vithana, EN
   Mathur, R
   Yong, VH
   Yeo, IY
   Thalamuthu, A
   Lee, MW
   Koh, AH
   Lim, MC
   How, AC
   Wong, DW
   Aung, T
AF Lee, Kelvin Y.
   Vithana, Eranga N.
   Mathur, Ranjana
   Yong, Victor H.
   Yeo, Ian Y.
   Thalamuthu, Anbupalam
   Lee, Mun-Wai
   Koh, Adrian H.
   Lim, Marcus C.
   How, Alicia C.
   Wong, Doric W.
   Aung, Tin
TI Association analysis of CFH, C2, BF, and HTRA1 gene polymorphisms in
   chinese patients with polypoidal choroidal Vasculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; MACULAR DEGENERATION; PROMOTER POLYMORPHISM;
   VARIANT; RISK; HAPLOTYPE; JAPANESE; SUSCEPTIBILITY; INCREASES
AB PURPOSE. Polypoidal choroidal vasculopathy (PCV) is a major cause of serosanguinous maculopathy in Chinese patients with age-related macular degeneration (AMD). Variants in the CFH and HTRA1/LOC387715 genes are strongly associated with AMD in Caucasians and Chinese. Variants in the C2 and BF genes have been found to confer a significantly reduced risk of AMD. This study was undertaken to determine whether these associations occur in Chinese patients with PCV.
   METHODS. Patients of Chinese ethnicity with clinically and angiographically diagnosed PCV and normal control subjects were recruited from the Singapore National Eye Centre. Five single-nucleotide polymorphisms (SNPs) in the CFH gene, two each within the C2 and BF genes and two variants located in the LOC387715 and HTRA1 genes, were screened in all patients and control subjects.
   RESULTS. Seventy-two patients with PCV and 93 normal control subjects were studied. A significant association was noted with CFH variants rs3753394 and rs800292 among the PCV cases (P = 0.0015 and P = 0.0045, respectively). Individuals homozygous for the TT genotype of rs3753394 had a significantly higher risk (P = 0.0076) of PCV (OR = 4.29; 95% CI: 1.47-12.50) than those carrying a single copy of the T allele (P = 0.3210; OR = 1.69; 95% CI: 0.60-4.78), after adjustment for such risk factors as age and sex. The genotype frequencies of rs11200638 and rs10490924 in HTRA1 and LOC387715, respectively, were also found to be significantly different between patients with PCV and normal control subjects (P = 0.00032 and P = 0.003, respectively). The AA genotype of rs11200638 and TT genotype of rs10490924 conferred a 4.9-fold (95% CI: 1.85-12.95) and 4.89-fold (95% CI: 1.85-12.90) increased risk of PCV, respectively, after adjustment for age and sex. The Y402H variant of CFH (rs1061170) and the BF and C2 variants were not significantly different in patients and normal control subjects.
   CONCLUSIONS. The SNPs rs3753394 and rs800292 of CFH and rs11200638 of HTRA1 are significantly associated with the risk of PCV in Chinese patients.
C1 [Lee, Kelvin Y.; Mathur, Ranjana; Yeo, Ian Y.; Lee, Mun-Wai; Koh, Adrian H.; Lim, Marcus C.; How, Alicia C.; Wong, Doric W.; Aung, Tin] Singapore Natl Eye Ctr, Singapore 168751, Singapore.
   [Lee, Kelvin Y.; Vithana, Eranga N.; Yong, Victor H.; Lim, Marcus C.; How, Alicia C.; Aung, Tin] Singapore Eye Res Inst, Singapore, Singapore.
   [Thalamuthu, Anbupalam] Genome Inst Singapore, Singapore, Singapore.
   [Aung, Tin] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117595, Singapore.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; Agency for Science Technology & Research
   (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National
   University of Singapore
RP Aung, T (通讯作者)，Singapore Natl Eye Ctr, 11 3rd Hosp Ave, Singapore 168751, Singapore.
EM tin11@pacific.net.sg
RI Thalamuthu, Anbupalam/Z-5545-2019
OI Thalamuthu, Anbupalam/0000-0002-7114-1260; Wong,
   Damon/0000-0003-4601-9121
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Chen LJ, 2006, MOL VIS, V12, P1536
   Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Issa PC, 2005, OPHTHALMOLOGE, V102, P1036, DOI 10.1007/s00347-005-1269-4
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MESANOBU U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Purcell S, 2007, BIOINFORMATICS, V23, P255, DOI 10.1093/bioinformatics/btl580
   R Development Core Team, 2007, R LANG ENV STAT COMP
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yoshida T, 2007, MOL VIS, V13, P545
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 35
TC 95
Z9 103
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2008
VL 49
IS 6
BP 2613
EP 2619
DI 10.1167/iovs.07-0860
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 307GG
UT WOS:000256306800043
PM 18515590
DA 2022-11-30
ER

PT J
AU Gao, L
   Tao, Y
   Liu, M
   Li, LL
   Zhang, P
   Wang, H
   Zhang, LN
AF Gao, Lei
   Tao, Yuan
   Liu, Min
   Li, Linlin
   Zhang, Peng
   Wang, Hong
   Zhang, Linna
TI Different conbercept injection strategies for the treatment of exudative
   age-related macular degeneration: A retrospective cohort study
SO MEDICINE
LA English
DT Article
DE best-corrected visual acuity; central retinal thickness; conbercept;
   exudative age-related macular degeneration; retrospective cohort study
ID RANIBIZUMAB; PREVALENCE; SAFETY; VEGF; BEVACIZUMAB; AFLIBERCEPT;
   EFFICACY; THERAPY; ATROPHY; TRIAL
AB Conbercept is a novel anti-vascular endothelial growth factor for the treatment of age-related macular degeneration (AMD). The most optimal injection strategy is unknown. To assess the effectiveness of intravitreal injection of conbercept using the 3 + pro re nata (PRN) and 3 + Q3M strategies for the treatment of exudative AMD.From January 2015 to January 2018, patients confirmed with exudative AMD at Qilu Hospital of Shandong University were included in this retrospective study. Intravitreal injection of 0.5mg of conbercept was conducted either with the 3 + PRN or 3 + Q3M strategy. Best-corrected visual acuity (BCVA), intraocular pressure, and optical coherence tomography were conducted at 1 and 2 weeks, then every month. fundus fluorescein angiography examination was conducted every 3 months.There were 106 eyes from 106 patients. The number of follow-ups (3 + Q3M: 12.41.3 vs 3 + PRN: 12.9 +/- 1.6, P=.079) and the follow-up time (3 + Q3M: 12.7 +/- 0.6 vs 3 + PRN: 12.5 +/- 0.7 months, P=.121) were similar in the 2 groups. The number of injections was less in 3 + PRN than 3 + Q3M (5.3 +/- 1.0 vs 6.0 +/- 0.0, P<.001) The BCVA at months 7 and 9 to 12 in the 3 + Q3M (n=51) group were lower than for 3 + PRN (n=55) (all P<.05). The CRT at months 9 to 12 in the 3 + Q3M group was lower than in the 3 + PRN group (all P<.05). There were no differences between the 2 groups regarding the exudation area during follow-up. No serious treatment-related ocular complications or serious systemic adverse events were found.The 3 + PRN and 3 + Q3M strategies of intravitreal injection of conbercept are effective in treating exudative AMD. The 3 + Q3M strategy needs more injection but is more effective in increasing visual acuity and reducing macular CRT than the 3 + PRN strategy.
C1 [Gao, Lei; Wang, Hong; Zhang, Linna] Shandong Univ, Qilu Hosp, Dept Ophthalmol, Jinan 250011, Shandong, Peoples R China.
   [Gao, Lei; Tao, Yuan; Zhang, Peng] Jinan 2 Peoples Hosp, Dept Ophthalmol, Jinan 251600, Shandong, Peoples R China.
   [Liu, Min] Jinan Lixia Dist Peoples Hosp, Dept Ophthalmol, Jinan 251600, Shandong, Peoples R China.
   [Li, Linlin] Jinan Shanghe Cty Peoples Hosp, Dept Ophthalmol, Jinan 251600, Shandong, Peoples R China.
C3 Shandong University
RP Wang, H; Zhang, LN (通讯作者)，Shandong Univ, Qilu Hosp, Dept Ophthalmol, Jinan 250011, Shandong, Peoples R China.
EM redbaby@sdu.edu.cn; linnazhang62@yahoo.com
RI ZHANG, LIN/GYD-9123-2022
CR Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   CHAKRAVARTHY U, 2010, BMJ-BRIT MED J, V340, DOI DOI 10.1136/BMJ.C981
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jin GM, 2018, BRIT J OPHTHALMOL, V102, P625, DOI 10.1136/bjophthalmol-2017-310368
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Lee PP, 2003, ARCH OPHTHALMOL-CHIC, V121, P1303, DOI 10.1001/archopht.121.9.1303
   Li H, 2012, EXP EYE RES, V97, P154, DOI 10.1016/j.exer.2011.09.002
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Song PG, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020703
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Ueta T, 2014, OPHTHALMOLOGY, V121, P2193, DOI 10.1016/j.ophtha.2014.05.022
   Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070544
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Wu ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057642
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
NR 30
TC 5
Z9 5
U1 4
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD FEB
PY 2020
VL 99
IS 7
AR e19007
DI 10.1097/MD.0000000000019007
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA LD2KP
UT WOS:000525861300021
PM 32049795
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Dilokthornsakul, P
   Chaiyakunapruk, N
   Ruamviboonsuk, P
   Ratanasukon, M
   Ausayakhun, S
   Tungsomeroengwong, A
   Pokawattana, N
   Chanatittarat, C
AF Dilokthornsakul, Piyameth
   Chaiyakunapruk, Nathorn
   Ruamviboonsuk, Paisan
   Ratanasukon, Mansing
   Ausayakhun, Somsanguan
   Tungsomeroengwong, Akrapope
   Pokawattana, Nattapol
   Chanatittarat, Chalakorn
TI Health resource utilization and the economic burden of patients with wet
   age-related macular degeneration in Thailand
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; health resource utilization; costs;
   Thailand
ID VISUAL IMPAIRMENT; PREVALENCE; POPULATION; ASSOCIATION; MACULOPATHY;
   COHORT; COSTS
AB AIM: To determine healthcare resource utilization and the economic burden associated with wet age -related macular degeneration (AMD) in Thailand
   METHODS: This study included patients diagnosed with wet AMD that were 60 years old or older, and had best corrected visual acuity (BCVA) measured at least two times during the follow -up period. We excluded patients having other eye diseases. Two separate sub-studies were conducted. The first sub -study was a retrospective cohort study; electronic medical charts were reviewed to estimate the direct medical costs. The second sub -study was a cross -sectional survey estimating the direct non-medical costs based on face-to-face interviews using a structured questionnaire. For the first sub -study, direct medical costs, including the cost of drugs, laboratory, procedures, and other treatments were obtained. For the second sub -study, direct non -medical costs, e.g. transportation, food, accessories, home renovation, and caregiver costs, were obtained from face-to-face interviews with patients and/or caregivers.
   RESULTS: For the first sub-study, sixty-four medical records were reviewed. The annual average number of medical visits was 11.1 +/- 6.0. The average direct medical costs were $3 604 +/- 4 530 per year. No statistically significant differences of the average direct medical costs among the BCVA groups were detected (P=0.98). Drug costs accounted for 77% of total direct medical costs. For direct non-medical costs, 67 patients were included. Forty-eight patients (71.6%) required the accompaniment of a person during the out -patient visit. Seventeen patients (25.4%) required a caregiver at home. The average direct non-medical cost was $2 927 +/- 6 560 per year. There were no statistically-significant differences in the average costs among the BCVA groups (P =0.74). Care-giver cost accounted for 87% of direct non-medical costs.
   CONCLUSION: Our study indicates that wet AMD is associated with a substantial economic burden, especially concerning drug and care-giver costs.
C1 [Dilokthornsakul, Piyameth; Chaiyakunapruk, Nathorn] Naresuan Univ, Fac Pharmaceut Sci, Dept Pharm Practice, Ctr Pharmaceut Outcomes Res, Phitsanulok 65000, Thailand.
   [Chaiyakunapruk, Nathorn] Monash Univ Malaysia, Discipline Pharm, Selangor 46150, Malaysia.
   [Chaiyakunapruk, Nathorn] Univ Queensland, Sch Populat Hlth, Brisbane, Qld 4072, Australia.
   [Chaiyakunapruk, Nathorn] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA.
   [Ruamviboonsuk, Paisan; Tungsomeroengwong, Akrapope; Pokawattana, Nattapol] Rajavithi Hosp, Dept Ophthalmol, Bangkok 10400, Thailand.
   [Ratanasukon, Mansing] Prince Songkla Univ, Fac Med, Dept Ophthalmol, Hat Yai 90110, Thailand.
   [Ausayakhun, Somsanguan] Chiang Mai Univ, Dept Ophthalmol, Fac Med, Chiangmai 50200, Thailand.
   [Chanatittarat, Chalakorn] Novartis Thailand Ltd, Bangkok 10110, Thailand.
C3 Naresuan University; Monash University; Monash University Sunway;
   University of Queensland; University of Wisconsin System; University of
   Wisconsin Madison; Rajavithi Hospital; Prince of Songkla University;
   Chiang Mai University
RP Chaiyakunapruk, N (通讯作者)，Monash Univ Malaysia, Discipline Pharm, Jalan Lagoo Selatan, Bandar Sunway 46150, Selangor, Malaysia.
EM nathorn.chaiyakunapruk@monash.edu
FU Novartis (Thailand) Ltd.; Thailand Research Fund through the Royal
   Golden Jubilee Ph.D. Program [PHD/0356/2550]
FX Foundation: Supported by Novartis (Thailand) Ltd.; Thailand Research
   Fund through the Royal Golden Jubilee Ph.D. Program (grant No.
   PHD/0356/2550 to PD).
CR Bandello F, 2008, DRUG AGING, V25, P255, DOI 10.2165/00002512-200825030-00007
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Dickinson AJ, 1997, EYE, V11, P301, DOI 10.1038/eye.1997.66
   Faramnuayphol P, 2007, HLTH SERVICES SYSTEM
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Javitt JC, 2007, OPHTHALMOLOGY, V114, P238, DOI 10.1016/j.ophtha.2006.07.054
   Jenchitr W, 2011, OPHTHAL EPIDEMIOL, V18, P48, DOI 10.3109/09286586.2010.545502
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Santoso B, 1997, HLTH EC DRUGS DAP SE
   Schmier JK, 2006, RETINA-J RET VIT DIS, V26, P1056, DOI 10.1097/01.iae.0000254890.48272.5a
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   United Nations Population Division, WORLD POP PROSP 2008
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
NR 22
TC 8
Z9 9
U1 0
U2 10
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD FEB 18
PY 2014
VL 7
IS 1
BP 145
EP 151
DI 10.3980/j.issn.2222-3959.2014.01.27
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AB0QS
UT WOS:000331497800027
PM 24634881
DA 2022-11-30
ER

PT J
AU Anderson, DH
   Talaga, KC
   Rivest, AJ
   Barron, E
   Hageman, GS
   Johnson, LV
AF Anderson, DH
   Talaga, KC
   Rivest, AJ
   Barron, E
   Hageman, GS
   Johnson, LV
TI Characterization of beta amyloid assemblies in drusen: the deposits
   associated with aging and age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; Alzheimer's disease; Bruch's membrane
ID RAPID CELLULAR DEGENERATION; ATOMIC-FORCE MICROSCOPY;
   ALZHEIMERS-DISEASE; CHOROID-PLEXUS; APOLIPOPROTEIN-E; BRUCHS MEMBRANE;
   COMPLEMENT ACTIVATION; RETINAL PATHOLOGY; OCULAR DRUSEN; HUMAN KIDNEY
AB Purpose. Recent studies strongly suggest that drusen, the extracellular deposits associated with age-related macular degeneration (AMD), are a manifestation of local inflammatory events. New evidence indicates that substructural elements within drusen contain activated complement components as well as amyloid beta (Abeta), a major pro-inflammatory component of Alzheimer's disease plaques. We characterized the ultrastructural organization and histochemical staining properties of these Abeta-containing elements in order to further assess their significance in drusen formation and AMD pathogenesis.
   Methods. We used differential interference contrast optics, laser scanning confocal immunofluorescence, and immunogold electron microscopy to characterize the structural properties and molecular composition of Abeta-containing elements in drusen. We obtained estimates of their frequency from montages of electron micrographs gathered from 152 human donor eyes ranging from 9 to 91 years of age.
   Results. Spherical Abeta-containing elements, which are typically organized as concentric ring-like structures, are common substructural components of drusen. They stain with thioflavin T, but are not stained by Congo red; nor do they bind cationic, lipophilic, or nucleic acid-binding fluorescent dyes. Ultrastructurally, they are composed of a central core, one or more concentric inner rings with intervening electron lucent layers, and an electron dense outer shell. Immunogold labeling indicates that most Abeta immunoreactivity is associated with the outer layers that consist of densely-packed spherical subunits. No longitudinally-oriented fibril arrays, characteristic of aggregated amyloid fibrils in the brain, are evident. Other prominent drusen-associated proteins including the terminal complement complex C5b-9, vitronectin, apolipoprotein E, serum amyloid P component, and ubiquitin are excluded from the spheres.
   Conclusions. These structures embedded in drusen appear to represent a new type of macromolecular assembly that contains Abeta as well as activated complement components. The presence of Abeta in these extracellular deposits is an additional indication that some of the pathogenic pathways that give rise to drusen and AMD may be shared with other neurodegenerative diseases characterized by misfolded protein deposition and aggregation. (C) 2003 Elsevier Ltd. All rights reserved.
C1 Univ Calif Santa Barbara, Ctr Study Macular Degenerat, Neurosci Res Inst, Santa Barbara, CA 93106 USA.
   Univ So Calif, Doheny Eye Inst, Los Angeles, CA USA.
   Univ Iowa, Ctr Macular Degenerat, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
C3 University of California System; University of California Santa Barbara;
   Doheny Eye Institute; University of Southern California; University of
   Iowa
RP Anderson, DH (通讯作者)，Univ Calif Santa Barbara, Ctr Study Macular Degenerat, Neurosci Res Inst, Santa Barbara, CA 93106 USA.
EM d_anders@lifesci.ucsb.edu
FU NATIONAL EYE INSTITUTE [R01EY011521, R01EY011527, R01EY011515] Funding
   Source: NIH RePORTER; NEI NIH HHS [EY11515, EY11527, EY11521] Funding
   Source: Medline
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Bhatia R, 2000, FASEB J, V14, P1233, DOI 10.1096/fasebj.14.9.1233
   Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699
   BLANKS JC, 1989, BRAIN RES, V501, P364, DOI 10.1016/0006-8993(89)90653-7
   Blanks JC, 1996, NEUROBIOL AGING, V17, P377, DOI 10.1016/0197-4580(96)00010-3
   Blanks JC, 1996, NEUROBIOL AGING, V17, P385, DOI 10.1016/0197-4580(96)00009-7
   BLANKS JC, 1991, ANN NY ACAD SCI, V640, P44
   Calero M, 2000, MICROSC RES TECHNIQ, V50, P305, DOI 10.1002/1097-0029(20000815)50:4<305::AID-JEMT10>3.3.CO;2-C
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dentchev T, 2003, MOL VIS, V9, P184
   Dickson TC, 2001, NEUROSCIENCE, V105, P99, DOI 10.1016/S0306-4522(01)00169-5
   FRACKOWIAK J, 1994, J NEUROPATH EXP NEUR, V53, P637, DOI 10.1097/00005072-199411000-00011
   Goldstein LE, 2003, LANCET, V361, P1258, DOI 10.1016/S0140-6736(03)12981-9
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999
   Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100
   JANCIAUSKIENE S, 1995, J BIOL CHEM, V270, P26041, DOI 10.1074/jbc.270.44.26041
   Jen LS, 1998, NATURE, V392, P140, DOI 10.1038/32327
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469
   Klunk WE, 1999, METHOD ENZYMOL, V309, P285
   Lal R, 2001, MICROSC RES TECHNIQ, V52, P273, DOI 10.1002/1097-0029(20010201)52:3<273::AID-JEMT1013>3.0.CO;2-M
   LeVine H, 1999, METHOD ENZYMOL, V309, P274
   Lin H, 2001, FASEB J, V15, P2433, DOI 10.1096/fj.01-0377com
   Malek G., 1998, IOVS, V39, pS369
   MCGEER PL, 1994, TOHOKU J EXP MED, V174, P269, DOI 10.1620/tjem.174.269
   Miklossy J, 1998, J NEUROPATH EXP NEUR, V57, P1202, DOI 10.1097/00005072-199812000-00012
   MORGAN BP, 1995, CRIT REV CL LAB SCI, V32, P265, DOI 10.3109/10408369509084686
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F
   ODA T, 1995, EXP NEUROL, V136, P22, DOI 10.1006/exnr.1995.1080
   Parbhu A, 2002, PEPTIDES, V23, P1265, DOI 10.1016/S0196-9781(02)00061-X
   Sasaki A, 1997, BRAIN RES, V755, P193, DOI 10.1016/S0006-8993(97)00097-8
   STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977
   TENNENT GA, 1995, P NATL ACAD SCI USA, V92, P4299, DOI 10.1073/pnas.92.10.4299
   Tsuzuki K, 1997, NEUROSCI LETT, V222, P163, DOI 10.1016/S0304-3940(97)13369-9
   Tsuzuki K, 2000, NEUROSCI LETT, V281, P171, DOI 10.1016/S0304-3940(00)00834-X
   Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945
   Walsh DT, 2002, NEUROBIOL DIS, V10, P20, DOI 10.1006/nbdi.2002.0485
   WEN GY, 1988, ARCH NEUROL-CHICAGO, V45, P1298, DOI 10.1001/archneur.1988.00520360016002
   Wen GY, 1999, BRAIN RES, V832, P40, DOI 10.1016/S0006-8993(99)01466-3
   Westlind-Danielsson A, 2001, BIOCHEMISTRY-US, V40, P14736, DOI 10.1021/bi010375c
   YAMAGUCHI H, 1992, AM J PATHOL, V141, P249
   Yao ZX, 2002, FASEB J, V16, P1677, DOI 10.1096/fj.02-0285fje
   Yao ZX, 2002, J NEUROCHEM, V83, P1110, DOI 10.1046/j.1471-4159.2002.01202.x
   Zhu YJ, 2000, FASEB J, V14, P1244, DOI 10.1096/fasebj.14.9.1244
NR 54
TC 247
Z9 282
U1 0
U2 22
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD FEB
PY 2004
VL 78
IS 2
BP 243
EP 256
DI 10.1016/j.exer.2003.10.011
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 773TQ
UT WOS:000188939200009
PM 14729357
DA 2022-11-30
ER

PT J
AU Rosenfeld, PJ
   Dugel, PU
   Holz, FG
   Heier, JS
   Pearlman, JA
   Novack, RL
   Csaky, KG
   Koester, JM
   Gregory, JK
   Kubota, R
AF Rosenfeld, Philip J.
   Dugel, Pravin U.
   Holz, Frank G.
   Heier, Jeffrey S.
   Pearlman, Joel A.
   Novack, Roger L.
   Csaky, Karl G.
   Koester, John M.
   Gregory, Jeffrey K.
   Kubota, Ryo
TI Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related
   Macular Degeneration A Randomized Clinical Trial
SO OPHTHALMOLOGY
LA English
DT Article
ID FUNDUS AUTOFLUORESCENCE; NATURAL-HISTORY; VITAMIN-A; PROGRESSION;
   EPIDEMIOLOGY; ASSOCIATION; ACU-4429; DISEASE; IMPACT; EYES
AB Purpose: To determine whether emixustat hydrochloride (emixustat) reduces the rate of enlargement of geographic atrophy (GA) compared with placebo in subjects with age-related macular degeneration (AMD) and to evaluate the safety and tolerability of emixustat over 24 months of treatment.
   Design: Multicenter, randomized, double-masked, placebo-controlled, phase 2b/3 clinical trial.
   Participants: Patients with GA secondary to AMD, a visual acuity score of at least 35 letters, and GA with a total area of 1.25 to 18 mm(2) were enrolled.
   Methods: Subjects were randomized (1:1:1:1) to emixustat 2.5 mg, 5 mg, 10 mg, or placebo, administered orally once daily for 24 months. Visits included screening, baseline, and months 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, and 25.
   Main Outcome Measures: The primary efficacy end point was the mean annual growth rate of total GA area in the study eye, as measured by a central reading center using fundus autofluorescence (FAF) images. The change from baseline in normal luminance best-corrected visual acuity (NL-BCVA) was a secondary efficacy end point.
   Results: Of 508 randomized subjects, 320 completed the study. Demographics and baseline characteristics were comparable between treatment groups. On average, GA lesions in the study eye grew at a similar rate in each group (emixustat: 1.69 to 1.84 mm(2)/year; placebo: 1.69 mm(2)/year; P >= 0.81). Changes in NL-BCVA were also comparable between groups. Subjects with a larger low luminance deficit (LLD) at baseline (>= 20 letters) demonstrated a more rapid growth of GA over 24 months. No relationship was observed between the risk-allele status of the AMD-associated single-nucleotide polymorphisms tested and the growth rate of GA. The most common adverse events in emixustat-treated subjects were delayed dark adaptation (55%), chromatopsia (18%), visual impairment (15%), and erythropsia (15%).
   Conclusions: Emixustat did not reduce the growth rate of GA in AMD. The most common adverse events were ocular in nature and likely related to the drug's mechanism of action. Data gained from this study over a 2-year period add to the understanding of the natural history of GA and the baseline characteristics affecting the growth rate of GA. (C) 2018 by the American Academy of Ophthalmology.
C1 [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Dugel, Pravin U.] Retinal Consultants Arizona, Phoenix, AZ USA.
   [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Heier, Jeffrey S.] Ophthalm Consultants Boston, Boston, MA USA.
   [Pearlman, Joel A.] Retinal Consultants Med Grp, Sacramento, CA USA.
   [Novack, Roger L.] Retina Vitreous Associates Med Grp, Los Angeles, CA USA.
   [Csaky, Karl G.] Texas Retina Associates, Dallas, TX USA.
   [Koester, John M.; Gregory, Jeffrey K.; Kubota, Ryo] Acucela Inc, Seattle, WA USA.
C3 Bascom Palmer Eye Institute; University of Miami; University of Bonn;
   Ophthalmic Consultants of Boston; Retina Vitreous Associates Medical
   Group
RP Rosenfeld, PJ (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@med.miami.edu
OI Heier, Jeffrey/0000-0003-4625-3145
FU Acucela; Roche/Genentech; Allergan; Ionis; Heidelberg Engineering;
   Novartis; Bayer; Pixium; Thrombogenics; Nightstar; Lin Bioscience;
   Centervue; Thea; Acucela Inc.; 4D Molecular Technologies; Adverum;
   Aerie; Aerpio; Allegro; Apellis; Asclepix; Astellas; BVI; Coda
   Therapeutix; Corcept; Daiichi Sankyo; Genentech/Roche; Genzyme;
   Heidelberg; Hemera; Janssen RD; Kanghong; Kodiak; Kodiak, Neurotech;
   Notal Vision; Ocular Therapeutix; Ophthotech; Optovue; Quark; Ra
   Pharmaceuticals; Regeneron; Regenxbio; Scifluor; Shire; Stealth
   Biotherapeutics; TLC; Tyrogenex; Genentech; Acucela Inc. [NCT01802866]
FX The author(s) have made the following disclosure(s): P.J.R.: Research
   support/consultant fees - Acucela.; P.U.D.: Site payment for conduct of
   study, Advisory Board member, Consultant - Acucela.; F.G.H.: Payment or
   services from a third party - Acucela, Roche/Genentech, Allergan, Ionis,
   Heidelberg Engineering; Financial relationships - Novartis, Bayer,
   Pixium, Thrombogenics, Nightstar, Lin Bioscience, Centervue, Thea.;
   J.S.H.: Payment or services from a third party - Acucela Inc.; Financial
   relationships - 4D Molecular Technologies, Adverum, Aerie, Aerpio,
   Allegro, Apellis, Asclepix, Astellas, Bayer, BVI, Coda Therapeutix,
   Corcept, Daiichi Sankyo, Genentech/Roche, Genzyme, Heidelberg, Hemera,
   Janssen R&D, Kanghong, Kodiak, Neurotech, Notal Vision, Novartis, Ocular
   Therapeutix, Ophthotech, Optovue, Quark, Ra Pharmaceuticals, Regeneron,
   Regenxbio, Scifluor, Shire, Stealth Biotherapeutics, Thrombogenics, TLC,
   Tyrogenex.; J.A.P.: Payment or services from a third party - Acucela
   Inc.; Financial relationships - Genentech.; R.L.N.: Payment or services
   from a third party - Acucela.; K.G.C.: Payment or services from a third
   party - Acucela; Financial relationships - Genentech, Allergan,
   Heidelberg Engineering, Ophthotech.; J.M.K.: Employment/stock options,
   stock grants - Acucela Inc.; J.K.G.: Employment, stock options, stock
   grants - Acucela Inc.; R.K.: Employment, stock options, stock grants -
   Acucela Inc.; Patents - US 12/830, 155, EP 10 794836.6, JP 5860398, JP
   6118886.; Funding for the study (NCT01802866) was provided by Acucela
   Inc. Acucela participated in all aspects of this study, including
   design, conduct, data collection, data management, data analysis, data
   interpretation, and the preparation, review, and approval of the
   manuscript.
CR Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Bavik C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124940
   Biarnes M, 2015, AM J OPHTHALMOL, V160, P345, DOI 10.1016/j.ajo.2015.05.009
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Claire J, 2014, JAMA OPHTHALMOL, V135, P528
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3456, DOI 10.1167/iovs.17-22339
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Dugel PU, 2015, RETINA-J RET VIT DIS, V35, P1173, DOI 10.1097/IAE.0000000000000606
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Kubota R, 2014, RETINA-J RET VIT DIS, V34, P603, DOI 10.1097/01.iae.0000434565.80060.f8
   Kubota R, 2012, RETINA-J RET VIT DIS, V32, P183, DOI 10.1097/IAE.0b013e318217369e
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1
   Mones J, 2018, BRIT J OPHTHALMOL, V102, P388, DOI 10.1136/bjophthalmol-2017-310268
   Owsley C, 2016, INVEST OPHTH VIS SCI, V57, P1782, DOI 10.1167/iovs.15-18962
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Petrukhin Konstantin, 2013, Drug Discov Today Ther Strateg, V10, pe11
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Sparrow JR, 2016, P NATL ACAD SCI USA, V113, P4564, DOI 10.1073/pnas.1600474113
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Wright CB, 2017, HANDB EXP PHARMACOL, V242, P321, DOI 10.1007/164_2016_36
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 36
TC 69
Z9 72
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2018
VL 125
IS 10
BP 1556
EP 1567
DI 10.1016/j.ophtha.2018.03.059
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GU1IF
UT WOS:000445012100022
PM 29716784
OA hybrid
DA 2022-11-30
ER

PT J
AU Gillies, MC
   Campain, A
   Barthelmes, D
   Simpson, JM
   Arnold, JJ
   Guymer, RH
   McAllister, IL
   Essex, RW
   Morlet, N
   Hunyor, AP
AF Gillies, Mark C.
   Campain, Anna
   Barthelmes, Daniel
   Simpson, Judy M.
   Arnold, Jennifer J.
   Guymer, Robyn H.
   McAllister, Ian L.
   Essex, Rohan W.
   Morlet, Nigel
   Hunyor, Alex P.
CA Fight Retinal Blindness Study Grp
TI Long-Term Outcomes of Treatment of Neovascular Age-Related Macular
   Degeneration Data from an Observational Study
SO OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; THERAPY
AB Purpose: To analyze the long-term outcomes of eyes with neovascular age-related macular degeneration (AMD) starting treatment with vascular endothelial growth factor (VEGF) inhibitors at least 5 years earlier.
   Design: Database observational study.
   Participants: Treatment-naive eyes with neovascular AMD tracked by the Fight Retinal Blindness outcome registry that received at least 1 anti-VEGF injection.
   Methods: Locally weighted scatterplot smoothing curves were used to display visual acuity (VA) results.
   Main Outcome Measures: Change in mean VA and number of injections and visits from baseline up to 7 years after initiating treatment.
   Results: The mean follow-up time of all 1212 identified eyes was 53.5 months, and 549 (45%) continued attending after 60 months. Mean VA improved from 55.1 to 61.4 letters after 6 months and remained above the mean presenting VA for approximately 6 years. After 7 years, mean VA was 2.6 letters lower than baseline for the 131 eyes still being followed; 40% had VA >= 70 (20/40) letters, and 18% had VA >= 35 letters (20/200). Of those with 20/40 VA before treatment, 40% had lost it after 7 years. Geographic atrophy affecting the fovea was thought to be the cause of a >= 10-letter loss after 6.5 years in 37% of a subset of such eyes that were retrospectively analyzed. A median of 6 injections and 9 visits were recorded over the first 12 months, and then 5 treatments and 7 to 9 visits per annum thereafter through 7 years. Treatment was discontinued for 663 eyes (53%) within the first 5 years. Despite initial gains in vision, the mean VA of these eyes had deteriorated to baseline or worse around the time treatment was discontinued. The rate of serious adverse events was low.
   Conclusions: Good long-term outcomes of VEGF inhibition for neovascular AMD were found in this study. These results may be better than other reports because more injections were given to our patients, possibly associated with a greater incentive for the physician to treat. Further studies to determine how to maximize the proportion of eyes that retain the initial VA gains of anti-VEGF are warranted. (C) 2015 by the American Academy of Ophthalmology.
C1 [Gillies, Mark C.; Campain, Anna; Barthelmes, Daniel; Hunyor, Alex P.] Univ Sydney, Save Sight Inst, Sydney Med Sch, Sydney, NSW 2006, Australia.
   [Barthelmes, Daniel] Univ Zurich, Dept Ophthalmol, Univ Zurich Hosp, Zurich, Switzerland.
   [Simpson, Judy M.] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia.
   [Arnold, Jennifer J.] Marsden Eye Specialists, Parramatta, NSW, Australia.
   [Guymer, Robyn H.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3010, Australia.
   [McAllister, Ian L.] Univ Western Australia, Lions Eye Inst, Ctr Ophthalmol & Vis Sci, Perth, WA 6009, Australia.
   [Essex, Rohan W.] Australian Natl Univ, Acad Unit Ophthalmol, Acton, ACT, Australia.
   [Morlet, Nigel] Univ Western Australia, Dept Populat Hlth, Perth, WA 6009, Australia.
   [Hunyor, Alex P.] Retina Associates, Chatswood, NSW, Australia.
C3 University of Sydney; University of Zurich; University Zurich Hospital;
   University of Sydney; Centre for Eye Research Australia; Royal Victorian
   Eye & Ear Hospital; University of Melbourne; Lions Eye Institute;
   University of Western Australia; Australian National University;
   University of Western Australia
RP Barthelmes, D (通讯作者)，Univ Zurich Hosp, Dept Ophthalmol, Frauenklinikstr 24, CH-8091 Zurich, Switzerland.
EM daniel.barthelmes@usz.ch
RI Hunyor, Alex/AAT-8205-2021
OI Hunyor, Alex/0000-0002-8182-6167; Simpson, Judy M/0000-0001-5172-3004;
   Guymer, Robyn/0000-0002-9441-4356; Essex, Rohan/0000-0001-5323-0334;
   Campain, Anna/0000-0003-1057-0085
FU Novartis; Bayer; Royal Australian New Zealand College of
   Ophthalmologists Eye Foundation; National Health and Medical Research
   Council, Australia (NHRMC) [ID 632663]; NHMRC; Walter and Gertrud
   Siegenthaler Foundation Zurich, Switzerland; Swiss National Foundation
FX J.J.A. and R.H.G.: Personal fees and other - Novartis and other from
   Bayer, outside the submitted work.; A.P.H.: Research grant - Novartis
   and Bayer.; Supported by a grant from the Royal Australian New Zealand
   College of Ophthalmologists Eye Foundation (2007-2009) and a grant from
   the National Health and Medical Research Council, Australia (NHRMC
   2010-2012; NHMRC grant no. ID 632663).; M.C.G. is a Sydney Medical
   Foundation Fellow and is supported by an NHMRC practitioner fellowship.
   D.B. was supported by the Walter and Gertrud Siegenthaler Foundation
   Zurich, Switzerland, and the Swiss National Foundation. Funding was also
   provided by Novartis and Bayer. These supporting organizations had no
   role in the design or conduct of the research.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   [Anonymous], 2012, R LANG ENV STAT COMP
   Barthelmes D, 2014, OPHTHALMOLOGY, V121, P2073, DOI 10.1016/j.ophtha.2014.05.007
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cleveland W, 1992, STAT MODELS, DOI 10.1201/9780203738535
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V120, P209
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SCHMITTLEIN DC, 1989, AM STAT, V43, P176, DOI 10.2307/2685070
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Vaze A, 2004, RETINA, V34, P1774
   Vaze A, 2014, ACTA OPHTHALMOL, V92, pe697, DOI 10.1111/aos.12417
   Wickremasinghe S, 2013, CLIN EXP OPHTHALMOL, V41, P723, DOI 10.1111/ceo.12212
NR 17
TC 170
Z9 173
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2015
VL 122
IS 9
BP 1837
EP 1845
DI 10.1016/j.ophtha.2015.05.010
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CP8BU
UT WOS:000360116900024
PM 26096346
DA 2022-11-30
ER

PT J
AU Huang, YM
   Dou, HL
   Huang, FF
   Xu, XR
   Zou, ZY
   Lu, XR
   Lin, XM
AF Huang, Yang-Mu
   Dou, Hong-Liang
   Huang, Fei-Fei
   Xu, Xian-Rong
   Zou, Zhi-Yong
   Lu, Xin-Rong
   Lin, Xiao-Ming
TI Changes following supplementation with lutein and zeaxanthin in retinal
   function in eyes with early age-related macular degeneration: a
   randomised, double-blind, placebo-controlled trial
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT OPTICAL-DENSITY; VISUAL-ACUITY; CAROTENOIDS; ANTIOXIDANTS;
   AUGMENTATION; MACULOPATHY; DISEASE
AB Aims To investigate functional and macular pigment (MP) changes in patients with early age-related macular degeneration (AMD) after multiple supplementation with lutein and zeaxanthin.
   Methods 112 patients with early AMD were randomly (1: 1: 1: 1) assigned to receive 10 mg lutein, 20 mg lutein, lutein (10 mg)+zeaxanthin (10 mg), or placebo daily for 2 years. MP optical density (MPOD) was recorded at baseline, 48 weeks and 2 years. Retinal sensitivities were measured by multifocal electroretinogram for peak-to-trough amplitude (N1P1) at baseline and at 48 weeks, and in terms of microperimeter-determined mean retinal sensitivity (MRS) at 48 weeks and 2 years.
   Results Supplementation with lutein and zeaxanthin augmented MPOD significantly in active treatment groups (all p<0.05). N1P1 response densities showed significant increases in ring 1 and ring 2 after 48 weeks of supplementation, while no significant changes were seen in rings 3-6. Significant increases in MRS were detected after supplementation with either 10 or 20 mg lutein, whereas no such increases were seen in the placebo arm.
   Conclusions Supplementation with lutein and/or zeaxanthin increases MPOD, and supplemental lutein enhances retinal sensitivity, in patients with early AMD.
C1 [Huang, Yang-Mu; Huang, Fei-Fei; Xu, Xian-Rong; Zou, Zhi-Yong; Lin, Xiao-Ming] Peking Univ, Sch Publ Hlth, Beijing 100191, Peoples R China.
   [Dou, Hong-Liang; Lu, Xin-Rong] Peking Univ, Ctr Eye, Hosp 3, Beijing 100191, Peoples R China.
C3 Peking University; Peking University
RP Lin, XM (通讯作者)，Peking Univ, Sch Publ Hlth, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
EM linbjmu@bjmu.edu.cn
RI Zou, Zhiyong/P-8066-2019
OI Zou, Zhiyong/0000-0001-5049-5425; Huang, Yangmu/0000-0002-3660-1276
FU Chinese National Natural Science Foundation [81273063]
FX Supported by the Chinese National Natural Science Foundation (grant
   81273063).
CR Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Connolly EE, 2010, CURR EYE RES, V35, P335, DOI 10.3109/02713680903521951
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Li BX, 2010, ARCH BIOCHEM BIOPHYS, V504, P56, DOI 10.1016/j.abb.2010.07.024
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Loughman J, 2012, INVEST OPHTH VIS SCI, V53, P7871, DOI 10.1167/iovs.12-10690
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Ma L, 2012, AM J OPHTHALMOL, V154, P625, DOI 10.1016/j.ajo.2012.04.014
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Parravano M, 2010, RETINA-J RET VIT DIS, V30, P1017, DOI 10.1097/IAE.0b013e3181cfd3c6
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Sabour-Pickett S, 2014, RETINA-J RET VIT DIS, V34, P1757, DOI 10.1097/IAE.0000000000000174
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Woo JH, 2009, EYE, V23, P2271, DOI 10.1038/eye.2009.4
   Wooten BR, 2002, PROG RETIN EYE RES, V21, P225, DOI 10.1016/S1350-9462(02)00003-4
NR 25
TC 31
Z9 33
U1 2
U2 33
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2015
VL 99
IS 3
BP 371
EP 375
DI 10.1136/bjophthalmol-2014-305503
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC0AU
UT WOS:000349998000017
PM 25228440
OA Bronze
DA 2022-11-30
ER

PT J
AU Liu, GF
   Han, L
   Lu, Y
   Wang, CG
   Ma, L
   Zhang, P
   Liu, C
   Lu, XR
   Ma, ZZ
AF Liu, Guangfeng
   Han, Liang
   Lu, Yao
   Wang, Changguan
   Ma, Lie
   Zhang, Pei
   Liu, Cong
   Lu, Xinrong
   Ma, Zhizhong
TI Clinicopathological study of the polypoidal lesions of polypoidal
   choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Bruch's membrane; Choroidal membrane; Polypoidal choroidal vasculopathy;
   Surgical specimens
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; ANGIOGRAPHY
AB Purpose To investigate the pathogenic features of the polypoidal lesions from the specimens of polypoidal choroidal vasculopathy extracted from human subjects. Methods Seven specimens of polypoidal lesions extracted from five eyes of six patients (mean age, 60.16 +/- 10.41 years) of polypoidal choroidal vasculopathy were examined. The polypoidal lesions were obtained by surgical excision. Thereafter, a histopathological analysis of the specimens was performed. Results The polypoidal lesions were oval nodules located underneath the retinal pigment epithelium. A pathological study of the lesions revealed that Bruch's membrane schisis was observed in all specimens and they were all located in the Bruch's membrane. The Bruch's membrane schisis and serosanguineous materials constituted the main structure of the lesions in five of the seven specimens, with small vessels being observed in two specimens. One specimen was composed of two polypoidal lesions of different characteristics, and one specimen had a neovessel membrane complex with several polypoidal lesions. Inflammatory cells and blood vessels were observed in the polypoidal lesion of the specimen with neovessel membrane complex. Conclusion Polypoidal lesions of polypoidal choroidal vasculopathy are abnormalities of the Bruch's membrane. The lesions are characterized by the Bruch's membrane schisis, which is filled with serosanguineous materials. The lesions are progressive and may contain inflammatory cells and blood vessels.
C1 [Liu, Guangfeng; Ma, Lie; Ma, Zhizhong] Peking Univ Int Hosp, Dept Ophthalmol, Life Sci Pk Zhong Guancun, Life Pk Rd 1, Beijing 102206, Peoples R China.
   [Han, Liang; Lu, Yao; Wang, Changguan; Zhang, Pei; Liu, Cong; Lu, Xinrong; Ma, Zhizhong] Peking Univ Third Hosp, Key Lab Restorat Damaged Ocular Nerve, Dept Ophthalmol, Peking Univ,Eye Ctr, Beijing 100191, Peoples R China.
   [Ma, Zhizhong] Peking Univ Third Hosp, Dept Ophthalmol, 49 North Huayuan Rd, Beijing 100191, Peoples R China.
C3 Peking University; Peking University
RP Ma, ZZ (通讯作者)，Peking Univ Int Hosp, Dept Ophthalmol, Life Sci Pk Zhong Guancun, Life Pk Rd 1, Beijing 102206, Peoples R China.; Ma, ZZ (通讯作者)，Peking Univ Third Hosp, Key Lab Restorat Damaged Ocular Nerve, Dept Ophthalmol, Peking Univ,Eye Ctr, Beijing 100191, Peoples R China.; Ma, ZZ (通讯作者)，Peking Univ Third Hosp, Dept Ophthalmol, 49 North Huayuan Rd, Beijing 100191, Peoples R China.
EM puh3_YK@bjmu.edu.cn
FU National Nature Science Foundation of China [81400409]
FX This study was supported by grants from the National Nature Science
   Foundation of China (81400409).
CR Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Chi YT, 2017, JAMA OPHTHALMOL, V135, P1310, DOI 10.1001/jamaophthalmol.2017.4360
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Han L, 2013, INVEST OPHTH VIS SCI, V54, P4956, DOI 10.1167/iovs.13-11957
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lim TH, 2019, JAMA OPHTHALMOL, V137, P650, DOI 10.1001/jamaophthalmol.2019.0412
   Lu Y, 2017, ACTA OPHTHALMOL, V95, pE443, DOI 10.1111/aos.13054
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Marelli-Berg FM, 2013, J CELL SCI, V126, P2343, DOI 10.1242/jcs.124099
   Moussa Kareem, 2017, Retin Cases Brief Rep, V11 Suppl 1, pS128, DOI 10.1097/ICB.0000000000000464
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V210, P405, DOI 10.1055/s-2008-1035085
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tso Mark O M, 2018, Am J Ophthalmol Case Rep, V11, P176, DOI 10.1016/j.ajoc.2017.10.012
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 26
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2022
VL 260
IS 7
BP 2369
EP 2377
DI 10.1007/s00417-021-05525-1
EA FEB 2022
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2H0GI
UT WOS:000754130800001
PM 35147748
DA 2022-11-30
ER

PT J
AU Rinninella, E
   Mele, MC
   Merendino, N
   Cintoni, M
   Anselmi, G
   Caporossi, A
   Gasbarrini, A
   Minnella, AM
AF Rinninella, Emanuele
   Mele, Maria Cristina
   Merendino, Nicolo
   Cintoni, Marco
   Anselmi, Gaia
   Caporossi, Aldo
   Gasbarrini, Antonio
   Minnella, Angelo Maria
TI The Role of Diet, Micronutrients and the Gut Microbiota in Age-Related
   Macular Degeneration: New Perspectives from the Gut-Retina Axis
SO NUTRIENTS
LA English
DT Review
DE age-related macular degeneration; gut-retina axis; gut microbiota;
   dietary habits; micronutrients; fish oil; omega-3 polyunsaturated fatty
   acids; personalised medicine
ID INDUCED ULCERATIVE-COLITIS; VITAMIN-D METABOLISM; LONG-TERM INCIDENCE;
   FATTY-ACID INTAKE; OXIDATIVE STRESS; EYE DISEASE; INTESTINAL-ABSORPTION;
   CLINICAL-OUTCOMES; 5-YEAR INCIDENCE; ZINC-DEFICIENCY
AB Age-related macular degeneration (AMD) is a complex multifactorial disease and the primary cause of legal and irreversible blindness among individuals aged >= 65 years in developed countries. Globally, it affects 30-50 million individuals, with an estimated increase of approximately 200 million by 2020 and approximately 300 million by 2040. Currently, the neovascular form may be able to be treated with the use of anti-VEGF drugs, while no effective treatments are available for the dry form. Many studies, such as the randomized controlled trials (RCTs) Age-Related Eye Disease Study (AREDS) and AREDS 2, have shown a potential role of micronutrient supplementation in lowering the risk of progression of the early stages of AMD. Recently, low-grade inflammation, sustained by dysbiosis and a leaky gut, has been shown to contribute to the development of AMD. Given the ascertained influence of the gut microbiota in systemic low-grade inflammation and its potential modulation by macro-and micro-nutrients, a potential role of diet in AMD has been proposed. This review discusses the role of the gut microbiota in the development of AMD. Using PubMed, Web of Science and Scopus, we searched for recent scientific evidence discussing the impact of dietary habits (high-fat and high-glucose or - fructose diets), micronutrients (vitamins C, E, and D, zinc, beta-carotene, lutein and zeaxanthin) and omega-3 fatty acids on the modulation of the gut microbiota and their relationship with AMD risk and progression.
C1 [Rinninella, Emanuele; Mele, Maria Cristina; Anselmi, Gaia; Gasbarrini, Antonio] Fdn Policlin Univ A Gemelli IRCCS, UOC Nutr Clin, Dipartimento Sci Gastroenterol Endocrinometab & N, Largo A Gemelli 8, I-00168 Rome, Italy.
   [Rinninella, Emanuele; Mele, Maria Cristina; Gasbarrini, Antonio] Univ Cattolica Sacro Cuore, Ist Patol Speciale Med, Largo F Vito 1, I-00168 Rome, Italy.
   [Merendino, Nicolo] Univ Tuscia, Lab Nutr Cellulare & Mol, Dipartimento Sci Ecol & Biol DEB, Largo Univ Snc, I-01100 Viterbo, Italy.
   [Cintoni, Marco] Univ Roma Tor Vergata, Scuola Specializzaz Sci Alimentaz, Via Montpellier 1, I-00133 Rome, Italy.
   [Caporossi, Aldo; Minnella, Angelo Maria] Fdn Policlin Univ A Gemelli IRCCS, UOC Oculist, Dipartimento Sci Invecchiamento Neurol Ortoped &, Largo A Gemelli 8, I-00168 Rome, Italy.
   [Caporossi, Aldo; Minnella, Angelo Maria] Univ Cattolica Sacro Cuore, Ist Oftalmol, Largo F Vito 1, I-00168 Rome, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; Tuscia University; University
   of Rome Tor Vergata; Catholic University of the Sacred Heart; IRCCS
   Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS
   Policlinico Gemelli
RP Mele, MC (通讯作者)，Fdn Policlin Univ A Gemelli IRCCS, UOC Nutr Clin, Dipartimento Sci Gastroenterol Endocrinometab & N, Largo A Gemelli 8, I-00168 Rome, Italy.; Mele, MC (通讯作者)，Univ Cattolica Sacro Cuore, Ist Patol Speciale Med, Largo F Vito 1, I-00168 Rome, Italy.
EM emanuele.rinninella@unicatt.it; mariacristina.mele@unicatt.it;
   merendin@unitus.it; marco.cintoni@gmail.com; gaia.anselmi@gmail.com;
   aldo.caporossi@unicatt.it; antonio.gasbarrini@unicatt.it;
   angelomaria.minnella@unicatt.it
RI Gasbarrini, Antonio/AAB-8487-2019; minnella, angelo maria/AAQ-6250-2020;
   Cintoni, Marco/Q-4083-2019; Merendino, Nicolò/N-7661-2013; Rinninella,
   Emanuele/I-9385-2019
OI minnella, angelo maria/0000-0001-5896-5313; Merendino,
   Nicolò/0000-0001-5044-1398; Rinninella, Emanuele/0000-0002-9165-2367;
   Gasbarrini, Antonio/0000-0003-4863-6924; Cintoni,
   Marco/0000-0002-9610-0748; Mele, Maria Cristina/0000-0002-8463-7062
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   [Anonymous], 2010, GLOBAL EC COST VISUA
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Arnold LE, 2017, J CHILD ADOL PSYCHOP, V27, P223, DOI 10.1089/cap.2016.0123
   Arteni AA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135779
   Bakke D, 2018, INFLAMM BOWEL DIS, V24, P1149, DOI 10.1093/ibd/izy092
   Bartlett H, 2010, CLIN EXP OPTOM, V93, P300, DOI 10.1111/j.1444-0938.2010.00499.x
   Bashir M, 2016, EUR J NUTR, V55, P1479, DOI 10.1007/s00394-015-0966-2
   Bernstein PS, 2010, VISION RES, V50, P716, DOI 10.1016/j.visres.2009.10.014
   Bidu C, 2018, DIABETES, V67, P1512, DOI 10.2337/db17-1488
   Bikle DD, 2014, CHEM BIOL, V21, P319, DOI 10.1016/j.chembiol.2013.12.016
   Binxing L., 2017, EXP EYE RES, V159, P123
   Braakhuis Andrea, 2017, Diseases, V5, DOI 10.3390/diseases5010003
   Burns A J, 2000, Curr Issues Intest Microbiol, V1, P13
   Calder PC, 2009, INT REV IMMUNOL, V28, P506, DOI 10.3109/08830180903197480
   Carneiro A., 2017, OXID MED CELL LONGEV
   Castenmiller JJM, 1998, ANNU REV NUTR, V18, P19, DOI 10.1146/annurev.nutr.18.1.19
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12914
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chhikara N, 2019, FOOD CHEM, V272, P192, DOI 10.1016/j.foodchem.2018.08.022
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Choi Dongseok, 2008, J Ocul Biol Dis Infor, V1, P37, DOI 10.1007/s12177-008-9007-1
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Clarke SF, 2012, GUT MICROBES, V3, P186, DOI 10.4161/gmic.20168
   Costantini L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122645
   David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Devkota S, 2012, NATURE, V487, P104, DOI 10.1038/nature11225
   Do MH, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060761
   During A, 2005, J NUTR, V135, P2305, DOI 10.1093/jn/135.10.2305
   Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591
   Eisenhauer B, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020120
   Engberg RM, 2000, POULTRY SCI, V79, P1311, DOI 10.1093/ps/79.9.1311
   Evans J. R., 2012, COCHRANE DATABASE SY
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Franceschi C, 2007, MECH AGEING DEV, V128, P92, DOI 10.1016/j.mad.2006.11.016
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Layana AG, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101120
   Garg M, 2018, J CROHNS COLITIS, V12, P963, DOI 10.1093/ecco-jcc/jjy052
   GIBSON GR, 1994, FEMS MICROBIOL LETT, V118, P121, DOI 10.1016/0378-1097(94)90606-8
   Gielda LM, 2012, MBIO, V3, DOI 10.1128/mBio.00171-12
   Gill CIR, 2002, BRIT J NUTR, V88, pS73, DOI 10.1079/BJN2002632
   Gill HS, 1998, INT DAIRY J, V8, P535, DOI 10.1016/S0958-6946(98)00074-0
   Gong Y, 2017, AM J CLIN NUTR, V106, P16, DOI 10.3945/ajcn.117.153825
   Gubatan J, 2018, CURR OPIN GASTROEN, V34, P217, DOI 10.1097/MOG.0000000000000449
   Hadden WL, 1999, J AGR FOOD CHEM, V47, P4189, DOI 10.1021/jf990096k
   Hammond BR, 2014, INVEST OPHTH VIS SCI, V55, P8583, DOI 10.1167/iovs.14-15573
   Hildebrandt MA, 2009, GASTROENTEROLOGY, V137, P1716, DOI 10.1053/j.gastro.2009.08.042
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   JOHNSON JA, 1995, CURR EYE RES, V14, P101, DOI 10.3109/02713689508999921
   Kanhere M, 2018, J CLIN ENDOCR METAB, V103, P564, DOI 10.1210/jc.2017-01983
   Karlsson FH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2266
   Kassi E, 2013, CIRCULATION, V128, P2517, DOI 10.1161/CIRCULATIONAHA.113.002654
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Kruidenier L, 2003, J PATHOL, V201, P7, DOI 10.1002/path.1407
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Laterza L, 2016, MEDITERR J HEMATOL I, V8, DOI 10.4084/MJHID.2016.025
   Lau K, 2017, NUTRIENTS, V9, DOI 10.3390/nu9080859
   Lawrenson J. G., 2015, COCHRANE DB SYST REV, V9
   Leung IYF, 2005, EXP EYE RES, V81, P513, DOI 10.1016/j.exer.2005.03.009
   LEUREDUPREE AE, 1982, INVEST OPHTH VIS SCI, V23, P425
   Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102
   Li L, 2017, CLIN NUTR, V36, P1097, DOI 10.1016/j.clnu.2016.06.029
   LI ZY, 1985, INVEST OPHTH VIS SCI, V26, P1589
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim SM, 2016, NUTR RES, V36, P337, DOI 10.1016/j.nutres.2015.12.001
   Luthold RV, 2017, METABOLISM, V69, P76, DOI 10.1016/j.metabol.2017.01.007
   Ma JL, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101124
   Ma L, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070426
   Maggini S, 2007, BRIT J NUTR, V98, pS29, DOI 10.1017/S0007114507832971
   Mandal S, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0200-3
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Matsuoka K, 2015, SEMIN IMMUNOPATHOL, V37, P47, DOI 10.1007/s00281-014-0454-4
   Menni C, 2017, SCI REP-UK, V7, DOI [10.1038/s41598-017-10382-2, 10.1038/s41598-017-13722-4]
   Merendino N, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/310186
   Meyers KJ, 2014, INVEST OPHTH VIS SCI, V55, P587, DOI 10.1167/iovs.13-13216
   Miles EA, 2012, BRIT J NUTR, V107, pS171, DOI 10.1017/S0007114512001560
   Mokkala K, 2016, J NUTR, V146, P1694, DOI 10.3945/jn.116.235358
   Molan AL, 2014, PHYTOTHER RES, V28, P416, DOI 10.1002/ptr.5009
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   Nolan JM, 2013, EYE, V27, P899, DOI 10.1038/eye.2013.98
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Nolan JM, 2016, INVEST OPHTH VIS SCI, V57, P3429, DOI 10.1167/iovs.16-19520
   Nolan JM, 2012, EXP EYE RES, V101, P9, DOI 10.1016/j.exer.2012.05.006
   Noriega BS, 2016, CASE REP MED, V2016, DOI 10.1155/2016/3089303
   Organisciak D., 2012, PHOTOCHEM PHOTOBIOL
   Packer L., 1999, ANTIOXIDANT MIRACLE
   Peeters A., 2008, ARCH OPHTHALMOL
   Pierre JF, 2018, J NUTR BIOCHEM, V54, P95, DOI 10.1016/j.jnutbio.2017.12.002
   Ponziani F. R., 2018, HEPATOLOGY
   Qiao Y, 2013, APPL MICROBIOL BIOT, V97, P1689, DOI 10.1007/s00253-012-4323-6
   Rabot S, 2010, FASEB J, V24, P4948, DOI 10.1096/fj.10-164921
   Reboul E, 2005, BIOCHEM J, V387, P455, DOI 10.1042/BJ20040554
   Reed S, 2015, NUTRIENTS, V7, P9768, DOI 10.3390/nu7125497
   Ren ZH, 2011, BIOL TRACE ELEM RES, V141, P170, DOI 10.1007/s12011-010-8734-x
   Riccio P, 2018, NEUROTHERAPEUTICS, V15, P75, DOI 10.1007/s13311-017-0581-4
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rinninella E, 2018, EUR REV MED PHARMACO, V22, P4288, DOI 10.26355/eurrev_201807_15425
   Rizzatti G, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9351507
   Robertson RC, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0476-6
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   Schaffler H, 2018, J DIGEST DIS, V19, P225, DOI 10.1111/1751-2980.12591
   Schleicher M, 2013, NUTRIENTS, V5, P2405, DOI 10.3390/nu5072405
   Schmidl D, 2015, ACTA OPHTHALMOL, V93, P105, DOI 10.1111/aos.12650
   Schwenger KJP, 2014, WORLD J GASTROENTERO, V20, P1712, DOI 10.3748/wjg.v20.i7.1712
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Sender R, 2016, CELL, V164, P337, DOI 10.1016/j.cell.2016.01.013
   Singh U, 2005, ANNU REV NUTR, V25, P151, DOI 10.1146/annurev.nutr.24.012003.132446
   Skrypnik K, 2018, J SCI FOOD AGR, V98, P2449, DOI 10.1002/jsfa.8724
   Smailhodzic D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112682
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Stanhope KL, 2016, CRIT REV CL LAB SCI, V53, P52, DOI 10.3109/10408363.2015.1084990
   Stringham JM, 2008, OPTOMETRY VISION SCI, V85, P82, DOI 10.1097/OPX.0b013e318162266e
   Subramanian VS, 2017, AM J PHYSIOL-GASTR L, V312, pG340, DOI 10.1152/ajpgi.00369.2016
   Tahan G, 2011, CAN J SURG, V54, P333, DOI 10.1503/cjs.013610
   Talsness CE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188011
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tang MH, 2016, J PEDIATR GASTR NUTR, V63, P379, DOI 10.1097/MPG.0000000000001154
   Ticinesi A, 2017, NUTRIENTS, V9, DOI 10.3390/nu9121303
   Trevithick-Sutton CC, 2006, MOL VIS, V12, P1127
   Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414
   van Bennekum A, 2005, BIOCHEMISTRY-US, V44, P4517, DOI 10.1021/bi0484320
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Villa CR, 2018, INT J OBESITY, V42, P696, DOI 10.1038/ijo.2017.294
   Vu HTV, 2006, BRIT J OPHTHALMOL, V90, P389, DOI 10.1136/bjo.2005.078055
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Wang Y, 2014, BRIT POULTRY SCI, V55, P403, DOI 10.1080/00071668.2014.919375
   Watanabe Y, 2017, EXPERT REV CLIN PHAR, V10, P865, DOI 10.1080/17512433.2017.1333902
   Watson H., 2017, GUT
   Westergren T, 2010, EUR J CLIN PHARMACOL, V66, P109, DOI 10.1007/s00228-009-0729-1
   Williams LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106159
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood JPM, 2003, NEUROCHEM RES, V28, P1525, DOI 10.1023/A:1025622425501
   Wright EK, 2015, INFLAMM BOWEL DIS, V21, P1219, DOI 10.1097/MIB.0000000000000382
   Xu JX, 2014, NUTRITION, V30, P584, DOI 10.1016/j.nut.2013.10.018
   Yan HY, 2015, INT J CLIN EXP MED, V8, P20245
   Yonekura L, 2007, MOL NUTR FOOD RES, V51, P107, DOI 10.1002/mnfr.200600145
   Zackular JP, 2016, NAT MED, V22, P1330, DOI 10.1038/nm.4174
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
   Zeng SM, 2012, INVEST OPHTH VIS SCI, V53, P1041, DOI 10.1167/iovs.11-8531
   Zhang CH, 2010, ISME J, V4, P232, DOI 10.1038/ismej.2009.112
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
NR 158
TC 68
Z9 71
U1 2
U2 35
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD NOV
PY 2018
VL 10
IS 11
AR 1677
DI 10.3390/nu10111677
PG 26
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA HC1GH
UT WOS:000451547700115
PM 30400586
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Zult, T
   Smith, L
   Stringer, C
   Pardhan, S
AF Zult, Tjerk
   Smith, Lee
   Stringer, Charlotte
   Pardhan, Shahina
TI Levels of self-reported and objective physical activity in individuals
   with age-related macular degeneration
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Visual impairment; Vision loss; Older adults; GPAQ; Accelerometer;
   Sedentary behaviour; Physical activity; Exercise
ID COGNITIVE IMPAIRMENT; HEALTH; PREVALENCE; VISION; BLINDNESS; EXERCISE;
   ADULTS
AB BackgroundSelf-report in people with age-related macular degeneration (AMD) shows that they lead less active lifestyles. Physical activity is important as it has been shown to improve quality of life, reduce co-morbidity and also slow down the progression of AMD. Self-reported measures of physical activity are prone to subjective biases and therefore less accurate in quantifying physical activity. This study compared self-reported and objective (accelerometer-based) physical activity levels and patterns in older adults with AMD.MethodsData were collected in 11 AMD subjects with binocular vision loss (aged 767years), 10 AMD subjects with good binocular vision (aged 767years), and 11 controls (aged 70 +/- 4years). Binocular vision was established using visual acuity score. Contrast sensitivity and visual fields were also measured. Self-reported sedentary behaviour and moderate-to-vigorous physical activity (MVPA) was assessed using the Global Physical Activity Questionnaire. Objective measurements were obtained with an Actigraph GT3X accelerometer being worn for seven consecutive days on the hip. The objective physical activity measures were sedentary behaviour, light physical activity, MVPA, and step count.Results p id=Par Objectively measured MVPA was 33-34% higher for controls compared to both AMD groups (p<0.05). There were no group differences for any of the other objectively measured physical activity variables and self-reported physical activity variables were also not significantly different (all p > 0.05). Comparing the objective with the self-report physical activity measure showed that all groups under-reported their sedentary behaviour and MVPA, but controls under-reported their MVPA more than both AMD groups (p <0.05). Weak to moderate correlations were observed between the severity of vision loss and objective physical activity measures (all -0.413<greater than or equal to>r <= 0.443), while correlations for self-reported physical activity measures were less strong (all -0.303 >= r <= 0.114).Conclusions p id=Par People with AMD, irrespective of whether they were vision impaired, were better able to estimate the time spent in MVPA compared to controls. However, objectively measured MVPA, was higher in controls than AMD subjects. Although clinicians may use self-report to monitor the compliance of AMD subjects with any prescribed exercise programs, they should be aware that a valid comparison with healthy controls can only be made when MVPA is objectively measured.
C1 [Zult, Tjerk; Pardhan, Shahina] Anglia Ruskin Univ, Fac Hlth Educ Med & Social Care, Vis & Eye Res Inst, Sch Med, East Rd, Cambridge CB1 1PT, England.
   [Smith, Lee; Stringer, Charlotte] Anglia Ruskin Univ, Cambridge Ctr Sport & Exercise Sci, Dept Life Sci, Cambridge, England.
C3 Anglia Ruskin University; University of Cambridge; Anglia Ruskin
   University
RP Zult, T (通讯作者)，Anglia Ruskin Univ, Fac Hlth Educ Med & Social Care, Vis & Eye Res Inst, Sch Med, East Rd, Cambridge CB1 1PT, England.
EM tjerk.zult@anglia.ac.uk
RI Pardhan, Shahina/AAZ-7509-2020
OI Zult, Tjerk/0000-0002-8217-4295
FU Anglia Ruskin Fellowship
FX This work was supported by an Anglia Ruskin Fellowship. The funders had
   no role in the study design; in the collection, analysis and
   interpretation of data; in writing of the report; or in the decision to
   submit the paper for publication.
CR Aadland E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134606
   [Anonymous], 1988, P CLIN VISION SCI CI
   Armstrong T, 2006, J PUBLIC HEALTH-HEID, V14, P66, DOI 10.1007/s10389-006-0024-x
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Bull FC, 2009, J PHYS ACT HEALTH, V6, P790, DOI 10.1123/jpah.6.6.790
   Capella-McDonnall M, 2007, J VISUAL IMPAIR BLIN, V101, P133, DOI 10.1177/0145482X0710100302
   CASPERSEN CJ, 1985, PUBLIC HEALTH REP, V100, P126
   Choi L, 2011, MED SCI SPORT EXER, V43, P357, DOI 10.1249/MSS.0b013e3181ed61a3
   Cleland CL, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1255
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Copeland JL, 2009, J AGING PHYS ACTIV, V17, P17, DOI 10.1123/japa.17.1.17
   CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386
   DUNBAR A, 1992, NATL FITNESS SURVEY
   Economics A, 2009, FUTURE SIGHT LOSS UK
   Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI 10.1161/CIRCULATIONAHA.107.185649
   Hawkesworth S, 2018, J EPIDEMIOL COMMUN H, V72, P121, DOI 10.1136/jech-2017-209440
   Kelly Louise A, 2013, BMC Med Phys, V13, P5, DOI 10.1186/1756-6649-13-5
   Loprinzi PD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125394
   Maberley DAL, 2006, EYE, V20, P341, DOI 10.1038/sj.eye.6701879
   Mcguinness MB, 2017, AM J OPHTHALMOL, V180, P29, DOI 10.1016/j.ajo.2017.05.016
   Nelson-Quigg JM, 2000, INVEST OPHTH VIS SCI, V41, P2212
   Nguyen AM, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0062-8
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Penedo FJ, 2005, CURR OPIN PSYCHIATR, V18, P189, DOI 10.1097/00001504-200503000-00013
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Sengupta S, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/1471-2415-15-9
   Shephard RJ, 2003, BRIT J SPORT MED, V37, P197, DOI 10.1136/bjsm.37.3.197
   Smith L, 2018, CANCER
   Stevens GA, 2013, OPHTHALMOLOGY, V120, P2377, DOI 10.1016/j.ophtha.2013.05.025
   Sutton J A, 2002, GUIDE MAKING DOUCMEN
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Tudor-Locke C, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-80
   Whitson HE, 2010, ARCH GERONTOL GERIAT, V50, P209, DOI 10.1016/j.archger.2009.03.010
   WHO, 2012, GLOB PHYS ACT QUEST, P1
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
NR 39
TC 6
Z9 6
U1 1
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD JUL 20
PY 2020
VL 20
IS 1
AR 1144
DI 10.1186/s12889-020-09255-7
PG 10
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA MR2UO
UT WOS:000553446100014
PM 32689987
OA Green Accepted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Akagi-Kurashige, Y
   Yamashiro, K
   Gotoh, N
   Miyake, M
   Morooka, S
   Yoshikawa, M
   Nakata, I
   Kumagai, K
   Tsujikawa, A
   Yamada, R
   Matsuda, F
   Saito, M
   Iida, T
   Sugahara, M
   Kurimoto, Y
   Cheng, CY
   Khor, CC
   Wong, TY
   Yoshimura, N
AF Akagi-Kurashige, Yumiko
   Yamashiro, Kenji
   Gotoh, Norimoto
   Miyake, Masahiro
   Morooka, Satoshi
   Yoshikawa, Munemitsu
   Nakata, Isao
   Kumagai, Kyoko
   Tsujikawa, Akitaka
   Yamada, Ryo
   Matsuda, Fumihiko
   Saito, Masaaki
   Iida, Tomohiro
   Sugahara, Masako
   Kurimoto, Yasuo
   Cheng, Ching-Yu
   Khor, Chiea-Chuen
   Wong, Tien-Yin
   Yoshimura, Nagahisa
CA Nagahama Cohort Res Grp
TI MMP20 and ARMS2/HTRA1 Are Associated with Neovascular Lesion Size in
   Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT-FACTOR-H; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   CHLAMYDIA-PNEUMONIAE INFECTION; RETINAL-PIGMENT EPITHELIUM; MATRIX
   METALLOPROTEINASES; PHOTODYNAMIC THERAPY; JAPANESE POPULATION; SUBGROUP
   ANALYSIS; RANIBIZUMAB; POLYMORPHISM
AB Purpose: Age-related macular degeneration (AMD) is the leading cause of severe visual impairment. Despite treatment, a central scotoma often remains. The size of the scotoma depends on the lesion size of the choroidal neovascular membrane and significantly affects the patient's quality of life, and the lesion size of neovascularization also affects response to treatments. The aim of this study was to identify genes associated with the neovascular lesion size in neovascular AMD.
   Design: A genome-wide association study (GWAS).
   Participants: We included 1146 Japanese patients with neovascular AMD.
   Methods: We performed a 2-stage GWAS for the lesion size of AMD as a quantitative trait among 1146 (first stage: 727, second stage: 419) Japanese patients with neovascular AMD. Lesion size was determined by the greatest linear dimension measured with fluorescein angiography examination before treatment. We examined the association between the genotypic distribution of each single nucleotide polymorphism (SNP) and the trait using an additive model adjusted for age and sex. To evaluate the associations between AMD development and SNPs associated with lesion size, we also performed a case-control study by using the genotype data from these 1146 Japanese patients as case subjects and the fixed dataset from the Nagahama Study as control subjects.
   Main Outcome Measures: Genes associated with the lesion size in neovascular AMD.
   Results: In the discovery stage, rs10895322 in MMP20 showed a genome-wide significant P value of 6.95x10(-8), and rs2284665 in ARMS2/HTRA1 showed a P value of 1.55x10(-7). The associations of these 2 SNPs were successfully replicated in the replication stage, and a meta-analysis of both stages showed genome-wide significant P values (2.80x10(-9) and 4.41x10(-9), respectively). In a case-control study using 3248 Japanese subjects as controls, we could not find contribution of MMP20 rs10895322 for AMD development. Although MMP20 has been thought to be expressed only in dental tissues, we confirmed MMP20 expression in the human retina and retinal pigment epithelium/choroid with polymerase chain reaction.
   Conclusions: The growth of choroidal neovascularization in AMD would be affected by 2 genes: MMP20, a newly confirmed gene expressed in the retina, and ARMS2/HTRA1, a well-known susceptibility gene for AMD. (C) 2015 by the American Academy of Ophthalmology.
C1 [Akagi-Kurashige, Yumiko; Yamashiro, Kenji; Gotoh, Norimoto; Miyake, Masahiro; Morooka, Satoshi; Yoshikawa, Munemitsu; Nakata, Isao; Kumagai, Kyoko; Tsujikawa, Akitaka; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Kyoto 6068507, Japan.
   [Akagi-Kurashige, Yumiko; Gotoh, Norimoto; Miyake, Masahiro; Yoshikawa, Munemitsu; Nakata, Isao; Yamada, Ryo; Matsuda, Fumihiko] Kyoto Univ, Grad Sch Med, Ctr Genom Med, Kyoto 6068507, Japan.
   [Saito, Masaaki] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima, Japan.
   [Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.
   [Sugahara, Masako; Kurimoto, Yasuo] Kobe City Med Ctr Gen Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
   [Cheng, Ching-Yu; Khor, Chiea-Chuen; Wong, Tien-Yin] Singapore Eye Res Inst, Singapore, Singapore.
   [Cheng, Ching-Yu; Wong, Tien-Yin] Duke Natl Univ Singapore, Grad Sch Med, Singapore, Singapore.
   [Cheng, Ching-Yu; Wong, Tien-Yin] Natl Univ Singapore, Dept Ophthalmol, Singapore 117548, Singapore.
   [Cheng, Ching-Yu; Wong, Tien-Yin] Natl Univ Hlth Syst, Singapore, Singapore.
   [Cheng, Ching-Yu; Wong, Tien-Yin] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Khor, Chiea-Chuen] Genome Inst Singapore, Div Human Genet, Singapore, Singapore.
   [Khor, Chiea-Chuen] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore.
   [Khor, Chiea-Chuen] Natl Univ Hlth Syst, Singapore, Singapore.
C3 Kyoto University; Kyoto University; Fukushima Medical University; Tokyo
   Women's Medical University; Kobe City Medical Center General Hospital;
   National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore;
   National University of Singapore; Singapore National Eye Center; Agency
   for Science Technology & Research (A*STAR); A*STAR - Genome Institute of
   Singapore (GIS); National University of Singapore; National University
   of Singapore
RP Yamashiro, K (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI Cheng, Ching-Yu/Y-2229-2019; KOSUGI, Shinji/GYR-2946-2022; Saito,
   Masaaki/ABI-2783-2020; Miyake, Masahiro/V-1261-2019; Wong, Tien
   Yin/AAC-9724-2020
OI Cheng, Ching-Yu/0000-0003-0655-885X; Saito, Masaaki/0000-0003-1494-6350;
   Miyake, Masahiro/0000-0001-7410-3764; Wong, Tien
   Yin/0000-0002-8448-1264; Yamada, Ryo/0000-0002-1587-630X; Khor, Chiea
   Chuen/0000-0002-1128-4729; Yamashiro, Kenji/0000-0001-9354-8558;
   Tsujikawa, Akitaka/0000-0003-0779-7799
FU Japan Society for the Promotion of Science, Tokyo, Japan [22791653,
   21249084]; Japan National Society for the Prevention of Blindness,
   Tokyo, Japan
FX Supported by Grants-in-Aid for Scientific Research (grant nos. 22791653
   and 21249084 to N.Y.) from the Japan Society for the Promotion of
   Science, Tokyo, Japan, and the Japan National Society for the Prevention
   of Blindness, Tokyo, Japan. The funding organizations had no role in the
   design or conduct of this research.
CR Austin BA, 2009, INVEST OPHTH VIS SCI, V50, P2896, DOI 10.1167/iovs.08-2495
   Bailey JNC, 2013, HUM MOL GENET, V22, pR59, DOI 10.1093/hmg/ddt396
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Bessho H, 2011, MOL VIS, V17, P977
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Chowers I, 2008, MOL VIS, V14, P2263
   Chowers I, 2008, MOL VIS, V14, P1829
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fujimoto T, 2010, INVEST OPHTH VIS SCI, V51, P4694, DOI 10.1167/iovs.09-4464
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Grant GM, 1999, MATRIX BIOL, V18, P145, DOI 10.1016/S0945-053X(99)00003-7
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Llano E, 1997, BIOCHEMISTRY-US, V36, P15101, DOI 10.1021/bi972120y
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Seitsonen S, 2008, ACTA OPHTHALMOL, V86, P390, DOI 10.1111/j.1600-0420.2007.01050.x
   Shen D, 2009, BRIT J OPHTHALMOL, V93, P405, DOI 10.1136/bjo.2008.145383
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Steinbugler WFC, ARCH OPHTHALMOL
   Tamura H, 2012, AM J OPHTHALMOL, V154, P542, DOI 10.1016/j.ajo.2012.03.042
   Wheeler HE, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000685
   Wolf-Schnurrbusch Ute E K, 2013, Ocul Immunol Inflamm, V21, P36, DOI 10.3109/09273948.2012.726393
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 40
TC 17
Z9 17
U1 1
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2015
VL 122
IS 11
BP 2295
EP +
DI 10.1016/j.ophtha.2015.07.032
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CU4IQ
UT WOS:000363491800032
PM 26337002
DA 2022-11-30
ER

PT J
AU Sloan, FA
   Hanrahan, BW
AF Sloan, Frank A.
   Hanrahan, Brian W.
TI The Effects of Technological Advances on Outcomes for Elderly Persons
   With Exudative Age-related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; RANDOMIZED CLINICAL-TRIAL;
   SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PROPENSITY SCORE; LASER
   PHOTOCOAGULATION; MYOCARDIAL-INFARCTION; PHOTODYNAMIC THERAPY; LEGAL
   BLINDNESS; UNITED-STATES; VISION LOSS
AB IMPORTANCE Exudative age-related macular degeneration (ARMD) is the major cause of blindness among US elderly. Developing effective therapies for this disease has been difficult.
   OBJECTIVES To assess the effects of introducing new therapies for treating exudative ARMD on vision of the affected population and other outcomes among Medicare beneficiaries newly diagnosed as having ARMD.
   DESIGN The study used data from a 5% sample of Medicare claims and enrollment data with a combination of a regression discontinuity design and propensity score matching to assess the effects on the introduction or receipt of new technologies on study outcomes during a 2-year follow-up period.
   SETTING AND PARTICIPANTS The analysis was based on longitudinal data for the United States, January 1, 1994, to December 31, 2011, for Medicare beneficiaries with fee-for-service coverage. The sample was limited to beneficiaries 68 years or older newly diagnosed as having exudative ARMD as indicated by beneficiaries having no claims with this diagnosis in a 3-year look-back period.
   EXPOSURES The comparisons with vision outcomes were after vs before the introduction of photodynamic therapy and anti-vascular endothelial growth factor (VEGF) therapy. The comparisons for depression and long-term care facility admission were between beneficiaries newly diagnosed as having exudative ARMD who received photodynamic therapy or anti-VEGF therapy compared with beneficiaries having the diagnosis who received no therapy for this disease.
   MAIN OUTCOMES AND MEASURES Onset of decrease in vision, vision loss or blindness, depression, and admission to a long-term care facility. RESULTS Among beneficiaries newly diagnosed as having exudative ARMD, the introduction of anti-VEGF therapy reduced vision loss by 41% (95% CI, 52%-68%) and onset of severe vision loss and blindness by 46% (95% CI, 47%-63%). Such beneficiaries who received anti-VEGF therapy and were not admitted to a long-term care facility during the look-back period were 19% (95% CI, 72%-91%) less likely on average to be admitted to a long-term care facility during the follow-up period.
   CONCLUSIONS AND RELEVANCE This study demonstrates gains in population vision from the introduction of anti-VEGF therapy for patients 68 years or older with an exudative ARMD diagnosis in community-based settings in the United States.
C1 [Sloan, Frank A.; Hanrahan, Brian W.] Duke Univ, Dept Econ, Durham, NC 27708 USA.
C3 Duke University
RP Sloan, FA (通讯作者)，Duke Univ, Dept Econ, 213 Social Sci Bldg,Campus Box 90097, Durham, NC 27708 USA.
EM fsloan@duke.edu
FU National Institute on Aging [R01-AG017473]; NATIONAL INSTITUTE ON AGING
   [R01AG017473] Funding Source: NIH RePORTER
FX This study was supported in part by grant R01-AG017473 from the National
   Institute on Aging (Dr Sloan and Mr Hanrahan).
CR [Anonymous], 1986, Arch Ophthalmol, V104, P694
   Austin PC, 2007, STAT MED, V26, P734, DOI 10.1002/sim.2580
   Becerra EM, 2011, CURR DRUG TARGETS, V12, P149
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Coleman AL, 1997, SURV OPHTHALMOL, V42, P271, DOI 10.1016/S0039-6257(97)00095-7
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FINE SL, 1983, ARCH OPHTHALMOL-CHIC, V101, P1358
   Gillies MC, 2007, AM J OPHTHALMOL, V144, P134, DOI 10.1016/j.ajo.2007.03.019
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hahn JY, 2001, ECONOMETRICA, V69, P201, DOI 10.1111/1468-0262.00183
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Javitt JC, 2007, OPHTHALMOLOGY, V114, P238, DOI 10.1016/j.ophtha.2006.07.054
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MITCHELL JB, 1994, MED CARE, V32, pJS38
   Normand SLT, 2001, J CLIN EPIDEMIOL, V54, P387, DOI 10.1016/S0895-4356(00)00321-8
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Stein JD, 2013, AM J OPHTHALMOL, V155, P688, DOI 10.1016/j.ajo.2012.10.003
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Vu HTV, 2005, BRIT J OPHTHALMOL, V89, P360, DOI 10.1136/bjo.2004.047498
   Wysong A, 2009, ARCH OPHTHALMOL-CHIC, V127, P320, DOI 10.1001/archophthalmol.2008.613
NR 35
TC 40
Z9 42
U1 0
U2 12
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD APR
PY 2014
VL 132
IS 4
BP 456
EP 463
DI 10.1001/jamaophthalmol.2013.7647
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AJ7QF
UT WOS:000337890500012
PM 24458013
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Krishnan, R
   Arora, R
   De Salvo, G
   Stinghe, A
   Severn, PS
   Pal, B
   Goverdhan, S
AF Krishnan, Radhika
   Arora, Rashi
   De Salvo, Gabriella
   Stinghe, Alina
   Severn, Philip S.
   Pal, Bishwanath
   Goverdhan, Srinivas
TI VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR
   TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; COMPLEMENT FACTOR-H; CHOROIDAL
   NEOVASCULARIZATION; PHARMACOLOGICAL VITREOLYSIS; PHOTODYNAMIC THERAPY;
   BEVACIZUMAB AVASTIN; DOSING REGIMEN; RANIBIZUMAB; ADHESION; OCRIPLASMIN
AB Purpose:
   To evaluate the effect of vitreomacular traction (VMT) on visual acuity outcomes and central retinal thickness (CRT) measurements after intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for treatment of exudative age-related macular degeneration (AMD).
   Methods:
   In this retrospective series, the authors evaluate the clinical records and optical coherence tomography of 34 eyes of 32 patients, with VMT confirmed on optical coherence tomography at baseline, to assess the effects of VMT on anti-VEGF therapy for newly diagnosed exudative wet AMD. Best-corrected visual acuity at baseline, 1, 3, 6, 9, and 12 months and CRT at baseline, 3, 6, and 12 months were assessed. Comparison was made with a control group of 29 eyes of 28 patients with wet AMD and no VMT on optical coherence tomography and with key variable-dosing studies for anti-VEGF in exudative AMD (CATT, HARBOR, PrONTO, SUSTAIN, and Gupta et al).
   Results:
   Best-corrected visual acuity results showed a visual acuity improvement that peaked at 3 months with 2.47 letters, well below other variable-dosing studies for anti-VEGF therapy in exudative AMD. This was then followed by a steady decline with mean best-corrected visual acuity at 12 months ending below the baseline level (-1.00 letters) compared with a gain of 9.39 letters in the control group at 12 months. Comparison of the mean CRT in the VMT group between baseline and 12 months showed no significant difference (P = 0.67), whereas the PrONTO study and control groups showed a highly significant difference at 12 months compared with baseline (P < 0.001). Mean CRT values at 6 months and 12 months were essentially at baseline levels (0.26 mu m, -0.62 mu m, respectively).
   Conclusion:
   Vitreomacular traction at baseline, existing concurrently with newly diagnosed exudative AMD treated with intravitreal anti-VEGF therapy on a variable-dosing regime, was associated with poorer visual outcomes and a decreased response to reduction in CRT, compared with a control group of wet AMD without VMT and compared with major variable-dosing studies for intravitreal anti-VEGF in exudative AMD.
C1 [Krishnan, Radhika; Arora, Rashi; De Salvo, Gabriella; Stinghe, Alina; Goverdhan, Srinivas] Southampton Univ Hosp, Southampton Eye Unit, Southampton SO16 6YD, Hants, England.
   [Krishnan, Radhika; Severn, Philip S.; Pal, Bishwanath] Moorfields Eye Hosp, London, England.
C3 University of Southampton; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust
RP Krishnan, R (通讯作者)，Southampton Univ Hosp, Southampton Eye Unit, Tremona Rd, Southampton SO16 6YD, Hants, England.
EM radhika.krishnan@uhs.nhs.uk
RI De Salvo, Gabriella/AAY-5016-2020
OI DE SALVO, Gabriella/0000-0002-1185-6942
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cho HJ, 2013, RETINA-J RET VIT DIS, V33, P2126, DOI 10.1097/IAE.0b013e3182899296
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Emoto Hirofumi, 2010, Retin Cases Brief Rep, V4, P312, DOI 10.1097/ICB.0b013e3181d426e8
   Filloy A, 2013, Arch Soc Esp Oftalmol, V88, P380, DOI 10.1016/j.oftal.2013.01.016
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Ikeda T, 2000, ACTA OPHTHALMOL SCAN, V78, P460, DOI 10.1034/j.1600-0420.2000.078004460.x
   Jackson TL, 2013, RETINA-J RET VIT DIS, V33, P1099, DOI 10.1097/IAE.0b013e31828991d6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rotsos T, 2010, BRIT J OPHTHALMOL, V94, P1205, DOI 10.1136/bjo.2009.173765
   Schmidt JC, 2006, BRIT J OPHTHALMOL, V90, P1361, DOI 10.1136/bjo.2006.094201
   Sebag J, 2009, RETINA-J RET VIT DIS, V29, P871, DOI 10.1097/IAE.0b013e3181ac7b3c
   Sebag J, 1998, RETINA-J RET VIT DIS, V18, P1
   Stalmans P, 2012, NEW ENGL J MED, V367, P606, DOI 10.1056/NEJMoa1110823
   Syed YY, 2013, DRUGS, V73, P1617, DOI 10.1007/s40265-013-0124-1
NR 29
TC 15
Z9 18
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2015
VL 35
IS 9
BP 1750
EP 1756
DI 10.1097/IAE.0000000000000714
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CR2YK
UT WOS:000361196600006
PM 26237240
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Jiang, H
   Shi, X
   Fan, YH
   Wang, DL
   Li, BY
   Zhou, J
   Pei, C
   Ma, L
AF Jiang, Hong
   Shi, Xin
   Fan, Yahui
   Wang, Duolao
   Li, Baoyu
   Zhou, Jin
   Pei, Cheng
   Ma, Le
TI Dietary omega-3 polyunsaturated fatty acids and fish intake and risk of
   age-related macular degeneration
SO CLINICAL NUTRITION
LA English
DT Article
DE Omega-3 polyunsaturated fatty acids; Fish; Age-related macular
   degeneration; Meta-analysis
ID DOCOSAHEXAENOIC ACID; EICOSAPENTAENOIC ACID; ASSOCIATION; HEALTH;
   CONSUMPTION; PROGRESSION; DISEASE; OMEGA-3-FATTY-ACIDS; MACULOPATHY
AB Background & aims: Epidemiologic studies are inconsistent regarding the association of dietary omega-3 polyunsaturated fatty acids (PUFA) and/or fish intake with risk of age-related macular degeneration (AMD) incidence and progression. The objective was to determine these associations by conducting a meta-analysis of available studies. Methods: Three electronic databases were searched for studies that quantified dietary omega-3 PUFA and/or fish intake from inception to December 2020 without language restriction. Three investigators independently assessed for inclusion and extracted data. Study-specific risk estimates were combined using random-effects model. Potential dose-response associations were explored with the use of generalized least-squares trend estimation. Results: 21 studies were included in the meta-analysis. Higher dietary intakes of omega-3 PUFA was significantly associated with 14% (relative risk [RR]: 0.86, 95% confidence interval [CI]: 0.77, 0.96) and 29% (RR: 0.71, 95% CI: 0.55, 0.91) lower risk of early and late AMD, respectively. The dose-response analysis showed a 6% and 22% decrease in the risk of early and late AMD for each additional 1 g/d omega-3 PUFA intake. For individual omega-3 PUFA, the intake of eicosapentaenoic acid and docosahexaenoic acid was inversely associated with lower AMD risk, whereas no association was found for the alpha-linolenic acid. Consistent inverse associations were also found between fish intake and AMD. The pooled RRs comparing extreme categories of fish intake were 0.79 (95% CI: 0.70, 0.90) and 0.71 (95% CI: 0.60, 0.85) for early and late AMD risk, respectively. Every 15 g/d of fish consumption was associated with 13% and 14% lower early and late AMD. In addition, fish intake was associated with a significantly reduced risk of AMD progression (RR: 0.73, 95% CI: 0.53, 1.00). Conclusions: A high intake of dietary omega-3 PUFA or fish was associated with a reduced risk of developing of AMD, which further supports that consumption of omega-3 PUFA-rich foods may be a new avenue nutritional approach to preventing AMD. Crown Copyright (c) 2021 Published by Elsevier Ltd. All rights reserved.
C1 [Jiang, Hong; Pei, Cheng] Xi An Jiao Tong Univ, Affiliated Hosp 1, Hlth Sci Ctr, Xian, Peoples R China.
   [Jiang, Hong] Xi An Jiao Tong Univ, Coll Stomatol, Key Lab Shaanxi Prov Craniofacial Precis Med Res, Xian, Peoples R China.
   [Jiang, Hong; Shi, Xin; Fan, Yahui; Li, Baoyu; Ma, Le] Xi An Jiao Tong Univ, Sch Publ Hlth, Hlth Sci Ctr, 76 Yanta West Rd, Xian, Peoples R China.
   [Wang, Duolao] Univ Liverpool Liverpool Sch Trop Med, Dept Clin Sci, Liverpool, Merseyside, England.
   [Zhou, Jin] Chinese Nutr Soc Acad Nutr & Hlth, Beijing Zhongyinghui Nutr & Hlth Res Inst, Beijing, Peoples R China.
   [Ma, Le] Xi An Jiao Tong Univ, Key Lab Environm & Genes Related Dis, Minist Educ China, Xian, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Jiaotong
   University; Liverpool School of Tropical Medicine; Ministry of
   Education, China; Xi'an Jiaotong University
RP Ma, L (通讯作者)，Xi An Jiao Tong Univ, Sch Publ Hlth, Hlth Sci Ctr, 76 Yanta West Rd, Xian, Peoples R China.; Zhou, J (通讯作者)，Chinese Nutr Soc Acad Nutr & Hlth, Beijing Zhongyinghui Nutr & Hlth Res Inst, Beijing, Peoples R China.; Pei, C (通讯作者)，Xi An Jiao Tong Univ, Hlth Sci Ctr, Affiliated Hosp 1, Dept Ophthalmol, Xian, Peoples R China.
EM zj@cnsoc.org; peich71@163.com; male@mail.xjtu.edu.cn
OI Wang, Duolao/0000-0003-2788-2464
FU National Natural Science Foundation of China [NSFC-82022062,
   NSFC-81973025, NSFC-81473059]; Beijing Zhongyinghui Nutrition and Health
   Research Institute; Chinese Nutrition Society Academy of Nutrition and
   Health [CNSCI2021043]; Nutrition Science Research Foundation of
   BY-HEALTH [TY0181101]; Natural Science Foundation of Shaanxi Province of
   China [2017JM8041]; New-star Plan of Science and Technology of Shaanxi
   Province [2015LJXX-07]; Nutrition Research Foundation Fund of the
   Chinese Nutrition Society-DSM Special Research Foundation
   [CNSDSM2016-041]; Funda-mental Research Funds for the Central
   Universities [qngz2016004, xzy032019008]
FX This work was Supported by the National Natural Science Foundation of
   China (NSFC-82022062; NSFC-81973025; NSFC-81473059) ; Beijing
   Zhongyinghui Nutrition and Health Research Institute, the Chinese
   Nutrition Society Academy of Nutrition and Health (CNSCI2021043) ;
   Nutrition Science Research Foundation of BY-HEALTH (TY0181101) ; the
   Natural Science Foundation of Shaanxi Province of China (2017JM8041) ;
   New-star Plan of Science and Technology of Shaanxi Province
   (2015LJXX-07) ; the Nutrition Research Foundation Fund of the Chinese
   Nutrition Society-DSM Special Research Foundation (CNSDSM2016-041) ; and
   the Funda-mental Research Funds for the Central Universities
   (qngz2016004; xzy032019008) .
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Agbaga MP, 2018, J LIPID RES, V59, P1586, DOI 10.1194/jlr.M082495
   Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Agron E, 2021, OPHTHALMOLOGY, V128, P425, DOI 10.1016/j.ophtha.2020.08.018
   Aldosari S, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7010014
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chowdhury R, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6698
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Ding M, 2015, CIRCULATION, V132, P2305, DOI 10.1161/CIRCULATIONAHA.115.017341
   Herforth A, 2019, ADV NUTR, V10, P590, DOI 10.1093/advances/nmy130
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Hu Y, 2018, GASTROENTEROLOGY, V154, P916, DOI 10.1053/j.gastro.2017.11.010
   Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193
   International Society for the Study of Fatty Acids, 2004, REP SUB COMM REC INT
   Jiang L, 2021, NUTRIENTS, V13, DOI 10.3390/nu13072342
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Keenan TD, 2020, OPHTHALMOLOGY, V127, P1515, DOI 10.1016/j.ophtha.2020.04.030
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Leung KS, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7080096
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Micha R, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2272
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041
   Orsini N, 2006, STATA J, V6, P40, DOI 10.1177/1536867X0600600103
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Qiu S, 2017, NEUROSCI LETT, V657, P53, DOI 10.1016/j.neulet.2017.07.041
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   Roh M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.20
   Rong Y, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e8539
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sasaki M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.23
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   So J, 2021, ATHEROSCLEROSIS, V316, P90, DOI 10.1016/j.atherosclerosis.2020.11.018
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Swanson D, 2012, ADV NUTR, V3, P1, DOI 10.3945/an.111.000893
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   von Schacky C, 1999, ANN INTERN MED, V130, P554, DOI 10.7326/0003-4819-130-7-199904060-00003
   Wells GA., NEWCASTLE OTTAWA SCA
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2017, OPHTHALMOLOGY, V124, P634, DOI 10.1016/j.ophtha.2016.12.033
   Zeng Xiantao, 2015, J Evid Based Med, V8, P2, DOI 10.1111/jebm.12141
   Zhang Y, 2018, J INTERN MED, V284, P399, DOI 10.1111/joim.12786
   Zheng JS, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3706
   Zhu W, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110743
NR 58
TC 3
Z9 3
U1 7
U2 16
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0261-5614
EI 1532-1983
J9 CLIN NUTR
JI Clin. Nutr.
PD DEC
PY 2021
VL 40
IS 12
BP 5662
EP 5673
DI 10.1016/j.clnu.2021.10.005
PG 12
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA YB7CY
UT WOS:000739166800003
PM 34749130
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Nakata, I
   Yamashiro, K
   Yamada, R
   Gotoh, N
   Nakanishi, H
   Hayashi, H
   Tsujikawa, A
   Otani, A
   Ooto, S
   Tamura, H
   Saito, M
   Saito, K
   Iida, T
   Oishi, A
   Kurimoto, Y
   Matsuda, F
   Yoshimura, N
AF Nakata, Isao
   Yamashiro, Kenji
   Yamada, Ryo
   Gotoh, Norimoto
   Nakanishi, Hideo
   Hayashi, Hisako
   Tsujikawa, Akitaka
   Otani, Atsushi
   Ooto, Sotaro
   Tamura, Hiroshi
   Saito, Masaaki
   Saito, Kuniharu
   Iida, Tomohiro
   Oishi, Akio
   Kurimoto, Yasuo
   Matsuda, Fumihiko
   Yoshimura, Nagahisa
TI Genetic Variants in Pigment Epithelium-Derived Factor Influence Response
   of Polypoidal Choroidal Vasculopathy to Photodynamic Therapy
SO OPHTHALMOLOGY
LA English
DT Article
ID GROWTH-FACTOR VEGF; MACULAR DEGENERATION; CIGARETTE-SMOKING;
   VERTEPORFIN; EXPRESSION; OUTCOMES; PEDF; POLYMORPHISMS; RECURRENCE;
   GENOTYPE
AB Purpose: To investigate whether photodynamic therapy (PDT) outcomes of polypoidal choroidal vasculopathy (PCV) are related to baseline clinical characteristics, smoking history, or genetic factors by analyzing the retreatment-free period after the first PDT.
   Design: Retrospective cohort study.
   Participants: The study consisted of 167 patients with PCV who underwent PDT as their first treatment.
   Methods: We targeted 638 single nucleotide polymorphisms (SNPs) in 42 possible susceptible genes for age-related macular degeneration to evaluate their relation to the effectiveness of PDT for PCV. For this evaluation, we used 2 methods: (1) survival analysis, with the retreatment-free period as the target; and (2) logistic regression test between the need for additional therapy within 3 months after the first PDT and the genotypes, with age, gender, smoking status, and greatest linear dimension (GLD) at baseline as covariates. The contributions of smoking status and GLD at baseline for the retreatment-free period also were evaluated. Contributions of these factors to visual prognosis were evaluated for 1 year after PDT.
   Main Outcome Measures: Retreatment-free period after the first PDT for PCV. Secondary outcome measures included correlation of the susceptible factor to the retreatment requirement within the 3-month follow-up and the mean visual acuity change.
   Results: In survival analyses, SERPINF1 rs12603825 showed a significant association with the retreatment-free period after the first PDT; those patients homozygous for the minor allele A of rs12603825 received additional treatment after PDT within significantly shorter times than those with other genotypes (P = 0.0038). There was no significant difference in the retreatment-free period between baseline GLD and smoking status. Retreatment within 3 months was required significantly more in patients with the AA genotype, even after taking into consideration the effect of clinical characteristics (age, gender), baseline PCV lesion size, and smoking status (P = 0.0027). Furthermore, patients with the AA genotype showed significantly worse visual prognosis after PDT (P = 0.013).
   Conclusions: Pigment epithelium-derived factor (SERPINF1 or PEDF) polymorphisms may influence the initial response to and visual prognosis after PDT for PCV. Our findings may lead to understanding the pathogenesis of PCV and modification of the effects of PDT.
C1 [Nakata, Isao; Yamashiro, Kenji; Gotoh, Norimoto; Nakanishi, Hideo; Hayashi, Hisako; Tsujikawa, Akitaka; Otani, Atsushi; Ooto, Sotaro; Tamura, Hiroshi; Yoshimura, Nagahisa] Kyoto Univ, Dept Ophthalmol, Grad Sch Med, Kyoto 6068507, Japan.
   [Nakata, Isao; Yamada, Ryo; Gotoh, Norimoto; Nakanishi, Hideo; Hayashi, Hisako; Matsuda, Fumihiko] Kyoto Univ, Grad Sch Med, Ctr Genom Med, Inserm,U852, Kyoto, Japan.
   [Saito, Masaaki; Saito, Kuniharu; Iida, Tomohiro] Fukushima Med Univ, Dept Ophthalmol, Fukushima, Japan.
   [Oishi, Akio; Kurimoto, Yasuo] Gen Hosp, Kobe City Med Ctr, Dept Ophthalmol, Kobe, Hyogo, Japan.
C3 Kyoto University; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Kyoto University; Fukushima Medical University; Kobe
   City Medical Center General Hospital
RP Yamashiro, K (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI Saito, Masaaki/ABI-2783-2020; Matsuda, Fumihiko/B-9893-2009; Oishi,
   Akio/AAE-9996-2020; TAMURA, Hiroshi/H-1855-2011
OI Saito, Masaaki/0000-0003-1494-6350; Oishi, Akio/0000-0002-0977-9458;
   TAMURA, Hiroshi/0000-0002-7740-2732; Yamada, Ryo/0000-0002-1587-630X;
   Yamashiro, Kenji/0000-0001-9354-8558; Tsujikawa,
   Akitaka/0000-0003-0779-7799
FU Japan Society for the Promotion of Science, Tokyo, Japan [21249084,
   200791294]; Japan National Society for the Prevention of Blindness,
   Tokyo, Japan
FX Supported in part by grants-in-aid for scientific research (Nos.
   21249084 and 200791294) from the Japan Society for the Promotion of
   Science, Tokyo, Japan, and the Japan National Society for the Prevention
   of Blindness, Tokyo, Japan. The funding organizations had no role in the
   design or conduct of this research.
CR Arias L, 2005, BRIT J OPHTHALMOL, V89, P312, DOI 10.1136/bjo.2004.050997
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Huber KE, 2009, SEMIN RADIAT ONCOL, V19, P204, DOI 10.1016/j.semradonc.2009.05.004
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Imai D, 2005, J CELL PHYSIOL, V202, P570, DOI 10.1002/jcp.20155
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Jalali S, 2006, AM J OPHTHALMOL, V142, P608, DOI 10.1016/j.ajo.2006.05.055
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Obata R, 2007, BRIT J OPHTHALMOL, V91, P100, DOI 10.1136/bjo.2006.098004
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Van den Eynde E, 2010, AIDS, V24, P975, DOI 10.1097/QAD.0b013e3283350f7c
   Yamashiro K, 2008, JPN J OPHTHALMOL, V52, P457, DOI 10.1007/s10384-008-0582-2
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yokoi M, 2007, BRIT J OPHTHALMOL, V91, P885, DOI 10.1136/bjo.2006.110890
   1999, ARCH OPHTHALMOL CHIC, V117, P1329
NR 50
TC 21
Z9 23
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2011
VL 118
IS 7
BP 1408
EP 1415
DI 10.1016/j.ophtha.2010.12.011
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 786JL
UT WOS:000292303000026
PM 21439646
OA Green Submitted
DA 2022-11-30
ER

PT J
AU van Dijk, EHC
   van Rijssen, TJ
   Subhi, Y
   Boon, CJF
AF van Dijk, Elon H. C.
   van Rijssen, Thomas J.
   Subhi, Yousif
   Boon, Camiel J. F.
TI Photodynamic Therapy for Chorioretinal Diseases: A Practical Approach
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Central serous chorioretinopathy; Choroidal hemangioma; Photodynamic
   therapy; Polypoidal choroidal vasculopathy
ID CENTRAL SEROUS CHORIORETINOPATHY; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   HALF-DOSE VERTEPORFIN; INDOCYANINE GREEN ANGIOGRAPHY; RANDOMIZED
   CLINICAL-TRIALS; EFFICACY; FLUENCE; HEMANGIOMA; SAFETY; LASER
AB Photodynamic therapy (PDT) using verteporfin (Visudyne (R); Bausch + Lomb) is a treatment that is widely used to elicit cell and tissue death. In ophthalmology, PDT targets choroidal vascular abnormalities and induces selective occlusion of vessels. PDT was originally used in combination with full-dose verteporfin to treat neovascular age-related macular degeneration. Since the introduction of treatment with vascular endothelial growth factor receptor inhibitors, the clinical targets of PDT have shifted to other chorioretinal conditions, such as central serous chorioretinopathy, polypoidal choroidal vasculopathy, and choroidal hemangioma. In recent years, clinical studies have facilitated the optimization of treatment outcomes through changes in protocols, including the introduction of reduced treatment settings, such as PDT with half-dose verteporfin and half-fluence PDT. Here, we review PDT and its use for chorioretinal diseases from a practical perspective.
C1 [van Dijk, Elon H. C.; van Rijssen, Thomas J.; Boon, Camiel J. F.] Leiden Univ, Med Ctr, Dept Ophthalmol, Leiden, Netherlands.
   [Subhi, Yousif] Zealand Univ Hosp, Dept Ophthalmol, Roskilde, Denmark.
   [Subhi, Yousif] Rigshosp, Dept Ophthalmol, Glostrup, Denmark.
   [Boon, Camiel J. F.] Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands.
C3 Leiden University; Leiden University Medical Center (LUMC); Leiden
   University - Excl LUMC; Rigshospitalet; University of Amsterdam
RP van Dijk, EHC (通讯作者)，Leiden Univ, Med Ctr, Dept Ophthalmol, Leiden, Netherlands.
EM ehcvandijk@lumc.nl
RI Subhi, Yousif/ABG-6330-2020
OI Subhi, Yousif/0000-0001-6620-5365
FU Stichting Macula Fonds; Retina Nederland Onderzoek Fonds; Stichting
   Blinden-Penning; Algemene Nederlandse Vereniging ter Voorkoming van
   Blindheid; Landelijke Stichting voor Blinden en Slechtzienden, which
   contributed through UitZicht (Delft, the Netherlands); Rotterdamse
   Stichting Blindenbelangen (Rotterdam, the Netherlands); Stichting Leids
   Oogheelkundig Ondersteuningsfonds (Leiden, the Netherlands); Haagse
   Stichting Blindenhulp (The Hague, the Netherlands); Stichting Ooglijders
   (Rotterdam, the Netherlands); Gisela Thier Fellowship of Leiden
   University, Leiden, the Netherlands; Netherlands Organisation for
   Scientific Research (VENI grant)
FX This study was supported by Stichting Macula Fonds; Retina Nederland
   Onderzoek Fonds; Stichting Blinden-Penning; Algemene Nederlandse
   Vereniging ter Voorkoming van Blindheid; Landelijke Stichting voor
   Blinden en Slechtzienden, which contributed through UitZicht (Delft, the
   Netherlands); Rotterdamse Stichting Blindenbelangen (Rotterdam, the
   Netherlands); Stichting Leids Oogheelkundig Ondersteuningsfonds (Leiden,
   the Netherlands); Haagse Stichting Blindenhulp (The Hague, the
   Netherlands); Stichting Ooglijders (Rotterdam, the Netherlands); the
   Gisela Thier Fellowship of Leiden University, Leiden, the Netherlands
   (CJFB); and the Netherlands Organisation for Scientific Research (VENI
   grant to CJFB). These funding organizations provided unrestricted grants
   and had no role in the design or conduct of this research. No funding or
   sponsorship was received for the publication of this article.
CR Alkin Z, 2014, CLIN OPHTHALMOL, V8, P685, DOI 10.2147/OPTH.S58617
   [Anonymous], 2008, INVESTIGATORS BROCHU
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Blasi MA, 2010, OPHTHALMOLOGY, V117, P1630, DOI 10.1016/j.ophtha.2009.12.033
   Boixadera A, 2009, OPHTHALMOLOGY, V116, P100, DOI 10.1016/j.ophtha.2008.08.029
   Bown SG, 1998, BRIT MED J, V316, P754, DOI 10.1136/bmj.316.7133.754
   Breukink MB, 2016, ACTA OPHTHALMOL, V94, P565, DOI 10.1111/aos.13059
   Chan WM, 2003, BRIT J OPHTHALMOL, V87, P1453, DOI 10.1136/bjo.87.12.1453
   Cheng CK, 2017, RETINA-J RET VIT DIS, V37, P325, DOI 10.1097/IAE.0000000000001138
   Chung CY, 2018, OPHTHALMOLOGICA, V240, P37, DOI 10.1159/000484100
   DANIELL MD, 1991, AUST NZ J SURG, V61, P340, DOI 10.1111/j.1445-2197.1991.tb00230.x
   Doble B, 2020, JAMA OPHTHALMOL, V138, P251, DOI 10.1001/jamaophthalmol.2019.5628
   Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   EPSTEIN JH, 1990, NEW ENGL J MED, V322, P1149, DOI 10.1056/NEJM199004193221609
   Farooq A, 2017, OSLI RETINA, V48, P34, DOI 10.3928/23258160-20161219-05
   GOMER CJ, 1989, SEMIN HEMATOL, V26, P27
   Haga F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181479
   HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x
   Jurklies B, 2003, BRIT J OPHTHALMOL, V87, P84, DOI 10.1136/bjo.87.1.84
   Karim R, 2013, CLIN OPHTHALMOL, V7, P1109, DOI 10.2147/OPTH.S40268
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lai FHP, 2016, AM J OPHTHALMOL, V170, P91, DOI 10.1016/j.ajo.2016.07.026
   Lai TYY, 2006, BRIT J OPHTHALMOL, V90, P869, DOI 10.1136/bjo.2006.090282
   Lai TYY, 2012, ASIA-PAC J OPHTHALMO, V1, P97, DOI 10.1097/APO.0b013e31823e5a95
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Liu CF, 2014, J OCUL PHARMACOL TH, V30, P400, DOI 10.1089/jop.2013.0169
   Lotery A, 2020, LANCET, V395, P294, DOI 10.1016/S0140-6736(19)32981-2
   Mohabati D, 2020, RETINA-J RET VIT DIS, V40, P1742, DOI 10.1097/IAE.0000000000002683
   Mohabati D, 2018, CLIN OPHTHALMOL, V12, P1061, DOI 10.2147/OPTH.S160956
   Newman DK, 2016, EYE, V30, P202, DOI 10.1038/eye.2015.251
   Nicolo M, 2014, AM J OPHTHALMOL, V157, P1033, DOI 10.1016/j.ajo.2014.01.022
   Nicolo M, 2012, AM J OPHTHALMOL, V153, P474, DOI 10.1016/j.ajo.2011.08.015
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Palkar AH, 2019, TAIWAN J OPHTHALMOL, V9, P72, DOI 10.4103/tjo.tjo_35_18
   Piccolino FC, 2003, RETINA-J RET VIT DIS, V23, P752, DOI 10.1097/00006982-200312000-00002
   Piccolino FC, 2008, RETINA-J RET VIT DIS, V28, P1008, DOI 10.1097/IAE.0b013e31816b4b86
   Porrini G, 2003, OPHTHALMOLOGY, V110, P674, DOI 10.1016/S0161-6420(02)01968-1
   Ruiz-Moreno JM, 2010, ACTA OPHTHALMOL, V88, P371, DOI 10.1111/j.1755-3768.2008.01408.x
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth UM, 2002, OPHTHALMOLOGY, V109, P2284, DOI 10.1016/S0161-6420(02)01454-9
   Shields CL, 2020, OPHTHALMOL RETINA, V4, P100, DOI 10.1016/j.oret.2019.08.004
   Shin JY, 2011, RETINA-J RET VIT DIS, V31, P119, DOI 10.1097/IAE.0b013e3181e378f2
   Singh AD, 2004, BRIT J OPHTHALMOL, V88, P1414, DOI 10.1136/bjo.2004.044396
   Taban M, 2004, AM J OPHTHALMOL, V137, P1073, DOI 10.1016/j.ajo.2004.01.043
   Theelen T, 2008, EUR J OPHTHALMOL, V18, P805, DOI 10.1177/112067210801800523
   Tseng CC, 2015, BRIT J OPHTHALMOL, V99, P1070, DOI 10.1136/bjophthalmol-2014-305353
   van Dijk EHC, 2018, OPHTHALMOLOGY, V125, P1547, DOI 10.1016/j.ophtha.2018.04.021
   van Dijk Elon H C, 2018, Retin Cases Brief Rep, V12, P266, DOI 10.1097/ICB.0000000000000498
   van Rijssen TJ, 2019, PROG RETIN EYE RES, V73, DOI 10.1016/j.preteyeres.2019.07.003
   van Rijssen TJ, 2018, GRAEF ARCH CLIN EXP, V256, P1395, DOI 10.1007/s00417-018-4003-z
   Verbraak FD, 2006, GRAEF ARCH CLIN EXP, V244, P1178, DOI 10.1007/s00417-005-0152-y
   Verbraak FD, 2003, GRAEF ARCH CLIN EXP, V241, P891, DOI 10.1007/s00417-003-0765-y
   Wang MSM, 2002, AM J OPHTHALMOL, V133, P787, DOI 10.1016/S0002-9394(02)01438-1
   Wong IY, 2018, RETINA-J RET VIT DIS, V38, P725, DOI 10.1097/IAE.0000000000001614
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Yannuzzi LA, 2003, RETINA-J RET VIT DIS, V23, P288, DOI 10.1097/00006982-200306000-00002
   Zhao MW, 2009, RETINA-J RET VIT DIS, V29, P1155, DOI 10.1097/IAE.0b013e3181a6c028
   Zhao MW, 2015, JAMA OPHTHALMOL, V133, P333, DOI 10.1001/jamaophthalmol.2014.5312
NR 61
TC 15
Z9 15
U1 2
U2 8
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD JUN
PY 2020
VL 9
IS 2
BP 329
EP 342
DI 10.1007/s40123-020-00250-0
EA APR 2020
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LJ0UY
UT WOS:000525154300001
PM 32279234
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Fleckenstein, M
   Schmitz-Valckenberg, S
   Adrion, C
   Kramer, I
   Eter, N
   Helb, HM
   Brinkmann, CK
   Issa, PC
   Mansmann, U
   Holz, FG
AF Fleckenstein, Monika
   Schmitz-Valckenberg, Steffen
   Adrion, Christine
   Kraemer, Irene
   Eter, Nicole
   Helb, Hans Martin
   Brinkmann, Christian K.
   Issa, Peter Charbel
   Mansmann, Ulrich
   Holz, Frank G.
TI Tracking Progression with Spectral-Domain Optical Coherence Tomography
   in Geographic Atrophy Caused by Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FUNDUS AUTOFLUORESCENCE PATTERNS; DISEASE PROGRESSION; NATURAL-HISTORY;
   JUNCTIONAL ZONE; CLINICAL-TRIALS; HIGH-RISK; IN-VIVO; MACULOPATHY; EYE;
   OCT
AB PURPOSE. To investigate, with the use of spectral-domain optical coherence tomography (SD-OCT), microstructural alterations over time in eyes with progressive geographic atrophy (GA) due to age-related macular degeneration.
   METHODS. Forty-six eyes of 26 patients (median age, 77.9 years [interquartile range (IQR), 71.8-81.0]) with GA without evidence of active or previous neovascular disease at baseline were examined by simultaneous confocal scanning laser ophthalmoscopy (cSLO) and SD-OCT. Serial examinations with alignment of follow-up to baseline scans were performed over a median period of 12.2 months (IQR, 10.2-15.3). Longitudinal SD-OCT variations were evaluated, including quantification of retinal thickness (RT) change and lateral spread of GA (LSGA) at a temporal, nasal, inferior, and superior GA border-section in each eye.
   RESULTS. GA-enlargement was characterized by progressive loss of the outer hyperreflective SD-OCT bands and by thinning of the outer nuclear layer with subsequent approach of the outer plexiform layer toward Bruch's membrane. In the perilesional zone, various dynamic changes were recorded, including migration of hyperreflective material and changes in drusen height. At the borders, there was a median RT change of -14.09 mu m/y (IQR -26.21 to -7.48 mu m/y). The median LSGA was 106.90 mu m/y (IQR, 55.44-161.70 mu m/y). Both parameters showed only moderate intraocular agreement (RT change: intraclass correlation coefficient [ICC], 0.54; 95% CI, 0.39-0.67; LSGA: ICC, 0.49; 95% CI, 0.34-0.64) and no statistical significant difference for one location (RT change, P = 0.125; LSGA, P = 0.516; likelihood ratio test).
   CONCLUSIONS. Combined cSLO and SD-OCT imaging provides unprecedented insight into dynamic microstructural changes of GA enlargement that may help to better understand the pathogenesis of the disease. Quantitative progression data indicate local factors may exist that drive progression in junctional areas (ClinicalTrials.gov number, NCT00393692). (Invest Ophthalmol Vis Sci. 2010; 51: 3846-3852) DOI: 10.1167/iovs.09-4533
C1 [Fleckenstein, Monika; Schmitz-Valckenberg, Steffen; Kraemer, Irene; Eter, Nicole; Helb, Hans Martin; Brinkmann, Christian K.; Issa, Peter Charbel; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Adrion, Christine; Mansmann, Ulrich] Univ Munich, Dept Med Informat Biometry & Epidemiol, Munich, Germany.
   [Issa, Peter Charbel] Univ Oxford, Nuffield Lab Ophthalmol, Oxford OX2 6AW, England.
C3 University of Bonn; University of Munich; University of Oxford
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM frank.holz@ukb.uni-bonn.de
RI Issa, Peter Charbel/F-9603-2011; Issa, Peter Charbel/O-2580-2019;
   Adrion, Christine/AAB-7247-2020; Issa, Peter Charbel/E-8935-2018
OI Issa, Peter Charbel/0000-0002-0351-6673; Adrion,
   Christine/0000-0003-2408-2533; Issa, Peter Charbel/0000-0002-0351-6673;
   Fleckenstein, Monika/0000-0001-8321-8037
FU German Research Council [SPP 1088, Ho 1926/1-3]; German Society of
   Ophthalmology; Faculty of Medicine, University of Bonn [O-137-0012];
   European Community [237238]
FX Supported by the German Research Council, Research Priority Program
   Age-Related Macular Degeneration SPP 1088, Ho 1926/1-3; German Society
   of Ophthalmology research grant; BONFOR Program Grant O-137-0012
   (Faculty of Medicine, University of Bonn); Marie Curie Intra-European
   Fellowship (237238), 7th European Community Framework Program.
   Heidelberg Engineering provided the Spectralis HRA + OCT.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   de Boer JF, 2003, OPT LETT, V28, P2067, DOI 10.1364/OL.28.002067
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   Drexler W, 2004, J BIOMED OPT, V9, P47, DOI 10.1117/1.1629679
   Drexler Wolfgang, 2007, Invest Ophthalmol Vis Sci, V48, P5339
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Fleckenstein M, 2008, ARCH OPHTHALMOL-CHIC, V126, P1461, DOI 10.1001/archopht.126.10.1461
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P637, DOI 10.1167/iovs.09-3547
   GREEN WR, 2005, T AM OPHTHALMOL S, V75, P180
   GREEN WR, 2005, T AM OPHTHALMOL S, V75, P250
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hassenstein A, 2009, CLIN EXP OPHTHALMOL, V37, P130, DOI 10.1111/j.1442-9071.2009.02017.x
   HELB HM, ACTA OPHTHA IN PRESS
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Issa PC, 2009, INVEST OPHTH VIS SCI, V50, P5913, DOI 10.1167/iovs.09-3541
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 2008, AM J OPHTHALMOL
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Sunness JS, 2007, RETINA-J RET VIT DIS, V27, P204, DOI 10.1097/01.iae.0000248148.56560.b1
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
NR 49
TC 94
Z9 95
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2010
VL 51
IS 8
BP 3846
EP 3852
DI 10.1167/iovs.09-4533
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 629JT
UT WOS:000280194100005
PM 20357194
DA 2022-11-30
ER

PT J
AU Veerappan, M
   El-Hage-Sleiman, AKM
   Tai, V
   Chiu, SJ
   Winter, KP
   Stinnett, SS
   Hwang, TS
   Hubbard, GB
   Michelson, M
   Gunther, R
   Wong, WT
   Chew, EY
   Toth, CA
AF Veerappan, Malini
   El-Hage-Sleiman, Abdul-Karim M.
   Tai, Vincent
   Chiu, Stephanie J.
   Winter, Katrina P.
   Stinnett, Sandra S.
   Hwang, Thomas S.
   Hubbard, G. Baker, III
   Michelson, Michelle
   Gunther, Randall
   Wong, Wai T.
   Chew, Emily Y.
   Toth, Cynthia A.
CA Age Related Eye Dis Study Ancillar
TI Optical Coherence Tomography Reflective Drusen Substructures Predict
   Progression to Geographic Atrophy in Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID EYE DISEASE; AUTOMATIC SEGMENTATION; COMPLEMENT ACTIVATION;
   HYPERREFLECTIVE FOCI; IDENTIFICATION; MACULOPATHY; EPITHELIUM;
   PATHOLOGY; IMAGES; SDOCT
AB Purpose: Structural and compositional heterogeneity within drusen comprising lipids, carbohydrates, and proteins have been previously described. We sought to detect and define phenotypic patterns of drusen heterogeneity in the form of optical coherence tomography-reflective drusen substructures (ODS) and examine their associations with age-related macular degeneration (AMD)-related features and AMD progression.
   Design: Retrospective analysis in a prospective study.
   Participants: Patients with intermediate AMD (n = 349) enrolled in the multicenter Age-Related Eye Disease Study 2 (AREDS2) ancillary spectral-domain optical coherence tomography (SD OCT) study.
   Methods: Baseline SD OCT scans of 1 eye per patient were analyzed for the presence of ODS. Cross-sectional and longitudinal associations of ODS presence with AMD-related features visible on SD OCT and color photographs, including drusen volume, geographic atrophy (GA), and preatrophic features, were evaluated for the entire macular region. Similar associations were also made locally within a 0.5-mm-diameter region around individual ODS and corresponding control region without ODS in the same eye.
   Main Outcome Measures: Preatrophy SD OCT changes and GA, central GA, and choroidal neovascularization (CNV) from color photographs.
   Results: Four phenotypic subtypes of ODS were defined: low reflective cores, high reflective cores, conical debris, and split drusen. Among the 349 participants, there were 307 eligible eyes and 74 (24%) had at least 1 ODS. The ODS at baseline were associated with (1) greater macular drusen volume at baseline (P < 0.001), (2) development of preatrophic changes at year 2 (P = 0.001-0.01), and (3) development of macular GA (P = 0.005) and preatrophic changes at year 3 (P = 0.002-0.008), but not development of CNV. The ODS at baseline in a local region were associated with (1) presence of preatrophy changes at baseline (P = 0.02-0.03) and (2) development of preatrophy changes at years 2 and 3 within the region (P = 0.008-0.05).
   Conclusions: Optical coherence tomography-reflective drusen substructures are optical coherence tomography-based biomarkers of progression to GA, but not to CNV, in eyes with intermediate AMD. Optical coherence tomography-reflective drusen substructures may be a clinical entity helpful in monitoring AMD progression and informing mechanisms in GA pathogenesis. (C) 2016 by the American Academy of Ophthalmology
C1 [Veerappan, Malini; El-Hage-Sleiman, Abdul-Karim M.; Tai, Vincent; Chiu, Stephanie J.; Winter, Katrina P.; Stinnett, Sandra S.; Hubbard, G. Baker, III; Michelson, Michelle; Chew, Emily Y.] Duke Univ, Med Ctr, Duke Eye Ctr, 2351 Erwin Rd,Box 3802, Durham, NC 27710 USA.
   [Hwang, Thomas S.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
   [Hubbard, G. Baker, III] Emory Univ, Emory Eye Ctr, Atlanta, GA 30322 USA.
   [Wong, Wai T.; Chew, Emily Y.] NEI, NIH, Bethesda, MD 20892 USA.
   [Toth, Cynthia A.] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA.
C3 Duke University; Oregon Health & Science University; Emory University;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Duke University
RP Veerappan, M (通讯作者)，Duke Univ, Med Ctr, Duke Eye Ctr, 2351 Erwin Rd,Box 3802, Durham, NC 27710 USA.
EM malini.veerappan@dm.duke.edu
RI Hwang, Thomas S./AAW-6618-2020; Hwang, Thomas/AAV-5146-2020; Sleiman,
   Karim/AAK-4247-2020; Toth, Cynthia/L-5534-2019; Mitchell,
   Paul/P-1498-2014; Wong, Wai/B-6118-2017
OI Hwang, Thomas S./0000-0002-0535-4823; Sleiman,
   Karim/0000-0002-4017-4908; Toth, Cynthia/0000-0002-2324-0854; Wong,
   Wai/0000-0003-0681-4016; Stinnett, Sandra/0000-0001-7192-0195; Farsiu,
   Sina/0000-0003-4872-2902
FU National Eye Institute; Genentech; Alcon; Bioptigen; NATIONAL EYE
   INSTITUTE [ZIAEY000554, ZIAEY000485, ZIAEY000541, R01EY023039] Funding
   Source: NIH RePORTER
FX The author(s) have made the following disclosure(s): A-K.M.E-H.S., V.T.,
   K.P.W., S.S.S., T.S.H., G.B.H., M.M., R.G., W.T.W., and E.Y.C.: Grants -
   National Eye Institute, Genentech, Alcon, and Bioptigen during the
   conduct of the study.; S.J.C.: Grants - National Eye Institute,
   Genentech, Alcon, and Bioptigen during the conduct of the study; Patent
   - segmentation and identification of layered structures in images (US
   20110182517 A1).; C.A.T.: Royalties - Alcon; Research grants for this
   study - National Eye Institute, Alcon, Bioptigen, and Genentech.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Horie-Inoue K, 2014, BIOCHEM BIOPH RES CO, V452, P263, DOI 10.1016/j.bbrc.2014.08.013
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kuhrt H, 1997, J BRAIN RES, V38, P223
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Loewenstein A, 2007, RETINA-J RET VIT DIS, V27, P873, DOI 10.1097/IAE.0b013e318050d2ec
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-58
   Querques G, 2011, AM J OPHTHALMOL, V152, P304, DOI 10.1016/j.ajo.2011.01.047
   Schlanitz FG, 2015, AM J OPHTHALMOL, V160, P335, DOI 10.1016/j.ajo.2015.05.008
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1163, DOI 10.1097/IAE.0b013e3181ed8d05
   Stopa M, 2008, RETINA-J RET VIT DIS, V28, P298, DOI 10.1097/IAE.0b013e3181567798
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Suzuki M, 2015, RETINA-J RET VIT DIS, V35, P859, DOI 10.1097/IAE.0000000000000503
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
NR 39
TC 42
Z9 44
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2016
VL 123
IS 12
BP 2554
EP 2570
DI 10.1016/j.ophtha.2016.08.047
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EE3YZ
UT WOS:000389539900023
PM 27793356
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Schmidt, S
   Scott, WK
   Postel, EA
   Agarwal, A
   Hauser, ER
   De La Paz, MA
   Gilbert, JR
   Weeks, DE
   Gorin, MB
   Haines, JL
   Pericak-Vance, MA
AF Schmidt, S
   Scott, WK
   Postel, EA
   Agarwal, A
   Hauser, ER
   De La Paz, MA
   Gilbert, JR
   Weeks, DE
   Gorin, MB
   Haines, JL
   Pericak-Vance, MA
TI Ordered subset linkage analysis supports a susceptibility locus for
   age-related macular degeneration on chromosome 16p12
SO BMC GENETICS
LA English
DT Article
ID STARGARDT-DISEASE GENE; APOLIPOPROTEIN-E GENE; BODY-MASS INDEX;
   RISK-FACTORS; ALLELIC VARIATION; GENOMEWIDE-SCAN;
   CARDIOVASCULAR-DISEASE; INTRAOCULAR-PRESSURE; ATHEROSCLEROSIS RISK;
   EPSILON-4 ALLELE
AB Background: Age-related macular degeneration (AMD) is a complex disorder that is responsible for the majority of central vision loss in older adults living in developed countries. Phenotypic and genetic heterogeneity complicate the analysis of genome-wide scans for AMD susceptibility loci. The ordered subset analysis (OSA) method is an approach for reducing heterogeneity, increasing statistical power for detecting linkage, and helping to define the most informative data set for follow-up analysis. OSA assesses the linkage evidence in subsets of potentially more homogeneous families by rank-ordering family-specific lod scores with respect to trait-associated covariates or phenotypic features. Here, we present results of incorporating five continuous covariates into our genome-wide linkage analysis of 389 microsatellite markers in 62 multiplex families: Body mass index (BMI), systolic (SBP) and diastolic (DBP) blood pressure, intraocular pressure (IOP), and pack-years of cigarette smoking. Chromosome-wide significance of increases in nonparametric multipoint lod scores in covariate-defined subsets relative to the overall sample was assessed by permutation.
   Results: Using a correction for testing multiple covariates, statistically significant lod score increases were observed for two chromosomal regions: 14q13 with a lod score of 3.2 in 28 families with average IOP less than or equal to 15.5 (p = 0.002), and 6q14 with a lod score of 1.6 in eight families with average BMI greater than or equal to 30.1 ( p = 0.0004). On chromosome 16p12, nominally significant lod score increases ( p = 0.05), up to a lod score of 2.9 in 32 families, were observed with several covariate orderings. While less significant, this was the only region where linkage evidence was associated with multiple clinically meaningful covariates and the only nominally significant finding when analysis was restricted to advanced forms of AMD. Families with linkage to 16p12 had higher averages of SBP, IOP and BMI and were primarily affected with neovascular AMD. For all three regions, linkage signals at or very near the peak marker have previously been reported.
   Conclusion: Our results suggest that a susceptibility gene on chromosome 16p12 may predispose to AMD, particularly to the neovascular form, and that further research into the previously suggested association of neovascular AMD and systemic hypertension is warranted.
C1 Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Duke Eye Ctr, Durham, NC USA.
   Vanderbilt Univ, Med Ctr, Dept Ophthalmol & Visual Sci, Nashville, TN USA.
   Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA.
   Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN USA.
C3 Duke University; Duke University; Vanderbilt University; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Vanderbilt
   University
RP Schmidt, S (通讯作者)，Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC 27710 USA.
EM silke.schmidt@duke.edu; bscott@chg.duhs.duke.edu; poste002@mc.duke.edu;
   anita.agarwal@vanderbilt.edu; bhauser@chg.duhs.duke.edu;
   poste002@mc.duke.edu; john@chg.duhs.duke.edu;
   dweeks@watson.hgen.pitt.edu; gorinmb@upmc.edu;
   jonathan@chgr.mc.vanderbilt.edu; mpv@chg.duhs.duke.edu
RI Weeks, Daniel E/B-2995-2012; Haines, Jonathan/C-3374-2012; Scott,
   William/A-7593-2009
OI Weeks, Daniel E/0000-0001-9410-7228; Haines,
   Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404;
   Hauser, Elizabeth/0000-0003-0367-9189
FU NATIONAL EYE INSTITUTE [R01EY009859, R01EY012118, U10EY012118] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG011268] Funding
   Source: NIH RePORTER
CR Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Atwood LD, 2002, AM J HUM GENET, V71, P1044, DOI 10.1086/343822
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Baird PN, 2002, INVEST OPHTH VIS SCI, V43, pU659
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011
   Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Elston RC, 2000, GENET EPIDEMIOL, V19, P1, DOI 10.1002/1098-2272(200007)19:1<1::AID-GEPI1>3.0.CO;2-E
   Epstein MP, 2000, AM J HUM GENET, V67, P1219, DOI 10.1016/S0002-9297(07)62952-8
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hauser ER, 1998, BIOMETRICS, V54, P1238, DOI 10.2307/2533653
   Hauser ER, 2004, GENET EPIDEMIOL, V27, P53, DOI 10.1002/gepi.20000
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Hennis A, 2003, OPHTHALMOLOGY, V110, P908, DOI 10.1016/S0161-6420(03)00075-7
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   KLAVER CC, 1998, AM J HUM GENET, V63, P1252
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein BEK, 2004, INVEST OPHTH VIS SCI, V45, P59, DOI 10.1167/iovs.03-0516
   KLEIN BEK, 1992, INVEST OPHTH VIS SCI, V33, P2224
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   Klein R, 1997, Trans Am Ophthalmol Soc, V95, P329
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kuroiwa S, 1999, BRIT J OPHTHALMOL, V83, P613, DOI 10.1136/bjo.83.5.613
   Leung H, 2003, INVEST OPHTH VIS SCI, V44, P2900, DOI 10.1167/iovs.02-1114
   Magnusson KP, 2002, INVEST OPHTH VIS SCI, V43, pU423
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   McPeek MS, 2000, AM J HUM GENET, V66, P1076, DOI 10.1086/302800
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Nemesure B, 2003, ARCH OPHTHALMOL-CHIC, V121, P856, DOI 10.1001/archopht.121.6.856
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   OTT J, 1983, ANN HUM GENET, V47, P311, DOI 10.1111/j.1469-1809.1983.tb01001.x
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   RISCH N, 1990, AM J HUM GENET, V46, P229
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2003, INVEST OPHTH VIS SCI, V44, P2868, DOI 10.1167/iovs.02-0957
   Schmidt S, 2000, MOL VIS, V6, P287
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Scott WK, 2004, INVEST OPHTH VIS SCI, V45, pU910
   Scott WK, 2003, AM J HUM GENET, V73, P1041, DOI 10.1086/379083
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Shao YJ, 2003, AM J HUM GENET, V72, P539, DOI 10.1086/367846
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2004, BRIT J OPHTHALMOL, V88, P104, DOI 10.1136/bjo.88.1.104
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Witte JS, 2000, AM J HUM GENET, V67, P92, DOI 10.1086/302960
   Wong TY, 2002, JAMA-J AM MED ASSOC, V287, P1153, DOI 10.1001/jama.287.9.1153
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 78
TC 37
Z9 39
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2156
J9 BMC GENET
JI BMC Genet.
PD JUL 6
PY 2004
VL 5
AR 18
DI 10.1186/1471-2156-5-18
PG 12
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 839ZT
UT WOS:000222827500001
PM 15238159
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Doney, ASF
   Leese, GP
   Olson, J
   Morris, AD
   Palmer, CNA
AF Doney, A. S. F.
   Leese, G. P.
   Olson, J.
   Morris, A. D.
   Palmer, C. N. A.
TI The Y402H variant of complement factor H is associated with age-related
   macular degeneration but not with diabetic retinal disease in the
   Go-DARTS study
SO DIABETIC MEDICINE
LA English
DT Article
DE age-related macular degeneration; complement factor H; diabetic
   retinopathy; Type 2 diabetes
ID C-REACTIVE PROTEIN; ADVANCED GLYCATION; DRUSEN FORMATION; RETINOPATHY;
   RISK; PATHOGENESIS; CFH; POLYMORPHISM; ACTIVATION; INHIBITORS
AB The Y402H variant of complement factor H (CFH) is associated with risk of age-related macular degeneration (ARMD). In common with ARMD, diabetic retinal disease also appears to involve complement activation. The aim was to investigate the impact of Y402H on both retinal pathologies in patients with Type 2 diabetes (T2DM) undergoing systematic eye screening.
   Patients with T2DM (n = 2350) were genotyped for the CFH Y402H variant. The association of genotype with retinal disease was determined in both retrospective and prospective models.
   The retrospective study demonstrated that the HH genotype was associated with an age-adjusted odds ratio of 7.4 for ARMD (P = 2.9 x 10(-11)). In a longitudinal study in the disease-free cohort, the age-adjusted hazard ratio was 2.8 (P = 2.4 x 10(-7)). The life-time hazard ratio was 3.4 (P = 2.1 x 10(-16)). We found no association of Y402H with development of referable diabetic retinal disease.
   The ARMD-associated Y402H variant in CFH does not appear to be associated with diabetic retinal disease, although complement activation is involved in the pathoaetiology of both conditions.
C1 [Doney, A. S. F.; Palmer, C. N. A.] Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.
   [Doney, A. S. F.; Leese, G. P.; Morris, A. D.] Univ Dundee, Dept Med & Therapeut, Populat Pharmacogenet Grp, Dundee DD1 9SY, Scotland.
   [Olson, J.] Inst Med Sci, Dept Ophthalmol, Aberdeen, Scotland.
C3 University of Dundee; University of Dundee; University of Aberdeen
RP Palmer, CNA (通讯作者)，Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.
EM nuclear-receptor@dundee.ac.uk
RI Doney, Alexander SF/P-7437-2017; Palmer, Colin NA/C-7053-2008; Morris,
   Andrew D/C-2837-2009; Study, GoDARTS/K-9448-2016
OI Doney, Alexander SF/0000-0002-6210-5620; Palmer, Colin
   NA/0000-0002-6415-6560; 
FU TENOVUS Scotland
FX We are grateful to TENOVUS Scotland, who provided financial support for
   the initial creation of the Go-DARTS collection. We also wish to
   acknowledge Alison Bell at the Health Informatics Department, University
   of Dundee who provided the carefully anonymized clinical data for
   linkage with genotypes.
CR Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Doggrell SA, 2005, EXPERT OPIN PHARMACO, V6, P1421, DOI 10.1517/14656566.6.8.1421
   Gerl VB, 2002, INVEST OPHTH VIS SCI, V43, P1104
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jha P, 2007, MOL IMMUNOL, V44, P3901, DOI 10.1016/j.molimm.2007.06.145
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje
   Kastelan S, 2007, MED HYPOTHESES, V68, P1016, DOI 10.1016/j.mehy.2006.05.073
   Krzystolik MG, 2006, ARCH OPHTHALMOL-CHIC, V124, P920, DOI 10.1001/archopht.124.6.920
   Leese GP, 2005, DIABETIC MED, V22, P1112, DOI 10.1111/j.1464-5491.2005.01603.x
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Stitt AW, 2003, EXP MOL PATHOL, V75, P95, DOI 10.1016/S0014-4800(03)00035-2
   Stitt AW, 2001, BRIT J OPHTHALMOL, V85, P746, DOI 10.1136/bjo.85.6.746
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Zee RYL, 2006, ATHEROSCLEROSIS, V187, P332, DOI 10.1016/j.atherosclerosis.2005.09.009
   Zhang A, 2002, DIABETES, V51, P3499
NR 26
TC 6
Z9 7
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3071
EI 1464-5491
J9 DIABETIC MED
JI Diabetic Med.
PD MAY
PY 2009
VL 26
IS 5
BP 460
EP 465
DI 10.1111/j.1464-5491.2009.02719.x
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 444LC
UT WOS:000265981500002
PM 19646183
DA 2022-11-30
ER

PT J
AU Sleiman, K
   Veerappan, M
   Winter, KP
   McCall, MN
   Yiu, G
   Farsiu, S
   Chew, EY
   Clemons, T
   Toth, CA
AF Sleiman, Karim
   Veerappan, Malini
   Winter, Katrina P.
   McCall, Michelle N.
   Yiu, Glenn
   Farsiu, Sina
   Chew, Emily Y.
   Clemons, Traci
   Toth, Cynthia A.
CA Age-Related Eye Dis Study 2 Ancil
TI Optical Coherence Tomography Predictors of Risk for Progression to
   Non-Neovascular Atrophic Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID GEOGRAPHIC ATROPHY; CHOROIDAL THICKNESS; RETICULAR PSEUDODRUSEN; EYE
   DISEASE; SD-OCT; AUTOMATIC SEGMENTATION; NATURAL-HISTORY; SEVERITY
   SCALE; DRUSEN VOLUME; AXIAL LENGTH
AB Purpose: Appearance of geographic atrophy (GA) on color photography (CP) is preceded by specific features on spectral-domain optical coherence tomography (SD OCT). We aimed to build SD OCT-based risk assessment models for 5-year new onset of GA and central GA on CP.
   Design: Prospective, longitudinal study.
   Participants: Age-Related Eye Disease Study 2 Ancillary SD OCT study participants with age-related macular degeneration (AMD) with bilateral large drusen or noncentral GA and at least 1 eye without advanced disease (n = 317).
   Methods: For 1 eye per participant, qualitative and quantitative SD OCT variables were derived from standardized grading and semiautomated segmentation, respectively, at baseline. Up to 7 years later, annual outcomes were extracted and analyzed to fit multivariate logistic regression models and build a risk calculator.
   Main Outcome Measures: New onset of CP-visible GA and central GA.
   Results: Over a follow-up median of 4.0 years and among 292 AMD eyes (without advanced disease at baseline) with complete outcome data, 46 (15.8%) developed central GA. Among 265 eyes without any GA on baseline CP, 70 (26.4%) developed CP-visible GA. Final multivariate models were adjusted for age. In the model for GA, the independent predicting SD OCT factors (P < 0.001-0.03) were: hyperreflective foci and retinal pigment epithelium (RPE) layer atrophy or absence, followed by choroid thickness in absence of subretinal drusenoid deposits, photoreceptor outer segment loss, RPE drusen complex volume, and RPE drusen complex abnormal thinning volume. For central GA, the factors (P < 0.001) were RPE drusen complex abnormal thinning volume, intraretinal fluid or cystoid spaces, hyperreflective foci, and RPE layer atrophy or absence. The models yielded a calculator that computes the probabilities of CP-visible, new-onset GA and central GA after 1 to 5 years.
   Conclusions: For AMD eyes with large drusen and no advanced disease, we built a novel risk assessment modeldbased on age and SD OCT segmentation, drusen characteristics, and retinal pathologydfor progression to CP-visible GA over up to 5 years. This calculator may simplify SD OCT grading and with future validation has a promising role as a clinical prognostic tool. (C) 2017 by the American Academy of Ophthalmology
C1 [Sleiman, Karim; Veerappan, Malini; Winter, Katrina P.; McCall, Michelle N.; Farsiu, Sina; Toth, Cynthia A.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Yiu, Glenn] Univ Calif Davis, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
   [Farsiu, Sina; Toth, Cynthia A.] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA.
   [Chew, Emily Y.] NEI, NIH, Bethesda, MD 20892 USA.
   [Clemons, Traci] Emmes Corp, Rockville, MD USA.
C3 Duke University; University of California System; University of
   California Davis; Duke University; National Institutes of Health (NIH) -
   USA; NIH National Eye Institute (NEI); Emmes Corporation
RP Toth, CA (通讯作者)，Duke Eye Ctr, DUMC 3802, Durham, NC 27710 USA.
EM cynthia.toth@dm.duke.edu
RI Toth, Cynthia/L-5534-2019; Sleiman, Karim/AAK-4247-2020; Yiu,
   Glenn/AAF-2858-2020
OI Toth, Cynthia/0000-0002-2324-0854; Sleiman, Karim/0000-0002-4017-4908;
   Yiu, Glenn/0000-0003-3061-3310; Farsiu, Sina/0000-0003-4872-2902
FU NIH [EY022691]; intramural program funds; Department of Health and Human
   Services, Bethesda, Maryland [HHS-N-260-2005-00007-C]; ADB
   [N01-EY-5-0007]; AREDS2 Ancillary SD OCT; Genentech, San Francisco,
   California; Alcon, Fort Worth, Texas; Bioptigen, Morrisville, North
   Carolina; National Eye Institute of the National Institutes of Health
   (NIH); NATIONAL EYE INSTITUTE [R01EY025009, R01EY023039, P30EY005722]
   Funding Source: NIH RePORTER
FX S.F.: Grants - NIH (EY022691), during the conduct of the study, and has
   patents issued: US Patents 8,811,745 and 9299155.; The Age-Related Eye
   Disease Study 2 (AREDS2) study was supported by the intramural program
   funds and contracts from the National Eye Institute of the National
   Institutes of Health (NIH), Department of Health and Human Services,
   Bethesda, Maryland (Contract No. HHS-N-260-2005-00007-C. ADB Contract
   No. N01-EY-5-0007.). The following sponsors supported the AREDS2
   Ancillary SD OCT Study and had no role in the design or conduct of this
   research: Genentech, San Francisco, California (research grant); Alcon,
   Fort Worth, Texas (research grant); and Bioptigen, Morrisville, North
   Carolina (research grant).
CR A Martillo Miguel, 2012, Med Hypothesis Discov Innov Ophthalmol, V1, P37
   Abbey AM, 2015, OSLI RETINA, V46, P18, DOI 10.3928/23258160-20150101-03
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Chakraborty R, 2011, INVEST OPHTH VIS SCI, V52, P5121, DOI 10.1167/iovs.11-7364
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kinoshita T, 2017, BRIT J OPHTHALMOL, V101, P360, DOI 10.1136/bjophthalmol-2016-308594
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lam AKC, 2001, OPHTHAL PHYSL OPT, V21, P477, DOI 10.1046/j.1475-1313.2001.00611.x
   Lee JY, 2014, OPHTHALMOLOGY, V121, P2423, DOI 10.1016/j.ophtha.2014.06.013
   Leisy HB, 2017, OPHTHALMOL RETINA, V1, P42, DOI 10.1016/j.oret.2016.08.011
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Meyers KJ, 2015, OPHTHALMOLOGY, V122, P2286, DOI 10.1016/j.ophtha.2015.07.029
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pilotto E, 2015, BRIT J OPHTHALMOL, V99, P1082, DOI 10.1136/bjophthalmol-2014-306338
   Rastogi N, 2016, SURV OPHTHALMOL, V61, P422, DOI 10.1016/j.survophthal.2015.10.003
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Thorell MR, 2015, OSLI RETINA, V46, P513, DOI 10.3928/23258160-20150521-02
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Vuong VS, 2016, AM J OPHTHALMOL, V169, P104, DOI 10.1016/j.ajo.2016.06.023
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Ying GS, 2011, OPHTHALMOLOGY, V118, P332, DOI 10.1016/j.ophtha.2010.06.030
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Yiu G, 2014, JAMA OPHTHALMOL, V132, P174, DOI 10.1001/jamaophthalmol.2013.7288
   Yuan E, 2013, INVEST OPHTH VIS SCI, V54
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 57
TC 54
Z9 55
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2017
VL 124
IS 12
BP 1764
EP 1777
DI 10.1016/j.ophtha.2017.06.032
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FM9JZ
UT WOS:000415586000016
PM 28847641
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Velaga, SB
   Nittala, MG
   Konduru, RK
   Heussen, F
   Keane, PA
   Sadda, SR
AF Velaga, S. B.
   Nittala, M. G.
   Konduru, R. K.
   Heussen, F.
   Keane, P. A.
   Sadda, S. R.
TI Impact of optical coherence tomography scanning density on quantitative
   analyses in neovascular age-related macular degeneration
SO EYE
LA English
DT Article
ID THICKNESS MEASUREMENTS; SEGMENTATION; SUBANALYSIS; PARAMETERS;
   ARTIFACTS; VOLUME; ERROR; OCT
AB Purpose To assess the influence of varying B-scan frame-sampling densities on retinal thickness and volume measurements from spectral domain optical coherence tomography (OCT) in eyes with neovascular age-related macular degeneration (AMD).
   Methods Volume OCT data (512 x 128 macular cube over 6x 6 mm) were collected from 39 eyes with neovascular AMD. All 128 B-scans in each image set were manually segmented, allowing quantification of the neurosensory retina, subretinal fluid (SRF), subretinal hyperreflective material (SRHM), and pigment epithelium detachment (PED). Thickness maps were generated for less dense subsets of scans, ranging from every other (64 B-scans) to every 64th (2 B-scans). For each less dense subset, foveal central subfield thickness and total macular volume (TMV) were compared with values obtained using all 128 scans (considered the reference).
   Results For each parameter, the mean absolute difference compared with the reference increased with reducing B-scan density. However, these differences did not reach statistical significance until framesampling density was reduced to every eighth scan (ie, 16 B-scans spaced 375 mu m apart) for neurosensory retina, and every fourth scan (ie, 32 B-scans spaced 188 mu m apart) for SRF, SRHM, and PED. For neurosensory retina, the mean (% error) and maximum (% error) absolute differences in TMV were 0.02 mm(3) (0.24%) and 0.06mm3 (0.79%), respectively. Similarly, at a density of 32 B-scans, mean and maximum differences for SRF were 0.004 mm(3) (3.47%) and 0.02 mm(3) (22.22%), respectively. The mean differences for SRHM and PED were 0.01 mm3 (8.03%) and 0.01 mm(3) (4.04%), respectively.
   Conclusions A minimum of 16 equally spaced B-scans, covering a 6x6mm area, appears necessary to generate retinal thickness measurements similar to those obtained using all 128 B-scans in eyes with choroidal neovascularization (CNV). When considering other CNV lesion features, a minimum of 16 B-scans for SRF and PED, and 32 B-scans for SRHM are required to generate volume maps similar to ground-truth values. These findings may have implications for the design of acquisition and grading protocols for clinical trials using OCT in neovascular AMD.
C1 [Velaga, S. B.; Nittala, M. G.; Konduru, R. K.; Sadda, S. R.] Doheny Eye Inst, Dept Ophthalmol, DVRC 211,1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Heussen, F.] Charite, Dept Ophthalmol, Berlin, Germany.
   [Keane, P. A.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, Dept Ophthalmol, London, England.
   [Keane, P. A.] UCL Inst Ophthalmol, London, England.
   [Sadda, S. R.] UCLA, Dept Ophthalmol, David Geffen Sch Med, Los Angeles, CA USA.
C3 Doheny Eye Institute; Free University of Berlin; Humboldt University of
   Berlin; Charite Universitatsmedizin Berlin; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA
RP Sadda, SR (通讯作者)，Doheny Eye Inst, Dept Ophthalmol, DVRC 211,1355 San Pablo St, Los Angeles, CA 90033 USA.
EM ssadda@doheny.org
RI Nittala, Muneeswar/AAT-7533-2020; Keane, Pearse/AAE-5709-2019
OI Keane, Pearse/0000-0002-9239-745X; Heussen, Florian
   Moritz/0000-0003-0536-9870
FU Deutsche Forschungsgemeinschaft (DFG) [He 6094/1-1]; NEI Grant [R01
   EY014375]; Research to Prevent Blindness Physician Scientist Award; Carl
   Zeiss Meditec; Optos; Optovue Inc.; Department of Health's NIHR
   Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital;
   UCL Institute of Ophthalmology; National Institute for Health Research
   [CS-2014-14-023, CL-2010-18-004] Funding Source: researchfish; NATIONAL
   EYE INSTITUTE [R01EY014375] Funding Source: NIH RePORTER
FX Supported in part by the Deutsche Forschungsgemeinschaft (DFG grant He
   6094/1-1), NEI Grant R01 EY014375, and Research to Prevent Blindness
   Physician Scientist Award. Dr Sadda receives royalties from intellectual
   property licensed to Topcon Medical Systems by the Doheny Eye Institute.
   He also serves on the scientific advisory board for Heidelberg
   Engineering and receives research support from Carl Zeiss Meditec,
   Optos, and Optovue Inc. Dr Keane is funded in part by the Department of
   Health's NIHR Biomedical Research Centre for Ophthalmology at Moorfields
   Eye Hospital and UCL Institute of Ophthalmology. The views expressed in
   the publication are those of the authors and not necessarily those of
   the Department of Health. In this study, we evaluated the impact of scan
   density on spectral domain OCT (SDOCT) thickness and volume measurements
   in patients with neovascular AMD. In particular, we define the minimum
   scanning density (32 B-scans) required to obtain reliable retinal
   thickness and volume maps for different CNV features like subretinal
   fluid, subretinal hyperreflective material, and PED.
CR Al-Latayfeh MM, 2010, SEMIN OPHTHALMOL, V25, P192, DOI 10.3109/08820538.2010.518107
   Alam S, 2006, OPHTHALMOLOGY, V113, P1425, DOI 10.1016/j.ophtha.2006.03.020
   Baranano AE, 2012, ACTA OPHTHALMOL, V90, pE274, DOI 10.1111/j.1755-3768.2012.02398.x
   Baskin DE, 2010, CURR OPIN OPHTHALMOL, V21, P172, DOI 10.1097/ICU.0b013e32833866ae
   Charafeddin W, 2015, OSLI RETINA, V46, P523, DOI 10.3928/23258160-20150521-03
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Giani A, 2010, RETINA-J RET VIT DIS, V30, P607, DOI 10.1097/IAE.0b013e3181c2e09d
   Hosseini H, 2010, RETINA-J RET VIT DIS, V30, P1084, DOI 10.1097/IAE.0b013e3181d8e7d1
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   Keane Pearse A, 2009, Int Ophthalmol Clin, V49, P61, DOI 10.1097/IIO.0b013e31819fd54f
   Keane PA, 2009, INVEST OPHTH VIS SCI, V50, P3378, DOI 10.1167/iovs.08-2728
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Legarreta JE, 2008, OPHTHAL SURG LAS IM, V39, pS43, DOI 10.3928/15428877-20080715-02
   Leung CKS, 2007, OPHTHALMOLOGY, V114, P263, DOI 10.1016/j.ophtha.2006.06.059
   Malamos P, 2011, RETINA-J RET VIT DIS, V31, P453, DOI 10.1097/IAE.0b013e3181eef031
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nittala MG, 2011, EYE, V25, P1347, DOI 10.1038/eye.2011.173
   Park SS, 2010, INVEST OPHTH VIS SCI, V51, P4200, DOI 10.1167/iovs.09-4256
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P399, DOI 10.1167/iovs.08-1697
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Sadda SR, 2010, INVEST OPHTH VIS SCI, V51, P1071, DOI 10.1167/iovs.09-4325
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Zhang L, 2015, INVEST OPHTH VIS SCI, V56, P3202, DOI 10.1167/iovs.14-15669
   Zhang L, 2012, INVEST OPHTH VIS SCI, V53, P7510, DOI 10.1167/iovs.12-10311
NR 28
TC 11
Z9 11
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JAN
PY 2017
VL 31
IS 1
BP 53
EP 61
DI 10.1038/eye.2016.260
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EL1AU
UT WOS:000394353700005
PM 27911444
OA Bronze, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Chen, ZQ
   Zhai, Y
   Zhang, W
   Teng, Y
   Yao, K
AF Chen, Zhiqing
   Zhai, Yi
   Zhang, Wei
   Teng, Yan
   Yao, Ke
TI Single Nucleotide Polymorphisms of the Sirtuin 1 (SIRT1) Gene are
   Associated With age-Related Macular Degeneration in Chinese Han
   Individuals A Case-Control Pilot Study
SO MEDICINE
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; 5-YEAR INCIDENCE; EXPRESSION; VARIANTS;
   PROMOTER; SUSCEPTIBILITY; MACULOPATHY; POPULATION
AB To investigate whether 3 variants in sirtuin 1 (SIRT1) gene contributed differently in patients with age-related macular degeneration (AMD) in a Chinese Han population.We conducted a case-control study in a group of Chinese patients with AMD (n=253) and contrasted the results against a control group (n=292). Three single nucleotide polymorphisms (SNPs) of SIRT1 gene including rs12778366, rs3740051, and rs4746720 were genotyped using improved multiplex ligase detection reaction. The association between targeted SNPs and AMD was then analyzed by codominant, dominant, recessive, and allelic models.The genotyping data of rs12778366, rs3740051, and rs4746720 revealed significant deviations from Hardy-Weinberg equilibrium tests in the AMD group but not in the control group.We detected significantly differences of rs12778366 allele distribution between 2 groups in recessive and codominant model (P<0.05). Homozygous carriers of the risk allele C displayed a higher chance of developing AMD (P=0.036, odds ratio=3.227; 95% confidence interval: 1.015-10.265).Our study, for the first time, raises the possibility that genetic variations of SIRT1 could be implicated in the pathophysiology of AMD in the Chinese Han population.
C1 [Chen, Zhiqing; Zhai, Yi; Teng, Yan; Yao, Ke] Zhejiang Univ, Coll Med, Ctr Eye, Affiliated Hosp 2, 88 Jiefang Rd, Hangzhou 310003, Zhejiang, Peoples R China.
   [Chen, Zhiqing; Zhai, Yi; Teng, Yan; Yao, Ke] Key Lab Ophthalmol Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China.
   [Zhang, Wei] Zhejiang Univ, Sch Med, Dept Pathol, Hangzhou 310003, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Yao, K (通讯作者)，Zhejiang Univ, Coll Med, Ctr Eye, Affiliated Hosp 2, 88 Jiefang Rd, Hangzhou 310003, Zhejiang, Peoples R China.
EM xlren@zju.edu.cn
RI Zhai, Yi/AAG-3378-2020; Yao, Ke/AAM-6866-2021
OI Zhai, Yi/0000-0002-7188-3125; Yao, Ke/0000-0002-6764-7365
FU Public Welfare Technology Project of Science Technology Department of
   Zhejiang Province [2012C23068]; Zhejiang Province Medical Platform
   Program [2013RCB008]; Zhejiang Key Laboratory Fund of China
   [2011E10006]; National Natural Science Foundation of China [81272214]
FX This work was supported by the Public Welfare Technology Project of
   Science Technology Department of Zhejiang Province (No. 2012C23068), the
   Zhejiang Province Medical Platform Program under Grant 2013RCB008, the
   Zhejiang Key Laboratory Fund of China (No. 2011E10006), and the National
   Natural Science Foundation of China (No. 81272214).
CR Alves LFD, 2012, CORNEA, V31, P817, DOI 10.1097/ICO.0b013e31823f7857
   Anekonda Thimmappa S, 2008, BMC Res Notes, V1, P122, DOI 10.1186/1756-0500-1-122
   Bhattacharya S, 2012, INVEST OPHTH VIS SCI, V53, P8350, DOI 10.1167/iovs.12-10495
   Biason-Lauber A, 2013, CELL METAB, V17, P448, DOI 10.1016/j.cmet.2013.02.001
   Consiglio CR, 2014, MOL BIOL REP, V41, P4233, DOI 10.1007/s11033-014-3294-3
   Cui YH, 2012, BIOCHEM BIOPH RES CO, V426, P232, DOI 10.1016/j.bbrc.2012.08.071
   Dong Y, 2011, MOL GENET METAB, V104, P661, DOI 10.1016/j.ymgme.2011.08.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Figarska SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058636
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Han J, 2014, TRANSL RES
   Hu YY, 2015, J ATHEROSCLER THROMB, V22, P165, DOI 10.5551/jat.24844
   Huang LZ, 2014, INVEST OPHTH VIS SCI, V55, P2534, DOI 10.1167/iovs.13-13437
   Jaliffa C, 2009, INVEST OPHTH VIS SCI, V50, P3562, DOI 10.1167/iovs.08-2817
   Kedenko L, 2014, BMC MED GENET, V15, DOI 10.1186/s12881-014-0112-7
   Kilic U, 2014, EUR J PEDIAT
   Kishi T, 2011, GENES BRAIN BEHAV, V10, P257, DOI 10.1111/j.1601-183X.2010.00661.x
   Kishi T, 2011, HUM PSYCHOPHARM CLIN, V26, P445, DOI 10.1002/hup.1223
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Kubota S, 2011, INVEST OPHTH VIS SCI, V52, P9142, DOI 10.1167/iovs.11-8041
   Kubota S, 2010, AM J PATHOL, V177, P1725, DOI 10.2353/ajpath.2010.100098
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Levecque C, 2003, HUM MOL GENET, V12, P79, DOI 10.1093/hmg/ddg009
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Lu F, 2013, INVEST OPHTH VIS SCI, V54, P2911, DOI 10.1167/iovs.12-11381
   Maeda S, 2011, CLIN EXP NEPHROL, V15, P381, DOI 10.1007/s10157-011-0418-0
   Maloney SC, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/908183
   Maloney SC, 2013, RETINA-J RET VIT DIS, V33, P862, DOI 10.1097/IAE.0b013e31826af556
   Mimura T, 2013, EXP EYE RES, V116, P17, DOI 10.1016/j.exer.2013.07.017
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P6576, DOI 10.1167/iovs.12-10219
   Nejentsev S, 2003, HUM IMMUNOL, V64, P345, DOI 10.1016/S0198-8859(02)00825-X
   Oka A, 1999, HUM MOL GENET, V8, P2165, DOI 10.1093/hmg/8.12.2165
   Peng CH, 2011, BIOMATERIALS, V32, P9077, DOI 10.1016/j.biomaterials.2011.08.008
   Rai E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048621
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Sundaresan P, 2012, INVEST OPHTH VIS SCI, V53, P7492, DOI 10.1167/iovs.12-10073
   Tanaka K, 2011, MOL VIS, V17, P2751
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
   Zhang AM, 2012, BIOCHEM BIOPH RES CO, V422, P693, DOI 10.1016/j.bbrc.2012.05.059
   Zhang WG, 2010, CLIN CHIM ACTA, V411, P1679, DOI 10.1016/j.cca.2010.06.030
   Zheng TY, 2011, CURR EYE RES, V36, P449, DOI 10.3109/02713683.2011.559301
   Zhuge CC, 2014, INVEST OPHTH VIS SCI, V55, P4628, DOI 10.1167/iovs.13-13732
NR 45
TC 10
Z9 13
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD DEC
PY 2015
VL 94
IS 49
AR e2238
DI 10.1097/MD.0000000000002238
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DC9KX
UT WOS:000369541600046
PM 26656366
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kovacevic, D
   Vuceric, TM
   Caljkusic-Mance, T
AF Kovacevic, Damir
   Vuceric, Tamara Misljenovic
   Caljkusic-Mance, Tea
TI Progression of Age Related Maculopathy in Phakic Versus Pseudophakic
   Eyes
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE pseudophakia; macular degeneration; lenses; intraocular; radiation;
   non-ionizing
ID BEAVER DAM EYE; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; MACULAR
   DEGENERATION; CATARACT-SURGERY; 10-YEAR INCIDENCE;
   ULTRAVIOLET-RADIATION; PHOTODYNAMIC THERAPY; CLINICAL-TRIALS;
   RISK-FACTOR; VERTEPORFIN
AB Age-related maculopathy (ARM) is one of the leading causes of central visual acuity loss in older western population. Many factors are responsible for the fast development of ARM. One of this is significant increases of optical radiations through artificial lens after removal of the catarctous lens. The aim of this study was to compare progression of ARM in phakic and pseudophakic patients and to calculate the possibility of pseudophakia as a risk factor for faster progression of ARM. Medical records of 76 patients, older than 60 years (32 male and 44 female) with early forms of ARM were randomly evaluated. They had undergone cataract removal by phacoemulsification with intraocular lens implantation from January 2002 to December 2006 at the Department of Ophthalmology, Rijeka University Hospital, Croatia. Patients were examined two weeks after the surgery and followed up for two years. The control group consisted of 48 patients (21 males and 27 females) with also early forms of ARM, older than 60 years, examined at the Policlinic Department from January 2006 to December 2006 and followed up at least for two years without any cataract surgery. Comparing progression of ARM in these two groups, a total of 19 patients (25%) in pseudophakic group showed progression to late forms of ARM, but only 6 patients (12.5 %) in the control group developed these aggressive ARM forms. More aggressive forms of ARM in pseudophakic group indicate that pseudophakia should be considered as a risk factor for development of ARM.
C1 [Kovacevic, Damir; Caljkusic-Mance, Tea] Rijeka Univ Hosp, Dept Ophthalmol, Rijeka 51000, Croatia.
   [Vuceric, Tamara Misljenovic] Eye Polyclin Dr L Pavicevic, Rijeka, Croatia.
C3 University of Rijeka
RP Kovacevic, D (通讯作者)，Rijeka Univ Hosp, Dept Ophthalmol, Kresimirova 42, Rijeka 51000, Croatia.
EM damir.kovacevic@ri.t-com.hr
RI Vuceric, Tamara Misljenovic/AAF-4128-2020
CR Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Curkovic T, 2005, COLLEGIUM ANTROPOL, V29, P103
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   Ivan D, 2005, COLLEGIUM ANTROPOL, V29, P55
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Kovacevic D, 2008, COLLEGIUM ANTROPOL, V32, P9
   LERMAN S, 1988, NEW ENGL J MED, V319, P1475, DOI 10.1056/NEJM198812013192208
   Libre PE, 2003, AM J OPHTHALMOL, V136, P961, DOI 10.1016/S0002-9394(03)00906-1
   LUI IY, 1989, AM J PUBLIC HEALTH, V79, P765
   Matsumura Y, 2004, TOXICOL APPL PHARM, V195, P298, DOI 10.1016/j.taap.2003.08.019
   MELLERIO J, 1994, PRINCIPLES PRACTICE
   Njiric S, 2007, COLLEGIUM ANTROPOL, V31, P107
   Pham TQ, 2007, EYE, V21, P512, DOI 10.1038/sj.eye.6702254
   Plestina-Borjan I, 2007, COLLEGIUM ANTROPOL, V31, P33
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Situm M, 2007, COLLEGIUM ANTROPOL, V31, P13
   Smith Bradley T, 2005, Curr Opin Ophthalmol, V16, P166, DOI 10.1097/01.icu.0000163030.33401.3d
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Tomany SC, 2003, OPHTHALMOLOGY, V110, P1526, DOI 10.1016/S0161-6420(03)00539-6
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Vojnikovic B, 2007, COLLEGIUM ANTROPOL, V31, P43
NR 33
TC 2
Z9 2
U1 0
U2 0
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RES, P O BOX 290, ULICA GRADA VUKOVARA 72/IV, 10000
   ZAGREB, CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD APR
PY 2010
VL 34
SU 2
BP 21
EP 23
PG 3
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 677AI
UT WOS:000283961100005
PM 21302700
DA 2022-11-30
ER

PT J
AU Kunzel, SH
   Lindner, M
   Sassen, J
   Moller, PT
   Goerdt, L
   Schmid, M
   Schmitz-Valckenberg, S
   Holz, FG
   Fleckenstein, M
   Pfau, M
AF Kuenzel, Sandrine H.
   Lindner, Moritz
   Sassen, Josua
   Moeller, Philipp T.
   Goerdt, Lukas
   Schmid, Matthias
   Schmitz-Valckenberg, Steffen
   Holz, Frank G.
   Fleckenstein, Monika
   Pfau, Maximilian
TI Association of Reading Performance in Geographic Atrophy Secondary to
   Age-Related Macular Degeneration With Visual Function and Structural
   Biomarkers
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID FIXATION PATTERNS; CENTRAL SCOTOMAS; EYES; ACUITY; PROGRESSION
AB Importance As a disabling and frequent disease, geographic atrophy secondary to age-related macular degeneration (AMD) constitutes an important study subject. Emerging clinical trials require suitable end points. The characterization and validation of reading performance as a functional outcome parameter is warranted. Objective To prospectively evaluate reading performance in geographic atrophy and to assess its association with established visual function assessments and structural biomarkers. Design, Setting, and Participants The noninterventional, prospective natural history Directional Spread in Geographic Atrophy study included patients with geographic atrophy secondary to AMD who were recruited at the University Hospital in Bonn, Germany. Participants were enrolled from June 2013 to June 2016. Analysis began December 2019 and ended January 2021. Main Outcomes and Measures Reading acuity and reading speed were assessed using Radner charts. Longitudinal fundus autofluorescence and infrared reflectance images were semiautomatically annotated for geographic atrophy, followed by extraction of shape-descriptive variables. Linear mixed-effects models were applied to investigate the association of those variables with reading performance. Results A total of 150 eyes of 85 participants were included in this study (median [IQR] age, 77.9 [72.4-82.1] years; 51 women [60%]; 34 men [40%]). Reading performance was impaired with a median (IQR) monocular reading acuity of 0.9 (0.4-1.3) logarithm of the reading acuity determination and a reading speed of 52.8 (0-123) words per minute. In the multivariable cross-sectional analysis, best-corrected visual acuity, area of geographic atrophy in the central Early Treatment Diabetic Retinopathy Study (ETDRS) subfield, classification of noncenter vs center-involving geographic atrophy, and area of geographic atrophy in the inner-right ETDRS subfield showed strongest associations with reading acuity (cross-validated R(2)for reading acuity = 0.69). Regarding reading speed, the most relevant variables were best-corrected visual acuity, low-luminance visual acuity, area of geographic atrophy in the central ETDRS subfield, in the inner-right ETDRS subfield, and in the inner-upper ETDRS subfield (R-2 for reading speed = 0.67). In the longitudinal analysis, a similar prediction accuracy for reading performance was determined (R-2 for reading acuity = 0.73; R-2 for reading speed = 0.70). Prediction accuracy did not improve when follow-up time was added as an independent variable. Binocular reading performance did not differ from reading performance in the better-seeing eye. Conclusions and Relevance The association of reading acuity and speed with visual functional and structural biomarkers supports the validity of reading performance as a meaningful end point in clinical trials. These findings suggest that measures in clinical and low-vision care for patients with geographic atrophy should focus primarily on the better-seeing eye.
   This cohort study assesses the structural and functional determinants of monocular reading performance to establish its concurrent validity in geographic atrophy, the ability to detect a change in reading performance, and whether patients with geographic atrophy are affected by binocular inhibition of reading performance.
   Question What is the association of reading performance in patients with geographic atrophy secondary to age-related macular degeneration with established visual function and structural biomarkers? Findings In this cohort study of 150 eyes of 85 participants, reading acuity was most strongly associated with best-corrected visual acuity and geographic atrophy area in the central and inner-right Early Treatment Diabetic Retinopathy Study subfield. Regarding reading speed, the most associated variables were best-corrected visual acuity, low-luminance visual acuity, and geographic atrophy area in the central, the inner-right, and the inner-upper Early Treatment Diabetic Retinopathy Study subfields. Meaning The association of reading performance with visual functional and structural biomarkers supports the validity of reading performance as an end point in clinical trials.
C1 [Kuenzel, Sandrine H.; Moeller, Philipp T.; Goerdt, Lukas; Schmitz-Valckenberg, Steffen; Holz, Frank G.; Pfau, Maximilian] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Lindner, Moritz] Univ Oxford, Sleep & Circadian Neurosci Inst, Nuffield Dept Clin Neurosci, Nuffield Lab Ophthalmol, Oxford, England.
   [Lindner, Moritz] Philipps Univ Marburg, Inst Physiol & Pathophysiol, Dept Neurophysiol, Marburg, Germany.
   [Sassen, Josua] Univ Bonn, Inst Numer Simulat, Bonn, Germany.
   [Schmid, Matthias] Univ Bonn, Med Fac, Inst Med Biometry Informat & Epidemiol, Bonn, Germany.
   [Schmitz-Valckenberg, Steffen; Fleckenstein, Monika] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT USA.
   [Pfau, Maximilian] NEI, NIH, Ophthalm Genet & Visual Funct Branch, Bethesda, MD 20892 USA.
C3 University of Bonn; University of Oxford; Philipps University Marburg;
   University of Bonn; University of Bonn; Utah System of Higher Education;
   University of Utah; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI)
RP Fleckenstein, M (通讯作者)，John A Moran Eye Ctr, 65 N Mario Capecchi, Salt Lake City, UT 84132 USA.
EM mfleckenstein@web.de
OI Pfau, Maximilian/0000-0001-9761-9640; Schmid,
   Matthias/0000-0002-0788-0317; Sassen, Josua/0000-0002-8069-4713
FU German Ophthalmological Society; German Research Foundation [PF 950/1-1,
   658/4-1, 658/4-2]; University Hospital Giessen and Marburg Research
   Funds [15/2020MR]; Bonfor Gerok Program of the Faculty of Medicine,
   University of Bonn [O-137.0022, O-137.0025]; National Institutes of
   Health [EY014800]; Research to Prevent Blindness
FX This work was supported by the German Ophthalmological Society
   (dissertation grant to Dr Kunzel), the German Research Foundation (grant
   PF 950/1-1 to Dr Pfau and grants 658/4-1 and 658/4-2 to Dr
   Fleckenstein), University Hospital Giessen and Marburg Research Funds
   (grant 15/2020MR to Dr Lindner), and the Bonfor Gerok Program of the
   Faculty of Medicine, University of Bonn (grants O-137.0022 and
   O-137.0025 to Dr Pfau). Drs Fleckenstein and Schmitz-Valckenberg were in
   part supported by a National Institutes of Health (grant EY014800) and
   an unrestricted grant from Research to Prevent Blindness to the
   Department of Ophthalmology & Visual Sciences, University of Utah.
   CenterVue SpA provided research material for the conduct of this study.
   CenterVue had no role in the design or conduct of the experiments.
CR [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373
   Cheong AMY, 2008, VISION RES, V48, P577, DOI 10.1016/j.visres.2007.11.022
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Crossland MD, 2011, INVEST OPHTH VIS SCI, V52, P411, DOI 10.1167/iovs.10-5473
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3456, DOI 10.1167/iovs.17-22339
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Hastie T., 2009, ELEMENTS STAT LEARNI, V2
   Heier JS, 2020, OPHTHALMOL RETINA, V4, P673, DOI 10.1016/j.oret.2020.01.019
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Kihara Y, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.8029
   Kimel M, 2016, INVEST OPHTH VIS SCI, V57, P6298, DOI 10.1167/iovs.16-20361
   Kunzel SH, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.63
   Lindner M, 2019, OPHTHALMOL RETINA, V3, P201, DOI 10.1016/j.oret.2018.11.005
   Lindner M, 2017, INVEST OPHTH VIS SCI, V58, pBIO61, DOI 10.1167/iovs.16-21210
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Morales MU, 2020, INT OPHTHALMOL, V40, P305, DOI 10.1007/s10792-019-01180-y
   Pelli DG, 2013, VISION RES, V90, P10, DOI 10.1016/j.visres.2013.04.015
   Pfau M, 2020, JAMA OPHTHALMOL, V138, P1026, DOI 10.1001/jamaophthalmol.2020.2914
   Pfau M, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100907
   Pfau M, 2020, OPHTHALMOLOGE, V117, P973, DOI 10.1007/s00347-020-01209-z
   Pfau M, 2020, AM J OPHTHALMOL, V217, P162, DOI 10.1016/j.ajo.2020.04.003
   Pfau M, 2019, RETINA-J RET VIT DIS, V39, P1527, DOI 10.1097/IAE.0000000000002206
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, pBIO121, DOI 10.1167/iovs.17-21764
   Radner W, 2017, GRAEF ARCH CLIN EXP, V255, P1465, DOI 10.1007/s00417-017-3659-0
   Rasmussen A, 2014, CURR OPIN OPHTHALMOL, V25, P158, DOI 10.1097/ICU.0000000000000050
   Rubin GS, 2000, INVEST OPHTH VIS SCI, V41, P3327
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sayegh RG, 2017, AM J OPHTHALMOL, V179, P118, DOI 10.1016/j.ajo.2017.03.031
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGICA, V235, P215, DOI 10.1159/000445217
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   Sunness JS, 2008, J VISUAL IMPAIR BLIN, V102, P600
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness Janet S, 2008, Retin Cases Brief Rep, V2, P83, DOI 10.1097/IAE.0b013e31802fa25d
   Sunness JS, 2005, AM J OPHTHALMOL, V140, P1085, DOI 10.1016/j.ajo.2005.07.040
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Timberlake GT, 2006, J REHABIL RES DEV, V43, P749, DOI 10.1682/JRRD.2005.06.0102
   Tzaridis S, 2019, INVEST OPHTH VIS SCI, V60, P3835, DOI 10.1167/iovs.18-26414
   Varma Rohit, 2018, Invest Ophthalmol Vis Sci, V59, pAMD195, DOI 10.1167/iovs.18-24238
   von der Emde L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47565-y
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
NR 45
TC 2
Z9 2
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD NOV
PY 2021
VL 139
IS 11
BP 1191
EP 1199
DI 10.1001/jamaophthalmol.2021.3826
EA SEP 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XA2TC
UT WOS:000702495300001
PM 34591067
OA Green Published
DA 2022-11-30
ER

PT J
AU Owsley, C
   McGwin, G
   Clark, ME
   Jackson, GR
   Callahan, MA
   Kline, LB
   Witherspoon, CD
   Curcio, CA
AF Owsley, Cynthia
   McGwin, Gerald, Jr.
   Clark, Mark E.
   Jackson, Gregory R.
   Callahan, Michael A.
   Kline, Lanning B.
   Witherspoon, C. Douglas
   Curcio, Christine A.
TI Delayed Rod-Mediated Dark Adaptation Is a Functional Biomarker for
   Incident Early Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBRETINAL DRUSENOID DEPOSITS; RETINAL-PIGMENT EPITHELIUM; RETICULAR
   PSEUDODRUSEN; GEOGRAPHIC ATROPHY; BRUCHS MEMBRANE; NATURAL-HISTORY; LOW
   LUMINANCE; MACULOPATHY; EYES; VISION
AB Purpose: To examine whether slowed rod-mediated dark adaptation (DA) in adults with normal macular health at baseline is associated with the incidence of age-related macular degeneration (AMD) 3 years later.
   Design: Prospective cohort.
   Participants: Adults aged >= 60 years were recruited from primary care ophthalmology clinics. Both eyes were required to be step 1 (normal) on the Age-Related Eye Disease Study 9-step AMD classification system based on color fundus photographs graded by experienced and masked evaluators.
   Methods: Rod-mediated DA was assessed at baseline in 1 eye after a photobleach using a computerized dark adaptometer with targets centered at 5 degrees on the inferior vertical meridian. Speed of DA was characterized by the rod-intercept value, with abnormal DA defined as rod-intercept >= 12.3 minutes. Demographic characteristics, best-corrected visual acuity, and smoking status were also assessed. Log-binomial regression was used to calculate unadjusted and adjusted risk ratios (RRs) and associated 95% confidence intervals (CIs) for the association between baseline DA and incident AMD.
   Main Outcome Measures: Presence of AMD at the 3-year follow-up visit for the eye tested for DA at baseline.
   Results: Both baseline and follow-up visits were completed by 325 persons (mean age, 67.8 years). At baseline, 263 participants had normal DA with mean rod-intercept of 9.1 (standard deviation [SD], 1.5), and 62 participants had abnormal DA with mean rod-intercept of 15.1 (SD, 4.0). After adjustment for age and smoking, those with abnormal DA in the tested eye at baseline were approximately 2 times more likely to have AMD in that eye (RR, 1.92; 95% CI, 1.03-3.62) by the time of the follow-up visit, compared with those who had normal DA at baseline.
   Conclusions: Delayed rod-mediated DA in older adults with normal macular health is associated with incident early AMD 3 years later, and thus is a functional biomarker for early disease. The biological relevance of this test is high, because it assesses translocation of vitamin A derivatives across the retinal pigment epithelium and Bruch's membrane, 2 tissues with prominent age-and AMD-related pathology. (C) 2016 by the American Academy of Ophthalmology.
C1 [Owsley, Cynthia; McGwin, Gerald, Jr.; Clark, Mark E.; Callahan, Michael A.; Kline, Lanning B.; Witherspoon, C. Douglas; Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol, Sch Med, Birmingham, AL 35233 USA.
   [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35233 USA.
   [Jackson, Gregory R.] MacuLogix Inc, Hummelstown, PA USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Owsley, C (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol, Callhan Eye Hosp, 700 S 18th St,Suite 609, Birmingham, AL 35233 USA.
EM owsley@uab.edu
OI Witherspoon, Clark/0000-0003-4456-9437
FU National Institute on Aging [R01AG04212]; National Eye Institute
   [R01EY06109]; National Institutes of Health (Bethesda, MD); EyeSight
   Foundation of Alabama (Birmingham, AL); International Retinal Research
   Foundation (Birmingham, AL); Ludwig von Sallmann Prize (New York, NY);
   Research to Prevent Blindness Inc (New York, NY); Alfreda J. Schueler
   Trust (Chicago, IL); NATIONAL EYE INSTITUTE [R01EY006109] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG004212] Funding
   Source: NIH RePORTER
FX Funded by the National Institute on Aging (R01AG04212) and National Eye
   Institute (R01EY06109), National Institutes of Health (Bethesda, MD);
   EyeSight Foundation of Alabama (Birmingham, AL); International Retinal
   Research Foundation (Birmingham, AL); Ludwig von Sallmann Prize (New
   York, NY); Research to Prevent Blindness Inc (New York, NY); and Alfreda
   J. Schueler Trust (Chicago, IL).
CR Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V15, P5535
   Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Cankova Z, 2011, EXP EYE RES, V93, P947, DOI 10.1016/j.exer.2011.10.016
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Clark ME, 2011, BRIT J OPHTHALMOL, V95, P1427, DOI 10.1136/bjo.2010.190355
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Ethier CR, 2004, ANNU REV BIOMED ENG, V6, P249, DOI 10.1146/annurev.bioeng.6.040803.140055
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Garlipp MA, 2013, EXP EYE RES, V113, P192, DOI 10.1016/j.exer.2013.02.003
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   Huang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   Jackson GR, 2014, OPTOMETRY VISION SCI, V91, P925, DOI 10.1097/OPX.0000000000000247
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Kim JH, 2015, RETINA
   Kubota R, 2014, RETINA-J RET VIT DIS, V34, P603, DOI 10.1097/01.iae.0000434565.80060.f8
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Leibrock CS, 1998, EYE, V12, P511, DOI 10.1038/eye.1998.139
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Ooto S, 2015, RETINA-J RET VIT DIS, V35, P1726, DOI 10.1097/IAE.0000000000000608
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2015, CURR EYE RES    0819
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Smith RT, 2014, BIOMED OPT EXPRESS, V5, P4171, DOI 10.1364/BOE.5.004171
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Wang JS, 2014, J NEUROSCI, V34, P11212, DOI 10.1523/JNEUROSCI.1245-14.2014
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Ying GS, 2008, OPHTHALMOLOGY, V115, P1876, DOI 10.1016/j.ophtha.2008.05.023
   Zarbin MA, 2014, DEV OPHTHALMOL, V53, P1, DOI 10.1159/000358536
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 57
TC 126
Z9 128
U1 1
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2016
VL 123
IS 2
BP 344
EP 351
DI 10.1016/j.ophtha.2015.09.041
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB2TK
UT WOS:000368362200027
PM 26522707
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Downie, LE
   Makrai, E
   Bonggotgetsakul, Y
   Dirito, LJ
   Kristo, K
   Pham, MAN
   You, M
   Verspoor, K
   Pianta, MJ
AF Downie, Laura E.
   Makrai, Eve
   Bonggotgetsakul, Yokim
   Dirito, Lucy J.
   Kristo, Kresimir
   Pham, Minh-An N.
   You, Mina
   Verspoor, Karin
   Pianta, Michael J.
TI Appraising the Quality of Systematic Reviews for Age-Related Macular
   Degeneration Interventions A Systematic Review
SO JAMA OPHTHALMOLOGY
LA English
DT Review
ID INTRAVITREAL BEVACIZUMAB AVASTIN; PHOTODYNAMIC THERAPY; METHODOLOGICAL
   QUALITY; RANIBIZUMAB LUCENTIS; TRIAL REGISTRATION; RANDOMIZED-TRIALS;
   ADVERSE EVENTS; SAFETY; METAANALYSIS; EFFICACY
AB IMPORTANCE Age-related macular degeneration (AMD) is a leading cause of vision impairment. It is imperative that AMD care is timely, appropriate, and evidence-based. It is thus essential that AMD systematic reviews are robust; however, little is known about the quality of this literature.
   OBJECTIVES To investigate the methodological quality of systematic reviews of AMD intervention studies, and to evaluate their use for guiding evidence-based care.
   EVIDENCE REVIEW This systematic review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. All studies that self-identified as a systematic review in their title or abstract or were categorized as a systematic review from a medical subject heading and investigated the safety, efficacy and/or effectiveness of an AMD intervention were included. Comprehensive electronic searches were performed in Ovid MEDLINE, Embase, and the Cochrane Library from inception to March 2017. Two reviewers independently assessed titles and abstracts, then full-texts for eligibility. Quality was assessed using the Assessing the Methodological Quality of Systematic Reviews (AMSTAR) tool. Study characteristics (publication year, type of intervention, journal, citation rate, and funding source) were extracted.
   FINDINGS Of 983 citations retrieved, 71 studies (7.6%) were deemed eligible. The first systematic review relating to an AMD intervention was published in 2003. More than half were published since 2014. Methodological quality was highly variable. The mean (SD) AMSTAR score was 5.8 (3.2) of 11.0, with no significant improvement over time (r = -0.03; 95% CI, -0.26 to 0.21; P=.83). Cochrane systematic reviews were overall of higher quality than reviews in other journals (mean [SD] AMSTAR score, 9.9 [1.2], n = 15 vs 4.7 [2.2], n = 56; P<.001). Overall, there was poor adherence to referring to an a priori design (22 articles [31%]) and reporting conflicts of interest in both the review and included studies (16 articles [23%]). Reviews funded by government grants and/or institutions were generally of higher quality than industry-sponsored reviews or where the funding source was not reported.
   CONCLUSIONS AND RELEVANCE There are gaps in the conduct of systematic reviews in the field of AMD. Enhanced endorsement of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement by refereed journals may improve review quality and improve the dissemination of reliable evidence relating to AMD interventions to clinicians.
C1 [Downie, Laura E.; Makrai, Eve; Bonggotgetsakul, Yokim; Dirito, Lucy J.; Kristo, Kresimir; Pham, Minh-An N.; You, Mina; Pianta, Michael J.] Univ Melbourne, Dept Optometry & Vis Sci, Alice Hoy Bldg, Parkville, Vic 3010, Australia.
   [Verspoor, Karin] Univ Melbourne, Sch Comp & Informat Syst, Parkville, Vic, Australia.
C3 University of Melbourne; University of Melbourne
RP Downie, LE (通讯作者)，Univ Melbourne, Dept Optometry & Vis Sci, Alice Hoy Bldg, Parkville, Vic 3010, Australia.
EM ldownie@unimelb.edu.au
RI Verspoor, Karin/G-6034-2016
OI Verspoor, Karin/0000-0002-8661-1544; Downie, Laura/0000-0002-1596-2259
FU National Health and Medical Research Translating Research Into Practice
   Fellowship [APP1091833]; 2015 Macular Disease Foundation Australia grant
FX This study was funded by a National Health and Medical Research
   Translating Research Into Practice Fellowship (grant APP1091833; Dr
   Downie) and a 2015 Macular Disease Foundation Australia grant (Dr
   Downie).
CR Andriolo RB, 2009, SAO PAULO MED J, V127, P84, DOI 10.1590/S1516-31802009000200006
   Anothaisintawee T, 2012, CLINICOECONOMIC OUTC, V4, P361, DOI 10.2147/CEOR.S37458
   Arnold JJ, 2007, BMJ CLIN EVID, V2007
   Aronow ME, 2014, CURR OPIN OPHTHALMOL, V25, P186, DOI 10.1097/ICU.0000000000000046
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Bekkering GE, 2009, STRAHLENTHER ONKOL, V185, P211, DOI 10.1007/s00066-009-1900-4
   Beri A, 2009, AM J CARDIOVASC DRUG, V9, P361, DOI 10.2165/11315710-000000000-00000
   Booth A, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-4
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brownson RC, 2009, AM J PUBLIC HEALTH, V99, P1576, DOI 10.2105/AJPH.2008.156224
   Campbell JM, 2017, J BURN CARE RES, V38, pE552, DOI 10.1097/BCR.0000000000000409
   Chen GH, 2015, RETINA-J RET VIT DIS, V35, P187, DOI 10.1097/IAE.0000000000000301
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Cruess AF, 2009, ACTA OPHTHALMOL, V87, P118, DOI 10.1111/j.1755-3768.2008.01218.x
   Cullis PS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175213
   Danyliv A, 2017, ADV THER, V34, P611, DOI 10.1007/s12325-017-0484-0
   DeAngelis CD, 2004, JAMA-J AM MED ASSOC, V292, P1363, DOI 10.1001/jama.292.11.1363
   Delaney A, 2005, CRIT CARE, V9, pR575, DOI 10.1186/cc3803
   Downie L, SYSTEMATIC APPRAISAL
   Downie LE, 2014, OPTOMETRY VISION SCI, V91, P821, DOI 10.1097/OPX.0000000000000285
   Barbosa BRD, 2014, BRAZ J PHARM SCI, V50, P63, DOI 10.1590/S1984-82502011000100006
   Elliott JH, 2017, J CLIN EPIDEMIOL, V91, P23, DOI 10.1016/j.jclinepi.2017.08.010
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Evans JR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004004.pub3
   Faggion CM, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0062-6
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gehlbach P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub5
   Geltzer A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005022.pub3
   Gerding H, 2016, KLIN MONATSBL AUGENH, V233, P471, DOI 10.1055/s-0041-111835
   Giansanti F, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006931.pub2
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Hodge WG, 2007, RETINA-J RET VIT DIS, V27, P216, DOI 10.1097/01.iae.0000233322.83713.2d
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jadad AR, 2000, BRIT MED J, V320, P537, DOI 10.1136/bmj.320.7234.537
   Jadad AR, 1998, JAMA-J AM MED ASSOC, V280, P278, DOI 10.1001/jama.280.3.278
   Jiang S, 2014, J CLIN PHARM THER, V39, P234, DOI 10.1111/jcpt.12146
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kelly KD, 2001, ANN EMERG MED, V38, P518, DOI 10.1067/mem.2001.115881
   Kim SJ, 2016, AM J OPHTHALMOL, V161, P221, DOI 10.1016/j.ajo.2015.10.005
   Kim SN, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S2-S5
   Kodjikian L, 2014, GRAEF ARCH CLIN EXP, V252, P1529, DOI 10.1007/s00417-014-2764-6
   Lavis JN, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000141
   Lawrenson JG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub3
   Liberati A, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2700, 10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]
   Liesegang TJ, 2014, AM J OPHTHALMOL, V158, P855, DOI 10.1016/j.ajo.2014.09.014
   Liu R, 2015, INVEST OPHTH VIS SCI, V56, P252, DOI 10.1167/iovs.14-15553
   Ma L, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070426
   Marshall IJ, 2016, J AM MED INFORM ASSN, V23, P193, DOI 10.1093/jamia/ocv044
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   Micieli JA, 2010, CAN J OPHTHALMOL, V45, P231, DOI 10.3129/i10-027
   Mikacic I, 2016, DRUG SAFETY, V39, P517, DOI 10.1007/s40264-016-0408-y
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   National Health and Medical Research Council (NHMRC), NHMRC LEV EV GRAD RE
   Ozkaya Abdullah, 2013, ISRN Ophthalmol, V2013, P151027, DOI 10.1155/2013/151027
   Parodi MB, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub2
   Penedones A, 2014, J OCUL PHARMACOL TH, V30, P729, DOI 10.1089/jop.2013.0206
   Poku E, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005244
   Polkki T, 2014, J CLIN NURS, V23, P315, DOI 10.1111/jocn.12132
   Reveiz L, 2010, J CLIN EPIDEMIOL, V63, P1216, DOI 10.1016/j.jclinepi.2010.01.013
   Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783
   Schmucker CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137866
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   Senra H, 2016, GRAEF ARCH CLIN EXP, V254, P1873, DOI 10.1007/s00417-016-3384-0
   Shea BJ, 2009, J CLIN EPIDEMIOL, V62, P1013, DOI 10.1016/j.jclinepi.2008.10.009
   Shea BJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001350
   Shin HJ, 2016, INVEST OPHTH VIS SCI, V57, P1798, DOI 10.1167/iovs.15-18404
   Si JK, 2014, INT J OPHTHALMOL-CHI, V7, P541, DOI 10.3980/j.issn.2222-3959.2014.03.28
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004004.PUB2
   Solomon SD, 2016, OPHTHALMOLOGY, V123, P70, DOI 10.1016/j.ophtha.2015.09.002
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Sophie Raafay, 2012, Biol Ther, V2, P3, DOI 10.1007/s13554-012-0003-4
   Spooner K, 2017, CLIN OPHTHALMOL, V11, P161, DOI 10.2147/OPTH.S125676
   Szabo SM, 2015, CURR MED RES OPIN, V31, P2031, DOI 10.1185/03007995.2015.1084909
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   Thomas J, 2017, J CLIN EPIDEMIOL, V91, P31, DOI 10.1016/j.jclinepi.2017.08.011
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   Tong Y, 2016, INT J OPHTHALMOL-CHI, V9, P1028, DOI 10.18240/ijo.2016.07.16
   Tunis AS, 2013, RADIOLOGY, V269, P413, DOI 10.1148/radiol.13130273
   Ueta T, 2014, OPHTHALMOLOGY, V121, P2193, DOI 10.1016/j.ophtha.2014.05.022
   van der Pol CB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119892
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub3
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109744
   Wang WJ, 2015, INT J OPHTHALMOL-CHI, V8, P138, DOI 10.3980/j.issn.2222-3959.2015.01.26
   Wang X, 2014, OPHTHALMIC RES, V52, P198, DOI 10.1159/000363327
   Whiting P, 2016, J CLIN EPIDEMIOL, V69, P225, DOI 10.1016/j.jclinepi.2015.06.005
   Williams MA, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009300.pub2
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   [Anonymous], 2000, JAMA, V284, P3043, DOI 10.1001/jama.2013.281053
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
   Wu B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101253
   Yusuf S, 1997, CONTROL CLIN TRIALS, V18, P594, DOI 10.1016/S0197-2456(97)00052-4
   Zhang XY, 2014, INT J OPHTHALMOL-CHI, V7, P355, DOI 10.3980/j.issn.2222-3959.2014.02.30
   Ziemssen F, 2009, DRUG AGING, V26, P295, DOI 10.2165/00002512-200926040-00002
NR 110
TC 12
Z9 12
U1 0
U2 14
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD SEP
PY 2018
VL 136
IS 9
BP 1051
EP 1061
DI 10.1001/jamaophthalmol.2018.2620
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA GT6QH
UT WOS:000444641800022
PM 29978192
OA Green Published
DA 2022-11-30
ER

PT J
AU Lazzara, F
   Conti, F
   Platania, CBM
   Eandi, CM
   Drago, F
   Bucolo, C
AF Lazzara, Francesca
   Conti, Federica
   Platania, Chiara Bianca Maria
   Eandi, Chiara M.
   Drago, Filippo
   Bucolo, Claudio
TI Effects of Vitamin D-3 and Meso-Zeaxanthin on Human Retinal Pigmented
   Epithelial Cells in Three Integrated in vitro Paradigms of Age-Related
   Macular Degeneration
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE 1; 25(OH)(2)D-3; meso-zeaxanthin; amyloid beta; inflammation; oxidative
   stress; cytokines
ID AMYLOID-BETA; EYE DISEASE; INFLAMMATION; ASSOCIATIONS; DRUSEN; RISK;
   SUPPLEMENTATION; ANTIOXIDANTS; PATHOGENESIS; CAROTENOIDS
AB Age-related macular degeneration (AMD) is a degenerative retinal disease and one of major causes of irreversible vision loss. AMD has been linked to several pathological factors, such as oxidative stress and inflammation. Moreover, A beta (1-42) oligomers have been found in drusen, the extracellular deposits that accumulate beneath the retinal pigmented epithelium in AMD patients. Hereby, we investigated the hypothesis that treatment with 1,25(OH) D-2(3) (vitamin D-3) and meso-zeaxathin, physiologically present in the eye, would counteract the toxic effects of three different insults on immortalized human retinal pigmented epithelial cells (ARPE-19). Specifically, ARPE-19 cells have been challenged with A beta (1-42) oligomers, H2O2, LPS, and TNF-alpha, respectively. In the present study, we demonstrated that the combination of 1,25(OH)(2)D-3 and meso-zeaxanthin significantly counteracted the cell damage induced by the three insults, at least in these in vitro integrated paradigms of AMD. These results suggest that combination of 1,25(OH)(2)D-3 and meso-zeaxathin could be a useful approach to contrast pathological features of AMD, such as retinal inflammation and oxidative stress.
C1 [Lazzara, Francesca; Conti, Federica; Platania, Chiara Bianca Maria; Drago, Filippo; Bucolo, Claudio] Univ Catania, Sch Med, Dept Biomed & Biotechnol Sci, Catania, Italy.
   [Eandi, Chiara M.] Univ Lausanne, Jules Gonin Eye Hosp, Fdn Asile des Aveugles, Dept Ophthalmol, Lausanne, Switzerland.
   [Eandi, Chiara M.] Univ Torino, Dept Surg Sci, Turin, Italy.
   [Drago, Filippo; Bucolo, Claudio] Univ Catania, Ctr Res Ocular Pharmacol CERFO, Catania, Italy.
C3 University of Catania; University of Lausanne; University of Turin;
   University of Catania
RP Bucolo, C (通讯作者)，Univ Catania, Sch Med, Dept Biomed & Biotechnol Sci, Catania, Italy.; Bucolo, C (通讯作者)，Univ Catania, Ctr Res Ocular Pharmacol CERFO, Catania, Italy.
EM bucoda@unict.it
RI Drago, Filippo/AAC-5090-2022; Platania, Chiara BM/AHE-1140-2022
OI Platania, Chiara Bianca Maria/0000-0002-8630-5993; Lazzara,
   Francesca/0000-0002-9825-2104
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Akuffo KO, 2017, INVEST OPHTH VIS SCI, V58, P5347, DOI 10.1167/iovs.16-21192
   Albert DM, 2007, INVEST OPHTH VIS SCI, V48, P2327, DOI 10.1167/iovs.06-1210
   Leal LKAM, 2020, EUR J PHARMACOL, V879, DOI 10.1016/j.ejphar.2020.173099
   An E., 2008, MOL VIS
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Annweiler C, 2016, MATURITAS, V88, P101, DOI 10.1016/j.maturitas.2016.04.002
   Biron KE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023789
   Bone RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-12
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Bucolo C, 2006, NEUROREPORT, V17, P287, DOI 10.1097/01.wnr.0000199469.21734.e1
   Bucolo C., 1999, J PHARMACOL EXP THER
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Calafiore M, 2012, J NEUROSCI RES, V90, P559, DOI 10.1002/jnr.22780
   Caruso G, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9050477
   Cascella R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/582842
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Di Filippo C, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/857958
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   Eliassen AH, 2015, AM J CLIN NUTR, V101, P1197, DOI 10.3945/ajcn.114.105080
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   Fernandez-Robredo P, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9090838
   Firdous AP, 2015, PHARM BIOL, V53, P961, DOI 10.3109/13880209.2014.950673
   Fisichella V, 2016, EUR J PHARMACOL, V787, P72, DOI 10.1016/j.ejphar.2016.02.002
   Layana AG, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101120
   Giordano M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207615
   Giurdanella G, 2015, BIOCHEM PHARMACOL, V96, P278, DOI 10.1016/j.bcp.2015.05.017
   Green-Gomez M, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9080767
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hernandez M, 2021, NUTRIENTS, V13, DOI 10.3390/nu13051423
   Hikage F, 2021, EXP CELL RES, V403, DOI 10.1016/j.yexcr.2021.112581
   Holekamp NM, 2019, AM J MANAG CARE, V25, pS172
   Hozawa A, 2006, AM J EPIDEMIOL, V163, P929, DOI 10.1093/aje/kwj136
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kan Emrah, 2020, Oman Med J, V35, pe83, DOI 10.5001/omj.2020.01
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Krohne TU, 2010, INVEST OPHTH VIS SCI, V51, P553, DOI 10.1167/iovs.09-3755
   Lee V, 2012, NEUROBIOL AGING, V33, P2382, DOI 10.1016/j.neurobiolaging.2011.12.002
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Maj E, 2018, INT J ONCOL, V52, P337, DOI 10.3892/ijo.2017.4228
   Majewski S, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 1, APRIL 1996, V1, P97
   McCarty MF, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042140
   McKay GJ, 2017, OPHTHALMOLOGY, V124, P90, DOI 10.1016/j.ophtha.2016.09.007
   Merle BMJ, 2017, INVEST OPHTH VIS SCI, V58, P4569, DOI 10.1167/iovs.17-21673
   Micera A, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.601647
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Nolan JM, 2013, EYE, V27, P899, DOI 10.1038/eye.2013.98
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nyska A, 2002, TOXICOL PATHOL, V30, P620, DOI 10.1080/01926230290166724
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Platania CBM, 2015, FRONT PHARMACOL, V6, DOI [10.3389/fphar.2015.00248, 10.3389/tphar.7015.00248]
   Platania CBM, 2019, BRIT J PHARMACOL, V176, P2179, DOI 10.1111/bph.14665
   Platania CBM, 2018, BIOCHEM PHARMACOL, V158, P13, DOI 10.1016/j.bcp.2018.09.016
   Platania CBM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102076
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Sahin K, 2017, FOOD NUTR RES, V61, DOI 10.1080/16546628.2017.1353360
   Sesso HD, 2004, AM J CLIN NUTR, V79, P47
   Shafiee A, 2011, INVEST OPHTH VIS SCI, V52, P1422, DOI 10.1167/iovs.10-5598
   Shyam R, 2017, P NATL ACAD SCI USA, V114, P10882, DOI 10.1073/pnas.1706332114
   Sultan Sadia, 2020, J Aging Res, V2020, P6097820, DOI 10.1155/2020/6097820
   Sung IS, 2019, LIFE SCI, V233, DOI 10.1016/j.lfs.2019.116727
   Thomas SE, 2016, J LIPID RES, V57, P1865, DOI 10.1194/jlr.M070193
   Thurnham DI, 2008, BRIT J NUTR, V100, P1307, DOI 10.1017/S0007114508971336
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Zajac-Pytrus HM, 2015, ADV CLIN EXP MED, V24, P1099, DOI 10.17219/acem/27093
NR 74
TC 0
Z9 0
U1 2
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 5
PY 2021
VL 12
AR 778165
DI 10.3389/fphar.2021.778165
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA XA8FE
UT WOS:000720875600001
PM 34803719
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Waldstein, SM
   Ritter, M
   Simader, C
   Mayr-Sponer, U
   Kundi, M
   Schmidt-Erfurth, U
AF Waldstein, Sebastian M.
   Ritter, Markus
   Simader, Christian
   Mayr-Sponer, Ulrike
   Kundi, Michael
   Schmidt-Erfurth, Ursula
TI Impact of Vitreomacular Adhesion on Ranibizumab Mono- and Combination
   Therapy for Neovascular Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   VERTEPORFIN PLUS RANIBIZUMAB; PHOTODYNAMIC THERAPY; INTRAVITREAL
   RANIBIZUMAB; DETACHMENT; INTERFACE; TRACTION; OUTCOMES; RISK
AB PURPOSE: To investigate the influence of vitreomacular adhesion on the efficacy of pro re nata (PRN) ranibizumab monotherapy and verteporfin photodynamic therapy (PDT) combination therapy for neovascular age-related macular degeneration.
   DESIGN: Post hoc analysis of prospective randomized 12-month multicenter clinical trial data.
   METHODS: PATIENT POPULATION: Total of 255 treatment-naive patients with subfoveal choroidal neovascularization. OBSERVATION PROCEDURE: Assessment of the vitreomacular interface on monthly optical coherence tomography with division of patients into the following categories according to continuous 1-year grading: posterior vitreous detachment (n = 154), dynamic release of vitreomacular adhesion (n = 32), stable vitreomacular adhesion (n = 51). MAIN OUTCOME MEASURES: Mean best-corrected visual acuity (BCVA) letter and central retinal thickness changes at month 12 in the vitreomacular interface groups.
   RESULTS: Mean BCVA changes at month 12 were +3.5 (posterior vitreous detachment), +4.3 (release of vitreomacular adhesion), and +6.3 (vitreomacular adhesion) in patients receiving monotherapy (P = .767), and +0.1 (posterior vitreous detachment), +6.6 (release of vitreomacular adhesion), and +9.2 (vitreomacular adhesion) in patients receiving combination therapy (P = .009). Mean central retinal thickness changes were -113 mu m (posterior vitreous detachment), -89 mu m (release of vitreomacular adhesion), and -122 mu m (vitreomacular adhesion) in monotherapy (P = .725) and -121 mu m (posterior vitreous detachment), -113 mu m (release of vitreomacular adhesion), and -113 mu m (vitreomacular adhesion) in combination therapy (P = .924). Mean ranibizumab retreatments during 12 months were 4.9 (posterior vitreous detachment), 6.6 (release of vitreomacular adhesion), and 5.3 (vitreomacular adhesion) in monotherapy (P = .018) and 4.7 (posterior vitreous detachment), 5.2 (release of vitreomacular adhesion), and 5.8 (vitreomacular adhesion) in combination therapy (P = .942).
   CONCLUSION: This study adds evidence that the vitreomacular interface status impacts functional outcomes and retreatment requirements. Patients with posterior vitreous detachment achieve acceptable results with fewer injections in PRN monotherapy, but lose potential vision gain with PDT. Patients with other vitreomacular interface configurations may potentially achieve optimized vision outcomes by combination of antiangiogenic treatment and vaso-occlusive PDT. ((C) 2014 by Elsevier Inc. All rights reserved.)
C1 [Waldstein, Sebastian M.; Ritter, Markus; Simader, Christian; Mayr-Sponer, Ulrike; Schmidt-Erfurth, Ursula] Med Univ Vienna, Vienna Reading Ctr, Dept Ophthalmol, Christian Doppler Lab Ophthalm Image Anal, A-1090 Vienna, Austria.
   [Kundi, Michael] Med Univ Vienna, Ctr Publ Hlth, Inst Environm Hlth, A-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Simader, C (通讯作者)，Med Univ Vienna, Vienna Reading Ctr, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM optima@meduniwien.ac.at
OI Ritter, Markus/0000-0003-1406-8340; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311; Waldstein, Sebastian/0000-0003-2899-6279
FU Austrian Federal Ministry of Economy, Family and Youth; National
   Foundation for Research, Technology and Development
FX Ursula Schmidt-Erfurth is a consultant for Alcon, Bayer, Boehringer
   Ingelheim, and Novartis. All other authors have no financial interest to
   disclose. The financial support of the Austrian Federal Ministry of
   Economy, Family and Youth and the National Foundation for Research,
   Technology and Development is gratefully acknowledged. The Department of
   Ophthalmology at the Medical University of Vienna served as a clinical
   site in the MONTBLANC study and received regular compensation for
   contract research performed (Vienna, Austria). The funding organizations
   had no role in the design or conduct of this study.
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chan WM, 2010, GRAEF ARCH CLIN EXP, V248, P613, DOI 10.1007/s00417-010-1307-z
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Geck U, 2013, GRAEFES ARCH CLIN EX, P1
   Green-Simms AE, 2013, RETINA-J RET VIT DIS, V33, P1359, DOI 10.1097/IAE.0b013e3182845d18
   Itakura H, 2013, JAMA OPHTHALMOL, V131, P1348, DOI 10.1001/jamaophthalmol.2013.4578
   Jackson TL, 2013, RETINA-J RET VIT DIS, V33, P1099, DOI 10.1097/IAE.0b013e31828991d6
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   KAKEHASHI A, 1994, OPHTHALMOLOGY, V101, P1515
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal KB, 2014, OPHTHALMOLOGY, V121, P1020, DOI 10.1016/j.ophtha.2013.11.030
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Simader C, 2014, OPHTHALMOLOGY
   Stalmans P, 2012, NEW ENGL J MED, V367, P606, DOI 10.1056/NEJMoa1110823
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Uney GO, 2014, RETINA-J RET VIT DIS, V34, P32, DOI 10.1097/IAE.0b013e318295f72e
   Waldstein SM, 2012, RETINA-J RET VIT DIS, V32, P424, DOI 10.1097/IAE.0b013e3182278b80
NR 37
TC 25
Z9 26
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2014
VL 158
IS 2
BP 328
EP 336
DI 10.1016/j.ajo.2014.04.028
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN6EB
UT WOS:000340686600017
PM 24794282
DA 2022-11-30
ER

PT J
AU Hariri, AH
   Nittala, MG
   Sadda, SR
AF Hariri, Amir H.
   Nittala, Muneeswar G.
   Sadda, SriniVas R.
TI Quantitative Characteristics of Spectral-Domain Optical Coherence
   Tomography in Corresponding Areas of Increased Autofluorescence at the
   Margin of Geographic Atrophy in Patients With Age-Related Macular
   Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; FUNDUS AUTOFLUORESCENCE; JUNCTIONAL ZONE;
   PROGRESSION; PATTERNS
AB BACKGROUND AND OBJECTIVE: To evaluate the spectral-domain optical coherence tomography (SD-OCT) characteristics of the junctional zone corresponding to areas of increased autofluorescence (IAF) at the margin of geographic atrophy (GA) in patients with age-related macular degeneration (AMD).
   PATIENTS AND METHODS: SD-OCT and fundus autofluorescence (FAF) images from untreated eyes with GA available from archived studies at Doheny Image Reading Center were evaluated. Areas of definite decreased autofluorescence (DDAF) corresponding to GA, and areas of IAF at the margins of the GA were manually segmented. Eyes with evidence of IAF were selected. Following manual registration of FAF and OCT data, areas of IAF and normal fluorescence were correlated with OCT features at these locations.
   RESULTS: Thirty eyes were included. The mean retinal pigment epithelium (RPE) thickness in areas of IAF was 40.6 mu m +/- 7.69 mu m, compared to 28.8 mu m +/- 7.09 mu m in normal adjacent areas (P <.001).
   CONCLUSION: Regions of IAF at the junctional zone of GA lesions appear to correspond to thickening of the presumed RPE band on OCT.
C1 [Hariri, Amir H.; Nittala, Muneeswar G.; Sadda, SriniVas R.] Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
C3 Doheny Eye Institute
RP Sadda, SR (通讯作者)，Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
EM SSadda@doheny.org
RI Nittala, Muneeswar/AAT-7533-2020
FU Beckman Macular Degeneration Research Center; Research to Prevent
   Blindness Physician Scientist Award; Carl Zeiss Meditec; Optovue
FX Supported by the Beckman Macular Degeneration Research Center and a
   Research to Prevent Blindness Physician Scientist Award.; Dr. Sadda is a
   consultant to Carl Zeiss Meditec, Allergan, Genentech, Regeneron, and
   Optos and has received research funding from Carl Zeiss Meditec and
   Optovue. The remaining authors report no relevant financial disclosures.
CR Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Christensen UC, 2008, BRIT J OPHTHALMOL, V92, P800, DOI 10.1136/bjo.2007.130500
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
NR 13
TC 8
Z9 8
U1 1
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD JUN
PY 2016
VL 47
IS 6
BP 523
EP 527
DI 10.3928/23258160-20160601-03
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA EJ3ER
UT WOS:000393095900004
PM 27327281
DA 2022-11-30
ER

PT J
AU Fitzgerald, PJ
AF Fitzgerald, Paul J.
TI Elevated norepinephrine may be an etiological factor in a wide range of
   diseases: Age-related macular degeneration, systemic lupus
   erythematosus, atrial fibrillation, metabolic syndrome
SO MEDICAL HYPOTHESES
LA English
DT Article
ID BODY-MASS INDEX; CARDIOVASCULAR RISK-FACTORS; CORONARY-HEART-DISEASE;
   BLUE-MOUNTAINS-EYE; RHEUMATOID-ARTHRITIS; BIPOLAR DISORDER;
   ALZHEIMERS-DISEASE; HEALTHY CONTROLS; NEUROPEPTIDE-Y; PREVALENCE
AB The neurotransmitter norepinephrine (NE) participates in a broad range of physiological functions, both in the brain and in the periphery, where it is a principal output molecule of the sympathetic nervous system. NE receptors are present in nearly all, if not all, organs of the body, which may allow this molecule to play a role in a variety of disease processes. This paper examines the hypothesis elevated NE signaling, through genetics and/or environmental factors, is an etiological factor in a variety of diseases outside of the brain, including age-related macular degeneration, systemic lupus erythematosus, atrial fibrillation, and metabolic syndrome. Lines of evidence presented to assess the hypothesis include: (1) studies of noradrenergic drugs modulating the four diseases; (2) association of these diseases with bipolar disorder, hypertension, and obesity, where the latter three conditions may involve elevated NE signaling; and (3) association with psychological stress, since NE is released in response to stress. Many of the studies cited tend to support the hypothesis, or are at least consistent with it. If the hypothesis is correct, perhaps a large number of individuals would benefit from chronically taking drugs that systemically diminish noradrenergic signaling, thereby helping prevent or treat a wide variety of diseases. (C) 2013 Elsevier Ltd. All rights reserved.
C1 Johns Hopkins Univ, Solomon H Snyder Dept Neurosci, Zanvyl Krieger Mind Brain Inst, Baltimore, MD 21218 USA.
C3 Johns Hopkins University
RP Fitzgerald, PJ (通讯作者)，Johns Hopkins Univ, Solomon H Snyder Dept Neurosci, Zanvyl Krieger Mind Brain Inst, 338 Krieger Hall,3400 N Charles St, Baltimore, MD 21218 USA.
EM pfitz@mbi.mb.jhu.edu
CR ADAMS SG, 1994, J BEHAV MED, V17, P459, DOI 10.1007/BF01857920
   Anderson JL, 1999, AM HEART J, V137, P388, DOI 10.1016/S0002-8703(99)70484-9
   Bachen EA, 2009, ARTHRIT RHEUM-ARTHR, V61, P822, DOI 10.1002/art.24519
   Badheka AO, 2010, AM J MED, V123, P646, DOI 10.1016/j.amjmed.2009.11.026
   Batsis JA, 2007, CLIN PHARMACOL THER, V82, P509, DOI 10.1038/sj.clpt.6100355
   Bourre JM, 2007, BIOMED PHARMACOTHER, V61, P105, DOI 10.1016/j.biopha.2006.09.015
   Bove M, 2010, AGING MENT HEALTH, V14, P801, DOI 10.1080/13607861003713299
   Brey RL, 2002, NEUROLOGY, V58, P1214, DOI 10.1212/WNL.58.8.1214
   Brunner EJ, 2002, CIRCULATION, V106, P2659, DOI 10.1161/01.CIR.0000038364.26310.BD
   Capellino S, 2008, J RHEUMATOL, V35, P91
   Cardenas J, 2008, J AFFECT DISORDERS, V106, P91, DOI 10.1016/j.jad.2007.05.030
   Carella AM, 2010, CURR DIABETES REV, V6, P215, DOI 10.2174/157339910791658844
   Chamberlain AM, 2010, AM HEART J, V159, P850, DOI 10.1016/j.ahj.2010.02.005
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Dell'Omo G, 2005, CORONARY ARTERY DIS, V16, P67, DOI 10.1097/00019501-200502000-00012
   Deng C, 2001, ARTHRITIS RHEUM, V44, P397, DOI 10.1002/1529-0131(200102)44:2<397::AID-ANR59>3.0.CO;2-N
   Dortland AKBV, 2010, ACTA PSYCHIAT SCAND, V122, P30, DOI 10.1111/j.1600-0447.2010.01565.x
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Eaker ED, 2005, PSYCHOSOM MED, V67, P692, DOI 10.1097/01.psy.0000174050.87193.96
   Fitzgerald PJ, 2010, CURR ALZHEIMER RES, V7, P506
   Fitzgerald P. J., 2009, Autonomic & Autacoid Pharmacology, V29, P143, DOI 10.1111/j.1474-8665.2009.00442.x
   Fitzgerald Paul J, 2012, Clin Epidemiol, V4, P151, DOI 10.2147/CLEP.S33695
   Fitzgerald Paul J, 2010, Clin Epidemiol, V2, P1
   Fitzgerald PJ, 2010, SEIZURE-EUR J EPILEP, V19, P311, DOI 10.1016/j.seizure.2010.04.011
   Fitzgerald PJ, 2009, INT J CANCER, V124, P257, DOI 10.1002/ijc.24063
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Gamez-Nava JI, 1998, J RHEUMATOL, V25, P1092
   Garcia-Portilla MP, 2008, J AFFECT DISORDERS, V106, P197, DOI 10.1016/j.jad.2007.06.002
   Gonzalez-Duarte A, 2008, EUR NEUROL, V59, P320, DOI 10.1159/000121423
   Gould PA, 2003, EUR HEART J, V24, P1657, DOI 10.1016/S0195-668X(03)00393-2
   Gould PA, 2006, PACE, V29, P821, DOI 10.1111/j.1540-8159.2006.00447.x
   Grassi G, 2005, DIABETOLOGIA, V48, P1359, DOI 10.1007/s00125-005-1798-z
   Grassi G, 2007, NUTR METAB CARDIOVAS, V17, P473, DOI 10.1016/j.numecd.2007.01.004
   Harle P, 2006, ANN RHEUM DIS, V65, P51, DOI 10.1136/ard.2005.038059
   Healey JS, 2006, CAN J CARDIOL, V22, P485, DOI 10.1016/S0828-282X(06)70265-3
   HINRICHSEN H, 1992, EUR J CLIN INVEST, V22, P21
   Hutchinson GA, 1996, W INDIAN MED J, V45, P48
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jacob S, 1996, J HYPERTENS, V14, P489
   Jacobs R, 2001, RHEUMATOLOGY, V40, P868, DOI 10.1093/rheumatology/40.8.868
   Jakovljevic Miro, 2006, Psychiatr Danub, V18, P169
   JIMERSON DC, 1981, ARCH GEN PSYCHIAT, V38, P1287
   Jongnarangsin K, 2008, J CARDIOVASC ELECTR, V19, P668, DOI 10.1111/j.1540-8167.2008.01118.x
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kalman JM, 1995, ANN THORAC SURG, V60, P1709, DOI 10.1016/0003-4975(95)00718-0
   Kannel WB, 1998, AM J CARDIOL, V82, p2N, DOI 10.1016/S0002-9149(98)00583-9
   Krishnaiah S, 2009, BRIT J OPHTHALMOL, V93, P1146, DOI 10.1136/bjo.2009.159723
   Lee ZSK, 2001, METABOLISM, V50, P135, DOI 10.1053/meta.2001.19502
   Lin HC, 2010, OPHTHALMOLOGY, V117, P2088, DOI 10.1016/j.ophtha.2010.03.003
   Mancia G, 2007, J HYPERTENS, V25, P909, DOI 10.1097/HJH.0b013e328048d004
   Masuo K, 2005, CIRCULATION, V111, P3429, DOI 10.1161/CIRCULATIONAHA.104.519652
   McLaurin EY, 2005, NEUROLOGY, V64, P297, DOI 10.1212/01.WNL.0000149640.78684.EA
   Moeini HA, 2005, BRIT J OPHTHALMOL, V89, P964, DOI 10.1136/bjo.2005.066241
   Mok CC, 2010, SCAND J RHEUMATOL, V39, P42, DOI 10.3109/03009740903046668
   Molina MJ, 2007, JCR-J CLIN RHEUMATOL, V13, P202, DOI 10.1097/RHU.0b013e318124a8af
   Morton NM, 2005, DIABETES, V54, P3371, DOI 10.2337/diabetes.54.12.3371
   Nitsch D, 2008, OPHTHALMOLOGY, V115, P1904, DOI 10.1016/j.ophtha.2008.06.035
   Oeser A, 2005, ARTHRITIS RHEUM-US, V52, P3651, DOI 10.1002/art.21400
   Parvez B, 2012, J AM COLL CARDIOL, V59, P49, DOI 10.1016/j.jacc.2011.08.061
   Pawlak CR, 1999, BRAIN BEHAV IMMUN, V13, P287, DOI 10.1006/brbi.1999.0553
   Puustinen PJ, 2011, PSYCHOSOM MED, V73, P158, DOI 10.1097/PSY.0b013e3182037315
   RUPP H, 1995, MED HYPOTHESES, V44, P217, DOI 10.1016/0306-9877(95)90139-6
   SANDLER B, 1993, UROLOGY, V41, P343, DOI 10.1016/0090-4295(93)90592-X
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Seferovic PM, 2006, RHEUMATOLOGY, V45, P39, DOI 10.1093/rheumatology/kel315
   Simpson CS, 2001, AM HEART J, V142, P294, DOI 10.1067/mhj.2001.116767
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   SOLT VB, 1990, AM J HYPERTENS, V3, P823, DOI 10.1093/ajh/3.11.823
   Stewart FM, 1999, AUST NZ J MED, V29, P51, DOI 10.1111/j.1445-5994.1999.tb01588.x
   Suvarna B S, 2008, Kathmandu Univ Med J (KUMJ), V6, P406
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Taylor V, 2006, J CLIN PSYCHIAT, V67, P1034, DOI 10.4088/JCP.v67n0704
   Tedrow UB, 2010, J AM COLL CARDIOL, V55, P2319, DOI 10.1016/j.jacc.2010.02.029
   Telles RW, 2010, LUPUS, V19, P803, DOI 10.1177/0961203309359781
   van der Goes MC, 2011, J RHEUMATOL, V38, P285, DOI 10.3899/jrheum.100572
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   Ward MM, 2002, RHEUMATOLOGY, V41, P184, DOI 10.1093/rheumatology/41.2.184
   Wilhelmsen L, 2001, J INTERN MED, V250, P382, DOI 10.1046/j.1365-2796.2001.00902.x
   WITMAN G, 1981, R I MED J, V64, P147
   Workman AJ, 2010, N-S ARCH PHARMACOL, V381, P235, DOI 10.1007/s00210-009-0474-0
   Zonana-Nacach A, 2008, JCR-J CLIN RHEUMATOL, V14, P74, DOI 10.1097/RHU.0b013e31816b2faa
NR 81
TC 12
Z9 13
U1 0
U2 8
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD MAY
PY 2013
VL 80
IS 5
BP 558
EP 563
DI 10.1016/j.mehy.2013.01.018
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 131LK
UT WOS:000317995000011
PM 23410497
DA 2022-11-30
ER

PT J
AU Liu, B
   Deng, T
   Zhong, JX
AF Liu, Bing
   Deng, Tuo
   Zhong, Jingxiang
TI Efficacy of combined intravitreal anti-vascular endothelial growth
   factor and photodynamic therapy for non-age related macular degeneration
   sourced choroidal neovascularization: a systematic review and
   meta-analysis
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Review
DE Anti-vascular endothelial growth factor; photo dynamic therapy;
   choroidal neovascularization; systematic review; meta-analysis
ID PATHOLOGICAL MYOPIA; ANTI-VEGF; RANIBIZUMAB; BEVACIZUMAB; COMBINATION;
   VERTEPORFIN; SECONDARY
AB Purpose: Our study aimed to explore the efficacy of combined photo dynamic therapy (PDT) and intravitreal anti-vascular endothelial growth factor (VEGF) agents for non-age related macular degeneration (AMD) sourced choroidal neovascularization (CNV) through a meta-analysis. Methods: A literature search on online databases was performed to extract relevant data. Mean differences (MDs) of best-corrected visual acuity (BCVA) changes and numbers of anti-VEGF injections from combined and monotherapy groups were pooled and compared. Results: No significant difference of BCVA changes was discovered between two groups (MD = -0.29, 95% CI, -0.86 to 0.28, P = 0.32). However, combined therapy could significantly reduce the number of anti-VEGF injections (MD = -1.08, 95% CI, -1.97 to -1.09, P = 0.02). Conclusions: We concluded that combined therapy was not superior to anti-VEGF injections in improving BCVA among patients suffering non-AMD sourced CNV. But combined therapy could decrease the number of anti-VEGF treatments, reduce severe side effects and relieve the burden of younger patients.
C1 [Liu, Bing; Zhong, Jingxiang] Jinan Univ, Affiliated Hosp 1, Dept Ophthalmol, 613 West Huangpu Rd, Guangzhou, Guangdong, Peoples R China.
   [Deng, Tuo] Guangzhou Med Univ, Affiliated Hosp 1, Minimally Invas Surg Ctr, Dept Urol, Guangzhou, Guangdong, Peoples R China.
   [Deng, Tuo] Guangzhou Inst Urol, Guangzhou, Guangdong, Peoples R China.
   [Deng, Tuo] Guangdong Key Lab Urol, Guangzhou, Guangdong, Peoples R China.
C3 Jinan University; Guangzhou Medical University
RP Zhong, JX (通讯作者)，Jinan Univ, Affiliated Hosp 1, Dept Ophthalmol, 613 West Huangpu Rd, Guangzhou, Guangdong, Peoples R China.
EM zjx85221206@yeah.net
FU Natural Science Foundation [2014A030313359]; Science and Technology
   Planning Project of Guangdong Province, China [2015B020226003]; China
   Postdoctoral Science Foundation [2017M612636, 2017M622912]
FX This work was supported by grants from Natural Science Foundation (No.
   2014A030313359), Science and Technology Planning Project (No.
   2015B020226003) of Guangdong Province, China, and China Postdoctoral
   Science Foundation (No. 2017M612636 and No. 2017M622912).
CR Chan WM, 2007, AM J OPHTHALMOL, V143, P977, DOI 10.1016/j.ajo.2007.02.039
   Chen L, 2011, RETINA-J RET VIT DIS, V31, P2078, DOI 10.1097/IAE.0b013e3182109074
   Cohen SY, 1996, OPHTHALMOLOGY, V103, P1241, DOI 10.1016/S0161-6420(96)30515-0
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   GROSSNIKLAUS HE, 1992, RETINA-J RET VIT DIS, V12, P127, DOI 10.1097/00006982-199212020-00009
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Han DP, 2010, EYE, V24, P713, DOI 10.1038/eye.2009.122
   Hayashi K, 2010, OPHTHALMOLOGY, V117, P1595, DOI 10.1016/j.ophtha.2009.11.003
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   [黄志坚 Huang Zhijian], 2011, [中国激光医学杂志, Chinese Journal of Laser Medicine and Surgery], V20, P77
   Inoue M, 2010, RETINA-J RET VIT DIS, V30, P733, DOI 10.1097/IAE.0b013e3181c9699c
   Kang HM, 2013, AM J OPHTHALMOL, V155, P713, DOI 10.1016/j.ajo.2012.10.010
   Li TT, 2015, CHIN CONTINUING MED, V7, P31
   Lindblom B, 1998, OPHTHALMOLOGY, V105, P1816, DOI 10.1016/S0161-6420(98)91021-1
   Mandal S, 2007, ARCH OPHTHALMOL-CHIC, V125, P1487, DOI 10.1001/archopht.125.11.1487
   Moshfeghi AA, 2011, RETINA-J RET VIT DIS, V31, P662, DOI 10.1097/IAE.0b013e31821067c4
   Osaadon P, 2014, EYE, V28, P510, DOI 10.1038/eye.2014.13
   Postelmans L, 2004, AM J OPHTHALMOL, V138, P803, DOI 10.1016/j.ajo.2004.06.033
   Rinaldi M, 2017, GRAEF ARCH CLIN EXP, V255, P529, DOI 10.1007/s00417-016-3498-4
   Rishi P, 2016, BRIT J OPHTHALMOL, V100, P1337, DOI 10.1136/bjophthalmol-2015-307802
   Saviano S, 2014, INT J OPHTHALMOL-CHI, V7, P335, DOI 10.3980/j.issn.2222-3959.2014.02.26
   Schauwvlieghe AME, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0043-x
   Shi XH, 2014, CHINESE MED J-PEKING, V127, P2279, DOI 10.3760/cma.j.issn.0366-6999.20140544
   Si JK, 2014, INT J OPHTHALMOL-CHI, V7, P541, DOI 10.3980/j.issn.2222-3959.2014.03.28
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Stuart A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007746
   Wong TY, 2014, AM J OPHTHALMOL, V157, P9, DOI 10.1016/j.ajo.2013.08.010
   Ye XX, 2014, CHINESE J OCU FUNDUS, V29, P362
   Yoon JU, 2010, RETINA-J RET VIT DIS, V30, P418, DOI 10.1097/IAE.0b013e3181bd2fe4
NR 31
TC 0
Z9 0
U1 0
U2 6
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2018
VL 11
IS 1
BP 33
EP 42
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FU3WS
UT WOS:000423783500004
DA 2022-11-30
ER

PT J
AU Chiu, YH
   Huang, JY
   Huang, YP
   Pan, SL
AF Chiu, Yi-Hsiang
   Huang, Jehn-Yu
   Huang, Ya-Ping
   Pan, Shin-Liang
TI Osteoarthritis Is Associated With an Increased Risk of Age-Related
   Macular Degeneration: A Population-Based Longitudinal Follow-Up Study
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE epidemiology study; inflammation; macular degeneration; osteoarthritis;
   risk factor
ID C-REACTIVE PROTEIN; VISUAL IMPAIRMENT; PHYSICAL-ACTIVITY; OXIDATIVE
   STRESS; KNEE; INFLAMMATION; HEALTH; HIP
AB AimsTo investigate the long-term risk of age-related macular degeneration (AMD) in persons with osteoarthritis (OA). MethodsThis retrospective cohort study first enrolled 71,609 subjects diagnosed with OA, and 236,169 without such a diagnosis between January 1, 2002 and December 31, 2005, from the Longitudinal Health Insurance Database 2005. All were aged 40-69. After excluding subjects who had pre-existing AMD and/or who had missing socioeconomic data, frequency matching by sex and age was performed. This resulted in there being 60,274 subjects in each of the final matched OA and non-OA groups. The study participants were followed up to the occurrence of AMD, death, or the end of 2011. We used Cox proportional-hazards regression to estimate the impact of OA on the risk of developing AMD, and performed subgroup analyses stratified by sex and age. ResultsThe median follow-up time was 8.9 years, with an interquartile range of 1.4 years. The incidence rate of AMD in the OA group was 2.77 per 1,000 person-years [95% confidence interval (CI), 2.62-2.92], and in the non-OA group, 2.06 per 1,000 person-years (95% CI, 1.94-2.19). The adjusted hazard ratio (HR) of AMD for the OA group was therefore 1.30 (95% CI, 1.20-1.41). In the subgroup analysis stratified by sex for the OA group, the adjusted HRs of AMD were 1.29 in the women's stratum and 1.31 in the men's. When stratified by age, the adjusted HRs of AMD for the younger (40-54 years) and older (55-69 years) strata were 1.28 and 1.31, respectively. ConclusionsPersons with OA have an increased risk of developing AMD, regardless of age and sex.
C1 [Chiu, Yi-Hsiang; Pan, Shin-Liang] Natl Taiwan Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan.
   [Huang, Jehn-Yu] Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Huang, Ya-Ping; Pan, Shin-Liang] Natl Taiwan Univ, Coll Med, Dept Phys Med & Rehabil, Taipei, Taiwan.
   [Huang, Ya-Ping] Natl Taiwan Univ Hosp, Dept Phys Med & Rehabil, Yun Lin Branch, Taipei, Yun Lin Cty, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital;
   National Taiwan University; National Taiwan University Hospital;
   National Taiwan University; National Taiwan University; National Taiwan
   University Hospital
RP Pan, SL (通讯作者)，Natl Taiwan Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan.; Pan, SL (通讯作者)，Natl Taiwan Univ, Coll Med, Dept Phys Med & Rehabil, Taipei, Taiwan.
EM panslcb@gmail.com
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Berenbaum F, 2013, OSTEOARTHR CARTILAGE, V21, P16, DOI 10.1016/j.joca.2012.11.012
   Callahan LF, 2015, OSTEOARTHR CARTILAGE, V23, P31, DOI 10.1016/j.joca.2014.09.027
   Chow YY, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/8293921
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Colak E, 2012, BIOCHEM MEDICA, V22, P39
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Layana AG, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101120
   Garfinkel RJ, 2017, ORTHOP J SPORTS MED, V5, DOI 10.1177/2325967117711376
   Goldring MB, 2011, CURR OPIN RHEUMATOL, V23, P471, DOI 10.1097/BOR.0b013e328349c2b1
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Goula T, 2015, J ORTHOP TRAUMATOL, V16, P35, DOI 10.1007/s10195-014-0322-y
   Hsieh CY, 2019, CLIN EPIDEMIOL, V11, P349, DOI 10.2147/CLEP.S196293
   Jansen JA, 2013, ANN ROY COLL SURG, V95, P569, DOI [10.1308/003588413X13781990150374, 10.1308/rcsann.2013.95.8.569]
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jin XZ, 2015, ANN RHEUM DIS, V74, P703, DOI 10.1136/annrheumdis-2013-204494
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   Katz JN, 2021, JAMA-J AM MED ASSOC, V325, P568, DOI 10.1001/jama.2020.22171
   Keenan TDL, 2015, RETINA-J RET VIT DIS, V35, P2613, DOI 10.1097/IAE.0000000000000651
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Laufs U, 2005, ARTERIOSCL THROM VAS, V25, P809, DOI 10.1161/01.ATV.0000158311.24443.af
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin SY, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15050902
   Liu CY., 2006, J HLTH MANAGEMENT, V4, P1, DOI DOI 10.29805/JHM.200606.0001
   Mcguinness MB, 2017, AM J OPHTHALMOL, V180, P29, DOI 10.1016/j.ajo.2017.05.016
   Millen AE, 2019, INVEST OPHTH VIS SCI, V60, P1362, DOI 10.1167/iovs.18-25945
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Ruan Y, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031296
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Spector TD, 1997, ARTHRITIS RHEUM, V40, P723, DOI 10.1002/art.1780400419
   Stannus O, 2010, OSTEOARTHR CARTILAGE, V18, P1441, DOI 10.1016/j.joca.2010.08.016
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   Wagner BD, 2022, OPHTHAL EPIDEMIOL, V29, P139, DOI 10.1080/09286586.2021.1910314
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Wu CY, 2012, JAMA-J AM MED ASSOC, V308, P1906, DOI 10.1001/2012.jama.11975
   Yildirim Z, 2012, INT J GERONTOL, V6, P101, DOI 10.1016/j.ijge.2012.01.018
   Zhu ZT, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-035805
   Zlateva GP, 2007, RETINA-J RET VIT DIS, V27, P1292, DOI 10.1097/01.iae.0000300915.81866.b8
NR 42
TC 0
Z9 0
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD MAY 10
PY 2022
VL 9
AR 854629
DI 10.3389/fmed.2022.854629
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 1M9HL
UT WOS:000800276000001
PM 35620721
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Nunes, S
   Alves, D
   Barreto, P
   Raimundo, M
   Cachulo, MD
   Farinha, C
   Lains, I
   Rodrigues, J
   Almeida, C
   Ribeiro, L
   Figueira, J
   Santos, L
   Silva, R
AF Nunes, Sandrina
   Alves, Dalila
   Barreto, Patricia
   Raimundo, Miguel
   Cachulo, Maria da Luz
   Farinha, Claudia
   Lains, Ines
   Rodrigues, Joao
   Almeida, Carlos
   Ribeiro, Luisa
   Figueira, Joao
   Santos, Lelita
   Silva, Rufino
TI Adherence to a Mediterranean diet and its association with age-related
   macular degeneration. The Coimbra Eye Study-Report 4
SO NUTRITION
LA English
DT Article
DE Epidemiology; Mediterranean diet; Nutrition; Nutrients; AMD
ID PHYSICAL-ACTIVITY; OXIDATIVE STRESS; SEVERITY SCALE; RISK-FACTORS;
   VISION LOSS; VITAMIN-C; MACULOPATHY; DISEASE; HEALTH; PROGRESSION
AB Objectives: This study aimed to characterize the association of lifestyle and nutritional risk profiles with age-related macular degeneration (AMD) in two subpopulations with differing AMD prevalence.
   Methods: This case-control study (n = 1992) included 768 patients with AMD and 1224 age- and sex - matched participants without AMD with a single visit at a primary health care unit. Enrolled participants completed a validated lifestyle and food frequency questionnaire. A score to measure adherence to the Mediterranean diet (mediSCORE; Range, 0-9) was constructed from individual food intakes, which were further analyzed by conversion to nutrient consumption.
   Results: Higher adherence to the Mediterranean diet (mediSCORE >= 6) was significantly associated with no AMD (odds ratio [OR] = 0.73; P = 0.009). The subpopulation with lower AMD prevalence presented significantly higher adherence to the Mediterranean diet in relation to all individual food groups that comprised the mediSCORE (P < 0.014) with the exception of cereals. Food group analysis showed significant associations between the increased consumption of vegetables (OR = 0.63; P < 0.001) and fruit and nuts (OR = 0.78; P = 0.010) with no AMD. Nutrient analysis revealed that an increased ingestion of water, fibers, total fat, monounsaturated and polyunsaturated fatty acids, linoleic acid, vitamins A and C, carotene, alpha-tocopherol, folate, magnesium, iron, and zinc were significantly associated with no AMD (P < 0.0013). Finally, regular physical activity was associated with no AMD (P = 0.003).
   Conclusions: High adherence to a Mediterranean diet and regular physical activity seem to be protective factors for AMD in a Portuguese population. The effect of the diet is likely driven by the increased consumption of vegetables, fruits, and nuts. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Nunes, Sandrina; Alves, Dalila; Barreto, Patricia; Cachulo, Maria da Luz; Farinha, Claudia; Ribeiro, Luisa; Figueira, Joao; Silva, Rufino] Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal.
   [Raimundo, Miguel; Cachulo, Maria da Luz; Farinha, Claudia; Lains, Ines; Figueira, Joao; Silva, Rufino] Ctr Hosp & Univ Coimbra, Ophthalmol Dept, Coimbra, Portugal.
   [Cachulo, Maria da Luz; Figueira, Joao; Santos, Lelita; Silva, Rufino] Univ Coimbra, Fac Med, Inst Biomed Imaging & Life Sci, Coimbra, Portugal.
   [Lains, Ines] Harvard Med Sch, Massachusetts Eye & Ear, Boston, MA USA.
   [Rodrigues, Joao] Unidade Saude Familiar Serra Lousa & Trevim Sol, Primary Hlth Care Unit Lousa, Coimbra, Portugal.
   [Almeida, Carlos] Primary Hlth Care Ctr Mira, Coimbra, Portugal.
   [Santos, Lelita] Ctr Hosp & Univ Coimbra, Serv Med Interna, Coimbra, Portugal.
C3 Universidade de Coimbra; Universidade de Coimbra; Centro Hospitalar e
   Universitario de Coimbra (CHUC); Universidade de Coimbra; Harvard
   University; Harvard Medical School; Massachusetts Eye & Ear Infirmary;
   Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC)
RP Nunes, S (通讯作者)，Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal.
EM Sandrina@aibili.pt
RI DE ALMEIDA, CARLOS CAETANO/K-4265-2016; Silva, Rufino M/J-2817-2012;
   Farinha, Claudia/R-1392-2017
OI DE ALMEIDA, CARLOS CAETANO/0000-0002-3215-5731; Silva, Rufino
   M/0000-0001-8676-0833; Alves, Dalila/0000-0003-3296-179X; Nunes,
   Sandrina/0000-0001-5401-9637; Cachulo, Maria Luz/0000-0002-0900-4548;
   Figueira, Joao P/0000-0002-3511-1515; Farinha,
   Claudia/0000-0003-4596-0913
FU Novartis Pharma AG
FX The authors gratefully acknowledge the financing by Novartis Pharma AG,
   which made this study possible as well as the collaboration and
   dedication of the personnel at the primary health care units of Mira and
   Lousa, namely Leonor Borralho, and the collaboration of Sonia Simoes,
   Joao Almeida, Miguel Costa, Liliana Carvalho e Vanessa Santos from the
   AIBILI Coordinating Center.
CR Adams SA, 2005, AM J EPIDEMIOL, V161, P389, DOI 10.1093/aje/kwi054
   Ahn GE, 2015, ARTHRIT CARE RES, V67, P701, DOI 10.1002/acr.22480
   Ballard-Barbash R, 2012, JNCI-J NATL CANCER I, V104, P815, DOI 10.1093/jnci/djs207
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown JC, 2012, COMPR PHYSIOL, V2, P2775, DOI 10.1002/cphy.c120005
   Cachulo MD, 2015, OPHTHALMOLOGICA, V233, P119, DOI 10.1159/000371584
   Cachulo MdaL, 2016, ACTA OPHTHALMOL, V94, P1
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Feart C, 2009, JAMA-J AM MED ASSOC, V302, P638, DOI 10.1001/jama.2009.1146
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Gopinath B, 2014, INVEST OPHTH VIS SCI, V55, P7799, DOI 10.1167/iovs.14-15575
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Ji Li Li, 2009, Infectious Disorders - Drug Targets, V9, P428
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Lopes C, 2000, VALIDACAO QUESTIONAR
   Loprinzi PD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125394
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Meyers KJ, 2015, OPHTHALMOLOGY, V122, P2286, DOI 10.1016/j.ophtha.2015.07.029
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Mozaffarieh M, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-20
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Porto Andreia, 2007, COMP ILD MART CONC E
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Shrank WH, 2011, J GEN INTERN MED, V26, P546, DOI 10.1007/s11606-010-1609-1
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Stasi R, 2003, CANCER-AM CANCER SOC, V98, P1786, DOI 10.1002/cncr.11742
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   TRICHOPOULOU A, 1995, BMJ-BRIT MED J, V311, P1457, DOI 10.1136/bmj.311.7018.1457
   Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039
   VanderBeek BL, 2013, RETINA-J RET VIT DIS, V33, P414, DOI 10.1097/IAE.0b013e318276e0cf
   Vincent HK, 2007, DIABETES OBES METAB, V9, P813, DOI 10.1111/j.1463-1326.2007.00692.x
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Willett W., 1998, NUTR EPIDEMIOL, V122, P101
   Williams PT, 2009, INVEST OPHTH VIS SCI, V50, P101, DOI 10.1167/iovs.08-2165
NR 53
TC 31
Z9 31
U1 1
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0899-9007
EI 1873-1244
J9 NUTRITION
JI Nutrition
PD JUL-AUG
PY 2018
VL 51-52
BP 6
EP 12
DI 10.1016/j.nut.2017.12.010
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA GI1AD
UT WOS:000434100700002
PM 29547735
DA 2022-11-30
ER

PT J
AU Keane, PA
   Liakopoulos, S
   Jivrajka, RV
   Chang, KT
   Alasil, T
   Walsh, AC
   Sadda, SR
AF Keane, Pearse A.
   Liakopoulos, Sandra
   Jivrajka, Renu V.
   Chang, Karen T.
   Alasil, Tarek
   Walsh, Alexander C.
   Sadda, Srinivas R.
TI Evaluation of Optical Coherence Tomography Retinal Thickness Parameters
   for Use in Clinical Trials for Neovascular Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAMS; EDEMA;
   REPRODUCIBILITY; RANIBIZUMAB; SUBANALYSIS; ERROR
AB PURPOSE. To investigate the relationship between automated and manually derived measurements of central retinal thickness from optical coherence tomography (OCT) and to determine the relationship between the foveal center point (FCP) and the foveal central subfield (FCS) in neovascular age-related macular degeneration (AMD).
   METHODS. Data were collected from 216 patients with newly diagnosed neovascular AMD, who underwent StratusOCT imaging at diagnosis. Raw StratusOCT images for each patient were analyzed with the publicly available custom software OCTOR, which allows accurate manual grading of OCT B-scans. Manually derived central retinal thickness measurements were compared with measurements obtained from automated StratusOCT analysis. Manually obtained measurements of FCP and FCS were also compared.
   RESULTS. The mean (+/- SD) difference in thickness between automated and manually derived FCP thickness was 7.9 mu m (+/- 90.8), but the maximum difference was 455 mu m. The limits of agreement (95% confidence interval), between automated and manually obtained FCP thicknesses, were -173.7 mu m (lower limit) and 189.6 mu m (upper limit), with a coefficient of determination (R-2) of 0.49 (P < 0.001). In contrast, the R-2 for manually derived FCP and manually derived FCS thickness was 0.94 (P < 0.001), with a smaller mean (+/- SD) difference in thickness of 13.8 mu m (+/- 29.8).
   CONCLUSIONS. Manual correction of errors in automated OCT segmentation may be necessary for accurate interpretation of anatomic outcomes for clinical trials of neovascular AMD. In addition, although measurement of FCS remains preferable for assessment of central retinal thickness, accurate measurement of FCP may represent an adequate alternative when FCS is unavailable. (Invest Ophthalmol Vis Sci. 2009;50:3378-3385) DOI:10.1167/iovs.08-2728
C1 [Sadda, Srinivas R.] Univ So Calif, Doheny Eye Inst, Doheny Image Reading Ctr, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Liakopoulos, Sandra] Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, D-5000 Cologne 41, Germany.
C3 Doheny Eye Institute; University of Southern California; University of
   Cologne
RP Sadda, SR (通讯作者)，Univ So Calif, Doheny Eye Inst, Doheny Image Reading Ctr, Keck Sch Med, 3623 1450 San Pablo St, Los Angeles, CA 90033 USA.
EM sadda@usc.edu
RI Keane, Pearse A/H-1860-2011; Keane, Pearse/AAE-5709-2019
OI Keane, Pearse/0000-0002-9239-745X
FU NIH [EY03040]; NEI [R01 EY014375]; NATIONAL EYE INSTITUTE [R01EY014375,
   P30EY003040] Funding Source: NIH RePORTER
FX Supported in part by NIH Grant EY03040 and NEI Grant R01 EY014375.
CR Alam S, 2006, OPHTHALMOLOGY, V113, P1425, DOI 10.1016/j.ophtha.2006.03.020
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Browning DJ, 2008, OPHTHALMOLOGY, V115, P1366, DOI 10.1016/j.ophtha.2007.12.004
   Browning DJ, 2007, OPHTHALMOLOGY, V114, P525, DOI 10.1016/j.ophtha.2006.06.052
   Chan A, 2005, ARCH OPHTHALMOL-CHIC, V123, P939, DOI 10.1001/archopht.123.7.939
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   Diabetic Retinopathy Clinical Research Network, 2008, OPHTHALMOLOGY, V115, P1447
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Glassman AR, 2009, INVEST OPHTH VIS SCI, V50, P560, DOI 10.1167/iovs.08-1881
   Hee MR, 1998, OPHTHALMOLOGY, V105, P360, DOI 10.1016/S0161-6420(98)93601-6
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Krebs I, 2008, BRIT J OPHTHALMOL, V92, P933, DOI 10.1136/bjo.2007.128447
   Krzystolik MG, 2007, OPHTHALMOLOGY, V114, P1520, DOI 10.1016/j.ophtha.2006.10.055
   Leung CKS, 2007, OPHTHALMOLOGY, V114, P263, DOI 10.1016/j.ophtha.2006.06.059
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P1084, DOI 10.1167/iovs.07-1203
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P399, DOI 10.1167/iovs.08-1697
   Paunescu LA, 2004, INVEST OPHTH VIS SCI, V45, P1716, DOI 10.1167/iovs.03-0514
   Pons ME, 2005, OPHTHALMOLOGY, V112, P1079, DOI 10.1016/j.ophtha.2004.11.061
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Voo Irene, 2004, Ophthalmol Clin North Am, V17, P21, DOI 10.1016/j.ohc.2003.12.002
   Zayit-Soudry S, 2007, RETINA-J RET VIT DIS, V27, P798, DOI 10.1097/IAE.0b013e31802c50a3
NR 30
TC 51
Z9 52
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2009
VL 50
IS 7
BP 3378
EP 3385
DI 10.1167/iovs.08-2728
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 461SP
UT WOS:000267292100045
PM 19264895
DA 2022-11-30
ER

PT J
AU Agarwal, A
   Lipshitz, I
   Jacob, S
   Lamba, M
   Tiwari, R
   Kumar, DA
   Agarwal, A
AF Agarwal, Amar
   Lipshitz, Isaac
   Jacob, Soosan
   Lamba, Mandeep
   Tiwari, Rahul
   Kumar, Divya A.
   Agarwal, Athiya
TI Mirror telescopic intraocular lens for age-related macular degeneration
   - Design and preliminary clinical results of the Lipshitz macular
   implant
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
ID EYES
AB PURPOSE: To conduct a pilot study evaluating the visual and surgical outcomes of an intraocular mirror telescopic intraocular lens, the Lipshitz macular implant (LMI) (Optolight Vision Technology), for age-related macular degeneration (ARMD) and other macular pathology.
   SETTING: Dr. Agarwal's Eye Hospital and Eye Research Centre, Chennai, India.
   METHODS: The LMI was implanted in patients with bilateral macular pathology and visual acuity worse than 20/200 in whom vision improved with a x2.5 external telescope preoperatively. The LMI was implanted after conventional phacoemulsification or microphakonit. The minimum follow-up was 6 months.
   RESULTS: Six eyes of 6 patients had surgery in the worse eye. Four eyes had ARMD, and 1 eye each had myopic macular degeneration or macular dystrophy. There were no intraoperative complications. The mean gain in distance acuity was 3.66 lines +/- 1.88 (SD), and the mean increase in the Early Treatment Diabetic Retinopathy Study score for near acuity was 50.83 +/- 9.15 logMAR. The best corrected distance acuity and near acuity improved significantly (both P = .014). The mean change in endothelial count was -5.79% +/- -4.07%. The mean postoperative corneal enclothelial-LMI distance was 3.15 +/- 0.31 mm. A good central fundus view was possible around the mirrors in all eyes. Fundus fluorescein angiography showed good visibility of the retina up to the midperiphery. The mean score on a quality-of-life questionnaire was 11.16 +/- 1.72 (SD) preoperatively and 4.50 +/- 0.83 postoperatively, a statistically significant improvement (P = .014).
   CONCLUSIONS: The LMI may be an effective solution for optical rehabilitation of patients with ARMD or other macular pathology by increasing the central image on the retina while preserving peripheral vision. The surgery and visual recovery were quick, and the improvement in quality of life was significant.
C1 [Agarwal, Amar; Jacob, Soosan; Lamba, Mandeep; Tiwari, Rahul; Kumar, Divya A.; Agarwal, Athiya] Dr Agarwals Eye Hosp, Madras 600086, Tamil Nadu, India.
   [Agarwal, Amar; Jacob, Soosan; Lamba, Mandeep; Tiwari, Rahul; Kumar, Divya A.; Agarwal, Athiya] Eye Res Ctr, Madras 600086, Tamil Nadu, India.
   [Lipshitz, Isaac] Private Eye Ctr, Tel Aviv, Israel.
RP Agarwal, A (通讯作者)，Dr Agarwals Eye Hosp, Cathedral Rd, Madras 600086, Tamil Nadu, India.
EM dragarwal@vsnl.com; dragarwal@vsnl.com
CR Agarwal A, 2007, J CATARACT REFR SURG, V33, P183, DOI 10.1016/j.jcrs.2006.12.007
   Alio JL, 2004, J CATARACT REFR SURG, V30, P1177, DOI 10.1016/j.jcrs.2003.10.038
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Dick B., 1995, Ophthalmologe, V92, P476
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Kaskaloglu M, 2001, J CATARACT REFR SURG, V27, P1751, DOI 10.1016/S0886-3350(01)00976-2
   Lipshitz I, 1997, OPHTHALMIC SURG LAS, V28, P513
   Rinnert T, 1999, KLIN MONATSBL AUGENH, V215, P305, DOI 10.1055/s-2008-1034719
   Riusala A, 2003, AM J OPHTHALMOL, V135, P206, DOI 10.1016/S0002-9394(02)01832-9
   Rosner M, 2003, J CATARACT REFR SURG, V29, P1005, DOI 10.1016/S0886-3350(02)01647-4
   Walkow T, 2000, J CATARACT REFR SURG, V26, P727, DOI 10.1016/S0886-3350(99)00462-9
NR 11
TC 22
Z9 23
U1 1
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0886-3350
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD JAN
PY 2008
VL 34
IS 1
BP 87
EP 94
DI 10.1016/j.jcrs.2007.08.031
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 250HR
UT WOS:000252291100027
PM 18165087
DA 2022-11-30
ER

PT J
AU Pinna, A
   Zinellu, A
   Tendas, D
   Blasetti, F
   Carru, C
   Castiglia, P
AF Pinna, Antonio
   Zinellu, Angelo
   Tendas, Donatella
   Blasetti, Francesco
   Carru, Ciriaco
   Castiglia, Paolo
TI Plasma Homocysteine and Asymmetrical Dimethyl-L-Arginine (ADMA) and
   Whole Blood DNA Methylation in Early and Neovascular Age-Related Macular
   Degeneration: A Pilot Study
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Early AMD; neovascular AMD; plasma asymmetrical dimethyl-l-arginine;
   plasma homocysteine; whole blood DNA methylation
ID ENDOGENOUS INHIBITOR; IL17RC PROMOTER; RISK-FACTORS; MACULOPATHY;
   HYPOMETHYLATION; DETERMINANTS; POLYMORPHISM; VITAMIN-B12; ASSOCIATION;
   NUTRITION
AB Purpose/Aim: To compare the plasma levels of homocysteine and asymmetrical dimethyl-l-arginine (ADMA) and the degree of whole blood DNA methylation in patients with early and neovascular age-related macular degeneration (AMD) and in controls without maculopathy of any sort.
   Materials and methods: This observational case-control pilot study included 39 early AMD patients, 27 neovascular AMD patients and 132 sex- and age-matched controls without maculopathy. Plasma homocysteine and ADMA concentrations and the degree of whole blood DNA methylation were measured. Quantitative variables were compared by Student's t-test or Mann-Whitney test. Logistic regression models were used to investigate the significance of the association between early or wet AMD and some variables.
   Results: There were no significant differences in mean plasma homocysteine and ADMA concentrations and in the degree of whole blood DNA methylation between patients with early or neovascular AMD and their controls. Similarly, logistic regression analysis disclosed that plasma homocysteine and ADMA levels were not associated with an increased risk for early or neovascular AMD.
   Conclusions: We failed to demonstrate an association between early or neovascular AMD and increased plasma homocysteine and/or ADMA. Results also suggest that the degree of whole blood DNA methylation is not a marker of AMD.
C1 [Pinna, Antonio; Tendas, Donatella; Blasetti, Francesco] Univ Sassari, Sect Ophthalmol, Dept Surg Microsurg & Med Sci, I-07100 Sassari, Italy.
   [Pinna, Antonio; Carru, Ciriaco; Castiglia, Paolo] Azienda Osped Univ Sassari, Sassari, Italy.
   [Zinellu, Angelo; Carru, Ciriaco] Univ Sassari, Clin Biochem Sect, Dept Biomed Sci, I-07100 Sassari, Italy.
   [Castiglia, Paolo] Univ Sassari, Lab Epidemiol & Biostat, Dept Biomed Sci, I-07100 Sassari, Italy.
C3 University of Sassari; University of Sassari; University of Sassari;
   University of Sassari
RP Pinna, A (通讯作者)，Univ Sassari, Sect Ophthalmol, Dept Surg Microsurg & Med Sci, Viale San Pietro 43 A, I-07100 Sassari, Italy.
EM apinna@uniss.it
RI Pinna, Antonio/H-5067-2018; Carru, Ciriaco/AAI-9996-2021
OI Pinna, Antonio/0000-0003-3052-2662; Castiglia,
   Paolo/0000-0002-0972-4828; Carru, Ciriaco/0000-0002-6985-4907; Zinellu,
   Angelo/0000-0002-8396-0968
CR Achan V, 2003, ARTERIOSCL THROM VAS, V23, P1455, DOI 10.1161/01.ATV.0000081742.92006.59
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Boger RH, 2003, CLIN CHEM LAB MED, V41, P1467, DOI 10.1515/CCLM.2003.225
   Boger RH, 2000, CIRC RES, V87, P99, DOI 10.1161/01.RES.87.2.99
   Boger RH, 2000, ARTERIOSCL THROM VAS, V20, P1557, DOI 10.1161/01.ATV.20.6.1557
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chambers JC, 1998, LANCET, V351, P36, DOI 10.1016/S0140-6736(05)78090-9
   Chen SF, 2012, INT J MOL SCI, V13, P15983, DOI 10.3390/ijms131215983
   COOKE JP, 1994, ARTERIOSCLER THROMB, V14, P653, DOI 10.1161/01.ATV.14.5.653
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   Hsu CP, 2012, ATHEROSCLEROSIS, V225, P504, DOI 10.1016/j.atherosclerosis.2012.09.040
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Jakubowski H, 2006, J NUTR, V136, p1741S, DOI 10.1093/jn/136.6.1741S
   Javadzadeh A, 2010, MOL VIS, V16, P2578
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Liu L, 2003, MECH AGEING DEV, V124, P989, DOI 10.1016/j.mad.2003.08.001
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Mujumdar VS, 2000, J CELL PHYSIOL, V183, P28, DOI 10.1002/(SICI)1097-4652(200004)183:1<28::AID-JCP4>3.0.CO;2-O
   Nurk E, 2001, J NUTR, V131, P1214, DOI 10.1093/jn/131.4.1214
   Nygard O, 1998, AM J CLIN NUTR, V67, P263, DOI 10.1093/ajcn/67.2.263
   Oliver VF, 2013, CELL REP, V5, P1527, DOI 10.1016/j.celrep.2013.11.042
   Pinna A, 2006, INVEST OPHTH VIS SCI, V47, P4067, DOI 10.1167/iovs.06-0290
   Refsum H, 1997, J INHERIT METAB DIS, V20, P286, DOI 10.1023/A:1005321225893
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Sotgia S, 2008, J CHROMATOGR A, V1185, P145, DOI 10.1016/j.chroma.2008.01.032
   Szuba Andrzej, 2006, Pharmacol Rep, V58 Suppl, P16
   VALLANCE P, 1992, LANCET, V339, P572
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Weiss N, 2005, CURR DRUG METAB, V6, P27, DOI 10.2174/1389200052997357
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zinellu A, 2008, CLIN CHEM LAB MED, V46, P387, DOI 10.1515/CCLM.2008.063
   Zinellu A, 2007, ELECTROPHORESIS, V28, P1942, DOI 10.1002/elps.200600534
NR 50
TC 10
Z9 10
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD JAN 2
PY 2016
VL 41
IS 1
BP 88
EP 96
DI 10.3109/02713683.2014.1002044
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DA1BE
UT WOS:000367530500012
PM 25611924
DA 2022-11-30
ER

PT J
AU Abbas, A
   O'Byrne, C
   Fu, DJ
   Moraes, G
   Balaskas, K
   Struyven, R
   Beqiri, S
   Wagner, SK
   Korot, E
   Keane, PA
AF Abbas, Abdallah
   O'Byrne, Ciara
   Fu, Dun Jack
   Moraes, Gabriella
   Balaskas, Konstantinos
   Struyven, Robbert
   Beqiri, Sara
   Wagner, Siegfried K.
   Korot, Edward
   Keane, Pearse A.
TI Evaluating an automated machine learning model that predicts visual
   acuity outcomes in patients with neovascular age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Automated machine learning; Neovascular age-related macular
   degeneration; Artificial intelligence; Anti-VEGF; OCT; Model
   interpretability
ID RANIBIZUMAB; EXPERIENCE; THERAPY; HEALTH; TRIAL
AB Purpose Neovascular age-related macular degeneration (nAMD) is a major global cause of blindness. Whilst anti-vascular endothelial growth factor (anti-VEGF) treatment is effective, response varies considerably between individuals. Thus, patients face substantial uncertainty regarding their future ability to perform daily tasks. In this study, we evaluate the performance of an automated machine learning (AutoML) model which predicts visual acuity (VA) outcomes in patients receiving treatment for nAMD, in comparison to a manually coded model built using the same dataset. Furthermore, we evaluate model performance across ethnic groups and analyse how the models reach their predictions. Methods Binary classification models were trained to predict whether patients' VA would be 'Above' or 'Below' a score of 70 one year after initiating treatment, measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. The AutoML model was built using the Google Cloud Platform, whilst the bespoke model was trained using an XGBoost framework. Models were compared and analysed using the What-if Tool (WIT), a novel model-agnostic interpretability tool. Results Our study included 1631 eyes from patients attending Moorfields Eye Hospital. The AutoML model (area under the curve [AUC], 0.849) achieved a highly similar performance to the XGBoost model (AUC, 0.847). Using the WIT, we found that the models over-predicted negative outcomes in Asian patients and performed worse in those with an ethnic category of Other. Baseline VA, age and ethnicity were the most important determinants of model predictions. Partial dependence plot analysis revealed a sigmoidal relationship between baseline VA and the probability of an outcome of 'Above'. Conclusion We have described and validated an AutoML-WIT pipeline which enables clinicians with minimal coding skills to match the performance of a state-of-the-art algorithm and obtain explainable predictions.
C1 [Abbas, Abdallah; Beqiri, Sara] UCL, Sch Med, London, England.
   [O'Byrne, Ciara; Fu, Dun Jack; Moraes, Gabriella; Balaskas, Konstantinos; Struyven, Robbert] Moorfields Eye Hosp, London, England.
   [O'Byrne, Ciara] Trinity Coll Dublin, Sch Med, Dublin, Ireland.
   [Wagner, Siegfried K.; Keane, Pearse A.] UCL, Inst Ophthalmol, Moorfields Eye Hosp, NIHR Biomed Res Ctr, London, England.
   [Korot, Edward] Stanford Univ, Byers Eye Inst, Palo Alto, CA 94304 USA.
C3 University of London; University College London; UCL Medical School;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; Trinity College Dublin; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   Stanford University
RP Abbas, A (通讯作者)，UCL, Sch Med, London, England.
EM Abdallah.abbas.18@ucl.ac.uk
RI Balaskas, Konstantinos/ABD-5979-2020
OI Balaskas, Konstantinos/0000-0002-7690-6277; Korot,
   Edward/0000-0002-5687-1564; Abbas, Abdallah/0000-0002-9035-5475; Fu, Dun
   Jack/0000-0003-2852-6912; Keane, Pearse/0000-0002-9239-745X; O'Byrne,
   Ciara/0000-0001-5172-0030
FU Moorfields Research Team by Google
FX The AutoML Tables model was built on the Google Cloud Platform using
   free credits provided to the Moorfields Research Team by Google.
CR Adrian ML, 2019, ACTA OPHTHALMOL, V97, P91, DOI 10.1111/aos.13864
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   Antaki F, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76665-3
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chang WB, 2019, DIAGNOSTICS, V9, DOI 10.3390/diagnostics9040178
   Cho PH, 2018, INTRO BOOSTED TREES
   Faes L, 2019, LANCET DIGIT HEALTH, V1, pE232, DOI 10.1016/S2589-7500(19)30108-6
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Fu DJ, 2021, OPHTHALMOL RETINA, V5, P1074, DOI 10.1016/j.oret.2021.01.009
   Gill CR, 2020, OPHTHALMOL THER, V9, P725, DOI 10.1007/s40123-020-00288-0
   Google Cloud AutoML Team, 2021, AUTOML TABL DOC
   Google Cloud Tech YouTube Channel, 2019, TACKL HIGH VAL BUS P
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hu CA, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-033898
   Kaushal A., 2020, SCI AM
   Keane PA, 2011, SAUDI J OPHTHALMOL, V25, P145, DOI 10.1016/j.sjopt.2011.01.003
   Korot E, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89743-x
   Korot E, 2021, NAT MACH INTELL, V3, P288, DOI 10.1038/s42256-021-00305-2
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Lundberg S, 2018, CONSISTENT INDIVIDUA
   Maleki S., 2013, ARXIV13064265
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McCloud C, 2015, EYE, V29, P1561, DOI 10.1038/eye.2015.167
   Molnar C., 2021, SHAPLEY VALUES INTER
   Moraes G, 2021, OPHTHALMOLOGY, V128, P693, DOI 10.1016/j.ophtha.2020.09.025
   Oakden-Rayner Luke, 2020, Proc ACM Conf Health Inference Learn (2020), V2020, P151, DOI 10.1145/3368555.3384468
   Obermeyer Z, 2019, SCIENCE, V366, P447, DOI 10.1126/science.aax2342
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rohm M, 2018, OPHTHALMOLOGY, V125, P1028, DOI 10.1016/j.ophtha.2017.12.034
   Rovner BW, 2014, OPHTHALMOLOGY, V121, P2204, DOI 10.1016/j.ophtha.2014.05.002
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Senra H, 2016, GRAEF ARCH CLIN EXP, V254, P1873, DOI 10.1007/s00417-016-3384-0
   Shamir RR, 2016, INT J OPHTHALMOL-CHI, V9, P119, DOI 10.18240/ijo.2016.01.20
   Spitzer MS, 2008, CLIN OPHTHALMOL, V2, P1
   UK Government, 2021, LIST ETHN GROUPS
   Vaid A, 2020, J MED INTERNET RES, V22, DOI 10.2196/24018
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   Vellido A, 2020, NEURAL COMPUT APPL, V32, P18069, DOI 10.1007/s00521-019-04051-w
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Wang LY, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8030247
   Waring J, 2020, ARTIF INTELL MED, V104, DOI 10.1016/j.artmed.2020.101822
   Wexler J, 2020, IEEE T VIS COMPUT GR, V26, P56, DOI 10.1109/TVCG.2019.2934619
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ying GS, 2018, OPHTHALMOL RETINA, V2, P525, DOI 10.1016/j.oret.2017.10.003
NR 45
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2022
VL 260
IS 8
BP 2461
EP 2473
DI 10.1007/s00417-021-05544-y
EA FEB 2022
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3F5UF
UT WOS:000751195800002
PM 35122132
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Xu, ZM
   Zhang, M
   Zhang, Q
   Xu, TJ
   Tao, LM
AF Xu, Ziming
   Zhang, Mei
   Zhang, Qing
   Xu, Tingjuan
   Tao, Liming
TI Thyroid Disease Is Associated with Higher Age-Related Macular
   Degeneration Risk: Results from a Meta-Analysis of Epidemiologic Studies
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Thyroid hormone; Thyrotropin; Thyroid medication; Age-related macular
   degeneration; Meta-analysis
ID OXIDATIVE STRESS; MEDICATION USE; PREVALENCE; DYSFUNCTION; MACULOPATHY
AB Background: Although epidemiologic studies have suggested that thyroid disease may be a risk factor for age-related macular degeneration (AMD), this finding is still controversial. Objectives: The aim of this meta-analysis was to investigate whether an association exists between thyroid disease and medication and AMD in epidemiologic studies. Methods: We searched PubMed, EMBASE, and Google Scholar from their inception to March 2020 for cross-sectional, case-control, and cohort studies that assessed thyroid function and AMD risk. Data from selected studies were extracted, and a meta-analysis was performed using fixed-effects or random-effects models. The statistical heterogeneity (I-2) among studies and the possibility of publication bias were evaluated. If I-2 >50%, a significant heterogeneity existed among studies, and a random-effects model was used to calculate the pooled RR. Otherwise, a fixed-effects model was performed. Results: A total of 13 epidemiologic studies that consisted of 7 thyroid disease and 7 thyroid medication studies were included. Statistically significant heterogeneity was observed in the study results (I-thyroid disease(2) = 80.1%; I-thyroid medication(2) = 69.0%). A significant positive association was found between thyroid disease and AMD, with an overall relative risk (RR) of 1.25 (95% CI: 1.02, 1.54). However, there was no statistical association between thyroid medication and AMD risk (pooled RR 1.26 [95% CI: 0.92-1.72]). Egger's test indicated that there was no significant publication bias for thyroid disease (p = 0.889) or thyroid medication (p = 0.226). Conclusions: Our findings indicate that thyroid disease is associated with higher AMD risk. Thyroid disease prevention strategies may have a significant effect on the prevention of AMD and warrant further evaluation. (C) 2021 S. Karger AG, Basel
C1 [Xu, Ziming; Zhang, Qing; Tao, Liming] Anhui Med Univ, Affiliated Hosp 2, Dept Ophthalmol, Hefei, Peoples R China.
   [Zhang, Mei] Univ Sci & Technol China, Sch Life Sci, Hefei, Peoples R China.
   [Xu, Tingjuan] Univ Sci & Technol China, Affiliated Hosp USTC 1, Gerontol Inst, Div Life Sci & Med, Hefei, Peoples R China.
   [Xu, Tingjuan] Anhui Prov Key Lab Tumor Immunotherapy & Nutr The, Hefei, Peoples R China.
C3 Anhui Medical University; Chinese Academy of Sciences; University of
   Science & Technology of China, CAS; Chinese Academy of Sciences;
   University of Science & Technology of China, CAS
RP Tao, LM (通讯作者)，Anhui Med Univ, Affiliated Hosp 2, Dept Ophthalmol, Hefei, Peoples R China.; Xu, TJ (通讯作者)，Univ Sci & Technol China, Affiliated Hosp USTC 1, Gerontol Inst, Div Life Sci & Med, Hefei, Peoples R China.; Xu, TJ (通讯作者)，Anhui Prov Key Lab Tumor Immunotherapy & Nutr The, Hefei, Peoples R China.
EM xutingjuan@163.com; lmtao9@163.com
FU Anhui Provincial Department of Education Project [2019jyxm1009]
FX The study was supported by Anhui Provincial Department of Education
   Project (2019jyxm1009).
CR Abdelkader M, 2019, IJOVS, V4, P101, DOI 10.11648/j.ijovs.20190404.18
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Biondi B, 2008, ENDOCR REV, V29, P76, DOI 10.1210/er.2006-0043
   Boyes WK, 2018, NEUROTOXICOLOGY, V67, P73, DOI 10.1016/j.neuro.2018.04.013
   Bromfield S, 2012, CURR EYE RES, V37, P549, DOI 10.3109/02713683.2011.647223
   Chaker L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0329-0
   Douglas IJ, 2007, OPHTHALMOLOGY, V114, P1164, DOI 10.1016/j.ophtha.2006.09.018
   Duncan KG, 1999, OPHTHALMIC RES, V31, P399, DOI 10.1159/000055564
   Eldred KC, 2018, SCIENCE, V362, P200, DOI 10.1126/science.aau6348
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   Madariaga AG, 2014, J CLIN ENDOCR METAB, V99, P923, DOI 10.1210/jc.2013-2409
   Gopinath B, 2016, INVEST OPHTH VIS SCI, V57, P5273, DOI 10.1167/iovs.16-19735
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   IntHout J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010247
   Ittermann T, 2014, THYROID, V24, P1473, DOI 10.1089/thy.2014.0190
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Ma HW, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-019-2216-7
   Ma HW, 2014, P NATL ACAD SCI USA, V111, P3602, DOI 10.1073/pnas.1317041111
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Reitmeir P, 2017, AGE AGEING, V46, P481, DOI 10.1093/ageing/afw234
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Smith AF, 2010, BRIT J OPHTHALMOL, V94, P1116, DOI 10.1136/bjo.2010.179945
   Tsai CC, 2007, ARCH OPHTHALMOL-CHIC, V125, P1652, DOI 10.1001/archopht.125.12.1652
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 31
TC 2
Z9 2
U1 1
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PD SEP
PY 2021
VL 64
IS 5
BP 696
EP 703
DI 10.1159/000515273
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YY2JO
UT WOS:000754619600002
PM 33596562
OA Bronze
DA 2022-11-30
ER

PT J
AU Kaur, I
   Katta, S
   Reddy, RK
   Narayanan, R
   Mathai, A
   Majji, AB
   Chakrabarti, S
AF Kaur, Inderjeet
   Katta, Saritha
   Reddy, Rajeev K.
   Narayanan, Raja
   Mathai, Annie
   Majji, Ajit B.
   Chakrabarti, Subhabrata
TI The Involvement of Complement Factor B and Complement Component C2 in an
   Indian Cohort with Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; GENETIC SUSCEPTIBILITY; LOC387715 GENES; EYE
   DISEASE; RISK; VARIANT; HTRA1; CFH; MACULOPATHY; ASSOCIATIONS
AB PURPOSE. Genes involved in the complement cascade such as complement factor B (CFB) and complement component C2 have been implicated in age-related macular degeneration (AMD) worldwide. In continuation of the analysis of CFH and LOC387715/HTRA1, this study was conducted to gain understanding of the role of CFB and C2 in an Indian AMD cohort.
   METHODS. Single nucleotide polymorphisms in CFB and C2 were screened in a cohort of clinically well-characterized patients with AMD (n = 177) and unaffected normal control subjects (n = 175). Screening was accomplished by a combination of customized genotyping followed by validation through resequencing. In addition, genotyping of two CFB variants (rs12614 and rs641153) that were in close proximity had to be resolved by resequencing. Estimates of allele and genotype frequencies, odds ratios, Hardy-Weinberg equilibrium, linkage disequilibrium (LD), and haplotype frequencies were also performed.
   RESULTS. Three SNPs in C2 (rs547154 [IVS10]; P = 5.4 x 10(-11)) and CFB (rs641153 [R32Q], P = 2.2 x 10(-7) and rs2072633 [IVS17]; P = 2.0 x 10(-4)) were strongly associated with reduced risk of AMD. The rs547154 and rs641153 were in strong LD (D' = 0.90, 95% CI = 0.81-0.96) and a protective haplotype T-A was observed (OR = 0.10, 95% CI = 0.05-0.20). LD was moderate (D' = 0.77, 95% CI = 0.67-0.85) between the rs547154 and the rs2072633 SNPs, and the haplotype T-T generated with these SNPs was relatively less protective (OR = 0.28, 95% CI = 0.18-0.44).
   CONCLUSIONS. The results of the present study provide an independent validation of the association of rs547154 (C2) and rs641153 (CFB) SNPs with reduced risk of AMD in an Indian cohort. (Invest Ophthalmol Vis Sci. 2010; 51: 59-63) DOI: 10.1167/iovs.09-4135
C1 [Chakrabarti, Subhabrata] LV Prasad Eye Inst, Brien Holden Eye Res Ctr, Kallam Anji Reddy Mol Genet Lab, Champalimaud Translat Ctr,Hyderabad Eye Res Fdn, Hyderabad 500034, Andhra Pradesh, India.
   [Reddy, Rajeev K.; Narayanan, Raja; Mathai, Annie; Majji, Ajit B.] LV Prasad Eye Inst, Brien Holden Eye Res Ctr, Hyderabad Eye Inst, Champalimaud Translat Ctr, Hyderabad 500034, Andhra Pradesh, India.
C3 L. V. Prasad Eye Institute; L. V. Prasad Eye Institute
RP Chakrabarti, S (通讯作者)，LV Prasad Eye Inst, Brien Holden Eye Res Ctr, Kallam Anji Reddy Mol Genet Lab, Champalimaud Translat Ctr,Hyderabad Eye Res Fdn, Hyderabad 500034, Andhra Pradesh, India.
EM subho@lvpei.org
RI Kaur, Inderjeet/ABD-1833-2021; Chakrabarti, Subhabrata/F-2468-2015;
   Narayanan, Raja/AAT-3098-2021
OI Chakrabarti, Subhabrata/0000-0003-3717-4963; Narayanan,
   Raja/0000-0001-9688-5859
FU Fast Track Research; Department of Science and Technology, Government of
   India [DST SR/FT/L-66/2006]; Council of Scientific and Industrial
   Research (CSIR), Government of India
FX Supported by Fast Track Research Grant DST SR/FT/L-66/2006, Department
   of Science and Technology, Government of India (IK). SK is the recipient
   of a senior research fellowship from the Council of Scientific and
   Industrial Research (CSIR), Government of India.
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Chanock SJ, 2007, NATURE, V447, P655, DOI 10.1038/447655a
   Clayton D, 2001, LANCET, V358, P1356, DOI 10.1016/S0140-6736(01)06418-2
   Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
NR 33
TC 38
Z9 41
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2010
VL 51
IS 1
BP 59
EP 63
DI 10.1167/iovs.09-4135
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 539OI
UT WOS:000273264200010
PM 19696172
DA 2022-11-30
ER

PT J
AU Shang, F
   Taylor, A
AF Shang, Fu
   Taylor, Allen
TI Roles for the ubiquitin-proteasome pathway in protein quality control
   and signaling in the retina: Implications in the pathogenesis of
   age-related macular degeneration
SO MOLECULAR ASPECTS OF MEDICINE
LA English
DT Review
DE Protein quality control; Signal transduction; Aging; Oxidative stress;
   Inflammation; Retina degeneration; Macula; Proteolysis
ID NF-KAPPA-B; PIGMENT EPITHELIAL-CELLS; ANTIOXIDANT RESPONSE ELEMENT;
   TRANSCRIPTION FACTOR NRF2; TRANSMEMBRANE CONDUCTANCE REGULATOR;
   DROSOPHILA EYE DEVELOPMENT; FAT-FACETS GENE; 26 S-PROTEASOME;
   AMYOTROPHIC-LATERAL-SCLEROSIS; GLYCATION END-PRODUCTS
AB The accumulation of damaged or postsynthetically modified proteins and dysregulation of inflammatory responses and angiogenesis in the retina/RPE are thought be etiologically related to formation of drusen and choroidal neovascularization (CNV), hallmarks of age-related macular degeneration (AMD). The ubiquitin-proteasome pathway (UPP) plays crucial roles in protein quality control, cell cycle control and signal transduction. Selective degradation of aberrant proteins by the UPP is essential for timely removal of potentially cytotoxic damaged or otherwise abnormal proteins. Proper function of the UPP is thought to be required for cellular function. In contrast, age - or stress induced - impairment the UPP or insufficient UPP capacity may contribute to the accumulation of abnormal proteins, cytotoxicity in the retina, and AMD. Crucial roles for the UPP in eye development, regulation of signal transduction, and antioxidant responses are also established. Insufficient UPP capacity in retina and RPE can result in dysregulation of signal transduction, abnormal inflammatory responses and CNV. There are also interactions between the UPP and lysosomal proteolytic pathways (LPPs). Means that modulate the proteolytic capacity are making their way into new generation of pharmacotherapies for delaying age-related diseases and may augment the benefits of adequate nutrition, with regard to diminishing the burden of AMD. (C) 2012 Published by Elsevier Ltd.
C1 [Shang, Fu; Taylor, Allen] USDA Human Nutr Res Ctr Aging, Lab Nutr & Vis Res, Boston, MA 02111 USA.
C3 United States Department of Agriculture (USDA)
RP Shang, F (通讯作者)，USDA Human Nutr Res Ctr Aging, Lab Nutr & Vis Res, 711 Washington St, Boston, MA 02111 USA.
EM fu.shang@tufts.edu
FU NIH [EY 011717, EY 013250, EY 021212]; USDA AFRI [2009-35200-05014];
   USDA [1950-510000-060-01A]; AHAF [M2010038]; Dennis L. Gierhart
   Charitable Gift Fund; NATIONAL EYE INSTITUTE [R29EY011717, R01EY013250,
   R01EY011717, R01EY021212] Funding Source: NIH RePORTER
FX This work is partially supported by NIH Grants EY 011717, EY 013250, EY
   021212, USDA AFRI Award 2009-35200-05014, USDA contract
   1950-510000-060-01A, AHAF Grant M2010038, Dennis L. Gierhart Charitable
   Gift Fund, and a gift from Alcon laboratories.
CR Adamo AM, 1999, J NEUROSCI RES, V55, P523, DOI 10.1002/(SICI)1097-4547(19990215)55:4<523::AID-JNR12>3.3.CO;2-H
   Adhikari A, 2007, ONCOGENE, V26, P3214, DOI 10.1038/sj.onc.1210413
   ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Angileri FF, 2008, CANCER-AM CANCER SOC, V112, P2258, DOI 10.1002/cncr.23407
   Arima K, 2011, P NATL ACAD SCI USA, V108, P14914, DOI 10.1073/pnas.1106015108
   Arjamaa O, 2006, EXP EYE RES, V83, P473, DOI 10.1016/j.exer.2006.01.016
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Balch WE, 2008, SCIENCE, V319, P916, DOI 10.1126/science.1141448
   Balog EM, 2009, BIOCHEMISTRY-US, V48, P3005, DOI 10.1021/bi802117k
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544
   Benaroudj N, 2000, NAT CELL BIOL, V2, P833, DOI 10.1038/35041081
   Benaroudj N, 2001, BIOCHIMIE, V83, P311, DOI 10.1016/S0300-9084(01)01244-5
   Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552
   Bendotti C., 2011, PROG NEUROBIOL
   Benharouga M, 2001, J CELL BIOL, V153, P957, DOI 10.1083/jcb.153.5.957
   Bennett EJ, 2005, MOL CELL, V17, P351, DOI 10.1016/j.molcel.2004.12.021
   Bento CF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015062
   Bian Q, 2008, MOL VIS, V14, P403
   BIZZI A, 1991, BRAIN RES, V548, P292, DOI 10.1016/0006-8993(91)91135-N
   Blazquez M, 1996, J BIOL CHEM, V271, P18638, DOI 10.1074/jbc.271.31.18638
   Bogdan S, 2001, MECH DEVELOP, V103, P61, DOI 10.1016/S0925-4773(01)00332-X
   Boulton M, 2004, GRAEF ARCH CLIN EXP, V242, P76, DOI 10.1007/s00417-003-0812-8
   Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043
   Brett FM, 2002, ARCH NEUROL-CHICAGO, V59, P464, DOI 10.1001/archneur.59.3.464
   Breusing N, 2008, BIOL CHEM, V389, P203, DOI 10.1515/BC.2008.029
   BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466
   Bulteau AL, 2002, FREE RADICAL BIO MED, V32, P1157, DOI 10.1016/S0891-5849(02)00816-X
   Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779
   Bush KT, 1997, J BIOL CHEM, V272, P9086
   Caballero M, 2003, BIOCHEM BIOPH RES CO, V308, P346, DOI 10.1016/S0006-291X(03)01385-8
   Campbell DS, 2001, NEURON, V32, P1013, DOI 10.1016/S0896-6273(01)00551-7
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Carbia-Nagashima A, 2004, IUBMB LIFE, V56, P83, DOI 10.1080/15216540410001668064
   Carthew RW, 2000, CURR BIOL, V10, pR532, DOI 10.1016/S0960-9822(00)00587-X
   CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923
   Chen F, 2006, CELL DEATH DIFFER, V13, P1835, DOI 10.1038/sj.cdd.4402014
   Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555
   Chen J, 2005, CURR NEUROVASC RES, V2, P189, DOI 10.2174/1567202054368344
   Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368
   CHEN ST, 1994, DEV BRAIN RES, V78, P265, DOI 10.1016/0165-3806(94)90035-3
   Chen X, 2000, DEV GENES EVOL, V210, P603, DOI 10.1007/s004270000109
   Chen YQ, 2011, J CELL SCI, V124, P161, DOI 10.1242/jcs.064576
   Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8
   Chen ZJ, 2006, CELL DEATH DIFFER, V13, P687, DOI 10.1038/sj.cdd.4401869
   Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758
   CHENG L, 1994, MOL GEN GENET, V243, P358, DOI 10.1007/BF00301072
   Cheng RZ, 2002, BBA-MOL BASIS DIS, V1587, P65, DOI 10.1016/S0925-4439(02)00069-8
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Chiu RK, 2006, PLOS GENET, V2, P1070, DOI 10.1371/journal.pgen.0020116
   Ciechanover A, 2000, J CELL BIOCHEM, P40
   Cohen E, 2008, NAT REV NEUROSCI, V9, P759, DOI 10.1038/nrn2474
   Conconi M, 1998, BIOCHEM J, V333, P407, DOI 10.1042/bj3330407
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cringle SJ, 2002, INVEST OPHTH VIS SCI, V43, P1922
   Cuervo AM, 2005, AUTOPHAGY, V1, P131, DOI 10.4161/auto.1.3.2017
   Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004
   Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4
   Davies KJA, 2006, NEUROLOGY, V66, pS93, DOI 10.1212/01.wnl.0000192308.43151.63
   DEAN RT, 1993, TRENDS BIOCHEM SCI, V18, P437, DOI 10.1016/0968-0004(93)90145-D
   Deblandre GA, 2001, DEV CELL, V1, P795, DOI 10.1016/S1534-5807(01)00091-0
   del Alamo D, 2006, DEV CELL, V11, P887, DOI 10.1016/j.devcel.2006.09.016
   Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4
   DeNiro M, 2009, EXP EYE RES, V89, P700, DOI 10.1016/j.exer.2009.06.013
   Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809
   Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506
   Ding QX, 2001, J NEUROCHEM, V77, P1010, DOI 10.1046/j.1471-4159.2001.00302.x
   Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984
   Dreger H, 2010, CARDIOVASC RES, V85, P395, DOI 10.1093/cvr/cvp279
   Dreger H, 2009, CARDIOVASC RES, V83, P354, DOI 10.1093/cvr/cvp107
   Drinjakovic J, 2010, NEURON, V65, P341, DOI 10.1016/j.neuron.2010.01.017
   Dudek EJ, 2010, INVEST OPHTH VIS SCI, V51, P4164, DOI 10.1167/iovs.09-4087
   Dudek EJ, 2005, FASEB J, V19, P1707, DOI 10.1096/fj.05-4049fje
   Dudek EJ, 2001, FREE RADICAL BIO MED, V31, P651, DOI 10.1016/S0891-5849(01)00634-7
   Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026
   Ethen CM, 2007, FEBS LETT, V581, P885, DOI 10.1016/j.febslet.2007.01.061
   ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54
   Feldman DE, 2000, CURR OPIN STRUC BIOL, V10, P26, DOI 10.1016/S0959-440X(99)00044-5
   Fernandes A.F., 2006, EXP EYE RES
   Fernandes AF, 2008, J BIOL CHEM, V283, P20745, DOI 10.1074/jbc.M800268200
   Fernandes AF, 2009, MOL BIOL CELL, V20, P3690, DOI 10.1091/mbc.E08-10-1068
   Ferrington DA, 2001, J BIOL CHEM, V276, P937, DOI 10.1074/jbc.M005356200
   Ferrington DA, 2008, J NEUROCHEM, V106, P158, DOI 10.1111/j.1471-4159.2008.05345.x
   FigueiredoPereira ME, 1997, MOL BIOL REP, V24, P35, DOI 10.1023/A:1006848405975
   FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2
   Fischer JA, 1997, DEV GENET, V21, P167, DOI 10.1002/(SICI)1520-6408(1997)21:2<167::AID-DVG6>3.3.CO;2-T
   FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985
   Fredrickson E.R., 2012, SEMIN CELL DEV BIOL
   Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396
   Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8
   Friguet B, 2006, FEBS LETT, V580, P2910, DOI 10.1016/j.febslet.2006.03.028
   Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005
   Galy A, 2002, DEV BIOL, V248, P251, DOI 10.1006/dbio.2002.0736
   Gelman MS, 2002, J BIOL CHEM, V277, P11709, DOI 10.1074/jbc.M111958200
   Geng F., 2012, ANN REV BIOCH
   Ghosh S, 2008, NAT REV IMMUNOL, V8, P837, DOI 10.1038/nri2423
   GIBLIN FJ, 1984, EXP EYE RES, V38, P87, DOI 10.1016/0014-4835(84)90142-8
   GIULIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329, DOI 10.1006/abbi.1994.1245
   Glabe CG, 2008, J BIOL CHEM, V283, P29639, DOI 10.1074/jbc.R800016200
   Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001
   Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263
   GOLDBERG AL, 1972, P NATL ACAD SCI USA, V69, P422, DOI 10.1073/pnas.69.2.422
   Gonen H, 1999, J BIOL CHEM, V274, P14823, DOI 10.1074/jbc.274.21.14823
   Grove D.E., 2009, MOL BIOL CELL
   Grune T, 2004, INT J BIOCHEM CELL B, V36, P2519, DOI 10.1016/j.biocel.2004.04.020
   Grune T, 1997, BIOFACTORS, V6, P165, DOI 10.1002/biof.5520060210
   GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344
   Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504
   Grune T, 2005, FREE RADICAL BIO MED, V39, P1208, DOI 10.1016/j.freeradbiomed.2005.06.009
   Grune T, 1998, J BIOL CHEM, V273, P10857, DOI 10.1074/jbc.273.18.10857
   Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076
   Ha KN, 2006, INVEST OPHTH VIS SCI, V47, P2709, DOI 10.1167/iovs.05-1322
   Haglund K., J CELL SCI 2, V125, P265
   HANDLEYGEARHART PM, 1994, BIOCHEM J, V304, P1015, DOI 10.1042/bj3041015
   HANDLEYGEARHART PM, 1994, J BIOL CHEM, V269, P33171
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Harhaj EW, 2011, CELL RES, V21, P22, DOI 10.1038/cr.2010.166
   Harper N, 2003, J BIOL CHEM, V278, P44338, DOI 10.1074/jbc.M307376200
   Hays R, 2002, NAT CELL BIOL, V4, P425, DOI 10.1038/ncb794
   HERSHKO A, 1982, J BIOL CHEM, V257, P3964
   HERSHKO A, 1986, J BIOL CHEM, V261, P1992
   Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425
   Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8
   Hoffman EK, 1996, J NEUROL SCI, V139, P15, DOI 10.1016/0022-510X(96)00031-7
   House CM, 2003, P NATL ACAD SCI USA, V100, P3101, DOI 10.1073/pnas.0534783100
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   HUANG LL, 1995, EXP EYE RES, V61, P45, DOI 10.1016/S0014-4835(95)80057-3
   HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828
   Hussong SA, 2010, J NEUROCHEM, V113, P1481, DOI 10.1111/j.1471-4159.2010.06688.x
   Hyun DH, 2003, J NEUROCHEM, V86, P363, DOI 10.1046/j.1471-4159.2003.01841.x
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Ishii T, 2005, BIOCHEMISTRY-US, V44, P13893, DOI 10.1021/bi051336u
   Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76
   Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817
   Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796
   JAHNGEN JH, 1986, J BIOL CHEM, V261, P3760
   JAHNGEN JH, 1990, ARCH BIOCHEM BIOPHYS, V276, P32, DOI 10.1016/0003-9861(90)90006-K
   JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218
   JAHNGENHODGE J, 1994, METHOD ENZYMOL, V233, P512
   Jiang X., NAT REV IMMUNOL, V12, P35
   Jin JP, 2007, NATURE, V447, P1135, DOI 10.1038/nature05902
   Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487
   JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x
   Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6
   JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0
   Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519
   Kapeta S, 2010, J BIOL CHEM, V285, P8171, DOI 10.1074/jbc.M109.031575
   Kapphahn RJ, 2007, EXP EYE RES, V84, P646, DOI 10.1016/j.exer.2006.12.002
   Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Komander D, 2009, EMBO REP, V10, P466, DOI 10.1038/embor.2009.55
   Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139
   Korolchuk VI, 2009, AUTOPHAGY, V5, P862, DOI 10.4161/auto.8840
   Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021
   Lai EC, 2001, DEV CELL, V1, P783, DOI 10.1016/S1534-5807(01)00092-2
   Le Bras S, 2011, TRAFFIC, V12, P149, DOI 10.1111/j.1600-0854.2010.01126.x
   Lee BH, 2010, NATURE, V467, P179, DOI 10.1038/nature09299
   Lee CS, 2004, J NEUROCHEM, V91, P996, DOI 10.1111/j.1471-4159.2004.02813.x
   Lee DH, 1998, MOL CELL BIOL, V18, P30, DOI 10.1128/MCB.18.1.30
   Lee JD, 2002, DEVELOPMENT, V129, P5697, DOI 10.1242/dev.00159
   Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200
   Leger F, 2011, J NEUROPATH EXP NEUR, V70, P63, DOI 10.1097/NEN.0b013e31820376cc
   Li Yanxia, 2004, BMC Dev Biol, V4, P5, DOI 10.1186/1471-213X-4-5
   Li ZB, 2005, EMBO REP, V6, P373, DOI 10.1038/sj.embor.7400377
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liu CW, 2002, J BIOL CHEM, V277, P26815, DOI 10.1074/jbc.M201782200
   Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7
   Loeffler KU, 1997, GRAEF ARCH CLIN EXP, V235, P248, DOI 10.1007/BF00941767
   LOU MF, 1992, EXP EYE RES, V55, P889, DOI 10.1016/0014-4835(92)90015-K
   Louie JL, 2002, EXP EYE RES, V75, P271, DOI 10.1006/exer.2002.2022
   Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Marques C, 2004, FASEB J, V18, P1424, DOI 10.1096/fj.04-1743fje
   Marques C, 2006, FASEB J, V20, P741, DOI 10.1096/fj.05-5080fje
   Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197
   Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091
   Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1
   Matsuzawa S, 2005, P NATL ACAD SCI USA, V102, P14982, DOI 10.1073/pnas.0507512102
   Mauger C, 1999, MOL BRAIN RES, V74, P35, DOI 10.1016/S0169-328X(99)00256-9
   Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287
   McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2
   Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509
   Meiners S, 2006, FREE RADICAL BIO MED, V40, P2232, DOI 10.1016/j.freeradbiomed.2006.03.003
   Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X
   Michelle C, 2009, J MOL EVOL, V68, P616, DOI 10.1007/s00239-009-9225-6
   Minnnaugh EG, 2004, MOL CANCER THER, V3, P551
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2006, AUTOPHAGY, V2, P302, DOI 10.4161/auto.2945
   Mocciaro A, 2012, J CELL SCI, V125, P255, DOI 10.1242/jcs.091199
   Morimoto RI, 2008, GENE DEV, V22, P1427, DOI 10.1101/gad.1657108
   Morishima Y, 2008, HUM MOL GENET, V17, P3942, DOI 10.1093/hmg/ddn296
   Mu TW, 2008, CELL, V134, P769, DOI 10.1016/j.cell.2008.06.037
   MURAKAMI K, 1990, FREE RADICAL BIO MED, V8, P217, DOI 10.1016/0891-5849(90)90066-R
   MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0
   Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246
   NAASH M, 1991, J NEUROSCI RES, V30, P433, DOI 10.1002/jnr.490300220
   Naash MI, 1997, INVEST OPHTH VIS SCI, V38, P2344
   Nagaraj RH, 2010, AMINO ACIDS
   Narimatsu M, 2009, CELL, V137, P295, DOI 10.1016/j.cell.2009.02.025
   Neves DDC, 2001, EUR J NEUROSCI, V13, P1938, DOI 10.1046/j.0953-816x.2001.01571.x
   Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200
   Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200
   Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561
   Obin M, 1999, J BIOL CHEM, V274, P11789, DOI 10.1074/jbc.274.17.11789
   Obin M, 2002, J BIOL CHEM, V277, P44566, DOI 10.1074/jbc.M205308200
   Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473
   OHTSUKA H, 1995, J GERONTOL A-BIOL, V50, pB277, DOI 10.1093/gerona/50A.5.B277
   Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787
   Ono K, 2009, P NATL ACAD SCI USA, V106, P14745, DOI 10.1073/pnas.0905127106
   Ou CY, 2007, DEV BIOL, V308, P106, DOI 10.1016/j.ydbio.2007.05.008
   Ou CY, 2002, GENE DEV, V16, P2403, DOI 10.1101/gad.1011402
   Overstreet E, 2003, CURR BIOL, V13, P854, DOI 10.1016/S0960-9822(03)00326-9
   Ozawa Y, 2008, J BIOL CHEM, V283, P24561, DOI 10.1074/jbc.M802238200
   PACIFICI RE, 1993, J BIOL CHEM, V268, P15405
   PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2
   PARKS AL, 1995, MECH DEVELOP, V50, P201, DOI 10.1016/0925-4773(94)00336-L
   Parry GCN, 1998, ARTERIOSCL THROM VAS, V18, P934, DOI 10.1161/01.ATV.18.6.934
   Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849
   Piccinini M, 1996, BIOCHEM J, V318, P711, DOI 10.1042/bj3180711
   Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009
   Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019
   Pickering AM, 2010, BIOCHEM J, V432, P585, DOI 10.1042/BJ20100878
   Pirlich M, 2002, FREE RADICAL BIO MED, V33, P283, DOI 10.1016/S0891-5849(02)00880-8
   Pitha-Rowe I, 2009, INVEST OPHTH VIS SCI, V50, P5339, DOI 10.1167/iovs.09-3648
   Plafker KS, 2010, J BIOL CHEM, V285, P23062, DOI 10.1074/jbc.M110.121913
   Poeck B, 2001, NEURON, V29, P99, DOI 10.1016/S0896-6273(01)00183-0
   Proctor CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013175
   RAMACHANDRAN S, 1991, EXP EYE RES, V53, P503, DOI 10.1016/0014-4835(91)90167-D
   Ramanathan M, 1999, NEUROREPORT, V10, P3797, DOI 10.1097/00001756-199912160-00014
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Ravid T, 2008, NAT REV MOL CELL BIO, V9, P679, DOI 10.1038/nrm2468
   Reinheckel T, 2000, ARCH BIOCHEM BIOPHYS, V377, P65, DOI 10.1006/abbi.2000.1717
   Rogers PR, 2001, IMMUNITY, V15, P445, DOI 10.1016/S1074-7613(01)00191-1
   Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   SADIS S, 1995, MOL CELL BIOL, V15, P4086
   Saksena S, 2007, TRENDS BIOCHEM SCI, V32, P561, DOI 10.1016/j.tibs.2007.09.010
   Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642
   SALO DC, 1990, J BIOL CHEM, V265, P11919
   Sano Y, 2006, AM J PATHOL, V169, P132, DOI 10.2353/ajpath.2006.060085
   Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934
   Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096
   Scrofano MM, 1998, MECH AGEING DEV, V105, P273, DOI 10.1016/S0047-6374(98)00097-9
   Scrofano MM, 1998, MECH AGEING DEV, V101, P277, DOI 10.1016/S0047-6374(97)00178-4
   Sekhar KR, 2002, ONCOGENE, V21, P6829, DOI 10.1038/sj.onc.1205905
   SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447
   Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677
   SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297
   Shang F, 2004, EXP EYE RES, V78, P1, DOI 10.1016/j.exer.2003.10.003
   Shang F, 1997, EXP EYE RES, V64, P21, DOI 10.1006/exer.1996.0176
   Shang F, 2001, EXP EYE RES, V73, P229, DOI 10.1006/exer.2001.1029
   Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086
   Shang F, 2005, J BIOL CHEM, V280, P20365, DOI 10.1074/jbc.M414356200
   SHANG F, 1994, CURR EYE RES, V13, P423, DOI 10.3109/02713689408999870
   Shang F, 2001, EXP EYE RES, V73, P827, DOI 10.1006/exer.2001.1091
   Shang F, 2006, ISR J CHEM, V46, P145, DOI 10.1560/A8AA-Y8RP-9DRW-Y8AX
   Shang F, 2011, FREE RADICAL BIO MED, V51, P5, DOI 10.1016/j.freeradbiomed.2011.03.031
   Shringarpure R, 2001, CELL MOL LIFE SCI, V58, P1442, DOI 10.1007/PL00000787
   Shringarpure R, 2003, J BIOL CHEM, V278, P311, DOI 10.1074/jbc.M206279200
   Shringarpure R, 2000, CELL MOL LIFE SCI, V57, P1802, DOI 10.1007/PL00000660
   Sitte N, 2000, FASEB J, V14, P2495, DOI 10.1096/fj.00-0209com
   Sitte N, 1998, FEBS LETT, V440, P399, DOI 10.1016/S0014-5793(98)01495-1
   Sitte N, 2000, FREE RADICAL BIO MED, V28, P701, DOI 10.1016/S0891-5849(99)00279-8
   Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8
   SPENCE J, 1995, MOL CELL BIOL, V15, P1265
   Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200
   Strickland E, 2000, J BIOL CHEM, V275, P5565, DOI 10.1074/jbc.275.8.5565
   Sun SC, 2008, TRENDS IMMUNOL, V29, P469, DOI 10.1016/j.it.2008.07.003
   SWAMY MS, 1993, EXP EYE RES, V56, P177, DOI 10.1006/exer.1993.1025
   TAKIZAWA N, 1993, BIOCHEM BIOPH RES CO, V192, P700, DOI 10.1006/bbrc.1993.1471
   Tarcsa E, 2000, J BIOL CHEM, V275, P20295, DOI 10.1074/jbc.M001555200
   Tauriello DVF, 2010, CELL CYCLE, V9, P3700, DOI 10.4161/cc.9.18.13204
   Taya S, 1999, GENES CELLS, V4, P757, DOI 10.1046/j.1365-2443.1999.00297.x
   TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3
   Taylor A, 2002, NES NUTR WS, V6, P163, DOI 10.1159/000061865
   Taylor A, 1997, MOL ASPECTS MED, V18, P307, DOI 10.1016/S0098-2997(95)00049-6
   Taylor A., 1999, CRC MOD NUT, V1st, P53
   Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94
   Tsirigotis M, 2001, J BIOL CHEM, V11, P11
   Uchiki T., 2011, AGING CELL
   Uetama T, 2003, J CELL PHYSIOL, V197, P77, DOI 10.1002/jcp.10342
   Ullrich O, 2001, FREE RADICAL BIO MED, V31, P887, DOI 10.1016/S0891-5849(01)00672-4
   Ungureanu Daniela, 2005, Sci STKE, V2005, ppe49, DOI 10.1126/stke.3042005pe49
   Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678
   Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641
   Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960
   Vernace VA, 2007, FASEB J, V21, P2672, DOI 10.1096/fj.06-6751com
   Villeneuve N.F., 2010, ANTIOXID REDOX SIGNA
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6
   Wei YH, 2011, FREE RADICAL BIO MED, V51, P216, DOI 10.1016/j.freeradbiomed.2011.04.026
   Weikel K.A., 2011, INVEST OPHTHALMOL VI
   Weinmaster G, 2011, DEV CELL, V21, P134, DOI 10.1016/j.devcel.2011.06.006
   Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev
   Westphal K, 2009, FREE RADICAL BIO MED, V47, P1652, DOI 10.1016/j.freeradbiomed.2009.09.017
   Wickliffe K, 2009, CHEM REV, V109, P1537, DOI 10.1021/cr800414e
   Wickliffe KE, 2011, TRENDS CELL BIOL, V21, P656, DOI 10.1016/j.tcb.2011.08.008
   Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627
   WILKINSON KD, 1992, BIOCHEM SOC T, V20, P631, DOI 10.1042/bst0200631
   Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799
   Wing JP, 2002, NAT CELL BIOL, V4, P451, DOI 10.1038/ncb800
   Wood SA, 1997, MECH DEVELOP, V63, P29, DOI 10.1016/S0925-4773(97)00672-2
   Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384
   Wu MX, 2009, FREE RADICAL BIO MED, V46, P62, DOI 10.1016/j.freeradbiomed.2008.09.021
   Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3
   Xu P, 2009, CELL, V137, P133, DOI 10.1016/j.cell.2009.01.041
   Xu WD, 2000, EXP CELL RES, V255, P135, DOI 10.1006/excr.2000.4803
   Yamamoto N, 2007, J BIOL CHEM, V282, P4364, DOI 10.1074/jbc.M603712200
   Yamanaka K, 2003, NAT CELL BIOL, V5, P336, DOI 10.1038/ncb952
   Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002
   Yang ZF, 2009, CURR TOP MICROBIOL, V335, P1, DOI 10.1007/978-3-642-00302-8_1
   Yao DD, 2004, P NATL ACAD SCI USA, V101, P10810, DOI 10.1073/pnas.0404161101
   Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486
   Yoshida T, 1997, BRAIN RES, V764, P283, DOI 10.1016/S0006-8993(97)00600-8
   Younger JM, 2006, CELL, V126, P571, DOI 10.1016/j.cell.2006.06.041
   Younger JM, 2004, J CELL BIOL, V167, P1075, DOI 10.1083/jcb.200410065
   Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zetterberg M, 2006, INVEST OPHTH VIS SCI, V47, P3467, DOI 10.1167/iovs.05-1664
   Zhang C, 2008, NAT MED, V14, P959, DOI 10.1038/nm.1851
   Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004
   Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158
   Zhang XY, 2008, INVEST OPHTH VIS SCI, V49, P3622, DOI 10.1167/iovs.07-1559
   Zhang XY, 2007, INVEST OPHTH VIS SCI, V48, P4200, DOI 10.1167/iovs.07-0196
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 339
TC 36
Z9 41
U1 0
U2 26
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0098-2997
EI 1872-9452
J9 MOL ASPECTS MED
JI Mol. Asp. Med.
PD AUG
PY 2012
VL 33
IS 4
SI SI
BP 446
EP 466
DI 10.1016/j.mam.2012.04.001
PG 21
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 983WR
UT WOS:000307149900008
PM 22521794
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Iannaccone, A
   Hollingsworth, TJ
   Koirala, D
   New, DD
   Lenchik, NI
   Beranova-Giorgianni, S
   Gerling, IC
   Radic, MZ
   Giorgianni, F
AF Iannaccone, Alessandro
   Hollingsworth, T. J.
   Koirala, Diwa
   New, David D.
   Lenchik, Nataliya I.
   Beranova-Giorgianni, Sarka
   Gerling, Ivan C.
   Radic, Marko Z.
   Giorgianni, Francesco
TI Retinal pigment epithelium and microglia express the CD5 antigen-like
   protein, a novel autoantigen in age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE CD5L; Retinal pigment epithelium; Microglia; Age-related macular
   degeneration; Auto-antibody; Scavenger receptor; Autoimmunity
ID APOPTOSIS INHIBITORY FACTOR; FACTOR-H POLYMORPHISM; GENE-EXPRESSION;
   BASAL DEPOSITS; MACROPHAGE SURVIVAL; AUTOPHAGY INDUCER;
   APOLIPOPROTEIN-B; OPTICAL-DENSITY; BRUCHS MEMBRANE; DRUSEN
AB We report on a novel autoantigen expressed in human macular tissues, identified following an initial Western blot (WB)-based screening of sera from subjects with age-related macular degeneration (AMD) for circulating auto-antibodies (AAbs) recognizing macular antigens. Immunoprecipitation, 2D-gel electrophoresis (2D-GE) and liquid chromatography-tandem mass spectrometry (LC-MS/MS), direct enzyme-linked immunosorbent assays (ELISA), WBs, immunohistochemistry (IHC), human primary and ARPE-19 immortalized cell cultures were used to characterize this novel antigen. An approximately 40kDa autoantigen in AMD was identified as the scavenger receptor CD5 antigen-like protein (CD5L), also known as apoptosis inhibitor of macrophage (AIM). CD5L/AIM was localized to human RPE by IHC and WB methods and to retinal microglial cells by IHC. ELISAs with recombinant CD5L/AIM on a subset of AMD sera showed a nearly 2-fold higher anti-CD5L/AIM reactivity in AMD vs. Control sera (p = 0.000007). Reactivity >0.4 was associated with 18-fold higher odds of having AMD (x2 = 21.42, p = 0.00063). Circulating CD5L/AIM levels were also nearly 2-fold higher in AMD sera compared to controls (p = 0.0052). The discovery of CD5L/AIM expression in the RPE and in retinal microglial cells adds to the known immunomodulatory roles of these cells in the retina. The discovery of AAbs recognizing CD5L/AIM identifies a possible novel disease biomarker and suggest a potential role for CD5L/AIM in the pathogenesis of AMD in situ. The possible mechanisms via which anti-CD5L/AIM AAbs may contribute to AMD pathogenesis are discussed. In particular, since CD5L is known to stimulate autophagy and to participate in oxidized LDL uptake in macrophages, we propose that anti-CD5L/AIM auto-antibodies may play a role in drusen biogenesis and inflammatory RPE damage in AMD. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Iannaccone, Alessandro; Hollingsworth, T. J.; Koirala, Diwa; New, David D.; Lenchik, Nataliya I.] Univ Tennessee, Hlth Sci Ctr, Hamilton Eye Inst, Dept Ophthalmol, Memphis, TN USA.
   [Iannaccone, Alessandro] Duke Univ, Duke Eye Ctr, Sch Med, Dept Ophthalmol, Durham, NC 27706 USA.
   [Koirala, Diwa; Beranova-Giorgianni, Sarka; Giorgianni, Francesco] Univ Tennessee, Hlth Sci Ctr, Dept Pharmaceut Sci, Memphis, TN USA.
   [Lenchik, Nataliya I.; Gerling, Ivan C.] Univ Tennessee, Hlth Sci Ctr, Dept Med, Div Endocrinol, Memphis, TN USA.
   [Radic, Marko Z.] Univ Tennessee, Hlth Sci Ctr, Dept Microbiol Immunol & Biochem, Memphis, TN USA.
C3 University of Tennessee System; University of Tennessee Health Science
   Center; Duke University; University of Tennessee System; University of
   Tennessee Health Science Center; University of Tennessee System;
   University of Tennessee Health Science Center; University of Tennessee
   System; University of Tennessee Health Science Center
RP Iannaccone, A (通讯作者)，Duke Univ, Duke Eye Ctr, Sch Med, Dept Ophthalmol, Durham, NC 27706 USA.
EM alessandro.iannaccone@duke.edu
RI Hollingsworth, T.J./AAD-2814-2022
OI Radic, Marko/0000-0002-8004-282X; Hollingsworth,
   T.J./0000-0002-2119-521X; Iannaccone, Alessandro/0000-0001-5737-8424
FU NEI/NIH [1R21EY018416, 1R01EY022706]; Research to Prevent Blindness,
   Inc., New York, NY; UTHSC College of Pharmacy Seed Grant; NIH
   [S10RR16679]; UTHSC College of Pharmacy; NATIONAL CENTER FOR RESEARCH
   RESOURCES [S10RR016679] Funding Source: NIH RePORTER; NATIONAL EYE
   INSTITUTE [R01EY022706, R21EY018416] Funding Source: NIH RePORTER
FX This investigation was supported by NEI/NIH grants 1R21EY018416 (AI) and
   1R01EY022706 (AI/FG) and by Research to Prevent Blindness, Inc., New
   York, NY (Physician Scientist Award to AI and unrestricted grant to
   UTHSC Ophthalmology). The LC-MS/MS portion of this project was funded in
   part also by a UTHSC College of Pharmacy Seed Grant (FG). Funds for the
   LTQ mass spectrometer were provided by NIH grant S10RR16679, and by the
   UTHSC College of Pharmacy.
CR Adamus G, 2012, MOL VIS, V18, P2323
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Amaral J., 2011, INVEST OPHTHALMOL, V52, P2303
   Amezaga N, 2014, J LEUKOCYTE BIOL, V95, P509, DOI 10.1189/jlb.1212660
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Arai S, 2005, CELL METAB, V1, P201, DOI 10.1016/j.cmet.2005.02.002
   Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002
   Becerra SP, 2006, EXP EYE RES, V82, P739, DOI 10.1016/j.exer.2005.10.016
   Bian ZM, 2001, EXP EYE RES, V73, P111, DOI 10.1006/exer.2001.1019
   Bian ZM, 2011, INVEST OPHTH VIS SCI, V52, P8646, DOI 10.1167/iovs.11-7570
   Bonanni A, 2015, AUTOIMMUN REV, V14, P692, DOI 10.1016/j.autrev.2015.04.004
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Chawla A, 2011, NAT REV IMMUNOL, V11, P738, DOI 10.1038/nri3071
   Chen L, 2002, OCUL IMMUNOL INFLAMM, V10, P27, DOI 10.1076/ocii.10.1.27.10328
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Crane IJ, 2000, IMMUNOLOGY, V101, P426, DOI 10.1046/j.0019-2805.2000.01105.x
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Egensperger R, 1996, DEV BRAIN RES, V97, P1, DOI 10.1016/S0165-3806(96)00119-8
   ELNER SG, 1991, LAB INVEST, V64, P819
   Elner VM, 1996, EXP EYE RES, V63, P297, DOI 10.1006/exer.1996.0118
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Martinez VG, 2011, PHARMACOL REV, V63, P967, DOI 10.1124/pr.111.004523
   Gallaher KT, 2007, VISION RES, V47, P1253, DOI 10.1016/j.visres.2007.01.013
   Gangadharan B, 2007, CLIN CHEM, V53, P1792, DOI 10.1373/clinchem.2007.089144
   Giorgianni F, 2004, ANAL CHEM, V76, P7028, DOI 10.1021/ac0493368
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Gray J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-271
   Gregerson DS, 2004, J IMMUNOL, V172, P6587, DOI 10.4049/jimmunol.172.11.6587
   Gu JY, 2010, ADV EXP MED BIOL, V664, P411, DOI 10.1007/978-1-4419-1399-9_47
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamada M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4147
   Haruta I, 2001, J BIOL CHEM, V276, P22910, DOI 10.1074/jbc.M100324200
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Iannaccone A, 2012, ADV EXP MED BIOL, V723, P11, DOI 10.1007/978-1-4614-0631-0_2
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Jablonski MM, 2000, J NEUROSCI, V20, P7149
   Jablonski MM, 2001, GLIA, V35, P14, DOI 10.1002/glia.1066
   Joseph SB, 2004, CELL, V119, P299, DOI 10.1016/j.cell.2004.09.032
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Karlstetter M, 2012, KLIN MONATSBL AUGENH, V229, P221, DOI 10.1055/s-0031-1282050
   Karlstetter M, 2014, ADV EXP MED BIOL, V801, P207, DOI 10.1007/978-1-4614-3209-8_27
   Karlstetter M, 2010, IMMUNOBIOLOGY, V215, P685, DOI 10.1016/j.imbio.2010.05.010
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kurokawa J, 2010, CELL METAB, V11, P479, DOI 10.1016/j.cmet.2010.04.013
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   lannaccone A., 2015, PLOS ONE, V10
   lannaccone A., 2007, INVEST OPHTH VIS SCI, V48, P1458
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li Y, 2011, CANCER RES, V71, P5488, DOI 10.1158/0008-5472.CAN-10-4225
   Lian XM, 2005, AM J PATHOL, V167, P813, DOI 10.1016/S0002-9440(10)62053-6
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Niu N, 2013, INVEST OPHTH VIS SCI, V54, P7045, DOI 10.1167/iovs.13-12531
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Pabst MJ, 2008, PROTEOME SCI, V6, DOI 10.1186/1477-5956-6-13
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Renganathan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076325
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Ryeom SW, 1996, J CELL SCI, V109, P387
   Saari JC, 2012, ANNU REV NUTR, V32, P125, DOI 10.1146/annurev-nutr-071811-150748
   Sanjurjo L, 2015, J LEUKOCYTE BIOL, V98, P173, DOI 10.1189/jlb.3RU0215-074R
   Sanjurjo L, 2015, AUTOPHAGY, V11, P487, DOI 10.1080/15548627.2015.1017183
   Sarrias MR, 2005, J BIOL CHEM, V280, P35391, DOI 10.1074/jbc.M505042200
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Vishwanathan R, 2014, AGE AGEING, V43, P271, DOI 10.1093/ageing/aft210
   Wang H, 2015, CHEM RES TOXICOL, V28, P967, DOI 10.1021/acs.chemrestox.5b00001
   Wang H, 2014, CHEM RES TOXICOL, V27, P2015, DOI 10.1021/tx500216a
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Yang DL, 2011, INVEST OPHTH VIS SCI, V52, P6026, DOI 10.1167/iovs.10-7023
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
   Zigler JS, 2011, J CELL SCI, V124, P523, DOI 10.1242/jcs.078790
NR 111
TC 16
Z9 18
U1 0
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD FEB
PY 2017
VL 155
BP 64
EP 74
DI 10.1016/j.exer.2016.12.006
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EQ4BF
UT WOS:000398017000007
PM 27989757
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kim, JH
   Sagong, M
   Woo, SJ
   Kim, YC
   Cho, H
   Lee, YH
   Byon, I
   Jo, YJ
   Chin, HS
   Lee, Y
   Chae, JE
   Kang, SW
AF Kim, Jae Hui
   Sagong, Min
   Woo, Se Joon
   Kim, Yu Cheol
   Cho, Heeyoon
   Lee, Young Hoon
   Byon, Iksoo
   Jo, Young Joon
   Chin, Hee Seung
   Lee, Youkyung
   Chae, Jae Eun
   Kang, Se Woong
TI A real-world study assessing the impact of retinal fluid on visual
   acuity outcomes in patients with neovascular age-related macular
   degeneration in Korea
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; GROWTH-FACTOR THERAPY; INTRAVITREAL
   RANIBIZUMAB; AFLIBERCEPT; GUIDELINES; AMD
AB To evaluate the real-world treatment outcomes in patients with neovascular age-related macular degeneration (nAMD) in Korea, focusing on retinal fluid resolution. This multi-institutional retrospective chart review study, analyzed medical records of patients with nAMD (age >= 50 years) who received their first anti-vascular endothelial growth factor (VEGF) treatment in ophthalmology clinics across South Korea between January 2017 and March 2019. The primary endpoint was the proportion of patients with retinal fluid after 12 months of anti-VEGF treatment. The association between fluid-free period and VA gains was also evaluated. A total of 600 patients were enrolled. At baseline, 97.16% of patients had retinal fluid; after 12 months of anti-VEGF treatment, 58.10% of patients had persistent retinal fluid. VA improvements were relatively better in patients with absence of retinal fluid compared with presence of retinal fluid (+ 12.29 letters vs. + 6.45 letters at month 12; P < .0001). Longer duration of absence of retinal fluid over first 12 months correlated with better VA gains at month 12 (P < .01). More than half of the study patients with nAMD had retinal fluid even after 12 months of treatment with their current anti-VEGF. Presence of retinal fluid was associated with relatively worse VA outcomes.
C1 [Kim, Jae Hui] Kims Eye Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Sagong, Min] Yeungnam Univ, Dept Ophthalmol, Coll Med, Daegu, South Korea.
   [Woo, Se Joon] Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Coll Med, Seongnam, South Korea.
   [Kim, Yu Cheol] Keimyung Univ, Dept Ophthalmol, Sch Med, Daegu, South Korea.
   [Cho, Heeyoon] Hanyang Univ, Guri Hosp, Dept Ophthalmol, Coll Med, Guri, South Korea.
   [Lee, Young Hoon] Konyang Univ, Dept Ophthalmol, Coll Med, Daejeon, South Korea.
   [Byon, Iksoo] Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Ophthalmol, Sch Med, Busan, South Korea.
   [Jo, Young Joon] Chungnam Natl Univ Hosp, Dept Ophthalmol, Daejeon, South Korea.
   [Chin, Hee Seung] Inha Univ, Dept Ophthalmol, Sch Med, Incheon, South Korea.
   [Lee, Youkyung] Novartis Korea, Clin Dev & Med Affairs, Seoul, South Korea.
   [Chae, Jae Eun] LSK Global Pharma Serv, Seoul, South Korea.
   [Kang, Se Woong] Sungkyunkwan Univ, Samsung Med Ctr, Dept Ophthalmol, Sch Med, 81 Irwon Ro, Seoul 06351, South Korea.
C3 Yeungnam University; Seoul National University (SNU); Keimyung
   University; Hanyang University; Konyang University; Konyang University
   Hospital; Pusan National University; Pusan National University Hospital;
   Chungnam National University; Chungnam National University Hospital;
   Inha University; Sungkyunkwan University (SKKU); Samsung Medical Center
RP Kang, SW (通讯作者)，Sungkyunkwan Univ, Samsung Med Ctr, Dept Ophthalmol, Sch Med, 81 Irwon Ro, Seoul 06351, South Korea.
EM kangsewoong@gmail.com
FU Novartis Korea Ltd.
FX Financial support was provided by Novartis Korea Ltd. The sponsor or
   funding organization participated in the design of the study;
   management, analysis, and interpretation of the data; and preparation,
   review, and approval of the manuscript.
CR Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Baek SK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49749-y
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Carrasco J, 2020, ADV THER, V37, P300, DOI 10.1007/s12325-019-01147-6
   Chakravarthy U, 2020, EYE, V34, P2249, DOI 10.1038/s41433-020-0799-y
   Chen SN, 2018, INT J OPHTHALMOL-CHI, V11, P1802, DOI 10.18240/ijo.2018.11.11
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P645, DOI 10.1016/j.oret.2018.01.006
   Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839
   Core JQ, 2022, OPHTHALMOL RETINA, V6, P771, DOI 10.1016/j.oret.2022.03.024
   Core JQ, 2021, OPHTHALMOL RETINA, V5, P962, DOI 10.1016/j.oret.2021.06.003
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Eldem B, 2018, GRAEF ARCH CLIN EXP, V256, P963, DOI 10.1007/s00417-017-3890-8
   Fang MY, 2021, BRIT J OPHTHALMOL, DOI 10.1136/bjophthalmol-2021-319602
   Finger RP, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01554-2
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Heier J. S., 2021, ANGIOGENESIS
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Hsu J, 2020, OPHTHALMOLOGY, V127, P1189, DOI 10.1016/j.ophtha.2020.03.034
   Hussain R. M, 2018, REV OPTHALMOLOGY
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Khanani AM, 2020, OPHTHALMOL RETINA, V4, P122, DOI 10.1016/j.oret.2019.09.009
   Khanani AM, 2018, RETINA-J RET VIT DIS, V38, P2103, DOI 10.1097/IAE.0000000000002195
   Klufas M. A., 2018, RETINA SPECILALIST
   Kodjikian L, 2021, EYE, V35, P2119, DOI 10.1038/s41433-021-01487-0
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Leung King Fai Calvin, 2018, Vision (Basel), V2, DOI 10.3390/vision2010005
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Mehta H, 2020, CLIN OPHTHALMOL, V14, P3331, DOI 10.2147/OPTH.S275977
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Mones J, 2020, OPHTHALMOLOGICA, V243, P1, DOI 10.1159/000502747
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Park SJ, 2015, OPHTHALMOLOGY, V122, P2063, DOI 10.1016/j.ophtha.2015.06.018
   Rahman EZ, 2020, DRUG TODAY, V56, P699, DOI 10.1358/dot.2020.56.11.3199812
   Reiter GS, 2021, RETINA-J RET VIT DIS, V41, P1318, DOI 10.1097/IAE.0000000000003023
   Sagong M, 2021, CLIN OPHTHALMOL, V15, P1995, DOI 10.2147/OPTH.S303884
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Singer M, 2022, OPHTHALMOL RETINA, V6, P97, DOI 10.1016/j.oret.2021.05.003
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   Woo Se Joon, 2019, Korean J Ophthalmol, V33, P150, DOI 10.3341/kjo.2018.0081
   World Health Organization Regional Office for the Western Pacific, 2000, AS PAC PERSP RED OB
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Zinkernagel M. S, 2019, EUROPEAN SOC RETINA
NR 49
TC 0
Z9 0
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 19
PY 2022
VL 12
IS 1
AR 14166
DI 10.1038/s41598-022-18158-z
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 3W7XC
UT WOS:000842561700030
PM 35986074
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hu, ZH
   Shi, Y
   Nandanan, K
   Sadda, SR
AF Hu, Zhihong
   Shi, Yue
   Nandanan, Kiran
   Sadda, Srinivas R.
CA APGS Study Grp
TI Semiautomated segmentation and analysis of retinal layers in
   three-dimensional spectral-domain optical coherence tomography images of
   patients with atrophic age-related macular degeneration
SO NEUROPHOTONICS
LA English
DT Article
DE semiautomated segmentation and analysis; retinal layers; spectral
   optical coherence tomography images; atrophic age-related macular
   degeneration
ID SUBRETINAL DRUSENOID DEPOSITS; SD-OCT IMAGES; GEOGRAPHIC-ATROPHY;
   RETICULAR PSEUDODRUSEN; PIGMENT EPITHELIUM; VISUAL-ACUITY; PROGRESSION;
   EYES; PATTERNS
AB Historically, regular drusen and geographic atrophy (GA) have been recognized as the hallmarks of nonneovascular age-related macular degeneration (AMD). Recent imaging developments have revealed another distinct nonneovascular AMD phenotype, reticular pseudodrusen (RPD). We develop an approach to semiautomatically quantify retinal surfaces associated with various AMD lesions (i.e., regular drusen, RPD, and GA) in spectral domain (SD) optical coherence tomography (OCT) images. More specifically, a graph-based algorithm was used to segment multiple retinal layers in SD-OCT volumes. Varying surface feasibility constraints based on the presegmentation were applied on the double-surface graph search to refine the surface segmentation. The thicknesses of these layers and their correlation with retinal functional measurements, including microperimetry (MP) sensitivity and visual acuity (VA), were investigated. The photoreceptor outer segment layer demonstrated significant thinning with a reduction in MP sensitivity and VA score when atrophic AMD lesions were present. Regular drusen and RPD were separately segmented on SD-OCT images to allow their characteristics and distribution to be studied separately. The mean thickness of regular drusen was found to significantly correlate with the VA score. RPD appeared to be distributed evenly throughout the macula and regular drusen appeared to be more concentrated centrally. (C) 2017 Society of Photo-Optical Instrumentation Engineers (SPIE)
C1 [Hu, Zhihong; Shi, Yue; Nandanan, Kiran; Sadda, Srinivas R.] Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [APGS Study Grp] Beckman AMD Phenotype Genotype Study APGS Grp, Los Angeles, CA USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA
RP Sadda, SR (通讯作者)，Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.; Sadda, SR (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
EM ssadda@doheny.org
FU Macula Vision Research Foundation; Beckman Macular Degeneration Research
   Center; Beckman AMD Phenotype Genotype Study (APGS) Group; Research to
   Prevent Blindness Physician Scientist Award
FX This work was supported in part by the Macula Vision Research
   Foundation, the Beckman Macular Degeneration Research Center, the
   Beckman AMD Phenotype Genotype Study (APGS) Group, and a Research to
   Prevent Blindness Physician Scientist Award.
CR BLAIR CJ, 1975, ARCH OPHTHALMOL-CHIC, V93, P19, DOI 10.1001/archopht.1975.01010020023003
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Garcia CAD, 2013, RETINA-J RET VIT DIS, V33, P1558, DOI 10.1097/IAE.0b013e318285cbd2
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hu Z., 2009, P SOC PHOTO-OPT INS, V7262
   Hu ZH, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.7.076006
   Hu ZH, 2013, INVEST OPHTH VIS SCI, V54, P1722, DOI 10.1167/iovs.12-10578
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Lazzeri S, 2013, J CLIN EXP OPHTHALMO, V4, P293, DOI [10.4172/2155-9570.1000293, DOI 10.4172/2155-9570.1000293.]
   Leung CKS, 2012, OPHTHALMOLOGY, V119, P1858, DOI 10.1016/j.ophtha.2012.03.044
   Li K, 2006, IEEE T PATTERN ANAL, V28, P119, DOI 10.1109/TPAMI.2006.19
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Rumsey D. J., 2010, STAT DUMMIES
   Sandberg MA, 2008, INVEST OPHTH VIS SCI, V49, P4568, DOI 10.1167/iovs.08-1992
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 29
TC 6
Z9 8
U1 0
U2 4
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 2329-423X
EI 2329-4248
J9 NEUROPHOTONICS
JI Neurophotonics
PD JAN
PY 2017
VL 4
IS 1
AR 011012
DI 10.1117/1.NPh.4.1.011012
PG 7
WC Neurosciences; Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Optics
GA EO0DM
UT WOS:000396368500012
PM 28180131
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Sreekumar, PG
   Kannan, R
AF Sreekumar, Parameswaran G.
   Kannan, Ram
TI Mechanisms of protection of retinal pigment epithelial cells from
   oxidant injury by humanin and other mitochondrial-derived peptides:
   Implications for age-related macular degeneration
SO REDOX BIOLOGY
LA English
DT Review
DE Mitochondria-derived peptides; Mitochondrial function; Retinal pigment
   epithelium; Oxidative stress; Signal mechanisms; Nano delivery
ID OXIDATIVE STRESS; ENDOPLASMIC-RETICULUM; GEOGRAPHIC ATROPHY;
   ALZHEIMERS-DISEASE; CEREBRAL ISCHEMIA/REPERFUSION; REPERFUSION INJURY;
   ANIMAL-MODELS; ER MEMBRANES; HIGH GLUCOSE; APOPTOSIS
AB The mitochondrial-derived peptides (MDPs) are a new class of small open reading frame encoded polypeptides with pleiotropic properties. The prominent members are Humanin (HN) and small HN-like peptide (SHLP) 2, which encode 16S rRNA, while mitochondrial open reading frame of the twelve S c (MOTS-c) encodes 12S rRNA of the mitochondrial genome. While the multifunctional properties of HN and its analog 14-HNG have been well documented, their protective role in the retinal pigment epithelium (RPE)/retina has been investigated only recently. In this review, we have summarized the multiple effects of HN and its analogs, SHLP2 and MOTS-c in oxidatively stressed human RPE and the regulatory pathways of signaling, mitochondrial function, senescence, and inter-organelle crosstalk. Emphasis is given to the mitochondrial functions such as biogenesis, bioenergetics, and autophagy in RPE undergoing oxidative stress. Further, the potential use of HN and its analogs in the prevention of age-related macular degeneration (AMD) are also presented. In addition, the role of novel, long-acting HN elastin-like polypeptides in nanotherapy of AMD and other ocular diseases stemming from oxidative damage is discussed. It is expected MDPs will become a promising group of mitochondrial peptides with valuable therapeutic applications in the treatment of retinal diseases.
C1 [Sreekumar, Parameswaran G.; Kannan, Ram] Doheny Eye Inst, Stephen J Ryan Initiat Macular Res RIMR, DVRC 203,1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Kannan, Ram] Univ Calif Los Angeles, Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA
RP Kannan, R (通讯作者)，Doheny Eye Inst, Stephen J Ryan Initiat Macular Res RIMR, DVRC 203,1355 San Pablo St, Los Angeles, CA 90033 USA.
EM rkannan@doheny.org
RI kannan, ram/ABB-7154-2020
OI kannan, ram/0000-0002-1583-3414; /0000-0002-9425-3986
FU National Institutes of Health [R01 EY30141]; Ryan Initiative for Macular
   Research (RIMR)
FX This work was supported by the National Institutes of Health (grant
   number R01 EY30141 (RK)) and the Ryan Initiative for Macular Research
   (RIMR).
CR Ahn CH, 2020, MOL BIOL REP, V47, P4029, DOI 10.1007/s11033-020-05429-z
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Area-Gomez E, 2016, CURR OPIN GENET DEV, V38, P90, DOI 10.1016/j.gde.2016.04.006
   Bai YJ, 2013, J OCUL PHARMACOL TH, V29, P619, DOI 10.1089/jop.2012.0225
   Bezard E, 2013, MOVEMENT DISORD, V28, P61, DOI 10.1002/mds.25108
   Bidwell GL, 2010, ADV DRUG DELIVER REV, V62, P1486, DOI 10.1016/j.addr.2010.05.003
   Biesemann N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27614-8
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Bodzioch M, 2009, GENOMICS, V94, P247, DOI 10.1016/j.ygeno.2009.05.006
   Bohr VA, 2002, GENE, V286, P127, DOI 10.1016/S0378-1119(01)00813-7
   Brown JC, 2014, OPHTHALMOLOGY, V121, P1655, DOI 10.1016/j.ophtha.2014.02.030
   BROWN WM, 1982, J MOL EVOL, V18, P225, DOI 10.1007/BF01734101
   Caricasole A, 2002, FASEB J, V16, P1331, DOI 10.1096/fj.02-0018fje
   Celvin B, 2020, CLIN EXP RHEUMATOL, V38, P129
   Chai GS, 2014, NEUROSCI BULL, V30, P923, DOI 10.1007/s12264-014-1479-3
   Childs BG, 2017, NAT REV DRUG DISCOV, V16, P718, DOI 10.1038/nrd.2017.116
   Cobb LJ, 2016, AGING-US, V8, P796, DOI 10.18632/aging.100943
   Conley KE, 2000, J PHYSIOL-LONDON, V526, P203, DOI 10.1111/j.1469-7793.2000.t01-1-00203.x
   Conte M, 2019, J GERONTOL A-BIOL, V74, P600, DOI 10.1093/gerona/gly153
   Cui AL, 2017, DRUG DES DEV THER, V11, P1243, DOI 10.2147/DDDT.S133042
   Cui AL, 2014, SCI WORLD J, DOI 10.1155/2014/341529
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Danis RP, 2015, CLIN OPHTHALMOL, V9, P2159, DOI 10.2147/OPTH.S92359
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dawson TM, 2017, ANNU REV PHARMACOL, V57, P437, DOI 10.1146/annurev-pharmtox-010716-105001
   Despanie J, 2016, J CONTROL RELEASE, V240, P93, DOI 10.1016/j.jconrel.2015.11.010
   Ding Y, 2019, LIPIDS, V54, P697, DOI 10.1002/lipd.12195
   Dorrell M, 2007, SURV OPHTHALMOL, V52, pS3, DOI 10.1016/j.survophthal.2006.10.017
   Dou GR, 2012, FREE RADICAL BIO MED, V53, P1111, DOI 10.1016/j.freeradbiomed.2012.06.042
   Emperador S, 2015, FRONT GENET, V5, DOI 10.3389/fgene.2014.00469
   Eriksson E, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt459
   Ferrington DA, 2020, TRENDS MOL MED, V26, P105, DOI 10.1016/j.molmed.2019.10.008
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Gottardo MF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111548
   Zuccato CF, 2019, EXPERT OPIN THER TAR, V23, P117, DOI 10.1080/14728222.2019.1559300
   Foster LJ, 2006, CELL, V125, P187, DOI 10.1016/j.cell.2006.03.022
   Frandsen JL, 2012, CHEM SOC REV, V41, P2696, DOI 10.1039/c2cs15303c
   Galtier N, 2006, GENOME RES, V16, P215, DOI 10.1101/gr.4305906
   Gao GS, 2017, NEUROL RES, V39, P895, DOI 10.1080/01616412.2017.1352187
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gong ZW, 2018, J CELL BIOL, V217, P635, DOI 10.1083/jcb.201606095
   Gong ZW, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00210
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Gultekin FA, 2017, SAUDI J GASTROENTERO, V23, P105, DOI 10.4103/sjg.SJG_318_16
   Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627
   Gurunathan S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184439
   Gustafsson CM, 2016, ANNU REV BIOCHEM, V85, P133, DOI 10.1146/annurev-biochem-060815-014402
   Hallberg BM, 2014, CELL METAB, V20, P226, DOI 10.1016/j.cmet.2014.07.001
   Harada M, 2004, BIOCHEM BIOPH RES CO, V324, P255, DOI 10.1016/j.bbrc.2004.09.046
   Hashimoto Y, 2005, LIFE SCI, V77, P3092, DOI 10.1016/j.lfs.2005.03.031
   Hashimoto Y, 2001, J NEUROSCI, V21, P9235, DOI 10.1523/JNEUROSCI.21-23-09235.2001
   Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498
   Hashimoto Y, 2009, MOL BIOL CELL, V20, P2864, DOI 10.1091/mbc.E09-02-0168
   He HJ, 2018, J AM CHEM SOC, V140, P1215, DOI 10.1021/jacs.7b11582
   Hoang PT, 2010, METABOLISM, V59, P343, DOI 10.1016/j.metabol.2009.08.001
   Holekamp NM, 2019, AM J MANAG CARE, V25, pS172
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Ikonen M, 2003, P NATL ACAD SCI USA, V100, P13042, DOI 10.1073/pnas.2135111100
   Jean SR, 2016, ACCOUNTS CHEM RES, V49, P1893, DOI 10.1021/acs.accounts.6b00277
   Jia Y, 2019, EXP MOL PATHOL, V109, P42, DOI 10.1016/j.yexmp.2019.104261
   Jung JE, 2020, J NEUROSCI, V40, P2154, DOI 10.1523/JNEUROSCI.2212-19.2020
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Kannan R, 2006, MOL VIS, V12, P1649
   Kariya S, 2002, NEUROREPORT, V13, P903, DOI 10.1097/00001756-200205070-00034
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Kim KH, 2018, CELL METAB, V28, P516, DOI 10.1016/j.cmet.2018.06.008
   Kim SJ, 2018, AGING-US, V10, P1239, DOI 10.18632/aging.101463
   Kim SJ, 2016, ONCOTARGET, V7, P46899, DOI 10.18632/oncotarget.10380
   Klein LE, 2013, BIOCHEM BIOPH RES CO, V440, P197, DOI 10.1016/j.bbrc.2013.08.055
   Knapp A, 2012, ARCH PHYSIOL BIOCHEM, V118, P128, DOI 10.3109/13813455.2012.668193
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Krejcova G, 2004, J PEPT SCI, V10, P636, DOI 10.1002/psc.569
   Kuliawat R, 2013, FASEB J, V27, P4890, DOI 10.1096/fj.13-231092
   Kumfu S, 2016, EXP PHYSIOL, V101, P697, DOI 10.1113/EP085749
   Lee C, 2015, CELL METAB, V21, P443, DOI 10.1016/j.cmet.2015.02.009
   Lee C, 2020, TECHNOVATION, V96-97, DOI [10.1016/j.technovation.2020.102140, 10.1016/j.tem.2013.01.005]
   Levine ZA, 2019, J AM CHEM SOC, V141, P14168, DOI 10.1021/jacs.9b04995
   Li D, 2019, MITOCHONDRION, V46, P313, DOI 10.1016/j.mito.2018.08.005
   Li X, 2013, NEURAL REGEN RES, V8, P2573, DOI 10.3969/j.issn.1673-5374.2013.27.009
   Li Z, 2020, NANOMED-NANOTECHNOL, V24, DOI 10.1016/j.nano.2019.102111
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Liu CH, 2017, FASEB J, V31, P4665, DOI 10.1096/fj.201700336R
   Liu Z, 2014, J MED GENET, V51, P176, DOI 10.1136/jmedgenet-2013-101818
   Lu HY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102456
   Lue YH, 2018, AM J PHYSIOL-HEART C, V315, pH634, DOI 10.1152/ajpheart.00155.2018
   Lue YH, 2015, ENDOCRINOLOGY, V156, P4511, DOI 10.1210/en.2015-1542
   Ma JHJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02213-1
   Ma ZW, 2018, ACTA PHARMACOL SIN, V39, P1012, DOI 10.1038/aps.2017.169
   Marengo B, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6235641
   Matsunaga D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165150
   Maximov V, 2002, MED HYPOTHESES, V59, P670, DOI 10.1016/S0306-9877(02)00223-2
   Mehta HH, 2019, METABOLOMICS, V15, DOI 10.1007/s11306-019-1549-7
   Mendelsohn AR, 2018, REJUV RES, V21, P369, DOI 10.1089/rej.2018.2114
   Mercer TR, 2011, CELL, V146, P645, DOI 10.1016/j.cell.2011.06.051
   Miao JT, 2008, NEUROPEPTIDES, V42, P557, DOI 10.1016/j.npep.2008.08.004
   Miceli MV, 2005, EXP CELL RES, V302, P270, DOI 10.1016/j.yexcr.2004.09.006
   Miceli MV, 2005, INVEST OPHTH VIS SCI, V46, P1765, DOI 10.1167/iovs.04-1327
   Miller B, 2020, EXP CELL RES, V393, DOI 10.1016/j.yexcr.2020.112056
   Minasyan L, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1675230
   Mishima K, 1999, INVEST OPHTH VIS SCI, V40, P1590
   Mishmar D, 2004, HUM MUTAT, V23, P125, DOI 10.1002/humu.10304
   Ayala MAM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65381-7
   Moretti E, 2010, FERTIL STERIL, V94, P2888, DOI 10.1016/j.fertnstert.2010.04.075
   Morris DL, 2019, J BIOL CHEM, V294, P19055, DOI 10.1074/jbc.RA119.011297
   Murakami M, 2017, NEUROPEPTIDES, V62, P65, DOI 10.1016/j.npep.2016.10.008
   Muzumdar RH, 2010, ARTERIOSCL THROM VAS, V30, P1940, DOI 10.1161/ATVBAHA.110.205997
   Muzumdar RH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006334
   Nashine S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051102
   Nashine S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33290-5
   Nashine S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.348
   Nayak K, 2018, BIOMED PHARMACOTHER, V107, P1564, DOI 10.1016/j.biopha.2018.08.138
   Niikura T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016259
   Nisoli E, 2004, P NATL ACAD SCI USA, V101, P16507, DOI 10.1073/pnas.0405432101
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Nozaki M, 2006, J CLIN INVEST, V116, P422, DOI 10.1172/JCI26316
   Oh YK, 2011, ATHEROSCLEROSIS, V219, P65, DOI 10.1016/j.atherosclerosis.2011.06.038
   Ottolini D, 2013, HUM MOL GENET, V22, P2152, DOI 10.1093/hmg/ddt068
   Paharkova V, 2015, MOL CELL ENDOCRINOL, V413, P96, DOI 10.1016/j.mce.2015.06.015
   Paillusson S, 2016, TRENDS NEUROSCI, V39, P146, DOI 10.1016/j.tins.2016.01.008
   Pershing S, 2013, OPHTHAL SURG LAS IM, V44, P460, DOI 10.3928/23258160-20130909-07
   Pons M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016722
   Pons M, 2011, INVEST OPHTH VIS SCI, V52, P3842, DOI 10.1167/iovs.10-6254
   Qin Q, 2018, AM J PHYSIOL-HEART C, V315, pH1127, DOI 10.1152/ajpheart.00685.2017
   Qin Q, 2018, INT J CARDIOL, V254, P23, DOI 10.1016/j.ijcard.2017.12.001
   Qin QQ, 2018, BIOCHEM BIOPH RES CO, V497, P292, DOI 10.1016/j.bbrc.2018.02.071
   Ren LJ, 2020, J CELL MOL MED, V24, P4773, DOI 10.1111/jcmm.15151
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   Ritz P, 2005, DIABETES METAB, V31, pS67, DOI 10.1016/S1262-3636(05)73654-5
   Rowland AA, 2012, NAT REV MOL CELL BIO, V13, P607, DOI 10.1038/nrm3440
   Sano R, 2009, MOL CELL, V36, P500, DOI 10.1016/j.molcel.2009.10.021
   Santarelli M, 2015, EXPERT OPIN PHARMACO, V16, P1769, DOI 10.1517/14656566.2015.1067679
   Santos JH, 2004, AGING CELL, V3, P399, DOI 10.1111/j.1474-9728.2004.00124.x
   Sharma A, 2018, THERANOSTICS, V8, P5529, DOI 10.7150/thno.29039
   Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5
   Singh R, 2020, NANOMED-NANOTECHNOL, V28, DOI 10.1016/j.nano.2020.102205
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Sreekumar PG, 2008, INVEST OPHTH VIS SCI, V49, P1210, DOI 10.1167/iovs.07-0667
   Sreekumar PG, 2006, BIOCHEM BIOPH RES CO, V346, P1200, DOI 10.1016/j.bbrc.2006.06.021
   Sreekumar PG, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9050411
   Sreekumar PG, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2583601
   Sreekumar PG, 2018, J CONTROL RELEASE, V283, P94, DOI 10.1016/j.jconrel.2018.05.014
   Sreekumar PG, 2017, NEURAL REGEN RES, V12, P35, DOI 10.4103/1673-5374.198970
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   Stoica R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4996
   Su YX, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00274
   Sunness JS, 2008, J VISUAL IMPAIR BLIN, V102, P600
   Tajima H, 2005, J NEUROSCI RES, V79, P714, DOI 10.1002/jnr.20391
   Tarallo V, 2012, INVEST OPHTH VIS SCI, V53, P7989, DOI 10.1167/iovs.12-10658
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Thummasorn S, 2018, MITOCHONDRION, V38, P31, DOI 10.1016/j.mito.2017.08.001
   Thummasorn S, 2016, CARDIOVASC THER, V34, P404, DOI 10.1111/1755-5922.12210
   Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225
   Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005
   van Vliet AR, 2014, BBA-MOL CELL RES, V1843, P2253, DOI 10.1016/j.bbamcr.2014.03.009
   Wallace DC, 2010, ANNU REV PATHOL-MECH, V5, P297, DOI 10.1146/annurev.pathol.4.110807.092314
   Wang M, 2016, NATURE, V529, P326, DOI 10.1038/nature17041
   Wang M, 2019, INVEST OPHTH VIS SCI, V60, P500, DOI 10.1167/iovs.18-25686
   Wang XH, 2018, MOL IMMUNOL, V101, P245, DOI 10.1016/j.molimm.2018.07.008
   Wei M, 2016, BIOCHEM BIOPH RES CO, V476, P412, DOI 10.1016/j.bbrc.2016.05.135
   Weng FB, 2019, EUR REV MED PHARMACO, V23, P10623, DOI 10.26355/eurrev_201912_19759
   Xie Y, 2014, DIABETES RES CLIN PR, V106, P560, DOI 10.1016/j.diabres.2014.09.020
   Xing HL, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870-014-0327-y
   Xu XS, 2008, BRAIN RES, V1227, P12, DOI 10.1016/j.brainres.2008.06.018
   Xu XS, 2006, STROKE, V37, P2613, DOI 10.1161/01.STR.0000242772.94277.1f
   Yamagishi Y, 2003, PEPTIDES, V24, P585, DOI 10.1016/S0196-9781(03)00106-2
   Yan Z, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104381
   Yang GB, 2018, NANO LETT, V18, P2475, DOI 10.1021/acs.nanolett.8b00040
   Yang L, 2014, SCI REP-UK, V4, DOI 10.1038/srep04089
   Yang XR, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102982
   Yen K, 2020, AGING-US, V12, P11185, DOI 10.18632/aging.103534
   Yi A, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951-020-0574-z
   Yin XQ, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2019.106174
   Zhai DY, 2005, J BIOL CHEM, V280, P15815, DOI 10.1074/jbc.M411902200
   Zhang XG, 2011, INVEST OPHTH VIS SCI, V52, P3160, DOI 10.1167/iovs.10-5156
   Zhang X, 2012, LIFE SCI, V91, P199, DOI 10.1016/j.lfs.2012.07.010
   Zhao ST, 2013, NEUROCHEM RES, V38, P581, DOI 10.1007/s11064-012-0951-6
   Zhu DH, 2009, J BIOL CHEM, V284, P9529, DOI 10.1074/jbc.M809393200
NR 188
TC 9
Z9 9
U1 5
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-2317
J9 REDOX BIOL
JI Redox Biol.
PD OCT
PY 2020
VL 37
AR 101663
DI 10.1016/j.redox.2020.101663
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA PO2NW
UT WOS:000605007400008
PM 32768357
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Eriksson, U
   Alm, A
   Larsson, E
AF Eriksson, Urban
   Alm, Albert
   Larsson, Eva
TI Is quantitative spectral-domain superior to time-domain optical
   coherence tomography (OCT) in eyes with age-related macular
   degeneration?
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; quantitative optical coherence
   tomography; repeatability; reproducibility
ID THICKNESS MEASUREMENTS; ULTRAHIGH-RESOLUTION; REPRODUCIBILITY; STRATUS;
   EDEMA; REPEATABILITY; RANIBIZUMAB; SUBANALYSIS; PATHOLOGY; NERVE
AB Purpose: The aim of this study was to determine the variability of macular map measurements, for two generations of optical coherence tomography (OCT) instruments, in eyes with wet age related macular degeneration (AMD) and low visual acuity.
   Methods: Patients were examined with Stratus OCT and Cirrus HD-OCT. The macular thickness was assessed with the macular thickness map scan and fast protocol in Stratus and with the 512 x 128 and 200 x 200 cube protocols in Cirrus OCT. Two measurements were taken one directly after the other, at the first visit to analyse repeatability. Approximately 1 week later, a third measurement was taken to analyse reproducibility. In Cirrus OCT, a manual correction of foveal location was also performed. Repeatability and reproducibility were calculated as a coefficient of variance (CoV) and a coefficient of repeatability/reproducibility.
   Results: Repeatability for central macular thickness (expressed as CoV) was about three per cent for all protocols, and the coefficient of repeatability between 34 and 54 mu m. Reproducibility (also expressed as CoV) was between four to seven per cent and coefficient of repeatability between 64 and 89 mu m. After manual adjustment of foveal location in Cirrus OCT, the coefficient of repeatability improved to 1218 mu m, and the coefficient of reproducibility to 4447 mu m.
   Conclusions: In eyes affected by wet AMD, there were small differences in repeatability and reproducibility when comparing quantitative maps in Stratus and Cirrus OCT. However, when the software for manual correction of foveal position in Cirrus OCT was used, the variability decreased markedly, and the repeatability was close to what had been reported in normal eyes, demonstrating a significant, potential advantage of spectral-domain over time-domain OCT.
C1 [Eriksson, Urban; Alm, Albert; Larsson, Eva] Univ Uppsala Hosp, Dept Ophthalmol, Uppsala, Sweden.
C3 Uppsala University; Uppsala University Hospital
RP Eriksson, U (通讯作者)，Uppsala Univ, Dept Neurosci Ophthalmol, Akad Sjukhuset, S-75185 Uppsala, Sweden.
EM urban.eriksson@akademiska.se
CR BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carl Zeiss Meditec Inc, 2010, US MAN CIRR HD OCT M
   Eriksson U, 2004, ACTA OPHTHALMOL SCAN, V82, P218, DOI 10.1111/j.1600-0420.2004.00227.x
   Eriksson U, 2009, ACTA OPHTHALMOL, V87, P741, DOI 10.1111/j.1755-3768.2008.01357.x
   Eriksson U, 2009, ACTA OPHTHALMOL, V87, P725, DOI 10.1111/j.1755-3768.2008.01345.x
   Frank RN, 2004, OPHTHALMOLOGY, V111, P211, DOI 10.1016/j.ophtha.2003.05.031
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gaudric A, 1999, ARCH OPHTHALMOL-CHIC, V117, P744
   Ghazi NG, 2009, AM J OPHTHALMOL, V148, P90, DOI 10.1016/j.ajo.2009.02.017
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hee MR, 2005, AM J OPHTHALMOL, V139, P154, DOI 10.1016/j.ajo.2004.08.066
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   HEE MR, 1995, AM J OPHTHALMOL, V120, P65, DOI 10.1016/S0002-9394(14)73760-2
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Krebs I, 2008, BRIT J OPHTHALMOL, V92, P933, DOI 10.1136/bjo.2007.128447
   Krebs I, 2010, OPHTHALMOLOGY, V117, P1577, DOI 10.1016/j.ophtha.2010.04.032
   Krebs I, 2009, INVEST OPHTH VIS SCI, V50, P995, DOI 10.1167/iovs.08-2617
   Krzystolik MG, 2007, OPHTHALMOLOGY, V114, P1520, DOI 10.1016/j.ophtha.2006.10.055
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Larsen M, 2005, INVEST OPHTH VIS SCI, V46, P2313, DOI 10.1167/iovs.04-0893
   Massin P, 2001, ARCH OPHTHALMOL-CHIC, V119, P1135, DOI 10.1001/archopht.119.8.1135
   Menke MN, 2009, ACTA OPHTHALMOL
   MEYER CH, 2008, INVEST OPHTHALMOL VI, V49
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Nassif NA, 2004, OPT EXPRESS, V12, P367, DOI 10.1364/OPEX.12.000367
   Parravano M, 2010, INVEST OPHTH VIS SCI, V51, P4788, DOI 10.1167/iovs.09-4976
   Patel PJ, 2009, ACTA OPHTHALMOL SCAN
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P1084, DOI 10.1167/iovs.07-1203
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P399, DOI 10.1167/iovs.08-1697
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Paunescu LA, 2004, INVEST OPHTH VIS SCI, V45, P1716, DOI 10.1167/iovs.03-0514
   Polito A, 2005, ARCH OPHTHALMOL-CHIC, V123, P1330, DOI 10.1001/archopht.123.10.1330
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Sharuk GS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1701
   Witkin AJ, 2009, OPHTHALMOLOGY, V116, P956, DOI 10.1016/j.ophtha.2008.12.018
   Wojtkowski M, 2002, J BIOMED OPT, V7, P457, DOI 10.1117/1.1482379
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
   Wolf-Schnurrbusch UEK, 2009, INVEST OPHTH VIS SCI, V50, P3432, DOI 10.1167/iovs.08-2970
NR 48
TC 15
Z9 15
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2012
VL 90
IS 7
BP 620
EP 627
DI 10.1111/j.1755-3768.2011.02112.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 030DG
UT WOS:000310548500017
PM 21371288
OA Bronze
DA 2022-11-30
ER

PT J
AU Takeuchi, K
   Kachi, S
   Iwata, E
   Ishikawa, K
   Terasaki, H
AF Takeuchi, K.
   Kachi, S.
   Iwata, E.
   Ishikawa, K.
   Terasaki, H.
TI Visual function 5 years or more after macular translocation surgery for
   myopic choroidal neovascularisation and age-related macular degeneration
SO EYE
LA English
DT Article
DE AMD; myopic CNV; long-term result; macular translocation; visual acuity;
   visual field
ID 360-DEGREE PERIPHERAL RETINECTOMY; TERM-FOLLOW-UP; FOVEAL TRANSLOCATION;
   RETINAL SEPARATION; RETINOTOMY; MACULOPATHY; EXPERIENCE; MANAGEMENT;
   RELOCATION; ERGS
AB Purpose To evaluate the changes in the best-corrected visual acuity (BCVA) after 1 year and after >= 5 years after macular translocation for age-related macular degeneration (AMD) or myopic choroidal neovascularisation (mCNV).
   Methods The medical records of 61 consecutive patients who underwent macular translocation with 360 degrees retinotomy for AMD (35 eyes) or mCNV (26 eyes) were reviewed. Overall, 40 patients, 17 mCNV and 23 AMD, were followed for at least 5 years. BCVA and area of the Goldmann visual field (VF) measured before, 12 months after surgery, and at the final visit.
   Results In the 23 AMD eyes followed for >= 5 years, the mean preoperative BCVA was 1.149 +/- 0.105 logMAR units, which significantly improved to 0.69 +/- 0.06 logMAR units at 1 year (P < 0.001). This BCVA was maintained at 0.633 +/- 0.083 logMAR units on their final examination. In the 17 eyes with mCNV followed for >= 5 years, the mean preoperative BCVA was 1.083 +/- 0.119 logMAR units, which was significantly improved to 0.689 +/- 0.121 logMAR units at 1 year (P = 0.001). This BCVA was maintained at 0.678 +/- 0.142 logMAR units on their final examination. The area of the VF was significantly decreased at 12 months and did not change significantly thereafter.
   Conclusions Our results show that macular translocation surgery significantly improves the BCVA and significantly decreases the VF area of eyes with mCNV or AMD after first 1 year. The BCVA and VF area do not change significantly from the values at 1 year for at least 5 years. Eye (2012) 26, 51-60; doi:10.1038/eye.2011.302; published online 16 December 2011
C1 [Terasaki, H.] Nagoya Univ, Dept Ophthalmol, Grad Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan.
C3 Nagoya University
RP Terasaki, H (通讯作者)，Nagoya Univ, Dept Ophthalmol, Grad Sch Med, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4668550, Japan.
EM terasaki@med.nagoya-u.ac.jp
RI Terasaki, Hiroko/M-5054-2014
FU Grants-in-Aid for Scientific Research [23390401] Funding Source: KAKEN
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Aisenbrey S, 2007, ARCH OPHTHALMOL-CHIC, V125, P1367, DOI 10.1001/archopht.125.10.1367
   Chan WM, 2005, BRIT J OPHTHALMOL, V89, P1522, DOI 10.1136/bjo.2005.074716
   Du HJ, 2011, SEMIN OPHTHALMOL, V26, P216, DOI 10.3109/08820538.2011.577498
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Fujii GY, 2001, AM J OPHTHALMOL, V131, P90, DOI 10.1016/S0002-9394(00)00769-8
   Fujikado T, 2001, AM J OPHTHALMOL, V131, P101, DOI 10.1016/S0002-9394(00)00770-4
   Fujikado T, 2002, AM J OPHTHALMOL, V134, P849, DOI 10.1016/S0002-9394(02)01756-7
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P629, DOI 10.1007/BF00921956
   Macular translocation, 2000, OPHTHALMOLOGY, V107, P1015
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Ohji M, 2001, AM J OPHTHALMOL, V132, P888, DOI 10.1016/S0002-9394(01)01255-7
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   Terasaki H, 2004, INVEST OPHTH VIS SCI, V45, P567, DOI 10.1167/iovs.03-0187
   Terasaki H, 2003, OPHTHALMOLOGY, V110, P2403, DOI 10.1016/S0161-6420(03)00829-7
   Terasaki H, 2002, INVEST OPHTH VIS SCI, V43, P452
   Toth CA, 2004, GRAEF ARCH CLIN EXP, V242, P541, DOI 10.1007/s00417-004-0867-1
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   Yamada Y, 2010, AM J OPHTHALMOL, V149, P453, DOI 10.1016/j.ajo.2009.09.014
NR 24
TC 18
Z9 21
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD JAN
PY 2012
VL 26
IS 1
BP 52
EP 60
DI 10.1038/eye.2011.302
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 892UN
UT WOS:000300311200006
PM 22173070
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Iwama, D
   Otani, A
   Sasahara, M
   Yodoi, Y
   Gotoh, N
   Tamura, H
   Tsujikawa, A
   Yoshimura, N
AF Iwama, D.
   Otani, A.
   Sasahara, M.
   Yodoi, Y.
   Gotoh, N.
   Tamura, H.
   Tsujikawa, A.
   Yoshimura, N.
TI Photodynamic therapy combined with low-dose intravitreal triamcinolone
   acetonide for age-related macular degeneration refractory to
   photodynamic therapy alone
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; CHORIORETINAL ANASTOMOSIS;
   VERTEPORFIN; INJECTION
AB Aim: To examine the effects of photodynamic therapy (PDT) with verteporfin combined with low-dose intra-vitreal triamcinolone acetonide (IVTA) for exudative age-related macular degeneration (AMD) that is resistant to PDT alone.
   Design: Retrospective case series.
   Methods: A retrospective review was performed, using the medical records of 22 eyes of 21 patients who consecutively received combined PDT and 2 mg of IVTA for exudative AMD with a suspected chorioretinal anastomosis or for AMD that was resistant to prior PDT alone. Only those patients who could be followed up for more than 12 months after this combined therapy were enrolled in the study. Best corrected visual acuity and intraocular pressure measurements were taken during each examination. Colour photography, fluorescein/indocyanine green angiography and optical coherence tomography were carried out at baseline and every 3 months thereafter. Need for retreatment was based on dye leakage and the presence of serous retinal detachement (SRD) seen by optical coherence tomography.
   Results: Visual acuity improved or was maintained in the majority of patients, with the mean change between baseline and the last visit being an improvement of 0.94 lines (p=0.45). Seventeen (77%) of the 22 eyes showed improved or maintained visual acuity after 12 months of follow-up. Eight (36%) of the 22 eyes continued to show an SRD at the 12- month follow-up; this corresponded to unchanged or even decreased leakage of dye. The mean number of retreatments was 1.36, but the incidence of side effects accompanying treatment was not as high as that reported previously for combined therapy that utilised higher-dose IVTA.
   Conclusions: PDT combined with low-dose IVTA for exudative AMD seems to be as effective and safe as combined therapy with the higher-dose IVTA that was reported previously.
C1 [Otani, A.] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Otani, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
EM otan@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Tsujikawa,
   Akitaka/0000-0003-0779-7799
CR Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Axer-Siegel R, 2002, OPHTHALMOLOGY, V109, P1726, DOI 10.1016/S0161-6420(02)01149-1
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Hori Y, 1996, BRIT J PHARMACOL, V118, P1584, DOI 10.1111/j.1476-5381.1996.tb15578.x
   Ishikawa K, 2007, INVEST OPHTH VIS SCI, V48, P2254, DOI 10.1167/iovs.06-1277
   Jonas JB, 2005, PROG RETIN EYE RES, V24, P587, DOI 10.1016/j.preteyeres.2005.01.004
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Luttrull JK, 2007, RETINA-J RET VIT DIS, V27, P688, DOI 10.1097/IAE.0b013e318030e999
   Perretti M, 2000, MICROCIRCULATION, V7, P147, DOI 10.1038/sj.mn.7300108
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Ruiz-Moreno JM, 2006, RETINA-J RET VIT DIS, V26, P602, DOI 10.1097/00006982-200607000-00003
   SCHOLES GN, 1985, ARCH OPHTHALMOL-CHIC, V103, P1567
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Silva RM, 2007, GRAEF ARCH CLIN EXP, V245, P1131, DOI 10.1007/s00417-006-0532-y
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Sutter FKP, 2003, BRIT J OPHTHALMOL, V87, P972, DOI 10.1136/bjo.87.8.972
   WILSON CA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1155, DOI 10.1001/archopht.1992.01080200135041
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yodoi Yuko, 2008, International Ophthalmology, V28, P297, DOI 10.1007/s10792-007-9129-7
NR 25
TC 7
Z9 7
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2008
VL 92
IS 10
BP 1352
EP 1356
DI 10.1136/bjo.2008.141754
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 352NJ
UT WOS:000259503600013
PM 18662914
DA 2022-11-30
ER

PT J
AU Revicki, DA
   Rentz, AM
   Harnam, N
   Thomas, VS
   Lanzetta, P
AF Revicki, Dennis A.
   Rentz, Anne M.
   Harnam, Neesha
   Thomas, Vince S.
   Lanzetta, Paolo
TI Reliability and Validity of the National Eye Institute Visual Function
   Questionnaire-25 in Patients with Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID QUALITY-OF-LIFE; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VISION-RELATED
   FUNCTION; ACUITY; RESPONSIVENESS; RANIBIZUMAB; HEALTH; AREDS; TRIAL
AB PURPOSE. To evaluate the psychometric characteristics of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in patients with age-related macular degeneration (AMD) who participated in two clinical trials.
   METHODS. A secondary analysis of data from two randomized clinical trials was performed. NEI VFQ-25 data were collected from 1134 of 1146 patients with subfoveal choroidal neovascularization due to AMD with minimally classic or occult with no classic types and predominantly classic type. The NEI VFQ-25 was administered at baseline and months 1, 2, 3, 6, 9, and 12, and the SF-36 Health survey was administered at baseline and months 6 and 12. Visual acuity assessments were completed monthly throughout the studies. Internal consistency reliability and construct validity were examined.
   RESULTS. The average age was 77 years (SD = 7.5; range, 52-96) with 59% women. At baseline, internal consistency reliability was 0.96 for the NEI VFQ-25 total score and ranged from 0.62 (ocular pain) to 0.91 (near activities) for the subscales. NEI VFQ-25 total and subscale scores correlated significantly with SF-36 scores (P < 0.05), and total, near activities, distance activities, and dependency scores correlated significantly with best corrected visual acuity (BCVA) in the better (P < 0.0001) and worse seeing eye (P < 0.0001). Mean NEI VFQ-25 total and subscale scores, except for ocular pain and general health, varied by BCVA group (P < 0.001), with higher impairment scores seen in the lower visual acuity groups.
   CONCLUSIONS. The NEI VFQ-25 demonstrated good reliability and construct validity as a measure of vision-related functioning outcomes in patients with AMD. (Invest Ophthalmol Vis Sci. 2010; 51: 712-717) DOI: 10.1167/iovs.09-3766
C1 [Revicki, Dennis A.; Rentz, Anne M.; Harnam, Neesha] United BioSource Corp, Ctr Hlth Outcomes Res, Bethesda, MD 20814 USA.
   [Thomas, Vince S.; Lanzetta, Paolo] Novartis Pharma AG, Basel, Switzerland.
C3 United Biosource Corporation; Novartis
RP Revicki, DA (通讯作者)，United BioSource Corp, Ctr Hlth Outcomes Res, 7101 Wisconsin Ave,Suite 600, Bethesda, MD 20814 USA.
EM dennis.revicki@unitedbiosource.com
FU Novartis Pharma AG, Basel, Switzerland
FX Supported by Novartis Pharma AG, Basel, Switzerland.
CR Bass EB, 2004, ARCH OPHTHALMOL-CHIC, V122, P1856
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1901
   Brooks R, 2003, MEASUREMENT VALUATIO
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297
   CULLINAN TR, 1977, 28 U KENT HLTH SERV
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Fine SL, 2005, AM J OPHTHALMOL, V139, P405, DOI 10.1016/j.ajo.2004.11.050
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GENENSKY SM, 1976, AM J OPTOM PHYS OPT, V53, P809
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   Hawkins BS, 2004, ARCH OPHTHALMOL-CHIC, V122, P1616, DOI 10.1001/archopht.122.11.1616
   Hays RD., 2005, ASSESSING QUALITY LI, V2, P25
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Mangione CM, 2000, NEI VFQ 25 SCORING A
   MATCHAR DB, 2006, MEASURING QUALITY LI
   MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Miskala PH, 2004, ARCH OPHTHALMOL-CHIC, V122, P758, DOI 10.1001/archopht.122.5.758
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   Ware JE., 1993, SCORING SF 36 SF 36
   Ware JE, 1994, SF 36 PHYS MENTAL HL
   *WHO, 2004, 282 WHO
NR 38
TC 57
Z9 60
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2010
VL 51
IS 2
BP 712
EP 717
DI 10.1167/iovs.09-3766
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 545AS
UT WOS:000273704700013
PM 19797233
DA 2022-11-30
ER

PT J
AU Zheng, F
   Zhang, QQ
   Motulsky, EH
   Dias, JRD
   Chen, CL
   Chu, ZD
   Miller, AR
   Feuer, W
   Gregori, G
   Kubach, S
   Durbin, MK
   Wang, RK
   Rosenfeld, PJ
AF Zheng, Fang
   Zhang, Qinqin
   Motulsky, Elie H.
   Dias, Joao Rafael de Oliveira
   Chen, Chieh-Li
   Chu, Zhongdi
   Miller, Andrew R.
   Feuer, William
   Gregori, Giovanni
   Kubach, Sophie
   Durbin, Mary K.
   Wang, Ruikang K.
   Rosenfeld, Philip J.
TI Comparison of Neovascular Lesion Area Measurements From Different
   Swept-Source OCT Angiographic Scan Patterns in Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE optical coherence tomography angiography; swept-source OCTA; neovascular
   AMD; choroidal neovascularization; quantified measurement comparison
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION;
   SPECTRAL-DOMAIN; MICROANGIOGRAPHY
AB PURPOSE. We compared area measurements for the same neovascular lesions imaged using swept source optical coherence tomography angiography (SS-OCTA) and enlarging scan patterns.
   METHODS. Patients with neovascular age-related macular degeneration were imaged using a 100-kHz SS-OCTA instrument (PLEX Elite 9000). The scanning protocols included the 3 X 3, 6 X 6, 9 X 9, and 12 X 12 mm fields of view. Two groups were studied. Group 1 included small lesions contained within the 3 X 3 mm scan, and Group 2 included larger lesions that were fully contained within the 6 X 6 mm scan.
   RESULTS. A total of 30 eyes of 26 patients were enrolled in Group 1 and 30 eyes of 25 patients were enrolled in Group 2. In Group 1, the automated mean lesion area measurements were 1.11 (SD = 0.78), 1.14 (SD = 0.80), and 1.27 (SD = 0.82) mm(2) for the 3 X 3, 6 X 6, and 12 X 12 mm scans, respectively (ANOVA P < 0.001; post hoc comparisons, P = 0.184, 3 X 3 vs. 6 X 6 mm; P < 0.001 for the other two pairs). In Group 2, the automated mean lesion area measurements were 5.43 (SD = 2.56), 5.53 (SD = 2.48), and 5.49 (SD = 2.65) mm(2) for the 6 X 6, 9 X 9, and 12 X 12 mm scans, respectively (ANOVA P = 0.435; post-hoc comparisons, P = 0.062,6 X 6vs. 9 X 9 mm; P= 0.553, 6 X 6vs. 12 X 12 mm; P= 0.654, 9 X 9vs. 12 X 12 mm).
   CONCLUSIONS. The similarity in lesion area measurements across different scan patterns suggests that SS-OCTA imaging can be used to follow quantitatively the enlargement of choroidal neovascularization as the disease progresses.
C1 [Zheng, Fang; Motulsky, Elie H.; Dias, Joao Rafael de Oliveira; Miller, Andrew R.; Feuer, William; Gregori, Giovanni; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Zheng, Fang] Tianjin Med Univ, Gen Hosp, Dept Ophthalmol, Tianjin, Peoples R China.
   [Zhang, Qinqin; Chen, Chieh-Li; Chu, Zhongdi; Wang, Ruikang K.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
   [Kubach, Sophie; Durbin, Mary K.] Carl Zeiss Meditec Inc, Adv Dev, Dublin, CA USA.
C3 Bascom Palmer Eye Institute; University of Miami; Tianjin Medical
   University; University of Washington; University of Washington Seattle;
   Carl Zeiss AG
RP Rosenfeld, PJ (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@miami.edu
RI Wang, Ruikang/L-3889-2019; Chu, Zhongdi/F-9604-2019
OI Wang, Ruikang/0000-0001-5169-8822; Chu, Zhongdi/0000-0001-7430-5032
FU Carl Zeiss Meditec, Inc. (Dublin, CA, USA); National Eye Institute
   [R01EY024158]; Research to Prevent Blindness, Inc., New York, NY, USA;
   National Eye Institute Center Core Grant [P30EY014801]; NATIONAL EYE
   INSTITUTE [R01EY024158, P30EY014801] Funding Source: NIH RePORTER
FX Supported by grants from Carl Zeiss Meditec, Inc. (Dublin, CA, USA), the
   National Eye Institute (R01EY024158), an unrestricted grant from the
   Research to Prevent Blindness, Inc., New York, NY, USA, and the National
   Eye Institute Center Core Grant (P30EY014801) to the Department of
   Ophthalmology, University of Miami Miller School of Medicine.
CR Cole ED, 2016, RETINA-J RET VIT DIS, V36, pS83, DOI 10.1097/IAE.0000000000001338
   Costanzo E, 2016, INVEST OPHTH VIS SCI, V57, pOCT307, DOI 10.1167/iovs.15-18830
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Huang YP, 2014, OSLI RETINA, V45, P382, DOI 10.3928/23258160-20140909-08
   Iafe NA, 2016, DEV OPHTHALMOL, V56, P45, DOI 10.1159/000442776
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Parravano M, 2017, ACTA OPHTHALMOL, V95, pE425, DOI 10.1111/aos.13180
   Potsaid B, 2010, OPT EXPRESS, V18, P20029, DOI 10.1364/OE.18.020029
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Souied EH, 2016, DEV OPHTHALMOL, V56, P52, DOI 10.1159/000442777
   Tomlins PH, 2005, J PHYS D APPL PHYS, V38, P2519, DOI 10.1088/0022-3727/38/15/002
   Wang RK, 2010, OPT LETT, V35, P1467, DOI 10.1364/OL.35.001467
   Zhang AQ, 2015, BIOMED OPT EXPRESS, V6, P4130, DOI 10.1364/BOE.6.004130
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
NR 22
TC 17
Z9 18
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2017
VL 58
IS 12
BP 5098
EP 5104
DI 10.1167/iovs.17-22506
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FL5JN
UT WOS:000414272100008
PM 28986595
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Subramanian, ML
   Abedi, G
   Ness, S
   Ahmed, E
   Fenberg, M
   Daly, MK
   Houranieh, A
   Feinberg, EB
AF Subramanian, M. L.
   Abedi, G.
   Ness, S.
   Ahmed, E.
   Fenberg, M.
   Daly, M. K.
   Houranieh, A.
   Feinberg, E. B.
TI Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year
   outcomes of a prospective, double-masked randomised clinical trial
SO EYE
LA English
DT Article
DE bevacizumab; ranibizumab; Avastin; Lucentis; macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB; CHOROIDAL
   NEOVASCULARIZATION; AVASTIN TREATMENT; SAFETY; VERTEPORFIN; THERAPY;
   PEGAPTANIB; EFFICACY
AB Purpose To report 1-year visual and anatomic outcomes of a prospective, double-masked randomised clinical trial comparing bevacizumab with ranibizumab for the treatment of age-related macular degeneration (AMD).
   Methods Patients who met inclusion criteria were randomised 2 : 1 to bevacizumab or ranibizumab. All subjects and investigators (except for the pharmacist responsible for study assignments) were masked to treatment arms. Visual acuity was taken on Early Treatment Diabetic Retinopathy Study chart. Patients were given either bevacizumab or ranibizumab every month for the first 3 months, followed by an optical coherence tomography-guided, variable-dosing treatment schedule. Main outcomes measured included visual acuity, foveal thickness, and total number of injections over the 1-year treatment period.
   Results In total, 15 patients received bevacizumab and 7 patients received ranibizumab. The average pre-operative visual acuity was 34.9 letters in the bevacizumab group, and 32.7 letters in the ranibizumab group. At 1-year follow-up, mean vision was 42.5 letters in the bevacizumab group, and 39.0 letters in the ranibizumab group. Two-tailed t-test failed to showed statistical significance between the two groups (P = 0.5). Patients in the bevacizumab group underwent an average of eight injections, whereas patients in the ranibizumab group underwent a mean of four injections (P = 0.001).
   Conclusion The 1-year outcomes of a prospective, double-masked, randomised clinical trial comparing bevacizumab with ranibizumab failed to show a difference in visual and anatomic outcomes between the two treatments for choroidal neovascularisation in AMD. Total injections given over the treatment period were significantly different between the two groups. Further studies with larger sample sizes are warranted. Eye (2010) 24, 1708-1715; doi: 10.1038/eye.2010.147; published online 1 October 2010
C1 [Subramanian, M. L.; Abedi, G.; Ness, S.; Ahmed, E.; Fenberg, M.; Daly, M. K.; Feinberg, E. B.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA.
   [Subramanian, M. L.; Abedi, G.; Ness, S.; Ahmed, E.; Fenberg, M.; Daly, M. K.; Houranieh, A.; Feinberg, E. B.] Vet Affairs Boston Healthcare Syst, Surg Serv, Jamaica Plain, MA USA.
C3 Boston University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Harvard University; VA Boston Healthcare System
RP Subramanian, ML (通讯作者)，Boston Univ, Sch Med, Dept Ophthalmol, 85 E Concord St,8826, Boston, MA 02118 USA.
EM manju.subramanian@bmc.org
OI Daly, Mary/0000-0002-3298-8901; Subramanian, Manju/0000-0002-0061-098X;
   Ness, Steven/0000-0002-5843-9476
FU Veterans Affairs Boston Healthcare System, Jamaica Plain, MA, USA; VA
   Boston
FX Al Ozonoff, with the Department of Biostatistics in the Boston
   University School of Public Health, was consulted during the protocol
   preparation phase of this study. Gheorghe Doros, with the Department of
   Biostatistics in the Boston University School of Public Health, aided in
   the statistical analysis of the data. This article is the result of work
   supported with resources and the use of facilities at the Veterans
   Affairs Boston Healthcare System, Jamaica Plain, MA, USA. The VA Boston
   funded the cost of medications for this study.
CR Abraham-Marin ML, 2007, GRAEF ARCH CLIN EXP, V245, P651, DOI 10.1007/s00417-006-0411-6
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   BORENSTEIN M, 2004, POWER PRECISION
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Ho QT, 2007, INT J BIOCHEM CELL B, V39, P1349, DOI 10.1016/j.biocel.2007.04.010
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Madhusudhana KC, 2007, BRIT J OPHTHALMOL, V91, P1716, DOI 10.1136/bjo.2006.108639
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Miller JW, 1997, AM J PATHOL, V151, P13
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
   Ziemssen Focke, 2008, International Ophthalmology, V28, P101, DOI 10.1007/s10792-007-9122-1
NR 37
TC 65
Z9 68
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD NOV
PY 2010
VL 24
IS 11
BP 1708
EP 1715
DI 10.1038/eye.2010.147
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 678WF
UT WOS:000284112900011
PM 20885427
OA Bronze
DA 2022-11-30
ER

PT J
AU Lalwani, GA
   Rosenfeld, PJ
   Fung, AE
   Dubovy, SR
   Michels, S
   Feuer, W
   Davis, JL
   Flynn, HW
   Esquiabro, M
AF Lalwani, Geeta A.
   Rosenfeld, Philip J.
   Fung, Anne E.
   Dubovy, Sander R.
   Michels, Stephen
   Feuer, William
   Davis, Janet L.
   Flynn, Harry W., Jr.
   Esquiabro, Maria
TI A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular
   Age-related Macular Degeneration: Year 2 of the PrONTO Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GEOGRAPHIC ATROPHY; PHOTODYNAMIC THERAPY; SUBGROUP ANALYSIS;
   VERTEPORFIN; ANCHOR; MARINA
AB PURPOSE: To assess the long-term efficacy of a variable-dosing regimen with ranibizumab in the Prospective Optical Coherence Tomography (OCT) Imaging of Patients with Neovascular Age-Related Macular Degeneration (AMID) Treated with intraOcular Ranibizumab (PrONTO) Study, patients were followed for 2 years.
   DESIGN: A 2-year prospective, uncontrolled, variable-dosing regimen with intravitreal ranibizumab based on OCT.
   METHODS: In this open-label, prospective, single,center, uncontrolled clinical study, AMD patients with neovascularization involving the central fovea and a central retinal thickness (CRT) of at least 300 mu m as measured by OCT were enrolled to receive 3 consecutive monthly intravitreal injections of ranibizumab (0.5 mg) [Lucentis; Genentech Inc, South San Francisco, California, USA]. During the first year, retreatment with ranibizumab was performed at each monthly visit if any criterion was fulfilled such as an increase in OCT CRT of at least 100 mu m or a loss of 5 letters or more. During the second year, the retreatment criteria were amended to include retreatment if any qualitative increase in the amount of fluid was detected using OCT.
   RESULTS: Forty patients were enrolled and 37 completed the 2-year study. At month 24, the mean visual acuity (VA) improved by 11.1 letters (P < .001) and the OCT-CRT decreased by 212 mu m (P < .001). VA improved by 15 letters or more in 43% of patients. These VA and OCT outcomes were achieved with an average of 9.9 injections over 24 months.
   CONCLUSIONS: The PrONTO Study using an OCT guided variable-dosing regimen with intravitreal ranibizumab resulted in VA outcomes comparable with the outcomes from the phase III clinical studies, but fewer intravitreal injections were required. (Am J Ophthalmol 2009; 148:43-58. (C) 2009 by Elsevier Inc. All rights reserved.)
C1 [Lalwani, Geeta A.; Rosenfeld, Philip J.; Fung, Anne E.; Dubovy, Sander R.; Michels, Stephen; Feuer, William; Davis, Janet L.; Flynn, Harry W., Jr.; Esquiabro, Maria] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Rosenfeld, PJ (通讯作者)，Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@med.miami.edu
RI Davis, Janet L/GPC-8037-2022
OI Davis, Janet L/0000-0001-6395-5881
FU GENENTECH INC, SOUTH SAN FRANCISCO, CALIFORNIA; THE DEPARTMENT OF
   OPHTHALmology at the Bascom Palmer Eye Institute, Miami, Florida;
   National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [P30 EY014801]; German Research Foundation (DFG), Bonn,
   Germany; Novortis Ophthalmics; Alcon Laboratories; CoMentis; Quark;
   NATIONAL EYE INSTITUTE [P30EY014801] Funding Source: NIH RePORTER
FX THIS STUDY WAS SUPPORTED BY GENENTECH INC, SOUTH SAN FRANCISCO,
   CALIFORNIA; THE DEPARTMENT OF OPHTHALmology at the Bascom Palmer Eye
   Institute, Miami, Florida; an Unrestricted Grant from Research to
   prevent Blindness Inc, New York, New York; Core Grant No. P30 EY014801
   from the National Eye Institute, National Institutes of Health,
   Bethesda, Maryland; and the German Research Foundation (DFG), Bonn,
   Germany. Drs Rosenfeld and Fung received research grants from Genentech
   Inc. Drs Rosenfeld, Fung, Davis, and Michels received clinical research
   grants from Novortis Ophthalmics, Alcon Laboratories, CoMentis, and
   Quark. Drs Rosenfeld, Fung, Michels, Davis, and Flynn have participated
   in competing scientific advisory boards and have received honorarium and
   reimbursement for travel expenses. Involved in design of study (P.J.R.,
   A.E.F., S.M., M.E.); conduct of study (P.J.R., G.A.L., A.E.F., M.E.);
   data collection (P.J.R., S.D., J.D., H.W.F.); managenicnr (P.J.R.,
   A.E.F., M.E., S.D.), analysis (P.J.R., G.A.L., W.F.), and interpretation
   of data (P.J.R., G.A.L., W.F.); and preparation (G.A.L., P.J.R., W.F.),
   review and approval of the manuscript (G.A.L., P.J.R., A.E.F., S.D.,
   S.M., H.W.F., J.D., M.E.). Before the initiation of the study, approval
   to perform the PrONTO Study was obtained from the FDA and the
   Institutional Review Board at the University of Miami Miller School of
   Medicine. The study was registered with www.clinicaltrials.gov (no.
   NCT00344227). The study was performed in accordance with Health
   Insurance Portability and Accountability Act regulations.
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
NR 12
TC 689
Z9 728
U1 2
U2 35
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2009
VL 148
IS 1
BP 43
EP 58
DI 10.1016/j.ajo.2009.01.024
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464CE
UT WOS:000267481700009
PM 19376495
DA 2022-11-30
ER

PT J
AU Fan, W
   Li, SS
   Tao, J
   Yu, CY
   Sun, M
   Xie, Z
   Wu, XJ
   Ge, L
   Wu, YQ
   Liu, YF
AF Fan, Wen
   Li, Shasha
   Tao, Juan
   Yu, Chenyang
   Sun, Meng
   Xie, Zhan
   Wu, Xinjing
   Ge, Liang
   Wu, Yiqun
   Liu, Yuanfen
TI Anti-Vascular Endothelial Growth Factor Drug Conbercept-Loaded Peptide
   Hydrogel Reduced Angiogenesis in the Neovascular Age-Related Macular
   Degeneration
SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
LA English
DT Article
DE nAMD; VEGF; Angiogenesis; Conbercept; Hydrogel
ID RETINAL VASCULAR ABNORMALITIES; PHOTODYNAMIC THERAPY
AB Age-related macular degeneration ( AMD) accounts for 8.7% of the global blindness and neovascular form of AMD (nAMD) occupies a large proportion of severe visual loss and legal blindness caused by AMD with a relatively low incidence rate. Choroidal neovascularization (CNV) is overwhelmingly responsible for the occurrence of nAMD as bleeding and fluid leakage followed by abnormal formation of blood vessels could directly lead to loss of central vision so that reduce the choroidal angiogenesis is an ideal treatment method of nAMD. VEGF is an important cytokine which promote the signaling pathway of angiogenesis and the abnormal expression of VEGF is verified in great many CNV cases. Several anti-VEGF drugs have been widely used in clinical treatments such as ranibizumab, bevacizumab and aflibercept. Conbercept, as an originally developed drug in China, has attracted great attention. For the purpose of better treatment efficacy, our group designed a short chain peptide (Sequence: DDIIIRH-NH2, M.W.880.99) for controlled drug release to remedy the drawback of the short half-time period. The peptide could self-assembled into a stable `hydrogel under pH 7.4 condition and the 3D structure was clearly observed in TEM study. Rheological study exhibited its great injectability so that the hydrogel was a material for intravitreal injection. Statistics exhibited that the hydrogel could release approximately 50% of total conbercept. The In vitro experiments showed that either dose-dependent or the time-dependent incubation with peptide would not decrease the cell viability of HREC, revealing that the peptide was biocompatible. The most important is that co-incubation with HREC obviously reduced the HREC proliferation and tube formation induced by VEGF, ensuring its potential for the treatment efficacy of nAMD.
C1 [Fan, Wen; Xie, Zhan; Wu, Xinjing] Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanjing 210000, Jiangsu, Peoples R China.
   [Liu, Yuanfen] Jiangsu Hlth Vocat Coll, Nanjing 210000, Jiangsu, Peoples R China.
   [Li, Shasha; Ge, Liang] Xinjiang Med Univ, Sch Pharm, Urumqi 830000, Xinjiang, Peoples R China.
   [Yu, Chenyang; Sun, Meng; Ge, Liang; Wu, Yiqun] China Pharmaceut Univ, Sch Pharm, State Key Lab Nat Med, Nanjing 210000, Jiangsu, Peoples R China.
   [Tao, Juan] Jiangsu Coll Nursing, Dept Pharm & Tradit Chinese Pharm, Huaian 223001, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Xinjiang Medical University; China
   Pharmaceutical University
RP Liu, YF (通讯作者)，Jiangsu Hlth Vocat Coll, Nanjing 210000, Jiangsu, Peoples R China.; Wu, YQ (通讯作者)，China Pharmaceut Univ, Sch Pharm, State Key Lab Nat Med, Nanjing 210000, Jiangsu, Peoples R China.
EM 2542240744@qq.com; liuyuanfen2010@gmail.com
FU Natural Science Foundation of Xinjiang Province [2017D01C200]
FX This study is supported by Natural Science Foundation of Xinjiang
   Province (No. 2017D01C200).
CR Braimah IZ, 2017, BRIT J OPHTHALMOL, V101, P1201, DOI 10.1136/bjophthalmol-2016-309994
   Clarke DE, 2018, ANGEW CHEM INT EDIT, V57, P7709, DOI 10.1002/anie.201801001
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Fan DY, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00675
   Fong AHC, 2011, GRAEF ARCH CLIN EXP, V249, P625, DOI 10.1007/s00417-010-1453-3
   Huang J, 2019, J BIOMED NANOTECHNOL, V15, P1357, DOI 10.1166/jbn.2019.2815
   Jackson TL, 2014, RETINA-J RET VIT DIS, V34, P568, DOI 10.1097/IAE.0b013e3182a487be
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Li T, 2011, MOL VIS, V17, P797
   Liu GT, 2020, CHINESE CHEM LETT, V31, P1817, DOI 10.1016/j.cclet.2020.03.005
   Liu HY, 2016, AM J OPHTHALMOL, V167, P57, DOI 10.1016/j.ajo.2016.04.001
   Luo SY, 2020, J BIOMED NANOTECHNOL, V16, P842, DOI 10.1166/jbn.2020.2935
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Parrozzani R, 2018, RETINA-J RET VIT DIS, V38, P585, DOI 10.1097/IAE.0000000000001578
   Peiretti E, 2018, RETINA-J RET VIT DIS, V38, P1526, DOI 10.1097/IAE.0000000000001750
   Sahu AK, 2010, RETINA-J RET VIT DIS, V30, P981, DOI 10.1097/IAE.0b013e3181dde596
   Sharma S, 2020, INT J BIOL MACROMOL, V162, P737, DOI 10.1016/j.ijbiomac.2020.06.110
   Wang S, 2006, OPHTHALMOLOGY, V113, P1752, DOI 10.1016/j.ophtha.2006.05.019
   Whitesides GM, 2002, P NATL ACAD SCI USA, V99, P4769, DOI 10.1073/pnas.082065899
   Wu J, 2014, J MATER CHEM B, V2, P6660, DOI 10.1039/c4tb00576g
   Wu J, 2012, ADV FUNCT MATER, V22, P3815, DOI 10.1002/adfm.201103147
   Xian CH, 2020, CHINESE CHEM LETT, V31, P19, DOI 10.1016/j.cclet.2019.03.052
   Zhu Y, 2020, BIOMATER SCI-UK, V8, P5415, DOI 10.1039/d0bm01004a
NR 23
TC 0
Z9 0
U1 2
U2 8
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1550-7033
EI 1550-7041
J9 J BIOMED NANOTECHNOL
JI J. Biomed. Nanotechnol.
PD JAN
PY 2022
VL 18
IS 1
BP 277
EP 287
DI 10.1166/jbn.2022.3227
PG 11
WC Nanoscience & Nanotechnology; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Materials Science
GA ZG6HN
UT WOS:000760357800001
PM 35180922
DA 2022-11-30
ER

PT J
AU Etminan, M
   Maberley, DA
   Babiuk, DW
   Carleton, BC
AF Etminan, Mahyar
   Maberley, David A.
   Babiuk, David W.
   Carleton, Bruce C.
TI Risk of Myocardial Infarction and Stroke With Single or Repeated Doses
   of Intravitreal Bevacizumab in Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; ADVERSE EVENTS; RANIBIZUMAB; INJECTION
AB PURPOSE: To examine the risk of myocardial infarction and stroke with single and repeated doses of intravitreal bevacizumab in wet age-related macular degeneration (AMD).
   DESIGN: Nested case-control study and retrospective cohort study.
   METHODS: SETTING: Two patient cohorts from British Columbia, Canada. STUDY POPULATION: Patients with wet AMD. INTERVENTION: For the cohort study, patients who received the first intravitreal bevacizumab; for the nested case-control study, repeated injections of intravitreal bevacizumab. MAIN OUTCOME MEASURES: Myocardial infarction for the retrospective cohort study; myocardial infarction and stroke for the nested case-control study.
   RESULTS: In the cohort analysis, there were 2564 AMD subjects not on a vascular endothelial growth factor (VEGF) inhibitor and 5644 subjects receiving intravitreal bevacizumab. The rate of myocardial infarction (MI) among bevacizumab users was 11/1000 person years, compared to 14.9/1000 person-years in nonusers. The adjusted rate ratio (RR) for MI was 0.70 (95% confidence interval [CI]: 0.50-1.00) and 0.74 (0.46-1.20) for the propensity score adjusted analysis. In the nested case-control analysis there were 7452 new users of VEGF inhibitors, within which there were 313 cases of MI with 3130 matched controls. The adjusted RR for MI among those receiving 3 or more injections compared to those receiving fewer than 3 was 0.71 (95% CI: 0.41-1.22). Also in the nested case-control analysis, the adjusted RR for stroke was 0.81 (95% CI: 0.39-1.65) for those receiving >= 4 injections vs those receiving fewer than 4 injections.
   CONCLUSION: Single or repeated doses of intravitreal bevacizumab were not shown to increase the risk of myocardial infarction or stroke in patients with wet AMD. (C) 2016 by Elsevier Inc. All rights reserved.
C1 [Etminan, Mahyar; Carleton, Bruce C.] British Columbia Children Hosp, Pharmaceut Outcomes Programme, Vancouver, BC, Canada.
   [Etminan, Mahyar; Carleton, Bruce C.] Univ British Columbia, Fac Med, Dept Pediat, Vancouver, BC V5Z 3N9, Canada.
   [Maberley, David A.] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC V5Z 3N9, Canada.
   [Babiuk, David W.] Cardiac Serv BC, Prov Hlth Serv Author, Vancouver, BC, Canada.
C3 University of British Columbia; University of British Columbia;
   University of British Columbia
RP Etminan, M (通讯作者)，Univ British Columbia, Eye Care Ctr, Room 323-2550 Willow St, Vancouver, BC V5Z 3N9, Canada.
EM etminanm@mail.ubc.ca
OI Carleton, Bruce/0000-0002-4485-4054
FU BRITISH COLUMBIA PROVINCIAL HEALTH SERVICES AUTHORity
FX THIS STUDY WAS FUNDED IN PART BY THE BRITISH COLUMBIA PROVINCIAL HEALTH
   SERVICES AUTHORity.
CR Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Breslow NE, 1996, J AM STAT ASSOC, V91, P14, DOI 10.2307/2291379
   British Columbia Ministry of Health, 2012, MED SERV PLAN MSP PA
   British Columbia Ministry of Health (creator), 2012, DISCH ABSTR DAT HOSP
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Etminan M, 2012, JAMA-J AM MED ASSOC, V307, P1414, DOI 10.1001/jama.2012.383
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Kokotailo RA, 2005, STROKE, V36, P1776, DOI 10.1161/01.STR.0000174293.17959.a1
   LUBIN JH, 1986, J CHRON DIS, V39, P379, DOI 10.1016/0021-9681(86)90124-4
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michels S, 2006, BRIT J OPHTHALMOL, V90, P1333, DOI 10.1136/bjo.2006.102293
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   Schlenker MB, 2015, AM J OPHTHALMOL, V160, P569, DOI 10.1016/j.ajo.2015.06.011
   Semeraro F, 2014, EXPERT OPIN DRUG SAF, V13, P785, DOI 10.1517/14740338.2014.911284
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   Varas-Lorenzo C, 2008, PHARMACOEPIDEM DR S, V17, P842, DOI 10.1002/pds.1619
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
   Zhang TT, 2013, EUR J CLIN PHARMACOL, V69, P581, DOI 10.1007/s00228-012-1343-1
NR 22
TC 15
Z9 15
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2016
VL 163
BP 53
EP 58
DI 10.1016/j.ajo.2015.11.030
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DF6EA
UT WOS:000371447500009
PM 26701272
DA 2022-11-30
ER

PT J
AU Gayadine-Harricham, Y
   Rufin, V
   Law-Koune, S
   Tran, TH
AF Gayadine-Harricham, Yanel
   Rufin, Virginie
   Law-Koune, Sandrine
   Tran, Thi Ha Chau
TI Four-Year Outcome of Aflibercept Treatment-Naive Patients for
   Neovascular Age-Related Macular Degeneration: Evidence from a Clinical
   Setting
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB; INJECTION
AB Introduction. The objective of the study is to report 4-year treatment outcome with intravitreal Aflibercept injections for neovascular age-related macular degeneration (nAMD) as first life therapy in real-life. Patients and Methods. This is a prospective, monocenter, observational case series analysis. Data from treatment-naive patients with nAMD with at least 4 years of follow-up were included in the analysis. Data including age, gender, and visual acuity measured on Early Treatment of Diabetic Retinopathy Study charts (ETDRS) and injection numbers were recorded. Spectral domain optical coherence tomography (SD-OCT) data at baseline, month 3, month 6, month 12, year 2, 3, and 4 were also recorded. Patients were treated with a modified treat and extend (T&E) regimen. Results. Of the 48 eyes with nAMD treated, only 31 eyes were available at the 4-year follow-up. The mean age was 81 +/- 8 years. The VA gain was 7.3 +/- 12.7 letters at 1 year 6.5 +/- 12.5 letters at 2 years, VA gain 5.2 +/- 17 letters at 3 years, and 6.2 +/- 18.6 letters at 4 years. The reduction of central retinal thickness was 118 +/- 187 mu m at 4 years. Complete resolution of fluid was obtained in 18/31 eyes. The total number of injections was 5.7 +/- 2.0 during the first year, 2.9 +/- 2.9 during the second year, 3.5 +/- 3.3 during the third year, and 4.0 +/- 3.4 during the fourth year. The total number of injections was 16 +/- 10.6, ranging from 3 to 52 injections. Ten eyes developed macular atrophy over the 4-year period. Conclusion. The results suggest that good long-term morphological and functional outcome can be achieved using Aflibercept in clinical setting.
C1 [Gayadine-Harricham, Yanel; Rufin, Virginie; Law-Koune, Sandrine; Tran, Thi Ha Chau] Lille Catholic Univ, Dept Ophthalmol, Lille Catholic Hosp, Lille, France.
RP Tran, TH (通讯作者)，Lille Catholic Univ, Dept Ophthalmol, Lille Catholic Hosp, Lille, France.
EM yanel.gayadine@gmail.com; vrufin@live.fr; lawkoune.sandrine@ghicl.net;
   tran.hachau@ghicl.net
RI TRAN, Thi Ha Chau/AAF-2162-2020
OI TRAN, Thi Ha Chau/0000-0001-9066-7092
CR [Anonymous], 2012, MED LETT DRUGS THER, V54, P9
   Aurell S, 2019, ACTA OPHTHALMOL, V97, P519, DOI 10.1111/aos.13989
   Barakat A, 2018, J FR OPHTALMOL, V41, P603, DOI 10.1016/j.jfo.2018.01.005
   Boulanger-Scemama E, 2016, J FR OPHTALMOL, V39, P668, DOI 10.1016/j.jfo.2016.06.001
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   European Medicines Agency, 2012, EYL 40 MG ML SOL INJ
   Gelman SK, 2014, RETINA-J RET VIT DIS, V34, P2088, DOI 10.1097/IAE.0000000000000207
   Guo MY, 2019, ACTA OPHTHALMOL, V97, pE1, DOI 10.1111/aos.13825
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kodjikian L, 2015, J FR OPHTALMOL, V38, P639, DOI 10.1016/j.jfo.2015.06.001
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Nishikawa K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39995-5
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tran THC, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/8984313
   Thi HCT, 2011, OPHTHAL SURG LAS IM, V42, P498, DOI 10.3928/15428877-20110804-04
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Tran THC, 2017, J FR OPHTALMOL, V40, pE99, DOI 10.1016/j.jfo.2016.11.007
   Tran THC, 2012, J FR OPHTALMOL, V35, P353, DOI 10.1016/j.jfo.2011.12.004
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
NR 25
TC 5
Z9 5
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD APR 1
PY 2020
VL 2020
AR 7465270
DI 10.1155/2020/7465270
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LE7VB
UT WOS:000526930500005
PM 32318284
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Chong, EWT
   Kreis, AJ
   Wong, TY
   Simpson, JA
   Guymer, RH
AF Chong, Elaine W-T.
   Kreis, Andreas J.
   Wong, Tien Y.
   Simpson, Julie A.
   Guymer, Robyn H.
TI Dietary omega-3 fatty acid and fish intake in the primary prevention of
   age-related macular degeneration - A systematic review and meta-analysis
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID FATTY-ACIDS; CIGARETTE-SMOKING; VISUAL IMPAIRMENT; RISK; MACULOPATHY;
   PREVALENCE; PATHOGENESIS; HEALTH; RANIBIZUMAB; QUALITY
AB Objective: To systematically review the evidence on dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration (AMD).
   Methods: Seven databases were systematically searched with no limits on publication year or language using standardized criteria. Randomized controlled trials and prospective cohort, case-control, and cross-sectional studies were included. Of 2754 abstracts identified, 3 prospective cohort, 3 case-control, and 3 cross-sectional studies met the criteria. Measures of associations were pooled quantitatively using meta-analytic methods.
   Results: Nine studies provided data on a total sample of 88 974 people, including 3203 AMD cases. A high dietary intake of omega-3 fatty acids was associated with a 38% reduction in the risk of late AMD(pooled odds ratio [OR], 0.62; 95% confidence interval [CI], 0.48-0.82). Fish intake at least twice a week was associated with a reduced risk of both early AMD (pooled OR, 0.76; 95% CI, 0.64-0.90) and late AMD (pooled OR, 0.67; 95% CI, 0.53-0.85).
   Conclusions: Although this meta-analysis suggests that consumption of fish and foods rich in omega-3 fatty acids may be associated with a lower risk of AMD, there is insufficient evidence from the current literature, with few prospective studies and no randomized clinical trials, to support their routine consumption for AMD prevention.
C1 [Chong, Elaine W-T.; Kreis, Andreas J.; Wong, Tien Y.; Guymer, Robyn H.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Simpson, Julie A.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic, Australia.
   [Wong, Tien Y.] Natl Univ Singapore, Eye Res Inst, Yong Loo Lin Sch Med, Singapore 117548, Singapore.
   [Simpson, Julie A.] Canc Council Victoria, Canc Epidemiol Ctr, Carlton, Vic, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Melbourne; National University of Singapore; Cancer Council Victoria
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Wong, Tien Yin/AAC-9724-2020; Simpson, Julie A/P-7299-2014
OI Wong, Tien Yin/0000-0002-8448-1264; Guymer, Robyn/0000-0002-9441-4356;
   Simpson, Julie/0000-0002-2660-2013
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Bazan N G, 1989, Prog Clin Biol Res, V312, P95
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Chong EWT, 2006, CLIN EXP OPHTHALMOL, V34, P464, DOI 10.1111/j.1442-9071.2006.01250.x
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Clarke M, 2000, LANCET, V355, P756, DOI 10.1016/S0140-6736(05)72172-3
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Deeks J J, 2003, Health Technol Assess, V7, piii
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7
   Egger M, 1998, BRIT MED J, V316, P140
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eter N, 2006, BIODRUGS, V20, P167, DOI 10.2165/00063030-200620030-00004
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gebauer S., 2005, HEALTHFUL LIPIDS, P221
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hodge WG, 2006, OPHTHALMOLOGY, V113, P1165, DOI 10.1016/j.ophtha.2006.02.043
   Hooper L, 2006, BMJ-BRIT MED J, V332, P752, DOI 10.1136/bmj.38755.366331.2F
   KIRSCHFELD K, 1982, PROC R SOC SER B-BIO, V216, P71, DOI 10.1098/rspb.1982.0061
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3
   Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5
   NETTLETON JA, 1991, J AM DIET ASSOC, V91, P331
   NEURINGER M, 1988, ANNU REV NUTR, V8, P517, DOI 10.1146/annurev.nu.08.070188.002505
   *NIH, AG REL EY DIS STUD, V2
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
NR 55
TC 181
Z9 186
U1 0
U2 24
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUN
PY 2008
VL 126
IS 6
BP 826
EP 833
DI 10.1001/archopht.126.6.826
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 310RX
UT WOS:000256548900010
PM 18541848
OA Bronze
DA 2022-11-30
ER

PT J
AU Blasiak, J
   Szczepanska, J
   Fila, M
   Pawlowska, E
   Kaarniranta, K
AF Blasiak, Janusz
   Szczepanska, Joanna
   Fila, Michal
   Pawlowska, Elzbieta
   Kaarniranta, Kai
TI Potential of Telomerase in Age-Related Macular Degeneration-Involvement
   of Senescence, DNA Damage Response and Autophagy and a Key Role of PGC-1
   alpha
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; AMD; telomerase; hTERT; autophagy;
   PGC-1 alpha; peroxisome proliferator-activated receptor gamma
   coactivator 1 alpha; mTORC1; senescence; DNA damage response
ID PIGMENT EPITHELIAL-CELLS; REVERSE-TRANSCRIPTASE; OXIDATIVE STRESS;
   MITOCHONDRIAL-DNA; GEOGRAPHIC ATROPHY; DYSFUNCTION; RPE; REPAIR;
   SUPPRESSION; METABOLISM
AB Age-related macular degeneration (AMD), the main cause of vision loss in the elderly, is associated with oxidation in the retina cells promoting telomere attrition. Activation of telomerase was reported to improve macular functions in AMD patients. The catalytic subunit of human telomerase (hTERT) may directly interact with proteins important for senescence, DNA damage response, and autophagy, which are impaired in AMD. hTERT interaction with mTORC1 (mTOR (mechanistic target of rapamycin) complex 1) and PINK1 (PTEN-induced kinase 1) activates macroautophagy and mitophagy, respectively, and removes cellular debris accumulated over AMD progression. Ectopic expression of telomerase in retinal pigment epithelium (RPE) cells lengthened telomeres, reduced senescence, and extended their lifespan. These effects provide evidence for the potential of telomerase in AMD therapy. Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 alpha) may be involved in AMD pathogenesis through decreasing oxidative stress and senescence, regulation of vascular endothelial growth factor (VEGF), and improving autophagy. PGC-1 alpha and TERT form an inhibitory positive feedback loop. In conclusion, telomerase activation and its ectopic expression in RPE cells, as well as controlled clinical trials on the effects of telomerase activation in AMD patients, are justified and should be assisted by PGC-1 alpha modulators to increase the therapeutic potential of telomerase in AMD.
C1 [Blasiak, Janusz] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, Pomorska 141-143, PL-90236 Lodz, Poland.
   [Szczepanska, Joanna] Med Univ Lodz, Dept Pediat Dent, PL-92216 Lodz, Poland.
   [Fila, Michal] Polish Mothers Mem Hosp, Dept Dev Neurol & Epileptol, Res Inst, PL-93338 Lodz, Poland.
   [Pawlowska, Elzbieta] Med Univ Lodz, Dept Orthodont, PL-92217 Lodz, Poland.
   [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio 70210, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70210, Finland.
C3 University of Lodz; Medical University Lodz; Polish Mother's Memorial
   Hospital - Research Institute; Medical University Lodz; University of
   Eastern Finland; Kuopio University Hospital; University of Eastern
   Finland
RP Blasiak, J (通讯作者)，Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, Pomorska 141-143, PL-90236 Lodz, Poland.; Kaarniranta, K (通讯作者)，Univ Eastern Finland, Dept Ophthalmol, Kuopio 70210, Finland.; Kaarniranta, K (通讯作者)，Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70210, Finland.
EM janusz.blasiak@biol.uni.lodz.pl; joanna.szczepanska@umed.lodz.pl;
   michalfila@poczta.onet.pl; elzbieta.pawlowska@umed.lodz.pl;
   kai.kaarniranta@uef.fi
OI Blasiak, Janusz/0000-0001-9539-9584
FU National Science Centre, Poland [2017/27/B/NZ3/00872]
FX This research was supported by the National Science Centre, Poland,
   grant number 2017/27/B/NZ3/00872.
CR Ahmed S, 2008, J CELL SCI, V121, P1046, DOI 10.1242/jcs.019372
   Ali M, 2016, BIOCHEM BIOPH RES CO, V478, P1198, DOI 10.1016/j.bbrc.2016.08.094
   Austin S, 2012, J CELL SCI, V125, P4963, DOI 10.1242/jcs.113662
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Banevicius M, 2021, OPHTHALMIC GENET, V42, P189, DOI 10.1080/13816810.2021.1881976
   Bar Christian, 2016, F1000Res, V5, DOI 10.12688/f1000research.7020.1
   Barnes RP, 2019, MECH AGEING DEV, V177, P37, DOI 10.1016/j.mad.2018.03.013
   Bell WR, 2019, BRAIN PATHOL, V29, P45, DOI 10.1111/bpa.12618
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bi JB, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/6946037
   Blasiak J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041684
   Blasiak J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228840
   Blasiak J, 2019, ACTA OPHTHALMOL, V97, DOI 10.1111/j.1755-3768.2019.5425
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Blasiak J, 2019, J CELL MOL MED, V23, P8464, DOI 10.1111/jcmm.14731
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Busquets MA, 2021, CURR OPIN OPHTHALMOL, V32, P240, DOI 10.1097/ICU.0000000000000756
   Campbell JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42201
   Casagrande S, 2019, BIOL LETTERS, V15, DOI 10.1098/rsbl.2018.0885
   Chen HT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1030-2
   Cheng HF, 2015, KIDNEY INT, V88, P85, DOI 10.1038/ki.2015.69
   Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   Desgarnier MCD, 2016, INVEST OPHTH VIS SCI, V57, P5547, DOI 10.1167/iovs.16-19878
   di Fagagna FD, 2004, GENE DEV, V18, P1781, DOI 10.1101/gad.1214504
   Diao JY, 2021, BIOCHEM BIOPH RES CO, V546, P29, DOI 10.1016/j.bbrc.2021.01.086
   Ding XL, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6636510
   Doksani Y, 2019, GENES-BASEL, V10, DOI 10.3390/genes10040318
   Dow CT, 2016, CLIN OPHTHALMOL, V10, P243, DOI 10.2147/OPTH.S100042
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Ferrara-Romeo I, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14962-1
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Fischer T, 2015, ORVOSI HETILAP, V156, P358, DOI 10.1556/OH.2015.30017
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Geng TY, 2011, AM J PATHOL, V178, P1738, DOI 10.1016/j.ajpath.2011.01.005
   Ghosh A, 2012, NAT CELL BIOL, V14, P1270, DOI 10.1038/ncb2621
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Green PD, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061509
   Guo A, 2020, BIOCHEM BIOPH RES CO, V526, P1069, DOI 10.1016/j.bbrc.2020.04.002
   Haendeler J, 2009, ARTERIOSCL THROM VAS, V29, P929, DOI 10.1161/ATVBAHA.109.185546
   Haferkamp S, 2009, AGING-US, V1, P542, DOI 10.18632/aging.100051
   Hao Q, 2021, J ENDOCRINOL INVEST, V44, P1857, DOI 10.1007/s40618-020-01493-1
   Harley CB, 2013, REJUV RES, V16, P386, DOI 10.1089/rej.2013.1430
   Hartmann A, 2003, MUTAGENESIS, V18, P45, DOI 10.1093/mutage/18.1.45
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Herrmann M, 2018, CLIN CHEM LAB MED, V56, P1210, DOI 10.1515/cclm-2017-0870
   Hiona A, 2008, EXP GERONTOL, V43, P24, DOI 10.1016/j.exger.2007.10.001
   Honda S, 2001, INVEST OPHTH VIS SCI, V42, P2139
   Honda S, 2001, BIOCHEM BIOPH RES CO, V282, P493, DOI 10.1006/bbrc.2001.4585
   Hughes JM, 2010, J HISTOCHEM CYTOCHEM, V58, P247, DOI 10.1369/jhc.2009.953786
   Hughes WE, 2021, ARTERIOSCL THROM VAS, V41, P446, DOI 10.1161/ATVBAHA.120.314944
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Immonen I, 2013, ACTA OPHTHALMOL, V91, P453, DOI 10.1111/j.1755-3768.2012.02427.x
   Jia PP, 2015, DNA REPAIR, V36, P137, DOI 10.1016/j.dnarep.2015.09.017
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79823-9
   Klionsky DJ, 2020, CELL DEATH DIFFER, V27, P831, DOI 10.1038/s41418-020-0511-6
   Koh CM, 2015, J CLIN INVEST, V125, P2109, DOI 10.1172/JCI79134
   Kosmidou C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17634-1
   Kozlowski MR, 2015, J OCUL PHARMACOL TH, V31, P87, DOI 10.1089/jop.2014.0071
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Lau BWM, 2007, J MOL NEUROSCI, V32, P160, DOI 10.1007/s12031-007-0031-6
   Lau BWM, 2008, J MOL NEUROSCI, V34, P63, DOI 10.1007/s12031-007-0072-x
   Lee J, 2008, ONCOGENE, V27, P3754, DOI 10.1038/sj.onc.1211037
   Lee JJ, 2021, SEMIN CELL DEV BIOL, V113, P88, DOI 10.1016/j.semcdb.2020.11.003
   Li Z, 2021, BIOGERONTOLOGY, V22, P165, DOI 10.1007/s10522-021-09910-5
   Liang HY, 2006, ADV PHYSIOL EDUC, V30, P145, DOI 10.1152/advan.00052.2006
   Maciejowski J, 2017, NAT REV MOL CELL BIO, V18, P175, DOI 10.1038/nrm.2016.171
   Mammadzada P, 2020, CELL MOL LIFE SCI, V77, P819, DOI 10.1007/s00018-019-03422-9
   Mao PS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12154
   Martens A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010027
   Martens DS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25165-6
   Matsunaga H, 1999, INVEST OPHTH VIS SCI, V40, P197
   Mendelsohn AR, 2015, REJUV RES, V18, P479, DOI 10.1089/rej.2015.1780
   Min Xiao-jie, 2009, Zhonghua Yan Ke Za Zhi, V45, P199
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Moran EP, 2016, AM J PHYSIOL-HEART C, V311, pH738, DOI 10.1152/ajpheart.00005.2016
   Nagpal N, 2020, STEM CELLS, V38, P1532, DOI 10.1002/stem.3270
   Nassour J, 2019, NATURE, V565, P659, DOI 10.1038/s41586-019-0885-0
   Nishio M, 2021, BIOSENS BIOELECTRON, V178, DOI 10.1016/j.bios.2021.113030
   Park JI, 2009, NATURE, V460, P66, DOI 10.1038/nature08137
   Park JK, 2002, EXP MOL MED, V34, P107, DOI 10.1038/emm.2002.16
   Patten IS, 2012, TRENDS ENDOCRIN MET, V23, P90, DOI 10.1016/j.tem.2011.09.007
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Petersen S, 1998, EXP CELL RES, V239, P152, DOI 10.1006/excr.1997.3893
   Podlevsky JD, 2008, NUCLEIC ACIDS RES, V36, pD339, DOI 10.1093/nar/gkm700
   Rambhatla L, 2002, INVEST OPHTH VIS SCI, V43, P1622
   Rastmanesh R, 2011, MED HYPOTHESES, V76, P79, DOI 10.1016/j.mehy.2010.08.036
   Richard AJ, 2021, CURR OPIN OPHTHALMOL, V32, P247, DOI 10.1097/ICU.0000000000000763
   Rius-Perez S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1452696
   Roh JI, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193182
   Rosales MAB, 2019, LIFE SCI ALLIANCE, V2, DOI [10.26508/lsa.201800212, 10.26508/lsa.201900436]
   Rousseau A, 2018, NAT REV MOL CELL BIO, V19, P697, DOI 10.1038/s41580-018-0040-z
   Rowe-Rendleman C, 2004, BRAIN RES BULL, V62, P549, DOI 10.1016/S0361-9230(03)00072-8
   Ruan Y, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031296
   Ruan Y, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9080761
   Sahin E, 2011, NATURE, V470, P359, DOI 10.1038/nature09787
   Satish S, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9248640
   Segal-Bendirdjian E, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00332
   Shafirovich V, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052698
   Sharma GG, 2003, ONCOGENE, V22, P131, DOI 10.1038/sj.onc.1206063
   Shibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031
   Shin WH, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2641-7
   Shu DY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094701
   Singhapol C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052989
   Sohal RS, 2002, FREE RADICAL BIO MED, V33, P575, DOI 10.1016/S0891-5849(02)00886-9
   Supruniuk E, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00923
   Tice R, 2015, MUTAT RES-GEN TOX EN, V786, P1, DOI 10.1016/j.mrgentox.2015.06.008
   Tormos Ana M, 2014, Free Radic Biol Med, V75 Suppl 1, pS52, DOI 10.1016/j.freeradbiomed.2014.10.823
   Tsunemi T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003799
   Vaiserman A, 2021, FRONT GENET, V11, DOI 10.3389/fgene.2020.630186
   Vaishnav RA, 2010, J NEUROTRAUM, V27, P1311, DOI 10.1089/neu.2009.1172
   Vatner SF, 2020, AGEING RES REV, V64, DOI 10.1016/j.arr.2020.101194
   Victorelli S, 2017, EBIOMEDICINE, V21, P14, DOI 10.1016/j.ebiom.2017.03.027
   von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2
   Wang HB, 2016, MOL VIS, V22, P189
   WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S
   Xiong SQ, 2015, CELL REP, V12, P1391, DOI 10.1016/j.celrep.2015.07.047
   Yeo NJY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01363
   Zhang M, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032698
   Zhang WJ, 2008, CIRCULATION, V117, P421, DOI 10.1161/CIRCULATIONAHA.107.725275
   Zhang YK, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/2876350
   Zhang YJ, 2019, ACCOUNTS CHEM RES, V52, P3164, DOI 10.1021/acs.accounts.9b00397
   Zientara-Rytter K, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010040
NR 141
TC 3
Z9 3
U1 4
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2021
VL 22
IS 13
AR 7194
DI 10.3390/ijms22137194
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA TG3MM
UT WOS:000671312100001
PM 34281248
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Steinberg, JS
   Auge, J
   Fleckenstein, M
   Holz, FG
   Schmitz-Valckenberg, S
AF Steinberg, Julia S.
   Auge, Jasmin
   Fleckenstein, Monika
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
TI Longitudinal Analysis of Reticular Drusen Associated with Age-Related
   Macular Degeneration Using Combined Confocal Scanning Laser
   Ophthalmoscopy and Spectral-Domain Optical Coherence Tomography Imaging
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Confocal scanning laser
   ophthalmoscopy; Reticular drusen; Reticular pseudodrusen;
   Spectral-domain optical coherence tomography; Subretinal deposits
ID GEOGRAPHIC-ATROPHY; HIGH-RESOLUTION; RISK-FACTOR; PSEUDODRUSEN;
   MACULOPATHY; DEPOSITS; MODEL; OCT
AB Purpose: To evaluate longitudinal variations of reticular drusen (RDR) in age-related macular degeneration using confocal scanning laser ophthalmoscopy (cSLO), near-infrared reflectance (NIR) and spectral-domain optical coherence tomography (SD-OCT) imaging. Methods: Eighteen eyes of 12 patients with RDR (median observational time 5 months, range 3-10) were included. Changes over time in the en face cSLO NIR images, the identical SD-OCT B scan (simple approach) and the dense SD-OCT volume scans (11 Linn between B scans, detailed approach) for 5 preselected RDR lesions were analysed, respectively. Results: Nineteen of 90 (21%) lesions were no longer detectable at the follow-up examination with the simple SD-OCT approach (increase 7/decrease 48/unchanged 15/not gradable 1). By contrast, no disappearance of single lesions was noted for both cSLO (3/8/61/18) and detailed SD-OCT image analysis (67/22/1/0). Within the dense SD-OCT volume scan, a median change of individual lesion height of 10 mu m/year was determined. Conclusions: The findings indicate a recordable progression of RDR lesions in lateral and vertical dimensions. Using dense SD-OCT volume scans, individual RDR lesion progression can be quantified and may be applied in future longitudinal studies. (C) 2014 S. Karger AG, Basel
C1 [Steinberg, Julia S.; Auge, Jasmin; Fleckenstein, Monika; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, DE-53127 Bonn, Germany.
C3 University of Bonn
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, DE-53127 Bonn, Germany.
EM steffen.schmitz-valckenberg@ukb.uni-bonn.de
OI Fleckenstein, Monika/0000-0001-8321-8037
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Auge J, 2014, OPHTHALMOLOGE, V111, P765, DOI 10.1007/s00347-013-2965-0
   Barteselli G, 2013, AM J OPHTHALMOL, V156, P588, DOI 10.1016/j.ajo.2013.04.030
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 20
TC 14
Z9 14
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2015
VL 233
IS 1
BP 35
EP 42
DI 10.1159/000368168
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CA5ST
UT WOS:000348968800006
PM 25413846
DA 2022-11-30
ER

PT J
AU Matos, AMF
   Cunha, LP
   Suzuki, ACF
   Mello, LGM
   Preti, RC
   Zacharias, LC
   Monteiro, MLR
AF Freitas Matos, Aline Mota
   Cunha, Leonardo Provetti
   Suzuki, Ana Claudia F.
   Marchesi Mello, Luiz Guilherme
   Preti, Rony C.
   Zacharias, Leandro C.
   Monteiro, Mario L. R.
TI Unilateral papilledema and peripapillary polypoidal choroidal
   vasculopathy as the presenting manifestations of intracranial
   hypertension
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Meningioma; Choroidal neovascularization; Papilledema; Pseudotumor
   cerebri; Vision disorder
ID SUB-RETINAL NEOVASCULARIZATION; PSEUDOTUMOR CEREBRI
AB We have reported here the case of a 54-year-old woman with intracranial hypertension that presented with the unique features of unilateral papilledema and peripapillary polypoidal choroidal vasculopathy. Our investigations lead to the diagnosis of idiopathic intracranial hypertension and an incidental small right frontal meningioma. The patient was accordingly treated with oral acetazolamide, followed by three consecutive monthly intravitreal injections of bevacizumab, which resulted in the inactivation of the polypoidal choroidal vasculopathy, marked reduction of lipid exudation, and complete absorption of the subretinal fluid. This case serves as the first documentation of polypoidal choroidal vasculopathy associated with papilledema. It also demonstrates that choroidal vascular abnormalities may occur even when optic disk edema is unilateral, which is an uncommon manifestation of increased intracranial pressure. Prompt recognition of such findings and its appropriate management are essential for adequate treatment and prevention of irreversible visual loss.
C1 [Freitas Matos, Aline Mota; Cunha, Leonardo Provetti; Suzuki, Ana Claudia F.; Marchesi Mello, Luiz Guilherme; Preti, Rony C.; Zacharias, Leandro C.; Monteiro, Mario L. R.] Univ Sao Paulo, Fac Med, Div Ophthalmol, Sao Paulo, SP, Brazil.
   [Cunha, Leonardo Provetti] Univ Fed Juiz de Fora, Fac Med, Juiz De Fora, MG, Brazil.
C3 Universidade de Sao Paulo; Universidade Federal de Juiz de Fora
RP Mello, LGM (通讯作者)，Univ Sao Paulo, Fac Med, Div Ophthalmol, Sao Paulo, SP, Brazil.
EM marchesi_lg@hotmail.com
RI Mello, Luiz Guilherme Marchesi/S-6506-2019; MONTEIRO, MARIO L
   R/C-8891-2012
OI Mello, Luiz Guilherme Marchesi/0000-0001-8347-2393; MONTEIRO, MARIO L
   R/0000-0002-7281-2791
CR Bidot S, 2015, J NEURO-OPHTHALMOL, V35, P31, DOI 10.1097/WNO.0000000000000205
   Chen John J, 2019, Int Ophthalmol Clin, V59, P3, DOI 10.1097/IIO.0000000000000274
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   COPPETO JR, 1985, J CLIN NEURO-OPHTHAL, V5, P45
   Friedman DI, 2013, NEUROLOGY, V81, P1159, DOI 10.1212/WNL.0b013e3182a55f17
   JAMISON RR, 1978, AM J OPHTHALMOL, V85, P78, DOI 10.1016/S0002-9394(14)76669-3
   Jamjoom BA, 2010, NEUROSCIENCES, V15, P200
   Monteiro MLR, 2014, EYE, V28, P390, DOI 10.1038/eye.2013.301
   MONTEIRO M L R, 1985, Arquivos de Neuro-Psiquiatria, V43, P154
   MORSE PH, 1981, AM J OPHTHALMOL, V91, P312, DOI 10.1016/0002-9394(81)90282-8
   Subramaniam S, 2017, J NEURO-OPHTHALMOL, V37, P197, DOI 10.1097/WNO.0000000000000448
   Villarruel JM, 2017, EUR J OPHTHALMOL, V27, P55, DOI 10.5301/ejo.5000806
   Wendel L, 2006, AM J OPHTHALMOL, V141, P573, DOI 10.1016/j.ajo.2005.09.030
NR 13
TC 1
Z9 1
U1 0
U2 0
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PY 2021
VL 84
IS 6
BP 598
EP 601
DI 10.5935/0004-2749.20210098
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XE1HN
UT WOS:000723146600012
PM 34431881
OA gold
DA 2022-11-30
ER

PT J
AU Pershing, S
   Talwar, N
   Armenti, ST
   Grubbs, J
   Rosenthal, JM
   Dedania, VS
   Stein, JD
AF Pershing, Suzann
   Talwar, Nidhi
   Armenti, Stephen T.
   Grubbs, Joseph, Jr.
   Rosenthal, Julie M.
   Dedania, Vaidehi S.
   Stein, Joshua D.
TI Use of Bevacizumab and Ranibizumab for Wet Age-Related Macular
   Degeneration: Influence of CATT Results and Introduction of Aflibercept
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL INJECTION; TREATMENT PATTERNS; MEDICARE; ENDOPHTHALMITIS;
   OUTBREAK; TRENDS; CARE
AB PURPOSE: To assess whether publication of Comparison of Age-related macular degeneration Treatment Trial (CATT) results and introduction of aflibercept to the marketplace affected intravitreal bevacizumab and ranibizumab utilization.
   DESIGN: Retrospective analysis of treatment patterns.
   METHODS: We calculated weekly bevacizumab and ranibizumab utilization during 3 timeframes: (1) before CATT publication, (2) between CATT publication (April 28, 2011) and assignment of a unique aflibercept billing code (January 1, 2013), and (3) afterward for 164,188 Medicare beneficiaries with neovascular macular degeneration receiving >= 1 anti-vascular endothelial growth factor injection(s) from January 1, 2008 to December 31, 2014. We identified ophthalmologists who predominantly (>= 80%) administered bevacizumab or ranibizumab and evaluated changes in preferences over the 3 periods. We replicated analyses on 881,381 commercially insured beneficiaries.
   RESULTS: Among 317 ophthalmologists administering predominantly ranibizumab to Medicare beneficiaries pre-CATT, 221 (69.7%) reduced ranibizumab use post-CATT, whereas 96 (30.3%) continued using ranibizumab >= 80% of the time. Findings were reversed among 1041 ophthalmologists who predominantly administered bevacizumab pre-CATT-777 (74.6%) continued bevacizumab-predominant use while 264 (25.4%) reduced bevacizumab use post-CATT. Among the 145 ophthalmologists who predominantly administered ranibizumab before aflibercept's availability, 77 (53.1%) reduced ranibizumab utilization and 68 (46.9%) continued using ranibizumab >= 80% of the time after aflibercept became available. Corresponding numbers among the 909 ophthalmologists who predominantly administered bevacizumab pre-aflibercept were 381 (41.9%) reducing and 528 (58.1%) continuing bevacizumab-predominant use. Similar results were observed for commercially insured patients.
   CONCLUSIONS: Many ophthalmologists who favored ranibizumab switched to bevacizumab after CATT publication, while most who favored bevacizumab before CATT publication continued favoring it afterward. Aflibercept's introduction had little impact on preferences for ranibizumab or bevacizumab. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Pershing, Suzann] Stanford Univ, Sch Med, Dept Ophthalmol, Byers Eye Inst, Palo Alto, CA 94304 USA.
   [Pershing, Suzann] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
   [Talwar, Nidhi; Armenti, Stephen T.; Grubbs, Joseph, Jr.; Rosenthal, Julie M.; Dedania, Vaidehi S.; Stein, Joshua D.] Univ Michigan, Med Sch, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   [Talwar, Nidhi; Stein, Joshua D.] Univ Michigan, Ctr Eye Policy & Innovat, Ann Arbor, MI 48109 USA.
   [Stein, Joshua D.] Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA.
C3 Stanford University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Palo Alto Health Care System; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan
RP Stein, JD (通讯作者)，WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, 1000 Wall St, Ann Arbor, MI 48105 USA.
EM jdstein@med.umich.edu
FU National Eye Institute [R01 EY026641]; National Institute on Aging [R03
   AG056453]; NATIONAL EYE INSTITUTE [R01EY026641] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON AGING [R03AG056453] Funding Source: NIH
   RePORTER
FX Publication of this article was supported by National Eye Institute
   grant R01 EY026641 (Dr Stein), National Institute on Aging grant R03
   AG056453 (Dr Pershing), and departmental support from Research to
   Prevent Blindness, New York, New York (Drs Pershing and Stein). The
   funding organizations had no role in the design or conduct of this
   research.
CR [Anonymous], 1983, OTABPH22 US C
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   BOISSEL JP, 1989, CONTROL CLIN TRIALS, V10, pS120
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Corbett-Corren J, 2011, WALL STR J
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   Davis D, 1999, JAMA-J AM MED ASSOC, V282, P867, DOI 10.1001/jama.282.9.867
   DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111
   Edison LS, 2015, EMERG INFECT DIS, V21, P171, DOI 10.3201/eid2101.141040
   Erie JC, 2016, OPHTHALMOLOGY, V123, P1257, DOI 10.1016/j.ophtha.2016.02.015
   Frost BA, 2011, NEW ENGL J MED, V365, P2238, DOI 10.1056/NEJMc1105759
   Goldberg RA, 2012, AM J OPHTHALMOL, V153, P204, DOI 10.1016/j.ajo.2011.11.035
   Goldberger JJ, 2010, AM HEART J, V160, P435, DOI 10.1016/j.ahj.2010.06.023
   Gower EW, 2017, AM J OPHTHALMOL, V184, P157, DOI 10.1016/j.ajo.2017.10.010
   Hutton D, 2014, HEALTH AFFAIR, V33, P931, DOI 10.1377/hlthaff.2013.0832
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Lenfant C, 2003, NEW ENGL J MED, V349, P868, DOI 10.1056/NEJMsa035507
   Lubloy A, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-469
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McLaughlin MD, 2017, OPHTHALMOLOGY, V124, P667, DOI 10.1016/j.ophtha.2017.01.001
   Parikh R, 2017, OPHTHALMOLOGY, V124, P352, DOI 10.1016/j.ophtha.2016.10.036
   Pershing S, 2015, HEALTH AFFAIR, V34, P229, DOI 10.1377/hlthaff.2014.1032
   Pollack A., 2011, NY TIMES, pB2
   Pollack A., 2011, NY TIMES, pB3
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Stein JD, 2013, AM J OPHTHALMOL, V155, P688, DOI 10.1016/j.ajo.2012.10.003
NR 30
TC 7
Z9 7
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2019
VL 207
BP 385
EP 394
DI 10.1016/j.ajo.2019.05.011
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JY3TK
UT WOS:000504341100042
PM 31100217
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kannan, R
   Sreekumar, PG
   Hinton, DR
AF Kannan, Ram
   Sreekumar, Parameswaran G.
   Hinton, David R.
TI Alpha crystallins in the retinal pigment epithelium and implications for
   the pathogenesis and treatment of age-related macular degeneration
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
LA English
DT Review
DE Crystallins; Subcellular localization; Apoptosis; Exosomes;
   Angiogenesis; Minichaperone peptide
ID HEAT-SHOCK-PROTEIN; STRESS-INDUCED APOPTOSIS; B-CRYSTALLIN;
   A-CRYSTALLIN; OXIDATIVE STRESS; ISCHEMIA-REPERFUSION; FUNCTIONAL
   ELEMENT; CHAPERONE ACTIVITY; BREAST-CANCER; RPE CELLS
AB Background: alpha A- and alpha B crystallins are principal members of the small heat shock protein family and elicit both a cell protective function and a chaperone function. alpha-Crystallins have been found to be prominent proteins in normal and pathological retina emphasizing the importance for in-depth understanding of their function and significance.
   Scope of review: Retinal pigment epithelial cells (RPE) play a vital role in the pathogenesis of age-related macular degeneration (AMD). This review addresses a number of cellular functions mediated by alpha-crystallins in the retina. Prominent expression of alpha B crystallin in mitochondria may serve to protect cells from oxidative injury, aB crystallin as secretory protein via exosomes can offer neuroprotection to adjacent RPE cells and photoreceptors. The availability of chaperone-containing minipeptides of aB crystallin could prove to be a valuable new tool for therapeutic treatment of retinal disorders.
   Major conclusions: alpha-Crystallins are expressed in cytosol and mitochondria of RPE cells and are regulated during oxygen-induced retinopathy and during development alpha-Crystallins protect RPE from oxidative-and ER stress-induced injury and autophagy. alpha B-Crystallin is a modulator of angiogenesis and vascular endothelial growth factor. alpha B Crystallin is secreted via exosomal pathway. Minichaperone peptides derived from alpha B Crystallin prevent oxidant induced cell death and have therapeutic potential.
   General significance: Overall, this review summarizes several novel properties of alpha-crystallins and their relevance to maintaining normal retinal function. In particular, the use of a-crystallin derived peptides is a promising therapeutic strategy to combat retinal diseases such as AMD. This article is part of a Special Issue entitled Crystallin biochemistry in health and disease. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Kannan, Ram; Sreekumar, Parameswaran G.] Doheny Eye Inst, Beckman Macular Res Ctr, Los Angeles, CA 90033 USA.
   [Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
   [Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California
RP Kannan, R (通讯作者)，Doheny Eye Inst, Beckman Macular Res Ctr, 1355 San Pablo St,DVRC 303, Los Angeles, CA 90033 USA.
EM rkannan@doheny.org
RI kannan, ram/ABB-7154-2020
OI kannan, ram/0000-0002-1583-3414; /0000-0002-9425-3986
FU National Eye Institute [EY03040, EY01545]; Research to Prevent
   Blindness; Arnold and Mabel Beckman Foundation; NATIONAL EYE INSTITUTE
   [R01EY001545, P30EY003040] Funding Source: NIH RePORTER
FX We apologize to researchers in the field whose work could not be cited
   due to space constraints. This work was supported by Grants EY03040 and
   EY01545 from the National Eye Institute; and funds from Research to
   Prevent Blindness, and the Arnold and Mabel Beckman Foundation. We are
   thankful to Dr. Satoru Kase for generating the data used in Fig. 1 and
   to Ernesto Barron for help with preparation of the figures.
CR Adhikari AS, 2004, EXP CELL RES, V299, P393, DOI 10.1016/j.yexcr.2004.05.032
   Alge CS, 2002, INVEST OPHTH VIS SCI, V43, P3575
   Alvarez ML, 2012, KIDNEY INT, V82, P1024, DOI 10.1038/ki.2012.256
   Andley UP, 2007, PROG RETIN EYE RES, V26, P78, DOI 10.1016/j.preteyeres.2006.10.003
   Bai F, 2003, J BIOL CHEM, V278, P36876, DOI 10.1074/jbc.M304010200
   Bhattacharyya J, 2006, BIOCHEMISTRY-US, V45, P3069, DOI 10.1021/bi0518141
   Bretz NP, 2013, J BIOL CHEM, V288, P36691, DOI 10.1074/jbc.M113.512806
   Caby MP, 2005, INT IMMUNOL, V17, P879, DOI 10.1093/intimm/dxh267
   Chen C, 2014, ANTIOXID REDOX SIGN, V20, P2091, DOI 10.1089/ars.2013.5240
   Chen ZJ, 2014, BREAST CANCER RES TR, V145, P45, DOI 10.1007/s10549-014-2940-8
   Chis R, 2012, AM J PHYSIOL-HEART C, V303, pH967, DOI 10.1152/ajpheart.00040.2012
   Cobb BA, 2000, J BIOL CHEM, V275, P6664, DOI 10.1074/jbc.275.9.6664
   Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   den Engelsman J, 2003, J BIOL CHEM, V278, P4699, DOI 10.1074/jbc.M211403200
   DERETIC D, 1994, J BIOL CHEM, V269, P16853
   Dimberg A, 2008, BLOOD, V111, P2015, DOI 10.1182/blood-2007-04-087841
   Dou GR, 2012, FREE RADICAL BIO MED, V53, P1111, DOI 10.1016/j.freeradbiomed.2012.06.042
   EL Andaloussi S, 2013, ADV DRUG DELIVER REV, V65, P391, DOI 10.1016/j.addr.2012.08.008
   Fleige E, 2012, ADV DRUG DELIVER REV, V64, P866, DOI 10.1016/j.addr.2012.01.020
   Gangalum RK, 2011, J BIOL CHEM, V286, P3261, DOI 10.1074/jbc.M110.160135
   Gangalum RK, 2004, J BIOL CHEM, V279, P43374, DOI 10.1074/jbc.C400371200
   Ghosh JG, 2005, BIOCHEMISTRY-US, V44, P14854, DOI 10.1021/bi0503910
   Ghosh JG, 2007, BIOCHEMISTRY-US, V46, P6308, DOI 10.1021/bi700149h
   HALBAN PA, 1994, BIOCHEM J, V299, P1
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Ito K, 2001, J BIOL CHEM, V276, P5346, DOI 10.1074/jbc.M009004200
   Jeong WJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045754
   Jiang BM, 2005, CELL STRESS CHAPERON, V10, P252, DOI 10.1379/CSC-124R.1
   Jin JK, 2008, AM J PHYSIOL-HEART C, V294, pH337, DOI 10.1152/ajpheart.00881.2007
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kannan R, 2012, PROG RETIN EYE RES, V31, P576, DOI 10.1016/j.preteyeres.2012.06.001
   Kase S, 2010, BLOOD, V115, P3398, DOI 10.1182/blood-2009-01-197095
   Kim YH, 2012, DIABETOLOGIA, V55, P2835, DOI 10.1007/s00125-012-2625-y
   Kost J, 2001, ADV DRUG DELIVER REV, V46, P125, DOI 10.1016/S0169-409X(00)00136-8
   Kurnellas MP, 2012, J BIOL CHEM, V287, P36423, DOI 10.1074/jbc.M112.371229
   Lasser C, 2015, EXPERT OPIN BIOL TH, V15, P103, DOI 10.1517/14712598.2015.977250
   Li DWC, 2005, MOL BIOL CELL, V16, P4437, DOI 10.1091/mbc.E05-01-0010
   Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007
   Liu JP, 2004, EXP EYE RES, V79, P393, DOI 10.1016/j.exer.2004.06.015
   Liu L, 2013, AM J PATHOL, V182, P1412, DOI 10.1016/j.ajpath.2012.12.020
   Liu S, 2007, BIOCHEM BIOPH RES CO, V354, P109, DOI 10.1016/j.bbrc.2006.12.152
   Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384
   Masilamoni JG, 2006, BBA-MOL BASIS DIS, V1762, P284, DOI 10.1016/j.bbadis.2005.11.007
   McGreal RS, 2012, BBA-GEN SUBJECTS, V1820, P921, DOI 10.1016/j.bbagen.2012.04.004
   MEHLEN P, 1995, J IMMUNOL, V154, P363
   Mitra A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.114
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Moyano JV, 2006, J CLIN INVEST, V116, P261, DOI 10.1172/JCI25888
   Muraleva NA, 2014, CELL CYCLE, V13, P3499, DOI 10.4161/15384101.2014.958393
   Nahomi RB, 2013, J BIOL CHEM, V288, P13022, DOI 10.1074/jbc.M112.440214
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Noh SJ, 2008, INVEST OPHTH VIS SCI, V49, P4753, DOI 10.1167/iovs.08-2166
   Ousman SS, 2007, NATURE, V448, P474, DOI 10.1038/nature05935
   Pangratz-Fuehrer S, 2011, EYE, V25, P809, DOI 10.1038/eye.2011.42
   Park H, 2015, INT J CARDIOL, V182, P399, DOI 10.1016/j.ijcard.2014.12.152
   Pattison JS, 2011, AUTOPHAGY, V7, P1259, DOI 10.4161/auto.7.10.16882
   Pattison JS, 2011, CIRC RES, V109, P151, DOI 10.1161/CIRCRESAHA.110.237339
   Piras A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022514
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Rao NA, 2008, INVEST OPHTH VIS SCI, V49, P1161, DOI 10.1167/iovs.07-1259
   Rao NA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033582
   Reddy MK, 2008, APPL BIOCHEM BIOTECH, V151, P565, DOI 10.1007/s12010-008-8232-1
   Reddy VS, 2015, CURR MOL MED, V15, P47, DOI 10.2174/1566524015666150114112853
   Reddy VS, 2013, INVEST OPHTH VIS SCI, V54, P7674, DOI 10.1167/iovs.13-12715
   Robinson M.L., 2006, INVEST OPHTH VIS SCI, V37, P2276
   Rothbard JB, 2012, J BIOL CHEM, V287, P9708, DOI 10.1074/jbc.M111.337691
   Sharma KK, 2000, J BIOL CHEM, V275, P3767, DOI 10.1074/jbc.275.6.3767
   Sreekumar PG, 2013, INVEST OPHTH VIS SCI, V54, P2787, DOI 10.1167/iovs.12-11571
   Sreekumar PG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033420
   Sreekumar PG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012578
   Stanley AC, 2010, PHYSIOLOGY, V25, P218, DOI 10.1152/physiol.00017.2010
   Street JM, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-5
   Stuart MAC, 2010, NAT MATER, V9, P101, DOI [10.1038/NMAT2614, 10.1038/nmat2614]
   Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30
   Vaishya R, 2015, EXPERT OPIN DRUG DEL, V12, P415, DOI 10.1517/17425247.2015.961420
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   van den IJssel P, 2003, EXP CELL RES, V287, P249, DOI 10.1016/S0014-4827(03)00092-2
   van Rijk AF, 2003, EUR J CELL BIOL, V82, P361, DOI 10.1078/0171-9335-00321
   Velotta JB, 2011, ANN THORAC SURG, V91, P1907, DOI 10.1016/j.athoracsur.2011.02.072
   Wang A.L, 2009, PLOS ONE, V4, pe5304, DOI DOI 10.1371/JOURNAL.PONE.0004160
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang W, 2014, J CONTROL RELEASE, V191, P4, DOI 10.1016/j.jconrel.2014.04.028
   Whiston EA, 2008, INFECT IMMUN, V76, P1781, DOI 10.1128/IAI.01285-07
   Xi JH, 2003, MOL VIS, V9, P410
   Xiao H, 2012, ANAL CHIM ACTA, V723, P61, DOI 10.1016/j.aca.2012.02.018
   Xu F, 2013, MOL BIOL REP, V40, P2517, DOI 10.1007/s11033-012-2332-2
   Xu Q, 2015, INVEST OPHTH VIS SCI, V56, P816, DOI 10.1167/iovs.14-14734
   Yang YY, 2001, BIOMATERIALS, V22, P231, DOI 10.1016/S0142-9612(00)00178-2
   Yaung J, 2008, EXP EYE RES, V86, P355, DOI 10.1016/j.exer.2007.11.007
   Yaung J, 2007, MOL VIS, V13, P566
   Zhang JL, 2015, INT J MOL SCI, V16, P1644, DOI 10.3390/ijms16011644
   Zhang SX, 2014, EXP EYE RES, V125, P30, DOI 10.1016/j.exer.2014.04.015
   Zhong YM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038616
   Zhou H, 2006, KIDNEY INT, V70, P1847, DOI 10.1038/sj.ki.5001874
   Zhou H, 2008, KIDNEY INT, V74, P613, DOI 10.1038/ki.2008.206
   Zhou P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098275
   Zhu W, 2012, EXP EYE RES, V98, P44, DOI 10.1016/j.exer.2012.03.005
   Zigler JS, 2011, J CELL SCI, V124, P523, DOI 10.1242/jcs.078790
NR 102
TC 42
Z9 46
U1 0
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4165
EI 1872-8006
J9 BBA-GEN SUBJECTS
JI Biochim. Biophys. Acta-Gen. Subj.
PD JAN
PY 2016
VL 1860
IS 1
SI SI
BP 258
EP 268
DI 10.1016/j.bbagen.2015.05.016
PN B
PG 11
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CY6SF
UT WOS:000366538400013
PM 26026469
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Polito, A
   Napolitano, MC
   Bandello, F
   Chiodini, RG
AF Polito, Antonio
   Napolitano, M. C.
   Bandello, Francesco
   Gortana Chiodini, Raffaella
TI The role of optical coherence tomography (OCT) in the diagnosis and
   management of retinal angiomatous proliferation (RAP) in patients with
   age-related macular degeneration
SO ANNALS ACADEMY OF MEDICINE SINGAPORE
LA English
DT Review
DE choroidal neovascularisation; laser coagulation; retinal imaging
ID CHOROIDAL NEOVASCULARIZATION; ANASTOMOSES; DETACHMENTS
AB Introduction: The aim of this review was to describe the use of optical coherence tomography (OCT) in the diagnosis and management of retinal angiornatous proliferation (RAP) in patients with age-related macular degeneration (AMD). Materials and Methods: We reviewed the tomographic characteristics of the eyes affected by RAP seen at our institution and imaged by OCT. Some eyes with RAP were also studied with OCT prior to and after laser treatment to determine the tomographic changes following laser photocoagulation. Results: In this preliminary report, OCT showed a typical pattern of structural changes in RAP: increased foveal thickness, cystoid macular oedema (CME) consisting of large central cysts and smaller cystoid spaces located mainly in the outer retinal layers, serous retinal detachment and a highly reflective intraretinal mass overlying a highly or moderately elevated retinal pigment epithelium (RPE). This mass corresponded to the hot spot observed on ICG angiography. After successful laser photocoagulation, significant decrease in foveal thickness, complete resolution of CME and retinal detachment with thinning of the neurosensory retina overlying the treated area could be observed. Conclusions: OCT appears to be useful in evaluating and documenting RAP in AMD patients both before and after laser photocoagulation. Longitudinal studies are required to determine its exact place and utility in clinical practice.
C1 Univ Udine, Dept Ophthalmol, I-33100 Udine, Italy.
   IRCCS, Fdn GB Bietti Oftalmol, Rome, Italy.
C3 University of Udine; IRCCS - Fondazione "G.B. Bietti" per lo Studio e la
   Ricerca in Oftalmologia
RP Polito, A (通讯作者)，Univ Udine, Dept Ophthalmol, Ple S Maria della Misericordia, I-33100 Udine, Italy.
EM antonio_polito@hotmail.com
RI bandello, francesco/AAH-2405-2019
OI bandello, francesco/0000-0003-3238-9682
CR Brancato R, 2002, EUR J OPHTHALMOL, V12, P467, DOI 10.5301/EJO.2008.2283
   Fernandes LHS, 2002, RETINA-J RET VIT DIS, V22, P557, DOI 10.1097/00006982-200210000-00005
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Hee MR, 1998, OPHTHALMOLOGY, V105, P360, DOI 10.1016/S0161-6420(98)93601-6
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Jaffe GJ, 2004, AM J OPHTHALMOL, V137, P156, DOI 10.1016/S0002-9394(03)00792-X
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Sahni J, 2005, BRIT J OPHTHALMOL, V89, P316, DOI 10.1136/bjo.2004.043364
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 14
TC 20
Z9 20
U1 0
U2 3
PU ACAD MEDICINE SINGAPORE
PI REPUBLIC SINGAPORE
PA 142 NEIL RD, REPUBLIC SINGAPORE 088871, SINGAPORE
SN 0304-4602
J9 ANN ACAD MED SINGAP
JI Ann. Acad. Med. Singap.
PD JUN
PY 2006
VL 35
IS 6
BP 420
EP 424
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 074LR
UT WOS:000239814200009
PM 16865194
DA 2022-11-30
ER

PT J
AU Giannakaki-Zimmermann, H
   Querques, G
   Munch, IC
   Shroff, D
   Sarraf, D
   Chen, XJ
   Cunha-Souza, E
   Mrejen, S
   Capuano, V
   Rodrigues, MW
   Gupta, C
   Ebneter, A
   Zinkernagel, MS
   Munk, MR
AF Giannakaki-Zimmermann, Helena
   Querques, Giuseppe
   Munch, Inger Christine
   Shroff, Daraius
   Sarraf, David
   Chen, Xuejing
   Cunha-Souza, Eduardo
   Mrejen, Sarah
   Capuano, Vittorio
   Rodrigues, Murilo W.
   Gupta, Charu
   Ebneter, Andreas
   Zinkernagel, Martin S.
   Munk, Marion R.
TI Atypical retinal pigment epithelial defects with retained photoreceptor
   layers: a so far disregarded finding in age related macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE RPE tear; Geographic atrophy; Age-related macular degeneration;
   RPE-aperture; Photoreceptor
ID OPTICAL COHERENCE TOMOGRAPHY; GOOD VISUAL-ACUITY; ANTI-VEGF THERAPY;
   GEOGRAPHIC ATROPHY; FUNDUS AUTOFLUORESCENCE; TEARS; DETACHMENT;
   MECHANISM; REPAIR; EVOLUTION
AB Background: To report patients with age-related macular degeneration and atypical central retinal pigment epithelium (RPE) defects not attributable to geographic atrophy (GA) or RPE-tears with overlying preserved photoreceptor layers.
   Methods: Multimodal imaging case-series evaluating the course of atypical RPE-defects in patients with AMD using Color fundus images, Optical coherence tomography (OCT), OCT-Angiography, fundus autofluorescence (FAF) and fluorescein-angiography (FA).
   Results: Ten patients were identified. Three patients had a prior RPE-rip and were excluded. Seven patients with a mean follow-up period of 47 +/- 38 months after the occurrence of the RPE-defect were included (age range 71-87 years). Mean distance Best corrected visual acuity (BCVA) at initial presentation was 0.36 +/- 0.29logMAR and at last follow-up visit 0.51 +/- 0.43logMAR. Patients presented with clinically apparent GA on funduscopy and FAF, but preserved photoreceptor layers on optical coherence tomography (OCT). On FA there was early hyperfluorescence and late pooling visible. Over time, migration of RPE/drusenoid material right above the Bruch's membrane with concomitant decrease of hypoautofluorescence was detectable in 4 cases. An enlargement of the RPE-defect was apparent in the remaining 3 cases. The majority (n = 4) showed a drusenoid pigment epithelium detachment (PED) preceding the lesion.
   Conclusions: Beside GA and characteristic RPE-tears, another atypical form of RPE-defect with overlying preserved photoreceptor layers are found in AMD. This so far disregarded subgroup of patients present with reasonable visual function and long-term survival of photoreceptors layers. Repair mechanisms such as ingrowth of RPE/drusenoid material and persistent subretinal fluid (SRF), but also a RPE-independent visual cycle for cone photopigment within the neurosensory retina may contribute to their favorable course.
C1 [Giannakaki-Zimmermann, Helena; Ebneter, Andreas; Zinkernagel, Martin S.; Munk, Marion R.] Univ Bern, Bern Univ Hosp, Dept Ophthalmol, Inselspital, Bern, Switzerland.
   [Giannakaki-Zimmermann, Helena; Ebneter, Andreas; Zinkernagel, Martin S.; Munk, Marion R.] Univ Bern, Bern Univ Hosp, Dept Clin Res, Inselspital, Bern, Switzerland.
   [Giannakaki-Zimmermann, Helena; Zinkernagel, Martin S.; Munk, Marion R.] Univ Clin Bern, Bern Photog Reading Ctr, Inselspital, Bern, Switzerland.
   [Querques, Giuseppe; Capuano, Vittorio] Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Milan, Italy.
   [Querques, Giuseppe] Univ Paris Est, CHI, Dept Ophthalmol, Creteil, France.
   [Munch, Inger Christine] Univ Copenhagen, Zealand Univ Hosp, Dept Ophthalmol, Copenhagen, Denmark.
   [Shroff, Daraius; Gupta, Charu] Shroff Eye Ctr, New Delhi, India.
   [Sarraf, David; Chen, Xuejing] Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90024 USA.
   [Sarraf, David] Greater VA Healthcare Ctr, Los Angeles, CA USA.
   [Cunha-Souza, Eduardo; Rodrigues, Murilo W.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Cunha-Souza, Eduardo] Fac Med Ribeirao Preto, Ribeirao Preto, Brazil.
   [Mrejen, Sarah] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Munk, Marion R.] Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA.
C3 University of Bern; University Hospital of Bern; University of Bern;
   University Hospital of Bern; Vita-Salute San Raffaele University; IRCCS
   Ospedale San Raffaele; Universite Paris-Est-Creteil-Val-de-Marne (UPEC);
   CHI Creteil; University of Copenhagen; University of California System;
   University of California Los Angeles; Universidade de Sao Paulo;
   Vitreous Retina Macula Consultants of New York; Northwestern University;
   Feinberg School of Medicine
RP Munk, MR (通讯作者)，Univ Bern, Bern Univ Hosp, Dept Ophthalmol, Inselspital, Bern, Switzerland.; Munk, MR (通讯作者)，Univ Bern, Bern Univ Hosp, Dept Clin Res, Inselspital, Bern, Switzerland.; Munk, MR (通讯作者)，Univ Clin Bern, Bern Photog Reading Ctr, Inselspital, Bern, Switzerland.; Munk, MR (通讯作者)，Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA.
EM marion_munk@hotmail.com
RI Ebneter, Andreas/C-5226-2017; Rodrigues, Murilo/P-3222-2019; Junior,
   Murilo Wendeborn Rodrigues/M-4125-2019; Rodrigues, Murilo
   W/GRR-8095-2022
OI Ebneter, Andreas/0000-0001-6666-2558; Rodrigues,
   Murilo/0000-0001-9734-8617; Rodrigues, Murilo W/0000-0001-9734-8617;
   Querques, Giuseppe/0000-0002-3292-9581; Gupta,
   Charu/0000-0002-8908-4911; Zinkernagel, Martin S./0000-0003-3447-2359;
   chen, xuejing/0000-0001-6827-0152
CR Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   BRESSLER NM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1694, DOI 10.1001/archopht.1990.01070140048026
   Caramoy A, 2012, BRIT J OPHTHALMOL, V96, P1211, DOI 10.1136/bjophthalmol-2012-301750
   Chan CK, 2007, EUR J OPHTHALMOL, V17, P674, DOI 10.1177/112067210701700432
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   Clemens CR, 2016, OPHTHALMOLOGICA, V235, P1, DOI 10.1159/000439445
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   GOLDSTEIN BG, 1987, BRIT J OPHTHALMOL, V71, P676, DOI 10.1136/bjo.71.9.676
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   HERIOT WJ, 1992, GRAEF ARCH CLIN EXP, V230, P91, DOI 10.1007/BF00166769
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Kroyer K, 2008, ACTA OPHTHALMOL, V86, P338, DOI 10.1111/j.1600-0420.2007.00993.x
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1
   Mukai R, 2015, RETINA-J RET VIT DIS, V35, P473, DOI 10.1097/IAE.0000000000000337
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Pece A, 2010, OPHTHALMOLOGICA, V224, P159, DOI 10.1159/000236910
   Querques G, 2016, RETINA-J RET VIT DIS, V36, pS65, DOI 10.1097/IAE.0000000000001231
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   Sato Taku, 2014, Retin Cases Brief Rep, V8, P120, DOI 10.1097/ICB.0000000000000019
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Sinawat Suthasinee, 2014, Journal of the Medical Association of Thailand, V97, pS115
   Yoshitani S, 2003, OPHTHALMIC SUR LA IM, V34, P217, DOI 10.3928/1542-8877-20030501-12
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
NR 30
TC 7
Z9 7
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD MAY 15
PY 2017
VL 17
AR 67
DI 10.1186/s12886-017-0452-0
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EV3ND
UT WOS:000401665200001
PM 28506260
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Karacorlu, M
   Karacorlu, S
   Ozdemir, H
AF Karacorlu, M
   Karacorlu, S
   Ozdemir, H
TI Photodynamic therapy with delayed light application for the treatment of
   bilateral subfoveal choroidal neovascularization in age-related macular
   degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; bilateral choroidal
   neovascularization; photodynamic therapy; verteporfin
ID LIPOPROTEIN-DELIVERED BENZOPORPHYRIN; RANDOMIZED CLINICAL-TRIAL;
   VERTEPORFIN; LESIONS; PHASE-1; EYE
AB Purpose: To determine if photodynamic therapy (PDT) with delayed light application at 17 minutes after the start of infusion was effective in the second eyes of patients with bilateral subfoveal classic choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
   Methods: The records of 20 patients with bilateral subfoveal classic CNV secondary to AMD who were treated with bilateral PDT in the same session were reviewed. Treatment for the second eye of patients was begun 120 seconds after termination of treatment for the first eye. This time interval was necessary for applying the contact lens and entering the new laser parameters, and it was kept constant in all cases. Best-corrected visual acuity (BCVA), ophthalmologic examinations, fluorescein and indocyanine angiograms were used to evaluate the results of PDT. Follow-up time ranged from 6 to 12 months with a mean of 8.7 (+/-2.1) months.
   Results: Mean (+/-SD) treatment sessions were 1.7 (+/-0.6) in first eyes and 1.7 (+/-0.5) in second eyes. Among first eyes, BCVA improved in 7 of the 20 eyes (35%); stabilized in 7 eyes (35%); and worsened in 6 eyes (30%). Among second eyes, BCVA improved in 5 of the 20 eyes (25%); stabilized in 8 eyes (40%); and worsened in 7 eyes (35%).
   Conclusions: In most cases, bilateral PDT in the same session achieved cessation of fluorescein leakage from CNV without loss of vision or growth of CNV in the second eyes of patients with bilateral subfoveal classic CNV secondary to AMD. Further studies with I larger number of patients and longer follow-up are necessary to confirm whether bilateral PDT in the same session is beneficial for bilateral subfoveal classic CNV related to AMD. (C) 2003 Japanese Ophthalmological Society.
C1 Istanbul Retina Inst, TR-80200 Istanbul, Turkey.
C3 Istanbul Retina Enstitusu
RP Karacorlu, M (通讯作者)，Istanbul Retina Inst, Sinoplu Cemal S 1-6, TR-80200 Istanbul, Turkey.
RI Karaçorlu, Murat/AFK-0782-2022; Karaçorlu, Murat/AAF-7763-2022
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   Haimovici R, 1997, CURR EYE RES, V16, P83, DOI 10.1076/ceyr.16.2.83.5088
   Husain D, 1996, ARCH OPHTHALMOL-CHIC, V114, P978, DOI 10.1001/archopht.1996.01100140186012
   Hyman L, 1992, AGE RELATED MACULAR, P1
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Ochsner M, 1997, J PHOTOCH PHOTOBIO B, V39, P1, DOI 10.1016/S1011-1344(96)07428-3
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   Soubrane G, 2001, BRIT J OPHTHALMOL, V85, P483, DOI 10.1136/bjo.85.4.483
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD NOV-DEC
PY 2003
VL 47
IS 6
BP 595
EP 598
DI 10.1016/j.jjo.2003.08.010
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 748DG
UT WOS:000186846500013
PM 14636851
DA 2022-11-30
ER

PT J
AU Lushchyk, T
   Amarakoon, S
   Martinez-Ciriano, JP
   van den Born, LI
   Baarsma, GS
   Missotten, T
AF Lushchyk, Tanya
   Amarakoon, Sankha
   Martinez-Ciriano, Jose P.
   van den Born, L. Ingeborgh
   Baarsma, G. Seerp
   Missotten, Tom
TI Bevacizumab in age-related macular degeneration: a randomized controlled
   trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE anti-vascular endothelial growth factor; age-related macular
   degeneration; bevacizumab; treatment
ID INTRAVITREAL RANIBIZUMAB LUCENTIS; VERTEPORFIN PHOTODYNAMIC THERAPY;
   PHARMACOKINETICS; AVASTIN; CANCER
AB Purpose: Several clinical trials have established the efficacy of ranibizumab therapy administered every 4weeks to treat exudative age-related macular degeneration (ARMD). Bevacizumab appears to be a cost-effective alternative to ranibizumab, although an optimal injection schedule has not yet been determined. In this study, we set out to determine whether bevacizumab treatment in exudative ARMD every 6 or 8weeks is non-inferior to bevacizumab treatment every 4weeks. Methods: A total of 191 patients with exudative ARMD were randomly assigned to a 1-year continuous regimen of intravitreal bevacizumab every 4 (n=64), 6 (n=63) or 8weeks (n=64). The primary outcome was visual acuity change after 1year of treatment. Results: In all three treatment groups, visual acuity improved between baseline and 1year. There was no statistically significant difference in the mean change of visual acuity score at 1year for bevacizumab administered every 4 (1.96 +/- 13.70), 6 (1.60 +/- 10.98) or 8weeks (5.98 +/- 8.88). Reduction in central retinal thickness was observed in all three study groups. At 1year, the mean decrease in central foveal thickness ranged from 86 +/- 97m in the every 6 weeks group to 109 +/- 90m in the group every 8 weeks group (p=0.30). Conclusion: At 1year, bevacizumab administered every 6 or 8weeks was not inferior to therapy administered every 4weeks.
C1 [Lushchyk, Tanya; Amarakoon, Sankha; Martinez-Ciriano, Jose P.; van den Born, L. Ingeborgh; Baarsma, G. Seerp; Missotten, Tom] Rotterdam Eye Hosp, NL-3011 BH Rotterdam, Netherlands.
   [Lushchyk, Tanya] Rotterdam Ophthalm Inst, Rotterdam, Netherlands.
C3 Rotterdam Eye Hospital
RP Missotten, T (通讯作者)，Rotterdam Eye Hosp, Schiedamsevest 180, NL-3011 BH Rotterdam, Netherlands.
EM t.missotten@oogziekenhuis.nl
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bakri SJ, 2006, AM J OPHTHALMOL, V142, P162, DOI 10.1016/j.ajo.2006.03.058
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Cohen MH, 2007, ONCOLOGIST, V12, P713, DOI 10.1634/theoncologist.12-6-713
   Cohen MH, 2009, ONCOLOGIST, V14, P1131, DOI 10.1634/theoncologist.2009-0121
   Cohen MH, 2006, CANCER BIOL THER, V5, P1425
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Frennesson Christina, 2007, Lakartidningen, V104, P486
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nalluri SR, 2008, JAMA-J AM MED ASSOC, V300, P2277, DOI 10.1001/jama.2008.656
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
NR 22
TC 22
Z9 22
U1 0
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2013
VL 91
IS 6
BP e456
EP e461
DI 10.1111/aos.12119
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 202GG
UT WOS:000323201500007
PM 23773796
OA Bronze
DA 2022-11-30
ER

PT J
AU Cohen, SY
   Mimoun, G
   Oubraham, H
   Zourdani, A
   Malbrel, C
   Quere, S
   Schneider, V
AF Cohen, Salomon Y.
   Mimoun, Gerard
   Oubraham, Hassiba
   Zourdani, Alain
   Malbrel, Christian
   Quere, Stephane
   Schneider, Veronique
CA LUMIERE Study Grp
TI CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR
   DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL
   PRACTICE The LUMIERE Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE compliance; everyday clinical practice; ranibizumab; visual acuity; wet
   age-related macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; PHOTODYNAMIC THERAPY; ANGIOGENESIS;
   VERTEPORFIN; MACULOPATHY; TRIAL
AB Purpose: To survey compliance with recommended intravitreal ranibizumab treatment protocols in daily clinical practice in France, with reference to outcomes.
   Methods: A retrospective, descriptive, observational study in patients with subfoveal wet age-related macular degeneration treated with ranibizumab. All historical data for the study period, including demographic, treatment, and disease details and visual acuity measurements (baseline, Month 3, and Month 12), were recorded retrospectively at least 12 months after the beginning of treatment.
   Results: In 551 patients followed by 16 ophthalmologists, 12 months of intravitreal ranibizumab treatment induced a mean visual acuity gain of 3.2 +/- 14.8 Early Treatment Diabetic Retinopathy Study-equivalent letters. Fewer than 40% of patients received the recommended treatment of initial 3 monthly injections. More than 50% had to wait >8 days between diagnosis and treatment. At Month 3, visual acuity gain was greater in patients who had received recommended induction and in whom treatment was initiated quickly. At Month 12, the induction-related effect had largely disappeared but the time-to-treatment effect persisted. Patients had an average of 5.1 injections (2.6 during induction period). No patients were monitored monthly as stipulated in the guidelines.
   Conclusion: Although poor compliance with recommendations has been reflected in mediocre outcomes, there is evidence that practice is improving. RETINA 33:474-481, 2013
C1 [Cohen, Salomon Y.] Ctr Ophtalmol Imagerie & Laser, Paris, France.
   [Mimoun, Gerard] Ctr Imagerie Ecole Militaire, Paris, France.
   [Oubraham, Hassiba] Ctr Hosp, Dept Ophthalmol, Orleans, France.
   [Malbrel, Christian] Clin Courlancy, Reims, France.
   [Quere, Stephane; Schneider, Veronique] Novartis Pharma SAS, Rueil Malmaison, France.
C3 Centre Hospitalier Regional d'Orleans; Novartis
RP Schneider, V (通讯作者)，Novartis Labs, 2-4 Rue Lionel Terray,BP 308, F-92506 Rueil Malmaison, France.
EM veronique.schneider@novartis.com
FU Novartis Pharma SAS, France
FX Supported by Novartis Pharma SAS, France.
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   [Anonymous], 2000, OPHTHALMOLOGY, V107, P2314
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Ferrara N, 2001, ACTA HAEMATOL-BASEL, V106, P148, DOI 10.1159/000046610
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Goodsell DS, 2002, ONCOLOGIST, V7, P569, DOI 10.1634/theoncologist.7-6-569
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   Holmes K, 2007, CELL SIGNAL, V19, P2003, DOI 10.1016/j.cellsig.2007.05.013
   Holz FG, 2009, ASS RES VIS OPHTH AN
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   Lee PN, GOOD EPIDEMIOLOGICAL
   Mones J, 2011, OPHTHALMOLOGICA, V225, P112, DOI 10.1159/000319906
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Rouvas A, 2011, RETINA-J RET VIT DIS, V31, P871, DOI 10.1097/IAE.0b013e3182003ca8
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
NR 25
TC 142
Z9 144
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2013
VL 33
IS 3
BP 474
EP 481
DI 10.1097/IAE.0b013e31827b6324
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 097DW
UT WOS:000315455200003
PM 23266880
DA 2022-11-30
ER

PT J
AU Saito, M
   Iida, T
   Kano, M
AF Saito, Masaaki
   Iida, Tomohiro
   Kano, Mariko
TI INTRAVITREAL RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY WITH
   RECURRENT OR RESIDUAL EXUDATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; ranibizumab; vascular endothelial
   growth factor; photodynamic therapy; age-related macular degeneration;
   retinal pigment epithelial detachment; optical coherence tomography;
   retinal pigment epithelium; fluorescein angiography; indocyanine green
   angiography
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; PHOTODYNAMIC
   THERAPY; MACULAR DEGENERATION; NEOVASCULAR MEMBRANES; VERTEPORFIN;
   BEVACIZUMAB; EXPRESSION; EFFICACY; EYES
AB Purpose: To clarify the efficiency of ranibizumab for polypoidal choroidal vasculopathy in patients with regressed polypoidal lesions after previous photodynamic therapy (PDT) applications but recurrent or residual exudation from branching vascular network vessels.
   Methods: We retrospectively reviewed 59 eyes of 59 Japanese patients (47 men and 12 women) with polypoidal choroidal vasculopathy. Treatments were chosen according to the period. Thirty-four patients were treated with PDT (PDT group) and 25 patients were treated with intravitreal injections of ranibizumab (ranibizumab group).
   Results: In the ranibizumab group, the mean best-corrected visual acuity levels at baseline and 6 months were 0.27 and 0.41, respectively, showing a significant (P < 1x 10(-5)) improvement from baseline. In the PDT group, the mean best-corrected visual acuity levels at baseline and 6 months were 0.29 and 0.24, respectively, showing a significant (P < 0.01) decline from baseline. The mean numbers of treatments at 6 months in the ranibizumab and the PDT groups were 3.6 and 1.4, respectively. A subretinal hemorrhage (>1 disk diameter) developed in 5 eyes in the PDT group.
   Conclusion: Intravitreal ranibizumab is an effective treatment for maintaining or improving visual acuity and the anatomical changes in patients with polypoidal choroidal vasculopathy with recurrent or residual exudation from branching vascular network vessels. RETINA 31:1589-1597, 2011
C1 [Saito, Masaaki; Iida, Tomohiro; Kano, Mariko] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima 9601295, Japan.
C3 Fukushima Medical University
RP Saito, M (通讯作者)，Fukushima Med Univ, Sch Med, Dept Ophthalmol, 1 Hikarigaoka, Fukushima 9601295, Japan.
EM smasaaki@fmu.ac.jp
RI Saito, Masaaki/ABI-2783-2020
OI Saito, Masaaki/0000-0003-1494-6350
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Ishikawa K, 2007, INVEST OPHTH VIS SCI, V48, P2254, DOI 10.1167/iovs.06-1277
   Klein KS, 2009, OPHTHALMOLOGY, V116, P1225, DOI 10.1016/j.ophtha.2009.02.031
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   MARUKO I, AM J OPHTHALMOL
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2008, GRAEF ARCH CLIN EXP, V246, P315, DOI 10.1007/s00417-007-0669-3
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Saito Masaaki, 2009, Nippon Ganka Gakkai Zasshi, V113, P792
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Tano Yasuo, 2009, Nippon Ganka Gakkai Zasshi, V113, P1098
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 38
TC 27
Z9 34
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2011
VL 31
IS 8
BP 1589
EP 1597
DI 10.1097/IAE.0b013e31820f4b21
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 814LS
UT WOS:000294456100018
PM 21654347
DA 2022-11-30
ER

PT J
AU Raman, R
   Biswas, S
   Gupta, A
   Kulothungan, V
   Sharma, T
AF Raman, R.
   Biswas, S.
   Gupta, A.
   Kulothungan, V.
   Sharma, T.
TI Association of macular pigment optical density with risk factors for wet
   age-related macular degeneration in the Indian population
SO EYE
LA English
DT Article
DE macular pigment optical density; age-related macular degeneration;
   ultraviolet index; smoking; obesity; dietary carotenoids
ID SPATIAL-DISTRIBUTION; SERUM CONCENTRATIONS; EYE DISEASE; CAROTENOIDS;
   MACULOPATHY; LUTEIN; ZEAXANTHIN; ANCILLARY; SUNLIGHT; SMOKING
AB Purpose To investigate macular pigment optical density (MPOD) in patients with and without wet age-related macular degeneration (AMD) and to elucidate the association between MPOD and the risk factors for AMD in an Indian population.
   Methods Thirty-three subjects with wet AMD and 29 controls above 50 years old underwent MPOD measurement with the 'Macular Densitometer'. The subjects were also tested for their smoking history, lifetime ultraviolet (UV) exposure, dietary intake of carotenoids, and body mass index (BMI).
   Results Smokers had a higher risk for AMD than the non-smokers (P = 0.032) and a lower MPOD level than non-smokers (mean (95% CI)) (0.16 (0.09-0.23) vs 0.28 (0.22-0.34), adjusted P = 0.026). Subjects with lowest UV exposure had higher MPOD than those with the highest (0.46 (0.38-0.54) vs 0.17 (0.01-0.33), P = 0.01). MPOD was significantly lower among those with the lowest quartile of dietary intake of carotenoids (0.14 (0.08-0.21) vs 0.25 (0.13-0.36), P = 0.012). Smoking, obesity, and UV index showed an inverse association with the MPOD. Low MPOD, smoking, and UV exposure had 5.11 (1.73-15.08), 3.54 (1.08-11.57), and 5.24 (1.06-25.96) odds for AMD, respectively, whereas higher dietary intake of carotenoids showed a protective effect for AMD.
   Conclusion We found an inverse association between wet AMD and MPOD. Among the established risk factors of wet AMD, we found an inverse association of smoking, UV index, and obesity with MPOD, whereas a positive association was found between dietary intake of carotenoids and MPOD. Eye (2012) 26, 950-957; doi:10.1038/eye.2012.69; published online 4 May 2012
C1 [Raman, R.; Gupta, A.; Sharma, T.] Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, Madras 600006, Tamil Nadu, India.
   [Biswas, S.] Elite Sch Optometry, Madras, Tamil Nadu, India.
   [Kulothungan, V.] Dept Prevent Ophthalmol Epidemiol & Biostat, Madras, Tamil Nadu, India.
RP Raman, R (通讯作者)，Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, 18 Coll Rd, Madras 600006, Tamil Nadu, India.
EM rajivpgraman@gmail.com
RI Biswas, Sayantan/AAQ-6183-2021; Biswas, Sayantan/AAR-8256-2021; Raman,
   Rajiv/A-7234-2009
OI Biswas, Sayantan/0000-0001-6011-0365; Biswas,
   Sayantan/0000-0001-6011-0365; Raman, Rajiv/0000-0001-5842-0233
CR Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TT, 2005, EXP EYE RES, V81, P602, DOI 10.1016/j.exer.2005.03.019
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Bone RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-12
   Bressler NM, J AM BOARD FAM PRACT, V15, P142
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Chang Y, 2002, MED PHYS, V29, P2621, DOI 10.1118/1.1515761
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Cuthbertson FM, 2009, J CATARACT REFR SURG, V35, P1281, DOI 10.1016/j.jcrs.2009.04.017
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hebert JR, 1998, PUBLIC HEALTH NUTR, V1, P123, DOI 10.1079/PHN19980019
   Jahn C, 2005, GRAEF ARCH CLIN EXP, V243, P222, DOI 10.1007/s00417-004-0995-7
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Leffondre K, 2002, AM J EPIDEMIOL, V156, P813, DOI 10.1093/aje/kwf122
   Mainster MA, 2010, OPHTHALMOLOGY, V117, P197, DOI 10.1016/j.ophtha.2009.11.046
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   McCarty CA, 1996, B WORLD HEALTH ORGAN, V74, P353
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   Nolan JM, 2007, INVEST OPHTH VIS SCI, V48, P571, DOI 10.1167/iovs.06-0864
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Obana A, 2008, OPHTHALMOLOGY, V115, P147, DOI 10.1016/j.ophtha.2007.02.028
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Wooten BR, 2005, OPTOMETRY VISION SCI, V82, P378, DOI 10.1097/01.OPX.0000162654.32112.A1
NR 33
TC 14
Z9 14
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2012
VL 26
IS 7
BP 950
EP 957
DI 10.1038/eye.2012.69
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 973LE
UT WOS:000306360800008
PM 22562185
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Tamura, H
   Goto, R
   Akune, Y
   Hiratsuka, Y
   Hiragi, S
   Yamada, M
AF Tamura, Hiroshi
   Goto, Rei
   Akune, Yoko
   Hiratsuka, Yoshimune
   Hiragi, Shusuke
   Yamada, Masakazu
TI The Clinical Effectiveness and Cost-Effectiveness of Screening for
   Age-Related Macular Degeneration in Japan: A Markov Modeling Study
SO PLOS ONE
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; VISUAL IMPAIRMENT; UTILITY
   ANALYSIS; PHOTODYNAMIC THERAPY; CATARACT-SURGERY; EYE DISEASE; FELLOW
   EYES; RANIBIZUMAB; PREVALENCE; POPULATION
AB Objective
   To investigate the cost-effectiveness of screening and subsequent intervention for age-related macular degeneration (AMD) in Japan.
   Methods
   The clinical effectiveness and cost-effectiveness of screening and subsequent intervention for AMD were assessed using a Markov model. The Markov model simulation began at the age of 40 years and concluded at the age of 90 years. The first-eye and second-eye combined model assumed an annual state-transition probability, development of prodromal symptoms, choroidal neovascularization (CNV), and reduction in visual acuity. Anti-vascular-endothelial-growth-factor (anti-VEGF) intravitreal injection therapy and photodynamic therapy (PDT) were performed to treat CNV. Intake of supplements was recommended to patients who had prodromal symptoms and unilateral AMD. Data on prevalence, morbidity, transition probability, utility value of each AMD patient, and treatment costs were obtained from published clinical reports.
   Results
   In the base-case analysis, screening for AMD every 5 years, beginning at the age of 50 years, showed a decrease of 41% in the total number of blind patients. The screening program reduced the incidence of blindness more than did the additional intake of supplements. However, the incremental cost-effectiveness ratio (ICER) of screening versus no screening was 27,486,352 Japanese yen (JPY), or 259,942 US dollars (USD) per quality-adjusted life year (QALY). In the sensitivity analysis, prodromal symptom-related factors for AMD had great impacts on the cost-effectiveness of screening. The lowest ICER obtained from the best scenario was 4,913,717 JPY (46,470 USD) per QALY, which was approximately equal to the willingness to pay in Japan.
   Conclusions
   Ophthalmologic screening for AMD in adults is highly effective in reducing the number of patients with blindness but not cost-effective as demonstrated by a Markov model based on clinical data from Japan.
C1 [Tamura, Hiroshi; Hiragi, Shusuke] Kyoto Univ Hosp, Div Med Informat Technol & Adm Planning, Sakyo Ku, Kyoto 6068507, Japan.
   [Tamura, Hiroshi] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
   [Goto, Rei] Kyoto Univ, Hakubi Ctr Adv Res, Sakyo Ku, Kyoto 6068501, Japan.
   [Goto, Rei] Kyoto Univ, Grad Sch Econ, Sakyo Ku, Kyoto 6068501, Japan.
   [Akune, Yoko] Natl Hosp Org, Tokyo Med Ctr, Natl Inst Sensory Organs, Tokyo, Japan.
   [Hiratsuka, Yoshimune] Natl Inst Publ Hlth, Dept Hlth & Welf Serv, Wako, Saitama 3510197, Japan.
   [Yamada, Masakazu] Kyorin Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
C3 Kyoto University; Kyoto University; Kyoto University; Kyoto University;
   National Institute of Public Health - Japan; Kyorin University
RP Tamura, H (通讯作者)，Kyoto Univ Hosp, Div Med Informat Technol & Adm Planning, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
EM htamura@kuhp.kyoto-u.ac.jp
RI Hiragi, Shusuke/AAF-4310-2019; TAMURA, Hiroshi/H-1855-2011; HIRAGI,
   Shusuke/GYA-3171-2022
OI Hiragi, Shusuke/0000-0003-1629-6195; TAMURA,
   Hiroshi/0000-0002-7740-2732; 
FU Japan Society for the Promotion of Science, Tokyo, Japan [24592626];
   Japan Ophthalmologists Association, Tokyo, Japan; Japan National Society
   for the Prevention of Blindness, Tokyo, Japan
FX This study was supported in part by grants-in-aid for scientific
   research (Nos. 24592626) from the Japan Society for the Promotion of
   Science, Tokyo, Japan, http://www.jsps.go.jp/j-grantsinaid/index.html;
   the Japan Ophthalmologists Association, Tokyo, Japan,
   http://www.gankaikai.or.jp/; and the Japan National Society for the
   Prevention of Blindness, Tokyo, Japan,
   http://www.business1.jp/jnspb/pc/index.html. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bonds DE, 2014, JAMA INTERN MED, V174, P763, DOI 10.1001/jamainternmed.2014.328
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Cheung CSY, 2012, OPHTHALMOLOGY, V119, P1609, DOI 10.1016/j.ophtha.2012.02.014
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cohen SY, 2008, GRAEF ARCH CLIN EXP, V246, P1527, DOI 10.1007/s00417-008-0890-8
   Fletcher EC, 2008, OPHTHALMOLOGY, V115, P2192, DOI 10.1016/j.ophtha.2008.07.018
   Hiratsuka Y, 2014, JPN J OPHTHALMOL, V58, P415, DOI 10.1007/s10384-014-0335-3
   Hiratsuka Y, 2013, JPN J OPHTHALMOL, V57, P391, DOI 10.1007/s10384-013-0238-8
   Hirneiss C, 2014, CLIN OPHTHALMOL, V8, P1703, DOI 10.2147/OPTH.S64200
   Holden BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1731, DOI 10.1001/archopht.126.12.1731
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hurley Susan F, 2008, Cost Eff Resour Alloc, V6, P12, DOI 10.1186/1478-7547-6-12
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Japan Ophthalmologists Association, 2009, SOC BURD VIS DIST JA
   Hernandez-Pastor LJ, 2010, GRAEF ARCH CLIN EXP, V248, P467, DOI 10.1007/s00417-009-1156-9
   Hernandez-Pastor LJ, 2008, CLIN THER, V30, P2436, DOI 10.1016/j.clinthera.2008.12.025
   Johannesson M, 1997, NEW ENGL J MED, V336, P332, DOI 10.1056/NEJM199701303360503
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kawasaki R, 2015, OPHTHAL EPIDEMIOL, V22, P4, DOI 10.3109/09286586.2014.988876
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Nakae K MK, 2006, GERIATR MED, V44, P1221
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Neubauer AS, 2010, CLIN THER, V32, P1343, DOI 10.1016/j.clinthera.2010.07.010
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pineles SL, 2011, AM J OPHTHALMOL, V152, P133, DOI 10.1016/j.ajo.2011.01.023
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Shiroiwa T, 2010, HEALTH ECON, V19, P422, DOI 10.1002/hec.1481
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Takahashi Kanji, 2012, Nippon Ganka Gakkai Zasshi, V116, P1150
   Tamura H, 2012, AM J OPHTHALMOL, V154, P542, DOI 10.1016/j.ajo.2012.03.042
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   Wako Rina, 2014, Nippon Ganka Gakkai Zasshi, V118, P495
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Weinstein M C, 2001, Value Health, V4, P348, DOI 10.1046/j.1524-4733.2001.45061.x
   Yanagi Yasuo, 2011, Nippon Ganka Gakkai Zasshi, V115, P825
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 62
TC 24
Z9 24
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 27
PY 2015
VL 10
IS 7
AR e0133628
DI 10.1371/journal.pone.0133628
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CN7DN
UT WOS:000358594300025
PM 26214804
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Calvo, P
   Ferreras, A
   Al Adel, F
   Wang, Y
   Brent, MH
AF Calvo, Pilar
   Ferreras, Antonio
   Al Adel, Fadwa
   Wang, Yao
   Brent, Michael H.
TI Dexamethasone intravitreal implant as adjunct therapy for patients with
   wet age-related macular degeneration with incomplete response to
   ranibizumab
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; TRIAMCINOLONE ACETONIDE; PHOTODYNAMIC
   THERAPY; VERTEPORFIN PDT; TACHYPHYLAXIS; COMBINATION; INJECTION
AB Purpose To evaluate the visual and anatomical outcomes of dexamethasone intravitreal implant (DXI; 700 mu g, Ozurdex; Allergan, Irvine, California, USA) as adjunctive therapy for patients with refractory wet age-related macular degeneration (AMD).
   Methods Retrospective review of the medical records of seven patients (seven eyes) who initially responded well to intravitreal ranibizumab but subsequently developed persistent intra/sub-retinal fluid (IRF/SRF) and underwent a single injection of DXI, between May 2012 and May 2013. Two weeks after DXI, the patients continued with their monthly ranibizumab injections. Best corrected visual acuity (BCVA) logarithm of the minimum angle of resolution (logMAR) and central retinal thickness (CRT) were recorded at baseline, 2 weeks, 6 weeks, 3 months and 6 months after DXI injection. Complications were recorded too.
   Results All patients had at least 24 months of ranibizumab treatment. Mean age was 81.5 +/- 5.8 years. At baseline, mean BCVA was 0.53 +/- 0.13 logMAR (20/70 Snellen) and mean CRT was 273.14 +/- 50.94 mu m. BCVA did not change significantly after DXI over the follow-up period. However, all eyes had lost fewer than 0.3 logMAR units. Complete resolution of the persistent IRF/SRF was achieved in five eyes (71.4%) at 6 weeks, and remained stable at 3 months. Two weeks after DXI injection, the mean CRT diminished compared with baseline (248.28 +/- 31.8 mm; p= 0.03) and the greatest reduction was observed at 3 months after DXI injection (241.5 +/- 36.6 mm; p= 0.04). Progression of lens opacity was detected in one case (50% of phakic eyes). Retreatment with DXI was performed in two eyes.
   Conclusions DXI appears to be effective in vision stabilisation, decreasing IRF/SRF and improvement of CRT in eyes with refractory wet AMD.
C1 [Calvo, Pilar; Ferreras, Antonio] Miguel Servet Univ Hosp, Dept Ophthalmol, Zaragoza, Spain.
   [Calvo, Pilar; Ferreras, Antonio] Univ Zaragoza, Zaragoza, Spain.
   [Al Adel, Fadwa; Brent, Michael H.] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
   [Wang, Yao; Brent, Michael H.] Univ Toronto, Fac Med, Toronto, ON, Canada.
C3 Miguel Servet University Hospital; University of Zaragoza; University of
   Toronto; University of Toronto
RP Brent, MH (通讯作者)，Toronto Western Hosp, Dept Ophthalmol, UHN, 6E-423 399 Bathurst St, Toronto, ON M5T 2S8, Canada.
EM mh.brent@utoronto.ca
RI Ferreras, Antonio/AAF-4220-2020
OI Ferreras, Antonio/0000-0002-2914-2593
FU Milton Harris Professorship in Adult Macular Degeneration
FX This study was supported in part by the Milton Harris Professorship in
   Adult Macular Degeneration.
CR Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Conti SM, 2006, CURR OPIN OPHTHALMOL, V17, P235, DOI 10.1097/01.icu.0000193107.00089.ee
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Gallego-Pinazo R., 2010, Arch Soc Esp Oftalmol, V85, P79
   Gopal Lekha, 2007, Indian Journal of Ophthalmology, V55, P431
   Haller JA, 2010, OPHTHALMOLOGY, V117, P1134, DOI 10.1016/j.ophtha.2010.03.032
   Jonas JB, 2006, OPHTHALMIC RES, V38, P218, DOI 10.1159/000093796
   Kim IK, 2006, INVEST OPHTH VIS SCI, V47, P357, DOI 10.1167/iovs.04-0087
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Oliver Alejandro, 2006, Ophthalmol Clin North Am, V19, P345
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Ranchod TM, 2013, RETINA-J RET VIT DIS, V33, P1600, DOI 10.1097/IAE.0b013e318285cb71
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
NR 16
TC 31
Z9 31
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2015
VL 99
IS 6
BP 723
EP 726
DI 10.1136/bjophthalmol-2014-305684
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CI7NO
UT WOS:000354950600002
PM 25425713
DA 2022-11-30
ER

PT J
AU Freeman, WR
   Kozak, I
   Yuson, RMS
   Nigam, N
   Cheng, LY
   Mojana, F
AF Freeman, William R.
   Kozak, Igor
   Yuson, Ritchie Martin S.
   Nigam, Nitin
   Cheng, Lingyun
   Mojana, Francesca
TI PROGNOSTIC IMPLICATIONS OF PIGMENT EPITHELIAL DETACHMENT IN BEVACIZUMAB
   (AVASTIN)-TREATED EYES WITH AGE-RELATED MACULAR DEGENERATION AND
   CHOROIDAL NEOVASCULARIZATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE pigment epithelial detachment; age-related macular degeneration;
   bevacizumab (Avastin); intravitreal
ID INTRAVITREAL BEVACIZUMAB; PHOTODYNAMIC THERAPY; AVASTIN THERAPY;
   PHOTOCOAGULATION; PREVALENCE; SECONDARY
AB Purpose: To evaluate the response to primary bevacizumab treatment of eyes with age-related macular degeneration (AMD) and choroidal neovascularization (CNV) with a large pigment epithelial detachment (PED) component and to compare the increase in visual acuity and reabsorption of retinal fluid in PED eyes with eyes with CNV in AMD with a minimal to no PED component.
   Methods: We reviewed 43 consecutive eyes with CNV and AMD on primary bevacizumab therapy. There were 13 eyes with a large PED component in AMD with CNV and 30 eyes with a minimal to no PED in CNV. Only patients with no previous treatment for AMD and those started on purely intravitreal bevacizumab treatment were taken in the study. Pigment epithelial detachment size, time to PED collapse, and retinal or subretinal fluid resolution were determined as was Early Treatment Diabetic Retinopathy Study vision. Time to resolution of intraretinal and subretinal fluid was compared between the PED group and the non-PED group using survival analysis.
   Results: In AMD with CNV eyes having a large PED component, sub-and intraretinal fluid initially resolved faster than the sub-PED fluid (P = 0.03). The subretinal pigment epithelial fluid itself was highly resistant. Visual acuity improvement was similar in both groups.
   Conclusion: Despite monthly intravitreal bevacizumab injections for neovascular AMD patients with a large component PED, the majority had minimal to no response of the PED. Sub-and intraretinal fluid response was faster in neovascular AMD without large PEDs, but after 7 months, vision change and reabsorption of intra-and subretinal fluid were similar in the two groups. Sub-and intraretinal fluid response did not appear to be related to PED size. Bevacizumab was very effective in reducing more of the sub-and intraretinal fluid than the PED fluid in AMD with CNV. RETINA 31: 1812-1818, 2011
C1 [Freeman, William R.; Kozak, Igor; Yuson, Ritchie Martin S.; Nigam, Nitin; Cheng, Lingyun; Mojana, Francesca] Univ Calif San Diego, Shiley Eye Ctr, Dept Ophthalmol, Jacobs Retina Ctr, La Jolla, CA 92037 USA.
C3 University of California System; University of California San Diego
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Shiley Eye Ctr, Dept Ophthalmol, Jacobs Retina Ctr, 9415 Campus Point Dr, La Jolla, CA 92037 USA.
EM freeman@eyecenter.ucsd.edu
RI Kozak, Igor/AAC-4645-2019
FU National Institutes of Health [EY07366]; WRF; FFB Inc, Bethesda, MD;
   Jacobs Retina Center; NATIONAL EYE INSTITUTE [R01EY007366] Funding
   Source: NIH RePORTER
FX Supported by the National Institutes of Health grant EY07366, WRF and
   FFB Inc, Bethesda, MD, and unrestricted funds from the Jacobs Retina
   Center.
CR Ablonczy Z, 2007, EXP EYE RES, V85, P762, DOI 10.1016/j.exer.2007.08.010
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   BARONDES MJ, 1992, BRIT J OPHTHALMOL, V76, P5, DOI 10.1136/bjo.76.1.5
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bolz M, 2007, BRIT J OPHTHALMOL, V91, P785, DOI 10.1136/bjo.2006.102467
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   EMERSON VM, 2007, RETINA, V27, P439
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gross-Jendroska M, 1998, AUST NZ J OPHTHALMOL, V26, P311, DOI 10.1111/j.1442-9071.1998.tb01335.x
   Hedaya J, 2008, RETINA-J RET VIT DIS, V28, P911, DOI 10.1097/IAE.0b013e3181733746
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Ladas ID, 2007, RETINA-J RET VIT DIS, V27, P891, DOI 10.1097/IAE.0b013e3180ca9ad9
   Leung CKS, 2008, INVEST OPHTH VIS SCI, V49, P4893, DOI 10.1167/iovs.07-1326
   Lim JI, 1997, AM J OPHTHALMOL, V123, P524, DOI 10.1016/S0002-9394(14)70178-3
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Nicolo M, 2005, EUR J OPHTHALMOL, V15, P415, DOI 10.1177/112067210501500318
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 23
TC 25
Z9 26
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2011
VL 31
IS 9
BP 1812
EP 1818
DI 10.1097/IAE.0b013e31821987a4
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 825YR
UT WOS:000295318800011
PM 21866073
DA 2022-11-30
ER

PT J
AU Vessey, KA
   Gu, BJ
   Jobling, AI
   Phipps, JA
   Greferath, U
   Tran, MX
   Dixon, MA
   Baird, PN
   Guymer, RH
   Wiley, JS
   Fletcher, EL
AF Vessey, Kirstan A.
   Gu, Ben J.
   Jobling, Andrew I.
   Phipps, Joanna A.
   Greferath, Ursula
   Tran, Mai X.
   Dixon, Michael. A.
   Baird, Paul N.
   Guymer, Robyn H.
   Wiley, James S.
   Fletcher, Erica L.
TI Loss of Function of P2X7 Receptor Scavenger Activity in Aging Mice A
   Novel Model for Investigating the Early Pathogenesis of Age-Related
   Macular Degeneration
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; MOUSE MODEL; EXTRACELLULAR ATP;
   DARK-ADAPTATION; BRUCHS MEMBRANE; FUNDUS AUTOFLUORESCENCE; P2X(7)
   RECEPTOR; PORE FORMATION; KNOCKOUT MICE; IN-VIVO
AB Age-related macular degeneration (AMD) is a leading cause of irreversible, severe vision toss in Western countries. Recently, we identified a novel pathway involving P2X7 receptor scavenger function expressed on ocular immune cells as a risk factor for advanced AMD. In this study, we investigate the effect of loss of P2X7 receptor function on retinal structure and function during aging. P2X7-null and wild-type C57bl6j mice were investigated at 4, 12, and 18 months of age for macrophage phagocytosis activity, ocular histological changes, and retinal. function. Phagocytosis activity of blood-borne macrophages decreased with age at 18 months in the wild-type mouse. Lack of P2X7 receptor function reduced phagocytosis at all ages compared to wild-type mice. At 12 months of age, P2X7-null mice had thickening of Bruchs membrane and retinal pigment epithelium dysfunction. By 18 months of age, P2X7-null mice displayed phenotypic characteristics consistent with early AMD, including Bruchs membrane thickening, retinal pigment epithelium cell loss, retinal functional deficits, and signs of subretinal inflammation. Our present study shows that loss of function of the P2X7 receptor in mice induces retinal changes representing characteristics of early AMD, providing a valuable model for investigating the role of scavenger receptor function and the immune system in the development of this age-related disease.
C1 [Vessey, Kirstan A.; Jobling, Andrew I.; Phipps, Joanna A.; Greferath, Ursula; Tran, Mai X.; Dixon, Michael. A.; Fletcher, Erica L.] Univ Melbourne, Dept Anat & Neurosci, Melbourne, Vic, Australia.
   [Baird, Paul N.; Guymer, Robyn H.] Univ Melbourne, Div Ophthalmol, Melbourne, Vic, Australia.
   [Baird, Paul N.; Guymer, Robyn H.] Univ Melbourne, Dept Surg, Melbourne, Vic, Australia.
   [Gu, Ben J.] Florey Inst Neurosci, Melbourne, Vic, Australia.
   [Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 University of Melbourne; University of Melbourne; University of
   Melbourne; Centre for Eye Research Australia; Royal Victorian Eye & Ear
   Hospital
RP Fletcher, EL (通讯作者)，Univ Melbourne, Dept Anat & Neurosci, Melbourne, Vic, Australia.
EM elf@unimelb.edu.au
RI ; Jobling, Andrew/C-8221-2015; Fletcher, Erica/E-6364-2012
OI Gu, Ben/0000-0001-5500-4453; Baird, Paul/0000-0002-1305-3502; Guymer,
   Robyn/0000-0002-9441-4356; Vessey, Kirstan/0000-0003-1031-1964; Dixon,
   Michael/0000-0003-2015-3656; Jobling, Andrew/0000-0002-7827-3135;
   Fletcher, Erica/0000-0001-9412-9523; Wiley, James/0000-0001-9421-4154
FU National Health and Medical Research Council (NHMRC) P2X7-grants
   [APP1061419, APP1120095]; Macular Disease Foundation of Australia; NHMRC
   Senior Research Fellowship [1028444]; NHMRC Principal Research
   Fellowship [1103013]
FX Supported by National Health and Medical Research Council (NHMRC)
   P2X7-grants APP1061419 (E.L.F., K.A.V., BIG., and R.H.G.) and APP1120095
   (R.H.G, E.L.F. B.J.G, and K.A.V); the Macular Disease Foundation of
   Australia, 2013 (ELF., K.A.V., B.J.G., R.H.G., and P.N.B.); NHMRC Senior
   Research Fellowship number 1028444 (P.N.B.); and NHMRC Principal
   Research Fellowship number 1103013 (R.H.G.). The Center for Eye Research
   Australia receives operational infrastructure support from the Victorian
   government.
CR Aplin FP, 2014, INVEST OPHTH VIS SCI, V55, P8319, DOI 10.1167/iovs.14-15732
   Aprahamian T, 2008, CLIN EXP IMMUNOL, V152, P448, DOI 10.1111/j.1365-2249.2008.03658.x
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   DELAFUENTE M, 1985, COMP BIOCHEM PHYS A, V81, P935, DOI 10.1016/0300-9629(85)90933-8
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   FEENEY L, 1973, INVEST OPHTH VISUAL, V12, P635
   Fernandez-Godino R, 2016, NAT PROTOC, V11, P1206, DOI 10.1038/nprot.2016.065
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Gu BJ, 2006, BLOOD, V107, P4946, DOI 10.1182/blood-2005-07-2994
   Gu BJ, 2013, FASEB J, V27, P1479, DOI 10.1096/fj.12-215368
   Gu BJ, 2010, BLOOD, V115, P1621, DOI 10.1182/blood-2009-11-251744
   Gu BJ, 2009, AM J PHYSIOL-CELL PH, V297, pC430, DOI 10.1152/ajpcell.00079.2009
   Guha S, 2013, FASEB J, V27, P4500, DOI 10.1096/fj.13-236166
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Ho T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029892
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   HOGAN MJ, 1967, ARCH OPHTHALMOL-CHIC, V77, P410, DOI 10.1001/archopht.1967.00980020412022
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Huang H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173716
   Issa PC, 2013, INVEST OPHTH VIS SCI, V54, P5602, DOI 10.1167/iovs.13-11688
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Jobling AI, 2013, INVEST OPHTH VIS SCI, V54, P3350, DOI 10.1167/iovs.13-11831
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   KLIFFEN M, 1995, LAB INVEST, V73, P267
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Linehan E, 2015, EUR J MICROBIOL IMMU, V5, P14, DOI [10.1556/EuJMI-D-14-00035, 10.1556/EUJMI-D-14-00035]
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Lyubarsky AL, 2000, J NEUROSCI, V20, P2209
   Lyzogubov VV, 2016, AM J PATHOL, V186, P2088, DOI 10.1016/j.ajpath.2016.03.021
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109
   Ng TF, 2001, INVEST OPHTH VIS SCI, V42, P3301
   Olivier E, 2016, BIOCHIMIE, V127, P70, DOI 10.1016/j.biochi.2016.04.014
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Raoul W, 2008, OPHTHAL RES, V40, P115, DOI 10.1159/000119860
   Reale E, 2009, CELLS TISSUES ORGANS, V190, P170, DOI 10.1159/000187632
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Smart ML, 2003, J BIOL CHEM, V278, P8853, DOI 10.1074/jbc.M211094200
   Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200
   Sparrow JR, 2013, INVEST OPHTH VIS SCI, V54, P2812, DOI 10.1167/iovs.12-11490
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Vessey KA, 2011, J COMP NEUROL, V519, P506, DOI 10.1002/cne.22530
   Vessey KA, 2015, INVEST OPHTH VIS SCI, V56, P1238, DOI 10.1167/iovs.14-15334
   Vessey KA, 2012, INVEST OPHTH VIS SCI, V53, P7833, DOI 10.1167/iovs.12-10650
   Vessey KA, 2012, PLOS ONE, V7, P290, DOI 10.1371/journal.pone.0029990
   Weber BHF, 2002, INVEST OPHTH VIS SCI, V43, P2732
   Weymouth AE, 2008, PROG RETIN EYE RES, V27, P1, DOI 10.1016/j.preteyeres.2007.09.003
   Wiley JS, 2011, TISSUE ANTIGENS, V78, P321, DOI 10.1111/j.1399-0039.2011.01780.x
   Wiley JS, 2012, PURINERG SIGNAL, V8, P579, DOI 10.1007/s11302-012-9308-5
   Worthington RA, 2002, FEBS LETT, V512, P43, DOI 10.1016/S0014-5793(01)03311-7
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Yang DL, 2011, INVEST OPHTH VIS SCI, V52, P1522, DOI 10.1167/iovs.10-6172
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 73
TC 25
Z9 27
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD AUG
PY 2017
VL 187
IS 8
BP 1670
EP 1685
DI 10.1016/j.ajpath.2017.04.016
PG 16
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA FB3ZC
UT WOS:000406080300003
PM 28628761
OA Bronze
DA 2022-11-30
ER

PT J
AU Lim, JH
   Wickremasinghe, SS
   Xie, J
   Chauhan, DS
   Baird, PN
   Robman, LD
   Hageman, G
   Guymer, RH
AF Lim, Jonathan H.
   Wickremasinghe, Sanjeewa S.
   Xie, Jing
   Chauhan, Devinder S.
   Baird, Paul N.
   Robman, Luba D.
   Hageman, Gregory
   Guymer, Robyn H.
TI Delay to Treatment and Visual Outcomes in Patients Treated With
   Anti-Vascular Endothelial Growth Factor for Age-Related Macular
   Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB AVASTIN; SUBGROUP ANALYSIS; RANIBIZUMAB;
   VERTEPORFIN
AB PURPOSE: To investigate the potential influences that affect visual acuity (VA) outcome in a clinic-based cohort of age-related macular degeneration (AMD) patients undergoing anti-vascular endothelial growth factor (anti-VEGF) treatment for choroidal neovascularization.
   DESIGN: Prospective interventional case series.
   METHODS: Patients with subfoveal choroidal neovascularization (CNV) secondary to AMD were prospectively recruited. A detailed questionnaire was given to patients at time of enrollment, to collect information relating to demographics, history of visual symptoms, visual acuity (VA), and treatment scheduling. Delay from symptoms to treatment ("Treatment delay") was measured in terms of weeks and analyzed in tertiles. Information pertaining to treatment outcomes was collected over a 6-month period.
   RESULTS: One hundred eighty-five eyes of 185 patients were recruited into the study. Longer delay from first symptoms suggestive of CNV to first injection was a significant predictor (P =.015) of poorer treatment outcome, when controlling for age, sex, and baseline VA. Patients with a delay in treatment of 21 weeks or more compared to a delay of 7 weeks or less had an odds ratio of 2.62 (1.20, 5.68) for worsening vision after treatment.
   CONCLUSIONS: Patients experiencing a longer delay between their first symptoms of CNV and their first anti-VEGF treatment have a significantly lower chance of improving vision at 6 months following anti-VEGF therapy. It is critical that this information reach those at potential vision loss from AMD, in order that prompt treatment may be instituted, to maximize the benefits of anti-VEGF treatment. (Am J Ophthalmol 2012;153: 678-686. (C) 2012 by Elsevier Inc. All rights reserved.)
C1 [Lim, Jonathan H.; Wickremasinghe, Sanjeewa S.; Xie, Jing; Baird, Paul N.; Robman, Luba D.; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Chauhan, Devinder S.] Vision Retinal Inst Eastern, Melbourne, Vic, Australia.
   [Hageman, Gregory] Univ Utah, Dept Ophthalmol & Visual Sci, John Moran Eye Ctr, Salt Lake City, UT USA.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Utah System of Higher Education; University of
   Utah
RP Wickremasinghe, SS (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM Sanj.Wickremasinghe@eyeandean.org.au
RI Chauhan, Devinder/W-8069-2019; xie, jing/GRY-1689-2022
OI Guymer, Robyn/0000-0002-9441-4356; Baird, Paul/0000-0002-1305-3502;
   /0000-0001-6694-3587
FU NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL (NHMRC, CANBERRA,
   Australia) [590205]; National Institute of Health (NIH, Bethesda,
   Maryland) [R24 EY]; Novartis; NATIONAL EYE INSTITUTE [R24EY017404]
   Funding Source: NIH RePORTER
FX PUBLICATION OF THIS ARTICLE WAS FUNDED BY NATIONAL HEALTH AND MEDICAL
   RESEARCH COUNCIL (NHMRC, CANBERRA, Australia) project grant 590205 and
   National Institute of Health (NIH, Bethesda, Maryland) R24 EY (G.H.,
   R.G., P.B.). The Centre for Eye Research Australia (CERA) receives
   Operational Infrastructure Support from the Victorian government. Dr
   Wickremasinghe was supported by a Novartis fellowship during the
   2008/2009 period. Involved in design and conduct of the study (G.H.,
   R.G.); collection (J.L., S.W., D.C.), management (S.W., J.L.), analysis
   (J.X, L.R.), and interpretation of the data (R.G., G.H., P.B.); and
   preparation (S.W., J.L.), review, or approval of the manuscript (R.G.,
   P.B., OH.). This study was approved by the Human Research and Ethics
   Committee of the Royal Victorian Eye and Ear Hospital (RVEEH) prior to
   study commencement. Research adhered to the tenets of the Declaration of
   Helsinki and participants provided written, informed consent prior to
   participation.
CR Arias L, 2009, EYE LOND, V23
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schalnus R, 2009, OPHTHALMOLOGICA, V224, P176
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
NR 14
TC 87
Z9 92
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2012
VL 153
IS 4
BP 678
EP 686
DI 10.1016/j.ajo.2011.09.013
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 920FC
UT WOS:000302387100014
PM 22245460
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Han, XK
   Ong, JS
   An, JY
   Hewitt, AW
   Gharahkhani, P
   MacGregor, S
AF Han, Xikun
   Ong, Jue-Sheng
   An, Jiyuan
   Hewitt, Alex W.
   Gharahkhani, Puya
   MacGregor, Stuart
TI Using Mendelian randomization to evaluate the causal relationship
   between serum C-reactive protein levels and age-related macular
   degeneration
SO EUROPEAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE C-reactive protein; Age-related macular degeneration; Mendelian
   randomization; Causal effect
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; GENETIC-VARIANTS; RISK;
   PREVALENCE; INFLAMMATION; MACULOPATHY; INFERENCE; PATHWAYS; POWER
AB Serum C-reactive protein (CRP), an important inflammatory marker, has been associated with age-related macular degeneration (AMD) in observational studies; however, the findings are inconsistent. It remains unclear whether the association between circulating CRP levels and AMD is causal. We used two-sample Mendelian randomization (MR) to evaluate the potential causal relationship between serum CRP levels and AMD risk. We derived genetic instruments for serum CRP levels in 418,642 participants of European ancestry from UK Biobank, and then conducted a genome-wide association study for 12,711 advanced AMD cases and 14,590 controls of European descent from the International AMD Genomics Consortium. Genetic variants which predicted elevated serum CRP levels were associated with advanced AMD (odds ratio [OR] for per standard deviation increase in serum CRP levels: 1.31, 95% confidence interval [CI]: 1.19-1.44, P=5.2x10(-8)). The OR for the increase in advanced AMD risk when moving from low (<3 mg/L) to high (>3 mg/L) CRP levels is 1.29 (95% CI: 1.17-1.41). Our results were unchanged in sensitivity analyses using MR models which make different modelling assumptions. Our findings were broadly similar across the different forms of AMD (intermediate AMD, choroidal neovascularization, and geographic atrophy). We used multivariable MR to adjust for the effects of other potential AMD risk factors including smoking, body mass index, blood pressure and cholesterol; this did not alter our findings. Our study provides strong genetic evidence that higher circulating CRP levels lead to increases in risk for all forms of AMD. These findings highlight the potential utility for using circulating CRP as a biomarker in future trials aimed at modulating AMD risk via systemic therapies.
C1 [Han, Xikun; Ong, Jue-Sheng; An, Jiyuan; Gharahkhani, Puya; MacGregor, Stuart] QIMR Berghofer Med Res Inst, Stat Genet, Brisbane, Qld 4006, Australia.
   [Han, Xikun] Univ Queensland, Sch Med, Brisbane, Qld, Australia.
   [Hewitt, Alex W.] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia.
   [Hewitt, Alex W.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 QIMR Berghofer Medical Research Institute; University of Queensland;
   University of Tasmania; Menzies Institute for Medical Research; Centre
   for Eye Research Australia; University of Melbourne
RP Han, XK (通讯作者)，QIMR Berghofer Med Res Inst, Stat Genet, Brisbane, Qld 4006, Australia.; Han, XK (通讯作者)，Univ Queensland, Sch Med, Brisbane, Qld, Australia.
EM Xikun.Han@qimrberghofer.edu.au
RI Macgregor, Stuart/C-6442-2009; An, Jiyuan/ABD-2471-2020; Ong, Jue
   Sheng/B-3595-2018
OI Macgregor, Stuart/0000-0001-6731-8142; Gharahkhani,
   Puya/0000-0002-4203-5952; Han, Xikun/0000-0002-3823-7308; Ong, Jue
   Sheng/0000-0002-6062-710X
FU MRC [MC_PC_12028] Funding Source: UKRI; Medical Research Council
   [MC_PC_12028, MC_PC_17228, MC_QA137853] Funding Source: Medline;
   National Health and Medical Research Council [1150144, 1116360, 1123248]
   Funding Source: Medline
CR Bowden J, 2017, STAT MED, V36, P1783, DOI 10.1002/sim.7221
   Bowden J, 2016, GENET EPIDEMIOL, V40, P304, DOI 10.1002/gepi.21965
   Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080
   Brion MJA, 2013, INT J EPIDEMIOL, V42, P1497, DOI 10.1093/ije/dyt179
   Burgess S, 2017, GENETICS, V207, P481, DOI 10.1534/genetics.117.300191
   Burgess S, 2017, EUR J EPIDEMIOL, V32, P377, DOI 10.1007/s10654-017-0255-x
   Burgess S, 2017, EPIDEMIOLOGY, V28, P30, DOI 10.1097/EDE.0000000000000559
   Burgess S, 2015, EUR J EPIDEMIOL, V30, P543, DOI 10.1007/s10654-015-0011-z
   Burgess S, 2015, AM J EPIDEMIOL, V181, P251, DOI 10.1093/aje/kwu283
   Burgess S, 2013, GENET EPIDEMIOL, V37, P658, DOI 10.1002/gepi.21758
   Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z
   Cipriani V, 2017, JAMA OPHTHALMOL, V135, P909, DOI 10.1001/jamaophthalmol.2017.2191
   Davey Smith G, 2014, HUM MOL GENET, V23, pR89, DOI 10.1093/hmg/ddu328
   Davies NM, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k601
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Hemani G, 2018, ELIFE, V7, DOI 10.7554/eLife.34408
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Howie B, 2012, NAT GENET, V44, P955, DOI 10.1038/ng.2354
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim IK, 2008, MOL VIS, V14, P1487
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Ligthart S, 2018, AM J HUM GENET, V103, P691, DOI 10.1016/j.ajhg.2018.09.009
   Loh PR, 2015, NAT GENET, V47, P284, DOI 10.1038/ng.3190
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Molins B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00808
   Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921
   Pingault JB, 2018, NAT REV GENET, V19, P566, DOI 10.1038/s41576-018-0020-3
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   R Core Team, 2017, R: A language and environment for statistical computing
   Sanderson E, 2019, INT J EPIDEMIOL, V48, P713, DOI 10.1093/ije/dyy262
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Verbanck M, 2018, NAT GENET, V50, P693, DOI 10.1038/s41588-018-0099-7
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Yavorska OO, 2017, INT J EPIDEMIOL, V46, P1734, DOI 10.1093/ije/dyx034
   Yip JLY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132565
NR 45
TC 26
Z9 26
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0393-2990
EI 1573-7284
J9 EUR J EPIDEMIOL
JI Eur. J. Epidemiol.
PD FEB
PY 2020
VL 35
IS 2
BP 139
EP 146
DI 10.1007/s10654-019-00598-z
PG 8
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA LN9DE
UT WOS:000533231000005
PM 31900758
DA 2022-11-30
ER

PT J
AU Rohrer, B
   Long, Q
   Coughlin, B
   Wilson, RB
   Huang, YX
   Qiao, F
   Tang, PH
   Kunchithapautham, K
   Gilkeson, GS
   Tomlinson, S
AF Rohrer, Baerbel
   Long, Qin
   Coughlin, Beth
   Wilson, R. Brooks
   Huang, Yuxiang
   Qiao, Fei
   Tang, Peter H.
   Kunchithapautham, Kannan
   Gilkeson, Gary S.
   Tomlinson, Stephen
TI A Targeted Inhibitor of the Alternative Complement Pathway Reduces
   Angiogenesis in a Mouse Model of Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   RETINAL VEIN OCCLUSION; FACTOR-B; VARIANT; MICE; RISK; SUSCEPTIBILITY;
   DISEASE; ACTIVATION
AB PURPOSE. Polymorphisms in factor H (fH), an inhibitor of the alternative pathway (AP) of complement activation, are associated with increased risk for age-related macular degeneration (AMD). The authors investigated the therapeutic use of a novel recombinant form of fH, CR2-fH, which is targeted to sites of complement activation, in mouse choroidal neovascularization (CNV). CR2-fH consists of the N terminus of mouse fH, which contains the AP-inhibitory domain, linked to a complement receptor 2 (CR2) targeting fragment that binds complement activation products.
   METHODS. Laser-induced CNV was analyzed in factor-B-deficient mice or in mice treated with CR2-fH, soluble CR2 (targeting domain), or PBS. CNV progression was analyzed by molecular, histologic, and electrophysiological readouts.
   RESULTS. Intravenously administered CR2-fH reduced CNV size, preserved retina function, and abrogated the injury-associated expression of C3 and VEGF mRNA. CR2 and PBS treatment was without effect. In therapeutically relevant paradigms involving delayed treatment after injury, CR2-fH was effective in reducing CNV and provided approximately 60% of the amount of protection of that seen in factor B-deficient mice that lacked functional AP. After intravenous injection, CR2-fH localized to sites of C3 deposition in RPE-choroid.
   CONCLUSIONS. Specific inhibition of the AP reduces angiogenesis in mouse CNV. Of note, intravenous injection of C3d-targeted CR2-fH is protective even though endogenous fH is present in serum at a higher relative concentration, and serum fH contains native C3d and cell surface binding domains that target it to cell surfaces. The most common AMD-associated variant of fH resides within a native cell-binding region of fH (Tyr402His). These data may open new avenues for AMD treatment strategies. (Invest Ophthalmol Vis Sci. 2009;50:3056-3064) DOI:10.1167/iovs.08-2222
C1 [Rohrer, Baerbel; Tang, Peter H.] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA.
   [Rohrer, Baerbel; Long, Qin; Coughlin, Beth; Wilson, R. Brooks; Kunchithapautham, Kannan] Med Univ S Carolina, Dept Neurosci, Div Res, Charleston, SC 29425 USA.
   [Huang, Yuxiang; Qiao, Fei; Tomlinson, Stephen] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
   [Gilkeson, Gary S.] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA.
C3 Medical University of South Carolina; Medical University of South
   Carolina; Medical University of South Carolina; Medical University of
   South Carolina
RP Rohrer, B (通讯作者)，Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
EM rohrer@musc.edu
RI Mohammed, Imran/J-8271-2012
OI Mohammed, Imran/0000-0002-8412-0768
FU National Institutes of Health [EY013520, EY017465, HL86576, C06
   RR015455]; Vision Core [EY014793]; Foundation Fighting Blindness;
   Medical University of South Carolina from Research to Prevent Blindness;
   NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015455] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY013520, R43EY017465, R24EY014793]
   Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [R01HL086576] Funding Source: NIH RePORTER
FX Supported in part by National Institutes of Health Grants EY013520 (BR),
   EY017465 (BR), HL86576 (ST), and Vision Core Grant EY014793; Foundation
   Fighting Blindness; and an unrestricted grant to Medical University of
   South Carolina from Research to Prevent Blindness. Animal studies were
   conducted in a facility constructed with support from the National
   Institutes of Health (Grant C06 RR015455).
CR Atkinson C, 2005, J CLIN INVEST, V115, P2444, DOI 10.1172/JCI25208
   Atkinson C, 2008, J IMMUNOL, V180, P1231, DOI 10.4049/jimmunol.180.2.1231
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bora PS, 2003, P NATL ACAD SCI USA, V100, P2679, DOI 10.1073/pnas.0438014100
   Caicedo A, 2005, J COMP NEUROL, V483, P263, DOI 10.1002/cne.20413
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2002, INVEST OPHTH VIS SCI, V43, P1567
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gresh J, 2003, VISUAL NEUROSCI, V20, P211, DOI 10.1017/S0952523803202108
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Hu WZ, 2009, EXP EYE RES, V88, P79, DOI 10.1016/j.exer.2008.10.014
   Huang YX, 2008, J IMMUNOL, V181, P8068, DOI 10.4049/jimmunol.181.11.8068
   JOHNSON MA, 1988, ARCH OPHTHALMOL-CHIC, V106, P348
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lohr HR, 2006, EXP EYE RES, V83, P380, DOI 10.1016/j.exer.2006.01.014
   MOLINA H, 1990, J IMMUNOL, V145, P2974
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   PUGH EN, 1998, ORIGIN MAJOR ROD AND, P93
   Richards A, 2006, VISUAL NEUROSCI, V23, P91, DOI 10.1017/S0952523806231080
   Rohrer B, 1999, J NEUROSCI, V19, P8919, DOI 10.1523/JNEUROSCI.19-20-08919.1999
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Rose KL, 2008, J CLIN INVEST, V118, P608, DOI 10.1172/JCI32525
   SABATES R, 1983, ARCH OPHTHALMOL-CHIC, V101, P232
   Song HB, 2003, J CLIN INVEST, V111, P1875, DOI 10.1172/JCI200317348
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 39
TC 124
Z9 150
U1 0
U2 11
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2009
VL 50
IS 7
BP 3056
EP 3064
DI 10.1167/iovs.08-2222
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 461SP
UT WOS:000267292100003
PM 19264882
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Geltzer, A
   Turalba, A
   Vedula, SS
AF Geltzer, Arthur
   Turalba, Angela
   Vedula, Satyanarayana S.
TI Surgical implantation of steroids with antiangiogenic characteristics
   for treating neovascular age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Angiogenesis Inhibitors [administration & dosage]; Choroidal
   Neovascularization [complications; drug therapy]; Drug Implants; Macular
   Degeneration [drug therapy; etiology]; Pregnadienediols [administration
   & dosage]; Randomized Controlled Trials as Topic; Triamcinolone
   Acetonide [administration & dosage]; Humans
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; ANECORTAVE ACETATE;
   ANGIOSTATIC STEROIDS; SAFETY
AB Background
   Neovascular age-related macular degeneration (AMD) is associated with rapid vision loss due to choroidal neovascularization (CNV), leakage, and scarring. Steroids have gained attention in their role for the treatment of neovascular AMD for their antiangiogenic and anti-inflammatory properties.
   Objectives
   This review aims to examine effects of steroids with antiangiogenic properties in the treatment of neovascular AMD.
   Search methods
   We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2012, Issue 11), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to November 2012), EMBASE (January 1980 to November 2012), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to November 2012), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 21 November 2012.
   Selection criteria
   We included randomized controlled clinical trials of intra-and peri-ocular antiangiogenic steroids in people diagnosed with neovascular AMD.
   Data collection and analysis
   Two authors independently screened abstracts and full-text articles, assessed risk of bias in the included trials, and extracted data. We did not conduct a meta-analysis.
   Main results
   We included three trials after screening a total of 1503 abstracts and 21 full-text articles. The three trials included a total of 809 participants. One trial compared different doses of acetonide anecortave acetate with placebo, a second trial compared triamcinolone acetonide versus placebo, and the third trial compared anecortave acetate against photodynamic therapy (PDT). We did not conduct a meta-analysis owing to heterogeneity of interventions and comparisons. The risk ratio for loss of 3 or more lines of vision at 12 months follow-up was 0.8 (95% confidence interval (CI) 0.45 to 1.45) with 3 mg anecortave acetate, 0.45 (95% CI = 0.21 to 0.97) with 15 mg anecortave acetate, 0.91 (0.52 to 1.58) with 30 mg anecortave acetate, 0.97 (95% CI 0.74 to 1.26) with triamcinolone acetonide, all compared to placebo and 1.08 (95% CI 0.91 to 1.29) with anecortave acetate compared with PDT.
   Authors' conclusions
   Based on the included trials, we found no evidence that antiangiogenic steroids prevent visual loss in patients with neovascular AMD. With the emergence of anti-vascular endothelial growth factor modalities, based on evidence summarized in this review, it is unclear what role steroids have in treating patients with neovascular AMD.
C1 [Geltzer, Arthur] Brown Univ, Providence, RI 02906 USA.
   [Turalba, Angela] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
   [Vedula, Satyanarayana S.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
C3 Brown University; Harvard University; Massachusetts Eye & Ear Infirmary;
   Johns Hopkins University; Johns Hopkins Bloomberg School of Public
   Health
RP Geltzer, A (通讯作者)，Brown Univ, 389 Benefit St, Providence, RI 02906 USA.
EM youngheeart@mac.com
FU Brown University, USA; Johns Hopkins University, USA; National Eye
   Institute, National Institutes of Health, USA [N-01-EY-2-1003, 1 U01
   EY020522-01]; NATIONAL EYE INSTITUTE [U01EY020522] Funding Source: NIH
   RePORTER
FX Internal sources; Brown University, USA.; Johns Hopkins University,
   USA.; External sources; Contract N-01-EY-2-1003, National Eye Institute,
   National Institutes of Health, USA.; Grant 1 U01 EY020522-01, National
   Eye Institute, National Institutes of Health, USA.
CR Agurto-Rivera Ricardo, 2005, BMC Ophthalmol, V5, P27
   Arias L, 2008, GRAEF ARCH CLIN EXP, V246, P245, DOI 10.1007/s00417-007-0642-1
   Augustin AJ, 2005, GRAEF ARCH CLIN EXP, V243, P9, DOI 10.1007/s00417-004-0961-4
   Bakri SJ, 2006, EXPERT OPIN INV DRUG, V15, P163, DOI 10.1517/13543784.15.2.163
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   BenEzra D, 1997, INVEST OPHTH VIS SCI, V38, P1954
   BLEI F, 1993, J CELL PHYSIOL, V155, P568, DOI 10.1002/jcp.1041550315
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Clark AF, 1999, INVEST OPHTH VIS SCI, V40, P2158
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Evans JR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004004.pub3
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Evans JR, 2013, COCHRANE DATABASE SY
   Arevalo JF, 2005, RETINA-J RET VIT DIS, V25, P719, DOI 10.1097/00006982-200509000-00006
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Geltzer A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005022.pub2
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Maberley D, 2009, OPHTHALMOLOGY, V116, P2149, DOI 10.1016/j.ophtha.2009.04.032
   Panel on Handling Missing Data in Clinical Trials National Research Council, 2010, PREV TREATM MISS DAT
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Reddy U, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005138.pub2
   Regillo CD, 2002, SAFETY ANECORTAVE AC, P282
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schmidt-Erfurth U, 2005, EUR J OPHTHALMOL, V15, P482, DOI 10.1177/112067210501500411
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   The Nordic Cochrane Centre The Cochrane Collaboration, 2011, REV MAN REVMAN 5 1
   Tielsch JM, 2002, VISION PROBLEMS US P
   Tsuchiya D, 2008, INVESTIGATIVE OPHTHA
   Van de Moere A, 2005, OPHTHALMOLOGY, V112, P1897, DOI 10.1016/j.ophtha.2005.06.018
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   WHO, 1997, FACT SHEET
   Wormald R, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub2
NR 47
TC 13
Z9 13
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2013
IS 1
AR CD005022
DI 10.1002/14651858.CD005022.pub3
PG 32
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 081JQ
UT WOS:000314315800022
PM 23440797
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ross, AH
   Donachie, PHJ
   Sallam, A
   Stratton, IM
   Mohamed, Q
   Scanlon, PH
   Kirkpatrick, JN
   Johnston, RL
AF Ross, A. H.
   Donachie, P. H. J.
   Sallam, A.
   Stratton, I. M.
   Mohamed, Q.
   Scanlon, P. H.
   Kirkpatrick, J. N.
   Johnston, R. L.
TI Which visual acuity measurements define high-quality care for patients
   with neovascular age-related macular degeneration treated with
   ranibizumab?
SO EYE
LA English
DT Article
DE ranibizumab; visual acuity; age-related macular degeneration;
   neovascular
ID INTRAVITREAL RANIBIZUMAB; SUBGROUP ANALYSIS; VERTEPORFIN; OUTCOMES;
   THERAPY; REGIMEN; ANCHOR
AB Purpose The purpose of this study is to define which visual acuity (VA) measurements are the best indicators of high-quality care for patients receiving intravitreal ranibizumab for neovascular age-related macular degeneration (nAMD).
   Methods Analysis of prospectively collected data recorded within an electronic medical record system on treatment-naive, first-eligible eyes with nAMD, treated with ranibizumab using an as-needed treatment regimen with a minimum follow-up of 1 year. Data collection included the following: age, gender, laterality, type of nAMD, VA, central 1 mm OCT retinal thickness, number of intravitreal injections, and number of follow-up assessments.
   Results Data were available on the first-treated eye from 406 patients with at least 1 year follow-up; of these, 198 had data at 2 years. The mean baseline VA of 54.4 Early Treatment Diabetic Retinopathy Study letters improved to 58.5 letters at 12 months and to 56.8 letters at 24 months. The mean VA changes from baseline to 1 year were +6.5, +7.5, +1.7, and -1.5 letters, respectively, for baseline VA categories of 23-35, 36-55, 56-70, and 470 letters. Change in mean VA from the end of the loading phase to year 1 ranged from -2.9 to +1.4 letters for the different baseline VA categories. The mean number of injections were similar across baseline VA categories ranging from 5.7 to 6.0 injections in year 1 and from 3.3 to 3.8 in year 2.
   Conclusions This large, real-world series demonstrates that mean change in VA is largely a function of selection criteria and baseline VA. The quality of a service is therefore better judged by actual VA outcomes and maintenance of vision after the loading phase. Eye (2013) 27, 56-64; doi:10.1038/eye.2012.225; published online 23 November 2012
C1 [Ross, A. H.; Sallam, A.; Mohamed, Q.; Scanlon, P. H.; Kirkpatrick, J. N.; Johnston, R. L.] Gloucestershire Royal Hosp, Dept Ophthalmol, Cheltenham, Glos, England.
   [Donachie, P. H. J.; Stratton, I. M.] Cheltenham Gen Hosp, Gloucestershire Retinal Res Grp, Cheltenham GL53 7AN, Glos, England.
C3 Gloucestershire Royal Hospital; Gloucestershire Hospitals NHS Foundation
   Trust; Cheltenham General Hospital
RP Johnston, RL (通讯作者)，Cheltenham Gen Hosp, Dept Ophthalmol, Cheltenham GL53 7AN, Glos, England.
EM rob.johnston@glos.nhs.uk
RI Sallam, Ahmed/A-4791-2014; stratton, irene/AAZ-3627-2020
OI Sallam, Ahmed/0000-0001-7207-6782; stratton, irene/0000-0003-1172-7865
CR Arias L, 2011, RETINA-J RET VIT DIS, V31, P1261, DOI 10.1097/IAE.0b013e318207d152
   Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michalova K, 2009, EYE, V23, P1633, DOI 10.1038/eye.2009.175
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Rotsos T, 2010, CLIN OPHTHALMOL, V4, P1271, DOI 10.2147/OPTH.S14684
   Shona O, 2011, CLIN EXP OPHTHALMOL, V39, P5, DOI 10.1111/j.1442-9071.2010.02424.x
   StataCorp, 2021, STATA STAT SOFTWARE
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
NR 25
TC 34
Z9 35
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD JAN
PY 2013
VL 27
IS 1
BP 56
EP 64
DI 10.1038/eye.2012.225
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 071AJ
UT WOS:000313557200008
PM 23174752
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Christen, WG
   Glynn, RJ
   Sesso, HD
   Kurth, T
   MacFadyen, J
   Bubes, V
   Buring, JE
   Manson, JE
   Gaziano, JM
AF Christen, William G.
   Glynn, Robert J.
   Sesso, Howard D.
   Kurth, Tobias
   MacFadyen, Jean
   Bubes, Vadim
   Buring, Julie E.
   Manson, JoAnn E.
   Gaziano, J. Michael
TI Vitamins E and C and Medical Record-Confirmed Age-related Macular
   Degeneration in a Randomized Trial of Male Physicians
SO OPHTHALMOLOGY
LA English
DT Article
ID BETA-CAROTENE; CARDIOVASCULAR-DISEASE; US PHYSICIANS; EYE DISEASE;
   SUPPLEMENTATION; MACULOPATHY; PREVENTION; HEALTH; MEN; CATARACT
AB Purpose: To test whether supplementation with alternate-day vitamin E or daily vitamin C affects the incidence of the diagnosis of age-related macular degeneration (AMD) in a large-scale randomized trial of male physicians.
   Design: Randomized, double-masked, placebo-controlled trial.
   Participants: We included 14 236 apparently healthy United States male physicians aged >= 50 years who did not report a diagnosis of AMD at baseline.
   Methods: Participants were randomly assigned to receive 400 international units (IU) of vitamin E or placebo on alternate days, and 500 mg of vitamin C or placebo daily. Participants reported new diagnoses of AMD on annual questionnaires and medical record data were collected to confirm the reports.
   Main Outcome Measures: Incident diagnosis of AMD responsible for a reduction in best-corrected visual acuity to <= 20/30.
   Results: After 8 years of treatment and follow-up, a total of 193 incident cases of visually significant AMD were documented. There were 96 cases in the vitamin E group and 97 in the placebo group (hazard ratio [HR], 1.03; 95% confidence interval [CI], 0.78-1.37). For vitamin C, there were 97 cases in the active group and 96 in the placebo group (HR, 0.99; 95% CI, 0.75-1.31).
   Conclusions: In a large-scale, randomized trial of United States male physicians, alternate-day use of 400 IU of vitamin E and/or daily use of 500 mg of vitamin C for 8 years had no appreciable beneficial or harmful effect on risk of incident diagnosis of AMD.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2012;119:1642-1649 (C) 2012 by the American Academy of Ophthalmology.
C1 [Christen, William G.; Glynn, Robert J.; Sesso, Howard D.; Kurth, Tobias; MacFadyen, Jean; Bubes, Vadim; Buring, Julie E.; Manson, JoAnn E.; Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA.
   [Buring, Julie E.] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA.
   [Sesso, Howard D.; Kurth, Tobias; Buring, Julie E.; Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MA 02115 USA.
   [Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Div Cardiovasc Dis, Boston, MA 02115 USA.
   [Gaziano, J. Michael] VA Boston Healthcare Syst, Boston, MA USA.
   [Sesso, Howard D.; Kurth, Tobias; Buring, Julie E.; Manson, JoAnn E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Kurth, Tobias] INSERM, Unit Neuroepidemiol 708, Paris, France.
C3 Harvard University; Brigham & Women's Hospital; Harvard University;
   Harvard Medical School; Harvard University; Brigham & Women's Hospital;
   Harvard University; Brigham & Women's Hospital; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); Harvard
   University; VA Boston Healthcare System; Harvard University; Harvard
   T.H. Chan School of Public Health; Institut National de la Sante et de
   la Recherche Medicale (Inserm)
RP Christen, WG (通讯作者)，900 Commonwealth Ave E, Boston, MA 02215 USA.
EM wchristen@rics.bwh.harvard.edu
RI Kurth, Tobias/A-9243-2012
OI Kurth, Tobias/0000-0001-7169-2620
FU National Institutes of Health (Bethesda, MD) [CA 97193, CA 34944, CA
   40360, HL 26490, HL 34595]; BASF Corporation (Florham Park, NJ);
   National Eye Institute; National Institute on Aging; NATIONAL CANCER
   INSTITUTE [R01CA040360, R01CA097193] Funding Source: NIH RePORTER;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASES [P30DK040561] Funding Source: NIH RePORTER
FX This work was supported by grants CA 97193 (which included funding from
   the National Eye Institute and the National Institute on Aging), CA
   34944, CA 40360, HL 26490, and HL 34595 from the National Institutes of
   Health (Bethesda, MD), and an investigator-initiated grant from BASF
   Corporation (Florham Park, NJ). Study agents and packaging were provided
   by Wyeth Pharmaceuticals (Madison, NJ), BASF Corporation, and DSM
   Nutritional Products Inc (formerly Roche Vitamins; Parsippany, NJ).
   Wyeth Pharmaceuticals, BASF Corporation, and DSM Nutritional Products,
   Inc, had no role in the design and conduct of the study; in the
   collection, analysis, and interpretation of the data; or in the
   preparation, review, or approval of the manuscript. Trial registration:
   clinicaltrials.gov Identifier: NCT00270647 Dr. Christen had full access
   to all the data in the study and takes responsibility for the integrity
   of the data and the accuracy of the data analysis.
CR Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Christen WG, 2000, ANN EPIDEMIOL, V10, P125, DOI 10.1016/S1047-2797(99)00042-3
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Christen WG, 2007, ARCH OPHTHALMOL-CHIC, V125, P333, DOI 10.1001/archopht.125.3.333
   Christen WG, 2010, ARCH OPHTHALMOL-CHIC, V128, P1397, DOI 10.1001/archophthalmol.2010.266
   Christen WG, 2010, OPHTHALMOLOGY, V117, P1163, DOI 10.1016/j.ophtha.2009.10.043
   Coleman H, 2007, CURR OPIN OPHTHALMOL, V18, P220, DOI 10.1097/ICU.0b013e32814a586b
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gaziano JM, 2009, JAMA-J AM MED ASSOC, V301, P52, DOI 10.1001/jama.2008.862
   Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801
   HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Seddon JM, 2007, AM J CLIN NUTR, V85, p304S, DOI 10.1093/ajcn/85.1.304S
   Sesso HD, 2008, JAMA-J AM MED ASSOC, V300, P2123, DOI 10.1001/jama.2008.600
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
NR 20
TC 21
Z9 21
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2012
VL 119
IS 8
BP 1642
EP 1649
DI 10.1016/j.ophtha.2012.01.053
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 982YA
UT WOS:000307080100023
PM 22503302
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Wang, JJ
   Mitchell, P
   Smith, W
   Gillies, M
   Billson, F
AF Wang, JJ
   Mitchell, P
   Smith, W
   Gillies, M
   Billson, F
TI Systemic use of anti-inflammatory medications and age-related
   maculopathy: the Blue Mountains Eye Study
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE age-related maculopathy; anti-inflammatory medication; NSAIDs; aspirin;
   corticosteroids; Blue Mountains Eye Study
ID SENILE MACULAR DEGENERATION; ALZHEIMERS-DISEASE; RETINAL PATHOLOGY;
   GRADING SYSTEM; INVOLVEMENT; EXPRESSION; ROTTERDAM; AUSTRALIA;
   MEMBRANES; FEATURES
AB PURPOSE To assess whether an association exists between systemic use of anti-inflammatory medications at baseline and the prevalence or incidence of either late or early age-related maculopathy (ARM) in a population-based cohort.
   METHODS 3654 participants of the Blue Mountains Eye Study baseline examination (1992-94) were followed during 1997-99. Use of antiinflammatory medication was recorded during the baseline interview. After excluding 543 persons who died since baseline, 2334 (75% Of the surviving participants) attended 5-year follow-up examinations. Retinal photographs taken during both examinations were graded using the Wisconsin Age-Related Maculopathy Grading System. Prevalence refers to the proportion of participants having ARM at baseline. Incidence refers to the proportion of participants without ARM at baseline who developed it over the 5-year period. Known ARM risk factors were adjusted, for when assessing the relationship between use of anti-inflammatory medications and ARM.
   RESULTS At baseline, 1010 (27.61%) Of 3654 participants were current users of non-steroidal antiinflammatory drugs (NSAIDs), 514 (14.1%) were past users and 1282 (35.1%) were ever users. The corresponding numbers of subjects reporting current, past or ever use of corticosteroids (including inhaled steroids) were 225 (6.2%), 519 (14.2) and 564 (15.4), respectively. Late ARM was present in 72 participants (2.0%) and early ARM was present in 171 participants 49%) at the baseline examination. During the follow-up period, 25 participants (1.1%) developed incident late ARM and 192 (8.7%) developed incident early ARM. After adjusting for age, sex, family history of ARM and smoking, no significant associations were evident for the use of NSAIDs or corticosteroids and the prevalence of either late or early ARM. There were also no associations found between use of these medications at baseline and the 5-year incidence of either late or early ARM.
   CONCLUSIONS No association was found between use of systemic anti-inflammatory medications and either the cross-sectional prevalence or longitudinal incidence of ARM in this population.
C1 Univ Sydney, Dept Ophthalmol, Westmead, NSW 2145, Australia.
   Univ Sydney, Save Sight Inst, Westmead, NSW 2145, Australia.
   Univ Sydney, Westmead Millennium Inst, Westmead, NSW 2145, Australia.
   Univ Newcastle, Ctr Biostat & Epidemiol, Newcastle, NSW 2308, Australia.
C3 University of Sydney; University of Sydney; University of Sydney;
   Westmead Institute for Medical Research; University of Newcastle
RP Mitchell, P (通讯作者)，Univ Sydney, Dept Ophthalmol, Hawkesbury Rd, Westmead, NSW 2145, Australia.
RI gillies, mark c/B-3242-2012
CR ANDERSEN K, 1995, NEUROLOGY, V45, P1441, DOI 10.1212/WNL.45.8.1441
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blanks JC, 1996, NEUROBIOL AGING, V17, P377, DOI 10.1016/0197-4580(96)00010-3
   Blanks JC, 1996, NEUROBIOL AGING, V17, P385, DOI 10.1016/0197-4580(96)00009-7
   BREITNER JCS, 1995, NEUROBIOL AGING, V16, P523, DOI 10.1016/0197-4580(95)00049-K
   GASS JDM, 1967, AM J OPHTHALMOL, V63, P573
   GASS JDM, 1967, AM J OPHTHALMOL, V63, P617
   GEHRS KM, 1992, ARCH OPHTHALMOL-CHIC, V110, P833, DOI 10.1001/archopht.1992.01080180105036
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   MAUMENEE A E, 1965, Trans Am Acad Ophthalmol Otolaryngol, V69, P691
   McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
NR 30
TC 23
Z9 25
U1 0
U2 1
PU SWETS ZEITLINGER PUBLISHERS
PI LISSE
PA P O BOX 825, 2160 SZ LISSE, NETHERLANDS
SN 0928-6586
J9 OPHTHALMIC EPIDEMIOL
JI Ophthalmic Epidemiol.
PD FEB
PY 2003
VL 10
IS 1
BP 37
EP 48
DI 10.1076/opep.10.1.37.13776
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 655BQ
UT WOS:000181531800006
PM 12607158
DA 2022-11-30
ER

PT J
AU Valverde-Megias, A
   Ruiz-Calvo, A
   Murciano-Cespedosa, A
   Hernandez-Ruiz, S
   Martinez-de-la-Casa, JM
   Garcia-Feijoo, J
AF Valverde-Megias, Alicia
   Ruiz-Calvo, Aurora
   Murciano-Cespedosa, Antonio
   Hernandez-Ruiz, Samuel
   Maria Martinez-de-la-Casa, Jose
   Garcia-Feijoo, Julian
TI Long-term effect of intravitreal ranibizumab therapy on retinal nerve
   fiber layer in eyes with exudative age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Nerve fiber layer; anti-VEGF; OCT; AMD; Ranibizumab
ID ENDOTHELIAL GROWTH-FACTOR; INTRAOCULAR-PRESSURE; THICKNESS; INJECTION;
   BEVACIZUMAB; DOMAIN
AB PurposeTo investigate long-term effect (96months) of intravitreal ranibizumab administered for exudative age-related macular degeneration (AMD) on retinal nerve fiber layer (RNFL) thickness when used following a pro re nata regimen.MethodsIn this prospective study, 20 eyes of 20 patients diagnosed with exudative AMD were included. Contralateral non-exudative AMD eyes of nine of these patients were included as controls. Data on intraocular pressure (IOP) and number of injections were recorded. Spectralis optic coherence tomography (OCT) of the circumpapillary RNFL was performed under dilation when diagnosis was made and before the three loading injections. Follow-up software was selected to accurately compare baseline with subsequent images through the 8years of the study.ResultsBaseline IOP was 14.1mmHg both in study (standard deviation, SD: 0.8) and control eyes (SD: 0.9) and remained unchanged during the study. Mean number of injections was 21 (SD: 2.8) at the end of the study. Mean average thickness of RNFL in the study eye group at the end of the study was 96.5m (SD: 2.1). Mean loss for the study period was 5.3m (SD: 0.7; p<0.0001). Corresponding RNFL values for controls were 92.9 (SD: 3.2) and 5.8m (SD: 1.2; p<0.001). Superior temporal sector had the greatest loss in both groups, followed by inferior and nasal sectors. No statistically significant differences were found when comparing losses in injected eyes versus control eyes.ConclusionsRNFL thickness decreased both equally in injected eyes and control eyes. Thus, no long-term effects of intravitreal ranibizumab were observed on the retinal nerve fiber layer thickness.
C1 [Valverde-Megias, Alicia; Hernandez-Ruiz, Samuel; Maria Martinez-de-la-Casa, Jose; Garcia-Feijoo, Julian] Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Hosp Clin San Carlos, Ophthalmol Unit, Madrid, Spain.
   [Valverde-Megias, Alicia] San Carlos Clin Hosp, Ophtalmol Dept, C Profesor Martin Lagos S-N, Madrid 28040, Spain.
   [Ruiz-Calvo, Aurora] Sureste Clin Hosp, Madrid, Spain.
   [Murciano-Cespedosa, Antonio] Univ Complutense Madrid, Fac Biol, Madrid, Spain.
C3 Hospital Clinico San Carlos; Complutense University of Madrid
RP Valverde-Megias, A (通讯作者)，Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Hosp Clin San Carlos, Ophthalmol Unit, Madrid, Spain.; Valverde-Megias, A (通讯作者)，San Carlos Clin Hosp, Ophtalmol Dept, C Profesor Martin Lagos S-N, Madrid 28040, Spain.
EM alicia.valgreen@gmail.com
OI Valverde-Megias, Alicia/0000-0002-6166-114X; MURCIANO CESPEDOSA,
   ANTONIO/0000-0001-6644-8420
CR [Anonymous], 2010, SPECTR HRA OCT US GU, P60
   Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   Bendschneider D, 2010, J GLAUCOMA, V19, P475, DOI 10.1097/IJG.0b013e3181c4b0c7
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Hammel N, 2017, AM J OPHTHALMOL, V178, P38, DOI 10.1016/j.ajo.2017.03.008
   Hougaard JL, 2006, GRAEF ARCH CLIN EXP, V244, P1607, DOI 10.1007/s00417-006-0372-9
   Jee D, 2012, CURR EYE RES, V37, P408, DOI 10.3109/02713683.2011.632108
   Jo Young-Joon, 2016, Korean J Ophthalmol, V30, P114, DOI 10.3341/kjo.2016.30.2.114
   Johnson DE, 2009, CAN J OPHTHALMOL, V44, P562, DOI 10.3129/i09-106
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Krohne TU, 2015, RETINA-J RET VIT DIS, V35, P69, DOI 10.1097/IAE.0000000000000265
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Loureiro Monica, 2017, J Curr Glaucoma Pract, V11, P38, DOI 10.5005/jp-journals-10028-1220
   Manjunath V, 2011, OPHTHALMOLOGY, V118, P531, DOI 10.1016/j.ophtha.2010.07.013
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Parikh RS, 2007, OPHTHALMOLOGY, V114, P921, DOI 10.1016/j.ophtha.2007.01.023
   Shin HJ, 2016, INVEST OPHTH VIS SCI, V57, P1798, DOI 10.1167/iovs.15-18404
   Sobaci G, 2013, INT J OPHTHALMOL-CHI, V6, P211, DOI 10.3980/j.issn.2222-3959.2013.02.20
   Soheilian M, 2017, GRAEF ARCH CLIN EXP, V255, P1705, DOI 10.1007/s00417-017-3702-1
   Song S, 2016, INDIAN J OPHTHALMOL, V64, P762, DOI 10.4103/0301-4738.195006
   Yang HS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170341
   Yannuzzi NA, 2014, AM J OPHTHALMOL, V158, P319, DOI 10.1016/j.ajo.2014.04.029
NR 22
TC 10
Z9 10
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2019
VL 257
IS 7
BP 1459
EP 1466
DI 10.1007/s00417-019-04325-y
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IC7WI
UT WOS:000471187800014
PM 31053943
DA 2022-11-30
ER

PT J
AU Fleckenstein, M
   Grassmann, F
   Lindner, M
   Pfau, M
   Czauderna, J
   Strunz, T
   von Strachwitz, C
   Schmitz-Valckenberg, S
   Holz, FG
   Weber, BHF
AF Fleckenstein, Monika
   Grassmann, Felix
   Lindner, Moritz
   Pfau, Maximilian
   Czauderna, Joanna
   Strunz, Tobias
   von Strachwitz, Claudia
   Schmitz-Valckenberg, Steffen
   Holz, Frank G.
   Weber, Bernhard H. F.
TI Distinct Genetic Risk Profile of the Rapidly Progressing
   Diffuse-Trickling Subtype of Geographic Atrophy in Age-Related Macular
   Degeneration (AMD)
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE AMD; fundus autofluorescence imaging; diffuse-trickling phenotype;
   late-onset retinal degeneration; C1QTNF5 gene; genetic risk factors
ID ONSET RETINAL DEGENERATION; PIGMENT-EPITHELIUM DEPOSITS; GENOME-WIDE
   ASSOCIATION; SUSCEPTIBILITY VARIANTS; MUTATION; C1QTNF5; DISEASE;
   DRUSEN; MODEL; CTRP5
AB PURPOSE. To genetically characterize a subphenotype of geographic atrophy (GA) in AMD associated with rapid progression and a diffuse-trickling appearance on fundus autofluorescence imaging.
   METHODS. Patients from the Fundus Autofluorescence in Age-Related Macular Degeneration Study were phenotyped for diffuse-trickling GA (dt-GA; n = 44). DNA was analyzed for 10 known AMD-associated genetic variants. A genetic risk score (GRS) was calculated and compared with patients with nondiffuse-trickling GA (ndt-GA; n = 311) and individuals from the 1000 genomes project (1000G; n = 267). Given the phenotypic overlap between diffuse trickling and late-onset retinal degeneration (LORD), all C1QTNF5 exons and their exon/ intron boundaries were sequenced.
   RESULTS. A statistically significant difference in allele frequencies between dt-GA and ndt-GA were found for CFH: rs1061170 and CFH: rs800292 (P-corrected = 0.03). The ARMS2 variant rs10490924 was significantly more frequent in dt-GA than in 1000G individuals (P-corrected < 0.01). The GRS of dt-GA patients was in-between the score of the 1000G individuals and that of patients with ndt-GA, significantly differing from both (P-corrected < 0.01). Sequencing of C1QTNF5 revealed 28 unique variants although none showed a statistically significant association with dt-GA when compared with 1000G individuals.
   CONCLUSIONS. The dt-GA phenotype shows a remarkably different genetic risk profile from other GA phenotypes secondary to AMD. Disease-associated C1QTNF5 mutations were not identified. Together, these results suggest that the dt-GA phenotype is associated with a genetic background substantially different from other GA phenotypes and underlines the necessity to refine the clinical phenotyping, specifically when aiming for individualized therapies in AMD.
C1 [Fleckenstein, Monika; Lindner, Moritz; Pfau, Maximilian; Czauderna, Joanna; Schmitz-Valckenberg, Steffen; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Grassmann, Felix; Strunz, Tobias; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.
   [von Strachwitz, Claudia] Eye Ctr Southwest, Stuttgart, Germany.
C3 University of Bonn; University of Regensburg
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de
RI Strunz, Tobias/ABB-6300-2020; Lindner, Moritz/AAC-8639-2021; Pfau,
   Maximilian/N-1888-2019; Strunz, Tobias/ABD-9798-2021
OI Lindner, Moritz/0000-0002-4416-3421; Pfau,
   Maximilian/0000-0001-9761-9640; Strunz, Tobias/0000-0002-3744-9595;
   Weber, Bernhard H.F./0000-0002-8808-7723; Fleckenstein,
   Monika/0000-0001-8321-8037; Grassmann, Felix/0000-0003-1390-7528
FU Deutsche Forschungsgemeinschaft (DFG-Germany Research Foundation, Bonn,
   Germany) [Ho1926/3-1, FL 658/4-1, WE 1259/19-2]; BONFOR program of the
   University of Bonn (Bonn, Germany) [O-137.0020]
FX Supported by grants by the Deutsche Forschungsgemeinschaft (DFG-Germany
   Research Foundation, Bonn, Germany): Ho1926/3-1 (FGH), FL 658/4-1 (MF),
   and WE 1259/19-2 (BHFW), and the BONFOR program of the University of
   Bonn: O-137.0020 (ML; Bonn, Germany).
CR [Anonymous], 2010, R LANG ENV STAT COMP
   Boon CJF, 2009, OPHTHALMOLOGY, V116, P771, DOI 10.1016/j.ophtha.2008.12.019
   Boon CJF, 2008, VISION RES, V48, P2569, DOI 10.1016/j.visres.2008.01.010
   Borooah S, 2009, BRIT J OPHTHALMOL, V93, P284, DOI 10.1136/bjo.2008.150151
   Fleckenstein M, 2014, INVEST OPHTH VIS SCI, V55, P2911, DOI 10.1167/iovs.13-13409
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2012, INVEST OPHTH VIS SCI, V53, P2112, DOI 10.1167/iovs.11-8785
   Grassmann F, 2015, NEUROMOLECULAR MED B, V95, P194
   Grassmann F, 2015, EUR J PHARM BIOPHARM, V95, P194, DOI 10.1016/j.ejpb.2015.04.039
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Grassmann F, 2014, ADV EXP MED BIOL, V801, P291, DOI 10.1007/978-1-4614-3209-8_37
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jacobson SG, 2014, JAMA OPHTHALMOL, V132, P1252, DOI 10.1001/jamaophthalmol.2014.2059
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   Lee Seunggeun, 2013, SKAT SNP SET SEQUENC
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Mandal MNA, 2006, INVEST OPHTH VIS SCI, V47, P5505, DOI 10.1167/iovs.06-0312
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Querques G, 2013, OPHTHALMOLOGY, V120, P429, DOI 10.1016/j.ophtha.2012.09.027
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Shu XH, 2006, ADV EXP MED BIOL, V572, P41
   Shu XH, 2006, HUM MOL GENET, V15, P1680, DOI 10.1093/hmg/ddl091
   So HC, 2011, GENET EPIDEMIOL, V35, P447, DOI 10.1002/gepi.20593
   So HC, 2011, GENET EPIDEMIOL, V35, P310, DOI 10.1002/gepi.20579
   So HC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013898
   Soumplis V, 2013, ACTA OPHTHALMOL, V91, pE191, DOI 10.1111/aos.12010
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   Wu MC, 2011, AM J HUM GENET, V89, P82, DOI 10.1016/j.ajhg.2011.05.029
NR 44
TC 16
Z9 16
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2016
VL 57
IS 6
BP 2463
EP 2471
DI 10.1167/iovs.15-18593
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DO8OA
UT WOS:000378041700013
PM 27149696
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Lavanya, R
   Kawasaki, R
   Tay, WT
   Cheung, GCM
   Mitchell, P
   Saw, SM
   Aung, T
   Wong, TY
AF Lavanya, Raghavan
   Kawasaki, Ryo
   Tay, Wan Ting
   Cheung, Gemmy C. M.
   Mitchell, Paul
   Saw, Seang-Mei
   Aung, Tin
   Wong, Tien Y.
TI Hyperopic Refractive Error and Shorter Axial Length Are Associated with
   Age-Related Macular Degeneration: The Singapore Malay Eye Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; BLUE MOUNTAINS EYE; RISK-FACTORS; BEIJING EYE;
   LONGITUDINAL DATA; ADULT-POPULATION; MACULOPATHY; PREVALENCE;
   ATHEROSCLEROSIS; POLYMORPHISM
AB PURPOSE. To describe the association between refractive errors, ocular biometry, and age-related macular degeneration (AMD) in an Asian Malay population in Singapore.
   METHODS. A population-based study of 3280 Malay individuals aged 40 to 80 years was conducted in Singapore. Early-and late-AMD signs were graded from retinal photographs according to the Wisconsin grading system. Autorefraction, followed by subjective refraction, was performed to obtain spherical equivalent refraction (SER) in diopters, with emmetropia defined as SER -0.5 to +0.5 D, hyperopia as > +0.5 D, and myopia as > -0.5 D. Partial coherence laser interferometry was used to measure axial length, anterior chamber depth, and corneal curvature. The association between refractive status, ocular biometry and the prevalence of both early and late AMD were analyzed.
   RESULTS. Hyperopic refractive error (odds ratio [OR] 1.54; 95% confidence interval [CI] 1.00-2.36; compared with myopia, P = 0.05), shorter axial length (OR, 1.91; CI, 1.05-3.46, comparing 1st vs. 4th quartiles; P = 0.03), and steeper corneal curvature (OR, 1.93; CI, 1.16-3.20, comparing 1st vs. 4th quartiles, P = 0.01) were significantly associated with early AMD, after adjustment for age, sex, smoking, education, height, and systolic blood pressure. Each diopter increase in hyperopic refraction and each millimeter decrease in axial length was associated with an 8% (OR, 1.08; CI, 1.01-1.16; P = 0.03) and 29% (OR, 1.29; CI, 1.06-1.57; P = 0.01) increased risk of early AMD, respectively. No significant association was noted of refractive error and ocular biometry with late AMD.
   CONCLUSIONS. Hyperopic refractive error and shorter axial length are associated with early AMD in Asian eyes. (Invest Ophthalmol Vis Sci. 2010;51:6247-6252) DOI:10.1167/iovs.10-5229
C1 [Lavanya, Raghavan; Tay, Wan Ting; Cheung, Gemmy C. M.; Saw, Seang-Mei; Aung, Tin; Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 168751, Singapore.
   [Kawasaki, Ryo; Wong, Tien Y.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Mitchell, Paul] Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Saw, Seang-Mei] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Epidemiol & Publ Hlth, Singapore 117595, Singapore.
   [Aung, Tin; Wong, Tien Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
C3 National University of Singapore; Singapore National Eye Center; Centre
   for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Sydney; National University of
   Singapore; National University of Singapore
RP Wong, TY (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 3rd Hosp Ave, Singapore 168751, Singapore.
EM ophwty@nus.edu.sg
RI Mitchell, Paul/P-1498-2014; Kawasaki, Ryo/H-9716-2019; Kawasaki,
   Ryo/B-7266-2009; Wong, Tien Yin/AAC-9724-2020
OI Kawasaki, Ryo/0000-0002-7492-6303; Wong, Tien Yin/0000-0002-8448-1264;
   Cheung, Chui Ming Gemmy/0000-0003-3358-3516
FU National Medical Research Council [0796/2003, 0863/2004, CSI/0002/2005];
   Biomedical Research Council [501/1/25-5]
FX Supported by National Medical Research Council Grants 0796/2003,
   0863/2004, and CSI/0002/2005, and Biomedical Research Council Grant
   501/1/25-5, with additional support from the Singapore Tissue Network
   and the Ministry of Health, Singapore.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BERGER JW, 1999, AGE RELATED MACULAR, pR13
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   KATZ J, 1994, INVEST OPHTH VIS SCI, V35, P2461
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   Lim LS, 2010, INVEST OPHTH VIS SCI, V51, P103, DOI 10.1167/iovs.09-3553
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Morris B, 2007, POSTGRAD MED J, V83, P301, DOI 10.1136/pgmj.2006.052944
   SANDBERG MA, 1993, OPHTHALMOLOGY, V100, P1009
   Saw SM, 2008, OPHTHALMOLOGY, V115, P1713, DOI 10.1016/j.ophtha.2008.03.016
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Tao Y, 2010, EYE, V24, P648, DOI 10.1038/eye.2009.160
   Ulvik SO, 2005, ACTA OPHTHALMOL SCAN, V83, P419, DOI 10.1111/J.1600-0420.2005.00520.x
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Wang JJ, 2004, CLIN EXP OPHTHALMOL, V32, P255, DOI 10.1111/j.1442-9071.2004.00813.x
   Wang JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   Wong TY, 2008, ARCH OPHTHALMOL-CHIC, V126, P1091, DOI 10.1001/archopht.126.8.1091
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   Wong TY, 2002, INVEST OPHTH VIS SCI, V43, P2869
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu L, 2007, OPHTHALMOLOGY, V114, P121, DOI 10.1016/j.ophtha.2006.05.071
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
NR 45
TC 47
Z9 48
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2010
VL 51
IS 12
BP 6247
EP 6252
DI 10.1167/iovs.10-5229
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 688GJ
UT WOS:000284837500021
PM 20671287
DA 2022-11-30
ER

PT J
AU Yeter, DY
   Dursun, D
   Bozali, E
   Ozec, AV
   Erdogan, H
AF Yeter, D. Y.
   Dursun, D.
   Bozali, E.
   Ozec, A., V
   Erdogan, H.
TI Effects of the COVID-19 pandemic on neovascular age-related macular
   degeneration and response to delayed Anti-VEGF treatment
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Article
DE COVID-19; Age-related macular degeneration; Anti-VEGF; Pandemic
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB; EYE
AB Objectives. - To investigate the effects of the COVID-19 pandemic on the treatment course of neovascular age-related macular degeneration (nAMD) patients who received anti-VEGF injection therapy with real-life data.
   Methods. - This retrospective study consisted of 116 eyes of 106 patients. Ophthalmic examination, assessment of best-corrected visual acuity (BCVA), optical coherence tomography (OCT) findings and data of last two visits before restrictions (V-2 and V-1) and the first visit (V0) after the release of national lockdown and subsequent visits (V1 and Vlast) were recorded. The lockdown period was determined by the time interval between March 11 and June 1, 2020.
   Main results. - The injection interval before V-1 was significantly longer than the interval after V0 (2.56 +/- 0.9 vs. 2.14 +/- 0.8 months, P = 0.02). While the median central macular thickness (CMT) was significantly increased at V0 compared to V-1 [274(132-711) vs. 238(136-628), P < 0.001], the median CMT was significantly lower at V1 compared to V0 [256 (136-591) vs. 274(132-711), P = 0.003]. The median BCVA was 0.67(0.1-1.1) logMAR at V-1 and significantly worsened to 0.78 (0.1-1.2) logMAR at V0 (P = 0.003). Although the median BCVA improved to 0.69 logMAR (0.1-1.2) at Vlast, the difference did not reach statistical significance compared to V0 (P = 0.08).
   Conclusion. - Treatment delay due to the COVID-19 pandemic cause progression of nAMD and visual impairment. To plan more frequent anti-VEGF treatments and visits may be an appropriate approach until the disease stabilizes. However, it should be kept in mind that despite the improvement in OCT findings, the desired success in VA could not be achieved in the short term. (C) 2021 Elsevier Masson SAS. All rights reserved.
C1 [Yeter, D. Y.; Dursun, D.; Bozali, E.; Ozec, A., V; Erdogan, H.] Cumhuriyet Univ, Fac Med, Dept Ophthalmol, TR-58140 Sivas, Turkey.
C3 Cumhuriyet University
RP Yeter, DY (通讯作者)，Cumhuriyet Univ, Fac Med, Dept Ophthalmol, TR-58140 Sivas, Turkey.
EM duyguyalinbas@gmail.com
RI Bozali, Erman/AHC-2965-2022; Bozali, Erman/AFM-1678-2022
OI Bozali, Erman/0000-0001-7918-8381; Yalinbas, Duygu/0000-0001-9001-0277
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Antaki F, 2020, GRAEFES ARCH CLIN EX
   Borrelli E, 2020, GRAEFES ARCH CLINEXP, V3, P1
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chen L, 2020, ACTA OPHTHALMOL
   Cheung SSL, 2020, INT J OPHTHALMOL-CHI, V13, P851, DOI 10.18240/ijo.2020.06.01
   Corazza P, 2020, INT J RETINA VITREOU, V6, P1
   Corradetti G, 2020, OPHTHALMOL RETINA, V4, P757, DOI 10.1016/j.oret.2020.05.015
   Danthuluri V, 2020, OPHTHALMOL THER, V9, P853, DOI 10.1007/s40123-020-00310-5
   Fu LW, 2020, J INFECTION, V80, P656, DOI 10.1016/j.jinf.2020.03.041
   Gerding H, 2013, GRAEFES ARCH CLIN EX, V251, P453
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Invernizzi A, 2020, ECLINICAL MED
   Khanna S, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000398
   Kim JH, 2017, RETINA-J RET VIT DIS, V37, P2254, DOI 10.1097/IAE.0000000000001494
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Olivares-de Emparan JP, 2020, ARQ BRAS OFTALMOL, V83, P250, DOI [10.5935/0004-2749.20200067., 10.5935/0004-2749.20200067]
   Querques L, 2020, BRIT J OPHTHALMOL, V104, P47, DOI 10.1136/bjophthalmol-2018-313685
   Romano F, 2020, OPHTHALMOL RETINA
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Teo KYC, 2020, OPHTHALMOL RETINA
   Wecker T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38934-8
NR 27
TC 15
Z9 15
U1 1
U2 3
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD MAR
PY 2021
VL 44
IS 3
BP 299
EP 306
DI 10.1016/j.jfo.2021.02.001
EA MAR 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QX1SK
UT WOS:000629128600015
PM 33608176
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Ranjbar, M
   Kurz, M
   Holzhey, A
   Rades, D
   Grisanti, S
AF Ranjbar, Mahdy
   Kurz, Maximilian
   Holzhey, Annekatrin
   Rades, Dirk
   Grisanti, Salvatore
TI Changes in Peripapillary Nerve Fiber Layer Thickness after Adjuvant
   Stereotactic Radiotherapy in Patients with Neovascular Age-Related
   Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Anti-VEGF; neovascular age-related macular degeneration; optical
   coherence tomography; peripapillary retinal nerve fiber layer thickness;
   stereotactic radiotherapy
ID ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY; HUMAN RPE
   CELLS; RADIATION-THERAPY; RANIBIZUMAB; VEGF; RADIOSURGERY; BEVACIZUMAB;
   IRRADIATION; SURVIVAL
AB Purpose: To evaluate the effect of stereotactic radiotherapy (SRT) in conjunction with intravitreal injections (IVI) of anti-vascular endothelial growth factor (anti-VEGF) drugs on peripapillary retinal nerve fiber layer (pRNFL) thickness in patients with neovascular age-related macular degeneration (nAMD).
   Methods: This was a retrospective, observational case series of patients with nAMD, who underwent SRT and subsequently had at least 12 months of complete follow-up. After SRT and one mandatory IVI, patients were examined monthly and received further treatment on a pro re nata basis. Examination included spectral-domain optical coherence tomography of the optic disc to measure pRNFL thickness. Patients' data were retrieved from medical records including demographics, disease duration, best-corrected visual acuity, previous number of intravitreal injections, and the type of drug applied.
   Results: A total of 35 eyes of 35 patients (76.23 +/- 7.05 years) were included. The mean duration of nAMD at time of irradiation was 34.57 +/- 16.96 months. During that time, patients received a mean total number of 15.83 +/- 6.29 intravitreal injections, 6.86 +/- 1.57 within the last 12 months before SRT. After SRT, on average 3.46 +/- 2.09 injections were administered over 12 months, resulting in a mean total number of 19.29 +/- 6.92 injections at final follow-up. The mean global pRNFL thickness was 97.23 +/- 12.55 mu m at time of irradiation, 95.54 +/- 11.07 mu m at 6 month (P = 0.299), and 95.29 +/- 12.07 mu m at 12 month (P = 0.373) follow-up.
   Conclusion: SRT in conjunction with anti-VEGF injections did not lead to any significant change in pRNFL thickness over 12 months in patients with nAMD. However, long-term results are not yet available. Therefore, prospective studies with longer follow-up are needed to corroborate these findings.
C1 [Ranjbar, Mahdy; Kurz, Maximilian; Grisanti, Salvatore] Univ Lubeck, Dept Ophthalmol, Lubeck, Germany.
   [Ranjbar, Mahdy; Kurz, Maximilian; Holzhey, Annekatrin] Univ Lubeck, Lab Angiogenesis & Ocular Cell Transplantat, Lubeck, Germany.
   [Rades, Dirk] Univ Lubeck, Dept Radiat Oncol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.
C3 University of Lubeck; University of Lubeck; University of Lubeck
RP Ranjbar, M (通讯作者)，Ratzeburger Allee 160, D-23538 Lubeck, Germany.
EM eye.research101@gmail.com
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Brar VS, 2010, MOL VIS, V16, P1848
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Cantley JL, 2013, PHYS MED BIOL, V58, P6887, DOI 10.1088/0031-9155/58/19/6887
   Durkin SR, 2007, ACTA OPHTHALMOL SCAN, V85, P240, DOI 10.1111/j.1600-0420.2006.00822.x
   Enders P, 2017, OPHTHALMOLOGICA, V237, P111, DOI 10.1159/000457907
   Finger PT, 2005, BRIT J OPHTHALMOL, V89, P730, DOI 10.1136/bjo.2004.052159
   Foxton RH, 2013, AM J PATHOL, V182, P1379, DOI 10.1016/j.ajpath.2012.12.032
   Girkin CA, 1997, OPHTHALMOLOGY, V104, P1634, DOI 10.1016/S0161-6420(97)30084-0
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hanlon J, 2011, INVEST OPHTH VIS SCI, V52, P2334, DOI 10.1167/iovs.10-6421
   Hanlon J, 2009, MED PHYS, V36, P3671, DOI 10.1118/1.3168554
   Hasegawa T, 2010, NEUROSURGERY, V66, P688, DOI 10.1227/01.NEU.0000367554.96981.26
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Jackson TL, 2015, OPHTHALMOLOGY, V122, P138, DOI 10.1016/j.ophtha.2014.07.043
   Kishan AU, 2013, INT J RADIAT ONCOL, V85, P583, DOI 10.1016/j.ijrobp.2012.07.2352
   Lee C, 2008, MED PHYS, V35, P5151, DOI 10.1118/1.2990780
   Mantel I, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.6
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Moshfeghi DM, 2011, BRIT J OPHTHALMOL, V95, P185, DOI 10.1136/bjo.2009.163907
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Raman R, 2010, CUTAN OCUL TOXICOL, V29, P57, DOI 10.3109/15569520903331674
   Ranjbar M, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005729
   Ranjbar M, 2016, CYTOKINE, V83, P210, DOI 10.1016/j.cyto.2016.04.014
   Ranjbar M, 2016, CELL PHYSIOL BIOCHEM, V38, P737, DOI 10.1159/000443030
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sengul EA, 2016, J OCUL PHARMACOL TH, V32, P665, DOI 10.1089/jop.2016.0014
   Seregard S, 2013, DEV OPHTHALMOL, V52, P114, DOI 10.1159/000351088
   Sharei V, 2010, EUR J OPHTHALMOL, V20, P174, DOI 10.1177/112067211002000124
   Shin HJ, 2014, INVEST OPHTH VIS SCI, V55, P2403, DOI 10.1167/iovs.13-13769
   Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999
   Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092
   Yousef YA, 2012, OPHTHAL SURG LAS IM, V43, P6, DOI 10.3928/15428877-20111129-09
   Zachary I, 2005, NEUROSIGNALS, V14, P207, DOI 10.1159/000088637
   Zinkernagel MS, 2015, INVEST OPHTH VIS SCI, V56, P1894, DOI 10.1167/iovs.14-16204
NR 40
TC 1
Z9 1
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2017
VL 42
IS 12
BP 1698
EP 1706
DI 10.1080/02713683.2017.1355972
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FT0XR
UT WOS:000422853400020
PM 28937877
DA 2022-11-30
ER

PT J
AU Liutkeviciene, R
   Cebatoriene, D
   Zaliuniene, D
   Lukauskiene, R
   Jasinskas, V
AF Liutkeviciene, Rasa
   Cebatoriene, Dzastina
   Zaliuniene, Dalia
   Lukauskiene, Rita
   Jasinskas, Vytautas
TI A new maximum color contrast sensitivity test for detecting early
   changes of visual function in age-related macular degeneration
SO Medicina-Lithuania
LA English
DT Article
DE Age-related macular degeneration; Color vision; Visual acuity;
   Farnsworth-Munsell 100 hue test
ID VISION; EYES; AMD
AB Background and objective: To determine the association between age-related macular degeneration (AMD) and color perception established by the Farnsworth-Munsell 100 hue (F-M 100) and maximum color contrast sensitivity (MCCS) tests.
   Materials and methods: We performed a case-control study, which comprised of 100 patients with AMD and 100 healthy controls. To test visual acuity (VA), a typical Snellen chart was used. The computerized F-M 100 and MCCS programs were used for color discrimination.
   Results: The results of VA, and the F-M 100 and MCCS tests in the healthy controls were statistically significantly better than in the patients with AMD (1.0 vs. 0.82 +/- 0.16, P = 0.005; 87.39 +/- 24.11 vs. 185.39 +/- 74.43, P = 0.005; 1.33 +/- 1.17 vs. 1.96 +/- 0.46, P = 0.005, respectively). When VA was 1.0 in patients with AMD, the total error scores of the F-M 100 test and MCCS test compared with healthy persons were even worse (166.09 +/- 66.57 vs. 87.39 +/- 24.11, P = 0.002; 1.67 +/- 0.92 vs. 1.33 +/- 1.17, P = 0.001, respectively). Analysis of the results of patients with AMD compared to healthy controls showed the highest error score in the blue color range.
   Conclusions: The results of the color contrast sensitivity test decreased by half in patients with AMD compared with ophthalmologically healthy patients when they performed the FM 100 test and by one and half when they performed a MCCS test in the blue color range. (C) 2014 Lithuanian University of Health Sciences. Production and hosting by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
C1 [Liutkeviciene, Rasa; Cebatoriene, Dzastina; Zaliuniene, Dalia; Lukauskiene, Rita; Jasinskas, Vytautas] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, LT-50161 Kaunas, Lithuania.
   [Liutkeviciene, Rasa] Lithuanian Univ Hlth Sci, Med Acad, Inst Neurosci, LT-50161 Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences
RP Liutkeviciene, R (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, LT-50161 Kaunas, Lithuania.
EM rliutkeviciene@gmail.com
CR Arden GB, 2004, BRIT J OPHTHALMOL, V88, P1180, DOI 10.1136/bjo.2003.033480
   Beirne RO, 2008, OPHTHAL PHYSL OPT, V28, P448, DOI 10.1111/j.1475-1313.2008.00593.x
   Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272
   Boyatzis CJ, 1994, J GENET PSYCHOL, V155, P79
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Conway BR, 2001, J NEUROSCI, V21, P2768, DOI 10.1523/JNEUROSCI.21-08-02768.2001
   Dain Stephen J, 2004, Clin Exp Optom, V87, P322
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   FRENNESSON C, 1995, DOC OPHTHALMOL, V90, P377, DOI 10.1007/BF01268123
   Ginsburg Arthur P., 2003, International Ophthalmology Clinics, V43, P5
   GUILFORD JP, 1959, AM J PSYCHOL, V72, P487, DOI 10.2307/1419491
   Holz F G, 1995, Ger J Ophthalmol, V4, P336
   Jaint Nidhi, 2010, Indian J Physiol Pharmacol, V54, P366
   Kessel L, 1999, BRIT J OPHTHALMOL, V83, P1042, DOI 10.1136/bjo.83.9.1042
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Mantyjarvi M, 2001, Doc Ophthalmol, V102, P73, DOI 10.1023/A:1017553532092
   Margolis S, ELECTRODIAGNOSIS HER
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MORELAND JD, 1995, DOC OPHTHALMOL P SER, V57, P517
   O'Neill-Biba M, 2010, OPHTHAL PHYSL OPT, V30, P705, DOI 10.1111/j.1475-1313.2010.00775.x
   Pickford R., 1951, INDIVIDUAL DIFFERENC
   Sable P, 2010, ASBBS ANN C LAS VEG, V17, P950
   Sinkunas K, 2008, THESIS KMU KAUNAS
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   STONE EM, 1994, ARCH OPHTHALMOL-CHIC, V112, P765, DOI 10.1001/archopht.1994.01090180063036
   The Age-Related Eye Disease Study Research Group, 2005, AM J OPHTHALMOL, V112, P533
   Viliunas V, 2006, OPHTHAL PHYSL OPT, V26, P580, DOI 10.1111/j.1475-1313.2006.00411.x
   Woo George C, 2002, Clin Exp Optom, V85, P372
   Yang Y, 2001, INT J APPL LINGUIST, V11, P238, DOI [10.1111/1473-4192.00016, DOI 10.1111/1473-4192.00016]
NR 31
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER URBAN & PARTNER SP. Z O O
PI WROCLAW
PA UL KOSCIUSZKI 29, WROCLAW, 50-011, POLAND
SN 1010-660X
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PY 2014
VL 50
IS 5
BP 281
EP 286
DI 10.1016/j.medici.2014.10.008
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CA1YO
UT WOS:000348705900005
PM 25488164
OA gold
DA 2022-11-30
ER

PT J
AU Khan, SA
   Das, T
   Kumar, SM
   Nutheti, R
AF Khan, SA
   Das, T
   Kumar, SM
   Nutheti, R
TI Low vision rehabilitation in patients with age-related macular
   degeneration at a tertiary eye care centre in southern India
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; low vision devices; south India
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; BLUE MOUNTAINS EYE; VISUAL
   IMPAIRMENT; PREVALENCE; TRANSLOCATION; MACULOPATHY; AIDS
AB Purpose: To evaluate the specific needs and types of low vision devices (LVDs) in patients with age-related macular degeneration (AMD) so as to use the residual vision effectively.
   Methods: One hundred consecutive patients with diagnosis of AMD were evaluated to ascertain the degree of visual disability. Different LVDs were used to suit the specific needs of individual patients. The distribution of LVDs for distance and near and other rehabilitation measures were stratified for vision greater than or equal to6/18 and <6/18. Statistical analysis was performed using &chi;(2) test/Fisher's exact test and paired t-test.
   Results: The percentage of patients with visual acuity <6/18 reduced from 72.2% (26/36) to 47.2% (17/36) with the use of standard spectacles (P = 0.03). Similarly, the percentage of patients with visual acuity <6/18 reduced from 85.7% (6/7) to 14.3% (1/7) with the use of a telescope ( P = 0.029). The optical devices for near tasks included spectacle magnifiers (n = 59), stand magnifiers ( n = 19), and hand magnifiers (n = 18). With these LVDs, the near vision improved from 0.13 (decimal notations) to 0.39 (P < 0.001). Eighty-six patients were given at least one of the LVDs and 20% were prescribed more than one near device ( bifocals, spectacle magnifiers, hand magnifiers, stand magnifiers). Additionally, patients also needed counselling ( n = 89) and training on eccentric viewing ( n = 39), coin identification ( n = 45), and independent mobility ( n = 41).
   Conclusion: The overall management of a patient with AMD must include counselling, prescription of appropriate LVDs and training to utilize the residual vision to its fullest advantage. This is expected to improve the patient's quality of life.
C1 LV Prasad Eye Inst, Meera & LB Deshpande Ctr Sight Enhancement, Hyderabad 500034, Andhra Pradesh, India.
   LV Prasad Eye Inst, Smt Kanuri Santhamma Retina Vitreous Ctr, Hyderabad 500034, Andhra Pradesh, India.
   LV Prasad Eye Inst, PRK Prasad Ctr Rehabil Blind & Visually Impaired, Hyderabad 500034, Andhra Pradesh, India.
   LV Prasad Eye Inst, Publ Hlth Ophthalmol Serv, Hyderabad 500034, Andhra Pradesh, India.
C3 L. V. Prasad Eye Institute; L. V. Prasad Eye Institute; L. V. Prasad Eye
   Institute; L. V. Prasad Eye Institute
RP Khan, SA (通讯作者)，LV Prasad Eye Inst, Vis Rehabil Ctr, LV Prasad Marg,Banjara Hills, Hyderabad 500034, Andhra Pradesh, India.
CR BLOOM SM, 1997, LASER SURG POSTERIOR, P173
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   FINE SL, 1980, ARCH OPHTHALMOL-CHIC, V98, P832
   HOLEKAMP NM, 2000, CLIN TRIALS OPHTHALM, P185
   JOSE RT, 1983, UNDERSTANDING LOW VI, P141
   Keeffe JE, 1996, AUST NZ J OPHTHALMOL, V24, P207, DOI 10.1111/j.1442-9071.1996.tb01582.x
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kupfer C, 2000, OPHTHALMOLOGY, V107, P229, DOI 10.1016/S0161-6420(99)00094-9
   Lange N, 2001, INVEST OPHTH VIS SCI, V42, P38
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   Margrain TH, 2000, BRIT J OPHTHALMOL, V84, P919, DOI 10.1136/bjo.84.8.919
   Mehr EB, 1975, LOW VISION CARE
   *MIN HLTH FAM WELF, 1991, HLTH INF IND, P56
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Narendran, 2000, INVEST OPHTH VIS SCI, V41, pS119
   ROBINS HG, 1981, AUST J OPTOM, V64, P243
   Rohrschneider K, 1999, OPHTHALMOLOGE, V96, P611
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   Thylefors B, 1998, Indian J Ophthalmol, V46, P129
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P295
   VIRTANEN P, 1991, ACTA OPHTHALMOL, V69, P484
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Weale RA, 1997, MECH AGEING DEV, V97, P55, DOI 10.1016/S0047-6374(97)01906-4
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   *WHO, 1996, WORKSH WHO PBL MADR
   *WHO, 1997, 146 WHO
   Wolffsohn JS, 1999, OPTOMETRY VISION SCI, V76, P747, DOI 10.1097/00006324-199911000-00023
   *WORLD BANK, 1999, WORLD DEV REP 1998 1, P190
   1999, HUMAN DEV REPORT UN, P164
NR 33
TC 13
Z9 14
U1 0
U2 1
PU BLACKWELL PUBLISHING ASIA
PI CARLTON
PA 54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA
SN 1442-6404
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD DEC
PY 2002
VL 30
IS 6
BP 404
EP 410
DI 10.1046/j.1442-9071.2002.00569.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 616CR
UT WOS:000179284600005
PM 12427230
DA 2022-11-30
ER

PT J
AU Yu, JJ
   Azzam, DB
   Chwa, M
   Schneider, K
   Cho, JH
   Hsiang, CH
   Klassen, H
   Kenney, MC
   Yang, J
AF Yu, Jeffrey J.
   Azzam, Daniel B.
   Chwa, Marilyn
   Schneider, Kevin
   Cho, Jang-Hyeon
   Hsiang, Chinhui
   Klassen, Henry
   Kenney, M. Cristina
   Yang, Jing
TI Age-Related Macular Degeneration (AMD) Transmitochondrial Cybrids
   Protected from Cellular Damage and Death by Human Retinal Progenitor
   Cells (hRPCs)
SO STEM CELLS INTERNATIONAL
LA English
DT Article
AB Purpose. One of the leading causes of irreversible blindness worldwide, age-related macular degeneration (AMD) is a progressive disorder leading to retinal degeneration. While several treatment options exist for the exudative form of AMD, there are currently no FDA-approved treatments for the more common nonexudative (atrophic) form. Mounting evidence suggests that mitochondrial damage and retinal pigment epithelium (RPE) cell death are linked to the pathogenesis of AMD. Human retinal progenitor cells (hRPCs) have been studied as a potential restorative therapy for degenerative conditions of the retina; however, the effects of hRPC treatment on retinal cell survival in AMD have not been elucidated. Methods. In this study, we used a cell coculture system consisting of hRPCs and AMD or age-matched normal cybrid cells to characterize the effects of hRPCs in protecting AMD cybrids from cellular and mitochondrial damage and death. Results. AMD cybrids cocultured with hRPCs showed (1) increased cell viability; (2) decreased gene expression related to apoptosis, autophagy, endoplasmic reticulum (ER) stress, and antioxidant pathways; and (3) downregulation of mitochondrial replication genes compared to AMD cybrids without hRPC treatment. Furthermore, hRPCs cocultured with AMD cybrids showed upregulation of (1) neuronal and glial markers, as well as (2) putative neuroprotective factors, responses not found when hRPCs were cocultured with age-matched normal cybrids. Conclusion. The current study provides the first evidence that therapeutic benefits may be obtainable using a progenitor cell-based approach for atrophic AMD. Our results suggest that bidirectional interactions exist between hRPCs and AMD cybrids such that hRPCs release trophic factors that protect the cybrids against the cellular and mitochondrial changes involved in AMD pathogenesis while, conversely, AMD cybrids upregulate the release of these neuroprotective factors by hRPCs while promoting hRPC differentiation. These in vitro data provide evidence that hRPCs may have therapeutic potential in atrophic AMD.
C1 [Yu, Jeffrey J.; Azzam, Daniel B.; Chwa, Marilyn; Schneider, Kevin; Cho, Jang-Hyeon; Hsiang, Chinhui; Klassen, Henry; Kenney, M. Cristina; Yang, Jing] Univ Calif Irvine, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA 92697 USA.
   [Kenney, M. Cristina] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine;
   University of California System; University of California Irvine
RP Yang, J (通讯作者)，Univ Calif Irvine, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA 92697 USA.
EM yujef@med.umich.edu; azzamd@uci.edu; mchwa@uci.edu; kschneid@hs.uci.edu;
   janghyec@uci.edu; chsiang@uci.edu; hklassen@hs.uci.edu;
   mkenney@hs.uci.edu; jyang22@hs.uci.edu
OI Azzam, Daniel/0000-0002-6145-8416; Chwa, Marilyn/0000-0002-1874-6041
FU Discovery Eye Foundation; Polly and Michael Smith; Edith and Roy Carver;
   Iris and B. Gerald Cantor Foundation; Max Factor Family Foundation; NEI
   [R01 EY0127363]; Research to Prevent Blindness; Institute for Clinical
   and Translational Science (ICTS) at the University of California, Irvine
FX This work was supported by the Discovery Eye Foundation; Polly and
   Michael Smith; Edith and Roy Carver; Iris and B. Gerald Cantor
   Foundation; Max Factor Family Foundation; and NEI R01 EY0127363 (MCK).
   This work was supported in part by an Unrestricted Departmental Grant
   from Research to Prevent Blindness. We acknowledge the support of the
   Institute for Clinical and Translational Science (ICTS) at the
   University of California, Irvine. J. J. Yu is an Arnold and Mabei
   Beckman Fellow in Retinal Degeneration.
CR Aftab U, 2009, EXP EYE RES, V89, P301, DOI 10.1016/j.exer.2009.03.025
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Au A, 2017, BRIT J OPHTHALMOL, V101, P970, DOI 10.1136/bjophthalmol-2016-309434
   Bartsch U, 2008, EXP EYE RES, V86, P691, DOI 10.1016/j.exer.2008.01.018
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381
   Campbell W.A., 2020, MIDKINE CHICK MOUSE, P1, DOI [10.1101/2020.08.12.248245v2, DOI 10.1101/2020.08.12.248245V2]
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GRAY MW, 1992, INT REV CYTOL, V141, P233, DOI 10.1016/S0074-7696(08)62068-9
   Hayat MJ, 2007, ONCOLOGIST, V12, P20, DOI 10.1634/theoncologist.12-1-20
   Nguyen H, 2019, STROKE, V50, P2197, DOI 10.1161/STROKEAHA.119.025249
   Izzotti A, 2010, ARCH OPHTHALMOL-CHIC, V128, P724, DOI 10.1001/archophthalmol.2010.87
   Jiang CH, 2010, MOL VIS, V16, P983
   Jung CG, 2004, FASEB J, V18, P1237, DOI 10.1096/fj.03-0927fje
   Kaarniranta K, 2012, FUTURE MED CHEM, V4, P2153, DOI [10.4155/FMC.12.169, 10.4155/fmc.12.169]
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kenney MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054339
   Klassen H, 2004, PROG RETIN EYE RES, V23, P149, DOI 10.1016/j.preteyeres.2004.01.002
   Klassen H, 2004, J NEUROSCI RES, V77, P334, DOI 10.1002/jnr.20183
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kowluru RA, 2015, BBA-MOL BASIS DIS, V1852, P2474, DOI 10.1016/j.bbadis.2015.08.001
   Luo J, 2014, J BIOL CHEM, V289, P6362, DOI 10.1074/jbc.M113.513713
   Ma HW, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-019-2216-7
   Mansergh FC, 2014, EUR J HUM GENET, V22, P1314, DOI 10.1038/ejhg.2014.26
   Manuguerra-Gagne R, 2013, STEM CELLS, V31, P1136, DOI 10.1002/stem.1364
   McCusker MM, 2016, CLIN DERMATOL, V34, P276, DOI 10.1016/j.clindermatol.2015.11.009
   Miceli MV, 2005, INVEST OPHTH VIS SCI, V46, P1765, DOI 10.1167/iovs.04-1327
   Nagashima M, 2020, J NEUROSCI, V40, P1232, DOI 10.1523/JNEUROSCI.1675-19.2019
   Nashine S, 2020, NUTRIENTS, V12, DOI 10.3390/nu12010159
   Nashine S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.348
   Nashine S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159828
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   O'Brien T, 2009, MAYO CLIN PROC, V84, P859, DOI 10.1016/S0025-6196(11)60501-6
   Ozal SA, 2018, CURR EYE RES, V43, P1169, DOI 10.1080/02713683.2018.1481517
   Ratajczak MZ, 2012, LEUKEMIA, V26, P1166, DOI 10.1038/leu.2011.389
   Roque R.S., 2006, INVEST OPHTH VIS SCI, V47, P5764
   Schmitt S, 2009, INVEST OPHTH VIS SCI, V50, P5901, DOI 10.1167/iovs.08-3067
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Singh MS, 2020, PROG RETIN EYE RES, V75, DOI 10.1016/j.preteyeres.2019.100779
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   Sun JN, 2015, STEM CELLS, V33, P1543, DOI 10.1002/stem.1960
   Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3
   UNOKI K, 1994, INVEST OPHTH VIS SCI, V35, P4063
   Wang X, 2019, MOL MED REP, V19, P59, DOI 10.3892/mmr.2018.9645
   Yu DY, 2011, EXPERT REV OPHTHALMO, V6, P395, DOI 10.1586/EOP.11.44
   Yu J., 2018, INVESTIG OPHTHALMOL, V59, P2468
   Zarbin M, 2016, TRENDS MOL MED, V22, P115, DOI 10.1016/j.molmed.2015.12.007
NR 50
TC 3
Z9 3
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-966X
EI 1687-9678
J9 STEM CELLS INT
JI Stem Cells Int.
PD FEB 9
PY 2021
VL 2021
AR 6655372
DI 10.1155/2021/6655372
PG 15
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA QM5WB
UT WOS:000621848300002
PM 33628267
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gonzalez-Gonzalo, C
   Sanchez-Gutierrez, V
   Hernandez-Martinez, P
   Contreras, I
   Lechanteur, YT
   Domanian, A
   van Ginneken, B
   Sanchez, CI
AF Gonzalez-Gonzalo, Cristina
   Sanchez-Gutierrez, Veronica
   Hernandez-Martinez, Paula
   Contreras, Ines
   Lechanteur, Yara T.
   Domanian, Artin
   van Ginneken, Bram
   Sanchez, Clara I.
TI Evaluation of a deep learning system for the joint automated detection
   of diabetic retinopathy and age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; automated detection; deep learning;
   diabetic retinopathy; observer study; validation
ID COST-EFFECTIVENESS; VISUAL IMPAIRMENT; GLOBAL PREVALENCE; RETINAL
   IMAGES; PRIMARY-CARE; DISEASE; VALIDATION; RISK
AB Purpose To validate the performance of a commercially available, CE-certified deep learning (DL) system, RetCAD v.1.3.0 (Thirona, Nijmegen, The Netherlands), for the joint automatic detection of diabetic retinopathy (DR) and age-related macular degeneration (AMD) in colour fundus (CF) images on a dataset with mixed presence of eye diseases. Methods Evaluation of joint detection of referable DR and AMD was performed on a DR-AMD dataset with 600 images acquired during routine clinical practice, containing referable and non-referable cases of both diseases. Each image was graded for DR and AMD by an experienced ophthalmologist to establish the reference standard (RS), and by four independent observers for comparison with human performance. Validation was furtherly assessed on Messidor (1200 images) for individual identification of referable DR, and the Age-Related Eye Disease Study (AREDS) dataset (133 821 images) for referable AMD, against the corresponding RS. Results Regarding joint validation on the DR-AMD dataset, the system achieved an area under the ROC curve (AUC) of 95.1% for detection of referable DR (SE = 90.1%, SP = 90.6%). For referable AMD, the AUC was 94.9% (SE = 91.8%, SP = 87.5%). Average human performance for DR was SE = 61.5% and SP = 97.8%; for AMD, SE = 76.5% and SP = 96.1%. Regarding detection of referable DR in Messidor, AUC was 97.5% (SE = 92.0%, SP = 92.1%); for referable AMD in AREDS, AUC was 92.7% (SE = 85.8%, SP = 86.0%). Conclusion The validated system performs comparably to human experts at simultaneous detection of DR and AMD. This shows that DL systems can facilitate access to joint screening of eye diseases and become a quick and reliable support for ophthalmological experts.
C1 [Gonzalez-Gonzalo, Cristina; Sanchez, Clara I.] Radboud Univ Nijmegen, Med Ctr, A Eye Res Grp, Nijmegen, Netherlands.
   [Gonzalez-Gonzalo, Cristina; van Ginneken, Bram; Sanchez, Clara I.] Radboud Univ Nijmegen, Med Ctr, Diagnost Image Anal Grp, Nijmegen, Netherlands.
   [Gonzalez-Gonzalo, Cristina; Sanchez, Clara I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands.
   [Gonzalez-Gonzalo, Cristina; Lechanteur, Yara T.; Domanian, Artin; Sanchez, Clara I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
   [Sanchez-Gutierrez, Veronica; Hernandez-Martinez, Paula; Contreras, Ines] Univ Hosp Ramon y Cajal, Ramon y Cajal Hlth Res Inst IRYCIS, Dept Ophthalmol, Madrid, Spain.
   [Contreras, Ines] Clin Rementeria, Madrid, Spain.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Radboud
   University Nijmegen; Radboud University Nijmegen; Hospital Universitario
   Ramon y Cajal
RP Gonzalez-Gonzalo, C (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Diagnost Image Anal Grp, Dept Radiol & Nucl Med, Geert Grootepl 10, NL-6525 GA Nijmegen, Netherlands.
EM Cristina.GonzalezGonzalo@radboudumc.nl
RI Lechanteur, Yara/ABB-6875-2020; Lehtimäki, Terho/AAD-1094-2022;
   Gonzalez-Gonzalo, Cristina/ABD-9032-2020; van Ginneken, Bram/A-3728-2012
OI Lechanteur, Yara/0000-0003-0951-4625; Lehtimäki,
   Terho/0000-0002-2555-4427; Gonzalez-Gonzalo,
   Cristina/0000-0001-8413-3297; van Ginneken, Bram/0000-0003-2028-8972;
   Contreras, Ines/0000-0003-3524-9335
CR AAO, 2017, PREF PRACT PATT DIAB
   AAO, 2015, PREF PRACT PATT AG R
   Abramoff MD, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0040-6
   Abramoff MD, 2013, JAMA OPHTHALMOL, V131, P351, DOI 10.1001/jamaophthalmol.2013.1743
   Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   ADCIS, MESS DAT
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Antony M, 2015, TEAM O O SOLUTION
   Arun CS, 2003, DIABETIC MED, V20, P186, DOI 10.1046/j.1464-5491.2003.t01-1-00899.x
   Burlina P, 2011, IEEE ENG MED BIO, P3962, DOI 10.1109/IEMBS.2011.6090984
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Chan CKW, 2015, OPHTHALMOLOGY, V122, P2278, DOI 10.1016/j.ophtha.2015.06.050
   Chew EY, 2015, OPHTHALMOLOGY, V122, P2155, DOI 10.1016/j.ophtha.2015.08.007
   Chollet F, 2017, PROC CVPR IEEE, P1800, DOI 10.1109/CVPR.2017.195
   Comer GM, 2004, DRUG AGING, V21, P967, DOI 10.2165/00002512-200421150-00002
   Cuadros Jorge, 2009, J Diabetes Sci Technol, V3, P509
   Cunha-Vaz J, 1998, DIABETIC MED, V15, pS47, DOI 10.1002/(SICI)1096-9136(1998120)15:4+<S47::AID-DIA739>3.3.CO;2-J
   Decenciere E, 2014, IMAGE ANAL STEREOL, V33, P231, DOI 10.5566/ias.1155
   Efron B, 1993, INTRO BOOTSTRAP, P202
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Guariguata L, 2014, DIABETES RES CLIN PR, V103, P137, DOI 10.1016/j.diabres.2013.11.002
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Harmon D, 2009, ACM T GRAPHIC, V28, DOI 10.1145/1531326.1531393
   Hernandez RA, 2008, INT J TECHNOL ASSESS, V24, P203, DOI 10.1017/S0266462308080288
   Hripcsak G, 2002, J BIOMED INFORM, V35, P99, DOI 10.1016/S1532-0464(02)00500-2
   Huang G, 2017, PROC CVPR IEEE, P2261, DOI 10.1109/CVPR.2017.243
   IAPB, 2016, DIABETIC RETINOPATHY
   IDF, 2017, IDF DIAB ATL 2017
   Jain S, 2006, EYE, V20, P471, DOI 10.1038/sj.eye.6701916
   James M, 2000, BRIT MED J, V320, P1627, DOI 10.1136/bmj.320.7250.1627
   Jones S, 2010, DIABETIC MED, V27, P249, DOI 10.1111/j.1464-5491.2009.02870.x
   Karnon J, 2008, NIHR J LIB
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   LaTIM, 2011, MESS 2 DAT
   Lecun Y, 1998, P IEEE, V86, P2278, DOI 10.1109/5.726791
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Li ZX, 2018, DIABETES CARE, V41, P2509, DOI 10.2337/dc18-0147
   Litjens G, 2017, MED IMAGE ANAL, V42, P60, DOI 10.1016/j.media.2017.07.005
   NEI, AREDS MAN OP STUD DE
   NEI, AREDS DBGAP DAT TABL
   NHS, 2014, DIAB EYE SCREEN PROG
   NOG, 2017, DIAB RETIN MULT GUID
   Ouyang YL, 2013, INVEST OPHTH VIS SCI, V54, P1460, DOI 10.1167/iovs.12-10727
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Pinero DP, 2013, J OPTOM, V6, P67
   Raman R, 2019, EYE, V33, P97, DOI 10.1038/s41433-018-0269-y
   Rowe S, 2004, JAMA-J AM MED ASSOC, V291, P1487, DOI 10.1001/jama.291.12.1487
   Sanchez CI, 2011, INVEST OPHTH VIS SCI, V52, P4866, DOI 10.1167/iovs.10-6633
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007
   Simonyan K., 2014, PREPRINT, DOI DOI 10.48550/ARXIV.1409.1556
   Szegedy C., 2017, INCEPTION V4, V31, P1, DOI 10.1609/aaai.v31i1.11231
   Szegedy C., 2015, IEEE C COMP VIS PATT, P1, DOI DOI 10.1109/CVPR.2015.7298594
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   United Nations Department of Economic and Social Affairs, 2017, WORLD POP AG REP 201
   University of Iowa Health Care, 2017, DEP OPHTHALMOLOGY VI
   WHO, 2013, GLOB ACT PLAN PREV A
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wormald R, 1999, Community Eye Health, V12, P29
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   ZWEIG MH, 1993, CLIN CHEM, V39, P561
NR 66
TC 35
Z9 35
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2020
VL 98
IS 4
BP 368
EP 377
DI 10.1111/aos.14306
EA NOV 2019
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LN3HJ
UT WOS:000498568000001
PM 31773912
OA Green Published, hybrid, Green Submitted
DA 2022-11-30
ER

PT J
AU Parlak, M
   Oner, FH
   Saatci, AO
AF Parlak, Melih
   Oner, F. Hakan
   Saatci, A. Osman
TI The long-term effect of intravitreal ranibizumab on retinal nerve fiber
   layer thickness in exudative age-related macular degeneration
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; INTRAOCULAR-PRESSURE; GANGLION-CELLS;
   OPTIC-NERVE; BEVACIZUMAB; INJECTIONS
AB The aim of this study was to evaluate the long-term effect of intravitreal ranibizumab on the retinal nerve fiber layer (RNFL) in exudative age-related macular degeneration (AMD). Patients with treatment naive neovascular AMD in one eye were enrolled into the study. Following 3 monthly intravitreal ranibizumab injections, the patients were evaluated according to disease activity and re-injections were performed according to "treat and extend" protocol. During the follow-up, peripapillary nerve fiber layer thickness measurements were compared with normal fellow eyes. Forty-four eyes of 11 women and 11 men with the mean age of 66.3 +/- A 8.8 years (50-80) were enrolled into the study. All patients had completed at least 12 months of follow-up time. Patients received an average of 4.7 (3-11 injections) intravitreal injections. At baseline, no significant difference was observed between two groups for RNFL thickness, which was assessed as quadrants (p = 0.250-0.944) and globally (p = 0.814). In each group, there was a significant RNFL thinning (p = 0.009 and 0.022) after the third month, whereas no significant difference was observed between treated and untreated eyes. Patients were also classified according to the number of injections, and RNFL thickness showed no difference between eyes treated with less or more than five intravitreal injections (p = 0.757-0.973). Although there was no statistically significant difference in RNFL thickness between study and control eyes during 12 months of follow-up, a significant thinning was recorded in both groups compared with baseline values. Cross-sectional images with higher resolutions and precise segmentation opportunities are needed to investigate the hypothesis "VEGF neutralization and inhibition of cell maintenance" in detail.
C1 [Parlak, Melih] Prof Dr Med M Reichel & Augenabteilung Klinikum K, Gemeinschaftspraxis FA Longere, D-78462 Constance, Germany.
   [Oner, F. Hakan; Saatci, A. Osman] Dokuz Eylul Univ, Dept Ophthalmol, Sch Med, TR-35340 Izmir, Turkey.
C3 Dokuz Eylul University
RP Parlak, M (通讯作者)，Prof Dr Med M Reichel & Augenabteilung Klinikum K, Gemeinschaftspraxis FA Longere, Marktstaette 11, D-78462 Constance, Germany.
EM melih@parlak.de
CR Arikan G, 2011, INT J OPHTHALMOL-CHI, V4, P402, DOI 10.3980/j.issn.2222-3959.2011.04.16
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Bendschneider D, 2010, J GLAUCOMA, V19, P475, DOI 10.1097/IJG.0b013e3181c4b0c7
   Brar VS, 2010, MOL VIS, V16, P1848
   Breen EC, 2007, J CELL BIOCHEM, V102, P1358, DOI 10.1002/jcb.21579
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Gamulescu MA, 2010, J OCUL PHARMACOL TH, V26, P213, DOI 10.1089/jop.2009.0126
   Girkin CA, 2011, OPHTHALMOLOGY, V118, P2403, DOI 10.1016/j.ophtha.2011.06.013
   Gismondi M, 2009, J GLAUCOMA, V18, P658, DOI 10.1097/IJG.0b013e31819c4893
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Kilic U, 2006, J NEUROSCI, V26, P12439, DOI 10.1523/JNEUROSCI.0434-06.2006
   Kim Eun-Ji, 2011, Korean J Ophthalmol, V25, P248, DOI 10.3341/kjo.2011.25.4.248
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Rouvas A, 2009, OPHTHALMOLOGICA, V223, P383, DOI 10.1159/000228590
   Seth RK, 2009, RETINA-J RET VIT DIS, V29, P956, DOI 10.1097/IAE.0b013e3181a91dfd
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Zhang Shui-Hu, 2009, Zhonghua Yan Ke Za Zhi, V45, P38
NR 22
TC 21
Z9 21
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD AUG
PY 2015
VL 35
IS 4
BP 473
EP 480
DI 10.1007/s10792-014-9972-2
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CL9HI
UT WOS:000357287700004
PM 25059401
DA 2022-11-30
ER

PT J
AU Tsuchihashi, T
   Mori, K
   Peyman, G
   Shimada, Y
   Yoneya, S
AF Tsuchihashi, Takashi
   Mori, Keisuke
   Peyman, Gholam
   Shimada, Yoshiaki
   Yoneya, Shin
TI PHOTODYNAMIC EFFECTS ON RETINAL OXYGEN SATURATION, BLOOD FLOW, AND
   ELECTROPHYSIOLOGICAL FUNCTION IN PATIENTS WITH NEOVASCULAR AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascular age-related macular degeneration; photodynamic therapy;
   retinal oxygen saturation; retinal blood flow; retina electrophysiology
ID CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL INJECTION; THERAPY; EYES
AB Purpose: To evaluate the effect of photodynamic therapy (PDT) on retinal functions, such as oxygen saturation, blood flow, and electrophysiological function using Fourier transform-based spectral retinal imaging (SRI), Heidelberg retinal flowmeter (HRF), and multifocal electroretinogram (mfERG).
   Methods: This was a prospective interventional case series. Twenty-two patients with age-related macular degeneration (AMD) with unilateral choroidal neovascularization (CNV) were examined using SRI, HRF, and mfERG before and 1 week and 1 month after PDT. Eleven fellow eyes without CNV and 11 control eyes of 11 age-matched healthy volunteers were also investigated. Eleven of 22 patients with neovascular AMD were retreated using verteporfin PDT and examined using a protocol similar to the one used for the first treatment.
   Results: Oxygen saturation levels in the macula of eyes with neovascular AMD were significantly higher than those in normal control eyes (P = 0.026) but were not significantly higher in eyes with nonneovascular AMD. Oxygen saturation levels decreased 1 week after a single treatment (P = 4.59 x 10(-3)) and retreatment (P = 0.0134) and recovered to baseline levels at 1 month follow-up (P > 0.05). HRF demonstrated reduced mean blood flow at 1 week after single treatment (P = 9.22 x 10(-4)) and retreatment (P = 0.0307). One month after PDT, mean blood flow tended to show recovery. There was a similar decrease in mfERG amplitude 1 week after treatment, but the logarithm of minimum angular resolution (logMAR) vision was stable or improved throughout follow-up.
   Conclusion: Oxygen saturation levels, mean blood flow, and mfERG amplitude decreased 1 week after PDT treatment in both single treatment and retreatment groups. Although logMAR vision is stable or improved, our data showed transient functional deterioration in the retina after PDT treatment. RETINA 29:1450-1456, 2009
C1 [Tsuchihashi, Takashi; Mori, Keisuke; Shimada, Yoshiaki; Yoneya, Shin] Saitama Med Univ, Sch Med, Dept Ophthalmol, Iruma, Saitama 3500495, Japan.
   [Peyman, Gholam] Univ Arizona, Coll Med, Dept Ophthalmol & Vis Sci, Tucson, AZ 85721 USA.
C3 Saitama Medical University; University of Arizona
RP Yoneya, S (通讯作者)，Saitama Med Univ, Sch Med, Dept Ophthalmol, 38 Morohongo, Iruma, Saitama 3500495, Japan.
EM shin@saitama-med.ac.jp
CR Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   GRADOUDAS ES, 2004, NEW ENGL J MED, V351, P2805
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Ito M, 2008, EXP EYE RES, V86, P512, DOI 10.1016/j.exer.2007.12.010
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2005, RETINA-J RET VIT DIS, V25, P430, DOI 10.1097/00006982-200506000-00006
   Nishiyama Y, 2001, RETINA-J RET VIT DIS, V21, P237, DOI 10.1097/00006982-200106000-00007
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Remsch H, 2000, GRAEF ARCH CLIN EXP, V238, P960, DOI 10.1007/s004170000202
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Shimada Y, 2003, INVEST OPHTH VIS SCI, V44, P1245, DOI 10.1167/iovs.02-0527
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Singh CN, 2008, RETINA-J RET VIT DIS, V28, P789, DOI 10.1097/IAE.0b013e31817082d7
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Yoneya S, 2002, OPHTHALMOLOGY, V109, P1521, DOI 10.1016/S0161-6420(02)01109-0
NR 24
TC 6
Z9 6
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2009
VL 29
IS 10
BP 1450
EP 1456
DI 10.1097/IAE.0b013e3181ac2403
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 519SH
UT WOS:000271787600010
PM 19816240
DA 2022-11-30
ER

PT J
AU Zhang, Y
   Gao, S
   Li, X
   Huang, X
   Zhang, Y
   Chang, TC
   Cai, ZL
   Zhang, MX
AF Zhang, Yun
   Gao, Sheng
   Li, Xun
   Huang, Xi
   Zhang, Yi
   Chang, Tiancong
   Cai, Zhaolun
   Zhang, Meixia
TI Efficacy and Safety of Anti-Vascular Endothelial Growth Factor
   Monotherapies for Neovascular Age-Related Macular Degeneration: A Mixed
   Treatment Comparison
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE anti-vascular endothelial growth factor monotherapy; neovascular
   age-related macular degeneration; efficacy; safety; mixed treatment
   comparison
ID VERTEPORFIN PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULARIZATION;
   RANIBIZUMAB; BEVACIZUMAB; AFLIBERCEPT; TRIAL; MANAGEMENT; METAANALYSIS;
   REGIMEN; EXTEND
AB Background: We aimed to evaluate the comparative efficacy and safety of anti-vascular endothelial growth factor (anti-VEGF) monotherapy to identify its utilization and prioritization in patients with neovascular age-related macular degeneration (nAMD).Methods: Eligible studies included randomized controlled trials comparing the recommended anti-VEGF agents (ranibizumab, bevacizumab, aflibercept, brolucizumab, and conbercept) under various therapeutic regimens. Outcomes of interest included the mean change in best-corrected visual acuity (BCVA), serious adverse events, the proportion of patients who gained >= 15 letters or lost <15 letters in BCVA, the mean change in central retinal thickness, and the number of injections within 12 months.Results: Twenty-seven trials including 10,484 participants and eighteen treatments were identified in the network meta-analysis. The aflibercept 2 mg bimonthly, ranibizumab 0.5 mg T&E, and brolucizumab 6 mg q12w/q8w regimens had better visual efficacy. Brolucizumab had absolute superiority in anatomical outcomes and a relative advantage of safety, as well as good performance of aflibercept 2 mg T&E. The proactive regimens had slightly better efficacy but a slightly increased number of injections versus the reactive regimen. Bevacizumab had a statistically non-significant trend toward a lower degree of efficacy and safety.Conclusion: The visual efficacy of four individual anti-VEGF drugs is comparable. Several statistically significant differences were observed considering special anti-VEGF regimens, suggesting that brolucizumab 6 mg q12w/q8w, aflibercept 2 mg bimonthly or T&E, and ranibizumab 0.5 mg T&E are the ideal anti-VEGF regimens for nAMD patients. In the current landscape, based on the premise of equivalent efficacy and safety, the optimal choice of anti-VEGF monotherapies seems mandatory to obtain maximal benefit.
C1 [Zhang, Yun; Gao, Sheng; Li, Xun; Huang, Xi; Zhang, Yi; Chang, Tiancong; Zhang, Meixia] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu, Peoples R China.
   [Zhang, Yun; Gao, Sheng; Li, Xun; Huang, Xi; Zhang, Yi; Chang, Tiancong; Zhang, Meixia] Sichuan Univ, West China Hosp, Res Lab Macular Dis, Chengdu, Peoples R China.
   [Cai, Zhaolun] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University
RP Zhang, MX (通讯作者)，Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu, Peoples R China.; Zhang, MX (通讯作者)，Sichuan Univ, West China Hosp, Res Lab Macular Dis, Chengdu, Peoples R China.; Cai, ZL (通讯作者)，Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu, Peoples R China.
EM caizhaolun@foxmail.com; zhangmeixia@scu.edu.cn
RI Cai, Zhaolun/Q-9930-2019
OI Cai, Zhaolun/0000-0002-3706-6703
FU 1.3.5 project for disciplines of excellence, West China Hospital,
   Sichuan University [ZYJC21025]; Postdoctoral Research Project, West
   China Hospital, Sichuan University [2020HXBH112]; China Postdoctoral
   Science Foundation [2021M692273]
FX This study is supported by the 1.3.5 project for disciplines of
   excellence, West China Hospital, Sichuan University (ZYJC21025), the
   Postdoctoral Research Project, West China Hospital, Sichuan University
   (2020HXBH112), and China Postdoctoral Science Foundation (2021M692273).
CR Amarakoon S, 2019, ACTA OPHTHALMOL, V97, P107, DOI 10.1111/aos.13774
   [Anonymous], 2018, NICE GUIDELINE NG82
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Dias S, 2010, STAT MED, V29, P932, DOI 10.1002/sim.3767
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   El-Mollayess GM, 2012, AM J OPHTHALMOL, V153, P481, DOI 10.1016/j.ajo.2011.08.018
   Feltgen N, 2017, GRAEF ARCH CLIN EXP, V255, P923, DOI 10.1007/s00417-017-3589-x
   Galvez MIL, 2020, ACTA OPHTHALMOL, V98, pE820, DOI 10.1111/aos.14399
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Haga A, 2018, ACTA OPHTHALMOL, V96, pE393, DOI 10.1111/aos.13607
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hiplot, 2021, DATA VISUALIZATION D
   Hong HK, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.22
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Kaiser PK, 2009, CURR MED RES OPIN, V25, P1853, DOI 10.1185/03007990903038616
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I., 2013, COMP RANIBIZUMAB MON
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Lumley T, 2002, STAT MED, V21, P2313, DOI 10.1002/sim.1201
   Lushchyk T, 2013, ACTA OPHTHALMOL, V91, pe456, DOI 10.1111/aos.12119
   MacDonald DA, 2016, ANGIOGENESIS, V19, P389, DOI 10.1007/s10456-016-9515-8
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Platania CBM, 2015, FRONT PHARMACOL, V6, DOI [10.3389/fphar.2015.00248, 10.3389/tphar.7015.00248]
   Plyukhova AA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051522
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Wang FH, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/7530458
   Weingessel B, 2016, WIEN KLIN WOCHENSCHR, V128, P560, DOI 10.1007/s00508-015-0772-0
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Lu Y, 2020, THER ADV CHRONIC DIS, V11, DOI 10.1177/2040622320953349
   Yeung L, 2021, J FORMOS MED ASSOC, V120, P2061, DOI 10.1016/j.jfma.2021.06.012
   Zhao XY, 2021, ACTA OPHTHALMOL, V99, pE1041, DOI 10.1111/aos.14756
NR 53
TC 3
Z9 3
U1 1
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD DEC 21
PY 2021
VL 12
AR 797108
DI 10.3389/fphar.2021.797108
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA YB5RM
UT WOS:000739069300001
PM 34992542
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Chen, QY
   Keenan, TDL
   Allot, A
   Peng, YF
   Agron, E
   Domalpally, A
   Klaver, CCW
   Luttikhuizen, DT
   Colyer, MH
   Cukras, CA
   Wiley, HE
   Magone, MT
   Cousineau-Krieger, C
   Wong, WT
   Zhu, YY
   Chew, EY
   Lu, ZY
AF Chen, Qingyu
   Keenan, Tiarnan D. L.
   Allot, Alexis
   Peng, Yifan
   Agron, Elvira
   Domalpally, Amitha
   Klaver, Caroline C. W.
   Luttikhuizen, Daniel T.
   Colyer, Marcus H.
   Cukras, Catherine A.
   Wiley, Henry E.
   Magone, M. Teresa
   Cousineau-Krieger, Chantal
   Wong, Wai T.
   Zhu, Yingying
   Chew, Emily Y.
   Lu, Zhiyong
CA AREDS2 Deep Learning Res Grp
TI Multimodal, multitask, multiattention (M3) deep learning detection of
   reticular pseudodrusen: Toward automated and accessible classification
   of age-related macular degeneration
SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
LA English
DT Article
DE reticular pseudodrusen; subretinal drusenoid deposits; age-related
   macular degeneration; Age-Related Eye Disease Study 2; deep learning;
   multimodal deep learning; multitask training; multiattention deep
   learning
ID EYE DISEASE; FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY; HIGH-RISK;
   TRIAL; DESIGN; HOME
AB Objective: Reticular pseudodrusen (RPD), a key feature of age-related macular degeneration (AMD), are poorly detected by human experts on standard color fundus photography (CFP) and typically require advanced imaging modalities such as fundus autofluorescence (FAF). The objective was to develop and evaluate the performance of a novel multimodal, multitask, multiattention (M3) deep learning framework on RPD detection.
   Materials and Methods: A deep learning framework (M3) was developed to detect RPD presence accurately using CFP alone, FAF alone, or both, employing >8000 CFP-FAF image pairs obtained prospectively (Age-Related Eye Disease Study 2). The M3 framework includes multimodal (detection from single or multiple image modalities), multitask (training different tasks simultaneously to improve generalizability), and multiattention (improving ensembled feature representation) operation. Performance on RPD detection was compared with state-of-the-art deep learning models and 13 ophthalmologists; performance on detection of 2 other AMD features (geographic atrophy and pigmentary abnormalities) was also evaluated.
   Results: For RPD detection, M3 achieved an area under the receiver-operating characteristic curve (AUROC) of 0.832, 0.931, and 0.933 for CFP alone, FAF alone, and both, respectively. M3 performance on CFP was very substantially superior to human retinal specialists (median F1 score = 0.644 vs 0.350). External validation (the Rotterdam Study) demonstrated high accuracy on CFP alone (AUROC, 0.965). The M3 framework also accurately detected geographic atrophy and pigmentary abnormalities (AUROC, 0.909 and 0.912, respectively), demonstrating its generalizability.
   Conclusions: This study demonstrates the successful development, robust evaluation, and external validation of a novel deep learning framework that enables accessible, accurate, and automated AMD diagnosis and prognosis.
C1 [Chen, Qingyu; Allot, Alexis; Peng, Yifan; Lu, Zhiyong] Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, 8600 Rockville Pike, Bethesda, MD 20209 USA.
   [Keenan, Tiarnan D. L.; Agron, Elvira; Cukras, Catherine A.; Wiley, Henry E.; Magone, M. Teresa; Cousineau-Krieger, Chantal; Wong, Wai T.; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Domalpally, Amitha] Univ Wisconsin, Fundus Photograph Reading Ctr, Madison, WI USA.
   [Klaver, Caroline C. W.; Luttikhuizen, Daniel T.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Colyer, Marcus H.] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA.
   [Wong, Wai T.] NEI, Sect Neuron Glia Interact Retinal Dis, Lab Retinal Cell & Mol Biol, NIH, Bethesda, MD 20892 USA.
   [Zhu, Yingying] Univ Texas Arlington, Dept Comp Sci & Engn, Arlington, TX 76019 USA.
   [Zhu, Yingying] NIH, Dept Radiol, Clin Ctr, Bldg 10, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Library of
   Medicine (NLM); National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI); University of Wisconsin System; University of
   Wisconsin Madison; Erasmus University Rotterdam; Erasmus MC; Uniformed
   Services University of the Health Sciences - USA; National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI); University of
   Texas System; University of Texas Arlington; National Institutes of
   Health (NIH) - USA; NIH Clinical Center (CC)
RP Lu, ZY (通讯作者)，Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, 8600 Rockville Pike, Bethesda, MD 20209 USA.
EM zhiyong.lu@nih.gov
RI Allot, Alexis/GWM-5716-2022; Chen, Qingyu/Q-8343-2019; Peng,
   Yifan/M-1605-2016
OI Allot, Alexis/0000-0002-2706-9054; Chen, Qingyu/0000-0002-6036-1516;
   Peng, Yifan/0000-0001-9309-8331
FU Research to Prevent Blindness; National Center for Biotechnology
   Information/National Library of Medicine/National Institutes of Health;
   National Eye Institute/National Institutes of Health, Department of
   Health and Human Services, Bethesda, Maryland [HHS-N-260-2005-00007-C,
   NO1-EY-5-0007, K99LM013001]; National Institutes of Health: Office of
   Dietary Supplements, National Center for Complementary and Alternative
   Medicine; National Institute on Aging; National Heart, Lung, and Blood
   Institute; National Institute of Neurological Disorders and Stroke
FX The study was supported in part by an unrestricted grant from Research
   to Prevent Blindness to the Department of Ophthalmology and Visual
   Sciences, University of Wisconsin-Madison. The work was supported by the
   intramural program funds and contracts from the National Center for
   Biotechnology Information/National Library of Medicine/National
   Institutes of Health, the National Eye Institute/National Institutes of
   Health, Department of Health and Human Services, Bethesda, Maryland
   (Contract HHS-N-260-2005-00007-C; ADB contract NO1-EY-5-0007; Grant No
   K99LM013001). Funds were generously contributed to these contracts by
   the following National Institutes of Health: Office of Dietary
   Supplements, National Center for Complementary and Alternative Medicine;
   National Institute on Aging; National Heart, Lung, and Blood Institute;
   and National Institute of Neurological Disorders and Stroke. The
   contents of this publication are the sole responsibility of the authors
   and do not necessarily reflect the views, opinions or policies of
   Uniformed Services University of the Health Sciences, the Department of
   Defense, the Departments of the Army, Navy, or Air Force. Mention of
   trade names, commercial products, or organizations does not imply
   endorsement by the U.S. government.
CR Abadi M., 2016, TENSORFLOW LARGE SCA
   Abramoff MD, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0040-6
   Acon D, 2018, ASIA-PAC J OPHTHALMO, V7, P22, DOI 10.22608/APO.2017504
   Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Alten F, 2014, GRAEF ARCH CLIN EXP, V252, P715, DOI 10.1007/s00417-013-2525-y
   American Academy of Ophthalmology, 2015, AGE RELATED MACULAR
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Batioglu F, 2015, SEMIN OPHTHALMOL, V30, P65, DOI 10.3109/08820538.2013.810285
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Chen Q, 2019, LECT NOTES COMPUT SC, V11922, P505, DOI 10.1007/978-3-030-34621-8_18
   Chen Qingyu, 2019, AMIA Jt Summits Transl Sci Proc, V2019, P505
   Cheng X, 2018, COMP M BIO BIO E-IV, V6, P248, DOI 10.1080/21681163.2015.1135299
   Chew EY, 2014, CONTEMP CLIN TRIALS, V37, P294, DOI 10.1016/j.cct.2014.02.003
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chollet Francois, 2015, KERAS
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Devlin J, 2018, NAACL, DOI DOI 10.18653/V1/N19-1423
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Domalpally A, 2019, OPHTHALMOL RETINA, V3, P326, DOI 10.1016/j.oret.2019.01.004
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Gao F, 2020, EXPERT SYST APPL, V143, DOI 10.1016/j.eswa.2019.112957
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Guo Z, 2019, IEEE T RADIAT PLASMA, V3, P162, DOI [10.1109/TRPMS.2018.2890359, 10.1109/trpms.2018.2890359]
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Hogg RE, 2019, OPHTHALMOLOGY, V126, P391, DOI 10.1016/j.ophtha.2018.09.032
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Kapoor R, 2019, SURV OPHTHALMOL, V64, P233, DOI 10.1016/j.survophthal.2018.09.002
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keenan TD, 2019, OPHTHALMOLOGY, V126, P1533, DOI 10.1016/j.ophtha.2019.06.005
   Keenan TDL, 2020, OPHTHALMOLOGY, V127, P1674, DOI 10.1016/j.ophtha.2020.05.036
   Kotikalapudi R, 2017, KERAS VIS
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   Litjens G, 2017, MED IMAGE ANAL, V42, P60, DOI 10.1016/j.media.2017.07.005
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Ortiz A, 2018, CURR ALZHEIMER RES, V15, P67, DOI 10.2174/1567205014666170922101135
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Quartilho A, 2016, EYE, V30, P602, DOI 10.1038/eye.2015.288
   Rahimy E, 2018, CURR OPIN OPHTHALMOL, V29, P254, DOI 10.1097/ICU.0000000000000470
   Ramachandram D, 2017, IEEE SIGNAL PROC MAG, V34, P96, DOI 10.1109/MSP.2017.2738401
   Ruder S., 2017, ARXIV170605098
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Sengupta S, 2020, ARTIF INTELL MED, V102, DOI 10.1016/j.artmed.2019.101758
   Shen DG, 2017, ANNU REV BIOMED ENG, V19, P221, DOI [10.1146/annurev-bioeng-071516044442, 10.1146/annurev-bioeng-071516-044442]
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Suk HI, 2014, NEUROIMAGE, V101, P569, DOI 10.1016/j.neuroimage.2014.06.077
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Tan Hao, 2019, P 2019 C EMP METH NA, DOI [10.18653/v1/D19-1514, DOI 10.18653/V1/D19-1514]
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Tsang SH, 2018, ADV EXP MED BIOL, V1085, P15, DOI 10.1007/978-3-319-95046-4_4
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Vaghefi E, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/7493419
   van Grinsven MJJP, 2015, INVEST OPHTH VIS SCI, V56, P633, DOI 10.1167/iovs.14-15019
   Wightman AJ, 2019, CLIN EXP OPTOM, V102, P455, DOI 10.1111/cxo.12842
   Wittenborn JS, 2017, JAMA OPHTHALMOL, V135, P452, DOI 10.1001/jamaophthalmol.2017.0255
   Yoo TK, 2019, MED BIOL ENG COMPUT, V57, P677, DOI 10.1007/s11517-018-1915-z
   Zhang Y., 2017, IEEE T KNOWL DATA EN
NR 62
TC 3
Z9 3
U1 4
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1067-5027
EI 1527-974X
J9 J AM MED INFORM ASSN
JI J. Am. Med. Inf. Assoc.
PD JUN
PY 2021
VL 28
IS 6
BP 1135
EP 1148
DI 10.1093/jamia/ocaa302
EA APR 2021
PG 14
WC Computer Science, Information Systems; Computer Science,
   Interdisciplinary Applications; Health Care Sciences & Services;
   Information Science & Library Science; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Computer Science; Health Care Sciences & Services; Information Science &
   Library Science; Medical Informatics
GA TF9JW
UT WOS:000671031900010
PM 33792724
OA Green Published
DA 2022-11-30
ER

PT J
AU Khurana, RN
   Hoang, C
   Khanani, AM
   Steklov, N
   Singerman, LJ
AF Khurana, Rahul N.
   Hoang, Carol
   Khanani, Arshad M.
   Steklov, Nikolai
   Singerman, Lawrence J.
TI A Smart Mobile Application to Monitor Visual Function in Diabetic
   Retinopathy and Age-Related Macular Degeneration: The CLEAR Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB center dot PURPOSE: The purpose of this study was to determine if a mobile application, the Checkup Vision Assessment System, could reliably monitor visual acuity (VA) and metamorphopsia remotely versus standard VA reference tests in the clinic. With the current COVID-19 pandemic, an even greater need for remote monitoring exists. Mobile tools enhance the ability to monitor patients virtually by enabling remote monitoring of VA and Amsler grid findings.
   center dot DESIGN: Prospective, multicenter reliability analysis.
   center dot METHODS: Participants: Patients (N = 108) with near corrected VA better than 20/200 and a diagnosis of age related macular degeneration, diabetic retinopathy, or healthy patients without retinal disease (best-corrected visual acuity [BCVA] of 20/32 or better). Intervention: participants were tested using the Checkup, reference VA, and Amsler tests, with the order of testing (Checkup or reference) randomized. Patients monitored their vision using Checkup at least twice a week at home between office visits. Main outcome measurements were near corrected VA and Amsler grid test results.
   center dot RESULTS: Agreement was strong between Checkup and reference tests for VA (r = 0.86) and Amsler grid (sensitivity: 93%; specificity: 92%). Home versus clinic testing showed excellent agreement (r = 0.96). Patients reported successful home use. There were no serious adverse events or discontinuations. Patients rated the usability of Checkup to be excellent.
   center dot CONCLUSIONS: There was good agreement between Checkup and in-clinic test results for VA and Amsler grid. The low variance of Checkup testing, agreement between in-clinic and home results, and excellent usability support Checkup as a reliable method for monitoring retinal pathology in clinic and home settings. (Am J Ophthalmol 2021;227: 222-230. (c) 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC ND license ( http://creativecommons.org/licenses/by-ncnd/4.0/ ))
C1 Northern Calif Retina Vitreous Associates, Mountain View, CA USA.
   Univ Calif San Francisco, San Francisco, CA 94143 USA.
   Clearside Biomed, Alpharetta, GA USA.
   Sierra Eye Associates, Reno, NV USA.
   Univ Nevada, Sch Med, Reno, NV 89557 USA.
   docai, San Francisco, CA USA.
   Retina Associates Cleveland, Cleveland, OH USA.
   Case Western Reserve Univ, Cleveland, OH 44106 USA.
   Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 University of California System; University of California San Francisco;
   Nevada System of Higher Education (NSHE); University of Nevada Reno;
   Retina Associates of Cleveland, Inc.; Case Western Reserve University;
   Bascom Palmer Eye Institute
RP Khurana, RN (通讯作者)，2495 Hosp Dr 545, Mountain View, CA 94040 USA.
EM mkhurana@gmail.com
OI Khurana, Rahul/0000-0001-5198-1353
FU Verana Health
FX This study was sponsored by Digisight (now Verana Health). The sponsor
   participated in the design of the study, data management, data analysis,
   interpretation of the data, and preparation, review, and approval of the
   manuscript.
CR Bland JM, 2007, J BIOPHARM STAT, V17, P571, DOI 10.1080/10543400701329422
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Dorsey ER, 2016, NEW ENGL J MED, V375, P154, DOI 10.1056/NEJMra1601705
   Huygens MWJ, 2017, BMC FAM PRACT, V18, DOI 10.1186/s12875-017-0615-3
   Ittiara S, 2020, BMJ OPEN OPHTHALMOL, V5, DOI 10.1136/bmjophth-2020-000451
   Kalavar M, 2020, CURR OPIN OPHTHALMOL, V31, P366, DOI 10.1097/ICU.0000000000000689
   Keesara S, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2005835
   LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051
   Mann DM, 2020, J AM MED INFORM ASSN, V27, P1132, DOI 10.1093/jamia/ocaa072
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Rauch R, 2012, RETINA-J RET VIT DIS, V32, P1260, DOI 10.1097/IAE.0b013e3182018df6
   Steren BJ, 2021, JAMA OPHTHALMOL, V139, P344, DOI 10.1001/jamaophthalmol.2020.6177
   The Vision Council, 2015, VIS LOSS AM AG LOW V
   Tiraset N, 2021, CLIN OPHTHALMOL, V15, P859, DOI 10.2147/OPTH.S304272
   Ying GS, 2018, OPHTHALMOL RETINA, V2, P525, DOI 10.1016/j.oret.2017.10.003
NR 16
TC 7
Z9 7
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2021
VL 227
BP 222
EP 230
DI 10.1016/i.aio.2021.03.033
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SP2EZ
UT WOS:000659487300024
PM 33831342
DA 2022-11-30
ER

PT J
AU Persad, PJ
   Heid, IM
   Weeks, DE
   Baird, PN
   de Jong, EK
   Haines, JL
   Pericak-Vance, MA
   Scott, WK
AF Persad, Patrice J.
   Heid, Iris M.
   Weeks, Daniel E.
   Baird, Paul N.
   de Jong, Eiko K.
   Haines, Jonathan L.
   Pericak-Vance, Margaret A.
   Scott, William K.
CA Int Age-Related Macular Degener
TI Joint Analysis of Nuclear and Mitochondrial Variants in Age-Related
   Macular Degeneration Identifies Novel Loci TRPM1 and ABHD2/RLBP1
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration (AMD); genetics; risk; mitochondrial
   DNA; genome-wide interaction study (GWIS); joint effect
ID GENOME BROWSER; ASSOCIATION; MELANOCYTES; GENE; EXPRESSION; MUTATIONS
AB PURPOSE. Presently; 52 independent nuclear single nucleotide polymorphisms (nSNPs) have been associated with age-related macular degeneration (AMD) but their effects do not explain all its variance. Genetic interactions between the nuclear and mitochondrial (mt) genome may unearth additional genetic loci previously unassociated with AMD risk.
   METHODS. joint effects of nSNPs and selected mtSNPs were analyzed by two degree of freedom. (2df.) joint tests of association in the International AMD Genomics Consortium (IAMDGC) dataset (17,832 controls and 16,144 advanced AMD cases of European ancestry). Subjects were genotyped on the Illumina HtunanCoreExome array. After imputation using MINIMAC and the 1000 Genomes Project Phase I reference panel, pairwise linkage disequilibrium pruning, and quality control, 3.9 million nS.NPs were analyzed for interaction with. mtSNPs chosen based on association in this dataset or publications: A49170, T5004C, 012771A, and C16069T.
   RESULTS. Novel locus TRPM1 was identified with genome-wide significant joint effects (P < 5.0 X 10(-8)) of two intronic TRPM1 nSNPs and AMD-associated nonsynonymous MT-ND2 mtSNP A49170. Stratified analysis by mt allele identified an association only in 4917A (major allele) carriers (P = 4.4 X 10(-9), odds ratio [OR] = 0.90, 95% confidence interval [CI] = 0.87-0.93). Intronic and intergenic ABHD2/RLBP1 nSNPs demonstrated genome-wide significant joint effects (2df joint test P values from 1.8 X 10(-8) to 4.9 X 10(-8)) and nominally statistically significant interaction effects with,MT-ND5, synonymous mtSNP 012771A. Although. a positive association was detected in. both strata, the association. was stronger in. 12771A subjects (P = 0.0020, OR 2.17, 95% CI 1.34-3.60).
   CONCLUSIONS. These results show that joint tests of main effects and gene-gene interaction
C1 [Persad, Patrice J.; Pericak-Vance, Margaret A.; Scott, William K.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Heid, Iris M.] Univ Regensburg, Dept Genet Epidemiol, Regensburg, Germany.
   [Weeks, Daniel E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
   [Weeks, Daniel E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Baird, Paul N.] Univ Melbourne, Dept Surg Ophthalmol, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, East Melbourne, Vic, Australia.
   [de Jong, Eiko K.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   [Haines, Jonathan L.] Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA.
C3 University of Miami; University of Regensburg; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Centre for Eye Research Australia; Royal Victorian Eye &
   Ear Hospital; University of Melbourne; Radboud University Nijmegen; Case
   Western Reserve University
RP Scott, WK (通讯作者)，Univ Miami, Hussman Inst Human Genom, 1501 NW 10th Ave,BRB 414, Miami, FL 33136 USA.
EM w.scott@med.miami.edu
RI Weeks, Daniel E/B-2995-2012; Haines, Jonathan/C-3374-2012; de Jong,
   Eiko/P-3407-2015
OI Weeks, Daniel E/0000-0001-9410-7228; Haines,
   Jonathan/0000-0002-4351-4728; de Jong, Eiko/0000-0001-6520-0407; Scott,
   William/0000-0001-9336-6404; Baird, Paul/0000-0002-1305-3502
FU Center for Inherited Disease Research (CIDR) Program
   [HHSN2682012000081]; National Health and Medical Research Council of
   Australia (NHMRC) Senior Research Fellowship [1028444]; 
   [1X0111G006934-01];  [R01 EYE022310];  [EY012118];  [5T32EY023194];
   NATIONAL EYE INSTITUTE [U10EY006594, T32EY023194, R01EY022310] Funding
   Source: NIH RePORTER
FX The authors thank the participants across all of the studies for their
   cooperation and time in allowing this research project to be
   accomplished. Resources were available from the computing centers of the
   University of Miami, University of Michigan, and IIniversity of
   Regensburg facilitated in the aforementioned analyses and data
   generation. For genotyping, the Center for Inherited Disease Research
   (CIDR) Program contract number is HHSN2682012000081.; Supported by
   1X0111G006934-01 (GRA), R01 EYE022310 (JLH), EY012118 (MAP-V, WKS, JLH),
   and 5T32EY023194 (PJP), and by a National Health and Medical Research
   Council of Australia (NHMRC) Senior Research Fellowship 1028444 (PNB).
CR Audo I, 2009, AM J HUM GENET, V85, P720, DOI 10.1016/j.ajhg.2009.10.013
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Chongsuvivatwong V., 2020, EPICALC EPIDEMIOLOGI
   Ciauderman WJ, 2016, QUANTO 1 2 4 COMPUTE
   Dessalces E, 2013, JAMA OPHTHALMOL, V131, P1314, DOI 10.1001/jamaophthalmol.2013.4476
   Devi S, 2009, AM J PHYSIOL-CELL PH, V297, pC679, DOI 10.1152/ajpcell.00092.2009
   Eichers ER, 2002, AM J HUM GENET, V70, P955, DOI 10.1086/339688
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Guo HZ, 2012, EXP DERMATOL, V21, P650, DOI 10.1111/j.1600-0625.2012.01565.x
   Hipp S, 2015, ACTA OPHTHALMOL, V93, pE281, DOI 10.1111/aos.12573
   Imboden M, 2015, ENVIRON HEALTH PERSP, V123, P72, DOI 10.1289/ehp.1307398
   Jacobson J, 2004, MOL CELL BIOCHEM, V256, P209, DOI 10.1023/B:MCBI.0000009869.29827.df
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kenney MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054339
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Kraft P, 2007, HUM HERED, V63, P111, DOI 10.1159/000099183
   Li Z, 2009, AM J HUM GENET, V85, P711, DOI 10.1016/j.ajhg.2009.10.003
   Miceli MV, 2005, INVEST OPHTH VIS SCI, V46, P1765, DOI 10.1167/iovs.04-1327
   Miller AJ, 2004, CANCER RES, V64, P509, DOI 10.1158/0008-5472.CAN-03-2440
   Miyata K, 2008, BIOCHEM BIOPH RES CO, V365, P207, DOI 10.1016/j.bbrc.2007.10.127
   Morgans CW, 2010, BIOESSAYS, V32, P609, DOI 10.1002/bies.200900198
   Mueller EE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030874
   Oancea E, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000146
   Ohia SE, 2005, MUTAT RES-FUND MOL M, V579, P22, DOI 10.1016/j.mrfmmm.2005.03.025
   Online Mendelian Inheritance in Man OMIM, 2016, ONL MEND INH MAN OMI
   Online Mendelian Inheritance in Man OMIM. johns Hopkins University Baltimore MD, 2010, ONL MEND INH MAN OMI
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   R Core Team, 2014, R LANG ENV STAT COMP
   Rosenbloom KR, 2013, NUCLEIC ACIDS RES, V41, pD56, DOI 10.1093/nar/gks1172
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Stranger BE, 2011, GENETICS, V187, P367, DOI 10.1534/genetics.110.120907
   Teduk KR., 2015, J NEUROSCI, V35, P7304
   Tilleul J, 2013, MOL VIS, V19, P1132
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   van Genderen MM, 2009, AM J HUM GENET, V85, P730, DOI 10.1016/j.ajhg.2009.10.012
   Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917
   Wen B, 2016, SCI REP-UK, V6, DOI 10.1038/srep21208
   Ying GS, 2008, OPHTHALMOLOGY, V115, P1876, DOI 10.1016/j.ophtha.2008.05.023
   Zhiqi S, 2004, MELANOMA RES, V14, P509, DOI 10.1097/00008390-200412000-00011
NR 40
TC 14
Z9 14
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2017
VL 58
IS 10
BP 4027
EP 4038
DI 10.1167/iovs.17-21734
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FH2AG
UT WOS:000410940400023
PM 28813576
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Souied, EH
   Oubraham, H
   Mimoun, G
   Cohen, SY
   Quere, S
   Derveloy, A
AF Souied, Eric H.
   Oubraham, Hassiba
   Mimoun, Gerard
   Cohen, Salomon Y.
   Quere, Stephane
   Derveloy, Audrey
CA TWIN Study Grp
TI CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR
   DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL
   PRACTICE The TWIN Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID PHOTODYNAMIC THERAPY; TRIAL
AB Purpose:
   The real-life LUMIERE study on patients with wet age-related macular degeneration treated with intravitreal ranibizumab in 2006 to 2009 showed that failure to follow recommendations was associated with lower efficacy than had been observed in the development phase. The TWIN Study reviewed the situation in 2010 to 2011.
   Methods:
   Retrospective, descriptive purely observational study of data acquired after 12 months of treatment with intravitreal ranibizumab.
   Results:
   In 881 patients (68% women, mean age, 79 years) treated by 21 ophthalmologists, the mean gain in visual acuity was +4.3 +/- 15.4 letters (up from 3.2 +/- 14.8 in 2006-2009; NS). Significant improvements were documented in the mean interval between diagnosis and treatment initiation (down from 12.6 +/- 26.4-7.7 +/- 10.9 days; P < 0.001), and in the percentage of patients who received a full course of induction treatment (56.6 vs. 39.6%; P < 0.001). After induction, hardly any patients were monitored every month as recommended, although retreatment was more assiduous (5.6 +/- 2.3 vs. 5.1 +/- 2.1 injections; P < 0.001).
   Conclusion:
   Despite improvements in key parameters, the effectiveness of intravitreal ranibizumab is still compromised by poor compliance with the guidelines, especially the frequency of postinduction monitoring that is now the most important determinant of successful treatment.
C1 [Souied, Eric H.] Univ Paris Est Creteil, Hop Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Oubraham, Hassiba] Ctr Hosp, Dept Ophthalmol, Orleans, France.
   [Mimoun, Gerard] Ecole Mil, Ctr Imagerie, Paris, France.
   [Cohen, Salomon Y.] Ctr Ophtalmol Imagerie & Laser, Paris, France.
   [Quere, Stephane; Derveloy, Audrey] Novartis Pharma SAS, Paris, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Centre
   Hospitalier Regional d'Orleans
RP Derveloy, A (通讯作者)，Novartis Labs, 2-4 Rue Lionel Terray,BP 308, F-92506 Rueil Malmaison, France.
EM audrey.derveloy@novartis.com
FU Novartis Pharma SAS, Paris, France
FX Supported by Novartis Pharma SAS, Paris, France.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Desmettre T, 2009, DEGENERESCENCE MACUL, V2nd, P140
   Deudon Combe A, ASS RES VIS OPHTH AR
   European Medicines Agency, EUR PUBL ASS REP EPA
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Holmes K, 2007, CELL SIGNAL, V19, P2003, DOI 10.1016/j.cellsig.2007.05.013
   Kovach JL, 2012, J OPHTHALMOL, V2012, P7868
   Lee PN, IEA GUID PROP COND E
   Mataix J, 2010, RETINA-J RET VIT DIS, V30, P1190, DOI 10.1097/IAE.0b013e3181d2f172
   Mones J, 2011, OPHTHALMOLOGICA, V225, P112, DOI 10.1159/000319906
   Oubraham H, 2010, RETINA, V31, P26
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spielberg L, 2010, GRAEF ARCH CLIN EXP, V248, P943, DOI 10.1007/s00417-009-1256-6
NR 16
TC 50
Z9 51
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2015
VL 35
IS 9
BP 1743
EP 1749
DI 10.1097/IAE.0000000000000548
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CR2YK
UT WOS:000361196600005
PM 25901835
DA 2022-11-30
ER

PT J
AU Quaranta, M
   Mauget-Faysse, M
   Coscas, G
AF Quaranta, M
   Mauget-Faysse, M
   Coscas, G
TI Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic
   therapy with verteporfin
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID IPCV
AB PURPOSE: To report two cases of exudative idiopathic polypoidal choroidal vasculopathy treated by photodynamic therapy with verteporfin.
   DESIGN: Interventional case reports.
   METHODS: Two patients, a man aged 58 years and a woman aged 57 years, with recent visual impairment in the right eye (OD) (both eyes best-corrected visual acuity: 10/50 and Pelli-Robson contrast sensitivity 1.35 and 1.20) and angiographically proved subfoveal idiopathic polypoidal choroidal vasculopathy were treated with photodynamic therapy using verteporfin (Visudyne; Novartis SA, Rueil Malmaison, France). Functional and angiographic outcomes were assessed 6 weeks and 3, 6, and 12 months after treatment.
   RESULTS: In Patient 1, 3 months after treatment, best, corrected visual acuity and contrast sensitivity improved (10/16 and 1.50) and then remained stable throughout the 12 months after treatment. In Patient 2, 6 weeks after treatment, vision and contrast sensitivity were 10/20 and 1.35; and at 3 months, were improved and stabilized at 10/12.5 and 1.50. Angiographically, photodynamic therapy with verteporfin was associated with nonperfusion and occlusion of the exudative polypoidal dilations. No acute recurrence was noted during the follow-up period.
   CONCLUSION: In subfoveal exudative idiopathic polypoidal choroidal vasculopathy, photodynamic therapy with verteporfin may be associated with beneficial functional results. (C) 2002 by Elsevier Science Inc. All rights reserved.
C1 Ctr Ophtalmol Rabelais, F-69003 Lyon, France.
   Univ Paris 12, Eye Univ Clin Creteil, Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC)
RP Quaranta, M (通讯作者)，Ctr Ophtalmol Rabelais, 12-14 Rue Rabelais, F-69003 Lyon, France.
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V210, P405, DOI 10.1055/s-2008-1035085
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 5
TC 80
Z9 91
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2002
VL 134
IS 2
BP 277
EP 280
DI 10.1016/S0002-9394(02)01516-7
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 579GB
UT WOS:000177169300024
PM 12140043
DA 2022-11-30
ER

PT J
AU Sanchez-Sanchez, C
   Rementeria-Capelo, LA
   Puerto, B
   Lopez-Caballero, C
   Moran, A
   Sanchez-Pina, JM
   Contreras, I
AF Sanchez-Sanchez, Carmen
   Rementeria-Capelo, Laureano A.
   Puerto, Beatriz
   Lopez-Caballero, Cristina
   Moran, Aida
   Sanchez-Pina, Jose Maria
   Contreras, Ines
TI Visual Function and Patient Satisfaction with Multifocal Intraocular
   Lenses in Patients with Glaucoma and Dry Age-Related Macular
   Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID IMPLANTATION; OUTCOMES; SURGERY; ACUITY; EYES
AB Purpose. To report visual function and self-reported satisfaction of patients with glaucoma and dry age-related macular degeneration (dAMD) implanted with multifocal intraocular lenses (MIOL). Methods. Patients with glaucoma or dAMD as well as healthy individuals implanted with MIOL were invited to participate. Explorations performed were uncorrected and corrected distance visual acuity (UDVA and CDVA), low-contrast visual acuity (LCVA), binocular contrast sensitivity, and defocus curves. Patients completed the Catquest-9 questionnaire and reported on the presence of dysphotopsias and the need for spectacles. Results. 38 subjects were included: 11 in the healthy/control group and 9 each in the preperimetric glaucoma, perimetric glaucoma, and dAMD groups. Controls had statistically better monocular UDVA, CDVA, and LCVA than patients with glaucoma and dAMD, as well as better binocular acuity in the defocus curves between -2.00 D and +0.50 D. Differences between controls and patients with preperimetric glaucoma were not statistically significant. Between -3.0 D and +0.5 D, all groups except dAMD achieved acuities better than 0.2 logMAR. Patients with dAMD had worse contrast sensitivity than all others for 3 cycles per degree (cpd), and patients with glaucoma had worse values than all others for 12 cpd; other differences did not reach statistical significance. Healthy subjects and patients with preperimetric glaucoma perceived halos more often than patients with glaucoma or dAMD, while suffering less from glare. Patients with glaucoma and dAMD found more difficulties when driving at night and required spectacles for near more often than the other subjects. Patients with dAMD were less satisfied with their vision. Conclusions. MIOLs may be implanted in patients with preperimetric glaucoma with little fear of patient dissatisfaction. In glaucoma and dAMD, MIOLs might be considered with caution, after explaining the increased risk of glare and the higher need for spectacle correction for reading.
C1 [Sanchez-Sanchez, Carmen; Rementeria-Capelo, Laureano A.; Puerto, Beatriz; Lopez-Caballero, Cristina; Moran, Aida; Sanchez-Pina, Jose Maria; Contreras, Ines] Clin Rementeria, Madrid, Spain.
   [Puerto, Beatriz; Lopez-Caballero, Cristina; Contreras, Ines] Hosp Univ Ramon y Cajal, Madrid, Spain.
   [Puerto, Beatriz; Contreras, Ines] Inst Ramon y Cajal Invest Sanitarias IRYCIS, Madrid, Spain.
C3 Hospital Universitario Ramon y Cajal
RP Contreras, I (通讯作者)，Clin Rementeria, Madrid, Spain.; Contreras, I (通讯作者)，Hosp Univ Ramon y Cajal, Madrid, Spain.; Contreras, I (通讯作者)，Inst Ramon y Cajal Invest Sanitarias IRYCIS, Madrid, Spain.
EM sanchez@clinicarementeria.es; rementeria@clinicarementeria.es;
   puerto@clinicarementeria.es; lopez@clinicarementeria.es;
   amoran@clinicarementeria.es; jsanchez@clinicarementeria.es;
   contreras@clinicarementeria.es
OI Contreras, Ines/0000-0003-3524-9335
CR Alio JL, 2017, SURV OPHTHALMOL, V62, P611, DOI 10.1016/j.survophthal.2017.03.005
   Bach M, 1996, OPTOMETRY VISION SCI, V73, P49, DOI 10.1097/00006324-199601000-00008
   Bach M, 2007, GRAEF ARCH CLIN EXP, V245, P965, DOI 10.1007/s00417-006-0474-4
   Braga-Mele R, 2014, J CATARACT REFR SURG, V40, P313, DOI 10.1016/j.jcrs.2013.12.011
   Cao K, 2019, SURV OPHTHALMOL, V64, P647, DOI 10.1016/j.survophthal.2019.02.012
   Gayton JL, 2012, J CATARACT REFR SURG, V38, P415, DOI 10.1016/j.jcrs.2011.12.022
   Grzybowski A, 2020, GRAEF ARCH CLIN EXP, V258, P805, DOI 10.1007/s00417-020-04603-0
   Ichhpujani P, 2020, J GLAUCOMA, V29, P71, DOI 10.1097/IJG.0000000000001379
   Jonker SMR, 2015, J CATARACT REFR SURG, V41, P1631, DOI 10.1016/j.jcrs.2015.08.011
   Ouchi M, 2015, EYE, V29, P649, DOI 10.1038/eye.2015.12
   Patel SB, 2019, CLIN OPHTHALMOL, V13, P723, DOI 10.2147/OPTH.S195928
   Pepose JS, 2014, AM J OPHTHALMOL, V158, P436, DOI 10.1016/j.ajo.2014.06.003
   Wang SY, 2017, EUR J OPHTHALMOL, V27, P387, DOI 10.5301/ejo.5000978
   Yeu E, 2021, OPHTHALMOLOGY, V128, pE132, DOI 10.1016/j.ophtha.2020.08.025
NR 14
TC 1
Z9 1
U1 1
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD JUN 11
PY 2021
VL 2021
AR 9935983
DI 10.1155/2021/9935983
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SY3MU
UT WOS:000665796200002
PM 34221497
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Inoue, M
   Kadonosono, K
   Arakawa, A
   Yamane, S
   Ishibashi, T
AF Inoue, Maiko
   Kadonosono, Kazuaki
   Arakawa, Akira
   Yamane, Shin
   Ishibashi, Tatsuro
TI Long-term outcome of intravitreal pegaptanib sodium as maintenance
   therapy in Japanese patients with neovascular age-related macular
   degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Pegaptanib sodium; Ranibizumab;
   Maintenance therapy
ID RANIBIZUMAB; MARINA; LEVEL; EYE
AB To evaluate the results of a 3-year follow-up of intravitreal pegaptanib sodium injection as maintenance therapy for the treatment of neovascular age-related macular degeneration (AMD) in Japanese patients.
   In this prospective, uncontrolled interventional study, 20 eyes of 19 patients with treatment-na < ve AMD who had received 3 consecutive monthly injections of 0.5 mg/0.05 mL ranibizumab as the induction treatment and had shown clinical/anatomical improvement were enrolled. An intravitreal injection of 0.3 mg/0.09 mL pegaptanib sodium was administered as the maintenance therapy every 6 weeks. Booster treatments using ranibizumab were allowed if clinical deterioration was judged to be present. The primary outcome measures were the best-corrected visual acuity (BCVA) and the central foveal thickness (CFT) as evaluated using spectral-domain optical coherence tomography.
   Sixteen of the 20 eyes (80 %) were assessed at the 3-year follow-up. The mean logMAR BCVA improved significantly from 0.56 +/- A 0.31 before the induction treatment to 0.24 +/- A 0.25 at baseline (P < 0.001) and was well maintained at 156 weeks (0.25 +/- A 0.28, P = 0.938). Moreover, the mean CFT also decreased significantly from 346 +/- A 111 mu m before the induction treatment to 232 +/- A 54 mu m at baseline (P < 0.001) and was well preserved at 156 weeks (210 +/- A 59 mu m, P = 0.278). Thirteen eyes (81.3 %) received an unscheduled booster treatment, and no severe systemic or ocular side effects occurred during follow-up.
   Intravitreal pegaptanib sodium injection as the maintenance therapy was effective in stabilizing the vision of patients with AMD in whom induction treatment led to improved BCVA, as evaluated at the 3-year follow-up.
C1 [Inoue, Maiko; Kadonosono, Kazuaki; Arakawa, Akira; Yamane, Shin] Yokohama City Univ, Med Ctr, Dept Ophthalmol, Minami Ku, Yokohama, Kanagawa 2320024, Japan.
   [Ishibashi, Tatsuro] Kyushu Univ, Dept Ophthalmol, Fukuoka 812, Japan.
C3 Yokohama City University; Kyushu University
RP Inoue, M (通讯作者)，Yokohama City Univ, Med Ctr, Dept Ophthalmol, Minami Ku, 4-57 Urafune Cho, Yokohama, Kanagawa 2320024, Japan.
EM maicoo@urahp.yokohama-cu.ac.jp
FU Pfizer
FX M. Inoue, Grant (Pfizer); K. Kadonosono, Grant (Pfizer); A. Arakawa,
   None; S. Yamane, None; T. Ishibashi, Grant (Pfizer).
CR Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2009, OPHTHALMOLOGY, V116, pe55
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friberg TR, 2010, BRIT J OPHTHALMOL, V94, P1611, DOI 10.1136/bjo.2009.174946
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ishibashi T, 2013, JPN J OPHTHALMOL, V57, P417, DOI 10.1007/s10384-013-0255-7
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Shiragami C, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000116
   Ueta T, 2014, OPHTHALMOLOGY, V121, pE5, DOI 10.1016/j.ophtha.2013.09.019
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
NR 19
TC 4
Z9 6
U1 1
U2 2
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAY
PY 2015
VL 59
IS 3
BP 173
EP 178
DI 10.1007/s10384-015-0374-4
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CH8OC
UT WOS:000354294700005
PM 25733493
DA 2022-11-30
ER

PT J
AU Barteselli, G
   Gomez, ML
   Doede, AL
   Chhablani, J
   Gutstein, W
   Bartsch, DU
   Dustin, L
   Azen, SP
   Freeman, WR
AF Barteselli, G.
   Gomez, M. L.
   Doede, A. L.
   Chhablani, J.
   Gutstein, W.
   Bartsch, D-U
   Dustin, L.
   Azen, S. P.
   Freeman, W. R.
TI Visual function assessment in simulated real-life situations in patients
   with age-related macular degeneration compared to normal subjects
SO EYE
LA English
DT Article
ID CONTRAST SENSITIVITY; DIABETIC-RETINOPATHY; ACUITY; CHARTS;
   REPEATABILITY; CATARACT; SURGERY; QUALITY; DISEASE; SNELLEN
AB Purpose To evaluate visual function variations in eyes with age-related macular degeneration (AMD) compared to normal eyes under different light/contrast conditions using a time-dependent visual acuity testing instrument, the Central Vision Analyzer (CVA).
   Methods Overall, 37 AMD eyes and 35 normal eyes were consecutively tested with the CVA after assessing best-corrected visual acuity (BCVA) using ETDRS charts. The CVA established visual thresholds for three mesopic environments (M1 (high contrast), M2 (medium contrast), and M3 (low contrast)) and three backlight-glare environments (G1 (high contrast, equivalent to ETDRS), G2 (medium contrast), and G3 (low contrast)) under timed conditions. Vision drop across environments was calculated, and repeatability of visual scores was determined.
   Results BCVA significantly reduced with decreasing contrast in all eyes. M1 scores for BCVA were greater than M2 and M3 (P<0.001); G1 scores were greater than G2 and G3 (P<0.01). BCVA dropped more in AMD eyes than in normal eyes between M1 and M2 (P = 0.002) and between M1 and M3 (P = 0.003). In AMD eyes, BCVA was better using ETDRS charts compared to G1 (P<0.001). The drop in visual function between ETDRS and G1 was greater in AMD eyes compared to normal eyes (P = 0.004). Standard deviations of test-retest ranged from 0.100 to 0.139 logMAR.
   Conclusion The CVA allowed analysis of the visual complaints that AMD patients experience with different lighting/contrast time-dependent conditions. BCVA changed significantly under different lighting/contrast conditions in all eyes, however, AMD eyes were more affected by contrast reduction than normal eyes. In AMD eyes, timed conditions using the CVA led to worse BCVA compared to non-timed ETDRS charts.
C1 [Barteselli, G.; Gomez, M. L.; Doede, A. L.; Bartsch, D-U; Freeman, W. R.] Univ Calif San Diego, Dept Ophthalmol, Jacobs Retina Ctr, Shiley Eye Ctr, San Diego, CA 92103 USA.
   [Barteselli, G.] Univ Milan, Ca Granda Fdn Osped Maggiore Policlin, Dept Clin Sci & Community Hlth, Ophthalmol Unit, Milan, Italy.
   [Chhablani, J.] LV Prasad Eye Inst, Hyderabad, Andhra Pradesh, India.
   [Gutstein, W.] Salus Univ, Elkins Pk, PA USA.
   [Dustin, L.; Azen, S. P.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
C3 University of California System; University of California San Diego;
   IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; L.
   V. Prasad Eye Institute; University of Southern California
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, Jacobs Retina Ctr, Shiley Eye Ctr, San Diego, CA 92103 USA.
EM freeman@eyecenter.ucsd.edu
RI Doede, Aubrey L/N-9859-2016
OI Doede, Aubrey L/0000-0002-9977-2806; Barteselli,
   Giulio/0000-0003-0533-1135
FU NIH [R01EY007366, R01EY018589 (WRF), R01EY016323 (D-UB)]; Research to
   Prevent Blindness to the Department of Ophthalmology, University of
   California, San Diego; NATIONAL EYE INSTITUTE [R01EY016323, R01EY007366,
   P30EY022589, R01EY018589] Funding Source: NIH RePORTER
FX This study was supported by NIH grants R01EY007366 and R01EY018589
   (WRF), R01EY016323 (D-UB), and in part by an unrestricted fund from
   Research to Prevent Blindness to the Department of Ophthalmology,
   University of California, San Diego.
CR ARDITI A, 1993, INVEST OPHTH VIS SCI, V34, P120
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Barteselli G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097023
   Bellmann C, 2003, GRAEF ARCH CLIN EXP, V241, P968, DOI 10.1007/s00417-003-0689-6
   Bland JM, 1996, BRIT MED J, V312, P1654, DOI 10.1136/bmj.312.7047.1654
   BRADLEY A, 1991, OPTOMETRY VISION SCI, V68, P418, DOI 10.1097/00006324-199106000-00003
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Fletcher DC, 2006, OPTOMETRY VISION SCI, V83, P178, DOI 10.1097/01.opx.0000204510.08026.7f
   Gomez ML, 2014, CURR OPIN OPHTHALMOL, V25, P3, DOI 10.1097/ICU.0000000000000011
   Gutstein W, 2010, OPTOMETRY, V81, P94, DOI 10.1016/j.optm.2009.09.017
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Lim LA, 2010, EYE, V24, P673, DOI 10.1038/eye.2009.147
   Luo MR, 2001, COLOR RES APPL, V26, P340, DOI 10.1002/col.1049
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Nguyen NX, 2009, ACTA OPHTHALMOL, V87, P849, DOI 10.1111/j.1755-3768.2008.01423.x
   PELI E, 1990, J OPT SOC AM A, V7, P2032, DOI 10.1364/JOSAA.7.002032
   Pesudovs K, 2004, BRIT J OPHTHALMOL, V88, P11, DOI 10.1136/bjo.88.1.11
   Raasch TW, 1998, OPTOMETRY VISION SCI, V75, P342, DOI 10.1097/00006324-199805000-00024
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruamviboonsuk P, 2003, AM J OPHTHALMOL, V136, P662, DOI 10.1016/S0002-9394(03)00394-5
   Vos Johannes J, 2003, Clin Exp Optom, V86, P363
   Yavuz GA, 2009, EYE, V23, P2082, DOI 10.1038/eye.2009.177
NR 24
TC 12
Z9 12
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD OCT
PY 2014
VL 28
IS 10
BP 1231
EP 1238
DI 10.1038/eye.2014.189
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AR7PG
UT WOS:000343771100014
PM 25081294
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Acar, IE
   Willems, E
   Kersten, E
   Keizer-Garritsen, J
   Kragt, E
   Bakker, B
   Galesloot, TE
   Hoyng, CB
   Fauser, S
   van Gool, AJ
   Lechanteur, YTE
   Koertvely, E
   Nogoceke, E
   Gloerich, J
   de Jonge, MI
   Lores-Motta, L
   den Hollander, AI
AF Acar, I. Erkin
   Willems, Esther
   Kersten, Eveline
   Keizer-Garritsen, Jenneke
   Kragt, Else
   Bakker, Bjorn
   Galesloot, Tessel E.
   Hoyng, Carel B.
   Fauser, Sascha
   van Gool, Alain J.
   Lechanteur, Yara T. E.
   Koertvely, Elod
   Nogoceke, Everson
   Gloerich, Jolein
   de Jonge, Marien I.
   Lores-Motta, Laura
   den Hollander, Anneke I.
TI Semi-Quantitative Multiplex Profiling of the Complement System
   Identifies Associations of Complement Proteins with Genetic Variants and
   Metabolites in Age-Related Macular Degeneration
SO JOURNAL OF PERSONALIZED MEDICINE
LA English
DT Article
DE age-related macular degeneration; AMD; complement system;
   semi-quantitative multiplex profilin; mass spectrometry; C4;
   vitronectin; factor I; genetic variants; metabolites; HDL
ID FACTOR-H POLYMORPHISM; RARE VARIANTS; HIGH-RISK; CFI GENE; COMMON;
   INCREASES; SUSCEPTIBILITY; PREVALENCE; ACTIVATION; COMPONENT
AB Age-related macular degeneration (AMD) is a major cause of vision loss among the elderly in the Western world. The complement system has been identified as one of the main AMD disease pathways. We performed a comprehensive expression analysis of 32 complement proteins in plasma samples of 255 AMD patients and 221 control individuals using mass spectrometry-based semi-quantitative multiplex profiling. We detected significant associations of complement protein levels with age, sex and body-mass index (BMI), and potential associations of C-reactive protein, factor H related-2 (FHR-2) and collectin-11 with AMD. In addition, we confirmed previously described associations and identified new associations of AMD variants with complement levels. New associations include increased C4 levels for rs181705462 at the C2/CFB locus, decreased vitronectin (VTN) levels for rs11080055 at the TMEM97/VTN locus and decreased factor I levels for rs10033900 at the CFI locus. Finally, we detected significant associations between AMD-associated metabolites and complement proteins in plasma. The most significant complement-metabolite associations included increased high density lipoprotein (HDL) subparticle levels with decreased C3, factor H (FH) and VTN levels. The results of our study indicate that demographic factors, genetic variants and circulating metabolites are associated with complement protein components. We suggest that these factors should be considered to design personalized treatment approaches and to increase the success of clinical trials targeting the complement system.
C1 [Acar, I. Erkin; Kersten, Eveline; Bakker, Bjorn; Hoyng, Carel B.; Lechanteur, Yara T. E.; Lores-Motta, Laura; den Hollander, Anneke I.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Med Ctr, NL-6525 GA Nijmegen, Netherlands.
   [Willems, Esther; de Jonge, Marien I.] Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Dept Lab Med, Lab Med Immunol,Med Ctr, NL-6525 GA Nijmegen, Netherlands.
   [Willems, Esther; de Jonge, Marien I.] Radboud Univ Nijmegen, Radboud Ctr Infect Dis, Med Ctr, NL-6525 GA Nijmegen, Netherlands.
   [Willems, Esther; Keizer-Garritsen, Jenneke; Kragt, Else; van Gool, Alain J.; Gloerich, Jolein] Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Dept Lab Med, Translat Metab Lab,Med Ctr, NL-6525 GA Nijmegen, Netherlands.
   [Galesloot, Tessel E.] Radboud Univ Nijmegen, Radboud Inst Hlth Sci, Dept Hlth Evidence, Med Ctr, NL-6525 GA Nijmegen, Netherlands.
   [Fauser, Sascha; Koertvely, Elod; Nogoceke, Everson; Lores-Motta, Laura] Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, 124 Grenzacherstr, CH-4070 Basel, Switzerland.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Human Genet, Med Ctr, NL-6525 GA Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Radboud
   University Nijmegen; Radboud University Nijmegen; Radboud University
   Nijmegen; Roche Holding; Radboud University Nijmegen
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Med Ctr, NL-6525 GA Nijmegen, Netherlands.; den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Human Genet, Med Ctr, NL-6525 GA Nijmegen, Netherlands.
EM erkin.acar@radboudumc.nl; Esther.Willems1@radboudumc.nl;
   Eveline.Kersten@radboudumc.nl; Jenneke.Keizer-Garritsen@radboudumc.nl;
   Else.Kragt@gmail.com; Bjorn.Bakker@radboudumc.nl;
   tessel.galesloot@radboudumc.nl; Carel.Hoyng@radboudumc.nl;
   sascha.fauser@roche.com; Alain.vanGool@radboudumc.nl;
   yara.lechanteur@radboudumc.nl; elod.koertvely@roche.com;
   everson.nogoceke@roche.com; Jolein.Gloerich@radboudumc.nl;
   marien.dejonge@radboudumc.nl; lauraloresmotta@protonmail.com;
   Anneke.denHollander@radboudumc.nl
RI de Jonge, Marien I./P-5869-2015; Gloerich, Jolein/L-4327-2015; Acar,
   Ilhan Erkin/B-7758-2018
OI de Jonge, Marien I./0000-0003-2812-5895; Gloerich,
   Jolein/0000-0001-5976-8426; Acar, Ilhan Erkin/0000-0002-2078-9905;
   Willems, Esther/0000-0002-7993-9613; den Hollander,
   Anneke/0000-0003-0634-5408; Keizer, Jenneke/0000-0003-1275-8778; van
   Gool, Alain/0000-0003-0010-5286; Kortvely, Elod/0000-0003-1599-3116
CR Acar IE, 2020, OPHTHALMOLOGY, V127, P1693, DOI 10.1016/j.ophtha.2020.06.020
   Biasella F, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.14.2
   Cipriani V, 2021, AM J HUM GENET, V108, P1385, DOI 10.1016/j.ajhg.2021.05.015
   Cipriani V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14499-3
   Coleman AL, 2010, AM J OPHTHALMOL, V149, P160, DOI 10.1016/j.ajo.2009.07.025
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   da Costa MG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02664
   de Breuk A, 2021, OPHTHALMOLOGY, V128, P1604, DOI 10.1016/j.ophtha.2020.07.037
   de Jong S, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100952
   de Jong S, 2020, HUM MOL GENET, V29, P2313, DOI 10.1093/hmg/ddaa114
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fanelli G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15212-z
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0548-0
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Higgins V, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgz161
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kumar-Singh R, 2019, EXP EYE RES, V184, P266, DOI 10.1016/j.exer.2019.05.006
   Lores-Motta L, 2021, AM J HUM GENET, V108, P1367, DOI 10.1016/j.ajhg.2021.06.002
   Lores-Motta L, 2018, OPHTHALMOLOGY, V125, P1064, DOI 10.1016/j.ophtha.2017.12.023
   MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054
   Moreno-Navarrete JM, 2010, DIABETES, V59, P200, DOI 10.2337/db09-0700
   McMahon O, 2021, HUM MOL GENET, V30, P1188, DOI 10.1093/hmg/ddab086
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Willems E, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1225
   Willems E, 2019, EBIOMEDICINE, V45, P303, DOI 10.1016/j.ebiom.2019.06.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
NR 50
TC 2
Z9 2
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4426
J9 J PERS MED
JI J. Pers. Med.
PD DEC
PY 2021
VL 11
IS 12
AR 1256
DI 10.3390/jpm11121256
PG 22
WC Health Care Sciences & Services; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; General & Internal Medicine
GA YJ6ZB
UT WOS:000744679300001
PM 34945728
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Liang, CL
   Wang, CM
   Jung, CR
   Chang, YC
   Lin, CJ
   Lin, YT
   Hwang, BF
AF Liang, Chung-Ling
   Wang, Chi-Min
   Jung, Chau-Ren
   Chang, Ya-Chu
   Lin, Chun-Ju
   Lin, Yu-Ting
   Hwang, Bing-Fang
TI Fine particulate matter measured by satellites predicts the risk of
   age-related macular degeneration in a longitudinal cohort study
SO ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
LA English
DT Article
DE Age-related macular degeneration; PM2 5; Cohort study; Satellite-based
   model; Distributed lag non-linear model
ID EXPOSURE; PREVALENCE; PM2.5
AB Although studies have revealed that ambient particulate matter (PM) has detrimental effects on the ocular surface, there have been limited reports detailing the effect of ambient PM on the posterior segment of the eye. A large-scale longitudinal cohort study evaluating the association between fine PM, especially PM2.5, and the retina could elucidate the risk of ambient pollutants for retinal diseases. We investigated the association between PM2.5 and the development of age-related macular degeneration (AMD). We conducted a population-based cohort study of 4,284,128 participants in Taiwan between 2001 and 2011. PM2.5 was continuously measured by satellites and subsequently assigned to each geographic district along with its postcode. A time-dependent Cox proportional-hazard model was used to assess the overall effects of average PM2.5. We used distributed lag non-linear models to evaluate the dose-response relationship between PM2.5 and AMD development. The annual mean of PM2.5 exposure was 34.23 +/- 7.17 mu g/m3. The PM2.5 concentrations were highest in spring, followed by those in winter, autumn, and summer. Twelve thousand ninety-five new AMD cases were reported during the study period. After adjusting for covariates, the AMD risk increased by 19% (95% confidence interval 1.13-1.25) for a 10 mu g/m3 PM2.5 increase. The present study demonstrated that chronic exposure to PM2.5 increases the risk of AMD. Almost half of the Taiwanese live in a polluted area where the PM2.5 levels are higher than the World Health Organization recommended air quality guideline of 10 mu g/m3 had a 1.4-fold risk, which significantly increases concern about their visual health and social burden.
C1 [Liang, Chung-Ling] China Med Univ Hosp, Ctr Myopia & Eye Dis, Dept Med Res, Taichung, Taiwan.
   [Liang, Chung-Ling] Bright Eyes Clin, Kaohsiung, Taiwan.
   [Wang, Chi-Min; Chang, Ya-Chu; Hwang, Bing-Fang] China Med Univ, Coll Publ Hlth, Dept Occupat Safety & Hlth, Taichung, Taiwan.
   [Jung, Chau-Ren] China Med Univ, Coll Publ Hlth, Dept Publ Hlth, Taichung, Taiwan.
   [Jung, Chau-Ren] Natl Inst Environm Studies, Japan Environm & Childrens Study Programme Off, Tsukuba, Ibaraki, Japan.
   [Lin, Chun-Ju] China Med Univ, China Med Univ Hosp, Dept Ophthalmol, Taichung, Taiwan.
   [Lin, Chun-Ju] China Med Univ, Coll Med, Sch Med, Taichung, Taiwan.
   [Lin, Chun-Ju] Asia Univ, Dept Optometry, Taichung, Taiwan.
   [Lin, Yu-Ting] China Med Univ, China Med Univ Hosp, Big Data Ctr, 2 Yude Rd, Taichung 40447, Taiwan.
   [Hwang, Bing-Fang] Asia Univ, Coll Med & Hlth Sci, Dept Occupat Therapy, 100 Sec 1, Taichung 406040, Taiwan.
C3 China Medical University Taiwan; China Medical University Hospital -
   Taiwan; China Medical University Taiwan; China Medical University
   Taiwan; National Institute for Environmental Studies - Japan; China
   Medical University Taiwan; China Medical University Hospital - Taiwan;
   China Medical University Taiwan; Asia University Taiwan; China Medical
   University Taiwan; China Medical University Hospital - Taiwan; Asia
   University Taiwan
RP Hwang, BF (通讯作者)，China Med Univ, Coll Publ Hlth, Dept Occupat Safety & Hlth, Taichung, Taiwan.; Hwang, BF (通讯作者)，Asia Univ, Coll Med & Hlth Sci, Dept Occupat Therapy, 100 Sec 1, Taichung 406040, Taiwan.
EM neolin73@gmail.com; bfhwang@mail.cmu.edu.tw
OI Jung, Chau-Ren/0000-0003-0673-9968; Lin, Yu-Ting/0000-0002-4821-9680
FU China Medical University [CMU108-MF-95, CMU108-MF-106]; China Medical
   University Hospital [DMR-108-BC-7]; Ministry of Science and Technology
   of Taiwan [MOST 108-2314-B-039 -049 -MY3]; "Drug Development Center,
   China Medical University" from The Featured Areas Research Center
   Program
FX This work was supported by the China Medical University intramural
   grants (CMU108-MF-95 and CMU108-MF-106), China Medical University
   Hospital (DMR-108-BC-7), Ministry of Science and Technology of Taiwan
   (MOST 108-2314-B-039 -049 -MY3), and the "Drug Development Center, China
   Medical University" from The Featured Areas Research Center Program
   within the framework of the Higher Education Sprout Project by the
   Ministry of Education in Taiwan.
CR Adar SD, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000372
   Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Bove H, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11654-3
   Bowe B, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.15834
   Cackett P, 2008, BRIT J OPHTHALMOL, V92, P1312, DOI 10.1136/bjo.2007.136077
   Chang KH, 2019, J INVEST MED, V67, P1076, DOI 10.1136/jim-2019-001007
   Chen RC, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16193652
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1305, DOI 10.1016/j.ophtha.2017.03.056
   Chow JC, 2006, J AIR WASTE MANAGE, V56, P1368, DOI 10.1080/10473289.2006.10464485
   Chua SYL, 2022, BRIT J OPHTHALMOL, V106, P705, DOI 10.1136/bjophthalmol-2020-316218
   Chua SYL, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.32
   Chua SYL, 2019, INVEST OPHTH VIS SCI, V60, P4915, DOI 10.1167/iovs.19-28346
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gasparrini A, 2014, STAT MED, V33, P881, DOI 10.1002/sim.5963
   Gatto NM, 2014, NEUROTOXICOLOGY, V40, P1, DOI 10.1016/j.neuro.2013.09.004
   He MS, 2018, DIABETES CARE, V41, P2202, DOI 10.2337/dc18-0707
   Hong JX, 2016, SCI REP-UK, V6, DOI 10.1038/srep23858
   Hsieh CY, 2019, CLIN EPIDEMIOL, V11, P349, DOI 10.2147/CLEP.S196293
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Jung CR, 2019, SCI TOTAL ENVIRON, V668, P342, DOI 10.1016/j.scitotenv.2019.03.018
   Kioumourtzoglou MA, 2016, ENVIRON HEALTH PERSP, V124, P23, DOI 10.1289/ehp.1408973
   Krause L, 2013, CURR MED RES OPIN, V29, P1391, DOI 10.1185/03007995.2013.832184
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lin HC, 2010, AUST NZ J PSYCHIAT, V44, P273, DOI 10.3109/00048670903487209
   Lin YT, 2021, THORAX, V76, P568, DOI 10.1136/thoraxjnl-2020-215025
   Lipecz A, 2019, GEROSCIENCE, V41, P813, DOI 10.1007/s11357-019-00138-3
   Mimura T, 2014, SCI TOTAL ENVIRON, V487, P493, DOI 10.1016/j.scitotenv.2014.04.057
   Mo Z, 2019, ENVIRON POLLUT, V246, P183, DOI 10.1016/j.envpol.2018.11.109
   Nurkiewicz TR, 2004, ENVIRON HEALTH PERSP, V112, P1299, DOI 10.1289/ehp.7001
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Ranft U, 2009, ENVIRON RES, V109, P1004, DOI 10.1016/j.envres.2009.08.003
   Rastogi N, 2016, SURV OPHTHALMOL, V61, P422, DOI 10.1016/j.survophthal.2015.10.003
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Therneau T, 2022, USING TIME DEPENDENT
   van Donkelaar A, 2010, ENVIRON HEALTH PERSP, V118, P847, DOI 10.1289/ehp.0901623
   Wang W, 2019, ACTA OPHTHALMOL, V97, pE349, DOI 10.1111/aos.14044
   Wang Y, 2009, BRIT J OPHTHALMOL, V93, P634, DOI 10.1136/bjo.2008.150276
   Weuve J, 2012, ARCH INTERN MED, V172, P219, DOI 10.1001/archinternmed.2011.683
   Yang Q, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109177
   Yu DH, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1794-6
   Zhang ZH, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.02.12
NR 43
TC 1
Z9 1
U1 3
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0944-1344
EI 1614-7499
J9 ENVIRON SCI POLLUT R
JI Environ. Sci. Pollut. Res.
PD JUL
PY 2022
VL 29
IS 34
SI SI
BP 51942
EP 51950
DI 10.1007/s11356-022-19278-9
EA MAR 2022
PG 9
WC Environmental Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology
GA 2Y8VB
UT WOS:000765690200010
PM 35257331
DA 2022-11-30
ER

PT J
AU Sharma, K
   Battu, P
   Singh, R
   Sharma, SK
   Anand, A
AF Sharma, Kaushal
   Battu, Priya
   Singh, Ramandeep
   Sharma, Suresh Kumar
   Anand, Akshay
TI Modulated anti-VEGF therapy under the influence of lipid metabolizing
   proteins in Age related macular degeneration: a pilot study
SO SCIENTIFIC REPORTS
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB; RANIBIZUMAB; ASSOCIATION; RECEPTOR-3; AVASTIN
AB Age-related macular degeneration (AMD) is a devastating retinal disease that results in irreversible vision loss in the aged population. The complex genetic nature and degree of genetic penetrance require a redefinition of the current therapeutic strategy for AMD. We aimed to investigate the role of modifiers for current anti-VEGF therapy especially for non-responder AMD patients. We recruited 78 wet AMD cases (out of 278 AMD patients) with their socio-demographic and treatment regimen. Serum protein levels were estimated by ELISA in AMD patients. Data pertaining to the number of anti-VEGF injections given (in 1 year) along with clinical images (FFA and OCT) of AMD patients were also included. Visual acuity data (logMAR) for 46 wet AMD cases out of a total of 78 patients were also retrieved to examine the response of anti-VEGF injections in wet AMD cases. Lipid metabolizing genes (LIPC and APOE) have been identified as chief biomarkers for anti-VEGF response in AMD patients. Both genotypes 'CC' and 'GC' of LIPC have found to be associated with a number of anti-VEGF injections in AMD patients which could influence the expression of B3GALTL,HTRA1, IER3, LIPC and SLC16A8 proteins in patients bearing both genotypes as compared to reference genotype. Elevated levels of APOE were also observed in group 2 wet AMD patients as compared to group 1 suggesting the significance of APOE levels in anti-VEGF response. The genotype of B3GALTL has also been shown to have a significant association with the number of anti-VEGF injections. Moreover, visual acuity of group 1 (<= 4 anti-VEGF injections/year) AMD patients was found significantly improved after 3 doses of anti-VEGF injections and maintained longitudinally as compared to groups 2 and 3. Lipid metabolising genes may impact the outcome of anti-VEGF AMD treatment.
C1 [Sharma, Kaushal; Battu, Priya; Anand, Akshay] Post Grad Inst Med Educ & Res, Dept Neurol, Neurosci Res Lab, Chandigarh, India.
   [Sharma, Kaushal] Post Grad Inst Med Educ & Res, Adv Pediat Ctr, Dept Pediat, Chandigarh, India.
   [Singh, Ramandeep] Post Grad Inst Med Educ & Res, Adv Eye Ctr, Dept Ophthalmol, Chandigarh, India.
   [Sharma, Suresh Kumar] Panjab Univ, Dept Stat, Chandigarh, India.
C3 Post Graduate Institute of Medical Education & Research (PGIMER),
   Chandigarh; Post Graduate Institute of Medical Education & Research
   (PGIMER), Chandigarh; Post Graduate Institute of Medical Education &
   Research (PGIMER), Chandigarh; Panjab University
RP Anand, A (通讯作者)，Post Grad Inst Med Educ & Res, Dept Neurol, Neurosci Res Lab, Chandigarh, India.; Singh, R (通讯作者)，Post Grad Inst Med Educ & Res, Adv Eye Ctr, Dept Ophthalmol, Chandigarh, India.
EM mankoo95@yahoo.com; akshay1anand@rediffmail.com
FU Department of Biotechnology [BT/PR17550/MED/30/1755/2016]; New Delhi,
   India
FX Department of Biotechnology (No. BT/PR17550/MED/30/1755/2016), New
   Delhi, India. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Anand A, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00115
   Anand A, 2014, CURR GENOMICS, V15, P266, DOI 10.2174/1389202915666140516204512
   Anand A, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/365046
   Anand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049905
   Battu P, 2021, CURR NEUROVASC RES, V18, P181, DOI 10.2174/1567202618666210531130711
   Cabral T, 2018, OPHTHALMOL RETINA, V2, P31, DOI 10.1016/j.oret.2017.04.004
   Cheng S, 2016, OSLI RETINA, V47, P458, DOI 10.3928/23258160-20160419-09
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Habibi I, 2016, KLIN MONATSBL AUGENH, V233, P465, DOI 10.1055/s-0041-111801
   Hwang RY, 2020, RETINA-J RET VIT DIS, V40, P679, DOI 10.1097/IAE.0000000000002446
   Rodriguez FJ, 2019, TAIWAN J OPHTHALMOL, V9, P243, DOI 10.4103/tjo.tjo_72_19
   Lores-Motta L, 2018, JAMA OPHTHALMOL, V136, P875, DOI 10.1001/jamaophthalmol.2018.2019
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Sharma K, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248523
   Sharma K, 2021, GENOMICS, V113, P514, DOI 10.1016/j.ygeno.2020.09.044
   Sharma K, 2017, J CELL BIOCHEM, V118, P2087, DOI 10.1002/jcb.25837
   Sharma K, 2015, ANN NEUROSCI, V22, P232, DOI 10.5214/ans.0972.7531.220408
   Sharma K, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00151
   Sharma NK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193423
   Sharma NK, 2014, MOL CELL BIOCHEM, V393, P1, DOI 10.1007/s11010-014-2040-4
   Sharma NK, 2013, GENE, V523, P106, DOI 10.1016/j.gene.2013.03.052
   Sharma NK, 2012, CURR NEUROVASC RES, V9, P256
NR 24
TC 2
Z9 2
U1 2
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 13
PY 2022
VL 12
IS 1
AR 714
DI 10.1038/s41598-021-04269-6
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA YG3SG
UT WOS:000742412100002
PM 35027571
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Rutledge, GA
   Pratt, SG
   Richer, SP
   Huntjens, B
   Perry, CB
   Pratt, G
   Podella, C
AF Rutledge, Grant A.
   Pratt, Steven G.
   Richer, Stuart P.
   Huntjens, Byki
   Perry, C. Blake
   Pratt, Gunilla
   Podella, Carla
TI Foveal macular pigment dip in offspring of age-related macular
   degeneration patients is inversely associated with omega-3 index
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Macular pigment (MP); Macular pigment optical density (MPOD); Foveal
   macular pigment dip (FMPD); Lutein; Zeaxanthin; Eicosapentaenoic acid
   (EPA); Docosahexaenoic acid (DHA); Omega-3 index
ID HETEROCHROMATIC FLICKER PHOTOMETRY; OPTICAL-DENSITY; DOCOSAHEXAENOIC
   ACID; SPATIAL PROFILE; SUPPLEMENTAL LUTEIN; RETINAL THICKNESS;
   RISK-FACTORS; MACULOPATHY; CAROTENOIDS; ZEAXANTHIN
AB Background Offspring of parent(s) with age-related macular degeneration (AMD) have a 45% lifetime risk of developing the disease. High foveal macular pigment optical density (MPOD) is protective, whereas individuals with a "foveal macular pigment dip" (FMPD) are at increased risk. Shortage of the dietary carotenoids lutein, zeaxanthin as well as fish consumption are reported AMD risk factors. This Early Biomarkers of AMD (EBAMD) study evaluates serum factors that protect foveal MPOD architecture in Caucasian offspring of parent(s) with AMD. Methods N = 130 subjects [mean (SD) age 62.8 (8.6) years; 36/94 male/female] were recruited from Scripps Health/ Scripps Memorial Hospital/ Scripps Mericos Eye Institute between 2012 and 2017. Macula pigment 3D topography was evaluated using specular reflectance. Buccal genetic cheek swab, circulating serum dietary carotenoids and long-term RBC omega-3 fatty acid status, as well as common secondary clinical structural and vision function parameters were obtained. Results 41 % of offspring of AMD parent(s) presented with FMPD. These offspring were about 4 years younger than those without FMPD (controls; P = 0.012) and had thinner foveas (P = 0.010). There were no differences in gender, BMI, % body fat, visual acuity or contrast sensitivity between those with and without FMPD. % RBC membrane docosahexaenoic acid (DHA) was reduced in FMPD offspring vs. control offspring (P = 0.04). The Omega-3 Index was significantly decreased in the FMPD group (P = 0.03). Conclusions The percentage of FMPD in AMD offspring is nearly twice that reported for the general population in the scientific literature. Offspring presenting FMPD had similar AMD genetic risk, but significantly reduced % RBC membrane omega-3 fatty acids and thinner foveas compared with those without FMPD. Our data supports the importance of 'essential fatty' acids as an independent AMD risk factor.
C1 [Rutledge, Grant A.; Pratt, Steven G.; Perry, C. Blake; Pratt, Gunilla] Scripps Mem Hosp, Scripps Hlth, Scripps Mericos Eye Inst, Scripps Clin Res Serv, La Jolla, CA USA.
   [Rutledge, Grant A.] Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92717 USA.
   [Rutledge, Grant A.] USDA, Human Nutr Res Ctr Aging, Boston, MA USA.
   [Richer, Stuart P.; Podella, Carla] Captain James A Lovell Fed Hlth Care Ctr, Eye Clin, N Chicago, IL USA.
   [Huntjens, Byki] City Univ London, Ctr Appl Vis Res, Div Optometry & Vis Sci, London, England.
C3 University of California System; University of California Irvine; United
   States Department of Agriculture (USDA); City University London
RP Rutledge, GA (通讯作者)，Scripps Mem Hosp, Scripps Hlth, Scripps Mericos Eye Inst, Scripps Clin Res Serv, La Jolla, CA USA.; Rutledge, GA (通讯作者)，Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92717 USA.
EM Grant.Rutledge@Tufts.edu
OI Huntjens, Byki/0000-0002-4864-0723; Rutledge, Grant/0000-0002-2093-4543
FU Scripps Health System [IRB-11-5677]; Fonseca estate grant [14110001579];
   Scripps Foundation
FX The Scripps Health System - IRB-11-5677, Fonseca estate grant
   14110001579 awarded in 2007 and 2012 for a total of $315,000. The
   remainder of the money used to finish this study was raised through the
   Scripps Foundation via a fund-raising event. The funding source did not
   have any role in the design of the study, collection, analysis and
   interpretation of the data, and in writing of the manuscript.
CR Arunkumar R, 2018, EYE, V32, P992, DOI 10.1038/s41433-018-0044-0
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Bazan NG, 2011, ANNU REV NUTR, V31, P321, DOI 10.1146/annurev.nutr.012809.104635
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TT, 2005, EXP EYE RES, V81, P602, DOI 10.1016/j.exer.2005.03.019
   Berendschot TTJM, 2006, INVEST OPHTH VIS SCI, V47, P709, DOI 10.1167/iovs.05-0663
   Berendschot TTJM, 2004, ARCH BIOCHEM BIOPHYS, V430, P149, DOI 10.1016/j.abb.2004.04.029
   Bhargava S, 2014, MOL CELL BIOCHEM, V387, P55, DOI 10.1007/s11010-013-1869-2
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Ciulla TA, 2004, AM J OPHTHALMOL, V138, P582, DOI 10.1016/j.ajo.2004.05.057
   Ciulla TA, 2001, OPHTHALMOLOGY, V108, P730, DOI 10.1016/S0161-6420(00)00655-2
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Connolly EE, 2010, CURR EYE RES, V35, P335, DOI 10.3109/02713680903521951
   Conrady CD, 2017, INVEST OPHTH VIS SCI, V58, P3616, DOI 10.1167/iovs.17-21818
   Ctori I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169520
   Davey PG, 2019, MACULAR PIGMENT REFL
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Delori FC, 2006, J OPT SOC AM A, V23, P521, DOI 10.1364/JOSAA.23.000521
   Dennison JL, 2013, EXP EYE RES, V116, P190, DOI 10.1016/j.exer.2013.08.014
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P8016, DOI 10.1167/iovs.11-7610
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Green-Gomez M, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.41
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   Harris G, 2013, FOOD NUTR DIS MANAGE, P1
   Harris WS, 2013, PROSTAG LEUKOTR ESS, V88, P257, DOI 10.1016/j.plefa.2012.12.004
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Hodge WG, 2007, RETINA-J RET VIT DIS, V27, P216, DOI 10.1097/01.iae.0000233322.83713.2d
   Howells O, 2011, GRAEF ARCH CLIN EXP, V249, P315, DOI 10.1007/s00417-010-1577-5
   Huntjens B, 2014, INVEST OPHTH VIS SCI, V55, P1440, DOI 10.1167/iovs.13-13204
   Iida T, 2003, RETINA-J RET VIT DIS, V23, P1, DOI 10.1097/00006982-200302000-00001
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Jorgenson E, 2016, EUR J HUM GENET, V24, P1049, DOI 10.1038/ejhg.2015.247
   Kanis MJ, 2007, EXP EYE RES, V84, P934, DOI 10.1016/j.exer.2007.01.020
   Kashani AH, 2010, AM J OPHTHALMOL, V149, P496, DOI 10.1016/j.ajo.2009.09.025
   Kirby ML, 2010, INVEST OPHTH VIS SCI, V51, P6722, DOI 10.1167/iovs.10-5344
   Kirby ML, 2009, INVEST OPHTH VIS SCI, V50, P1383, DOI 10.1167/iovs.08-2494
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Komar B, 2014, GRAEF ARCH CLIN EXP, V252, P1717, DOI 10.1007/s00417-014-2627-1
   Lam RF, 2005, CURR EYE RES, V30, P799, DOI 10.1080/02713680590968439
   Lambertus S, 2016, INVEST OPHTH VIS SCI, V57, P6824, DOI 10.1167/iovs.16-20963
   Liew SHM, 2006, EXP EYE RES, V82, P915, DOI 10.1016/j.exer.2005.10.014
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Nolan JM, 2008, INVEST OPHTH VIS SCI, V49, P2134, DOI 10.1167/iovs.07-0933
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Nolan JM, 2012, EXP EYE RES, V101, P9, DOI 10.1016/j.exer.2012.05.006
   Nusinowitz S, 2018, CURR EYE RES, V43, P376, DOI 10.1080/02713683.2017.1401646
   Obana A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.11.28
   Obana A, 2020, JPN J OPHTHALMOL, V64, P160, DOI 10.1007/s10384-020-00716-5
   Obana A, 2017, INVEST OPHTH VIS SCI, V58, P5157, DOI 10.1167/iovs.17-22347
   Pratt S, 2013, INVEST OPHTH VIS SCI, V54
   Putnam CM, 2013, OPTOMETRY VISION SCI, V90, pE206, DOI 10.1097/OPX.0b013e318299386e
   Richer S. P., 2017, ADV OPHTHALMOL VIS S, V7
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Thuppal SV, 2017, NUTRIENTS, V9, DOI 10.3390/nu9090930
   van der Veen RLP, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3275481
   Van Der Veen RLP, 2009, EUR J OPHTHALMOL, V19, P836, DOI 10.1177/112067210901900524
   Wagner-Schuman M, 2011, INVEST OPHTH VIS SCI, V52, P625, DOI 10.1167/iovs.10-5886
   Warwick A, 2018, EYE, V32, P849, DOI 10.1038/eye.2017.245
   Wolf-Schnurrbusch UEK, 2007, INVEST OPHTH VIS SCI, V48, P3783, DOI 10.1167/iovs.06-1218
   Zeimer M, 2012, INVEST OPHTH VIS SCI, V53, P4852, DOI 10.1167/iovs.12-9713
NR 71
TC 3
Z9 3
U1 2
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD DEC 2
PY 2020
VL 20
IS 1
AR 473
DI 10.1186/s12886-020-01742-0
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PD9CD
UT WOS:000597972900003
PM 33267825
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ranjbar, M
   Kurz, M
   Holzhey, A
   Rades, D
   Grisanti, S
AF Ranjbar, Mahdy
   Kurz, Maximilian
   Holzhey, Annekatrin
   Rades, Dirk
   Grisanti, Salvatore
TI Subfoveal Choroidal Thickness as a Potential Predictor of Clinical
   Response to Stereotactic Radiotherapy for Neovascular Age-Related
   Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID GROWTH-FACTOR THERAPY; HUMAN RPE CELLS; RANIBIZUMAB; BEVACIZUMAB
AB BACKGROUND AND OBJECTIVE: Stereotactic radiotherapy (SRT) is a new adjuvant treatment modality that has been shown to reduce the need for repetitive intravitreal injections (IVIs) in patients with neovascular age-related macular degeneration (nAMD). The authors aimed to determine baseline predictors of clinical response to SRT.
   PATIENTS AND METHODS: This was a retrospective, observational case series of patients with nAMD who underwent SRT and subsequently had at least 12 months of complete follow-up. After SRT and one mandatory IVI, patients were examined every 4 weeks and received further treatment on a pro re nata basis. Examination included enhanced depth imaging spectral-domain optical coherence tomography (SD-OCT) to measure subfoveal choroidal thickness (SFCT) and central macular thickness (CMT). Patients' data wore retrieved from medical records and included demographics, disease duration, lesion size, best-corrected visual acuity (BCVA), previous number of IVIs, and type of drug applied.
   RESULTS: A total of 35 eyes of 35 patients (76.23 years +/- 7.05 years) were included, and 21 eyes (60%) responded well to SRT. The annual injection rate decreased from 6.86 before SRT to 3.46 afterward, whereas BCVA improved from 0.49 logMAR at baseline to 0.37 logMAR at final follow-up. From a morphologic point of viewy CMT and SFCT decreased by 71 mu m and 37 mu m, respectively, at 12-month follow-up compared to baseline. Of all investigated parameters, only SFCT proved to be significant, as a higher baseline SFCT was found to be a strong negative predictor for the number of IVIs needed after SRT (regression coefficient: -0.678; P < .001).
   CONCLUSIONS: Baseline SFCT may help predict which patients with nAMD will respond more favorably to SRT. The authors found eyes with a thicker baseline SFCT needed fewer IVIs after SRT.
C1 [Ranjbar, Mahdy; Kurz, Maximilian; Grisanti, Salvatore] Univ Lubeck, Dept Ophthalmol, Lubeck, Germany.
   [Ranjbar, Mahdy; Kurz, Maximilian; Holzhey, Annekatrin] Univ Lubeck, Lab Angiogenesis & Ocular Cell Transplantat, Lubeck, Germany.
   [Rades, Dirk] Univ Lubeck, Dept Radiat Oncol, Lubeck, Germany.
C3 University of Lubeck; University of Lubeck; University of Lubeck
RP Ranjbar, M (通讯作者)，Ratzeburger Allee 160, D-23538 Lubeck, Germany.
EM eye.research101@gmail.com
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chakraborty R, 2011, INVEST OPHTH VIS SCI, V52, P5121, DOI 10.1167/iovs.11-7364
   CHAKRAVARTHY U, 1989, CURR EYE RES, V8, P337, DOI 10.3109/02713688908996381
   Deissler H, 2008, BRIT J OPHTHALMOL, V92, P839, DOI 10.1136/bjo.2007.135640
   Esmaeelpour M, 2014, INVEST OPHTH VIS SCI, V55, P5074, DOI 10.1167/iovs.14-14646
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   German Ophthalmological Society the German Retina Society and the Professional Association of German Ophthalmologists. [Statement of the German Ophthalmological Society the German Retina Society and the Professional Association of German Ophthalmologists, 2015, KLIN MONBL AUGENHEIL, V232, P202
   Holz FG, 1997, FRONT RADIAT THER ON, V30, P238
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Inoue M, 2016, AM J OPHTHALMOL, V169, P95, DOI 10.1016/j.ajo.2016.06.021
   Jackson TL, 2015, RETINA-J RET VIT DIS, V35, P194, DOI 10.1097/IAE.0000000000000283
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kim H, 2016, GRAEF ARCH CLIN EXP, V254, P1497, DOI 10.1007/s00417-015-3221-x
   Kim JH, 2015, INVEST OPHTH VIS SCI, V56, P1909, DOI 10.1167/iovs.14-16000
   Lassota N, 2008, ACTA OPHTHALMOL, V86, P495, DOI [10.1111/j.1600-0420.2007.01127.x, 10.1111/j.1755-3768.2008.01412.x]
   Mantel I, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.6
   Moshfeghi DM, 2011, BRIT J OPHTHALMOL, V95, P185, DOI 10.1136/bjo.2009.163907
   Neffendorf JE, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1676-7
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Ranjbar M, 2017, CURRENT EYE RES, P1
   Ranjbar M, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005729
   Ranjbar M, 2016, CYTOKINE, V83, P210, DOI 10.1016/j.cyto.2016.04.014
   Ranjbar M, 2016, CELL PHYSIOL BIOCHEM, V38, P737, DOI 10.1159/000443030
   Rayess N, 2016, AM J OPHTHALMOL, V171, P47, DOI 10.1016/j.ajo.2016.08.026
   Rayess N, 2015, AM J OPHTHALMOL, V159, P85, DOI 10.1016/j.ajo.2014.09.033
   Razavi S, 2015, AM J OPHTHALMOL, V160, P1006, DOI 10.1016/j.ajo.2015.08.009
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Taddei PJ, 2010, PHYS MED BIOL, V55, P7037, DOI 10.1088/0031-9155/55/23/S06
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
NR 33
TC 6
Z9 6
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAY
PY 2018
VL 49
IS 5
BP 320
EP 328
DI 10.3928/23258160-20180501-05
PG 9
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA GG9DF
UT WOS:000433000200005
PM 29772042
DA 2022-11-30
ER

PT J
AU Lambert, NG
   Zhang, XH
   Rai, RR
   Uehara, H
   Choi, S
   Carroll, LS
   Das, SK
   Cahoon, JM
   Kirk, BH
   Bentley, BM
   Ambati, BK
AF Lambert, Nathan G.
   Zhang, Xiaohui
   Rai, Ruju R.
   Uehara, Hironori
   Choi, Susie
   Carroll, Lara S.
   Das, Subrata K.
   Cahoon, Judd M.
   Kirk, Brian H.
   Bentley, Blaine M.
   Ambati, Balamurali K.
TI Subretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and
   vascular endothelial growth factor in a murine model of age-related
   macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization; Vascular
   endothelial growth factor; Cartilage oligomeric matrix protein;
   Angiopoietin-1; Adeno-associated virus; Subretinal injection
ID LEBER CONGENITAL AMAUROSIS; ADENOASSOCIATED VIRUS VECTORS; PIGMENT
   EPITHELIAL-CELLS; ACUTE LUNG INJURY; HUMAN RPE CELLS; TARGETING
   HIF-1-ALPHA; VISUAL IMPAIRMENT; GENE-TRANSFER; IN-VIVO; ANGIOPOIETIN-1
   VARIANT
AB To assess whether Tie2-mediated vascular stabilization ameliorates neovascular age-related macular degeneration (AMD), we investigated the impact of adeno-associated virus-mediated gene therapy with cartilage oligomeric matrix protein angiopoietin-1 (AAV2.COMP-Ang1) on choroidal neovascularization (CNV), vascular endothelial growth factor (VEGF), and hypoxia-inducible factor (HIF) in a mouse model of the disease. We treated mice with subretinal injections of AAV2.COMP-Ang1 or control (AAV2.AcGFP, AAV2.LacZ, and phosphate-buffered saline). Subretinal AAV2 localization and plasmid protein expression was verified in the retinal pigment epithelium (RPE)/choroid of mice treated with all AAV2 constructs. Laser-assisted simulation of neovascular AMD was performed and followed by quantification of HIF, VEGF, and CNV in each experimental group. We found that AAV2.COMP-Ang1 was associated with a significant reduction in VEGF levels (29-33%, p < 0.01) and CNV volume (60-70%, p < 0.01), without a concomitant decrease in HIF1-alpha, compared to all controls. We concluded that a) AAV2 is a viable vector for delivering COMP-Ang1 to subretinal tissues, b) subretinal COMP-Ang1 holds promise as a prospective treatment for neovascular AMD, and c) although VEGF suppression in the RPE/choroid may be one mechanism by which AAV2.COMP-Ang1 reduces CNV, this therapeutic effect may be hypoxia-independent. Taken together, these findings suggest that AAV2.COMP-Ang1 has potential to serve as an alternative or complementary option to anti-VEGF agents for the long-term amelioration of neovascular AMD. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Lambert, Nathan G.; Zhang, Xiaohui; Rai, Ruju R.; Uehara, Hironori; Choi, Susie; Carroll, Lara S.; Das, Subrata K.; Cahoon, Judd M.; Kirk, Brian H.; Bentley, Blaine M.; Ambati, Balamurali K.] John A Moran Eye Ctr, Ambati Lab, Salt Lake City, UT USA.
   [Zhang, Xiaohui; Rai, Ruju R.; Uehara, Hironori; Choi, Susie; Carroll, Lara S.; Das, Subrata K.; Ambati, Balamurali K.] Univ Utah, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
C3 Utah System of Higher Education; University of Utah
RP Ambati, BK (通讯作者)，Univ Utah, Ambati Lab, John A Moran Eye Ctr, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM bala.ambati@utah.edu
OI Lambert, Nathan/0000-0001-5705-7081; DAS, SUBRATA/0000-0001-8608-3270
FU Research to Prevent Blindness; National Institutes of Health Diabetes
   T32 Training Grant; Fight for Sight; Diabetes Metabolism Consortium
   Training Grant; NATIONAL EYE INSTITUTE [R01EY017182, R01EY026029]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASES [P30DK020579] Funding Source: NIH RePORTER
FX Supported in part by an Unrestricted Grant from Research to Prevent
   Blindness, a Diabetes Metabolism Consortium Training Grant, and a
   National Institutes of Health Diabetes T32 Training Grant. Funding from
   Fight for Sight is also gratefully acknowledged.
CR Amado D, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000659
   Ashikari M, 2010, INVEST OPHTH VIS SCI, V51, P3820, DOI 10.1167/iovs.09-5121
   Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639
   Baffert F, 2006, AM J PHYSIOL-HEART C, V290, pH107, DOI 10.1152/ajpheart.00542.2005
   Bennett J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002865
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Broadhead GK, 2014, ACTA OPHTHALMOL, V92, P713, DOI 10.1111/aos.12463
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cahoon JM, 2015, DIABETES, V64, P4247, DOI 10.2337/db14-1030
   Calvo P, 2015, BRIT J OPHTHALMOL, V99, P723, DOI 10.1136/bjophthalmol-2014-305684
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Campochiaro PA, 2011, HUM GENE THER, V22, P523, DOI 10.1089/hum.2011.050
   Cereso N, 2014, MOL THER-METH CLIN D, V1, DOI 10.1038/mtm.2014.11
   Cheng Y, 2013, CURR GENE THER, V13, P182, DOI 10.2174/1566523211313030003
   Cho CH, 2004, P NATL ACAD SCI USA, V101, P5547, DOI 10.1073/pnas.0307574101
   Colella P, 2010, CURR GENE THER, V10, P371, DOI 10.2174/156652310793180670
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cronin T, 2012, PHARMACEUTICALS, V5, P447, DOI 10.3390/ph5050447
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Daya S, 2008, CLIN MICROBIOL REV, V21, P583, DOI 10.1128/CMR.00008-08
   Dismuke DJ, 2013, CURR GENE THER, V13, P434
   Ehlers JP, 2015, OSLI RETINA, V46, P327, DOI 10.3928/23258160-20150323-05
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fukuhara S, 2010, HISTOL HISTOPATHOL, V25, P387, DOI 10.14670/HH-25.387
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Fuxe J, 2011, AM J PATHOL, V178, P2897, DOI 10.1016/j.ajpath.2011.02.008
   Gaddipati S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121185
   Gavard J, 2008, DEV CELL, V14, P25, DOI 10.1016/j.devcel.2007.10.019
   Giannotta M, 2013, DEV CELL, V26, P441, DOI 10.1016/j.devcel.2013.08.020
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gu HP, 2010, BIOCHEM BIOPH RES CO, V392, P178, DOI 10.1016/j.bbrc.2010.01.009
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   He DK, 2014, INHAL TOXICOL, V26, P185, DOI 10.3109/08958378.2013.872213
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hojo M, 2004, INVEST OPHTH VIS SCI, V45, P3721, DOI 10.1167/iovs.04-0059
   Hou X, 2010, P NATL ACAD SCI USA, V107, P12216, DOI 10.1073/pnas.1004143107
   Hwang SJ, 2008, PROTEIN J, V27, P319, DOI 10.1007/s10930-008-9140-5
   Ismail H, 2012, ARTERIOSCL THROM VAS, V32, P1707, DOI 10.1161/ATVBAHA.112.251546
   Itaya M, 2007, INVEST OPHTH VIS SCI, V48, P5677, DOI 10.1167/iovs.07-0156
   Jacobson SG, 2006, HUM GENE THER, V17, P845, DOI 10.1089/hum.2006.17.845
   Jacobson SG, 2006, MOL THER, V13, P1074, DOI 10.1016/j.ymthe.2006.03.005
   JOMARY C, 1994, FEBS LETT, V347, P117, DOI 10.1016/0014-5793(94)00512-5
   Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005
   Kim SR, 2008, EXP MOL MED, V40, P320, DOI 10.3858/emm.2008.40.3.320
   Koh GY, 2013, TRENDS MOL MED, V19, P31, DOI 10.1016/j.molmed.2012.10.010
   KVANTA A, 1995, CURR EYE RES, V14, P1015, DOI 10.3109/02713689508998523
   Lai CM, 2012, GENE THER, V19, P999, DOI 10.1038/gt.2011.169
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lazarovici P, 2006, CURR PHARM DESIGN, V12, P2609, DOI 10.2174/138161206777698738
   Lee J, 2014, INVEST OPHTH VIS SCI, V55, P2191, DOI 10.1167/iovs.14-13897
   Li QH, 2008, MOL VIS, V14, P1760
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mizutani T, 2013, INVEST OPHTH VIS SCI, V54, P1564, DOI 10.1167/iovs.11-9095
   Moisseiev E, 2014, EUR J OPHTHALMOL, V24, P925, DOI 10.5301/ejo.5000500
   Muhlfriedel Regine, 2013, Methods Mol Biol, V935, P343, DOI 10.1007/978-1-62703-080-9_24
   Murakami T, 2009, J BIOL CHEM, V284, P21036, DOI 10.1074/jbc.M109.016766
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Nakajima T, 2013, MOL CELL BIOCHEM, V383, P113, DOI 10.1007/s11010-013-1760-1
   Nambu H, 2005, J CELL PHYSIOL, V204, P227, DOI 10.1002/jcp.20292
   Nambu H, 2004, GENE THER, V11, P865, DOI 10.1038/sj.gt.3302230
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nozaki M, 2006, J CLIN INVEST, V116, P422, DOI 10.1172/JCI26316
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Romano MR, 2012, BRAIN RES, V1478, P55, DOI 10.1016/j.brainres.2012.08.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roy K, 2010, HUM GENE THER, V21, P915, DOI 10.1089/hum.2010.041
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Shin Joo Young, 2013, Korean J Ophthalmol, V27, P425, DOI 10.3341/kjo.2013.27.6.425
   Simonelli F, 2010, MOL THER, V18, P643, DOI 10.1038/mt.2009.277
   Sivaprasad S, 2013, BRIT MED BULL, V105, P201, DOI 10.1093/bmb/ldt004
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Testa F, 2013, OPHTHALMOLOGY, V120, P1283, DOI 10.1016/j.ophtha.2012.11.048
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Tranos P, 2013, DRUG DES DEV THER, V7, P485, DOI 10.2147/DDDT.S43470
   Uehara H, 2013, FASEB J, V27, P76, DOI 10.1096/fj.12-213835
   Wang AY, 2004, HUM GENE THER, V15, P405, DOI 10.1089/104303404322959551
   Wang Y, 2013, SAUDI MED J, V34, P584
   Xiao Q, 2008, J HUAZHONG U SCI-MED, V28, P460, DOI 10.1007/s11596-008-0419-8
   Yang XM, 2009, INVEST OPHTH VIS SCI, V50, P1873, DOI 10.1167/iovs.08-2591
   Yodoi Y, 2009, AM J OPHTHALMOL, V147, P816, DOI 10.1016/j.ajo.2008.11.020
   Zhang P, 2007, OPHTHALMOLOGICA, V221, P411, DOI 10.1159/000107502
   Zhang SH, 2012, INVEST OPHTH VIS SCI, V53, P2675, DOI 10.1167/iovs.11-8856
   Zhang XH, 2015, MOL THER, V23, P226, DOI 10.1038/mt.2014.199
   Zhao W, 2008, GRAEF ARCH CLIN EXP, V246, P1413, DOI 10.1007/s00417-008-0858-8
   Zhu YG, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/560194
NR 101
TC 10
Z9 12
U1 1
U2 12
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD APR
PY 2016
VL 145
BP 248
EP 257
DI 10.1016/j.exer.2016.01.009
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL1DL
UT WOS:000375372300028
PM 26775053
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Rajapakse, D
   Peterson, K
   Mishra, S
   Wistow, G
AF Rajapakse, Dinusha
   Peterson, Katherine
   Mishra, Sanghamitra
   Wistow, Graeme
TI Serum starvation of ARPE-19 changes the cellular distribution of
   cholesterol and Fibulin3 in patterns reminiscent of age-related macular
   degeneration
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Aging; Retinal pigment epithelium; Age-related macular degeneration;
   Cholesterol; Fibulin 3; Serum deprivation
ID BRUCHS MEMBRANE; APOLIPOPROTEIN-B; BASAL DEPOSITS; DRUSEN; ACCUMULATION;
   PARTICLES; DIFFUSION; CELLS; EYES
AB Retinal pigment epithelium (RPE) has been implicated as key source of cholesterol-rich deposits at Bruch's membrane (BrM) and in drusen in aging human eye. We have shown that serum-deprivation of confluent RPE cells is associated with upregulation of cholesterol synthesis and accumulation of unesterifled cholesterol (UC). Here we investigate the cellular processes involved in this response. We compared the distribution and localization of UC and esterified cholesterol (EC); the age-related macular degeneration (AMD) associated EFEMP1/Fibulin3 (Fib3); and levels of acyl-coenzyme A (CoA): cholesterol acyltransferases (ACAT) ACAT1, ACAT2 and Apolipoprotein B (ApoB) in ARPE-19 cells cultured in serum-supplemented and serum-free media. The results were compared with distributions of these lipids and proteins in human donor eyes with AMD. Serum deprivation of ARPE-19 was associated with increased formation of FM dye-positive membrane vesicles, many of which co-labeled for UC. Additionally, UC colocalized with Fib3 in distinct granules. By day 5, serum-deprived cells grown on transwells secreted Fib3 basally into the matrix. While mRNA and protein levels of ACTA1 were constant over several days of serum-deprivation, ACAT2 levels increased significantly after serum-deprivation, suggesting increased formation of EC. The lower levels of intracellular EC observed under serum-deprivation were associated with increased formation and secretion of ApoB. The responses to serum-deprivation in RPEderived cells: accumulation and secretion of lipids, lipoproteins, and Fib3 are very similar to patterns seen in human donor eyes with AMD and suggest that this model mimics processes relevant to disease progression.
C1 [Rajapakse, Dinusha; Peterson, Katherine; Mishra, Sanghamitra; Wistow, Graeme] NEI, Sect Mol Struct & Funct Genom, NIH, Bldg 6 Room 106, Bethesda, MD 20892 USA.
   [Mishra, Sanghamitra] Medgenome Labs Pvt Ltd, 3rd Floor Narayana Nethralaya Bldg,Hosur Rd, Bangalore 560099, Karnataka, India.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Wistow, G (通讯作者)，NEI, Sect Mol Struct & Funct Genom, NIH, Bldg 6 Room 106, Bethesda, MD 20892 USA.
EM dinusha.rajapakse@nih.gov; petersonk@nei.nih.gov;
   sanghamitra.m@medgenome.com; graeme@helix.nih.gov
OI Rajapakse, Dinusha/0000-0002-5210-6494
FU Intramural Program of the National Eye Institute; NATIONAL EYE INSTITUTE
   [ZIAEY000433] Funding Source: NIH RePORTER
FX This work was supported by the Intramural Program of the National Eye
   Institute.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Bommer GT, 2011, CELL METAB, V13, P241, DOI 10.1016/j.cmet.2011.02.004
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Castoreno AB, 2005, P NATL ACAD SCI USA, V102, P13129, DOI 10.1073/pnas.0506716102
   Chang TY, 2009, AM J PHYSIOL-ENDOC M, V297, pE1, DOI 10.1152/ajpendo.90926.2008
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chew EY, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12914
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   During A, 2008, J LIPID RES, V49, P1715, DOI 10.1194/jlr.M700580-JLR200
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Kiser PD, 2014, CHEM REV, V114, P194, DOI 10.1021/cr400107q
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Miersch S, 2008, J BIOL CHEM, V283, P18513, DOI 10.1074/jbc.M800440200
   Mishra S, 2016, MOL VIS, V22, P1387
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Pucadyil TJ, 2006, CHEM PHYS LIPIDS, V143, P11, DOI 10.1016/j.chemphyslip.2006.04.003
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Temel RE, 2007, J LIPID RES, V48, P1618, DOI 10.1194/jlr.M700109-JLR200
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   WOLTER JR, 1962, ARCH OPHTHALMOL-CHIC, V68, P219
   Wyatt MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068088
   Xu Hui-Zhuo, 2011, J Ocul Biol Dis Infor, V4, P83, DOI 10.1007/s12177-011-9068-4
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
NR 39
TC 9
Z9 9
U1 2
U2 6
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD DEC 15
PY 2017
VL 361
IS 2
BP 333
EP 341
DI 10.1016/j.yexcr.2017.10.036
PG 9
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FP6YU
UT WOS:000417774300016
PM 29097185
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kvannli, L
   Krohn, J
AF Kvannli, Line
   Krohn, Jorgen
TI Switching from pro re nata to treat-and-extend regimen improves visual
   acuity in patients with neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; anti-VEGF therapy; pro re nata;
   treat-and-extend; treat-and-observe
ID INTRAVITREAL AFLIBERCEPT; DOSING REGIMEN; RANIBIZUMAB; BEVACIZUMAB;
   TRIAL
AB Purpose: To evaluate the visual outcome after transitioning from a pro re nata (PRN) intravitreal injection regimen to a treat-and-extend (TAE) regimen for patients with neovascular age-related macular degeneration (AMD).
   Methods: A retrospective review of patients who were switched from a PRN regimen with intravitreal injections of bevacizumab, ranibizumab or aflibercept to a TAE regimen. The best corrected visual acuity (BCVA), central retinal thickness (CRT) and type of medication used at baseline, at the time of changing treatment regimen and at the end of the study were analysed.
   Results: Twenty-one eyes of 21 patients met the inclusion criteria. Prior to the switch, the patients received a mean of 13.8 injections (median, 10; range, 3-39 injections) with the PRN regimen for 44months (range, 3-100months), which improved the visual acuity in five patients (24%). After a mean of 6.1 injections (median, 5; range, 3-14 injections) with the TAE regimen over 8months (range, 2-16months), the visual acuity improved in 12 patients (57%). The improvement in visual acuity during treatment with the TAE regimen was statistically significant (p=0.005). The proportion of patients with a visual acuity of 0.2 or better was significantly higher after treatment with the TAE regimen than after treatment with the PRN regimen (p=0.048). No significant differences in CRT were found between the two treatment regimens.
   Conclusion: Even after prolonged treatment and a high number of intravitreal injections, switching AMD patients from a PRN regimen to a strict TAE regimen significantly improves visual acuity.
C1 [Kvannli, Line; Krohn, Jorgen] Haukeland Hosp, Dept Ophthalmol, N-5021 Bergen, Norway.
   [Kvannli, Line] Innlandet Hosp Trust, Div Lillehammer, Dept Ophthalmol, Lillehammer, Norway.
   [Krohn, Jorgen] Univ Bergen, Sect Ophthalmol, Dept Clin Med, Bergen, Norway.
C3 University of Bergen; Haukeland University Hospital; Innlandet Hospital
   Trust; University of Bergen
RP Krohn, J (通讯作者)，Haukeland Hosp, Dept Ophthalmol, N-5021 Bergen, Norway.
EM jorgen.krohn@helse-bergen.no
CR Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Eadie JA, 2014, OSLI RETINA, V45, P394, DOI 10.3928/23258160-20140909-03
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Ferrone PJ, 2014, BRIT J OPHTHALMOL, V98, P17, DOI 10.1136/bjophthalmol-2013-304474
   Forooghian F, 2008, INVEST OPHTH VIS SCI, V49, P4290, DOI 10.1167/iovs.08-2113
   Forte R, 2009, EYE, V23, P2071, DOI 10.1038/eye.2008.363
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Hatz K, 2016, BRIT J OPHTHALMOL, V100, P1341, DOI 10.1136/bjophthalmol-2015-307299
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Homer N, 2015, EYE, V29, P1152, DOI 10.1038/eye.2015.87
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Panchmatia HR, 2016, ACTA OPHTHALMOL, V94, P441, DOI 10.1111/aos.12964
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   van Asten F, 2015, ACTA OPHTHALMOL, V93, P126, DOI 10.1111/aos.12610
NR 22
TC 32
Z9 33
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2017
VL 95
IS 7
BP 678
EP 682
DI 10.1111/aos.13356
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FM0JE
UT WOS:000414648500029
PM 28139082
OA Bronze
DA 2022-11-30
ER

PT J
AU Alaimo, A
   Linares, GG
   Bujjamer, JM
   Gorojod, RM
   Alcon, SP
   Martinez, JH
   Baldessari, A
   Grecco, HE
   Kotler, ML
AF Alaimo, Agustina
   Garcia Linares, Guadalupe
   Marco Bujjamer, Juan
   Mayra Gorojod, Roxana
   Porte Alcon, Soledad
   Hebe Martinez, Jimena
   Baldessari, Alicia
   Edgardo Grecco, Hernan
   Lidia Kotler, Monica
TI Toxicity of blue led light and A2E is associated to mitochondrial
   dynamics impairment in ARPE-19 cells: implications for age-related
   macular degeneration
SO ARCHIVES OF TOXICOLOGY
LA English
DT Article
DE Age-related macular degeneration; RPE cells; Aging; Light pollution;
   Phototoxicity; A2E; Oxidative stress; Mitochondrial dynamics
ID RETINAL-PIGMENT EPITHELIUM; QUALITY-CONTROL; OXIDATIVE STRESS; DNA
   DAMAGE; LIPOFUSCIN; INVOLVEMENT; APOPTOSIS; EXPOSURE; DEATH; DYSFUNCTION
AB Age-related macular degeneration (AMD) is a multifactorial retinal disease characterized by a progressive loss of central vision. Retinal pigment epithelium (RPE) degeneration is a critical event in AMD. It has been associated to A2E accumulation, which sensitizes RPE to blue light photodamage. Mitochondrial quality control mechanisms have evolved to ensure mitochondrial integrity and preserve cellular homeostasis. Particularly, mitochondrial dynamics involve the regulation of mitochondrial fission and fusion to preserve a healthy mitochondrial network. The present study aims to clarify the cellular and molecular mechanisms underlying photodamage-induced RPE cell death with particular focus on the involvement of defective mitochondrial dynamics. Light-emitting diodes irradiation (445 +/- 18 nm; 4.43 mW/cm(2)) significantly reduced the viability of both unloaded and A2E-loaded human ARPE-19 cells and increased reactive oxygen species production. A2E along with blue light, triggered apoptosis measured by MC540/PI-flow cytometry and activated caspase-3. Blue light induced mitochondrial fusion/fission imbalance towards mitochondrial fragmentation in both non-loaded and A2E-loaded cells which correlated with the deregulation of mitochondria-shaping proteins level (OPA1, DRP1 and OMA1). To our knowledge, this is the first work reporting that photodamage causes mitochondrial dynamics deregulation in RPE cells. This process could possibly contribute to AMD pathology. Our findings suggest that the regulation of mitochondrial dynamics may be a valuable strategy for treating retinal degeneration diseases, such as AMD.
C1 [Alaimo, Agustina; Mayra Gorojod, Roxana; Porte Alcon, Soledad; Hebe Martinez, Jimena; Lidia Kotler, Monica] Univ Buenos Aires, CONICET, Inst Quim Biol Ciencias Exactas & Nat IQUIBICEN, Dept Quim Biol,Fac Ciencias Exactas & Nat, Pabellon 2,Ciudad Univ, RA-1428 Buenos Aires, DF, Argentina.
   [Garcia Linares, Guadalupe; Baldessari, Alicia] Univ Buenos Aires, CONICET, Unidad Microanal & Metodos Fis Quim Organ UMYNFOR, Dept Quim Organ,Fac Ciencias Exactas & Nat, Pabellon 2,Ciudad Univ, RA-1428 Buenos Aires, DF, Argentina.
   [Marco Bujjamer, Juan; Edgardo Grecco, Hernan] Univ Buenos, CONICET, Inst Fis Buenos Aires IFIBA, Dept Fis,Fac Ciencias Exactas & Nat, Pabellon 1,Ciudad Univ, RA-1428 Buenos Aires, DF, Argentina.
C3 Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   University of Buenos Aires; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET); University of Buenos Aires; Consejo
   Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University
   of Buenos Aires
RP Kotler, ML (通讯作者)，Univ Buenos Aires, CONICET, Inst Quim Biol Ciencias Exactas & Nat IQUIBICEN, Dept Quim Biol,Fac Ciencias Exactas & Nat, Pabellon 2,Ciudad Univ, RA-1428 Buenos Aires, DF, Argentina.
EM aataimo@qb.fcen.uba.ar; linares@qo.fcen.uba.ar; jubujjamer@df.uba.ar;
   rgorojod@qb.fcen.uba.ar; sportealcon@qb.fcen.uba.ar;
   jhebemartinez@gmail.com; alib@qo.fcen.uba.ar; hgrecco@df.uba.ar;
   kotler@qb.fcen.uba.ar
OI Gorojod, Roxana Mayra/0000-0002-9820-3978; Kotler, Monica
   Lidia/0000-0002-3555-7621; Porte Alcon, Soledad/0000-0002-0381-0880
FU Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)
   [PIP 0771, PIP 0653]; University of Buenos Aires [UBACYT
   20020130100212BA, 20020130200271BA, 20020170100755BA]; CONICET
   scholarship
FX This work was supported by grants from the Consejo Nacional de
   Investigaciones Cientificas y Tecnicas (CONICET PIP 0771, PIP 0653) and
   University of Buenos Aires (UBACYT 20020130100212BA, 20020130200271BA
   and 20020170100755BA). J.M.B, R.M.G., S.P.A., J.H.M. are supported by a
   CONICET scholarship. A.A., G.G.L., A.B., H.E.G. and M.L.K. are
   researcher members at CONICET.
CR Alaimo A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091848
   Alaimo A, 2013, NEUROSCI LETT, V554, P76, DOI 10.1016/j.neulet.2013.08.061
   Alaimo A, 2011, NEUROCHEM INT, V59, P297, DOI 10.1016/j.neuint.2011.06.001
   Contin MA, 2013, MOL VIS, V19, P1614
   Ao J, 2018, CLIN EXP OPHTHALMOL, V46, P670, DOI 10.1111/ceo.13121
   Arnault E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071398
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Berman K, 2006, INT PSYCHOGERIATR, V18, P415, DOI 10.1017/S1041610205002905
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034
   Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   Chahory S, 2010, NEUROCHEM INT, V57, P278, DOI 10.1016/j.neuint.2010.06.006
   Chamorro E, 2013, PHOTOCHEM PHOTOBIOL, V89, P468, DOI 10.1111/j.1751-1097.2012.01237.x
   Chauhan A, 2014, BIOGERONTOLOGY, V15, P1, DOI 10.1007/s10522-013-9474-z
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Fernandez-Robredo P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/510285
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Gao ML, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.13
   Gea M, 2018, J TOXICOL ENV HEAL A, V81, P998, DOI 10.1080/15287394.2018.1510350
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220
   Gorojod RM, 2015, FREE RADICAL BIO MED, V87, P237, DOI 10.1016/j.freeradbiomed.2015.06.034
   Huang C, 2014, APOPTOSIS, V19, P922, DOI 10.1007/s10495-014-0983-2
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Jaadane I, 2017, J CELL MOL MED, V21, P3453, DOI 10.1111/jcmm.13255
   Jaadane I, 2015, FREE RADICAL BIO MED, V84, P373, DOI 10.1016/j.freeradbiomed.2015.03.034
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kotiadis VN, 2014, BBA-GEN SUBJECTS, V1840, P1254, DOI 10.1016/j.bbagen.2013.10.041
   Kuse Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep05223
   Laakko T, 2002, J IMMUNOL METHODS, V261, P129, DOI 10.1016/S0022-1759(01)00562-2
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Liesa M, 2009, PHYSIOL REV, V89, P799, DOI 10.1152/physrev.00030.2008
   Lin CH, 2017, TOXICOL SCI, V157, P196, DOI 10.1093/toxsci/kfx030
   Lionaki E, 2015, BBA-BIOENERGETICS, V1847, P1412, DOI 10.1016/j.bbabio.2015.04.010
   Lu B, 2017, OPHTHALMIC RES, V57, P252, DOI 10.1159/000452282
   MacVicar T, 2016, J CELL SCI, V129, P2297, DOI 10.1242/jcs.159186
   Marie M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0331-5
   Gorojod RM, 2018, TOXICOL LETT, V295, P357, DOI 10.1016/j.toxlet.2018.07.045
   McBride H, 2013, BBA-MOL CELL RES, V1833, P148, DOI 10.1016/j.bbamcr.2012.11.001
   McBride H, 2010, CURR BIOL, V20, pR274, DOI 10.1016/j.cub.2010.02.011
   Moon J, 2017, INTEGR BIOL-UK, V9, P436, DOI 10.1039/c7ib00032d
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Nita Malgorzata, 2016, Oxid Med Cell Longev, V2016, P3164734, DOI 10.1155/2016/3164734
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Alcon SP, 2018, NEUROSCIENCE, V393, P206, DOI 10.1016/j.neuroscience.2018.10.006
   Robinson KM, 2008, NAT PROTOC, V3, P941, DOI 10.1038/nprot.2008.56
   Roehlecke C, 2009, MOL VIS, V15, P1929
   Shutt TE, 2013, BBA-MOL CELL RES, V1833, P417, DOI 10.1016/j.bbamcr.2012.05.024
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Stotland A, 2015, BBA-MOL CELL RES, V1853, P2802, DOI 10.1016/j.bbamcr.2014.12.041
   Suen DF, 2008, GENE DEV, V22, P1577, DOI 10.1101/gad.1658508
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Torriglia A, 2016, CURR OPIN NEUROL, V29, P55, DOI 10.1097/WCO.0000000000000272
   Tosini G, 2016, MOL VIS, V22, P61
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wihlmark U, 1997, FREE RADICAL BIO MED, V22, P1229, DOI 10.1016/S0891-5849(96)00555-2
   Winkler BS, 1999, MOL VIS, V5
   Wojtala A, 2014, METHOD ENZYMOL, V542, P243, DOI 10.1016/B978-0-12-416618-9.00013-3
   Wolf G, 2003, NUTR REV, V61, P342, DOI 10.1301/nr.2003.oct.342-346
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JM, 2002, INVEST OPHTH VIS SCI, V43, P3349
   Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697
   Zhang K, 2014, EMBO REP, V15, P576, DOI 10.1002/embr.201338240
NR 74
TC 38
Z9 41
U1 4
U2 36
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5761
EI 1432-0738
J9 ARCH TOXICOL
JI Arch. Toxicol.
PD MAY
PY 2019
VL 93
IS 5
BP 1401
EP 1415
DI 10.1007/s00204-019-02409-6
PG 15
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA IA7UI
UT WOS:000469762400017
PM 30778631
OA Green Published
DA 2022-11-30
ER

PT J
AU Bokinni, Y
   Shah, N
   Maguire, O
   Laidlaw, DAH
AF Bokinni, Y.
   Shah, N.
   Maguire, O.
   Laidlaw, D. A. H.
TI Performance of a computerised visual acuity measurement device in
   subjects with age-related macular degeneration: comparison with gold
   standard ETDRS chart measurements
SO EYE
LA English
DT Article
ID TREATMENT DIABETIC-RETINOPATHY; AMBLYOPIC CHILDREN; TESTING PROTOCOL;
   LOGMAR; RELIABILITY; VALIDATION; DISEASE; SNELLEN; SCORES
AB Purpose The aim of the study was to compare the performance of two different COMPlog computerised, single letter scoring, visual acuity (VA) measurements against gold standard Early Treatment Diabetic Retinopathy Study (ETDRS) chart measurements in patients with age-related macular degeneration (AMD). One computerised algorithm presented five and the other presented three letters per line; both computerised algorithms utilised half, rather than the full-letter width spacing standard on ETDRS charts that might induce crowding, fixation problems, increased test-retest variability (TRV), and bias.
   Methods Fifty patients with AMD (mean age 83 years) underwent timed test and retest VA measurements using ETDRS charts and COMPlog five (C5) and three (C3) letters per line computerised VA measurement algorithms. All tests utilised single-letter scoring methodology. Bland and Altman methods were employed. Performance was measured in terms of bias, TRV, and test time.
   Results The C5 and C3 scores showed no bias compared with the ETDRS chart measurements. C5 measurements had equal TRV to the ETDRS chart (+/- 0.13 logMAR) with similar median test times (105 and 96 s, respectively). C3 measurements were slightly more variable (TRV +/- 0.17 logMAR), but 30 s quicker than ETDRS chart measurements.
   Conclusions The closer letter spacing employed in COMPlog testing algorithms appears to have no adverse effect on VA measurements compared with the gold standard ETDRS chart in patients with AMD. The three letter per line testing algorithm facilitates faster testing but with a two letter increase in TRV.
C1 [Bokinni, Y.] Cambridge Univ NHS Fdn Trust, Addenbrookess Hosp, Cambridge, England.
   [Shah, N.; Maguire, O.; Laidlaw, D. A. H.] St Thomas Hosp, Dept Ophthalmol, London SE1 7EH, England.
C3 Guy's & St Thomas' NHS Foundation Trust
RP Laidlaw, DAH (通讯作者)，St Thomas Hosp, Dept Ophthalmol, Lambeth Palace Rd, London SE1 7EH, England.
EM Alistair.Laidlaw@gstt.nhs.uk
OI Shah, Nilpa/0000-0003-3127-500X
CR Altman A., 1952, Q REV OPHTHALMOL, V8, P4
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   ARDITI A, 1993, INVEST OPHTH VIS SCI, V34, P120
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Cacho I, 2007, OPTOMETRY VISION SCI, V84, P487, DOI 10.1097/OPX.0b013e318073c2f2
   Camparini M, 2001, INVEST OPHTH VIS SCI, V42, P1226
   Carkeet A, 2001, OPTOMETRY VISION SCI, V78, P529, DOI 10.1097/00006324-200107000-00017
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   Chew EY, 2009, ARCH OPHTHALMOL-CHIC, V127, P1678, DOI 10.1001/archophthalmol.2009.312
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Cotter SA, 2003, AM J OPHTHALMOL, V136, P655, DOI 10.1016/S0002-9394(03)00388-X
   Cousens SN, 2004, OPTOMETRY VISION SCI, V81, P673, DOI 10.1097/01.opx.0000144745.42600.76
   Crossland MD, 2011, RETINA-J RET VIT DIS, V31, P2109, DOI 10.1097/IAE.0b013e31820d3fba
   Ehrmann K, 2009, CONTACT LENS ANTERIO, V32, P133, DOI 10.1016/j.clae.2008.09.005
   ELLIOTT DB, 1988, OPHTHAL PHYSL OPT, V8, P397, DOI 10.1111/j.1475-1313.1988.tb01176.x
   Hussain B, 2006, CLIN EXP OPHTHALMOL, V34, P6, DOI 10.1111/j.1442-9071.2006.01135.x
   Laidlaw DAH, 2008, BRIT J OPHTHALMOL, V92, P241, DOI 10.1136/bjo.2007.121715
   Laidlaw DAH, 2003, BRIT J OPHTHALMOL, V87, P1232, DOI 10.1136/bjo.87.10.1232
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   LOVIEKITCHIN JE, 1988, OPHTHAL PHYSL OPT, V8, P363, DOI 10.1111/j.1475-1313.1988.tb01170.x
   Noushad Babu, 2012, Oman J Ophthalmol, V5, P87
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   REEVES BC, 1991, OPTOMETRY VISION SCI, V68, P728, DOI 10.1097/00006324-199109000-00010
   Rosser DA, 2001, BRIT J OPHTHALMOL, V85, P432, DOI 10.1136/bjo.85.4.432
   Shah N, 2012, EYE, V26, P593, DOI 10.1038/eye.2011.333
   Shah N, 2010, OPHTHAL PHYSL OPT, V30, P200, DOI 10.1111/j.1475-1313.2009.00700.x
   Siderov J, 1999, ACTA OPHTHALMOL SCAN, V77, P673, DOI 10.1034/j.1600-0420.1999.770613.x
   Williams MA, 2008, INVEST OPHTH VIS SCI, V49, P4321, DOI 10.1167/iovs.07-0511
NR 30
TC 17
Z9 18
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2015
VL 29
IS 8
BP 1085
EP 1091
DI 10.1038/eye.2015.94
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CO9GF
UT WOS:000359481500014
PM 26043703
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Spindler, J
   Zandi, S
   Pfister, IB
   Gerhardt, C
   Garweg, JG
AF Spindler, Jan
   Zandi, Souska
   Pfister, Isabel B.
   Gerhardt, Christin
   Garweg, Justus G.
TI Cytokine profiles in the aqueous humor and serum of patients with dry
   and treated wet age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; BIOMARKERS; EXPRESSION; CHEMOKINE;
   ANGIOGENESIS; INFLAMMATION; RANIBIZUMAB; PROGRESSION; MECHANISMS;
   SENESCENCE
AB Purpose
   To identify disease-specific cytokine profile differences in the aqueous humor (AH) (other than the vascular endothelial growth factor) between patients with dry and treated wet age-related macular degeneration (AMD) and healthy controls.
   Methods
   This retrospective study drew on a case-series of patients diagnosed with dry AMD (n=25) and treated wet AMD (n=19), as well as on healthy controls (no systemic therapy; n=20) undergoing phacoemulsification or vitrectomy. Samples of AH and serum were collected in parallel at the beginning of surgery. The levels of 43 cytokines were simultaneously determined using the Bio-Plex (R) multiplex beads system. Differences between the three groups were statistically compared using the Kruskal-Wallis H-Test after applying the Bonferroni correction for multiple comparisons (p<0.0012).
   Results
   The concentrations of three cytokines were elevated in the AH of patients with dry AMD (CXCL6; p=0.00067) and treated wet AMD (CXCL5, CXCL6, MIG/XCXL; all p<0.001) relative to those in the healthy controls. No other differences between the three groups were identified. The AH levels of seven cytokines (16%), including CXCL6, ranged below the lower limit of quantitation of the assay. Without the correction for multiple comparisons (p<0.05), the levels of 31 of the 43 cytokines in the AH of patients with AMD would have differed significantly from those in the control. The systemic cytokine profiles (serum) were similar in all three groups.
   Conclusions
   No systematic differences in the AH cytokine environment were identified between patients with dry AMD and those with treated wet AMD. This finding might indicate that AMD is either the result of a persistent imbalance in the physiological tissue milieu, or that the localized process induces no significant change in the cytokine environment of the anterior ocular segment.
C1 [Spindler, Jan; Zandi, Souska; Pfister, Isabel B.; Gerhardt, Christin; Garweg, Justus G.] Swiss Eye Inst, Bern, Switzerland.
   [Spindler, Jan; Zandi, Souska; Pfister, Isabel B.; Gerhardt, Christin; Garweg, Justus G.] Berner Augenklin Lindenhofspital, Bern, Switzerland.
   [Spindler, Jan; Pfister, Isabel B.; Gerhardt, Christin; Garweg, Justus G.] Univ Bern, Bern, Switzerland.
C3 University of Bern
RP Garweg, JG (通讯作者)，Swiss Eye Inst, Bern, Switzerland.; Garweg, JG (通讯作者)，Berner Augenklin Lindenhofspital, Bern, Switzerland.; Garweg, JG (通讯作者)，Univ Bern, Bern, Switzerland.
EM garweg@swiss-eye-institute.com
OI Zandi, Souska/0000-0001-9351-4278
FU Scientific Funds of the Lindenhof Foundation
FX The manuscript was partially funded by a grant from the Scientific Funds
   of the Lindenhof Foundation without commercial interests. There was no
   additional external funding received for this study. The funder had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049905
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Bartlett DB, 2012, AGING CELL, V11, P912, DOI 10.1111/j.1474-9726.2012.00849.x
   Bauer ME, 2016, MECH AGEING DEV, V158, P27, DOI 10.1016/j.mad.2016.01.001
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Camelo S, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/532487
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Cha DM, 2013, INVEST OPHTH VIS SCI, V54, P7038, DOI 10.1167/iovs.13-12730
   Chaudhary V, 2016, CAN J OPHTHALMOL, V51, P302, DOI 10.1016/j.jcjo.2016.04.020
   Dace DS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003381
   Danis RP, 2015, CLIN OPHTHALMOL, V9, P2159, DOI 10.2147/OPTH.S92359
   Falk MK, 2014, INVEST OPHTH VIS SCI, V55, P4050, DOI 10.1167/iovs.14-14107
   Fauser S, 2016, BRIT J OPHTHALMOL, V100, P1494, DOI 10.1136/bjophthalmol-2015-308264
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Folkman J, 2004, APMIS, V112, P496, DOI 10.1111/j.1600-0463.2004.apm11207-0809.x
   Fox SE, 2005, CYTOKINE, V29, P135, DOI 10.1016/j.cyto.2004.10.007
   FRASCA D, 2016, BIOGERONTOLOGY, V17, P7, DOI DOI 10.1007/S10522-015-9578-8
   Fujimura S, 2012, INVEST OPHTH VIS SCI, V53, P1999, DOI 10.1167/iovs.11-8232
   Gallenga CE, 2014, INFLAMM RES, V63, P105, DOI 10.1007/s00011-013-0684-2
   Garweg JG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182571
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hong HS, 2015, WOUND REPAIR REGEN, V23, P268, DOI 10.1111/wrr.12264
   Hooks JJ, 2008, J IMMUNOL, V180, P3789, DOI 10.4049/jimmunol.180.6.3789
   Huang H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173716
   Jonas JB, 2007, OPHTHAL RES, V39, P139, DOI 10.1159/000102935
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Juel HB, 2012, INVEST OPHTH VIS SCI, V53, P8472, DOI 10.1167/iovs.12-9963
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kawai M, 2012, INVEST OPHTH VIS SCI, V53, P7951, DOI 10.1167/iovs.12-10231
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Kutty RK, 2015, CYTOKINE, V74, P335, DOI 10.1016/j.cyto.2015.03.016
   Torres KCL, 2018, EXP GERONTOL, V103, P47, DOI 10.1016/j.exger.2017.12.006
   Lin Tony, 2013, Cytokine, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Liu F, 2016, MOL VIS, V22, P352
   Ma YG, 2018, TRANSL RES, V191, P15, DOI 10.1016/j.trsl.2017.10.001
   Machado-Silva W, 2016, J STROKE CEREBROVASC, V25, P2851, DOI 10.1016/j.jstrokecerebrovasdis.2016.07.047
   Marquioni-Ramella MD, 2015, PHOTOCH PHOTOBIO SCI, V14, P1560, DOI 10.1039/c5pp00188a
   Marshall A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172821
   Martinez-Cengotitabengoa M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122022
   Miao H, 2012, MOL VIS, V18, P574
   Miller Jr R. G, 1981, SIMULTANEOUS STAT IN, P67
   Minciullo PL, 2016, ARCH IMMUNOL THER EX, V64, P111, DOI 10.1007/s00005-015-0377-3
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Opal SM, 2000, CHEST, V117, P1162, DOI 10.1378/chest.117.4.1162
   Parmar T, 2016, INVEST OPHTH VIS SCI, V57, P3257, DOI 10.1167/iovs.15-18993
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Rutar M, 2016, ADV EXP MED BIOL, V854, P11, DOI 10.1007/978-3-319-17121-0_2
   Sakamoto S, 2017, BR J OPHTHALMOL
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Sharma R, 2014, NUTR RES, V34, P968, DOI 10.1016/j.nutres.2014.09.006
   Shen DF, 2011, INVEST OPHTH VIS SCI, V52, P2897, DOI 10.1167/iovs.10-6114
   Shevchenko A V, 2016, Vestn Oftalmol, V132, P8, DOI 10.17116/oftalma201613228-13
   Shi G, 2008, INVEST OPHTH VIS SCI, V49, P4620, DOI 10.1167/iovs.08-1816
   Shurin GV, 2007, CYTOKINE, V39, P123, DOI 10.1016/j.cyto.2007.06.006
   Shwu-Jiuan S, 2012, TAIWAN J OPHTHALMOLO, V2, P51, DOI [10.1016/j.tjo.2012.02.002, DOI 10.1016/J.TJO.2012.02.002]
   Silvestre JS, 2000, CIRC RES, V87, P448
   van der Kraan P, 2017, GERONTOLOGY, V63, P29, DOI 10.1159/000448711
   Ventura Maria Teresa, 2017, Clin Mol Allergy, V15, P21, DOI 10.1186/s12948-017-0077-0
   Wuyts A, 2000, BIOCHEMISTRY-US, V39, P14549, DOI 10.1021/bi0011227
   Zandi S, 2016, INVEST OPHTH VIS SCI, V57, P6320, DOI 10.1167/iovs.16-20657
   Zandi S, 2015, CELL REP, V10, P1173, DOI 10.1016/j.celrep.2015.01.050
   Zehetner C, 2014, INVEST OPHTH VIS SCI, V55, P337, DOI 10.1167/iovs.13-12978
   Zhu DH, 2009, AGING-US, V1, P740, DOI 10.18632/aging.100078
NR 69
TC 25
Z9 26
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 29
PY 2018
VL 13
IS 8
AR e0203337
DI 10.1371/journal.pone.0203337
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GR9JD
UT WOS:000443071400103
PM 30157273
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Ho, AC
   Chang, TS
   Samuel, M
   Williamson, P
   Willenbucher, RF
   Malone, T
AF Ho, Allen C.
   Chang, Tom S.
   Samuel, Michael
   Williamson, Paul
   Willenbucher, Robert F.
   Malone, Terri
TI Experience With a Subretinal Cell-based GossMark Therapy in Patients
   With Geographic Atrophy Secondary to Age-related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID TISSUE-DERIVED CELLS; IMPROVEMENT; MODEL
AB PURPOSE: To evaluate the safety and tolerability of and clinical response to a single, subretinal dose of human umbilical tissue derived cells (palucorcel [CNTO-2476]) in the eyes of adults aged >= 50 years with bilateral geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
   DESIGN: Phase 1/2a, multicenter, open-label, dose escalation, fellow-eye controlled study.
   METHODS: In the phase 1 portion, eyes were assigned to receive a single, subretinal dose of palucorcel (ranging from 6.0 x 10(4) to 5.6 x 10(5) viable cells). In the phase 2a portion, eyes were assigned to one of 2 palucorcel doses (6.0 x 10(4) or 3.0 x 10(5) cells) determined during the phase 1 portion. The intervention eye was the eye with worse baseline visual acuity.
   RESULTS: A total of 35 eligible subjects underwent at least a partial surgical procedure. Palucorcel was administered in 33 eyes. Overall, 17.1% (6/35) of subjects experienced retinal detachments and 37.1% (13/35) experienced retinal perforations. No episodes of immune rejection or tumor formation were observed. At 1 year, 1.0- and 15-letter gains in best-corrected visual acuity were observed in 34.5% (10/29) and 24.1% (7/29) of eyes receiving palucorcel, respectively, and in 3.3% (1/30; for both) of fellow eyes.
   CONCLUSIONS: The subretinal delivery procedure in this study was associated with a high rate of retinal perforations (n = 13) and retinal detachments (n = 6). When cells were sequestered in the subretinal space, palucorcel was well tolerated and may be associated with improvements in visual acuity. Larger randomized controlled studies are required to confirm these results. Future studies would require a modified surgical approach. (C) 2017 The Author(s). Published by Elsevier Inc.
C1 [Ho, Allen C.] Wills Eye Hosp & Res Inst, Mid Atlantic Retina, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
   [Chang, Tom S.; Samuel, Michael] Retina Inst Calif, Pasadena, CA USA.
   [Williamson, Paul; Willenbucher, Robert F.; Malone, Terri] Janssen Res & Dev, Cell Therapy, Spring House, PA USA.
C3 Jefferson University; Johnson & Johnson; Janssen Pharmaceuticals
RP Ho, AC (通讯作者)，Wills Eye Hosp & Res Inst, Mid Atlantic Retina, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM achomd@gmail.com
OI Ho, Allen/0000-0003-3921-608X
FU JANSSEN RESEARCH & DEVELOPMENT, LLC, SPRING HOUSE, PA
FX JANSSEN RESEARCH & DEVELOPMENT, LLC, SPRING HOUSE, PA, SUPPORTED THIS
   STUDY.
CR Alder J, 2012, DEV NEUROBIOL, V72, P755, DOI 10.1002/dneu.20980
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bissell AJ, 2005, ACTA OPHTHALMOL SCAN, V83, P514, DOI 10.1111/j.1600-0420.2005.00441.x
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Cao J, 2016, STEM CELLS, V34, P367, DOI 10.1002/stem.2239
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Hawkins BS, 1999, MOL VIS, V5
   Koh S, 2015, J NEUROSCI, V35, P15649, DOI 10.1523/JNEUROSCI.1364-15.2015
   Lund RD, 2007, STEM CELLS, V25, P602, DOI 10.1634/stemcells.2006-0308
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Schulz KF, 2002, ANN INTERN MED, V136, P254, DOI 10.7326/0003-4819-136-3-200202050-00022
   SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Strauss O, 1998, ACTA ANAT, V162, P101
   Sunness JS, 2015, LANCET, V386, P29, DOI 10.1016/S0140-6736(15)61201-6
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Sunness JS, 2000, RETINA-J RET VIT DIS, V20, P162, DOI 10.1097/00006982-200002000-00009
NR 20
TC 36
Z9 36
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2017
VL 179
BP 67
EP 80
DI 10.1016/j.ajo.2017.04.006
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FA0YY
UT WOS:000405163900009
PM 28435054
OA hybrid
DA 2022-11-30
ER

PT J
AU Semeraro, F
   Gambicordi, E
   Cancarini, A
   Morescalchi, F
   Costagliola, C
   Russo, A
AF Semeraro, Francesco
   Gambicordi, Elena
   Cancarini, Anna
   Morescalchi, Francesco
   Costagliola, Ciro
   Russo, Andrea
TI Treatment of exudative age-related macular degeneration with aflibercept
   combined with pranoprofen eye drops or nutraceutical support with
   omega-3: A randomized trial
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE aflibercept; age-related macular degeneration; multivitamin antioxidant;
   omega-3; pranoprofen
ID ENDOTHELIAL GROWTH-FACTOR; POLYUNSATURATED FATTY-ACIDS; PROSTAGLANDIN
   E-2 LEVELS; KETOROLAC EYEDROPS; VEGF TRAP; RANIBIZUMAB; REDUCTION;
   BROMFENAC; SUPPLEMENTATION; DISEASE
AB Aims The aim of this study was to determine whether a combination of intravitreal aflibercept (IVA) and pranoprofen eyedrops or nutraceutical support provides additional benefit over IVA monotherapy for the treatment of choroidal neovascularization (CNV) in age-related macular degeneration. Methods This was a prospective, randomized, pilot study in 60 patients with treatment-naive CNV. Patients were randomized 1:1:1 into three groups: aflibercept monotherapy (AM), aflibercept plus pranoprofen (AP) or aflibercept plus nutraceutical (AN) tablets containing multivitamin antioxidant and mineral supplementation plus omega-3. Results At 12 months, all groups showed significant improvement in both best-corrected visual acuity (BCVA) and central retinal thickness (CRT). The mean BCVA change from baseline to 12 months was -0.26 +/- 0.06 LogMAR, -0.30 +/- 0.06 LogMAR and -0.24 +/- 0.04 LogMAR in the AM, AP and AN groups, respectively. The mean CRT change from baseline to 12 months was -76.9 +/- 10.9 mu m, -129 +/- 19.9 mu m and -105 +/- 11.6 mu m in the AM, AP and AN groups, respectively. The AN group required one less IVA injection than the AM group. Conclusions Compared with AM, both combination groups acted synergistically, although no significant benefits in BCVA were found over AM. Nutraceutical support with omega-3 leads to a reduced need for IVA.
C1 [Semeraro, Francesco; Gambicordi, Elena; Cancarini, Anna; Morescalchi, Francesco; Russo, Andrea] Univ Brescia, Dept Neurol & Vis Sci, Eye Clin, Piazzale Spedale Civili 1, I-25100 Brescia, Italy.
   [Costagliola, Ciro] Univ Molise, Dept Hlth Sci, Eye Clin, Campobasso, Italy.
C3 Hospital Spedali Civili Brescia; University of Brescia; University of
   Molise
RP Russo, A (通讯作者)，Univ Brescia, Dept Neurol & Vis Sci, Eye Clin, Piazzale Spedale Civili 1, I-25100 Brescia, Italy.
EM dott.andrea.russo@gmail.com
RI Semeraro, Francesco fs/K-8667-2016; Russo, Andrea/K-8550-2016
OI Semeraro, Francesco fs/0000-0002-2275-4917; Russo,
   Andrea/0000-0002-1566-3662
CR Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Erie JC, 2016, OPHTHALMOLOGY, V123, P1257, DOI 10.1016/j.ophtha.2016.02.015
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   Fetterman JW, 2009, AM J HEALTH-SYST PH, V66, P1169, DOI 10.2146/ajhp080411
   Flaxel C, 2012, RETINA-J RET VIT DIS, V32, P417, DOI 10.1097/IAE.0b013e318229b0af
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Gomi F, 2012, RETINA-J RET VIT DIS, V32, P1804, DOI 10.1097/IAE.0b013e31825be87f
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim SJ, 2010, SURV OPHTHALMOL, V55, P108, DOI 10.1016/j.survophthal.2009.07.005
   Lin T, 2013, CYTOKINE, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rezende FA, 2014, AM J OPHTHALMOL, V158, P1071, DOI 10.1016/j.ajo.2014.07.036
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Russo A, 2016, RETINA-J RET VIT DIS, V36, P1227, DOI 10.1097/IAE.0000000000000860
   Russo A, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/476525
   Russo A, 2013, BRIT J OPHTHALMOL, V97, P1273, DOI 10.1136/bjophthalmol-2013-303417
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Schoenberger SD, 2014, JAMA OPHTHALMOL, V132, P150, DOI 10.1001/jamaophthalmol.2013.5692
   Schoenberger SD, 2014, JAMA OPHTHALMOL, V132, P32, DOI 10.1001/jamaophthalmol.2013.6203
   Semeraro F, 2015, RETINA-J RET VIT DIS, V35, P1547, DOI 10.1097/IAE.0000000000000525
   Stahl A, 2010, CIRC RES, V107, P495, DOI 10.1161/CIRCRESAHA.110.221317
   von Euler US, 1936, J PHYSIOL-LONDON, V88, P213, DOI 10.1113/jphysiol.1936.sp003433
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Wymann MP, 2008, NAT REV MOL CELL BIO, V9, P162, DOI 10.1038/nrm2335
NR 31
TC 6
Z9 6
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0306-5251
EI 1365-2125
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
PD MAY
PY 2019
VL 85
IS 5
BP 908
EP 913
DI 10.1111/bcp.13871
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HU4JR
UT WOS:000465241100005
PM 30680768
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Cui, CM
   Lu, H
AF Cui, Chunmei
   Lu, Hong
TI Clinical observations on the use of new anti-VEGF drug, conbercept, in
   age-related macular degeneration therapy: a meta-analysis
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Article
DE AMD; VEGF; conbercept; BCVA; CRT
ID ENDOTHELIAL GROWTH-FACTOR; TRANSPUPILLARY THERMOTHERAPY; CHOROIDAL
   NEOVASCULARIZATION; RANIBIZUMAB; PATHOGENESIS; BEVACIZUMAB; AFLIBERCEPT;
   DISEASES; SERUM; FP3
AB Purpose: Conbercept is a new anti-vascular endothelial growth factor (VEGF) drug approved for the treatment of age-related macular degeneration (AMD). Although this novel drug has been widely used in clinic, unlike other anti-VEGF drugs, validation and consensus on its method of clinical application and clinical safety have not yet been achieved.
   Methods: Relevant literature was searched on PubMed, Web of Science, China National Knowledge Internet, and Wanfang Data. Stata 12.0 was used for data analysis. Random-and fixed-effect models were employed to evaluate heterogeneity. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were utilized to measure the improvement of AMD patients.
   Results: In this study, we analyzed conbercept administration and compared its application with other control clinical methods for AMD treatment. Ranibizumab, triamcinolone, and traditional transpupillary thermotherapy (TTT) were administered in the control group. No differences were found in the BCVA and CRT improvement between the groups treated with conbercept and ranibizumab. However, the conbercept group had a lower serum VEGF level. After 3 months of treatment, conbercept led to a more significant BCVA and CRT improvement than triamcinolone. A more considerable BCVA improvement was observed in the group treated with conbercept than in the group treated with TTT. Moreover, even 6 months after the treatment, the effect of conbercept on CRT improvement was still more pronounced than that of TTT.
   Conclusion: In AMD patients, conbercept exerts considerably more positive effects on the long-term BCVA and CRT improvement than triamcinolone and TTT. The serum VEGF level in the conbercept group was lower than that in the ranibizumab group.
C1 [Cui, Chunmei; Lu, Hong] Beijing Chao Yang Hosp, Dept Ophthalmol, Workers Stadium Rd 8, Beijing 100020, Peoples R China.
C3 Capital Medical University
RP Lu, H (通讯作者)，Beijing Chao Yang Hosp, Dept Ophthalmol, Workers Stadium Rd 8, Beijing 100020, Peoples R China.
EM honglu_2016@163.com
CR Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P110, DOI 10.1034/j.1600-0420.2003.00041.x
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bourla DH, 2006, J AM GERIATR SOC, V54, P1130, DOI 10.1111/j.1532-5415.2006.00771.x
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   Del Priore LV, 2006, PROG RETIN EYE RES, V25, P539, DOI 10.1016/j.preteyeres.2006.08.001
   Dong YX, 2016, DRUGS CLIN, V31, P358
   FOLLMANN D, 1992, J CLIN EPIDEMIOL, V45, P769, DOI 10.1016/0895-4356(92)90054-Q
   Gal D, 2012, J CONSUM RES, V38, P1022, DOI 10.1086/661766
   Gragoudas ES, 2004, AM J OPHTHALMOL, V139, P761
   [韩姬 Han Ji], 2015, [中国全科医学, Chinese General Practice], V18, P502
   He, 2015, INT J OPHTHALMOL, V15, P1603, DOI [10.3980/j.issn.1672-5123.2015.9.30, DOI 10.3980/J.ISSN.1672-5123.2015.9.30]
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Higgins J., 2008, IEEE INT S INF THEOR, DOI [10.1109/ISIT.2017.8006970, DOI 10.1109/ISIT.2017.8006970]
   Hoerster R, 2013, ACTA OPHTHALMOL, V91, pe74, DOI 10.1111/j.1755-3768.2012.02469.x
   Jin E, 2016, RETINA, V37, P971
   Jin KT, 2011, CLIN TRANSL ONCOL, V13, P878, DOI 10.1007/s12094-011-0749-z
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   [李筱荣 Li Xiaorong], 2012, [中华实验眼科杂志, Chinese Journal of Experimental Ophthalmology], V30, P289
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Liu J, 2016, J HLTH CARE GUIDE, P18
   [刘瑞 Liu Rui], 2015, [中国中西医结合杂志, Chinese Journal of Integrated Traditional and Western Medicine], V35, P104
   Long S., 2015, J NIHON U MED ASS, V74, P134
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Nguyen TT, 2015, EXPERT REV CLIN PHAR, V8, P541, DOI 10.1586/17512433.2015.1075879
   Niu JY, 2016, GUANGXI MED J, V38
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ozkiris A, 2010, EXPERT OPIN THER PAT, V20, P103, DOI 10.1517/13543770902762885
   Platania CBM, 2015, FRONT PHARMACOL, V6, DOI [10.3389/fphar.2015.00248, 10.3389/tphar.7015.00248]
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Ren Y., 2016, CHINESE J MED DEVICE, V29
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Song YM, 2015, 2 FOR EXCH CLIN ACT
   Sozen-Delil FI, 2016, ACTA OPTHALMOL, V94
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Wang H, 2010, CANCER IMMUNOL IMMUN, V59, P239, DOI 10.1007/s00262-009-0744-1
   Wang XY, 2014, AM J OPHTHALMOL, V158, P738, DOI 10.1016/j.ajo.2014.06.009
   Wang XX, 2015, MATERNAL CHILD WORLD
   Wu WC, 2017, RETINA-J RET VIT DIS, V37, P694, DOI 10.1097/IAE.0000000000001209
   Wu Z, 2013, PLOS ONE, V8
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yip PP, 2009, BRIT J OPHTHALMOL, V93, P754, DOI 10.1136/bjo.2008.150987
   Yu DC, 2012, MOL THER, V20, P938, DOI 10.1038/mt.2011.285
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
   Zhang XZ, 2015, CHINA COMMUN, V12, P21, DOI 10.1109/CC.2015.7084399
   Zhao JL, 2014, GENE, V542, P182, DOI 10.1016/j.gene.2014.03.036
   Zhao YZ, 2015, WORLD LATEST MED INF
   Zhu ZL, 2015, INT J OPHTHALMOL, P1881
NR 53
TC 11
Z9 13
U1 1
U2 12
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2018
VL 13
BP 51
EP 62
DI 10.2147/CIA.S151225
PG 12
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA FR5JV
UT WOS:000419103700002
PM 29343949
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chang, MA
   Bressler, SB
   Munoz, B
   West, SK
AF Chang, Margaret A.
   Bressler, Susan B.
   Munoz, Beatriz
   West, Sheila K.
TI Racial differences and other risk factors for incidence and progression
   of age-related macular degeneration: Salisbury Eye Evaluation (SEE)
   project
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BEAVER DAM EYE; BLUE-MOUNTAINS EYE; ENDOTHELIAL GROWTH-FACTOR; FACTOR-H
   POLYMORPHISM; 5-YEAR INCIDENCE; 10-YEAR INCIDENCE; POOLED FINDINGS;
   CATARACT-SURGERY; 3 CONTINENTS; MACULOPATHY
AB PURPOSE. To evaluate risk factors for the incidence and progression of age-related macular degeneration (AMD) in a racially heterogeneous, geriatric population.
   METHODS. Subjects (n = 2240) aged 65 to 84 years underwent 2 examinations separated by 2 years, of which 1937 subjects (85%) were included in this report. Fundus photographs were performed at each examination and were graded by trained readers. Multivariate logistic regression models adjusted for age, sex, race, and clustering between eyes were used to evaluate risk factors for AMD incidence and progression.
   RESULTS. Smoking was a strong, dose-dependent, risk factor for progression from medium size drusen to large drusen or pigmentary abnormalities within the central 1500-mu m macular zone. Smoking was also a strong risk factor for development of incident focal pigmentation within 3000 mu m of the foveal center. White participants were significantly more likely than blacks to develop large drusen and focal pigmentation and to progress from medium- to large-sized drusen or pigment abnormalities within the central 1500 mu m macular zone. However, whites did not have an increased risk of progression from large drusen or pigment abnormalities within the central 1500-mu m perimacular zone to foveal GA or CNV when compared with blacks.
   CONCLUSIONS. Smoking and race are important risk factors for progression from medium to large drusen or to pigment abnormalities within the central 1500-mu m macular zone. Limitations in the power of this study preclude assessment of the roles of smoking and race on the ultimate progression to foveal GA or CNV once central large drusen or pigment abnormalities are present.
C1 [Chang, Margaret A.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21287 USA.
   Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine
RP Chang, MA (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, 600 N Wolfe St,Maumenee 211, Baltimore, MD 21287 USA.
EM mchang19@jhmi.edu
FU NATIONAL INSTITUTE ON AGING [R01AG016294] Funding Source: NIH RePORTER;
   NIA NIH HHS [AG16294] Funding Source: Medline
CR AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   Akishima S, 2007, CIRC J, V71, P418, DOI 10.1253/circj.71.418
   Alberg AJ, 2002, TOXICOLOGY, V180, P121, DOI 10.1016/S0300-483X(02)00386-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Duncan DD, 1997, INVEST OPHTH VIS SCI, V38, P1003
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   JAMPOL LM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1699, DOI 10.1001/archopht.1992.01080240039024
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Sastry BVR, 1998, J OCUL PHARMACOL TH, V14, P447, DOI 10.1089/jop.1998.14.447
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   West SK, 1998, JAMA-J AM MED ASSOC, V280, P714, DOI 10.1001/jama.280.8.714
   Wong TY, 2002, INVEST OPHTH VIS SCI, V43, P2869
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 43
TC 32
Z9 32
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2008
VL 49
IS 6
BP 2395
EP 2402
DI 10.1167/iovs.07-1584
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 307GG
UT WOS:000256306800014
PM 18263809
DA 2022-11-30
ER

PT J
AU Quist, SW
   de Jong, LA
   van Asten, F
   Knoester, P
   Postma, MJ
   Freriks, RD
AF Quist, S. W.
   de Jong, L. A.
   van Asten, F.
   Knoester, P.
   Postma, M. J.
   Freriks, R. D.
TI Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs
   in patients with neovascular age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Anti-VEGFs; Treat-and-extend regimen; Age-related macular degeneration;
   Cost minimisation
ID GROWTH-FACTOR TREATMENT; INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB;
   BEVACIZUMAB
AB Purpose Although intraocular anti-vascular endothelial growth factors (anti-VEGFs) are effective as treatment of neovascular age-related macular degeneration (nAMD), the (economic) burden on the healthcare system is considerable. A treat-and-extend (T&E) regimen is associated with a lower number of injections without compromising the effectiveness and can therefore help optimise nAMD treatment. This study investigates the per-patient costs associated with nAMD treatment, when using aflibercept, bevacizumab, or ranibizumab with a T&E regimen. Methods In this cost-minimisation model, the per-patient costs in the Netherlands were modelled using a healthcare payers' perspective over a 3-year time horizon with the assumption that efficacy of treatments is similar. Additionally, the break-even price of the different anti-VEGFs was calculated relative to the cheapest option and injection frequency. Results The injection frequency varied from 14.2 for aflibercept to 27.4 for bevacizumab in 3 years. Nonetheless, bevacizumab remains the cheapest treatment option (euro14,215), followed by aflibercept (euro18,202) and ranibizumab (euro31,048). The medication covers the majority of the per-patient costs for aflibercept and ranibizumab, while administration covers the majority of the per-patient costs for bevacizumab. The break-even prices of aflibercept and ranibizumab are respectively euro507 and euro60.58 per injection. Brolucizumab was included in the scenario analysis and was more expensive than aflibercept (euro20,446). Brolucizumab should reduce to 13.8 injections over 3 years to be as costly as aflibercept. Conclusion Bevacizumab is the cheapest anti-VEGF treatment. The list prices of all anti-VEGFs should reduce to be as costly as bevacizumab. Aflibercept is the second-choice treatment and so far brolucizumab is not.
C1 [Quist, S. W.; de Jong, L. A.; Postma, M. J.] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Hanzepl 1, Groningen, Netherlands.
   [Quist, S. W.; de Jong, L. A.; Freriks, R. D.] Asc Acad, Prof Enno Dirk Wiersmastr 5, Groningen, Netherlands.
   [van Asten, F.] Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, Philips Van Leydenlaan 15, Nijmegen, Netherlands.
   [Knoester, P.] Alrijne Hosp, Dept Pharm, Simon Smitweg 1, Leiderdorp, Netherlands.
   [Postma, M. J.; Freriks, R. D.] Univ Groningen, Fac Econ & Business, Dept Econ Econometr & Finance, Nettelbosje 2, Groningen, Netherlands.
C3 University of Groningen; Philips; Radboud University Nijmegen;
   University of Groningen
RP Quist, SW (通讯作者)，Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Hanzepl 1, Groningen, Netherlands.; Quist, SW (通讯作者)，Asc Acad, Prof Enno Dirk Wiersmastr 5, Groningen, Netherlands.
EM s.w.quist@student.rug.nl
OI quist, sara/0000-0003-3871-4239; de Jong, Lisa/0000-0001-8814-0670;
   Postma, Maarten/0000-0002-6306-3653; Freriks, Roel/0000-0002-9458-1832
CR Abdin AD, 2019, GRAEF ARCH CLIN EXP, V257, P1671, DOI 10.1007/s00417-019-04360-9
   [Anonymous], 2020, NEDERLANDSE VERENIGI
   [Anonymous], 2020, GEZICHTSSTOORNISSEN
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   Briggs A., 2006, DECISION MODELLING H
   Bro T, 2020, GRAEF ARCH CLIN EXP, V258, P503, DOI 10.1007/s00417-019-04569-8
   Carrasco J, 2020, ADV THER, V37, P300, DOI 10.1007/s12325-019-01147-6
   Centraal Bureau voor de Statistiek, 2020, STATLINE LEV GESL LE
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Clinicaltrials.gov, 2019, STUD ASS EFF SAF BRO
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Euretina, 2020, SRC REP
   European Medicines Agency, 2020, EPAR BEOV
   European Medicines Agency, 2020, EPAR LUC
   European Medicines Agency, 2020, EPAR AV
   European Medicines Agency, 2020, EPAR EYL
   Fulcher C, 2020, EUR J OPHTHALMOL, V30, P543, DOI 10.1177/1120672119839299
   Gayadine-Harricham Y, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/7465270
   Gillies MC, 2020, OPHTHALMOLOGY, V127, P198, DOI 10.1016/j.ophtha.2019.08.023
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Hernandez L, 2018, J MANAG CARE SPEC PH, V24, P608, DOI 10.18553/jmcp.2018.24.7.608
   Itagaki K, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01542-6
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Joko T, 2020, PATIENT PREFER ADHER, V14, P553, DOI 10.2147/PPA.S228890
   Kertes PJ, 2020, JAMA OPHTHALMOL, V138, P244, DOI 10.1001/jamaophthalmol.2019.5540
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Mekjavic PJ, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-1005-x
   Nederlands Oogheelkundig Gezelschap, 2014, RICHTL LEEFT MAC
   Nederlands Oogheelkundig Gezelschap, 2020, ADV STAPP OOG WERKGR
   Nederlandse Zorgautoriteit, 2020, TAR DIAGN OND
   Nederlandse Zorgautoriteit, 2017, WACHTT MED SPEC ZORG
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Panchmatia HR, 2016, ACTA OPHTHALMOL, V94, P441, DOI 10.1111/aos.12964
   Payne JF, 2019, AM J OPHTHALMOL, V202, P91, DOI 10.1016/j.ajo.2019.02.005
   Ross AH, 2020, EYE, V34, P1825, DOI 10.1038/s41433-019-0747-x
   Rutten-Van M?lken M., 2008, PHARM WEEKBLAD, V143, P75
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Singh G, 2017, PHARM MED TRANSL CLI, P1
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Valverde-Megias A, 2017, GRAEF ARCH CLIN EXP, V255, P2091, DOI 10.1007/s00417-017-3748-0
   van Asten F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197670
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
   Verbraak FD, 2021, ACTA OPHTHALMOL, V99, pE884, DOI 10.1111/aos.14712
   Volksgezondheidszorg.info, 2020, ZIEK CIJF CONT
   Vottonen P, 2016, ACTA OPHTHALMOL, V94, P652, DOI 10.1111/aos.13185
   Werkgroep Medische Retina, 2021, STANDP WERKGR MED RE
   Wong TY, 2019, RETINA-J RET VIT DIS, V39, P537, DOI 10.1097/IAE.0000000000001986
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Z-index, 2020, Z IND AFL
   Z-index, 2020, Z IND BEV
   Z-index, 2020, Z IND BROL
   Z-index, 2020, Z IND RAN
   Zorginstituut Nederland, 2016, GUID EC EV HEALTHC
   Zorginstituut Nederland, 2019, SCREEN SYST AN ZIEKT
NR 66
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2022
VL 260
IS 4
BP 1083
EP 1095
DI 10.1007/s00417-021-05359-x
EA OCT 2021
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZR0FZ
UT WOS:000706937700001
PM 34643793
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Tsunekawa, Y
   Kataoka, K
   Asai, K
   Ito, Y
   Terasaki, H
AF Tsunekawa, Yuma
   Kataoka, Keiko
   Asai, Keiko
   Ito, Yasuki
   Terasaki, Hiroko
TI Four-year outcome of aflibercept administration using a treat-and-extend
   regimen in eyes with recurrent neovascular age-related macular
   degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Treat-and-extend; Aflibercept; Age-related macular degeneration;
   Long-term outcome
ID INTRAVITREAL AFLIBERCEPT; 2-YEAR OUTCOMES; RANIBIZUMAB; VERTEPORFIN;
   THERAPY; TRIAL
AB Purpose To investigate the 4-year outcome of aflibercept treatment using a treat-and-extend (TAE) regimen for recurrent neovascular age-related macular degeneration (AMD). Study design Retrospective observational study. Methods Data of eyes with recurrent AMD previously treated with anti-vascular endothelial growth factor agents or photodynamic therapy and had started aflibercept treatment using a TAE regimen for the first time were collected. Best-corrected visual acuity (BCVA), intervals of treatments, the presence of exudation, central foveal thickness (CFT), and central choroidal thickness (CCT) were analyzed. Results Of 47 consecutive eyes, 30 of the 47 eyes completed a 4-year follow-up. The mean BCVA (logMAR) was sustained over the 4 years (0.37 at baseline, 0.36 at 1 year, 0.36 at 2 years, 0.41 at 3 years, and 0.43 at 4 years, P = 0.21). Of the 30 eyes that completed the follow-up, BCVA of two eyes deteriorated by 0.3 logMAR or more at 4 years. At 4 years, 67% of eyes had extended treatment intervals to > 8 weeks, and 47% of eyes had extended intervals to > 12 weeks. Exudative changes in the macula, seen in all eyes at baseline, were only seen in 50% of the eyes at 4 years. The mean CFT and CCT decreased significantly at 4 years from 332 mu m to 248 mu m and from 218 mu m to 183 mu m, respectively. Conclusion In clinical settings, aflibercept treatment using a TAE regimen may successfully maintain visual acuity for up to 4 years even in recurrent cases of AMD.
C1 [Tsunekawa, Yuma] Handa City Hosp, Dept Ophthalmol, Handa, Japan.
   [Kataoka, Keiko; Asai, Keiko; Ito, Yasuki; Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsurumai, Nagoya 4668550, Japan.
C3 Nagoya University
RP Kataoka, K (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsurumai, Nagoya 4668550, Japan.
EM kkeiko@med.nagoya-u.ac.jp
CR Adrean SD, 2018, OPHTHALMOL RETINA, V2, P225, DOI 10.1016/j.oret.2017.07.009
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Barthelmes D, 2016, BRIT J OPHTHALMOL, V100, P1640, DOI 10.1136/bjophthalmol-2015-308090
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Giannakaki-Zimmermann H, 2016, OPHTHALMOLOGICA, V236, P201, DOI 10.1159/000452929
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hosokawa M, 2017, JPN J OPHTHALMOL, V61, P150, DOI 10.1007/s10384-016-0492-7
   Ito A, 2017, OPHTHALMOLOGICA, V238, P236, DOI 10.1159/000479937
   Kvannli L, 2017, ACTA OPHTHALMOL, V95, P678, DOI 10.1111/aos.13356
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2020, OPHTHALMOL RETINA, V4, P767, DOI 10.1016/j.oret.2020.03.010
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Morizane Y, 2019, JPN J OPHTHALMOL, V63, P26, DOI 10.1007/s10384-018-0623-4
   Nakano Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216304
   Nguyen V, 2019, OPHTHALMOL RETINA, V3, P623, DOI 10.1016/j.oret.2019.05.013
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spooner K, 2017, CLIN OPHTHALMOL, V11, P161, DOI 10.2147/OPTH.S125676
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yamamoto A, 2017, OPHTHALMOLOGICA, V237, P139, DOI 10.1159/000458538
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 37
TC 4
Z9 4
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JAN
PY 2021
VL 65
IS 1
BP 69
EP 76
DI 10.1007/s10384-020-00783-8
EA NOV 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QA5QB
UT WOS:000587287000001
PM 33159611
DA 2022-11-30
ER

PT J
AU Kumar, A
   Midha, N
   Mohanty, S
   Chohan, A
   Seth, T
   Gogia, V
   Gupta, S
AF Kumar, Atul
   Midha, Neha
   Mohanty, Sujata
   Chohan, Annu
   Seth, Tulika
   Gogia, Varun
   Gupta, Shikha
TI Evaluating role of bone marrow-derived stem cells in dry age-related
   macular degeneration using multifocal electroretinogram and fundus
   autofluorescence imaging
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE dry age-related macular degeneration; multifocal electroretinogram; stem
   cells; fundus autofluorescence imaging
ID GEOGRAPHIC ATROPHY; RETINAL CELLS; DIFFERENTIATION; TRANSPLANTATION;
   FEASIBILITY; PREVALENCE; THERAPY; DISEASE
AB AIM: To evaluate the role of bone marrow-derived stem cells in the treatment of advanced dry age-related macular degeneration (AMD) using multifocal electroretinogram (mf-ERG) and fundus autofluorescence imaging.
   METHODS: Thirty patients (60 eyes) with bilateral central geographic atrophy (GA) were recruited. Worse eye of each patient received autologous bone marrow-derived hematopoietic stem cells (BM-HSCs) (group 1) and the fellow eye with better visual acuity served as control (group 2). The effect of stem cell therapy was determined in terms of visual acuity, amplitude and implicit time in mf-ERG and size of GA on fundus autofluorescence imaging. These tests were performed at presentation and first, third and sixth month follow up. Adverse events (if any) were also monitored.
   RESULTS: At 6mo follow-up there was no statistically significant improvement in median logMAR best corrected visual acuity (BCVA) in either group. Mf-ERG revealed significant improvement in amplitude and implicit time in the intervention group. A significant decrease was also noted in greatest linear dimension (GLD) of GA in the eyes receiving stem cells [6.78 +/- 2.60 mm at baseline to 6.56 +/- 2.59 mm at 6mo (P=0.021)]. However, no such improvement was noted in the control group.
   CONCLUSION: Electrophysiological and anatomical improvement in the intervention group sheds light on the therapeutic role of BM-HSCs. Further studies are required to determine the stage of disease at which the maximal benefit can be achieved and to standardize the dose and frequency of stem cell injection.
C1 [Kumar, Atul; Midha, Neha; Chohan, Annu; Gogia, Varun; Gupta, Shikha] All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, India.
   [Mohanty, Sujata] All India Inst Med Sci, Stem Cell Facil, New Delhi 110029, India.
   [Seth, Tulika] All India Inst Med Sci, Dept Hematol, New Delhi 110029, India.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi; Dr. Rajendra
   Prasad Centre for Ophthalmic Sciences; All India Institute of Medical
   Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences
   (AIIMS) New Delhi
RP Midha, N (通讯作者)，All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, India.
EM neha.midha1@gmail.com
CR BERTHOLD F, 1981, BLUT, V43, P367, DOI 10.1007/BF00320315
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Djojosubroto M, 2009, INVEST OPHTH VIS SCI, V50, P5975, DOI 10.1167/iovs.08-3091
   Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Hess DC, 2002, STROKE, V33, P1362, DOI 10.1161/01.STR.0000014925.09415.C3
   Hood DC, 2012, DOC OPHTHALMOL, V124, P1, DOI 10.1007/s10633-011-9296-8
   Huang Shizhou, 2000, Documenta Ophthalmologica, V101, P115
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   John S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/465169
   Jonas JB, 2008, ACTA OPHTHALMOL, V86, P225, DOI 10.1111/j.1600-0420.2007.00987.x
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, pe131, DOI 10.1111/j.1755-3768.2009.01564.x
   Kashani AH, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-17681
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Krause DS, 2002, GENE THER, V9, P754, DOI 10.1038/sj.gt.3301760
   MacLaren RE, 2007, EYE, V21, P1352, DOI 10.1038/sj.eye.6702842
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Otani A, 2004, J CLIN INVEST, V114, P765, DOI 10.1172/JCI200421686
   Posel C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050293
   Raheja A, 2012, J NEUROSURG, V117, P1170, DOI 10.3171/2012.8.JNS111446
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rencova E, 2013, ACTA OPHTHALMOL, V91, pE406, DOI 10.1111/j.1755-3768.2012.02503.x
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Siqueira RC, 2010, ARQ BRAS OFTALMOL, V73, P474, DOI 10.1590/S0004-27492010000500019
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Sunness JS, 2007, RETINA-J RET VIT DIS, V27, P204, DOI 10.1097/01.iae.0000248148.56560.b1
   Takahashi Masayo, 2013, Rinsho Shinkeigaku, V53, P1016
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tomita M, 2002, STEM CELLS, V20, P279, DOI 10.1634/stemcells.20-4-279
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 34
TC 3
Z9 4
U1 0
U2 9
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD OCT 18
PY 2017
VL 10
IS 10
BP 1552
EP 1558
DI 10.18240/ijo.2017.10.12
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FJ0ZP
UT WOS:000412440900012
PM 29062775
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Wood, JM
   Lacherez, P
   Black, AA
   Cole, MH
   Boon, MY
   Kerr, GK
AF Wood, Joanne M.
   Lacherez, Philippe
   Black, Alex A.
   Cole, Michael H.
   Boon, Mei Ying
   Kerr, Graham K.
TI Risk of Falls, Injurious Falls, and Other Injuries Resulting from Visual
   Impairment among Older Adults with Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FIELD LOSS INCREASES; HIP FRACTURE; POSTURAL STABILITY; WATERLOO VISION;
   MOBILITY; PEOPLE; ACCIDENTS; VALIDITY; GAIT; PERFORMANCE
AB PURPOSE. Age-related macular degeneration (AMD) is the leading cause of irreversible visual impairment among older adults. This study explored the relationship between AMD, fall risk, and other injuries and identified visual risk factors for these adverse events.
   METHODS. Participants included 76 community-dwelling individuals with a range of severity of AMD (mean age, 77.0 +/- 6.9 years). Baseline assessment included binocular visual acuity, contrast sensitivity, and merged visual fields. Participants completed monthly falls and injury diaries for 1 year after the baseline assessment.
   RESULTS. Overall, 74% of participants reported having either a fall or a non-fall-related injury. Fifty-four percent of participants reported a fall and 30% reported more than one fall; of the 102 falls reported, 63% resulted in an injury. Most occurred outdoors (52%), between late morning and late afternoon (61%) and when navigating on level ground (62%). The most common non-fall-related injuries were lacerations (36%) and collisions with an object (35%). Reduced contrast sensitivity and visual acuity were associated with increased fall rate, after controlling for age, sex, cognitive function, cataract severity, and self-reported physical function. Reduced contrast sensitivity was the only significant predictor of non-fall-related injuries.
   CONCLUSIONS. Among older adults with AMD, increased visual impairment was significantly associated with an increased incidence of falls and other injuries. Reduced contrast sensitivity was significantly associated with both increased rates of falls and other injuries, while reduced visual acuity was only associated with increased fall rate. These findings have important implications for the assessment of visually impaired older adults. (Invest Ophthalmol Vis Sci. 2011;52:5088-5092) DOI:10.1167/iovs.10-6644
C1 [Wood, Joanne M.; Lacherez, Philippe; Black, Alex A.; Boon, Mei Ying] Queensland Univ Technol, Sch Optometry, Brisbane, Qld 4059, Australia.
   [Wood, Joanne M.; Lacherez, Philippe; Black, Alex A.; Cole, Michael H.; Boon, Mei Ying; Kerr, Graham K.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia.
   [Cole, Michael H.; Kerr, Graham K.] Queensland Univ Technol, Sch Human Movement Studies, Brisbane, Qld 4059, Australia.
   [Cole, Michael H.] Australian Catholic Univ, Sch Exercise Sci, Brisbane, Qld, Australia.
   [Boon, Mei Ying] Univ New S Wales, Sch Optometry & Vision Sci, Sydney, NSW, Australia.
C3 Queensland University of Technology (QUT); Queensland University of
   Technology (QUT); Queensland University of Technology (QUT); University
   of Queensland; Australian Catholic University; University of New South
   Wales Sydney
RP Wood, JM (通讯作者)，Queensland Univ Technol, Sch Optometry, Brisbane, Qld 4059, Australia.
EM j.wood@qut.edu.au
RI Boon, Mei Ying/F-2194-2016; Black, Alex/I-9727-2012; Cole, Michael
   H/O-6816-2018; Kerr, Graham/I-9705-2012
OI Boon, Mei Ying/0000-0002-9759-8402; Black, Alex/0000-0002-8671-5167;
   Kerr, Graham/0000-0002-1008-256X; Lacherez,
   Philippe/0000-0001-5717-4966; Cole, Michael/0000-0003-1817-7528; ,
   Joanne/0000-0002-0776-7736
FU NHMRC
FX Supported by the NHMRC Prevention of Injuries in Older People
   Partnership in Injury grant.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Almog Y, 2004, ARCH OPHTHALMOL-CHIC, V122, P1052, DOI 10.1001/archopht.122.7.1052
   Carter SE, 2000, AUST NZ J PUBL HEAL, V24, P633, DOI 10.1111/j.1467-842X.2000.tb00532.x
   Chia EM, 2006, ANN ACAD MED SINGAP, V35, P461
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Coleman AL, 2004, OPHTHALMOLOGY, V111, P857, DOI 10.1016/j.ophtha.2003.09.033
   Coleman AL, 2007, J AM GERIATR SOC, V55, P357, DOI 10.1111/j.1532-5415.2007.01094.x
   COVINGTON DL, 1993, J AM GERIATR SOC, V41, P847, DOI 10.1111/j.1532-5415.1993.tb06182.x
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   de Boer MR, 2004, J BONE MINER RES, V19, P1539, DOI 10.1359/JBMR.040504
   ELLIOTT DB, 1995, OPHTHAL PHYSL OPT, V15, P553, DOI 10.1016/0275-5408(95)00025-9
   FELSON DT, 1989, J AM GERIATR SOC, V37, P495, DOI 10.1111/j.1532-5415.1989.tb05678.x
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Freeman EE, 2007, INVEST OPHTH VIS SCI, V48, P4445, DOI 10.1167/iovs.07-0326
   GRAHAM HJ, 1992, BRIT MED J, V305, P30, DOI 10.1136/bmj.305.6844.30
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   Haymes SA, 2004, OPTOMETRY VISION SCI, V81, P308, DOI 10.1097/01.opx.0000134904.21274.db
   Heun R, 1998, INT J GERIATR PSYCH, V13, P368, DOI 10.1002/(SICI)1099-1166(199806)13:6<368::AID-GPS775>3.3.CO;2-0
   Hu GQ, 2010, INJURY PREV, V16, P26, DOI 10.1136/ip.2009.023481
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Ivers RQ, 2003, J AM GERIATR SOC, V51, P356, DOI 10.1046/j.1532-5415.2003.51109.x
   Johnson CA, 2002, OPHTHALMOLOGY, V109, P432, DOI 10.1016/S0161-6420(01)00948-4
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   Klein BEK, 1998, OPHTHALMOLOGY, V105, P160, DOI 10.1016/S0161-6420(98)91911-X
   Kuyk T, 1999, J REHABIL RES DEV, V36, P303
   Lamb SE, 2005, J AM GERIATR SOC, V53, P1618, DOI 10.1111/j.1532-5415.2005.53455.x
   Legood R, 2002, INJ PREV, V8, P155, DOI 10.1136/ip.8.2.155
   LILLEY JM, 1995, AGE AGEING, V24, P346, DOI 10.1093/ageing/24.4.346
   Lord SR, 2000, GERONTOLOGY, V46, P306, DOI 10.1159/000022182
   Lord SR, 2003, PHYS THER, V83, P237, DOI 10.1093/ptj/83.3.237
   Lord SR, 2001, J AM GERIATR SOC, V49, P508, DOI 10.1046/j.1532-5415.2001.49107.x
   Lord SR, 2006, AGE AGEING, V35, P42, DOI 10.1093/ageing/afl085
   Nelson-Quigg JM, 2000, INVEST OPHTH VIS SCI, V41, P2212
   Orme J.G., 2009, MULTIPLE REGRESSION
   Parker MJ, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001255.pub3
   SPAULDING SJ, 1994, OPTOMETRY VISION SCI, V71, P770, DOI 10.1097/00006324-199412000-00007
   SPAULDING SJ, 1995, GAIT POSTURE, V3, P227
   Szabo SM, 2010, OSTEOPOROSIS INT, V21, P855, DOI 10.1007/s00198-009-1025-8
   Szabo SM, 2008, J AM GERIATR SOC, V56, P800, DOI 10.1111/j.1532-5415.2008.01666.x
   Turano KA, 1996, INVEST OPHTH VIS SCI, V37, P1483
   vanderSluis CK, 1996, J TRAUMA, V40, P78, DOI 10.1097/00005373-199601000-00015
   VERBAKEN JH, 1986, AM J OPTOM PHYS OPT, V63, P724
   WOLF ME, 1992, ANNU REV PUBL HEALTH, V13, P509, DOI 10.1146/annurev.publhealth.13.1.509
   Wood JM, 2009, INVEST OPHTH VIS SCI, V50, P482, DOI 10.1167/iovs.08-1942
   Xiang H, 2005, INJURY PREV, V11, P157, DOI 10.1136/ip.2004.006429
NR 45
TC 94
Z9 95
U1 1
U2 25
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2011
VL 52
IS 8
BP 5088
EP 5092
DI 10.1167/iovs.10-6644
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 800QC
UT WOS:000293377400012
PM 21474773
OA Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Razavi, S
   Souied, EH
   Darvizeh, F
   Querques, G
AF Razavi, Sam
   Souied, Eric H.
   Darvizeh, Fatemeh
   Querques, Giuseppe
TI Assessment of Choroidal Topographic Changes by Swept-Source Optical
   Coherence Tomography After Intravitreal Ranibizumab for Exudative
   Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID THICKNESS; THERAPY; VOLUME
AB PURPOSE: To investigate choroidal topographic changes by swept-source optical coherence tomography (Swept-OCT) in patients undergoing intravitreal injections of anti-vascular endothelial growth factor (VEGF) for exudative age-related macular degeneration (AMD).
   DESIGN: Prospective interventional study.
   METHODS: Consecutive patients with unilateral treatment-nave exudative AMD were entered into the study over 6 months. Changes in choroidal thickness after intravitreal ranibizumab injections, overall in the macula and in neovascular and non-neovascular areas, from baseline to month 3 (loading phase) and month 6 (pro re nata phase), were investigated by means of Swept-OCT maps.
   RESULTS: Forty-one eyes of 41 patients (mean age: 79.4 +/- 7.3 years) were analyzed. Choroidal thickness at study entry was significantly thicker in the study eyes as compared to fellow eyes (P < .05). Analysis of sectorial choroidal thickness over time in study eyes revealed a significant reduction in both neovascular and non-neovascular areas from baseline to month 3 and month 6 (P < .0001 for all). Central choroidal thickness revealed significant variation between treated and fellow eyes from baseline to month 3 (P = .017) and month 6 (P = .045). The visual gain was significantly higher (P = .02) in patients with a larger choroidal thickness reduction (29 pm, n = 11) vs the others (n = 30).
   CONCLUSIONS: The thinning of the macular choroid (affected or not by choroidal neovascularization), along with the significantly thicker choroid in exudative AMD eyes before treatment initiation compared to fellow eyes, allows the hypothesis that anti-VEGF treatment may favorably influence the choroidal exudation by reducing choroidal vascular hyperpermeability. (C) 2015 by Elsevier Inc. All rights reserved.
C1 [Razavi, Sam] Transparency Eye Clin, Tours, France.
   [Razavi, Sam; Souied, Eric H.; Querques, Giuseppe] Univ Paris Est Creteil, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, F-94000 Creteil, France.
   [Darvizeh, Fatemeh; Querques, Giuseppe] Univ Vita Salute San Raffaele, IRCCS, Dept Ophthalmol, San Raffaele Sci Inst, Milan, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Querques, G (通讯作者)，Univ Paris Est Creteil, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
OI Darvizeh, Fatemeh/0000-0002-3735-0472; Querques,
   Giuseppe/0000-0002-3292-9581
CR Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   Branchini L, 2013, JAMA OPHTHALMOL, V131, P693, DOI 10.1001/jamaophthalmol.2013.692
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chung SE, 2011, AM J OPHTHALMOL, V152, P663
   de Bruin DM, 2008, INVEST OPHTH VIS SCI, V49, P4545, DOI 10.1167/iovs.07-1553
   Ellabban AA, 2012, CLIN OPHTHALMOL, V6, P837, DOI 10.2147/OPTH.S30907
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kim JH, 2015, INVEST OPHTH VIS SCI, V56, P1909, DOI 10.1167/iovs.14-16000
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Kuroda S, 2013, RETINA-J RET VIT DIS, V33, P302, DOI 10.1097/IAE.0b013e318263d11f
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Mansouri K, 2013, OPHTHALMOLOGY, V120, P2508, DOI 10.1016/j.ophtha.2013.07.040
   Mazaraki K, 2015, BR J OPHTHALMOL, DOI [http://dx.doi.org/10.1136/bjophthalmol-2015-306636, DOI 10.1136/BJ0PHTHALM01-2015-306636]
   McDonnell EC, 2014, EUR J OPHTHALMOL, V24, P897, DOI 10.5301/ejo.5000509
   Potsaid B, 2010, OPT EXPRESS, V18, P20029, DOI 10.1364/OE.18.020029
   Razavi S, 2014, AM J OPHTHALMOL, V157, P852, DOI 10.1016/j.ajo.2013.12.029
   Sizmaz S, 2014, EUR J OPHTHALMOL, V24, P904, DOI 10.5301/ejo.5000478
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yasuno Y, 2007, OPT EXPRESS, V15, P6121, DOI 10.1364/OE.15.006121
NR 22
TC 28
Z9 28
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2015
VL 160
IS 5
BP 1006
EP 1013
DI 10.1016/j.ajo.2015.08.009
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CV0CK
UT WOS:000363914800021
PM 26275471
DA 2022-11-30
ER

PT J
AU Messenger, WB
   Campbell, JP
   Faridi, A
   Shippey, L
   Bailey, ST
   Lauer, AK
   Flaxel, CJ
   Hwang, TS
AF Messenger, Wyatt B.
   Campbell, J. Peter
   Faridi, Ambar
   Shippey, Loton
   Bailey, Steven T.
   Lauer, Andreas K.
   Flaxel, Christina J.
   Hwang, Thomas S.
TI Injection frequency and anatomic outcomes 1 year following conversion to
   aflibercept in patients with neovascular age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB; BEVACIZUMAB; RESISTANT; THERAPY;
   FLUID; EYES
AB Background/Aim To evaluate the clinical, anatomic and functional effects of conversion to aflibercept following ranibizumab and/or bevacizumab in patients with neovascular age-related macular degeneration (AMD).
   Methods A retrospective review of patients with neovascular AMD treated with intravitreal ranibizumab and/or bevacizumab who were switched to aflibercept was performed. The primary outcome was change in injection frequency in the year following the change. Secondary outcomes included change in central macular thickness (CMT) at 6 months and 1 year, presence of intraretinal and subretinal fluid at 6 months and visual acuity at 1 year.
   Results A total of 109 eyes with neovascular AMD were switched to aflibercept and met inclusion criteria. Overall, aflibercept injection frequency was unchanged with patients receiving 7.4 antivascular endothelial growth factor (VEGF) injections the year prior to conversion compared with 7.2 aflibercept injections in the year following (p=0.47). However, the change to aflibercept was associated with improvement in CMT from 324 to 295 mu m (p=0.0001) at 6 months and 299 mu m (p=0.0047) at 1 year. There was no effect on visual acuity at 1 year. In a subgroup analysis, patients who had received >= 10 anti-VEGF injections in the year prior had fewer injections (11.1 to 8.4, p<0.0001) and clinic visits (13.9 to 9.6, p<0.0001) as well as a significant decrease in CMT (-35 mu m, p=0.02).
   Conclusions In our population, switching to aflibercept therapy was not associated with a change in injection frequency nor improved visual acuity, but was associated with improved CMT at 6 months and 1 year. In patients who received at least 10 anti-VEGF injections in the year prior, transitioning to aflibercept was associated with a reduced injection frequency and CMT, suggesting potential cost savings in this population.
C1 [Messenger, Wyatt B.; Campbell, J. Peter; Faridi, Ambar; Shippey, Loton; Bailey, Steven T.; Lauer, Andreas K.; Flaxel, Christina J.; Hwang, Thomas S.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
   [Faridi, Ambar] Duke Univ, Duke Eye Ctr, Durham, NC USA.
C3 Oregon Health & Science University; Duke University
RP Hwang, TS (通讯作者)，Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM hwangt@ohsu.edu
RI Hwang, Thomas/AAV-5146-2020; Hwang, Thomas S./AAW-6618-2020
OI Hwang, Thomas S./0000-0002-0535-4823; Bailey, Steven/0000-0003-4949-1464
FU Research to Prevent Blindness, New York, NY, USA
FX This study was provided for by an unrestricted grant from Research to
   Prevent Blindness, New York, NY, USA.
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 11
TC 37
Z9 38
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2014
VL 98
IS 9
BP 1205
EP 1207
DI 10.1136/bjophthalmol-2013-304829
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN3QW
UT WOS:000340504400011
PM 24795334
DA 2022-11-30
ER

PT J
AU Obata, R
   Yanagi, Y
AF Obata, Ryo
   Yanagi, Yasuo
TI Quantitative Analysis of Cone Photoreceptor Distribution and Its
   Relationship with Axial Length, Age, and Early Age-Related Macular
   Degeneration
SO PLOS ONE
LA English
DT Article
ID OUTER NUCLEAR LAYER; ADAPTIVE OPTICS; PACKING DENSITY; FELLOW EYE;
   MACULOPATHY; IMAGES; ECCENTRICITY
AB Purpose: It has not been clarified whether early age-related macular degeneration (AMD) is associated with cone photoreceptor distribution. We used adaptive optics fundus camera to examine cone photoreceptors in the macular area of aged patients and quantitatively analyzed its relationship between the presence of early AMD and cone distribution.
   Methods: Sixty cases aged 50 or older were studied. The eyes were examined with funduscopy and spectral-domain optical coherence tomography to exclude the eyes with any abnormalities at two sites of measurement, 2 degrees superior and 5 degrees temporal to the fovea. High-resolution retinal images with cone photoreceptor mosaic were obtained with adaptive optics fundus camera (rtx1, Imagine Eyes, France). After adjusting for axial length, cone packing density was calculated and the relationship with age, axial length, or severity of early AMD based on the age-related eye disease study (AREDS) classification was analyzed.
   Results: Patient's age ranged from 50 to 77, and axial length from 21.7 to 27.5 mm. Mean density in metric units and that in angular units were 24,900 cells/mm(2), 2,170 cells/deg(2) at 2 degrees superior, and 18,500 cells/mm(2), 1,570 cels/deg(2) at 5 degrees temporal, respectively. Axial length was significantly correlated with the density calculated in metric units, but not with that in angular units. Age was significantly correlated with the density both in metric and angular units at 2 degrees superior. There was no significant difference in the density in metric and angular units between the eyes with AREDS category one and those with categories two or three.
   Conclusion: Axial length and age were significantly correlated with parafoveal cone photoreceptor distribution. The results do not support that early AMD might influence cone photoreceptor density in the area without drusen or pigment abnormalities.
C1 [Obata, Ryo; Yanagi, Yasuo] Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 113, Japan.
C3 University of Tokyo
RP Obata, R (通讯作者)，Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 113, Japan.
EM robata-tky@umin.ac.jp
RI Yanagi, Yasuo/AAA-5441-2022; Yanagi, Yasuo/AAF-2670-2020
OI Yanagi, Yasuo/0000-0002-0362-7285; Obata, Ryo/0000-0002-1762-0797
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [24791837]
FX This study was supported in part by a Grant in Aid for scientific
   research (B) number 24791837 from the Ministry of Education, Culture,
   Sports, Science and Technology of Japan. The funder had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript. No additional external funding was
   received for this study.
CR BENNETT AG, 1994, GRAEF ARCH CLIN EXP, V232, P361, DOI 10.1007/BF00175988
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boretsky A, 2012, LASER SURG MED, V44, P603, DOI 10.1002/lsm.22070
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P450
   Chui TYP, 2012, INVEST OPHTH VIS SCI, V53, P3545, DOI 10.1167/iovs.11-8694
   Chui TYP, 2008, INVEST OPHTH VIS SCI, V49, P4679, DOI 10.1167/iovs.08-2135
   Cooper RF, 2013, OPHTHAL PHYSL OPT, V33, P540, DOI 10.1111/opo.12070
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   CURCIO CA, 1992, VISUAL NEUROSCI, V9, P169, DOI 10.1017/S0952523800009639
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Duncan JL, 2007, INVEST OPHTH VIS SCI, V48, P3283, DOI 10.1167/iovs.06-1422
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   Garrioch R, 2012, OPTOMETRY VISION SCI, V89, P632, DOI 10.1097/OPX.0b013e3182540562
   GARTNER S, 1981, BRIT J OPHTHALMOL, V65, P23, DOI 10.1136/bjo.65.1.23
   Godara P, 2010, OPTOMETRY VISION SCI, V87, P930, DOI 10.1097/OPX.0b013e3181ff9a8b
   IWASAKI M, 1988, INVEST OPHTH VIS SCI, V29, P671
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kanis MJ, 2008, INVEST OPHTH VIS SCI, V49, P2077, DOI 10.1167/iovs.07-1181
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kitaguchi Y, 2007, JPN J OPHTHALMOL, V51, P456, DOI 10.1007/s10384-007-0477-7
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Li KY, 2007, J OPT SOC AM A, V24, P1358, DOI 10.1364/JOSAA.24.001358
   Li KY, 2010, INVEST OPHTH VIS SCI, V51, P6858, DOI 10.1167/iovs.10-5499
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lombardo M, 2014, RETINA-J RET VIT DIS, V34, P546, DOI 10.1097/IAE.0b013e3182a10850
   Lombardo M, 2013, SENSORS-BASEL, V13, P334, DOI 10.3390/s130100334
   Lombardo M, 2012, OPHTHALMOLOGY, V119, P1498, DOI 10.1016/j.ophtha.2012.03.019
   Miller DT, 1996, VISION RES, V36, P1067, DOI 10.1016/0042-6989(95)00225-1
   Mrejen S, 2013, OPHTHALMOLOGY, DOI [10.1016/j.ophtha.2013.09.026, DOI 10.1016/J.0PHTHA.2013.09.026]
   Ooto S, 2011, OPHTHALMOLOGY, V118, P873, DOI 10.1016/j.ophtha.2010.08.032
   Ooto S, 2010, OPHTHALMOLOGY, V117, P1800, DOI 10.1016/j.ophtha.2010.01.042
   PandaJonas S, 1995, OPHTHALMOLOGY, V102, P1853, DOI 10.1016/S0161-6420(95)30784-1
   Park SP, 2013, EXP EYE RES, V108, P1, DOI 10.1016/j.exer.2012.12.011
   Roorda A, 1999, NATURE, V397, P520, DOI 10.1038/17383
   SANDBERG MA, 1993, INVEST OPHTH VIS SCI, V34, P3477
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Song HX, 2011, INVEST OPHTH VIS SCI, V52, P7376, DOI 10.1167/iovs.11-7199
   SWANN PG, 1991, OPHTHAL PHYSL OPT, V11, P59, DOI 10.1016/0275-5408(91)90012-8
   Tojo N, 2013, CLIN OPHTHALMOL, V7, P203, DOI 10.2147/OPTH.S39879
   TUCKER GS, 1986, INVEST OPHTH VIS SCI, V27, P708
   Wolfing JI, 2006, OPHTHALMOLOGY, V113, P1014, DOI 10.1016/j.ophtha.2006.01.056
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P2800, DOI 10.1167/iovs.13-11613
NR 50
TC 24
Z9 24
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 14
PY 2014
VL 9
IS 3
AR e91873
DI 10.1371/journal.pone.0091873
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AC9MJ
UT WOS:000332858400112
PM 24632778
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Erol, MK
   Ozdemir, O
   Coban, DT
   Ceran, BB
   Bulut, M
AF Erol, Muhammet Kazim
   Ozdemir, Ozdemir
   Coban, Deniz Turgut
   Ceran, Basak Bostanci
   Bulut, Mehmet
TI Ranibizumab Treatment for Choroidal Neovascularization Secondary to
   Causes Other than Age-Related Macular Degeneration with Good Baseline
   Visual Acuity
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Central serous chorioretinopathy; multffocal choroiditis; myopia;
   punctate inner choroidopathy
ID CENTRAL SEROUS CHORIORETINOPATHY; INTRAVITREAL BEVACIZUMAB AVASTIN;
   PHOTODYNAMIC THERAPY; VERTEPORFIN; INJECTION; REGIMEN; MYOPIA; EYES
AB Purpose: To report a retrospective series of choroidal neovascularization (CNV) patients treated with intravitreal ranibizumab with good baseline vision from causes other than age-related macular degeneration (AMD). Methods: We retrospectively reviewed 12 eyes of 12 patients with CNV secondary to non-AMD who received intravitreal ranibizumab injections. Patients with baseline best-corrected visual acuity (BCVA) above 20/63 were included in the study. All patients were followed up at least for 12 months. BCVA measurement, fundus examination, and OCT examination of the patients were performed at each visit. Optical coherence tomography (OCT), fundus photo, fundus autofluorescence, and fundus fluorescein angiography examination of the eyes were obtained. Primary outcome measures were the changing in BCVA and central foveal thickness (CFT). Any ocular or systemic side-effects were recorded. Results: The ages of patients ranged from 17 to 60. Twelve patients were diagnosed with non-AMD associated CNV: myopia (n = 3), central serous chorioretinopathy (n = 3), idiopathic (n = 2), multifocal choroiditis (n = 2), punctate inner choroidopathy (n = 1), and photo toxicity (n = 1). The improvement in visual acuity was statistically significant (p = 0.001). In the 12-month visit, all eyes had improvement in visual acuity except two eyes. The reduction of the mean CFT was statistically significant (p = 0.001). The CFT of all patients decreased in the 12-month visit. There was no significant difference in comparison of the mean intraocular pressure (p = 0.790). The group received a total of 52 intravitreal injections. The mean number of intravitreal injections was 4.3 (ranged from 3-8). Conclusion: Ranibizumab seems to be an effective and safe treatment option for CNVs secondary to non-AMD causes in patients with relatively good baseline BCVAs.
C1 [Erol, Muhammet Kazim; Coban, Deniz Turgut; Ceran, Basak Bostanci; Bulut, Mehmet] Antalya Educ & Res Hosp, Dept Ophthalmol, Antalya, Turkey.
   [Ozdemir, Ozdemir] Zekai Tahir Burak Kadin Sagligi Egitim & Arastirm, Dept Ophthalmol, Ankara, Turkey.
C3 Antalya Training & Research Hospital; Dr. Zekai Tahir Burak Women's
   Health Research & Education Hospital
RP Ozdemir, O (通讯作者)，Zekai Tahir Burak Kadin Sagligi Egitim & Arastirm, Goz Hastaliklari Poliklin, Talatpasa Bulvari, Ankara, Turkey.
EM ozdemirozdemir@yahoo.com
RI BULUT, MEHMET/V-3604-2017; EROL, Muhammet Kazim/T-3728-2019; Ceran,
   Basak Bostanci/Y-9324-2019; Ozdemir, Ozdemir/Q-2433-2015
OI BULUT, MEHMET/0000-0001-8619-8078; EROL, Muhammet
   Kazim/0000-0002-1720-8065; Ozdemir, Ozdemir/0000-0002-4833-8567;
   Bostanci, Basak/0000-0001-5483-2767
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2007, AM J OPHTHALMOL, V143, P977, DOI 10.1016/j.ajo.2007.02.039
   Chang LK, 2008, ARCH OPHTHALMOL-CHIC, V126, P941, DOI 10.1001/archopht.126.7.941
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Green WR, 1986, OPHTHALMOLOGY, V93, P1169
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Gupta B, 2010, EYE, V24, P203, DOI 10.1038/eye.2009.201
   HAMPTON GR, 1983, OPHTHALMOLOGY, V90, P923
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Hawldns BS, 2004, ARCH OPHTHALMOL-CHIC, V122, P1597
   Heier JS, 2011, OPHTHALMOLOGY, V118, P111, DOI 10.1016/j.ophtha.2010.04.016
   Konstantinidis L, 2010, EUR J OPHTHALMOL, V20, P955, DOI 10.1177/112067211002000524
   Lee YA, 2009, EYE, V23, P645, DOI 10.1038/eye.2008.17
   Mandal S, 2011, INDIAN J OPHTHALMOL, V59, P338, DOI 10.4103/0301-4738.82021
   Mansour AM, 2008, AM J OPHTHALMOL, V146, P410, DOI 10.1016/j.ajo.2008.05.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mones J, 2012, GRAEF ARCH CLIN EXP, V250, P1737, DOI 10.1007/s00417-012-2009-5
   OGUZ YG, 2011, RETINA VITREUS, V19, P231
   Ozdek S, 2012, J PEDIAT OPHTH STRAB, V49, P216, DOI 10.3928/01913913-20111004-01
   Postel EA, 1998, ARCH OPHTHALMOL-CHIC, V116, P753, DOI 10.1001/archopht.116.6.753
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz-Moreno JM, 2009, BRIT J OPHTHALMOL, V93, P448, DOI 10.1136/bjo.2008.145391
   Ruiz-Oliva F, 2002, OPHTHALMOLOGY, V109, P1043, DOI 10.1016/S0161-6420(02)00972-7
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1250, DOI 10.1097/IAE.0b013e318236e503
   Sawa M, 2009, AM J OPHTHALMOL, V148, P584, DOI 10.1016/j.ajo.2009.04.026
   Skalicky SE, 2012, OPHTHAL SURG LAS IM, V43, P328, DOI 10.3928/15428877-20120618-01
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tabandeh H, 1999, OPHTHALMOLOGY, V106, P2063, DOI 10.1016/S0161-6420(99)90484-0
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P67, DOI 10.1111/j.1442-9071.2011.02719.x
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
NR 31
TC 8
Z9 8
U1 0
U2 2
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAR
PY 2014
VL 29
IS 2
BP 108
EP 113
DI 10.3109/08820538.2013.839716
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AC8XQ
UT WOS:000332818800009
PM 24409939
DA 2022-11-30
ER

PT J
AU Yu, Y
   Reynolds, R
   Rosner, B
   Daly, MJ
   Seddon, JM
AF Yu, Yi
   Reynolds, Robyn
   Rosner, Bernard
   Daly, Mark J.
   Seddon, Johanna M.
TI Prospective Assessment of Genetic Effects on Progression to Different
   Stages of Age-Related Macular Degeneration Using Multistate Markov
   Models
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; VARIANT; RISK; SUSCEPTIBILITY; ASSOCIATION; DRUSEN;
   POLYMORPHISM; MACULOPATHY; CFH; INCREASES
AB PURPOSE. Understanding the effect of genes on progression to different stages of age-related macular degeneration (AMD) may suggest stage-specific therapeutic targets and more precise prediction of the development of this disease.
   METHODS. Progression events and time to each stage of AMD were derived from the longitudinal data of 2560 subjects without advanced AMD. SNPs in 12 AMD risk loci were genotyped. A multistate Markov model for progression from normal to intermediate drusen, then to large drusen, and eventually to neovascular disease (NV) or geographic atrophy (GA) was applied to estimate stage-specific hazard ratios for each SNP. The effects of these genetic factors were also estimated by a multivariate multistate Markov model adjusted for baseline age, sex, smoking, body mass index (BMI), education, antioxidant treatment, and the status of AMD in the fellow eye.
   RESULTS. Controlling for demographic and behavioral factors and other SNPs, the TT genotype of rs10468017 in LIPC was associated with decreased risk of progression from large drusen to NV (HR = 0.57, P = 0.04) and tended to reduce the risk of progression from normal to intermediate drusen (HR = 0.72, P = 0.07). The SNP rs1883025 (T allele) in ABCA1 was associated with decreased risk of progression from normal to intermediate drusen (HR per allele = 0.82 per allele, P = 9.7 x 10(-3)) and from intermediate drusen to large drusen (HR per allele = 0.77, P = 5.2 x 10(-3)). The genes CFH, C3, CFB, and ARMS2/HTRA1 were associated with progression from intermediate drusen to large drusen and from large drusen to GA or NV.
   CONCLUSIONS. Genes in different pathways influence progression to different stages of AMD. (Invest Ophthalmol Vis Sci. 2012;53:1548-1556) DOI:10.1167/iovs.11-8657
C1 [Yu, Yi; Reynolds, Robyn; Seddon, Johanna M.] Tufts Med Ctr, Dept Ophthalmol, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA 02111 USA.
   [Rosner, Bernard] Channing Labs, Boston, MA USA.
   [Daly, Mark J.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   [Daly, Mark J.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
C3 Tufts Medical Center; Harvard University; Massachusetts General
   Hospital; Harvard University; Massachusetts Institute of Technology
   (MIT); Broad Institute; Tufts University
RP Seddon, JM (通讯作者)，Tufts Med Ctr, Dept Ophthalmol, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, 800 Washington St,450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
RI Daly, Mark J/B-2453-2017
OI Daly, Mark J/0000-0002-0949-8752
FU National Institutes of Health, Bethesda, MD [R01-EY11309]; Massachusetts
   Lions Eye Research Fund, Inc.; Research to Prevent Blindness, Inc., New
   York, NY; American Macular Degeneration Foundation, Northampton, MA;
   Elizabeth O'Brien Trust; Ophthalmic Epidemiology and Genetics Service,
   New England Eye Center, Tufts Medical Center, Tufts University School of
   Medicine, Boston, MA; Virginia B. Smith Trust; NATIONAL EYE INSTITUTE
   [R01EY011309] Funding Source: NIH RePORTER
FX Supported by an anonymous donor (JMS) and in part by Grants R01-EY11309
   from the National Institutes of Health, Bethesda, MD; Massachusetts
   Lions Eye Research Fund, Inc.; Unrestricted grant from Research to
   Prevent Blindness, Inc., New York, NY; the American Macular Degeneration
   Foundation, Northampton, MA; Elizabeth O'Brien Trust; Virginia B. Smith
   Trust; and the Macular Degeneration Research Fund of the Ophthalmic
   Epidemiology and Genetics Service, New England Eye Center, Tufts Medical
   Center, Tufts University School of Medicine, Boston, MA.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   de Wreede LC, 2010, COMPUT METH PROG BIO, V99, P261, DOI 10.1016/j.cmpb.2010.01.001
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mann SS, 2011, GRAEF ARCH CLIN EXP, V249, P209, DOI 10.1007/s00417-010-1483-x
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Munch IC, 2010, INVEST OPHTH VIS SCI, V51, P2317, DOI 10.1167/iovs.09-4482
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Putter H, 2007, STAT MED, V26, P2389, DOI 10.1002/sim.2712
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Seddon J, 2007, PRINCIPLES PRACTICE, P413
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2010, MOL VIS, V16, P2412
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
NR 35
TC 79
Z9 86
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2012
VL 53
IS 3
BP 1548
EP 1556
DI 10.1167/iovs.11-8657
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 925VT
UT WOS:000302790700063
PM 22247473
OA Green Published
DA 2022-11-30
ER

PT J
AU Seredyka-Burduk, M
   Wicinski, M
   Liberski, S
   Marczak, D
   Pol, M
   Malinowski, B
   Kaluzny, BJ
AF Seredyka-Burduk, Malgorzata
   Wicinski, Michal
   Liberski, Slawomir
   Marczak, Daria
   Pol, Magdalena
   Malinowski, Bartosz
   Kaluzny, Bartlomiej J.
TI Elevated Levels of Serum IL-17A Secondary to Repeated Intravitreal
   Injections of Aflibercept in Treatment-Naive Patients with Neovascular
   Age-Related Macular Degeneration
SO APPLIED SCIENCES-BASEL
LA English
DT Article
DE aflibercept; interleukin-17; IL-17; monocyte chemoattractant protein 1;
   MCP-1; CCL2; vascular endothelial growth factor; VEGF; placental growth
   factor; PlGF; age-related macular degeneration; AMD
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR VEGF; RANIBIZUMAB; INFLAMMATION;
   BEVACIZUMAB; RESISTANCE; CELLS
AB We evaluated the effect of three monthly intravitreal injections of aflibercept on the serum concentration of interleukin 17A (IL-17A), monocyte chemoattractant protein 1 (MCP-1/CCL2), vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) in treatment-naive patients with neovascular age-related macular degeneration (nAMD). Twenty-two eyes of twenty-two patients with nAMD scheduled for the initial loading phase of intravitreal aflibercept (2 mg/0.05 mL) were included. Serum VEGF, PlGF, MCP-1/CCL2 and IL-17A levels were determined four times in each individual-just before the first injection, 2-3 days after the first injection, just before the third injection, and then 2-3 days after the third aflibercept injection. A statistically significant difference was found between the serum PlGF and IL-17A levels measured before the first injection and after the initial loading phase, with a mean value (MV) of 440.884 vs. 302.151 (p= 0.023) for PlGF and MV = 139.088 pg/mL vs. 151.233 pg/mL (p= 0.016) for IL-17A, respectively. There were no statistically significant differences for VEGF and MCP-1/CCL2 between any of the compared measurements. We reveal that repeated injections of aflibercept promote an increase in serum IL-17A concentration, which may lead to a systemic inflammatory response mediated by IL-17A, but not by MCP-1.
C1 [Seredyka-Burduk, Malgorzata; Pol, Magdalena; Kaluzny, Bartlomiej J.] Nicolaus Copernicus Univ, Coll Med Bydgoszcz, Fac Med, Div Ophthalmol & Optometry,Dept Ophthalmol, M Curie 9, PL-85090 Bydgoszcz, Poland.
   [Wicinski, Michal; Liberski, Slawomir; Marczak, Daria; Malinowski, Bartosz] Nicolaus Copernicus Univ, Coll Med Bydgoszcz, Fac Med, Dept Pharmacol & Therapeut, M Curie 9, PL-85090 Bydgoszcz, Poland.
C3 Nicolaus Copernicus University; Nicolaus Copernicus University
RP Liberski, S (通讯作者)，Nicolaus Copernicus Univ, Coll Med Bydgoszcz, Fac Med, Dept Pharmacol & Therapeut, M Curie 9, PL-85090 Bydgoszcz, Poland.
EM mburduk@wp.pl; wicinski4@wp.pl; liberski.slawomir@gmail.com;
   dariamarczak1@wp.pl; magdalena.pol@cm.umk.pl;
   bartosz.malinowski@cm.umk.pl; b.kaluzny@cm.umk.pl
RI Kaluzny, Bartlomiej J/F-1183-2014
OI Kaluzny, Bartlomiej J/0000-0002-1332-3592
FU Nicolaus Copernicus University
FX This work was supported by Nicolaus Copernicus University.
CR Agrahari V, 2016, DRUG DELIV TRANSL RE, V6, P735, DOI 10.1007/s13346-016-0339-2
   Arnott C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150688
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Balaratnasingam C, 2015, CLIN OPHTHALMOL, V9, P2355, DOI 10.2147/OPTH.S80040
   Cai S, 2017, CURR OPIN OPHTHALMOL, V28, P636, DOI 10.1097/ICU.0000000000000424
   Chung AS, 2013, NAT MED, V19, P1114, DOI 10.1038/nm.3291
   Chyuan IT, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/2403935
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Fogli S, 2018, EYE, V32, P1010, DOI 10.1038/s41433-018-0021-7
   Carvalho JF, 2007, J CLIN IMMUNOL, V27, P246, DOI 10.1007/s10875-007-9083-1
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Hasegawa E, 2013, J IMMUNOL, V190, P1778, DOI 10.4049/jimmunol.1202495
   Hirano T, 2018, RETINA-J RET VIT DIS, V38, P1801, DOI 10.1097/IAE.0000000000002004
   Liu HY, 2018, ONCOTARGET, V9, P2887, DOI 10.18632/oncotarget.20812
   Maniati E, 2013, NAT MED, V19, P1092, DOI 10.1038/nm.3333
   Mastropasqua R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35036-9
   Ozaki E, 2014, ADV EXP MED BIOL, V801, P229, DOI 10.1007/978-1-4614-3209-8_30
   Qiu AW, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.117
   Sato T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19594-6
   Shin JI, 2013, NAT REV IMMUNOL, V13, DOI 10.1038/nri3459-c1
   Sigurdardottir S, 2019, CELL IMMUNOL, V341, DOI 10.1016/j.cellimm.2019.04.009
   Sugimoto M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48869-9
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Wang XY, 2014, AM J OPHTHALMOL, V158, P738, DOI 10.1016/j.ajo.2014.06.009
   Wojkowska DW, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051000
   Yannuzzi NA, 2019, CLIN OPHTHALMOL, V13, P1323, DOI 10.2147/OPTH.S184706
   Yoshida I, 2014, GRAEF ARCH CLIN EXP, V252, P1483, DOI 10.1007/s00417-014-2717-0
   You T, 2017, SCI REP-UK, V7, DOI 10.1038/srep41779
   Zehetner C, 2015, INVEST OPHTH VIS SCI, V56, P3279, DOI 10.1167/iovs.15-16686
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
   Zhang J, 2010, PROG MOL BIOL TRANSL, V95, P31, DOI 10.1016/B978-0-12-385071-3.00003-4
   Zhong JX, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00737
NR 33
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3417
J9 APPL SCI-BASEL
JI Appl. Sci.-Basel
PD JUN
PY 2020
VL 10
IS 12
AR 4109
DI 10.3390/app10124109
PG 10
WC Chemistry, Multidisciplinary; Engineering, Multidisciplinary; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Engineering; Materials Science; Physics
GA MR3JB
UT WOS:000553485500001
OA gold
DA 2022-11-30
ER

PT J
AU AnandBabu, K
   Bharathidevi, SR
   Sripriya, S
   Sen, P
   Prakash, VJ
   Bindu, A
   Viswanathan, N
   Angayarkanni, N
AF AnandBabu, Kannadasan
   Bharathidevi, S. R.
   Sripriya, Sarangapani
   Sen, Parveen
   Prakash, Vadivelu Jaya
   Bindu, Appukuttan
   Viswanathan, Natarajan
   Angayarkanni, Narayanasamy
TI Serum Paraoxonase activity in relation to lipid profile in Age-related
   Macular Degeneration patients
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Paraoxonase; Age-related Macular Degeneration; oxLDL; PBMC; PON1
   polymorphism; Lipids; Homocysteine thiolactone
ID HIGH-DENSITY-LIPOPROTEIN; HOMOCYSTEINE-THIOLACTONE; OXIDATIVE STRESS;
   RURAL-POPULATION; RISK-FACTORS; PON1; INFLAMMATION; POLYMORPHISM;
   ASSOCIATION; PREVALENCE
AB Age-related Macular Degeneration (AMD) is a multifactorial disease causing visual impairment in old age. Oxidative stress is one of the main contributors for the disease progression. Paraoxonase (PON), a HDL-resident antioxidant enzyme which removes oxidized low density lipoprotein (oxLDL), which is not studied much in AMD. This study assesses the PON activities in relation to the lipid status and genetic variants in AMD patients. In this prospective case-control study, a total of 48 AMD patients and 30 unrelated healthy controls were recruited. The serum oxLDL and Plasma Homocysteine (Hcy) levels were estimated by ELISA. Plasma Homocysteine thiolactone (HCTL) was estimated by HPLC. Serum PON activities were estimated by spectrophotometry. PON gene expression was assessed by qPCR and protein expression by western blot, immunofluorescence and FACS analysis. Two known single nucleotide polymorphisms (SNPs) in the coding region of PON1, Q192R and L55M variants were checked in the AMD patients and controls and their association with PON activity and lipid levels were determined. Serum paraoxonase (PONase) and thiolactonase (PON-HCTLase) activities were significantly elevated in AMD patients than in controls apart from elevated serum levels of total cholesterol (TC), triglycerides (TG), oxLDL. While serum LDL levels in AMD patients correlate positively with PON HCTLase activity, the serum high density lipoprotein (HDL) correlates with both PONase and PON-HCTLase activities. However, multiple regression analysis showed that, amongst the parameters, only serum TG was a significant risk factor for AMD, after adjusting for demographic parameters as well as cataract. PON2 was significantly increased at the level of gene expression (p = 0.03) as seen in circulating peripheral blood mononuclear cells (PBMC) of AMD patients possibly mediated by the transcription factor SP1, that showed 2-fold increase. PON1 and 2 protein expressions also showed significant increase in the PBMC of AMD patients. At serum level, PON1 protein was significantly increased in AMD patients. Cholesterol transporters such as CD36, SR-B1 and ABCA1 gene expressions were also found to be higher (1.5, 1.9 and 2.4-fold respectively) in AMD, though not statistically significant. While the wet AMD (CNV) was found to be associated with increase in oxLDL and serum PONase activity, the dry AMD was associated with increased HDL and serum PON-HCTLase activity. The genotype and allele frequencies of Q192R & L55M were not significantly different between AMD patients and controls. However, altered lipid status and PON activities were associated with the genotype in AMD patients. A higher enzyme activity was observed for the RR genotype of Q192R in the cohort, irrespective of case and control. Thus the PON genotype and phenotype seem to play a role in the pathogenesis of AMD. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [AnandBabu, Kannadasan; Bharathidevi, S. R.; Angayarkanni, Narayanasamy] Sankara Nethralaya, Vis Res Fdn, KBIRVO, RS Mehta Jain Dept Biochem & Cell Biol, 41 Coll Rd, Chennai 600006, Tamil Nadu, India.
   [AnandBabu, Kannadasan] SASTRA Univ, Sch Chem & Biotechnol, Thanjavur 613401, India.
   [Sripriya, Sarangapani] Vis Res Fdn, SN ONGC Dept Genet & Mol Biol, Chennai 600006, Tamil Nadu, India.
   [Sen, Parveen; Prakash, Vadivelu Jaya; Bindu, Appukuttan] Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, Chennai 600006, Tamil Nadu, India.
   [Viswanathan, Natarajan] Sankara Nethralaya, Vis Res Fdn, Dept Biostat, Chennai 600006, Tamil Nadu, India.
C3 Shanmugha Arts, Science, Technology & Research Academy (SASTRA)
RP Angayarkanni, N (通讯作者)，Sankara Nethralaya, Vis Res Fdn, KBIRVO, RS Mehta Jain Dept Biochem & Cell Biol, 41 Coll Rd, Chennai 600006, Tamil Nadu, India.
EM kabpharm@gmail.com; drsbarathi@snmail.org; drss@snmail.org;
   drpka@snmail.org; drvjp@snmail.org; docbindu@gmail.com;
   vichu3651@yahoo.co.in; drak@snmail.org
RI Sen, Parveen/W-4707-2019; K, Anand Babu/AAN-8619-2020; Narayanasamy,
   Angayarkanni/ABD-8584-2020
OI K, Anand Babu/0000-0002-9910-2044; 
FU DBT, Govt. of India [BT/PR13630/BRB/10/776/2010]
FX Financial support from DBT, Govt. of India (Grant Number:
   BT/PR13630/BRB/10/776/2010) is gratefully acknowledged.
CR Agrawal S, 2009, Indian J Med Sci, V63, P335, DOI 10.4103/0019-5359.55884
   Akiba S, 2003, BIOCHEM BIOPH RES CO, V310, P491, DOI 10.1016/j.bbrc.2003.09.042
   Angayarkanni N, 2008, EYE, V22, P969, DOI 10.1038/sj.eye.6703062
   Arora B, 2014, J CHROMATOGR B, V944, P49, DOI 10.1016/j.jchromb.2013.11.011
   Ates O, 2009, TOHOKU J EXP MED, V217, P17, DOI 10.1620/tjem.217.17
   Aviram M, 2000, CIRCULATION, V101, P2510, DOI 10.1161/01.CIR.101.21.2510
   Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649
   Aynacioglu AS, 2000, INT J CARDIOL, V74, P33, DOI 10.1016/S0167-5273(00)00242-4
   Cabana VG, 2003, J LIPID RES, V44, P780, DOI 10.1194/jlr.M200432-JLR200
   Chawhan SS, 2015, J CLIN DIAGN RES, V9, pBC01, DOI 10.7860/JCDR/2015/15345.6707
   Chwatko G, 2005, ANAL BIOCHEM, V337, P271, DOI 10.1016/j.ab.2004.11.035
   Colak E, 2012, AGING CLIN EXP RES, V24, P588, DOI 10.3275/8593
   Colak E, 2011, OPHTHALMIC RES, V46, P125, DOI 10.1159/000323815
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Davari MH, 2013, J RES HEALTH SCI, V13, P98
   Deakin S, 2002, J BIOL CHEM, V277, P4301, DOI 10.1074/jbc.M107440200
   Draganov DI, 2004, N-S ARCH PHARMACOL, V369, P78, DOI 10.1007/s00210-003-0833-1
   Durrington PN, 2001, ARTERIOSCL THROM VAS, V21, P473, DOI 10.1161/01.ATV.21.4.473
   ECKERSON HW, 1983, AM J HUM GENET, V35, P214
   Feng JW, 2000, J LIPID RES, V41, P688
   Gaidukov L, 2007, J LIPID RES, V48, P1637, DOI 10.1194/jlr.D600045-JLR200
   Gaidukov L, 2006, J LIPID RES, V47, P2492, DOI 10.1194/jlr.M600297-JLR200
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Holven K.B., 2013, PLOS ONE, V8
   Jakubowski H, 2002, ANAL BIOCHEM, V308, P112, DOI 10.1016/S0003-2697(02)00224-5
   James RW, 2004, FREE RADICAL BIO MED, V37, P1986, DOI 10.1016/j.freeradbiomed.2004.08.012
   Jasna JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101380
   Jenkins AJ, 2000, DIABETES, V49, P2160, DOI 10.2337/diabetes.49.12.2160
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   KLEINVELD HA, 1992, CLIN CHEM, V38, P2066
   Kontush A, 2006, PHARMACOL REV, V58, P342, DOI 10.1124/pr.58.3.1
   Kopprasch S, 2003, J CLIN ENDOCR METAB, V88, P1711, DOI 10.1210/jc.2002-021561
   Kulkarni SR, 2013, INDIAN J OPHTHALMOL, V61, P196, DOI 10.4103/0301-4738.99870
   Mackness M, 2015, GENE, V567, P12, DOI 10.1016/j.gene.2015.04.088
   Martinelli N, 2012, EXP DIABETES RES, DOI 10.1155/2012/231502
   Ng CJ, 2001, J BIOL CHEM, V276, P44444, DOI 10.1074/jbc.M105660200
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Onat A, 2011, METABOLISM, V60, P499, DOI 10.1016/j.metabol.2010.04.018
   Pauer GJT, 2010, AM J OPHTHALMOL, V149, P513, DOI 10.1016/j.ajo.2009.09.024
   PrimoParmo SL, 1996, GENOMICS, V33, P498, DOI 10.1006/geno.1996.0225
   Reddy ST, 2001, ARTERIOSCL THROM VAS, V21, P542, DOI 10.1161/01.ATV.21.4.542
   Sampson MJ, 2005, CLIN SCI, V109, P189, DOI 10.1042/CS20050089
   Savu O, 2014, J INT MED RES, V42, P523, DOI 10.1177/0300060513516287
   Sayin Kocakap D.B., 2015, ANATOL J CARDIOL
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Sen-Banerjee S, 2000, ARTERIOSCL THROM VAS, V20, P2120, DOI 10.1161/01.ATV.20.9.2120
   Shih DM, 1996, J CLIN INVEST, V97, P1630, DOI 10.1172/JCI118589
   Sreckovic I, 2014, BBA-MOL CELL BIOL L, V1841, P1619, DOI 10.1016/j.bbalip.2014.07.021
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Ugurlu N, 2013, CURR EYE RES, V38, P497, DOI 10.3109/02713683.2013.774023
   Van Eck M, 2005, CURR OPIN LIPIDOL, V16, P307
   Veiga L, 2011, EUR J ENDOCRINOL, V164, P213, DOI 10.1530/EJE-10-0825
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zafiropoulos A, 2010, J LIPID RES, V51, P1991, DOI 10.1194/jlr.P004960
NR 60
TC 7
Z9 7
U1 0
U2 10
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD NOV
PY 2016
VL 152
BP 100
EP 112
DI 10.1016/j.exer.2016.09.009
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EC1AL
UT WOS:000387835800011
PM 27693409
DA 2022-11-30
ER

PT J
AU Thakkinstian, A
   McKay, GJ
   McEvoy, M
   Chakravarthy, U
   Chakrabarti, S
   Silvestri, G
   Kaur, I
   Li, XX
   Attia, J
AF Thakkinstian, Ammarin
   McKay, Gareth J.
   McEvoy, Mark
   Chakravarthy, Usha
   Chakrabarti, Subhabrata
   Silvestri, Giuliana
   Kaur, Inderjeet
   Li, Xiaoxin
   Attia, John
TI Systematic Review and Meta-Analysis of the Association Between
   Complement Component 3 and Age-related Macular Degeneration: A HuGE
   Review and Meta-Analysis
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Review
DE complement component factor 3; epidemiology; genetic association
   studies; genetics; macular degeneration; meta-analysis
ID FACTOR-B BF; FACTOR-H; PUBLICATION BIAS; FUNNEL PLOTS; RISK-FACTOR; 2
   C2; C3; GENE; MACULOPATHY; LOC387715
AB The authors performed a meta-analysis to estimate the magnitude of polymorphism effects for the complement component C3 gene (C3) and their possible mode of action on age-related macular degeneration (AMD). The meta-analysis included 16 and 7 studies for rs2230199 and rs1047286, respectively. Data extraction and risk of bias assessments were performed in duplicate, and heterogeneity and publication bias were explored. There was moderate evidence for association between both polymorphisms and AMD in Caucasians. For rs2230199, patients with CG and GG genotypes were 1.44 (95% confidence interval (CI): 1.33, 1.56) and 1.88 (95% CI: 1.59, 2.23) times more likely to have AMD than patients with the CC genotype. For rs1047286, GA and AA genotypes had 1.27 (95% CI: 1.15, 1.41) and 1.70 (95% CI: 1.27, 2.11) times higher risk of AMD than did GG genotypes. These gene effects suggested an additive model. The population attributable risks for the GG/GC and AA/GA genotypes are approximately 5%-10%. Subgroup analysis by ethnicity indicates that these variants are very infrequent in Asians and that the observed gene effects are based largely on the high frequency within Caucasian populations. This meta-analysis supports the association between C3 and AMD and provides a robust estimate of the genetic risk.
C1 [Thakkinstian, Ammarin] Mahidol Univ, Ramathibodi Hosp, Fac Med, Sect Clin Epidemiol & Biostat, Bangkok 10400, Thailand.
   [McKay, Gareth J.] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Chakravarthy, Usha; Silvestri, Giuliana] Queens Univ Belfast, Ctr Vision & Vasc Sci, Belfast, Antrim, North Ireland.
   [McEvoy, Mark; Attia, John] Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2300, Australia.
   [Chakrabarti, Subhabrata; Kaur, Inderjeet] LV Prasad Eye Inst, Brien Holden Eye Res Ctr, Hyderabad, Andhra Pradesh, India.
   [Li, Xiaoxin] Peking Univ, Peoples Hosp, Peoples Eye Ctr, Beijing 100871, Peoples R China.
   [Li, Xiaoxin] Peking Univ, Peoples Hosp, Inst Eye, Beijing 100871, Peoples R China.
   [Attia, John] Hunter Med Res Inst, Newcastle, NSW, Australia.
   [Attia, John] John Hunter Hosp, Dept Gen Med, Newcastle, NSW, Australia.
C3 Mahidol University; Queens University Belfast; Queens University
   Belfast; University of Newcastle; L. V. Prasad Eye Institute; Peking
   University; Peking University; Hunter Medical Research Institute;
   University of Newcastle; John Hunter Hospital
RP Thakkinstian, A (通讯作者)，Mahidol Univ, Ramathibodi Hosp, Fac Med, Sect Clin Epidemiol & Biostat, 270 Rama 6 Rd, Bangkok 10400, Thailand.
EM raatk@mahidol.ac.th
RI Kaur, Inderjeet/ABD-1833-2021; Thakkinstian, Ammarin/J-4788-2019;
   Chakrabarti, Subhabrata/F-2468-2015; McKay, Gareth/AAZ-2601-2020; Attia,
   John R/F-5376-2013
OI Chakrabarti, Subhabrata/0000-0003-3717-4963; McKay,
   Gareth/0000-0001-8197-6280; Attia, John R/0000-0001-9800-1308;
   Silvestri, Giuliana/0000-0001-5662-5374; Chakravarthy,
   Usha/0000-0002-2606-3734; McEvoy, Mark/0000-0002-5505-5557
CR Attia J, 2003, J CLIN EPIDEMIOL, V56, P297, DOI 10.1016/S0895-4356(03)00011-8
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Cui L, 2010, INVEST OPHTH VIS SCI, V51, P1116, DOI 10.1167/iovs.09-4265
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   EGGER M, 2001, SYSTEMATIC REV HLTH
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Hayden KM, 2005, J AM GERIATR SOC, V53, P935, DOI 10.1111/j.1532-5415.2005.53301.x
   HERNANDEZ JL, 1989, BIOMETRICS, V45, P53, DOI 10.2307/2532034
   Ioannidis JPA, 2008, INT J EPIDEMIOL, V37, P120, DOI 10.1093/ije/dym159
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   KAUR I, 2009, INVEST OPHTH VIS SCI, V51, P59
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   LITTLE J, 2006, HUGE REV HDB VERSION
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Mckay GJ, 2010, MOL VIS, V16, P194
   Minelli C, 2005, INT J EPIDEMIOL, V34, P1319, DOI 10.1093/ije/dyi169
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moreno SG, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2981
   *NAT LIB MED, 2010, RS2230199 NAT CTR BI
   *NAT LIB MED, 2010, RS1047286 NAT CTR BI
   Nuesch E, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3515
   Palmer TM, 2008, STATA J, V8, P242, DOI 10.1177/1536867X0800800206
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Peters JL, 2008, J CLIN EPIDEMIOL, V61, P991, DOI 10.1016/j.jclinepi.2007.11.010
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rossman MD, 2003, AM J HUM GENET, V73, P720, DOI 10.1086/378097
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Spiegelhalter D., 2007, WINBUGS USER MANUAL
   StataCorp LP, 2009, STATA STAT SOFTW REL
   Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thompson JR, 2005, STAT MED, V24, P2241, DOI 10.1002/sim.2100
   Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V
   Thompson SG, 1997, STAT MED, V16, P2741, DOI 10.1002/(SICI)1097-0258(19971215)16:23<2741::AID-SIM703>3.0.CO;2-0
   THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351
   Trikalinos TA, 2006, AM J EPIDEMIOL, V163, P300, DOI 10.1093/aje/kwj046
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 63
TC 104
Z9 108
U1 0
U2 17
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD JUN 15
PY 2011
VL 173
IS 12
BP 1365
EP 1379
DI 10.1093/aje/kwr025
PG 15
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 775UK
UT WOS:000291488700003
PM 21576320
OA Bronze
DA 2022-11-30
ER

PT J
AU Spaide, RF
AF Spaide, Richard F.
TI OUTER RETINAL ATROPHY AFTER REGRESSION OF SUBRETINAL DRUSENOID DEPOSITS
   AS A NEWLY RECOGNIZED FORM OF LATE AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; atrophy; choroidal neovascularization;
   geographic atrophy; optical coherence tomography; outer retinal atrophy
ID RETICULAR PSEUDODRUSEN; RISK-FACTORS; CHOLESTEROL; PREVALENCE;
   MACULOPATHY; EYES
AB Purpose: To investigate the long-term clinical course of eyes with pseudodrusen appearance caused by subretinal drusenoid deposits.
   Methods: Eyes from the original study identifying subretinal deposits of material as the cause of pseudodrusen appearance were evaluated in a retrospective study of outer retinal morphology. The distance between the inner plexiform layer and the retinal pigment epithelium, termed the photoreceptor length, was measured from optical coherence tomography approximately 2 mm superior to the fovea at baseline and at follow-up visits. The choroidal thickness was measured directly under this retinal area.
   Results: Of the 21 eyes available for follow-up, 9 (42.9%) eventually developed choroidal neovascularization over a mean 2.9-year follow-up period. Regression of subretinal drusenoid deposits was seen in 9 eyes (42.9%) as well. Those with regression of subretinal drusenoid deposits had a decrease in the photoreceptor length with the final photoreceptor length being 74.4% of the initial length (P < 0.001). In eyes with regression, the underlying choroid was 81.4% of its initial value (P = 0.01) at the final follow-up. Eyes with regression also showed loss of the ellipsoid band. Eyes without regression had no change in photoreceptor length, choroidal thickness, or outer retinal architecture.
   Conclusion: Eyes with regression of subretinal drusenoid deposits develop outer retinal atrophy and loss of the underlying choroidal thickness. This finding seems common in eyes having pseudodrusen and represents a late form of age-related macular degeneration that is not in current classification systems. Further study is needed to determine both the true prevalence and the effects on visual function.
C1 Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
C3 Vitreous Retina Macula Consultants of New York
RP Spaide, RF (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM rickspaide@gmail.com
RI Spaide, Richard/ABD-7368-2020
FU Macula Foundation, New York, NY
FX Supported in part by the Macula Foundation, New York, NY.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Hamel CP, 2009, AM J OPHTHALMOL, V147, P609, DOI 10.1016/j.ajo.2008.10.022
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Spaide R, 2008, RETINA-J RET VIT DIS, V28, P5, DOI 10.1097/IAE.0b013e318158eca4
   Spaide RF, 2012, OPHTHALMOLOGY, V119, P2203, DOI 10.1016/j.ophtha.2012.09.009
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wang MSM, 2002, AM J OPHTHALMOL, V133, P787, DOI 10.1016/S0002-9394(02)01438-1
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 27
TC 129
Z9 132
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2013
VL 33
IS 9
BP 1800
EP 1808
DI 10.1097/IAE.0b013e31829c3765
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297DL
UT WOS:000330235500007
PM 23764969
DA 2022-11-30
ER

PT J
AU Wang, XT
   Qin, D
   Liu, Y
   Lei, RJ
   Ren, MX
   Wang, RS
   Wang, Y
AF Wang, Xiaotang
   Qin, Dan
   Liu, Yong
   Lei, Runjia
   Ren, Meixia
   Wang, Runsheng
   Wang, Ying
TI Comparing bevacizumab and ranibizumab for treatment of neovascular
   age-related macular degeneration: a meta-analysis of noninferiority
   randomized controlled trials
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Neovascular age-related macular degeneration; bevacizumab; ranibizumab;
   meta-analysis
ID CLINICAL MEASURES; VISUAL FUNCTION; THERAPY; AVASTIN
AB Neovascular age-related macular degeneration (nAMD) is the main cause of blindness in populations aged over 50 years old. The objective of this meta-analysis was to compare the efficacy and safety of off-label use of bevacizumab with licensed ranibizumab for the treatment of nAMD. Five noninferiority randomized controlled trials (RCTs) comparing bevacizumab with ranibizumab for treatment of nAMD were included. Three reviewers independently extracted data. Data on efficacy and safety outcomes were collected. Pooled risk ratios, weighted mean difference (WMD), and associated 95% confidence interval (CI) were calculated. There were 1,346 patients in the bevacizumab group and 1,392 patients in the ranibizumab group. There were no significant differences between the two drugs in the change of BCVA (WMD=-0.63; 95% CI, -1.72 to 0.46, P=0.26). The mean difference was -0.63 letters with a lower limit in the 95% CI of -1.72 letters. This lower bound was above all the noninferiority margins chosen in the RCTs (-3.5 to -5). Bevacizumab was more effective in reducing central retinal thickness than ranibizumab (WMD=11.14; 95% CI, 2.12 to 20.15, P=0.02). The pooled risk ratios comparing the incidences of death, arteriothrombotic events, venous thrombotic events, >= 1 serious systemic events, and ocular adverse events were not statistically different. The pooled evidence confirmed that bevacizumab is non-inferior to ranibizumab for treatment of nAMD. However, bevacizumab tended to have better anatomical outcome. There was no difference in adverse events between the two drugs. Further trials are still needed to strengthen results because of the limited number of studies.
C1 [Wang, Xiaotang; Qin, Dan; Wang, Ying] Xi An Jiao Tong Univ, Honghui Hosp, Dept Ophthalmol, 555 Youyi East Rd, Xian 710054, Shaanxi, Peoples R China.
   [Liu, Yong] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurosurg, Xian 710038, Shaanxi, Peoples R China.
   [Lei, Runjia] Xian 1 Hosp, Dept Ophthalmol, Xian 710002, Shaanxi, Peoples R China.
   [Ren, Meixia; Wang, Runsheng] Xian 4 Hosp, Dept Ophthalmol, Xian 710004, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University; Air Force Military Medical University
RP Wang, Y (通讯作者)，Xi An Jiao Tong Univ, Honghui Hosp, Dept Ophthalmol, 555 Youyi East Rd, Xian 710054, Shaanxi, Peoples R China.
EM liu868yong@163.com
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown EG, 2003, DRUG SAFETY, V26, P145, DOI 10.2165/00002018-200326030-00002
   Campbell RJ, 2013, CURR OPIN OPHTHALMOL, V24, P197, DOI 10.1097/ICU.0b013e32835f8bbe
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen GH, 2015, RETINA-J RET VIT DIS, V35, P187, DOI 10.1097/IAE.0000000000000301
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, COCHRANE HDB SYSTEMA, P155
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Kodjikian L, 2014, GRAEF ARCH CLIN EXP, V252, P1529, DOI 10.1007/s00417-014-2764-6
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Li XX, 2012, OPHTHALMOLOGY, V119, P2087, DOI 10.1016/j.ophtha.2012.05.016
   Lushchyk T, 2013, ACTA OPHTHALMOL, V91, pe456, DOI 10.1111/aos.12119
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Menke MN, 2014, BRIT J OPHTHALMOL, V98, P1197, DOI 10.1136/bjophthalmol-2013-304775
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Pagliarini S, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/857148
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Stein Joshua D, 2013, Trans Am Ophthalmol Soc, V111, P56
   Unver YB, 2009, EYE, V23, P453, DOI 10.1038/eye.2008.349
NR 26
TC 0
Z9 0
U1 0
U2 1
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2018
VL 11
IS 11
BP 11663
EP 11672
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA HC5SO
UT WOS:000451862900029
DA 2022-11-30
ER

PT J
AU Khan, JC
   Shahid, H
   Thurlby, DA
   Yates, JRW
   Moore, AT
AF Khan, Jane C.
   Shahid, Humma
   Thurlby, Deborah A.
   Yates, John R. W.
   Moore, Anthony T.
TI Charles Bonnet syndrome in age-related macular degeneration: The nature
   and frequency of images in subjects with end-stage disease
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE aging; Charles Bonnet; hallucination; macular degeneration
ID CHARLES-BONNET-SYNDROME; ISOLATED VISUAL HALLUCINATIONS; BONNET,CHARLES
   SYNDROME; PERCEPTUAL DISORDERS; OPHTHALMOLOGY; POPULATION; ANATOMY;
   VISION
AB Introduction: The term Charles Bonnet syndrome (CBS) is used to describe visual hallucinations resulting from ocular pathology. As part of a larger case-control study we assessed factors which may predispose to this phenomenon in Age-related macular degeneration (AMD). Methods: Three-hundred and sixty cases of late AMD underwent a detailed questionnaire about visual symptoms experienced. Potential ocular and environmental risk factors were compared in two groups; those experiencing symptoms of CBS (n = 97) and those not experiencing CBS symptoms (n = 263). Results: Twenty-seven percent experienced CBS. Poor visual acuity was the only factor associated with the development of these images in AMD with an odds ratio of 3.50 (95% CI 1.64-7.48, p = 0.001) for those with best binocular visual acuity worse than 6/36. In those who experienced CBS, the images tended to be straight ahead (84.5%), colored (72.2%), have moving parts (62.9%), and occur on average once per day (34%). The most common visual image was of people (19.6%) followed by geometric patterns (15.8%). The majority (71.1%) felt the experience to be neither pleasant nor unpleasant. In 41% images were present throughout the course of their disease. There was no association between visual acuity and complexity of images. Conclusion: The prevalence of CBS in late AMD is high, the main risk factor being poor better eye visual acuity. The most commonly experienced hallucinations were of people. Although most patients were unperturbed by the images, reassurance of their benign nature was welcomed. Practitioners should be aware that resolution of symptoms over time does not always occur.
C1 [Khan, Jane C.; Shahid, Humma; Thurlby, Deborah A.; Yates, John R. W.] Univ Cambridge, Dept Med Genet, Cambridge, England.
   [Moore, Anthony T.] UCL, Inst Ophthalmol, Moorfields Eye Hosp, London, England.
C3 University of Cambridge; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust
RP Khan, JC (通讯作者)，Royal Perth Hosp, Dept Ophthalmol, Wellington Street Campus,Box X2213, Perth, WA 6847, Australia.
EM jckhan@gmail.com
FU Medical Research Council [G0000067] Funding Source: Medline; MRC
   [G0000067] Funding Source: UKRI
CR BERRIOS GE, 1982, AGE AGEING, V11, P17, DOI 10.1093/ageing/11.1.17
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BROWN GC, 1992, ARCH OPHTHALMOL-CHIC, V110, P1251, DOI 10.1001/archopht.1992.01080210069027
   Burke W, 2002, J NEUROL NEUROSUR PS, V73, P535, DOI 10.1136/jnnp.73.5.535
   COGAN DG, 1973, A GRAEF ARCH KLIN EX, V188, P139, DOI 10.1007/BF00407835
   DAMASMORA J, 1982, PSYCHOL MED, V12, P251, DOI 10.1017/S0033291700046584
   de Morsier G, 1967, Ann Med Psychol (Paris), V2, P678
   Ffytche DH, 1998, NAT NEUROSCI, V1, P738, DOI 10.1038/3738
   ffytche DH, 1999, BRAIN, V122, P1247, DOI 10.1093/brain/122.7.1247
   GOLD K, 1989, COMPR PSYCHIAT, V30, P90, DOI 10.1016/0010-440X(89)90122-3
   Holroyd S, 1996, J NERV MENT DIS, V184, P188, DOI 10.1097/00005053-199603000-00008
   HOLROYD S, 1994, J NERV MENT DIS, V182, P273, DOI 10.1097/00005053-199405000-00004
   HOLROYD S, 1992, AM J PSYCHIAT, V149, P1701
   Menon GJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P349, DOI 10.1001/archopht.123.3.349
   Menon GJ, 2003, SURV OPHTHALMOL, V48, P58, DOI 10.1016/S0039-6257(02)00414-9
   Mitchell J, 2002, BRIT J OPHTHALMOL, V86, P777, DOI 10.1136/bjo.86.7.777
   Nadarajah J, 1998, AUST NZ J OPHTHALMOL, V26, P63, DOI 10.1111/j.1442-9071.1998.tb01444.x
   NORTONWILLSON L, 1987, FAM PRACT, V4, P27, DOI 10.1093/fampra/4.1.27
   OLBRICH HM, 1987, GRAEF ARCH CLIN EXP, V225, P217, DOI 10.1007/BF02175452
   Pliskin NH, 1996, J AM GERIATR SOC, V44, P1055, DOI 10.1111/j.1532-5415.1996.tb02937.x
   Santhouse AM, 2000, BRAIN, V123, P2055, DOI 10.1093/brain/123.10.2055
   SCHULTZ G, 1991, PERCEPTION, V20, P809, DOI 10.1068/p200809
   Scott IU, 2001, AM J OPHTHALMOL, V131, P590, DOI 10.1016/S0002-9394(01)00833-9
   Shiraishi Y, 2004, J PSYCHIATR RES, V38, P207, DOI 10.1016/S0022-3956(03)00090-6
   Smith MR, 2003, ATHEROSCLEROSIS, V169, P331, DOI 10.1016/S0021-9150(03)00200-4
   TEUNISSE RJ, 1995, BRIT J PSYCHIAT, V166, P254, DOI 10.1192/bjp.166.2.254
   Teunisse RJ, 1996, LANCET, V347, P794, DOI 10.1016/S0140-6736(96)90869-7
   TEUNISSE RJ, 1994, COMPR PSYCHIAT, V35, P70, DOI 10.1016/0010-440X(94)90172-4
NR 28
TC 47
Z9 50
U1 0
U2 18
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PY 2008
VL 15
IS 3
BP 202
EP 208
DI 10.1080/09286580801939320
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 318CN
UT WOS:000257069300010
PM 18569816
DA 2022-11-30
ER

PT J
AU Liutkeviciene, R
   Vilkeviciute, A
   Kriauciuniene, L
   Deltuva, VP
AF Liutkeviciene, Rasa
   Vilkeviciute, Alvita
   Kriauciuniene, Loresa
   Deltuva, Vytenis Pranas
TI SIRT1 rs12778366, FGFR2 rs2981582, STAT3 rs744166, LIPC rs10468017,
   rs493258 and LPL rs12678919 genotypes and haplotype evaluation in
   patients with age-related macular degeneration
SO GENE
LA English
DT Article
DE Age-related macular degeneration; Gene polymorphisms; Early, exudative
   and atrophic AMD
ID BREAST-CANCER RISK; SINGLE-NUCLEOTIDE POLYMORPHISMS; GENOME-WIDE
   ASSOCIATION; HEPATIC LIPASE; GENETIC-VARIANTS; LIPOPROTEIN-LIPASE;
   SIGNAL TRANSDUCER; STAT3 ACTIVATION; OXIDATIVE STRESS; TRANSCRIPTION 3
AB Objective: Age-related macular degeneration (AMD) is the leading cause of blindness in elderly individuals in the developed countries. The etiology of AMD is thought to be multifactorial, including environmental and genetic factors. Our purpose was to determine the genotype frequencies of six different SNPs in genes that encode proteins involved in AMD-related molecular changes (SIRT1 rs12778366, FGFR2 rs2981582, STAT3 rs744166, LIPC rs10468017, rs493258 and LPL rs12678919) for evaluation of haplotype risk in patients with AMD.
   Methods: The study cohort consisted of 652 AMD patients and 829 healthy controls. The genotyping was carried out using the RT-PCR.
   Results: TT genotype of the LIPC rs493258 polymorphism was associated with decreased odds of early AMD development under the codominant and recessive models (OR = 0.446; 95% CI: 0.258-0.772; p = 0.004 and OR = 0.455; 95% CI: 0.274-0.756; p = 0.002, respectively) after Bonferroni correction, (p > 0.05/6, since we analyzed 6 different SNPs). The haplotype containing the two minor alleles T-T in rs10468017-rs493258 were significantly (p = 0.034) associated with early AMD development decreasing. There were no associations found with atrophic AMD development.
   Conclusion: The study showed that LIPC rs493258 gene and haplotype containing the two minor alleles T-T in rs10468017-rs493258 may decrease AMD development.
C1 [Liutkeviciene, Rasa; Kriauciuniene, Loresa] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2 Str, LT-50161 Kaunas, Lithuania.
   [Liutkeviciene, Rasa; Vilkeviciute, Alvita; Kriauciuniene, Loresa; Deltuva, Vytenis Pranas] Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Eiveniu Str 2, LT-50161 Kaunas, Lithuania.
   [Vilkeviciute, Alvita] Lithuanian Univ Hlth Sci, Med Acad, Eiveniu 2 Str, LT-50161 Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences; Lithuanian University of Health Sciences
RP Liutkeviciene, R (通讯作者)，Lithuanian Univ Hlth Sci, Neurosci Inst, Eiveniu 2, Kaunas, Lithuania.
EM rasa.liutkeviciene@lsmuni.lt
FU Research Council of Lithuania [SEN-11/2015]
FX This work was funded by a grant (No. SEN-11/2015) from the Research
   Council of Lithuania.
CR American Academy of Ophthalmology, 2015, AG REL MAC DEG PPP U
   [Anonymous], 2011, AM J OPHTHALMOL, V132, P668
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Avalle L, 2017, CYTOKINE, V98, P42, DOI 10.1016/j.cyto.2017.03.018
   Bass TM, 2007, MECH AGEING DEV, V128, P546, DOI 10.1016/j.mad.2007.07.007
   Beuselinck B, 2013, BRIT J CANCER, V108, P887, DOI 10.1038/bjc.2012.548
   Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364
   Chatterjee C, 2011, AM J PATHOL, V178, P1429, DOI 10.1016/j.ajpath.2010.12.050
   Chen M, 2016, CURR MOL MED, V16, P412, DOI 10.2174/1566524016666160324130031
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen Y, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0795-7
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chen ZQ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002238
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Donmez Gizem, 2012, Int J Alzheimers Dis, V2012, P509529, DOI 10.1155/2012/509529
   Edmondson AC, 2011, CIRC-CARDIOVASC GENE, V4, P145, DOI 10.1161/CIRCGENETICS.110.957563
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Forbes LR, 2016, CURR OPIN HEMATOL, V23, P23, DOI 10.1097/MOH.0000000000000206
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gan L, 2008, NEURON, V58, P10, DOI 10.1016/j.neuron.2008.03.015
   Ganji PN, 2013, ANGIOGENESIS, V16, P903, DOI 10.1007/s10456-013-9364-7
   Ghosh HS, 2008, CURR OPIN INVEST DR, V9, P1095
   Grarup N, 2008, J CLIN ENDOCR METAB, V93, P2294, DOI 10.1210/jc.2007-2815
   Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Hou YT, 2018, HEPATOL INT, V12, P56, DOI 10.1007/s12072-017-9836-8
   Hsieh YC, 2017, BREAST CANCER RES TR, V163, P131, DOI 10.1007/s10549-017-4144-5
   Hu YY, 2015, J ATHEROSCLER THROMB, V22, P165, DOI 10.5551/jat.24844
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kilic U, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117954
   Kilic U, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090428
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383
   Ledwon JK, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-510
   Lee SH, 2000, J BIOL CHEM, V275, P33679, DOI 10.1074/jbc.M004994200
   Li LG, 2015, MOL MED REP, V12, P2231, DOI 10.3892/mmr.2015.3570
   Liu CL, 2013, J BREAST CANCER, V16, P366, DOI 10.4048/jbc.2013.16.4.366
   Liutkeviciene R, 2017, GENE, V636, P30, DOI 10.1016/j.gene.2017.09.022
   Lv YB, 2017, CANCER MANAG RES, V9, P381, DOI 10.2147/CMAR.S142677
   Maiese K, 2015, WORLD J STEM CELLS, V7, P235, DOI 10.4252/wjsc.v7.i2.235
   Martin Amy J, 2011, BMC Res Notes, V4, P72, DOI 10.1186/1756-0500-4-72
   Mazhar A, 2016, MOL MED REP, V14, P3443, DOI 10.3892/mmr.2016.5633
   Mead JR, 2002, J MOL MED, V80, P753, DOI 10.1007/s00109-002-0384-9
   Mead JR, 2002, CARDIOVASC RES, V55, P261, DOI 10.1016/S0008-6363(02)00405-4
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Meyer KB, 2008, PLOS BIOL, V6, P1098, DOI 10.1371/journal.pbio.0060108
   Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033
   Miles FL, 2015, INT J CLIN EXP MED, V8, P11470
   Mimura T, 2013, EXP EYE RES, V116, P17, DOI 10.1016/j.exer.2013.07.017
   Murillo-Zamora E, 2013, ARCH MED RES, V44, P459, DOI 10.1016/j.arcmed.2013.08.006
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ozawa Y, 2010, OPHTHALMIC RES, V44, P199, DOI 10.1159/000316484
   Ozgoz A, 2013, J CANCER RES THER, V9, P370, DOI 10.4103/0973-1482.114434
   Patel Amit K, 2013, JAKSTAT, V2, pe25434, DOI 10.4161/jkst.25434
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Peter I, 2011, AM J OPHTHALMOL, V152, P1005, DOI 10.1016/j.ajo.2011.05.016
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Potente M, 2007, GENE DEV, V21, P2644, DOI 10.1101/gad.435107
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rosenthal R, 2005, BIOCHEM BIOPH RES CO, V337, P241, DOI 10.1016/j.bbrc.2005.09.028
   Rufibach LE, 2006, J LIPID RES, V47, P1463, DOI 10.1194/jlr.M600082-JLR200
   Sanders BD, 2010, BBA-PROTEINS PROTEOM, V1804, P1604, DOI 10.1016/j.bbapap.2009.09.009
   Sciacca S, 2013, HEART VESSELS, V28, P268, DOI 10.1007/s00380-012-0238-5
   Seddon JM, 2010, MOL VIS, V16, P2412
   Slattery ML, 2013, BREAST CANCER RES TR, V140, P587, DOI 10.1007/s10549-013-2644-5
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   Srivastava I, 2017, Adv Gerontol, V30, P427
   Sun C, 2010, CANCER GENET CYTOGEN, V197, P193, DOI 10.1016/j.cancergencyto.2009.11.006
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Wang H, 2009, AM J PHYSIOL-ENDOC M, V297, pE271, DOI 10.1152/ajpendo.90920.2008
   Wang YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep15711
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
   Willson TA, 2012, J PEDIATR GASTR NUTR, V55, P32, DOI 10.1097/MPG.0b013e318246be78
   Yan L, 2015, EXP THER MED, V9, P2195, DOI 10.3892/etm.2015.2409
   Yang G, 2018, J BONE MINER RES, V33, P91, DOI 10.1002/jbmr.3285
   Yang JL, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171145
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
   Zhang YF, 2017, ONCOTARGET, V8, P3454, DOI 10.18632/oncotarget.13839
   Zhou MW, 2018, INT J MOL MED, V42, P13, DOI 10.3892/ijmm.2018.3623
   Zhu W, 2014, NUTR METAB, V11, DOI 10.1186/1743-7075-11-35
NR 91
TC 8
Z9 9
U1 1
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD FEB 20
PY 2019
VL 686
BP 8
EP 15
DI 10.1016/j.gene.2018.11.004
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA HI9DM
UT WOS:000456755500002
PM 30399423
DA 2022-11-30
ER

PT J
AU Gale, RP
   Pearce, I
   Eter, N
   Ghanchi, F
   Holz, FG
   Schmitz-Valckenberg, S
   Balaskas, K
   Burton, BL
   Downes, SM
   Eleftheriadis, H
   George, S
   Gilmour, D
   Hamilton, R
   Lotery, AJ
   Patel, N
   Prakash, P
   Santiago, C
   Thomas, S
   Varma, D
   Walters, G
   Williams, M
   Wolf, A
   Zakri, RH
   Igwe, F
   Ayan, F
AF Gale, Richard P.
   Pearce, Ian
   Eter, Nicole
   Ghanchi, Faruque
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
   Balaskas, Konstantinos
   Burton, Ben J. L.
   Downes, Susan M.
   Eleftheriadis, Haralabos
   George, Sheena
   Gilmour, David
   Hamilton, Robin
   Lotery, Andrew J.
   Patel, Nishal
   Prakash, Priya
   Santiago, Cynthia
   Thomas, Saju
   Varma, Deepali
   Walters, Gavin
   Williams, Michael
   Wolf, Armin
   Zakri, Rosina H.
   Igwe, Franklin
   Ayan, Filis
TI Anatomical and functional outcomes following switching from aflibercept
   to ranibizumab in neovascular age-related macular degeneration in
   Europe: SAFARI study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE clinical trial; degeneration; imaging; macula; neovascularisation
ID ANTI-VEGF THERAPY; PREVALENCE; TACHYPHYLAXIS; BEVACIZUMAB; MANAGEMENT
AB Background/Aims
   Prospective data on switching anti-vascular endothelial growth factors in patients with neovascular age-related macular degeneration (nAMD) who have previously shown no/partial response are limited. This prospective study assessed the effect of switching from aflibercept to ranibizumab on anatomical and functional outcomes in patients with persistent/recurrent disease activity.
   Methods
   SAFARI (NCT02161575) was a 6-month, prospective, single-arm study conducted in the UK and Germany. Patients, meeting strict eligibility criteria for one of two subgroups (primary treatment failure or suboptimal treatment response), received 3 monthly intravitreal ranibizumab injections (0.5 mg). Thereafter, ranibizumab was administered pro re nata at monthly visits. The primary endpoint was change from baseline (CfB) to day 90 in central subfield retinal thickness (CSRT). Best-corrected visual acuity (BCVA) and retinal morphology parameters were assessed.
   Results
   One hundred patients were enrolled (primary treatment failure, 1; suboptimal treatment response, 99). In the overall population, there was a significant CfB in median CSRT of -30.75 mu m (95% CI -59.50,-20.50; p<0.0001) to day 90. Improvements were also observed in other quantitative and qualitative optical coherence tomography parameters. In Early Treatment Diabetic Retinopathy Study letters assessed by category, 55% and 59% of patients gained 0->= 15 letters versus baseline at day 90 and day 180, respectively. However, mean improvements in BCVA (CfB) to each time point were small (<= 2 letters). No new safety signals were identified.
   Conclusion
   Switching from aflibercept to ranibizumab led to a significant improvement in CSRT, with similar to 60% experiencing stabilised/improved BCVA. Therefore, patients with nAMD who have shown a suboptimal response to aflibercept may benefit from switching to ranibizumab.
C1 [Gale, Richard P.] York Teaching Hosp NHS Fdn Trust, York YO31 8HE, N Yorkshire, England.
   [Pearce, Ian] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England.
   [Eter, Nicole] Univ Munster, Dept Ophthalmol, Med Ctr, Munster, Germany.
   [Ghanchi, Faruque] Bradford Teaching Hosp NHS Trust, Bradford, W Yorkshire, England.
   [Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, GRADE Reading Ctr, Bonn, Germany.
   [Balaskas, Konstantinos] Moorfields Eye Hosp NHS Fdn Trust, London, England.
   [Burton, Ben J. L.] James Paget Univ Hosp NHS Fdn Trust, Great Yarmouth, England.
   [Burton, Ben J. L.] Univ East Anglia, Norwich, Norfolk, England.
   [Downes, Susan M.] Oxford Univ Hosp NHS Fdn Trust, Oxford, England.
   [Eleftheriadis, Haralabos] Kings Coll London, London, England.
   [George, Sheena] Hillingdon Hosp NHS Fdn Trust, Uxbridge, Middx, England.
   [George, Sheena] NW London Clin Res Network, London, England.
   [Gilmour, David] NHS Greater Glasgow & Clyde, Glasgow, Lanark, Scotland.
   [Lotery, Andrew J.] Univ Southampton, Fac Med, Southampton, Hants, England.
   [Patel, Nishal; Zakri, Rosina H.] East Kent Hosp Univ NHS Fdn Trust, Canterbury, Kent, England.
   [Prakash, Priya] Princess Alexandra Hosp NHS Trust, Harlow, Essex, England.
   [Santiago, Cynthia] Aberdeen Royal Infirm, NHS Grampian, Aberdeen, Scotland.
   [Thomas, Saju] Cty Durham & Darlington NHS Fdn Trust, Darlington, Durham, England.
   [Varma, Deepali] City Hosp Sunderland NHS Fdn Trust, Sunderland, England.
   [Walters, Gavin] Harrogate & Dist NHS Fdn Trust, Harrogate, England.
   [Williams, Michael] Queens Univ Belfast, Belfast, Antrim, North Ireland.
   [Williams, Michael] Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland.
   [Wolf, Armin] Univ Munich, Munich, Germany.
   [Igwe, Franklin; Ayan, Filis] Novartis Pharmaceut UK Ltd, Surrey, England.
C3 Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal
   Liverpool University Hospital; University of Liverpool; University of
   Munster; University of Bonn; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust; University of East
   Anglia; Oxford University Hospitals NHS Foundation Trust; University of
   London; King's College London; University of Southampton; Princess
   Alexandra Hospital NHS Trust; University of Aberdeen; Sunderland Royal
   Hospital; Queens University Belfast; University of Munich; Novartis
RP Gale, RP (通讯作者)，York Teaching Hosp NHS Fdn Trust, York YO31 8HE, N Yorkshire, England.
EM gale@york.nhs.uk
RI Balaskas, Konstantinos/ABD-5979-2020
OI Balaskas, Konstantinos/0000-0002-7690-6277; Burton,
   Ben/0000-0001-9579-9078; Lotery, Andrew/0000-0001-5541-4305
FU Novartis Pharmaceuticals UK Limited
FX Funding for this study was provided by Novartis Pharmaceuticals UK
   Limited.
CR Brigo F, 2016, SEIZURE-EUR J EPILEP, V42, P29, DOI 10.1016/j.seizure.2016.08.007
   CHAKRAVARTHY U, 2010, BMJ-BRIT MED J, V340, DOI DOI 10.1136/BMJ.C981
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Despreaux R, 2016, GRAEF ARCH CLIN EXP, V254, P639, DOI 10.1007/s00417-015-3084-1
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Garcia-Layana A, 2015, DRUG AGING, V32, P797, DOI 10.1007/s40266-015-0300-y
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2017, EYE, V31, P166, DOI 10.1038/eye.2016.276
   Holz FG, 2017, OPHTHALMIC RES, V58, P49, DOI 10.1159/000449001
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Mantel I, 2018, SURV OPHTHALMOL, V63, P638, DOI 10.1016/j.survophthal.2018.02.004
   Mantel I, 2016, RETINA-J RET VIT DIS, V36, P53, DOI 10.1097/IAE.0000000000000664
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sanson-Fisher RW, 2007, AM J PREV MED, V33, P155, DOI 10.1016/j.amepre.2007.04.007
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
NR 24
TC 15
Z9 15
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2020
VL 104
IS 4
BP 493
EP 499
DI 10.1136/bjophthalmol-2019-314251
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LB3EI
UT WOS:000524520300008
PM 31383649
OA Green Published, hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Quellec, G
   Russell, SR
   Seddon, JM
   Reynolds, R
   Scheetz, T
   Mahajan, VB
   Stone, EM
   Abramoff, MD
AF Quellec, Gwenole
   Russell, Stephen R.
   Seddon, Johanna M.
   Reynolds, Robyn
   Scheetz, Todd
   Mahajan, Vinit B.
   Stone, Edwin M.
   Abramoff, Michael D.
TI Automated Discovery and Quantification of Image-Based Complex
   Phenotypes: A Twin Study of Drusen Phenotypes in Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BASAL LAMINAR DEPOSIT; EYE; RISK; SEGMENTATION; PHOTOGRAPHS;
   MACULOPATHY; PREVALENCE; MORPHOLOGY; DIAGNOSIS; DISEASE
AB PURPOSE. Determining the relationships between phenotype and genotype of many disorders can improve clinical diagnoses, identify disease mechanisms, and enhance therapy. Most genetic disorders result from interaction of many genes that obscure the discovery of such relationships. The hypothesis for this study was that image analysis has the potential to enable formalized discovery of new visible phenotypes. It was tested in twins affected with age-related macular degeneration (AMD).
   METHODS. Fundus images from 43 monozygotic (MZ) and 32 dizygotic (DZ) twin pairs with AMD were examined. First, soft and hard drusen were segmented. Then newly defined phenotypes were identified by using drusen distribution statistics that significantly separate MZ from DZ twins. The ACE model was used to identify the contributions of additive genetic (A), common environmental (C), and nonshared environmental (E) effects on drusen distribution phenotypes.
   RESULTS. Four drusen distribution characteristics significantly separated MZ from DZ twin pairs. One encoded the quantity, and the remaining three encoded the spatial distribution of drusen, achieving a zygosity prediction accuracy of 76%, 74%, 68%, and 68%. Three of the four phenotypes had a 55% to 77% genetic effect in an AE model, and the fourth phenotype showed a nonshared environmental effect (E model).
   CONCLUSIONS. Computational discovery of genetically determined features can reveal quantifiable AMD phenotypes that are genetically determined without explicitly linking them to specific genes. In addition, it can identify phenotypes that appear to result predominantly from environmental exposure. The approach is rapid and unbiased, suitable for large datasets, and can be used to reveal unknown phenotype-genotype relationships. (Invest Ophthalmol Vis Sci. 2011;52:9195-9206) DOI: 10.1167/iovs.10-6793
C1 [Quellec, Gwenole; Russell, Stephen R.; Stone, Edwin M.; Abramoff, Michael D.] Univ Iowa Hosp & Clin, Inst Vis Res, Iowa City, IA 52242 USA.
   [Quellec, Gwenole; Scheetz, Todd; Abramoff, Michael D.] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA.
   [Scheetz, Todd; Abramoff, Michael D.] Univ Iowa, Dept Elect & Comp Engn, Iowa City, IA 52242 USA.
   [Russell, Stephen R.; Stone, Edwin M.; Abramoff, Michael D.] Univ Iowa, Carver Family Ctr Macular Degenerat, Iowa City, IA USA.
   [Stone, Edwin M.] Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA.
   [Seddon, Johanna M.; Reynolds, Robyn] Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [Abramoff, Michael D.] Iowa City VA Med Ctr, Ctr Excellence Prevent & Treatment Visual Loss, Dept Vet Affairs, Iowa City, IA USA.
C3 University of Iowa; University of Iowa; University of Iowa; University
   of Iowa; Howard Hughes Medical Institute; University of Iowa; Tufts
   Medical Center; Tufts University; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Iowa City VA Health Care System
RP Abramoff, MD (通讯作者)，Univ Iowa Hosp & Clin, Inst Vis Res, 200 Hawkins Dr,11290C PFP, Iowa City, IA 52242 USA.
EM michael-abramoff@uiowa.edu
RI Quellec, Gwenole/L-9946-2015; Abramoff, Michael D/A-5836-2009
OI Quellec, Gwenole/0000-0003-1669-7140; Abramoff, Michael
   D/0000-0002-3490-0037; Stone, Edwin M./0000-0003-3343-4414; Scheetz,
   Todd/0000-0002-1965-5811; Russell, Stephen/0000-0003-3776-1367; Mahajan,
   Vinit/0000-0003-1886-1741
FU National Eye Institute [R01 EY017066, R01 EY11309, R01 EY16822];
   Research to Prevent Blindness; Department of Veterans Affairs; Carver
   Family Center for Macular Degeneration; Howard Hughes Medical Institute;
   Massachusetts Lions Eye Research Fund, Inc., New Bedford, MA; Macular
   Degeneration Research Fund; Tufts Medical Center; Tufts University
   School of Medicine; NATIONAL EYE INSTITUTE [R01EY011309, R01EY016822,
   R01EY017066] Funding Source: NIH RePORTER
FX Supported by National Eye Institute Grants R01 EY017066, R01 EY11309,
   and R01 EY16822; Research to Prevent Blindness; the Department of
   Veterans Affairs; the Carver Family Center for Macular Degeneration; the
   Howard Hughes Medical Institute; the Massachusetts Lions Eye Research
   Fund, Inc., New Bedford, MA; the Macular Degeneration Research Fund; and
   Tufts Medical Center and Tufts University School of Medicine.
CR Abramoff MD, 2007, INVEST OPHTH VIS SCI, V48, P1665, DOI 10.1167/iovs.06-1081
   AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   Barthes A, 2001, MED PHYS, V28, P2410, DOI 10.1118/1.1420735
   Beyene J, 2007, GENET EPIDEMIOL, V31, pS103, DOI 10.1002/gepi.20286
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Chew EY, 2009, ARCH OPHTHALMOL-CHIC, V127, P1678, DOI 10.1001/archophthalmol.2009.312
   Cressie N, 1993, STAT SPATIAL DATA
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delaunay B., 1934, IZV AKAD NAUK SSSR O, P793
   FASANO G, 1987, MON NOT R ASTRON SOC, V225, P155, DOI 10.1093/mnras/225.1.155
   FLANDRIN P, 1992, IEEE T INFORM THEORY, V38, P910, DOI 10.1109/18.119751
   Foley J.D., 1990, SYSTEMS PROGRAMMING
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gass JD, 1997, STEREOSCOPIC ATLAS M
   GASTWIRTH JL, 1988, J STAT PLAN INFER, V18, P267, DOI 10.1016/0378-3758(88)90104-8
   Geary R., 1954, ICORPORPORATED STAT, V5, P115, DOI [DOI 10.2307/2986645, 10.2307/2986645]
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hegele RA, 2007, EXP CELL RES, V313, P2134, DOI 10.1016/j.yexcr.2007.03.023
   Howells W.W., 1989, SKULL SHAPES MAP CRA
   IWAO S, 1976, Researches on Population Ecology (Tokyo), V17, P240, DOI 10.1007/BF02530775
   JABLON S, 1967, AM J HUM GENET, V19, P133
   Jones TR, 2009, P NATL ACAD SCI USA, V106, P1826, DOI 10.1073/pnas.0808843106
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lefever DW, 1926, AM J SOCIOL, V32, P88, DOI 10.1086/214027
   Martinez-Perez ME, 2002, IEEE T BIO-MED ENG, V49, P912, DOI 10.1109/TBME.2002.800789
   MORAN PAP, 1950, BIOMETRIKA, V37, P17, DOI 10.2307/2332142
   NEALE MC, 1994, BEHAV GENET, V24, P239, DOI 10.1007/BF01067191
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   O'Neill M, 2001, IEEE T EVOLUT COMPUT, V5, P349, DOI 10.1109/4235.942529
   ODEN NL, 1986, SYST ZOOL, V35, P608, DOI 10.2307/2413120
   *OPENMX, 2007, ADV STRUCT EQUAT MOD
   Oti M, 2007, CLIN GENET, V71, P1, DOI 10.1111/j.1399-0004.2006.00708.x
   Pieramici D J, 1998, Curr Opin Ophthalmol, V9, P38, DOI 10.1097/00055735-199806000-00007
   Plomin R, 2008, BEHAV GENETICS
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Press W. H., 1992, NUMERICAL RECIPES C, V2nd
   Quellec G, 2008, IEEE T MED IMAGING, V27, P1230, DOI 10.1109/TMI.2008.920619
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   Sobrin L, 2010, EUR J HUM GENET, V18, P496, DOI 10.1038/ejhg.2009.185
   Tang L, 2010, INVEST OPHTH VIS SCI, V51, P5870, DOI 10.1167/iovs.10-5527
   Upton G., 1985, Spatial data analysis by example. Volume 1: Point pattern and quantitative data.
   Van de Wouwer G, 1999, IEEE T IMAGE PROCESS, V8, P592, DOI 10.1109/83.753747
   VANDERSCHAFT TL, 1991, ARCH OPHTHALMOL-CHIC, V109, P420, DOI 10.1001/archopht.1991.01080030122052
   Von Mises R., 1964, MATH THEORY PROBABIL
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wiggs JL, 2010, ARCH OPHTHALMOL-CHIC, V128, P934, DOI 10.1001/archophthalmol.2010.108
NR 62
TC 7
Z9 7
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2011
VL 52
IS 12
BP 9195
EP 9206
DI 10.1167/iovs.10-6793
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 856IB
UT WOS:000297631400055
PM 22039249
OA Green Published
DA 2022-11-30
ER

PT J
AU Rangel, CM
   Villota, E
   Gonzalez, AFV
   Sanchez-Avila, RM
AF Rangel, Carlos M.
   Villota, Eva
   Fernandez-Vega Gonzalez, Alvaro
   Sanchez-Avila, Ronald M.
TI Intravitreal bevacizumab associated with photodynamic therapy in a case
   of polypoidal choroidal vasculopathy associated with choroidal nevus: A
   case report
SO MEDICINE
LA English
DT Article
DE antiangiogenic therapy; bevacizumab; choroid neoplasms; choroidal nevus;
   combined modality therapy; photodynamic therapy
AB Rationale:Report the clinical findings and management of a case of polypoidal choroidal vasculopathy associated with choroidal nevus which received combination therapy.Patient concerns:Decreased visual acuity in a woman with polypoidal choroidal vasculopathy and choroidal nevus.Diagnoses:Polypoidal choroidal vasculopathy and choroidal nevus.Interventions:The initial visual acuity was 0.5. After the first treatment with photodynamic therapy, exudation and bleeding appeared around the lesion. After this, the patient received 3 doses of intravitreal bevacizumab.Outcomes:After treatment with combination therapy, visual acuity, clinical and imaging findings improved, with no recurrence of exudation and bleeding.Lessons:Intravitreal bevacizumab as an adjunctive treatment after photodynamic therapy is a good option for patients with polypoidal choroidal vasculopathy associated with choroidal nevus.
C1 [Rangel, Carlos M.; Villota, Eva; Fernandez-Vega Gonzalez, Alvaro; Sanchez-Avila, Ronald M.] Fdn Invest Oftalmol, Inst Univ Fernandez Vega, Oviedo, Spain.
   [Rangel, Carlos M.] Fdn Oftalmol Santander FOSCAL, Third Floor,Module 7, Floridablanca, Colombia.
RP Sanchez-Avila, RM (通讯作者)，Fdn Invest Oftalmol, Inst Univ Fernandez Vega, Oviedo, Spain.; Rangel, CM (通讯作者)，Fdn Oftalmol Santander FOSCAL, Third Floor,Module 7, Floridablanca, Colombia.; Sanchez-Avila, RM (通讯作者)，Avda Dres Fernandez Vega 34, E-33012 Oviedo, Principado De A, Spain.
EM carlosmrangel@gmail.com; ronald.sanchezavila@gmail.com
RI Rangel, Carlos M/AAP-5054-2020
OI Rangel, Carlos M/0000-0002-6198-0503; Fernandez-Vega Gonzalez,
   Alvaro/0000-0002-9104-7917
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Diwo E, 2014, J FR OPHTALMOL, V37, pE119, DOI 10.1016/j.jfo.2014.01.013
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   MINES JA, 1985, OPHTHALMOLOGICA, V190, P210, DOI 10.1159/000309520
   Peiretti Enrico, 2009, Retin Cases Brief Rep, V3, P12, DOI 10.1097/ICB.0b013e318166bd70
   Querques Giuseppe, 2008, Retin Cases Brief Rep, V2, P216, DOI 10.1097/ICB.0b013e3180653d53
   Romeo Giuseppe F, 2010, Retin Cases Brief Rep, V4, P381, DOI 10.1097/ICB.0b013e3181c6548a
   WALTMAN DD, 1978, AM J OPHTHALMOL, V85, P704, DOI 10.1016/S0002-9394(14)77109-0
   Wong James G, 2016, Retin Cases Brief Rep, V10, P221, DOI 10.1097/ICB.0000000000000233
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   ZIMMERMAN LORENZ E., 1965, INVEST OPHTHALMOL, V4, P11
NR 11
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD DEC
PY 2017
VL 96
IS 52
AR e9400
DI 10.1097/MD.0000000000009400
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FW5VC
UT WOS:000425386300025
PM 29384917
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Piermarocchi, S
   Sartore, M
   Lo Giudice, G
   Monterosso, G
   Pilotto, E
   Segato, T
AF Piermarocchi, S.
   Sartore, M.
   Lo Giudice, G.
   Monterosso, G.
   Pilotto, E.
   Segato, T.
TI Is there any relationship between photodynamic therapy for exudative
   age-related macular degeneration and choroidal neovascularization
   recurrence? A rationale for combined treatments
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   choroidal neovascularization recurrence; photodynamic
ID VERTEPORFIN; EXPRESSION
AB PURPOSE. Photodynamic therapy (PDT) is the treatment of choice for subfoveal choroidal neovascularization (CNV) in age-related macular degeneration (ARMD). Interpretation of PDT mechanism of action is not yet fully understood and causes of CNV recurrences are unclear. The authors have conducted a retrospective analysis of fluorescein and indocyanine green angiographies in patients treated with multiple PDT in order to identify risk factors for recurrence.
   METHODS. A total of 342 eyes of 342 patients (207 women and 135 men) with ARMD and subfoveal CNV were treated with at least two PDT Angiographic (fluorescein and indocyanine green) features of recurrences were confronted to pretreatment examinations in all patients.
   RESULTS. Post-PDT angiographies showed in all eyes a dark circle corresponding to the laser spot even 1 year after treatment. Persistence or progressive regrowth of CNV developed in an area adjacent or corresponding to the original lesion, without any specific relationship with the location of fluorescein and indocyanine green late leakage or with presence of abnormal fluorescence due to pigment abnormalities. At the 3-month angiographic follow-up, 23 patients (6.7%) showed a recurrent CNV resembling shape and dimension of the laser spot used for the PDT treatment.
   CONCLUSIONS. The authors failed to identify angiographic signs helpful to predict the risk of CNV persistence or recurrence. PDT leaves minor but persistent changes in the choroidal vasculature within the treatment area. In some cases, the recurrent CNV seems to be related to the laser spot of the PDT.
C1 Univ Padua, Dept Ophthalmol, I-35100 Padua, Italy.
C3 University of Padua
RP Piermarocchi, S (通讯作者)，Univ Padua, Dept Ophthalmol, Via Giustiniani 2, I-35100 Padua, Italy.
EM stefano.piermarocchi@unipd.it
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arroyo JG, 2003, ARCH OPHTHALMOL-CHIC, V121, P898, DOI 10.1001/archopht.121.6.898
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Eter N, 2003, EUR J OPHTHALMOL, V13, P687, DOI 10.1177/112067210301300804
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Isola V, 2004, RETINA-J RET VIT DIS, V24, P618, DOI 10.1097/00006982-200408000-00020
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Piermarocchi S, 2002, AM J OPHTHALMOL, V133, P572, DOI 10.1016/S0002-9394(01)01370-8
   Postelmans L, 2004, AM J OPHTHALMOL, V138, P803, DOI 10.1016/j.ajo.2004.06.033
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Rudolf M, 2004, KLIN MONATSBL AUGENH, V221, P1026, DOI 10.1055/s-2004-813851
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P162
NR 26
TC 2
Z9 2
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP-OCT
PY 2006
VL 16
IS 5
BP 686
EP 694
DI 10.1177/112067210601600505
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 117TJ
UT WOS:000242895900006
PM 17061219
DA 2022-11-30
ER

PT J
AU Delcourt, C
   Cougnard-Gregoire, A
   Boniol, M
   Carriere, I
   Dore, JF
   Delyfer, MN
   Rougie, MB
   Le Goff, M
   Dartigues, JF
   Barberger-Gateau, P
   Korobelnik, JF
AF Delcourt, Cecile
   Cougnard-Gregoire, Audrey
   Boniol, Mathieu
   Carriere, Isabelle
   Dore, Jean-Francois
   Delyfer, Marie-Noelle
   Rougie, Marie-Benedicte
   Le Goff, Melanie
   Dartigues, Jean-Francois
   Barberger-Gateau, Pascale
   Korobelnik, Jean-Francois
TI Lifetime Exposure to Ambient Ultraviolet Radiation and the Risk for
   Cataract Extraction and Age-Related Macular Degeneration: The Alienor
   Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE macular degeneration; cataract; light exposure; ultraviolet radiation;
   risk factors; epidemiology
ID COMPLEMENT FACTOR-H; BEAVER DAM EYE; NUTRITION EXAMINATION SURVEY;
   PATHOLOGIES-OCULAIRES-LIEES; VITAMIN-D; SUNLIGHT EXPOSURE; 10-YEAR
   INCIDENCE; NATIONAL-HEALTH; LIGHT EXPOSURE; EUROPEAN EYE
AB PURPOSE. While exposure to ultraviolet radiation (UVR) is a recognized risk factor for cataract, its association is more controversial with age-related macular degeneration (AMD). We report the associations of lifetime exposure to ambient UVR with cataract extraction and AMD.
   METHODS. The Alienor Study is a population-based study of 963 residents of Bordeaux (France), aged 73 years or more. Lifetime exposure to ambient UVR was estimated from residential history and Eurosun satellite-based estimations of ground UVR. It was divided in three groups (lower quartile, intermediate quartiles, upper quartile), using the intermediate quartiles as the reference. Early and late AMD was classified from retinal color photographs. Cataract extraction was defined as absence of the natural lens at slit-lamp.
   RESULTS. After multivariate adjustment, subjects in the upper quartile of lifetime ambient UVR exposure were at increased risk for cataract extraction (odds ratio [OR] = 1.53; 95% confidence interval [CI], 1.04-2.26; P = 0.03) and for early AMD (OR = 1.59; 95% CI, 1.042.44; P = 0.03), by comparison with subjects in the intermediate quartiles. Subjects in the lower quartile of UVR exposure also were at increased risk for early AMD (OR = 1.69; 95% CI, 1.06-2.69; P = 0.03), by comparison with those with medium exposure. Associations of late AMD with UVR exposure was not statistically significant.
   CONCLUSIONS. This study further confirms the increased risk for cataract extraction in subjects exposed to high ambient UVR. Moreover, it suggests that risk for early AMD is increased in subjects exposed to high UVR, but also to low UVR, by comparison with medium exposures.
C1 [Delcourt, Cecile; Cougnard-Gregoire, Audrey; Delyfer, Marie-Noelle; Le Goff, Melanie; Dartigues, Jean-Francois; Barberger-Gateau, Pascale; Korobelnik, Jean-Francois] Univ Bordeaux, F-33076 Bordeaux, France.
   [Delcourt, Cecile; Cougnard-Gregoire, Audrey; Delyfer, Marie-Noelle; Le Goff, Melanie; Dartigues, Jean-Francois; Barberger-Gateau, Pascale; Korobelnik, Jean-Francois] INSERM, ISPED, Ctr INSERM U897 Epidemiol Biostat, Bordeaux, France.
   [Boniol, Mathieu] Int Prevent Res Inst, Lyon, France.
   [Carriere, Isabelle] INSERM, U1061, Montpellier, France.
   [Carriere, Isabelle] Univ Montpellier I, Montpellier, France.
   [Dore, Jean-Francois] CNRS, INSERM, Ctr Rech Cancerol Lyon, UMR U1052,U5286, Lyon, France.
   [Delyfer, Marie-Noelle; Rougie, Marie-Benedicte; Korobelnik, Jean-Francois] CHU Bordeaux, Serv Ophtalmol, Bordeaux, France.
C3 UDICE-French Research Universities; Universite de Bordeaux; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite de
   Montpellier; Universite de Montpellier; Centre National de la Recherche
   Scientifique (CNRS); Institut National de la Sante et de la Recherche
   Medicale (Inserm); UNICANCER; Centre Leon Berard; CHU Bordeaux
RP Delcourt, C (通讯作者)，Univ Bordeaux, INSERM, ISPED, U897, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM cecile.delcourt@isped.fr
RI Boniol, Mathieu/F-9623-2011; Delyfer, Marie-Noelle/T-3304-2019;
   KOROBELNIK, Jean-Francois/A-5448-2016; DARTIGUES, Jean
   François/T-4513-2019; LE GOFF, Mélanie/A-3541-2016; Carrière,
   Isabelle/W-8728-2019; COUGNARD-GREGOIRE, Audrey/T-4443-2019; Delcourt,
   Cecile/I-2627-2013
OI Boniol, Mathieu/0000-0003-1052-5604; COUGNARD-GREGOIRE,
   Audrey/0000-0002-1494-5764; Delcourt, Cecile/0000-0002-2099-0481; LE
   GOFF, Melanie/0000-0003-2848-6287; Carriere,
   Isabelle/0000-0002-3617-0752
FU Laboratoires Thea (Clermont-Ferrand, France); Fondation Voir et Entendre
   (Paris, France); European Union [2006320]
FX Supported by Laboratoires Thea (Clermont-Ferrand, France) and Fondation
   Voir et Entendre (Paris, France), and by the European Union's Public
   Health Executive Agency under Grant Agreement No. 2006320 (EUROSUN
   project). The authors alone are responsible for the content and writing
   of the paper.
CR Al-Delaimy WK, 2004, PUBLIC HEALTH NUTR, V7, P713, DOI 10.1079/PHN2004598
   Alperovitch A, 2003, NEUROEPIDEMIOLOGY, V22, P316, DOI 10.1159/000072920
   [Anonymous], 1992, Arch Ophthalmol, V110, P1701
   Asbell PA, 2005, LANCET, V365, P599
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRILLIANT LB, 1983, AM J EPIDEMIOL, V118, P250, DOI 10.1093/oxfordjournals.aje.a113632
   Chakravarthy U, 2013, OPHTHALMOLOGY, V120, P342, DOI 10.1016/j.ophtha.2012.08.004
   Chowdhury R, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1903
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Czernichow S, 2005, J AM DIET ASSOC, V105, P1889, DOI 10.1016/j.jada.2005.09.004
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Delcourt C, 2000, ARCH OPHTHALMOL-CHIC, V118, P385, DOI 10.1001/archopht.118.3.385
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Delcourt C, 2012, ARCH OPHTHALMOL-CHIC, V130, P1077, DOI 10.1001/archophthalmol.2012.420
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Ewbank DC, 2004, J GERONTOL A-BIOL, V59, P16
   Feart C, 2007, BRIT J NUTR, V98, P1046, DOI 10.1017/S0007114507756520
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   HILLER R, 1983, AM J EPIDEMIOL, V118, P239, DOI 10.1093/oxfordjournals.aje.a113631
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lucas R, 2006, SOLAR ULTRAVIOLET RA
   Lucas RM, 2008, INT J EPIDEMIOL, V37, P654, DOI 10.1093/ije/dyn017
   McCarty CA, 2002, DEV OPHTHALMOL, V35, P21
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Pham TQ, 2009, OPHTHAL EPIDEMIOL, V16, P136, DOI 10.1080/09286580701299395
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosmini Francesco, 1994, Annals of Epidemiology, V4, P266
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sreenivas V, 1999, J Epidemiol, V9, P327
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   TAYLOR HR, 1988, NEW ENGL J MED, V319, P1429, DOI 10.1056/NEJM198812013192201
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   West SK, 1998, JAMA-J AM MED ASSOC, V280, P714, DOI 10.1001/jama.280.8.714
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
NR 55
TC 56
Z9 58
U1 0
U2 29
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2014
VL 55
IS 11
BP 7619
EP 7627
DI 10.1167/iovs.14-14471
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX9IR
UT WOS:000347217300073
PM 25335979
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Wysokinski, D
   Zaras, M
   Dorecka, M
   Waszczyk, M
   Szaflik, J
   Blasiak, J
   Szaflik, JP
AF Wysokinski, Daniel
   Zaras, Malgorzata
   Dorecka, Mariola
   Waszczyk, Maja
   Szaflik, Jerzy
   Blasiak, Janusz
   Szaflik, Jacek P.
TI An association between environmental factors and the IVS4+44C > A
   polymorphism of the DMT1 gene in age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE AMD; Age-related macular degeneration; Oxidative stress; Iron
   homeostasis; Gene polymorphism; Divalent metal transporter 1; DMT1
ID RETINAL-PIGMENT EPITHELIUM; IRON-OVERLOAD; RISK-FACTORS; MICROCYTIC
   ANEMIA; 10-YEAR INCIDENCE; MACULOPATHY; SMOKING; PROTECTS; DISEASE;
   DIAGNOSIS
AB Age-related macular degeneration (AMD) is an ocular disease affecting macula - the central part of the retina, resulting in the degeneration of photoreceptors and retinal epithelium and causing severe central vision impairment. The pathophysiology of the disease is not completely known, but a significant role is attributed to genetic factors. The contribution of oxidative stress in AMD as a trigger of the degenerative process is well-established. Iron ions may act as a source of reactive oxygen species; therefore, maintaining iron homeostasis is important for redox balance in the organism. Diversity in iron homeostasis genes may counterpart in unbalanced redox state, and thus be involved in AMD pathophysiology.
   In this work, we searched for an association between some single nucleotide polymorphisms in the divalent metal transporter 1 (DMT1) gene intronic IVS4+44C > A (rs224589) and 3'-UTR c.2044T > C (rs2285230) and environmental factors and AMD. Genotyping was performed using the PCR-RFLP method. DNA was obtained from 436 AMD patients and 168 controls.
   We did not find any association between the genotypes of the two polymorphisms and AMD occurrence. However, we observed that AMD patients living in a rural environment and having the CC genotype of the IVS4+44C > A polymorphism had an increased risk of AMD, while individuals with the CA genotype or the A allele had a decreased risk of the disease. Moreover, in male AMD patients the C allele increased the risk of the disease, while the AA genotype decreased it.
   These results suggest that the VS4+44C > A polymorphism of the DMT1 gene may interact with place of living and gender to modulate the risk of AMD.
C1 [Zaras, Malgorzata; Waszczyk, Maja; Szaflik, Jerzy; Szaflik, Jacek P.] Med Univ Warsaw, Dept Ophthalmol, PL-03709 Warsaw, Poland.
   [Wysokinski, Daniel; Blasiak, Janusz] Univ Lodz, Dept Mol Genet, PL-90236 Lodz, Poland.
   [Zaras, Malgorzata; Waszczyk, Maja; Szaflik, Jerzy; Szaflik, Jacek P.] Samodzielny Publi Klin Szpital Okulisty, PL-03709 Warsaw, Poland.
   [Dorecka, Mariola] Med Univ Silesia, Dept Ophthalmol, PL-40514 Katowice, Poland.
C3 Medical University of Warsaw; University of Lodz; Medical University
   Silesia
RP Szaflik, JP (通讯作者)，Med Univ Warsaw, Dept Ophthalmol, Sierakowskiego 13, PL-03709 Warsaw, Poland.
EM szaflik@ophthalmology.pl
OI Szaflik, Jerzy/0000-0002-7601-1326; Dorecka,
   Mariola/0000-0003-1768-9628; Blasiak, Janusz/0000-0001-9539-9584
FU Polish Ministry of Science and Higher Education [N N402 248 336]
FX This work was supported by grant N N402 248 336 from Polish Ministry of
   Science and Higher Education.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Andrews NC, 1999, INT J BIOCHEM CELL B, V31, P991, DOI 10.1016/S1357-2725(99)00065-5
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Brewer GJ, 2010, CHEM RES TOXICOL, V23, P319, DOI 10.1021/tx900338d
   Brissot P, 2010, EXPERT REV MOL DIAGN, V10, P755, DOI 10.1586/ERM.10.55
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Camaschella C, 2011, CURR OPIN PEDIATR, V23, P14, DOI 10.1097/MOP.0b013e3283425591
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   Garrick DM, 2009, BIOCHIM BIOPHYS ACTA, V1790, P309
   Garrick MD, 2011, GENES NUTR, V6, P45, DOI 10.1007/s12263-010-0184-8
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P959, DOI 10.1167/iovs.10-6207
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P109, DOI 10.1167/iovs.10-6113
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hamdi HK, 2003, FRONT BIOSCI-LANDMRK, V8, pE305, DOI 10.2741/1019
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Iolascon A, 2006, BLOOD, V107, P349, DOI 10.1182/blood-2005-06-2477
   Jomova K, 2011, TOXICOLOGY, V283, P65, DOI 10.1016/j.tox.2011.03.001
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   Kayaalti Z, 2011, MOL BIOL REP, V38, P2679, DOI 10.1007/s11033-010-0410-x
   Kelleher T, 2004, BLOOD CELL MOL DIS, V33, P35, DOI 10.1016/j.bcmd.2004.04.005
   Klein BEK, 1998, ARCH OPHTHALMOL-CHIC, V116, P219, DOI 10.1001/archopht.116.2.219
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lau LI, 2011, INVEST OPHTH VIS SCI, V52, P6832, DOI 10.1167/iovs.11-7815
   Liutkeviciene R, 2010, MEDICINA-LITHUANIA, V46, P89, DOI 10.3390/medicina46020013
   Steegmann-Olmedillas JL, 2011, CLIN TRANSL ONCOL, V13, P71, DOI 10.1007/s12094-011-0621-1
   Lukinova N, 2009, INVEST OPHTH VIS SCI, V50, P1440, DOI 10.1167/iovs.08-2545
   Mackenzie B, 2005, AM J PHYSIOL-GASTR L, V289, pG981, DOI 10.1152/ajpgi.00363.2005
   Mackenzie B, 2007, BIOCHEM J, V403, P59, DOI 10.1042/BJ20061290
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mims MP, 2005, BLOOD, V105, P1337, DOI 10.1182/blood-2004-07-2966
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Murdaugh LS, 2010, J MASS SPECTROM, V45, P1139, DOI 10.1002/jms.1795
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Pietrangelo A, 2010, GASTROENTEROLOGY, V139, P393, DOI 10.1053/j.gastro.2010.06.013
   Pons M, 2011, INVEST OPHTH VIS SCI, V52, P3842, DOI 10.1167/iovs.10-6254
   Prevent Blindness America, 2002, VIS PROBL US PREV AD, P1
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Salazar J, 2008, P NATL ACAD SCI USA, V105, P18578, DOI 10.1073/pnas.0804373105
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Shander A, 2009, VOX SANG, V97, P185, DOI 10.1111/j.1423-0410.2009.01207.x
   Sliney DH, 2002, INT J TOXICOL, V21, P501, DOI 10.1080/10915810290169927
   Stokkers PCF, 2000, INFLAMM BOWEL DIS, V6, P92, DOI 10.1097/00054725-200005000-00004
   Tazi J, 2009, BBA-MOL BASIS DIS, V1792, P14, DOI 10.1016/j.bbadis.2008.09.017
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wang D, 2011, BBA-BIOMEMBRANES, V1808, P1639, DOI 10.1016/j.bbamem.2010.11.005
   Ward AJ, 2010, J PATHOL, V220, P152, DOI 10.1002/path.2649
   Weinberg ED, 2010, METALLOMICS, V2, P732, DOI 10.1039/c0mt00023j
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Xu JZ, 2010, MECH AGEING DEV, V131, P487, DOI 10.1016/j.mad.2010.04.007
NR 65
TC 9
Z9 9
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2012
VL 250
IS 7
BP 1057
EP 1065
DI 10.1007/s00417-012-1966-z
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 964IB
UT WOS:000305686300015
PM 22371024
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Ross, AH
   Downey, L
   Devonport, H
   Gale, RP
   Kotagiri, A
   Mahmood, S
   Mehta, H
   Narendran, N
   Patel, PJ
   Parmar, N
   Jain, N
AF Ross, Adam H.
   Downey, Louise
   Devonport, Helen
   Gale, Richard P.
   Kotagiri, Ajay
   Mahmood, Sajjad
   Mehta, Hemal
   Narendran, Niro
   Patel, Praveen J.
   Parmar, Nina
   Jain, Nitin
TI Recommendations by a UK expert panel on an aflibercept treat-and-extend
   pathway for the treatment of neovascular age-related macular
   degeneration
SO EYE
LA English
DT Article
ID GROWTH-FACTOR THERAPY; REAL-WORLD OUTCOMES; ANTI-VEGF TREATMENT;
   VISUAL-ACUITY; RANIBIZUMAB; MANAGEMENT
AB Objectives This report aims to provide clear recommendations and practical guidance from a panel of UK retinal experts on an aflibercept treat-and-extend (T&E) pathway that can be implemented in clinical practice. These recommendations may help service providers across the NHS intending to implement a T&E approach, with the aim of effectively addressing the capacity and resource issues putting strain on UK neovascular age-related macular degeneration (nAMD) services while promoting patients' best interests throughout. Methods Two structured roundtable meetings of retinal specialists were held in London, UK on 7 December 2018 and 1 March 2019. These meetings were organised and funded by Bayer. Results The panel provided recommendations for an aflibercept T&E pathway and developed specific criteria based on visual acuity, retinal morphology and optical coherence tomography imaging to guide reduction, maintenance and extension of injection intervals. They also discussed the extension of treatment intervals by 2- or 4-week adjustments to a maximum treatment interval of 16 weeks, the management of retinal fluid and the stopping of treatment. Conclusions The long-term benefits of implementing a T&E pathway may include superior visual outcomes compared with a pro re nata (PRN; as needed) protocol, and a lower treatment burden compared with a fixed protocol, which is likely to improve service capacity. Furthermore, the predictable nature of a T&E approach compared with a PRN service may aid capacity planning for the future nAMD treatment demand.
C1 [Ross, Adam H.] Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England.
   [Downey, Louise] Hull Univ Teaching Hosp NHS Trust, Kingston Upon Hull, N Humberside, England.
   [Devonport, Helen] Bradford Teaching Hosp NHS Fdn Trust, Bradford, W Yorkshire, England.
   [Gale, Richard P.] York Teaching Hosp NHS Fdn Trust, York, N Yorkshire, England.
   [Kotagiri, Ajay] South Tyneside & Sunderland NHS Fdn Trust, Sunderland, England.
   [Mahmood, Sajjad] Manchester Univ NHS Fdn Trust, Manchester Royal Eye Hosp, Manchester, Lancs, England.
   [Mehta, Hemal] Royal Free London NHS Fdn Trust, London, England.
   [Narendran, Niro] Royal Wolverhampton NHS Trust, Wolverhampton, England.
   [Patel, Praveen J.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Patel, Praveen J.] UCL Inst Ophthalmol, London, England.
   [Parmar, Nina; Jain, Nitin] Bayer PLC, Reading, Berks, England.
C3 University of Bristol; Manchester Royal Eye Hospital; University of
   London; University College London; Royal Free London NHS Foundation
   Trust; University of London; University College London; Moorfields Eye
   Hospital NHS Foundation Trust; University of London; University College
   London; Bayer AG
RP Ross, AH (通讯作者)，Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England.
EM adamross@doctors.org.uk
RI Mahmood, Sajjad/AAK-7645-2021
CR Almuhtaseb H, 2017, EYE, V31, P878, DOI 10.1038/eye.2017.6
   Bayer AG, 2018, EYL 40MG ML SOL INJ
   Burton BJ, 2017, ASS RES VIS OPHTH AR
   Chew JK, 2017, OPHTHALMOLOGICA, V238, P23, DOI 10.1159/000469652
   EDNA, 2015, EARL DET NEOV AG REL
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   Gale RP, 2019, EYE, V33, DOI 10.1038/s41433-018-0300-3
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   ISRCTN registry, COMM CAR NEOV AG REL
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Lee AY, 2017, BRIT J OPHTHALMOL, V101, P1683, DOI 10.1136/bjophthalmol-2016-309818
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Ohji M, 2018, 18 EUR SOC RET SPEC
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Quartilho A, 2016, EYE, V30, P602, DOI 10.1038/eye.2015.288
   Real JP, 2015, GRAEF ARCH CLIN EXP, V253, P1859, DOI 10.1007/s00417-014-2885-y
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   The Royal College of Ophthalmologists, WAY FORW AG MAC DEG
   The Vision Academy, BIL ANT TREATM
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Wickremasinghe SS, 2012, OPHTHALMOLOGY, V119, P2413, DOI 10.1016/j.ophtha.2012.06.056
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 31
TC 18
Z9 22
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD OCT
PY 2020
VL 34
IS 10
BP 1825
EP 1834
DI 10.1038/s41433-019-0747-x
EA JAN 2020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NQ3AN
UT WOS:000508160700002
PM 31900438
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Vilkeviciute, A
   Kriauciuniene, L
   Chaleckis, R
   Deltuva, VP
   Liutkeviciene, R
AF Vilkeviciute, Alvita
   Kriauciuniene, Loresa
   Chaleckis, Romanas
   Deltuva, Vytenis Pranas
   Liutkeviciene, Rasa
TI RAD51B (rs8017304 and rs2588809), TRIB1 (rs6987702, rs4351379, and
   rs4351376), COL8A1 (rs13095226), and COL10A1 (rs1064583) Gene Variants
   with Predisposition to Age-Related Macular Degeneration
SO DISEASE MARKERS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; RISK-FACTORS; CARDIOVASCULAR-DISEASE;
   RHEUMATOID-ARTHRITIS; 5-YEAR INCIDENCE; COMMON VARIANTS; VIII COLLAGEN;
   LIPID-LEVELS; DNA-DAMAGE; EXPRESSION
AB Background. Age-related macular degeneration (AMD) is a progressive neurodegenerative disease of a central part of the neural retina (macula) and a leading cause of blindness in elderly people. While it is known that the AMD is a multifactorial disease, genetic factors involved in lipid metabolism, inflammation, and neovascularization are currently being widely studied in genome-wide association studies (GWAS). The aim of our study was to evaluate the impact of new single nucleotide polymorphisms (SNPs) in RAD51B, TRIB1, COL8A1, and COL10A1 genes on AMD development. Methods. Case-control study involved 254 patients diagnosed with early AMD, 244 patients with exudative AMD, and 942 control subjects. The genotyping of RAD51B (rs8017304 and rs2588809), TRIB1 (rs6987702, rs4351379, and rs4351376), COL8A1 (rs13095226), and COL10A1 (rs1064583) was carried out using TaqMan assays by a real-time polymerase chain reaction (RT-PCR) method. Results. Statistically significant difference was found in genotype (TT, TC, and CC) distribution of COL8A1 rs13095226 between exudative AMD and control groups (60.2%, 33.6%, and 6.1% vs. 64.9%, 32.3%, and 2.9%, respectively, p=0.036). Also, comparing with TT+TC, rs13095226 CC genotype was associated with 3.5-fold increased odds of exudative AMD development (OR=3.540; 95% CI: 1.415-8.856; p=0.007). Conclusion. Our study revealed a strong association between a variant in COL8A1 (rs13095226) and exudative AMD development.
C1 [Vilkeviciute, Alvita; Kriauciuniene, Loresa; Deltuva, Vytenis Pranas; Liutkeviciene, Rasa] Lithuanian Univ Hlth Sci, Neurosci Inst, Med Acad, Eiveniu 2, LT-50161 Kaunas, Lithuania.
   [Kriauciuniene, Loresa; Liutkeviciene, Rasa] Lithuanian Univ Hlth Sci, Dept Ophthalmol, Med Acad, Eiveniu 2, LT-50161 Kaunas, Lithuania.
   [Chaleckis, Romanas] Gunma Univ Initiat Adv Res, Maebashi, Gunma 3718512, Japan.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences
RP Vilkeviciute, A (通讯作者)，Lithuanian Univ Hlth Sci, Neurosci Inst, Med Acad, Eiveniu 2, LT-50161 Kaunas, Lithuania.
EM alvita.vilkeviciute@lsmuni.lt
RI Chaleckis, Romanas/K-2629-2014
OI Chaleckis, Romanas/0000-0001-8042-1005
FU Research Council of Lithuania [SEN-11/2015]
FX This work was funded by a grant (No. SEN-11/2015) from the Research
   Council of Lithuania.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Aung LHH, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-230
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P400, DOI [10.1111/j.1600-0420.2005.00474.x, 10.1111/j.1600-0420.2005.thesis.x]
   Burkhardt R, 2010, J CLIN INVEST, V120, P4410, DOI 10.1172/JCI44213
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Cascella Raffaella, 2018, Oncotarget, V9, P7812, DOI 10.18632/oncotarget.23241
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chapman KB, 2012, FUTURE ONCOL, V8, P1031, DOI [10.2217/fon.12.79, 10.2217/FON.12.79]
   Chu XK, 2014, AGE, V36, P1453, DOI 10.1007/s11357-014-9627-2
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Douvris A, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.000884
   Engel J, 1997, SCIENCE, V277, P1785, DOI 10.1126/science.277.5333.1785
   Ershov AV, 2000, J NEUROSCI RES, V60, P328, DOI 10.1002/(SICI)1097-4547(20000501)60:3<328::AID-JNR7>3.0.CO;2-5
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Figueroa JD, 2011, HUM MOL GENET, V20, P4693, DOI 10.1093/hmg/ddr368
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Hegedus Z, 2007, CELL SIGNAL, V19, P238, DOI 10.1016/j.cellsig.2006.06.010
   Hegele RA, 2009, HUM MOL GENET, V18, P4189, DOI 10.1093/hmg/ddp361
   HEWITT AT, 1985, CURR EYE RES, V4, P169, DOI 10.3109/02713688509000846
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Kiss-Toth E, 2004, J BIOL CHEM, V279, P42703, DOI 10.1074/jbc.M407732200
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Lin T, 2013, CYTOKINE, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Liutkeviciene R, 2019, GENE, V686, P8, DOI 10.1016/j.gene.2018.11.004
   Liutkeviciene R, 2017, GENE, V636, P30, DOI 10.1016/j.gene.2017.09.022
   McAllister K, 2013, ARTHRITIS RHEUM-US, V65, P3058, DOI 10.1002/art.38183
   McCarthy JB, 1996, BIOPOLYMERS, V40, P371, DOI 10.1002/(SICI)1097-0282(1996)40:4<371::AID-BIP3>3.3.CO;2-2
   Miller JW, 2016, INVEST OPHTH VIS SCI, V57, P6911, DOI 10.1167/iovs.16-21201
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Orr N, 2012, NAT GENET, V44, P1182, DOI 10.1038/ng.2417
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Qin HD, 2011, CANCER RES, V71, P3000, DOI 10.1158/0008-5472.CAN-10-0469
   Lamas JR, 2010, ANN RHEUM DIS, V69, P1880, DOI 10.1136/ard.2009.122564
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Ryan S. J., 2006, RETINA
   Sandor C, 2017, SCI REP-UK, V7, DOI 10.1038/srep41188
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Shu XO, 2012, CANCER RES, V72, P1182, DOI 10.1158/0008-5472.CAN-11-2561
   Singh DK, 2009, BIOGERONTOLOGY, V10, P235, DOI 10.1007/s10522-008-9205-z
   Sung HY, 2006, IMMUNOL LETT, V104, P171, DOI 10.1016/j.imlet.2005.11.010
   Suwaki N, 2011, SEMIN CELL DEV BIOL, V22, P898, DOI 10.1016/j.semcdb.2011.07.019
   Suzuki M, 2007, MOL VIS, V13, P772
   Szaflik JP, 2009, MUTAT RES-FUND MOL M, V669, P169, DOI 10.1016/j.mrfmmm.2009.06.008
   Takata M, 2000, MOL CELL BIOL, V20, P6476, DOI 10.1128/MCB.20.17.6476-6482.2000
   TAMURA Y, 1991, INVEST OPHTH VIS SCI, V32, P2636
   Thomas G, 2009, NAT GENET, V41, P579, DOI 10.1038/ng.353
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Ulas F, 2013, INT OPHTHALMOL, V33, P485, DOI 10.1007/s10792-013-9728-4
   Varga TV, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004388
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang L, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944-015-0043-0
   Waterworth DM, 2010, ARTERIOSCL THROM VAS, V30, P2264, DOI 10.1161/ATVBAHA.109.201020
   Wilson DM, 2007, DNA REPAIR, V6, P544, DOI 10.1016/j.dnarep.2006.10.017
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wozniak K, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/827562
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Xu R, 2001, BIOCHEM BIOPH RES CO, V289, P264, DOI 10.1006/bbrc.2001.5970
   Yu Y, 2015, INT J CLIN EXP PATHO, V8, P11635
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zareen N, 2013, CELL DEATH DIFFER, V20, P1719, DOI 10.1038/cdd.2013.128
   Zhi LQ, 2017, SCI REP-UK, V7, DOI 10.1038/srep45876
NR 76
TC 4
Z9 4
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0278-0240
EI 1875-8630
J9 DIS MARKERS
JI Dis. Markers
PY 2019
VL 2019
AR 5631083
DI 10.1155/2019/5631083
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine; Pathology
GA IG1RW
UT WOS:000473572800001
PM 31191752
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Minaker, SA
   Mason, RH
   Luna, GL
   Bapat, P
   Muni, RH
AF Minaker, Samuel A.
   Mason, Ryan H.
   Luna, Gabriela Lahaie
   Bapat, Priya
   Muni, Rajeev H.
TI Changes in aqueous and vitreous inflammatory cytokine levels in
   neovascular age-related macular degeneration: a systematic review and
   meta-analysis
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration; cytokines; meta-analysis; ocular
   biomarkers
ID ENDOTHELIAL GROWTH-FACTOR; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   EPITHELIUM-DERIVED FACTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1;
   INTRAVITREAL BEVACIZUMAB; HUMOR LEVELS; AFLIBERCEPT TREATMENT;
   RANIBIZUMAB TREATMENT; DIABETIC-RETINOPATHY; FACTOR VEGF
AB Inflammatory cytokines are involved in the pathogenesis of neovascular age-related macular degeneration (nAMD) and have been shown to be useful as diagnostic and predictive biomarkers. Given the heterogeneity of data within the literature, we aimed to quantitatively summarize data related to inflammatory cytokines in nAMD. A systematic search without year limitation was performed up to 13 April 2020. Studies were included if they provided data on aqueous or vitreous cytokine concentrations in patients with nAMD. Data were extracted from 95 studies that encompassed 3105 study eyes with nAMD and 1209 control eyes. Effect sizes were generated as standardized mean differences (SMDs) of cytokine concentrations between patients with nAMD and controls. Among the 4314 eyes in 95 studies, aqueous concentrations (standard mean difference, 95% confidence interval and p-value) of MCP-1 (0.43, 0.09 to 0.77 and p = 0.01), MIG (0.63, 0.31 to 0.94 and p = 0.0001), TGF-beta (0.45, 0.07 to 0.82 and p = 0.02) and VEGF (0.64, 0.31 to 0.98 and p = 0.0001) were significantly higher in patients with nAMD compared to healthy controls. No differences, failed sensitivity analyses or insufficient data were found between patients with nAMD and healthy controls for the concentrations of the remaining cytokines and with all vitreous samples. Previous studies had shown conflicting associations with nAMD for all 27 cytokines assessed. Our analysis indicates multiple candidate cytokines other than VEGF that are implicated in nAMD and adds clarity to the previous literature. This will help focus translational research in nAMD investigating biomarkers and therapeutic targets.
C1 [Minaker, Samuel A.; Mason, Ryan H.; Bapat, Priya; Muni, Rajeev H.] St Michaels Hosp, Unity Hlth Toronto, Dept Ophthalmol, Suite 801-61 Queen St East, Toronto, ON M5C 2T2, Canada.
   [Minaker, Samuel A.; Mason, Ryan H.; Bapat, Priya; Muni, Rajeev H.] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
   [Minaker, Samuel A.; Mason, Ryan H.; Bapat, Priya; Muni, Rajeev H.] Kensington Vis & Res Ctr, Toronto, ON, Canada.
   [Luna, Gabriela Lahaie] Queens Univ, Dept Ophthalmol, Kingston, ON, Canada.
C3 University of Toronto; University Toronto Affiliates; Saint Michaels
   Hospital Toronto; University of Toronto; Queens University - Canada
RP Muni, RH (通讯作者)，St Michaels Hosp, Unity Hlth Toronto, Dept Ophthalmol, Suite 801-61 Queen St East, Toronto, ON M5C 2T2, Canada.
EM rajeev.muni@gmail.com
OI Muni, Rajeev/0000-0003-0465-6472
CR Absar SF, 2012, INVEST OPHTH VIS SCI, V53, P376
   Agawa T, 2014, RETINA-J RET VIT DIS, V34, P1811, DOI 10.1097/IAE.0000000000000157
   Agrawal R, 2019, INVEST OPHTH VIS SCI, V60, P376, DOI 10.1167/iovs.18-24387
   Ahn JK, 2009, AM J OPHTHALMOL, V148, P718, DOI 10.1016/j.ajo.2009.06.012
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Baba T, 2014, CURR EYE RES, V39, P830, DOI 10.3109/02713683.2013.877935
   Bai YJ, 2014, MOL VIS, V20, P1258
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   CABRAL T, 2015, INVEST OPHTH VIS SCI, V56
   Cabral T, 2018, OPHTHALMOL RETINA, V2, P31, DOI 10.1016/j.oret.2017.04.004
   Cabral T, 2016, INVEST OPHTH VIS SCI, V57
   Cacciamani A, 2016, CURR EYE RES, V41, P971, DOI 10.3109/02713683.2015.1080282
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Campochiaro PA, 2009, OPHTHALMOLOGY, V116, P2158, DOI 10.1016/j.ophtha.2009.04.038
   Celik N, 2015, INVEST OPHTH VIS SCI, V56, P5574, DOI 10.1167/iovs.15-16418
   Cha DM, 2013, INVEST OPHTH VIS SCI, V54, P7038, DOI 10.1167/iovs.13-12730
   Chalam KV, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/502174
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P1308, DOI 10.1097/IAE.0b013e31818358b2
   Cho YG, 2011, LAB INVEST, V91, P519, DOI 10.1038/labinvest.2010.184
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Dell'Omo R, 2012, AM J OPHTHALMOL, V153, P155, DOI 10.1016/j.ajo.2011.06.001
   ECKER SM, 2014, INVEST OPHTH VIS SCI, V55
   Ecker SM, 2012, MOL VIS, V18, P1658
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   Fauser S, 2016, BRIT J OPHTHALMOL, V100, P1494, DOI 10.1136/bjophthalmol-2015-308264
   Fauser S, 2015, ACTA OPHTHALMOL, V93, P734, DOI 10.1111/aos.12770
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Fayzrakhmanov R, 2015, CYTOKINE PROFILE AQU
   Feng J, 2018, INT J CLIN EXP MED, V11, P7270
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Gadde SGKGK, 2017, INVEST OPHTH VIS SCI, V58
   GHOSH A, 2017, INVEST OPHTH VIS SCI, V58
   Glaser BM, 2014, INVEST OPHTH VIS SCI, V55
   Hata M, 2017, RETINA-J RET VIT DIS, V37, P1320, DOI 10.1097/IAE.0000000000001370
   Hayden JA, 2006, ANN INTERN MED, V144, P427, DOI 10.7326/0003-4819-144-6-200603210-00010
   HINES JC, 2014, INVEST OPHTH VIS SCI, V55
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Hsu MY, 2016, SCI REP-UK, V6, DOI 10.1038/srep34631
   Huber M, 2012, OPHTHALMOLOGICA, V228, P188, DOI 10.1159/000339952
   Jonas JB, 2007, OPHTHAL RES, V39, P139, DOI 10.1159/000102935
   Jonas JB, 2007, CLIN EXP OPHTHALMOL, V35, P186, DOI 10.1111/j.1442-9071.2006.01437.x
   Jonas JB, 2018, LANCET, V392, P86
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   KATO Y, 2019, INVEST OPHTH VIS SCI, V60
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kim JH, 2018, RETINA-J RET VIT DIS, V38, P523, DOI 10.1097/IAE.0000000000001554
   Kim TW, 2012, J PROTEOME RES, V11, P4034, DOI 10.1021/pr300080s
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kramer M, 2012, CLIN EXP OPHTHALMOL, V40, P617, DOI 10.1111/j.1442-9071.2011.02747.x
   Kreissig I, 2010, INVEST OPHTH VIS SCI, V51
   Kuiper JJW, 2017, SCI REP-UK, V7, DOI 10.1038/srep41595
   Liu F, 2016, MOL VIS, V22, P352
   Madhusudhana KC, 2016, BRIT J OPHTHALMOL, V100, P1617, DOI 10.1136/bjophthalmol-2015-308077
   Manresa N, 2015, RETINA-J RET VIT DIS, V35, P1765, DOI 10.1097/IAE.0000000000000552
   Meacock WR, 2000, BRIT J OPHTHALMOL, V84, P332, DOI 10.1136/bjo.84.3.332
   Mehrad B, 2007, THROMB HAEMOSTASIS, V97, P755, DOI 10.1160/TH07-01-0040
   Mesquita J, 2018, GROWTH FACTORS, V36, P48, DOI 10.1080/08977194.2018.1477140
   Miao H, 2012, MOL VIS, V18, P574
   Mimura T, 2019, OPHTHALMOLOGICA, V241, P81, DOI 10.1159/000490153
   Minaker SA, 2019, J VITREORETINAL DIS, V4, P36
   Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b4037, 10.1371/journal.pmed.1000097]
   Motohashi R, 2018, J INFLAMM-LOND, V15, DOI 10.1186/s12950-018-0203-x
   Motohashi R, 2018, INVEST OPHTH VIS SCI, V59
   Motohashi R, 2017, OPHTHALMIC RES, V58, P209, DOI 10.1159/000478705
   Muether PS, 2013, AM J OPHTHALMOL, V156, P989, DOI 10.1016/j.ajo.2013.06.020
   Muether PS, 2013, RETINA-J RET VIT DIS, V33, P1809, DOI 10.1097/IAE.0b013e318285cd9e
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Nagaraj S, 2016, INVEST OPHTH VIS SCI, V57
   Ng DS, 2017, SCI REP-UK, V7, DOI 10.1038/srep45081
   Nielsen MK, 2019, ACTA OPHTHALMOL, V97, P84, DOI 10.1111/aos.13894
   Nogoceke E, 2016, INVEST OPHTH VIS SCI, V57
   Nomura Y, 2016, GRAEF ARCH CLIN EXP, V254, P53, DOI 10.1007/s00417-015-3006-2
   PARK DH, 2017, INVEST OPHTH VIS SCI, V58
   Pongsachareonnont P, 2018, CLIN OPHTHALMOL, V12, P1877, DOI 10.2147/OPTH.S171636
   Pongsachareonnont P, 2017, INVEST OPHTH VIS SCI, V58
   Qin XY, 2016, JAMA NEUROL, V73, P1316, DOI 10.1001/jamaneurol.2016.2742
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Rezende FA, 2014, AM J OPHTHALMOL, V158, P1071, DOI 10.1016/j.ajo.2014.07.036
   Roh MI, 2010, GRAEF ARCH CLIN EXP, V248, P635, DOI 10.1007/s00417-009-1254-8
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Sakamoto S, 2018, BRIT J OPHTHALMOL, V102, P448, DOI 10.1136/bjophthalmol-2017-310284
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Sato S, 2015, INVEST OPHTH VIS SCI, V56
   SATO T, 2018, INVEST OPHTH VIS SCI, V59
   SATO T, 2019, INVEST OPHTH VIS SCI, V60
   Sato T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55191-x
   Sato T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19594-6
   Saunders DJ, 2015, BRIT J OPHTHALMOL, V99, P1554, DOI 10.1136/bjophthalmol-2015-306771
   Sawada O, 2010, RETINA-J RET VIT DIS, V30, P1034, DOI 10.1097/IAE.0b013e3181ce74c8
   Sawada T, 2018, CLIN EXP OPHTHALMOL, V46, P46, DOI 10.1111/ceo.13002
   Schori C, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.18-24122
   Shchuko AG, 2014, OPHTHALMOLOGICA, V232, P29
   Sitnilska V, 2019, OPHTHALMOLOGICA, V241, P154, DOI 10.1159/000492924
   Spindler J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203337
   Sung HJ, 2012, MOL VIS, V18, P234
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   TAKAHASHI H, 2013, INVEST OPHTH VIS SCI, V54
   Takahashi H, 2016, INVEST OPHTH VIS SCI, V57, P462, DOI 10.1167/iovs.15-18245
   Takahashi S, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/4256183
   ten Berge JC, 2019, ACTA OPHTHALMOL, V97, P185, DOI 10.1111/aos.13899
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tosi GM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113363
   Tosi GM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26442-0
   Tosi GM, 2017, J CELL PHYSIOL, V232, P1767, DOI 10.1002/jcp.25689
   Wakshull E, 2018, INVEST OPHTH VIS SCI, V59
   Wang HB, 2016, MOL VIS, V22, P189
   Warwick A, 2018, EYE, V32, P849, DOI 10.1038/eye.2017.245
   Wei X, 2018, INVEST OPHTH VIS SCI, V59
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yi QY, 2020, ACTA OPHTHALMOL, V98, pE309, DOI 10.1111/aos.14248
   Yuan JS, 2019, EXP THER MED, V17, P4249, DOI 10.3892/etm.2019.7427
   Zandi S, 2016, INVEST OPHTH VIS SCI, V57, P6320, DOI 10.1167/iovs.16-20657
   Zapata MA, 2010, INVEST OPHTH VIS SCI, V51
   Zhao M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125150
   Zhou HY, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-019-1278-8
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
NR 124
TC 5
Z9 5
U1 1
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2021
VL 99
IS 2
BP 134
EP 155
DI 10.1111/aos.14537
EA JUN 2020
PG 22
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QT2FQ
UT WOS:000544006100001
PM 32602185
DA 2022-11-30
ER

PT J
AU Dawson, SR
   Mallen, CD
   Gouldstone, MB
   Yarham, R
   Mansell, G
AF Dawson, Sarah R.
   Mallen, Christian D.
   Gouldstone, Matthew B.
   Yarham, Robert
   Mansell, Gemma
TI The prevalence of anxiety and depression in people with age-related
   macular degeneration: a systematic review of observational study data
SO BMC OPHTHALMOLOGY
LA English
DT Review
DE Macular degeneration; Depression; Anxiety; Prevalence; Epidemiology
ID QUALITY-OF-LIFE; RESOURCE UTILIZATION; OLDER-PEOPLE; DISABILITY; BURDEN;
   DISORDERS; SYMPTOMS; ILLNESS; VISION; VALIDITY
AB Background: Comorbid mental health problems have been shown to have an adverse effect on the quality of life of people with common eye disorders. This study aims to assess whether symptoms of anxiety and/or depression are more prevalent in people with age-related macular degeneration (AMD) than in people without this condition.
   Methods: A systematic search of electronic databases (Medline, CINAHL, EMBASE, PsycINFO) from inception to February 2012 was conducted to identify studies of AMD populations which measured symptoms of anxiety and/or depression. Reference checking of relevant articles was also performed. Data on the study setting, prevalence and how anxiety and depression were measured were extracted from the papers. Critical appraisal was performed using the Critical Appraisal Skills Programme (CASP) tools.
   Results: A total of 16 papers were included in the review, from an original search result of 597. The prevalence estimates, taken from nine cross-sectional and cohort studies, ranged from 15.7%-44% for depressive symptoms and 9.6%-30.1% for anxiety symptoms in people with AMD. The seven case-control studies found that people with AMD were more likely to experience symptoms of depression compared with those without AMD, but not more likely to experience symptoms of anxiety.
   Conclusions: Overall, the evidence suggests that symptoms of depression are more prevalent amongst AMD populations than anxiety symptoms. The heterogeneity of the studies included in this review means that it is difficult to draw strong conclusions as to the true estimates of depression and anxiety symptoms in AMD populations and prevented formal meta-analysis. Further research which specifies clinical anxiety and gives clear definitions as to the type of AMD being investigated is required.
C1 [Dawson, Sarah R.; Mallen, Christian D.; Gouldstone, Matthew B.; Yarham, Robert; Mansell, Gemma] Keele Univ, Arthrit Res UK Primary Care Ctr, Keele ST5 5BG, Staffs, England.
C3 Keele University
RP Mallen, CD (通讯作者)，Keele Univ, Arthrit Res UK Primary Care Ctr, Keele ST5 5BG, Staffs, England.
EM c.d.mallen@keele.ac.uk
OI Mansell, Gemma/0000-0002-5479-2678
FU Arthritis Research UK Clinician Scientist Award; Versus Arthritis
   [19634] Funding Source: researchfish
FX CDM is funded by an unrestricted Arthritis Research UK Clinician
   Scientist Award. The authors would like to thank Jo Jordan for her
   contribution to the search strategy used in this review and her guidance
   on systematic review methodology, and the reviewers for their helpful
   comments on the content of this manuscript.
CR Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Beekman ATF, 1997, PSYCHOL MED, V27, P231, DOI 10.1017/S0033291796003510
   Bowler GS, 2011, BR J OPHTHALMOL, V95, P308
   Brenes Gretchen A, 2007, Prim Care Companion J Clin Psychiatry, V9, P437
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Casten RJ, 2002, J VISUAL IMPAIR BLIN, V96, P399, DOI 10.1177/0145482X0209600603
   Casten R, 2010, ARCH OPHTHALMOL-CHIC, V128, P506, DOI 10.1001/archophthalmol.2010.24
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Colquitt J, 2006, PEGAPTANIB RANIBIZUM
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Godlee F, 2012, BMJ-BRIT MED J, V344, pe3162
   GOLDBERG D, 1988, BRIT MED J, V297, P897, DOI 10.1136/bmj.297.6653.897
   Keller BK, 1999, J AM GERIATR SOC, V47, P1319, DOI 10.1111/j.1532-5415.1999.tb07432.x
   King M, 2008, BRIT J PSYCHIAT, V192, P362, DOI 10.1192/bjp.bp.107.039966
   KLEINSCHMIDT JJ, 1995, J HLTH ED, V26, P26, DOI DOI 10.1080/10556699.1995.10603073
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Mathew RS, 2011, OPHTHAL PHYSL OPT, V31, P375, DOI 10.1111/j.1475-1313.2011.00848.x
   Mental Health Foundation, MENT HLTH STAT MOST
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Popescu ML, 2012, INVEST OPHTH VIS SCI, V53, P2308, DOI 10.1167/iovs.11-9330
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rovner BW, 1996, J AM GERIATR SOC, V44, P181, DOI 10.1111/j.1532-5415.1996.tb02436.x
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Rovner BW, 2001, J AM GERIATR SOC, V49, P1097, DOI 10.1046/j.1532-5415.2001.49215.x
   Roy-Byrne PP, 2008, GEN HOSP PSYCHIAT, V30, P208, DOI 10.1016/j.genhosppsych.2007.12.006
   Ruiz-Moreno JM, 2008, CURR MED RES OPIN, V24, P2103, DOI [10.1185/03007990802214300 , 10.1185/03007990802214300]
   Sareen J, 2006, ARCH INTERN MED, V166, P2109, DOI 10.1001/archinte.166.19.2109
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Sun C, 2007, OPHTHAL EPIDEMIOL, V14, P127, DOI 10.1080/09286580601186742
   Wysong A, 2009, ARCH OPHTHALMOL-CHIC, V127, P320, DOI 10.1001/archophthalmol.2008.613
   YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4
   Zhang XZ, 2013, JAMA OPHTHALMOL, V131, P573, DOI 10.1001/jamaophthalmol.2013.2597
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 38
TC 52
Z9 53
U1 0
U2 21
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUN 12
PY 2014
VL 14
AR 78
DI 10.1186/1471-2415-14-78
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA AL0BD
UT WOS:000338791400001
PM 24923726
OA Green Published, gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Fong, KCS
   Kirkpatrick, N
   Mohamed, Q
   Johnston, RL
AF Fong, Kenneth C. S.
   Kirkpatrick, Nigel
   Mohamed, Quresh
   Johnston, Robert L.
TI Intravitreal bevacizumab (Avastin) for neovascular age-related macular
   degeneration using a variable frequency regimen in eyes with no previous
   treatment
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; bevacizumab; prognostic factors
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB
   LUCENTIS; PHOTODYNAMIC THERAPY; SHORT-TERM; PHARMACOKINETICS; SECONDARY
AB To evaluate a variable frequency regimen with intravitreal bevacizumab for treatment of neovascular age-related macular degeneration (AMD) in eyes that have not received any previous treatment.
   Retrospective review of patients with neovascular AMD who were treated with three consecutive monthly intravitreal injections of bevacizumab (1.25 mg) and retreated based on the PrONTO study criteria. Outcome measures included visual acuity (VA) and central retinal thickness. Subgroup analysis was conducted to identify pretreatment characteristics that could determine visual outcome with treatment.
   A total of 109 eyes of 109 patients were treated. The mean age was 82 years, and the mean follow-up period was 9.4 months (range 6-12 months). At baseline, the mean VA was 45.6 letters (6/37.5) and mean central retinal thickness 343 mu m. This improved to 51 letters (6/30) (P < 0.001)) and 231 mu m (P < 0.001) at 6 months. At 6 months, VA was improved by at least five letters in 50%, remained stable in 30% and worsened by at least five letters in 20% of patients. Patients with large intraretinal cysts on optical coherence tomography before treatment had an increased risk of worse vision (odds ratio 10.5, 95% confidence interval 1.69-64.99; P = 0.018).
   The majority of patients had improvement or stability of VA regardless of the angiographic type of choroidal neovascularization. Intravitreal bevacizumab with this tailored regimen is beneficial in the treatment of neovascular AMD in the short term. The presence of large intraretinal cysts on optical coherence tomography is a poor prognostic factor for visual improvement with this treatment.
C1 [Fong, Kenneth C. S.; Kirkpatrick, Nigel; Mohamed, Quresh; Johnston, Robert L.] Cheltenham Gen Hosp, Dept Ophthalmol, Cheltenham GL53 7AN, Glos, England.
C3 Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General
   Hospital
RP Fong, KCS (通讯作者)，Cheltenham Gen Hosp, Dept Ophthalmol, Sandford Rd, Cheltenham GL53 7AN, Glos, England.
EM fongcsk@yahoo.co.uk
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan A, 2005, ARCH OPHTHALMOL-CHIC, V123, P939, DOI 10.1001/archopht.123.7.939
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sahni J, 2005, BRIT J OPHTHALMOL, V89, P316, DOI 10.1136/bjo.2004.043364
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stone EM, 2006, NEW ENGL J MED, V355, P1493, DOI 10.1056/NEJMe068191
   Van de Moere A, 2006, BRIT J OPHTHALMOL, V90, P304, DOI 10.1136/bjo.2005.079947
NR 18
TC 24
Z9 27
U1 0
U2 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1442-6404
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD NOV
PY 2008
VL 36
IS 8
BP 748
EP 755
DI 10.1111/j.1442-9071.2008.01873.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 389OX
UT WOS:000262105500011
PM 19128380
DA 2022-11-30
ER

PT J
AU Manku, KK
   Rotchford, A
   Whitaker, J
   Amoaku, WM
AF Manku, Kiran K.
   Rotchford, Alan
   Whitaker, John
   Amoaku, Winfried M.
TI Factors influencing poor visual outcome in patients treated with
   photodynamic therapy for choroidal neovascularization secondary to
   age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   photodynamic therapy; Verteporfin
ID RANDOMIZED CLINICAL-TRIALS; VERTEPORFIN THERAPY; LESION SIZE; TAP;
   ACUITY; IMPACT
AB Background: This study evaluated patients with choroidal neovascular membranes secondary to age-related macular degeneration for factors that may predict the visual outcome after photodynamic therapy.
   Methods:A retrospective review of 172 eyes of 172 consecutive patients who received photodynamic therapy for predominantly classic with and without occult, minimally classic and occult choroidal neovascular membranes secondary to macular degeneration in private practice from June 2000 to September 2004 was undertaken. All eyes had a baseline vision of 6/12 to 6/60. Classification of lesion composition, retreatment and follow up adhered to published photodynamic therapy guidelines. The primary outcomes measured were effects of patient age, baseline visual acuity, lesion composition and lesion size on final visual acuity and loss of less than 15 letters of logMAR at 12 months.
   Results: All eyes were followed up for 12 months. Baseline mean logMAR visual acuity was logMAR 0.64. Using multivariate logistic regression, loss of logMAR vision at 12 months was independently associated with increasing age (P = 0.004), better baseline vision (P = 0.009) and increasing lesion size (P = 0.035). However, there was no association with lesion composition (P = 0.16). At 12 months the loss of 15 letters or less was found in 101 (59.7%; 95% confidence interval: 51.0-66.2%) of all patients.
   Conclusions: This study found no statistically significant association between lesion composition defined on fluorescein angiography and loss of visual acuity compared with previous studies. Factors associated with an increased rate of loss of 15 letters were increasing age of the patient, increasing lesion size and better baseline logMAR vision.
C1 Queens Med Ctr, Nottingham NG7 2UH, England.
C3 University of Nottingham
RP Manku, KK (通讯作者)，Unit 3-7 Lambton Rd, Broadmeadows, NSW 2290, Australia.
EM ravkiran@optusnet.com.au
OI Amoaku, Winfried/0000-0001-5028-7984
CR [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Arias L, 2005, BRIT J OPHTHALMOL, V89, P312, DOI 10.1136/bjo.2004.050997
   Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Barnes RM, 2004, EYE, V18, P809, DOI 10.1038/sj.eye.6701329
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Buggage RR, 1999, ARCH OPHTHALMOL-CHIC, V117, P1239
   *NAT I CLIN EXC, FIN APPR DET PHOT TH
NR 14
TC 6
Z9 7
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD MAY-JUN
PY 2007
VL 35
IS 4
BP 330
EP 334
DI 10.1111/j.1442-9071.2007.01482.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 172GC
UT WOS:000246791100007
PM 17539784
DA 2022-11-30
ER

PT J
AU Morrison, MA
   Magalhaes, TR
   Ramke, J
   Smith, SE
   Ennis, S
   Simpson, CL
   Portas, L
   Murgia, F
   Ahn, J
   Dardenne, C
   Mayne, K
   Robinson, R
   Morgan, DJ
   Brian, G
   Lee, L
   Woo, SJ
   Zacharaki, F
   Tsironi, EE
   Miller, JW
   Kim, IK
   Park, KH
   Bailey-Wilson, JE
   Farrer, LA
   Stambolian, D
   DeAngelis, MM
AF Morrison, Margaux A.
   Magalhaes, Tiago R.
   Ramke, Jacqueline
   Smith, Silvia E.
   Ennis, Sean
   Simpson, Claire L.
   Portas, Laura
   Murgia, Federico
   Ahn, Jeeyun
   Dardenne, Caitlin
   Mayne, Katie
   Robinson, Rosann
   Morgan, Denise J.
   Brian, Garry
   Lee, Lucy
   Woo, Se J.
   Zacharaki, Fani
   Tsironi, Evangelia E.
   Miller, Joan W.
   Kim, Ivana K.
   Park, Kyu H.
   Bailey-Wilson, Joan E.
   Farrer, Lindsay A.
   Stambolian, Dwight
   DeAngelis, Margaret M.
TI Ancestry of the Timorese: age-related macular degeneration associated
   genotype and allele sharing among human populations from throughout the
   world
SO FRONTIERS IN GENETICS
LA English
DT Article
ID FACTOR-H POLYMORPHISM; Y-CHROMOSOME; GENETIC SUSCEPTIBILITY;
   MITOCHONDRIAL-DNA; EAST-ASIA; RISK; PREVALENCE; DIVERSITY; COMMON; EYE
AB We observed that the third leading cause of blindness in the world, age-related macular degeneration (AMD), occurs at a very low documented frequency in a population-based cohort from Timor-Leste. Thus, we determined a complete catalog of the ancestry of the Timorese by analysis of whole exome chip data and haplogroup analysis of SNP genotypes determined by sequencing the Hypervariable I and II regions of the mitochondrial genome and 17 genotyped YSTR markers obtained from 535 individuals. We genotyped 20 previously reported AMD-associated SNPs in the Timorese to examine their allele frequencies compared to and between previously documented AMD cohorts of varying ethnicities. For those without AMD (average age > 55 years), genotype and allele frequencies were similar for most SNPs with a few exceptions. The major risk allele of HTRA1 rs11200638 (10q26) was at a significantly higher frequency in the Timorese, as well as 3 of the 5 protective CFH (1q32) SNPs (rs800292, rs2284664, and rs12066959). Additionally, the most commonly associated AMD-risk SNP, CFH rs1061170 (Y402H), was also seen at a much lower frequency in the Korean and Timorese populations than in the assessed Caucasian populations (C similar to 7 vs. similar to 40%, respectively). The difference in allele frequencies between the Timorese population and the other genotyped populations, along with the haplogroup analysis, also highlight the genetic diversity of the Timorese. Specifically, the most common ancestry groupings were Oceanic (Melanesian and Papuan) and Eastern Asian (specifically Han Chinese). The low prevalence of AMD in the Timorese population (2 of 535 randomly selected participants) may be due to the enrichment of protective alleles in this population at the 1q32 locus.
C1 [Morrison, Margaux A.; Smith, Silvia E.; Dardenne, Caitlin; Mayne, Katie; Robinson, Rosann; Morgan, Denise J.; DeAngelis, Margaret M.] Univ Utah, Ophthalmol & Visual Sci, John A Moran Eye Ctr, Salt Lake City, UT 84132 USA.
   [Magalhaes, Tiago R.] Our Ladys Children Hosp, Natl Childrens Res Ctr, Dublin, Ireland.
   [Magalhaes, Tiago R.; Ennis, Sean] Univ Coll Dublin, Acad Ctr Rare Dis, Sch Med & Med Sci, Dublin 2, Ireland.
   [Ramke, Jacqueline; Brian, Garry; Lee, Lucy] Fred Hollows Fdn New Zealand, Auckland, New Zealand.
   [Ennis, Sean] Our Ladys Children Hosp, Natl Ctr Med Genet, Dublin, Ireland.
   [Simpson, Claire L.; Portas, Laura; Murgia, Federico; Bailey-Wilson, Joan E.] NHGRI, Computat & Stat Genom Branch, NIH, Baltimore, MD USA.
   [Portas, Laura; Murgia, Federico] CNR, Inst Populat Genet, Sassari, Italy.
   [Ahn, Jeeyun; Woo, Se J.; Park, Kyu H.] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
   [Ahn, Jeeyun] Seoul Natl Univ, Seoul Metropolitan Govt, Dept Ophthalmol, Boramae Med Ctr, Seoul, South Korea.
   [Lee, Lucy] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Woo, Se J.; Park, Kyu H.] Seoul Natl Univ, Dept Ophthalmol, Bundang Hosp, Songnam, South Korea.
   [Zacharaki, Fani; Tsironi, Evangelia E.] Univ Thessaly, Sch Med, Dept Ophthalmol, Larisa, Greece.
   [Miller, Joan W.; Kim, Ivana K.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv & Ophthalmol, Boston, MA USA.
   [Farrer, Lindsay A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
   [Farrer, Lindsay A.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
   [Farrer, Lindsay A.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
   [Farrer, Lindsay A.] Harvard Univ, Sch Med, Boston, MA USA.
   [Farrer, Lindsay A.] Harvard Univ, Sch Med, Dept Biostat, Boston, MA USA.
   [Farrer, Lindsay A.] Harvard Univ, Sch Publ Hlth, Dept Med, Boston, MA 02115 USA.
   [Farrer, Lindsay A.] Harvard Univ, Sch Publ Hlth, Dept Ophthalmol, Boston, MA 02115 USA.
   [Farrer, Lindsay A.] Harvard Univ, Sch Publ Hlth, Dept Neurol, Boston, MA 02115 USA.
   [Farrer, Lindsay A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Farrer, Lindsay A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Stambolian, Dwight] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 Utah System of Higher Education; University of Utah; National Children's
   Research Centre (NCRC); Trinity College Dublin; University College
   Dublin; National Children's Research Centre (NCRC); National Institutes
   of Health (NIH) - USA; NIH National Human Genome Research Institute
   (NHGRI); NIH National Institute on Aging (NIA); Consiglio Nazionale
   delle Ricerche (CNR); Seoul National University (SNU); Seoul National
   University (SNU); Seoul National University Hospital; University of
   London; London School of Hygiene & Tropical Medicine; Seoul National
   University (SNU); University of Thessaly; Harvard University; Harvard
   Medical School; Massachusetts Eye & Ear Infirmary; Harvard University;
   Harvard Medical School; Harvard University; Harvard Medical School;
   Harvard University; Harvard Medical School; Harvard University; Harvard
   Medical School; Harvard University; Harvard Medical School; Harvard
   University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard T.H. Chan School of Public Health; University of
   Pennsylvania
RP DeAngelis, MM (通讯作者)，Univ Utah, Sch Med, John A Moran Eye Ctr, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM margaret.deangelis@utah.edu
RI DeAngelis, e/J-7863-2015; Ramke, Jacqueline/I-8844-2019; Farrer,
   Lindsay/AAS-1035-2020
OI Ramke, Jacqueline/0000-0002-5764-1306; Ahn, Jeeyun/0000-0001-9017-1652;
   Portas, Laura/0000-0003-1789-1893; Farrer, Lindsay/0000-0001-5533-4225;
   R Magalhaes, Tiago/0000-0002-5528-2119; Bailey-Wilson,
   Joan/0000-0002-9153-2920; Simpson, Claire/0000-0003-2244-7690; Kim,
   Ivana/0000-0003-0310-6129; Ennis, Sean/0000-0002-4330-1386; Murgia,
   Federico/0000-0002-3608-845X
FU NATIONAL EYE INSTITUTE [P30EY001583] Funding Source: NIH RePORTER;
   NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG200327] Funding Source:
   NIH RePORTER; NEI NIH HHS [R01 EY020483, R01 EY014458, P30 EY014800, P30
   EY001583] Funding Source: Medline
CR Alexander DH, 2009, GENOME RES, V19, P1655, DOI 10.1101/gr.094052.109
   Altshuler DM, 2010, NATURE, V467, P52, DOI 10.1038/nature09298
   Cann HM, 2002, SCIENCE, V296, P261
   CAVALLISFORZA LL, 1991, GENOMICS, V11, P490, DOI 10.1016/0888-7543(91)90169-F
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   DeAngelis MM, 2004, ARCH OPHTHALMOL-CHIC, V122, P575, DOI 10.1001/archopht.122.4.575
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Herraez DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007888
   Hill C, 2007, AM J HUM GENET, V80, P29, DOI 10.1086/510412
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hurles ME, 2005, AM J HUM GENET, V76, P894, DOI 10.1086/430051
   Jun GG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025775
   Karafet TM, 2010, MOL BIOL EVOL, V27, P1833, DOI 10.1093/molbev/msq063
   Kayser M, 2003, AM J HUM GENET, V72, P281, DOI 10.1086/346065
   Kayser M, 2001, AM J HUM GENET, V68, P173, DOI 10.1086/316949
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li JZ, 2008, SCIENCE, V319, P1100, DOI 10.1126/science.1153717
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Magalhaes TR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049438
   Melton T, 1998, AM J HUM GENET, V63, P1807, DOI 10.1086/302131
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mona S, 2009, MOL BIOL EVOL, V26, P1865, DOI 10.1093/molbev/msp097
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Nonyane BAS, 2010, INVEST OPHTH VIS SCI, V51, P2393, DOI 10.1167/iovs.09-4228
   Patterson N, 2006, PLOS GENET, V2, P2074, DOI 10.1371/journal.pgen.0020190
   Pluzhnikov A, 2008, GENET EPIDEMIOL, V32, P676
   Pluzhnikov A, 2010, AM J HUM GENET, V87, P123, DOI 10.1016/j.ajhg.2010.06.005
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Ramke J, 2012, OPHTHAL EPIDEMIOL, V19, P52, DOI 10.3109/09286586.2011.645108
   Rosenberg NA, 2005, PLOS GENET, V1, P660, DOI 10.1371/journal.pgen.0010070
   Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311
   Schaumberg DA, 2010, ARCH OPHTHALMOL-CHIC, V128, P1462, DOI 10.1001/archophthalmol.2010.261
   Shtir CJ, 2009, BMC GENET, V10, DOI 10.1186/1471-2156-10-71
   Silveira AC, 2010, VISION RES, V50, P698, DOI 10.1016/j.visres.2009.09.016
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Souto L, 2006, FORENSIC SCI INT, V156, P261, DOI 10.1016/j.forsciint.2005.02.015
   Stoneking M, 2010, CURR BIOL, V20, pR188, DOI 10.1016/j.cub.2009.11.052
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tabbada KA, 2010, MOL BIOL EVOL, V27, P21, DOI 10.1093/molbev/msp215
   Tishkoff SA, 2009, SCIENCE, V324, P1035, DOI 10.1126/science.1172257
   Tumonggor MK, 2014, J HUM GENET, V59, P494, DOI 10.1038/jhg.2014.62
   van Oven M, 2012, J HUM GENET, V57, P65, DOI 10.1038/jhg.2011.120
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
   Zhong H, 2011, MOL BIOL EVOL, V28, P717, DOI 10.1093/molbev/msq247
   Ziskind A, 2008, OPHTHALMIC GENET, V29, P117, DOI 10.1080/13816810802216472
NR 62
TC 7
Z9 7
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD JUL 9
PY 2015
VL 6
AR 238
DI 10.3389/fgene.2015.00238
PG 11
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA CP1QW
UT WOS:000359651300001
PM 26217379
OA gold, Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Eton, EA
   Wubben, TJ
   Besirli, CG
   Wang, SY
AF Eton, Emily A.
   Wubben, Thomas J.
   Besirli, Cagri G.
   Wang, Sophia Y.
TI Association of Ocular Antihypertensive Medications and the Development
   and Progression of Age-related Macular Degeneration in a US Insurance
   Claims Database
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; ocular antihypertensives; primary
   open-angle glaucoma
ID TOPICAL DORZOLAMIDE; RACIAL-DIFFERENCES; GLOBAL PREVALENCE;
   GROWTH-FACTOR; MACULOPATHY; GLAUCOMA; BURDEN; RISK
AB Purpose/Aim: To assess whether ocular antihypertensives are associated with the development and progression of age-related macular degeneration (AMD).
   Materials and Methods: This retrospective, observational cohort study using healthcare claims data from a U.S. nationwide managed-care network between January 1, 2006 and December 31, 2016, included enrollees >= 40 years old with primary open-angle glaucoma with or without a diagnosis of nonexudative AMD at the index date. Hazard ratios (HR) for developing AMD or progressing from nonexudative to exudative AMD with exposure to ocular antihypertensive medications were analyzed.
   Results: Of 132 963 eligible enrollees, 118 174 (87.5%) had no diagnosis of AMD at baseline while 14 789 (12.5%) had adiagnosis of nonexudative AMD. Prostaglandin analog exposure had adecreased hazard of developing AMD among individuals without baseline disease (HR, 0.90; 95% CI, 0.87-0.94; p< .0001), while topical alpha(2)-agonist exposure demonstrated an increased hazard of AMD development (HR, 1.08; 95% CI, 1.03-1.14; p= .004). Among patients with baseline nonexudative AMD, topical carbonic anhydrase inhibitor exposure was associated with adecreased hazard of progressing to exudative disease (HR, 0.84; 95% CI, 0.71-0.99; p= .04) while topical alpha(2)-agonists had increased hazard (HR, 1.17; 95% CI, 1.01-1.36; p= .04).
   Conclusions: Certain ocular antihypertensive medications may be associated with development or progression of AMD. Their role in AMD pathogenesis should be better understood as they are considered for therapeutics in this disease.
C1 [Eton, Emily A.; Wubben, Thomas J.; Besirli, Cagri G.] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   [Wang, Sophia Y.] Stanford Univ, Byers Eye Inst, Dept Ophthalmol, Palo Alto, CA 94303 USA.
C3 University of Michigan System; University of Michigan; Stanford
   University
RP Wang, SY (通讯作者)，Stanford Univ, Byers Eye Inst, Palo Alto, CA 94303 USA.
EM sywang@stanford.edu
OI Wang, Sophia/0000-0003-0916-9403; Besirli, Cagri/0000-0001-7154-2024;
   Eton, Emily/0000-0003-4212-7184
FU NEI NIH HHS [P30 EY007003, P30 EY026877, K08 EY031757] Funding Source:
   Medline
CR Adijanto J, 2012, CURR TOP MEMBR, V70, P275, DOI 10.1016/B978-0-12-394316-3.00009-0
   [Anonymous], ALL AS EFF STUD BRIM
   Augustin AJ, 2013, EXPERT OPIN INV DRUG, V22, P803, DOI 10.1517/13543784.2013.794782
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Chakravarthy U, 2018, OPHTHALMOLOGY, V125, P842, DOI 10.1016/j.ophtha.2017.11.036
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Danesh-Meyer HV, 2011, CURR OPIN OPHTHALMOL, V22, P78, DOI 10.1097/ICU.0b013e32834372ec
   Freeman WR, 2018, AAO ANN M RET SUBSP
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Genead MA, 2010, ARCH OPHTHALMOL-CHIC, V128, P190, DOI 10.1001/archophthalmol.2009.398
   Grover S, 2006, AM J OPHTHALMOL, V141, P850, DOI 10.1016/j.ajo.2005.12.030
   Grunwald JE, 1998, INVEST OPHTHALMOL VI, V39
   Han JYS, 2020, FASEB J, V34, P5401, DOI 10.1096/fj.201902961R
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hsu J, 2020, JAMA OPHTHALMOL, V138, P560, DOI 10.1001/jamaophthalmol.2020.0724
   Hu CC, 2017, EYE, V31, P872, DOI 10.1038/eye.2016.325
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kingman S., 2004, B WHO, V82
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, DOI [10.1001/archopht.117.9.1203, DOI 10.1001/ARCHOPHT.117.9.1203]
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kolomeyer AM, 2019, RETINA-J RET VIT DIS, V39, P918, DOI 10.1097/IAE.0000000000002059
   Lee JH, 2019, RETINA-J RET VIT DIS, V39, P1953, DOI 10.1097/IAE.0000000000002293
   Maralani HG, 2015, RETINA-J RET VIT DIS, V35, P459, DOI 10.1097/IAE.0000000000000338
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Polska E, 2002, ARCH OPHTHALMOL-CHIC, V120, P348
   Saylor M, 2009, ARCH OPHTHALMOL-CHIC, V127, P402, DOI 10.1001/archophthalmol.2009.9
   Scherer WJ, 2006, J OCUL PHARMACOL TH, V22, P139, DOI 10.1089/jop.2006.22.139
   Scott WK, 2007, OPHTHALMOLOGY, V114, P1151, DOI 10.1016/j.ophtha.2006.08.054
   Sridhar J, 2016, JAMA OPHTHALMOL, V134, P437, DOI 10.1001/jamaophthalmol.2016.0045
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wen R, 1996, J NEUROSCI, V16, P5986
   WoldeMussie E, 2001, INVEST OPHTHALMOL VI, V42
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization (WHO), 2018, INT CLASSIFICATION D, V11th Revision (ICD-11)
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
NR 41
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD JUL 3
PY 2021
VL 46
IS 7
BP 995
EP 1001
DI 10.1080/02713683.2020.1849731
EA DEC 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SO3TL
UT WOS:000597053400001
PM 33174463
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Homer, N
   Grewal, DS
   Mirza, RG
   Lyon, AT
   Gill, MK
AF Homer, N.
   Grewal, D. S.
   Mirza, R. G.
   Lyon, A. T.
   Gill, M. K.
TI Transitioning to intravitreal aflibercept following a previous
   treat-and-extend dosing regimen in neovascular age-related macular
   degeneration: 24-month results
SO EYE
LA English
DT Article
ID ANATOMICAL OUTCOMES; RANIBIZUMAB; EYES
AB Purpose: To evaluate frequency of injections, visual and anatomical outcomes of neovascular age-related macular degeneration (nAMD) patients transitioned to intravitreal aflibercept after failure to extend treatment interval beyond 8 weeks with prior intravitreal bevacizumab or ranibizumab.
   Methods: Retrospective review of patients with nAMD switched to aflibercept following >= 6 prior intravitreal ranibizumab or bevacizumab injections at 4-8-week intervals. Three monthly aflibercept injections were given followed by a treat-and-extend dosing regimen.
   Results: Twenty-one eyes of 18 patients who had received a mean of 23.8 +/- 18.8 (mean +/- SD; range 6-62) prior ranibizumab or bevacizumab injections were included. Over a mean follow-up of 24 months after the transition, 9.2 +/- 2.9 (range 4-21) aflibercept injections were required. Interval between aflibercept injections increased to 57.3 days (range 35-133 days), as compared with 37 +/- 6.1 days (range 29-54 days) with the prior agents (P = 0.01). Mean best-corrected visual acuity was preserved (0.42 +/- 0.31 vs 0.42 +/- 0.23 logMAR; P = 0.2). Mean OCT central subfoveal thickness (292.1 +/- 83.2 mu m to 283.6 +/- 78.6 mu m; P = 0.4) and mean macular volume (7.9 +/- 0.95 mm(3) to 7.67 +/- 0.94 mm(3); P = 0.16) remained stable.
   Conclusion: Patients requiring treatment more frequently than every 8 weeks with ranibizumab and bevacizumab were transitioned to 48-week treatment interval with aflibercept while maintaining the anatomic and visual gains.
C1 [Homer, N.; Grewal, D. S.; Mirza, R. G.; Lyon, A. T.; Gill, M. K.] Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Grewal, D. S.] Duke Univ, Ctr Eye, Dept Ophthalmol, Durham, NC 27710 USA.
C3 Northwestern University; Feinberg School of Medicine; Duke University
RP Gill, MK (通讯作者)，Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, 645 North Michigan Ave,Suite 440, Chicago, IL 60611 USA.
EM mgill@nmff.org
OI Grewal, Dilraj/0000-0002-2229-5343
FU Research to Prevent Blindness, NY
FX This work was supported in part by a unrestricted grant from Research to
   Prevent Blindness, NY.
CR Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Messenger WB, 2014, BR J OPHTHALMOL, V98, P1205
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
NR 8
TC 15
Z9 16
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2015
VL 29
IS 9
BP 1152
EP 1155
DI 10.1038/eye.2015.87
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CR0XD
UT WOS:000361046000004
PM 26021870
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Hara, C
   Sawa, M
   Sayanagi, K
   Nishida, K
AF Hara, Chikako
   Sawa, Miki
   Sayanagi, Kaori
   Nishida, Kohji
TI ONE-YEAR RESULTS OF INTRAVITREAL AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL
   VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aflibercept; bevacizumab; indocyanine green angiography; optical
   coherence tomography; polypoidal choroidal vasculopathy; polypoidal
   lesion; ranibizumab
ID INDOCYANINE GREEN ANGIOGRAPHY; PHOTODYNAMIC THERAPY; MACULAR
   DEGENERATION; VEGF TRAP; RANIBIZUMAB; BEVACIZUMAB; EFFICACY;
   VERTEPORFIN; OUTCOMES; FLUID
AB Purpose:To evaluate the 1-year results of intravitreal aflibercept injections for polypoidal choroidal vasculopathy based on indocyanine green angiography findings.Methods:Twenty-nine eyes with treatment-naive polypoidal choroidal vasculopathy treated with intravitreal aflibercept injections and followed longer than 1 year were retrospectively reviewed. The best-corrected visual acuity, optical coherence tomography findings, and polypoidal lesions in indocyanine green angiography were evaluated.Results:The mean number of injections through 1 year was 3.9 1.9 (range: 1-8). Fourteen eyes (48%) were received no additional injections because of no recurrence of exudative change after the first loading dose. The mean best-corrected visual acuity levels at 6 months and 1 year significantly improved, and the mean central retinal thickness significantly decreased at all observation points from the baseline. At 3 months, the polypoidal lesions completely resolved in 19 (66%) eyes. At 1 year, the complete resolution of polypoidal lesions was seen in 4 of 10 eyes with persistent polypoidal lesions at 3 months. However, polypoidal lesions recurred at 1 year in 5 of 19 eyes (26%) with complete resolution of polypoidal lesions at 3 months.Conclusion:Aflibercept is effective for the eyes with treatment-naive polypoidal choroidal vasculopathy to achieve the resolution of polypoidal lesions. The athors need to carefully observe the eyes after confirming complete resolution of polypoidal lesion because of recurrent polyps seen in one-quarter of the study eyes.
C1 [Hara, Chikako; Sawa, Miki; Sayanagi, Kaori; Nishida, Kohji] Osaka Univ, Grad Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan.
C3 Osaka University
RP Hara, C (通讯作者)，Osaka Univ, Grad Sch Med, Dept Ophthalmol, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.
EM chikako.ueno@ophthal.med.osaka-u.ac.jp
OI Nishida, Kohji/0000-0001-9069-3610
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hara R, 2010, GRAEF ARCH CLIN EXP, V248, P931, DOI 10.1007/s00417-010-1343-8
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Hosokawa M, 2015, BR J OPHTHA IN PRESS
   Ijiri S, 2015, GRAEF ARCH CLIN EXP, V253, P351, DOI 10.1007/s00417-014-2707-2
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Lee YH, 2011, RETINA-J RET VIT DIS, V31, P1287, DOI 10.1097/IAE.0b013e3182003ccd
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Sagong M, 2012, AM J OPHTHALMOL, V153, P873, DOI 10.1016/j.ajo.2011.09.031
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Ueno C, 2012, RETINA-J RET VIT DIS, V32, P2006, DOI 10.1097/IAE.0b013e31825c1c31
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Yonekawa Y, 2013, CAN J OPHTHALMOL, V48, pE59, DOI 10.1016/j.jcjo.2012.12.015
NR 51
TC 21
Z9 22
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2016
VL 36
IS 1
BP 37
EP 45
DI 10.1097/IAE.0000000000000767
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DA2BN
UT WOS:000367600400005
PM 26383709
DA 2022-11-30
ER

PT J
AU Moschos, MM
   Brouzas, D
   Chatziralli, IP
   Ladas, I
AF Moschos, Marilita M.
   Brouzas, Dimitrios
   Chatziralli, Irini P.
   Ladas, Ioannis
TI Ranibizumab in the treatment of choroidal neovascularisation due to
   age-related macular degeneration: an optical coherence tomography and
   multifocal electroretinography study
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE age&#8208; related macular degeneration; multifocal electroretinogram;
   optical coherence tomography; ranibizumab
ID BEVACIZUMAB AVASTIN; PATHOGENESIS; PEGAPTANIB; ERG; AMD
AB Background: The aim of this study was to evaluate, by optical coherence tomography (OCT) and multifocal electroretinography (mfERG), the macular function of eyes with choroidal neovascularisation due to age-related macular degeneration (AMD) before and after the intravitreal use of ranibizumab. Methods: Fifteen eyes with choroidal neovascularisation due to AMD were studied with OCT and mfERG before, during and at the end of the treatment, one year after the first injection of ranibizumab. The eyes received 0.5-mg ranibizumab every month for the first three months, followed by doses every three months. Thus, during the 12-month study, a total of six ranibizumab injections were given. Results: The level of visual acuity increased significantly with time. A linear mixed-effect analysis showed a borderline negative association between the amount of foveal thickness and time, with a decrease in the mean foveal thickness for one time increment. The retinal response density of the mfERG showed a significant increase in ring 1 and remained almost unchanged in ring 2, whereas there was a statistically insignificant increase in ring 3. Finally, the mean latency remained unchanged throughout the 12-months of treatment in all three rings. Conclusion: The intravitreal use of ranibizumab might result in an increase of the mfERG in the foveal area. Only a borderline inverse association was shown between the amount of foveal thickness and time. Also, the level of visual acuity statistically significantly improved over time. Randomised long-term clinical trials are needed to determine the potential clinical benefit of ranibizumab.
C1 [Moschos, Marilita M.; Brouzas, Dimitrios; Chatziralli, Irini P.; Ladas, Ioannis] Univ Athens, Dept Ophthalmol, 6 Ikarias St, Athens 14578, Greece.
C3 National & Kapodistrian University of Athens
RP Moschos, MM (通讯作者)，Univ Athens, Dept Ophthalmol, 6 Ikarias St, Athens 14578, Greece.
EM moschosmarilita@yahoo.fr
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   CHANG TS, 1994, RETINA-J RET VIT DIS, V14, P114, DOI 10.1097/00006982-199414020-00004
   Feigl B, 2007, CLIN OPHTHALMOL, V1, P167
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hood DC, 2008, DOC OPHTHALMOL, V116, P1, DOI 10.1007/s10633-007-9089-2
   Kroll P, 2006, BRIT J OPHTHALMOL, V90, P128, DOI 10.1136/bjo.2005.083337
   Lipski A, 2007, RETINA-J RET VIT DIS, V27, P864, DOI 10.1097/IAE.0b013e318154b9b9
   Moschos MM, 2007, DOC OPHTHALMOL, V114, P37, DOI 10.1007/s10633-006-9036-7
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Yip YWY, 2010, DOC OPHTHALMOL, V120, P193, DOI 10.1007/s10633-010-9213-6
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 18
TC 6
Z9 8
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD MAY 1
PY 2011
VL 94
IS 3
BP 268
EP 275
DI 10.1111/j.1444-0938.2011.00589.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA VJ8QW
UT WOS:000640406500004
PM 21385210
OA Bronze
DA 2022-11-30
ER

PT J
AU Motohashi, R
   Noma, H
   Yasuda, K
   Kotake, O
   Goto, H
   Shimura, M
AF Motohashi, Ryosuke
   Noma, Hidetaka
   Yasuda, Kanako
   Kotake, Osamu
   Goto, Hiroshi
   Shimura, Masahiko
TI Dynamics of soluble vascular endothelial growth factor receptors and
   their ligands in aqueous humour during ranibizumab for age-related
   macular degeneration
SO JOURNAL OF INFLAMMATION-LONDON
LA English
DT Article
ID RETINAL VEIN OCCLUSION; TYROSINE KINASE; ANGIOGENESIS; VEGF;
   INFLAMMATION; INJECTIONS; ROLES
AB Background: Intravitreal ranibizumab injection (IRI) is effective for patients with exudative age-related macular degeneration (AMD) and decreases intraocular levels of vascular endothelial growth factor (VEGF), but VEGF receptor intraocular dynamics after IRI are unclear. Therefore, we evaluated changes in the aqueous humor levels of soluble vascular endothelial growth factor receptor (sVEGFR)-1, sVEGFR-2, and their ligands for these receptors (VEGF) patients with AMD receiving IRI.
   Methods: The subjects were 24 patients with AMD (24 eyes) who received 3 doses of IRI at monthly intervals. Aqueous humor samples were obtained when each IRI dose was given (visits 0, 1, and 2 at 4-week intervals). Then the suspension array method was employed to measure sVEGFR-1, sVEGFR-2, VEGF, and placental growth factor (PlGF) in aqueous humor samples from the 24 AMD patients and 13 cataract patients (as controls). Best corrected visual acuity (BCVA; logMAR) chart and central macular thickness (CMT; optical coherence tomography) were also assessed over time.
   Results: At baseline, the aqueous humor levels of sVEGFR-1, sVEGFR-2, VEGF, and PlGF were significantly higher in the AMD group than in the control group. There was a significant correlation between VEGF and PlGF or between sVEGFR-1 and sVEGFR-2. BCVA and CMT both improved significantly after IRI, and the aqueous humor levels of VEGF, PlGF, and sVEGFR-1 also decreased significantly.
   Conclusions: VEGFRs may be involved in the pathogenesis of AMD. IRI improves clinical parameters in AMD patients by suppressing intraocular levels of VEGF, PlGF, and sVEGFR-1.
C1 [Motohashi, Ryosuke; Noma, Hidetaka; Yasuda, Kanako; Kotake, Osamu; Shimura, Masahiko] Tokyo Med Univ, Hachioji Med Ctr, Dept Ophthalmol, 1163 Tatemachi, Hachioji, Tokyo 1930998, Japan.
   [Goto, Hiroshi] Tokyo Med Univ, Dept Ophthalmol, Tokyo, Japan.
C3 Tokyo Medical University; Tokyo Medical University
RP Noma, H (通讯作者)，Tokyo Med Univ, Hachioji Med Ctr, Dept Ophthalmol, 1163 Tatemachi, Hachioji, Tokyo 1930998, Japan.
EM noma-hide@umin.ac.jp
CR Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hornig C, 2000, LAB INVEST, V80, P443, DOI 10.1038/labinvest.3780050
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kiba A, 2003, BIOCHEM BIOPH RES CO, V301, P371, DOI 10.1016/S0006-291X(02)03033-4
   Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731
   Matsunaga N, 2008, OPHTHALMOLOGY, V115, P1916, DOI 10.1016/j.ophtha.2008.06.025
   Noma H, 2015, INVEST OPHTH VIS SCI, V56, P1122, DOI 10.1167/iovs.14-15789
   Noma H, 2014, INVEST OPHTH VIS SCI, V55, P3878, DOI 10.1167/iovs.14-13961
   Noma H, 2013, JAMA OPHTHALMOL, V131, P160, DOI 10.1001/2013.jamaophthalmol.228
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   Shibuya M, 2006, J BIOCHEM MOL BIOL, V39, P469
   Shibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Wang XY, 2014, GRAEF ARCH CLIN EXP, V252, P1033, DOI 10.1007/s00417-013-2505-2
   Yang XJ, 2013, P NATL ACAD SCI USA, V110, P13932, DOI 10.1073/pnas.1309629110
   Yuan JZ, 2013, NEPHROL DIAL TRANSPL, V28, P2356, DOI 10.1093/ndt/gft256
NR 24
TC 6
Z9 6
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-9255
J9 J INFLAMM-LOND
JI J. Inflamm.-Lond.
PD DEC 4
PY 2018
VL 15
AR 26
DI 10.1186/s12950-018-0203-x
PG 6
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA HD2IR
UT WOS:000452334800001
PM 30534004
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Cui, L
   Zhou, HY
   Yu, J
   Sun, ED
   Zhang, YB
   Jia, W
   Jiao, YQ
   Snellingen, T
   Liu, XP
   Lim, A
   Wang, NL
   Liu, NP
AF Cui, Lei
   Zhou, Haiying
   Yu, Jie
   Sun, Erdan
   Zhang, Yinbo
   Jia, Wei
   Jiao, Yiqun
   Snellingen, Torkel
   Liu, Xipu
   Lim, Apiradee
   Wang, Ningli
   Liu, Ningpu
TI Noncoding Variant in the Complement Factor H Gene and Risk of Exudative
   Age-Related Macular Degeneration in a Chinese Population
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID JAPANESE POPULATION; HEMICENTIN-1 GENES; Y402H POLYMORPHISM; STRONG
   ASSOCIATION; ADULT-POPULATION; NO ASSOCIATION; CFH GENE; MACULOPATHY;
   PREVALENCE; DRUSEN
AB PURPOSE. To investigate whether the previously reported non-coding variant of the complement factor H (CFH) gene and two coding variants of the complement component 3 (C3) gene are associated with exudative age-related macular degeneration (AMD) in Chinese patients.
   METHODS. One hundred fifty Chinese patients with exudative AMD and 161 control individuals without AMD were recruited for the study. Genomic DNA was extracted from blood leukocytes. The non-coding variant of the CFH gene (rs1410996) and two coding variants of the C3 gene (rs2230199 and rs1047286) were genotyped by polymerase chain reaction (PCR) followed by allele-specific restriction enzyme digestion and direct sequencing.
   RESULTS. Significant association was detected for exudative AMD with the CFH noncoding variant rs1410996. Frequencies of the risk C allele at rs1410996 were 72.0% in AMD cases versus 55.6% in controls (P < 0.001). The odds ratio for risk of AMD was 1.71 (95% confidence interval [CI], 0.82-3.54) for heterozygous TC genotype and 3.85 (95% CI, 1.84-8.05) for homozygous CC genotype compared with the wild TT genotype. In contrast, the C3 variants rs2230199 and rs1047286 were not associated with exudative AMD in the studied subjects. Frequencies of the risk G allele at rs2230199 and of the risk T allele at rs1047286 were 0.3% to 1.0% in both cases and controls.
   CONCLUSIONS. The data suggest that the noncoding variant rs1410996 of the CFH gene moderately increased the risk of exudative AMD in a Chinese population. The C3 variants were rare and not associated with exudative AMD in this Chinese cohort. (Invest Ophthalmol Vis Sci. 2010;51:1116-1120) DOI:10.1167/iovs.09-4265
C1 [Cui, Lei; Zhou, Haiying; Yu, Jie; Sun, Erdan; Zhang, Yinbo; Wang, Ningli; Liu, Ningpu] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, Beijing 100730, Peoples R China.
   [Jia, Wei; Jiao, Yiqun; Snellingen, Torkel; Liu, Xipu] Sekwa Eye Hosp, Beijing, Peoples R China.
C3 Capital Medical University
RP Liu, NP (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, 1 Dong Jiao Min Xiang, Beijing 100730, Peoples R China.
EM nliu001@gmail.com
FU National Basic Research Program of China [2007CB512201]; Beijing Medical
   Development Foundation [2002-1019]
FX Supported by the National Basic Research Program of China (Program 973)
   Grant 2007CB512201 and the Beijing Medical Development Foundation Grant
   2002-1019.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chowers I, 2008, MOL VIS, V14, P1829
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Dewan A, 2007, CURR OPIN GENET DEV, V17, P228, DOI 10.1016/j.gde.2007.04.004
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Okamoto H, 2006, MOL VIS, V12, P156
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seitsonen S, 2006, MOL VIS, V12, P796
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Souied EH, 2005, MOL VIS, V11, P1135
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Topouzis F, 2006, AM J OPHTHALMOL, V142, P1076, DOI 10.1016/j.ajo.2006.07.042
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu YL, 2008, MOL VIS, V14, P1373
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zipfel PF, 1999, MOL IMMUNOL, V36, P241, DOI 10.1016/S0161-5890(99)00038-3
NR 53
TC 22
Z9 27
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2010
VL 51
IS 2
BP 1116
EP 1120
DI 10.1167/iovs.09-4265
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 545AS
UT WOS:000273704700068
PM 19850835
DA 2022-11-30
ER

PT J
AU Tabandeh, H
   Chaudhry, NA
   Boyer, DS
   Kon-Jara, VA
   Flynn, HW
AF Tabandeh, Homayoun
   Chaudhry, Nauman A.
   Boyer, David S.
   Kon-Jara, Veronica A.
   Flynn, Harry W., Jr.
TI Outcomes of cataract surgery in patients with neovascular age-related
   macular degeneration in the era of anti-vascular endothelial growth
   factor therapy
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB; CONTROLLED-TRIAL; RANIBIZUMAB; RISK;
   PROGRESSION; EXTRACTION; EYE
AB PURPOSE: To evaluate the visual outcomes, choroidal neovascular complex status, and adverse events in patients with visually significant cataract and neovascular age-related macular degeneration (AMD) who had cataract surgery.
   SETTING: Private practices, Beverly Hills, California, and New London, Connecticut, USA.
   DESIGN: Case series.
   METHODS: Data were abstracted from the medical records of patients with neovascular AMD treated by anti-vascular endothelial growth factor (anti-VEGF) therapy who had cataract surgery. The main outcome measures were Snellen corrected distance visual acuity (CDVA), perioperative adverse events, and status of the choroidal neovascular complex.
   RESULTS: The study enrolled 30 eyes of 28 patients. The CDVA was 20/40 or better in 10% of eyes preoperatively and 40% postoperatively; 20/50 to 20/100 in 53% and 33%, respectively; and 20/200 or worse in 37% and 27%, respectively. The change in CDVA from preoperatively to postoperatively was statistically significant, with a mean change of 0.22 logMAR +/- 0.27 (SD) at 2 months (P<.0001), 0.22 +/- 0.36 logMAR at 6 months (P=.001), and 0.17 +/- 0.54 logMAR at the last follow-up (P=.01). Patients received a mean of 0.32 injections per month postoperatively compared with 0.49 injections per month preoperatively. Perioperative macular adverse events did not occur in any eye.
   CONCLUSIONS: With regular evaluations and appropriate treatment with anti-VEGF agents, cataract surgery did not appear to be associated with an increased incidence of perioperative complications or macular adverse events.
C1 [Tabandeh, Homayoun; Boyer, David S.] Retina Vitreous Associates Med Grp, Beverly Hills, CA 90211 USA.
   [Chaudhry, Nauman A.; Kon-Jara, Veronica A.] New England Retina Associates, New London, CT USA.
   [Flynn, Harry W., Jr.] Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Retina Vitreous Associates Medical Group; Bascom Palmer Eye Institute
RP Tabandeh, H (通讯作者)，Retina Vitreous Associates Med Grp, 8641 Wilshire Blvd,Suite 210, Beverly Hills, CA 90211 USA.
EM tabandeh@att.net
FU Allergan; Alcon; Genentech; Pfizer
FX Dr. Tabandeh is a consultant/advisor to Alcon and Allergan. Dr. Boyer is
   a consultant/advisor to Alcon, Allergan, Genentech, Regeneron, Novartis,
   Pfizer, and Optos and has received lecture fees from Allergan, Alcon,
   Genentech, and Pfizer. No other author has a financial or proprietary
   interest in any material or method mentioned.
CR Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Dong LM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1412, DOI 10.1001/archophthalmol.2009.152
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Furino C, 2009, J CATARACT REFR SURG, V35, P1518, DOI 10.1016/j.jcrs.2009.04.032
   Hooper CY, 2009, CLIN EXP OPHTHALMOL, V37, P570, DOI 10.1111/j.1442-9071.2009.02095.x
   Jonas JB, 2007, J OCUL PHARMACOL TH, V23, P599, DOI 10.1089/jop.2007.0050
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   Klein BEK, 2009, ARCH OPHTHALMOL-CHIC, V127, P1528, DOI 10.1001/archophthalmol.2009.258
   Pollack A, 1998, OPHTHALMIC SURG LAS, V29, P286
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
NR 21
TC 25
Z9 26
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0886-3350
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD APR
PY 2012
VL 38
IS 4
BP 677
EP 682
DI 10.1016/j.jcrs.2011.10.036
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 920RA
UT WOS:000302423500019
PM 22284725
DA 2022-11-30
ER

PT J
AU SanGiovanni, JP
   Chew, EY
   Agron, E
   Clemons, TE
   Ferris, FL
   Gensler, G
   Lindblad, AS
   Milton, RC
   Seddon, JM
   Klein, R
   Sperduto, RD
AF SanGiovanni, John Paul
   Chew, Emily Y.
   Agron, Elvira
   Clemons, Traci E.
   Ferris, Frederick L., III
   Gensler, Gary
   Lindblad, Anne S.
   Milton, Roy C.
   Seddon, Johanna M.
   Klein, Ronald
   Sperduto, Robert D.
CA Age-Related Eye Dis Study Res Grp
TI The relationship of dietary omega-3 long-chain polyunsaturated fatty
   acid intake with incident age-related macular degeneration - AREDS
   report no. 23
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID OXIDATIVE STRESS; RISK; MACULOPATHY; APOPTOSIS; HEALTH
AB Objective: To examine the association of dietary omega-3 long-chain polyunsaturated fatty acid and fish intake with incident neovascular age-related macular degeneration (AMD) and central geographic atrophy (CGA).
   Methods: Multicenter clinic-based prospective cohort study from a clinical trial including Age-Related Eye Disease Study (AREDS) participants with bilateral drusen at enrollment. Main outcome measures were incident neovascular AMD and CGA, ascertained from annual stereoscopic color fundus photographs (median follow-up, 6.3 years). We estimated nutrient and food intake from a validated food frequency questionnaire (FFQ) at baseline, with intake of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), combined EPA and DHA, and fish as primary exposures.
   Results: After controlling for known covariates, we observed a reduced likelihood of progression from bilateral drusen to CGA among people who reported the highest levels of EPA (odds ratio [OR], 0.44; 95% confidence interval [CI], 0.23-0.87) and EPA + DHA ( OR, 0.45; 95% CI, 0.23-0.90) consumption. Levels of DHA were associated with CGA in age- ,sex-, and calorie-adjusted models (OR, 0.51; 95% CI, 0.26-1.00); however, this statistical relationship did not persist in multivariable models.
   Conclusions: Dietary lipid intake is a modifiable factor that may influence the likelihood of developing sight-threatening forms of AMD. Our findings suggest that dietary omega-3 long-chain polyunsaturated fatty acid intake is associated with a decreased risk of progression from bilateral drusen to CGA.
C1 [SanGiovanni, John Paul; Clemons, Traci E.; Gensler, Gary; Lindblad, Anne S.; Milton, Roy C.] EMMES Corp, AREDS Coordinating Ctr, Rockville, MD 20850 USA.
   [SanGiovanni, John Paul; Chew, Emily Y.; Agron, Elvira; Ferris, Frederick L., III; Sperduto, Robert D.] NEI, Bethesda, MD 20892 USA.
   [Seddon, Johanna M.] Tufts Univ New England Med Ctr, New England Eye Ctr, Boston, MA USA.
   [Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.
C3 Emmes Corporation; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); Tufts Medical Center; University of
   Wisconsin System; University of Wisconsin Madison
RP SanGiovanni, JP (通讯作者)，EMMES Corp, AREDS Coordinating Ctr, 401 N Washington St,Ste 700, Rockville, MD 20850 USA.
EM aredspub@emmes.com
RI SanGiovanni, John Paul/A-7605-2008; SanGiovanni, John Paul/AAU-3895-2020
FU National Eye Institute; National Institutes of Health, Department of
   Health and Human Services; NATIONAL EYE INSTITUTE [ZIEEY000487] Funding
   Source: NIH RePORTER
FX This study was supported by contracts from the National Eye Institute,
   National Institutes of Health, Department of Health and Human Services.
CR [Anonymous], 2002, VIS PROBL US PREV AD
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Chucair AJ, 2007, INVEST OPHTH VIS SCI, V48, P5168, DOI 10.1167/iovs.07-0037
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Institute for Medicine of the National Academies Food and Nutrition Board, 2005, DIET REF INT EN CARB
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kherjee PKM, 2007, PROSTAG LEUKOTR ESS, V77, P233, DOI 10.1016/j.plefa.2007.10.022
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   KURINIJ N, 1998, INT C DIET ASS METH
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13152, DOI 10.1073/pnas.0705949104
   ROSNER B, 1988, AM J EPIDEMIOL, V127, P377, DOI 10.1093/oxfordjournals.aje.a114811
   Rotstein NP, 2003, INVEST OPHTH VIS SCI, V44, P2252, DOI 10.1167/iovs.02-0901
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2004, ARCH OPHTHALMOL-CHIC, V122, P426
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Serhan CN, 2004, PROSTAG OTH LIPID M, V73, P155, DOI 10.1016/j.prostaglandins.2004.03.005
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   *US DEP HHS, 1999, NIH PUBL
   *USDA AGR RES SERV, CONT SURV FOOD INT I
NR 29
TC 142
Z9 149
U1 0
U2 25
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD SEP
PY 2008
VL 126
IS 9
BP 1274
EP 1279
DI 10.1001/archopht.126.9.1274
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 345XQ
UT WOS:000259031500015
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Lee, B
   Yoo, G
   Yun, C
   Oh, J
AF Lee, Boram
   Yoo, Gyeongmin
   Yun, Cheolmin
   Oh, Jaeryung
TI Short-term effects of anti-vascular endothelial growth factor on
   peripapillary choroid and choriocapillaris in eyes with neovascular
   age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Optical coherence tomography
   angiography; Peripapillary choriocapillaris; Peripapillary choroidal
   thickness
ID ANTI-VEGF THERAPY; INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB INJECTIONS;
   THICKNESS; SUBFOVEAL
AB Purpose To investigate the effects of anti-vascular endothelial growth factor (anti-VEGF) on the peripapillary choroid and choriocapillaris in eyes with neovascular age-related macular degeneration (nAMD). Methods We included consecutive patients who underwent three monthly intravitreal injections of aflibercept or ranibizumab for nAMD, followed by swept-source optical-coherence tomography angiography (SS-OCTA). Peripapillary choroidal thickness (CT) and vascular density (VD) of the peripapillary choriocapillaris were measured in SS-OCT and OCTA images at baseline and at 1 month after three monthly injections of anti-VEGF. Results In 68 eyes of 68 patients with nAMD, peripapillary CT decreased from 124.5 +/- 69.9 mu m to 116.5 +/- 68.2 mu m (P = 0.003) after three monthly intravitreal injections of anti-VEGF. The mean vascular density (VD) of the peripapillary choriocapillaris also decreased from 73.99 +/- 6.33 to 71.82 +/- 6.51 (P < 0.001). The change in the peripapillary choriocapillaris VD was significantly affected by baseline peripapillary choriocapillaris VD, baseline peripapillary CT, and type of nAMD (P = 0.004, P = 0.028, P = 0.015, respectively). The baseline VD of the choriocapillaris was lower in non-responders (median, 70.63; 25-75%, 68.12-71.27) than in responders (median, 75.32; 25-75%, 70.09-79.96) (P = 0.032). Conclusion These results suggest that anti-VEGF injection influences the peripapillary choriocapillaris flow out of exudative lesions, and that its effects depend on the baseline status of the choroid and choriocapillaris.
C1 [Lee, Boram; Yoo, Gyeongmin; Yun, Cheolmin; Oh, Jaeryung] Korea Univ, Dept Ophthalmol, Coll Med, 73 Inchon Ro, Seoul 02841, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine)
RP Oh, J (通讯作者)，Korea Univ, Dept Ophthalmol, Coll Med, 73 Inchon Ro, Seoul 02841, South Korea.
EM ojr4991@korea.ac.kr
RI Oh, Jaeryung/ABD-3090-2021
OI Oh, Jaeryung/0000-0002-1036-6562
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education [NRF-2017R1D1A1B03033092]
FX This study was funded by a grant from the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education (NRF-2017R1D1A1B03033092).
CR Ahn J, 2018, GRAEF ARCH CLIN EXP, V256, P11, DOI 10.1007/s00417-017-3814-7
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Cole ED, 2016, INVEST OPHTH VIS SCI, V57, pOCT356, DOI 10.1167/iovs.15-18473
   De Carlo TE, 2015, RETINA-J RET VIT DIS, V35, P2364, DOI 10.1097/IAE.0000000000000882
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gharbiya M, 2018, CURR EYE RES, V43, P391, DOI 10.1080/02713683.2017.1405045
   Gharbiya M, 2015, J OCUL PHARMACOL TH, V31, P357, DOI 10.1089/jop.2014.0160
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kim JH, 2016, BRIT J OPHTHALMOL, V100, P1634, DOI 10.1136/bjophthalmol-2015-308074
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Lutty G, 1999, MOL VIS, V5
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Shimomura Y, 2009, GRAEF ARCH CLIN EXP, V247, P1089, DOI 10.1007/s00417-009-1054-1
   Shin JY, 2015, ACTA OPHTHALMOL, V93, P524, DOI 10.1111/aos.12653
   Sugimoto Y, 2013, CURR EYE RES, V38, P487, DOI 10.3109/02713683.2013.763990
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P1693, DOI 10.1007/s00417-015-3260-3
   Yun C, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0203-7
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P427, DOI 10.1007/s00417-015-3054-7
   Yun C, 2015, RETINA-J RET VIT DIS, V35, P1860, DOI 10.1097/IAE.0000000000000539
   Zarbin M, 2019, OPHTHALMOLOGY, V126, P849, DOI 10.1016/j.ophtha.2019.01.003
NR 27
TC 7
Z9 7
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2019
VL 257
IS 10
BP 2163
EP 2172
DI 10.1007/s00417-019-04432-w
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JN2DL
UT WOS:000496711200012
PM 31367847
DA 2022-11-30
ER

PT J
AU Zhang, Y
   Chioreso, C
   Schweizer, ML
   Abramoff, MD
AF Zhang, Yan
   Chioreso, Catherine
   Schweizer, Marin L.
   Abramoff, Michael D.
TI Effects of Aflibercept for Neovascular Age-Related Macular Degeneration:
   A Systematic Review and Meta-Analysis of Observational Comparative
   Studies
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Review
DE aflibercept; age-related macular degeneration; comparative effectiveness
ID RANIBIZUMAB VS. AFLIBERCEPT; VEGF TRAP-EYE; INTRAVITREAL AFLIBERCEPT;
   TREATMENT PATTERNS; 12-MONTH OUTCOMES; BEVACIZUMAB; EPIDEMIOLOGY;
   INJECTION; EFFICACY; THERAPY
AB PURPOSES. To compare the effects of aflibercept and other anti-vascular endothelial growth factor (anti-VEGF) medications on both functional and anatomical outcomes for treatmentnaive neovascular age-related macular degeneration (nAMD) in the real world.
   METHODS. A systematic review and meta-analysis of observational comparative studies.
   RESULTS. A total of 18 studies remained after literature selection and quality assessment of 1697 studies. The most common aflibercept treatment regimen was three monthly injections followed by pro re nata (PRN). Aflibercept and ranibizumab had similar effects in 2-year treatment. At 3, 6, 12, and 24 months, the differences in the logarithm of minimum angle of resolution (logMAR) decrease in aflibercept and ranibizumab groups were 0.00 (95% confidence interval [CI]: -0.03 to 0.02); 0.01 (95% CI: -0.02 to 0.05); -0.03 (95% CI: -0.07 to 0.01); and -0.06 (95% CI: -0.30 to 0.17), respectively; the differences in decrease of central retinal thickness (CRT) were 3.25 jtm (95% CI: -15.03 to 21.53); 7.89 jim (95% CI: -31.91 to 47.69); 2.89 mu m (95% CI: -18.33 to 24.11); and -2.42 mu m (95% CI: -77.87 to 73.03), respectively. However, aflibercept was significantly more effective in patients with initial reduced visual acuity (IogMAR >0.6 or <55 letters; P = 0.001). In the first year, treatment frequency was not significantly different for aflibercept and ranibizumab, but aflibercept required fewer injections than ranibizumab with PRN regimen (mean -0.90; 95% CI: -1.80 to 0.00).
   CONCLUSIONS. Aflibercept has comparable effects with ranibizumab for treatment-naive nAMD in the real world, and may be more effective for patients with initial lower visual acuity.
C1 [Zhang, Yan; Chioreso, Catherine] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA.
   [Schweizer, Marin L.] Univ Iowa, Carver Coll Med, Dept Internal Med, Iowa City, IA USA.
   [Abramoff, Michael D.] Univ Iowa, Stephen A Wynn Inst Vis Res, Iowa City, IA USA.
   [Abramoff, Michael D.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
   [Abramoff, Michael D.] Univ Iowa, Dept Elect & Comp Engn, Iowa City, IA 52242 USA.
   [Abramoff, Michael D.] Iowa City VA Hlth Care Syst, Iowa City, IA USA.
   [Abramoff, Michael D.] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA.
   [Abramoff, Michael D.] VA Ctr Diag & Treatment Visual Loss, Iowa City, IA USA.
C3 University of Iowa; University of Iowa; University of Iowa; University
   of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Iowa City VA Health Care System; University
   of Iowa
RP Abramoff, MD (通讯作者)，Univ Iowa, 11205 Pomerantz Family Pavil, Iowa City, IA 52242 USA.
EM michael-abramoff@uiowa.edu
RI Abramoff, Michael D/A-5836-2009
OI Abramoff, Michael D/0000-0002-3490-0037; Zhang, Yan/0000-0002-8526-9599;
   Schweizer, Marin/0000-0002-3604-0093
FU Department of Veterans Affairs; VA Health Services Research and
   Development Career Development Award [11-215]
FX Supported in part by the Department of Veterans Affairs and a VA Health
   Services Research and Development Career Development Award 11-215 (MLS);
   M.D. Abramoff is the Robert C. Watzke, MD Professor of Ophthalmology and
   Visual Sciences.
CR Altman DG, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d2304
   Arroyo JG, AGE RELATED MACULAR
   Au A, 2017, BRIT J OPHTHALMOL, V101, P970, DOI 10.1136/bjophthalmol-2016-309434
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Balaskas K, 2017, RETINA-J RET VIT DIS, V37, P1297, DOI 10.1097/IAE.0000000000001342
   Calvo P, 2015, DRUGS, V75, P1461, DOI 10.1007/s40265-015-0447-1
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Centers for Disease Control and Prevention (CDC), PREV DIS ASS HLTH CO
   Centers for Disease Control and Prevention (CDC), WHY IS VIS LOSS PUBL
   Centers for Disease Control and Prevention (CDC), BURD VIS LOSS
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Cotter SA, 2003, AM J OPHTHALMOL, V136, P655, DOI 10.1016/S0002-9394(03)00388-X
   Dirani A, 2015, AM J OPHTHALMOL, V160
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Garweg JG, 2017, J OCUL PHARMACOL TH, V33, P567, DOI 10.1089/jop.2017.0031
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Heier JS, 2014, OPHTHALMOLOGY, V121, P1414, DOI 10.1016/j.ophtha.2014.01.027
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   Inoue M, 2016, AM J OPHTHALMOL, V169, P95, DOI 10.1016/j.ajo.2016.06.021
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnston SS, 2013, ADV THER, V30, P1111, DOI 10.1007/s12325-013-0078-4
   Kano M, 2015, CLIN OPHTHALMOL, V9, P2049, DOI 10.2147/OPTH.S90932
   Kim JH, 2016, GRAEF ARCH CLIN EXP, V254, P2101, DOI 10.1007/s00417-016-3353-7
   Lazzeri S, 2015, ANGIOGENESIS, V18, P397, DOI 10.1007/s10456-015-9483-4
   Lee AY, 2017, BRIT J OPHTHALMOL, V101, P1683, DOI 10.1136/bjophthalmol-2016-309818
   Legare F, 2012, PATIENT, V5, P1, DOI 10.2165/11592180-000000000-00000
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3
   Miyamoto N, 2017, CLIN OPHTHALMOL, V11, DOI 10.2147/OPTH.S133332
   Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b4037, 10.1371/journal.pmed.1000097]
   Mueller S, 2016, OPHTHALMOLOGY, V123, P876, DOI 10.1016/j.ophtha.2015.12.001
   Park DH, 2017, INT OPHTHALMOL, V37, P1205, DOI 10.1007/s10792-016-0391-4
   Rasmussen A, 2017, ACTA OPHTHALMOL, V95, P128, DOI 10.1111/aos.13233
   Regeneron Pharmaceuticals I, 2012, EYLEA AFL INJ APPR T
   Reich O, 2015, RISK MANAG HEALTHC P, V8, P55, DOI 10.2147/RMHP.S80536
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   Selid PD, 2014, OSLI RETINA, V45, P275, DOI 10.3928/23258160-20140709-03
   Singh RP, 2015, CLIN OPHTHALMOL, V9, P1759, DOI 10.2147/OPTH.S87043
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Spooner K, 2017, CLIN OPHTHALMOL, V11, P161, DOI 10.2147/OPTH.S125676
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Subhi Y, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7194927
   Szabo SM, 2015, CURR MED RES OPIN, V31, P2031, DOI 10.1185/03007995.2015.1084909
   U. S. Food & Drug Administration, FDA APPR EYLEA EYE D
   U. S. Food & Drug Administration (FDA), EYLEA AFL INJ LAB
   Verner-Cole EA, 2012, DRUG TODAY, V48, P317, DOI 10.1358/dot.2012.48.5.1805931
   Wells GA., NEWCASTLE OTTAWA SCA
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Wilkes MM, 2010, OSTEOPOROSIS INT, V21, P679, DOI 10.1007/s00198-009-0991-1
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P1693, DOI 10.1007/s00417-015-3260-3
NR 58
TC 28
Z9 30
U1 1
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2017
VL 58
IS 13
BP 5616
EP 5627
DI 10.1167/iovs.17-22471
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FR4YC
UT WOS:000419071600002
PM 29094167
DA 2022-11-30
ER

PT J
AU Yanagisawa, S
   Kondo, N
   Miki, A
   Matsumiya, W
   Kusuhara, S
   Tsukahara, Y
   Honda, S
   Negi, A
AF Yanagisawa, Suiho
   Kondo, Naoshi
   Miki, Akiko
   Matsumiya, Wataru
   Kusuhara, Sentaro
   Tsukahara, Yasutomo
   Honda, Shigeru
   Negi, Akira
TI A Common Complement C3 Variant Is Associated with Protection against Wet
   Age-Related Macular Degeneration in a Japanese Population
SO PLOS ONE
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; FACTOR-H POLYMORPHISM; GENE
   POLYMORPHISMS; FACTOR-I; R102G POLYMORPHISM; CHINESE POPULATION; HUMAN
   GENOME; FACTOR-B; RISK; COMPONENT
AB Background: Genetic variants in the complement component 3 gene (C3) have been shown to be associated with age-related macular degeneration (AMD) in Caucasian populations of European descent. In particular, a nonsynonymous coding variant, rs2230199 (R102G), is presumed to be the most likely causal variant in the C3 locus based on strong statistical evidence for disease association and mechanistic functional evidence. However, the risk allele is absent or rare (<1%) in Japanese and Chinese populations, and the association of R102G with AMD has not been reported in Asian populations. Genetic heterogeneity of disease-associated variants among different ethnicities is common in complex diseases. Here, we sought to examine whether other common variants in C3 are associated with wet AMD, a common advanced-stage manifestation of AMD, in a Japanese population.
   Methodology/Principal Findings: We genotyped 13 tag single nucleotide polymorphisms (SNPs) that capture the majority of common variations in the C3 locus and tested for associations between these SNPs and wet AMD in a Japanese population comprising 420 case subjects and 197 controls. A noncoding variant in C3 (rs2241394) exhibited statistically significant evidence of association (allelic P = 8.32x10(-4); odds ratio = 0.48 [95% CI = 0.31-0.74] for the rs2241394 C allele). Multilocus logistic regression analysis confirmed that the effect of rs2241394 was independent of the previously described loci at ARMS2 and CFH, and that the model including variants in ARMS2 and CFH plus C3 rs2241394 provided a better fit than the model without rs2241394. We found no evidence of epistasis between variants in C3 and CFH, despite the fact that they are involved in the same biological pathway.
   Conclusions: Our study provides evidence that C3 is a common AMD-associated locus that transcends racial boundaries and provides an impetus for more detailed genetic characterization of the C3 locus in Asian populations.
C1 [Yanagisawa, Suiho; Kondo, Naoshi; Miki, Akiko; Matsumiya, Wataru; Kusuhara, Sentaro; Tsukahara, Yasutomo; Honda, Shigeru; Negi, Akira] Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg, Kobe, Hyogo 657, Japan.
C3 Kobe University
RP Yanagisawa, S (通讯作者)，Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg, Kobe, Hyogo 657, Japan.
EM nskondo@gmail.com
RI Honda, Shigeru/W-4761-2019
OI Kondo, Naoshi/0000-0001-6025-3876; Kusuhara, Sentaro/0000-0002-6458-539X
FU Ministry of Education, Science, and Culture, Tokyo, Japan [23592567]
FX This study was supported by a Grant-in Aid for (C) 23592567 from the
   Ministry of Education, Science, and Culture, Tokyo, Japan. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   ARAKAWA S, 2011, NAT GENET IN PRESS
   ARVILOMMI H, 1974, NATURE, V251, P740, DOI 10.1038/251740a0
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Blom AM, 2003, ARCH BIOCHEM BIOPHYS, V418, P108, DOI 10.1016/j.abb.2003.08.018
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Ioannidis JPA, 2004, NAT GENET, V36, P1312, DOI 10.1038/ng1474
   Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Kondo N, 2010, EUR J HUM GENET, V18, P634, DOI 10.1038/ejhg.2009.243
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Sun LD, 2011, NAT GENET, V43, P690, DOI 10.1038/ng.851
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   WELCH TR, 1990, J PEDIATR-US, V116, pS92, DOI 10.1016/S0022-3476(05)82709-X
   Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yuan HY, 2006, NUCLEIC ACIDS RES, V34, pW635, DOI 10.1093/nar/gkl236
   Zerbib J, 2010, MOL VIS, V16, P1324
NR 53
TC 19
Z9 22
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 12
PY 2011
VL 6
IS 12
AR e28847
DI 10.1371/journal.pone.0028847
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 866FT
UT WOS:000298366600043
PM 22174912
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Taylor, DJ
   Smith, ND
   Jones, PR
   Binns, AM
   Crabb, DP
AF Taylor, Deanna J.
   Smith, Nicholas D.
   Jones, Pete R.
   Binns, Alison M.
   Crabb, David P.
TI Measuring dynamic levels of self-perceived anxiety and concern during
   simulated mobility tasks in people with non-neovascular age-related
   macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE degeneration; macula; rehabilitation; vision
ID OLDER-ADULTS; VISION; PERFORMANCE; LIMITATIONS; GAZE; RISK; FEAR
AB Background/aims
   To assess response to real-world mobility scenarios in people with dry age-related macular degeneration (AMD) using a computer-based test.
   Methods
   Participants were shown 18 point-of-view computer-based movies simulating walking through real-world scenarios, and pressed a button during scenes which would cause them self-perceived anxiety or concern in their day-to-day life. Button pressure was recorded throughout. Pressure traces were generated, which aligned with each movie time point. Group averages based on AMD severity were generated. Bootstrapped confidence intervals (CIs) for responses by group were generated around traces. Traces were examined to discover events causing the greatest differences between groups.
   Results
   Participants had early/no AMD (n=8), intermediate AMD (n=7) or geographic atrophy (n=15 (GA)). Median (IQR) logMAR visual acuity was 0.04 (-0.04, 0.18), 0.26 (0.10, 0.40) and 0.32 (0.20, 0.56), respectively. Participants with intermediate AMD or GA recorded greater pressure than those with early and no AMD (Kruskal-Wallis, p=0.04). Four events involving navigating stairs and three under low luminance elicited greatest differences between groups (p<0.001).
   Conclusion
   People with intermediate AMD or GA likely experience higher levels of concern associated with mobility. The test highlights areas of specific concern. Results should be useful in patient management and educating the public about the everyday effects of AMD.
C1 [Taylor, Deanna J.; Smith, Nicholas D.; Jones, Pete R.; Binns, Alison M.; Crabb, David P.] City Univ London, Div Optometry & Visual Sci, London EC1V 0HB, England.
C3 City University London
RP Crabb, DP (通讯作者)，City Univ London, Div Optometry & Visual Sci, London EC1V 0HB, England.
EM David.Crabb.1@city.ac.uk
RI Jones, Pete R/U-7235-2019
OI Jones, Pete R/0000-0001-7672-8397; Taylor, Deanna/0000-0001-8261-5225;
   Crabb, David/0000-0001-8754-3902; Binns, Alison/0000-0001-8621-498X
FU Roche Products Ltd, UK
FX This study was funded as part of an unrestricted investigator-initiated
   research grant from Roche Products Ltd, UK, awarded to DPC.
CR Aspinall PA, 2014, BRIT J OPHTHALMOL, V98, P1393, DOI 10.1136/bjophthalmol-2014-305032
   Authie CN, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00387
   Bibby SA, 2007, CLIN EXP OPTOM, V90, P115, DOI 10.1111/j.1444-0938.2007.00120.x
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P733
   Collins AL, 2008, J GERONTOL B-PSYCHOL, V63, pP321, DOI 10.1093/geronb/63.6.P321
   Curriero FC, 2013, JAMA OPHTHALMOL, V131, P1420, DOI 10.1001/jamaophthalmol.2013.4471
   Denollet J, 2005, PSYCHOSOM MED, V67, P89, DOI 10.1097/01.psy.0000149256.81953.49
   Donoghue OA, 2014, GERIATR GERONTOL INT, V14, P827, DOI 10.1111/ggi.12174
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Geruschat DR, 2006, OPTOMETRY VISION SCI, V83, P550, DOI 10.1097/01.opx.0000232219.23362.a6
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   Kotecha A, 2013, INVEST OPHTH VIS SCI, V54, P5408, DOI 10.1167/iovs.12-12026
   Kuyk T, 1998, OPTOMETRY VISION SCI, V75, P174, DOI 10.1097/00006324-199803000-00022
   LOVIEKITCHIN JE, 1986, AM J OPTOM PHYS OPT, V63, P366
   Mathew RS, 2008, INVEST OPHTHALMOL VI, V49
   McCarthy I, 2016, HLTH AGING RES, V5, P1, DOI DOI 10.1097/01.HXR.0000508387.10630.8D
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Popescu ML, 2012, INVEST OPHTH VIS SCI, V53, P2308, DOI 10.1167/iovs.11-9330
   Popescu ML, 2011, INVEST OPHTH VIS SCI, V52, P7168, DOI 10.1167/iovs.11-7564
   Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087
   Sengupta S, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/1471-2415-15-9
   Sengupta S, 2014, OPHTHALMOLOGY, V121, P727, DOI 10.1016/j.ophtha.2013.09.042
   Shimada H, 2010, ARCH GERONTOL GERIAT, V50, P140, DOI 10.1016/j.archger.2009.02.015
   Spielberger CD, 1983, STATE TRAIT ANXIETY
   Startzell JK, 2000, J AM GERIATR SOC, V48, P567, DOI 10.1111/j.1532-5415.2000.tb05006.x
   Subhi H, 2017, OPHTHAL PHYSL OPT, V37, P399, DOI 10.1111/opo.12362
   Szabo SM, 2010, OSTEOPOROSIS INT, V21, P855, DOI 10.1007/s00198-009-1025-8
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Turano KA, 2004, OPTOMETRY VISION SCI, V81, P298, DOI 10.1097/01.opx.0000134903.13651.8e
   Wang MY, 2012, INVEST OPHTH VIS SCI, V53, P7967, DOI 10.1167/iovs.12-10701
   Wood JM, 2009, INVEST OPHTH VIS SCI, V50, P482, DOI 10.1167/iovs.08-1942
   Xue QL, 2008, AM J EPIDEMIOL, V167, P240, DOI 10.1093/aje/kwm270
NR 33
TC 8
Z9 8
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2020
VL 104
IS 4
BP 529
EP 534
DI 10.1136/bjophthalmol-2019-313864
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA LB3EI
UT WOS:000524520300015
PM 31289034
OA Green Published, hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Senra, H
   Balaskas, K
   Mahmoodi, N
   Aslam, T
AF Senra, Hugo
   Balaskas, Konstantinos
   Mahmoodi, Neda
   Aslam, Tariq
TI Experience of Anti-VEGF Treatment and Clinical Levels of Depression and
   Anxiety in Patients With Wet Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MINI-MENTAL-STATE; VISION LOSS; HOSPITAL ANXIETY; PAIN INTENSITY;
   META-SYNTHESIS; SIGHT LOSS; PEOPLE; PREVALENCE; DISABILITY; INJECTION
AB PURPOSE: To investigate detailed patient experiences specific to receiving vascular endothelial growth factor inhibitors (anti-VEGF) for wet age-related macular degeneration (wAMD), and to acquire a snapshot of the frequency of clinically significant levels of depression, anxiety, and posttraumatic stress among patients and levels of burden in patients' carers.
   DESIGN: Observational cross-sectional mixed-methods study.
   METHODS: Three hundred patients with wAMD receiving anti-VEGF treatment and 100 patient carers were recruited. Qualitative data on patients' experience of treatment were collected using a structured survey. Standardized validated questionnaires were used to quantify clinically significant levels of anxiety, depression, and posttraumatic stress, as well as cognitive function and carers' burden.
   RESULTS: Qualitative data showed that 56% of patients (n = 132) reported anxiety related to anti-VEGF treatment. The main sources of anxiety were fear of going blind owing to intravitreal injections and concerns about treatment effectiveness, rather than around pain. From validated questionnaires, 17% of patients (n = 52) showed clinical levels of anxiety and 12% (n = 36) showed clinical levels of depression. Depression levels, but not anxiety,were significantly higher in patients who received up to 3 injections compared with patients who received from 4 to 12 injections (analysis of variance [ANOVA] P = .027) and compared with patients who received more than 12 injections (ANOVA P = .001).
   CONCLUSIONS: Anti-VEGF treatment is often experienced with some anxiety related to treatment, regardless of the number of injections received. Clinical levels of depression seem to be more frequent in patients at early stages of anti-VEGF treatment. Strategies to improve patient experience of treatment and minimize morbidity are suggested. (C) 2017 Published by Elsevier Inc. All rights reserved.
C1 [Senra, Hugo; Aslam, Tariq] Univ Manchester, Fac Biol Med & Hlth, Div Pharm & Optometry, Sch Hlth Sci,Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
   [Balaskas, Konstantinos; Aslam, Tariq] Cent Manchester Fdn Trust, Manchester Royal Eye Hosp, Manchester, Lancs, England.
   [Mahmoodi, Neda] Leeds Beckett Univ, Fac Hlth & Social Sci, Sch Psychol, Leeds, W Yorkshire, England.
C3 University of Manchester; Manchester Royal Eye Hospital; Leeds Beckett
   University
RP Aslam, T (通讯作者)，Manchester Royal Eye Hosp, Oxford Rd, Manchester M13 9PL, Lancs, England.
EM Tariq.Aslam@cmft.nhs.uk
RI Balaskas, Konstantinos/ABD-5979-2020; Aslam, Tariq/A-8532-2016
OI Balaskas, Konstantinos/0000-0002-7690-6277; Aslam,
   Tariq/0000-0002-9739-7280
FU BAYER, LEVERKUSEN, GERMANY [R117779]
FX THIS WORK WAS SUPPORTED BY A GRANT RECEIVED FROM BAYER, LEVERKUSEN,
   GERMANY - REFERENCE no: R117779.
CR Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Banerjee A, 2008, INDIAN J OPHTHALMOL, V56, P469
   Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   Blaha GR, 2011, RETINA-J RET VIT DIS, V31, P535, DOI 10.1097/IAE.0b013e3181eac724
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   Casten R, 2008, J VISUAL IMPAIR BLIN, V102, P591, DOI 10.1177/0145482X0810201003
   Casten R, 2010, ARCH OPHTHALMOL-CHIC, V128, P506, DOI 10.1001/archophthalmol.2010.24
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Chua PYS, 2009, ARCH OPHTHALMOL-CHIC, V127, P939, DOI 10.1001/archophthalmol.2009.139
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   De Leo D, 1999, PSYCHOSOMATICS, V40, P339, DOI 10.1016/S0033-3182(99)71229-6
   Dreer LE, 2008, BRIT J HEALTH PSYCH, V13, P449, DOI 10.1348/135910707X209835
   Eramudugolla R, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00056
   Evans JR, 2007, OPHTHALMOLOGY, V114, P283, DOI 10.1016/j.ophtha.2006.10.006
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Garcia-Perez MA, 2003, EDUC PSYCHOL MEAS, V63, P825, DOI 10.1177/0013164403251280
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   Henriksen K., 2013, INT J OPHTHALMIC PRA, V1, P68, DOI [10.12968/ijop.2010.1.2.68, DOI 10.12968/ijop.2010.1.2.68, DOI 10.12968/IJOP.2010.1.2.68]
   Holloway EE, 2015, AUST J PRIM HEALTH, V21, P169, DOI 10.1071/PY13085
   LaHood BR, 2011, CLIN EXP OPHTHALMOL, V39, P184, DOI 10.1111/j.1442-9071.2010.02432.x
   Lee WJ, 2013, ASIA-PAC J OPHTHALMO, V2, P23, DOI 10.1097/APO.0b013e31827be8b1
   Mathew RS, 2011, OPHTHAL PHYSL OPT, V31, P375, DOI 10.1111/j.1475-1313.2011.00848.x
   McCloud C, 2014, OPTOMETRY VISION SCI, V91, P966, DOI 10.1097/OPX.0000000000000320
   McManus S, ADULT PSYCHIAT MORBI
   Moisseiev E, 2012, CURR EYE RES, V37, P813, DOI 10.3109/02713683.2012.681335
   Ribeiro MVMR, 2015, ARQ BRAS OFTALMOL, V78, P197, DOI 10.5935/0004-2749.20150051
   NICE, 2011, COMM MENT HLTH DIS G
   Nyman SR, 2010, BRIT J VISUAL IMPA, V28, P175, DOI 10.1177/0264619610374171
   Nyman SR, 2012, DISABIL REHABIL, V34, P971, DOI 10.3109/09638288.2011.626487
   Papadopoulos K, 2014, RES DEV DISABIL, V35, P1734, DOI 10.1016/j.ridd.2014.02.019
   Poole NA, 2006, GEN HOSP PSYCHIAT, V28, P55, DOI 10.1016/j.genhosppsych.2005.08.004
   Rees G, 2010, EXPERT REV OPHTHALMO, V5, P385, DOI 10.1586/EOP.10.32
   Rees G, 2010, INVEST OPHTH VIS SCI, V51, P2891, DOI 10.1167/iovs.09-5080
   REINHARD SC, 1994, EVAL PROGRAM PLANN, V17, P261, DOI 10.1016/0149-7189(94)90004-3
   Rifkin L, 2012, RETINA-J RET VIT DIS, V32, P696, DOI 10.1097/IAE.0b013e3182252ad3
   Roth DB, 2006, AM J OPHTHALMOL, V142, P492, DOI 10.1016/j.ajo.2006.03.042
   Segal O, 2016, ACTA OPHTHALMOL, V94, P203, DOI 10.1111/aos.12802
   Senra H, 2016, GRAEF ARCH CLIN EXP, V254, P1873, DOI 10.1007/s00417-016-3384-0
   Senra H, 2013, J REHABIL RES DEV, V50, P1301, DOI 10.1682/JRRD.2012.08.0138
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   Solomon SD, 2016, OPHTHALMOLOGY, V123, P70, DOI 10.1016/j.ophtha.2015.09.002
   Tailor R, 2011, CLIN OPHTHALMOL, V5, P1499, DOI 10.2147/OPTH.S24358
   Thetford C, 2013, BRIT J VISUAL IMPA, V31, P89, DOI 10.1177/0264619613481778
   Varano M, 2016, CLIN OPHTHALMOL, V10, P257, DOI 10.2147/OPTH.S92616
   Vink D, 2008, J AFFECT DISORDERS, V106, P29, DOI 10.1016/j.jad.2007.06.005
   Walker JG, 2006, BRIT J HEALTH PSYCH, V11, P303, DOI 10.1348/135910705X68681
   Weiss DS, 1997, IMPACT EVENT SCALE R
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   WULSIN LR, 1993, DIABETES CARE, V16, P1061, DOI 10.2337/diacare.16.8.1061
   Zhang XZ, 2013, JAMA OPHTHALMOL, V131, P573, DOI 10.1001/jamaophthalmol.2013.2597
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 54
TC 45
Z9 45
U1 2
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2017
VL 177
BP 213
EP 224
DI 10.1016/j.ajo.2017.03.005
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA EU3TS
UT WOS:000400954500028
PM 28302534
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Cho, BJ
   Heo, JW
   Shin, JP
   Ahn, J
   Kim, TW
   Chung, H
AF Cho, Bum-Joo
   Heo, Jang Won
   Shin, Jae Pil
   Ahn, Jeeyun
   Kim, Tae Wan
   Chung, Hum
TI Epidemiological Association Between Systemic Diseases and Age-Related
   Macular Degeneration: The Korea National Health and Nutrition
   Examination Survey 2008-2011
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; risk factor; diabetes mellitus; liver
   cancer
ID BEAVER-DAM EYE; CARDIOVASCULAR RISK-FACTORS; VISUAL IMPAIRMENT;
   FACTOR-H; DIABETIC-RETINOPATHY; TERM INCIDENCE; MACULOPATHY; PREVALENCE;
   POPULATION; COMPLEMENT
AB PURPOSE. We examined the epidemiological association between systemic diseases and age-related macular degeneration (AMD) in the general Korean population.
   METHODS. This cross-sectional study involved nationally representative data obtained from the 2008 to 2011 Korea National Health and Nutrition Examination Surveys. A total of 14,352 subjects aged >= 40 years participated in standardized health interviews regarding physician-diagnosis of several systemic diseases as well as physical examinations, including fundus photography for the evaluation of AMD.
   RESULTS. The overall prevalence rates of early, late, and any AMD were 6.0%, 0.6%, and 6.6%, respectively. In univariate logistic regression analyses adjusted for age and sex as well as smoking in late AMD, any AMD and late AMD were less prevalent among diabetic patients and more prevalent in participants with a history of liver cancer. A history of liver cirrhosis was associated with a higher prevalence of any AMD. In the final multivariate model, the associated factors for any AMD included age (odds ratio [OR], 1.09), the presence of diabetes mellitus (DM; OR, 0.74), and a history of liver cancer (OR, 4.32). Factors associated with late AMD included age (OR, 1.09), ever-smoking history (OR, 2.45), the presence of DM (OR, 0.22), and a history of liver cancer (OR, 12.51). The presence of diabetic retinopathy was associated with a lower prevalence of any AMD (OR, 0.35).
   CONCLUSIONS. When adjusted for confounders, any AMD and late AMD were less prevalent in diabetic patients. In contrast, a history of liver cancer was associated with a higher prevalence of any AMD and late AMD.
C1 [Cho, Bum-Joo; Heo, Jang Won; Ahn, Jeeyun; Kim, Tae Wan; Chung, Hum] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 110744, South Korea.
   [Cho, Bum-Joo; Heo, Jang Won; Chung, Hum] Seoul Natl Univ Hosp, Dept Ophthalmol, Seoul 110744, South Korea.
   [Shin, Jae Pil] Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Taegu, South Korea.
   [Ahn, Jeeyun; Kim, Tae Wan] Seoul Natl Univ, Boramae Med Ctr, Seoul Metropolitan Govt, Dept Ophthalmol, Seoul 110744, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University Hospital; Kyungpook National University; Seoul
   National University (SNU); Seoul National University Hospital
RP Heo, JW (通讯作者)，Seoul Natl Univ, Coll Med, Dept Ophthalmol, 101 Daehang No, Seoul 110744, South Korea.
EM jangwonheo@gmail.com
OI Ahn, Jeeyun/0000-0001-9017-1652; Cho, Bum-Joo/0000-0002-0244-388X
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boon CJF, 2009, MOL IMMUNOL, V46, P1573, DOI 10.1016/j.molimm.2009.02.013
   Borrone R, 2008, EUR J OPHTHALMOL, V18, P949, DOI 10.1177/112067210801800615
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Cheung N, 2007, ARCH OPHTHALMOL-CHIC, V125, P1241, DOI 10.1001/archopht.125.9.1241
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Choi J, 2011, OPHTHAL EPIDEMIOL, V18, P259, DOI 10.3109/09286586.2011.602509
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cummings M, 2008, CLIN OPHTHALMOL, V2, P369
   Frank RN, 2013, RETINA-J RET VIT DIS, V33, P899, DOI 10.1097/IAE.0b013e318287d882
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Halme J, 2009, MOL IMMUNOL, V46, P2284, DOI 10.1016/j.molimm.2009.04.005
   Khandhadia S, 2013, OPHTHALMOLOGY, V120, P1612, DOI 10.1016/j.ophtha.2013.01.004
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Moorthy S, 2011, AM J OPHTHALMOL, V151, P375, DOI 10.1016/j.ajo.2010.09.001
   Nagaoka T, 2004, BRIT J OPHTHALMOL, V88, P1060, DOI 10.1136/bjo.2003.035345
   Park SJ, 2014, OPHTHALMOLOGY, DOI [10.1016/j.ophtha.2014.03.022, DOI 10.1016/J.OPHTHA.2014.03.022]
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pawlak K, 2008, CYTOKINE, V43, P98, DOI 10.1016/j.cyto.2008.03.011
   Roh MI, 2008, YONSEI MED J, V49, P931, DOI 10.3349/ymj.2008.49.6.931
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Sander B, 2001, INVEST OPHTH VIS SCI, V42, P433
   SCHULZ TF, 1986, MOL IMMUNOL, V23, P1243, DOI 10.1016/0161-5890(86)90158-6
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Voutilainen-Kaunisto RM, 2000, DIABETES CARE, V23, P1672, DOI 10.2337/diacare.23.11.1672
   Yoon Kyung-Chul, 2011, Korean J Ophthalmol, V25, P421, DOI 10.3341/kjo.2011.25.6.421
   Yoshikawa T, 2011, JPN J OPHTHALMOL, V55, P235, DOI 10.1007/s10384-011-0010-x
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Zylbermann R, 1997, EYE, V11, P872, DOI 10.1038/eye.1997.224
NR 39
TC 13
Z9 13
U1 1
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2014
VL 55
IS 7
BP 4430
EP 4437
DI 10.1167/iovs.14-14379
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AL9UI
UT WOS:000339487000052
PM 24970257
DA 2022-11-30
ER

PT J
AU Khanani, AM
   Hershberger, VS
   Pieramici, DJ
   Khurana, RN
   Brunstein, F
   Ma, L
   Maass, KF
   Honigberg, LA
   Tom, I
   Chen, H
   Strauss, EC
   Lai, P
AF Khanani, Arshad M.
   Hershberger, Vrinda S.
   Pieramici, Dante J.
   Khurana, Rahul N.
   Brunstein, Flavia
   Ma, Ling
   Maass, Katie F.
   Honigberg, Lee A.
   Tom, Irene
   Chen, Hao
   Strauss, Erich C.
   Lai, Phillip
CA Phase I Investigators
TI Phase 1 Study of the Anti-HtrA1 Antibody-binding Fragment FHTR2163 in
   Geographic Atrophy Secondary to Age-related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SERINE-PROTEASE; HTRA1; PHARMACOKINETICS; PREVALENCE; EXPRESSION;
   VARIANT
AB PURPOSE: FHTR2163 is a novel antigen-binding fragment (Fab) directed against high-temperature requirement protein A1 (HtrA1). HTRA1 inhibition may preserve retinal integrity and slow disease progression in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This study examined the safety, pharmacokinetics, immunogenicity, and changes in the HTRA1-specific substrate Dickkop-related protein 3 (DKK3) in patients with GA who received FHTR2163.
   DESIGN: Phase I, open-label, single ascending dose escalation and multiple-dose expansion study.
   METHODS: Adults aged >= 50 years with GA secondary to AMD with best corrected visual acuity ranging between Snellen 20/125 and 20/400 were enrolled. In the first stage, a single intravitreal injection of FHTR2163 was given in 5 dose-escalation cohorts ranging from 1 to 20 mg (n = 3 patients/cohort; n = 15 total patients). The second stage evaluated the maximum tested dose of 20 mg administered every 4 weeks for 3 doses (n = 13 patients).
   RESULTS: No dose limiting toxicities or ocular serious AEs were reported. The most frequently reported AEs in the study eye were conjunctival hemorrhage (n = 7), conjunctival hyperemia (n = 4), and eye pain (n = 2). No non-ocular or ocular AEs were assessed as drug related. There were no clinically significant changes in ocular exams. A sustained pharmacodynamic effect of anti-HtrA1 was observed in the aqueous humor, as measured by levels of cleaved DKK3.
   CONCLUSIONS: FHTR2163, a novel Fab directed against HtrA1, was well tolerated with no DLTs or significant ocular AEs. The molecule when injected intravitreally for 3 doses showed a sustained pharmacodynamic effect at the maximum tested dose of 20 mg. (C) 2021 The Author(s). Published by Elsevier Inc.
C1 [Khanani, Arshad M.] Sierra Eye Associates, Reno, NV 89502 USA.
   Univ Nevada, Reno Sch Med, Reno, NV 89557 USA.
   Florida Eye Associates, Melbourne, FL USA.
   Calif Retina Consultants, Santa Barbara, CA USA.
   Northern Calif Retina Vitreous Associates, Mountain View, CA USA.
   Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA.
   Genentech Inc, San Francisco, CA 94080 USA.
C3 Nevada System of Higher Education (NSHE); University of Nevada Reno;
   University of California System; University of California San Francisco;
   Roche Holding; Genentech
RP Khanani, AM (通讯作者)，Sierra Eye Associates, Reno, NV 89502 USA.
EM arshad.khanani@gmail.com
OI Hershberger, Vrinda/0000-0001-8677-8582; Maass,
   Katie/0000-0002-0493-2863; Khurana, Rahul/0000-0001-5198-1353
FU Genentech
FX This work was supported by Genentech. Genentech was involved in the
   study design, data interpretation, and the decision to submit for
   publication in conjunction with the authors.
CR Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Ciferri C, 2015, BIOCHEM J, V472, P169, DOI 10.1042/BJ20150601
   Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5
   Dere E, 2020, TOXICOL PATHOL
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Do DV, 2014, RETINA-J RET VIT DIS, V34, P313, DOI 10.1097/IAE.0b013e3182979ddd
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Holekamp N, 2020, OPHTHALMOLOGY, V127, P769, DOI 10.1016/j.ophtha.2019.12.009
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Le KN, 2015, CPT-PHARMACOMET SYST, V4, P595, DOI 10.1002/psp4.12031
   Liao SM, 2017, MOL VIS, V23, P318
   Lin MK, 2018, AGING CELL, V17, DOI 10.1111/acel.12710
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Tom I, 2020, P NATL ACAD SCI USA, V117, P9952, DOI 10.1073/pnas.1917608117
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
NR 26
TC 5
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2021
VL 232
BP 49
EP 57
DI 10.1016/j.ajo.2021.06.017
EA OCT 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WH1TP
UT WOS:000707469700006
PM 34214452
OA hybrid
DA 2022-11-30
ER

PT J
AU Bhutto, IA
   Uno, K
   Merges, C
   Zhang, L
   McLeod, DS
   Lutty, GA
AF Bhutto, Imran A.
   Uno, Koichi
   Merges, Carol
   Zhang, Lei
   McLeod, D. Scott
   Lutty, Gerard A.
TI Reduction of endogenous angiogenesis inhibitors in Bruch's membrane of
   the submacular region in eyes with age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL-CELL MIGRATION; CHOROIDAL
   NEOVASCULARIZATION; COLLAGEN-XVIII; RETINAL NEOVASCULARIZATION; OCULAR
   NEOVASCULARIZATION; GROWTH-FACTOR; TUMOR-GROWTH; FACTOR PEDF; ENDOSTATIN
AB Objectives: To determine the relative levels of 3 potent inhibitors of angiogenesis ( endostatin, pigment epithelium-derived factor, and thrombospondin 1) in the retinal pigment epithelium-Bruch's membrane choriocapillaris complex in the submacular region in aged control eyes and eyes with age-related macular degeneration (AMD).
   Methods: Immunohistochemical analysis with antibodies against endostatin, pigment epithelium-derived factor, and thrombospondin 1 was performed on the macular region of aged control donor eyes (n=8; mean age, 79.8 years) and eyes with AMD ( n=12; mean age, 83.9 years). Three independent masked observers scored the reaction product ( scored from 0-7). Mean scores from the control eyes and the eyes with AMD were analyzed using 1-way analysis of variance and unpaired t test. Results: In control eyes, strong immunoreactivity of all 3 inhibitors was observed in the retinal pigment epithelium-Bruch's membrane-choriocapillaris complex. Immunoreactivity for endostatin, pigment epithelium derived factor, and thrombospondin 1 in Bruch's membrane was significantly lower in eyes with AMD compared with aged control eyes ( analysis of variance, P=.003, P=.009, and P <.001, respectively). In the choriocapillaris, a significant reduction was observed in endostatin ( analysis of variance, P=.02) and thrombospondin 1 ( analysis of variance, P=.005) in eyes with AMD.
   Conclusions: These findings suggest that endogenous angiogenesis inhibitors in the retinal pigment epithelium Bruch's membrane-choriocapillaris complex may provide a biochemical barrier for choroidal neovascular invasion. Clinical Relevance: Decreased levels of angiogenic inhibitors at the retinal pigment epithelium-Bruch's membrane-choriocapillaris complex in eyes with AMD make Bruch's membrane vulnerable to choroidal neovascularization.
C1 [Bhutto, Imran A.; Uno, Koichi; Merges, Carol; Zhang, Lei; McLeod, D. Scott; Lutty, Gerard A.] Johns Hopkins Univ Hosp, Dept Ophthalmol, Wilmer Ophthalmol Inst, Sch Med, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Lutty, GA (通讯作者)，Johns Hopkins Univ Hosp, Dept Ophthalmol, Wilmer Ophthalmol Inst, Sch Med, 170 Woods Res Bldg,600 N Wolfe St, Baltimore, MD 21287 USA.
EM glutty@jhmi.edu
FU NEI NIH HHS [R01 EY016151-05, R01-EY016151, P30 EY001765, EY-01765, R01
   EY016151] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY001765,
   R01EY016151] Funding Source: NIH RePORTER
CR Abdollahi A, 2004, MOL CELL, V13, P649, DOI 10.1016/S1097-2765(04)00102-9
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   *ANG FDN, ANG UND ANG
   Auricchio A, 2002, MOL THER, V6, P490, DOI 10.1006/mthe.2002.0702
   Becerra SP, 2006, EXP EYE RES, V82, P739, DOI 10.1016/j.exer.2005.10.016
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6
   Campbell SC, 1998, CANCER RES, V58, P1298
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Chader GJ, 2001, P NATL ACAD SCI USA, V98, P2122, DOI 10.1073/pnas.061024098
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
   Eriksson K, 2003, FEBS LETT, V536, P19, DOI 10.1016/S0014-5793(03)00003-6
   Esemuede N, 2004, J SURG RES, V122, P135, DOI 10.1016/j.jss.2004.05.015
   Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1
   Ferreras M, 2000, FEBS LETT, V486, P247, DOI 10.1016/S0014-5793(00)02249-3
   Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608
   Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   He Shikun, 2006, Yan Ke Xue Bao, V22, P265
   HISCOTT P, 1992, EYE, V6, P566, DOI 10.1038/eye.1992.123
   Kramerov AA, 2006, AM J PATHOL, V168, P1722, DOI 10.2353/ajpath.2006.050533
   LAHAV J, 1988, EXP CELL RES, V177, P199, DOI 10.1016/0014-4827(88)90037-7
   LUTTY GA, 1993, INVEST OPHTH VIS SCI, V34, P477
   Marneros AG, 2004, EMBO J, V23, P89, DOI 10.1038/sj.emboj.7600014
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Miyajima-Uchida H, 2000, INVEST OPHTH VIS SCI, V41, P561
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   PAGE C, 1992, AM J PATHOL, V141, P673
   Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Reich SJ, 2003, CURR OPIN GENET DEV, V13, P317, DOI 10.1016/S0959-437X(03)00043-1
   Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249
   Sheibani N, 2000, BIOCHEM BIOPH RES CO, V267, P257, DOI 10.1006/bbrc.1999.1903
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Talks KL, 2000, BRIT J HAEMATOL, V109, P477, DOI 10.1046/j.1365-2141.2000.01864.x
   TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765
   TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   Uno K, 2006, BRIT J OPHTHALMOL, V90, P48, DOI 10.1136/bjo.2005.074005
   VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436
   VOGEL T, 1993, J CELL BIOCHEM, V53, P1
   Wang SJ, 2003, DEV DYNAM, V228, P630, DOI 10.1002/dvdy.10412
   Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zatterstrom UK, 2000, CELL STRUCT FUNCT, V25, P97
NR 51
TC 44
Z9 48
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAY
PY 2008
VL 126
IS 5
BP 670
EP 678
DI 10.1001/archopht.126.5.670
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 299UO
UT WOS:000255780700010
PM 18474778
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Maeda, T
   Maeda, A
   Matosky, M
   Okano, K
   Roos, S
   Tang, J
   Palczewski, K
AF Maeda, Tadao
   Maeda, Akiko
   Matosky, Melissa
   Okano, Kiichiro
   Roos, Satsumi
   Tang, Johnny
   Palczewski, Krzysztof
TI Evaluation of Potential Therapies for a Mouse Model of Human Age-Related
   Macular Degeneration Caused by Delayed all-trans-Retinal Clearance
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID VISUAL CYCLE; CHOROIDAL NEOVASCULARIZATION; RETINITIS-PIGMENTOSA;
   CELL-DEATH; VITAMIN-C; MICE; ACCUMULATION; RAPAMYCIN; PROTEIN;
   SUPPLEMENTATION
AB PURPOSE. Evaluate the efficacy of potential therapeutics in Rdh8(-/-) Abca4(-/-) mice, a rodent model of human age-related macular degeneration (AMD).
   METHODS. Therapeutic efficacy of several antioxidant agents (ascorbic acid, alpha-lipoic acid, alpha-tocopherol, Mn(III)-tetrakis(4-benzoic acid)-porphyrin, and butylated hydroxytoluene), an immunosuppressive agent with antivascular endothelial growth factor (VEGF) activity (sirolimus, also known as rapamycin), a retinoid cycle inhibitor (retinylamine), and an artificial chromophore (9-cis-retinyl acetate) were evaluated side by side in a recently described murine model of AMD, the Rdh8(-/-) Abca4(-/-) mouse. This animal exhibits a retinopathy caused by delayed all-trans-retinal clearance resulting from the absence of both ATP-binding cassette transporter 4 (Abca4) and retinol dehydrogenase 8 (Rdh8) activities. Drug efficacy was evaluated by retinal histologic analyses and electroretinograms (ERGs).
   RESULTS. All tested agents partially prevented atrophic changes in the Rdh8(-/-) Abca4(-/-) retina with retinylamine demonstrating the greatest efficacy. A significant reduction of complement deposition on Bruch's membrane was observed in sirolimus-treated mice, although the severity of retinal degeneration was similar to that observed in antioxidant-and 9-cis-retinyl acetate-treated mice. Sirolimus treatment of 6-month-old Rdh8(-/-) Abca4(-/-) mice for 4 months prevented choroidal neovascularization without changing retinal VEGF levels.
   CONCLUSIONS. Mechanism-based therapy with retinylamine markedly attenuated degenerative retinopathy in Rdh8(-/-) Abca4(-/-) mice. Further understanding of pathogenic mechanisms involved in AMD is needed to develop more effective therapeutics. (Invest Ophthalmol Vis Sci. 2009; 50: 4917-4925) DOI: 10.1167/iovs.09-3581
C1 [Maeda, Tadao; Maeda, Akiko; Matosky, Melissa; Okano, Kiichiro; Roos, Satsumi; Palczewski, Krzysztof] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA.
   [Maeda, Tadao; Maeda, Akiko; Tang, Johnny] Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA.
   [Tang, Johnny] Louis Stokes Cleveland VA Med Ctr, Res Serv, Cleveland, OH USA.
C3 Case Western Reserve University; Case Western Reserve University; US
   Department of Veterans Affairs; Veterans Health Administration (VHA);
   Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs
   Medical Center
RP Maeda, T (通讯作者)，Case Western Reserve Univ, Sch Med, Dept Ophthalmol & Visual Sci, 11100 Euclid Ave, Cleveland, OH 44106 USA.
EM txm88@case.edu
FU VAMC Career Development Grant; Ohio Lions Research Foundation; National
   Institutes of Health [EY019031, EY09339, P30 EY11373, EY08123]; NATIONAL
   EYE INSTITUTE [R01EY008123, R01EY009339, K08EY019031, P30EY011373]
   Funding Source: NIH RePORTER
FX Supported by funding from VAMC Career Development Grant, Research to
   Prevent Blindness, the Ohio Lions Research Foundation, and Grants
   EY019031, EY09339, P30 EY11373, and EY08123 from the National Institutes
   of Health.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200
   BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Chowers I, 2008, MOL VIS, V14, P2263
   Dejneka NS, 2004, MOL VIS, V10, P964
   DORRELL MI, 2009, J CLIN INVEST
   Golczak M, 2005, P NATL ACAD SCI USA, V102, P8162, DOI 10.1073/pnas.0503318102
   Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Haines JL, 2007, P NATL ACAD SCI USA, V104, P16725, DOI 10.1073/pnas.0708151104
   Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Kim IK, 2008, MOL VIS, V14, P1487
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152
   Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103
   Maeda A, 2006, BIOCHEMISTRY-US, V45, P4210, DOI 10.1021/bi052382x
   Maeda A, 2005, J BIOL CHEM, V280, P18822, DOI 10.1074/jbc.M501757200
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2007, P NATL ACAD SCI USA, V104, P19565, DOI 10.1073/pnas.0707477104
   Maeda A, 2006, MOL PHARMACOL, V70, P1220, DOI 10.1124/mol.106.026823
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Maeda T, 2009, HUM MOL GENET, V18, P2277, DOI 10.1093/hmg/ddp163
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7
   Molday RS, 2007, J BIOENERG BIOMEMBR, V39, P507, DOI 10.1007/s10863-007-9118-6
   Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743
   Radu RA, 2008, INVEST OPHTH VIS SCI, V49, P3821, DOI 10.1167/iovs.07-1470
   Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sun H, 2000, NAT GENET, V26, P242, DOI 10.1038/79994
   Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225
   Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wenzel A, 2001, J NEUROSCI, V21, P53, DOI 10.1523/JNEUROSCI.21-01-00053.2001
   2001, ARCH OPHTHALMOL, V119, P1417
NR 39
TC 35
Z9 37
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2009
VL 50
IS 10
BP 4917
EP 4925
DI 10.1167/iovs.09-3581
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 497XE
UT WOS:000270097200052
PM 19494204
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Aslankurt, M
   Aslan, L
   Aksoy, A
   Erden, B
   Cekic, O
AF Aslankurt, Murat
   Aslan, Lokman
   Aksoy, Adnan
   Erden, Burak
   Cekic, Osman
TI The results of switching between 2 anti-VEGF drugs, bevacizumab and
   ranibizumab, in the treatment of neovascular age-related macular
   degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Anti-VEGF switch; Bevacizumab;
   Choroidal neovascularization; Intravitreal injection; Ranibizumab
ID INTRAVITREAL BEVACIZUMAB; SAFETY; PREVALENCE; EFFICACY; AVASTIN; TRIAL
AB Purpose: To report the results of switching from intravitreal bevacizumab to ranibizumab or vice versa in the treatment of choroidal neovascularization (CNV) due to age-related macular degeneration.
   Methods: Twenty eyes of 18 patients that underwent switch from intravitreal bevacizumab to ranibizumab and 10 eyes of 8 patients that underwent switch from ranibizumab to bevacizumab were retrospectively analyzed. The results were compared with 41 eyes of 37 patients treated with ranibizumab only. All eyes initially received 3 injections of ranibizumab or bevacizumab, which were repeated as needed (PRN dosing). Anti-vascular endothelial growth factor therapies were switched because of general health insurance applications and cost problems. The main outcome measures were best-corrected visual acuity (BCVA), injection number, and central macular thickness (CMT) obtained by optical coherence tomography.
   Results: Once all patients evaluated together at the final visit, the mean BCVA improved and CMT decreased. When switching groups were taken into consideration, switching yielded improved BCVA and reduced CMT following switching. After switching, BCVA continuously improved in the bevacizumab to ranibizumab group, but stayed stable in the ranibizumab to bevacizumab group. The CMT was reduced at the switching time in both groups, but did not change after the switch. Final visual acuity improved or stabilized in all eyes in the ranibizumab-only group. The BCVA worsened in 20% of eyes in the bevacizumab to ranibizumab group and in 40% of eyes in the ranibizumab to bevacizumab group.
   Conclusions: The ranibizumab-only group and the switching from bevacizumab to ranibizumab group seemed superior to the ranibizumab to bevacizumab group.
C1 [Aslankurt, Murat; Aslan, Lokman; Aksoy, Adnan] Kahramanmaras Sutcu Imam Univ, Dept Ophthalmol, TR-46050 Kahramanmaras, Turkey.
   [Erden, Burak; Cekic, Osman] Okmeydani Training & Res Hosp, Dept Ophthalmol, Istanbul, Turkey.
C3 Kahramanmaras Sutcu Imam University; Istanbul Okmeydani Training &
   Research Hospital
RP Aslankurt, M (通讯作者)，KSU Med Fac, TR-46050 Kahramanmaras, Turkey.
EM maslankurt80@hotmail.com
RI Cekic, Osman/H-3027-2019
OI Cekic, Osman/0000-0003-0911-8649; ERDEN, BURAK/0000-0003-0650-4552
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Dhoot DS, 2012, EXPERT OPIN BIOL TH, V12, P371, DOI 10.1517/14712598.2012.660523
   Ehlers JP, 2010, OPHTHAL SURG LAS IM, V41, P182, DOI 10.3928/15428877-20100303-05
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Karagiannis DA, 2009, CLIN INTERV AGING, V4, P457
   Karagiannis DA, 2009, OPHTHALMOLOGICA, V223, P279, DOI 10.1159/000213644
   Kent JS, 2012, CAN J OPHTHALMOL, V47, P159, DOI 10.1016/j.jcjo.2012.01.003
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Velez-Montoya R, 2012, RETINA
   Yamada K, 2011, ISRN OPHTHALMOLOGY
NR 22
TC 18
Z9 19
U1 0
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JUL-AUG
PY 2013
VL 23
IS 4
BP 553
EP 557
DI 10.5301/ejo.5000268
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 214RE
UT WOS:000324152400014
PM 23516253
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Lai, TYY
   Teo, K
   Ruamviboonsuk, P
   Chen, SJ
   Kim, JE
   Gomi, F
   Koh, AH
   Kokame, G
   Jordan-Yu, JM
   Corvi, F
   Invernizzi, A
   Ogura, Y
   Tan, C
   Mitchell, P
   Gupta, V
   Chhablani, J
   Chakravarthy, U
   Sadda, SR
   Wong, TY
   Staurenghi, G
   Lee, WK
AF Cheung, Chui M.
   Lai, Timothy Y. Y.
   Teo, Kelvin
   Ruamviboonsuk, Paisan
   Chen, Shih-Jen
   Kim, Judy E.
   Gomi, Fumi
   Koh, Adrian H.
   Kokame, Gregg
   Jordan-Yu, Janice Marie
   Corvi, Federico
   Invernizzi, Alessandro
   Ogura, Yuichiro
   Tan, Colin
   Mitchell, Paul
   Gupta, Vishali
   Chhablani, Jay
   Chakravarthy, Usha
   Sadda, Srinivas R.
   Wong, Tien Y.
   Staurenghi, Giovanni
   Lee, Won Ki
TI Polypoidal Choroidal Vasculopathy Consensus Nomenclature and
   Non-Indocyanine Green Angiograph Diagnostic Criteria from the
   Asia-Pacific Ocular Imaging Society PCV Workgroup
SO OPHTHALMOLOGY
LA English
DT Article
AB Purpose: To develop consensus terminology in the setting of polypoidal choroidal vasculopathy (PCV) and to develop and validate a set of diagnostic criteria not requiring indocyanine green angiography (ICGA) for differentiating PCV from typical neovascular age-related macular degeneration (nAMD) based on a combination of OCT and color fundus photography findings.
   Design: Evaluation of diagnostic test results.
   Participants: Panel of retina specialists.
   Methods: As part of the Asia-Pacific Ocular Imaging Society, an international group of experts surveyed and discussed the published literature regarding the current nomenclature and lesion components for PCV, and proposed an updated consensus nomenclature that reflects our latest understanding based on imaging and histologic reports. The workgroup evaluated a set of diagnostic features based on OCT images and color fundus photographs for PCV that may distinguish it from typical nAMD and assessed the performance of individual and combinations of these non-ICGA features, aiming to propose a new set of diagnostic criteria that does not require the use of ICGA. The final recommendation was validated in 80 eyes from 2 additional cohorts.
   Main Outcome Measures: Consensus nomenclature system for PCV lesion components and non-ICGA-based criteria to differentiate PCV from typical nAMD.
   Results: The workgroup recommended the terms polypoidal lesion and branching neovascular network for the 2 key lesion components in PCV. For the diagnosis of PCV, the combination of 3 OCT-based major criteria (sub-retinal pigment epithelium [RPE] ring-like lesion, en face OCT complex RPE elevation, and sharp-peaked PED) achieved an area under the receiver operating characteristic curve of 0.90. Validation of this new scheme in a separate subset 80 eyes achieved an accuracy of 82%.
   Conclusions: We propose updated terminology for PCV lesion components that better reflects the nature of these lesions and is based on international consensus. A set of practical diagnostic criteria applied easily to spectral-domain OCT results can be used for diagnosing PCV with high accuracy in clinical settings in which ICGA is not performed routinely. (C) 2020 by the American Academy of Ophthalmology.
C1 [Cheung, Chui M.; Teo, Kelvin; Koh, Adrian H.; Jordan-Yu, Janice Marie; Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Med Retina Dept, Singapore, Singapore.
   [Cheung, Chui M.; Teo, Kelvin; Koh, Adrian H.; Chakravarthy, Usha; Wong, Tien Y.] Natl Univ Singapore, Duke NUS Med Sch, Singapore, Singapore.
   [Lai, Timothy Y. Y.] Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Ruamviboonsuk, Paisan] Rajavithi Hosp, Dept Ophthalmol, Bangkok, Thailand.
   [Chen, Shih-Jen] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chen, Shih-Jen] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
   [Kim, Judy E.] Med Coll Wisconsin, Dept Ophthalmol & Visual Sci, Milwaukee, WI 53226 USA.
   [Gomi, Fumi] Hyogo Coll Med, Dept Ophthalmol, Nishinomiya, Hyogo, Japan.
   [Koh, Adrian H.] Camden Med Ctr, Eye & Retina Surg, Singapore, Singapore.
   [Kokame, Gregg] Univ Hawaii, Div Ophthalmol, Dept Surg, Sch Med, Honolulu, HI 96822 USA.
   [Corvi, Federico; Invernizzi, Alessandro; Staurenghi, Giovanni] Univ Milan, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
   [Invernizzi, Alessandro] Univ Sydney, Fac Hlth & Med, Save Sight Inst, Sydney, NSW, Australia.
   [Ogura, Yuichiro] Nagoya City Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med Sci, Nagoya, Aichi, Japan.
   [Tan, Colin] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore, Singapore.
   [Mitchell, Paul] Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Gupta, Vishali] Post Grad Inst Med Educ & Res PGIMER, Adv Eye Ctr, Dept Ophthalmol, Chandigarh, India.
   [Chhablani, Jay] Univ Pittsburgh, Eye Ctr, Pittsburgh, PA USA.
   [Chakravarthy, Usha] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland.
   [Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Doheny Eye Inst, Los Angeles, CA 90095 USA.
   [Lee, Won Ki] Nune Eye Hosp, Seoul, South Korea.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Chinese University of Hong Kong;
   Rajavithi Hospital; National Yang Ming Chiao Tung University; Taipei
   Veterans General Hospital; National Yang Ming Chiao Tung University;
   Medical College of Wisconsin; Hyogo College of Medicine; University of
   Hawaii System; University of Milan; Luigi Sacco Hospital; University of
   Sydney; Nagoya City University; Tan Tock Seng Hospital; University of
   Sydney; Westmead Institute for Medical Research; Post Graduate Institute
   of Medical Education & Research (PGIMER), Chandigarh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Queens University Belfast; Doheny Eye Institute; University
   of California System; University of California Los Angeles; University
   of California Los Angeles Medical Center; David Geffen School of
   Medicine at UCLA
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Tan, Colin S/K-8972-2012; Wong, Tien Yin/AAC-9724-2020; Gupta,
   Vishali/AAU-2549-2021
OI Tan, Colin S/0000-0003-3088-5690; Wong, Tien Yin/0000-0002-8448-1264;
   Corvi, Federico/0000-0002-2661-5500; Teo, Kelvin/0000-0002-7458-7081;
   Chhablani, Jay/0000-0003-1772-3558; Gupta, Vishali/0000-0001-8216-4620
FU National Medical Research Council Singapore, Republic of Singapore
   [NMRC/LCG/004/2018]
FX Supported by the National Medical Research Council Singapore, Republic
   of Singapore (open fund large collaborative grant no.:
   NMRC/LCG/004/2018).
CR Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Azuma K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212055
   Baek J, 2019, EYE, V33, P419, DOI 10.1038/s41433-018-0228-7
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Bo QY, 2019, JAMA OPHTHALMOL, V137, P642, DOI 10.1001/jamaophthalmol.2019.0449
   Byeon SH, 2010, ACTA OPHTHALMOL, V88, P660, DOI 10.1111/j.1755-3768.2009.01517.x
   Chaikitmongkol V, 2019, JAMA OPHTHALMOL, V137, P661, DOI 10.1001/jamaophthalmol.2019.0565
   Cheung CMG, 2011, NEW ENGL J MED, V365, P2237, DOI 10.1056/NEJMc1107895
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2019, RETINA-J RET VIT DIS, V39, P1655, DOI 10.1097/IAE.0000000000002228
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   Cho HJ, 2019, J OCUL PHARMACOL TH, V35, P174, DOI 10.1089/jop.2018.0107
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   de Carlo TE, 2019, RETINA-J RET VIT DIS, V39, P1343, DOI 10.1097/IAE.0000000000002139
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Gupta P, 2017, RETINA-J RET VIT DIS, V37, P2269, DOI 10.1097/IAE.0000000000001481
   Kameda T, 2007, CLIN EXP OPHTHALMOL, V35, P596, DOI 10.1111/j.1442-9071.2007.01554.x
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Kokame GT, 2020, OPHTHALMOLOGICA, V243, P178, DOI 10.1159/000503834
   Kokame GT, 2019, OPHTHALMOL RETINA, V3, P744, DOI 10.1016/j.oret.2019.04.018
   Kokame GT, 2012, RETINA-J RET VIT DIS, V32, P1446, DOI 10.1097/IAE.0b013e3182695bf8
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Li ML, 2019, OPHTHALMOL RETINA, V3, P99, DOI 10.1016/j.oret.2018.08.008
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Pereira FB, 2015, OPHTHALMOLOGICA, V234, P233, DOI 10.1159/000439359
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sayanagi K, 2015, BRIT J OPHTHALMOL, V99, P29, DOI 10.1136/bjophthalmol-2013-304658
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Teo KYC, 2019, OPHTHALMOL RETINA, V3, P220, DOI 10.1016/j.oret.2018.11.003
   Teo KYC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092611
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tranos P, 2013, DRUG DES DEV THER, V7, P485, DOI 10.2147/DDDT.S43470
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 57
TC 48
Z9 52
U1 4
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2021
VL 128
IS 3
BP 443
EP 452
DI 10.1016/j.ophtha.2020.08.006
EA FEB 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QY6YQ
UT WOS:000630184400014
PM 32795496
OA hybrid, Green Published
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Feigl, B
   Morris, CP
   Brown, B
   Zele, AJ
AF Feigl, Beatrix
   Morris, C. Phillip
   Brown, Brian
   Zele, Andrew J.
TI Relationship Among CFH and ARMS2 Genotypes, Macular Pigment Optical
   Density, and Neuroretinal Function in Persons Without Age-Related
   Macular Degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID MEDIATED MULTIFOCAL ELECTRORETINOGRAM; FOVEAL FLICKER SENSITIVITY;
   RETINAL FUNCTION; DARK-ADAPTATION; CONE DYSTROPHY; GLARE RECOVERY; RISK;
   ROD; ERG; ABNORMALITIES
AB Objectives: To determine whether there is a difference in neuroretinal function and in macular pigment optical density between persons with high- and low-risk gene variants for age-related macular degeneration (AMD) and no ophthalmoscopic signs of AMD, and to compare the results on neuroretinal function to patients with manifest early AMD.
   Methods: Neuroretinal function was assessed with the multifocal electroretinogram for 32 participants (22 healthy persons with no AMD and 10 patients with early AMD). The 22 healthy participants with no AMD had either high-or low-risk genotypes for CFH (rs380390) and/or ARMS2 (rs10490924). Trough-to-peak response densities and peak-implicit times were analyzed in 5 concentric rings. Macular pigment optical density was assessed by use of customized heterochromatic flicker photometry.
   Results: Trough-to-peak response densities for concentric rings 1 to 3 were, on average, significantly greater in participants with high- risk genotypes than in participants with low-risk genotypes and in persons with early AMD after correction for age and smoking (P < .05). The group peak-implicit times for ring 1 were, on average, delayed in the patients with early AMD compared with the participants with high- or low-risk genotypes, although these differences were not significant. There was no significant correlation between genotypes and macular pigment optical density.
   Conclusions: Increased neuroretinal activity in persons who carry high-risk AMD genotypes may be due to genetically determined subclinical inflammatory and/or histological changes in the retina. Neuroretinal function in healthy persons genetically susceptible to AMD may be a useful additional early biomarker (in combination with genetics) of AMD before there is a clinical manifestation.
C1 [Feigl, Beatrix; Morris, C. Phillip; Brown, Brian; Zele, Andrew J.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia.
   [Feigl, Beatrix] Queensland Eye Inst, Brisbane, Qld, Australia.
C3 Queensland University of Technology (QUT); Queensland Eye Institute
RP Feigl, B (通讯作者)，Queensland Univ Technol, Inst Hlth & Biomed Innovat, 60 Musk Ave, Brisbane, Qld 4059, Australia.
EM b.feigl@qut.edu.au
OI Feigl, Beatrix/0000-0001-7198-7373; Morris, Phillip/0000-0001-8976-619X;
   Zele, Andrew/0000-0003-0291-9929
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bearse MA, 2004, INVEST OPHTH VIS SCI, V45, P296, DOI 10.1167/iovs.03-0424
   Bird AC, 2003, CLIN EXP OPHTHALMOL, V31, P461, DOI 10.1046/j.1442-9071.2003.00721.x
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P450
   Charng J, 2011, INVEST OPHTH VIS SCI, V52, P8891, DOI 10.1167/iovs.11-7602
   COLLINS M, 1989, CLIN VISION SCI, V4, P145
   COLLINS M, 1989, CLIN VISION SCI, V4, P155
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Feigl B, 2006, VISUAL NEUROSCI, V23, P863, DOI 10.1017/S0952523806230190
   Feigl B, 2005, INVEST OPHTH VIS SCI, V46, P4722, DOI 10.1167/iovs.05-0795
   Feigl B, 2005, EYE, V19, P431, DOI 10.1038/sj.eye.6701503
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   Feigl B, 2002, GRAEF ARCH CLIN EXP, V240, P615, DOI 10.1007/s00417-002-0478-7
   Feigl B, 2008, INVEST OPHTH VIS SCI, V49, P807, DOI 10.1167/iovs.07-0994
   Feigl Beatrix, 2005, Clin Exp Optom, V88, P304
   Feigl B, 2006, CURR EYE RES, V31, P635, DOI 10.1080/02713680600762739
   Feigl B, 2011, CURR MED RES OPIN, V27, P1745, DOI 10.1185/03007995.2011.603301
   Feigl B, 2011, INVEST OPHTH VIS SCI, V52, P1145, DOI 10.1167/iovs.10-5967
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   FOERSTER MH, 1990, GRAEF ARCH CLIN EXP, V228, P116, DOI 10.1007/BF00935718
   Gaffney AJ, 2011, OPTOMETRY VISION SCI, V88, P1080, DOI 10.1097/OPX.0b013e3182223697
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Gin TJ, 2011, INVEST OPHTH VIS SCI, V52, P9267, DOI 10.1167/iovs.11-8517
   GOURAS P, 1992, INVEST OPHTH VIS SCI, V33, P508
   GOURAS P, 1983, ARCH OPHTHALMOL-CHIC, V101, P718, DOI 10.1001/archopht.1983.01040010718003
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Gundogan FC, 2008, DOC OPHTHALMOL, V117, P175, DOI 10.1007/s10633-008-9119-8
   HAEGERSTROMPORTNOY G, 1989, CLIN VISION SCI, V4, P165
   Hageman GS, 1999, MOL VIS, V5
   Harrison WW, 2011, INVEST OPHTH VIS SCI, V52, P772, DOI 10.1167/iovs.10-5931
   Hoang QV, 2002, VISUAL NEUROSCI, V19, P395, DOI 10.1017/S0952523802194028
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Hood DC, 2002, INVEST OPHTH VIS SCI, V43, P1673
   Hood DC, 2000, PROG RETIN EYE RES, V19, P607, DOI 10.1016/S1350-9462(00)00013-6
   Hood DC, 2012, DOC OPHTHALMOL, V124, P1, DOI 10.1007/s10633-011-9296-8
   IKEDA H, 1989, DOC OPHTHALMOL, V73, P387, DOI 10.1007/BF00154494
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Jelcick AS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021858
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KNAVE B, 1970, Acta Ophthalmologica, V48, P136
   Kremers J, 2009, DOC OPHTHALMOL, V118, P205, DOI 10.1007/s10633-008-9159-0
   Li Y, 1999, VISION SCI ITS APPL, P52
   Loane E, 2011, EXP EYE RES, V93, P592, DOI 10.1016/j.exer.2011.07.005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Mohand-Said S, 1998, P NATL ACAD SCI USA, V95, P8357, DOI 10.1073/pnas.95.14.8357
   Moschos MM, 2011, CLIN EXP OPTOM, V94, P268, DOI 10.1111/j.1444-0938.2011.00589.x
   Moschos MM, 2004, J FR OPHTALMOL, V27, P1001, DOI 10.1016/S0181-5512(04)96255-9
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Palmowski AM, 1999, DOC OPHTHALMOL, V99, P41, DOI 10.1023/A:1002432113628
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Raman R, 2011, INVEST OPHTH VIS SCI, V52, P7910, DOI 10.1167/iovs.11-7636
   Rangaswamy NV, 2003, INVEST OPHTH VIS SCI, V44, P3233, DOI 10.1167/iovs.03-0009
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   STANFORD MR, 1988, BRIT J OPHTHALMOL, V72, P88, DOI 10.1136/bjo.72.2.88
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   SWANN PG, 1991, OPHTHAL PHYSL OPT, V11, P59, DOI 10.1016/0275-5408(91)90012-8
   Tzekov RT, 2004, GRAEF ARCH CLIN EXP, V242, P549, DOI 10.1007/s00417-004-0892-0
   Williamson JF, 2011, GENOMICS, V98, P412, DOI 10.1016/j.ygeno.2011.08.002
   Wood A, 2011, GRAEF ARCH CLIN EXP, V249, P1359, DOI 10.1007/s00417-011-1627-7
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zele AJ, 2006, GRAEF ARCH CLIN EXP, V244, P425, DOI 10.1007/s00417-005-0121-5
   Zele AJ, 2008, VISION RES, V48, P2593, DOI 10.1016/j.visres.2008.04.003
NR 82
TC 5
Z9 5
U1 1
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2012
VL 130
IS 11
BP 1402
EP 1409
DI 10.1001/archophthalmol.2012.1940
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 035XN
UT WOS:000310986700005
PM 22777494
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Zhao, Z
   Yang, F
   Gong, YY
   Yu, SQ
   Liu, HY
   Wang, H
   Wang, FH
   Sun, XD
AF Zhao, Zhi
   Yang, Fan
   Gong, Yuanyuan
   Yu, Suqin
   Liu, Haiyun
   Wang, Hong
   Wang, Fenghua
   Sun, Xiaodong
TI The Comparison of Morphologic Characteristics of Type 1 and Type 2
   Choroidal Neovascularization in Eyes with Neovascular Age-Related
   Macular Degeneration using Optical Coherence Tomography Angiography
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization; Optical
   coherence tomography angiography; Vascular caliber; Morphology
ID ANTI-VEGF THERAPY; ANTIANGIOGENIC THERAPY; RANIBIZUMAB; BEVACIZUMAB;
   AFLIBERCEPT; SECONDARY
AB Purpose: The purpose of this study was to use optical coherence tomography angiography (OCTA) to compare the morphology characteristics of type 1 and 2 choroidal neovascularization (CNV) in neovascular age-related macular degeneration (nAMD) patients. Materials and Methods: This is a retrospective, observational study of 51 eyes with nAMD using OCTA from July 2016 through March 2017. Results: In total, 51 eyes of 50 patients were included in the analysis. According to the anatomical classification based on OCT, 27 eyes (53%) were diagnosed with type 1 CNV, and 24 eyes (47%) were type 2 CNV. Type 2 CNV was characterized by smaller flow area, smaller greatest vascular caliber (GVC), smaller greatest linear dimension (GLD), and shorter duration of disease. The duration of disease only correlated with GVC (p = 0.026) in multivariate linear regression results. Meanwhile, GLD correlated with GVC and flow area whereas GVC was not associated with flow area. Conclusion: This study demonstrated that type 2 CNV was characterized by shorter duration of disease, smaller GVC, smaller GLD, and smaller flow area compared with type 1 CNV. Additionally, we showed that the duration of the disease correlated with GVC of the CNV.
C1 [Zhao, Zhi; Yang, Fan; Gong, Yuanyuan; Yu, Suqin; Liu, Haiyun; Wang, Hong; Wang, Fenghua; Sun, Xiaodong] Nanjing Med Univ, Shanghai Peoples Hosp 1, Shanghai Gen Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
   [Zhao, Zhi] Jiangsu Univ, Affiliated Peoples Hosp, Dept Ophthalmol, Zhenjiang, Jiangsu, Peoples R China.
   [Wang, Fenghua; Sun, Xiaodong] Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.
   [Sun, Xiaodong] Shanghai Key Lab Fundus Dis, Shanghai, Peoples R China.
C3 Nanjing Medical University; Jiangsu University
RP Wang, FH; Sun, XD (通讯作者)，Shanghai Gen Hosp, Shanghai Engn Ctr Visual Sci & Photomed, Dept Ophthalmol, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM shretina@sjtu.edu.cn; xdsun@sjtu.edu.cn
RI 俞, 素勤/HDO-8369-2022
OI Feng, Jingyang/0000-0001-6031-7980
FU National Natural Science Foundation [81730026]; Frontier Project of
   Shanghai Hospital Development Center [SHDC12016105]; Translational
   Medicine Grant of Shanghai Jiao Tong University, School of Medicine
   [TM201722]; Shanghai Science and Technology Committee [17411953000];
   Shanghai Engineering Center for Visual Science and Photomedicine
   [16dz2251500]
FX Supporting Grants: This work was supported by the National Natural
   Science Foundation (81730026), Frontier Project of Shanghai Hospital
   Development Center (SHDC12016105), Translational Medicine Grant of
   Shanghai Jiao Tong University, School of Medicine (TM201722), Shanghai
   Science and Technology Committee (17411953000) and the Shanghai
   Engineering Center for Visual Science and Photomedicine (16dz2251500).
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Casalino G, 2016, INVEST OPHTH VIS SCI, V57, pOCT288, DOI 10.1167/iovs.15-18753
   Chen XJ, 2016, RETINA-J RET VIT DIS, V36, pS50, DOI 10.1097/IAE.0000000000001271
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Gharbiya M, 2018, CURR EYE RES, V43, P391, DOI 10.1080/02713683.2017.1405045
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Helfrich I, 2010, J EXP MED, V207, P491, DOI 10.1084/jem.20091846
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kitchens JW, 2013, CLIN OPHTHALMOL, V7, P1987, DOI 10.2147/OPTH.S39635
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lee JE, 2015, RETINA-J RET VIT DIS, V35, P999, DOI 10.1097/IAE.0000000000000432
   Lee Ji Young, 2016, Korean J Ophthalmol, V30, P17, DOI 10.3341/kjo.2016.30.1.17
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Phasukkijwatana N, 2017, BRIT J OPHTHALMOL, V101, P597, DOI 10.1136/bjophthalmol-2016-308815
   Piermarocchi S, 2002, AM J OPHTHALMOL, V133, P572, DOI 10.1016/S0002-9394(01)01370-8
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shiraga F, 1998, OPHTHALMOLOGY, V105, P662, DOI 10.1016/S0161-6420(98)94021-0
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wietecha MS, 2013, CURR TOP MICROBIOL, V367, P3, DOI 10.1007/82_2012_287
   Wirth MA, 2017, ACTA OPHTHALMOL, V95, P428, DOI 10.1111/aos.13226
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 32
TC 5
Z9 5
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD SEP
PY 2019
VL 242
IS 3
BP 178
EP 186
DI 10.1159/000497491
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JB3KQ
UT WOS:000488456500003
PM 31195396
DA 2022-11-30
ER

PT J
AU Lanzetta, P
AF Lanzetta, Paolo
TI Anti-VEGF therapies for age-related macular degeneration: a powerful
   tactical gear or a blunt weapon? The choice is ours
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE Blindness; Visual impairment; Vision loss; Age-related macular
   degeneration; Anti-VEGF; Health care model
ID ENDOTHELIAL GROWTH-FACTOR; LEGAL BLINDNESS; TIME TRENDS; RANIBIZUMAB
AB Purpose Blindness and vision loss are still frequent disabilities associated with a relevant impact on health care and quality of life, and a high economic burden. Supranational programs established by the World Health Organization (WHO), International Agency for the Prevention of Blindness (IAPB), and World Health Assembly (WHA) aim at reducing avoidable visual impairment. Age-related macular degeneration (AMD), diabetic retinopathy (DR), and other retinal diseases are well known causes of visual disability. Since more than a decade, intravitreal agents are available for the treatment of these diseases. The aim of this study is to review whether pharmacotherapy with anti-vascular endothelial growth factor (VEGF) drugs has led to a decrease in the prevalence of blindness with emphasis on AMD and different countries. A brief analysis of other factors correlated to changes in the rate of blindness is also presented.
   Methods PubMed and Scopus web platforms were used to identify relevant studies on epidemiology of blindness and vision impairment, the influence of intravitreal therapies, and the existence of different vision care models. Additional data and material was searched in web internet accessed by the web browser Firefox.
   Results Age-standardized prevalence of blindness secondary to AMD has started to decline as testified by a number of studies in different countries. This is due to the adoption of anti-VEGF therapy and its adequate management. The frequency of treatment and regimens applied are indirect signs of successful treatment. Local rules and regulations may represent an obstacle.
   Conclusions This review shows that by implementing existing health care systems and dispensing adequate therapies in the field of retinal diseases, the prevalence of blindness due to these conditions can decline.
C1 [Lanzetta, Paolo] Univ Udine, Dept Med Ophthalmol, Udine, Italy.
   [Lanzetta, Paolo] Ist Europeo Microchirurg Oculare IEMO, Via MA Fiducio 8, I-33100 Udine, Italy.
C3 University of Udine
RP Lanzetta, P (通讯作者)，Univ Udine, Dept Med Ophthalmol, Udine, Italy.; Lanzetta, P (通讯作者)，Ist Europeo Microchirurg Oculare IEMO, Via MA Fiducio 8, I-33100 Udine, Italy.
EM paolo.lanzetta@uniud.it
OI Lanzetta, Paolo/0000-0003-3746-141X
CR Amoaku W, 2012, EYE, V26, pS2, DOI 10.1038/eye.2011.343
   Belkin M, 2013, AM J OPHTHALMOL, V155, P404, DOI 10.1016/j.ajo.2012.09.017
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Borooah S, 2015, EYE, V29, P1156, DOI 10.1038/eye.2015.83
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Cheung N, 2012, AM J OPHTHALMOL, V153, P193, DOI 10.1016/j.ajo.2011.11.022
   Ciulla TA, 2018, RETINA-J RET VIT DIS, V38, P1688, DOI 10.1097/IAE.0000000000001761
   Claessen H, 2021, GRAEF ARCH CLIN EXP, V259, P1089, DOI 10.1007/s00417-020-04885-4
   Claessen H, 2012, EUR J EPIDEMIOL, V27, P519, DOI 10.1007/s10654-012-9705-7
   dell'Omo R, 2022, EUR J OPHTHALMOL, V32, P695, DOI 10.1177/11206721211002442
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Jeffery RHC, 2021, ASIA-PAC J OPHTHALMO, V10, P442, DOI 10.1097/APO.0000000000000415
   Hollaus M, 2021, KLIN MONATSBL AUGENH, DOI 10.1055/a-1473-5713
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kim LA, 2012, AM J PATHOL, V181, P376, DOI 10.1016/j.ajpath.2012.06.006
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Mauschitz MM, 2019, OPHTHALMOLOGE, V116, P201, DOI 10.1007/s00347-019-0853-y
   Patel P, 2021, J CLIN MED, V10, DOI 10.3390/jcm10112436
   Resnikoff S, 2008, ANN TROP MED PARASIT, V102, P3, DOI 10.1179/136485908X337409
   Rim TH, 2017, CLIN EXP OPHTHALMOL, V45, P773, DOI 10.1111/ceo.12962
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schultz NM, 2021, CLIN THER, V43, P1792, DOI 10.1016/j.clinthera.2021.08.011
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   World Health Organization, 2014, UN EYE HLTH GLOB ACT
   Lu Y, 2020, THER ADV CHRONIC DIS, V11, DOI 10.1177/2040622320953349
NR 28
TC 2
Z9 2
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2021
VL 259
IS 12
BP 3561
EP 3567
DI 10.1007/s00417-021-05451-2
EA OCT 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WW6CP
UT WOS:000709273200001
PM 34669026
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Bui, PTA
   Reiter, GS
   Fabianska, M
   Waldstein, SM
   Grechenig, C
   Bogunovic, H
   Arikan, M
   Schmidt-Erfurth, U
AF Bui, Patricia T. A.
   Reiter, Gregor S.
   Fabianska, Maria
   Waldstein, Sebastian M.
   Grechenig, Christoph
   Bogunovic, Hrvoje
   Arikan, Mustafa
   Schmidt-Erfurth, Ursula
TI Fundus autofluorescence and optical coherence tomography biomarkers
   associated with the progression of geographic atrophy secondary to
   age-related macular degeneration
SO EYE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; RETICULAR PSEUDODRUSEN; HYPERREFLECTIVE
   FOCI; NATURAL-HISTORY; END-POINTS; EYES; PREDICTION; PATTERNS; DISEASE
AB Objectives To investigate the impact of qualitatively graded and deep learning quantified imaging biomarkers on growth of geographic atrophy (GA) secondary to age-related macular degeneration. Methods This prospective study included 1062 visits of 181 eyes of 100 patients with GA. Spectral-domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF) images were acquired at each visit. Hyperreflective foci (HRF) were quantitatively assessed in SD-OCT volumes using a validated deep learning algorithm. FAF images were graded for FAF patterns, subretinal drusenoid deposits (SDD), GA lesion configuration and atrophy enlargement. Linear mixed models were calculated to investigate associations between all parameters and GA progression. Results FAF patterns were significantly associated with GA progression (p < 0.001). SDD was associated with faster GA growth (p = 0.005). Eyes with higher HRF concentrations showed a trend towards faster GA progression (p = 0.072) and revealed a significant impact on GA enlargement in interaction with FAF patterns (p = 0.01). The fellow eye status had no significant effect on lesion enlargement (p > 0.05). The diffuse-trickling FAF pattern exhibited significantly higher HRF concentrations than any other pattern (p < 0.001). Conclusion Among a wide range of investigated biomarkers, SDD and FAF patterns, particularly in interaction with HRF, significantly impact GA progression. Fully automated quantification of retinal imaging biomarkers such as HRF is both reliable and merited as HRF are indicators of retinal pigment epithelium dysmorphia, a central pathogenetic mechanism in GA. Identifying disease markers using the combination of FAF and SD-OCT is of high prognostic value and facilitates individualized patient management in a clinical setting.
C1 [Bui, Patricia T. A.; Reiter, Gregor S.; Fabianska, Maria; Waldstein, Sebastian M.; Grechenig, Christoph; Bogunovic, Hrvoje; Arikan, Mustafa; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, Christian Doppler Lab Ophthalm Image Anal, Vienna, Austria.
C3 Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Christian Doppler Lab Ophthalm Image Anal, Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
RI ; Bogunovic, Hrvoje/J-3445-2014
OI Reiter, Gregor/0000-0001-7661-4015; Waldstein,
   Sebastian/0000-0003-2899-6279; Bogunovic, Hrvoje/0000-0002-9168-0894;
   Bui, Patricia Thao-An/0000-0001-5625-1755; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311
CR Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Curcio C, 2017, INVEST OPHTH VIS SCI, V58
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Frampton GK, 2017, EYE, V31, P995, DOI 10.1038/eye.2017.19
   Gerendas, 2018, ARXIV18050327
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Liefers B, 2020, OPHTHALMOLOGY, V127, P1086, DOI 10.1016/j.ophtha.2020.02.009
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Mones J, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.6.40
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Reiter GS, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.11
   Reiter GS, 2020, RETINA-J RET VIT DIS, V40, P1657, DOI 10.1097/IAE.0000000000002653
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sadda SR, 2016, RETINA-J RET VIT DIS, V36, P1806, DOI 10.1097/IAE.0000000000001283
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schmidt-Erfurth U, 2020, AM J OPHTHALMOL, V216, P257, DOI 10.1016/j.ajo.2020.03.042
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Shen LBL, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.1.2
   Shen LBL, 2019, OPHTHALMOL RETINA, V3, P305, DOI 10.1016/j.oret.2018.11.013
   Shen LBL, 2019, RETINA-J RET VIT DIS, V39, P1829, DOI 10.1097/IAE.0000000000002480
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Sunness JS, 1999, MOL VIS, V5
   van Grinsven MJJP, 2015, INVEST OPHTH VIS SCI, V56, P633, DOI 10.1167/iovs.14-15019
   Wightman AJ, 2019, CLIN EXP OPTOM, V102, P455, DOI 10.1111/cxo.12842
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 38
TC 2
Z9 2
U1 0
U2 3
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD OCT
PY 2022
VL 36
IS 10
BP 2013
EP 2019
DI 10.1038/s41433-021-01747-z
EA AUG 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4S0NN
UT WOS:000685374400002
PM 34400806
OA Bronze
DA 2022-11-30
ER

PT J
AU Durkin, SR
   Farmer, LDM
   Kulasekara, S
   Gilhotra, J
AF Durkin, Shane R.
   Farmer, Lachlan D. M.
   Kulasekara, Susith
   Gilhotra, Jagjit
TI Change in vision after retinal pigment epithelium tear following the use
   of anti-VEGF therapy for age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Bevacizumab; Ranibizumab; Retinal pigment epithelium; Rip; Tear; Visual
   acuity
ID OPTICAL COHERENCE TOMOGRAPHY; INTRAVITREAL INJECTION; BEVACIZUMAB
   AVASTIN
AB Purpose We investigated visual acuity outcomes and their associations in the setting of retinal pigment epithelium tear (RPET) following the use of anti-vascular endothelial growth factor (anti-VEGF) agents.
   Methods This retrospective review included all patients treated for neovascular age-related macular degeneration (AMD) with an anti-VEGF agent who subsequently developed an RPET. All patients who developed an RPET were identified and outcome measures data were recorded and analysed. The main outcome measures were best corrected visual acuity (BCVA) and spectral domain optical coherence tomography characteristics.
   Results Among the 14 participants identified, a subfoveal RPET was associated with the loss of one or more lines of vision from baseline (p=0.03). There was no association between the size of the RPET and BCVA at the time of the RPET or final BCVA. The development of a disciform scar was associated both with a BCVA at the time of the RPET of<6/24 (p=0.02) and a final BCVA of <6/24 (p=0.02). Ongoing treatment with an anti-VEGF agent following an RPET saw five patients (35.7 %) have an improvement in their BCVA and all patients maintained their BCVA following the RPET with ongoing anti-VEGF treatment.
   Conclusions Visual decline following an RPET is associated with subfoveal location of the RPET (p=0.03) and later development of a disciform scar. These data also suggest that the ongoing use of an anti-VEGF agent may stabilise vision in some patients following an RPET and for some patients there may be an improvement in visual acuity despite the RPET, depending on its location.
C1 [Durkin, Shane R.; Farmer, Lachlan D. M.; Gilhotra, Jagjit] Univ Adelaide, Royal Adelaide Hosp, Discipline Ophthalmol & Visual Sci, Level 8,East Wing,North Terrace, Adelaide, SA 5000, Australia.
   [Kulasekara, Susith] Royal Adelaide Hosp, Dept Ophthalmol, Adelaide, SA 5000, Australia.
   [Durkin, Shane R.; Gilhotra, Jagjit] Adelaide Eye & Retina Ctr, 18 North Terrace, Adelaide, SA, Australia.
C3 Royal Adelaide Hospital; University of Adelaide; Royal Adelaide Hospital
RP Farmer, LDM (通讯作者)，Univ Adelaide, Royal Adelaide Hosp, Discipline Ophthalmol & Visual Sci, Level 8,East Wing,North Terrace, Adelaide, SA 5000, Australia.
EM lachlan.farmer@gmail.com
CR HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Karadimas P, 2006, EUR J OPHTHALMOL, V16, P767, DOI 10.1177/112067210601600520
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Moroz I, 2009, OPHTHAL SURG LAS IM, V40, P570, DOI 10.3928/15428877-20091030-06
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
NR 9
TC 9
Z9 12
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2016
VL 254
IS 1
BP 1
EP 6
DI 10.1007/s00417-015-2978-2
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DD5ZT
UT WOS:000370004200001
PM 25749721
DA 2022-11-30
ER

PT J
AU Waugh, N
   Loveman, E
   Colquitt, J
   Royle, P
   Yeong, JL
   Hoad, G
   Lois, N
AF Waugh, Norman
   Loveman, Emma
   Colquitt, Jill
   Royle, Pamela
   Yeong, Jian Lee
   Hoad, Geraldine
   Lois, Noemi
TI Treatments for dry age-related macular degeneration and Stargardt
   disease: a systematic review
SO HEALTH TECHNOLOGY ASSESSMENT
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; PROPHYLACTIC LASER TREATMENT; TRANSCORNEAL
   ELECTRICAL-STIMULATION; MEMBRANE DIFFERENTIAL FILTRATION; IMPLANTABLE
   MINIATURE TELESCOPE; REDUCTASE INHIBITORS STATINS; FILTERING INTRAOCULAR
   LENSES; VISUAL-ACUITY LOSS; GEOGRAPHIC ATROPHY SECONDARY; CONTROLLED
   CLINICAL-TRIAL
AB Background: Age-related macular degeneration (AMD) is the leading cause of visual loss in older people. Advanced AMD takes two forms, neovascular (wet) and atrophic (dry). Stargardt disease (STGD) is the commonest form of inherited macular dystrophy.
   Objective: To carry out a systematic review of treatments for dry AMD and STGD, and to identify emerging treatments where future NIHR research might be commissioned.
   Design: Systematic review.
   Methods: We searched MEDLINE, EMBASE, Web of Science and The Cochrane Library from 2005 to 13 July 2017 for reviews, journal articles and meeting abstracts. We looked for studies of interventions that aim to preserve or restore vision in people with dry AMD or STGD. The most important outcomes are those that matter to patients: visual acuity (VA), contrast sensitivity, reading speed, ability to drive, adverse effects of treatment, quality of life, progression of disease and patient preference. However, visual loss is a late event and intermediate predictors of future decline were accepted if there was good evidence that they are strong predictors of subsequent visual outcomes. These include changes detectable by investigation, but not necessarily noticed by people with AMD or STGD. ClinicalTrials.gov, the World Health Organization search portal and the UK Clinical Trials gateway were searched for ongoing and recently completed clinical trials.
   Results: The titles and abstracts of 7948 articles were screened for inclusion. The full text of 398 articles were obtained for further screening and checking of references and 112 articles were included in the final report. Overall, there were disappointingly few good-quality studies (including of sufficient size and duration) reporting useful outcomes, particularly in STGD. However we did identify a number of promising research topics, including drug treatments, stem cells, new forms of laser treatment, and implantable intraocular lens telescopes. In many cases, research is already under way, funded by industry or governments.
   Limitations: In AMD, the main limitation came from the poor quality of much of the evidence. Many studies used VA as their main outcome despite not having sufficient duration to observe changes. The evidence on treatments for STGD is sparse. Most studies tested interventions with no comparison group, were far too short term, and the quality of some studies was poor.
   Future work: We think that the topics on which the Health Technology Assessment (HTA) and Efficacy Mechanism and Evaluation (EME) programmes might consider commissioning primary research are in STGD, a HTA trial of fenretinide (ReVision Therapeutics, San Diego, CA, USA), a visual cycle inhibitor, and EME research into the value of lutein and zeaxanthin supplements, using short-term measures of retinal function. In AMD, we suggest trials of fenretinide and of a potent statin. There is epidemiological evidence from the USA that the drug, levodopa, used for treating Parkinson's disease, may reduce the incidence of AMD. We suggest that similar research should be carried out using the large general practice databases in the UK. Ideally, future research should be at earlier stages in both diseases, before vision is impaired, using sensitive measures of macular function. This may require early detection of AMD by screening.
C1 [Waugh, Norman] Univ Warwick, Div Hlth Sci, Coventry, W Midlands, England.
   [Loveman, Emma; Colquitt, Jill] Effect Evidence, Waterlooville, England.
   [Yeong, Jian Lee; Lois, Noemi] Royal Victoria Hosp, Ophthalmol, Belfast, Antrim, North Ireland.
   [Hoad, Geraldine] Macular Soc, Andover, England.
   [Lois, Noemi] Queens Univ, Wellcome Wolfson Ctr Expt Med, Belfast, Antrim, North Ireland.
C3 University of Warwick; Queens University Belfast
RP Waugh, N (通讯作者)，Univ Warwick, Div Hlth Sci, Coventry, W Midlands, England.
EM Norman.Waugh@warwick.ac.uk
OI Colquitt, Jillian Leigh/0000-0001-5962-2689; Waugh,
   Norman/0000-0003-0934-4961; Yeong, Jian Lee/0000-0001-8203-0438; Hoad,
   Geraldine/0000-0002-6881-6781; Loveman, Emma/0000-0001-8226-2634
FU National Institute for Health Research HTA programme
FX The National Institute for Health Research HTA programme.
CR AAO Complementary Therapy Task Force, 2007, AC AG REL MAC DEG CT
   AAO Complementary Therapy Task Force, 2004, MICR STIM MAC DEG
   Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Agarwal A, 2008, J CATARACT REFR SURG, V34, P87, DOI 10.1016/j.jcrs.2007.08.031
   Ahmadi A, 2009, AFR J TRADIT COMPLEM, V6, P549
   Akuffo KO, 2015, EYE, V29, P902, DOI 10.1038/eye.2015.64
   Al-Holou SN, 2015, OPHTHALMOLOGY, V122, P2490, DOI 10.1016/j.ophtha.2015.08.028
   Aleman TS, 2007, INVEST OPHTH VIS SCI, V48, P1319, DOI 10.1167/iovs.06-0764
   Ali F, DRY AGE RELATED MACU
   Allen MJ, 1998, J ORTHOMOLECULAR MED, V13, P211
   ALVAREZ JA, 2016, INVEST OPHTH VIS SCI, V57
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anastassiou G, 2013, RESTOR NEUROL NEUROS, V31, P571, DOI 10.3233/RNN-130322
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Andreatta W, 2014, OPHTHALMOLOGICA, V231, P185, DOI 10.1159/000357528
   [Anonymous], 1998, Ophthalmology, V105, P11
   [Anonymous], BUSINESS WIRE
   Antoniu S, 2014, EXPERT OPIN ORPHAN D, V2, P311, DOI 10.1517/21678707.2014.897942
   Arnold C, 2013, JAMA OPHTHALMOL, V131, P564, DOI 10.1001/jamaophthalmol.2013.2851
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Arora S, 2004, EYE, V18, P470, DOI 10.1038/sj.eye.6700700
   Augustin AJ, 2013, EXPERT OPIN INV DRUG, V22, P803, DOI 10.1517/13543784.2013.794782
   Auricchio A, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017301
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Banin E, 2017, AM AC OPHTH ANN M 11
   Barbosa DTQ, 2014, EYE, V28, P472, DOI 10.1038/eye.2014.8
   Barnett BR, 2013, GERONTOLOGY, V59, P297, DOI 10.1159/000346169
   Bartlett H, 2003, OPHTHAL PHYSL OPT, V23, P383, DOI 10.1046/j.1475-1313.2003.00130.x
   Bartlett HE, 2007, EUR J CLIN NUTR, V61, P1121, DOI 10.1038/sj.ejcn.1602626
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Beatty S, 2013, OPHTHALMOLOGY, V120, P645, DOI 10.1016/j.ophtha.2012.09.013
   Beaumont P, 2011, CLIN EXP OPHTHALMOL, V39, P30
   Berrow EJ, 2013, BRIT J NUTR, V109, P2008, DOI 10.1017/S0007114512004187
   Betteridge DJ, 2000, METABOLISM, V49, P3, DOI 10.1016/S0026-0495(00)80077-3
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bisti S, 2014, VISUAL NEUROSCI, V31, P355, DOI 10.1017/S0952523814000108
   Blaha M, 2013, ATHEROSCLEROSIS SUPP, V14, P179, DOI 10.1016/j.atherosclerosissup.2012.10.023
   Bocci V, 2007, BRIT J BIOMED SCI, V64, P44, DOI 10.1080/09674845.2007.11732755
   Bocci V., 2010, OZONE NEW MED DRUG, V2nd, P336, DOI [10.1007/978-90-481-9234-2, DOI 10.1007/978-90-481-9234-2]
   Bocci Velio, 2015, Cardiovascular & Hematological Disorders - Drug Targets, V15, P127, DOI 10.2174/1871529X1502151209114642
   Borrelli Emma, 2013, Med Hypothesis Discov Innov Ophthalmol, V2, P47
   Borrelli E, 2012, INT J OPHTHALMOL-CHI, V5, P708, DOI 10.3980/j.issn.2222-3959.2012.06.11
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Boyer D, 2015, CLIN OPHTHALMOL, V9, P1099, DOI 10.2147/OPTH.S86208
   Brader HS, 2016, SEMIN OPHTHALMOL, V31, P30, DOI 10.3109/08820538.2015.1114837
   Brandl C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167181
   Brilliant MH, 2016, AM J MED, V129, P292, DOI 10.1016/j.amjmed.2015.10.015
   Bringmann A, 2016, MOL VIS, V22, P1437
   Broadhead G, 2016, CLIN EXP OPHTHALMOL, V44, P31
   Broadhead GK, 2015, NUTR REV, V73, P448, DOI 10.1093/nutrit/nuv005
   Brockmann C, 2008, J CATARACT REFR SURG, V34, P1161, DOI 10.1016/j.jcrs.2008.03.039
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Brown GC, 2011, OPHTHALMOLOGY, V118, P1834, DOI 10.1016/j.ophtha.2011.02.012
   Brunner R, 1996, TRANSFUS SCI, V17, P493, DOI 10.1016/S0955-3886(96)90083-1
   Brunner R, 2000, RETINA-J RET VIT DIS, V20, P483, DOI 10.1097/00006982-200009000-00009
   Brunner R, 1995, INT J ARTIF ORGANS, V18, P794, DOI 10.1177/039139889501801208
   Buitendijk GHS, 2016, INVEST OPHTH VIS SCI, V57, P5593, DOI 10.1167/iovs.15-18816
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Business Wire. OccuLogix Inc, 2005, BUSINESS WIRE
   Camerini T, 2001, J CLIN ONCOL, V19, P1664, DOI 10.1200/JCO.2001.19.6.1664
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Caramoy A, 2010, BRIT J OPHTHALMOL, V94, P1040, DOI 10.1136/bjo.2009.161299
   Carpentier S, 2009, CRIT REV FOOD SCI, V49, P313, DOI 10.1080/10408390802066979
   Chaikin L, 2015, CLIN OPHTHALMOL, V9, P2345, DOI [10.2147/OPTH.S92296, 10.2147/OPTH.892296]
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chan H, 2016, INVEST OPHTH VIS SCI, V57, P3058, DOI 10.1167/iovs.16-19487
   Chew EY, 2015, INVEST OPHTH VIS SCI, V56
   Chew EY, 2015, OPHTHALMOLOGY, V122, P2155, DOI 10.1016/j.ophtha.2015.08.007
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   CHIESA F, 1993, J CELL BIOCHEM, P255
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chong CF, 2011, CLIN EXP OPHTHALMOL, V39, P23
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Christen WG, 2007, ARCH OPHTHALMOL-CHIC, V125, P333, DOI 10.1001/archopht.125.3.333
   Christen WG, 2015, OPHTHAL EPIDEMIOL, V22, P85, DOI 10.3109/09286586.2015.1012272
   Christen WG, 2014, OPHTHALMOLOGY, V121, P525, DOI 10.1016/j.ophtha.2013.09.038
   Christen WG, 2010, OPHTHALMOLOGY, V117, P1163, DOI 10.1016/j.ophtha.2009.10.043
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P834, DOI 10.1097/IAE.0b013e31822058a3
   Colak Emina S, 2011, EJIFCC, V22, P16
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cornish KS, 2017, OPHTHALMOL RETINA, V1, P508, DOI 10.1016/j.oret.2017.03.001
   Corporation O, 2016, CLIN TRIAL ASS SAF E
   Corvi F, 2017, BRIT J OPHTHALMOL, V101, P770, DOI 10.1136/bjophthalmol-2016-309115
   COSTA A, 1989, EUR J CANCER CLIN ON, V25, P805, DOI 10.1016/0277-5379(89)90124-7
   Cougnard-Gregoire A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160240
   Crossland MD, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-5
   Cuevas P, 2012, BMJ Case Rep, V2012, DOI 10.1136/bcr.02.2012.5942
   Cuevas Pedro, 2012, BMJ Case Rep, V2012, DOI 10.1136/bcr-2012-007128
   Cukras C, 2017, JAMA OPHTHALMOL, V135, P704, DOI 10.1001/jamaophthalmol.2017.1544
   Cukras Catherine, 2007, International Ophthalmology Clinics, V47, P75, DOI 10.1097/IIO.0b013e31802bda65
   Cuthbertson FM, 2009, J CATARACT REFR SURG, V35, P1281, DOI 10.1016/j.jcrs.2009.04.017
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Dalkara D, 2016, HUM GENE THER, V27, P134, DOI 10.1089/hum.2015.147
   Danis RP, 2015, CLIN OPHTHALMOL, V9, P2159, DOI 10.2147/OPTH.S92359
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   Davison JA, 2011, GRAEF ARCH CLIN EXP, V249, P957, DOI 10.1007/s00417-011-1697-6
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   de Jong PTVM, 2013, AGE RELATED MACULA D, P3, DOI DOI 10.1007/978-3-642-22107-1_1
   DEPALO G, 1995, J CELL BIOCHEM, P11
   Diaz ER, 2016, INVEST OPHTH VIS SCI, V57
   Dobri N, 2013, INVEST OPHTH VIS SCI, V54, P85, DOI 10.1167/iovs.12-10050
   Downes SM, 2016, EYE, V30, P215, DOI 10.1038/eye.2015.267
   Dugel PU, 2015, RETINA-J RET VIT DIS, V35, P1173, DOI 10.1097/IAE.0000000000000606
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Etminan M, 2008, CURR DRUG SAF, V3, P24, DOI 10.2174/157488608783333952
   European Medicines Agency, 2013, SOR TREATM STARG DIS
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub4
   Evans JR, 2014, OPHTHAL PHYSL OPT, V34, P390, DOI 10.1111/opo.12142
   Evans JR, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001775.pub2
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Figueroa MS, 1997, RETINA-J RET VIT DIS, V17, P378
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fishman GA, 2010, OPHTHALMIC GENET, V31, P183, DOI 10.3109/13816810.2010.499887
   Fleckenstein M, 2013, AGE RELATED MACULAR, P121, DOI [10.1007/978-3-642-22107-1_8, DOI 10.1007/978-3-642-22107-1_8]
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Fong DS, 2010, AM J OPHTHALMOL, V149, P955, DOI 10.1016/j.ajo.2009.12.037
   Forte R, 2014, OPHTHALMIC RES, V51, P32, DOI 10.1159/000354117
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   Frennesson CI, 2009, ACTA OPHTHALMOL, V87, P720, DOI 10.1111/j.1755-3768.2008.01396.x
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Fujinami K, 2013, AM J OPHTHALMOL, V155, P1075, DOI 10.1016/j.ajo.2013.01.018
   Gallego-Pinazo R, 2011, CLIN OPHTHALMOL, V5, P161, DOI 10.2147/OPTH.S15832
   Gamboa OL, 2010, EXP EYE RES, V91, P195, DOI 10.1016/j.exer.2010.04.018
   Planas MG, 2016, INVEST OPHTH VIS SCI, V57
   Garcia-Layana A, 2013, NUTRIENTS, V5, P543, DOI 10.3390/nu5020543
   Gass J D, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P580
   Gehlbach P, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub4
   Geneva II, 2016, INT J OPHTHALMOL-CHI, V9, P145, DOI 10.18240/ijo.2016.01.24
   Giani A, 2012, INVEST OPHTH VIS SCI, V53, P3999, DOI 10.1167/iovs.11-9258
   Gil JQ, 2017, EYE, V31, P364, DOI 10.1038/eye.2016.207
   Girmens JF, 2012, INTRACTABLE RARE DIS, V1, P103, DOI 10.5582/irdr.2012.v1.3.103
   Gopinath B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04697-3
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Gorovits R, 1997, P NATL ACAD SCI USA, V94, P7024, DOI 10.1073/pnas.94.13.7024
   Gregori N, 2017, AAO ANN M NEW ORL LA
   Gregori Ninel Z, 2015, Curr Ophthalmol Rep, V3, P34, DOI 10.1007/s40135-014-0059-z
   Grob SR, 2016, MIDDLE EAST AFR J OP, V23, P49, DOI 10.4103/0974-9233.173135
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guo XL, 2016, EXP EYE RES, V147, P37, DOI 10.1016/j.exer.2016.04.021
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Guymer RH, 2008, CLIN INTERV AGING, V3, P581
   Haddley K., 2011, DRUGS FUTURE, V36, P7, DOI DOI 10.1358/D0F.2011.036.07.1673558
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Halloran G., BIOELECTRICAL STIMUL
   Han ZC, 2014, ADV EXP MED BIOL, V801, P719, DOI 10.1007/978-1-4614-3209-8_90
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   Hau VS, 2016, OPHTHALMOL THER, V5, P21, DOI 10.1007/s40123-016-0047-5
   Henderson BA, 2010, SURV OPHTHALMOL, V55, P284, DOI 10.1016/j.survophthal.2009.07.007
   Hengerer FH, 2015, J REFRACT SURG, V31, P158, DOI 10.3928/1081597X-20150220-03
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928
   Ho AC, 2017, AM J OPHTHALMOL, V179, P67, DOI 10.1016/j.ajo.2017.04.006
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Holz FG, 2016, NEGATIVE DRY AMD RES
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Hsu J, 2005, CAN J OPHTHALMOL, V40, P320, DOI 10.1016/S0008-4182(05)80075-4
   Huang PR, 2015, SCI REP-UK, V5, DOI 10.1038/srep10585
   Huang YM, 2015, BRIT J OPHTHALMOL, V99, P371, DOI 10.1136/bjophthalmol-2014-305503
   Huang YM, 2013, NUTRITION, V29, P387, DOI 10.1016/j.nut.2012.06.009
   Huang Y, 2015, J CHEM-NY, V2015, DOI 10.1155/2015/297686
   Huang YX, 2011, CHINESE MED J-PEKING, V124, P541, DOI 10.3760/cma.j.issn.0366-6999.2011.04.011
   Hudson HL, 2008, AM J OPHTHALMOL, V146, P664, DOI 10.1016/j.ajo.2008.07.003
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Institut de la Macula, STATINS4DRUSEN
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Issa PC, 2015, P NATL ACAD SCI USA, V112, P8415, DOI 10.1073/pnas.1506960112
   Ivandic BT, 2008, PHOTOMED LASER SURG, V26, P241, DOI 10.1089/pho.2007.2132
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Johnson EJ, 2010, CURR OPIN CLIN NUTR, V13, P28, DOI 10.1097/MCO.0b013e32833308ff
   Jurgensmeier C, 2007, CURR EYE RES, V32, P911, DOI 10.1080/02713680701616156
   KAISER HJ, 1995, OPHTHALMOLOGICA, V209, P302, DOI 10.1159/000310646
   Kaiser RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P826
   Kaiserman N, 2009, CURR EYE RES, V34, P304, DOI 10.1080/02713680902741670
   Kalloniatis M., 1995, WEBVISION ORG RETINA
   Kamami-Levy CJ, 2014, INVEST OPHTH VIS SCI, V55
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keech A, 2005, LANCET, V366, P1849, DOI 10.1016/S0140-6736(05)67667-2
   Kefauver SC, 2014, DRUG FUTURE, V39, P615, DOI 10.1358/dof.2014.039.09.2207181
   Kelly D, 2017, BRIT J NUTR, V117, P108, DOI 10.1017/S0007114516003895
   Kelly ER, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092659
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Kimel M, 2016, INVEST OPHTH VIS SCI, V57, P6298, DOI 10.1167/iovs.16-20361
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Klingel R, 2010, THER APHER DIAL, V14, P276, DOI 10.1111/j.1744-9987.2010.00807.x
   Kondrot EC, 2002, TOWNSEND LETT DOCTOR, V231, P65
   Kondrot EC, 2015, ALTERN THER HEALTH M, V21, P22
   Kong X, 2016, OPHTHALMOLOGY, V123, P1887, DOI 10.1016/j.ophtha.2016.05.027
   Koss MJ, 2009, GRAEF ARCH CLIN EXP, V247, P1297, DOI 10.1007/s00417-009-1113-7
   Kovach JL, 2016, OPHTHALMOLOGY, V123, P921, DOI 10.1016/j.ophtha.2015.10.036
   Krenn H, 2008, DTSCH Z AKUPUNKT, V51, P25, DOI 10.1016/j.dza.2008.08.001
   Kuppermann BD, 2017, INVEST OPHTH VIS SCI, V58
   Kurimoto T, 2010, CLIN OPHTHALMOL, V4, P1441, DOI 10.2147/OPTH.S14573
   Kuriyan AE, 2017, NEW ENGL J MED, V376, P1047, DOI 10.1056/NEJMoa1609583
   Ladewig MS, 2005, PROSTAG LEUKOTR ESS, V72, P251, DOI 10.1016/j.plefa.2004.11.006
   Lai E, 2014, CURR OPIN OPHTHALMOL, V25, P35, DOI 10.1097/ICU.0000000000000016
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lak Dariusz, 2007, Roczniki Pomorskiej Akademii Medycznej w Szczecinie, V53, P43
   Lambertus S, 2016, INVEST OPHTH VIS SCI, V57, P6824, DOI 10.1167/iovs.16-20963
   Lambertus S, 2016, INVEST OPHTH VIS SCI, V57, P5186, DOI 10.1167/iovs.16-19833
   Landa G, 2011, J OCUL PHARMACOL TH, V27, P77, DOI 10.1089/jop.2010.0109
   Landa G, 2008, CURR EYE RES, V33, P1011, DOI 10.1080/02713680802484637
   Lane N., 2004, RHEOPHERESIS READY P
   Lane SS, 2006, CURR OPIN OPHTHALMOL, V17, P94, DOI 10.1097/01.icu.0000193067.86627.a1
   Lashay Alireza, 2016, Med Hypothesis Discov Innov Ophthalmol, V5, P32
   Lavric A, 2014, OPTOMETRY VISION SCI, V91, P1348, DOI 10.1097/OPX.0000000000000390
   Lawrenson JG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub3
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   Lek JJ, 2017, OPHTHALMOL RETINA, V1, P227, DOI 10.1016/j.oret.2016.12.001
   Leung EH, 2016, OSLI RETINA, V47, P600, DOI 10.3928/23258160-20160601-16
   Liew G, 2016, OPHTHALMOLOGY, V123, P1874, DOI 10.1016/j.ophtha.2016.05.043
   Lin BioScience, LBS 008
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   Liu R, 2015, INVEST OPHTH VIS SCI, V56, P252, DOI 10.1167/iovs.14-15553
   LOC Support Unit, 2017, NAT EYE HLTH EP MOD
   Lois N, 2004, AM J OPHTHALMOL, V138, P55, DOI 10.1016/j.ajo.2004.02.056
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Lois N, 2001, ARCH OPHTHALMOL-CHIC, V119, P359, DOI 10.1001/archopht.119.3.359
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Lommatzsch A, 2013, AGE RELATED MACULAR, P77, DOI [10.1007/978-3-642-22107-1_5, DOI 10.1007/978-3-642-22107-1_5]
   London Project to Cure Blindness, 2017, 1 PAT REC POT NEW TR
   Lu LJ, 2017, GRAEF ARCH CLIN EXP, V255, P1057, DOI 10.1007/s00417-017-3619-8
   Luttrull JK, 2016, INVEST OPHTH VIS SCI, V57, P265, DOI 10.1167/iovs.15-18163
   Ma L, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070426
   Ma L, 2015, SCI REP-UK, V5, DOI 10.1038/srep18280
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Ma L, 2012, AM J OPHTHALMOL, V154, P625, DOI 10.1016/j.ajo.2012.04.014
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Mackie Eyecare, 2016, AMD SCREEN
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   Marangoni D, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-228
   Marshall J, 2015, EYE, V29, P46, DOI 10.1038/eye.2014.240
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martin L, 2017, CLIN OPTOM, V9, P77, DOI 10.2147/OPTO.S129942
   MARTINI E, 1991, Annali di Ottalmologia e Clinica Oculistica, V117, P1121
   Mastellos DC, 2015, EUR J CLIN INVEST, V45, P423, DOI 10.1111/eci.12419
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   McBain VA, 2012, AM J OPHTHALMOL, V154, P146, DOI 10.1016/j.ajo.2012.01.019
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   Mcguinness MB, 2017, AM J OPHTHALMOL, V180, P29, DOI 10.1016/j.ajo.2017.05.016
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   McKeague C, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-246
   Merle BMJ, 2016, AM J CLIN NUTR, V103, P1135, DOI 10.3945/ajcn.115.117606
   Merry GF, 2017, ACTA OPHTHALMOL, V95, pE270, DOI 10.1111/aos.13354
   Michael DL, 1993, J ORTHOMOL MED, V8, P161
   Midena E, 2017, EYE, V31, P985, DOI 10.1038/eye.2017.34
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Midena E, 2010, OPHTHALMOLOGY, V117, P1571, DOI 10.1016/j.ophtha.2009.12.044
   Milajerdi A., 2015, Journal of Medicinal Plants, V14, P9
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Moiseyev GP, 2016, INVEST OPHTH VIS SCI, V57
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Murray I, 2016, INVEST OPHTH VIS SCI, V57
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Murro V, 2017, EUR J OPHTHALMOL, V27, P740, DOI 10.5301/ejo.5000972
   Nagai H, 2015, J CATARACT REFR SURG, V41, P1855, DOI 10.1016/j.jcrs.2015.01.017
   Natarajan S, 2009, INVEST OPHTH VIS SCI, V50, P4924
   Natarajan S, 2008, DOC OPHTHALMOL, V117, P24, DOI [10.1007/s10633-008-9140-y, DOI 10.1007/S10633-008-9140-Y]
   National Institute for Health and Care Excellence (NICE), 2018, AG REL MAC DEG NG82
   National Institute for Health Research, 2017, RAND PLAC CONTR CLIN
   Naycheva L, 2012, INVEST OPHTH VIS SCI, V53, P7440, DOI 10.1167/iovs.12-9612
   Neely DC, 2017, JAMA OPHTHALMOL, V135, P570, DOI 10.1001/jamaophthalmol.2017.0830
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   NHS Health Research Authority, 2016, EFF TEL MIRR IMPL AG
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   NIH Heart Lung and Blood Institute, 2014, STUD QUAL ASS TOOLS
   Nishi T., 2014, RANDOMIZED CONTROLLE
   Nishi T, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007930
   Nolan JM, 2016, INVEST OPHTH VIS SCI, V57, P3429, DOI 10.1167/iovs.16-19520
   Nommiste B, 2017, PROG BRAIN RES, V231, P225, DOI 10.1016/bs.pbr.2017.03.003
   Olk R Joseph, 2015, Int J Retina Vitreous, V1, P22, DOI 10.1186/s40942-015-0019-2
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Ooto S, 2015, RETINA-J RET VIT DIS, V35, P1726, DOI 10.1097/IAE.0000000000000608
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Owens SL, 2006, AM J OPHTHALMOL, V141, P276, DOI 10.1016/j.ajo.2005.08.019
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   OxfordBioMedica, 2013, SAR 422459 GEN BAS T
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Park SS, 2015, INVEST OPHTH VIS SCI, V56, P81, DOI 10.1167/iovs.14-15415
   Parodi MB, 2016, DEV OPHTHALMOL, V55, P205, DOI 10.1159/000431125
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pellegrini M, 2016, OPHTHALMOLOGY, V123, P1879, DOI 10.1016/j.ophtha.2016.05.041
   Peng ML, 2016, J FUNCT FOODS, V24, P122, DOI 10.1016/j.jff.2016.04.006
   Peponis V, 2010, CLIN OPHTHALMOL, V4, P865
   Pescosolido N, 2014, PLANTA MED, V80, P249, DOI 10.1055/s-0033-1351074
   Petrou PA, 2015, INVEST OPHTH VIS SCI, V56, P330, DOI 10.1167/iovs.14-15877
   Petrukhin Konstantin, 2013, Drug Discov Today Ther Strateg, V10, pe11
   Pham JC, 2013, JAMA-J AM MED ASSOC, V310, P208, DOI 10.1001/jama.2013.7825
   Piccardi M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429124
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Pipis A, 2015, EUR J OPHTHALMOL, V25, P128, DOI 10.5301/ejo.5000520
   Prahs P, 2010, GRAEF ARCH CLIN EXP, V248, P651, DOI 10.1007/s00417-009-1208-1
   Prenner JL, 2011, RETINA-J RET VIT DIS, V31, P401, DOI 10.1097/IAE.0b013e3181eef2ad
   PRWeb, 2017, NOV OC ENL INT AUD I
   Pulido J, 2005, J CLIN APHERESIS, V20, P185, DOI 10.1002/jca.20047
   Pulido Jose S, 2006, Trans Am Ophthalmol Soc, V104, P221
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   Pulido JS, 2005, CAN J OPHTHALMOL, V40, P332, DOI 10.1016/S0008-4182(05)80076-6
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2014, OPHTHALMIC RES, V52, P107, DOI 10.1159/000363187
   Querques G, 2014, SURV OPHTHALMOL, V59, P532, DOI 10.1016/j.survophthal.2014.01.001
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2010, CLIN OPHTHALMOL, V4, P575
   Quiroz-Mercado H, 2017, INVEST OPHTH VIS SCI, V58
   Qureshi MA, 2017, EUR J OPHTHALMOL, DOI 10.S301/ejo.5001052
   Qureshi MA, 2015, J CATARACT REFR SURG, V41, P2125, DOI 10.1016/j.jcrs.2015.03.021
   Radu RA, 2008, INVEST OPHTH VIS SCI, V49, P3821, DOI 10.1167/iovs.07-1470
   Ramsden CM, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18643
   Rein DB, 2007, OPHTHALMOLOGY, V114, P1319, DOI 10.1016/j.ophtha.2006.10.041
   Remky A, 2005, ACTA OPHTHALMOL SCAN, V83, P154, DOI 10.1111/j.1600-0420.2005.00406.x
   Rencova E, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/359747
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Riazi A, 2017, ITAL J MED, V11, P196, DOI 10.4081/itjm.2016.758
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer S, 2013, NUTRIENTS, V5, P1989, DOI 10.3390/nu5061989
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   Rock T, 2011, ARVO M, V52, P1870
   Rock T, 2013, OPHTHALMOLOGE, V110, P68, DOI 10.1007/s00347-012-2749-y
   Rotenstreich Y, 2003, OPHTHALMOLOGY, V110, P1151, DOI 10.1016/S0161-6420(03)00333-6
   Ruiz-Moreno JM, 2003, RETINA-J RET VIT DIS, V23, P315, DOI 10.1097/00006982-200306000-00005
   Saad L, 2016, ADV EXP MED BIOL, V854, P355, DOI 10.1007/978-3-319-17121-0_47
   Saade C, 2014, CLIN EXP OPHTHALMOL, V42, P865, DOI 10.1111/ceo.12353
   Sakai City Medical Center, 2016, RAND PAR GROUP TRIAL
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Saxena N, 2015, INDIAN J OPHTHALMOL, V63, P516, DOI 10.4103/0301-4738.158533
   Scalinci SZ, 2015, INVEST OPHTH VIS SCI, V56
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Scharioth GB, 2015, J CATARACT REFR SURG, V41, P1559, DOI 10.1016/j.jcrs.2015.07.018
   Schmidl D, 2015, ACTA OPHTHALMOL, V93, P105, DOI 10.1111/aos.12650
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Scorolli L, 2003, CAN J OPHTHALMOL, V38, P489, DOI 10.1016/S0008-4182(03)80028-5
   Scripsema NK, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/865179
   ScyFIX, CLIN STUD
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Sehic A, 2016, AM J PATHOL, V186, P2783, DOI 10.1016/j.ajpath.2016.07.017
   Shalev V, 2011, OPHTHAL EPIDEMIOL, V18, P83, DOI 10.3109/09286586.2011.560746
   Shinoda K, 2008, OPEN OPHTHALMOL J, V2, P132, DOI 10.2174/1874364100802010132
   Silvestri G, EFF TEL MIRR IMPL AG
   Simunovic MP, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.3.10
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   SLEZAK M., 2013, NEW SCI, V217, P8
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Smeeth L, 2009, BRIT J CLIN PHARMACO, V67, P99, DOI 10.1111/j.1365-2125.2008.03308.x
   Smith J, 2015, EYE, V29, P1131, DOI 10.1038/eye.2015.115
   Sofi F, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0187-3
   Sohrab MA, 2010, AM J OPHTHALMOL, V149, P651, DOI 10.1016/j.ajo.2009.11.029
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Souied EH, 2016, OPHTHALMIC RES, V55, P62, DOI 10.1159/000441359
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Sternberg P, 2010, INVEST OPHTH VIS SCI, V51
   Sternberg P, 2003, OPHTHALMOLOGY, V110, P971, DOI 10.1016/S0161-6420(03)00098-8
   Stevens R, 2015, CLIN NUTR ESPEN, V10, pE112, DOI 10.1016/j.clnesp.2015.03.080
   Strauss RW, 2017, JAMA OPHTHALMOL, V135, P687, DOI 10.1001/jamaophthalmol.2017.1121
   Studnicka J, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/135798
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 2014, JAMA OPHTHALMOL, V132, P356, DOI 10.1001/jamaophthalmol.2014.21
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Swartz M, 1999, INVEST OPHTH VIS SCI, V40, pS319
   Tabernero J, 2015, BIOMED OPT EXPRESS, V6, P1010, DOI 10.1364/BOE.6.001010
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Tanna P, 2017, BRIT J OPHTHALMOL, V101, P25, DOI 10.1136/bjophthalmol-2016-308823
   Tao Y, 2016, TOHOKU J EXP MED, V240, P209, DOI 10.1620/tjem.240.209
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   Teussink MM, 2015, AM J OPHTHALMOL, V159, P964, DOI 10.1016/j.ajo.2015.02.004
   The Niche-Knoepfler lab stem cell blog, 2016, NICHE KNOEPFLER LAB
   Thomas AS, 2015, RETINA-J RET VIT DIS, V35, P1964, DOI 10.1097/IAE.0000000000000603
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Tsao SW, 2013, DRUG AGING, V30, P205, DOI 10.1007/s40266-013-0061-4
   Huynh TP, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/549174
   Tzotzas T, 2006, ATHEROSCLEROSIS SUPP, V7, P568, DOI 10.1016/S1567-5688(06)82299-3
   van der Made SM, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/9035745
   van Huet RAC, 2014, INVEST OPHTH VIS SCI, V55, P7467, DOI 10.1167/iovs.13-13825
   VanderBeek BL, 2013, RETINA-J RET VIT DIS, V33, P414, DOI 10.1097/IAE.0b013e318276e0cf
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub3
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
   Vishwanathan R, 2009, AM J CLIN NUTR, V90, P1272, DOI 10.3945/ajcn.2009.28013
   Vojnikovic B, 2008, COLLEGIUM ANTROPOL, V32, P351
   Waern M, 2002, BMJ-BRIT MED J, V324, P1355, DOI 10.1136/bmj.324.7350.1355
   Wallace I., 1997, J OPTOMETRIC PHOTOTH, P4
   Wang LL, 2013, MOL NUTR FOOD RES, V57, P1557, DOI 10.1002/mnfr.201200718
   Wang Q, 2011, INVEST OPHTH VIS SCI, V52, P6292, DOI 10.1167/iovs.10-6424
   Wang X, 2014, OPHTHALMIC RES, V52, P198, DOI 10.1159/000363327
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Weingessel B, 2009, EYE, V23, P1052, DOI 10.1038/eye.2008.237
   Widder RA, 2002, INVEST OPHTH VIS SCI, V43, P2906
   Wilde C, 2017, EYE, V31, P1042, DOI 10.1038/eye.2017.30
   Williams MA, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009300.pub2
   Wilson DJ, 2017, INVEST OPHTH VIS SCI, V58
   Wittes J, 2009, OPHTHALMOLOGY, V116, pS8, DOI 10.1016/j.ophtha.2009.06.050
   Wolf-Schnurrbusch UEK, 2015, INVEST OPHTH VIS SCI, V56, P8069, DOI 10.1167/iovs.15-17586
   Wong DT, 2006, INVEST OPHTH VIS SCI, V47, P3543
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Wu J, 2017, OPHTHALMOLOGY, V124, P634, DOI 10.1016/j.ophtha.2016.12.033
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2013, AGE RELATED MACULAR, P263, DOI [DOI 10.1007/978-3-642-22107-1_17, 10.1007/978-3-642-22107-1_17]
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Ying GS, 2008, OPHTHALMOLOGY, V115, P1876, DOI 10.1016/j.ophtha.2008.05.023
   Zanardi I, 2016, CURR MED CHEM, V23, P304, DOI 10.2174/0929867323666151221150420
   Zarbin M, 2016, TRENDS MOL MED, V22, P115, DOI 10.1016/j.molmed.2015.12.007
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zhu W, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110743
NR 456
TC 28
Z9 29
U1 1
U2 26
PU NIHR JOURNALS LIBRARY
PI SOUTHAMPTON
PA UNIV SOUTHAMPTON, EVALUATION, TRIALS & STUDIES COORDINATING CENTRE,
   ALPHA HOUSE, ENTERPRISE RD, SOUTHAMPTON, SO16 7NS, ENGLAND
SN 1366-5278
EI 2046-4924
J9 HEALTH TECHNOL ASSES
JI Health Technol. Assess.
PD MAY
PY 2018
VL 22
IS 27
BP 1
EP +
DI 10.3310/hta22270
PG 169
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA GH5ZD
UT WOS:000433516300001
PM 29846169
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Zehetner, C
   Kralinger, MT
   Kieselbach, GF
AF Zehetner, C.
   Kralinger, M. T.
   Kieselbach, G. F.
TI Intravitreal anti-VEGF therapy in neovascular age-related macular
   degeneration: Bevacizumab versus Ranibizumab
SO SPEKTRUM DER AUGENHEILKUNDE
LA English
DT Article
ID AVASTIN; SECONDARY
AB PURPOSE: To compare and review the effectiveness and safety of intravitreal injections of ranibizumab and bevacizumab for neovascular age-related macular degeneration.
   METHODS: We reviewed the clinical records of 125 consecutive patients with neovascular AMD, who had undergone intravitreal anti-VEGF injections during 2006 and 2007 at the University Clinic of Ophthalmology in Innsbruck, Austria, with a follow-up time range between 6 and 12 months aftr initial treatment. The study comprised three groups. The first group comprised patients, who received ranibizumab (n = 34). The second group patients, who received bevacizumab (n = 42) and the third group patients, who initally received ranibizumab followed by bevacizumab (n = 49). Reinjections were performed upon signs of disease activity assessed by persistence or increase of retinal edema as determined by slit lamp biomicroscopy, OCT or fluorescein angiography. RESULTS: In the ranibizumab group the baseline VA changed from 0.14 +/- 0.13 to 0.15 +/- 0.13 at 6 months, and 0.15 +/- 0.11 at the final examination at 12 months. Compared to baseline VA 9 (26.5%) patients at 3 months, 9 (26.5%) at 6 months and 5 (29.4%) at 12 months gained 3 or more lines. Patients, who lost three or more lines were 10 (29.1%) at 3 months of follow-up, 9 (26.5%) at 6 months and 4 (23.5%) at 12 months of follow-up. In the bevacizumab group the course of VA was 0.24 +/- 0.14 at baseline, 0.24 +/- 0.21 at 6 months, and 0.27 +/- 0.23 at 12 months of follow-up. Compared to baseline VA 6 (14.3%) patients at 3 months, 5 (11.9%) at 6 months and 2 (18.2%) at 12 months gained 3 or more lines. Patients, who lost more than 3 lines were 8 (19.0%) at 3 months of follow-up, 11 (26.2%) at 6 months and 1 (9.0%) at 12 months of follow-up. In the group of patients, who initially received ranibizumab and then bevacizumab the baseline visual acuity changed from 0.19 +/- 0.15 to 0.22 +/- 0.20 at 6 months, and 0.21 +/- 0.18 at the final examination at 12 months. Compared to baseline VA 11 (22.4%) patients at 3 months, 13 (26.5%) at 6 months and 6 (25%) at 12 months gained 3 or more lines. Patients, who lost more than 3 lines were 6 (12.2%) at 3 months of follow-up, 13 (26.5%) at 6 months and 6 (25.0%) at 12 months of follow-up. We denotated no significant increase or decrease of mean VA in all three groups which depicts an overall stabilization of VA. We denotated one case of apoplexia and one case of severe cardiac arrhythmia in the bevacizumab group. CONCLUSION: We found no statistically significant difference comparing the data of our ranibizumab and bevacizumab groups. Our results confirm that therapy of neovascular AMD based on an as-needed basis reinjection scheme with ranibizumab as well as bevacizumab is effective in stabilizing visual acuity.
C1 [Zehetner, C.; Kralinger, M. T.; Kieselbach, G. F.] Innsbruck Med Univ, Dept Ophthalmol, A-6020 Innsbruck, Austria.
C3 Medical University of Innsbruck
RP Zehetner, C (通讯作者)，Innsbruck Med Univ, Dept Ophthalmol, Anichstr 35, A-6020 Innsbruck, Austria.
EM claus.zehetner@i-med.ac.at
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
NR 9
TC 1
Z9 1
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0930-4282
J9 SPEKTRUM AUGENHEILKD
JI Spektrum Augenheilkd.
PD DEC
PY 2008
VL 22
IS 6
BP 370
EP 375
DI 10.1007/s00717-008-0293-6
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 394XB
UT WOS:000262485400007
DA 2022-11-30
ER

PT J
AU Parmeggiani, F
   Gallenga, CE
   Costagliola, C
   Semeraro, F
   Romano, MR
   Dell'Omo, R
   Russo, A
   De Nadai, K
   Gemmati, D
   D'Angelo, S
   Bolletta, E
   Sorrentino, FS
AF Parmeggiani, Francesco
   Gallenga, Carla Enrica
   Costagliola, Ciro
   Semeraro, Francesco
   Romano, Mario R.
   Dell'Omo, Roberto
   Russo, Andrea
   De Nadai, Katia
   Gemmati, Donato
   D'Angelo, Sergio
   Bolletta, Elena
   Sorrentino, Francesco Saverio
TI Impact of methylenetetrahydrofolate reductase C677T polymorphism on the
   efficacy of photodynamic therapy in patients with neovascular
   age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RETINAL-PIGMENT EPITHELIUM;
   VERTEPORFIN PLUS RANIBIZUMAB; RANDOMIZED CLINICAL-TRIALS; VASCULAR
   OXIDANT STRESS; QUALITY-OF-LIFE; VISUAL-ACUITY; ENDOTHELIAL DYSFUNCTION;
   GENE POLYMORPHISMS; LEGAL BLINDNESS
AB The most severe visual impairments due to age-related macular degeneration (AMD) are frequently caused by the occurrence of choroidal neovascularization (CNV). Although photodynamic therapy with verteporfin (PDT-V) is currently a second-line treatment for neovascular AMD, it can be conveniently combined with drugs acting against vascular endothelial growth factor (anti-VEGF) to reduce the healthcare burden associated with the growing necessity of anti-VEGF intravitreal re-injection. Because the common 677C > T polymorphism of the methylenetetrahydrofolate reductase gene (MTHFR-C677T; rs1801133) has been described as predictor of satisfactory short-term responsiveness of AMD-related CNV to PDT-V, we retrospectively examined the outcomes of 371 Caucasian patients treated with standardized, pro-re-nata, photodynamic regimen for 24 months. Responder (R) and non-responder (NR) patients were distinguished on the basis of the total number of scheduled PDT-V (TN-PDT-V) and change of best-corrected visual acuity (Delta-BCVA). The risk for both TN-PDT-V and Delta-BCVA to pass from R to NR group was strongly correlated with CT and TT genotypes of MTHFR-C677T variant resulting, respectively, in odd ratios of 0.19 [95% CI, 0.12-0.32] and 0.09 [95% CI, 0.04-0.21] (P < 0.001), and odd ratios of 0.24 [95%CI, 0.15-0.39] and 0.03 [95%CI, 0.01-0.11] (P < 0.001). These pharmacogenetic findings indicate a rational basis to optimize the future clinical application of PDT-V during the combined treatments of AMD-related CNV, highlighting the role of thrombophilia to be aware of the efficacy profile of photodynamic therapy.
C1 [Parmeggiani, Francesco; De Nadai, Katia] Univ Ferrara, Dept Morphol Surg & Expt Med, I-44121 Ferrara, Italy.
   [Parmeggiani, Francesco] Univ Ferrara, Ctr Study Inflammat, I-44121 Ferrara, Italy.
   [Gallenga, Carla Enrica; Gemmati, Donato; D'Angelo, Sergio; Bolletta, Elena] Univ Ferrara, Dept Biomed & Specialty Surg Sci, I-44121 Ferrara, Italy.
   [Costagliola, Ciro; Dell'Omo, Roberto] Univ Molise, Dept Med & Hlth Sci, I-86100 Campobasso, Italy.
   [Semeraro, Francesco; Russo, Andrea] Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, I-25121 Brescia, Italy.
   [Romano, Mario R.] Humanitas Univ, Dept Biomed Sci, I-20090 Milan, Italy.
   [De Nadai, Katia] Azienda ULSS 6 Euganea, Ctr Retinitis Pigmentosa Veneto Reg, Camposampiero Hosp, I-35131 Padua, Italy.
   [Sorrentino, Francesco Saverio] Azienda USL Bologna, Dept Surg Sci, Maggiore Hosp, I-40124 Bologna, Italy.
C3 University of Ferrara; University of Ferrara; University of Ferrara;
   University of Molise; University of Brescia; Humanitas University; ULSS
   6 Euganea; Ospedale di Camposampiero; AUSL di Bologna
RP Parmeggiani, F (通讯作者)，Univ Ferrara, Dept Morphol Surg & Expt Med, I-44121 Ferrara, Italy.; Parmeggiani, F (通讯作者)，Univ Ferrara, Ctr Study Inflammat, I-44121 Ferrara, Italy.
EM francesco.parmeggiani@unife.it
RI Semeraro, Francesco fs/K-8667-2016; dell'Omo, Roberto/K-7328-2016;
   Russo, Andrea/K-8550-2016
OI Semeraro, Francesco fs/0000-0002-2275-4917; dell'Omo,
   Roberto/0000-0002-7663-8874; Gemmati, Donato/0000-0001-6213-6120; Russo,
   Andrea/0000-0002-1566-3662; D'Angelo, Sergio/0000-0003-1118-3845;
   PARMEGGIANI, FRANCESCO/0000-0002-9296-0986; Gallenga, Carla
   Enrica/0000-0002-7426-8603
CR Abais JM, 2014, J BIOL CHEM, V289, P27159, DOI 10.1074/jbc.M114.567537
   Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Acker G, 2016, J NEURO-ONCOL, V129, P33, DOI 10.1007/s11060-016-2143-8
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Arias L, 2005, BRIT J OPHTHALMOL, V89, P312, DOI 10.1136/bjo.2004.050997
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P258, DOI 10.1016/j.ajo.2003.08.009
   Bandello F, 2007, INVEST OPHTH VIS SCI, V48, P96, DOI 10.1167/iovs.06-0283
   Bashshur ZF, 2011, RETINA-J RET VIT DIS, V31, P636, DOI 10.1097/IAE.0b013e3181fe54ab
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blasiak J, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6819736
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Campa C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/546826
   Castro R, 2006, J INHERIT METAB DIS, V29, P3, DOI 10.1007/s10545-006-0106-5
   Chakravarthy U, 2006, BRIT J OPHTHALMOL, V90, P1188, DOI 10.1136/bjo.2005.082255
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Christenbury JG, 2018, RETINA-J RET VIT DIS, V38, P1276, DOI 10.1097/IAE.0000000000001766
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Craige SM, 2015, CIRC J, V79, P1145, DOI 10.1253/circj.CJ-15-0464
   Datseris I, 2015, SEMIN OPHTHALMOL, V30, P112, DOI 10.3109/08820538.2013.833268
   Dewi NA, 2008, JPN J OPHTHALMOL, V52, P277, DOI 10.1007/s10384-008-0551-9
   Dong Y, 2016, EXP THER MED, V12, P3923, DOI 10.3892/etm.2016.3886
   Englander M, 2013, CURR OPIN OPHTHALMOL, V24, P233, DOI 10.1097/ICU.0b013e32835f8eaa
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FRYER RH, 1993, ARTERIOSCLER THROMB, V13, P1327, DOI 10.1161/01.ATV.13.9.1327
   Gallenga CE, 2014, INFLAMM RES, V63, P105, DOI 10.1007/s00011-013-0684-2
   Gemmati D, 2004, CANCER EPIDEM BIOMAR, V13, P787
   Gemmati D, 2016, CURR PHARM DESIGN, V22, P1449, DOI 10.2174/1381612822666151210122954
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Han DP, 2013, JAMA OPHTHALMOL, V131, P1124, DOI 10.1001/jamaophthalmol.2013.432
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Hatz K, 2015, OPHTHALMOLOGICA, V233, P66, DOI 10.1159/000367603
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holven KB, 2007, J THROMB HAEMOST, V5, P193, DOI 10.1111/j.1538-7836.2006.02275.x
   Holven KB, 2003, J NUTR, V133, P3588, DOI 10.1093/jn/133.11.3588
   Hung CH, 2015, CLIN SCI, V129, P477, DOI 10.1042/CS20150127
   Incorvaia C, 2008, RETINA-J RET VIT DIS, V28, P289, DOI 10.1097/IAE.0b013e31813ffe90
   Isola V, 2006, AM J OPHTHALMOL, V142, P680, DOI 10.1016/j.ajo.2006.04.028
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kanani PM, 1999, CIRCULATION, V100, P1161, DOI 10.1161/01.CIR.100.11.1161
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Keenan TDL, 2013, BRIT J OPHTHALMOL, V97, P1168, DOI 10.1136/bjophthalmol-2013-303233
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Koizumi H, 2010, ARCH OPHTHALMOL-CHIC, V128, P259, DOI 10.1001/archophthalmol.2009.369
   Krebs I, 2013, ACTA OPHTHALMOL, V91, pE178, DOI 10.1111/aos.12018
   Lai WKC, 2015, ANN NUTR METAB, V67, P1, DOI 10.1159/000437098
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lindsley K, 2016, OPHTHALMOLOGY, V123, P884, DOI 10.1016/j.ophtha.2015.12.004
   Maeda H, 2016, MICROCIRCULATION, V23, P173, DOI 10.1111/micc.12228
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mataix J, 2009, OPHTHAL SURG LAS IM, V40, P277, DOI 10.3928/15428877-20090430-09
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Moll S, 2015, CIRCULATION, V132, pe6, DOI 10.1161/CIRCULATIONAHA.114.013311
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Murjaneh S, 2009, BRIT J OPHTHALMOL, V93, P468, DOI 10.1136/bjo.2008.141366
   NEMERSON Y, 1992, SEMIN HEMATOL, V29, P170
   Pang XM, 2014, ATHEROSCLEROSIS, V236, P73, DOI 10.1016/j.atherosclerosis.2014.06.021
   Papatheodorou L, 2007, ANTIOXID REDOX SIGN, V9, P1941, DOI 10.1089/ars.2007.1750
   Parmeggiani F, 2006, OPHTHALMOLOGY, V113, P157
   Parmeggiani F, 2008, INVEST OPHTH VIS SCI, V49, P3100, DOI 10.1167/iovs.07-1654
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   Parmeggiani F, 2015, INT J MOL SCI, V16, P19796, DOI 10.3390/ijms160819796
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Parmeggiani F, 2011, MOL DIAGN THER, V15, P195, DOI 10.2165/11592270-000000000-00000
   Parmeggiani F, 2011, CURR DRUG TARGETS, V12, P138, DOI 10.2174/138945011794182773
   Parmeggiani F, 2010, ARCH OPHTHALMOL-CHIC, V128, P1632, DOI 10.1001/archophthalmol.2010.285
   Parmeggiani Francesco, 2009, Recent Pat DNA Gene Seq, V3, P114
   Parmeggiani F, 2010, OPHTHALMOLOGY, V117, P517, DOI 10.1016/j.ophtha.2009.08.028
   Parmeggiani F, 2009, PHARMACOGENOMICS, V10, P81, DOI 10.2217/14622416.10.1.81
   Parodi MB, 2007, ACTA OPHTHALMOL SCAN, V85, P50, DOI 10.1111/j.1600-0420.2006.00738.x
   Peng FY, 2001, INT J MOL MED, V8, P509
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Reeves BC, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16060
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rishi Ekta, 2016, Oman J Ophthalmol, V9, P87, DOI 10.4103/0974-620X.184511
   Rosenberg N, 2002, AM J HUM GENET, V70, P758, DOI 10.1086/338932
   Rozen R, 1997, THROMB HAEMOSTASIS, V78, P523
   Sachdeva S, 2012, BIOCHEM GENET, V50, P893, DOI 10.1007/s10528-012-9529-x
   Sakurai K, 2003, J PHARMACOL SCI, V91, P182
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2009, PROG RETIN EYE RES, V28, P145, DOI 10.1016/j.preteyeres.2009.01.001
   Schmier JK, 2016, PHARMACOECONOMICS, V34, P259, DOI 10.1007/s40273-015-0347-y
   Si JK, 2014, INT J OPHTHALMOL-CHI, V7, P541, DOI 10.3980/j.issn.2222-3959.2014.03.28
   Sirotkina MA, 2017, SCI REP-UK, V7, DOI 10.1038/srep41506
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Sorrentino FS, 2018, EYE, V32, P1157, DOI 10.1038/s41433-018-0032-4
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Stevens GA, 2013, OPHTHALMOLOGY, V120, P2377, DOI 10.1016/j.ophtha.2013.05.025
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Tanaka K, 2011, MOL VIS, V17, P2751
   Tong Y, 2016, INT J OPHTHALMOL-CHI, V9, P1028, DOI 10.18240/ijo.2016.07.16
   Tsuchihashi T, 2014, CLIN OPHTHALMOL, V8, P2471, DOI 10.2147/OPTH.S71305
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P518, DOI 10.1007/s00417-003-0650-8
   Wang XM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152414
   Weinberger D, 2005, CURR EYE RES, V30, P269, DOI 10.1080/02713680590927597
   Weiss N, 2005, CURR DRUG METAB, V6, P27, DOI 10.2174/1389200052997357
   Wilcken B, 2003, J MED GENET, V40, P619, DOI 10.1136/jmg.40.8.619
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HLTH, V2
   Wormald R, 2007, COCHRANE DB SYST REV, V3
   Wu MX, 2017, BRIT J OPHTHALMOL, V101, P976, DOI 10.1136/bjophthalmol-2016-309418
   Yamashiro K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09632-0
NR 120
TC 3
Z9 3
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 22
PY 2019
VL 9
AR 2614
DI 10.1038/s41598-019-38919-7
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HM3UI
UT WOS:000459399400083
PM 30796269
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ozturk, M
   Harris, ML
   Nguyen, V
   Barthelmes, D
   Gillies, MC
   Mehta, H
AF Ozturk, Mehmet
   Harris, Martin L.
   Vuong Nguyen
   Barthelmes, Daniel
   Gillies, Mark C.
   Mehta, Hemal
TI Real-world visual outcomes in patients with neovascular age-related
   macular degeneration receiving aflibercept at fixed intervals as per UK
   licence
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE aflibercept; age-related macular degeneration; neovascular; real-world
   outcomes
ID ACUITY OUTCOMES; RANIBIZUMAB; AMD
AB ImportanceTo assess the impact of injection frequency on visual outcomes in patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal aflibercept.
   BackgroundThe UK licence for treatment of nAMD with aflibercept is based on the VIEW protocol. We tested the hypothesis that patients receiving fewer than the eight recommended injections in the first year would experience worse visual outcomes.
   DesignRetrospective, single-centre observational study.
   ParticipantsThere were 42 eyes from 42 patients included.
   MethodsFight Retinal Blindness! software was used to record real-world outcomes of all treatment-naive eyes receiving aflibercept for at least 1 year.
   Main Outcome MeasuresVisual acuity (VA) at 1 year in eyes which received the recommended eight injections versus those receiving seven or fewer injections.
   ResultsThere were 21 eyes (50%) that received the recommended eight aflibercept injections in the first year of treatment, whilst 14 eyes received seven injections, five received six injections and two received only five injections, with median VA change +7.0, +5.0, -4.0 and -6.5 LogMAR letters, respectively. Those eyes receiving seven or fewer injections had worse baseline vision. The main reasons for patients being undertreated were insufficient clinic capacity and non-attendance due to illness.
   Conclusions and RelevancePatients in the real-world receiving aflibercept for nAMD at fixed intervals as per UK licence could achieve similar visual improvement at 1 year compared with phase III clinical trials. Undertreated patients had worse visual outcomes. Measures need to be introduced to increase clinic capacity and closely follow non-attenders to improve future outcomes.
C1 [Ozturk, Mehmet; Harris, Martin L.; Mehta, Hemal] Royal Free London NHS Fdn Trust, Dept Ophthalmol, London, England.
   [Vuong Nguyen; Barthelmes, Daniel; Gillies, Mark C.; Mehta, Hemal] Univ Sydney, Save Sight Inst, Macular Res Grp, Sydney, NSW, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Zurich Hosp, Dept Ophthalmol, Zurich, Switzerland.
C3 University of London; University College London; Royal Free London NHS
   Foundation Trust; University of Sydney; University of Zurich; University
   Zurich Hospital
RP Mehta, H (通讯作者)，Royal Free London NHS Fdn Trust, Pond St, London NW3 2QG, England.
EM hm@cantab.net
OI Nguyen, Vuong/0000-0001-9070-9803
CR Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Foot B, 2017, EYE, V31, P771, DOI 10.1038/eye.2017.1
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2006, OPHTHALMOLOGY, V113, pe1, DOI DOI 10.1016/J.0PHTHA.2005.10.052)
   Keenan TDL, 2013, BRIT J OPHTHALMOL, V97, P1168, DOI 10.1136/bjophthalmol-2013-303233
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
NR 12
TC 18
Z9 18
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD MAY-JUN
PY 2018
VL 46
IS 4
BP 407
EP 411
DI 10.1111/ceo.13085
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GJ2DX
UT WOS:000435080700013
PM 29044979
DA 2022-11-30
ER

PT J
AU Grassmann, F
   Cantsilieris, S
   Schulz-Kuhnt, AS
   White, SJ
   Richardson, AJ
   Hewitt, AW
   Vote, BJ
   Schmied, D
   Guymer, RH
   Weber, BHF
   Baird, PN
AF Grassmann, Felix
   Cantsilieris, Stuart
   Schulz-Kuhnt, Anja-Sabrina
   White, Stefan J.
   Richardson, Andrea J.
   Hewitt, Alex W.
   Vote, Brendan J.
   Schmied, Denise
   Guymer, Robyn H.
   Weber, Bernhard H. F.
   Baird, Paul N.
TI Multiallelic copy number variation in the complement component 4A (C4A)
   gene is associated with late-stage age-related macular degeneration
   (AMD)
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Age-related macular degeneration; AMD; C4; Complement; Copy number
   variation (CNV); Multiallelic; Genetic association
ID DEPENDENT PROBE AMPLIFICATION; GENOME-WIDE ASSOCIATION; 4TH COMPONENT;
   RISK-FACTORS; SUSCEPTIBILITY; POLYMORPHISMS; PATHOGENESIS; IMMUNOLOGY;
   PSORIASIS; HAPLOTYPE
AB Background: Age-related macular degeneration (AMD) is the leading cause of vision loss in Western societies with a strong genetic component. Candidate gene studies as well as genome-wide association studies strongly implicated genetic variations in complement genes to be involved in disease risk. So far, no association of AMD with complement component 4 (C4) was reported probably due to the complex nature of the C4 locus on chromosome 6.
   Methods: We used multiplex ligation-dependent probe amplification (MLPA) to determine the copy number of the C4 gene as well as of both relevant isoforms, C4A and C4B, and assessed their association with AMD using logistic regression models.
   Results: Here, we report on the analysis of 2645 individuals (1536 probands and 1109 unaffected controls), across three different centers, for multiallelic copy number variation (CNV) at the C4 locus. We find strong statistical significance for association of increased copy number of C4A (OR 0.81 (0.73; 0.89); P = 4.4 x 10(-5)), with the effect most pronounced in individuals over 78 years (OR 0.67 (0.55; 0.81)) and females (OR 0.77 (0.68; 0.87)). Furthermore, this association is independent of known AMD-associated risk variants in the nearby CFB/C2 locus, particularly in females and in individuals over 78 years.
   Conclusions: Our data strengthen the notion that complement dysregulation plays a crucial role in AMD etiology, an important finding for early intervention strategies and future therapeutics. In addition, for the first time, we provide evidence that multiallelic CNVs are associated with AMD pathology.
C1 [Grassmann, Felix; Schulz-Kuhnt, Anja-Sabrina; Schmied, Denise; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
   [Cantsilieris, Stuart; Richardson, Andrea J.; Hewitt, Alex W.; Guymer, Robyn H.; Baird, Paul N.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res, Melbourne, Vic, Australia.
   [Hewitt, Alex W.; Vote, Brendan J.] Univ Tasmania, Sch Med, Menzies Res Inst Tasmania, Hobart, Tas, Australia.
   [White, Stefan J.] Leiden Univ, Med Ctr, Leiden, Netherlands.
C3 University of Regensburg; Royal Victorian Eye & Ear Hospital; University
   of Melbourne; University of Tasmania; Menzies Institute for Medical
   Research; Leiden University; Leiden University Medical Center (LUMC);
   Leiden University - Excl LUMC
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.; Baird, PN (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res, Melbourne, Vic, Australia.
EM bweb@klinik.uni-regensburg.de; pnb@unimelb.edu.au
OI Grassmann, Felix/0000-0003-1390-7528; Guymer, Robyn/0000-0002-9441-4356;
   Weber, Bernhard H.F./0000-0002-8808-7723; Baird,
   Paul/0000-0002-1305-3502; Hewitt, Alex/0000-0002-5123-5999
FU Deutsche Forschungsgemeinschaft [WE 1259/19-1, WE 1259/19-2]; Alcon
   Research Institute; National Health and Medical Research Council (NHMRC)
   [1028444]; NHMRC [1073726]; CIDR [HHSN268201200008I, EY022310,
   1X01HG006934-01]; NATIONAL EYE INSTITUTE [R01EY022310] Funding Source:
   NIH RePORTER
FX This study was supported in parts by the Deutsche Forschungsgemeinschaft
   (WE 1259/19-1 and WE 1259/19-2 to BHFW) and the Alcon Research Institute
   (to BHFW). PNB was supported by a National Health and Medical Research
   Council (NHMRC) Senior Research Fellowship (#1028444) and SC by an NHMRC
   CJ Martin Biomedical Fellowship (#1073726). The Centre for Eye Research
   Australia (CERA) receives Operational Infrastructure Support from the
   Victorian Government. We would like to thank the International AMD
   Genomics Consortium (IAMDGC, http://eaglep.case.edu/iamdgc_web/) for
   providing the genotypes at the C2/CFB locus for our samples. The samples
   were genotyped as part of the IAMDGC exome-chip project supported by
   CIDR contract number HHSN268201200008I and funded by EY022310 (to
   Jonathan L. Haines) and 1X01HG006934-01 (to Goncalo R. Abecasis). We
   thank The Gandel Charitable Trust Sequencing Centre for the use of the
   sequencing facility. We thank Nicole Tindill and Melinda Cain for their
   assistance in the data management and patient recruitment.
CR Aldhous MC, 2010, HUM MOL GENET, V19, P4930, DOI 10.1093/hmg/ddq411
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   BARBA GMR, 1994, EUR J IMMUNOGENET, V21, P325, DOI 10.1111/j.1744-313X.1994.tb00203.x
   Bay JT, 2013, KIDNEY INT, V84, P562, DOI 10.1038/ki.2013.195
   Boteva L, 2012, AM J HUM GENET, V90, P445, DOI 10.1016/j.ajhg.2012.01.012
   Candore G, 2003, BIOMED PHARMACOTHER, V57, P274, DOI 10.1016/S0753-3322(03)00079-9
   Cantsilieris S, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-329
   Cantsilieris S, 2013, HUM MUTAT, V34, P1, DOI 10.1002/humu.22172
   Cantsilieris S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035255
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Dodds AW, 1996, NATURE, V379, P177, DOI 10.1038/379177a0
   Ersoy L, 2014, INVEST OPHTH VIS SCI, V55, P1842, DOI 10.1167/iovs.13-13420
   Feng YX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016865
   Fernando MMA, 2010, HUM MUTAT, V31, P866, DOI 10.1002/humu.21259
   Flachsbart F, 2010, MUTAT RES-FUND MOL M, V694, P13, DOI 10.1016/j.mrfmmm.2010.08.006
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2015, NAT GENET IN PRESS
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2015, ANNU REV VIS SCI, V1, P73, DOI 10.1146/annurev-vision-082114-035609
   Grassmann F, 2015, EUR J PHARM BIOPHARM, V95, P194, DOI 10.1016/j.ejpb.2015.04.039
   Grassmann F, 2015, NEUROMOL MED, V17, P111, DOI 10.1007/s12017-015-8342-1
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hollox E, 2012, GENOMIC STRUCTURAL V
   Hollox EJ, 2008, NAT GENET, V40, P23, DOI 10.1038/ng.2007.48
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   KRAMER J, 1991, HUM GENET, V86, P595
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   O'Connell J, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004234
   Pinto D, 2011, NAT BIOTECHNOL, V29, P512, DOI 10.1038/nbt.1852
   Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Stuart PE, 2012, J INVEST DERMATOL, V132, P2407, DOI 10.1038/jid.2012.191
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Usher CL, 2015, BRIEF FUNCT GENOMICS, V14, P329, DOI 10.1093/bfgp/elv028
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   White SJ, 2007, CYTOGENET GENOME RES, V118, P19, DOI 10.1159/000106437
   White SJ, 2004, HUM MUTAT, V24, P86, DOI 10.1002/humu.20054
   Wouters D, 2009, MOL IMMUNOL, V46, P592, DOI 10.1016/j.molimm.2008.07.028
   Yang Y, 2003, J IMMUNOL, V171, P2734, DOI 10.4049/jimmunol.171.5.2734
   Yang Y, 2007, AM J HUM GENET, V80, P1037, DOI 10.1086/518257
   YU CY, 1986, EMBO J, V5, P2873, DOI 10.1002/j.1460-2075.1986.tb04582.x
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 49
TC 21
Z9 21
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD APR 18
PY 2016
VL 13
AR 81
DI 10.1186/s12974-016-0548-0
PG 9
WC Immunology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Neurosciences & Neurology
GA DJ5YB
UT WOS:000374285600003
PM 27090374
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ma, XY
   Li, HR
   Wang, YP
   Wang, J
   Zheng, QX
   Hua, JJ
   Yang, J
   Pan, L
   Lu, F
   Qu, J
   Hou, L
AF Ma, Xiaoyin
   Li, Huirong
   Wang, Yipin
   Wang, Jing
   Zheng, Qinxiang
   Hua, Jiajia
   Yang, Juan
   Pan, Li
   Lu, Fan
   Qu, Jia
   Hou, Ling
TI DAPL1, a susceptibility locus for age-related macular degeneration, acts
   as a novel suppressor of cell proliferation in the retinal pigment
   epithelium
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID HUMAN RPE; VITREORETINOPATHY
AB The retinal pigment epithelium (RPE) forms a monolayer at the back of the vertebrate eye and is fundamental to retinal function and homoeostasis. During early development, RPE cells undergo rapid proliferation, but in the adult, they remain normally nonproliferative throughout life. Nevertheless, under pathological conditions such as in proliferative vitreoretinopathy or after retinal ablation, mature RPE cells can re-enter the cell cycle and form nodules or multiple cell layers. Here we show that Dapl1, whose human homolog represents a susceptibility locus for age-related macular degeneration (AMD), is highly up-regulated in quiescent but not proliferating RPE cells and that experimental overexpression of DAPL1 in proliferating RPE cells inhibits their proliferation. Consistent with this observation, the percent of Ki67-positive cells is significantly higher in E11.5 Dapl1 knockout mouse embryos compared to age-matched controls. In adult Dapl1-/- mice, which survive without showing any overt pathology, RPE overgrowth leads to multiple cell layers and/or cellular nodules. The antiproliferative effect of DAPL1 is associated with an increase in CDKN1A protein levels. Reduction of CDKN1A by siRNA in DAPL1-overexpressing RPE cells in vitro partially restores cell proliferation. Hence, we show that DAPL1 is a novel regulator of RPE cell proliferation that is important for the maintenance of the RPE as a monolayer. The findings suggest that DAPL1 dysregulation may be involved in abnormal RPE-related proliferative diseases and corresponding retinal dysfunctions in humans.
C1 [Ma, Xiaoyin; Li, Huirong; Wang, Yipin; Wang, Jing; Hua, Jiajia; Yang, Juan; Pan, Li; Hou, Ling] Wenzhou Med Univ, Lab Dev Cell Biol & Dis, Sch Ophthalmol & Optometry, Wenzhou, Peoples R China.
   [Ma, Xiaoyin; Li, Huirong; Wang, Yipin; Wang, Jing; Hua, Jiajia; Yang, Juan; Pan, Li; Hou, Ling] Wenzhou Med Univ, Hosp Eye, Wenzhou, Peoples R China.
   [Ma, Xiaoyin; Wang, Jing; Zheng, Qinxiang; Lu, Fan; Qu, Jia; Hou, Ling] Minist Hlth, State Key Lab, Wenzhou 325003, Peoples R China.
   [Ma, Xiaoyin; Wang, Jing; Zheng, Qinxiang; Lu, Fan; Qu, Jia; Hou, Ling] Minist Hlth, Key Lab Vision Sci, Wenzhou 325003, Peoples R China.
   [Ma, Xiaoyin; Wang, Jing; Zheng, Qinxiang; Lu, Fan; Qu, Jia; Hou, Ling] Zhejiang Prov Key Lab Ophthalmol, Wenzhou 325003, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University
RP Hou, L (通讯作者)，Wenzhou Med Univ, Wenzhou, Peoples R China.
EM lhou@mail.eye.ac.cn
RI hua, jiajia/GVT-5178-2022
OI Ma, Xiaoyin/0000-0002-3564-1647; Hou, Ling/0000-0003-0705-8099; Hua,
   Jiajia/0000-0002-9152-7013
FU National Natural Science Foundation of China [81570892, 81600748];
   National Basic Research Program (973 Program) [2009CB526502]; Zhejiang
   Provincial NSF [Y2101213, LZ12C12001, LY13C090004, LQ13H120004]; Medical
   Scientific Research Foundation of Zhejiang Province, China [2016KYB205,
   2017 KY487]; Wenzhou Medical University; Wenzhou Medical University Eye
   Hospital
FX National Natural Science Foundation of China (81570892, 81600748),
   National Basic Research Program (973 Program, 2009CB526502), Zhejiang
   Provincial NSF (Y2101213, LZ12C12001, LY13C090004, LQ13H120004), Medical
   Scientific Research Foundation of Zhejiang Province, China (2016KYB205,
   2017 KY487), and Research Grant of Wenzhou Medical University and
   Wenzhou Medical University Eye Hospital.
CR ANDERSON DH, 1981, INVEST OPHTH VIS SCI, V21, P10
   Bharti K, 2006, PIGM CELL RES, V19, P380, DOI 10.1111/j.1600-0749.2006.00318.x
   Casaroli-Marano RP, 1999, INVEST OPHTH VIS SCI, V40, P2062
   Chiba C, 2014, EXP EYE RES, V123, P107, DOI 10.1016/j.exer.2013.07.009
   Georgiadis A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015730
   Grassmann F, 2015, NEUROMOL MED, V17, P111, DOI 10.1007/s12017-015-8342-1
   Hou Q, 2013, INVEST OPHTH VIS SCI, V54, P6481, DOI 10.1167/iovs.13-11873
   Leiderman YI, 2009, SEMIN OPHTHALMOL, V24, P62, DOI 10.1080/08820530902800082
   Li R, 2007, INVEST OPHTH VIS SCI, V48, P5722, DOI 10.1167/iovs.07-0327
   Liu YQ, 2009, INVEST OPHTH VIS SCI, V50, P5080, DOI 10.1167/iovs.08-2911
   Macaluso M, 2005, SEMIN ONCOL, V32, P452, DOI 10.1053/j.seminoncol.2005.07.009
   Pastor JC, 2002, PROG RETIN EYE RES, V21, P127, DOI 10.1016/S1350-9462(01)00023-4
   Peiretti E, 2006, RETINA-J RET VIT DIS, V26, P1097, DOI 10.1097/01.iae.0000233328.68999.5f
   Polito A, 2006, ANN ACAD MED SINGAP, V35, P420
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Schouwey K, 2011, ONCOGENE, V30, P313, DOI 10.1038/onc.2010.428
   Shen B, 2013, CELL RES, V23, P720, DOI 10.1038/cr.2013.46
   Shields JA, 2009, OPHTHALMOLOGY, V116, P2213, DOI 10.1016/j.ophtha.2009.04.048
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Steindl-Kuscher K, 2009, INVEST OPHTH VIS SCI, V50, P4471, DOI 10.1167/iovs.08-3139
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun L, 2006, J CELL PHYSIOL, V206, P103, DOI 10.1002/jcp.20433
   TSUKIJI N, 2009, Patent No. 326335
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wang Y, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-144
   Wu Wen-Chuan, 2000, Kaohsiung Journal of Medical Sciences, V16, P614
   Yang L, 2004, INVEST OPHTH VIS SCI, V45, P648, DOI 10.1167/iovs.03-0827
   Yepez JB, 2015, CASE REP OPHTHALMOL, V2015, DOI 10.1155/2015/153831
NR 29
TC 13
Z9 14
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 1
PY 2017
VL 26
IS 9
BP 1612
EP 1621
DI 10.1093/hmg/ddx063
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA EU3EU
UT WOS:000400912200002
PM 28334846
OA Bronze
DA 2022-11-30
ER

PT J
AU Holz, FG
   Bindewald, A
   Schutt, F
   Specht, H
AF Holz, FG
   Bindewald, A
   Schutt, F
   Specht, H
TI Intraocular microablation of choroidal tissue by a 308 nm AIDA excimer
   laser for RPE-transplantation in patients with age-related macular
   degeneration
SO BIOMEDIZINISCHE TECHNIK
LA English
DT Article
DE retinal pigment epithelial cells; AIDA excimer laser; choroid; macular
   degeneration; transplantation
ID RETINAL-PIGMENT EPITHELIUM; NEOVASCULARIZATION; ABLATION; REMOVAL
AB Age-related macular degeneration (AMD) is the leading cause of legal blindness in the western nations beyond 50 years of age. The most frequent cause for severe visual loss is the growth of neovascular membranes from the choroid into the subretinal space. This usually results in irreversible degeneration of the overlying retina. Surgical removal of the membrane is feasible, however, usually results in functional loss of apposing retinal photoreceptors since retinal pigment epithelial (RPE) cells are removed concurrently due to their tight adherence to the neovascular complex. Therefore, various attempts have been undertaken to fill the resulting RIPE cell defect with either heterologous or autologous RPE cell transplants. So far cell survival, function and subsequent visual function has been disappointing. To minimize trauma and resulting dedifferentiation harvesting in the eye and transplantation in whole sheets and without temporary removal from the eyes would be desirable. This may be achieved by isolating grafts consisting of choroid, Bruch's membrane and RPE cells from the peripheral retina and transplantation of this graft under the neurosensory retina after removal of the choroidal neovascularization. However, the choroidal component of such a graft would be expected to interfere with diffusion of metabolites to and from the retina. Therefore, outcome would be expected to be better if the choroidal tissue would be removed before translocation. In preclinical experiments we used a 308 nm UV AIDA excimer laser to microablate choroidal tissue from such a graft in human donor eyes.
C1 Univ Heidelberg, Augenklin, D-69120 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; University of Hamburg; University
   Medical Center Hamburg-Eppendorf
RP Holz, FG (通讯作者)，Univ Heidelberg, Augenklin, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.
OI Bindewald-Wittich, Almut/0000-0002-8151-3953
CR ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   BIRD AC, 1996, BR J OPHTHALMOL, V80, P1
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   HOLZ FG, 1997, PAULEIKHOFF ALTERSAB
   KAUFMANN R, 1989, LASER SURG MED, V9, P132, DOI 10.1002/lsm.1900090208
   MARTIN C, 1992, TRENDS GENET, V8, P368
   PRODOEHL JA, 1994, LASER SURG MED, V15, P263, DOI 10.1002/lsm.1900150305
   Rezai KA, 1999, CURR EYE RES, V18, P430, DOI 10.1076/ceyr.18.6.430.5269
   Schutt F, 2002, EXP EYE RES, V74, P155, DOI 10.1006/exer.2001.1102
   Stanga Paulo E., 2001, International Ophthalmology, V23, P297, DOI 10.1023/A:1014482025960
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   VANMEURS J, 2002, CLUB GON M
   Vogel M, 1997, OPHTHALMOLOGE, V94, P665, DOI 10.1007/s003470050180
   WOODBURN KW, 2002, RETINA, V22, P527
NR 20
TC 12
Z9 27
U1 0
U2 2
PU FACHVERLAG SCHIELE SCHON
PI BERLIN
PA MARKGRAFENSTRASSE 11, D-10969 BERLIN, GERMANY
SN 0013-5585
J9 BIOMED TECH
JI Biomed. Tech.
PD APR
PY 2003
VL 48
IS 4
BP 82
EP 85
PG 4
WC Engineering, Biomedical; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Medical Informatics
GA 671PG
UT WOS:000182472800002
PM 12749285
DA 2022-11-30
ER

PT J
AU Faria, BM
   Duman, F
   Zheng, CX
   Waisbourd, M
   Gupta, L
   Ali, M
   Zangalli, C
   Lu, L
   Wizov, SS
   Spaeth, E
   Richman, J
   Spaeth, GL
AF Faria, Bruno M.
   Duman, Fulya
   Zheng, Cindy X.
   Waisbourd, Michael
   Gupta, Lalita
   Ali, Mohsin
   Zangalli, Camila
   Lu, Lan
   Wizov, Sheryl S.
   Spaeth, Eric
   Richman, Jesse
   Spaeth, George L.
TI EVALUATING CONTRAST SENSITIVITY IN AGE-RELATED MACULAR DEGENERATION
   USING A NOVEL COMPUTER-BASED TEST, THE SPAETH/RICHMAN CONTRAST
   SENSITIVITY TEST
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE contrast sensitivity; age-related macular degeneration; Spaeth; Richman
   contrast sensitivity test; SPARCS; Pelli-Robson
ID VISUAL IMPAIRMENT; CHOROIDAL NEOVASCULARIZATION; MOBILITY PERFORMANCE;
   UNITED-STATES; SEE PROJECT; LOW VISION; ACUITY; PREVALENCE; RELIABILITY;
   POPULATION
AB Background:Contrast sensitivity (CS) is a valuable measure of visual function in patients with age-related macular degeneration (AMD). The authors aimed to compare a novel computer-based test (the Spaeth/Richman Contrast Sensitivity test) with Pelli-Robson test for evaluating CS in patients with AMD.Methods:In this prospective cross-sectional study, CS was evaluated in patients with various stages of AMD and healthy controls using Spaeth/Richman Contrast Sensitivity test and Pelli-Robson test. Spaeth/Richman Contrast Sensitivity test determined CS scores for 5 areas of vision for each eye (central, superonasal, superotemporal, inferonasal, and inferotemporal) and the total score. Test scores between the two methods were compared using mixed-effects linear regression. Spearman's rank correlation coefficient was used to determine correlations. Test-retest reliability was determined using the intraclass correlation coefficient.Results:Of 35 participants with AMD (54 eyes) and 34 controls (66 eyes), 51% were female and 93% were of European descent. The mean Spaeth/Richman Contrast Sensitivity test score for the central area and each of the 4 peripheral quadrants was significantly lower for patients with AMD versus controls (P < 0.001 for all). The mean Pelli-Robson score was also significantly lower in patients with AMD versus controls (P < 0.001). The intraclass correlation coefficient for Spaeth/Richman Contrast Sensitivity test total score and Pelli-Robson score was 0.87 and 0.92, respectively.Conclusion:Spaeth/Richman Contrast Sensitivity test, a novel Internet-based method of testing CS, had significantly lower scores for patients with AMD compared with controls for central and peripheral vision. This test is a valuable tool for assessing CS in AMD.
C1 [Faria, Bruno M.; Duman, Fulya; Zheng, Cindy X.; Waisbourd, Michael; Gupta, Lalita; Ali, Mohsin; Zangalli, Camila; Lu, Lan; Wizov, Sheryl S.; Spaeth, Eric; Richman, Jesse; Spaeth, George L.] Thomas Jefferson Univ, Wills Eye Hosp, Glaucoma Res Ctr, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Spaeth, GL (通讯作者)，Thomas Jefferson Univ, Wills Eye Hosp, Glaucoma Res Ctr, 840 Walnut St,Suite 1110, Philadelphia, PA 19107 USA.
EM gspaeth@willseye.org
RI Duman, Fulya/AAD-2507-2019; Ali, Mohsin/GRY-0476-2022; DUMAN,
   FULYA/ABA-2041-2021
OI Duman, Fulya/0000-0002-5582-2568; 
FU Pfizer [WS698663]; Allergan; Merck
FX Supported by a Pfizer Grant (#WS698663), Allergan, and Merck.
CR Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Bellmann C, 2003, GRAEF ARCH CLIN EXP, V241, P968, DOI 10.1007/s00417-003-0689-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DEREFELDT G, 1979, ACTA OPHTHALMOL, V57, P679
   EVANS DW, 1985, HUM FACTORS, V27, P637, DOI 10.1177/001872088502700602
   Fletcher DC, 2006, OPTOMETRY VISION SCI, V83, P178, DOI 10.1097/01.opx.0000204510.08026.7f
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   JONES HS, 1994, OPHTHAL PHYSL OPT, V14, P287, DOI 10.1111/j.1475-1313.1994.tb00009.x
   Klein BEK, 1998, OPHTHALMOLOGY, V105, P160, DOI 10.1016/S0161-6420(98)91911-X
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Kuyk T, 1999, J REHABIL RES DEV, V36, P303
   LEAT SJ, 1993, OPHTHAL PHYSL OPT, V13, P9, DOI 10.1111/j.1475-1313.1993.tb00420.x
   LENNERSTRAND G, 1989, ACTA OPHTHALMOL, V67, P225
   MARRON JA, 1982, AM J OPTOM PHYS OPT, V59, P413
   Mones J, 2005, EYE, V19, P1142, DOI 10.1038/sj.eye.6701717
   NACHMIAS J, 1967, J OPT SOC AM, V57, P421, DOI 10.1364/JOSA.57.000421
   OWSLEY C, 1981, INVEST OPHTH VIS SCI, V21, P362
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Pesudovs K, 2004, BRIT J OPHTHALMOL, V88, P11, DOI 10.1136/bjo.88.1.11
   REEVES BC, 1991, OPTOMETRY VISION SCI, V68, P728, DOI 10.1097/00006324-199109000-00010
   REGAN D, 1983, OPHTHALMOLOGY, V90, P1192
   Richman J, 2013, J CATARACT REFR SURG, V39, P1100, DOI 10.1016/j.jcrs.2013.05.001
   Richman J, 2010, ARCH OPHTHALMOL-CHIC, V128, P1576, DOI 10.1001/archophthalmol.2010.275
   ROSS JE, 1985, BRIT J OPHTHALMOL, V69, P51, DOI 10.1136/bjo.69.1.51
   RUBIN GS, 1988, CLIN VISION SCI, V2, P169
   RUBIN GS, 1989, VISION RES, V29, P79, DOI 10.1016/0042-6989(89)90175-2
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   Scott IU, 2002, AM J OPHTHALMOL, V133, P350, DOI 10.1016/S0002-9394(01)01406-4
   Spaeth GL, 2012, ACTA OPHTHALMOL COPE, V90
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   West SK, 2002, ARCH OPHTHALMOL-CHIC, V120, P774
NR 37
TC 30
Z9 31
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2015
VL 35
IS 7
BP 1465
EP 1473
DI 10.1097/IAE.0000000000000474
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CM2AA
UT WOS:000357480600024
PM 25658175
DA 2022-11-30
ER

PT J
AU Okur, V
   Cetin, O
   Cetin, E
   Tepeli, E
   Bulgu, Y
   Yildirim, C
AF Okur, Volkan
   Cetin, Ozan
   Cetin, Ebru
   Tepeli, Emre
   Bulgu, Yunus
   Yildirim, Cem
TI HIF1A as a major vascular endothelial growth factor regulator: do its
   polymorphisms have an association with age-related macular degeneration?
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE AMD; CFH; HIF1A; MYRIP; SKIV2L
ID FACTOR-H POLYMORPHISM; CHINESE POPULATION; GENE POLYMORPHISM; RISK; CFH;
   EXPRESSION; VARIANT; SKIV2L
AB BackgroundTo investigate the association between age-related macular degeneration (AMD) and the polymorphisms of HIF1A, a major vascular epithelial growth factor regulator under hypoxic conditions. The associations of AMD and polymorphisms of genes CFH, SKIV2L and MYRIP were also studied.
   DesignProspective study.
   ParticipantsEighty-seven AMD patients and 80 healthy subjects admitted to the Department of Ophthalmology at Pamukkale University Hospital, Denizli, Turkey, were included: 45 (52%) had wet type AMD, and 42 (48%) had dry type AMD.
   MethodsPolymorphisms rs1061170 (CFH), rs429608 (SKIV2L), rs2679798 (MYRIP) and both rs11549465 and rs11549467 (HIF1A) were investigated in DNA isolated from peripheral blood samples of the cases and controls by dye-termination DNA sequencing.
   Main Outcome MeasuresGenotype distribution of rs1061170 (CFH), rs429608 (SKIV2L), rs2679798 (MYRIP) and both rs11549465 and rs11549467 (HIF1A) in AMD cases and healthy controls; association between genotypes and AMD subtypes.
   ResultsGiven the significant difference between the mean age of case and control groups (72.135.77 vs. 62.80 +/- 5.22, respectively) (P=.000), subsequent analyses were adjusted for age. We found that having at least one C allele for polymorphism rs1061170 increases AMD risk independent of age (OR=2.42, 95% confidence interval [CI], 1.22-4.81). The ancestral T allele for polymorphism rs1061170 has a protective effect for AMD (OR=0.53, 95% CI, 0.34-0.83). No statistically significant difference for distributions of other single nucleotide polymorphisms (SNPs) emerged between patients and healthy subjects.
   ConclusionsNo associations appeared between HIF1A SNPs and AMD, which were studied here for the first time; however, polymorphism rs1061170 of the CFH gene is associated with AMD in our population.
C1 [Okur, Volkan; Cetin, Ozan; Tepeli, Emre] Pamukkale Univ, Dept Med Genet, Sch Med, Denizli, Turkey.
   [Cetin, Ebru; Bulgu, Yunus; Yildirim, Cem] Pamukkale Univ, Dept Ophthalmol, Sch Med, Denizli, Turkey.
C3 Pamukkale University; Pamukkale University
RP Cetin, O (通讯作者)，Pamukkale Univ Hastanesi, Tibbi Genet AD, TR-20070 Kinikli, Denizli, Turkey.
EM ocetin@pau.edu.tr
RI Okur, Volkan/AAJ-9785-2020; cetin, ebru/AAF-2986-2020
OI Okur, Volkan/0000-0001-6461-0957; 
FU Pamukkale University Scientific Research Unit [2012TPF021]
FX Funding sources: This study was financially supported by Pamukkale
   University Scientific Research Unit (Grant No: 2012TPF021).
CR Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Gao P, 2007, CANCER CELL, V12, P230, DOI 10.1016/j.ccr.2007.08.004
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hanout M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/830837
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lu F, 2013, INVEST OPHTH VIS SCI, V54, P2911, DOI 10.1167/iovs.12-11381
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Michaud SE, 2003, FASEB J, V17, P1150, DOI 10.1096/fj.02-0172fje
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Shimada H, 2007, GRAEF ARCH CLIN EXP, V245, P295, DOI 10.1007/s00417-006-0367-6
   Soysal Y, 2012, DNA CELL BIOL, V31, P322, DOI 10.1089/dna.2011.1214
   Wang VM, 2012, MOL VIS, V18, P2578
   Wysokinski D, 2013, EXP EYE RES, V106, P14, DOI 10.1016/j.exer.2012.10.003
   Xu YL, 2008, MOL VIS, V14, P1373
   Zhang QZ, 2007, CLIN CANCER RES, V13, P4686, DOI 10.1158/1078-0432.CCR-06-2898
NR 31
TC 5
Z9 5
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JAN-FEB
PY 2015
VL 43
IS 1
BP 47
EP 53
DI 10.1111/ceo.12376
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CA4TR
UT WOS:000348898800009
PM 24995509
DA 2022-11-30
ER

PT J
AU van Zeeburg, EJT
   Maaijwee, KJM
   Missotten, TOAR
   Heimann, H
   van Meurs, JC
AF van Zeeburg, Elsbeth J. T.
   Maaijwee, Kristel J. M.
   Missotten, Tom O. A. R.
   Heimann, Heinrich
   van Meurs, Jan C.
TI A Free Retinal Pigment Epithelium-Choroid Graft in Patients With
   Exudative Age-Related Macular Degeneration: Results up to 7 Years
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID TISSUE-PLASMINOGEN ACTIVATOR; PHOTODYNAMIC THERAPY; FOLLOW-UP;
   INTRAVITREAL BEVACIZUMAB; AUTOLOGOUS TRANSLOCATION; OPHTHALMIC FINDINGS;
   MANAGEMENT; RETINOTOMY; VERTEPORFIN; RANIBIZUMAB
AB PURPOSE: To report and analyze long-term best-corrected visual acuity (BCVA) outcomes following a free autologous retinal pigment epithelium (RPE)-choroid graft translocation in patients with exudative age-related macular degeneration (AMD).
   DESIGN: Prospective cohort study.
   METHODS: SETTING: Institutional. STUDY POPULATION: One hundred and thirty consecutive patients (133 eyes) with AMD underwent RPE-choroid graft translocation between October 2001 and February 2006. All patients had a subfoveal choroidal neovascular membrane with or without hemorrhage and/or an RPE tear. All were either ineligible for or nonresponsive to photodynamic therapy, the standard treatment at the time of surgery. OBSERVATION PROCEDURES: Data collection included preoperative and postoperative visual acuity measurements, fundus photography, fluorescein and indocyanine green angiography, and microperimetry. MAIN OUTCOME MEASURES: Postoperative BCVA.
   RESULTS: The mean preoperative BCVA was 20/250. Four years after surgery, 15% of the eyes had a BCVA of >20/200, and 5% had a BCVA of >= 20/40. One patient achieved a BCVA of 20/32, which was maintained at 7 years after surgery. Complications consisted of proliferative vitreoretinopathy (n = 13), recurrent neovascularization (n = 13), and hypotony (n = 2).
   CONCLUSIONS: RPE-choroid graft transplantation may maintain macular function for up to 7 years after surgery, with relatively low complication and recurrence rates. Retinal sensitivity, BCVA data, and fixation on the graft suggest that the graft, rather than simply the removal of submacular hemorrhage and/or choroidal neovascular membrane, was responsible for the preservation of macular function. This surgery may be an alternative for patients with AMD who cannot undergo other standard treatment. (Am J Ophthalmol 2012;153:120-127. (C) 2012 by Elsevier Inc. All rights reserved.)
C1 [van Zeeburg, Elsbeth J. T.] Rotterdam Ophthalm Inst, NL-3011 BH Rotterdam, Netherlands.
   [van Zeeburg, Elsbeth J. T.; Maaijwee, Kristel J. M.; Missotten, Tom O. A. R.; van Meurs, Jan C.] Rotterdam Eye Hosp, Rotterdam, Netherlands.
   [van Meurs, Jan C.] Erasmus MC, Univ Med Ctr, Rotterdam, Netherlands.
   [Heimann, Heinrich] Royal Liverpool & Broadgreen Univ Hosp, Liverpool, Merseyside, England.
C3 Rotterdam Eye Hospital; Erasmus University Rotterdam; Erasmus MC; Royal
   Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool
   University Hospital
RP van Meurs, JC (通讯作者)，Rotterdam Ophthalm Inst, Schiedamse Vest 160-D, NL-3011 BH Rotterdam, Netherlands.
EM e.vanzeeburg@oogziekenhuis.nl
RI Heimann, Heinrich/AAP-8747-2020
OI Heimann, Heinrich/0000-0002-3298-4644
FU ROTTERDAM EYE HOSPITAL FLIERINGA RESEARCH FOUNDATION, Rotterdam, The
   Netherlands; Royal Visio, Rotterdam, The Netherlands; Alcon; Alcon and
   Novartis
FX PUBLICATION OF THIS ARTICLE WAS SUPPORTED BY THE ROTTERDAM EYE HOSPITAL
   FLIERINGA RESEARCH FOUNDATION, Rotterdam, The Netherlands; and Royal
   Visio, Rotterdam, The Netherlands. H. Heimann has received lecture fees
   from Alcon and Novartis. Involved in conception and design of the study
   (E.v.Z., KM., J.v.M.); analysis and interpretation (E.v.Z., KM., T.M.,
   HI-I., J.v.M.); writing the article (E.v.Z., J.v.M.); critical revision
   of the article (E.v.Z., KM., TM., H.H., J.v.M.); final approval of the
   article (E.v.Z., KM., TM., H.H., J.v.M.); data collection (E.v.Z., KM.,
   J.v.M.); provision of materials, patients, or resources (E.v.Z., KM.,
   J.v.M.); statistical expertise (E.v.Z., J.v.M; obtaining funding
   (J.v.M.); literature search (E.v.Z.,J.v.M.); and administrative,
   technical, or logistic support (E.v.Z., KM., J.v.M.). The Institutional
   Review Board of the Rotterdam Eye Hospital approved the study (REH
   2006-20). Written informed consent was obtained from all patients and
   the study was in adherence to the tenets of the Declaration of Helsinki.
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Aisenbrey S, 2007, ARCH OPHTHALMOL-CHIC, V125, P1367, DOI 10.1001/archopht.125.10.1367
   Arias L, 2010, CLIN OPHTHALMOL, V4, P67
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P1848, DOI 10.1167/iovs.08-2845
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Franzco FKC, 2009, CLIN EXP OPHTHALMOL, V37, P275, DOI 10.1111/j.1442-9071.2009.01915.x
   Gelisken F, 2009, EYE, V23, P694, DOI 10.1038/sj.eye.6703098
   Gelisken F, 2007, GRAEF ARCH CLIN EXP, V245, P1085, DOI 10.1007/s00417-006-0524-y
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Heussen FMA, 2008, EYE, V22, P799, DOI 10.1038/sj.eye.6702823
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Luke M, 2009, GRAEF ARCH CLIN EXP, V247, P745, DOI 10.1007/s00417-009-1050-5
   MAAIJWEE K, 2007, DLMAS, P562
   Maaijwee K, 2008, INVEST OPHTH VIS SCI, V49, P1629, DOI 10.1167/iovs.07-1220
   Maaijwee K, 2008, INVEST OPHTH VIS SCI, V49, P758, DOI 10.1167/iovs.07-0510
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Polito A, 2011, BRIT J OPHTHALMOL, V95, P74, DOI 10.1136/bjo.2009.170381
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
   Stanga Paulo E., 2001, International Ophthalmology, V23, P297, DOI 10.1023/A:1014482025960
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Treumer F, 2007, BRIT J OPHTHALMOL, V91, P349, DOI 10.1136/bjo.2006.102152
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
NR 41
TC 91
Z9 94
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2012
VL 153
IS 1
BP 120
EP 127
DI 10.1016/j.ajo.2011.06.007
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 865LP
UT WOS:000298312700017
PM 21907969
DA 2022-11-30
ER

PT J
AU Turksever, C
   Prunte, C
   Hatz, K
AF Turksever, Cengiz
   Prunte, Christian
   Hatz, Katja
TI Baseline Optical Coherence Tomography Findings as Outcome Predictors
   after Switching from Ranibizumab to Aflibercept in Neovascular
   Age-Related Macular Degeneration following a Treat-and-Extend Regimen
SO OPHTHALMOLOGICA
LA English
DT Article
DE Anti-vascular endothelial growth factor; Ranibizumab; Aflibercept;
   Neovascular age-related macular degeneration; Hyperreflective foci;
   Optical coherence tomography
ID HYPERREFLECTIVE FOCI; VEGF TRAP; BEVACIZUMAB; TACHYPHYLAXIS; MANAGEMENT;
   THERAPY
AB Purpose: To evaluate outcome predictors of aflibercept in neovascular age-related macular degeneration pretreated with ranibizumab based on a treat-and-extend regimen (TER). Methods: We performed a retrospective evaluation of 18-month follow-up of 45 consecutive patients with limited response to ranibizumab. Results: At month 18, mean central retinal thickness and intraretinal fluid (IRF) height were significantly reduced. The recurrence-free treatment interval (RFTI) increased from 7.0 +/- 1.8 to 8.5 +/- 2.4 weeks (p = 0.01); visual acuity remained stable. At month 18, 58.1% of patients showed a longer RFTI. At month 12, eyes with baseline subretinal fluid (SRF) had a shorter RFTI than those without SRF (p = 0.032). Eyes with baseline IRF showed a longer RFTI than those without IRF (p = 0.037). Baseline hyperre-flective foci (HRF) presence indicated improvement in SRF (p = 0.024) and IRF at month 12 (p = 0.049). Conclusion: Baseline HRF presence predicted better morphological outcome, while SRF predicted a shorter RFTI and IRF a longer RFTI after switching from ranibizumab to aflibercept within a TER. (c) 2017 S. Karger AG, Basel
C1 [Turksever, Cengiz; Hatz, Katja] Vista Klin, Hauptstr 55, CH-4102 Binningen, Switzerland.
   [Prunte, Christian] Kantonsspital Liestal, Dept Ophthalmol, Liestal, Switzerland.
   [Prunte, Christian; Hatz, Katja] Univ Basel, Dept Ophthalmol, Basel, Switzerland.
C3 Kantonsspital Baselland; University of Basel
RP Hatz, K (通讯作者)，Vista Klin, Hauptstr 55, CH-4102 Binningen, Switzerland.
EM khatz@vistaklinik.ch
RI Türksever, Cengiz/AAB-3134-2019
CR Aghdam KA, 2015, INVEST OPHTH VIS SCI, V56, P6448, DOI 10.1167/iovs.15-17338
   [Anonymous], 52 WMA GEN ASS
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Chen KC, 2016, AM J OPHTHALMOL, V164, P89, DOI 10.1016/j.ajo.2016.02.002
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   De Massougnes S, 2016, RETINA-J RET VIT DIS, V36, P881, DOI 10.1097/IAE.0000000000000813
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   European Agency for the Evaluation of Medicinal Products, EUR AG EV MED PROD I
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kim YM, 2012, AM J OPHTHALMOL, V154, P164, DOI 10.1016/j.ajo.2012.01.030
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lazzeri S, 2015, ANGIOGENESIS, V18, P397, DOI 10.1007/s10456-015-9483-4
   Lee H, 2016, RETINA-J RET VIT DIS, V36, P1372, DOI 10.1097/IAE.0000000000000929
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Regatieri Caio V, 2012, Int Ophthalmol Clin, V52, P33, DOI 10.1097/IIO.0b013e318265d439
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Segal O, 2016, RETINA-J RET VIT DIS, V36, P2175, DOI 10.1097/IAE.0000000000001033
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
NR 31
TC 5
Z9 5
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2017
VL 238
IS 3
BP 172
EP 178
DI 10.1159/000477856
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FG4EA
UT WOS:000410182000008
PM 28772268
DA 2022-11-30
ER

PT J
AU Abraham, P
   Yue, HB
   Wilson, L
AF Abraham, Prema
   Yue, Huibin
   Wilson, Laura
TI Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for
   Neovascular Age-Related Macular Degeneration: PIER Study Year 2
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY
AB PURPOSE: To evaluate efficacy and safety of quarterly (and then monthly) ranibizumab during the 2-year Phase IIIb, multicenter, randomized, double-masked, sham injection controlled study of the efficacy and safety of ranibizumab in subjects with subfoveal CNV with or without classic CNV secondary to AMD (PIER) study.
   DESIGN: Phase IIIb, multicenter, randomized, double-masked, sham injection-controlled trial in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
   METHODS: Patients were randomized 1:1:1 to sham injection (n = 63) or 0.3 mg (n = 60) or 0.5 mg (n = 61) intravitreal ranibizumab monthly for 3 months and then quarterly. During study year 2, eligible sham-group patients crossed over to 0.5 mg ranibizumab quarterly. Later in year 2, all eligible randomized patients rolled over to 0.5 mg ranibizumab monthly. Key efficacy and safety outcomes of the 2-year trial are reported.
   RESULTS: At month 24, visual acuity (VA) had decreased an average of 21.4, 2.2, and 2.3 letters from baseline in the sham, 0.3 mg, and 0.5 mg groups (P < .0001 for each ranibizumab group vs sham). VA of sham patients who crossed over (and subsequently rolled over) to ranibizumab decreased across time, with an average loss of 3.5 letters 10 months after crossover. VA of 0.3 mg and 0.5 mg group patients who rolled over to monthly ranibizumab increased for an average gain of 2.2 and 4.1 letters, respectively, 4 months after rollover. The ocular safety profile of ranibizumab was favorable and consistent with previous reports.
   CONCLUSIONS: Ranibizumab provided significant VA benefit in patients with AMD-related CNV compared with sham injection. Ranibizumab appeared to provide additional VA benefit to treated patients who rolled over to monthly dosing, but not to patients who began receiving ranibizumab after >14 months of sham injections. (Am J Ophthalmol 2010;150:315-324. (C) 2010 by Elsevier Inc. All rights reserved.)
C1 [Abraham, Prema] Black Hills Reg Eye Inst, Rapid City, SD 57701 USA.
   [Yue, Huibin; Wilson, Laura] Genentech Inc, San Francisco, CA USA.
C3 Roche Holding; Genentech
RP Abraham, P (通讯作者)，Black Hills Reg Eye Inst, 2800 3rd St, Rapid City, SD 57701 USA.
EM retina@bhrei.com
FU Alcon Laboratories, Fort Worth, Texas; Eli Lilly, Indianapolis, Indiana;
   Genentech, South San Francisco, California; Regeneron, Tarrytown, New
   York; Novartis, Basel, Switzerland; Schering Plough, Des Plaines,
   Illinois; Jerini Ophthalmic, New York, New York; Opko Health, Miami,
   Florida; Pfizer Ophthalmic, New York, New York; Alimera Sciences,
   Alpharetta, Georgia; Allergan, Irvine, California; Vitreoretinal
   Technologies, Irvine, California
FX PREMA ABRAHAM HAS RECEIVED INDUSTRY SUPPORT FOR CARE/TESTING PER PATIENT
   ENROLLED IN SPONSORED CLINICAL trials. Supporters include Alcon
   Laboratories, Fort Worth, Texas; Eli Lilly, Indianapolis, Indiana;
   Genentech, South San Francisco, California; Regeneron, Tarrytown, New
   York; Novartis, Basel, Switzerland; Schering Plough, Des Plaines,
   Illinois; Jerini Ophthalmic, New York, New York; Opko Health, Miami,
   Florida; Pfizer Ophthalmic, New York, New York; Alimera Sciences,
   Alpharetta, Georgia; Allergan, Irvine, California; and Vitreoretinal
   Technologies, Irvine, California. Laura Wilson and Huibin Yue are
   employees of Genentech, Inc. and own Roche stock. Involved in design and
   conduct of the study (P.A., LW., H.Y.); collection, management,
   analysis, and interpretation of the data (P.A., L.W., H.Y.); and
   preparation, review, or approval of the manuscript (P.A., LW., H.Y.).
   The Institutional Review Board for each study site approved the study
   protocol. All sites were compliant with the US Health Insurance
   Portability and Accountability Act of 1996. This study is registered at
   ClinicalTrials.gov (NCT00090623).
CR ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campbell AJ, 2005, BMJ-BRIT MED J, V331, P817, DOI 10.1136/bmj.38601.447731.55
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 12
TC 208
Z9 222
U1 1
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2010
VL 150
IS 3
BP 315
EP 324
DI 10.1016/j.ajo.2010.04.011
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 649ON
UT WOS:000281781800004
PM 20598667
DA 2022-11-30
ER

PT J
AU Faudi, E
   Gauthier, AS
   Delbosc, B
   Saleh, M
AF Faudi, Emilien
   Gauthier, Anne-Sophie
   Delbosc, Bernard
   Saleh, Maher
TI To investigate treat and extend versus pro re nata regimen in
   neovascular age-related macular degeneration: results from the IDEM
   study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Anti-VEGF; Neovascular age-related macular degeneration;
   Non-inferiority; Pro re nata; Treat and extend
ID INTRAVITREAL RANIBIZUMAB; DOSING REGIMEN; OUTCOMES; BEVACIZUMAB;
   EFFICACY; THERAPY; SAFETY; EYES
AB Purpose The purpose of this study is to report the 24-month outcomes of a pro re nata (PRN) compared with a treat and extend (T&E) regimen in patients previously treated for neovascular age-related macular degeneration (nAMD).
   Methods This was a 2-year prospective, single-center study. Previously treated patients for nAMD were randomized into two regimen groups: T&E and PRN groups. Main outcome measured was change in best corrected visual acuity (BCVA) from baseline to month 24. Secondary outcomes encompassed anatomical features such as central retinal thickness (CRT), number of intravitreal injections (IVI), and visits required.
   Results A total of 124 eyes received the T&E (n = 61) or PRN (n = 63) regimen. At month 24, the mean BCVA change was -4.4 early treatment diabetic retinopathy study (ETDRS) letters (T&E) and -3.4 ETDRS letters (PRN), with a difference of +1.1 ETDRS letters (95% CI [-2.25]; p = 0.006). The mean change in CRT was -10.6 mu m (T&E) and -7.9 mu m (PRN), with a difference of +2.6 mu m (95% CI [+19.2]; p = 0.004). The T&E group had received a mean of +4.6 more injections (95% CI [-7.06; -2.12]; p < 0.001) at month 24.
   Conclusion There was statistically proven non-inferiority between the PRN and T&E regimens in terms of visual and anatomical outcomes at 24 months, with significantly more IVI administered in the T&E regimen.
C1 [Faudi, Emilien; Gauthier, Anne-Sophie; Delbosc, Bernard; Saleh, Maher] Besancon Univ Hosp, Dept Ophthalmol, Besancon, France.
C3 CHU Besancon
RP Saleh, M (通讯作者)，Besancon Univ Hosp, Dept Ophthalmol, Besancon, France.
EM drmahersaleh@gmail.com
CR Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Kim JH, 2020, SEMIN OPHTHALMOL, V35, P33, DOI 10.1080/08820538.2019.1701045
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Kvannli L, 2017, ACTA OPHTHALMOL, V95, P678, DOI 10.1111/aos.13356
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mathalone N, 2012, GRAEF ARCH CLIN EXP, V250, P1435, DOI 10.1007/s00417-012-1981-0
   Mones J, 2020, OPHTHALMOLOGICA, V243, P1, DOI 10.1159/000502747
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Stone TW., 2017, GLOBAL TRENDS RETINA
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 28
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2022
VL 260
IS 7
BP 2149
EP 2156
DI 10.1007/s00417-021-05543-z
EA JAN 2022
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2H0GI
UT WOS:000741888500001
PM 35020019
DA 2022-11-30
ER

PT J
AU Khan, KN
   Mahroo, OA
   Khan, RS
   Mohamed, MD
   McKibbin, M
   Bird, A
   Michaelides, M
   Tufail, A
   Moore, AT
AF Khan, Kamron N.
   Mahroo, Omar A.
   Khan, Rehna S.
   Mohamed, Mom D.
   McKibbin, Martin
   Bird, Alan
   Michaelides, Michel
   Tufail, Adnan
   Moore, Anthony T.
TI Differentiating drusen: Drusen and drusen-like appearances associated
   with ageing, age-related macular degeneration, inherited eye disease and
   other pathological processes
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Retinal drusen; Macular degeneration; Retinal dystrophy
ID RETINAL-PIGMENT EPITHELIUM; OPTICAL COHERENCE TOMOGRAPHY; BASAL LAMINAR
   DRUSEN; II MESANGIOCAPILLARY GLOMERULONEPHRITIS; FACTOR-H POLYMORPHISM;
   CAUSE PSEUDOXANTHOMA ELASTICUM; ACQUIRED PARTIAL LIPODYSTROPHY; SORSBYS
   FUNDUS DYSTROPHY; LARGE COLLOID DRUSEN; PARTIAL TRISOMY 10Q
AB Drusen are discussed frequently in the context of their association with age-related macular degeneration (AMD). Some types may, however, be regarded as a normal consequence of ageing; others may be observed in young age groups. They also occur in a number of inherited disorders and some systemic conditions. Whilst drusen are classically located external (sclerad) to the retinal pigment epithelium, accumulations of material internal (vitread to) this layer can display a drusen-like appearance, having been variously termed pseudodrusen or subretinal drusenoid deposits. This review first briefly presents an overview of drusen biogenesis and subclinical deposit. The (frequently overlapping) subtypes of clinically detectable deposit, seen usually in the context of ageing or AMD, are then described in more detail, together with appearance on imaging modalities: these include hard and soft drusen, cuticular drusen, reticular pseudodrusen and "ghost drusen". Eye disorders other than AMD which may exhibit drusen or drusen-like features are subsequently discussed: these include monogenic conditions as well as conditions with undefined inheritance, the latter including some types of early onset drusen such as large colloid drusen. A number of systemic conditions in which drusen-like deposits may be seen are also considered. Throughout this review, high resolution images are presented for most of the conditions discussed, particularly the rarer ones, providing a useful reference library for images of the range of conditions associated with drusen-like appearances. In the final section, some common themes are highlighted, as well as a brief discussion of some future avenues for research. Crown Copyright (C) 2016 Published by Elsevier Ltd. All rights reserved.
C1 [Khan, Kamron N.; Mahroo, Omar A.; Bird, Alan; Michaelides, Michel; Tufail, Adnan; Moore, Anthony T.] UCL, Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
   [Khan, Kamron N.; Mahroo, Omar A.; Bird, Alan; Michaelides, Michel; Tufail, Adnan; Moore, Anthony T.] Moorfields Eye Hosp, Med Retina Serv, 162 City Rd, London EC1V 2PD, England.
   [Khan, Kamron N.; McKibbin, Martin] Univ Leeds, St Jamess Univ Hosp, Sect Ophthalmol & Neurosci, Leeds Inst Mol Med, Leeds LS9 7TF, W Yorkshire, England.
   [Mahroo, Omar A.] Kings Coll London, Dept Ophthalmol, St Thomas Hosp Campus,Westminster Bridge Rd, London SE1 7EH, England.
   [Mahroo, Omar A.] Univ Cambridge, Physiol Dev & Neurosci, Downing St, Cambridge CB2 3EG, England.
   [Khan, Rehna S.] Calderdale & Huddersfield NHS Fdn Trust, Dept Ophthalmol, Acre St, Huddersfield HD3 3EA, W Yorkshire, England.
   [Mohamed, Mom D.] Guys & St Thomas NHS Fdn Trust, Dept Ophthalmol, Westminster Bridge Rd, London SE1 7EH, England.
   [Moore, Anthony T.] UCSF Sch Med, Dept Ophthalmol, San Francisco, CA 94143 USA.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   Saint James's University Hospital; University of Leeds; University of
   London; King's College London; University of Cambridge; Guy's & St
   Thomas' NHS Foundation Trust; University of California System;
   University of California San Francisco
RP Khan, KN (通讯作者)，UCL, Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM K.N.Khan@leeds.ac.uk
OI Mahroo, Omar/0000-0003-1254-0832; Tufail, Adnan/0000-0001-6131-7640
FU National Institute for Health Research (NIHR) Biomedical Research Centre
   at Moorfields Eye Hospital National Health Service Foundation Trust; UCL
   Institute of Ophthalmology (UK); Research to Prevent Blindness USA;
   Fight for Sight (UK); Foundation Fighting Blindness (FFB, USA);
   Retinitis Pigmentosa Fighting Blindness (UK); FFB; NIHR Rare Disease
   Fellowship; National Institute for Health Research Rare Diseases
   Translational Research Collaboration (NIHR RD-TRC); National Institute
   for Health Research [CL-2011-17-501] Funding Source: researchfish; Fight
   for Sight [1409/10] Funding Source: researchfish
FX The authors acknowledge the following funding sources: National
   Institute for Health Research (NIHR) Biomedical Research Centre at
   Moorfields Eye Hospital National Health Service Foundation Trust and UCL
   Institute of Ophthalmology (UK; KNK, OAM, AT, AB, ATM, MM), Research to
   Prevent Blindness USA (ATM); Fight for Sight (UK; OAM, MM), the
   Foundation Fighting Blindness (FFB, USA; ATM, MM), Retinitis Pigmentosa
   Fighting Blindness (UK; ATM, MM). MM is a recipient of a Career
   Development award from FFB. KNK is supported by an NIHR Rare Disease
   Fellowship. This research has been supported by the National Institute
   for Health Research Rare Diseases Translational Research Collaboration
   (NIHR RD-TRC). The views expressed are those of the authors and not
   necessarily those of the NHS, the NIHR or the Department of Health.
CR Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Acharya S, 2000, J BIOL CHEM, V275, P6945, DOI 10.1074/jbc.275.10.6945
   Ahir A, 2002, INVEST OPHTH VIS SCI, V43, P458
   Ala-Laurila P, 2006, J GEN PHYSIOL, V128, P153, DOI 10.1085/jgp.200609557
   Albig AR, 2005, MOL BIOL CELL, V16, P609, DOI 10.1091/mbc.e04-06-0479
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Alten F, 2014, GRAEF ARCH CLIN EXP, V252, P715, DOI 10.1007/s00417-013-2525-y
   Amel T, 2000, Tunis Med, V78, P658
   Anderson DH, 1999, INVEST OPHTH VIS SCI, V40, P3305
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Appiah KK, 2014, J BIOMOL SCREEN, V19, P595, DOI 10.1177/1087057113511111
   Arana LA, 2010, ARCH OPHTHALMOL-CHIC, V128, P1362, DOI 10.1001/archophthalmol.2010.242
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Aydin E, 2007, OPHTHAL RES, V39, P344, DOI 10.1159/000109990
   Ba-Abbad R, 2013, MOL VIS, V19, P2250
   Bandah-Rozenfeld D, 2010, AM J HUM GENET, V87, P199, DOI 10.1016/j.ajhg.2010.07.004
   BAUDOUIN C, 1992, JPN J OPHTHALMOL, V36, P443
   Beattie S., 2009, LIPIDS RN, V72, P20
   Beharry S, 2004, J BIOL CHEM, V279, P53972, DOI 10.1074/jbc.M405216200
   Bergen AAB, 2000, NAT GENET, V25, P228, DOI 10.1038/76109
   Biesemeier A, 2015, EXP EYE RES, V137, P39, DOI 10.1016/j.exer.2015.05.019
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BISCHLER V, 1955, Praxis, V44, P1110
   Bonnet C, 2014, RETINA-J RET VIT DIS, V34, P1524, DOI 10.1097/IAE.0000000000000165
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   BUNTMILAM AH, 1983, J CELL BIOL, V97, P703, DOI 10.1083/jcb.97.3.703
   Bursted MSI, 2010, ARCH OPHTHALMOL-CHIC, V128, P989, DOI 10.1001/archophthalmol.2010.167
   CAPON MRC, 1989, OPHTHALMOLOGY, V96, P1769
   CHARLES SJ, 1991, BRIT J OPHTHALMOL, V75, P125, DOI 10.1136/bjo.75.2.125
   Cohen B, 2012, MOL VIS, V18, P2915
   COHEN Y, 1994, BRIT J OPHTHALMOL, V78, P437
   Colville D, 2003, AM J KIDNEY DIS, V42, DOI 10.1016/S0272-6386(03)00665-6
   CROUCH RK, 1992, PHOTOCHEM PHOTOBIOL, V56, P251, DOI 10.1111/j.1751-1097.1992.tb02154.x
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2015, AM J OPHTHALMOL, V160, P1024, DOI 10.1016/j.ajo.2015.08.001
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   D'Agati VD, 2012, KIDNEY INT, V82, P379, DOI 10.1038/ki.2012.80
   D'souza Y, 2008, BRIT J OPHTHALMOL, V92, P950, DOI 10.1136/bjo.2007.130138
   D'souza YB, 2009, KIDNEY INT, V75, P824, DOI 10.1038/ki.2008.658
   Dalvin LA., 2015, CASES BRIEF REP, V10
   Dasari B, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-22
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DEGROUCH.J, 1965, ANN GENET-PARIS, V8, pG16
   DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688
   Del Turco C, 2015, EUR J OPHTHALMOL, V25, P177, DOI 10.5301/ejo.5000526
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Donders FC, 1854, ARCH OPHTHALMOL-CHIC, V1, P106
   Doyne R., 1899, T OPHTHAL SOC UK, V19, P71
   DRIESSEN CAGG, 1995, INVEST OPHTH VIS SCI, V36, P1988
   Dugel PU, 2015, RETINA-J RET VIT DIS, V35, P1173, DOI 10.1097/IAE.0000000000000606
   Duncan JL, 2012, ARCH OPHTHALMOL-CHIC, V130, P1301, DOI 10.1001/archophthalmol.2012.1906
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P297, DOI 10.1136/bjo.73.4.297
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eichers ER, 2002, AM J HUM GENET, V70, P955, DOI 10.1086/339688
   Elsner A.E., 1990, QUANTITATIVE REFLECT, P109
   Fakhouri F, 2010, NAT REV NEPHROL, V6, P494, DOI 10.1038/nrneph.2010.85
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   Felbor U, 1998, CYTOGENET CELL GENET, V81, P12, DOI 10.1159/000015001
   FELL HB, 1969, AM J CLIN NUTR, V22, P975
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fisher D.E., 2016, OPHTHALMOLO IN PRESS
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Folwell AJ, 1997, BRIT J UROL, V80, P480, DOI 10.1046/j.1464-410X.1997.00360.x
   Francis PJ, 2003, BRIT J OPHTHALMOL, V87, P893, DOI 10.1136/bjo.87.7.893
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fried M., 1972, AV GRAEFES ARCH KLIN, V211, P307
   Frisch IB, 2002, OPHTHALMOLOGY, V109, P1484, DOI 10.1016/S0161-6420(02)01110-7
   Fuchs A, 1928, Br J Ophthalmol, V12, P65, DOI 10.1136/bjo.12.2.65
   FUCHS A, 1959, AM J OPHTHALMOL, V48, P101, DOI 10.1016/0002-9394(59)90294-6
   Gass JD., 1977, STEREOSCOPIC ATLAS M, V2
   GASS JDM, 1985, AM J OPHTHALMOL, V99, P445
   GASS JDM, 1994, ARCH OPHTHALMOL-CHIC, V112, P738, DOI 10.1001/archopht.1994.01090180036013
   Gauter-Fleckenstein B, 2008, FREE RADICAL BIO MED, V44, P982, DOI 10.1016/j.freeradbiomed.2007.10.058
   Gliem M, 2015, INVEST OPHTH VIS SCI, V56, P2664, DOI 10.1167/iovs.14-15733
   Gliem M, 2015, JAMA OPHTHALMOL, V133, P581, DOI 10.1001/jamaophthalmol.2015.117
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grewal DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092841
   Guigui B, 2011, BRIT J OPHTHALMOL, V95, P238, DOI 10.1136/bjo.2009.178400
   Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Han DP, 2009, ARCH OPHTHALMOL-CHIC, V127, P577, DOI 10.1001/archophthalmol.2009.38
   Hanein S, 2008, AM J HUM GENET, V82, P992, DOI 10.1016/j.ajhg.2008.03.004
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   Heiferman M.J., 2015, RETINA, V35
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Holder G.E., 2014, INHERITED CHORIORETI, P213, DOI [10.1007/978-3-540-69466-3_19., DOI 10.1007/978-3-540-69466-3_19]
   HOLZ FG, 1994, BRIT J OPHTHALMOL, V78, P79, DOI 10.1136/bjo.78.1.79-a
   JAGELL S, 1980, ACTA OPHTHALMOL, V58, P321
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Jansen J., 2013, BMJ CASE REP, V2013
   Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042
   Joachim N, 2014, INVEST OPHTH VIS SCI, V55, P4421, DOI 10.1167/iovs.14-14476
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   KANDORI F, 1966, YONAGO ACTA MED, V10, P98
   KANDORI F, 1972, AM J OPHTHALMOL, V73, P673, DOI 10.1016/0002-9394(72)90385-6
   KANDORI F, 1959, JPN J OPHTHALMOL, V13, P384
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   KENYON KR, 1985, AM J OPHTHALMOL, V100, P119, DOI 10.1016/S0002-9394(14)74993-1
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   KJELLIN K, 1959, ARCH NEUROL-CHICAGO, V1, P133, DOI 10.1001/archneur.1959.03840020007002
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KRUTH HS, 1985, ATHEROSCLEROSIS, V57, P337, DOI 10.1016/0021-9150(85)90045-0
   Kuehn M H, 1999, Mol Cell Biol Res Commun, V2, P103, DOI 10.1006/mcbr.1999.0161
   Kumari R, 2009, EYE, V23, P2134, DOI 10.1038/eye.2008.392
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lam F W, 2000, J Med Genet, V37, pE24, DOI 10.1136/jmg.37.9.e24
   Lamb TD, 2013, PROG RETIN EYE RES, V36, P52, DOI 10.1016/j.preteyeres.2013.06.001
   LAURENT C, 1973, HUMANGENETIK, V18, P321, DOI 10.1007/BF00291129
   Le Saux O, 2000, NAT GENET, V25, P223, DOI 10.1038/76102
   Lee MY, 2014, RETINA-J RET VIT DIS, V34, P69, DOI 10.1097/IAE.0b013e318295f701
   LEFLER WH, 1971, AM J OPHTHALMOL, V71, P224, DOI 10.1016/0002-9394(71)90394-1
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Littink KW, 2012, OPHTHALMOLOGY, V119, P1899, DOI 10.1016/j.ophtha.2012.02.037
   Loeffler KU, 1998, BRIT J OPHTHALMOL, V82, P1104, DOI 10.1136/bjo.82.10.1104
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Macauley SL, 2012, ANN NEUROL, V71, P797, DOI 10.1002/ana.23545
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   MALORNI W, 1991, CHEM-BIOL INTERACT, V80, P217, DOI 10.1016/0009-2797(91)90026-4
   Manes G, 2013, AM J HUM GENET, V93, P571, DOI 10.1016/j.ajhg.2013.07.018
   Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Mata NL, 2004, J BIOL CHEM, V279, P635, DOI 10.1074/jbc.M310042200
   Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1
   MATHIESON PW, 1993, J EXP MED, V177, P1827, DOI 10.1084/jem.177.6.1827
   McAvoy CE, 2005, EYE, V19, P985, DOI 10.1038/sj.eye.6701697
   Meadway A, 2014, BIOMED OPT EXPRESS, V5, P713, DOI 10.1364/BOE.5.000713
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P1101, DOI 10.1097/IAE.0b013e3181451617
   Michaelides M, 2003, INVEST OPHTH VIS SCI, V44, P2178, DOI 10.1167/iovs.02-1094
   Michaelides M, 2006, INVEST OPHTH VIS SCI, V47, P3085, DOI 10.1167/iovs.05-1600
   Michaelides M, 2012, BRIT J OPHTHALMOL, V96, P917, DOI 10.1136/bjophthalmol-2011-300994
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mirshahi Ahmad, 2009, International Ophthalmology, V29, P541, DOI 10.1007/s10792-008-9264-9
   Misra A, 2004, MEDICINE, V83, P18, DOI 10.1097/01.md.0000111061.69212.59
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Muller H., 1856, GRAEFES ARCH CLIN EX, V2, P1, DOI DOI 10.1007/BF02720657
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins Robert F., 2007, International Ophthalmology Clinics, V47, P1, DOI 10.1097/IIO.0b013e31802bd3e6
   Nadim Farah, 2001, International Ophthalmology, V24, P113, DOI 10.1023/A:1021189215498
   Nan R, 2013, J BIOL CHEM, V288, P19197, DOI 10.1074/jbc.M113.476143
   NEELY K, 1988, AM J OPHTHALMOL, V106, P82, DOI 10.1016/S0002-9394(14)76393-7
   Nguyen AD, 2004, CIRC RES, V95, P1067, DOI 10.1161/01.RES.0000149568.85071.FB
   Nolis T, 2014, J HUM GENET, V59, P16, DOI 10.1038/jhg.2013.107
   OBRIEN C, 1993, BRIT J OPHTHALMOL, V77, P778, DOI 10.1136/bjo.77.12.778
   OKAJIMA TIL, 1994, J BIOL CHEM, V269, P21983
   ONO K, 1974, JPN J HUM GENET, V19, P235
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   Orlen H, 2009, AM J MED GENET B, V150B, P984, DOI 10.1002/ajmg.b.30928
   Osusky R, 1997, OCUL IMMUNOL INFLAMM, V5, P43, DOI 10.3109/09273949709085049
   Ozaki S, 1999, BIOCHEM BIOPH RES CO, V258, P524, DOI 10.1006/bbrc.1999.0672
   Patel D, 2006, POSTGRAD MED J, V82, P774, DOI 10.1136/pgmj.2006.047001
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Pauleikhoff D, 1997, OPHTHALMOLOGE, V94, P882, DOI 10.1007/s003470050216
   Pichi F, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/634351
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Pilli S, 2011, RETINA-J RET VIT DIS, V31, P812, DOI 10.1097/IAE.0b013e318207d112
   Platano D, 2005, J CLIN ENDOCR METAB, V90, P2192, DOI 10.1210/jc.2004-1819
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Procter KL, 2008, SOC SCI MED, V67, P341, DOI 10.1016/j.socscimed.2008.02.029
   PROSPERI L, 1977, OPHTHALMOLOGICA, V175, P269, DOI 10.1159/000308668
   Puech B, 2011, OPHTHALMOLOGY, V118, P564, DOI 10.1016/j.ophtha.2010.07.024
   Querques G, 2013, GRAEF ARCH CLIN EXP, V251, P705, DOI 10.1007/s00417-012-2106-5
   Querques G, 2012, ACTA OPHTHALMOL, V90, pE327, DOI 10.1111/j.1755-3768.2011.02228.x
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Rattner A, 2001, NEURON, V32, P775, DOI 10.1016/S0896-6273(01)00531-1
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102
   Ringpfeil F, 2000, P NATL ACAD SCI USA, V97, P6001, DOI 10.1073/pnas.100041297
   Rogers GR, 1997, GENOMICS, V39, P127, DOI 10.1006/geno.1996.4501
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3
   SAARI JC, 1982, METHOD ENZYMOL, V81, P819
   SAARI JC, 1989, J BIOL CHEM, V264, P8636
   SAARI JC, 1985, J BIOL CHEM, V260, P195
   Saksens NTM, 2014, PROG RETIN EYE RES, V39, P23, DOI 10.1016/j.preteyeres.2013.11.001
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Savage DB, 2009, J CLIN ENDOCR METAB, V94, P10, DOI 10.1210/jc.2008-1703
   Savige J, 2011, J AM SOC NEPHROL, V22, P1403, DOI 10.1681/ASN.2010090965
   Savige J, 2010, INVEST OPHTH VIS SCI, V51, P1621, DOI 10.1167/iovs.08-3323
   Savige J, 2009, NAT REV NEPHROL, V5, P356, DOI 10.1038/nrneph.2009.65
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Sergouniotis PI, 2011, AM J HUM GENET, V89, P782, DOI 10.1016/j.ajhg.2011.11.004
   Sergouniotis PI, 2011, OPHTHALMOLOGY, V118, P1661, DOI 10.1016/j.ophtha.2010.12.031
   Servais A, 2007, J MED GENET, V44, P193, DOI 10.1136/jmg.2006.045328
   Shashi V, 2003, CLIN GENET, V64, P361, DOI 10.1034/j.1399-0004.2003.00146.x
   SHIMIZU K, 1961, JPN J OPHTHALMOL, V5, P1
   Shu XH, 2006, HUM MOL GENET, V15, P1680, DOI 10.1093/hmg/ddl091
   SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979
   SKARLATOS SI, 1993, VIRCHOWS ARCH B, V64, P241, DOI 10.1007/BF02915118
   Small KW, 2016, OPHTHALMOLOGY, V123, P9, DOI 10.1016/j.ophtha.2015.10.006
   SMALL KW, 1992, GENOMICS, V13, P681, DOI 10.1016/0888-7543(92)90141-E
   SMALL KW, 1991, BRIT J OPHTHALMOL, V75, P401, DOI 10.1136/bjo.75.7.401
   SMALL KW, 1989, OPHTHALMOLOGY, V96, P1747
   SMITH JG, 1964, J INVEST DERMATOL, V43, P429
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohn EH, 2015, RETINA-J RET VIT DIS, V35, P48, DOI 10.1097/IAE.0000000000000263
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   SORSBY A, 1949, Acta Neurol Psychiatr Belg, V49, P611
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   STEINMETZ RL, 1992, INVEST OPHTH VIS SCI, V33, P1633
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Suzuki M, 2015, RETINA-J RET VIT DIS, V35, P859, DOI 10.1097/IAE.0000000000000503
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Tabandeh H, 2000, RETINA-J RET VIT DIS, V20, P678, DOI 10.1097/00006982-200006000-00020
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Trabucchi G, 1998, BRIT J OPHTHALMOL, V82, P326, DOI 10.1136/bjo.82.3.326
   Tuten WS, 2012, OPTOMETRY VISION SCI, V89, P563, DOI 10.1097/OPX.0b013e3182512b98
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Uyemura M., 1928, KLIN MONATSBL AUGENH, P471
   van de Ven JPH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1038, DOI 10.1001/archophthalmol.2012.265
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   VANDERSCHAFT TL, 1991, ARCH OPHTHALMOL-CHIC, V109, P420, DOI 10.1001/archopht.1991.01080030122052
   VENKATASWAMY G, 1967, BRIT J OPHTHALMOL, V51, P854, DOI 10.1136/bjo.51.12.854
   Vogt A., 1925, GRAEFE SAEMISCH HDB, P1
   Voigt M, 2010, AM J OPHTHALMOL, V150, P330, DOI 10.1016/j.ajo.2010.04.001
   Wang A.L, 2009, PLOS ONE, V4, pe5304, DOI DOI 10.1371/JOURNAL.PONE.0004160
   Wang Q, 1996, INVEST OPHTH VIS SCI, V37, P2234
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Weleber RG, 2011, INVEST OPHTH VIS SCI, V52, P292, DOI 10.1167/iovs.10-6106
   Wu QQ, 2007, BIOCHEMISTRY-US, V46, P8669, DOI 10.1021/bi7004619
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yang ZL, 2008, VISION RES, V48, P470, DOI 10.1016/j.visres.2007.09.015
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   YUNIS JJ, 1974, J PEDIATR-US, V84, P567, DOI 10.1016/S0022-3476(74)80683-9
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhou Q., 2016, OPHTHALMOLOGY
   Zweifel SA, 2012, KLIN MONATSBL AUGENH, V229, P399, DOI 10.1055/s-0031-1299404
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 261
TC 99
Z9 102
U1 3
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JUL
PY 2016
VL 53
BP 70
EP 106
DI 10.1016/j.preteyeres.2016.04.008
PG 37
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DQ3JS
UT WOS:000379099200004
PM 27173377
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Clark, SJ
   Perveen, R
   Hakobyan, S
   Morgan, BP
   Sim, RB
   Bishop, PN
   Day, AJ
AF Clark, Simon J.
   Perveen, Rahat
   Hakobyan, Svetlana
   Morgan, B. Paul
   Sim, Robert B.
   Bishop, Paul N.
   Day, Anthony J.
TI Impaired Binding of the Age-related Macular Degeneration-associated
   Complement Factor H 402H Allotype to Bruch's Membrane in Human Retina
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID C-REACTIVE PROTEIN; DISEASE-ASSOCIATED FORM; AMINO-ACID SEQUENCE;
   HEPARIN; POLYMORPHISM; RECOGNITION; VARIANT; SITE; IDENTIFICATION;
   LOCALIZATION
AB Age-related macular degeneration (AMD) is the predominant cause of blindness in the industrialized world where destruction of the macula, i.e. the central region of the retina, results in loss of vision. AMD is preceded by the formation of deposits in the macula, which accumulate between the Bruch's membrane and the retinal pigment epithelium (RPE). These deposits are associated with complement-mediated inflammation and perturb retinal function. Recent genetic association studies have demonstrated that a common allele (402H) of the complement factor H (CFH) gene is a major risk factor for the development of AMD; CFH suppresses complement activation on host tissues where it is believed to bind via its interaction with polyanionic structures. We have shown previously that this coding change (Y402H; from a tyrosine to histidine residue) alters the binding of the CFH protein to sulfated polysaccharides. Here we demonstrate that the AMD-associated polymorphism profoundly affects CFH binding to sites within human macula. Notably, the AMD-associated 402H variant binds less well to heparan sulfate and dermatan sulfate glycosaminoglycans within Bruch's membrane when compared with the 402Y form; both allotypes exhibit a similar level of binding to the RPE. We propose that the impaired binding of the 402H variant to Bruch's membrane results in an overactivation of the complement pathway leading to local chronic inflammation and thus contributes directly to the development and/or progression of AMD. These studies therefore provide a putative disease mechanism and add weight to the genetic association studies that implicate the 402H allele as an important risk factor in AMD.
C1 [Clark, Simon J.; Bishop, Paul N.; Day, Anthony J.] Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Fac Life Sci, Manchester M13 9PT, Lancs, England.
   [Perveen, Rahat; Bishop, Paul N.] Univ Manchester, Sch Biomed, Fac Med & Human Sci, Manchester M13 9PT, Lancs, England.
   [Perveen, Rahat; Bishop, Paul N.] Cent Manchester Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester M13 9WL, Lancs, England.
   [Hakobyan, Svetlana; Morgan, B. Paul] Cardiff Univ, Complement Biol Grp, Dept Med Biochem & Immunol, Sch Med, Cardiff CF14 4XN, S Glam, Wales.
   [Sim, Robert B.] Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England.
C3 University of Manchester; University of Manchester; University of
   Manchester; Cardiff University; University of Oxford
RP Bishop, PN (通讯作者)，Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Fac Life Sci, Oxford Rd, Manchester M13 9PT, Lancs, England.
EM paul.n.bishop@manchester.ac.uk; anthony.day@manchester.ac.uk
RI Sim, Bob/A-1354-2008; Day, Anthony/O-1658-2015
OI Sim, Bob/0000-0002-2855-7455; Day, Anthony/0000-0002-1415-3134; Morgan,
   Paul/0000-0003-4075-7676; Bishop, Paul/0000-0001-7937-7932; Clark,
   Simon/0000-0001-8394-8355
FU Macular Disease Society, Medical Research Council [G0900592]; University
   of Manchester Intellectual Property Ltd.; Manchester National Institute
   for Health Research Biomedical Research Centre; Biotechnology and
   Biological Sciences Research Council; Wellcome Trust; University of
   Manchester; MRC [G0900538] Funding Source: UKRI; Medical Research
   Council [G0900538] Funding Source: researchfish
FX This work was supported by the Macular Disease Society, Medical Research
   Council (Grant G0900592), University of Manchester Intellectual Property
   Ltd., and Manchester National Institute for Health Research Biomedical
   Research Centre.; We thank Dr. I. Zambrano and colleagues at the
   Manchester Royal Eye Hospital Eye Bank for supplying donor eye tissue
   used in this study, Dr. Barbara Mulloy (National Institute for
   Biological Standards and Control) for supplying heparin and DS
   glycosaminoglycans and Jane Knott for help with the microscopy. We also
   thank Prof. John Gallagher for discussion and advice on technical
   aspects of the research project. The Bioimaging Facility microscopes
   used in this study were purchased with grants from the Biotechnology and
   Biological Sciences Research Council, Wellcome Trust, and University of
   Manchester Strategic Fund.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Barlow PN, 2008, ADV EXP MED BIOL, V632, P117, DOI 10.1007/978-0-387-78952-1_10
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   CALL TW, 1990, EXP EYE RES, V51, P451, DOI 10.1016/0014-4835(90)90158-Q
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   CLARK SJ, 2010, BIOCH SOC T IN PRESS
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458
   Ferreira VP, 2006, J IMMUNOL, V177, P6308, DOI 10.4049/jimmunol.177.9.6308
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7
   Haapasalo K, 2008, MOL MICROBIOL, V70, P583, DOI 10.1111/j.1365-2958.2008.06347.x
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200
   KAZATCHKINE MD, 1979, J EXP MED, V150, P1202, DOI 10.1084/jem.150.5.1202
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Mahoney DJ, 2004, ANAL BIOCHEM, V330, P123, DOI 10.1016/j.ab.2004.03.055
   Marson A, 2009, GLYCOBIOLOGY, V19, P1537, DOI 10.1093/glycob/cwp132
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   MULLOY B, 1994, CARBOHYD RES, V255, P1, DOI 10.1016/S0008-6215(00)90968-6
   Mulloy B, 2000, THROMB HAEMOSTASIS, V84, P1052
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200
   PANGBURN MK, 1991, J BIOL CHEM, V266, P16847
   Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Schneider MC, 2009, NATURE, V458, P890, DOI 10.1038/nature07769
   SIM E, 1983, BIOSCIENCE REP, V3, P1119, DOI 10.1007/BF01120205
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
NR 39
TC 137
Z9 139
U1 0
U2 18
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 24
PY 2010
VL 285
IS 39
BP 30192
EP 30202
DI 10.1074/jbc.M110.103986
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 652EK
UT WOS:000281984300056
PM 20660596
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Abdelfattah, NS
   Al-Sheikh, M
   Pitetta, S
   Mousa, A
   Sadda, SR
   Wykoff, CC
AF Abdelfattah, Nizar S.
   Al-Sheikh, Mayss
   Pitetta, Sean
   Mousa, Ahmed
   Sadda, SriniVas R.
   Wykoff, Charles C.
CA Treat Extend Age Related Macular
TI Macular Atrophy in Neovascular Age-Related Macular Degeneration with
   Monthly versus Treat-and-Extend Ranibizumab
SO OPHTHALMOLOGY
LA English
DT Article
ID GEOGRAPHIC ATROPHY; CHOROIDAL THICKNESS; NATURAL-HISTORY; RISK-FACTORS;
   EYE DISEASE; PROGRESSION; MACULOPATHY; SECONDARY; SEVERITY
AB Purpose: To compare the enlargement rate of macular atrophy (ERMA) in eyes treated with ranibizumab monthly or using a treat-and-extend (TREX) regimen for neovascular age-related macular degeneration (AMD) or fellow control eyes, as well as analyze risk factors for macular atrophy (MA) development and progression.
   Design: Eighteen-month, multicenter, randomized, controlled clinical trial.
   Participants: Sixty patients with treatment-nave neovascular AMD in 1 eye randomized 1: 2 to monthly or TREX ranibizumab.
   Methods: Patients' study and fellow eyes were followed for 18 months using spectral-domain optical coherence tomography (SD OCT) and fundus autofluorescence (FAF) imaging. The MA was quantified on FAF images using Heidelberg Region Finder software (Heidelberg Engineering, Heidelberg, Germany), with suspected areas of atrophy confirmed by SD OCT and infrared reflectance imaging. For eyes without baseline MA yet developed MA by 18 months, intervening visits were assessed to determine the first visit at which MA appeared to define progression rates. Foveal choroidal thickness (FCT), subretinal hyperreflective material (SHRM), and pigment epithelial detachment (PED), were assessed at baseline to determine whether they influenced MA progression.
   Main Outcome Measures: Mean ERMA at 18 months. Relationship between visual acuity and MA, and the baseline risk factors for ERMA were also assessed.
   Results: The final analysis cohort included 88 eyes in 3 groups: monthly (n = 19), TREX (n = 30), and control fellow eyes (n = 39). Mean ERMA over 18 months was 0.39 +/- 0.67 (monthly), 1.1 +/- 1.9 (TREX), and 0.49 +/- 1 mm(2) (control, P = 0.12). Mean ERMA per group among the 40.9% (n = 36) of baseline patients with MA was 0.9 +/- 1, 1.9 +/- 2.2, and 1 = 1.3 mm(2), respectively (P = 0.31). The incidence rate of MA in the 3 groups was 40%, 0%, and 8.3%, respectively. Mann-Whitney U test revealed a statistically significant association between baseline FCT (127 +/- 46 vs. 155 +/- 55 mu m, P = 0.01) and SHRM thickness (106 +/- 131 vs. 50 +/- 85 mu m, P = 0.02) on MA. In eyes with no baseline MA, presence of SHRM, SHRM, and PED thickness, and presence of baseline hemorrhage were all significant predictors of new MA development (P = 0.04, 0.01, 0.04, 0.004, 0.01, respectively).
   Conclusions: Ranibizumab did not show a statistically significant influence on new MA development in eyes with neovascular AMD, whether dosed monthly or per TREX regimen. The FCT, SHRM thickness, and hemorrhage at baseline were all significant predictors of new MA. Ophthalmology 2017; 124: 215-223 (C) 2016 by the American Academy of Ophthalmology
C1 [Abdelfattah, Nizar S.; Al-Sheikh, Mayss; Pitetta, Sean; Sadda, SriniVas R.] Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA USA.
   [Abdelfattah, Nizar S.; Al-Sheikh, Mayss; Sadda, SriniVas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA USA.
   [Mousa, Ahmed] King Saud Univ, Coll Med, Dept Ophthalmol, Riyadh, Saudi Arabia.
   [Wykoff, Charles C.] Retina Consultants Houston, Houston, TX USA.
   [Wykoff, Charles C.] Houston Methodist Hosp & Weill Cornell Med Coll, Blanton Eye Inst, Houston, TX USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; King Saud University;
   The Methodist Hospital System; The Methodist Hospital - Houston
RP Abdelfattah, NS (通讯作者)，Univ Calif Los Angeles, Doheny Eye Inst, Dept Ophthalmol, 1355 San Pablo St,Suite 100, Los Angeles, CA 90033 USA.
EM nizar@ucla.edu
RI Mousa, Ahmed Amin/AAH-2827-2019; Abdelfattah, Nizar Saleh/H-6908-2019
OI Abdelfattah, Nizar Saleh/0000-0002-9396-3054; Wang,
   Rui/0000-0002-0900-7714; Schefler, Amy/0000-0001-9829-8164
FU Carl Zeiss Meditec; Optos; Allergan; Genentech; Alcon; Allegro; Acucela;
   Ampio; Apellis Pharmaceutical; Clearside Biomedical; Iconic
   Therapeutics; Xoma; Santeen; pSivida; Regeneron; DRCR Network; Pfizer;
   Ophthotech Corp; ThromboGenics; Tyrogenex; Lecturer -Allergan and
   Regeneron
FX The authors have made the following disclosure(s): S.R.S.: Consultant e
   Carl Zeiss Meditec, Optos, Allergan, Genentech, Alcon, Novartis, and
   Roche; Research support - Carl Zeiss Meditec, Optos, Allergan, and
   Genentech. CCW: Consultant e Alcon, Allergan, Alimera, Bayer, Clearside
   Biomedical, DORC, Genentech, ONL Therapeutics, Regeneron, and
   Thrombogenics; Minor equity e ONL Therapeutics; Research support -
   Alcon, Allegro, Acucela, Allergan, Ampio, Apellis Pharmaceutical,
   Clearside Biomedical, Iconic Therapeutics, Xoma, Santeen, pSivida,
   Genentech, Regeneron, DRCR Network, Pfizer, Ophthotech Corp,
   ThromboGenics, and Tyrogenex; Lecturer -Allergan and Regeneron.
CR Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Adhi M, 2014, RETINA-J RET VIT DIS, V34, P306, DOI 10.1097/IAE.0b013e3182993e09
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cella F, 2012, REV OPTOM, V9, P6
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Karmel M, 2013, EYENET MAGAZINE, P37
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Rezaei KA, 2015, ASRS GLOBAL TRENDS R
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 2006, RETINA-J RET VIT DIS, V26, P666, DOI 10.1097/00006982-200607000-00013
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 33
TC 48
Z9 49
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2017
VL 124
IS 2
BP 215
EP 223
DI 10.1016/j.ophtha.2016.10.002
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EP2PT
UT WOS:000397226300023
PM 27863845
DA 2022-11-30
ER

PT J
AU Fenwick, EK
   Cheung, GCM
   Gan, ATL
   Tan, G
   Lee, SY
   Wong, D
   Yeo, I
   Mathur, R
   Wong, TY
   Lamoureux, EL
AF Fenwick, Eva K.
   Cheung, Gemmy Chui Ming
   Gan, Alfred T. L.
   Tan, Gavin
   Lee, Shu Yen
   Wong, Doric
   Yeo, Ian
   Mathur, Ranjana
   Wong, Tien Y.
   Lamoureux, Ecosse L.
TI Change in vision-related quality of life and influencing factors in
   Asians receiving treatment for neovascular age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; vision-related quality of life;
   treatment; visual acuity; change
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; RANIBIZUMAB TREATMENT; VISUAL-ACUITY;
   IMPACT; OUTCOMES; AFLIBERCEPT; PROTOCOL
AB Aim To assess the change in vision-related quality of life (VRQoL) after treatment for neovascular age-related macular degeneration (nAMD) and factors influencing this change in an Asian population.
   Methods In this longitudinal study, 116 patients (mean ageSD=66.59.9 years; 59.5% male) who underwent treatment for nAMD were recruited from a tertiary eye centre in Singapore. Best-corrected visual acuity (BCVA) and the Impact of Vision Impairment (IVI) questionnaire were evaluated at baseline and month 12. We defined three categories of BCVA change in the treated eye: BCVA gain 2 lines; no change in BCVA; BCVA loss 2 lines. The main outcome measures were the Rasch-derived IVI Reading, Mobility, and Emotional Scores. Multivariable linear regression analyses assessed the influence of sociodemographic, clinical and treatment-related factors on change in VRQoL.
   Results Following treatment, mean treated-eye BCVA improved by almost 2 lines (-0.22 +/- 0.40logMAR, p<0.001) and 43% (n=50) patients reported a gain in BCVA of 2 lines. Mean +/- SD scores for Reading, Mobility and Emotional demonstrated positive changes of 0.43 +/- 1.73, 0.45 +/- 1.54and 0.66 +/- 1.6, respectively (p<0.001 for all). In multivariable models, a 2line improvement in BCVA was independently associated with a 47% (=0.20; CI 0.01 to 0.39) increase in Reading Scores, but was not independently associated with Mobility or Emotional Scores.
   Conclusion Nearly half of patients undergoing treatment for nAMD reported a 2-line improvement in vision which was, in turn, associated with substantial positive increases in Reading Scores. Improvements in Mobility and Emotional Scores appear to be driven by factors other than visual acuity.
C1 [Fenwick, Eva K.; Cheung, Gemmy Chui Ming; Gan, Alfred T. L.; Tan, Gavin; Lee, Shu Yen; Wong, Doric; Yeo, Ian; Mathur, Ranjana; Wong, Tien Y.; Lamoureux, Ecosse L.] Singapore Eye Res Inst, Singapore Natl Eye Ctr, Populat Hlth, Singapore, Singapore.
   [Fenwick, Eva K.; Wong, Tien Y.; Lamoureux, Ecosse L.] Duke NUS Med Sch, Off Clin Sci, Singapore, Singapore.
   [Cheung, Gemmy Chui Ming; Tan, Gavin; Lee, Shu Yen; Wong, Doric; Yeo, Ian; Mathur, Ranjana; Wong, Tien Y.; Lamoureux, Ecosse L.] Natl Univ Singapore, Ophthalmol & Visual Sci Acad Clin Program, Duke NUS Med Sch, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore
RP Cheung, GCM (通讯作者)，Singapore Eye Res Inst, Singapore Natl Eye Ctr, Populat Hlth, Singapore, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Wong, Tien Yin/AAC-9724-2020; Lamoureux, Ecosse/Z-5482-2019
OI Wong, Tien Yin/0000-0002-8448-1264; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Wong, Damon/0000-0003-4601-9121
FU National Medical Research Council [STaR/0003/2008, NIG/1003/2009];
   National Medical Research Council grant [NMRC/NIG/1003/2009]; Singapore
   Bio Imaging Consortium [C-011/2006]; Biomedical Research Council
   [08/1/35/19/550]
FX This study was supported by grants from the National Medical Research
   Council (STaR/0003/2008 and NIG/1003/2009), National Medical Research
   Council grant NMRC/NIG/1003/2009; the Singapore Bio Imaging Consortium
   (C-011/2006) and the Biomedical Research Council (08/1/35/19/550).
CR Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2017, SCI REP-UK, V7, DOI 10.1038/srep41386
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Eleftheriadou M, 2017, AM J OPHTHALMOL, V174, P160, DOI 10.1016/j.ajo.2016.09.038
   Fenwick EK, 2017, JAMA OPHTHALMOL, V135, P469, DOI 10.1001/jamaophthalmol.2017.0266
   Fenwick EK, 2017, BRIT J OPHTHALMOL, V101, P591, DOI 10.1136/bjophthalmol-2016-308541
   Fenwick EK, 2016, QUAL LIFE RES, V25, P871, DOI 10.1007/s11136-015-1141-1
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Lamoureux EL, 2008, OPHTHAL EPIDEMIOL, V15, P105, DOI 10.1080/09286580701840354
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lim A S, 2000, Psychol Health, V14, P965, DOI 10.1080/08870440008407361
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Linacre, 2014, USERS GUIDE WINSTEPS
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Wolfe E W, 1999, J Outcome Meas, V3, P134
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zheng HM, 2014, FRONT PSYCHOL, V5, DOI [10.3389/fpsyg.2014.00856, 10.3389/fpsyg.2014.01574]
NR 25
TC 6
Z9 6
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2018
VL 102
IS 3
BP 377
EP 382
DI 10.1136/bjophthalmol-2017-310532
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GC5HJ
UT WOS:000429817700016
PM 28659392
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kim, JW
   Kim, CG
   Lee, DW
AF Kim, Jae Hui
   Kim, Jong Woo
   Kim, Chul Gu
   Lee, Dong-Won
TI Decreased Periodicity of Reactivation Interval in Neovascular
   Age-Related Macular Degeneration in Patients with a Late First
   Reactivation After Initial Treatment
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   antivascular endothelial growth factor; reactivation; recurrence;
   ranibizumab; aflibercept
ID ENDOTHELIAL GROWTH-FACTOR; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   INTRAVITREAL RANIBIZUMAB; RECURRENCE; THERAPY; EXTEND; REGIMENS; NEED
AB Purpose:To evaluate the periodicity of the intervals of lesion reactivation in patients with neovascular age-related macular degeneration (AMD). Methods:This retrospective study included 139 eyes diagnosed with treatment-naive neovascular AMD and treated with antivascular endothelial growth factor (VEGF) therapy. Patients were initially treated with 3 loading anti-VEGF injections using either ranibizumab or aflibercept. Additional treatment was administered only when lesion reactivation was noted. The difference between the time intervals to the first and the second reactivations was evaluated. The included eyes were divided into 2 groups according to the time interval to the first reactivation: the early reactivation group (<= 6 months,n = 86) and the late reactivation group (>6 months,n = 53). The association between the time intervals to the first and the second reactivations was evaluated within each group. Results:The mean follow-up period was 52.7 +/- 8.9 months. The first reactivation was noted at mean 9.4 +/- 10.4 months after the loading injections. The second reactivation was noted at mean 6.2 +/- 4.9 months after the treatment for the first reactivation. The time interval to the second reactivation was significantly shorter compared with the first reactivation (P = 0.018). The association between the time interval to the first and the second reactivations was significant only in the early reactivation group (P = 0.002). Conclusions:A short first reactivation interval suggests that there is a high likelihood that the second reactivation will also be short. However, a long first reactivation interval does not suggest that the second reactivation interval will be similarly long.
C1 [Kim, Jae Hui; Kim, Jong Woo; Kim, Chul Gu; Lee, Dong-Won] Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Kim, JH (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
FU Kim's Eye Hospital Research Center
FX This study was supported by Kim's Eye Hospital Research Center.
CR Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Fauser S, 2016, BRIT J OPHTHALMOL, V100, P1494, DOI 10.1136/bjophthalmol-2015-308264
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Giannakaki-Zimmermann H, 2016, OPHTHALMOLOGICA, V236, P201, DOI 10.1159/000452929
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Hatz K, 2016, BRIT J OPHTHALMOL, V100, P1341, DOI 10.1136/bjophthalmol-2015-307299
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Horster R, 2011, GRAEF ARCH CLIN EXP, V249, P645, DOI 10.1007/s00417-010-1588-2
   Kang HM, 2016, GRAEF ARCH CLIN EXP, V254, P1519, DOI 10.1007/s00417-015-3241-6
   Kim J, 2017, EYE, V31, P1678, DOI 10.1038/eye.2017.126
   Kim JH, 2019, GRAEF ARCH CLIN EXP, V257, P1183, DOI 10.1007/s00417-019-04306-1
   Kim JH, 2020, SEMIN OPHTHALMOL, V35, P33, DOI 10.1080/08820538.2019.1701045
   Kim JH, 2017, J OCUL PHARMACOL TH, V33, P445, DOI 10.1089/jop.2016.0098
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Kokame GT, 2019, OPHTHALMOL RETINA, V3, P744, DOI 10.1016/j.oret.2019.04.018
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Kvannli L, 2017, ACTA OPHTHALMOL, V95, P678, DOI 10.1111/aos.13356
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   McClintic SM, 2018, OPHTHALMOL RETINA, V2, P931, DOI 10.1016/j.oret.2018.01.014
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   Muller S, 2017, GRAEF ARCH CLIN EXP, V255, P2237, DOI 10.1007/s00417-017-3739-1
   Mueller S, 2016, OPHTHALMOLOGY, V123, P876, DOI 10.1016/j.ophtha.2015.12.001
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 31
TC 1
Z9 1
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD NOV 1
PY 2020
VL 36
IS 9
BP 703
EP 710
DI 10.1089/jop.2019.0158
EA JUN 2020
PG 8
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA OM1UM
UT WOS:000541864400001
PM 32552280
DA 2022-11-30
ER

PT J
AU Kim, SH
   Park, JW
AF Kim, Sung Hwan
   Park, Jeen-Woo
TI Morin hydrate attenuates CSE-induced lipid accumulation, ER stress, and
   oxidative stress in RPE cells: implications for age-related macular
   degeneration
SO FREE RADICAL RESEARCH
LA English
DT Article
DE Antioxidant; cell signaling; cigarettes smoke; endoplasmic reticulum;
   oxidative stress; retina
ID CARBOXAMIDE RIBONUCLEOTIDE AICAR; CIGARETTE-SMOKE; TRANSCRIPTION FACTOR;
   PROTEIN-KINASE; MECHANISM; NRF2; CONSTITUENTS; HOMEOSTASIS; ACTIVATION;
   PARTICLES
AB Oxidative stress has a key role in the pathogenesis of age-related macular degeneration (AMD). Cigarette smoking is known to the one of the main risk factors of AMD through oxidative stress-mediated endoplasmic reticulum (ER) stress and lipid accumulation in human retinal pigment epithelium (RPE) cells. A number of studies have investigated the benefits of antioxidants in the AMD. However, previous studies have not shown that efficacy of antioxidant in the treatment of AMD. Recent studies demonstrated that morin hydrate (MH) has antioxidant properties, anti-inflammatory, and antiapoptosis effects, however, the protective effects of MH against cigarette smoke extract (CSE)-induced AMD have not been studied in detail. We tested the potential effect of MH against the CSE-induced lipid accumulation in RPE cells and mice RPE layer. Herein, we observed that expose of RPE cells to CSE reduced cell viability, increased the lipid accumulation, ER stress, and oxidative stress. Concomitantly, CSE treatment to mice induced AMD associated histopathological changes, lipid accumulation, ER stress and oxidative stress in RPE layer. MH significantly attenuated cytotoxicity, lipid accumulation, ER stress, and oxidative stress via activated AMPK-Nrf2 signaling pathway in RPE cells and mice RPE layer. In addition, AMPK inhibition reversed MH-induced RPE cell protection against CSE. Thus, we conclude that MH protects RPE cells from CSE through reduced oxidative stress, ER stress, and lipid accumulation via activated AMPK-Nrf2-HO-1 signaling pathway. These findings suggest that MH treatment may be exploited in effective strategy against CSE-induced AMD.
C1 [Kim, Sung Hwan; Park, Jeen-Woo] Kyungpook Natl Univ, Sch Life Sci & Biotechnol, Plus KNU Creat BioRes Grp BK21, Coll Nat Sci, Daegu, South Korea.
C3 Kyungpook National University
RP Park, JW (通讯作者)，Kyungpook Natl Univ, Sch Life Sci & Biotechnol, Plus KNU Creat BioRes Grp BK21, Coll Nat Sci, Daegu, South Korea.
EM parkjw@knu.ac.kr
FU National Research Foundation of Korea (NRF) - Korea Government (MSIP)
   [NRF-2015R1A4A1042271]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea Government (MSIP)
   (NRF-2015R1A4A1042271).
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bengoechea-Alonso MT, 2007, CURR OPIN CELL BIOL, V19, P215, DOI 10.1016/j.ceb.2007.02.004
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cano M, 2014, FREE RADICAL BIO MED, V69, P1, DOI 10.1016/j.freeradbiomed.2014.01.004
   CARP H, 1978, AM REV RESPIR DIS, V118, P617
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Eberle D, 2004, BIOCHIMIE, V86, P839, DOI 10.1016/j.biochi.2004.09.018
   Edirisinghe I, 2008, FASEB J, V22, P2297, DOI 10.1096/fj.07-099481
   Ferre P, 2007, HORM RES, V68, P72, DOI 10.1159/000100426
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finn L, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-23
   Fowles J, 2003, TOB CONTROL, V12, P424, DOI 10.1136/tc.12.4.424
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369
   Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943
   Jain AK, 2007, J BIOL CHEM, V282, P16502, DOI 10.1074/jbc.M611336200
   Jakhar R, 2014, INT IMMUNOPHARMACOL, V22, P356, DOI 10.1016/j.intimp.2014.07.020
   Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]
   Joo MS, 2016, MOL CELL BIOL, V36, P1931, DOI 10.1128/MCB.00118-16
   Kanzler MH, 2003, J AM ACAD DERMATOL, V48, P780, DOI 10.1067/mjd.2003.284
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Li ZY, 2005, J BIOL CHEM, V280, P37798, DOI 10.1074/jbc.M508575200
   Liu XN, 2014, MOL CANCER THER, V13, P596, DOI 10.1158/1535-7163.MCT-13-0579
   Marella M, 2007, J BIOL CHEM, V282, P24146, DOI 10.1074/jbc.M701819200
   Mo YQ, 2012, TOXICOL IN VITRO, V26, P295, DOI 10.1016/j.tiv.2011.12.001
   Rizvi F, 2015, APOPTOSIS, V20, P1296, DOI 10.1007/s10495-015-1160-y
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Salazar M, 2006, J BIOL CHEM, V281, P14841, DOI 10.1074/jbc.M513737200
   Smith CJ, 2001, ATHEROSCLEROSIS, V158, P257, DOI 10.1016/S0021-9150(01)00570-6
   Suzuki J, 2012, INVEST OPHTH VIS SCI, V53, P4158, DOI 10.1167/iovs.11-9323
   Suzuki J, 2011, INVEST OPHTH VIS SCI, V52, P6565, DOI 10.1167/iovs.11-7331
   Theodoropoulou S, 2010, FASEB J, V24, P2620, DOI 10.1096/fj.09-152546
   Treutiger CJ, 2003, J INTERN MED, V254, P375, DOI 10.1046/j.1365-2796.2003.01204.x
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Viollet B, 2009, ACTA PHYSIOL, V196, P81, DOI 10.1111/j.1748-1716.2009.01970.x
   WU TW, 1993, LIFE SCI, V53, pPL213, DOI 10.1016/0024-3205(93)90266-6
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
NR 40
TC 10
Z9 10
U1 0
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1071-5762
EI 1029-2470
J9 FREE RADICAL RES
JI Free Radic. Res.
PD AUG 3
PY 2019
VL 53
IS 8
BP 865
EP 874
DI 10.1080/10715762.2019.1637862
EA JUL 2019
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA IZ4FK
UT WOS:000478343400001
PM 31257945
DA 2022-11-30
ER

PT J
AU Bandukwala, T
   Muni, RH
   Schwartz, C
   Eng, KT
   Kertes, PJ
AF Bandukwala, Taha
   Muni, Rajeev H.
   Schwartz, Carol
   Eng, Kenneth T.
   Kertes, Peter J.
TI Effectiveness of intravitreal ranibizumab for the treatment of
   neovascular age-related macular degeneration in a Canadian retina
   practice: a retrospective review
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Review
DE ranibizumab; lucentis; age-related macular degeneration; efficacy;
   effectiveness
AB Objective: To assess the effectiveness of intravitreal ranibizumab for neovascular age-related macular degeneration (AMD) in a tertiary care retina practice and compare these results with published efficacy data from randomized clinical trials.
   Design: Nonrandomized, consecutive, single-centre, retrospective chart review analysis.
   Participants: Ninety-four patients (95 eyes) with neovascular AMD.
   Methods: All treatment-naive patients with neovascular AMD who received ranibizumab and for whom 1 year of follow-up was available were included in the analysis. The following information was gathered from each patient's chart: age, sex, ocular history, treated eye, duration of symptoms at presentation, subtype of choroidal neovascular membrane, Snellen visual acuity at each visit, number of injections, visits, and optical coherence tomography measurements.
   Results: Subjects had a mean age of 81 (SD 7.11) years. The mean number of injections was 5.1 (SD 2.85) with a mean of 9.4 (SD 2.27) visits in the 12-month period. Overall, there was a gain of 2.88 (SD 24.6) letters in all eyes, and a loss of 2.5 (SD 23.1) letters in patients who met the visual acuity inclusion criteria for the clinical trials. Of the patients who met the inclusion criteria, 75% lost fewer than 15 letters and 11% gained more than 15 letters.
   Conclusions: Visual outcomes in our study patients compared poorly with the clinical trials. Possibilities for the disparity include gaps in the number and frequency of follow-up visits, patient or doctor assessment fatigue, or gaps in optical coherence tomography utilization and the number of injections administered.
C1 [Schwartz, Carol; Eng, Kenneth T.; Kertes, Peter J.] Sunnybrook Hlth Sci Ctr, John & Liz Tory Eye Ctr, Toronto, ON M4N 3M5, Canada.
   [Muni, Rajeev H.] St Michaels Hosp, Dept Ophthalmol, Toronto, ON M5B 1W8, Canada.
   [Bandukwala, Taha] McMaster Univ, Sch Med, Hamilton, ON L8S 4L8, Canada.
C3 University of Toronto; Sunnybrook Research Institute; University Toronto
   Affiliates; Sunnybrook Health Science Center; University of Toronto;
   University Toronto Affiliates; Saint Michaels Hospital Toronto; McMaster
   University
RP Kertes, PJ (通讯作者)，Sunnybrook Hlth Sci Ctr, John & Liz Tory Eye Ctr, Room M1-202A,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
EM peter.kertes@sunnybrook.ca
FU Novartis Ophthalmics Canada
FX Drs. Kertes and Schwartz received honoraria and research funding from
   Novartis Ophthalmics Canada. Dr. Eng, Dr. Muni, and T. Bandukwala have
   no proprietary or commercial interest in any materials discussed in this
   article.
CR Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Eng KT, 2006, CLIN INTERV AGING, V1, P451, DOI 10.2147/ciia.2006.1.4.451
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Jonas JB, 2008, EYE, V22, P590, DOI 10.1038/eye.2008.10
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Michalova K, 2009, EYE, V23, P1633, DOI 10.1038/eye.2009.175
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 11
TC 31
Z9 31
U1 0
U2 0
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD DEC
PY 2010
VL 45
IS 6
BP 590
EP 595
DI 10.3129/i10-082
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 719PQ
UT WOS:000287218300006
PM 21135894
DA 2022-11-30
ER

PT J
AU Ibuki, M
   Shoda, C
   Miwa, Y
   Ishida, A
   Tsubota, K
   Kurihara, T
AF Ibuki, Mari
   Shoda, Chiho
   Miwa, Yukihiro
   Ishida, Ayako
   Tsubota, Kazuo
   Kurihara, Toshihide
TI Therapeutic Effect of Garcinia cambogia Extract and Hydroxycitric Acid
   Inhibiting Hypoxia-Inducible Factor in a Murine Model of Age-Related
   Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE hydroxycitric acid; Garcinia cambogia; age-related macular degeneration;
   laser induced neovascularization; hypoxia-inducible factor; retina;
   choroid
ID (-)-HYDROXYCITRIC ACID; IN-VIVO; RETINAL NEOVASCULARIZATION; VISUAL
   IMPAIRMENT; OXIDATIVE STRESS; ANGIOGENESIS; INFLAMMATION; SUPPRESSION;
   METABOLISM; MECHANISM
AB Background: Age-related macular degeneration (AMD) is the leading cause of blindness and can be classified into two types called atrophic AMD (dry AMD) and neovascular AMD (wet AMD). Dry AMD is characterized by cellular degeneration of the retinal pigment epithelium, choriocapillaris, and photoreceptors. Wet AMD is characterized by the invasion of abnormal vessels from the choroid. Although anti-vascular endothelial growth factor (VEGF) therapy has a potent therapeutic effect against the disease, there is a possibility of chorio-retinal atrophy and adverse systemic events due to long-term robust VEGF antagonism. We focused on hypoxia-inducible factor (HIF) regulation of VEGF transcription, and report the suppressive effects of HIF inhibition against ocular phenotypes in animal models. Many of the known HIF inhibitors are categorized as anti-cancer drugs, and their systemic side effects are cause for concern in clinical use. In this study, we explored food ingredients that have HIF inhibitory effects and verified their effects in an animal model of AMD. Methods: Food ingredients were screened using a luciferase assay. C57BL6/J mice were administered the Garcinia cambogia extract (Garcinia extract) and hydroxycitric acid (HCA). Choroidal neovascularization (CNV) was induced by laser irradiation. Results: Garcinia extract and HCA showed inhibitory effects on HIF in the luciferase assay. The laser CNV model mice showed significant reduction of CNV volume by administering Garcinia extract and HCA. Conclusions: Garcinia extract and HCA showed therapeutic effects in a murine AMD model.
C1 [Ibuki, Mari; Shoda, Chiho; Miwa, Yukihiro; Ishida, Ayako; Tsubota, Kazuo; Kurihara, Toshihide] Keio Univ, Sch Med, Lab Photobiol, Tokyo 1608582, Japan.
   [Ibuki, Mari; Miwa, Yukihiro; Kurihara, Toshihide] Keio Univ, Sch Med, Dept Ophthalmol, Tokyo 1608582, Japan.
   [Shoda, Chiho] Nihon Univ, Dept Ophthalmol, Tokyo 1018309, Japan.
C3 Keio University; Keio University; Nihon University
RP Tsubota, K; Kurihara, T (通讯作者)，Keio Univ, Sch Med, Lab Photobiol, Tokyo 1608582, Japan.; Kurihara, T (通讯作者)，Keio Univ, Sch Med, Dept Ophthalmol, Tokyo 1608582, Japan.
EM shirayuki0727@yahoo.co.jp; syouda.chiho@nihon-u.ac.jp;
   yukihiro226@gmail.com; ayakoishida9696@keio.jp; tsubota@z3.keio.jp;
   kurihara@z8.keio.jp
RI Kurihara, Toshihide/ABA-7058-2020; Tsubota, Kazuo/M-1915-2013
OI Kurihara, Toshihide/0000-0002-5457-2720; Miwa,
   Yukihiro/0000-0002-5377-6772; Tsubota, Kazuo/0000-0002-8874-7111
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT)
   [15K10881, 18K09424]; ROHTO Pharmaceutical
FX The Grants-in-Aid for Scientific Research (KAKENHI, number 15K10881 and
   18K09424) from the Ministry of Education, Culture, Sports, Science and
   Technology (MEXT) to TK funded this work. The current study was
   conducted with financial support from ROHTO Pharmaceutical.
CR AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Asghar M, 2007, MOL CELL BIOCHEM, V304, P93, DOI 10.1007/s11010-007-9489-3
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Goudarzvand M, 2016, NEURAL REGEN RES, V11, P1610, DOI 10.4103/1673-5374.193240
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guo JX, 2017, J OCUL PHARMACOL TH, V33, P50, DOI 10.1089/jop.2016.0153
   Hoskins P, 1998, J CLIN ONCOL, V16, P2233, DOI 10.1200/JCO.1998.16.6.2233
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Jena BS, 2002, J AGR FOOD CHEM, V50, P10, DOI 10.1021/jf010753k
   Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim KY, 2008, BIOSCI BIOTECH BIOCH, V72, P1772, DOI 10.1271/bbb.80072
   Koo T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04175-y
   Kunimi H, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133171
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Li LL, 2017, CELL PHYSIOL BIOCHEM, V43, P812, DOI 10.1159/000481564
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Miwa Y, 2019, NEUROCHEM INT, V128, P21, DOI 10.1016/j.neuint.2019.03.008
   Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200
   Montezuma SR, 2015, CURR EYE RES, V40, P946, DOI 10.3109/02713683.2014.969808
   Mori K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36576-w
   Nisha VM, 2014, FREE RADICAL RES, V48, P1386, DOI 10.3109/10715762.2014.959514
   Ohia SE, 2002, MOL CELL BIOCHEM, V238, P89, DOI 10.1023/A:1019911205672
   Ono H, 2006, J FOOD HYG SOC JPN, V47, P80, DOI 10.3358/shokueishi.47.80
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pieramici DJ, 2008, EYE, V22, P1330, DOI 10.1038/eye.2008.88
   Preuss HG, 2005, INT J CLIN PHARM RES, V25, P133
   Rahtu-Korpela L, 2014, DIABETES, V63, P3324, DOI 10.2337/db14-0472
   Rapisarda A, 2004, CANCER RES, V64, P1475, DOI 10.1158/0008-5472.CAN-03-3139
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   STALLINGS WC, 1979, ARCH BIOCHEM BIOPHYS, V193, P431, DOI 10.1016/0003-9861(79)90050-X
   Uddin MI, 2016, SCI REP-UK, V6, DOI 10.1038/srep31011
   WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230
   Wu JM, 2016, INT J BIOL SCI, V12, P1363, DOI 10.7150/ijbs.16334
   Yang C, 2016, MOL MED REP, V13, P1287, DOI 10.3892/mmr.2015.4679
   Yoshida T, 2010, FASEB J, V24, P1759, DOI 10.1096/fj.09-145664
   Yu TC, 2017, YONSEI MED J, V58, P489, DOI 10.3349/ymj.2017.58.3.489
NR 38
TC 10
Z9 10
U1 2
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT 2
PY 2019
VL 20
IS 20
AR 5049
DI 10.3390/ijms20205049
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA JQ3AZ
UT WOS:000498822800081
PM 31614647
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Seddon, JM
   McLeod, DS
   Bhutto, IA
   Villalonga, MB
   Silver, RE
   Wenick, AS
   Edwards, MM
   Lutty, GA
AF Seddon, Johanna M.
   McLeod, D. Scott
   Bhutto, Imran A.
   Villalonga, Mercedes B.
   Silver, Rachel E.
   Wenick, Adam S.
   Edwards, Malia M.
   Lutty, Gerard A.
TI Histopathological Insights Into Choroidal Vascular Loss in Clinically
   Documented Cases of Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; BLOOD-FLOW; CHORIOCAPILLARIS; EYES;
   NEOVASCULARIZATION; PROGRESSION; PREVALENCE; EXPRESSION; SMOKING; RISK
AB IMPORTANCE Age-related macular degeneration (AMD) is a multifactorial disease with genetic and environmental factors contributing to risk. Histopathologic changes underlying AMD are not fully understood, particularly the relationship between choriocapillaris (CC) dysfunction and phenotypic variability of this disease.
   OBJECTIVE To examine histopathologic changes in the CC of eyes with clinically documented AMD.
   DESIGN, SETTING, AND PARTICIPANTS The study was designed in 2011. Tissues were collected post mortem (2012-2016), and histopathological images were obtained from participants enrolled in AMD studies since 1988. Clinical records and images were collected from participants as standard protocol. Eyes without AMD (n = 4) and eyes with early (n = 9), intermediate (n = 5), and advanced stages of AMD (geographic atrophy, n = 5; neovascular disease, n = 13) were evaluated. Choroidal vasculature was labeled using Ulex europaeus agglutinin lectin and examined using confocal microscopy.
   MAIN OUTCOMES AND MEASURES A standardized classification system was applied to determine AMD stage. Ocular records and images were reviewed and histopathologic analyses performed. Viability of the choroidal vasculature was analyzed for each AMD stage.
   RESULTS All participants were white. Fourteen were male, and 16 were female. The mean age was 90.5 years among AMD patients and 88.5 years among control participants. Submacular CC dropout without retinal pigment eipthelial (RPE) loss was observed in all cases with early stages of AMD. Higher vascular area loss for each AMD stage was observed compared with control participants: 20.5% in early AMD (95% CI, 11.2%-40.2%; P < .001), 12.5% in intermediate AMD (95% CI, 2.9%-21.4%; P = .01), 39.0% loss in GA (95% CI, 32.1%-45.4%; P < .001), and 38.2% loss in neovascular disease where RPE remained intact (95% CI, 27.7%-47.9%; P < .001). Hypercellular, apparent neovascular buds were adjacent to areas of CC loss in 22.2% of eyes with early AMD and 40% of eyes with intermediate AMD.
   CONCLUSIONS AND RELEVANCE Retinal pigment epithelial atrophy preceded CC loss in geographic atrophy, but CC loss occurred in the absence of RPE atrophy in 2 of 9 eyes with early-stage AMD. Given the cross-sectional nature of this study and the small number of eyes evaluated, definitive conclusions regarding this progression cannot be determined with certainty. We speculate that neovascular buds may be a precursor to neovascular disease. Hypoxic RPE resulting from reduced blood supply might upregulate production of vascular endothelial growth factor, providing the stimulus for neovascular disease.
C1 [Seddon, Johanna M.; Villalonga, Mercedes B.; Silver, Rachel E.] Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA.
   [McLeod, D. Scott; Bhutto, Imran A.; Wenick, Adam S.; Edwards, Malia M.; Lutty, Gerard A.] Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, Dept Ophthalmol, Baltimore, MD 21287 USA.
C3 Tufts Medical Center; Tufts University; Tufts University; Johns Hopkins
   University; Johns Hopkins Medicine
RP Lutty, GA (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, M041 Smith Bldg,400 N Broadway, Baltimore, MD 21287 USA.
EM glutty@jhmi.edu
FU National Institutes of Health [EY016151, EY01765, EY011309]; Arnold and
   Mabel Beckman Foundation; Research to Prevent Blindness unrestricted
   grant; Macular Degeneration Research Fund, Tufts Medical Center; Tufts
   University School of Medicine, Boston, Massachussetts; NATIONAL EYE
   INSTITUTE [R01EY011309, R01EY016151, P30EY001765, U10EY011309] Funding
   Source: NIH RePORTER
FX This research was supported by National Institutes of Health grants
   EY016151 (Dr Lutty), EY01765 (Wilmer), and EY011309 (Dr Seddon); Arnold
   and Mabel Beckman Foundation (Drs Lutty and Seddon); a Research to
   Prevent Blindness unrestricted grant; and the Macular Degeneration
   Research Fund, Tufts Medical Center and Tufts University School of
   Medicine, Boston, Massachussetts (Dr Seddon).
CR Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   de Carlo TE, 2015, OSLI RETINA, V46, P611, DOI 10.3928/23258160-20150610-03
   Edwards MM, 2015, EXP EYE RES
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Lane M, 2016, OSLI RETINA, V47, P778, DOI 10.3928/23258160-20160808-13
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lutty G, 1999, MOL VIS, V5
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Schwartz DM, 2014, OPHTHALMOLOGY, V121, P180, DOI 10.1016/j.ophtha.2013.09.002
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
NR 30
TC 103
Z9 105
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD NOV 1
PY 2016
VL 134
IS 11
BP 1272
EP 1280
DI 10.1001/jamaophthalmol.2016.3519
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EC6GY
UT WOS:000388235700017
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Jang, S
   Park, SY
   Ahn, SM
   Hwang, SY
   Kim, SW
   Oh, J
   Yun, CM
AF Jang, Sungmin
   Park, Seo Yeon
   Ahn, So Min
   Hwang, Soon-Young
   Kim, Seong-Woo
   Oh, Jaeryung
   Yun, Cheolmin
TI MORPHOLOGIC FEATURES OF THE RETINAL PIGMENT EPITHELIUM AND ASSOCIATED
   CHORIORETINAL CHARACTERISTICS IN EYES WITH EARLY AGE-RELATED MACULAR
   DEGENERATION AND SUBRETINAL DRUSENOID DEPOSITS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE early age-related macular degeneration; optical coherence tomography;
   optical coherence tomography angiography; subretinal drusenoid deposits;
   retinal pigment epithelium
ID OPTICAL COHERENCE TOMOGRAPHY; RETICULAR PSEUDODRUSEN; GEOGRAPHIC
   ATROPHY; QUANTITATIVE-ANALYSIS; CHOROIDAL THICKNESS; CLINICAL-TRIAL;
   SYSTEM; RPE
AB Purpose: To investigate the features of the retinal pigment epithelium (RPE) on optical coherence tomography in eyes with early age-related macular degeneration with subretinal drusenoid deposit. Methods: We classified the eyes into three types: nonundulating RPE, undulating RPE, and wedge-shaped RPE. We compared the retinal vessel densities, retinal thickness, and choroidal thickness of a 3-mm-diameter zone. Results: We classified 33, 27, and 20 as nonundulating RPE, undulating RPE, and wedge-shaped RPE eyes, respectively. The vascular densities of the superficial and deep capillary plexus showed differences; nonundulating RPE group (23.93 +/- 2.26% and 23.54 +/- 1.78%), undulating RPE group (22.29 +/- 2.80% and 21.94 +/- 2.42%), and wedge-shaped RPE group (21.93 +/- 2.70% and 20.63 +/- 2.42%, P = 0.010 and P < 0.001). The mean retinal thickness and choroidal thickness were also different, nonundulating RPE group (298.26 +/- 13.81 mu m and 180.08 +/- 55.49 mu m), undulating RPE group (285.29 +/- 21.88 mu m and 148.45 +/- 55.08 mu m), and wedge-shaped RPE group (274.86 +/- 20.62 mu m and 135.75 +/- 39.77 mu m) (P = 0.001 and P = 0.007). Conclusion: Altered features of the RPE on optical coherence tomography may indicate advancement in disease and be part of an overall degeneration process in these eyes.
C1 [Jang, Sungmin; Park, Seo Yeon; Ahn, So Min; Kim, Seong-Woo; Oh, Jaeryung; Yun, Cheolmin] Korea Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
   [Hwang, Soon-Young] Korea Univ, Coll Med, Dept Biostat, Seoul, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine); Korea
   University; Korea University Medicine (KU Medicine)
RP Yun, CM (通讯作者)，Korea Univ, Coll Med, Dept Ophthalmol, 123 Jeokgeum Ro, Ansan 15355, Gyeonggi Do, South Korea.
EM yuncheolmin@gmail.com
RI Oh, Jaeryung/ABD-3090-2021
OI Oh, Jaeryung/0000-0002-1036-6562; Hwang, Soon Young/0000-0001-7474-1803
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education [NRF-2017R1D1A1B03033092]
FX Supported by the Basic Science Research Program through the National
   Research Foundation of Korea (NRF) funded by the Ministry of Education
   (NRF-2017R1D1A1B03033092).
CR A Martillo Miguel, 2012, Med Hypothesis Discov Innov Ophthalmol, V1, P37
   Ahn SM, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0866-3
   Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Bonnet C, 2014, RETINA-J RET VIT DIS, V34, P1524, DOI 10.1097/IAE.0000000000000165
   Cicinelli MV, 2018, BRIT J OPHTHALMOL, V102, P1192, DOI 10.1136/bjophthalmol-2017-311317
   Coscas G, 2018, OPHTHALMOLOGICA, V239, P61, DOI 10.1159/000485323
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Fujiwara A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188572
   Garrity ST, 2017, INVEST OPHTH VIS SCI, V58, P5548, DOI 10.1167/iovs.17-22036
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Iafe NA, 2016, INVEST OPHTH VIS SCI, V57, P5780, DOI 10.1167/iovs.16-20045
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lutty G, 1999, MOL VIS, V5
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mones J, 2018, BRIT J OPHTHALMOL, V102, P388, DOI 10.1136/bjophthalmol-2017-310268
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Samara WA, 2015, RETINA-J RET VIT DIS, V35, P2188, DOI 10.1097/IAE.0000000000000847
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Tan CS, 2016, INVEST OPHTH VIS SCI, V57, pOCT224, DOI 10.1167/iovs.15-18869
   Toto L, 2017, BRIT J OPHTHALMOL, V101, P774, DOI 10.1136/bjophthalmol-2016-309160
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Xu XY, 2017, AM J OPHTHALMOL, V175, P87, DOI 10.1016/j.ajo.2016.11.021
   Yun C, 2016, INVEST OPHTH VIS SCI, V57, P6604, DOI 10.1167/iovs.16-19989
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zarbin MA, 2006, BRIT J OPHTHALMOL, V90, P396, DOI 10.1136/bjo.2005.086041
   Zhao T, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0337-1
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 45
TC 1
Z9 1
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2020
VL 40
IS 4
BP 686
EP 694
DI 10.1097/IAE.0000000000002528
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LB2WI
UT WOS:000524497800012
PM 30950969
DA 2022-11-30
ER

PT J
AU Su, YX
   Wu, JW
   Gu, Y
AF Su, Yongxian
   Wu, Jiawei
   Gu, Yu
TI Photodynamic therapy in combination with ranibizumab versus ranibizumab
   monotherapy for wet age-related macular degeneration: A systematic
   review and meta-analysis
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Review
DE Photodynamic therapy; Ranibizumab; Age-related macular degeneration;
   Systematic review; Meta-analysis
ID VERTEPORFIN PLUS RANIBIZUMAB; FINNISH NATIONAL GUIDELINE; CHOROIDAL
   NEOVASCULARIZATION; INTRAVITREAL RANIBIZUMAB; VEGF INHIBITION;
   FOLLOW-UP; MANAGEMENT; PDT; BEVACIZUMAB; DIAGNOSIS
AB Objective: To evaluate the efficacy and safety between photodynamic therapy (PDT) combined with intravitreal ranibizumab (IVR) and ranibizumab monotherapy in treating wet age-related macular degeneration (AMD).
   Methods: A systematic search was performed in the PubMed, Embase, Web of Science and the Cochrane Library databases through December 31, 2017. The methodological quality of the references was evaluated according to the Cochrane quality assessment. RevMan 5.3 software was used to perform the meta-analysis.
   Results: Eight RCTs involving 817 participants were included. Wet AMD eyes in the mono-group achieved better best-corrected vision acuity (BCVA) than the combination group in month 12 (WMD = -0.19, 95% CI = -0.32 to -0.06, P = 0.004, I-2 = 18%). The proportion of patients gaining more than 15 letters from baseline in the mono group was larger than that in the combination group (RR = 0.70, 95% CI: 0.56 to 0.87, P = 0.001). However, the number of ranibizumab injections with combination therapy was smaller than that with mono-therapy (MD = -1.13, 95% CI: -2.11 to -0.15, P = 0.02, I-2 = 85%). No significant differences were observed in the proportions of patients losing more than 15 letters, central retinal thickness (CRT), lesion size of choroidal neovascularization (CNV) and adverse events.
   Conclusions: Combination therapy decreased the number of injections of ranibizumab, although its BCVA improvement was inferior to that of monotherapy over 12 months of follow-up. Given the inherent limitations of the included trials, more studies are needed to further validate and update the findings in this area.
C1 [Su, Yongxian; Wu, Jiawei; Gu, Yu] Southern Med Univ, Affiliated Hosp 2, Guangzhou 510000, Guangdong, Peoples R China.
C3 Southern Medical University - China
RP Su, YX (通讯作者)，Southern Med Univ, Affiliated Hosp 2, Guangzhou 510000, Guangdong, Peoples R China.
EM 2094522731@qq.com
RI YU, GU/AAQ-4509-2020
OI YU, GU/0000-0002-5683-8078
CR Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Bashshur ZF, 2011, RETINA-J RET VIT DIS, V31, P636, DOI 10.1097/IAE.0b013e3181fe54ab
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen E, 2010, CLIN OPHTHALMOL, V4, P1073, DOI 10.2147/OPTH.S13969
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Cruess AF, 2012, CAN J OPHTHALMOL, V47, P227, DOI 10.1016/j.jcjo.2012.03.007
   Debefve E, 2009, PHOTOCHEM PHOTOBIOL, V85, P1400, DOI 10.1111/j.1751-1097.2009.00604.x
   Diago T, 2008, MAYO CLIN PROC, V83, P231
   Dong Y, 2016, EXP THER MED, V12, P3923, DOI 10.3892/etm.2016.3886
   Hatz K, 2015, OPHTHALMOLOGICA, V233, P66, DOI 10.1159/000367603
   Hodge W, 2010, CAN J OPHTHALMOL, V45, P223, DOI 10.3129/i10-047
   Hernandez-Pastor LJ, 2008, CLIN THER, V30, P2436, DOI 10.1016/j.clinthera.2008.12.025
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kawczyk-Krupka A, 2015, PHOTODIAGN PHOTODYN, V12, P161, DOI 10.1016/j.pdpdt.2015.03.007
   Koh A, 2011, SINGAP MED J, V52, P232
   Krebs I, 2013, ACTA OPHTHALMOL, V91, pE178, DOI 10.1111/aos.12018
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Li SS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184998
   Liu L, 2017, PHOTODIAGN PHOTODYN, V20, P215, DOI 10.1016/j.pdpdt.2017.09.008
   Michels S, 2005, KLIN MONATSBL AUGENH, V222, P480, DOI 10.1055/s-2005-858315
   Ou WC, 2017, AM J OPHTHALMOL, V180, P8, DOI 10.1016/j.ajo.2017.05.014
   Ozkaya Abdullah, 2017, Korean J Ophthalmol, V31, P424, DOI 10.3341/kjo.2016.0125
   Peters S, 2007, BRIT J OPHTHALMOL, V91, P827, DOI 10.1136/bjo.2006.109702
   Ranchod TM, 2013, RETINA-J RET VIT DIS, V33, P1600, DOI 10.1097/IAE.0b013e318285cb71
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Semeraro F, 2015, RETINA-J RET VIT DIS, V35, P1547, DOI 10.1097/IAE.0000000000000525
   Shah GK, 2009, RETINA-J RET VIT DIS, V29, P133, DOI 10.1097/IAE.0b013e3181960a28
   Si JK, 2014, INT J OPHTHALMOL-CHI, V7, P541, DOI 10.3980/j.issn.2222-3959.2014.03.28
   Sivaprasad S, 2013, BRIT MED BULL, V105, P201, DOI 10.1093/bmb/ldt004
   Soderberg AC, 2012, BRIT J OPHTHALMOL, V96, P714, DOI 10.1136/bjophthalmol-2011-300721
   Spaide Richard F, 2009, Retina, V29, pS5, DOI 10.1097/IAE.0b013e3181ad237a
   Stahl A, 2009, GRAEF ARCH CLIN EXP, V247, P767, DOI 10.1007/s00417-009-1058-x
   Stewart MW, 2015, J CLIN MED, V4, P1079, DOI 10.3390/jcm4051079
   Teper SJ, 2016, PHOTODIAGN PHOTODYN, V13, P108, DOI 10.1016/j.pdpdt.2016.01.006
   Tong Y, 2016, INT J OPHTHALMOL-CHI, V9, P1028, DOI 10.18240/ijo.2016.07.16
   Tuuminen R, 2017, ACTA OPHTHALMOL, V95, P649, DOI 10.1111/aos.13341
   Tuuminen R, 2017, ACTA OPHTHALMOL, V95, DOI 10.1111/aos.13501
   Vallance JH, 2010, EYE, V24, P1561, DOI 10.1038/eye.2010.84
   Volcker M, 2006, OPHTHALMOLOGE, V103, P476, DOI 10.1007/s00347-006-1356-1
   Weingessel B, 2016, WIEN KLIN WOCHENSCHR, V128, P560, DOI 10.1007/s00508-015-0772-0
   Wroblewski JJ, 2016, OSLI RETINA, V47, P914, DOI 10.3928/23258160-20161004-04
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 46
TC 10
Z9 11
U1 2
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD JUN
PY 2018
VL 22
BP 263
EP 273
DI 10.1016/j.pdpdt.2018.05.002
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GJ1UR
UT WOS:000435053900044
PM 29753123
DA 2022-11-30
ER

PT J
AU Daniel, E
   Pan, W
   Ying, GS
   Kim, BJ
   Grunwald, JE
   Ferris, FL
   Jaffe, GJ
   Toth, CA
   Martin, DF
   Fine, SL
   Maguire, MG
AF Daniel, Ebenezer
   Pan, Wei
   Ying, Gui-shuang
   Kim, Benjamin J.
   Grunwald, Juan E.
   Ferris, Frederick L., III
   Jaffe, Glenn J.
   Toth, Cynthia A.
   Martin, Daniel F.
   Fine, Stuart L.
   Maguire, Maureen G.
CA Comparison Age-Related Macular Deg
TI Development and Course of Scars in the Comparison of Age-Related Macular
   Degeneration Treatments Trials
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; LONG-TERM
   OUTCOMES; SUBRETINAL HEMORRHAGE; RANIBIZUMAB; ATROPHY; EYES; LESIONS;
   GROWTH; CELLS
AB Purpose: To describe risk factors for scar formation and changes to fibrotic scar through 5 years in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).
   Design: Multicenter, prospective cohort study.
   Participants: A total of 1061 subjects in CATT.
   Methods: Color photographic and fluorescein angiographic images from baseline and 1, 2, and 5 years were evaluated. Incidence of scar formation was estimated with KaplaneMeier curves. Risk factors were assessed with Cox regression models.
   Main Outcome Measures: Scar formation, fibrotic scar area, and macular atrophy associated with fibrotic scar ("atrophy").
   Results: Cumulative proportion of eyes with scar was 32%, 46%, and 56% at years 1, 2, and 5, respectively. Baseline factors associated with increased risk (adjusted hazards ratio [aHR] and 95% confidence interval [CI]) were classic choroidal neovascularization (CNV) (aHR, 4.49; 95% CI, 3.34-6.04) versus occult, hemorrhage > 1 disc area (DA) (aHR, 2.28; 95% CI, 1.49-3.47) versus no hemorrhage, retinal thickness > 212 mm (aHR, 2.58; 95% CI, 1.69-3.94) versus < 120 mm, subretinal tissue complex thickness > 275 mm (aHR, 2.64; 95% CI, 1.81-3.84) versus <= 75 mm, subretinal fluid thickness > 25 mm (aHR, 1.31; 95% CI, 0.97-1.75) versus no fluid, visual acuity (VA) in fellow eye 20/20 (aHR, 1.72; 95% CI, 1.25-2.36) versus 20/50 or worse, retinal pigment epithelium elevation absence (aHR, 1.71; 95% CI, 1.21-2.41), and subretinal hyperreflective material (aHR, 1.72; 95% CI, 1.25-2.36). Among 68 eyes that developed fibrotic scar at year 1, VA decreased by a mean of additional 13 letters between years 1 and 5. Mean scar area was 1.2, 1.2, and 1.9 DA at 1, 2, and 5 years, respectively. Atrophy was present in 18%, 24%, and 54% of these eyes at years 1, 2, and 5, respectively; the mean areas were 1.6, 2.0, and 3.1 DA, respectively. Atrophy replaced fibrotic scar in 8 eyes at year 5. There was no significant correlation between scar growth and atrophy growth. The rate of growth for both was similar between the clinical trial and observation periods.
   Conclusions: Several morphologic features, including classic CNV and large hemorrhage, are associated with scar formation. Rate of new scar formation declined after 2 years. Most fibrotic scars and accompanying macular atrophy expanded over time, reducing VA. (C) 2018 by the American Academy of Ophthalmology
C1 [Daniel, Ebenezer; Pan, Wei; Ying, Gui-shuang; Kim, Benjamin J.; Grunwald, Juan E.; Maguire, Maureen G.] Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA.
   [Ferris, Frederick L., III] NEI, Bethesda, MD 20892 USA.
   [Jaffe, Glenn J.; Toth, Cynthia A.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Fine, Stuart L.] Univ Colorado, Sch Med, Dept Ophthalmol, Aurora, CO USA.
C3 University of Pennsylvania; Pennsylvania Medicine; National Institutes
   of Health (NIH) - USA; NIH National Eye Institute (NEI); Duke
   University; Cleveland Clinic Foundation; University of Colorado System;
   University of Colorado Anschutz Medical Campus
RP Daniel, E (通讯作者)，Univ Penn, Ophthalmol Reading Ctr, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
EM ebdaniel@mail.med.upenn.edu
RI Kim, Benjamin/AAG-3786-2019; Toth, Cynthia/L-5534-2019
OI Kim, Benjamin/0000-0003-0230-3868; Toth, Cynthia/0000-0002-2324-0854;
   Ferris, Frederick/0000-0002-4933-0639
FU Chengdu Kanghong Biotech Co. Ltd.; Ziemer Ophthalmic Systems AG; Synergy
   Research; Alcon; National Eye Institute, National Institutes of Health
   [U10 EY017823, U10 EY017825, U10 EY017826, U10 EY017828, U10 EY023530,
   R21EY023689]; Department of Health and Human Services; NATIONAL EYE
   INSTITUTE [P30EY001583, R21EY023689, U10EY017826, U10EY017825,
   U10EY017828, U10EY017823, U10EY023530] Funding Source: NIH RePORTER
FX The author(s) have made the following disclosure(s): G-s.Y.: Consultant
   - Janssen R & D; Personal fees - Chengdu Kanghong Biotech Co. Ltd.,
   Ziemer Ophthalmic Systems AG.; B.J.K: Personal fees - Synergy Research.;
   C.A.T.: Grants - Genentech; Personal fees - Alcon.; Supported by
   cooperative agreements U10 EY017823, U10 EY017825, U10 EY017826, U10
   EY017828, U10 EY023530, and R21EY023689 from the National Eye Institute,
   National Institutes of Health, and Department of Health and Human
   Services. ClinicalTrials.gov identifier NCT00593450. The funding
   organization had no role in the design or conduct of this research.
CR Ahn SJ, 2016, RETINA-J RET VIT DIS, V36, P2140, DOI 10.1097/IAE.0000000000001043
   Altaweel MM, 2015, OPHTHALMOLOGY, V122, P391, DOI 10.1016/j.ophtha.2014.08.020
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   BENNER JD, 1994, OPHTHALMOLOGY, V101, P672
   Bhisitkul RB, 2008, INVEST OPHTH VIS SCI, V49, P4071, DOI 10.1167/iovs.08-1892
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GRISANTI S, 1995, INVEST OPHTH VIS SCI, V36, P391
   Grossniklaus HE, 2006, AM J OPHTHALMOL, V141, P93, DOI 10.1016/j.ajo.2005.07.076
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Kachi I, 2016, JPN J OPHTHALMOL, V60, P179, DOI 10.1007/s10384-016-0434-4
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miura M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03529-8
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Roberts PK, 2017, BRIT J OPHTHALMOL, V101, P1361, DOI 10.1136/bjophthalmol-2016-310004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarks J, 2006, BRIT J OPHTHALMOL, V90, P442, DOI 10.1136/bjo.2005.083022
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Siedlecki J, 2017, GRAEF ARCH CLIN EXP, V255, P963, DOI 10.1007/s00417-017-3595-z
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Tanaka E, 2015, OPHTHALMOLOGY, V122, P153, DOI 10.1016/j.ophtha.2014.07.046
   TOTH CA, 1992, AM J OPHTHALMOL, V113, P175, DOI 10.1016/S0002-9394(14)71530-2
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zhang RS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146808
NR 46
TC 42
Z9 42
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2018
VL 125
IS 7
BP 1037
EP 1046
DI 10.1016/j.ophtha.2018.01.004
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GL0DD
UT WOS:000436632700021
PM 29454660
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Gupta, A
   Lam, J
   Custis, P
   Munz, S
   Fong, D
   Koster, M
AF Gupta, Amisha
   Lam, Jessica
   Custis, Peter
   Munz, Stephen
   Fong, Donald
   Koster, Marguerite
TI Implantable miniature telescope (IMT) for vision loss due to end-stage
   age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID VISUAL-ACUITY; SAFETY
AB Background
   Age-related macular degeneration (AMD) causes progressive and irreversible damage to the retina, resulting in loss of central vision. AMDis the third leading cause of irreversible visual impairment worldwide and the leading cause of blindness in industrialized countries. Since AMD is more common in older individuals, the number of affected individuals will increase significantly as the population ages. The implantable miniature telescope (IMT) is an ophthalmic device developed to improve vision in individuals who have lost vision due to AMD. Once implanted, the IMT is used to enlarge objects in the central visual field and focus them onto healthy areas of the retina not affected by AMD, allowing individuals to recognize objects that they otherwise could not see. It is unclear whether and how much the IMT can improve vision in individuals with end-stage AMD.
   Objectives
   To assess the effectiveness and safety of the IMT in improving visual acuity and quality of life in people with late or advanced AMD.
   Search methods
   We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2017, Issue 11); Ovid MEDLINE; Embase. com; PubMed; LILACS; AMED; Web of Science Conference Proceedings Citation Index-Science; OpenSIGLE; the met a Register of Controlled Trials (mRCT) (last searched 27 June 2014); ClinicalTrials. gov; the ICTRP and the US Food and Drug Administration (FDA) Medical Devices database. The date of the search was 2 November 2017, with the exception of mRCT which is no longer in service.
   Selection criteria
   We planned to include randomized controlled trials (RCTs) and quasi-randomized trials that compared the IMT versus no IMT.
   Data collection and analysis
   Two review authors independently assessed all studies for inclusion, using standard methodological procedures expected by Cochrane.
   Main results
   Our search yielded 1042 unique records. We removed irrelevant studies after screening titles and abstracts, and evaluated five full-text reports from four studies; three were non-randomized studies. There was one ongoing RCT that compared the OriLens intraocular telescope with standard low vision training in eyes with end-stage AMD. Results for this study are expected in 2020.
   Authors' conclusions
   We found no RCT or quasi-RCT and can draw no conclusion about the effectiveness and safety of the IMT in improving visual acuity in individuals with late or advanced AMD. Since the IMT is typically implanted monocularly based upon which eye has better best-corrected distance visual acuity, randomization between eyes within an individual may not be acceptable. Studies are needed that compare outcomes between individuals randomized to the device versus individuals not implanted, at least during study follow-up, who serve as controls.
C1 [Gupta, Amisha; Lam, Jessica] Kaiser Permanente, EBM Serv, Dept Clin Anal, 393 E Walnut Ave,6th Floor, Pasadena, CA 91188 USA.
   [Custis, Peter] Kaiser Permanente, Ophthalmol, San Diego, CA USA.
   [Munz, Stephen] Kaiser Permanente, Ophthalmol, Yorba Linda, CA USA.
   [Fong, Donald] Kaiser Permanente, Ophthalmol, Baldwin Pk, CA USA.
   [Koster, Marguerite] Kaiser Permanente Southern Calif, EBM Serv, Dept Clin Anal, Pasadena, CA USA.
C3 Kaiser Permanente; Kaiser Permanente; Kaiser Permanente; Kaiser
   Permanente; Kaiser Permanente
RP Gupta, A (通讯作者)，Kaiser Permanente, EBM Serv, Dept Clin Anal, 393 E Walnut Ave,6th Floor, Pasadena, CA 91188 USA.
EM amisha.gupta@kp.org
FU Kaiser Permanente, USA; National Eye Institute, National Institutes of
   Health, USA [1 U01 EY020522]; National Institute for Health Research
   (NIHR), UK; Department of Health through NIHR to Moorfields Eye Hospital
   NHS Foundation Trust; UCL Institute of Ophthalmology for a Specialist
   Biomedical Research Centre for Ophthalmology; NIHR; NATIONAL EYE
   INSTITUTE [U01EY020522] Funding Source: NIH RePORTER
FX Internal sources; Kaiser Permanente, USA.; External sources;
   Methodologic support provided by the Cochrane Eyes and Vision US
   Project, funded by Grant 1 U01 EY020522, National Eye Institute,
   National Institutes of Health, USA.; National Institute for Health
   Research (NIHR), UK.; Richard Wormald, Co-ordinating Editor for Cochrane
   Eyes and Vision (CEV) acknowledges financial support for his CEV
   research sessions from the Department of Health through the award made
   by the NIHR to Moorfields Eye Hospital NHS Foundation Trust and UCL
   Institute of Ophthalmology for a Specialist Biomedical Research Centre
   for Ophthalmology.; This review was supported by the NIHR, via Cochrane
   Infrastructure funding to the CEV UK editorial base.
CR Abba K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008122.pub2
   Beck RW, 2007, OPHTHALMOLOGY, V114, P1804, DOI 10.1016/j.ophtha.2007.06.047
   Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   Brown GC, 2011, OPHTHALMOLOGY, V118, P1834, DOI 10.1016/j.ophtha.2011.02.012
   FDA, 2014, IMPL MIN TEL MOD WID
   FDA, FDA OPHTH DEV ADV PA, VI
   FDA, IMPL MIN TEL
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Gehlbach P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub5
   GRADE Working Group McMaster University, 2014, GRADEPRO GDT VERS
   Gupta A, 2014, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD011140, DOI 10.1002/14651858.CD011140]
   Hau VS, 2016, OPHTHALMOL THER, V5, P21, DOI 10.1007/s40123-016-0047-5
   Hawkins BS, 2005, ARCH OPHTHALMOL-CHIC, V123, P78, DOI 10.1001/archopht.123.1.78
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Hudson HL, 2008, AM J OPHTHALMOL, V146, P664, DOI 10.1016/j.ajo.2008.07.003
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Lane SS, 2004, AM J OPHTHALMOL, V137, P993, DOI 10.1016/j.ajo.2004.01.030
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   National Eye Institute, FACTS AG REL MAC DEG
   Nordic Cochrane Centre The Cochrane Collaboration, 2014, REV MAN 5 REVMAN 5 V
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sterne JAC, 2011, COCHRANE HDB SYSTEMA
   The Foundation of the American Academy of Ophthalmology, TOP 5 RISK FACT AMD
   VisionCare Ophthalmic Technologies, 2010, VIS CAR IMPL MIN TEL
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   World Health Organization, 2012, PREV BLINDN VIS IMP
NR 29
TC 5
Z9 5
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2018
IS 5
AR CD011140
DI 10.1002/14651858.CD011140.pub2
PG 21
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GH8AS
UT WOS:000433887900012
PM 29847689
OA Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Beka, S
   Strauss, RW
   Podkowinski, D
   Mursch-Edlmayr, AS
   Mariacher, S
   Hofer, AS
   Bolz, M
AF Beka, Sophie
   Strauss, Rupert Wolfgang
   Podkowinski, Dominika
   Mursch-Edlmayr, Anna Sophie
   Mariacher, Siegfried
   Hofer, Anna-Sophie
   Bolz, Matthias
TI Efficacy of a Disease Management Program of a Tertiary Center and
   Ophthalmologic Practitioners for the Treatment of Neovascular
   Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Medical retina; Retina; Disease
   management; Public health
ID OPTICAL COHERENCE TOMOGRAPHY; QUALITY-OF-LIFE; VISUAL-ACUITY;
   RANIBIZUMAB TREATMENT; INTRAVITREAL BEVACIZUMAB; DIABETIC-RETINOPATHY;
   OUTCOMES; PREVALENCE; PREDICTORS; DOMAIN
AB Purpose: The aim of the study was to examine real-world data of patients with neovascular age-related macular degeneration (nAMD) within a disease management program (DMP) treated with anti-VEGF. Methods: A monocentric, retrospective chart review of 379 eyes of a local DMP was conducted at the Department of Ophthalmology, Kepler University Clinic Linz. Eyes were treated either with bevacizumab or aflibercept using a pro re nata scheme, consisting of 3 injections every 4 weeks in case of presence of disease activity. The observational period was up to 24 months. Disease activity was monitored by visual acuity (VA), clinical examination, and optical coherence tomography (OCT). For (re-)treatments, ophthalmologic practitioners referred patients directly to the intravitreal injection, avoiding redundant examinations. Results: VA improved significantly for all patients after 2 months (logMAR 0.47 +/- 0.36; p = 0.000) compared to baseline (0.55 +/- 0.37), and for the aflibercept group for up to 6 months (0.36 +/- 0.27; p = 0.018). After 12 months, VA remained stable without further significant improvement and decreased by 24 months compared to baseline. The median number of injections was 6 over the first 12 months and 4 in the second year. Conclusion: Data revealed the efficacy of a DMP for nAMD involving both ophthalmologic practitioners and a tertiary center. Avoiding redundant examinations increased the efficacy of a clinical setting. (C) 2021 S. Karger AG, Basel
C1 [Beka, Sophie; Strauss, Rupert Wolfgang; Podkowinski, Dominika; Mursch-Edlmayr, Anna Sophie; Mariacher, Siegfried; Bolz, Matthias] Johannes Kepler Univ Linz, Kepler Univ Hosp GmbH, Dept Ophthalmol & Optometry, Linz, Austria.
   [Hofer, Anna-Sophie] Med Univ Graz, Graz, Austria.
C3 Johannes Kepler University Linz; Medical University of Graz
RP Bolz, M (通讯作者)，Johannes Kepler Univ Linz, Kepler Univ Hosp GmbH, Dept Ophthalmol & Optometry, Linz, Austria.
EM matthias.bolz@kepleruniklinikum.at
RI Bolz, Matthias/HCI-0622-2022
CR [Anonymous], 2018, NICE GUIDELINE NG82
   Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Beard JR, 2016, GERONTOLOGIST, V56, pS163, DOI 10.1093/geront/gnw037
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Conill AM., 1999, SEMIN MED PRACT, V2, P4
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Flores R, 2019, REV MED CHILE, V147, P444, DOI 10.4067/S0034-98872019000400444
   Fuchs S., 2014, DIS MANAGEMENT PROGR, V3, P453
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mathew R, 2014, OPHTHALMOLOGICA, V231, P153, DOI 10.1159/000355091
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Reeves BC, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010685
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross AH, 2013, EYE, V27, P56, DOI 10.1038/eye.2012.225
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Von der Heidt A, 2014, WIEN KLIN WOCHENSCHR, V126, P734, DOI 10.1007/s00508-014-0665-7
   Weinstein O, 2020, EUR J OPHTHALMOL, V30, P66, DOI 10.1177/1120672118823128
   Wickremasinghe SS, 2012, OPHTHALMOLOGY, V119, P2413, DOI 10.1016/j.ophtha.2012.06.056
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 38
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2022
VL 245
IS 1
BP 10
EP 18
DI 10.1159/000517188
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2P4NS
UT WOS:000819720600003
PM 34023820
DA 2022-11-30
ER

PT J
AU Tsuchihashi, T
   Mori, K
   Horie-Inoue, K
   Gehlbach, PL
   Kabasawa, S
   Takita, H
   Ueyama, K
   Okazaki, Y
   Inoue, S
   Awata, T
   Katayama, S
   Yoneya, S
AF Tsuchihashi, Takashi
   Mori, Keisuke
   Horie-Inoue, Kuniko
   Gehlbach, Peter L.
   Kabasawa, Sho
   Takita, Hiroyasu
   Ueyama, Kazuhiro
   Okazaki, Yasushi
   Inoue, Satoshi
   Awata, Takuya
   Katayama, Shigehiro
   Yoneya, Shin
TI Complement Factor H and High-Temperature Requirement A-1 Genotypes and
   Treatment Response of Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; PHOTODYNAMIC THERAPY; GENOME SCAN;
   GENE; POLYMORPHISM; VARIANT; SUSCEPTIBILITY; LOC387715; HTRA1;
   NEOVASCULARIZATION
AB Purpose: To determine whether there is an association between complement factor H (CFH), high-temperature requirement A-1 (HTRA1), vascular endothelial growth factor (VEGF), and pigment epithelium-derived factor (PEDF) genotypes and response to treatment with photodynamic therapy (PDT) for age-related macular degeneration (AMD) in a Japanese population.
   Design: Prospective, case-control study.
   Participants: One hundred ten patients with exudative AMD treated by verteporfin PDT were recruited prospectively at the Department of Ophthalmology, Saitama Medical University Hospital, Saitama, Japan.
   Methods: The patients were genotyped for 4 single nucleotide polymorphisms (SNPs; rs800292, rs1061170, rs1410996, rs2274700) in the CFH gene, a rs11200638-SNP in the HTRA1 gene, 3 SNPs (rs699947, rs1570360, rs2010963) in the VEGF gene, and 4 SNPs (rs12150053, rs12948385, rs9913583, rs1136287) in the PEDF gene using a TaqMan assay.
   Main Outcome Measures: The treatment outcomes and genotypes of CFH, HTRA1, VEGF, and PEDF polymorphisms.
   Results: Best-corrected visual acuity 1 year after PDT was significantly increased in patients with the HTRA1-rs11200638 GG genotype as compared with patients with the GA or AA genotypes (P = 2.9 x 10(-2), 7.0 x 10(-4), respectively). The rate of recurrence in the 12-month period after PDT was also associated with HTRA1-rs11200638 genotype (P = 3.12 x 10(-2)). Patients with the AA genotype of HTRA1-rs11200638 had an approximately 6-fold greater risk of the recurrence than patients with the GG genotype (P = 5.58 x 10(-3)). Significant differences were demonstrated in the mean time interval from the initial treatment to the time of recurrence for the genotypes of CFH-rs1410996/-rs2274700 (P = 8.50 x 10(-3)).
   Conclusions: The HTRA1-rs11200638 and CFH-rs1410996/-rs2274700 variants were associated with response to PDT in this study population. These variants may be used for genetic biomarkers to estimate visual outcomes and recurrences in the response to PDT with significant predictive power.
C1 [Tsuchihashi, Takashi; Mori, Keisuke; Kabasawa, Sho; Takita, Hiroyasu; Ueyama, Kazuhiro; Yoneya, Shin] Saitama Med Univ, Dept Ophthalmol, Iruma, Saitama 3500495, Japan.
   [Horie-Inoue, Kuniko; Inoue, Satoshi] Saitama Med Univ, Div Gene Regulat & Signal Transduct, Res Ctr Genom Med, Iruma, Saitama 3500495, Japan.
   [Gehlbach, Peter L.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
   [Okazaki, Yasushi] Saitama Med Univ, Div Translat Res, Res Ctr Genom Med, Iruma, Saitama 3500495, Japan.
   [Awata, Takuya; Katayama, Shigehiro] Saitama Med Univ, Div Endocrinol & Diabet, Dept Med, Iruma, Saitama 3500495, Japan.
   [Awata, Takuya] Saitama Med Univ, Div RI Lab, Biomed Res Ctr, Iruma, Saitama 3500495, Japan.
C3 Saitama Medical University; Saitama Medical University; Johns Hopkins
   University; Saitama Medical University; Saitama Medical University;
   Saitama Medical University
RP Mori, K (通讯作者)，Saitama Med Univ, Dept Ophthalmol, 38 Morohongo, Iruma, Saitama 3500495, Japan.
EM keisuke@saitama-med.ac.jp
OI Okazaki, Yasushi/0000-0003-3241-5502; Awata, Takuya/0000-0003-2622-8129
FU Eye Research Foundation for the Aged; Medical Research Center, Saitama
   Medical University [20-1-2-02]; Ministry of Education, Culture and
   Science in Japan [21592242]
FX Supported in part by a Grant from the Eye Research Foundation for the
   Aged (KM), an Institutional Grant from the Medical Research Center,
   Saitama Medical University (#20-1-2-02, KM) and a grant-in-aid for
   scientific research (21592242) from the Ministry of Education, Culture
   and Science in Japan (KM).
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2006, JPN J OPHTHALMOL, V50, P161, DOI 10.1007/s10384-005-0259-z
   Chang TS, 1999, CAN J OPHTHALMOL, V34, P266
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Chowers I, 2008, MOL VIS, V14, P2263
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Goverdhan SV, 2007, EYE LOND, V22, P849
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Parmeggiani F, 2008, INVEST OPHTH VIS SCI, V49, P3100, DOI 10.1167/iovs.07-1654
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Theodossiadis GP, 2003, GRAEF ARCH CLIN EXP, V241, P13, DOI 10.1007/s00417-002-0579-3
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 51
TC 43
Z9 54
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2011
VL 118
IS 1
BP 93
EP 100
DI 10.1016/j.ophtha.2010.04.007
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 701PF
UT WOS:000285832500016
PM 20678803
DA 2022-11-30
ER

PT J
AU Vu, KV
   Mitchell, P
   Detaram, HD
   Burlutsky, G
   Liew, G
   Gopinath, B
AF Vu, Kim Van
   Mitchell, Paul
   Dharamdasani Detaram, Harshil
   Burlutsky, George
   Liew, Gerald
   Gopinath, Bamini
TI Prevalence and risk factors for depressive symptoms in patients with
   neovascular age-related macular degeneration who present for anti-VEGF
   therapy
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE depression; macular degeneration; older adults; self-rated health;
   activities of daily living; visual function; functional impairment
ID VISUAL IMPAIRMENT; SOMATIC COMPLAINTS; OLDER; HEALTH; IMPACT; VISION;
   ASSOCIATION; DISABILITY; VALIDITY; BURDEN
AB Purpose To examine the prevalence and risk factors for depressive symptoms in patients with neovascular age-related macular degeneration (nAMD) presenting for anti-vascular endothelial growth factor (anti-VEGF) therapy. Methods In a clinic-based cohort of 547 patients with nAMD who presented for treatment, the Centre of Epidemiological Studies Depression 10-point scale (CES-D-10) and Mental Health Index (MHI) component of the 36-item Short Form Survey were administered to assess for the presence of depressive symptoms. Logistic regression analyses were used to calculate odds ratios and 95% confidence intervals for factors associated with an increased likelihood of depressive symptoms. Results The prevalence of depressive symptoms was 42.04% and 31.78% as per the CES-D-10 and MHI scales, respectively. Poor self-rated health (SRH) is associated with increased odds of depressive symptoms [multivariable-adjusted OR: 3.00 (95% CI 1.90-4.73) for CES-D-10; OR: 2.67 (95% CI 1.67-4.28) for MHI]. Impaired activities of daily living (ADLs) [multivariable-adjusted OR: 2.62 (95% CI 1.56-4.38) for CES-D-10; OR: 3.59 (95% CI 2.10-6.15) for MHI] and a visual function score within the two lowest quartiles were also associated with increased odds of depressive symptoms using both scales. Conclusion A high prevalence of depressive symptoms was observed among nAMD patients presenting for treatment. Poorer SRH, ADL impairment and reduced visual function were associated with increased odds of depressive symptoms.
C1 [Vu, Kim Van; Mitchell, Paul; Dharamdasani Detaram, Harshil; Burlutsky, George; Liew, Gerald; Gopinath, Bamini] Univ Sydney, Westmead Inst Med Res, Ctr Vis Res, Sydney, NSW, Australia.
C3 University of Sydney; Westmead Institute for Medical Research
RP Gopinath, B (通讯作者)，Univ Sydney, Westmead Hosp, Westmead Inst, Ctr Vis Res, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM bamini.gopinath@sydney.edu.au
RI Liew, Gerald/AAB-6870-2022
FU Macular Disease Foundation Australia (MDFA)
FX This study received funding or support from the Macular Disease
   Foundation Australia (MDFA). There are no conflicts of interest to
   declare.
CR Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Casten R, 2008, J VISUAL IMPAIR BLIN, V102, P591, DOI 10.1177/0145482X0810201003
   Casten R, 2010, ARCH OPHTHALMOL-CHIC, V128, P506, DOI 10.1001/archophthalmol.2010.24
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Detaram HD, 2020, ACTA OPHTHALMOL, V98, pE814, DOI 10.1111/aos.14394
   Dougherty BE, 2018, INVEST OPHTH VIS SCI, V59
   Duke University Centre for the Study of Aging and Human Development, 1975, OARS MULT FUNCT ASS
   FOELKER GA, 1992, J AM GERIATR SOC, V40, P259, DOI 10.1111/j.1532-5415.1992.tb02079.x
   Fong CSU, 2013, OPHTHALMOLOGY, V120, P1720, DOI 10.1016/j.ophtha.2013.02.009
   Friedman B, 2005, J AM GERIATR SOC, V53, P1978, DOI 10.1111/j.1532-5415.2005.00469.x
   Gopinath B, 2016, BRIT J NUTR, V116, P2109, DOI 10.1017/S0007114516004311
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   Hong T, 2015, BRIT J OPHTHALMOL, V99, P1017, DOI 10.1136/bjophthalmol-2014-306308
   Irwin M, 1999, ARCH INTERN MED, V159, P1701, DOI 10.1001/archinte.159.15.1701
   Jivraj J, 2013, CAN J OPHTHALMOL, V48, P269, DOI 10.1016/j.jcjo.2013.03.007
   Karpa MJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P1347, DOI 10.1001/archophthalmol.2009.240
   Kato A, 2018, INVEST OPHTH VIS SCI, V59
   MacLeod KE, 2014, J TRANSP HEALTH, V1, P86, DOI 10.1016/j.jth.2014.03.001
   Mulsant BH, 1997, J AM GERIATR SOC, V45, P954, DOI 10.1111/j.1532-5415.1997.tb02966.x
   Noel PH, 2004, ANN FAM MED, V2, P555, DOI 10.1370/afm.143
   Nollett C, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026163
   Pepin R, 2009, AGING MENT HEALTH, V13, P769, DOI 10.1080/13607860902918231
   Pirkis J, 2009, J AFFECT DISORDERS, V115, P54, DOI 10.1016/j.jad.2008.08.014
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Rovner BW, 2007, INT J GERIATR PSYCH, V22, P789, DOI 10.1002/gps.1742
   Rovner BW, 1996, J AM GERIATR SOC, V44, P181, DOI 10.1111/j.1532-5415.1996.tb02436.x
   Ryu So Jung, 2017, Korean J Ophthalmol, V31, P412, DOI 10.3341/kjo.2016.0086
   Senra H, 2017, AM J OPHTHALMOL, V177, P213, DOI 10.1016/j.ajo.2017.03.005
   Senra H, 2016, GRAEF ARCH CLIN EXP, V254, P1873, DOI 10.1007/s00417-016-3384-0
   Wang JJ, 2000, INVEST OPHTH VIS SCI, V41, P49
   WAXMAN HM, 1985, GERONTOLOGIST, V25, P501, DOI 10.1093/geront/25.5.501
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang XZ, 2013, JAMA OPHTHALMOL, V131, P573, DOI 10.1001/jamaophthalmol.2013.2597
NR 34
TC 4
Z9 4
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2021
VL 99
IS 4
BP E547
EP E554
DI 10.1111/aos.14635
EA SEP 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SZ5CP
UT WOS:000572810800001
PM 32981226
DA 2022-11-30
ER

PT J
AU Vessey, KA
   Ho, T
   Jobling, AI
   Mills, SA
   Tran, MX
   Brandli, A
   Lam, J
   Guymer, RH
   Fletcher, EL
AF Vessey, Kirstan A.
   Ho, Tracy
   Jobling, Andrew I.
   Mills, Samuel A.
   Tran, Mai X.
   Brandli, Alice
   Lam, Jackson
   Guymer, Robyn H.
   Fletcher, Erica L.
TI Nanosecond Laser Treatment for Age-Related Macular Degeneration Does Not
   Induce Focal Vision Loss or New Vessel Growth in the Retina
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE retina; nanosecond laser; retinal rejuvenation therapy (2RT); retinal
   pigmented epithelium (RPE); choroid; vasculature; angiogenesis; mouse;
   human
ID EPITHELIUM-DERIVED FACTOR; 3-NANOSECOND PULSE LASER; CONVENTIONAL
   PHOTOCOAGULATOR; CHOROIDAL NEOVASCULARIZATION; PIGMENT EPITHELIUM;
   MACULOPATHY; DRUSEN; DAMAGE; CELLS; ANGIOGENESIS
AB PURPOSE. Subthreshold, nanosecond pulsed laser treatment shows promise as a treatment for age-related macular degeneration (AMD); however, the safety profile needs to be robustly examined. The aim of this study was to investigate the effects of laser treatment in humans and mice.
   METHODS. Patients with AMD were treated with nanosecond pulsed laser at subthreshold (no visible retinal effect) energy doses (0.15-0.45 mJ) and retinal sensitivity was assessed with microperimetry. Adult C57BL6J mice were treated at subthreshold (0.065 mJ) and suprathreshold (photoreceptor loss, 0.5 mJ) energy settings. The retinal and vascular responses were analyzed by fundus imaging, histologic assessment, and quantitative PCR.
   RESULTS. Microperimetry analysis showed laser treatment had no effect on retinal sensitivity under treated areas in patients 6 months to 7 years after treatment. In mice, subthreshold laser treatment induced RPE loss at 5 hours, and by 7 days the RPE had retiled. Fundus imaging showed reduced RPE pigmentation but no change in retinal thickness up to 3 months. Electron microscopy revealed changes in melanosomes in the RPE, but Bruch's membrane was intact across the laser regions. Histologic analysis showed normal vasculature and no neovascularization. Suprathreshold laser treatment did not induce changes in angiogenic genes associated with neovascularization. Instead pigment epithelium-derived factor, an antiangiogenic factor, was upregulated.
   CONCLUSIONS. In humans, low-energy, nanosecond pulsed laser treatment is not damaging to local retinal sensitivity. In mice, treatment does not damage Bruch's membrane or induce neovascularization, highlighting a reduced side effect profile of this nanosecond laser when used in a subthreshold manner.
C1 [Vessey, Kirstan A.; Ho, Tracy; Jobling, Andrew I.; Mills, Samuel A.; Tran, Mai X.; Brandli, Alice; Lam, Jackson; Fletcher, Erica L.] Univ Melbourne, Dept Anat & Neurosci, Med Bldg,Level 7,East Corner Grattan St, Melbourne, Vic 3010, Australia.
   [Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Dept Surg Ophthalmol, Melbourne, Vic, Australia.
C3 University of Melbourne; Centre for Eye Research Australia; Royal
   Victorian Eye & Ear Hospital; University of Melbourne
RP Fletcher, EL (通讯作者)，Univ Melbourne, Dept Anat & Neurosci, Med Bldg,Level 7,East Corner Grattan St, Melbourne, Vic 3010, Australia.
EM elf@unimelb.edu.au
RI Brandli, Alice/AAM-3803-2021; Fletcher, Erica/E-6364-2012; Jobling,
   Andrew/C-8221-2015
OI brandli, alice/0000-0002-4842-3438; Fletcher, Erica/0000-0001-9412-9523;
   Ho, Tracy/0000-0002-9277-7823; Guymer, Robyn/0000-0002-9441-4356;
   Jobling, Andrew/0000-0002-7827-3135; Vessey, Kirstan/0000-0003-1031-1964
FU ARC Linkage [LP150100482]; National Health & Medical Research Council of
   Australia [NH MRC] [1061418, 1138253]; NH MRC Fellowship [GNT1103013]
FX Supported by No. LP150100482 (ARC Linkage to ELF), No. 1061418, No.
   1138253 (National Health & Medical Research Council of Australia [NH &
   MRC] Project Grant to ELF); NH & MRC Fellowship GNT1103013 (RHG).
CR Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Bressler NM, 1996, ARCH OPHTHALMOL-CHIC, V114, P1456, DOI 10.1001/archopht.1996.01100140654002
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Casson RJ, 2012, CLIN EXP OPHTHALMOL, V40, P604, DOI 10.1111/j.1442-9071.2012.02756.x
   Chidlow G, 2016, LASER SURG MED, V48, P602, DOI 10.1002/lsm.22506
   Chidlow G, 2013, INVEST OPHTH VIS SCI, V54, P2319, DOI 10.1167/iovs.12-11204
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dorin Giorgio, 2004, Semin Ophthalmol, V19, P62, DOI 10.1080/08820530490884173
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   FITZPATRICK TB, 1950, SCIENCE, V112, P223, DOI 10.1126/science.112.2904.223
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gao H, 1996, EXP EYE RES, V62, P181, DOI 10.1006/exer.1996.0022
   Ghadially FN, 1982, ULTRASTRUCT PATHOL, P599
   Gross-Jendroska M, 1998, AM J OPHTHALMOL, V126, P77, DOI 10.1016/S0002-9394(98)00061-0
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Ho T, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00389
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   HOGAN MJ, 1967, ARCH OPHTHALMOL-CHIC, V77, P410, DOI 10.1001/archopht.1967.00980020412022
   Hooper CY, 2003, CLIN EXP OPHTHALMOL, V31, P376, DOI 10.1046/j.1442-9071.2003.00683.x
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   Kojima H, 2011, BLOOD, V117, P1091, DOI 10.1182/blood-2010-05-286963
   Lek JJ, 2016, CLIN EXP OPHTHALMOL, V44, P118
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   MORGAN CM, 1989, OPHTHALMOLOGY, V96, P96
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Oishi A, 2008, INVEST OPHTH VIS SCI, V49, P5629, DOI 10.1167/iovs.08-1711
   Owens SL, 2006, AM J OPHTHALMOL, V141, P276, DOI 10.1016/j.ajo.2005.08.019
   Owens SL, 1999, AM J OPHTHALMOL, V127, P681, DOI 10.1016/S0002-9394(99)00043-4
   Parodi MB, 2009, COCHRANE DATATBASE S, V3, P1
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Pelosini L, 2013, RETINA-J RET VIT DIS, V33, P548, DOI 10.1097/IAE.0b013e3182670fea
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Reale E, 2009, CELLS TISSUES ORGANS, V190, P170, DOI 10.1159/000187632
   Roider J, 1998, GRAEF ARCH CLIN EXP, V236, P213, DOI 10.1007/s004170050067
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shibeeb O, 2014, EXP EYE RES, V127, P77, DOI 10.1016/j.exer.2014.07.008
   TALBOT JF, 1980, T OPHTHAL SOC UK, V100, P423
   Toy BC, 2013, AM J OPHTHALMOL, V156, P532, DOI 10.1016/j.ajo.2013.04.031
   Vessey KA, 2015, INVEST OPHTH VIS SCI, V56, P1238, DOI 10.1167/iovs.14-15334
   Vessey KA, 2014, J COMP NEUROL, V522, P2928, DOI 10.1002/cne.23558
   Virgili G, 2015, COCHRANE DB SYST REV, V10, P1
   Wood JPM, 2013, INVEST OPHTH VIS SCI, V54, P2305, DOI 10.1167/iovs.12-11203
   Wood JPM, 2011, LASER SURG MED, V43, P499, DOI 10.1002/lsm.21087
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P3714, DOI 10.1167/iovs.15-18294
   Yung Madeline, 2016, Int J Retina Vitreous, V2, P12, DOI 10.1186/s40942-016-0035-x
   Zhang JJ, 2012, INVEST OPHTH VIS SCI, V53, P2928, DOI 10.1167/iovs.11-8585
   Zhang Q, 2016, BRIT J OPHTHALMOL, V100, P1443, DOI 10.1136/bjophthalmol-2015-308199
NR 52
TC 11
Z9 12
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2018
VL 59
IS 2
BP 731
EP 745
DI 10.1167/iovs.17-23098
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FX8LO
UT WOS:000426346300015
PM 29392319
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Devarajan, G
   Niven, J
   Forrester, JV
   Crane, IJ
AF Devarajan, Gayathri
   Niven, Jennifer
   Forrester, John V.
   Crane, Isabel J.
TI Retinal Pigment Epithelial Cell Apoptosis is Influenced by a Combination
   of Macrophages and Soluble Mediators Present in Age-Related Macular
   Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE AMD; cytokine; macrophage; microglia; RPE
ID AQUEOUS-HUMOR; SUBRETINAL MICROGLIA; NADPH OXIDASE; ACCUMULATION;
   INFLAMMATION; PROPORTION; CYTOKINES; MEMBRANE; INCREASE; DRUSEN
AB Purpose: Age-related macular degeneration (AMD) is one of the leading causes of blindness in the elderly population aged 60 years. Previous studies have shown that retinal pigment epithelial cell (RPE) degeneration is one of the early and crucial stages in AMD. It has been suggested that microglia and macrophages may be involved in the impairment of RPE, but how they and RPE are influenced by other factors present as AMD develops is unclear. Therefore the purpose of this study was to determine the role of macrophages in RPE degeneration in the presence of cytokines and oxidative stress likely to be present as AMD develops.Methods: A co-culture model system was set up using bone marrow-derived macrophages and brain or retinal microglia cultured with RPE. Cytokines (IL-1, TNF-, IFN-, and IL-6) and oxidized low-density lipoprotein were included in the culture at concentrations estimated to be likely during AMD, and apoptosis of RPE cells determined using flow cytometry to detect annexin V.Results: Macrophages were shown capable of enhancing the apoptosis of RPE cells in a contact-dependent manner. IL-1, IFN-, IL-6, TNF-, and oxLDL increased apoptosis; they increased RPE cell apoptosis directly, increased the susceptibility of RPE to subsequent apoptosis in the presence of microglia/macrophages, and increased the ability of microglia/macrophages to cause apoptosis.Conclusions: These findings indicate that microglia and macrophages are capable of enhancing the degeneration of RPE, which are crucial in AMD development. However this is dependent on the microenvironment present as AMD develops.
C1 [Devarajan, Gayathri; Niven, Jennifer; Forrester, John V.; Crane, Isabel J.] Univ Aberdeen, Div Appl Med, Inst Med Sci, Aberdeen, Scotland.
C3 University of Aberdeen
RP Crane, IJ (通讯作者)，Univ Aberdeen, Inst Med Sci, Foresterhill, Aberdeen AB25 2ZD, Scotland.
EM i.j.crane@abdn.ac.uk
FU Medical Research Council UK; Chief Scientist Office [ETM/351] Funding
   Source: researchfish
FX This work was supported by the Medical Research Council UK.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Chen M, 2011, PETROLEUM PROJECT RO, P6
   Chen M, 2008, INVEST OPHTH VIS SCI, V49, P3699, DOI 10.1167/iovs.07-1522
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Devarajan G, 2014, SCI WORLD J, DOI 10.1155/2014/894368
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   ELLIOTT JA, 1986, INFECT IMMUN, V51, P31, DOI 10.1128/IAI.51.1.31-36.1986
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Horiuchi T, 2010, RHEUMATOLOGY, V49, P1215, DOI 10.1093/rheumatology/keq031
   Javadzadeh A, 2010, MOL VIS, V16, P2578
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Kramer M, 2012, CLIN EXP OPHTHALMOL, V40, P617, DOI 10.1111/j.1442-9071.2011.02747.x
   Leung KW, 2009, MOL IMMUNOL, V46, P1374, DOI 10.1016/j.molimm.2008.12.001
   Liu B, 2011, J TRANSL MED, V9
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Ma WJ, 2009, PLOS ONE, P4
   McCarthy CA, 2013, CLIN EXP PHARMACOL P, V40, P571, DOI 10.1111/1440-1681.12099
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Rogue RS, 1999, BRAIN RES, V836, P110, DOI 10.1016/S0006-8993(99)01625-X
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Suzuki M, 2007, MOL VIS, V13, P772
   Wan L, 2010, RETINA-J RET VIT DIS, V30, P1595, DOI 10.1097/IAE.0b013e3181dc58a6
   Wardman P, 2007, FREE RADICAL BIO MED, V43, P995, DOI 10.1016/j.freeradbiomed.2007.06.026
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yang D, 2007, EXP EYE RES, V85, P462, DOI 10.1016/j.exer.2007.06.013
   Yildirim Z, 2012, INT J GERONTOL, V6, P101, DOI 10.1016/j.ijge.2012.01.018
   Yoshida A, 2003, LAB INVEST, V83, P1117, DOI 10.1097/01.LAB.0000082393.02727.B5
   Zamiri P, 2006, INVEST OPHTH VIS SCI, V47, P3912, DOI 10.1167/iovs.05-1267
   Zeng H, 2014, NEUROSCIENCE, V275, P54, DOI 10.1016/j.neuroscience.2014.05.065
NR 40
TC 13
Z9 13
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD SEP
PY 2016
VL 41
IS 9
BP 1235
EP 1244
DI 10.3109/02713683.2015.1109129
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DX0QX
UT WOS:000384070400016
PM 27015409
DA 2022-11-30
ER

PT J
AU Xing, C
   Liu, XF
   Zhang, CF
   Yang, L
AF Xing, Chen
   Liu, Xiao-Feng
   Zhang, Chun-Feng
   Yang, Liu
TI Hsp90-associated DNA replication checkpoint protein and
   proteasome-subunit components are involved in the age-related macular
   degeneration
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE Age-related macular degeneration; Retinal pigment epithelium; Cell
   senescence; HSP90AA1; DNA damage checkpoint; Proteasomal subunit
   components
ID RETINAL-PIGMENT EPITHELIUM; FUNCTIONAL-ANALYSIS; HSP90; EXPRESSION;
   INHIBITION; MODELS; TARGET; NAMPT; CHK1
AB Background: Age-related macular degeneration (AMD) is the leading cause of vision loss worldwide. However, the mechanisms involved in the development and progression of AMD are poorly delineated. We aimed to explore the critical genes involved in the progression of AMD. Methods: The differentially expressed genes (DEGs) in AMD retinal pigment epithelial (RPE)/choroid tissues were identified using the microarray datasets GSE99248 and GSE125564, which were downloaded from the gene expression omnibus database. The overlapping DEGs from the two datasets were screened to identify DEG-related biological pathways using gene ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses. The hub genes were identified from these DEGs through protein-protein interaction network analyses. The expression levels of hub genes were evaluated by quantitative real-time polymerase chain reaction following the induction of senescence in ARPE-19 with FK866. Following the identification of AMD-related key genes, the potential small molecule compounds targeting the key genes were predicted by PharmacoDB. Finally, a microRNA-gene interaction network was constructed. Results: Microarray analyses identified 174 DEGs in the AMD RPE compared to the healthy RPE samples. These DEGs were primarily enriched in the pathways involved in the regulation of DNA replication, cell cycle, and proteasome-mediated protein polyubiquitination. Among the top ten hub genes, HSP90AA1, CHEK1, PSMA4, PSMD4, and PSMD8 were upregulated in the senescent ARPE-19 cells. Additionally, the drugs targeting HSP90AA1, CHEK1, and PSMA4 were identified. We hypothesize that Hsa-miR-16-5p might target four out of the five key DEGs in the AMD RPE. Conclusions: Based on our findings, HSP90AA1 is likely to be a central gene controlling the DNA replication and proteasome-mediated polyubiquitination during the RPE senescence observed in the progression of AMD. Targeting HSP90AA1, CHEK1, PSMA4, PSMD4, and/or PSMD8 genes through specific miRNAs or small molecules might potentially alleviate the progression of AMD through attenuating RPE senescence.
C1 [Xing, Chen; Yang, Liu] Peking Univ First Hosp, Dept Ophthalmol, 8 Xishiku St, Beijing 100034, Peoples R China.
   [Liu, Xiao-Feng] Peking Univ, Hepatopancreatobiliary Surg Dept 1, Key Lab Carcinogenesis & Translat Res, Minist Educ,Canc Hosp & Inst, Beijing 100142, Peoples R China.
   [Zhang, Chun-Feng] Peking Univ, Sch Basic Med Sci, Dept Med Genet, Hlth Sci Ctr, Beijing 100191, Peoples R China.
C3 Peking University; Peking University
RP Yang, L (通讯作者)，Peking Univ First Hosp, Dept Ophthalmol, 8 Xishiku St, Beijing 100034, Peoples R China.
EM liu_yang@bjmu.edu.cn
RI Liu, Xiaofeng/AAR-2488-2020
FU National Natural Science Foundation of China [81670841]
FX This study was supported by grant from the National Natural Science
   Foundation of China (No. 81670841).
CR Aguila M, 2016, ADV EXP MED BIOL, V854, P161, DOI 10.1007/978-3-319-17121-0_22
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Arlander SJH, 2006, J BIOL CHEM, V281, P2989, DOI 10.1074/jbc.M508687200
   Bennis A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141597
   BOK D, 1993, J CELL SCI, P189
   CARR AM, 1995, CURR BIOL, V5, P1179, DOI 10.1016/S0960-9822(95)00234-X
   Chen JQ, 2021, FASEB J, V35, DOI 10.1096/fj.202000645RR
   de Guimaraes TAC, 2022, BRIT J OPHTHALMOL, V106, P297, DOI 10.1136/bjophthalmol-2020-318452
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Fan YN, 2018, METHODS MOL BIOL, V1819, P215, DOI 10.1007/978-1-4939-8618-7_10
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gelfman CM, 2021, J OCUL PHARMACOL TH, V37, P181, DOI 10.1089/jop.2021.0001
   Genier S, 2016, MOL BIOL CELL, V27, P3800, DOI 10.1091/mbc.E16-04-0224
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gong J, 2020, STEM CELL TRANSL MED, V9, P364, DOI 10.1002/sctm.19-0321
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Huber N, 2009, HEPATOLOGY, V49, P1718, DOI 10.1002/hep.22840
   Intartaglia D, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.589985
   Jadeja RN, 2018, AGING-US, V10, P1306, DOI 10.18632/aging.101469
   Jones MJK, 2021, MOL CELL, V81, P426, DOI 10.1016/j.molcel.2021.01.004
   Kanamaru C, 2014, J TOXICOL SCI, V39, P59, DOI 10.2131/jts.39.59
   Kim EJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21104-7
   Konig S, 2019, J PROTEOMICS, V191, P1, DOI 10.1016/j.jprot.2018.05.016
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Li WT, 2012, J BIOINF COMPUT BIOL, V10, DOI 10.1142/S0219720012310038
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin JB, 2016, CELL REP, V17, P69, DOI 10.1016/j.celrep.2016.08.073
   Mateos MV, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01071-9
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   O'Brien R, 2015, J BIOL CHEM, V290, P19287, DOI 10.1074/jbc.M114.623561
   Ouyang Y, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89778-0
   Peck D, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-r61
   Quadroni M, 2015, J PROTEOMICS, V120, P215, DOI 10.1016/j.jprot.2015.02.020
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Smirnov P, 2018, NUCLEIC ACIDS RES, V46, pD994, DOI 10.1093/nar/gkx911
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sundberg JP, 2016, VET PATHOL, V53, P456, DOI 10.1177/0300985815612556
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Tian YY, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106970
   Walter W, 2015, BIOINFORMATICS, V31, P2912, DOI 10.1093/bioinformatics/btv300
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yadavalli T, 2020, OCUL SURF, V18, P221, DOI 10.1016/j.jtos.2019.11.011
   Yano K, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.100882
   Yin J, 2012, BIOL CELL, V104, P695, DOI 10.1111/boc.201200011
   Yu T, 2020, BIOCHEM PHARMACOL, V174, DOI 10.1016/j.bcp.2020.113797
   Zhang JY, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/2714746
   Zhao B, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0498-z
NR 50
TC 0
Z9 0
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0366-6999
EI 2542-5641
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD OCT 5
PY 2021
VL 134
IS 19
BP 2322
EP 2332
DI 10.1097/CM9.0000000000001773
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA WE0MO
UT WOS:000705324300010
PM 34629418
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Machalinska, A
   Paczkowska, E
   Pabin, T
   Safranow, K
   Karczewicz, D
   Machalinski, B
AF Machalinska, Anna
   Paczkowska, Edyta
   Pabin, Tomasz
   Safranow, Krzysztof
   Karczewicz, Danuta
   Machalinski, Boguslaw
TI Influence of Ranibizumab on Vascular Endothelial Growth Factor Plasma
   Level and Endothelial Progenitor Cell Mobilization in Age-Related
   Macular Degeneration Patients: Safety of Intravitreal Treatment for
   Vascular Homeostasis
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID BEVACIZUMAB; PHARMACOKINETICS; REPAIR
AB Purpose: Intravitreal ranibizumab, which neutralizes vascular endothelial growth factor (VEGF), nowadays constitutes the first-line treatment in neovascular age-related macular degeneration (AMD). However, its potential systemic effect on vascular homeostasis as the consequence of such therapy has not been extensively investigated.
   Methods: Peripheral blood (PB) samples from 12 patients with newly diagnosed neovascular AMD were analyzed before as well as 1 and 4 weeks after intravitreal treatment with ranibizumab. VEGF plasma levels, the number of circulating endothelial progenitor cells (EPCs), and the intracellular expression of hypoxia-inducible factor (HIF) in PB cells were determined by enzyme-linked immunosorbent assay, flow cytometry, and real-time quantitative reverse transcriptase-polymerase chain reaction assays, respectively.
   Results: No significant changes within the analyzed parameters were found in the first or fourth weeks after ranibizumab injection compared with the primary, basic values before treatment. Based on our findings, intravitreal ranibizumab does not induce significant systemic effects or vascular impairment.
   Conclusions: Evaluation of the VEGF plasma level, the PB EPC concentration, and intracellular HIF expression may be supportive indicators of drug safety for ranibizumab.
C1 [Machalinska, Anna] Pomeranian Med Univ, Dept Histol & Embryol, PL-70111 Szczecin, Poland.
   [Machalinska, Anna; Pabin, Tomasz; Karczewicz, Danuta] Pomeranian Med Univ, Dept Ophthalmol, PL-70111 Szczecin, Poland.
   [Paczkowska, Edyta; Machalinski, Boguslaw] Pomeranian Med Univ, Dept Gen Pathol, PL-70111 Szczecin, Poland.
   [Safranow, Krzysztof] Pomeranian Med Univ, Dept Biochem & Med Chem, PL-70111 Szczecin, Poland.
C3 Pomeranian Medical University; Pomeranian Medical University; Pomeranian
   Medical University; Pomeranian Medical University
RP Machalinska, A (通讯作者)，Pomeranian Med Univ, Dept Histol & Embryol, Powstancow Wlkp 72, PL-70111 Szczecin, Poland.
EM annam@sci.pam.szczecin.pl; machalin@sci.pam.szczecin.pl
RI Paczkowska, Edyta/N-1209-2014; Machaliński, Bogusław/P-3025-2014;
   Machalinska, Anna/P-6701-2014; Safranow, Krzysztof/B-5127-2015;
   Paczkowska, Edyta/AAX-2347-2021
OI Paczkowska, Edyta/0000-0001-7052-9741; Safranow,
   Krzysztof/0000-0001-9415-2758; Machalinski, Boguslaw/0000-0002-6013-0419
FU Polish Ministry of Science and Higher Education [N N402 172137]
FX This work was supported by the Polish Ministry of Science and Higher
   Education (grant number: N N402 172137 to AM).
CR Abouammoh M, 2011, CURR OPIN OPHTHALMOL, V22, P152, DOI 10.1097/ICU.0b013e32834595d0
   Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014
   Gamulescu MA, 2010, J OCUL PHARMACOL TH, V26, P213, DOI 10.1089/jop.2009.0126
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Hunting CB, 2005, VOX SANG, V88, P1, DOI 10.1111/j.1423-0410.2005.00589.x
   Kourlas H, 2007, CLIN THER, V29, P1850, DOI 10.1016/j.clinthera.2007.09.008
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Miller-Kasprzak E, 2007, ARCH IMMUNOL THER EX, V55, P247, DOI 10.1007/s00005-007-0027-5
   Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4
   Pelle G, 2011, AM J KIDNEY DIS, V57, P756, DOI 10.1053/j.ajkd.2010.11.030
   Prater DN, 2007, LEUKEMIA, V21, P1141, DOI 10.1038/sj.leu.2404676
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2010, EXPERT OPIN DRUG SAF, V9, P149, DOI 10.1517/14740330903418422
   Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003
   Wu ZQ, 2008, ANN ACAD MED SINGAP, V37, P591
NR 18
TC 8
Z9 8
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD OCT
PY 2011
VL 27
IS 5
BP 471
EP 475
DI 10.1089/jop.2011.0091
PG 5
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 841GP
UT WOS:000296501100008
PM 21830945
DA 2022-11-30
ER

PT J
AU Jonasson, F
   Fisher, DE
   Eiriksdottir, G
   Sigurdsson, S
   Klein, R
   Launer, LJ
   Harris, T
   Gudnason, V
   Cotch, MF
AF Jonasson, Fridbert
   Fisher, Diana E.
   Eiriksdottir, Gudny
   Sigurdsson, Sigurdur
   Klein, Ronald
   Launer, Lenore J.
   Harris, Tamara
   Gudnason, Vilmundur
   Cotch, Mary Frances
TI Five-Year Incidence, Progression, and Risk Factors for Age-Related
   Macular Degeneration The Age, Gene/Environment Susceptibility Study
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL IMPAIRMENT; 4-YEAR INCIDENCE; MACULOPATHY; PREVALENCE; REYKJAVIK;
   OLDER; ASSOCIATION; BLINDNESS; CHOLESTEROL; ICELANDERS
AB Objective: To investigate the incidence and progression of age-related macular degeneration (AMD) and associated risk factors.
   Design: Population-based, prospective, cohort study.
   Participants: We included 2868 participants from the Age Gene/Environment Susceptibility-Reykjavik Study with retinal data at baseline and 5-year follow-up.
   Methods: Digital macular photographs were graded for presence of AMD. Participants completed a questionnaire and extensive clinical battery. Biomarkers were assessed. Risk factors for AMD were analyzed using multivariate regression analysis with odds ratios (ORs) and 95% CIs.
   Main Outcome Measures: We assessed AMD, defined as early or late.
   Results: Among 2196 participants free of AMD at baseline, 14.9% developed incident AMD. In multivariate models, incident AMD was significantly associated with age (OR per year, 1.14; 95% CI, 1.11-1.17), current smoking (OR, 2.07; 95% CI, 1.38-3.11), former smoking (OR, 1.36; 95% CI, 1.04-1.79), plasma high-density lipoprotein (HDL) cholesterol level (OR, 1.62 per mmol/L; 95% CI, 1.19-2.22), and body mass index (BMI; OR, 1.04 per kg/m(2); 95% CI, 1.01-1.07). Among 563 participants with early AMD at baseline, 22.7% progressed to late AMD (11.0% pure geographic atrophy [GA] and 11.7% exudative AMD). On multivariate analyses, age was significantly associated with progression to GA (OR 1.14; 95% CI, 1.07-1.21) and exudative AMD (OR, 1.08; 95% CI, 1.01-1.14). Adjusting for age, female sex was associated with exudative AMD (OR, 2.10; 95% CI, 1.10-3.98) and plasma HDL cholesterol with GA (OR, 2.03 per mmol/L; 95% CI, 1.02-4.05).
   Conclusions: By age 85, 57.4% of participants had signs of AMD. Age, smoking, plasma HDL cholesterol, BMI, and female sex are associated with AMD. Elevated HDL cholesterol is associated with GA development. (C) 2014 American Academy of Ophthalmology.
C1 [Jonasson, Fridbert] Landspitali Univ Hosp, Dept Ophthalmol, Reykjavik, Iceland.
   [Jonasson, Fridbert; Gudnason, Vilmundur] Univ Iceland, Fac Med, IS-101 Reykjavik, Iceland.
   [Fisher, Diana E.; Cotch, Mary Frances] NEI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA.
   [Eiriksdottir, Gudny; Sigurdsson, Sigurdur; Gudnason, Vilmundur] Iceland Heart Assoc, Kopavogur, Iceland.
   [Klein, Ronald] Univ Wisconsin, Madison, WI USA.
   [Launer, Lenore J.; Harris, Tamara] NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, Bethesda, MD 20892 USA.
C3 Landspitali National University Hospital; University of Iceland;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Icelandic Heart Association; University of Wisconsin System;
   University of Wisconsin Madison; National Institutes of Health (NIH) -
   USA; NIH National Institute on Aging (NIA)
RP Jonasson, F (通讯作者)，Univ Iceland, IS-101 Reykjavik, Iceland.
EM fridbert@landspitali.is
RI Jonasson, Fridbert/ABA-9889-2021; Gudnason, Vilmundur/AAE-7126-2019;
   Gudnason, Vilmundur/K-6885-2015
OI Gudnason, Vilmundur/0000-0001-5696-0084; Gudnason,
   Vilmundur/0000-0001-5696-0084; Cotch, Mary Frances/0000-0002-2046-4350
FU National Institute of Health (Intramural Research Program of the
   National Institute of Aging and the National Eye Institute)
   [ZIAEY00401]; National Institute of Health [N01-AG-1-2100]; Icelandic
   Heart Association; Icelandic Parliament; University of Iceland Research
   Fund; Helga Jonsdottir and Sigurlidi Kristjansson Research Fund;
   NATIONAL EYE INSTITUTE [ZIAEY000401] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGING [ZIAAG007380] Funding Source: NIH RePORTER
FX Supported by the National Institute of Health (Intramural Research
   Program of the National Institute of Aging and the National Eye
   Institute, ZIAEY00401), National Institute of Health contract number
   N01-AG-1-2100, the Icelandic Heart Association, the Icelandic
   Parliament, the University of Iceland Research Fund, and the Helga
   Jonsdottir and Sigurlidi Kristjansson Research Fund. The funders had no
   role in data collection, management, analysis and interpretation of the
   data, preparation, writing and approval of the manuscript, and decision
   to submit the manuscript for publication.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Aspelund T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013957
   Barter PJ, 2004, CIRC RES, V95, P764, DOI 10.1161/01.RES.0000146094.59640.13
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Gunnlaugsdottir E, 2008, ACTA OPHTHALMOL, V86, P778, DOI 10.1111/j.1755-3768.2008.01191.x
   Gunnlaugsdottir E, 2010, ACTA OPHTHALMOL, V88, P358, DOI 10.1111/j.1755-3768.2008.01445.x
   Harris TB, 2007, AM J EPIDEMIOL, V165, P1076, DOI 10.1093/aje/kwk115
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Mora S, 2013, CIRCULATION, V128, P1189, DOI 10.1161/CIRCULATIONAHA.113.002671
   Qiu CX, 2008, DIABETES, V57, P1645, DOI 10.2337/db07-1455
   Qiu CX, 2012, NEUROBIOL AGING, V33, P2935, DOI 10.1016/j.neurobiolaging.2012.01.012
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Varma R, 2010, AM J OPHTHALMOL, V149, P741, DOI 10.1016/j.ajo.2010.01.009
   Voight BF, 2012, LANCET, V380, P572, DOI 10.1016/S0140-6736(12)60312-2
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
NR 44
TC 57
Z9 58
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2014
VL 121
IS 9
BP 1766
EP 1772
DI 10.1016/j.ophtha.2014.03.013
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO2KY
UT WOS:000341151800027
PM 24768241
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Krishnaiah, S
   Das, T
   Nirmalan, PK
   Nutheti, R
   Shamanna, BR
   Rao, GN
   Thomas, R
AF Krishnaiah, S
   Das, T
   Nirmalan, PK
   Nutheti, R
   Shamanna, BR
   Rao, GN
   Thomas, R
TI Risk factors for age-related macular degeneration: Findings from the
   Andhra Pradesh Eye Disease Study in South India
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BLUE-MOUNTAINS EYE; BEAVER DAM EYE; ARAVIND COMPREHENSIVE EYE; LENS
   OPACITIES; VISUAL IMPAIRMENT; RURAL-POPULATION; CATARACT-SURGERY;
   ANTERIOR CHAMBER; POOLED FINDINGS; MACULOPATHY
AB PURPOSE. To assess prevalence, potential risk factors, and population attributable risk percentage (PAR%) for age-related macular degeneration (AMD) in the Indian state of Andhra Pradesh.
   METHODS. A population-based study, using a stratified, random, cluster, systematic sampling strategy, was conducted in the state of Andhra Pradesh in India from 1996 to 2000. Participants from 94 clusters in one urban and three rural areas representative of the population of Andhra Pradesh underwent a detailed interview and a detailed dilated ocular evaluation by trained professionals. In this report, the authors present the prevalence estimates of AMD and examine the association of AMD with potential risk factors in persons aged 40 to 102 years (n = 3723). AMD was defined according to the international classification and grading system. Standard bivariate and multivariate analyses were performed to identify the potential risk factors for AMD. PAR% was calculated by Levin's formula.
   RESULTS. AMD was present in 71 subjects-an age-gender-area adjusted prevalence of 1.82% (95% confidence interval [CI], 1.39%-2.25%). Risk factors that were significant in bivariate analyses were considered for multivariate logistic regression analysis. Multivariate analysis showed that the adjusted prevalence of AMD was significantly higher in those 60 years of age or older (odds ratio [OR], 3.55; 95% CI, 1.61-7.82) and history of prior cigar smoking (OR, 3.29; 95% CI, 1.42-7.57). Presence of cortical cataract and prior cataract surgery were significantly associated with increased prevalence of AMD (adjusted OR, 2.87; 95% CI, 1.57-5.26 and 3.79; 95% CI, 2.1-6.78), respectively. The prevalence of AMD was significantly lower in light alcohol drinkers (adjusted OR, 0.38; 95% CI, 0.19-0.76) compared with nondrinkers. The PAR% for hypertension and heavy cigar smoking was 10% and 14%, respectively, in this population.
   CONCLUSIONS. The prevalence of AMD in this south Indian population is similar to those reported in other developed countries. Abstinence from smoking may reduce the risk of AMD in this population.
C1 LV Prasad Eye Inst, Hyderabad 500034, Andhra Pradesh, India.
C3 L. V. Prasad Eye Institute
RP Krishnaiah, S (通讯作者)，LV Prasad Eye Inst, Banjara Hills, Hyderabad 500034, Andhra Pradesh, India.
EM krishnaiah@lvpei.org
RI Thomas, Ravi/A-3377-2011
OI Thomas, Ravi/0000-0003-0341-341X; Nirmalan, Praveen/0000-0003-0655-8104
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BELL SF, 2005, AM J OPHTHALMOL, V139, P30
   BENNETT S, 1991, World Health Statistics Quarterly, V44, P98
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Dandona L, 1998, LANCET, V351, P1312, DOI 10.1016/S0140-6736(97)09509-3
   Dandona L, 2001, INVEST OPHTH VIS SCI, V42, P908
   Dandona R, 2002, BRIT J OPHTHALMOL, V86, P373, DOI 10.1136/bjo.86.4.373
   Dandona Rakhi, 1997, Indian Journal of Ophthalmology, V45, P251
   DELANEY WV, 1982, ANN OPHTHALMOL, V14, P21
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Hafron J, 2005, J UROLOGY, V173, P1513, DOI 10.1097/01.ju.0000154352.54965.14
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   HYMAN L, 2003, CURR OPIN OPHTHALMOL, V13, P171
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   KAHN HS, 1997, AM J EPIDEMIOL, V106, P33
   KAUNISTO RMV, 2000, DIABETES CARE, V23, P1672
   Khan SA, 2002, CLIN EXP OPHTHALMOL, V30, P404, DOI 10.1046/j.1442-9071.2002.00569.x
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   KLEIN R, 1998, AGE RELATED MACULAR, P31
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   KORNZWEIG AL, 1977, ANN OPHTHALMOL, V9, P753
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Maguire MG, 1999, AGE RELATED MACULAR, P17
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Nirmalan PK, 2003, INVEST OPHTH VIS SCI, V44, P4639, DOI 10.1167/iovs.03-0011
   NORTHRIDGE ME, 1995, AM J PUBLIC HEALTH, V85, P1202, DOI 10.2105/AJPH.85.9.1202
   Obisesan TO, 1998, J AM GERIATR SOC, V46, P1
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   PEARCE N, 1989, INT J EPIDEMIOL, V18, P976, DOI 10.1093/ije/18.4.976
   Rockhill B, 1998, AM J PUBLIC HEALTH, V88, P15, DOI 10.2105/AJPH.88.1.15
   ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P84
   SCHEIE HG, 1957, ARCH OPHTHALMOL-CHIC, V58, P510, DOI 10.1001/archopht.1957.00940010526005
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   SPERDUTO RD, 1981, ARCH OPHTHALMOL-CHIC, V99, P1004
   Taylor H, 1988, LENS RES, V5, P175
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   VANHERICK W, 1969, AM J OPHTHALMOL, V68, P626, DOI 10.1016/0002-9394(69)91241-0
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
NR 59
TC 91
Z9 93
U1 1
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2005
VL 46
IS 12
BP 4442
EP 4449
DI 10.1167/iovs.05-0853
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 988FV
UT WOS:000233578600014
PM 16303932
DA 2022-11-30
ER

PT J
AU La, TY
   Cho, E
   Kim, EC
   Kang, S
   Jee, D
AF La, Tae Yoon
   Cho, Eunyoung
   Kim, Eun Chul
   Kang, Seungbum
   Jee, Donghyun
TI Prevalence and Risk Factors for Age-Related Macular Degeneration: Korean
   National Health and Nutrition Examination Survey 2008-2011
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Korean; prevalence; risk factor;
   smoking
ID PRADESH EYE DISEASE; CARDIOVASCULAR-DISEASE; JAPANESE POPULATION;
   ADULT-POPULATION; MACULOPATHY; INDIA
AB Purpose: To evaluate the prevalence of and risk factors for age-related macular degeneration (AMD) in a representative Korean population.
   Materials and Methods: A nationwide population-based cross-sectional study was conducted among the civilian, noninstitutionalized Korean population aged 40 and older (mean age, 55.7 years; 95% confidence interval [CI], 55.4-56.0). A total of 16,109 older (>= 40 years of age) subjects participated in the Korean National Health and Nutrition Survey 2008-2011. All participants underwent standardized interviews and comprehensive ophthalmic examinations. Using physiologic mydriasis, a 45 degrees digital fundus photograph was taken of both eyes of each participant. All fundus photographs were graded according to an international classification and grading system. Main outcome measures consisted of prevalence of early-and late-AMD.
   Results: Of the 16,109 subjects, fundus photographs were gradable for 14,352 (89.1%). The prevalence of early- and late-AMD in the Korean population was 6.0 and 0.6%, respectively. The prevalence of early-AMD increased from 1.5% in those aged 40-49 years to 16.2% in those aged >= 70 years. After adjusting for confounders, the prevalence of early-AMD increased with increasing age (odds ratio [OR], 1.08; CI, 1.06-1.09). For late-AMD, old age (OR, 1.09; CI, 1.04-1.14), male gender (OR, 2.45; CI, 1.11-5.37), high systolic blood pressure (OR, 1.03; CI, 1.00-1.06) and high fasting glucose level (OR, 0.97; CI, 0.94-0.99) were significant risk factors. Smoking was not associated with either early-or late-AMD in this Korean population.
   Conclusions: The present study provides the first population-based data on the prevalence of and risk factors for AMD in a representative Korean population. The prevalences of early-and late-AMD in this population were 6.0 and 0.6%, respectively. The prevalence of AMD in Koreans is higher than for those in other Asian countries and similar to that of Caucasians in Western countries.
C1 [La, Tae Yoon; Jee, Donghyun] St Vincents Hosp, Dept Ophthalmol & Visual Sci, Suwon, South Korea.
   [Cho, Eunyoung] Brigham & Womens Hosp, Channing Div Network Med, Suwon, South Korea.
   [Cho, Eunyoung] Harvard Univ, Sch Med, Suwon, South Korea.
   [Kim, Eun Chul] St Marys Hosp, Dept Ophthalmol & Visual Sci, Suwon, South Korea.
   [Kang, Seungbum] Catholic Univ Korea, Coll Med, Daejon St Marys Hosp, Dept Ophthalmol & Visual Sci, Suwon, South Korea.
C3 Catholic University of Korea; Catholic University Korea Hospital;
   Catholic University of Korea
RP Jee, D (通讯作者)，Catholic Univ Korea, Coll Med, St Vincents Hosp, Dept Ophthalmol & Visual Sci, 93-6 Ji Dong, Suwon 442723, Gyeonggi Do, South Korea.
EM donghyunjee@catholic.ac.kr
RI Cho, Eunyoung/AAV-4469-2020
OI Cho, Eunyoung/0000-0001-6594-2582
FU Industry-Academic Cooperation Foundation in Medical College, Catholic
   University of Korea [5-2013-D0383-00002]
FX This study was supported in part by a fund from Industry-Academic
   Cooperation Foundation (5-2013-D0383-00002) in Medical College, Catholic
   University of Korea.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Coleman AL, 2010, AM J OPHTHALMOL, V149, P160, DOI 10.1016/j.ajo.2009.07.025
   Coleman HR, 2011, AGE-RELATED MACULAR DEGENERATION DIAGNOSIS AND TREATMENT, P15, DOI 10.1007/978-1-4614-0125-4_2
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kim I K, 1996, J Cross Cult Gerontol, V11, P369, DOI 10.1007/BF00115802
   Kim Yangho, 2013, J Prev Med Public Health, V46, P96, DOI 10.3961/jpmph.2013.46.2.96
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Krishnaiah S, 2009, BRIT J OPHTHALMOL, V93, P1146, DOI 10.1136/bjo.2009.159723
   Lechanteur YTE, 2012, INVEST OPHTH VIS SCI, V53, P5846, DOI 10.1167/iovs.11-7731
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Park HA, 2013, KOREAN J FAM MED, V34, P79, DOI 10.4082/kjfm.2013.34.2.79
   Park SH, 2010, INT J CARDIOL, V139, P234, DOI 10.1016/j.ijcard.2008.10.011
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
NR 30
TC 23
Z9 23
U1 0
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD DEC
PY 2014
VL 39
IS 12
BP 1232
EP 1239
DI 10.3109/02713683.2014.907431
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AT2MJ
UT WOS:000344768600013
PM 24754248
DA 2022-11-30
ER

PT J
AU Yan, Y
   Jin, K
   Gao, ZY
   Huang, XL
   Wang, FY
   Wang, Y
   Ye, J
AF Yan, Yan
   Jin, Kai
   Gao, Zhiyuan
   Huang, Xiaoling
   Wang, Fanyi
   Wang, Yao
   Ye, Juan
TI Attention-based deep learning system for automated diagnoses of
   age-related macular degeneration in optical coherence tomography images
SO MEDICAL PHYSICS
LA English
DT Article
DE age-related macular degeneration; attention mechanism; deep learning;
   optical coherence tomography
ID DISEASES
AB Purpose The progression of age-related macular degeneration (AMD) is critical to treatment decisions in clinical practice. The disease can be classified into four categories namely, drusen, inactive choroidal neovascularization (CNV), active CNV, and normal, according to severity based on optical coherence tomography (OCT) images. Interpreting numerous OCT images is still time-consuming and labor-intensive, especially for the detection of the CNV activity. To address this problem, we developed a deep learning (DL) system based on OCT images, with the assistance of an attention mechanism, to automatically diagnose AMD. Methods A public dataset (total 51,140 OCT images) and a private dataset (total 4951 OCT images) were utilized as a training dataset and a clinical validation dataset, respectively, to develop the DL model. A ResNet-34 DL model, with convolutional block attention module (CBAM) block integrated into each unit, was pretrained on the public dataset first and then finetuned on our private dataset to automatically diagnose AMD and assist clinical decision-making. GradCam, a visualization technique, was used to improve the interpretability of our model. Results The precision and recall of our model were, respectively, 84.3% and 87.3% for drusen, 81.2% and 80.0% for inactive CNV, 97.7% and 90.2% for active CNV, and 93.7% and 96.5% for normal. The area under the curve (AUC) corresponding to drusen, inactive CNV, active CNV, and normal for our model reached 0.9395, 0.9476, 0.9880, and 0.9925, respectively. The heatmaps indicated a high level of correspondence in the region of interest between our model and ophthalmologists on the diagnosis. Conclusions The implementation of finetuning and attention mechanism improve the performance of our model in a distinct dataset. Our model successfully assisted in the diagnosis of AMD and achieved a detection precision and recall equal to those of ophthalmologists. The results of our study could contribute to the precise diagnosis of and decision-making regarding AMD.
C1 [Yan, Yan; Jin, Kai; Gao, Zhiyuan; Huang, Xiaoling; Wang, Yao; Ye, Juan] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Ophthalmol, Hangzhou 310009, Peoples R China.
   [Wang, Fanyi] Zhejiang Univ, State Key Lab Modern Opt Instrumentat, Dept Opt Engn, Hangzhou 310027, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Wang, Y; Ye, J (通讯作者)，Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Ophthalmol, Hangzhou 310009, Peoples R China.
EM wangyao@zju.edu.cn; yejuan@zju.edu.cn
FU National Key Research and Development Program of China [2019YFC0118401];
   Zhejiang Provincial Key Research and Development Plan [2019C03020];
   Natural Science Foundation of Zhejiang Province [LQ21H120002]; Medical
   and Health Science and Technology Program of Zhejiang Province
   [2021RC064]; Natural Science Foundation of China [81670888]
FX National Key Research and Development Program of China, Grant/Award
   Number: 2019YFC0118401; Zhejiang Provincial Key Research and Development
   Plan, Grant/Award Number: 2019C03020; Natural Science Foundation of
   Zhejiang Province, Grant/Award Number: LQ21H120002; Medical and Health
   Science and Technology Program of Zhejiang Province, Grant/Award Number:
   2021RC064; Natural Science Foundation of China, Grant/Award Number:
   81670888
CR Alqudah AM, 2020, MED BIOL ENG COMPUT, V58, P41, DOI 10.1007/s11517-019-02066-y
   Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   Bian W, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-031020
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Gualino V, 2019, RETINA-J RET VIT DIS, V39, P1664, DOI 10.1097/IAE.0000000000002220
   He K., 2016, P IEEE COMPUTER SOC, P630, DOI DOI 10.1109/CVPR.2016.90
   Hwang DK, 2019, THERANOSTICS, V9, P232, DOI 10.7150/thno.28447
   Kermany Daniel, 2018, Mendeley Data, V3, DOI 10.17632/RSCBJBR9SJ.3
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Li F, 2019, BIOMED OPT EXPRESS, V10, P6204, DOI 10.1364/BOE.10.006204
   Li L, 2020, IEEE T MED IMAGING, V39, P413, DOI 10.1109/TMI.2019.2927226
   Lu W, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.6.41
   Miotto S, 2018, J OCUL PHARMACOL TH, V34, P298, DOI 10.1089/jop.2017.0022
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Ravera V, 2019, RETINA-J RET VIT DIS, V39, P281, DOI 10.1097/IAE.0000000000001960
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Selvaraju RR, 2020, INT J COMPUT VISION, V128, P336, DOI 10.1007/s11263-019-01228-7
   Sun YK, 2020, J BIOMED OPT, V25, DOI 10.1117/1.JBO.25.9.096004
   Volz C, 2019, OPHTHALMOLOGICA, V241, P32, DOI 10.1159/000489344
   Wang J, 2020, IEEE T MED IMAGING, V39, P2572, DOI 10.1109/TMI.2020.2994908
   Woo SH, 2018, LECT NOTES COMPUT SC, V11211, P3, DOI 10.1007/978-3-030-01234-2_1
   Zhang J., 2019, IEEE T MED IMAGING, V1
   ZHOU B, 2016, PROC CVPR IEEE, P2921, DOI DOI 10.1109/CVPR.2016.319
NR 23
TC 3
Z9 3
U1 4
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0094-2405
EI 2473-4209
J9 MED PHYS
JI Med. Phys.
PD SEP
PY 2021
VL 48
IS 9
BP 4926
EP 4934
DI 10.1002/mp.15002
EA AUG 2021
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA WG2RF
UT WOS:000682959000001
PM 34042194
DA 2022-11-30
ER

PT J
AU Gill, K
   Mao, A
   Powell, AM
   Sheidow, T
AF Gill, K.
   Mao, A.
   Powell, A. M.
   Sheidow, T.
TI Digital reader vs print media: the role of digital technology in reading
   accuracy in age-related macular degeneration
SO EYE
LA English
DT Article
DE low vision; macular degeneration; reading speed/accuracy; digital
   devices
ID LOW-VISION AIDS; VISUAL IMPAIRMENT; EYE; RANIBIZUMAB; PREVALENCE; ANCHOR
AB Purpose To compare patient satisfaction, reading accuracy, and reading speed between digital e-readers (Sony eReader, Apple iPad) and standard paper/print media for patients with stable wet age-related macular degeneration (AMD).
   Methods Patients recruited for the study were patients with stable wet AMD, in one or both eyes, who would benefit from a low-vision aid. The selected text sizes by patients reflected the spectrum of low vision in regard to their macular disease. Stability of macular degeneration was assessed on a clinical examination with stable visual acuity. Patients recruited for the study were assessed for reading speeds on both digital readers and standard paper text. Standardized and validated texts for reading speeds were used. Font sizes in the study reflected a spectrum from newsprint to large print books. Patients started with the smallest print size they could read on the standardized paper text. They then used digital readers to read the same size standardized text. Reading speed was calculated as words per minute by the formula (correctly read words/reading time (s).60). The visual analog scale was completed by patients after reading each passage. These included their assessment on 'ease of use' and 'clarity of print' for each device and the print paper.
   Results A total of 27 patients were used in the study. Patients consistently read faster (P < 0.0003) on the Apple iPad with larger text sizes (size 24 or greater) when compared with paper, and also on the paper compared with the Sony eReader (P < 0.03) in all text group sizes. Patients chose the iPad to have the best clarity and the print paper as the easiest to use.
   Conclusions This study has demonstrated that digital devices may have a use in visual rehabilitation for low-vision patients. Devices that have larger display screens and offer high contrast ratios will benefit AMD patients who require larger texts to read.
C1 [Gill, K.; Mao, A.; Powell, A. M.; Sheidow, T.] Univ Western Ontario, Dept Ophthalmol, London, ON N6A 4V2, Canada.
C3 Western University (University of Western Ontario)
RP Gill, K (通讯作者)，Univ Western Ontario, St Josephs Hosp, Ivey Eye Inst, 268 Grosvenor St,POB 5777, London, ON N6A 4V2, Canada.
EM kulbir.gill@gmail.com
OI Sheidow, Tom/0000-0001-6370-1857
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Crossland MD, 2010, BRIT J OPHTHALMOL, V94, P1109, DOI 10.1136/bjo.2009.170167
   DANA MR, 1990, JAMA-J AM MED ASSOC, V264, P2400, DOI 10.1001/jama.264.18.2400
   Hahn GA, 2006, BRIT J OPHTHALMOL, V90, P480, DOI 10.1136/bjo.2005.087379
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Keane PA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/483034
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Lillakas L, 2011, ARVO
   Lockyer S, 2005, HEALTH INFO LIBR J, V22, P243, DOI 10.1111/j.1471-1842.2005.00616.x
   Nguyen NX, 2009, ACTA OPHTHALMOL, V87, P849, DOI 10.1111/j.1755-3768.2008.01423.x
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Rubin GS, 2001, EYE, V15, P430, DOI 10.1038/eye.2001.148
   Zechmeister-Koss I, 2012, BRIT J OPHTHALMOL, V96, P167, DOI 10.1136/bjophthalmol-2011-300674
NR 16
TC 31
Z9 31
U1 0
U2 51
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD MAY
PY 2013
VL 27
IS 5
BP 639
EP 643
DI 10.1038/eye.2013.14
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 140XF
UT WOS:000318689100010
PM 23492860
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Despreaux, R
   Cohen, SY
   Semoun, O
   Zambrowski, O
   Jung, C
   Oubraham, H
   Souied, EH
AF Despreaux, Raphaelle
   Cohen, Salomon Y.
   Semoun, Oudy
   Zambrowski, Olivia
   Jung, Camille
   Oubraham, Hassiba
   Souied, Eric H.
TI Short-term results of switchback from aflibercept to ranibizumab in
   neovascular age-related macular degeneration in clinical practice
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization; Switch;
   Switchback; Anti-VEGF; Ranibizumab; Aflibercept
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; ANTI-VEGF THERAPY; INTRAVITREAL
   AFLIBERCEPT; ANATOMICAL OUTCOMES; TACHYPHYLAXIS; BEVACIZUMAB; EYES;
   RESPONDERS; CONVERSION; INJECTION
AB This work was undertaken to analyze the efficacy of switchback from aflibercept to ranibizumab in patients with neovascular age-related macular degeneration (nAMD) who had previously switched from ranibizumab to aflibercept.
   This retrospective double-center study included 45 patients with nAMD who were previously treated with ranibizumab, then aflibercept, and then ranibizumab again, regardless of the number of intravitreal injections received. The primary outcome was change in best-corrected visual acuity (BCVA) measured on the Early Treatment Diabetic Retinopathy Study ETDRS chart before (T0) and after (T1) the switch, and 3 months after the switchback (T2). Secondary outcomes included changes in central foveal thickness (CFT) measured at T0, T1, and T2, as analyzed on spectral-domain optical coherence tomography (SD-OCT), and the percentage of patients gaining five letters or better.
   Forty-seven eyes of 45 patients were switched back from aflibercept to ranibizumab. The mean BCVA was 67.4 +/- 13.4 at T0, 66.7 +/- 14.4 at T1, and 68.2 +/- 13.9 at T2. BCVA was significantly improved between T1 and T2 (p = 0.0230), but not between T0 and T1 (p = 0.5153) or between T0 and T2 (p = 0.4248). The mean CFT decreased from 317.8 mu m +/- 89.6 at T0 to 306.9 mu m +/- 68.0 at T1, and to 291.2 mu m +/- 76.6 at T2. The decrease in CFT was not statistically significant between either T0 and T1 or T1 and T2, but was significant between T0 and T2, when compared before switch and after switchback (p = 0.0027). However, when considering eyes that received three or more consecutive intravitreal injections of aflibercept before switchback, the statistical significance between T1 and T2 was lost, although a trend towards significance remained (p = 0.06). Thirteen eyes (27.7 %) gained five letters or more (range, 5-15 letters) after switchback.
   A short-term benefit of switchback from one anti-VEGF agent to another was observed in patients with nAMD who had shown no benefit from the initial switch.
C1 [Despreaux, Raphaelle; Cohen, Salomon Y.; Semoun, Oudy; Zambrowski, Olivia; Oubraham, Hassiba; Souied, Eric H.] Univ Paris Est Creteil, Hop Intercommunal Creteil, Fac Med Henri Mondor, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
   [Cohen, Salomon Y.] Ctr Ophtalmol Imagerie & Laser, Paris, France.
   [Jung, Camille; Souied, Eric H.] Univ Paris Est Creteil, Hop Intercommunal Creteil, Fac Med Henri Mondor, Ctr Ressources Biol,Ctr Rech Clin, 40 Ave Verdun, F-94000 Creteil, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; CHI Creteil; Assistance Publique Hopitaux Paris
   (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital
   Universitaire Henri-Mondor - APHP; CHI Creteil
RP Cohen, SY (通讯作者)，Univ Paris Est Creteil, Hop Intercommunal Creteil, Fac Med Henri Mondor, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.; Cohen, SY (通讯作者)，Ctr Ophtalmol Imagerie & Laser, Paris, France.
EM sycsyc75@gmail.com
OI JUNG, Camille/0000-0001-8486-8939
FU CIL-ASSOC (Paris, France)
FX This work was supported by an unrestricted grant from CIL-ASSOC (Paris,
   France), a research and education association. The funding organization
   had no role in the design or conduct of this research.
CR [Anonymous], 2012, DEGENERESCENCE MACUL
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Cohen SY, 2011, GRAEF ARCH CLIN EXP, V249, P521, DOI 10.1007/s00417-010-1553-0
   Eadie JA, 2014, OSLI RETINA, V45, P394, DOI 10.3928/23258160-20140909-03
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Ferrone PJ, 2014, BRIT J OPHTHALMOL, V98, P17, DOI 10.1136/bjophthalmol-2013-304474
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P155
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Miura M, 2013, CLIN OPHTHALMOL, V7, P1591, DOI 10.2147/OPTH.S50634
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 23
TC 19
Z9 21
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2016
VL 254
IS 4
BP 639
EP 644
DI 10.1007/s00417-015-3084-1
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DH2IJ
UT WOS:000372608100004
PM 26092633
DA 2022-11-30
ER

PT J
AU Do, DV
AF Do, Diana V.
TI Implications of the Comparisons of Age-Related Macular Degeneration
   Treatments Trials on Clinical Practice What Have We Learned?
SO OPHTHALMOLOGY
LA English
DT Article
AB Topic: Discussion of Comparisons of Age-Related Macular Degeneration (AMD) Treatments Trials (CATT) results and the potential impact on neovascular AMD treatment.
   Clinical Relevance: Ranibizumab and bevacizumab are most commonly used for treatment of neovascular AMD. Although bevacizumab costs less, its use primarily has been based on retrospective studies without level 1 medical evidence. Thus, there was an unmet need to determine whether there is any difference in efficacy and safety between the 2 agents when used monthly or as needed (pro re nata [PRN]).
   Methods: Review of CATT (focusing on 1-year data because 2-year data were not released at the time of this symposium), a randomized clinical trial evaluating the efficacy and safety of monthly and PRN dosing of ranibizumab and bevacizumab.
   Results: At the 1-year primary end point, eyes that received monthly ranibizumab gained an average of 8.5 letters; those that received monthly bevacizumab gained a mean of 8 letters. Eyes randomized to PRN ranibizumab gained an average of 6.8 letters; those randomized to PRN bevacizumab gained a mean of 5.9 letters. In the pairwise comparisons, PRN bevacizumab compared with monthly bevacizumab and PRN bevacizumab compared with monthly ranibizumab both were found to be inconclusive. At the 2-year end point, eyes that received monthly ranibizumab gained an average of 8.8 letters; those that received monthly bevacizumab gained a mean of 7.8 letters; those randomized to PRN ranibizumab gained an average of 6.7 letters; those randomized to PRN bevacizumab gained a mean of 5 letters. A higher rate of serious systemic adverse events also was detected among bevacizumab-treated subjects.
   Conclusions: The CATT demonstrated that PRN ranibizumab is equivalent to monthly ranibizumab at the 1-year primary outcome. Monthly bevacizumab also is equivalent to monthly ranibizumab at the 1-year end point. The 2-year data showed less visual acuity gain with PRN dosing of either drug than monthly dosing.
C1 [Do, Diana V.] Johns Hopkins Univ Hosp, Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Do, DV (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Eye Inst, 600 North Wolfe St,Maumenee Bldg 745, Baltimore, MD 21287 USA.
EM ddo@jhmi.edu
FU Genentech, Inc.; Heidelberg Engineering; Regeneron Pharmaceuticals,
   Inc.; Abbott Laboratories; Lux Biosciences; Novartis Pharmaceuticals
   Corporation; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc, Tarrytown, NY
FX Diana V. Do - Financial support - Genentech, Inc., Heidelberg
   Engineering, and Regeneron Pharmaceuticals, Inc.; Consultant/advisory
   board member - ISTA Pharmaceuticals; Quan Dong Nguyen (Dr. Do's spouse)
   - Financial support - Abbott Laboratories, Genentech, Inc., Heidelberg
   Engineering, Lux Biosciences, Novartis Pharmaceuticals Corporation,
   Pfizer, Inc., and Regeneron Pharmaceuticals, Inc.; Consultant - Bausch &
   Lomb and Santen Pharmaceutical, Inc.; Supported by an educational grant
   from Regeneron Pharmaceuticals, Inc, Tarrytown, NY.
CR Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Dasgupta A, 2010, AM J HEALTH-SYST PH, V67, P1337, DOI 10.2146/ajhp090507
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mousa SA, 2010, BIODRUGS, V24, P183, DOI 10.2165/11318550-000000000-00000
   National Eye Institute, AV LUC AR EQ TREAT A
NR 7
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2013
VL 120
IS 5
SU S
BP S8
EP S10
DI 10.1016/j.ophtha.2013.01.058
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 140UW
UT WOS:000318682500003
PM 23642785
DA 2022-11-30
ER

PT J
AU Kim, SJ
   Lee, SJ
   Kim, NR
   Chin, HS
AF Kim, Suk Jin
   Lee, Soo Jeong
   Kim, Na Rae
   Chin, Hee Seung
TI Association of polymorphisms in C2, CFB and C3 with exudative
   age-related macular degeneration in a Korean population
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; polymorphisms; complement component 2;
   complement factor B; complement component 3
ID COMPLEMENT-FACTOR-H; FACTOR-B; GENE POLYMORPHISMS; COMPONENT 2;
   NONCODING VARIANT; RISK; SUSCEPTIBILITY; HTRA1; DRUSEN; MACULOPATHY
AB This study was to investigate the association of genetic polymorphisms in complement component 2 (C2), complement factor B (CFB) and complement component 3 (C3) with exudative age-related macular degeneration (AMD) in a Korean population and the gene-gene and gene-environment interactions in the development of AMD. A total of six SNPs that are located in the C2 (rs547154, rs9332739), CFB (rs4151667, rs641153) and C3 (rs1047286, rs2230199) genes were genotyped in 350 samples comprised of 153 cases, 197 controls. The risk allele frequencies for rs547154 in C2 were 6.54% and 8.12% in AMD patients and controls. Those for rs641153 in CFB were 6.54% and 8.63% in AMD patients and controls. The risk allele frequency for rs9332739 in C2 (AMD, 0.65%, control, 2.03%) and rs4151667 in CFB (AMD, 0.65%, control, 1.78%) was very low. The protective allele of four SNPs was not significantly associated with decreased risk for AMD (P = 0.427, P = 0.199, P = 0.312, P = 0.303, respectively). The homozygotes for the protective allele of four SNPs were not significantly associated with decreased risk for AMD (P = 0.324, P = 0.474, P = 0.309, P = 0.411, respectively). The genetic effect of two SNPs in C3 could not be investigated because the variants were not observed. There was no evidence to support an interaction of these SNPs with LOC387715/HTRA1 variants or with environmental exposure like smoking. In conclusion, the genetic effect of C2, CFB and C3 polymorphisms, which are known to be important for AMD in Caucasian, were not significant in the Korean population. The low minor allele frequency of these SNPs in Koreans might have affected the results of this study. Ethnic differences in the roles of C2, CFB and C3 in conferring a risk of AMD should be further investigated. (C) 2012 Elsevier Ltd. All rights reserved.
C1 Inha Univ, Sch Med, Dept Ophthalmol, Inchon, South Korea.
   Inha Univ, Sch Med, Inha Vis Sci Lab, Inchon, South Korea.
C3 Inha University; Inha University
RP Chin, HS (通讯作者)，Inha Univ Hosp, Dept Ophthalmol, Inha Vis Sci Lab, 7-206 Shinheung Dong, Inchon 400711, South Korea.
EM hschin@inha.ac.kr
FU Inha University, Incheon, Korea
FX This work was supported by Inha University Research Grant, Incheon,
   Korea.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Chanock SJ, 2007, NATURE, V447, P655, DOI 10.1038/447655a
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Cui L, 2010, INVEST OPHTH VIS SCI, V51, P1116, DOI 10.1167/iovs.09-4265
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lee SJ, 2010, CLIN EXP OPHTHALMOL, V38, P698, DOI 10.1111/j.1442-9071.2010.02316.x
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Mullins Robert F., 2007, International Ophthalmology Clinics, V47, P1, DOI 10.1097/IIO.0b013e31802bd3e6
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 42
TC 25
Z9 27
U1 0
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAR
PY 2012
VL 96
IS 1
BP 42
EP 47
DI 10.1016/j.exer.2012.01.005
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 911BU
UT WOS:000301693100006
PM 22273503
DA 2022-11-30
ER

PT J
AU Degenring, RF
   Cordes, A
   Schrage, NF
AF Degenring, Robert F.
   Cordes, Andreas
   Schrage, Nobert F.
TI Autologous translocation of the retinal pigment epithelium and choroid
   in the treatment of neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; choroid; choroidal neovascularization;
   retinal pigment epithelium; submacular haemorrhage; subretinal surgery;
   translocation
ID FOLLOW-UP; SUBRETINAL HEMORRHAGES; TRANSPLANTATION; GRAFT; RPE; SURGERY;
   REVASCULARIZATION; BEVACIZUMAB; RETINOTOMY
AB Purpose: To evaluate clinical results of an autologous translocation of retinal pigment epithelium (RPE) and choroid in the treatment of neovascular age-related macular degeneration (AMD).
   Methods: Twelve eyes which underwent surgery for neovascular AMD were included into the study, in four eyes moderate or massive submacular haemorrhage was present. The surgical procedure included standard pars plana vitrectomy; cataract surgery in phakic patients; peripheral 180 degrees-retinotomy; extraction of the submacular neovascular complex and removal of blood if present; preparation of a full-thickness graft consisting of RPE, Bruch's membrane and choroid; translocation of the graft to the macular area; and silicone oil endotamponade.
   Results: Visual acuity (VA) ranged from perception of hand movements (HM) to 20/125 (median, counting fingers (CF)-1/50) before surgery. During follow-up (FU) mean, 11.1 months, VA increased to a maximum median of 1/10 (range, HM-20/40). At the end of FU, VA had dropped to a median of CF-1/40 (range, HM-20/50). Comparing VA preoperatively and at the end of FU, VA had improved in six eyes, was unchanged in three eyes, and had deteriorated in three eyes. One eye had reading ability. Surgery-associated postoperative complications impairing the functional outcome occurred in five eyes, including rhegmatogenous retinal detachment and proliferative vitreoretinopathy. Revision surgery had to be performed in four eyes (30%). Three eyes had to be left with permanent silicone endotamponade. Results tended to be better in the subgroup of eyes with massive submacular haemorrhage preoperatively.
   Conclusion: Functional results of a translocation of RPE and choroid were heterogeneous and rather disappointing in this study. Results may have been influenced negatively by case selection. We found a relatively high rate of adverse events in the postoperative course. In selected cases, e.g. massive submacular haemorrhage or progressive neovascular AMD unresponsive to other treatment options, autologous translocation of RPE and choroid may still be considered.
C1 [Degenring, Robert F.] Eye Ctr Tuttlingen, D-78532 Tuttlingen, Germany.
   [Degenring, Robert F.; Cordes, Andreas; Schrage, Nobert F.] Cologne Hosp, Dept Ophthalmol Cologne Merheim, Cologne, Germany.
RP Degenring, RF (通讯作者)，Eye Ctr Tuttlingen, Zeppelinstr 21, D-78532 Tuttlingen, Germany.
EM degenring@augenzentrumtuttlingen.de
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Aisenbrey S, 2006, ARCH OPHTHALMOL-CHIC, V124, P183, DOI 10.1001/archopht.124.2.183
   Aisenbrey S, 2007, ARCH OPHTHALMOL-CHIC, V125, P1367, DOI 10.1001/archopht.125.10.1367
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Cereda MG, 2010, GRAEF ARCH CLIN EXP, V248, P37, DOI 10.1007/s00417-009-1201-8
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P1848, DOI 10.1167/iovs.08-2845
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Franzco FKC, 2009, CLIN EXP OPHTHALMOL, V37, P275, DOI 10.1111/j.1442-9071.2009.01915.x
   Gibran S, 2009, GRAEF ARCH CLIN EXP, V247, P187, DOI 10.1007/s00417-008-0958-5
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Hasler PW, 2007, ACTA OPHTHALMOL SCAN, V85, P577, DOI 10.1111/j.1600-0420.2007.00914.x
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Heussen FMA, 2008, EYE, V22, P799, DOI 10.1038/sj.eye.6702823
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Joussen AM, 2007, OPHTHALMOLOGY, V114, P551, DOI 10.1016/j.ophtha.2006.08.016
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Krebs I, 2008, ACTA OPHTHALMOL, V86, P504, DOI 10.1111/j.1600-0420.2007.01087.x
   Lappas A, 2004, GRAEF ARCH CLIN EXP, V242, P638, DOI 10.1007/s00417-003-0764-z
   Maaijwee K, 2008, BRIT J OPHTHALMOL, V92, P526, DOI 10.1136/bjo.2007.131383
   Maaijwee K, 2008, RETINA-J RET VIT DIS, V28, P498, DOI 10.1097/IAE.0b013e318159ec24
   Maaijwee K, 2008, INVEST OPHTH VIS SCI, V49, P758, DOI 10.1167/iovs.07-0510
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   Maaijwee K, 2006, OPHTHALMOLOGY, V113, P1471, DOI 10.1016/j.ophtha.2006.04.011
   Maaijwee KJM, 2007, BRIT J OPHTHALMOL, V91, P546, DOI 10.1136/bjo.2006.103259
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Petersen J, 2008, KLIN MONATSBL AUGENH, V225, P286, DOI 10.1055/s-2008-1027238
   Schmidt JC, 2004, OPHTHALMOLOGE, V101, P584, DOI 10.1007/s00347-003-0912-1
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Thumann G, 2004, OPHTHALMOLOGE, V101, P882, DOI 10.1007/s00347-004-1084-3
   Treumer F, 2007, BRIT J OPHTHALMOL, V91, P349, DOI 10.1136/bjo.2006.102152
   Uppal G, 2007, CLIN EXP OPHTHALMOL, V35, P448, DOI 10.1111/j.1442-9071.2007.01528.x
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   Van Meurs JC, 2005, ESSENT OPHTHALMOL, P73
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   Zhang TR, 2009, INVEST OPHTH VIS SCI, V50, P2982, DOI 10.1167/iovs.08-2131
NR 40
TC 9
Z9 10
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2011
VL 89
IS 7
BP 654
EP 659
DI 10.1111/j.1755-3768.2010.01867.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 838ZB
UT WOS:000296332000026
PM 20346087
OA Bronze
DA 2022-11-30
ER

PT J
AU Algvere, PV
   Libert, C
   Lindgarde, G
   Seregard, S
AF Algvere, PV
   Libert, C
   Lindgarde, G
   Seregard, S
TI Transpupillary thermotherapy of predominantly occult choroidal
   neovascularization in age-related macular degeneration with 12 months
   follow-up
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE transpupillary thermotherapy; age-related macular degeneration; occult
   choroidal neovascularization; minimally classic choroidal
   neovascularization; 12 month results
ID MELANOMA; TTT
AB Purpose: To perform a phase I/II safety and efficacy study in order to assess the outcome following transpupillary thermotherapy (TTT) for occult choroidal neovascularization (CNV) with no or minimally classic CNV in age-related macular degeneration.
   Methods: The study comprised 113 referred patients (79 females, 34 males) aged 59-89 years (mean 77.7 years) with predominantly occult CNV. There were 49 cases of occult with no classic CNV and 64 of occult with minimally classic CNV. According to their greatest linear dimension, lesions were classified as being <3.0 mm or >3.0 mm. Transpupillary thermotherapy was delivered with a diode laser, emission at 810 nm, duration 60 seconds, laser power 500-800 mW. Clinical examination, ETDRS logMAR visual acuity and fluorescein angiography were carried out at baseline, and at 3, 6 and 12 months in all cases.
   Results: The average baseline visual acuity was 0.20 (50.6 letters). Following TTT, it was 0.12 (42.0 letters) at 6 months and 0.12 (38.0 letters) at 12 months. Visual acuity improved in 9/113 eyes (8.0%), remained unchanged in 46 (40.7%) eyes, and deteriorated in 58 (51.3%) eyes. There was no significant difference in the proportion of eyes that had lost at least 15 letters at 12 months in the subgroup of occult with no classic CNV (18/49; 36.7%) versus those with minimally classic lesions <3.0 mm (15/39; 38.5%). However, 13/25 (52.0%) of cases with minimally classic lesions >3.0 mm had lost at least 15 letters at 12 months (p=0.31). The most common complications in the 46 eyes that suffered visual loss comprised subretinal progressive fibrosis (18 eyes) and atrophy of the retinal pigment epithelium (13 eyes).
   Conclusion: This study shows that TTT generally prevents moderate and severe visual loss at 12 months follow-up in occult CNV with no classic CNV. Eyes with minimally classic lesions with a greatest linear dimension of <3.0 mm also show the same positive outcome. These results compare favourably with published data on the natural course of the disease. However, minimally classic lesions of >3.0 mm responded poorly in this treatment setting.
C1 St Eriks Eye Hosp, Karolinska Inst, Dept Ophthalmol, SE-11282 Stockholm, Sweden.
C3 Karolinska Institutet
RP Algvere, PV (通讯作者)，St Eriks Eye Hosp, Karolinska Inst, Dept Ophthalmol, Polhemsgatan 50, SE-11282 Stockholm, Sweden.
CR Algvere P V, 2001, Semin Ophthalmol, V16, P90, DOI 10.1076/soph.16.2.90.4210
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Ciulla TA, 2001, INVEST OPHTH VIS SCI, V42, P3337
   Kim J E, 2001, Semin Ophthalmol, V16, P86, DOI 10.1076/soph.16.2.86.4212
   Kiratli H, 2002, ACTA OPHTHALMOL SCAN, V80, P401, DOI 10.1034/j.1600-0420.2002.800410.x
   Lanzetta P, 2002, OPHTHALMOLOGY, V109, P1098, DOI 10.1016/S0161-6420(02)01034-5
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Robertson DM, 2002, ARCH OPHTHALMOL-CHIC, V120, P648
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Stoffelns BM, 2002, ACTA OPHTHALMOL SCAN, V80, P25, DOI 10.1034/j.1600-0420.2002.800106.x
NR 13
TC 30
Z9 33
U1 0
U2 1
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD APR
PY 2003
VL 81
IS 2
BP 110
EP 117
DI 10.1034/j.1600-0420.2003.00041.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 677WZ
UT WOS:000182833200004
PM 12752047
OA Bronze
DA 2022-11-30
ER

PT J
AU Thoongsuwan, S
   Hanutsaha, P
   Chantarasorn, Y
   Ruamviboonsuk, P
   Vongkulsiri, S
   Kungwanpongpun, P
AF Thoongsuwan, Somanus
   Hanutsaha, Prut
   Chantarasorn, Yodpong
   Ruamviboonsuk, Paisan
   Vongkulsiri, Sritatath
   Kungwanpongpun, Pavinee
TI Treatment Outcome of Wet Age-Related Macular Degeneration Management in
   Thailand: A Retrospective Real-World Study (TOWER Study)
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Aflibercept; Anti-VEGF; Bevacizumab; nAMD; Neovascular age-related
   macular degeneration; Ranibizumab; Real-world study
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; VISUAL-ACUITY; INTRAVITREAL
   AFLIBERCEPT; PHOTODYNAMIC THERAPY; NEOVASCULAR AMD; RANIBIZUMAB; EXTEND;
   GUIDELINES; MORPHOLOGY; EFFICACY
AB Introduction To present real-world outcomes of neovascular age-related macular degeneration (nAMD) management in Thailand. Methods This multicenter retrospective study reviewed medical records of naive nAMD patients diagnosed from 1 January 2016 until 31 December 2018. The patients received at least one intravitreal anti-vascular endothelial growth factor (VEGF) treatment and had captured visual acuity (VA) at baseline and at month 12. Treatment outcomes were assessed at month 12, 24, and 36. The primary outcome was a mean change in VA from baseline to month 12. Results Five hundred seventy-two (572) eyes were included in this study and of these eyes, 222 and 96 had 2- and 3-year follow-up periods, respectively. At month 12, the mean improvement of VA (ETDRS letter) was six letters (P < 0.0001), and central retinal thickness (CRT) decreased on average by 104 microns (P < 0.0001). However, visual improvement by 0.1 letters at month 36 did not show statistical significance. The presence of fluid was found in approximately half of patients throughout the study period (45.98%, 48.85%, and 50.91% at month 12, 24, and 36, respectively). Mean number of injections (SD) was 6.06 (3.00), 3.44 (2.94), and 2.71 (3.07) for years 1, 2, and 3, respectively. The mean number of visits (SD) in year 1 was 9.01 (2.60) and declined to 5.67 (2.69) in year 2 and 4.93 (2.49) in year 3. Patients who had an average injection interval of <= 8 weeks were 74.46% in year 1, 51.28% in year 2, and 45.24 in year 3; 35.31% of patients were lost to follow-up. Conclusions This analysis reflects real-world nAMD management with significant improvement of outcomes. At the same time, the study reveals unmet needs in anti-VEGF therapy in nAMD including persistent disease activities, inadequacy of available treatment, and lack of treatment adherence leading to visual deterioration in the long-term.
C1 [Thoongsuwan, Somanus] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Ophthalmol, Bangkok, Thailand.
   [Hanutsaha, Prut] Mahidol Univ, Fac Med, Dept Ophthalmol, Ramathibodi Hosp, Bangkok, Thailand.
   [Chantarasorn, Yodpong] Navamindradhiraj Univ, Vajira Hosp, Dept Ophthalmol, Bangkok, Thailand.
   [Ruamviboonsuk, Paisan] Rajavithi Hosp, Fac Med, Dept Ophthalmol, Bangkok, Thailand.
   [Vongkulsiri, Sritatath] Phramongkutklao Hosp, Phramongkutklao Coll Med, Dept Ophthalmol, Bangkok, Thailand.
   [Kungwanpongpun, Pavinee] Novartis Thailand Ltd, Bangkok, Thailand.
C3 Mahidol University; Mahidol University; Rajavithi Hospital;
   Phramongkutklao College of Medicine; Phramongkutklao Hospital
RP Hanutsaha, P (通讯作者)，Mahidol Univ, Fac Med, Dept Ophthalmol, Ramathibodi Hosp, Bangkok, Thailand.
EM prut.han@mahidol.ac.th
FU Novartis (Thailand) Limited - Novartis (Thailand) Limited
FX This study was funded by Novartis (Thailand) Limited. The journal's
   Rapid Service fees were funded by Novartis (Thailand) Limited.
CR Bhoomibunchoo C, 2017, CLIN OPHTHALMOL, V11, P317, DOI 10.2147/OPTH.S126226
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cruess AF, 2012, CAN J OPHTHALMOL, V47, P227, DOI 10.1016/j.jcjo.2012.03.007
   Fenner BJ, 2020, OPHTHALMOL RETINA, V4, P403, DOI 10.1016/j.oret.2019.10.019
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Koh A, 2017, ASIA-PAC J OPHTHALMO, V6, P296, DOI 10.22608/APO.2016125
   Kumluang S, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1086-1
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Mehta H, 2020, CLIN OPHTHALMOL, V14, P3331, DOI 10.2147/OPTH.S275977
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mones J, 2020, OPHTHALMOLOGICA, V243, P1, DOI 10.1159/000502747
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Patel PJ, 2017, CLIN OPHTHALMOL, V11, P1957, DOI 10.2147/OPTH.S145732
   Reiter GS, 2021, RETINA-J RET VIT DIS, V41, P1318, DOI 10.1097/IAE.0000000000003023
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Siktberg J, 2020, INVEST OPHTH VIS SCI, V61
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Verbraak FD, 2021, ACTA OPHTHALMOL, V99, pE884, DOI 10.1111/aos.14712
   Wakabayashi T, 2012, BRIT J OPHTHALMOL, V96, P394, DOI 10.1136/bjo.2011.204123
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
NR 36
TC 2
Z9 2
U1 1
U2 2
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD APR
PY 2022
VL 11
IS 2
BP 739
EP 757
DI 10.1007/s40123-022-00471-5
EA FEB 2022
PG 19
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZU8LH
UT WOS:000754145800001
PM 35149964
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Nashine, S
   Cohen, P
   Chwa, M
   Lu, S
   Nesburn, AB
   Kuppermann, BD
   Kenney, MC
AF Nashine, Sonali
   Cohen, Pinchas
   Chwa, Marilyn
   Lu, Stephanie
   Nesburn, Anthony B.
   Kuppermann, Baruch D.
   Kenney, M. Cristina
TI Humanin G (HNG) protects age-related macular degeneration (AMD)
   transmitochondrial ARPE-19 cybrids from mitochondrial and cellular
   damage
SO CELL DEATH & DISEASE
LA English
DT Article
ID OXIDATIVE STRESS; ALZHEIMERS-DISEASE; RESCUE FACTOR; NEUROPROTECTIVE
   FACTOR; PEPTIDE HUMANIN; DNA; APOPTOSIS; DEATH; CELLS; MECHANISMS
AB Age-related macular degeneration (AMD) ranks third among the leading causes of visual impairment with a blindness prevalence rate of 8.7%. Despite several treatment regimens, such as anti-angiogenic drugs, laser therapy, and vitamin supplementation, being available for wet AMD, to date there are no FDA-approved therapies for dry AMD. Substantial evidence implicates mitochondrial damage and retinal pigment epithelium (RPE) cell death in the pathogenesis of AMD. However, the effects of AMD mitochondria and Humanin G (HNG), a more potent variant of the mitochondrial-derived peptide (MDP) Humanin, on retinal cell survival have not been elucidated. In this study, we characterized mitochondrial and cellular damage in transmitochondrial cybrid cell lines that contain identical nuclei but possess mitochondria from either AMD or age-matched normal (Older-normal (NL)) subjects. AMD cybrids showed (1) reduced levels of cell viability, lower mtDNA copy numbers, and downregulation of mitochondrial replication/transcription genes and antioxidant enzyme genes; and (2) elevated levels of genes related to apoptosis, autophagy and ER-stress along with increased mtDNA fragmentation and higher susceptibility to amyloid-beta-induced toxicity compared to NL cybrids. In AMD cybrids, HNG protected the AMD mitochondria, reduced pro-apoptosis gene and protein levels, upregulated gp130 (a component of the HN receptor complex), and increased the protection against amyloid-beta-induced damage. In summary, in cybrids, damaged AMD mitochondria mediate cell death that can be reversed by HNG treatment. Our results also provide evidence of Humanin playing a pivotal role in protecting cells with AMD mitochondria. In the future, it may be possible that AMD patient's blood samples containing damaged mitochondria may be useful as biomarkers for this condition. In conclusion, HNG may be a potential therapeutic target for treatment of dry AMD, a debilitating eye disease that currently has no available treatment. Further studies are needed to establish HNG as a viable mitochondria-targeting therapy for dry AMD.
C1 [Nashine, Sonali; Chwa, Marilyn; Lu, Stephanie; Nesburn, Anthony B.; Kuppermann, Baruch D.; Kenney, M. Cristina] Univ Calif Irvine, Dept Ophthalmol, Gavin Herbert Eye Inst, Irvine, CA USA.
   [Cohen, Pinchas] Univ Southern Calif, Davis Sch Gerontol, Los Angeles, CA USA.
   [Lu, Stephanie] VA Med Ctr Long Beach Hosp, Long Beach, CA USA.
   [Nesburn, Anthony B.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
   [Kenney, M. Cristina] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA USA.
C3 University of California System; University of California Irvine;
   University of Southern California; Cedars Sinai Medical Center;
   University of California System; University of California Irvine
RP Kenney, MC (通讯作者)，Univ Calif Irvine, Ophthalmol Res Lab, Gavin Herbert Eye Inst, Hewitt Hall,Room 2028,843 Hlth Sci Rd, Irvine, CA 92697 USA.
EM mkenney@uci.edu
RI NASHINE, SONALI/AAG-1474-2020
FU Arnold and Mabel Beckman Foundation; UCI School of Medicine; Discovery
   Eye Foundation; Guenther Foundation; Beckman Initiative for Macular
   Research; Polly and Michael Smith Foundation; Max Factor Family
   Foundation; Iris and B. Gerald Cantor Foundation; RPB (Research to
   Prevent Blindness); Arnold and Mabel Beckman Postdoctoral Fellowship
FX This research work was supported by the Arnold and Mabel Beckman
   Foundation, UCI School of Medicine, Discovery Eye Foundation, Guenther
   Foundation, Beckman Initiative for Macular Research, Polly and Michael
   Smith Foundation, Max Factor Family Foundation, Iris and B. Gerald
   Cantor Foundation; research was supported in part by an unrestricted
   grant from RPB (Research to Prevent Blindness). Dr. Sonali Nashine holds
   the Arnold and Mabel Beckman Postdoctoral Fellowship. We thank Dr.
   Kelvin Yen for technical assistance with Humanin peptide.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Arakawa T, 2008, CURR MED CHEM, V15, P2086, DOI 10.2174/092986708785747616
   Atilano SR, 2015, HUM MOL GENET, V24, P4491, DOI 10.1093/hmg/ddv173
   Au A, 2017, BRIT J OPHTHALMOL, V101, P970, DOI 10.1136/bjophthalmol-2016-309434
   Bazan NG, 2007, INVEST OPHTH VIS SCI, V48, P4866, DOI 10.1167/iovs.07-0918
   Bellizzi D, 2012, EPIGENOMICS-UK, V4, P17, DOI [10.2217/EPI.11.109, 10.2217/epi.11.109]
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Carri MT, 2017, BIOCHEM BIOPH RES CO, V483, P1187, DOI 10.1016/j.bbrc.2016.07.055
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Cobb LJ, 2016, AGING-US, V8, P796, DOI 10.18632/aging.100943
   D'Aquila P, 2015, BIOGERONTOLOGY, V16, P569, DOI 10.1007/s10522-015-9562-3
   Dao-Yi Yu, 2014, EXP REV OPHTHALMOL, V6, P395
   Dib B, 2015, BBA-MOL CELL RES, V1853, P2897, DOI 10.1016/j.bbamcr.2015.08.012
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Eriksson E, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt459
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Gong ZW, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00210
   Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627
   Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498
   Hashimoto Y, 2001, BIOCHEM BIOPH RES CO, V283, P460, DOI 10.1006/bbrc.2001.4765
   Hashimoto Y, 2009, MOL BIOL CELL, V20, P2864, DOI 10.1091/mbc.E09-02-0168
   Ikonen M, 2003, P NATL ACAD SCI USA, V100, P13042, DOI 10.1073/pnas.2135111100
   Izzotti A, 2010, ARCH OPHTHALMOL-CHIC, V128, P724, DOI 10.1001/archophthalmol.2010.87
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jin H, 2010, NEUROCHEM INT, V56, P417, DOI 10.1016/j.neuint.2009.11.015
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kim Min-Ho, 2003, Korean J Ophthalmol, V17, P19
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kowluru RA, 2015, BBA-MOL BASIS DIS, V1852, P2474, DOI 10.1016/j.bbadis.2015.08.001
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Lee C, 2015, CELL METAB, V21, P443, DOI 10.1016/j.cmet.2015.02.009
   Lee C, 2020, TECHNOVATION, V96-97, DOI [10.1016/j.technovation.2020.102140, 10.1016/j.tem.2013.01.005]
   Lue YH, 2015, ENDOCRINOLOGY, V156, P4511, DOI 10.1210/en.2015-1542
   Mamiya T, 2001, BRIT J PHARMACOL, V134, P1597, DOI 10.1038/sj.bjp.0704429
   McCusker MM, 2016, CLIN DERMATOL, V34, P276, DOI 10.1016/j.clindermatol.2015.11.009
   Miceli MV, 2005, INVEST OPHTH VIS SCI, V46, P1765, DOI 10.1167/iovs.04-1327
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Moreira PI, 2010, BBA-MOL BASIS DIS, V1802, P2, DOI 10.1016/j.bbadis.2009.10.006
   Muzumdar RH, 2010, ARTERIOSCL THROM VAS, V30, P1940, DOI 10.1161/ATVBAHA.110.205997
   Muzumdar RH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006334
   Nashine S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159828
   Nashine S, 2015, INVEST OPHTH VIS SCI, V56, P221, DOI 10.1167/iovs.14-15447
   Nashine S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063205
   Niikura T, 2006, CURR NEUROPHARMACOL, V4, P139, DOI 10.2174/157015906776359577
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Romano Antonino D, 2010, J Nephrol, V23 Suppl 15, pS29
   Sponne I, 2004, MOL CELL NEUROSCI, V25, P95, DOI 10.1016/j.mcn.2003.09.017
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3
   Takahashi T, 2010, J MOL CELL BIOL, V2, P180, DOI 10.1093/jmcb/mjq005
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Winklhofer KF, 2010, BBA-MOL BASIS DIS, V1802, P29, DOI 10.1016/j.bbadis.2009.08.013
   Xu XS, 2006, STROKE, V37, P2613, DOI 10.1161/01.STR.0000242772.94277.1f
   Yamagishi Y, 2003, PEPTIDES, V24, P585, DOI 10.1016/S0196-9781(03)00106-2
   Zhang WJ, 2012, PHARMACOL BIOCHEM BE, V100, P361, DOI 10.1016/j.pbb.2011.09.012
   Zhu DH, 2009, J BIOL CHEM, V284, P9529, DOI 10.1074/jbc.M809393200
NR 60
TC 48
Z9 50
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUL
PY 2017
VL 8
AR e2951
DI 10.1038/cddis.2017.348
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FC5GR
UT WOS:000406870400040
PM 28726777
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Eng, VA
   Rayess, N
   Nguyen, HV
   Leng, T
AF Eng, Victor A.
   Rayess, Nadim
   Nguyen, Huy, V
   Leng, Theodore
TI Complete RPE and outer retinal atrophy in patients receiving anti-VEGF
   treatment for neovascular age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; GEOGRAPHIC-ATROPHY; DISEASE; RISK;
   AFLIBERCEPT; MACULOPATHY; PREDICTOR; EYES
AB Importance
   Neovascular age-related macular degeneration (nAMD) is a leading cause of blindness with several intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents available for its management such as aflibercept, bevacizumab, and ranibizumab. However, direct comparisons between these three agents among the same patient population are limited.
   Objective
   To assess the rate and growth of complete retinal pigment epithelium and outer retinal atrophy (cRORA) in eyes with nAMD treated with aflibercept, bevacizumab, and/or ranibizumab.
   Method
   Retrospective cohort study of patients with treatment-naive neovascular AMD seen at an academic hospital between October 2006 and February 2019. Study eyes were treated with intravitreal injections of aflibercept, bevacizumab, and/or ranibizumab and followed for two years.
   Main outcomes and measures
   cRORA prevalence, location, size, and growth rate. Eyes were imaged with Cirrus spectral domain optical coherence tomography (SD-OCT). Presence and size of cRORA were calculated using the FDA-approved Advanced RPE Analysis software. Linear regression models were used to correlate cRORA progression with baseline demographic and ocular characteristics, anti-VEGF drug, and number of injections. Unpaired t-tests, ANOVA, and linear regression models were computed with SAS 9.4.
   Results
   197 eyes from 158 patients (mean age 78.9, 62.9% women) received an average of 13 anti-VEGF injections over 24 months. 22% developed new cRORA. Mean cRORA area increased from 1.71 mm(2) to 2.93 mm(2). At 24 months, eyes with 11+ injections had significantly less cRORA area (11+ injections, 4.02 mm(2);. 10 injections, 2.46 mm(2); p = 0.01) and growth rate (11+ injections, 0.41 mm(2)/year;. 10 injections, 1.05 mm(2)/year; p = 0.02). Choice of anti-VEGF drug yielded no significant difference in cRORA progression.
   Conclusions and relevance
   Treating nAMD with aflibercept, bevacizumab or ranibizumab demonstrated comparable cRORA development at 24 months. Number of injections inversely correlated with cRORA area and growth. These results warrant further investigation in the pathophysiology of cRORA in anti-VEGF treated eyes.
C1 [Eng, Victor A.; Rayess, Nadim; Nguyen, Huy, V; Leng, Theodore] Stanford Univ, Sch Med, Byers Eye Inst Stanford, Palo Alto, CA 94304 USA.
C3 Stanford University
RP Leng, T (通讯作者)，Stanford Univ, Sch Med, Byers Eye Inst Stanford, Palo Alto, CA 94304 USA.
EM tedleng@stanford.edu
OI Nguyen, Huy/0000-0002-5463-1081; Leng, Theodore/0000-0002-8461-3562
FU Stanford Medical School Medical Scholars Program; Research to Prevent
   Blindness; National Eye Institute [P30-EY026877]
FX Victor Eng is supported by a research fellowship grant from the Stanford
   Medical School Medical Scholars Program. Theodore Leng is supported by
   an unrestricted grant from Research to Prevent Blindness, the National
   Eye Institute P30-EY026877. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   [Anonymous], 2015, MED LETT DRUGS THER, V57, P41
   [Anonymous], 2015, OPHTHALMOLOGY, V122, P809, DOI [10.1016/j.ophtha.2014.11.007, DOI 10.1016/T0PHTHA.2014.11.00'7]
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Folgar FA, 2016, OPHTHALMOLOGY
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI [10.1056/NERVIct1000495, DOI 10.1056/NERVICT1000495]
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI [10.1016/6ophthe.2012.09.006, DOI 10.1016/6OPHTHE.2012.09.006]
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Murdoch IE, 1998, BRIT J OPHTHALMOL, V82, P971, DOI 10.1136/bjo.82.8.971
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Steinbrook R., 2006, NEW ENGL J MED, V355, P1409, DOI [10.1056/NEJP61p068185, DOI 10.1056/NEJP61P068185]
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Wong T, 2008, OPHTHALMOLOGY, V115, DOI [10.1016/tophtha.2007.03.008, DOI 10.1016/T0PHTHA.2007.03.008]
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Yehoshua Z, 2013, LASERS IMAGING RETIN, V44, P127
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
NR 39
TC 8
Z9 8
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 5
PY 2020
VL 15
IS 5
AR e0232353
DI 10.1371/journal.pone.0232353
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LT7XS
UT WOS:000537280000027
PM 32369500
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wang, DC
   Jiang, Y
   He, M
   Scheetz, J
   Wang, W
AF Wang, Decai
   Jiang, Yu
   He, Miao
   Scheetz, Jane
   Wang, Wei
TI Disparities in the Global Burden of Age-Related Macular Degeneration: An
   Analysis of Trends from 1990 to 2015
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Macular degeneration; health burden; DALY; socioeconomic; human
   development index; gross domestic product
ID VISUAL IMPAIRMENT; PHYSICAL-ACTIVITY; HEALTH BURDEN; CATARACT;
   PREVALENCE; SINGAPORE; BLINDNESS; SURGERY
AB Purpose: The purpose of this study was to evaluate the disparities in burden of disease of age-related macular degeneration (AMD) in terms of disability-adjusted life years (DALYs).Method: This is an international, database observational study. The DALYs due to AMD were retrieved from the 2015 Global Burden of Disease study. The human development index (HDI) and gross domestic product (GDP) per capita across countries were obtained from the 2016 Human Development Report and the World Bank. Other related data were obtained from the World Health Organization and United Nations.Results: A total of 195 countries were included in this study. From 1990 to 2015, the AMD-related global DALY numbers, crude DALY rate, and age-standardized DALY rate increased by 147.66%, 78.13%, and 19.3%, respectively. Global DALY rates increased with age and females had higher DALY numbers and rates than males in each age group (all P <0.01). The age-standardized DALY rate was positively associated with HDI and GDP per capita (P <0.001). An analysis by HDI ordering showed substantial socioeconomic inequality, with a concentration index of 0.322 for DALY numbers, 0.472 for crude DALY rate, and 0.142 for age-standardized DALY rate, respectively. The country-wide mean body mass index (BMI), serum cholesterol concentration, alcohol consumption, physical inactivity, percent of cell phone subscribers, and urbanization rate were also significantly associated with age-standardized DALY rate. Four variables (GDP per capita, mean BMI, alcohol consumption, and urbanization rate) explained 36.48% of the variation of age-standardized DALY rate across countries.Conclusion: The global health burden of AMD is constantly increasing, implying more demand for AMD services in the coming decades. Older age, female gender, higher socioeconomic development, physical inactivity, and urbanization rate were related to higher AMD burden. These findings may raise the public concern and awareness of the global impact of AMD burden and are valuable for policy planning.
C1 [Wang, Decai; Jiang, Yu; Wang, Wei] Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou 510060, Guangdong, Peoples R China.
   [He, Miao] Guangdong Acad Med Sci, Guangdong Eye Inst, Guangdong Gen Hosp, Dept Ophthalmol, Guangzhou, Guangdong, Peoples R China.
   [Scheetz, Jane] Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Scheetz, Jane] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
C3 Sun Yat Sen University; Guangdong Academy of Medical Sciences &
   Guangdong General Hospital; Centre for Eye Research Australia;
   University of Melbourne
RP Wang, W (通讯作者)，Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou 510060, Guangdong, Peoples R China.
EM zoc_wangwei@yahoo.com
RI Wang, Wei/J-4000-2016
OI Wang, Wei/0000-0002-5273-3332
FU Fundamental Research Funds of the State Key Laboratory in Ophthalmology
FX This research was supported in part by the grant from the Fundamental
   Research Funds of the State Key Laboratory in Ophthalmology. No
   additional external funding was received. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Cackett P, 2008, BRIT J OPHTHALMOL, V92, P1312, DOI 10.1136/bjo.2007.136077
   Finger RP, 2017, CLIN EXP OPHTHALMOL, V45, P143, DOI 10.1111/ceo.12804
   Gilbert CE, 2016, OPHTHALMOLOGY, V123, P1245, DOI 10.1016/j.ophtha.2016.01.048
   Global Burden of Disease Study, 2016, GLOB BURD DIS STUD 2
   Guthold R, 2018, LANCET GLOB HEALTH, V6, pE1077, DOI [10.1016/s2214-109x(18)30357-7, 10.1016/S2214-109X(18)30357-7]
   He M, 2017, INVEST OPHTH VIS SCI, V58, P4299, DOI 10.1167/iovs.17-21459
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   Kassebaum NJ, 2016, LANCET, V388, P1603, DOI [10.1016/S0140-6736(16)31460-X, 10.1016/S0140-6736(16)31470-2]
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lou LX, 2016, INVEST OPHTH VIS SCI, V57, P6271, DOI 10.1167/iovs.16-20242
   Mahr MA, 2017, MAYO CLIN PROC, V92, P870, DOI 10.1016/j.mayocp.2017.02.017
   Mcguinness MB, 2017, AM J OPHTHALMOL, V180, P29, DOI 10.1016/j.ajo.2017.05.016
   Meyers KJ, 2015, OPHTHALMOLOGY, V122, P2286, DOI 10.1016/j.ophtha.2015.07.029
   Ono K, 2010, AM J PUBLIC HEALTH, V100, P1784, DOI 10.2105/AJPH.2009.187930
   Parikh R, 2017, OPHTHALMOLOGY, V124, P352, DOI 10.1016/j.ophtha.2016.10.036
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Saxena N, 2016, OPHTHAL EPIDEMIOL, V23, P232, DOI 10.1080/09286586.2016.1193617
   United Nations Development Programme, 2016, HUM DEV REP 2016
   Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]
   Wang W, 2017, JAMA OPHTHALMOL, V135, P1295, DOI 10.1001/jamaophthalmol.2017.3449
   Wang W, 2017, INVEST OPHTH VIS SCI, V58, P3669, DOI 10.1167/iovs.17-21489
   Wang W, 2016, INVEST OPHTH VIS SCI, V57, P5872, DOI 10.1167/iovs.16-19894
   Williams PT, 2009, INVEST OPHTH VIS SCI, V50, P101, DOI 10.1167/iovs.08-2165
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 28
TC 10
Z9 10
U1 0
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD JUN 3
PY 2019
VL 44
IS 6
BP 657
EP 663
DI 10.1080/02713683.2019.1576907
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ID8OD
UT WOS:000471943300013
PM 30703332
DA 2022-11-30
ER

PT J
AU Yehoshua, Z
   Wang, FH
   Rosenfeld, PJ
   Penha, FM
   Feuer, WJ
   Gregori, G
AF Yehoshua, Zohar
   Wang, Fenghua
   Rosenfeld, Philip J.
   Penha, Fernando M.
   Feuer, William J.
   Gregori, Giovanni
TI Natural History of Drusen Morphology in Age-Related Macular Degeneration
   Using Spectral Domain Optical Coherence Tomography
SO OPHTHALMOLOGY
LA English
DT Article
ID GEOGRAPHIC ATROPHY; SEVERITY SCALE; MACULOPATHY; DISEASE; SYSTEM
AB Purpose: To characterize the natural history of drusen using spectral-domain optical coherence tomography (SD-OCT) imaging of eyes from patients with nonexudative age-related macular degeneration (AMD).
   Design: Prospective, longitudinal, natural history study.
   Participants: We included 143 eyes of 100 patients with at least 6 months of follow-up.
   Methods: Patients with drusen secondary to nonexudative AMD were scanned using the Cirrus SD-OCT instrument. Eyes were imaged using the 200x200 A-scan raster pattern contained within a 6x6 mm area. Custom software was used to quantify volumetric changes in drusen over a period of >= 6 months and for as long as 24 months. Drusen volume and drusen area were measured within circular regions centered at the fovea having diameters of 3 and 5 mm. The measurements were analyzed using a suitable scale transformation. For drusen volume, a cube root transformation strategy was used.
   Main Outcome Measures: Change in drusen volume and area over time.
   Results: We analyzed 143 eyes of 100 patients with 69 eyes followed for 6 months, 106 eyes followed for 12 months, 48 eyes followed for 18 months, and 48 eyes followed for 24 months. The 3 mm circle baseline drusen volume ranged from 0.0009 to 0.7479 mm(3) or 0.10 to 0.91 mm using the cube root scale. On average, drusen volume and drusen area increased over time with the magnitude of the increase dependent on the length of follow-up (P = 0.001, 3 mm circle). In the eyes with a decrease in drusen volume, the magnitude of this decrease was dependent on the baseline drusen volume (P = 0.001, 3 mm circle) and independent of the follow-up interval. After 12 months, drusen volume increased in 48% of eyes, remained stable in 40%, and decreased in 12%.
   Conclusions: Imaging with SD-OCT revealed a dynamic, undulating growth pattern for drusen with a tendency for drusen to increase in volume and area over time. An appreciation of the quantitative changes in drusen volume over time using SD-OCT imaging provides a novel strategy for following normal disease progression and for identifying novel clinical trial end points to be used when investigating therapies for the treatment of nonexudative AMD.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2011; 118: 2434-2441 (C) 2011 by the American Academy of Ophthalmology.
C1 [Yehoshua, Zohar; Wang, Fenghua; Rosenfeld, Philip J.; Penha, Fernando M.; Feuer, William J.; Gregori, Giovanni] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
   [Wang, Fenghua] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Ophthalmol, Shanghai, Peoples R China.
C3 Bascom Palmer Eye Institute; University of Miami; Shanghai Jiao Tong
   University
RP Rosenfeld, PJ (通讯作者)，Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@med.miami.edu
RI Penha, Fernando M/G-1784-2012
OI Penha, Fernando/0000-0002-1038-5472
FU Carl Zeiss Meditec, Inc.; American Physicians Fellowship for Medicine in
   Israel; Shanghai Pujiang Project [2010-00049]; Chinese National "863"
   Project [2008AA030118]; Chinese National "973" Project [2011CB707500];
   Carl Zeiss Meditec, Inc., Dublin, CA; Research to Prevent Blindness.
   Inc.; NEI core center [P30 EY014801]; Macula Vision Research Foundation;
   Feig Family Foundation; Gemcon Family Foundation; Carl and Lily
   Pforzheimer Foundation; Emma Clyde Hodge Memorial Foundation; NATIONAL
   EYE INSTITUTE [P30EY014801] Funding Source: NIH RePORTER
FX Zohar Yehoshua - Research Support - Carl Zeiss Meditec, Inc.; Fellowship
   Grant recipient - American Physicians Fellowship for Medicine in
   Israel.; Fenghua Wang - Research Support - Carl Zeiss Meditec, Inc.;
   Support - Shanghai Pujiang Project (2010-00049), the Chinese National
   "863" Project (2008AA030118), and the Chinese National "973" Project
   (2011CB707500).; Research supported by a grant from Carl Zeiss Meditec,
   Inc., Dublin, CA; an unrestricted grant from Research to Prevent
   Blindness. Inc.; NEI core center grant P30 EY014801 to the University of
   Miami, the Jerome A. Yavitz Charitable Foundation; the Macula Vision
   Research Foundation; Feig Family Foundation; the Gemcon Family
   Foundation; the Carl and Lily Pforzheimer Foundation; and the Emma Clyde
   Hodge Memorial Foundation.
CR Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   Friberg TR, 2007, OPHTHAL SURG LAS IM, V38, P126, DOI 10.3928/15428877-20070301-07
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Sallo FB, 2009, BRIT J OPHTHALMOL, V93, P1345, DOI 10.1136/bjo.2008.150334
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Shin DS, 1999, OPHTHALMOLOGY, V106, P1119, DOI 10.1016/S0161-6420(99)90257-9
   Smith RT, 2010, BRIT J OPHTHALMOL, V94, P1618, DOI 10.1136/bjo.2009.166843
   Smith RT, 2005, BRIT J OPHTHALMOL, V89, P87, DOI 10.1136/bjo.2004.042937
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
NR 26
TC 116
Z9 117
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2011
VL 118
IS 12
BP 2434
EP 2441
DI 10.1016/j.ophtha.2011.05.008
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 863BO
UT WOS:000298138000019
PM 21724264
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Millen, AE
   Nie, J
   Mares, JA
   Lutsey, PL
   LaMonte, MJ
   Meuer, SM
   Sahli, MW
   Andrews, CA
   Klein, BEK
   Klein, R
AF Millen, Amy E.
   Nie, Jing
   Mares, Julie A.
   Lutsey, Pamela L.
   LaMonte, Michael J.
   Meuer, Stacy M.
   Sahli, Michelle W.
   Andrews, Christopher A.
   Klein, Barbara E. K.
   Klein, Ronald
TI Serum 25-Hydroxyvitamin D Concentrations and Incidence of Age-Related
   Macular Degeneration: The Atherosclerosis Risk in Communities Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE vitamin D; 25-hydroxyvitamin D; macular degeneration; retinal diseases;
   epidemiology; cohort studies
ID VITAMIN-D DEFICIENCY; PHYSICAL-ACTIVITY; HYPOVITAMINOSIS D; ASSOCIATION;
   QUESTIONNAIRE; OMEGA-3-FATTY-ACIDS; EDUCATION; ABILITY; VISION; DESIGN
AB PURPOSE. To investigate the association between serum 25-hydroxyvitamin D (25[OH]D) concentrations at visit 2 (1990-1992) and the 18-year incidence of age-related macular degeneration (AMD) between visit 3 (1993-1995) and visit 5 (2011-2013).
   METHODS. This prospective analysis was conducted in a subset of participants (n = 1225) from the Atherosclerosis Risk in Communities Study. We evaluated the incidence of any, early, and late AMD from visit 3 to 5. The 25(OH)D concentrations were assessed in 2012-2013 by using stored serum from visit 2. Retinal fundus photographs taken at both visits were graded side by side to determine the incidence of AMD. Logistic regression was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for incident AMD outcomes during 18 years of follow-up (1993-1995 to 2011-2013) by tertile of 25(OH)D adjusted for age, race, and smoking status. P for linear trend was estimated by using continuous 25(OH)D concentrations. Sensitivity analyses applied inverse probability weights to account for selection to have eye photographs, death, and loss to follow-up.
   RESULTS. There was a decreased odds of any incident AMD (n = 139) and large, soft drusen (n = 80) in 25(OH)D tertile 3 versus 1, with OR (95% CI) = 0.57 (0.36-0.90), P trend = 0.11 and with 0.52 (0.28-0.93), P trend = 0.18, respectively. Applying sampling weights attenuated these results to 0.66 (0.38-1.16), P trend = 0.32 (any incident AMD) and 0.54 (0.27-1.09), P trend = 0.36 (large, soft drusen), respectively, suggesting these associations may be biased by loss to follow-up and sampling for retinal photographs at visit 5. No statistically significant results were observed with pigmentary abnormalities (n = 46) or incident late AMD (n = 26).
   CONCLUSIONS. High 25(OH)D concentrations, approximately >70 nM, may be associated with decreased odds of incident early AMD.
C1 [Millen, Amy E.; Nie, Jing; LaMonte, Michael J.] Univ Buffalo State Univ New York, Dept Epidemiol & Environm Hlth, Sch Publ Hlth & Hlth Profess, 270 Farber Hall, Buffalo, NY 14214 USA.
   [Mares, Julie A.; Meuer, Stacy M.; Klein, Barbara E. K.; Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Lutsey, Pamela L.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
   [Sahli, Michelle W.] Univ Michigan, Dept Publ Hlth & Hlth Sci, Sch Hlth Profess & Studies, Flint, MI 48503 USA.
   [Andrews, Christopher A.] Univ Michigan, Dept Ophthalmol & Visual Sci, Med Sch, Ann Arbor, MI 48109 USA.
C3 State University of New York (SUNY) System; State University of New York
   (SUNY) Buffalo; University of Wisconsin System; University of Wisconsin
   Madison; University of Minnesota System; University of Minnesota Twin
   Cities; University of Michigan System; University of Michigan;
   University of Michigan Flint; University of Michigan System; University
   of Michigan
RP Millen, AE (通讯作者)，Univ Buffalo State Univ New York, Dept Epidemiol & Environm Hlth, Sch Publ Hlth & Hlth Profess, 270 Farber Hall, Buffalo, NY 14214 USA.
EM aemillen@buffalo.edu
RI LaMonte, Mike/AAC-9953-2021
OI Lutsey, Pamela/0000-0002-1572-1340; Andrews, Chris/0000-0001-5130-6374
FU component of the National Institutes of Health (NIH) [UL1RR025005]; NIH
   Roadmap for Medical Research (Bethesda, MD, USA); NIH National Institute
   on Aging [R01 AG041776]; NIH National Heart, Lung, and Blood Institute
   (NHLBI) [R01 HL103706]; NIH Office of Dietary Supplements Grant [R01
   HL103706-S1]; Research to Prevent Blindness; NHLBI [HHSN268201700001I,
   HHSN268201700002I, HHSN268201700003I, HHSN268201700004I,
   HHSN268201700005I, R01HL087641, R01HL086694, R01-HL70825]; National
   Human Genome Research Institute [U01HG004402]; NIH [HHSN268200625226C];
   NIH Roadmap for Medical Research; NATIONAL HEART, LUNG, AND BLOOD
   INSTITUTE [U01HL096917, R01HL086694, U01HL096899, U01HL096902,
   U01HL096812, U01HL096814] Funding Source: NIH RePORTER
FX The authors thank the staff and participants of the ARIC Study for their
   important contributions. Infrastructure was partly supported by Grant
   No. UL1RR025005, a component of the National Institutes of Health (NIH)
   and NIH Roadmap for Medical Research (Bethesda, MD, USA).; Supported by
   the NIH National Institute on Aging Grant No. R01 AG041776, NIH National
   Heart, Lung, and Blood Institute (NHLBI) Grant No. R01 HL103706, and the
   NIH Office of Dietary Supplements Grant No. R01 HL103706-S1 and an
   unrestricted grant from Research to Prevent Blindness. The
   Atherosclerosis Risk in Communities Study has been funded in whole or in
   part with federal funds from the NHLBI contracts (contract Nos.
   HHSN268201700001I, HHSN268201700002I, HHSN268201700003I,
   HHSN268201700004I, and HHSN268201700005I), R01HL087641, R01HL086694;
   National Human Genome Research Institute contract U01HG004402; and NIH
   contract HHSN268200625226C. Infrastructure was partly supported by Grant
   Number UL1RR025005, a component of the National Institutes of Health and
   NIH Roadmap for Medical Research. Neurocognitive data are collected by
   U01 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, 2U01HL096917
   from the NIH (NHLBI, National Institute of Neurological Disorders and
   Stroke [NINDS], National Institute on Aging [NIA], National Institute on
   Deafness and Other Communication Disorders [NIDCD]), and with previous
   brain MRI examinations funded by R01-HL70825 from the NHLBI.
CR [Anonymous], 1991, Ophthalmology, V98, P786
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   ARIC, 2015, VIS 5 NCS AN MAN
   ARIC Neurocognitive Study, 2011, RET IM PROT
   Assel MJ, 2018, OPHTHALMOLOGY, V125, P391, DOI 10.1016/j.ophtha.2017.09.008
   Atherosclerosis Risk in Communities (ARIC), 2005, CAR MRI STUD MAN 1 D
   Atherosclerosis Risk in Communities (ARIC) Study Research Group, 1988, MAN 7 BLOOD COLL, V10, P16
   BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198-014-2794-2
   Cougnard-Greoire A, 2015, J NUTR, V145, P1865, DOI 10.3945/jn.115.214387
   Day S, 2012, ARCH OPHTHALMOL-CHIC, V130, P1070, DOI 10.1001/archophthalmol.2012.439
   Ganji V, 2012, J NUTR, V142, P498, DOI 10.3945/jn.111.151977
   Golan S, 2011, EYE, V25, P1122, DOI 10.1038/eye.2011.174
   Gottesman RF, 2014, AM J EPIDEMIOL, V179, P956, DOI 10.1093/aje/kwu020
   Graffe A, 2012, J AM GERIATR SOC, V60, P1367, DOI 10.1111/j.1532-5415.2012.04015.x
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Institute of Medicine, 2011, DIETARY REFERENCE IN, DOI [10.17226/13050, DOI 10.17226/13050]
   Itty S, 2014, RETINA-J RET VIT DIS, V34, P1779, DOI 10.1097/IAE.0000000000000178
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P4823, DOI 10.1167/iovs.14-14763
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kluczynski MA, 2011, ANN EPIDEMIOL, V21, P440, DOI 10.1016/j.annepidem.2010.11.011
   Knopman David S, 2016, Alzheimers Dement (Amst), V2, P1
   Lutsey PL, 2015, CLIN CHIM ACTA, V442, P75, DOI 10.1016/j.cca.2014.12.036
   Mcguinness MB, 2017, AM J OPHTHALMOL, V180, P29, DOI 10.1016/j.ajo.2017.05.016
   McKay GJ, 2017, OPHTHALMOLOGY, V124, P90, DOI 10.1016/j.ophtha.2016.09.007
   Merle BMJ, 2017, INVEST OPHTH VIS SCI, V58, P4569, DOI 10.1167/iovs.17-21673
   Millen AE, 2017, J NUTR HEALTH AGING, V21, P772, DOI 10.1007/s12603-016-0827-6
   Millen AE, 2015, JAMA OPHTHALMOL, V133, P1171, DOI 10.1001/jamaophthalmol.2015.2715
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Millen AE, 2010, AM J CLIN NUTR, V91, P1324, DOI 10.3945/ajcn.2009.28908
   Morris MC, 2011, JAMA-J AM MED ASSOC, V305, P1348, DOI 10.1001/jama.2011.383
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   POLS MA, 1995, INT J EPIDEMIOL, V24, P381, DOI 10.1093/ije/24.2.381
   Psaty BM, 2009, CIRC-CARDIOVASC GENE, V2, P73, DOI 10.1161/CIRCGENETICS.108.829747
   Reed-Jones RJ, 2013, MATURITAS, V75, P22, DOI 10.1016/j.maturitas.2013.01.019
   RICHARDSON MT, 1995, INT J EPIDEMIOL, V24, P685, DOI 10.1093/ije/24.4.685
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Singh A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070948
   West CG, 2002, J AM GERIATR SOC, V50, P136, DOI 10.1046/j.1532-5415.2002.50019.x
   WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184
   2012, CONTEMP CLIN TRIALS, V33, P159, DOI DOI 10.1016/J.CCT.2011.09.009
NR 45
TC 9
Z9 9
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2019
VL 60
IS 5
BP 1362
EP 1371
DI 10.1167/iovs.18-25945
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HW5VL
UT WOS:000466757300010
PM 30934055
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Castro-Navarro, V
   Cervera-Taulet, E
   Montero-Hernandez, J
   Navarro-Palop, C
AF Castro-Navarro, Veronica
   Cervera-Taulet, Enrique
   Montero-Hernandez, Javier
   Navarro-Palop, Catalina
TI One-Year Outcomes of the Treat-and-Extend Approach with Aflibercept in
   Age-Related Macular Degeneration: Effects on Typical Choroidal
   Neovascularization and Retinal Angiomatous Proliferation
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization; Retinal
   angiomatous proliferation; Treat-and-extend regimen; Aflibercept
ID GROWTH-FACTOR THERAPY; INTRAVITREAL BEVACIZUMAB; PREDICTIVE FACTORS;
   RANIBIZUMAB; REGIMEN; MEMBRANES; EYES
AB Objective: To investigate functional/morphological outcomes of the treat-and-extend regimen (TER) with aflibercept in typical choroidal neovascularization (CNV) and retinal angiomatous proliferation (RAP) secondary to exudative age-related macular degeneration (AMD). Methods: This was a retrospective study of 37 eyes treated with 2 mg aflibercept according to a TER protocol. Examinations included best corrected visual acuity (BCVA), numbers of injections, and visits needed. Additionally, quantitative/qualitative analyses with fluorescein angiography and spectral domain optical coherence tomography were conducted at baseline as well as at 3, 6, and 12 months. Results: BCVA significantly improved from 0.6 +/- 0.27 to 0.4 +/- 0.34 logMAR. The final mean numbers of injections were 8.03 +/- 1.27 and 7.28 +/- 0.75 and the numbers of visits 6.5 +/- 1.09 and 7.14 +/- 1.57 in typical CNV and in RAP or atypical CNV, respectively, and they did not differ between the different subtypes of CNV (p > 0.05). Conclusions: Aflibercept in TER is effective for all exudative AMD subtypes. The patient's visual gain, the mean number of injections, and the number of visits needed did not depend on the subtype of CNV. (C) 2016 S. Karger AG, Basel
C1 [Castro-Navarro, Veronica; Cervera-Taulet, Enrique; Montero-Hernandez, Javier; Navarro-Palop, Catalina] Univ Valencia, Gen Hosp, Ave Tres Cruces S-N, ES-46016 Valencia, Spain.
   [Castro-Navarro, Veronica] Univ Catolica Valencia San Vicente Martir, Escuela Doctorado, Valencia, Spain.
C3 University of Valencia; Universidad Catolica de Valencia San Vicente
   Martir
RP Castro-Navarro, V (通讯作者)，Univ Valencia, Gen Hosp, Ave Tres Cruces S-N, ES-46016 Valencia, Spain.
EM veronicacastronavarro@gmail.com
CR Akagi-Kurashige Y, 2012, GRAEF ARCH CLIN EXP, V250, P1129, DOI 10.1007/s00417-012-1928-5
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chirco K. R., 2016, EYE LOND
   Coscas F, 2015, INVEST OPHTH VIS SCI, V56, P4129, DOI 10.1167/iovs.15-16735
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gallego-Pinazo R, 2016, ARCH SOC ESP OFTALMO
   Garcia-Layana A, 2015, DRUG AGING, V32, P797, DOI 10.1007/s40266-015-0300-y
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Matsumoto H, 2016, RETINA-J RET VIT DIS, V36, P2282, DOI 10.1097/IAE.0000000000001104
   Mrejen S, 2015, J CLIN MED, V4, P1380, DOI 10.3390/jcm4071380
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P435, DOI 10.1007/s00417-012-2034-4
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Tao Y, 2010, RETINA-J RET VIT DIS, V30, P1426, DOI 10.1097/IAE.0b013e3181d5e964
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 24
TC 8
Z9 8
U1 0
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2016
VL 236
IS 4
BP 215
EP 222
DI 10.1159/000453281
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EI5UG
UT WOS:000392559700006
PM 27997921
DA 2022-11-30
ER

PT J
AU Lei, JQ
   Balasubramanian, S
   Abdelfattah, NS
   Nittala, MG
   Sadda, SR
AF Lei, Jianqin
   Balasubramanian, Siva
   Abdelfattah, Nizar Saleh
   Nittala, Muneeswar G.
   Sadda, SriniVas R.
TI Proposal of a simple optical coherence tomography-based scoring system
   for progression of age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Optical coherence tomography;
   Progression; Score
ID PIGMENT EPITHELIAL DETACHMENT; RETICULAR PSEUDODRUSEN; SEVERITY SCALE;
   EYE DISEASE; FELLOW-EYES; NEOVASCULARIZATION; ASSOCIATION; MACULOPATHY
AB Purpose To develop a simple, clinically practical, optical coherence tomography (OCT)-based scoring system for early age-related macular degeneration (AMD) to prognosticate risk for progression to late AMD.
   Methods We retrospectively reviewed OCT images (512 x 128 macular cube, Cirrus) from 138 patients diagnosed of early AMD in at least one eye and follow-up of at least 12 months. For patients with early AMD in both eyes, only the right eye was chosen as the study eye for longitudinal assessment. Scans were graded on four SD-OCT criteria associated with disease progression in previous studies: drusen volume within a central 3-mm circle >= 0.03 mm(3), intraretinal hyperreflective foci (HRF), hyporeflective foci (hRF) within a drusenoid lesion (DL), and subretinal drusenoid deposits (SDD). Each criterion was assigned one point. For risk assessment of the study eye, the baseline status of the fellow eye was also considered, and thus these four features were also assessed in the fellow eye. The number of risk factors were summed for both eyes, yielding a total score (TS) of 0 to 8 for each patient. A fellow eye with evident choroidal neovascularization (CNV) or atrophy automatically received 4 points. Scores were then grouped into four categories to facilitate comparative analysis: I. (TS of 0, 1, 2), II. (TS of 3, 4), III. (TS of 5, 6) and IV. (TS of 7, 8). Correlation of baseline category assignment with progression to late AMD (defined as the presence of atrophy or CNV on OCT) by the last follow-up visit was evaluated with logistic regression analysis.
   Results The rate of progression to late AMD was 39.9% (55/138). Progression rates by category (I to IV) were 0, 14.3, 47.5, and 73.3%, respectively. Logistic regression analysis showed risk of progression to late AMD was 3.0 times (95% CI: 1.2-7.9) higher for an eye assigned to category IV than for an eye in category III and 16.4 (95% CI: 4.7-58.8) times higher than for an eye in category II.
   Conclusions A simple scoring system relevant to prognosis for early AMD, and practical for use in a busy clinic, can be developed using SD-OCT criteria alone.
C1 [Lei, Jianqin; Balasubramanian, Siva; Abdelfattah, Nizar Saleh; Nittala, Muneeswar G.; Sadda, SriniVas R.] Doheny Eye Inst, Doheny Image Reading Ctr, 1350 San Pablo St,DVRC211, Los Angeles, CA 90033 USA.
   [Lei, Jianqin; Balasubramanian, Siva; Abdelfattah, Nizar Saleh; Nittala, Muneeswar G.; Sadda, SriniVas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Lei, Jianqin] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Xi'an Jiaotong
   University
RP Sadda, SR (通讯作者)，Doheny Eye Inst, Doheny Image Reading Ctr, 1350 San Pablo St,DVRC211, Los Angeles, CA 90033 USA.
EM ssadda@doheny.org
RI Abdelfattah, Nizar Saleh/H-6908-2019; Nittala, Muneeswar/AAT-7533-2020
OI Abdelfattah, Nizar Saleh/0000-0002-9396-3054; 
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Jack LS, 2016, DEV OPHTHALMOL, V55, P302, DOI 10.1159/000438954
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Schaal KB, 2015, OSLI RETINA, V46, P550, DOI 10.3928/23258160-20150521-06
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
NR 21
TC 52
Z9 54
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2017
VL 255
IS 8
BP 1551
EP 1558
DI 10.1007/s00417-017-3693-y
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FC8GR
UT WOS:000407080300011
PM 28534244
DA 2022-11-30
ER

PT J
AU Lu, LN
   Xu, SQ
   He, FL
   Liu, Y
   Zhang, YD
   Wang, J
   Wang, ZL
   Fan, XQ
AF Lu, Linna
   Xu, Shiqiong
   He, Fangling
   Liu, Yan
   Zhang, Yidan
   Wang, Jing
   Wang, Zhiliang
   Fan, Xianqun
TI Assessment of Choroidal Microstructure and Subfoveal Thickness Change in
   Eyes With Different Stages of Age-Related Macular Degeneration
SO MEDICINE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; BLOOD-FLOW; PREVALENCE; CHORIOCAPILLARIS;
   ANGIOGRAPHY; POPULATION; MEMBRANE; SEVERITY; RPE
AB Age-related macular degeneration (AMD) is a major cause of irreversible blindness. Choroidal structural changes seem to be inevitable in AMD pathogenesis. Our study revealed associated choroidal microstructural changes in AMD eyes.
   The aim of the study was to compare choroidal microstructural changes in eyes with AMD of different stages.
   The study was a retrospective, cross-sectional case series.
   The participants comprised of 32 age-matched normal eyes as controls, and 26 fellow uninvolved eyes of intermediate/late AMD, 29 of early AMD, 28 of intermediate AMD, and 39 of late AMD.
   All subjects underwent comprehensive ophthalmologic examination. The choroid images, including subfoveal choroidal thickness, percentage of Sattler layer area, and en face images of the choroid, were obtained using spectral-domain optical coherence tomography.
   The main outcome measures were subfoveal choroidal thickness changes, percentage of Sattler layer area changes, and en face images of the choroid in AMD eyes.
   One hundred fifty-four eyes of 96 individuals with mean age of 67.1+/-9.2 years were included. The mean subfoveal choroidal thickness was 295.4+/-56.8 mu m in age-matched normal eyes, 306.7+/-68.4 mu m in fellow uninvolved eyes with AMD, 293.8+/-80.4 mu m in early AMD, 215.6+/-80.4 mu m in intermediate AMD, and 200.4+/-66.6 mu m in late AMD (F = 14.2, all P < 0.001). Choroidal thickness was greater in early AMD eyes than in intermediate/late AMD eyes (P < 0.001). Mean percentage of Sattler layer area in each group showed a similar tendency. Microstructure of the choroid showed reduced vascular density of Sattler layer areas in late AMD eyes compared with normal eyes.
   Decreasing subfoveal choroidal thickness and percentage of Sattler layer area were demonstrated in the progression of AMD. The choroidal change was related to atrophy of the microstructural changes of underlying capillaries and medium-sized vessels.
C1 [Lu, Linna; Xu, Shiqiong; He, Fangling; Liu, Yan; Zhang, Yidan; Wang, Jing; Wang, Zhiliang; Fan, Xianqun] Shanghai Jiao Tong Univ, Peoples Hosp 9, Dept Ophthalmol, Sch Med, 639 ZhiZaoJu Rd, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University
RP Wang, ZL; Fan, XQ (通讯作者)，Shanghai Jiao Tong Univ, Peoples Hosp 9, Dept Ophthalmol, Sch Med, 639 ZhiZaoJu Rd, Shanghai 200011, Peoples R China.
EM 215769592@qq.com; fanxq@sh163.net
CR Barkmeier AJ, 2011, SEMIN OPHTHALMOL, V26, P94, DOI 10.3109/08820538.2011.571055
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Capuano V, 2015, BR J OPHTHALMOL
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Fein JG, 2014, OPHTHAL SURG LAS IM, V45, P32, DOI 10.3928/23258160-20131220-04
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flower RW, 2001, AM J OPHTHALMOL, V132, P85, DOI 10.1016/S0002-9394(01)00872-8
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Gliem M, 2014, AM J OPHTHALMOL, V158, P198, DOI 10.1016/j.ajo.2014.04.005
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   Hua R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083494
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Jia RB, 2014, JAMA OPHTHALMOL, V132, P942, DOI 10.1001/jamaophthalmol.2013.8229
   Jirarattanasopa P, 2012, OPHTHALMOLOGY, V119, P1666, DOI 10.1016/j.ophtha.2012.02.021
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Sim DA, 2013, INVEST OPHTH VIS SCI, V54, P2893, DOI 10.1167/iovs.12-11085
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Staurenghi G, OPHTHALMOLOGY
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
NR 35
TC 14
Z9 14
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD MAR
PY 2016
VL 95
IS 10
AR e2967
DI 10.1097/MD.0000000000002967
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DK8WM
UT WOS:000375209300006
PM 26962799
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Papavasileiou, E
   Zygoura, V
   Richardson, T
   Cortis, D
   Eleftheriadis, H
   Jackson, TL
AF Papavasileiou, Evangelia
   Zygoura, Vasiliki
   Richardson, Theresa
   Cortis, Dominic
   Eleftheriadis, Haralabos
   Jackson, Timothy L.
TI Intravitreal aflibercept (A-IVI) for the treatment of neovascular age
   related macular degeneration (nv-AMD): one year experience
SO HELLENIC JOURNAL OF NUCLEAR MEDICINE
LA English
DT Article
DE Aflibercept; Intravitreal; Neovascular age; Related macular degeneration
ID TRAP-EYE; RANIBIZUMAB; PREVALENCE
AB Objective: To report the anatomical and functional results of intravitreal injections of aflibercept (Eylea) (A-IVI) for the treatment of naive eyes with neovascular age-related macular degeneration (nv-AMD). Subjects and Methods: This retrospective, one center, non-comparative chart review included 26 treatment naive eyes with nv-AMD of 26 patients (14 male) with a mean age of 80.5 (range 63-91) who had a complete follow-up of 14 months. The morphological analysis included spectral domain optical coherence tomography and fundus fluorescein angiography, while the functional assessment included logarithm of the minimum angle of resolution (LogMAR) best correct visual acuity (BCVA). The timing of the follow-up was: baseline, 3, 6, and 14 months. All patients received 8 A-IVI according to the protocol (first 3 consecutive monthly A-IVI, followed by bi-monthly retreatment for the first year, regardless of disease activity as per local guidelines). Statistical analysis was performed using ANOVA. Improvement of visual acuity more than 15 letters was considered as 'improvement', less than 5 letters as 'stable' and any letter loss as 'worsening'. Results: Mean standard deviation LogMAR visual acuity improved from 0.26 +/- 0.15 at presentation to 0.14 +/- 0.20 at the final follow-up of 14 months (P=0.02). BCVA was stable in 23.1%, improved in 61.5% (16 eyes) worsened in 15.4%. A mean pretreatment central macular thickness of 409 mu m reduced significantly to 229 mu m at month 14 (P<0.02). The OCT of eyes with worsened BCVA showed resolution of retinal fluid but presence of subretinal fibrosis. No adverse events were attributed to aflibercept. Conclusions: Patients who had a worsening in visual acuity were found to have longer duration of symptoms prior to treatment and presence of geographic atrophy, and/or subretinal haemorrhage and/or subretinal fibrosis at baseline. From our experience, with 14 months follow-up, A-IVI is an effective treatment for treatment naive patients with nv-AMD. Our real world results were similar to pivotal trials.
C1 [Papavasileiou, Evangelia] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
   [Papavasileiou, Evangelia; Eleftheriadis, Haralabos; Jackson, Timothy L.] Kings Coll Hosp London, London, England.
   [Zygoura, Vasiliki] Moorfields Eye Hosp, London, England.
   [Richardson, Theresa] Imperial Coll Healthcare NHS Trust, Western Eye Hosp, London, England.
   [Cortis, Dominic] Univ Leicester, Dept Math, Leicester LE1 7RH, Leics, England.
   [Jackson, Timothy L.] Kings Coll London, London WC2R 2LS, England.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; King's College Hospital NHS Foundation Trust; King's College
   Hospital; University of London; University College London; Moorfields
   Eye Hospital NHS Foundation Trust; Imperial College London; University
   of Leicester; University of London; King's College London
RP Papavasileiou, E (通讯作者)，Kings Coll Hosp London, Dept Ophthalmol, Denmark Hill, London SE5 9RS, England.
EM liapapava@hotmail.com
OI Jackson, Timothy/0000-0001-7618-1555
CR American Foundation for the Blind (AFB), 2013, SPEC REP AG VIS LOSS
   Bird AC, 1995, SURV OPHTHALMOL, V39, P367
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Freund KB, 2010, RETINA, P1333
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier J, 2009, RETINAL PHYS
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Olson IR, 2007, BRAIN, V130, P1718, DOI 10.1093/brain/awm052
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 16
TC 4
Z9 4
U1 0
U2 2
PU HELLENIC SOC NUCLEAR MEDICINE
PI THESSALONIKI
PA 51 HERMU ST, THESSALONIKI, 546 23, GREECE
SN 1790-5427
J9 HELL J NUCL MED
JI Hell. J. Nucl. Med.
PD SEP-DEC
PY 2015
VL 18
IS 3
BP 29
EP 32
PG 4
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA DD1RT
UT WOS:000369699900005
PM 26665209
DA 2022-11-30
ER

PT J
AU Han, FY
   Chen, XW
   Zhao, RY
   Jin, X
   Tan, W
   Zhang, Y
AF Han, Fangyuan
   Chen, Xingwang
   Zhao, Ruyi
   Jin, Xin
   Tan, Wei
   Zhang, Ying
TI The effect of vitreomacular interface in neovascular age-related macular
   degeneration treated with intravitreal injection of anti-VEGF
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Vitreomacular interface; Intravitreal injection; anti-VEGF; Age-related
   macular degeneration
ID TRACTION; PROGRESSION
AB Background: The purpose of this study is to study the effect of repeated intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) drugs on vitreomacular interface.
   Methods: Neovascular age-related macular degeneration patients who received intravitreal injections of anti-VEGF drugs were included. Eyes with severe vitreous opacity, uveitis, complicated cataract surgery and previous vitrectomy were excluded. Vitreomacular interface, best corrected visual acuity (BCVA) and central retinal thickness (CRT) assessment were performed once a month for at least 3 months. The nature and time of the change event are recorded. Groups were divided according to whether vitreomacular interface change events occurred. To analyse the risk factors of vitreomacular interface changes and their influence on treatment effect.
   Results: A total of 87 eyes were evaluated. Vitreomacular interface change event occurred in 9 eyes. Pre-existing vitreomacular interface abnormality (VMIA) was a risk factor for the VMI change (P = 0.033, OR = 16.518, 95% CI: 1.258 to 216.939). 60% of interface events occurred in the first 3 months of treatment. The final BCVA of eyes with vitreomacular interface unchanged was significantly higher than that at baseline (P = 0.001), and the final CRT was also significantly lower than that at baseline (P < 0.001). The final CRT of eyes vitreomacular interface changed was significantly lower than that at baseline (P = 0.015), however, there was no statistical significance in BCVA (P = 0.468).
   Conclusion: Intravitreal injection of anti-VEGF drugs has a certain probability to cause changes in the vitreomacular interface, and the risk is higher in eyes with pre-existing vitreomacular interface abnormality. The effect of intravitreal injections on the vitreomacular interface was concentrated in the first three injections, and subsequent increases in the number of injections did not significantly increase the risk of vitreomacular interface abnormality. Ophthalmologists should increase attention to the vitreomacular interface in the early stages of anti-VEGF therapy and counsel patients accordingly.
C1 [Han, Fangyuan; Zhao, Ruyi; Jin, Xin; Tan, Wei; Zhang, Ying] Zunyi Med Univ, Affiliated Hosp 3, Peoples Hosp Zunyi 1, Dept Ophthalmol, 98 Fenghuang North Rd, Zunyi 563000, Guizhou, Peoples R China.
   [Chen, Xingwang] Zunyi Med Univ, Dept Ophthalmol, Affiliated Hosp, Zunyi, Guizhou, Peoples R China.
   [Chen, Xingwang; Tan, Wei; Zhang, Ying] Zunyi Med Univ, Special Key Lab Ocular Dis Guizhou Prov, Zunyi, Guizhou, Peoples R China.
C3 Zunyi Medical University; Zunyi Medical University; Zunyi Medical
   University
RP Zhang, Y (通讯作者)，Zunyi Med Univ, Affiliated Hosp 3, Peoples Hosp Zunyi 1, Dept Ophthalmol, 98 Fenghuang North Rd, Zunyi 563000, Guizhou, Peoples R China.; Zhang, Y (通讯作者)，Zunyi Med Univ, Special Key Lab Ocular Dis Guizhou Prov, Zunyi, Guizhou, Peoples R China.
EM 1176792753@qq.com
FU Zunyi science and Technology Bureau [(2018)166]
FX This work was supported by the Zunyi science and Technology Bureau under
   Grant [(2018)166].
CR CAMPOCHIARO PA, 1987, ARCH OPHTHALMOL-CHIC, V105, P1567
   Chang CK, 2017, EYE, V31, P762, DOI 10.1038/eye.2016.317
   Cho HJ, 2017, J OCUL PHARMACOL TH, V33, P452, DOI 10.1089/jop.2016.0178
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Edwards MM, 2016, EXP EYE RES, V150, P44, DOI 10.1016/j.exer.2015.07.016
   Gao M, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000009345
   Granstam E, 2021, GRAEF ARCH CLIN EXP, V259, P2085, DOI 10.1007/s00417-020-05059-y
   Hayashi K, 2009, EYE, V23, P774, DOI 10.1038/eye.2008.161
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Katira RC, 2008, RETINA-J RET VIT DIS, V28, P744, DOI 10.1097/IAE.0b013e318162b031
   Kim Minho, 2022, PLoS One, V17, pe0273674, DOI 10.1371/journal.pone.0273674
   Kinra V, 2018, INT OPHTHALMOL, V38, P549, DOI 10.1007/s10792-017-0490-x
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Liang XD, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1087-0
   MESTER U, 1988, OPHTHALMIC SURG LAS, V19, P482
   Ng DSC, 2022, EXPERT OPIN DRUG SAF, V21, P43, DOI 10.1080/14740338.2021.1952979
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Ota Ayumi, 2016, Clin Ophthalmol, V10, P7, DOI 10.2147/OPTH.S89683
   Phillips JD, 2022, J MECH BEHAV BIOMED, V134, DOI 10.1016/j.jmbbm.2022.105399
   Polat OA, 2022, CORNEA, V41, P317, DOI 10.1097/ICO.0000000000002836
   Ricci F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218242
   Stalmans P, 2012, NEW ENGL J MED, V367, P606, DOI 10.1056/NEJMoa1110823
   Taniguchi H, 2021, BMC OPHTHALMOL, V21, DOI 10.1186/s12886-021-01944-0
   Thomas CN, 2022, BRIT J PHARMACOL, V179, P1908, DOI 10.1111/bph.15459
   Tsukahara M, 2018, OPHTHALMOLOGY, V125, P1372, DOI 10.1016/j.ophtha.2018.02.039
   Veloso CE, 2015, OPHTHALMOLOGY, V122, P1569, DOI 10.1016/j.ophtha.2015.04.028
NR 26
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD NOV 3
PY 2022
VL 22
IS 1
AR 419
DI 10.1186/s12886-022-02640-3
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5X5WI
UT WOS:000878669700002
PM 36329392
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Steinberg, JS
   Sassmannshausen, M
   Pfau, M
   Fleckenstein, M
   Finger, RP
   Holz, FG
   Schmitz-Valckenberg, S
AF Steinberg, Julia S.
   Sassmannshausen, Marlene
   Pfau, Maximilian
   Fleckenstein, Monika
   Finger, Robert P.
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
TI Evaluation of Two Systems for Fundus-Controlled Scotopic and Mesopic
   Perimetry in Eye with Age-Related Macular Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE fundus-controlled perimetry; microperimetry; scotopic; mesopic; MP-1S;
   S-MAIA; drusen; age-related macular degeneration
ID OPTICAL COHERENCE TOMOGRAPHY; GEOGRAPHIC ATROPHY; RETICULAR DRUSEN;
   VISUAL-ACUITY; AUTOFLUORESCENCE; MICROPERIMETRY; PREVALENCE; MAIA
AB Purpose: The purpose of this study was to evaluate and compare the MP-1S (Nidek Technologies, Padova, Italy) and the S-MAIA (CenterVue, Padova, Italy) for mesopic and scotopic fundus-controlled perimetry (FCP) in age-related macular degeneration (AMD).
   Methods: Eleven eyes from 11 patients underwent mesopic and, after 30 minutes of dark adaptation, scotopic (MP-1S: Goldmann V, 200 ms, background luminance 0.0032 cd/m(2); S-MAIA: Goldman III, 200 ms, background luminance,0.0001 cd/m(2)) FCP. For the S-MAIA device, cyan (505 nm) and red (627 nm) scotopic FCP were performed. For both devices, a grid of 56 stimulus points covering 16 degrees of the central macula was used. Examination time, fixation stability, and threshold values were analyzed.
   Results: The upper end of the dynamic range (<= 4 dB of lowest threshold) was frequently reached by the MP-1S for mesopic testing (median 34 of 56 stimuli), while threshold values within the lower 4 dB of the dynamic range were occasionally found with the S-MAIA for scotopic testing (median 3 for cyan, median 2 for red). After correction of the stimulus intensity for the S-MAIA results, the median difference for all stimuli between both devices for mesopic testing was - 2.0 dB (interquartile range [- 4; 0], range -14 to 6).
   Conclusions: The results indicate that robust testing of mesopic and scotopic function is feasible with both devices in patients with AMD, although both devices are susceptible to floor and ceiling effects.
   Translational Relevance: The interpretation and particularly the comparison of both scotopic and mesopic FCP results between the MP-1S and the S-MAIA in AMD eyes need to consider variable susceptibility of floor and ceiling effects. Further software updates are desirable as FCP captures visual functional loss that is not noted with best-corrected central visual acuity and is important for clinical trials in AMD.
C1 [Steinberg, Julia S.; Sassmannshausen, Marlene; Pfau, Maximilian; Fleckenstein, Monika; Finger, Robert P.; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
C3 University of Bonn
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM steffen.schmitz-valckenberg@ukb.uni-bonn.de
RI Pfau, Maximilian/N-1888-2019
OI Pfau, Maximilian/0000-0001-9761-9640; Finger, Robert
   P/0000-0003-4253-7597; Fleckenstein, Monika/0000-0001-8321-8037
FU Gertrud Kusen Foundation; University of Bonn Bonfor [O-137.0021,
   O-137.0022]; DFG [FL 658/4-1, FL 658/4-2]
FX Supported by Gertrud Kusen Foundation; University of Bonn Bonfor Grant
   O-137.0021(to JSS) and Grant O-137.0022 (to MP); DFG Grant FL 658/4-1
   and FL 658/4-2.
CR Bellmann C, 2004, OPHTHALMOLOGY, V111, P2265, DOI 10.1016/j.ophtha.2004.06.019
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crossland MD, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-5
   Crossland MD, 2009, RETINA-J RET VIT DIS, V29, P651, DOI 10.1097/IAE.0b013e318196bd65
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Forte R, 2013, RETINA-J RET VIT DIS, V33, P482, DOI 10.1097/IAE.0b013e318276e11e
   Fraser RG, 2016, INVEST OPHTH VIS SCI, V57, P5436, DOI 10.1167/iovs.16-19295
   Hirooka K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151000
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   NEBBIOSO M, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/671529
   Parodi MB, RETINA
   Pfau M, 2017, OPHTHALMOLOGICA, V237, P42, DOI 10.1159/000453079
   Pilotto E, 2013, BRIT J OPHTHALMOL, V97, P622, DOI 10.1136/bjophthalmol-2012-302633
   Resnikoff S, 2002, B WORLD HEALTH ORGAN, V82, P844
   Rogala J, 2015, INVEST OPHTH VIS SCI, V56, P1689, DOI 10.1167/iovs.14-16221
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   SLOAN LL, 1950, AM J OPHTHALMOL, V33, P1077, DOI 10.1016/0002-9394(50)91722-3
   Steinberg JS, 2016, AM J OPHTHALMOL, V168, P52, DOI 10.1016/j.ajo.2016.04.025
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Sunness JS, 2008, J VISUAL IMPAIR BLIN, V102, P600
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Vujosevic SC, 2014, MICROPERIMETRY MULTI, P13
   Wong EN, 2016, CLIN EXP OPHTHALMOL, V44, P15, DOI 10.1111/ceo.12629
NR 29
TC 30
Z9 30
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JUL
PY 2017
VL 6
IS 4
AR 7
DI 10.1167/tvst.6.4.7
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FH2HH
UT WOS:000410959300007
PM 28713647
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Tomany, SC
   Klein, R
   Klein, BEK
AF Tomany, SC
   Klein, R
   Klein, BEK
TI The relationship between iris color, hair color, and skin sun
   sensitivity and the 10-year incidence of age-related maculopathy - The
   beaver dam eye study
SO OPHTHALMOLOGY
LA English
DT Article
ID SENILE MACULAR DEGENERATION; RACIAL-DIFFERENCES; 5-YEAR INCIDENCE;
   NATIONAL-HEALTH; VISUAL-ACUITY; RISK-FACTORS; PREVALENCE; POPULATION;
   PROGRESSION; EXPOSURE
AB Purpose: To examine the association between iris color, hair color, and skin sun sensitivity and the 10-year incidence of age-related maculopathy (ARM).
   Design: Population-based cohort study.
   Participants: A population of 4926 adults (range, 43-86 years of age at baseline) living in Beaver Dam, Wisconsin, was studied at baseline (1988-1990); of these, 3684 and 2764 subjects, respectively, participated in 5-year and 10-year follow-up examinations.
   Methods: Data on hair color at age 15 years and skin responsiveness to sun exposure were obtained from a standardized questionnaire administered at the baseline examination. Iris color was determined with penlight illumination during the baseline examination by using photographic standards. Age-related maculopathy status was determined by grading stereoscopic color fundus photos with the Wisconsin Age-Related Maculopathy Grading System.
   Main Outcome Measures: Incidence and progression of ARM.
   Results: When controlling for age and gender, people with brown eyes were significantly more likely to develop soft indistinct drusen (risk ratio [RR], 1.53; 95% confidence interval [CI], 1.19-1.97; P < 0.01) than were people with blue eyes. However, people with brown eyes were significantly less likely to develop retinal pigment epithelial depigmentation (RR, 0.58; 95% CI, 0.41-0.82; P < 0.01) than were people with blue eyes. When compared with persons with blond hair, persons with brown hair were at decreased risk of developing pigmentary abnormalities (RR, 0.73; 95% CI, 0.53-1.00; P = 0.05). Iris color, hair color, and skin sun sensitivity were not associated with the development of late ARM.
   Conclusion: Iris color and hair color were found to be associated with the 10-year incidence of pigmentary abnormalities. Iris color seems to be inconsistently related to the 10-year incidence of early ARM lesions and the progression of ARM. (C) 2003 by the American Academy of Ophthalmology.
C1 Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med, 610 N Walnut St,4th Floor WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wise.edu
OI Klein, Ronald/0000-0002-4428-6237
FU NEI NIH HHS [EY06594] Funding Source: Medline
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   *FUND PHOT READ CT, AREDS SUMM GRAD PROT
   HOLZ FG, 1991, AM J OPHTHALMOL, V17, P19
   HOSMER DW, 1989, APPL LOGISTIC REGRES, P90
   JAMPOL LM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1699, DOI 10.1001/archopht.1992.01080240039024
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   KLEIN BE, 1990, NATL TECHNICAL INFOR, P1
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 1995, NTIS PUBLICATION, VPB95-273827
   KLEIN R, 1991, NTIS PUBLICATION
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   MENON IA, 1992, J OCUL PHARMACOL, V8, P35, DOI 10.1089/jop.1992.8.35
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   Prevent Blindness America, 2002, VIS PROBL US PREV AD, P1
   SCHACHAT AP, 1997, ARCH OPHTHALMOL-CHIC, V113, P728
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P53
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
NR 42
TC 40
Z9 41
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2003
VL 110
IS 8
BP 1526
EP 1533
DI 10.1016/S0161-6420(03)00539-6
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 710VK
UT WOS:000184703400011
PM 12917167
DA 2022-11-30
ER

PT J
AU Hammer, M
   Konigsdorffer, E
   Liebermann, C
   Framme, C
   Schuch, G
   Schweitzer, D
   Strobel, J
AF Hammer, Martin
   Koenigsdoerffer, Ekkehart
   Liebermann, Christiane
   Framme, Carsten
   Schuch, Guenter
   Schweitzer, Dietrich
   Strobel, Juergen
TI Ocular fundus auto-fluorescence observations at different wavelengths in
   patients with age-related macular degeneration and diabetic retinopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Fundus auto-fluorescence; age-related macular degeneration; diabetic
   retinopathy; colour-autofluorescence imaging
ID RETINAL-PIGMENT EPITHELIUM; TIME-RESOLVED AUTOFLUORESCENCE; GLYCATION
   END-PRODUCTS; GEOGRAPHIC ATROPHY; IN-VIVO; BRUCHS MEMBRANE; JUNCTIONAL
   ZONE; RPE CELLS; HIGH-RISK; LIPOFUSCIN
AB Background Post-translational protein modification by lipid peroxidation products or glycation is a feature of aging as well as pathologic processes in postmitotic cells at the ocular fundus exposed to an oxidative environment. The accumulation of modified proteins such as those found in lipofuscin and advanced glycation end products (AGEs) contribute greatly to the fundus auto-fluorescence. The distinct fluorescence spectra of lipofuscin and AGE enable their differentiation in multispectral fundus fluorescence imaging.
   Method A dual-centre consecutive case series of 78 pseudo-phacic patients is reported. Digital colour fundus photographs as well as auto-fluorescence images were taken from 33 patients with age related macular degeneration (AMD), 13 patients with diabetic retinopathy (RD), or from 32 cases without pathologic findings (controls). Fluorescence was excited at 475-515 nm or 476-604 nm and recorded in the emission bands 530-675 nm or 675-715 nm, respectively. Fluorescence images excited at 475-515 nm were taken by a colour CCD-camera (colour-fluorescence imaging) enabling the separate recording of green and red fluorescence. The ratio of green versus red fluorescence was calculated within a representative region of each image.
   Results The 530-675 nm auto-fluorescence in AMD patients was dominated by the red emission (green vs. red ratio, g/r=0.861). In comparison, the fluorescence of the diabetics was green-shifted (g/r=0.946; controls: g/r=0.869). Atrophic areas (geographic atrophy, laser scars) showed massive hypo-fluorescence in both emission bands. Hyper-fluorescent drusen and exudates, unobtrusive in the colour fundus images as well as in the fluorescence images with emission > 667 nm, showed an impressive green-shift in the colour-fluorescence image.
   Conclusions Lipofuscin is the dominant fluorophore at long wavelengths (> 675 nm or red channel of the colour fluorescence image). In the green spectral region, we found an additional emission of collagen and elastin (optic disc, sclera) as well as deposits in drusen and exudates. The green shift of the auto-fluorescence in RD may be a hint of increased AGE concentrations.
C1 Univ Jena, Dept Ophthalmol, D-07740 Jena, Germany.
   Univ Regensburg, Dept Ophthalmol, D-93053 Regensburg, Germany.
C3 Friedrich Schiller University of Jena; University of Regensburg
RP Hammer, M (通讯作者)，Univ Jena, Dept Ophthalmol, Bachstr 18, D-07740 Jena, Germany.
EM martin.hammer@med.uni-jena.de
CR [Anonymous], 1991, Ophthalmology, V98, P786
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bindewald-Wittich A, 2006, INVEST OPHTH VIS SCI, V47, P4553, DOI 10.1167/iovs.05-1562
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   DELORI FC, 1994, APPL OPTICS, V33, P7439, DOI 10.1364/AO.33.007439
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Diabet Control Complications Trial Res Grp, 1995, OPHTHALMOLOGY, V102, P647
   Dillon J, 2004, EXP EYE RES, V79, P537, DOI 10.1016/j.exer.2004.06.024
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   Hammer M, 2004, OPHTHALMOLOGE, V101, P1189, DOI 10.1007/s00347-004-1019-z
   Hammer M, 2006, MOL VIS, V12, P1348
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2001, OPHTHALMOLOGE, V98, P10, DOI 10.1007/s003470170194
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   Munch G, 1997, BRAIN RES REV, V23, P134, DOI 10.1016/S0165-0173(96)00016-1
   Radu RA, 2004, P NATL ACAD SCI USA, V101, P5928, DOI 10.1073/pnas.0308302101
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schweitzer D, 2007, MICROSC RES TECHNIQ, V70, P410, DOI 10.1002/jemt.20427
   Schweitzer D, 2004, J BIOMED OPT, V9, P1214, DOI 10.1117/1.1806833
   Schweitzer D, 2003, PROC SPIE, V5141, P8, DOI 10.1117/12.499641
   Schweitzer D, 2001, PROC SPIE, V4432, P29, DOI 10.1117/12.447153
   Schweitzer D, 2002, OPHTHALMOLOGE, V99, P774, DOI 10.1007/s00347-002-0656-3
   Schweitzer D, 2006, PROC SPIE, V6138, DOI 10.1117/12.644692
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Solbach U, 1997, RETINA-J RET VIT DIS, V17, P385
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Staudt S, 2000, INVEST OPHTH VIS SCI, V41, pS168
   Stitt AW, 2001, BRIT J OPHTHALMOL, V85, P746, DOI 10.1136/bjo.85.6.746
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Von Ruckmann A, 2002, AM J OPHTHALMOL, V133, P780, DOI 10.1016/S0002-9394(02)01428-9
   von Ruckmann A, 1999, GRAEF ARCH CLIN EXP, V237, P1, DOI 10.1007/s004170050186
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   vonRuckmann A, 1997, ARCH OPHTHALMOL-CHIC, V115, P609, DOI 10.1001/archopht.1997.01100150611006
   VONRUCKMANN A, 1995, INVEST OPHTHALMOL, V36, P238
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
NR 53
TC 33
Z9 34
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2008
VL 246
IS 1
BP 105
EP 114
DI 10.1007/s00417-007-0639-9
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 233LQ
UT WOS:000251092800014
PM 17653752
DA 2022-11-30
ER

PT J
AU Wong, TY
   Klein, R
   Klein, BEK
   Tomany, SC
AF Wong, TY
   Klein, R
   Klein, BEK
   Tomany, SC
TI Refractive errors and 10-year incidence of age-related maculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BEAVER-DAM EYE; SENILE MACULAR DEGENERATION; RISK-FACTORS;
   VISUAL-ACUITY; LONGITUDINAL DATA; POPULATION; PROGRESSION; MODELS
AB PURPOSE. To describe the relationship of refractive errors to the 10-year incidence of age-related maculopathy (ARM) in a defined white population.
   METHODS. Persons aged 43 to 86 years of age in Beaver Dam, Wisconsin, were invited for a baseline examination from 1988 through 1990, and follow-up examinations 5 and 10 years later (n = 3684). Refraction was measured at baseline, with myopia defined as a spherical equivalent of -1.00 D or less, emmetropia as -0.75,to +0.75 D and hyperopia as +1.00 D or more. At each examination, signs of ARM were ascertained from grading stereoscopic color fundus photographs based on a standard protocol. The association between baseline refractive status and the 10-year incidence and progression of ARM was analyzed.
   RESULTS. The 10-year cumulative incidence for early ARM was 7.1%, 7.7%, and 11.7%, in eyes with myopia, emmetropia, and hyperopia, respectively. The corresponding 10-year cumulative incidence for late ARM was 0.3%, 0.8%, and 2.2%. When age was controlled for, there was no association between myopia and incident early (relative risk [RR] 1.0, 95% confidence interval [CI], 0.7-1-3) and late (RR 0.5, 95% CI, 0.2-1.5) ARM. Similarly, after controlling for age, hyperopia was not associated with incident early (RR 0.9, 95% CI, 0.7- 1.1) or late (RR 1.2, 95% CI, 0.6-2.3) ARM.
   CONCLUSIONS. These prospective population-based data provide no evidence of an association between refractive errors and risk of ARM.
C1 Natl Univ Singapore, Dept Ophthalmol, Singapore 119074, Singapore.
   Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
C3 National University of Singapore; University of Wisconsin System;
   University of Wisconsin Madison
RP Wong, TY (通讯作者)，Natl Univ Singapore, Dept Ophthalmol, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore.
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Klein, Ronald/0000-0002-4428-6237
FU NEI NIH HHS [EYO6594] Funding Source: Medline
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   GIBSON JM, 1986, T OPHTHAL SOC UK, V105, P463
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Hosmer DW, 1989, APPL LOGISTIC REGRES, P238
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, IN PRESS OPHTHALMOLO
   KLEIN R, 1991, BEAVER DAM EYE STUDY
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Pierscionek BK, 1996, GERONTOLOGY, V42, P257, DOI 10.1159/000213800
   SANDBERG MA, 1993, OPHTHALMOLOGY, V100, P1009
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   Wang JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   WANG Q, 1994, INVEST OPHTH VIS SCI, V35, P4344
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
NR 28
TC 31
Z9 32
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2002
VL 43
IS 9
BP 2869
EP 2873
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 589FN
UT WOS:000177748200009
PM 12202504
DA 2022-11-30
ER

PT J
AU Daien, V
   Nguyen, V
   Essex, RW
   Morlet, N
   Barthelmes, D
   Gillies, MC
AF Daien, Vincent
   Vuong Nguyen
   Essex, Rohan W.
   Morlet, Nigel
   Barthelmes, Daniel
   Gillies, Mark C.
CA Fight Retinal Blindness Study Grp
TI Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis
   after Intravitreal Injections for Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID ACUTE INTRAOCULAR INFLAMMATION; GROWTH-FACTOR AGENTS; CATARACT-SURGERY;
   RISK-FACTORS; BEVACIZUMAB; RANIBIZUMAB; SAFETY; DISCONTINUATION;
   METAANALYSIS; PREVENTION
AB Purpose: To assess the incidence, cumulative rate, and long-term outcomes of infectious and noninfectious endophthalmitis after intravitreal injections (IVTs) of anti-vascular endothelial growth factor (VEGF) agents.
   Design: Database study, prospectively designed.
   Participants: Treatment-naive eyes with neovascular age-related macular degeneration (nAMD) tracked by the Fight Retinal Blindness! (FRB!) registry that commenced anti-VEGF therapy between January 1, 2006, and November 30, 2016.
   Methods: Cumulative rate of endophthalmitis and survival curves were measured using Cox-proportional hazards models. Locally weighted scatterplot smoothing curves were used to display visual acuity (VA).
   Main Outcome Measures: Incidence and cumulative rate of endophthalmitis, and change in VA 12 months after endophthalmitis.
   Results: Infectious endophthalmitis developed in 18 of 88 150 injections (1/4897 injections [0.020%]; 95% confidence interval [CI], 0.012-0.032) with no difference found between types of anti-VEGF medications (P = 0.896). The cumulative rate of infectious endophthalmitis per patient was 0.055%, 0.183%, 0.360%, 0.360%, 0.555%, and 0.843% after 10, 20, 30, 40, 50, and 60 IVTs, respectively. However, the "risk" of infectious endophthalmitis did not increase with each successive injection (P = 0.202). Noninfectious endophthalmitis developed in 11 of 88 150 injections (1/8013 injections [0.012%]; 95% CI, 0.006-0.022). The cumulative rate of noninfectious endophthalmitis per patient was 0.087% and 0.228% after 10 and 20 IVTs, respectively, and then remained stable up to 60 IVTs. The incidence of noninfectious endophthalmitis was higher for bevacizumab (8/9931, 0.081%) compared with ranibizumab (3/54 776, 0.005%; P = 0.005) and aflibercept (0/23 425; P = 0.016), and no differences were observed between ranibizumab and aflibercept (P = 1.0). The 12-month VA in infectious and noninfectious endophthalmitis was within +/- 2 lines of before endophthalmitis in 53% and 75% of eyes, respectively; a loss > 2 lines was observed in 31% and 25% of eyes, respectively.
   Conclusions: The incidences of infectious and noninfectious endophthalmitis after IVT were low, and the risk did not increase with each successive injection. We found higher rates of noninfectious endophthalmitis with bevacizumab compared with ranibizumab or aflibercept. Three quarters of cases with infectious and two thirds of cases with noninfectious endophthalmitis retained vision within 10 letters of the pre-endophthalmitis level. (C) 2017 by the American Academy of Ophthalmology
C1 [Daien, Vincent; Vuong Nguyen; Barthelmes, Daniel; Gillies, Mark C.] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia.
   [Daien, Vincent] Gui De Chauliac Hosp, Dept Ophthalmol, Montpellier, France.
   [Daien, Vincent] INSERM, U1061, Montpellier, France.
   [Essex, Rohan W.] Australian Natl Univ, Acad Unit Ophthalmol, Acton, NSW, Australia.
   [Morlet, Nigel] Univ Western Australia, Dept Populat Hlth, Perth, WA, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
C3 University of Sydney; Universite de Montpellier; CHU de Montpellier;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Montpellier; Australian National University; University of
   Western Australia; University of Zurich; University Zurich Hospital
RP Daien, V (通讯作者)，Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia.
EM vincent.daien@sydney.edu.au
RI DAIEN, Vincent/Z-5516-2019
OI DAIEN, Vincent/0000-0001-5675-0861; lake, stewart/0000-0003-0078-3319;
   Guymer, Robyn/0000-0002-9441-4356; Hunt, Adrian/0000-0002-6261-4679;
   Essex, Rohan/0000-0001-5323-0334; Nguyen, Vuong/0000-0001-9070-9803;
   Fraser-Bell, Samantha/0000-0001-5646-9359
FU French Society of Ophthalmology; National Health and Medical Research
   Council practitioner fellowship; Walter and Gertrud Siegenthaler
   Foundation Zurich, Switzerland; Swiss National Foundation; Royal
   Australian NZ College of Ophthalmologists Eye Foundation; National
   Health and Medical Research Council, Australia; Macular Disease
   Foundation, Australia; Novartis; Bayer
FX The author(s) made the following disclosures: V.D.: Research grant of
   the French Society of Ophthalmology.; M.C.G.: Sydney Medical Foundation
   Fellow; Support - National Health and Medical Research Council
   practitioner fellowship.; D.B.: Support - Walter and Gertrud
   Siegenthaler Foundation Zurich, Switzerland, and the Swiss National
   Foundation.; Supported by grants from the Royal Australian NZ College of
   Ophthalmologists Eye Foundation (2007-2009), the National Health and
   Medical Research Council, Australia (2010-2012), and the Macular Disease
   Foundation, Australia. Funding was provided by Novartis and Bayer. These
   supporting organizations had no role in the design or conduct of the
   research.
CR Agrawal S, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/943409
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Casparis H, 2014, RETINA-J RET VIT DIS, V34, P12, DOI 10.1097/IAE.0b013e31829f74b0
   Chen E, 2011, RETINA-J RET VIT DIS, V31, P1525, DOI 10.1097/IAE.0b013e318221594a
   Chong DY, 2010, RETINA-J RET VIT DIS, V30, P1432, DOI 10.1097/IAE.0b013e3181dc04da
   Creuzot-Garcher C, 2016, OPHTHALMOLOGY, V123, P1414, DOI 10.1016/j.ophtha.2016.02.019
   Daien V, 2016, JAMA OPHTHALMOL, V134, P810, DOI 10.1001/jamaophthalmol.2016.1351
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Dossarps D, 2015, AM J OPHTHALMOL, V160, pe1, DOI DOI 10.1016/J.AJ0.2015.04.013
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Fileta JB, 2014, OSLI RETINA, V45, P143, DOI 10.3928/23258160-20140306-08
   Freiberg FJ, 2017, RETINA
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Green-Simms AE, 2011, AM J OPHTHALMOL, V151, P329, DOI 10.1016/j.ajo.2010.08.039
   Gregori NZ, 2015, OSLI RETINA, V46, P643, DOI 10.3928/23258160-20150610-08
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho DE, 2011, J STAT SOFTW, V42
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Kay CN, 2011, OPHTHAL SURG LAS IM, V42, P292, DOI 10.3928/15428877-20110603-04
   Lyall DAM, 2012, EYE, V26, P1517, DOI 10.1038/eye.2012.199
   McCannel CA, 2011, RETINA-J RET VIT DIS, V31, P654, DOI 10.1097/IAE.0b013e31820a67e4
   Meredith TA, 2015, OPHTHALMOLOGY, V122, P817, DOI 10.1016/j.ophtha.2014.10.027
   Moshfeghi AA, 2011, RETINA-J RET VIT DIS, V31, P662, DOI 10.1097/IAE.0b013e31821067c4
   Nentwich MM, 2014, RETINA-J RET VIT DIS, V34, P943, DOI 10.1097/IAE.0000000000000011
   Ness T, 2010, RETINA-J RET VIT DIS, V30, P332, DOI 10.1097/IAE.0b013e3181baf691
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shah CP, 2011, OPHTHALMOLOGY, V118, P2028, DOI 10.1016/j.ophtha.2011.02.034
   Storey P, 2014, OPHTHALMOLOGY, V121, P283, DOI 10.1016/j.ophtha.2013.08.037
   Team RC, 2013, R LANG ENV STAT COMP
   Vaze A, 2014, RETINA-J RET VIT DIS, V34, P1774, DOI 10.1097/IAE.0000000000000173
   von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010
   Wang FH, 2013, OPHTHALMOLOGY, V120, P355, DOI 10.1016/j.ophtha.2012.07.083
   Wickremasinghe SS, 2008, OPHTHALMOLOGY, V115, P1911, DOI 10.1016/j.ophtha.2008.05.007
   Williams, 2014, REV OPHTHALMOLOGY
   Williams PD, 2016, RETINA-J RET VIT DIS, V36, P909, DOI 10.1097/IAE.0000000000000801
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 39
TC 47
Z9 48
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2018
VL 125
IS 1
BP 66
EP 74
DI 10.1016/j.ophtha.2017.07.005
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FT0CC
UT WOS:000422787000028
PM 28801117
OA Bronze
DA 2022-11-30
ER

PT J
AU Kodjikian, L
   Souied, EH
   Mimoun, G
   Mauget-Faysse, M
   Behar-Cohen, F
   Decullier, E
   Huot, L
   Aulagner, G
AF Kodjikian, Laurent
   Souied, Eric H.
   Mimoun, Gerard
   Mauget-Faysse, Martine
   Behar-Cohen, Francine
   Decullier, Evelyne
   Huot, Laure
   Aulagner, Gilles
CA GEFAL Study Grp
TI Ranibizumab versus Bevacizumab for Neovascular Age-related Macular
   Degeneration: Results from the GEFAL Noninferiority Randomized Trial
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL-ACUITY; INTRAVITREAL INJECTION; ENDOPHTHALMITIS
AB Objective: To evaluate the relative efficacy and safety profile of bevacizumab versus ranibizumab intravitreal injections for the treatment of neovascular age-related macular degeneration (AMD).
   Design: Multicenter, prospective, noninferiority, double-masked, randomized clinical trial performed in 38 French ophthalmology centers. The noninferiority limit was 5 letters.
   Participants: Patients aged >= 50 years were eligible if they presented with subfoveal neovascular AMD, with best-corrected visual acuity (BVCA) in the study eye of between 20/32 and 20/320 measured on the Early Treatment of Diabetic Retinopathy Study chart and a lesion area of less than 12 optic disc areas (DA).
   Methods: Patients were randomly assigned to intravitreal administration of bevacizumab (1.25 mg) or ranibizumab (0.50 mg). Hospital pharmacies were responsible for preparing, blinding, and dispensing treatments. Patients were followed for 1 year, with a loading dose of 3 monthly intravitreal injections, followed by an asneeded regimen (1 injection in case of active disease) for the remaining 9 months with monthly follow-up.
   Main Outcome Measures: Mean change in visual acuity at 1 year.
   Results: Between June 2009 and November 2011, 501 patients were randomized. In the per protocol analysis, bevacizumab was noninferior to ranibizumab (bevacizumab minus ranibizumab +1.89 letters; 95% confidence interval [CI], -1.16 to +4.93, P< 0.0001). The intention-to-treat analysis was concordant. The mean number of injections was 6.8 in the bevacizumab group and 6.5 in the ranibizumab group (P=0.39). Both drugs reduced the central subfield macular thickness, with a mean decrease of 95 mm for bevacizumab and 107 mm for ranibizumab (P=0.27). There were no significant differences in the presence of subretinal or intraretinal fluid at final evaluation, dye leakage on angiogram, or change in choroidal neovascular area. The proportion of patients with serious adverse events was 12.6% in the bevacizumab group and 12.1% in the ranibizumab group (P=0.88). The proportion of patients with serious systemic or ocular adverse events was similar in both groups.
   Conclusions: Bevacizumab was noninferior to ranibizumab for visual acuity at 1 year with similar safety profiles. Ranibizumab tended to have a better anatomic outcome. The results are similar to those of previous head-to-head studies. (C) 2013 by the American Academy of Ophthalmology.
C1 [Kodjikian, Laurent] Hop Croix Rousse, Hosp Civils Lyon, Grp Hosp Nord, Serv Ophtalmol, F-69317 Lyon 04, France.
   [Kodjikian, Laurent; Decullier, Evelyne; Huot, Laure; Aulagner, Gilles] Univ Lyon, Lyon, France.
   [Kodjikian, Laurent; Aulagner, Gilles] CNRS, UMR Mateis 5510, Villeurbanne, France.
   [Souied, Eric H.] Ctr Hosp Intercommunal Creteil, Serv Ophtalmol, Creteil, France.
   [Souied, Eric H.; Mimoun, Gerard] Univ Paris Est Creteil, CRC, Creteil, France.
   [Mimoun, Gerard] Ecole Mil, Ctr Ophtalmol Imagerie, Paris, France.
   [Mauget-Faysse, Martine] Ctr Ophtalmol Rabelais, Lyon, France.
   [Behar-Cohen, Francine] Hop Hotel Dieu, Assistance Publ Hop Paris, F-75181 Paris, France.
   [Behar-Cohen, Francine] Univ Paris 05, Paris, France.
   [Behar-Cohen, Francine] Univ Paris 06, Paris, France.
   [Behar-Cohen, Francine] INSERM, UMR S 872, Ctr Rech Cordeliers, Paris, France.
   [Decullier, Evelyne; Huot, Laure] Hosp Civils Lyon, Unite Rech Clin, Pole Informat Med Evaluat Rech, Lyon, France.
   [Decullier, Evelyne; Huot, Laure] Univ Lyon 1, EAM Sante Individu Soc 4128, F-69365 Lyon, France.
   [Aulagner, Gilles] Hosp Civils Lyon, Grp Hosp Est, Serv Pharmaceut, Bron, France.
   [Aulagner, Gilles] Univ Lyon 1, Inst Sci Pharmaceut & Biol, Fac Pharm, F-69365 Lyon, France.
C3 CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Institut
   National des Sciences Appliquees de Lyon - INSA Lyon; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux
   Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French
   Research Universities; Aix-Marseille Universite; Assistance
   Publique-Hopitaux de Marseille; Universite Paris Cite; UDICE-French
   Research Universities; Universite Paris Cite; UDICE-French Research
   Universities; Sorbonne Universite; Institut National de la Sante et de
   la Recherche Medicale (Inserm); UDICE-French Research Universities;
   Sorbonne Universite; Universite Paris Cite; CHU Lyon; UDICE-French
   Research Universities; Universite Claude Bernard Lyon 1; Assistance
   Publique Hopitaux Paris (APHP); CHU Lyon; UDICE-French Research
   Universities; Universite Claude Bernard Lyon 1; Universite de
   Franche-Comte
RP Kodjikian, L (通讯作者)，Hop Croix Rousse, Hosp Civils Lyon, Grp Hosp Nord, Serv Ophtalmol, 103 Grande Rue Croix Rousse, F-69317 Lyon 04, France.
EM laurent.kodjikian@chu-lyon.fr
RI Huot, Laure/GLS-5988-2022; decullier, evelyne/AAL-5861-2021; Huot,
   Laure/F-1850-2014
OI Huot, Laure/0000-0002-7870-9912; 
FU French Ministry of Health; French Health Insurance System
FX Supported by a grant from the French Ministry of Health ("Programme
   Hospitalier de Recherche Clinique National 2008"). The French Health
   Insurance System co-financed the study and funded drugs. The funding
   organizations had no role in designing or carrying out this research.
CR Arevalo JF, 2008, RETINA-J RET VIT DIS, V28, P1387, DOI 10.1097/IAE.0b013e3181884ff4
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Goldberg RA, 2012, AM J OPHTHALMOL, V153, P204, DOI 10.1016/j.ajo.2011.11.035
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McCannel CA, 2011, RETINA-J RET VIT DIS, V31, P654, DOI 10.1097/IAE.0b013e31820a67e4
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shah N, 2011, INVEST OPHTH VIS SCI, V52, P9397, DOI 10.1167/iovs.11-7797
   Smiddy WE, 2009, OPHTHALMOLOGY, V116, P481, DOI 10.1016/j.ophtha.2008.10.029
   Stein JD, 2013, AM J OPHTHALMOL, V155, P688, DOI 10.1016/j.ajo.2012.10.003
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 23
TC 195
Z9 200
U1 0
U2 30
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2013
VL 120
IS 11
BP 2300
EP 2309
DI 10.1016/j.ophtha.2013.06.020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 248FT
UT WOS:000326681700028
PM 23916488
DA 2022-11-30
ER

PT J
AU Cruess, AF
   Zlateva, G
   Xu, X
   Soubrane, G
   Pauleikhoff, D
   Lotery, A
   Mones, J
   Buggage, R
   Schaefer, C
   Knight, T
   Goss, TF
AF Cruess, Alan F.
   Zlateva, Gergana
   Xu, Xiao
   Soubrane, Gisele
   Pauleikhoff, Daniel
   Lotery, Andrew
   Mones, Jordi
   Buggage, Ronald
   Schaefer, Caroline
   Knight, Tyler
   Goss, Thomas F.
TI Economic burden of bilateral neovascular age-related macular
   degeneration - Multi-country observational study
SO PHARMACOECONOMICS
LA English
DT Article
ID VISUAL IMPAIRMENT; RANIBIZUMAB; MACULOPATHY; POPULATION; PEGAPTANIB; EYE
AB Background: There is limited previous research examining the healthcare costs of neovascular age-related macular degeneration (NV-AMD), which constrains our understanding of the economic impact of this condition. With aging populations, this leading cause of rapid vision loss in Western countries is expected to become a pressing health predicament, requiring decision makers to evaluate alternative treatment strategies for AMD.
   Objective: To document the economic burden of bilateral NV-AMD, the late stage of AMD, in elderly patients, from a societal perspective.
   Study design, setting and participants: A cross-sectional, observational study surveyed 401 patients with bilateral NV-AMD and 471 non-AMD subjects in Canada, France, Germany, Spain and the UK. Physicians' records and subjects' standardized telephone interviews were used to record medical resource utilization, assistance with daily living and social benefits. Annual bilateral NV-AMD-related socioeconomic costs were calculated in E, year 2005 values.
   Main outcome measures: Societal costs including direct vision-related medical costs (e.g. treatment of AMD and vision-related equipment), direct non-vision-related medical costs (e.g. medications) and direct non-medical-related costs (e.g. home healthcare and social services) were the main outcome measures.
   Results: The demographic profile of NV-AMD patients was similar across countries; however, co-morbid condition profiles varied. NV-AMD patients reported substantial health-related problems and associated health resource utilization (HRU). In the previous 12 months, 12-22% of patients fell, and half of these patients required medical treatments. More than 20% (range 21-59%) of patients were prescribed vision-enhancing equipment. More than half of the patients (54-81%) were living with a spouse or family member and 19-41% reported receiving assistance for activities of daily living.
   The average annual societal cost per bilateral NV-AMD patient treated was estimated to be (sic)7879 in Canada, (sic)7349 in France, E 12 445 in Germany, (sic)5732 in Spain and (sic)5300 in the UK, and direct vision-related medical costs accounted for 23-63% of the total cost. Half of the patients were diagnosed with bilateral NV-AMD for <1 year, with an average length of 5 months; there were no statistically significant differences in total annual costs per patient between these patients and those who were diagnosed with bilateral disease for >= l year. Estimated annual societal costs of bilateral NV-AMD patients in these countries ranged from 46268 to (sic)1311 million. Estimated annual societal costs of all NV-AMD patients in these countries ranged from (sic)671 to (sic)3278 million.
   Conclusions: Bilateral NV-AMD imposes significant functional impairment on patients, leading to increased HRU and a high societal cost burden. Differences in national healthcare systems and NV-AMD treatment patterns were reflected in the wide variation of NV-AMD costs across the five surveyed countries. Even though the prevalence rates and per-patient costs varied by country, the societal costs of NV-AMD patients were substantial in each country. Earlier intervention with effective therapies is expected to reduce disease burden and disability associated with NV-AMD and, thus, decrease the overall societal cost.
C1 [Cruess, Alan F.] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS B3H 2Y9, Canada.
   [Zlateva, Gergana; Buggage, Ronald] Pfizer Ophthalm, New York, NY USA.
   [Xu, Xiao; Schaefer, Caroline; Knight, Tyler; Goss, Thomas F.] Covance Market Access Serv Inc, Gaithersburg, MD USA.
   [Soubrane, Gisele] Univ Paris 12, Ctr Hosp Intercommunal, Dept Ophthalmol, Creteil, France.
   [Pauleikhoff, Daniel] Augenarztpraxis St Franziskus Hosp, Munster, Germany.
   [Lotery, Andrew] Univ Southampton, Southampton Eye Unit, Southampton, Hants, England.
   [Mones, Jordi] Inst Microcirugia Ocular Barcelona, Ctr Medico Teknon, Barcelona, Spain.
C3 Dalhousie University; Pfizer; Covance; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; St.
   Franziskus-Hospital; University of Southampton
RP Cruess, AF (通讯作者)，Dalhousie Univ, Dept Ophthalmol & Visual Sci, 2 W Victoria,Room 2035,1278 Tower Rd, Halifax, NS B3H 2Y9, Canada.
EM alan.cruess@dal.ca
RI mones, jordi/CAJ-2963-2022
OI mones, jordi/0000-0003-3685-2160; Lotery, Andrew/0000-0001-5541-4305
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bonastre J, 2002, Eur J Health Econ, V3, P94, DOI 10.1007/s10198-002-0104-y
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   *CAN I HLTH INF, AN 2003 DAT CAN MIS
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   *CTR STUD HLTH EC, 2005, DAT SPAN HLTH COSTS
   Curtis L, 2004, UNIT COSTS HLTH SOCI
   DargentMolina P, 1996, LANCET, V348, P145, DOI 10.1016/S0140-6736(96)01440-7
   DESAI M, 2001, 2 NAT CTR HLTH STAT
   *FRENCH NAT AUTH H, 2005, COMM CLASS MED SERV
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Lee HKM, 2003, AGE AGEING, V32, P643, DOI 10.1093/ageing/afg110
   *M JACK GROUP, 2003, EP AG REL MAC DEG
   *NAT ASS SICKN FUN, 2005, UN VAL SCAL
   OECD, PURCH POW PART PPP
   Rizzo JA, 1998, MED CARE, V36, P1174, DOI 10.1097/00005650-199808000-00006
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmier JK, 2006, PHARMACOECONOMICS, V24, P319, DOI 10.2165/00019053-200624040-00003
   SHARMA S, 2004, ANN M ASS RES VIS OP
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   *TECHN AG INF HOSP, 2005, PROGR MED INF SYST
   Verma Lalit, 2000, Indian Journal of Ophthalmology, V48, P263
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   [No title captured]
NR 27
TC 85
Z9 86
U1 0
U2 11
PU ADIS INT LTD
PI AUCKLAND
PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW
   ZEALAND
SN 1170-7690
J9 PHARMACOECONOMICS
JI Pharmacoeconomics
PY 2008
VL 26
IS 1
BP 57
EP 73
DI 10.2165/00019053-200826010-00006
PG 17
WC Economics; Health Care Sciences & Services; Health Policy & Services;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Business & Economics; Health Care Sciences & Services; Pharmacology &
   Pharmacy
GA 257XQ
UT WOS:000252832900006
PM 18088159
DA 2022-11-30
ER

PT J
AU Saleh, M
   Kheliouen, M
   Tebeanu, E
   Ballonzoli, L
   Bourcier, T
   Speeg-Schatz, C
   Gaucher, D
AF Saleh, Maher
   Kheliouen, Mehdi
   Tebeanu, Eliza
   Ballonzoli, Laurent
   Bourcier, Tristan
   Speeg-Schatz, Claude
   Gaucher, David
TI Retreatment by series of three intravitreal injections of ranibizumab in
   neovascular age-related macular degeneration: long-term outcomes
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Intravitreal injections; Ranibizumab;
   Retreatment protocol
ID VERTEPORFIN; THERAPY; DELAY
AB The purpose of this study was to analyze the results of a retreatment regimen using a series of three monthly intravitreal ranibizumab injections (IVR), instead of one injection, and to determine if this treatment scheme can safely reduce the number of injections and the number of visits compared to the widely used PrONTO study retreatment protocol.
   > Sixty-six eyes of 60 patients with exudative age-related macular degeneration (AMD) were included. The mean follow-up period was 27 months (range, 11-48 months). The mean age of the patients was 79 years (range, 65-93 years). All patients received three initial IVRs, and were retreated with a new series of three monthly IVRs when needed. The retreatment criteria were: visual loss of a parts per thousand yen5 ETDRS letters and/or signs of retinal exudation on OCT, new macular hemorrhage, expansion of new vessels. Follow-up visits were conducted 1 month after the last IVR of each series, and renewed on a monthly basis when no retreatment was required. Each visit included a comprehensive ophthalmological examination with BCVA measurement and OCT examination.
   Mean VA did not improve during follow-up (53.18 letters at the initial visit versus 54.18 at the last visit, p > 0.05). However, VA stabilized or improved in 66.6 % of the eyes. A gain of a parts per thousand yen15 letters was observed in 28.8 % of eyes. On average, over 2 years, the number of IVRs was five per year, and the number of follow-up visits was four per year.
   Even if no gain in VA is observed after 2 years, this treatment regimen reduces the number of IVRs and control visits. The proportion of patients with a VA gain of three lines or more was smaller than the one reported in the original PrONTO study, but higher than the rates reported in other studies implementing the PrONTO recommendations in everyday practice. The benefit of the three IVR retreatment scheme should be prospectively studied and compared to the PRN regimen.
C1 [Saleh, Maher] Univ Franche Comte, Univ Hosp Jean Minjoz Besancon, Dept Ophthalmol, F-25000 Besancon, France.
   [Kheliouen, Mehdi; Tebeanu, Eliza; Ballonzoli, Laurent; Bourcier, Tristan; Speeg-Schatz, Claude; Gaucher, David] Strasbourg Univ, Univ Hosp Strasbourg, Nouvel Hop Civil, Dept Ophthalmol, F-67000 Strasbourg, France.
   [Bourcier, Tristan; Gaucher, David] Univ Strasbourg, Inst Bacteriol, Unite EA Virulence Bacterienne Precoce 7290, FMTS, Strasbourg, France.
   [Gaucher, David] Strasbourg Univ, Univ Hosp Strasbourg, Nouvel Hop Civil, Dept Ophthalmol, F-67091 Strasbourg, France.
C3 CHU Besancon; Universite de Franche-Comte; CHU Strasbourg; UDICE-French
   Research Universities; Universites de Strasbourg Etablissements
   Associes; Universite de Strasbourg; UDICE-French Research Universities;
   Universites de Strasbourg Etablissements Associes; Universite de
   Strasbourg; CHU Strasbourg; UDICE-French Research Universities;
   Universites de Strasbourg Etablissements Associes; Universite de
   Strasbourg
RP Gaucher, D (通讯作者)，Strasbourg Univ, Univ Hosp Strasbourg, Nouvel Hop Civil, Dept Ophthalmol, 1 Pl Hop, F-67091 Strasbourg, France.
EM david.gaucher@chru-strasbourg.fr
CR Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Dunavoelgyi R, 2012, RETINA, V12, P2223
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
NR 22
TC 2
Z9 3
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2013
VL 251
IS 8
BP 1901
EP 1907
DI 10.1007/s00417-013-2284-9
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 196PE
UT WOS:000322786900004
PM 23430191
DA 2022-11-30
ER

PT J
AU Baird, PN
   Guida, E
   Chu, DT
   Vu, HTV
   Guymer, RH
AF Baird, PN
   Guida, E
   Chu, DT
   Vu, HTV
   Guymer, RH
TI The epsilon 2 and epsilon 4 alleles of the apolipoprotein gene are
   associated with age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BEAVER DAM EYE; VISUAL IMPAIRMENT PROJECT; RISK-FACTORS; DIETARY-FAT;
   CARDIOVASCULAR-DISEASE; MACULOPATHY; ATHEROSCLEROSIS; CHOLESTEROL;
   PREVALENCE; AUSTRALIA
AB PURPOSE. To date, of all the genes studied in relation to age-related macular degeneration (AMD), the alleles of the apolipoprotein (apoE) gene have been the most consistently associated with disease. However, not all apoE studies have found an association, and among these the associations differ. The current study was conducted to investigate further the association of this gene in AMD.
   METHODS. Three hundred twenty-two unrelated individuals with diagnosed AMD and 123 unrelated but ethnically matched control subjects were analyzed. All subjects completed a standard questionnaire and were given a fundus examination. A blood sample was collected for DNA extraction. The common allelic variants of apoE were screened through the use of polymerase chain reaction (PCR) and restriction enzyme digestion followed by statistical analysis.
   RESULTS. Individuals with the epsilon3 epsilon4 genotype of apoE had an approximate halving of disease risk for late (end-stage) AMD (odds ratio [OR] 0.58, 95% confidence interval [CI] 0.34-0.98) relative to the e3 e3 genotype at age of ascertainment. Stratification of late AMD into atrophic and neovascular disease revealed that the greatest protective effect for the epsilon3 epsilon4 genotype was in individuals with atrophic disease (OR 0.35, 95% Cl 0.13-0.92). Men with the epsilon3 epsilon4 genotype also showed almost a threefold reduction in risk of disease in late AMD (OR 0.36, 95% Cl 0.16-0.82). However, individuals with late AMD and the epsilon2 epsilon3 genotype had a significantly earlier mean age of diagnosis of disease (3.4 years, P = 0.015) compared with those with the e3 e3 genotype, and this was most evident in women (3.9 years, P = 0.011) and in individuals with neovascular disease (4.7 years, P = 0.003).
   CONCLUSIONS. The alleles of apoE appear to have a role in the etiology of AMD, with the epsilon4 allele being protective, or at the very least, delaying the age of diagnosis of disease, whereas the epsilon2 allele appears to have a modifier effect by bringing forward the mean age of disease diagnosis.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
C3 Centre for Eye Research Australia; University of Melbourne
RP Baird, PN (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM pnb@unimelb.edu.au
OI Guymer, Robyn/0000-0002-9441-4356; Baird, Paul/0000-0002-1305-3502
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Davignon J, 1999, CLIN CHIM ACTA, V286, P115, DOI 10.1016/S0009-8981(99)00097-2
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein BEK, 1997, AM J OPHTHALMOL, V123, P338, DOI 10.1016/S0002-9394(14)70129-1
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Lucotte G, 1997, HUM BIOL, V69, P253
   MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Sambrook J., 1989, MOL CLONING LAB MANU
   Schmidt S, 2000, MOL VIS, V6, P287
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   SCHULTZ DW, 2003, EPIDEMIOLOGY, V121, P679
   Scuteri A, 2001, AM J MED, V110, P28, DOI 10.1016/S0002-9343(00)00639-2
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725
   Taylor HR, 1997, AM J OPHTHALMOL, V123, P328, DOI 10.1016/S0002-9394(14)70128-X
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
NR 30
TC 144
Z9 152
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2004
VL 45
IS 5
BP 1311
EP 1315
DI 10.1167/iovs.03-1121
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 816BF
UT WOS:000221084700006
PM 15111582
DA 2022-11-30
ER

PT J
AU Lee, SJ
   Koh, HJ
AF Lee, Sung Jun
   Koh, Hyoung Jun
TI Effects of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth
   Factor Treatment for Exudative Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; COMPLEMENT FACTOR-H; CHOROIDAL
   NEOVASCULARIZATION; LOC387715 GENOTYPES; BEVACIZUMAB AVASTIN;
   RANIBIZUMAB; PATHOGENESIS; PHARMACOKINETICS; INFLAMMATION; ASSOCIATION
AB Objective: To evaluate the effect of posterior vitreomacular adhesion (VMA), documented by optical coherence tomography (OCT), on the outcome of anti-vascular endothelial growth factor (VEGF) treatment for exudative age-related macular degeneration (AMD).
   Design: Retrospective comparative series.
   Participants: A total of 148 patients (148 eyes) who were newly diagnosed with exudative AMD and were treated by anti-VEGF in 1 eye from 2005 to 2008 with a minimum of 12 months follow-up.
   Methods: We retrospectively reviewed OCT and medical records of 148 patients with exudative AMD and categorized them according to the presence of posterior VMA into 2 subgroups: VMA (+) group (38 eyes) and VMA (-) group (110 eyes). Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) after anti-VEGF treatment were compared between the 2 groups at baseline; at 1, 3, 6, and 12months; and at the last visit (mean = 21 months).
   Main Outcome Measures: Mean changes in BCVA, which was converted to logarithm of the minimum angle of resolution (logMAR) values and CRT after anti-VEGF treatment.
   Results: Mean BCVA significantly decreased over time in the VMA (+) group compared with the VMA (-) group (P = 0.039). At the last follow-up, mean BCVA had deteriorated from 0.87 logMAR (20/149 Snellen equivalent; baseline) to 0.98 logMAR (20/189 Snellen equivalent) in the VMA (+) group, but improved from 0.82 logMAR (20/132 Snellen equivalent, baseline) to 0.72 logMAR (20/104, Snellen equivalent) in the VMA (-) group (P = 0.028). In paired comparisons of BCVA between baseline and each follow-up visit, the VMA (-) group showed significant improvement of BCVA at every follow-up visit (P < 0.05); however, the VMA (+) group did not show significant visual improvement at any follow-up visit despite anti-VEGF treatment (P > 0.05). Comparison of mean CRT between baseline and each follow-up visit showed a statistically significant decrease at every follow-up in both groups (P < 0.05).
   Conclusions: Posterior VMA was associated with an inferior visual outcome after intravitreal anti-VEGF treatment for exudative AMD. Our results suggest that chronic tractional forces may antagonize the effect of anti-VEGF treatment, resulting in poor response to anti-VEGF treatment with patients with VMA.
C1 [Koh, Hyoung Jun] Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, Seoul 120752, South Korea.
   [Lee, Sung Jun] Dongguk Univ, Sch Med, Dept Ophthalmol, Ilsan Hosp, Gyeonggido, South Korea.
C3 Yonsei University; Yonsei University Health System; Dongguk University;
   NHIS Ilsan Hospital
RP Koh, HJ (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, 134 Shinchon Dong, Seoul 120752, South Korea.
EM hjkoh@yuhs.ac
OI Koh, Hyoung Jun/0000-0002-5932-8516
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chang LK, 2008, AM J OPHTHALMOL, V146, P121, DOI 10.1016/j.ajo.2008.03.001
   DiLoreto DA, 2003, ARCH OPHTHALMOL-CHIC, V121, P1586, DOI 10.1001/archopht.121.11.1586
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Freeman WR, 2006, RETINA-J RET VIT DIS, V26, P853, DOI 10.1097/01.iae.0000244722.35073.7c
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Ikeda T, 2000, ACTA OPHTHALMOL SCAN, V78, P460, DOI 10.1034/j.1600-0420.2000.078004460.x
   Jabs DA, 2005, AM J OPHTHALMOL, V139, P900, DOI 10.1016/j.ajo.2004.12.009
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Nomoto H, 2009, INVEST OPHTH VIS SCI, V50, P4807, DOI 10.1167/iovs.08-3148
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Quaranta-El Maftouhi M, 2006, EUR J OPHTHALMOL, V16, P134
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt JC, 2006, BRIT J OPHTHALMOL, V90, P1361, DOI 10.1136/bjo.2006.094201
   Sebag J, 2008, GRAEF ARCH CLIN EXP, V246, P329, DOI 10.1007/s00417-007-0743-x
   Sebag J, 2004, GRAEF ARCH CLIN EXP, V242, P690, DOI 10.1007/s00417-004-0980-1
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 34
TC 68
Z9 73
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2011
VL 118
IS 1
BP 101
EP 110
DI 10.1016/j.ophtha.2010.04.015
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 701PF
UT WOS:000285832500017
PM 20678805
DA 2022-11-30
ER

PT J
AU Loane, E
   Kelliher, C
   Beatty, S
   Nolan, JM
AF Loane, E.
   Kelliher, C.
   Beatty, S.
   Nolan, J. M.
TI The rationale and evidence base for a protective role of macular pigment
   in age-related maculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID LONG-TERM INCIDENCE; VITAMIN-E; OXIDATIVE STRESS; BETA-CAROTENE; DIETARY
   ANTIOXIDANTS; ALPHA-TOCOPHEROL; EPITHELIAL-CELLS; NATIONAL-HEALTH;
   RISK-FACTORS; BINDING-PROTEIN
AB Age-related maculopathy (ARM) remains the most common cause of blind registration in people aged 50 years or over in the developed world, and its prevalence continues to rise. Although effective new treatments have become available in the recent past, these are expensive and cumbersome to the healthcare provider and to the patient, and many cases remain resistant to such therapy. There is a biologically plausible rationale whereby macular pigment, which is entirely of dietary origin, may prevent or delay the onset, or ameliorate the clinical course, of ARM. In this article, we review this rationale, and critically appraise the current evidence base germane to the use of supplements containing the macular carotenoids in patients with, or at risk of developing, ARM.
C1 [Loane, E.; Beatty, S.; Nolan, J. M.] Waterford Inst Technol, Macular Pigment Res Grp, Waterford, Ireland.
   [Kelliher, C.; Beatty, S.] Waterford Reg Hosp, Dept Ophthalmol, Waterford, Ireland.
C3 South East Technological University (SETU)
RP Nolan, JM (通讯作者)，Waterford Inst Technol, Macular Pigment Res Grp, Cork Rd, Waterford, Ireland.
EM jnolan@wit.ie
RI Nolan, John/N-4921-2014
OI Nolan, John/0000-0002-5503-7084
FU Bausch & Lomb Ireland Limited
FX EL is currently conducting research towards a PhD degree, part-funded by
   a grant from Bausch & Lomb Ireland Limited.
CR Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   AOKI K, 1987, JPN J CANCER RES, V78, P1049
   Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Bandello F, 2007, INVEST OPHTH VIS SCI, V48, P96, DOI 10.1167/iovs.06-0283
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Belda JI, 1999, MECH AGEING DEV, V107, P159, DOI 10.1016/S0047-6374(98)00144-4
   Bernstein PS, 1997, INVEST OPHTH VIS SCI, V38, P167
   Bhosale P, 2005, BBA-MOL BASIS DIS, V1740, P116, DOI 10.1016/j.bbadis.2005.02.002
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   BUNCE C, 1999, CAUSES BLIN IN PRESS
   Cantrell A, 2003, ARCH BIOCHEM BIOPHYS, V412, P47, DOI 10.1016/S0003-9861(03)00014-6
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Chucair AJ, 2007, INVEST OPHTH VIS SCI, V48, P5168, DOI 10.1167/iovs.07-0037
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Kalariya NM, 2008, EXP EYE RES, V86, P70, DOI 10.1016/j.exer.2007.09.010
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kelliher C, 2006, BRIT J OPHTHALMOL, V90, P367, DOI 10.1136/bjo.2005.075861
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   KIRSCHFELD K, 1982, PROC R SOC SER B-BIO, V216, P71, DOI 10.1098/rspb.1982.0061
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   MAOKA T, 1986, COMP BIOCHEM PHYS B, V83, P121, DOI 10.1016/0305-0491(86)90341-X
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Nebeling LC, 1997, AM J PUBLIC HEALTH, V87, P268, DOI 10.2105/AJPH.87.2.268
   Nebeling LC, 1997, J AM DIET ASSOC, V97, P991, DOI 10.1016/S0002-8223(97)00239-3
   NEELAM K, OPHTHALMIC IN PRESS
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Richer S, 1999, J Am Optom Assoc, V70, P24
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schork NJ, 1997, AM J RESP CRIT CARE, V156, pS103, DOI 10.1164/ajrccm.156.4.12-tac-5
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Shaban H, 2002, EXP EYE RES, V75, P99, DOI 10.1006/exer.2001.1192
   Siems WG, 1999, BIOFACTORS, V10, P105, DOI 10.1002/biof.5520100204
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Smith W, 1997, AM J OPHTHALMOL, V124, P838, DOI 10.1016/S0002-9394(14)71702-7
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Sommerburg Olaf, 2000, Biofactors, V11, P3
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Stringham JM, 2006, OPTOMETRY VISION SCI, V83, P887, DOI 10.1097/01.opx.0000249976.00534.2d
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Suzuki M, 2007, MOL VIS, V13, P772
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Trevithick-Sutton CC, 2006, MOL VIS, V12, P1127
   TRIESCHMANN M, EYE IN PRESS
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   TSANG NCK, 1992, DOC OPHTHALMOL, V81, P387
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   Wrona M, 2004, FREE RADICAL BIO MED, V36, P1094, DOI 10.1016/j.freeradbiomed.2004.02.005
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   VITAMINS WHAT THEY D
NR 93
TC 74
Z9 76
U1 0
U2 10
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2008
VL 92
IS 9
BP 1163
EP 1168
DI 10.1136/bjo.2007.135566
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 340UA
UT WOS:000258669300002
PM 18669545
DA 2022-11-30
ER

PT J
AU Stifter, E
   Weghaupt, H
   Benesch, T
   Thaler, A
   Radner, W
AF Stifter, E
   Weghaupt, H
   Benesch, T
   Thaler, A
   Radner, W
TI Discriminative power of reading tests to differentiate visual impairment
   caused by cataract and age-related macular degeneration
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
ID QUALITY-OF-LIFE; WAVE-FRONT ANALYSIS; SPEED TEST; SURGERY; SYSTEM;
   ACUITY; PSYCHOPHYSICS; RELIABILITY; PERFORMANCE; OUTCOMES
AB Purpose: To determine whether preoperative reading tests can be used for differentiating visual impairments with regard to the diagnosis of cataract and age-related macular degeneration (ARMD).
   Setting: Department of Ophthalmology, Medical University of Vienna, Vienna, Austria.
   Methods: Reading performance of patients with nuclear cataract, posterior subcapsular cataract, and ARMD were evaluated with respect to reading acuity, maximum reading speed, and critical print size; normal-sighted participants were tested as controls. A multivariate discriminant analysis of the 4 groups (100 eyes of 100 participants) was performed to evaluate how many patients could be correctly diagnosed by significant differences in the tested reading parameters. Subsequently, the nuclear cataract and posterior subcapsular cataract patients were compared with cataract patients with coexisting ARMD.
   Results: Distance visual acuity was comparable in the nuclear cataract, posterior subcapsular cataract, and ARMD groups (P>.05). Reading acuity was significantly reduced in posterior subcapsular cataract and ARMD patients compared with nuclear cataract patients and controls (P<.0001). No significant difference in maximum reading speed was found between the nuclear cataract patients and the controls (P=.07), whereas the maximum reading speed of the posterior subcapsular cataract and ARMD patients was significantly reduced (P<.0001). In the discriminant analysis, it was possible to assign the correct diagnosis to 72% of the nuclear cataract patients, 76% of the posterior subcapsular cataract patients, 72% of the ARMD patients, and 92% of the controls. Comparing the reading performance of nuclear cataract and posterior subcapsular cataract patients and cataract patients with coexisting ARMD showed that reading performance was significantly impaired in the comorbid patients (nuclear cataract and ARMD, P<.001; posterior subcapsular cataract and ARMD, P<.05).
   Conclusion: The high discriminant accuracy shows that this standardized reading test system is a valuable diagnostic tool for evaluating functional visual impairments when distance visual acuity alone cannot elucidate the origin of functional impairment. Considering the significant discrepancies in reading performance among patients with nuclear cataract, posterior subcapsular cataract, and ARMD, reading tests may relevantly improve the clinical evaluation of patients with visual loss, even of patients with ocular comorbidity.
C1 Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
   Med Univ Vienna, Dept Med Stat, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Radner, W (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM wolfgang.radner@meduniwien.ac.at
CR ABHAY RV, 2004, J CATARACT REFR SURG, V30, P2097
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   AHN SJ, 1995, VISION RES, V35, P1939, DOI 10.1016/0042-6989(94)00294-V
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   BATES AK, 1992, BRIT J OPHTHALMOL, V76, P32, DOI 10.1136/bjo.76.1.32
   BULLIMORE MA, 1995, OPTOMETRY VISION SCI, V72, P125, DOI 10.1097/00006324-199502000-00011
   *CEN, 1996, 8596 CEN EN ISO
   Chen SN, 2003, J CATARACT REFR SURG, V29, P983, DOI 10.1016/S0886-3350(02)01700-5
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Davis J., 1986, STAT DATA ANAL GEOLO
   Davison JA, 2003, J CATARACT REFR SURG, V29, P138, DOI 10.1016/S0886-3350(02)01839-4
   ELLIOTT DB, 1989, OPHTHAL PHYSL OPT, V9, P25, DOI 10.1111/j.1475-1313.1989.tb00800.x
   Elliott DB, 2001, INVEST OPHTH VIS SCI, V42, P1945
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   JAVITT JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P686, DOI 10.1001/archopht.1993.01090050120041
   Jobson J. D., 1991, APPL MULTIVARIATE DA
   Kuroda T, 2002, J CATARACT REFR SURG, V28, P438, DOI 10.1016/S0886-3350(01)01176-2
   Kuroda T, 2002, AM J OPHTHALMOL, V134, P1, DOI 10.1016/S0002-9394(02)01402-2
   LEGGE GE, 1985, VISION RES, V25, P239, DOI 10.1016/0042-6989(85)90117-8
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   LEGGE GE, 1992, INVEST OPHTH VIS SCI, V33, P677
   Lux S, 2004, NEUROSCIENCE, V124, P113, DOI 10.1016/j.neuroscience.2003.10.044
   MANGIONE CM, 1994, ARCH OPHTHALMOL-CHIC, V112, P1419, DOI 10.1001/archopht.1994.01090230033017
   Martin BK, 2001, J CLIN EPIDEMIOL, V54, P376, DOI 10.1016/S0895-4356(00)00294-8
   Monestam E, 1997, ACTA OPHTHALMOL SCAN, V75, P569
   Monestam E, 1999, J CATARACT REFR SURG, V25, P1127, DOI 10.1016/S0886-3350(99)00135-2
   Pesudovs K, 2002, CLIN EXP OPHTHALMOL, V30, P183, DOI 10.1046/j.1442-9071.2002.00522.x
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Radner T, 1998, KLIN MONATSBL AUGENH, V213, P174, DOI 10.1055/s-2008-1034969
   RICHTERMUEKSCH S, 2005, GRAEFES ARCH CLIN EX, V27, P1
   Riusala A, 2003, AM J OPHTHALMOL, V135, P206, DOI 10.1016/S0002-9394(02)01832-9
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   Stifter E, 2004, GRAEF ARCH CLIN EXP, V242, P31, DOI 10.1007/s00417-003-0776-8
   Stifter E, 2004, J CATARACT REFR SURG, V30, P1259, DOI 10.1016/j.jcrs.2003.11.051
   Tannenbaum DP, 2004, OPHTHALMOLOGY, V111, P259, DOI 10.1016/j.ophtha.2003.05.015
   Uusitalo RJ, 1999, J CATARACT REFR SURG, V25, P989, DOI 10.1016/S0886-3350(99)00082-6
   Uusitalo RJ, 1998, J CATARACT REFR SURG, V24, P212, DOI 10.1016/S0886-3350(98)80202-2
   1980, ADV OPHTHALMOL, V41, P103
NR 40
TC 23
Z9 23
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0886-3350
EI 1873-4502
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD NOV
PY 2005
VL 31
IS 11
BP 2111
EP 2119
DI 10.1016/j.jcrs.2005.03.080
PG 9
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 004XU
UT WOS:000234786800025
PM 16412924
DA 2022-11-30
ER

PT J
AU Farinha, C
   Barreto, P
   Coimbra, R
   Iutis, A
   Cachulo, ML
   Cunha-Vaz, J
   Lechanteur, YTE
   Hoyng, CB
   Silva, R
AF Farinha, Claudia
   Barreto, Patricia
   Coimbra, Rita
   Iutis, Adela
   Cachulo, Maria Luz
   Cunha-Vaz, Jose
   Lechanteur, Yara T. E.
   Hoyng, Carel B.
   Silva, Rufino
TI Phenotypic Expression of CFH Rare Variants in Age-Related Macular
   Degeneration Patients in the Coimbra Eye Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; Coimbra Eye Study; rare CFH variants;
   AMD phenotype; genotype-phenotype associations
ID COMPLEMENT FACTOR-H; RARE GENETIC-VARIANTS; RISK-FACTORS; ASSOCIATION;
   PREVALENCE; DRUSEN; MACULOPATHY; PORTUGAL; ATROPHY; SYSTEM
AB PURPOSE. To determine the association between rare genetic variants in complement factor H (CFH) and phenotypic features in age-related macular degeneration (AMD) patients from the Coimbra Eye Study (CES). METHODS. AMD patients from the Incidence CES (NCT02748824) underwent ophthalmologic examination and color fundus photography, spectral-domain optical coherence tomography (SD-OCT), fundus autofluorescence, and near-infrared imaging. Multimodal phenotypic characterization was carried out in a centralized reading center. The coding and splice-site regions of the CFH gene were sequenced through single-molecule molecular inversion probe-based next-generation sequencing in association with the EYE-RISK consortium. Variants with minor allele frequency < 0.05 resulting in splice-site or protein change were selected. Differences in phenotypic features between carriers and noncarriers were analyzed using generalized estimated equations logistic regression models, considering intereye correlations. RESULTS. We included 39 eyes of 23 patients carrying rare CFH variants and 284 eyes of 188 noncarriers. Carrier status was associated with having higher drusen burden in the macula in the inner Early Treatment Diabetic Retinopathy Study circle (odds ratio [OR], 5.44 [95% confidence interval {CI}, 1.61-18.37]; P = 0.006), outer circle (OR, 4.37 [95% CI, 1.07-17.77]; P = 0.04), and full grid (OR, 4.82 [95% CI, 1.13-20.52]; P = 0.033). In SD-OCT, a lower total macular volume and lower inner retinal layers' volume (OR, 0.449 [95% CI, 0.226-0.894]; P = 0.023; OR, 0.496 [95% CI, 0.252-0.979]; P = 0.043) and pigment epithelial detachments (PEDs) (OR, 5.24 [95% CI, 1.08-25.44]; P = 0.04) were associated with carrying a rare CFH variant. Carriers with subretinal drusenoid deposits (SDD) had the rare variant P258L in all cases except one. CONCLUSIONS. We identified in our cohort phenotypic differences between carriers and noncarriers of rare variants in the CFH gene. Carriers had more severe disease, namely superior drusen burden, PEDs, and thinner retinas. The rare variant P258L may be associated with SDD. Carriers are probably at increased risk of progression.
C1 [Farinha, Claudia; Barreto, Patricia; Coimbra, Rita; Cachulo, Maria Luz; Cunha-Vaz, Jose; Silva, Rufino] AIBILI Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal.
   [Farinha, Claudia; Cachulo, Maria Luz; Silva, Rufino] Ctr Hosp & Univ Coimbra CHUC, Ophthalmol Dept, Coimbra, Portugal.
   [Farinha, Claudia; Cachulo, Maria Luz; Cunha-Vaz, Jose; Silva, Rufino] Clin Acad Ctr Coimbra CACC, Coimbra, Portugal.
   [Farinha, Claudia; Cachulo, Maria Luz; Cunha-Vaz, Jose; Silva, Rufino] Univ Coimbra, Coimbra Inst Clin & Biomed Res, Fac Med iCBR FMUC, Coimbra, Portugal.
   [Iutis, Adela] Univ Aveiro, Dept Math, Aveiro, Portugal.
   [Lechanteur, Yara T. E.; Hoyng, Carel B.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   [Farinha, Claudia] AIBILI, Edificio Prof Doutor Jose Cunha Vaz,Azinhaga Sta C, P-3000548 Coimbra, Portugal.
C3 Universidade de Coimbra; Universidade de Coimbra; Centro Hospitalar e
   Universitario de Coimbra (CHUC); Universidade de Coimbra; Universidade
   de Coimbra; Universidade de Aveiro; Radboud University Nijmegen;
   Universidade de Coimbra
RP Farinha, C (通讯作者)，AIBILI, Edificio Prof Doutor Jose Cunha Vaz,Azinhaga Sta C, P-3000548 Coimbra, Portugal.
EM cfarinha@aibili.pt
RI Farinha, Claudia/R-1392-2017
OI Farinha, Claudia/0000-0003-4596-0913
FU Novartis
FX Supported by Novartis.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bonyadi MHJ, 2018, ACTA OPHTHALMOL, V96, pe105, DOI 10.1111/aos.13494
   Cachulo MD, 2016, ACTA OPHTHALMOL, V94, pE442, DOI 10.1111/aos.12950
   Cachulo MD, 2015, OPHTHALMOLOGICA, V233, P119, DOI 10.1159/000371584
   Colijn JM, 2021, OPHTHALMOLOGY, V128, P1039, DOI 10.1016/j.ophtha.2020.11.024
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Corominas J, 2018, OPHTHALMOLOGY, V125, P1433, DOI 10.1016/j.ophtha.2018.03.040
   de Breuk A, 2021, OPHTHALMOLOGY, V128, P1604, DOI 10.1016/j.ophtha.2020.07.037
   de Jong S, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100952
   Dietzel M, 2014, GRAEF ARCH CLIN EXP, V252, P1273, DOI 10.1007/s00417-014-2690-7
   Dutheil C, 2020, JAMA OPHTHALMOL, V138, P467, DOI 10.1001/jamaophthalmol.2020.0266
   Farinha C, 2021, GRAEF ARCH CLIN EXP, V259, P2545, DOI 10.1007/s00417-021-05140-0
   Farinha C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051329
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gattoussi S, 2019, ACTA OPHTHALMOL, V97, P364, DOI 10.1111/aos.13883
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Kersten E, 2017, JAMA OPHTHALMOL, V135, P1037, DOI 10.1001/jamaophthalmol.2017.3195
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lin LY, 2018, JAMA OPHTHALMOL, V136, P682, DOI 10.1001/jamaophthalmol.2018.1231
   Farinha CVL, 2019, OPHTHALMIC RES, V61, P226, DOI 10.1159/000496393
   Marques JP., 2013, ISRN OPHTHALMOLOGY, V2013, P1
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Nunes S, 2018, NUTRITION, V51-52, P6, DOI 10.1016/j.nut.2017.12.010
   Panthier C, 2014, RETINA-J RET VIT DIS, V34, P576, DOI 10.1097/01.iae.0000433986.32991.1e
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Seddon JM, 2019, INVEST OPHTH VIS SCI, V60, P4469, DOI 10.1167/iovs.19-27475
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Sitnilska V, 2020, OPHTHALMOLOGICA, V243, P444, DOI 10.1159/000507196
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Thee EF, 2022, OPHTHALMOLOGY, V129, P752, DOI 10.1016/j.ophtha.2022.02.026
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 41
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2022
VL 63
IS 9
AR 5
DI 10.1167/iovs.63.9.5
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3X4AL
UT WOS:000842984700005
PM 35925583
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Razavi, S
   Kodjikian, L
   Giocanti-Auregan, A
   Dufour, I
   Souied, E
AF Razavi, Sam
   Kodjikian, Laurent
   Giocanti-Auregan, Audrey
   Dufour, Ingrid
   Souied, Eric
TI Efficacy and safety of intravitreal aflibercept in
   ranibizumab-refractory patients with neovascular age-related macular
   degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Retina; Age-related macular degeneration; Exudative; Switch;
   Observational
AB BackgroundAnti-vascular endothelial growth factor (anti-VEGF) agents have become the standard of care in neovascular age-related macular degeneration (nAMD). Despite generally excellent response rates to anti-VEGF therapy, some patients do not respond or may respond suboptimally. In the case of refractory or rapidly recurring fluid in nAMD, clinicians may switch to another anti-VEGF agent. TITAN was an observational study that assessed the effectiveness and safety of intravitreal aflibercept (IVT-AFL) in patients with nAMD refractory to ranibizumab who switched to IVT-AFL after less than 12months of ranibizumab treatment in routine clinical practice in France.MethodsTITAN was an observational, retrospective and prospective 12-month study conducted at 28 centres in France. Patients with nAMD refractory to ranibizumab were enrolled. Patients who were switched from ranibizumab to IVT-AFL were followed for 12months. Data were obtained from medical records for retrospectively included patients, and at routine follow-up visits for those included prospectively. The main outcome measure was percentage of patients who achieved treatment success (gain of >= 1 Early Treatment Diabetic Retinopathy Study letters in best-corrected visual acuity [BCVA] and/or any reduction in central retinal thickness [CRT]) from baseline to 12months after switching. A sample size of 225 patients was determined based on a 2-sided 95% confidence interval with a width equal to 0.12 when the sample proportion was 0.70.ResultsWe analysed safety data (N =217) and clinical outcomes from patients in the per-protocol population (n =125). The mean (standard deviation) number of IVT-AFL injections was 7.5 (2.6). Treatment success was achieved in 68.8% of patients. Mean BCVA change from baseline to Month 12 was +1.5 letters (P =0.105) and the mean CRT change was -45.0 mu m (P < 0.001). In a subgroup analysis, in patients who received three initial monthly IVT-AFL injections, mean BCVA gain was 3.3 letters at Month 12 (P =0.015). Excluding lack of efficacy and inappropriate scheduling of drug administration, the most common adverse event was eye pain (2.3%).ConclusionsSwitching ranibizumab-refractory patients with nAMD to IVT-AFL may improve visual outcomes in some patients, particularly those who receive three initial monthly injections.Trial registrationClinicalTrials.gov, NCT02321241. First posted: December 22, 2014; Last update posted: July 2, 2018
C1 [Razavi, Sam] Ctr Ophtalmol, 30 Blvd Heurteloup, F-37000 Tours, France.
   [Kodjikian, Laurent] Univ Lyon, Ctr Hosp Cr Rousse, Lyon, France.
   [Giocanti-Auregan, Audrey] Univ Paris 13, Hop Avicenne, AP HP, DHU Vis & Handicaps, Bobigny, France.
   [Dufour, Ingrid] Bayer HealthCare SAS, 220 Ave Rech, F-59120 Loos, France.
   [Souied, Eric] Ctr Hosp Intercommunal Creteil, 40 Verdun Ave, F-94000 Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Avicenne - APHP; Universite Paris 13; Bayer AG; Bayer Healthcare
   Pharmaceuticals; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI
   Creteil
RP Razavi, S (通讯作者)，Ctr Ophtalmol, 30 Blvd Heurteloup, F-37000 Tours, France.
EM razavisam3@gmail.com
FU Bayer HealthCare SAS, France
FX The TITAN study was sponsored by Bayer HealthCare SAS, France. The
   sponsor participated in the design and conduct of the study, analysis of
   the data, and preparation of the manuscript.
CR Aghdam KA, 2016, EUR J OPHTHALMOL, V26, P473, DOI 10.5301/ejo.5000757
   [Anonymous], 2018, EYL PRESCR INF
   [Anonymous], 2018, LUC PRESCR INF
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Blanco-Garavito R, 2018, RETINA-J RET VIT DIS, V38, P2285, DOI 10.1097/IAE.0000000000001928
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Empeslidis T, 2019, ADV THER, V36, P1532, DOI 10.1007/s12325-019-00971-0
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Ohr M, 2012, EXPERT OPIN PHARMACO, V13, P585, DOI 10.1517/14656566.2012.658368
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Verner-Cole EA, 2012, DRUG TODAY, V48, P317, DOI 10.1358/dot.2012.48.5.1805931
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 26
TC 1
Z9 2
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD FEB 17
PY 2021
VL 21
IS 1
AR 90
DI 10.1186/s12886-021-01841-6
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QL3JA
UT WOS:000620975100003
PM 33596867
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Folgar, FA
   Jaffe, GJ
   Ying, GS
   Maguire, MG
   Toth, CA
AF Folgar, Francisco A.
   Jaffe, Glenn J.
   Ying, Gui-Shuang
   Maguire, Maureen G.
   Toth, Cynthia A.
CA Comparison Age-Related Macular Deg
TI Comparison of Optical Coherence Tomography Assessments in the Comparison
   of Age-Related Macular Degeneration Treatments Trials
SO OPHTHALMOLOGY
LA English
DT Article
ID TIME-DOMAIN; THICKNESS MEASUREMENTS; CATEGORICAL DATA; HIGH-SPEED;
   REPRODUCIBILITY; AGREEMENT; RANIBIZUMAB; BEVACIZUMAB; MORPHOLOGY;
   RESOLUTION
AB Objective: To determine agreement between spectral-domain (SD) and time-domain (TD) optical coherence tomography (OCT) image assessments by certified readers in eyes treated for neovascular age-related macular degeneration (AMD).
   Design: Cross-sectional study within the Comparison of AMD Treatments Trials (CATT).
   Participants: During year 2 of CATT, 1213 pairs of SD OCT and TD OCT scans were compared from a subset of 384 eyes.
   Methods: Masked readers independently graded OCT scans for presence of intraretinal fluid (IRF), subretinal fluid (SRF), and sub-retinal pigment epithelium (RPE) fluid and performed manual measurements of retinal, SRF, and subretinal tissue complex thicknesses at the foveal center.
   Main Outcome Measures: Presence of fluid was evaluated with percent agreement, kappa coefficients with 95% confidence intervals (CIs), and McNemar tests. Thickness measurements were evaluated with mean difference (Delta) +/- 95% limits of agreement and intraclass correlation coefficients (ICCs) with 95% CIs.
   Results: Between SD OCT and TD OCT, agreement on presence of any fluid was 82% (kappa = 0.46; 95% CI, 0.40-0.52), with 5% more SD OCT scans demonstrating fluid (P < 0.001). Agreement on presence of SRF was 87% and sub-RPE fluid was 80%, with more SD OCT scans demonstrating fluid (both P < 0.001). Agreement on IRF was 73% (kappa = 0.47; 95% CI, 0.42-0.52), with 6% more TD OCT scans demonstrating fluid (P < 0.001). Between SD OCT and TD OCT, mean thickness of the retina was Delta = 5 +/- 67 mu m, SRF was Delta = 1.5 +/- 35 mu m, and subretinal tissue complex was Delta = 5 +/- 86 mu m. Thickness measurements were reproducible for retina (ICC = 0.84; 95% CI, 0.83-0.86), SRF (ICC = 0.88; 95% CI, 0.86-0.89), and subretinal tissue complex (ICC = 0.91; 95% CI, 0.89-0.92), with <= 25-mu m difference in these measurements in 71%, 94%, and 61% of paired scans, respectively.
   Conclusions: Agreement on fluid presence and manual thickness measurements between paired scans from each OCT modality was moderate, providing a reasonable basis to compare CATT results with future SD OCT-based trials. Fluid was detected 5% more frequently with SD OCT, which may increase frequency of fluid-based treatment. Lower-resolution and artifactual interpretation of dark areas as cystoid edema may explain the greater frequency of IRF detected with TD OCT. (C) 2014 by the American Academy of Ophthalmology
C1 [Folgar, Francisco A.; Jaffe, Glenn J.; Toth, Cynthia A.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Ying, Gui-Shuang; Maguire, Maureen G.] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 Duke University; University of Pennsylvania
RP Toth, CA (通讯作者)，Duke Eye Ctr, DUMC 3802, Durham, NC 27710 USA.
EM cynthia.toth@dm.duke.edu
RI Ciulla, Thomas/AAA-1299-2020; Toth, Cynthia/L-5534-2019
OI Ciulla, Thomas/0000-0001-5557-6777; Toth, Cynthia/0000-0002-2324-0854;
   Vavvas, Demetrios/0000-0002-8622-6478; Folk, James/0000-0002-6271-2906;
   Losordo, Douglas/0000-0002-6857-7506
FU National Institutes of Health, Bethesda, Maryland [U10 EY017823, U10
   EY017825, U10 EY017826, U10 EY017828]; Regeneron; Genentech; Bioptigen;
   Physical Sciences Inc. Alcon Laboratories; National Institutes of Health
   (NIH); National Eye Institute (NEI); NIH; NEI Grant; NATIONAL EYE
   INSTITUTE [U10EY017823, U10EY017828, U10EY017825] Funding Source: NIH
   RePORTER
FX The author(s) have made the following disclosure( s): Glenn J. Jaffe:
   Consultant - Heidelberg Engineering; Financial support - Regeneron.
   Cynthia A. Toth: Financial support - Genentech, Bioptigen, Physical
   Sciences Inc. Alcon Laboratories, National Institutes of Health (NIH),
   National Eye Institute (NEI); patents pending on optical coherence
   tomography image processing. Maureen G. Maguire: Financial support -
   NIH, NEI Grant.; The Comparison of Age-Related Macular Degeneration
   Treatments Trials (ClinicalTrials.gov identifier, NCT00593450) were
   supported by the National Institutes of Health, Bethesda, Maryland
   (grant nos.: U10 EY017823, U10 EY017825, U10 EY017826, and U10
   EY017828).
CR Browning DJ, 2004, AM J OPHTHALMOL, V137, P1116, DOI 10.1016/j.ajo.2003.12.013
   Chen TC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1715, DOI 10.1001/archopht.123.12.1715
   Choma M, 2003, OPT EXPRESS, V11, P2183
   de Boer JF, 2003, OPT LETT, V28, P2067, DOI 10.1364/OL.28.002067
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Eriksson U, 2012, ACTA OPHTHALMOL, V90, P620, DOI 10.1111/j.1755-3768.2011.02112.x
   FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P543, DOI 10.1016/0895-4356(90)90158-L
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P7395, DOI 10.1167/iovs.12-10379
   Giani A, 2010, AM J OPHTHALMOL, V150, P815, DOI 10.1016/j.ajo.2010.06.025
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Han IC, 2009, AM J OPHTHALMOL, V147, P847, DOI 10.1016/j.ajo.2008.11.019
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Jaffe GJ, 2004, AM J OPHTHALMOL, V137, P156, DOI 10.1016/S0002-9394(03)00792-X
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   KOCH GG, 1977, BIOMETRICS, V33, P133, DOI 10.2307/2529309
   Krebs I, 2010, OPHTHALMOLOGY, V117, P1577, DOI 10.1016/j.ophtha.2010.04.032
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Leung CKS, 2008, INVEST OPHTH VIS SCI, V49, P4893, DOI 10.1167/iovs.07-1326
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Ritter M, 2011, BRIT J OPHTHALMOL, V95, P381, DOI 10.1136/bjo.2009.175976
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Shahidi M, 2005, AM J OPHTHALMOL, V139, P1056, DOI 10.1016/j.ajo.2005.01.012
   Stopa M, 2008, RETINA-J RET VIT DIS, V28, P298, DOI 10.1097/IAE.0b013e3181567798
   Wojtkowski M, 2004, OPT EXPRESS, V12, P2404, DOI 10.1364/OPEX.12.002404
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   YUODELIS C, 1986, VISION RES, V26, P847, DOI 10.1016/0042-6989(86)90143-4
   Zhang N, 2007, AM J OPHTHALMOL, V144, P37, DOI 10.1016/j.ajo.2007.03.056
NR 28
TC 24
Z9 24
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2014
VL 121
IS 10
BP 1956
EP +
DI 10.1016/j.ophtha.2014.04.020
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ3ME
UT WOS:000342697300025
PM 24835760
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Coco-Martin, MB
   Cuadrado-Asensio, R
   Lopez-Miguel, A
   Mayo-Iscar, A
   Maldonado, MJ
   Pastor, JC
AF Coco-Martin, Maria B.
   Cuadrado-Asensio, Ruben
   Lopez-Miguel, Alberto
   Mayo-Iscar, Agustin
   Maldonado, Miguel J.
   Pastor, Jose C.
TI Design and Evaluation of a Customized Reading Rehabilitation Program for
   Patients with Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID LOW-VISION REHABILITATION; QUALITY-OF-LIFE; OPTICAL MAGNIFIERS;
   EYE-MOVEMENTS; PERFORMANCE; PSYCHOPHYSICS; IMPROVE; PEOPLE; TRIAL; SPEED
AB Purpose: To evaluate the efficacy of a reading rehabilitation program (RRP) specifically designed for patients with impaired central vision from age-related macular degeneration (AMD) and the impact of the program on the quality of life (QoL) and to determine any predictable reading performance improvements between visits.
   Design: Prospective case series.
   Participants: Forty-one patients with AMD who attended to the Institute of Applied Ophthalmobiology Eye Institute.
   Methods: An ad hoc-created RRP comprising 4 customized in-office training and in-home training visits over 6 weeks was undertaken by AMD patients. The RRP was based on the principle of stepwise progressive goal achievement: the difficulty of training tasks increased depending on the success obtained when performing previous easier ones. Reading performance was evaluated during each in-office training visit, and the individual's perception of his or her QoL was assessed before and after the RRP. Reading performance parameters were assessed to evaluate RRP effectiveness.
   Main Outcome Measures: Best-corrected visual acuity (BCVA), reading speed, reading duration, near visual acuity (VA), font size, and the World Health Organization Quality of Life (WHOQOL-BREF) questionnaire scores. The effect sizes (mean differences and standard deviations) also were calculated.
   Results: The mean distance BCVA was 0.81 +/- 0.29 logarithm of the minimum angle of resolution units. The mean near VA with the appropriate low-vision aid was 0.91 +/- 0.18 (M notation) at baseline. The mean near magnification was 4.32 +/- 1.15 at the last in-office visit. The mean reading speed, reading duration, and font size improvement after the reading rehabilitation program were 48.31 +/- 22.06 words per minute (P<0.001), 35.46 +/- 15.68 minutes (P<0.001), and -4.08 +/- 2.19 font points (P<0.001), respectively. The effect sizes of reading speed, reading duration, and font size after the last visit were 2.19, 2.26, and -1.86, respectively. The final score of each WHOQOL-BREF domain improved significantly (P <= 0.004) after the RRP. The increased ability to read a smaller font size was correlated with improvement in the physical health domain score of the WHOQOL-BREF (r = 0.35; P = 0.04).
   Conclusions: This customized RRP significantly enhanced reading performance and perceived QoL in patients with AMD. The improvement between visits seemed to be consistent.
C1 [Coco-Martin, Maria B.; Cuadrado-Asensio, Ruben; Lopez-Miguel, Alberto; Mayo-Iscar, Agustin; Maldonado, Miguel J.; Pastor, Jose C.] Univ Valladolid, Inst Appl Ophthalmobiol IOBA, E-47011 Valladolid, Spain.
   [Mayo-Iscar, Agustin] Univ Valladolid, Dept Stat & Operat Res, Fac Sci, E-47011 Valladolid, Spain.
   [Lopez-Miguel, Alberto] Vis I D SL, Valladolid, Spain.
   [Pastor, Jose C.] Hosp Clin Univ, Dept Ophthalmol, Valladolid, Spain.
C3 Universidad de Valladolid; Universidad de Valladolid; Universidad de la
   Laguna
RP Coco-Martin, MB (通讯作者)，Univ Valladolid, Inst Appl Ophthalmobiol IOBA, Paseo Belen 17, E-47011 Valladolid, Spain.
EM bego@ioba.med.uva.es
RI Jimeno, J Carlos Pastor/AAP-1156-2020; López-Miguel,
   Alberto/K-6117-2014; Cuadrado-Asensio, Rubén/G-8374-2017; Mayo-Iscar,
   Agustin/L-7215-2014
OI Jimeno, J Carlos Pastor/0000-0001-5934-7306; López-Miguel,
   Alberto/0000-0001-9429-1571; Cuadrado-Asensio,
   Rubén/0000-0002-8507-306X; Mayo-Iscar, Agustin/0000-0003-0951-6508;
   Coco-Martin, Maria Begona/0000-0001-9977-429X; Maldonado, Miguel
   J./0000-0002-1021-3275
FU Research and Cooperation Network of Ophthalmology [RETICS RD07/0062]
FX Supported in part by the Research and Cooperation Network of
   Ophthalmology (RETICS RD07/0062: Ocular Diseases Related to Aging;
   Quality of Vision and Quality of Life, Instituto de Salud Carlos III,
   Madrid, Spain.
CR Beckmann PJ, 1996, VISION RES, V36, P3723, DOI 10.1016/0042-6989(96)00084-3
   Bowers A, 2007, OPTOMETRY VISION SCI, V84, P9, DOI 10.1097/01.opx.0000254035.39055.05
   Bowers AR, 2001, OPTOMETRY VISION SCI, V78, P325, DOI 10.1097/00006324-200105000-00016
   BULLIMORE MA, 1995, OPTOMETRY VISION SCI, V72, P125, DOI 10.1097/00006324-199502000-00011
   Cheong Allen C Y, 2002, Clin Exp Optom, V85, P229
   Cheong AMY, 2008, VISION RES, V48, P577, DOI 10.1016/j.visres.2007.11.022
   Cheong AM, 2003, THESIS QUEENSLAND U, P122
   Cheong AMY, 2005, OPTOMETRY VISION SCI, V82, P114, DOI 10.1097/01.OPX.0000153244.93582.FF
   Chung STL, 2010, OPTOMETRY VISION SCI, V87, P276, DOI 10.1097/OPX.0b013e3181c91347
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Crossland MD, 2005, OPTOMETRY VISION SCI, V82, P11
   Elliott DB, 1997, INVEST OPHTH VIS SCI, V38, P2566
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Goodrich G., 2004, VIS IMPAIR RES, V6, P135, DOI [10.1080/13882350490903690, DOI 10.1080/13882350490903690]
   GOODRICH GL, 1977, J VISUAL IMPAIR BLIN, V71, P377
   Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667
   KLEEN SR, 1981, AM J OPTOM PHYS OPT, V58, P200
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1476, DOI 10.1167/iovs.06-0610
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   Lovie-Kitchin Jan E, 1999, Clin Exp Optom, V82, P214
   Low Vision Services Consensus Group, 1999, LOW VIS SERV REC FUT, P14
   Nguyen NX, 2011, ACTA OPHTHALMOL, V89, pE82, DOI 10.1111/j.1755-3768.2010.02081.x
   Nguyen NX, 2009, ACTA OPHTHALMOL, V87, P849, DOI 10.1111/j.1755-3768.2008.01423.x
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   NILSSON UL, 1986, DOC OPHTHALMOL, V62, P345, DOI 10.1007/BF00168266
   Palmer S, 2010, BRIT J OPHTHALMOL, V94, P494, DOI 10.1136/bjo.2008.152231
   Reeves BC, 2004, BRIT J OPHTHALMOL, V88, P1443, DOI 10.1136/bjo.2003.037457
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   SHUTTLEWORTH GN, 1995, BRIT J OPHTHALMOL, V79, P719, DOI 10.1136/bjo.79.8.719
   Skevington SM, 2004, QUAL LIFE RES, V13, P299, DOI 10.1023/B:QURE.0000018486.91360.00
   Stelmack JA, 2004, J REHABIL RES DEV, V41, P729, DOI 10.1682/JRRD.2003.08.0136
   Stelmack JA, 2003, J VISUAL IMPAIR BLIN, V97, P521, DOI 10.1177/0145482X0309700904
   Stelmack JA, 2008, ARCH OPHTHALMOL-CHIC, V126, P608, DOI 10.1001/archopht.126.5.608
   Stelmack JA, 2007, ARCH PHYS MED REHAB, V88, P691, DOI 10.1016/j.apmr.2007.03.025
   Vukicevic M, 2005, VISUAL IMPAIRMENT RE, V7, P79, DOI DOI 10.1080/133882350500377762
   Vukicevic M, 2009, J VISUAL IMPAIR BLIN, V103, P277, DOI 10.1177/0145482X0910300506
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
   Wright V, 2010, LEARN USE YOUR VISIO, P29
   Yalcin BM, 2008, DIABETES EDUCATOR, V34, P1013, DOI 10.1177/0145721708327303
   Yu DY, 2010, VISION RES, V50, P860, DOI 10.1016/j.visres.2010.02.006
NR 40
TC 21
Z9 24
U1 1
U2 30
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2013
VL 120
IS 1
BP 151
EP 159
DI 10.1016/j.ophtha.2012.07.035
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 063PI
UT WOS:000313011700022
PM 23031670
DA 2022-11-30
ER

PT J
AU Hagstrom, SA
   Ying, GS
   Pauer, GJT
   Sturgill-Short, GM
   Huang, JY
   Callanan, DG
   Kim, IK
   Klein, ML
   Maguire, MG
   Martin, DF
AF Hagstrom, Stephanie A.
   Ying, Gui-shuang
   Pauer, Gayle J. T.
   Sturgill-Short, Gwen M.
   Huang, Jiayan
   Callanan, David G.
   Kim, Ivana K.
   Klein, Michael L.
   Maguire, Maureen G.
   Martin, Daniel F.
CA Comparison AMD Treatments Trials R
TI Pharmacogenetics for Genes Associated with Age-related Macular
   Degeneration in the Comparison of AMD Treatments Trials (CATT)
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; INTRAVITREAL RANIBIZUMAB; POLYMORPHISM; HTRA1;
   SUSCEPTIBILITY; Y402H
AB Purpose: To evaluate the pharmacogenetic relationship between genotypes of single nucleotide polymorphisms (SNPs) known to be associated with age-related macular degeneration (AMD) and response to treatment withranibizumab (Lucentis; Genentech, South San Francisco, CA) or bevacizumab (Avastin; Genentech) for neovascular AMD.
   Design: Clinical trial.
   Participants: Eight hundred thirty-four (73%) of 1149 patients participating in the Comparison of AMD Treatments Trials (CATT) were recruited through 43 CATT clinical centers.
   Methods: Each patient was genotyped for SNPs rs1061170 (CFH), rs10490924 (ARMS2), rs11200638 (HTRA1), and rs2230199 (C3), using TaqMan SNP genotyping assays (Applied Biosystems, Foster City, CA).
   Main Outcomes Measures: Genotypic frequencies were compared with clinical measures of response to therapy at one year, including mean visual acuity (VA), mean change in VA, 15-letter or more increase in VA, retinal thickness, mean change in total foveal thickness, presence of fluid on OCT, presence of leakage on fluorescein angiography (FA), mean change in lesion size, and mean number of injections administered. Differences in response by genotype were evaluated with tests of linear trend calculated from logistic regression models for categorical outcomes and linear regression models for continuous outcomes. To adjust for multiple comparisons, P <= 0.01 was considered statistically significant.
   Results: No statistically significant differences in response by genotype were identified for any of the clinical measures studied. Specifically, there were no high-risk alleles that predicted final VA or change in VA, the degree of anatomic response (fluid on OCT or FA, retinal thickness, change in total foveal thickness, change in lesion size), or the number of injections. Furthermore, a stepwise analysis failed to show a significant epistatic interaction among the variants analyzed; that is, response did not vary by the number of risk alleles present. The lack of association was similar whether patients were treated with ranibizumab or bevacizumab or whether they received monthly or pro re nata dosing.
   Conclusions: Although specific alleles for CFH, ARMS2, HTRA1, and C3 may predict the development of AMD, they did not predict response to anti-vascular endothelial growth factor therapy.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2013;120:593-599 (C) 2013 by the American Academy of Ophthalmology.
C1 [Hagstrom, Stephanie A.; Pauer, Gayle J. T.; Sturgill-Short, Gwen M.; Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44195 USA.
   [Hagstrom, Stephanie A.] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Dept Ophthalmol, Cleveland, OH 44106 USA.
   [Ying, Gui-shuang; Huang, Jiayan; Maguire, Maureen G.] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Callanan, David G.] Texas Retina Associates, Arlington, TX USA.
   [Kim, Ivana K.] Harvard Univ, Sch Med, Dept Ophthalmol, Retina Serv,Massachusetts Eye & Ear Infirm, Boston, MA USA.
   [Klein, Michael L.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR USA.
C3 Cleveland Clinic Foundation; Case Western Reserve University; Cleveland
   Clinic Foundation; University of Pennsylvania; Harvard University;
   Harvard Medical School; Massachusetts Eye & Ear Infirmary; Oregon Health
   & Science University
RP Hagstrom, SA (通讯作者)，Cleveland Clin, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM hagstrs@ccf.org
OI Kim, Ivana/0000-0003-0310-6129
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [U10 EY017823, U10 EY017825, U10 EY017826, U10 EY017828];
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000439]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [U10EY017828]
   Funding Source: NIH RePORTER
FX Supported by the National Eye Institute, National Institutes of Health,
   Bethesda, Maryland (cooperative agreement nos.: U10 EY017823, U10
   EY017825, U10 EY017826, and U10 EY017828). The sponsor or funding
   organization had no role in the design or conduct of this research.
CR Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Chan A, 2006, ARCH OPHTHALMOL-CHIC, V124, P193, DOI 10.1001/archopht.124.2.193
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Roberts DG, 2009, BIOTECHNIQUES, V46, pIX, DOI 10.2144/000112887
   Schwartz SG, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/252549
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tong Y, 2010, MOL VIS, V16, P1958
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
NR 23
TC 117
Z9 122
U1 0
U2 42
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2013
VL 120
IS 3
BP 593
EP 599
DI 10.1016/j.ophtha.2012.11.037
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 100XJ
UT WOS:000315738200025
PM 23337555
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ziemssen, F
   Grisanti, S
   Bartz-Schmidt, KU
   Spitzer, MS
AF Ziemssen, Focke
   Grisanti, Salvatore
   Bartz-Schmidt, Karl Ulrich
   Spitzer, Martin S.
TI Off-Label Use of Bevacizumab for the Treatment of Age-Related Macular
   Degeneration What is the Evidence?
SO DRUGS & AGING
LA English
DT Review
ID PIGMENT EPITHELIAL TEAR; CHOROIDAL NEOVASCULARIZATION SECONDARY;
   ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY;
   INTRAOCULAR-PRESSURE CHANGES; ANTI-VEGF ANTIBODY; INTRAVITREAL
   BEVACIZUMAB; AVASTIN TREATMENT; PHOTODYNAMIC THERAPY; RANIBIZUMAB
   LUCENTIS
AB There is an active and controversial debate about the role of intravitreal bevacizumab versus approved drugs in the treatment of neovascular age-related macular degeneration (AMD). Because bevacizumab was available prior to the launch of ranibizumab, off-label use of the former became widespread and the cancer drug bevacizumab is the most commonly used medication in ophthalmology nowadays.
   This review considers every publication identified in MEDLINE using the keywords 'bevacizumab' and 'Avastin' between I June 2005 and 31 July 2008. The search identified 511 papers that were evaluated. In 33 studies, there was consistent and clear evidence for the efficacy of bevacizumab in neovascular AMD. However, the highest grade studies (three prospective, randomized, controlled trials) did not attain better than grade 2b level of evidence, and objective evaluation of the benefit of bevacizumab relative to representative controls was therefore not possible. Certainly, the available evidence is inferior to that obtained from the approval studies of ranibizumab and this should influence treatment selection and guidance of patients. These considerations indicate that important quality criteria need to be included in future studies to ensure more meaningful conclusions can be drawn. These include clearly defined inclusion criteria, information about the recruitment procedure (including data on withdrawals, excluded patients, concealed treatment allocation, use of intention-to-treat analyses and blinded assessment procedures). Although preclinical studies have almost exclusively found bevacizumab to be safe, the design utilized in clinical case series cannot rule out a possible increase in adverse events, which already show a high spontaneous incidence in elderly AM D patients. The superior evidence level for ranibizumab and the limited safety data for bevacizumab must be taken into consideration when evaluating the costs that a healthcare system is willing to spend. However, the superior grade of evidence for ranibizumab should not be confused with the (still missing) evidence for superior efficacy.
   The results of ongoing randomized, controlled, comparative trials will provide further data on the efficacy and cost effectiveness of bevacizumab and ranibizumab in the treatment of AMD. In the meantime, patients should be informed about the alternatives, the price differences and the restricted liability issue when off-label use of bevacizumab is offered.
C1 [Ziemssen, Focke; Bartz-Schmidt, Karl Ulrich; Spitzer, Martin S.] Univ Tubingen, Ctr Ophthalmol, Univ Eye Hosp, D-1572076 Tubingen, Germany.
   [Grisanti, Salvatore] Schleswig Holstein Univ, Hosp Eye, Lubeck, Germany.
C3 Eberhard Karls University of Tubingen
RP Ziemssen, F (通讯作者)，Univ Tubingen, Ctr Ophthalmol, Univ Eye Hosp, Schleichstr 12, D-1572076 Tubingen, Germany.
EM focke.ziemssen@med.uni-tuebingen.de
RI , Ziemssen/B-9564-2009; Ziemssen, Focke/AAY-1686-2021
OI , Ziemssen/0000-0002-3873-0581; 
CR Abraham-Marin ML, 2007, GRAEF ARCH CLIN EXP, V245, P651, DOI 10.1007/s00417-006-0411-6
   Aggio FB, 2007, EYE, V21, P408, DOI 10.1038/sj.eye.6702683
   Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   ALKURAYA HS, INT OPHTHALMOL
   Amselem L, 2009, ACTA OPHTHALMOL, V87, P110, DOI 10.1111/j.1755-3768.2007.01154.x
   Arias L, 2007, EUR J OPHTHALMOL, V17, P992, DOI 10.1177/112067210701700622
   Atkins D, 2004, BMC HEALTH SERV RES, V4, DOI 10.1186/1472-6963-4-38
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Azad RV, 2008, JPN J OPHTHALMOL, V52, P52, DOI 10.1007/s10384-007-0496-4
   Azad Rajvardhan, 2007, Indian Journal of Ophthalmology, V55, P441
   Bakri SJ, 2007, EYE, V21, P424, DOI 10.1038/sj.eye.6702700
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P779, DOI 10.1007/s00417-007-0754-7
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2006, RETINA-J RET VIT DIS, V26, P519, DOI 10.1097/01.iae.0000225354.92444.7a
   Bakri SJ, 2006, AM J OPHTHALMOL, V142, P162, DOI 10.1016/j.ajo.2006.03.058
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Buys YM, 2007, CAN J OPHTHALMOL, V42, P789, DOI 10.3129/i07-176
   BYEON SH, ACTA OPHTHALMOL
   Canning C, 2006, EYE, V20, P985, DOI 10.1038/sj.eye.6702501
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Charatan F, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a778
   Charles S, 2007, RETINA-J RET VIT DIS, V27, P813, DOI 10.1097/IAE.0b013e318154b9f2
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   CHIANG A, RETINA
   Chieh JJ, 2007, ANN OPHTHALMOL, V39, P51, DOI 10.1007/BF02697326
   Chong NV, 2007, EYE, V21, P313, DOI 10.1038/sj.eye.6702699
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Cohen DJ, 2007, CLIN BREAST CANCER, V7, pS21, DOI 10.3816/CCC.2008.s.004
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   CSAKY KC, 2007, INVEST OPHTH VIS SCI, V48, pA4936
   Dafer Rima M, 2007, Semin Ophthalmol, V22, P201, DOI 10.1080/08820530701543024
   De Caro JJ, 2008, RETINA-J RET VIT DIS, V28, P877, DOI 10.1097/IAE.0b013e31816b3180
   de Gramont A, 2005, ONCOLOGY-BASEL, V69, P46, DOI 10.1159/000088483
   DELUCAS JAM, 2007, ARCH SOC ESP OFTALMO, V82, P257
   Dib E, 2008, INVEST OPHTH VIS SCI, V49, P1097, DOI 10.1167/iovs.07-1225
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P1044, DOI 10.1097/IAE.0b013e3180592ba6
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   Feiner L, 2006, RETINA-J RET VIT DIS, V26, P882, DOI 10.1097/01.iae.0000230717.85319.f5
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   Forooghian F, 2008, CAN J OPHTHALMOL, V43, P246, DOI 10.3129/i08-017
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gamulescu MA, 2007, GRAEF ARCH CLIN EXP, V245, P1037, DOI 10.1007/s00417-007-0551-3
   Garg S, 2008, CLIN EXP OPHTHALMOL, V36, P252, DOI 10.1111/j.1442-9071.2008.01710.x
   GELISKEN F, 2008, EYE
   Gelisken F, 2006, ACTA OPHTHALMOL SCAN, V84, P833, DOI 10.1111/j.1600-0420.2006.00765.x
   *GEN INC, 2008, AV INF
   *GGMBH KLIN BREM M, NCT005597151 CLINICA
   Ghazi NG, 2008, RETINA-J RET VIT DIS, V28, P689, DOI 10.1097/IAE.0b013e318162d982
   Giansanti F, 2007, EUR J OPHTHALMOL, V17, P230, DOI 10.1177/112067210701700213
   Gillies MC, 2006, ARCH OPHTHALMOL-CHIC, V124, P1478, DOI 10.1001/archopht.124.10.1478
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P210, DOI 10.1136/bjo.2007.127902
   Hannan SR, 2007, BRIT J OPHTHALMOL, V91, P977, DOI 10.1136/bjo.2006.101899
   Hasler S, 2008, KLIN MONATSBL AUGENH, V225, P446, DOI 10.1055/s-2008-1027315
   Hayden EC, 2008, NAT MED, V14, P108, DOI 10.1038/nm0208-108
   Heiduschka P, 2008, RETINA-J RET VIT DIS, V28, P46, DOI 10.1097/IAE.0b013e31815e9368
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Heimes B, 2008, GRAEF ARCH CLIN EXP, V246, P1229, DOI 10.1007/s00417-008-0854-z
   Hetland ML, 2008, DIS MARKERS, V24, P1
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Inan UU, 2007, INVEST OPHTH VIS SCI, V48, P1773, DOI 10.1167/iovs.06-0828
   Iriyama A, 2007, BRIT J OPHTHALMOL, V91, P1230, DOI 10.1136/bjo.2007.117309
   Jalil A, 2007, EYE, V21, P1541, DOI 10.1038/sj.eye.6703018
   Joeres S, 2007, GRAEF ARCH CLIN EXP, V245, P1597, DOI 10.1007/s00417-007-0580-y
   Jonas JB, 2008, EYE, V22, P590, DOI 10.1038/eye.2008.10
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Jonas JB, 2007, J OCUL PHARMACOL TH, V23, P240, DOI 10.1089/jop.2006.0146
   Kaempf S, 2008, INVEST OPHTH VIS SCI, V49, P3164, DOI 10.1167/iovs.07-1265
   Karanjia R, 2008, BRIT J OPHTHALMOL, V92, P1248, DOI 10.1136/bjo.2008.138800
   Kawashima M, 2008, JPN J OPHTHALMOL, V52, P142, DOI 10.1007/s10384-008-0510-5
   Kernt M, 2007, ACTA OPHTHALMOL SCAN, V85, P119, DOI 10.1111/j.1600-0420.2006.00819.x
   Kim JH, 2008, NEUROTOXICOLOGY, V29, P1131, DOI 10.1016/j.neuro.2008.06.006
   Kimmelman J, 2007, RETINA-J RET VIT DIS, V27, P1166, DOI 10.1097/IAE.0b013e31815ee57e
   Klein RM, 2007, RETINA-J RET VIT DIS, V27, P1163, DOI 10.1097/IAE.0b013e31815e9322
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Kopel AC, 2008, OPHTHAL SURG LAS IM, V39, P153, DOI 10.3928/15428877-20080301-10
   Krebs I, 2008, GRAEF ARCH CLIN EXP, V246, P811, DOI 10.1007/s00417-007-0755-6
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Kumar N, 2007, CAN J OPHTHALMOL, V42, P760, DOI 10.3129/i07-139
   *L BOLTZM I RET BI, NCT00710229 CLINICAL
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   la Cour M, 2007, ACTA OPHTHALMOL SCAN, V85, P2, DOI 10.1111/j.1600-0420.2006.00869.x
   LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473
   Lazic R, 2007, COLLEGIUM ANTROPOL, V31, P77
   Lazic R, 2007, COLLEGIUM ANTROPOL, V31, P71
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   LEVY J, INT OPHTHALMOL
   Lu JF, 2008, CANCER CHEMOTH PHARM, V62, P779, DOI 10.1007/s00280-007-0664-8
   Luke M, 2006, BRIT J OPHTHALMOL, V90, P1178, DOI 10.1136/bjo.2006.094995
   Luthra S, 2006, RETINA-J RET VIT DIS, V26, P512, DOI 10.1097/01.iae.0000222547.35820.52
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Madhusudhana KC, 2007, BRIT J OPHTHALMOL, V91, P1716, DOI 10.1136/bjo.2006.108639
   Manegold C, 2008, EXPERT REV ANTICANC, V8, P689, DOI 10.1586/14737140.8.5.689
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Mason JO, 2008, RETINA-J RET VIT DIS, V28, P564, DOI 10.1097/IAE.0b013e3181633fee
   Mathews JP, 2007, EYE, V21, P1004, DOI 10.1038/sj.eye.6702805
   McGimpsey SJ, 2008, BRIT J OPHTHALMOL, V92, P436, DOI 10.1136/bjo.2007.125070
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   Mennel S, 2007, ACTA OPHTHALMOL SCAN, V85, P689, DOI 10.1111/j.1600-0420.2007.00926.x
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Meyer CH, 2007, AM J OPHTHALMOL, V143, P169, DOI 10.1016/j.ajo.2006.08.003
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P451, DOI 10.1097/IAE.0b013e318030ea80
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Michels S, 2006, BRIT J OPHTHALMOL, V90, P1333, DOI 10.1136/bjo.2006.102293
   Monés J., 2007, Arch Soc Esp Oftalmol, V82, P529
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Moschos MM, 2008, DOC OPHTHALMOL, V116, P147, DOI 10.1007/s10633-007-9110-9
   Muhsin M, 2004, NAT REV DRUG DISCOV, V3, P995, DOI 10.1038/nrd1601
   *NEI, NCT00593450 CLINICAL
   Neri Piergiorgio, 2008, International Ophthalmology, V28, P425, DOI 10.1007/s10792-007-9152-8
   Neubauer AS, 2007, KLIN MONATSBL AUGENH, V224, P727, DOI 10.1055/s-2007-963470
   Nicolo M, 2006, EUR J OPHTHALMOL, V16, P770, DOI 10.1177/112067210601600521
   Olsen TW, 2007, AM J OPHTHALMOL, V144, P281, DOI 10.1016/j.ajo.2007.05.005
   *OXF CTR EV BAS ME, LEV EV GRAD REC CEBM
   Pande A, 2007, ANTICANCER RES, V27, P3465
   Park Hee-Jung, 2007, Binocul Vis Strabismus Q, V22, P209
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P1084, DOI 10.1167/iovs.07-1203
   Pedersen R, 2007, ACTA OPHTHALMOL SCAN, V85, P526, DOI 10.1111/j.1600-0420.2007.00895.x
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Peters S, 2007, BRIT J OPHTHALMOL, V91, P827, DOI 10.1136/bjo.2006.109702
   Pieramici DJ, 2006, RETINA-J RET VIT DIS, V26, P841, DOI 10.1097/01.iae.0000234629.22614.cd
   Pilu S, 2008, AM J OPHTHALMOL, V145, P879, DOI 10.1016/j.ajo.2007.12.036
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Raftery JP, 2007, BRIT MED J, V334, P381, DOI 10.1136/bmj.39128.708565.3A
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rodrigues EB, 2007, ACTA OPHTHALMOL SCAN, V85, P915, DOI 10.1111/j.1600-0420.2007.00968.x
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   SCARTOZZI R, EYE
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Shaikh Saad, 2007, Indian Journal of Ophthalmology, V55, P470
   Shetty R, 2008, DOC OPHTHALMOL, V116, P129, DOI 10.1007/s10633-007-9090-9
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   Smit DP, 2007, CLIN OPHTHALMOL, V1, P273
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spalding B J, 2008, Nat Biotechnol, V26, P365, DOI 10.1038/nbt0408-365b
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   Spitzer MS, 2006, BRIT J OPHTHALMOL, V90, P1316, DOI 10.1136/bjo.2006.095190
   Spitzer MS, 2007, GRAEF ARCH CLIN EXP, V245, P1837, DOI 10.1007/s00417-007-0568-7
   Stahl A, 2009, DOC OPHTHALMOL, V118, P81, DOI 10.1007/s10633-008-9136-7
   Stewart MW, 2007, RETINA-J RET VIT DIS, V27, P1196, DOI 10.1097/IAE.0b013e318158ea28
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Subramanyam Anand, 2007, Indian J Ophthalmol, V55, P483
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Waisbourd M, 2007, DRUG AGING, V24, P643, DOI 10.2165/00002512-200724080-00003
   Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Weinberger AWA, 2007, AM J OPHTHALMOL, V144, P294, DOI 10.1016/j.ajo.2007.03.024
   Wong D, 2006, BRIT J OPHTHALMOL, V90, P1218, DOI 10.1136/bjo.2006.102426
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yenerel NM, 2008, J OCUL PHARMACOL TH, V24, P362, DOI 10.1089/jop.2007.0126
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
   Zachary I, 2005, NEUROSIGNALS, V14, P207, DOI 10.1159/000088637
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
   Ziemssen F, 2008, KLIN MONATSBL AUGENH, V225, P770, DOI 10.1055/s-2008-1027487
   Ziemssen F, 2008, OPHTHALMOLOGE, V105, P180, DOI 10.1007/s00347-008-1712-4
   Ziemssen F, 2006, BRIT J OPHTHALMOL, V90, P1440
   Ziemssen F, 2006, OPHTHALMOLOGE, V103, P484, DOI 10.1007/s00347-006-1354-3
   Ziemssen F, 2006, BRIT J OPHTHALMOL, V90, P922, DOI 10.1136/bjo.2006.092262
   ZIEMSSEN F, INT OPHTHALMOL
   Ziemssen F, 2007, RETINA-J RET VIT DIS, V27, P1154, DOI 10.1097/IAE.0b013e3180ca7daf
   Ziemssen Focke, 2008, International Ophthalmology, V28, P101, DOI 10.1007/s10792-007-9122-1
   INTRAVITREAL USE BEV
NR 181
TC 26
Z9 27
U1 0
U2 7
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PY 2009
VL 26
IS 4
BP 295
EP 320
DI 10.2165/00002512-200926040-00002
PG 26
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 461CW
UT WOS:000267243200002
PM 19476398
DA 2022-11-30
ER

PT J
AU Cahill, MT
   Stinnett, SS
   Banks, AD
   Freedman, SF
   Toth, CA
AF Cahill, MT
   Stinnett, SS
   Banks, AD
   Freedman, SF
   Toth, CA
TI Quality of life after macular translocation with 360 degrees peripheral
   retinectomy for age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL FUNCTION QUESTIONNAIRE; MACULOPATHY
AB Purpose: To determine patients' quality of life (QOL) after macular translocation with 3600 peripheral retinectomy (MT360) for age-related macular degeneration.
   Design: Prospective, interventional, consecutive, noncomparative case series.
   Methods: A prospective study assessed QOL 1 year after MT360 and its relation to postoperative visual function. The 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) and the Medical Outcomes Study 12-item short form (SF-12) health survey were used to assess vision-related QOL and general health, respectively. Surveys were administered preoperatively and postoperatively. Postoperative NEI VFQ-25 QOL and SF-12 subscale scores for all patients were compared with the preoperative scores. Preoperative and postoperative distance and near visual acuities (VAs) and reading speed were assessed. Changes in NEI VFQ-25 QOL subscale scores were compared in patients with and without improved visual function. Postoperative NEI VFQ-25 QOL subscale scores in patients with distance VA of greater than or equal to69 Early Treatment Diabetic Retinopathy Study letters, near VA of greater than or equal to20/70, and reading speed of greater than or equal to90 words per minute were compared with subscale scores in patients with worse postoperative visual function.
   Main Outcome Measures: National Eye Institute VFQ-25 and SF-12 QOL scores and their association with distance VA, near VA, and reading speed.
   Results: In total, 50 patients with a mean age of 76.9 years were studied. Postoperative mean NEI VFQ-25 QOL scores were higher than the preoperative mean scores, and this difference was significant for important vision-specific subscales. Patients with improved visual function had greater mean changes in NEI VFQ-25 QOL scores than those with no improvement. Patients with the outlined higher levels of visual function had greater mean NEI VFQ-25 QOL scores than those who had worse visual function. Preoperative and postoperative mean SF-12 QOL scores were similar.
   Conclusions: Macular translocation with 3600 peripheral retinectomy was associated with improvement in vision-related QOL. The amount of improvement was greatest in patients with postoperative improvement in visual function, and the best postoperative vision-related QOL was seen in patients with better postoperative visual function. This was not associated with a change in patients' general health. (C) 2005 by the American Academy of Ophthalmology.
C1 Duke Univ, Ctr Eye, Durham, NC 27710 USA.
C3 Duke University
RP Toth, CA (通讯作者)，Duke Univ, Ctr Eye, Erwin Rd,POB 3802, Durham, NC 27710 USA.
EM toth0004@mc.duke.edu
RI toth, cynthia a/F-5614-2011; Toth, Cynthia/L-5534-2019
OI Toth, Cynthia/0000-0002-2324-0854; Stinnett, Sandra/0000-0001-7192-0195;
   Freedman, Sharon/0000-0003-3615-3511
FU NATIONAL EYE INSTITUTE [R21EY011725] Funding Source: NIH RePORTER; NEI
   NIH HHS [EY11725] Funding Source: Medline
CR Bass E, 2000, AM J OPHTHALMOL, V130, P408
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Cahill MT, 2003, ARCH OPHTHALMOL-CHIC, V121, P132
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Freedman SF, 2003, AM J OPHTHALMOL, V136, P640, DOI 10.1016/S0002-9394(03)00334-9
   Globe DR, 2002, OPHTHALMOLOGY, V109, P1793, DOI 10.1016/S0161-6420(02)01124-7
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   *SAS I, 1998, SAS COMP PROGR VERS
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003
   WARE JE, 2000, SCORE SF 12 PHYS MEN
NR 23
TC 57
Z9 59
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2005
VL 112
IS 1
BP 144
EP 151
DI 10.1016/j.ophtha.2004.06.035
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 886QG
UT WOS:000226242800025
PM 15629835
DA 2022-11-30
ER

PT J
AU Joeres, S
   Kaplowitz, K
   Brubaker, JW
   Updike, PG
   Collins, AT
   Walsh, AC
   Romano, PW
   Sadda, SR
AF Joeres, Sandra
   Kaplowitz, Kevin
   Brubaker, Jacob W.
   Updike, Paul G.
   Collins, Allyson T.
   Walsh, Alexander C.
   Romano, Peggy W.
   Sadda, Srinivas R.
TI Quantitative comparison of optical coherence tomography after pegaptanib
   or bevacizumab in neovascular age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL BEVACIZUMAB; PHOTODYNAMIC
   THERAPY; AVASTIN; VERTEPORFIN; INJECTION
AB Purpose: To demonstrate the benefit of enhanced quantitative analysis of optical coherence tomography (OCT) images using computer-assisted grading to compare the short-term morphologic effects of pegaptanib and bevacizumab treatment for neovascular age-related macular degeneration (AMD).
   Design: Retrospective consecutive case series.
   Participants: Fifty-three cases with neovascular AMD undergoing pegaptanib or bevacizumab therapy.
   Methods: Fifty-three consecutive cases of patients who underwent StratusOCT imaging followed by treatment with either intravitreal pegaptanib (n = 18) or bevacizumab (n = 35) for neovascular AMD were retrospectively collected. Raw exported StratusOCT images were analyzed using publicly available custom software (OCTOR) designed to define the boundaries of various spaces manually. Changes in thickness and volume of the retina, subretinal fluid (SRF), subretinal tissue, and pigment epithelial detachments (PEDs) before treatment and at 3 months after treatment were calculated and compared between treatment groups. OCTOR software measurements after manual grading were also compared with the automated StratusOCT output.
   Main Outcome Measures: Volume and thickness measurements calculated by the automated StratusOCT software and the manual grading software OCTOR.
   Results: Intravitreal bevacizumab resulted in a statistically significant greater reduction of total retinal volume than pegaptanib (-0.88 +/- 1.4 mm(3) VS.-0.07 +/- 0.5 mm(3), p = 0.003). Mean foveal central subfield (FCS) retinal volume decreased from 0.26 +/- 0.1 mm(3) to 0.21 +/- 0.1 mm(3) (p = 0.001) in the bevacizumab group and remained constant at 0.22 +/- 0.1 in the pegaptanib group 3 months after injection. Subanalysis of the SRF, subretinal tissue, and PEDs revealed statistically significant reductions of the total volume of all 3 spaces after bevacizumab injections but no significant change after pegaptanib treatment. Automated StratusOCT output measurements of FCS thickness, foveal center point thickness, and total volume of the retina did not reveal a statistically significant difference between the treatments.
   Conclusions: Differences in morphologic response between treatments were less apparent on automated StratusOCT output than on computer-assisted analysis. Although intravitreal bevacizumab was associated with a greater short-term reduction in features of exudation than pegaptanib therapy, the retrospective design of the study limits the significance of this finding. Computer-assisted subanalysis of OCT data, however, may be a useful tool in more precisely defining the anatomic effects of therapies for neovascular AMD.
C1 [Joeres, Sandra; Kaplowitz, Kevin; Brubaker, Jacob W.; Updike, Paul G.; Collins, Allyson T.; Walsh, Alexander C.; Romano, Peggy W.; Sadda, Srinivas R.] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA 90033 USA.
C3 Doheny Eye Institute; University of Southern California
RP Sadda, SR (通讯作者)，Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Image Reading Ctr, DEI 3623,1450 San Pablo St, Los Angeles, CA 90033 USA.
OI Brubaker, Jacob W./0000-0001-5023-9480
FU NEI NIH HHS [EY015914, EY03040, R01 EY014375] Funding Source: Medline;
   NATIONAL EYE INSTITUTE [R01EY014375, P30EY003040, R21EY015914] Funding
   Source: NIH RePORTER
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hee MR, 2005, AM J OPHTHALMOL, V139, P154, DOI 10.1016/j.ajo.2004.08.066
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Voo Irene, 2004, Ophthalmol Clin North Am, V17, P21, DOI 10.1016/j.ohc.2003.12.002
NR 18
TC 35
Z9 40
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2008
VL 115
IS 2
BP 347
EP 354
DI 10.1016/j.ophtha.2007.03.082
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 258AJ
UT WOS:000252840500020
PM 17628685
DA 2022-11-30
ER

PT J
AU Jackson, TL
   Desai, R
   Simpson, A
   Neffendorf, JE
   Petrarca, R
   Smith, K
   Wittes, J
   Lewis, C
   Membrey, L
   Haynes, R
   Costen, M
   Steel, DHW
   Muldrew, A
   Chakravarthy, U
AF Jackson, Timothy L.
   Desai, Riti
   Simpson, Andrew
   Neffendorf, James E.
   Petrarca, Robert
   Smith, Kelly
   Wittes, Janet
   Lewis, Cornelius
   Membrey, Luke
   Haynes, Richard
   Costen, Mark
   Steel, David H. W.
   Muldrew, Alyson
   Chakravarthy, Usha
CA Macular Epiretinal Brachytherapy V
TI Epimacular Brachytherapy for Previously Treated Neovascular Age-Related
   Macular Degeneration (MERLOT) A Phase 3 Randomized Controlled Trial
SO OPHTHALMOLOGY
LA English
DT Article
ID EPIRETINAL BRACHYTHERAPY; DOSING REGIMEN; SAFETY; BEVACIZUMAB;
   RANIBIZUMAB; VITRECTOMY; MERITAGE; EFFICACY
AB Purpose: To assess the safety and efficacy of epimacular brachytherapy (EMB) for patients with chronic, active, neovascular age-related macular degeneration (AMD).
   Design: Phase 3 randomized controlled trial.
   Participants: Patients (n = 363) with neovascular AMD already receiving intravitreal ranibizumab injections. Intervention: Either pars plana vitrectomy with 24-gray EMB and ongoing pro re nata (PRN) ranibizumab (n = 224) or ongoing PRN ranibizumab monotherapy (n = 119).
   Main Outcome Measures: The coprimary outcomes, at 12 months, were the number of PRN ranibizumab injections and Early Treatment of Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (VA). Secondary outcomes included the proportion of participants losing fewer than 15 ETDRS letters, angiographic total lesion size, choroidal neovascularization (CNV) size, and optical coherence tomography (OCT) foveal thickness. A predefined subgroup analysis tested the influence of baseline ocular characteristics on the response to EMB.
   Results: The mean number of PRN ranibizumab injections was 4.8 in the EMB arm and 4.1 in the ranibizumab monotherapy arm (P = 0.068). The mean VA change was -4.8 letters in the EMB arm and -0.9 letters in the ranibizumab arm (95% confidence interval of difference between groups, -6.6 to -1.8 letters). The proportion of participants losing fewer than 15 letters was 84% in the EMB arm and 92% in the ranibizumab arm (P = 0.007). In the EMB arm, the mean total lesion size increased by 1.2 mm(2) versus 0.4 mm(2) in the ranibizumab arm (P = 0.27). The CNV size decreased by 0.5 mm(2) in the EMB arm and by 1.3 mm(2) in the ranibizumab arm (P = 0.27). The OCT foveal thickness decreased by 1.0 mm in the EMB arm and by 15.7 mm in the ranibizumab arm (P = 0.43). Most subgroups favored ranibizumab monotherapy, some significantly so. One participant showed retinal vascular abnormality attributed to radiation, but otherwise safety was acceptable.
   Conclusions: These results do not support the use of EMB for chronic, active, neovascular AMD. Safety is acceptable out to 12 months, but radiation retinopathy can occur later, so further follow-up is planned. Crown Copyright (C) 2016 Published by Elsevier Inc. on behalf of American Academy of Ophthalmology.
C1 [Jackson, Timothy L.; Simpson, Andrew; Neffendorf, James E.; Petrarca, Robert; Lewis, Cornelius] Kings Coll London, Sch Med, London WC2R 2LS, England.
   [Jackson, Timothy L.; Desai, Riti; Simpson, Andrew; Neffendorf, James E.; Petrarca, Robert] Kings Coll Hosp London, Dept Ophthalmol, Denmark Hill, London SE5 9RS, England.
   [Smith, Kelly; Wittes, Janet] Stat Collaborat Inc, Washington, DC USA.
   [Lewis, Cornelius] Kings Coll Hosp London, Dept Engn & Phys, Denmark Hill, London SE5 9RS, England.
   [Membrey, Luke] Maidstone Hlth Author, Dept Ophthalmol, Maidstone, Kent, England.
   [Haynes, Richard] Bristol Eye Hosp, Bristol BS1 2LX, Avon, England.
   [Costen, Mark] Hull & East Yorkshire Eye Hosp, Kingston Upon Hull, N Humberside, England.
   [Steel, David H. W.] Sunderland Eye Infirm, Sunderland, Tyne & Wear, England.
   [Steel, David H. W.] Newcastle Univ, Inst Med Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Muldrew, Alyson; Chakravarthy, Usha] Queens Univ Belfast, Cent Angiog Reading Ctr, Belfast, Antrim, North Ireland.
C3 University of London; King's College London; King's College Hospital NHS
   Foundation Trust; King's College Hospital; King's College Hospital NHS
   Foundation Trust; King's College Hospital; Bristol Eye Hospital;
   Newcastle University - UK; Queens University Belfast
RP Jackson, TL (通讯作者)，Kings Coll Hosp London, Dept Ophthalmol, Sch Med, Kings Coll London, Denmark Hill, London SE5 9RS, England.
EM t.jackson1@nhs.net
RI ; Steel, David/I-8053-2015
OI Desai, Riti/0000-0001-6425-0648; Petrarca, Robert/0000-0001-8693-3423;
   Jackson, Timothy/0000-0001-7618-1555; Chakravarthy,
   Usha/0000-0002-2606-3734; Steel, David/0000-0001-8734-3089
FU NeoVista; Oraya (Newark, CA); Novartis (Frimley, UK); NeoVista (Fremont,
   CA); Genentech (South San Francisco, CA); Alcon (Fort Worth, TX)
FX The author(s) have made the following disclosure(s): T.L.J.: Financial
   support - NeoVista (Fremont, CA); Financial support (to employer) -
   NeoVista; Oraya (Newark, CA); Novartis (Frimley, UK); K.S.: Financial
   support - NeoVista (Fremont, CA); Genentech (South San Francisco, CA);
   Alcon (Fort Worth, TX); R.H.: Financial support - NeoVista (Fremont,
   CA); NeoVista (Fremont, CA) provided unrestricted research funding but
   had no role in data collection, analysis, or in the preparation or
   review of this manuscript.
CR Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   CHAKRAVARTHY U, 1989, CURR EYE RES, V8, P337, DOI 10.3109/02713688908996381
   Chin HS, 2005, RETINA-J RET VIT DIS, V25, P556, DOI 10.1097/00006982-200507000-00002
   Christoforidis JB, 2013, CURR EYE RES, V38, P761, DOI 10.3109/02713683.2013.763988
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Dugel PU, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.014
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jackson TL, 2013, EYE, V27, P644, DOI 10.1038/eye.2013.12
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1597, DOI 10.1016/j.ophtha.2013.01.074
   Kakinoki M, 2012, INVEST OPHTH VIS SCI, V53, P5877, DOI 10.1167/iovs.12-10164
   Kirwan JF, 2003, EYE, V17, P207, DOI 10.1038/sj.eye.6700306
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Petrarca R, 2013, RETINA-J RET VIT DIS, V33, P1232, DOI 10.1097/IAE.0b013e3182794b22
   Petrarca R, 2013, OPHTHALMOLOGY, V120, P328, DOI 10.1016/j.ophtha.2012.07.091
   Petrarca R, 2011, CLIN OPHTHALMOL, V5, P57, DOI 10.2147/OPTH.S16444
   Spaide Richard F, 2009, Retina, V29, pS5, DOI 10.1097/IAE.0b013e3181ad237a
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
NR 20
TC 10
Z9 11
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2016
VL 123
IS 6
BP 1287
EP 1296
DI 10.1016/j.ophtha.2016.02.028
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DM7BD
UT WOS:000376506400025
PM 27086023
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Landa, G
   Rosen, RB
   Patel, A
   Lima, VC
   Tai, KW
   Perez, VR
   Aizman, A
   Garcia, PMT
AF Landa, Gennady
   Rosen, Richard B.
   Patel, Amar
   Lima, Veronica Castro
   Tai, Katy W.
   Perez, Violete R.
   Aizman, Alexander
   Garcia, Patricia M. T.
TI Qualitative Spectral OCT/SLO Analysis of Drusen Change in Dry
   Age-Related Macular Degeneration Patients Treated with Copaxone
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; SEVERITY
   SCALE; MACULOPATHY; EYES; PREVALENCE; OCT
AB Purpose: High-resolution spectral domain OCT/SLO (SD-OCT) has become an increasingly useful tool for differentiating drusen morphologic parameters such as shape, internal reflectivity, homogeneity, and presence of overlying hyperreflective foci. Our purpose was to evaluate which types of drusen may respond to Copaxone (glatiramer acetate) treatment of dry age-related macular degeneration (AMD) patients by shrinking or disappearing.
   Methods: A prospective and interventional clinical trial of patients with dry AMD who received subcutaneous treatment with Copaxone or sham injections was conducted. SD-OCT images were used for analysis of drusen ultrastructure. Morphologic characteristics for specific drusen within the macular region were assessed with serial studies. Pre- and posttreatment statuses of drusen were compared. Main outcome measure was a change of drusen morphologic parameters in Copaxone-treated and sham-treated dry AMD patients between baseline and 12 weeks of treatment.
   Results: Three hundred eleven drusen from 26 eyes of 14 dry AMD patients were evaluated. One hundred seventy-two drusen from 14 eyes (7 patients) of Copaxone-treated and 139 drusen from 12 eyes sham-treated (7 patients) were included. Overall, between baseline and 12-week visit, the percentage of drusen that disappeared/shrank in the Copaxone-treated group was 19.2% versus 6.5% in the sham-treated group (P = 0.13). The percentage of convex drusen that shrank or disappeared after 12 weeks of treatment was significantly higher in the Copaxone-treated group (27.8%) in comparison with the sham-treated group (6.8%) (P = 0.008). The difference between the groups was found to be statistically significant for drusen with low and medium internal reflectivity (P = 0.019 and P = 0.036, respectively).
   Conclusions: Convex shape and low/medium internal reflectivity were found to be favorable parameters in prediction of drusen reduction in the Copaxone-treated patients. This study represents a preliminary attempt to identify SD-OCT features of drusen that may predict susceptibility to Copaxone treatment and therefore help clinicians decide which patients to treat.
C1 [Landa, Gennady; Rosen, Richard B.; Patel, Amar; Lima, Veronica Castro; Tai, Katy W.; Perez, Violete R.; Garcia, Patricia M. T.] New York Eye & Ear Infirm, Dept Ophthalmol, Retina Ctr, New York, NY 10003 USA.
   [Landa, Gennady; Rosen, Richard B.; Garcia, Patricia M. T.] New York Med Coll, Dept Ophthalmol, Valhalla, NY 10595 USA.
   [Lima, Veronica Castro] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Aizman, Alexander] NYU, Med Ctr, Dept Ophthalmol, New York, NY 10016 USA.
C3 New York Eye & Ear Infirmary of Mount Sinai; New York Medical College;
   Universidade Federal de Sao Paulo (UNIFESP); New York University
RP Rosen, RB (通讯作者)，New York Eye & Ear Infirm, Dept Ophthalmol, Retina Ctr, 310 E 14th St, New York, NY 10003 USA.
EM rrosen@nyee.edu
CR BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Chen YL, 2009, OPT EXPRESS, V17, P4046, DOI 10.1364/OE.17.004046
   Coscas G, 2008, J FR OPHTALMOL, V31, P353, DOI 10.1016/S0181-5512(08)71429-3
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Green W Richard, 2005, Retina, V25, P1519, DOI 10.1097/00006982-200507001-00015
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Landa G, 2008, CURR EYE RES, V33, P1011, DOI 10.1080/02713680802484637
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Parodi MB, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub2
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   SEBAG M, 1991, ACTA OPHTHALMOL, V69, P603
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Spraul CW, 1998, KLIN MONATSBL AUGENH, V212, P141, DOI 10.1055/s-2008-1034850
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
NR 27
TC 20
Z9 22
U1 0
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD FEB
PY 2011
VL 27
IS 1
BP 77
EP 82
DI 10.1089/jop.2010.0109
PG 6
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 723BU
UT WOS:000287482000012
PM 21254921
DA 2022-11-30
ER

PT J
AU Feng, XF
   Xiao, J
   Longville, B
   Tan, AXJ
   Wu, XN
   Cooper, MN
   McAllister, IL
   Isaacs, T
   Palmer, LJ
   Constable, IJ
AF Feng, Xuefeng
   Xiao, Jing
   Longville, Brooke
   Tan, Alexander X. J.
   Wu, Xia Ni
   Cooper, Matthew N.
   McAllister, Ian L.
   Isaacs, Timothy
   Palmer, Lyle J.
   Constable, Ian J.
TI Complement Factor H Y402H and C-Reactive Protein Polymorphism and
   Photodynamic Therapy Response in Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID CRP LEVELS; CARDIOVASCULAR RISK; GENE POLYMORPHISMS; ASSOCIATION; LEVEL;
   INFLAMMATION; PREDISPOSES; VARIABILITY; BIOMARKERS; VARIANTS
AB Purpose: To investigate the association between complement factor H (CFH) and C-reactive protein (CRP) genotypes and response to photodynamic therapy (PDT) treatment for neovascular age-related macular degeneration (AMD).
   Design: Retrospective cohort study.
   Participants: The study cohort consisted of 273 neovascular AMD patients treated with PDT.
   Methods: Genotypes were determined for the common T-->C single nucleotide polymorphism (SNP) in exon 9 of the CFH gene (rs1061170; Y402H), as well as 9 selected tagging SNPs across the CRP gene (rs2808635, rs1417938, rs1800947, rs1130864, rs1205, rs3093077, rs876538, rs876537, and rs1572970). Visual acuity outcome after PDT was retrospectively calculated and patients were classified as PDT-positive responders or PDT-negative responders. Logistic regression analysis was used to evaluate the association between individual SNPs and PDT treatment response while adjusting for relevant covariates.
   Main Outcome Measures: Response to PDT treatment defined by visual acuity; genotypes of CFH Y402H and CRP polymorphism.
   Results: Of the 273 patients, 75 had a positive response after PDT treatment. The frequency of CC genotype of the CFH Y402H polymorphism in the PDT-positive response group was lower than in the negative PDT response group (26.4% vs 31.6%) but this difference failed to reach statistical significance. Two CRP SNPs (rs2808635 and rs876538) were significantly associated with PDT treatment response. Positive treatment response was seen in individuals homozygous for the minor allele of the rs2808635 (GG; odds ratio [OR], 3.92; 95% confidence interval [CI], 1.40-10.97; P = 0.048) and rs876538 (AA; OR, 6.49; 95% Cl, 1.65-25.47; P = 0.048) variants after adjusting for relevant covariates. The remaining 7 CRP genetic variants did not reveal any significant association with treatment response.
   Conclusions: Our data did not show significant association between the CFH Y402H polymorphism and PDT treatment response for neovascular AMD; however, CRP genetic variants were associated with a positive response to PDT treatment for neovascular AMD.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2009; 116:1908-1912 (C) 2009 by the American Academy of Ophthalmology.
C1 [Xiao, Jing; Tan, Alexander X. J.; Wu, Xia Ni] Univ W Australia, Sch Med & Dent, Perth, WA, Australia.
   [Xiao, Jing; Longville, Brooke; Tan, Alexander X. J.; Wu, Xia Ni; Cooper, Matthew N.; Palmer, Lyle J.] Univ Western Australia, Med Res Ctr, Perth, WA 6009, Australia.
   [Xiao, Jing; Longville, Brooke; Tan, Alexander X. J.; Wu, Xia Ni; Cooper, Matthew N.; Palmer, Lyle J.] Univ Western Australia, Ctr Genet Epidemiol & Biostat, Perth, WA 6009, Australia.
   [Feng, Xuefeng] Peking Univ, Hosp 3, Ctr Eye, Beijing 100871, Peoples R China.
   [Feng, Xuefeng; McAllister, Ian L.; Isaacs, Timothy; Constable, Ian J.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA 6009, Australia.
C3 University of Western Australia; University of Western Australia;
   University of Western Australia; Peking University; Lions Eye Institute;
   University of Western Australia
RP Constable, IJ (通讯作者)，AA Block,2 Verdun St, Nedlands, WA 6009, Australia.
EM ian.constable@lei.org.au
RI Cooper, Matthew N/J-4420-2014; Palmer, Lyle John/N-1948-2019; Palmer,
   Lyle John/K-3196-2014
OI Cooper, Matthew N/0000-0003-1139-3682; Palmer, Lyle
   John/0000-0002-1628-3055; Palmer, Lyle John/0000-0002-1628-3055
FU Wind Over Foundation, Perth, Australia
FX Supported in part by a philanthropic donation from the Wind Over
   Foundation, Perth, Australia.
CR Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brull DJ, 2003, ARTERIOSCL THROM VAS, V23, P2063, DOI 10.1161/01.ATV.0000084640.21712.9C
   Carlson CS, 2005, AM J HUM GENET, V77, P64, DOI 10.1086/431366
   Crawford DC, 2006, CIRCULATION, V114, P2458, DOI 10.1161/CIRCULATIONAHA.106.615740
   De La Vega FA, 2005, MUTAT RES-FUND MOL M, V573, P111, DOI 10.1016/j.mrfmmm.2005.01.008
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Du Clos TW, 2000, ANN MED, V32, P274, DOI 10.3109/07853890009011772
   Dupuis J, 2005, ATHEROSCLEROSIS, V182, P307, DOI 10.1016/j.atherosclerosis.2005.02.015
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eklund C, 2008, ATHEROSCLEROSIS, V196, P841, DOI 10.1016/j.atherosclerosis.2007.01.027
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Kathiresan S, 2006, CIRCULATION, V113, P1415, DOI 10.1161/CIRCULATIONAHA.105.591271
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kolz M, 2008, EUR HEART J, V29, P1250, DOI 10.1093/eurheartj/ehm442
   Miller DT, 2005, ANN HUM GENET, V69, P623, DOI 10.1111/j.1529-8817.2005.00210.x
   Pankow JS, 2001, ATHEROSCLEROSIS, V154, P681, DOI 10.1016/S0021-9150(00)00586-4
   Russell AI, 2004, HUM MOL GENET, V13, P137, DOI 10.1093/hmg/ddh021
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Thorisson GA, 2005, GENOME RES, V15, P1592, DOI 10.1101/gr.4413105
   Wang QW, 2006, AM J PHYSIOL-HEART C, V291, pH2752, DOI 10.1152/ajpheart.01164.2005
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Weller JI, 1998, GENETICS, V150, P1699
NR 30
TC 42
Z9 49
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2009
VL 116
IS 10
BP 1908
EP 1912
DI 10.1016/j.ophtha.2009.03.011
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 506RX
UT WOS:000270794600012
PM 19692124
DA 2022-11-30
ER

PT J
AU Pulido, JS
   McConnell, JP
   Lennon, RJ
   Bryant, SC
   Peterson, LM
   Berger, PB
   Somers, V
   Highsmith, WE
AF Pulido, Jose S.
   McConnell, Joseph P.
   Lennon, Ryan J.
   Bryant, Sandra C.
   Peterson, Lisa M.
   Berger, Peter B.
   Somers, Virend
   Highsmith, W. Edward
TI Relationship between age-related macular degeneration-associated
   variants of complement factor H and LOC387715 with coronary artery
   disease
SO MAYO CLINIC PROCEEDINGS
LA English
DT Article
ID C-REACTIVE PROTEIN; RETINAL-PIGMENT EPITHELIUM; OXIDIZED PHOSPHOLIPIDS;
   MYOCARDIAL-INFARCTION; GEOGRAPHIC ATROPHY; STATIN THERAPY; Y402H
   VARIANT; RISK-FACTORS; POLYMORPHISM; GENE
AB OBJECTIVE: To determine whether either of the gene variants associated with age-related mabular degeneration is associated with coronary artery disease (CAD).
   PATIENTS AND METHODS: This study consisted of 493 patients who underwent clinically indicated coronary angiography between June 1, 1998, and January 1, 1999. The Y402H variant of the complement factor H (CFH) gene and the A69S variant of the LOC387715 gene locus were examined by restriction fragment length polymorphism. Multiple logistic regression models were used to assess the association of CFH and LOC gene variants with CAD. Covariates with well-established associations with CAD were also evaluated.
   RESULTS: Seventy patients (14%) were homozygous for the histidine variant (HH) of CFH, 237 (48%) were heterozygous for the histidine variant (HY), and 186 (38%) were homozygous for the tyrosine variant (YY). Three hundred eight patients (62%) were homozygous for the alanine allele of LOC387715, 170 (34%) were heterozygous for Ala and Ser alleles, and 15 (3%) were homozygous for the serine variant. The overall association of the CFH genotype with CAD was not statistically significant (P=.08). However, some evidence (P=.046) suggested that CAD was increased for the HH genotype compared to the homozygous wild-type YY genotype (odds ratio, 1.95; 95% confidence interval, 1.01-3.76). Male sex, hypertension, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and age were other variables that demonstrated significant associations with CAD. The overall effect of the LOC genotype was not statistically significant (131-.06). Heterozygosity for the serine variant was (P=.02) associated with the absence of CAD vs the AS genotype (odds ratio, 0.59; confidence interval, 0.38-.91; P=.02).
   CONCLUSION: The CFH genotype may have an independent association with CAD, although our evidence did not show statistical significance. Controlling for known risk factors, the age-related macular degeneration-associated HH variant appears to be associated with CAD. The LOC387715 gene may also play a role in CAD.
C1 Mayo Clin & Mayo Fdn, Coll Med, Genet Mol Lab, Dept Lab Med & Pathol, Rochester, MN 55905 USA.
   Mayo Clin & Mayo Fdn, Coll Med, Dept Ophthalmol, Rochester, MN 55905 USA.
   Mayo Clin & Mayo Fdn, Coll Med, Div Biostat, Rochester, MN 55905 USA.
   Mayo Clin & Mayo Fdn, Coll Med, Div Cardiovasc Dis, Rochester, MN 55905 USA.
   Geisinger Ctr Hlth Res, Danville, PA USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Highsmith, WE (通讯作者)，Mayo Clin & Mayo Fdn, Coll Med, Genet Mol Lab, Dept Lab Med & Pathol, 200 1st St SW, Rochester, MN 55905 USA.
EM highsmith.w@mayo.edu
RI Highsmith, William E/B-6175-2008
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brilakis ES, 2005, EUR HEART J, V26, P137, DOI 10.1093/eurheartj/ehi010
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Donaldson MJ, 2006, CURR OPIN OPHTHALMOL, V17, P267, DOI 10.1097/01.icu.0000193101.13551.e5
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Giannakis E, 2001, INT IMMUNOPHARMACOL, V1, P433, DOI 10.1016/S1567-5769(00)00040-0
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Nissen SE, 2005, NEW ENGL J MED, V352, P29, DOI 10.1056/NEJMoa042000
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Ridker PM, 2001, NEW ENGL J MED, V344, P1959, DOI 10.1056/NEJM200106283442601
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Souied EH, 2005, MOL VIS, V11, P1135
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tsimikas S, 2005, NEW ENGL J MED, V353, P46, DOI 10.1056/NEJMoa043175
   Tsimikas S, 2004, CIRCULATION, V109, P3164, DOI 10.1161/01.CIR.0000130844.01174.55
   Zee RYL, 2006, ATHEROSCLEROSIS, V187, P332, DOI 10.1016/j.atherosclerosis.2005.09.009
NR 33
TC 14
Z9 17
U1 0
U2 0
PU MAYO CLINIC PROCEEDINGS
PI ROCHESTER
PA 660 SIEBENS BLDG MAYO CLINIC, ROCHESTER, MN 55905 USA
SN 0025-6196
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD MAR
PY 2007
VL 82
IS 3
BP 301
EP 307
DI 10.4065/82.3.301
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 143BM
UT WOS:000244695000008
PM 17352366
DA 2022-11-30
ER

PT J
AU Berendschot, TTJM
   Willemse-Assink, JJM
   Bastiaanse, M
   de Jong, PTVM
   van Norren, D
AF Berendschot, TTJM
   Willemse-Assink, JJM
   Bastiaanse, M
   de Jong, PTVM
   van Norren, D
TI Macular pigment and melanin in age-related maculopathy in a general
   population
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BEAVER DAM EYE; RISK-FACTORS; 5-YEAR INCIDENCE; OPTICAL-DENSITY; PRIMATE
   RETINAS; DEGENERATION; LUTEIN; PREVALENCE; ZEAXANTHIN; FUNDUS
AB PURPOSE. It has been suggested that macular pigment (MP) and melanin may protect against age-related maculopathy (ARM). To check this, MP and melanin optical density were measured in a random population-based sample of subjects 55 years of age or older.
   METHODS. Spectral fundus reflectance of the fovea was measured in one eye per subject in a 2.3degrees detection field with a fundus reflectometer. The sample consisted of 199 men and 236 women. Analysis with a fundus reflectance model yielded individual estimates for the MP and melanin optical density. Diagnosis of ARM was based on grading of standardized fundus transparencies. Eyes were stratified in four exclusive stages of ARM.
   RESULTS. MP optical density (at 460 nm) was 0.33 +/- 0.15 in eyes without ARM (n = 289) and 0.33 +/- 0.16 in eyes at any stage of ARM (n = 146). Melanin optical density (at 500 nm) was 1.18 +/- 0.19 in eyes without ARM and 1.20 +/- 0.21 in eyes at any stage of ARM. We found no gender differences for either MP or melanin optical density.
   CONCLUSIONS. No differences in MP and melanin optical density were found between eyes with and without ARM or between the various ARM stages.
C1 UMC Utrecht, Dept Ophthalmol, NL-3508 GA Utrecht, Netherlands.
   Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands.
   Netherlands Ophthalm Res Inst, NL-1100 AC Amsterdam, Netherlands.
   Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
   Org Appl Sci Res TNO, Human Factors, Soesterberg, Netherlands.
C3 Utrecht University; Utrecht University Medical Center; Erasmus
   University Rotterdam; Royal Netherlands Academy of Arts & Sciences;
   Netherlands Institute for Neuroscience (NIN-KNAW); University of
   Amsterdam; Academic Medical Center Amsterdam; Netherlands Organization
   Applied Science Research
RP Berendschot, TTJM (通讯作者)，UMC Utrecht, Dept Ophthalmol, AZU E03-136,POB 85500, NL-3508 GA Utrecht, Netherlands.
EM tosb@isi.uu.nl
RI Berendschot, Tos TJM/M-8509-2016
OI Berendschot, Tos TJM/0000-0002-8101-939X
CR Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BONE RA, 1971, VISION RES, V11, P1057, DOI 10.1016/0042-6989(71)90112-X
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BROEKMANS WMR, IN PRESS AM J CLIN N
   CHINN S, 1990, STAT MED, V9, P351, DOI 10.1002/sim.4780090402
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Curran-Celentano J, 1999, INVEST OPHTH VIS SCI, V40, pS568
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   DELORI FC, 1989, APPL OPTICS, V28, P1061, DOI 10.1364/AO.28.001061
   Delori FC, 1996, J OPT SOC AM A, V13, P215, DOI 10.1364/JOSAA.13.000215
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   GABEL VP, 1978, EXCERPTA MED INT C S, P658
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HAMMOND BR, 1992, INVEST OPHTH VIS SCI, V33, P350
   HAMMOND BR, 1995, INVEST OPHTH VIS SCI, V36, P2531
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sharpe LT, 1998, VISION RES, V38, P3233, DOI 10.1016/S0042-6989(97)00457-4
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   vandeKraats J, 1996, VISION RES, V36, P2229, DOI 10.1016/0042-6989(96)00001-6
   VANNORREN D, 1989, VISION RES, V29, P369, DOI 10.1016/0042-6989(89)90085-0
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   WERNER JS, 1987, VISION RES, V27, P257, DOI 10.1016/0042-6989(87)90188-X
NR 56
TC 115
Z9 119
U1 0
U2 12
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2002
VL 43
IS 6
BP 1928
EP 1932
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 557VA
UT WOS:000175927800036
PM 12037001
DA 2022-11-30
ER

PT J
AU Essex, RW
   Tufail, A
   Bunce, C
   Aylward, GW
AF Essex, Rohan W.
   Tufail, Adnan
   Bunce, Catie
   Aylward, G. William
TI Two-year results of surgical removal of choroidal neovascular membranes
   related to non-age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OCULAR HISTOPLASMOSIS SYNDROME; RANDOMIZED CLINICAL-TRIAL; NUCLEAR
   SCLEROTIC CATARACT; PHOTODYNAMIC THERAPY; MULTIFOCAL CHOROIDITIS;
   EPIRETINAL MEMBRANES; PATHOLOGICAL MYOPIA; OPHTHALMIC FINDINGS;
   SUBMACULAR SURGERY; NATURAL-HISTORY
AB Purpose: To present the 2-year outcomes of surgical removal of non-age-related macular degeneration (AMD)-related choroidal neovascular membranes and to evaluate any association between visual outcome and baseline clinical factors.
   Methods: Retrospective consecutive case series. All patients who had surgery for non-AMD-related choroidal neovascularisation (CNV) between November 1997 and March 2003 under the care of a single surgeon (WA) were included in the study. Baseline data including patient age, duration of subfoveal CNV, preoperative visual acuity (VA), lesion size, lesion components and aetiology were collected. The primary outcome was VA change with secondary outcomes retinal detachment, operative peripheral retinal break formation, CNV recurrence and cataract.
   Results: A total of 52 eyes were included in the study. The aetiology of CNV was: punctate inner choridopathy 21 (40%); idiopathic 8 (15%); pathologic myopia 6 (12%); ocular histoplasmosis syndrome 1 (2%); and other 16 (31%). The mean age of patients was 41(range 14-72) years. 24-month follow-up was available for 41 (80%) eyes. The mean logMAR equivalent baseline acuity was 1.1 and mean lesion size 1.2 disc areas. An improvement in VA >1 Snellen line was noted in 26 (63%) eyes, whereas 10 (24%) eyes remained the same (within 1 line) and 5 (12%) lost >1 line of acuity. Improvement in VA was associated with worse baseline VA (84% for eyes with VA <= 6/36 vs 31% for those with VA >6/36, p = 0.001). No evidence of association between 2-year visual outcome and any other baseline factor under study was observed. Peripheral retinal breaks were noted in 5 (10%) eyes at the time of surgery, and 3 (5.8%) eyes developed postoperative retinal detachments. Persistent/recurrent CNV was noted in 17 (33%) eyes. The median time to presentation of CNV in these eyes was 27 (range 2-172) weeks. Five eyes underwent cataract surgery during the follow-up period. The mean age of these patients was significantly higher than the mean age of those who did not require cataract surgery (57 vs 37 years, p = 0.014).
   Conclusions: Surgical excision of non-AMD-related CNV resulted in improvement of VA in the majority of eyes. Worse presenting acuity was associated with better visual improvements.
C1 Moorfields Eye Hosp, London EC1V 2PD, England.
   UCL, Inst Ophthalmol, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London
RP Aylward, GW (通讯作者)，Moorfields Eye Hosp, City Rd, London EC1V 2PD, England.
EM bill.aylward@moorfields.nhs.uk
OI Tufail, Adnan/0000-0001-6131-7640; Bunce, Catey/0000-0002-0935-3713;
   Essex, Rohan/0000-0001-5323-0334
CR Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Barbazetto IA, 2004, EXP EYE RES, V78, P917, DOI 10.1016/j.exer.2004.01.003
   Berger AS, 1997, ARCH OPHTHALMOL-CHIC, V115, P991, DOI 10.1001/archopht.1997.01100160161004
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Busquets MA, 2003, RETINA-J RET VIT DIS, V23, P299, DOI 10.1097/00006982-200306000-00003
   Chan WM, 2003, OPHTHALMOLOGY, V110, P2395, DOI 10.1016/S0161-6420(03)00788-7
   CHERFAN GM, 1991, AM J OPHTHALMOL, V111, P434, DOI 10.1016/S0002-9394(14)72377-3
   Dees C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1456, DOI 10.1001/archopht.116.11.1456
   Dunlop AAS, 1998, ARCH OPHTHALMOL-CHIC, V116, P801, DOI 10.1001/archopht.116.6.801
   Eckstein M, 1998, EYE, V12, P775, DOI 10.1038/eye.1998.201
   Ezra E, 2004, ARCH OPHTHALMOL-CHIC, V122, P224, DOI 10.1001/archopht.122.2.224
   Flaxel CJ, 1998, EYE, V12, P266, DOI 10.1038/eye.1998.62
   Gass J D, 1994, Trans Am Ophthalmol Soc, V92, P91
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   HO AC, 1995, OPHTHALMOLOGY, V102, P782, DOI 10.1016/S0161-6420(95)30968-2
   Holekamp NM, 1997, OPHTHALMOLOGY, V104, P22, DOI 10.1016/S0161-6420(97)30367-4
   Holekamp NM, 2005, AM J OPHTHALMOL, V139, P302, DOI 10.1016/j.ajo.2004.09.046
   Hubbard GB, 2004, ARCH OPHTHALMOL-CHIC, V122, P1597, DOI 10.1001/archopht.122.11.1597
   Leslie T, 2005, BRIT J OPHTHALMOL, V89, P147, DOI 10.1136/bjo.2004.046623
   Liu JC, 2004, RETINA-J RET VIT DIS, V24, P863, DOI 10.1097/00006982-200412000-00004
   MELBERG NS, 1995, OPHTHALMOLOGY, V102, P1466
   Mimouni KF, 2003, AM J OPHTHALMOL, V135, P900, DOI 10.1016/S0002-9394(02)02224-9
   Parodi MB, 2004, AM J OPHTHALMOL, V138, P263, DOI 10.1016/j.ajo.2004.03.029
   Postelmans L, 2004, AM J OPHTHALMOL, V138, P803, DOI 10.1016/j.ajo.2004.06.033
   Rechtman E, 2003, AM J OPHTHALMOL, V136, P739, DOI 10.1016/S0002-9394(03)00389-1
   Rosenfeld PJ, 2004, OPHTHALMOLOGY, V111, P1725, DOI 10.1016/j.ophtha.2004.02.014
   Shah GK, 2005, RETINA-J RET VIT DIS, V25, P26, DOI 10.1097/00006982-200501000-00003
   Sickenberg M, 2000, ARCH OPHTHALMOL-CHIC, V118, P327, DOI 10.1001/archopht.118.3.327
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P545, DOI 10.1097/00006982-200210000-00003
   Spaide RF, 2002, AM J OPHTHALMOL, V134, P62, DOI 10.1016/S0002-9394(02)01452-6
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   THOMAS MA, 1991, AM J OPHTHALMOL, V111, P1, DOI 10.1016/S0002-9394(14)76888-6
   Thompson JT, 2004, AM J OPHTHALMOL, V137, P250, DOI 10.1016/j.ajo.2003.09.020
   Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P899, DOI 10.1007/s00417-003-0734-5
NR 37
TC 16
Z9 18
U1 0
U2 0
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2007
VL 91
IS 5
BP 649
EP 654
DI 10.1136/bjo.2005.089458
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 158XW
UT WOS:000245829900025
PM 17446505
OA Green Published
DA 2022-11-30
ER

PT J
AU Marioli, DI
   Pharmakakis, N
   Deli, A
   Havvas, I
   Zarkadis, IK
AF Marioli, Dimitra I.
   Pharmakakis, Nikolaos
   Deli, Angeliki
   Havvas, Ioannis
   Zarkadis, Ioannis K.
TI Complement factor H and LOC387715 gene polymorphisms in a Greek
   population with age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Complement factor H; LOC387715;
   Polymorphism; Greek population
ID BODY-MASS INDEX; ENVIRONMENTAL ASSOCIATIONS; CHROMOSOME 10Q26; CFH GENE;
   Y402H; RISK; SUSCEPTIBILITY; SMOKING; VARIANT; AMD
AB Age-related macular degeneration (AMD) is the leading cause of severe visual loss among people over 60 years old. The lack of a broadly effective treatment for AMD underscores the need to identify causative biomarkers that could serve as preventive targets. Thus far, two major susceptibility loci for AMD have been identified, CFH T1277C and LOC387715 G270T. The primary goal of the present study was to elucidate whether these polymorphisms are major genetic determinants of AMD in a Greek population.
   A clinic-based, case-control association study was conducted, comprising 100 Greek patients with early and late-stage AMD and 115 independent controls of Caucasian origin. All participants underwent clinical examination including best-corrected visual acuity, intraocular pressure, and dilated fundus examination. Moreover, they were genotyped for CFH T1277C and LOC387715 G270T polymorphisms, by direct sequencing and ARMS PCR, respectively.
   The frequency of the CFH 1277C allele was significantly higher in AMD patients in comparison with controls while the odds ratios (ORs) for AMD were 4.4-5.5. Statistical comparison of early and advanced AMD patients, on the basis of CFH genotype, revealed that the CFH 1277C allele was associated with both subgroups when compared with the controls (P < 0.001). When statistical comparison was performed between early and advanced patients on the basis of CFH genotypic frequencies, the CC genotype was found to be more prevalent in advanced AMD patients (P = 0.008, OR = 2.3). The frequency of the LOC387715 270 T allele was higher in AMD patients in comparison with controls (P < 0.04) while the ORs for AMD were 1.4-2. No statistically significant differences were located between the early AMD patients and controls, on the basis of LOC387715 genotype (P = 0.189). On the contrary, the T270G polymorphism was associated with advanced AMD (P = 0.04). Moreover, the TT genotype was more prevalent in patients with advanced AMD (P = 0.011, OR = 1.7) when compared with early AMD patients. Assessment of the combined contribution of CFH T1277C and LOC387715 G270T SNPs showed an independent manner of action of these polymorphisms in the development of the disease.
   The replication of the reported associations of CFH T1277C polymorphism with AMD suggest that the 1277C allele could serve as a high-risk genetic marker for the development of AMD and the progression of the disease to the advanced clinical stage in the Greek population.
C1 [Marioli, Dimitra I.; Zarkadis, Ioannis K.] Univ Patras, Dept Biol, Sch Med, Patras 26500, Greece.
   [Pharmakakis, Nikolaos; Deli, Angeliki; Havvas, Ioannis] Univ Patras, Sch Med, Dept Ophthalmol, Univ Hosp Patras, Patras 26500, Greece.
C3 University of Patras; University of Patras
RP Zarkadis, IK (通讯作者)，Univ Patras, Dept Biol, Sch Med, Patras 26500, Greece.
EM zarkadis@med.upatras.gr
CR Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Francis PJ, 2008, MOL VIS, V14, P1395
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Souied EH, 2005, MOL VIS, V11, P1135
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   *WHO, 282 WHO
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 31
TC 11
Z9 11
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2009
VL 247
IS 11
BP 1547
EP 1553
DI 10.1007/s00417-009-1129-z
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 503NB
UT WOS:000270541500012
PM 19568762
DA 2022-11-30
ER

PT J
AU Chen, L
   Cao, DF
   Messinger, JD
   Ach, T
   Ferrara, D
   Freund, KB
   Curcio, CA
AF Chen, Ling
   Cao, Dongfeng
   Messinger, Jeffrey D.
   Ach, Thomas
   Ferrara, Daniela
   Freund, K. Bailey
   Curcio, Christine A.
TI Histology and clinical imaging lifecycle of black pigment in fibrosis
   secondary to neovascular age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Color fundus photography; Fibrosis;
   Histopathology; Melanosomes; Optical coherence tomography; Retinal
   pigment epithelium
ID OPTICAL COHERENCE TOMOGRAPHY; ULTRASTRUCTURAL FEATURES; CHOROIDAL
   MACROPHAGES; HYPERREFLECTIVE FOCI; EPITHELIUM; RETINA; AUTOFLUORESCENCE;
   MELANOSOMES; ATROPHY; EYES
AB Purpose: Melanotic cells with large spherical melanosomes, thought to originate from retinal pigment epithelium (RPE), are found in eyes with neovascular age-related macular degeneration (nvAMD). To generate hypotheses about RPE participation in fibrosis, we correlate histology to clinical imaging in an eye with prominent black pigment in fibrotic scar secondary to nvAMD.
   Methods: Macular findings in a white woman with untreated inactive subretinal fibrosis due to nvAMD in her right eye were documented over 9 years with color fundus photography (CFP), fundus autofluorescence (FAF) imaging, and optical coherence tomography (OCT). After death (age 90 years), this index eye was prepared for light and electron microscopy to analyze 7 discrete zones of pigmentation in the fibrotic scar. In additional donor eyes with nvAMD, we determined the frequency of black pigment (n = 36 eyes) and immuno-labeled for retinoid, immunologic, and microglial markers (RPE65, CD68, Iba1, TMEM119; n = 3 eyes).
   Results: During follow-up of the index eye, black pigment appeared and expanded within a hypoautofluorescent fibrotic scar. The blackest areas correlated to melanotic cells (containing large spherical melanosomes), some in multiple layers. Pale areas had sparse pigmented cells. Gray areas correlated to cells with RPE organelles entombed in the scar and multinucleate cells containing sparse large spherical melanosomes. In 94% of nvAMD donor eyes, hyperpigmentation was visible. Certain melanotic cells expressed some RPE65 and mostly CD68. Iba1 and TMEM119 immunoreactivity, found both in retina and scar, did not co-localize with melanotic cells.
   Conclusion: Hyperpigmentation in CFP results from both organelle content and optical superimposition effects. Black fundus pigment in nvAMD is common and corresponds to cells containing numerous large spherical melanosomes and superimposition of cells containing sparse large melanosomes, respectively. Melanotic cells are molecularly distinct from RPE, consistent with a process of transdifferentiation. The subcellular source of spherical melanosomes remains to be determined. Detailed histology of nvAMD eyes will inform future studies using technologies for spatially resolved molecular discovery to generate new therapies for fibrosis. The potential of black pigment as a biomarker for fibrosis can be investigated in clinical multimodal imaging datasets.
C1 [Chen, Ling] Chongqing Med Univ, Chongqing Eye Inst, Chongqing Key Lab Ophthalmol, Affiliated Hosp 1,Chongqing Branch,Natl Clin Res, Chongqing, Peoples R China.
   [Chen, Ling; Cao, Dongfeng; Messinger, Jeffrey D.; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL USA.
   [Ach, Thomas] Univ Hosp Bonn, Dept Ophthalmol, Bonn, Germany.
   [Ferrara, Daniela] Genentech Inc, San Francisco, CA 94080 USA.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA.
C3 Chongqing Medical University; University of Alabama System; University
   of Alabama Birmingham; University of Bonn; Roche Holding; Genentech;
   Vitreous Retina Macula Consultants of New York; New York University
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Sch Med, EyeSight Fdn Alabama Vis Res Labs, Dept Ophthalmol & Visual Sci, 1670 Univ Blvd,Room 360, Birmingham, AL 35294 USA.
EM christinecurcio@uabmc.edu
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773; Curcio,
   Christine/0000-0001-9769-1538; Ferrara, Daniela/0000-0002-1380-7562
FU Genentech/Hoffman LaRoche; Heidelberg Engineering; Macula Foundation,
   Inc., New York, NY; Research to Prevent Blindness, Inc.; EyeSight
   Foundation of Alabama; NIH [R01EY015520, R01EY027948, R01EY06019, P30
   EY003039]; IZKF Wurzburg [N-304]; International Retinal Research
   Foundation; Edward N. and Della L. Thome Foundation; Arnold and Mabel
   Beckman Initiative for Macular Research
FX Supported by Genentech/Hoffman LaRoche, Heidelberg Engineering, The
   Macula Foundation, Inc., New York, NY; unrestricted funds to the
   Department of Ophthalmology and Visual Sciences (UAB) from Research to
   Prevent Blindness, Inc., and EyeSight Foundation of Ala-bama.
   Acquisition of human tissues for immunohistochemistry was funded by NIH
   grant R01EY015520 (CAC) and R01EY027948 (CAC, TA) and IZKF Wurzburg
   (N-304, TA) . The Project MACULA website and re-covery of human donor
   eyes for research was supported by NIH grants R01EY06019 and P30
   EY003039, EyeSight Foundation of Alabama, International Retinal Research
   Foundation, Edward N. and Della L. Thome Foundation, the Arnold and
   Mabel Beckman Initiative for Macular Research, and Research to Prevent
   Blindness Inc.
CR Anderson DMG, 2020, J AM SOC MASS SPECTR, V31, P2426, DOI 10.1021/jasms.0c00119
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113
   Bermond K, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.35
   Bonilha VL, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.8.15
   Bowman SL, 2019, TRAFFIC, V20, P404, DOI 10.1111/tra.12646
   Brooks PJ, 2019, AM J PATHOL, V189, P1145, DOI 10.1016/j.ajpath.2019.02.006
   Buchwalow IB, 2010, IMMUNOHISTOCHEMISTRY: BASICS AND METHODS, P1, DOI 10.1007/978-3-642-04609-4
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   Cao DF, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.10.34
   Chen KC, 2016, AM J OPHTHALMOL, V164, P89, DOI 10.1016/j.ajo.2016.02.002
   Chen L, 2021, OPHTHALMOL RETINA, V5, P1085, DOI 10.1016/j.oret.2021.01.012
   Chen L, 2021, OPHTHALMOL RETINA, V5, P730, DOI 10.1016/j.oret.2020.11.006
   Chen L, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.8.8
   Chen L, 2020, OPHTHALMOLOGY, V127, P931, DOI 10.1016/j.ophtha.2020.01.040
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chistiakov DA, 2017, LAB INVEST, V97, P4, DOI 10.1038/labinvest.2016.116
   Cho SM, 2019, REGUL TOXICOL PHARM, V106, P7, DOI 10.1016/j.yrtph.2019.04.006
   Corradetti G, 2022, EYE, V36, P1560, DOI 10.1038/s41433-021-01670-3
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2015, AM J OPHTHALMOL, V160, P1024, DOI 10.1016/j.ajo.2015.08.001
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   De Rosa I, 2020, RETINA-J RET VIT DIS, V40, P2277, DOI 10.1097/IAE.0000000000002771
   Elleder M, 2001, HISTOCHEM J, V33, P273, DOI 10.1023/A:1017925023408
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   Gouras P, 2018, CURR EYE RES, V43, P1019, DOI 10.1080/02713683.2018.1464194
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Guan ZQ, 2020, MOLECULES, V25, DOI 10.3390/molecules25061413
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jaffe G.J., 2018, OPHTHALMOLOGY
   Jaissle GB, 2010, GRAEF ARCH CLIN EXP, V248, P1063, DOI 10.1007/s00417-009-1253-9
   Jakobiec FA, 2021, AM J OPHTHALMOL, V222, P388, DOI 10.1016/j.ajo.2020.09.020
   Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042
   Kashani AH, 2020, OPHTHALMOL RETINA, V4, P264, DOI 10.1016/j.oret.2019.09.017
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   KROLL AJ, 1968, AM J OPHTHALMOL, V66, P410, DOI 10.1016/0002-9394(68)91524-9
   Lee B, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.7.12
   Leung I, 2018, RETINA-J RET VIT DIS, V38, pS43, DOI 10.1097/IAE.0000000000001842
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   LI ZY, 1995, OPHTHALMOLOGY, V102, P805, DOI 10.1016/S0161-6420(95)30953-0
   Lindquist NG, 1998, EXP EYE RES, V67, P259, DOI 10.1006/exer.1998.0513
   Liu ZP, 2021, STEM CELL REP, V16, P237, DOI 10.1016/j.stemcr.2020.12.007
   LLOYD WC, 1990, OPHTHALMOLOGY, V97, P1052
   Lopes VS, 2007, MOL BIOL CELL, V18, P3914, DOI 10.1091/mbc.E07-03-0268
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Marx V, 2021, NAT METHODS, V18, P9, DOI 10.1038/s41592-020-01033-y
   McGill TJ, 2018, INVEST OPHTH VIS SCI, V59, P1374, DOI 10.1167/iovs.17-22467
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   NIR I, 1995, EXP EYE RES, V61, P363, DOI 10.1016/S0014-4835(05)80130-7
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   ORLOW SJ, 1995, J INVEST DERMATOL, V105, P3, DOI 10.1111/1523-1747.ep12312291
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   Pollreisz A, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.8.13
   Pollreisz A, 2018, EXP EYE RES, V166, P131, DOI 10.1016/j.exer.2017.10.018
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sadda SR, 2020, OPHTHALMOLOGY, V127, P1360, DOI 10.1016/j.ophtha.2020.03.031
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Shirazi MF, 2020, BIOMED OPT EXPRESS, V11, P4520, DOI 10.1364/BOE.393906
   Shu DY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124271
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Storm T, 2019, INVEST OPHTH VIS SCI, V60, P322, DOI 10.1167/iovs.18-25667
   Su N, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.29
   Sura AA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.19
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Taubitz T, 2019, EBIOMEDICINE, V48, P592, DOI 10.1016/j.ebiom.2019.09.048
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Warburton S, 2007, MOL VIS, V13, P318
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zhang TW, 2019, BIOMED OPT EXPRESS, V10, P2918, DOI 10.1364/BOE.10.002918
NR 79
TC 2
Z9 2
U1 0
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JAN
PY 2022
VL 214
AR 108882
DI 10.1016/j.exer.2021.108882
EA DEC 2021
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XW4HL
UT WOS:000735582300001
PM 34890604
DA 2022-11-30
ER

PT J
AU Okada, M
   Wong, TY
   Mitchell, P
   Eldem, B
   Talks, SJ
   Aslam, T
   Daien, V
   Rodriguez, FJ
   Gale, R
   Barratt, J
   Finger, RP
   Loewenstein, A
AF Okada, Mali
   Wong, Tien Yin
   Mitchell, Paul
   Eldem, Bora
   Talks, S. James
   Aslam, Tariq
   Daien, Vincent
   Rodriguez, Francisco J.
   Gale, Richard
   Barratt, Jane
   Finger, Robert P.
   Loewenstein, Anat
TI Defining Nonadherence and Nonpersistence to Anti-Vascular Endothelial
   Growth Factor Therapies in Neovascular Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID ANTI-VEGF THERAPY; INTRAVITREAL RANIBIZUMAB; TREATMENT PATTERNS;
   VISUAL-ACUITY; ADHERENCE; DISCONTINUATION; OUTCOMES; AMD; AFLIBERCEPT;
   PERSISTENCE
AB IMPORTANCE Poor adherence or persistence to treatment can be a barrier to optimizing clinical practice (real-world) outcomes to intravitreal injection therapy in patients with neovascular age-related macular degeneration (nAMD). Currently, there is a lack of consensus on the definition and classification of adherence specific to this context.
   OBJECTIVE To describe the development and validation of terminology on patient nonadherence and nonpersistence to anti-vascular endothelial growth factor therapy.
   DESIGN, SETTING, AND PARTICIPANTS Following a systematic review of currently used terminology in the literature, a subcommittee panel of retinal experts developed a set of definitions and classification for validation. Definitions were restricted to use in patients with nAMD requiring intravitreal anti-vascular endothelial growth factor therapy. Validation by the full nAMD Barometer Leadership Coalition was established using a modified Delphi approach, with predetermined mean scores of 7.5 or more signifying consensus. Subsequent endorsement of the definitions was provided from a second set of retinal experts, with more than 50% members agreeing or strongly agreeing with all definitions.
   MAIN OUTCOMES AND MEASURES Development of consensus definitions for the terms adherence and persistence and a classification system for the factors associated with treatment nonadherence or nonpersistence in patients with nAMD.
   RESULTS Nonadherence was defined as missing 2 or more treatment or monitoring visits over a period of 12 months, with a visit considered missed if it exceeded more than 2 weeks from the recommended date. Nonpersistence was defined by nonattendance or an appointment not scheduled within the last 6 months. The additional terms planned discontinuation and transfer of care were also established. Reasons for treatment nonadherence and nonpersistence were classified into 6 dimensions: (1) patient associated, (2) condition associated, (3) therapy associated, (4) health system and health care team associated, (5) social/economic, and (6) other, with subcategories specific to treatment for nAMD.
   CONCLUSIONS AND RELEVANCE This classification system provides a framework for assessing treatment nonadherence and nonpersistence over time and across different health settings in the treatment of nAMD with current intravitreal anti-vascular endothelial growth factor treatments. This may have additional importance, given the potential association of the coronavirus pandemic on adherence to treatment in patients with nAMD.
C1 [Okada, Mali] Royal Victorian Eye & Ear Hosp, 32 Gisborne St E, Melbourne, Vic 3002, Australia.
   [Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Wong, Tien Yin] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program, Singapore, Singapore.
   [Mitchell, Paul] Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Eldem, Bora] Hacettepe Univ, Dept Ophthalmol, Ankara, Turkey.
   [Talks, S. James] Newcastle Upon Tyne Hosp NHS Fdn, Newcastle Upon Tyne, Tyne & Wear, England.
   [Aslam, Tariq] Univ Manchester, Fac Biol Med & Hlth, Div Pharm & Optometry, Sch Hlth Sci, Manchester, Lancs, England.
   [Daien, Vincent] Montpellier Univ Hosp, Montpellier, France.
   [Rodriguez, Francisco J.] Univ Rosario, Fdn Oftalmol Nacl, Sch Med, Bogota, Colombia.
   [Gale, Richard] York Teaching Hosp NHS Fdn Trust, Dept Ophthalmol, York, N Yorkshire, England.
   [Barratt, Jane] Int Federat Ageing, Toronto, ON, Canada.
   [Finger, Robert P.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Loewenstein, Anat] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Div Ophthalmol, Tel Aviv, Israel.
C3 Royal Victorian Eye & Ear Hospital; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   University of Sydney; Westmead Institute for Medical Research; Hacettepe
   University; Newcastle Upon Tyne Hospitals NHS Foundation Trust;
   University of Manchester; Universite de Montpellier; CHU de Montpellier;
   Universidad del Rosario; University of Bonn; Tel Aviv University;
   Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center
RP Okada, M (通讯作者)，Royal Victorian Eye & Ear Hosp, 32 Gisborne St E, Melbourne, Vic 3002, Australia.
EM mali.okada@eyeandear.org.au
RI Wong, Tien Yin/AAC-9724-2020; Aslam, Tariq/A-8532-2016
OI Wong, Tien Yin/0000-0002-8448-1264; Aslam, Tariq/0000-0002-9739-7280;
   Talks, James/0000-0001-6126-6476
FU Bayer Consumer Care AG, Basel, Switzerland
FX This study was sponsored by Bayer Consumer Care AG, Basel, Switzerland.
CR Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Boyle Jessica, 2018, Psychol Health Med, V23, P127, DOI 10.1080/13548506.2016.1274040
   Burnier M, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01540
   Chang A, 2018, CLIN EXP OPHTHALMOL, V46, P92
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cramer JA, 2008, VALUE HEALTH, V11, P44, DOI 10.1111/j.1524-4733.2007.00213.x
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   DALKEY N, 1969, FUTURES, V1, P408, DOI 10.1016/S0016-3287(69)80025-X
   de Gage SB, 2021, JAMA OPHTHALMOL, V139, P240, DOI 10.1001/jamaophthalmol.2020.5594
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Ehlken C, 2018, RETINA-J RET VIT DIS, V38, P1134, DOI 10.1097/IAE.0000000000001681
   Ehlken C, 2018, CLIN OPHTHALMOL, V12, P11, DOI 10.2147/OPTH.S151611
   Eldem BM, 2015, ACTA OPHTHALMOL, V93, pE458, DOI 10.1111/aos.12540
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Glombiewski JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050537
   Heimes B, 2016, OPHTHALMOLOGE, V113, P925, DOI 10.1007/s00347-016-0275-z
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Jelin E, 2018, ACTA OPHTHALMOL, V96, P804, DOI 10.1111/aos.13847
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Krivosic V, 2017, J FR OPHTALMOL, V40, P642, DOI 10.1016/j.jfo.2017.03.005
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Massamba N, 2015, EYE, V29, P1453, DOI 10.1038/eye.2015.128
   McGrath LA, 2013, ASIA-PAC J OPHTHALMO, V2, P295, DOI 10.1097/APO.0b013e31829dc65a
   Nunes RP, 2010, ARQ BRAS OFTALMOL, V73, P146, DOI 10.1590/S0004-27492010000200009
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Okada M, 2021, OPHTHALMOLOGY, V128, P234, DOI 10.1016/j.ophtha.2020.07.060
   Ozturk M, 2018, CLIN EXP OPHTHALMOL, V46, P407, DOI 10.1111/ceo.13085
   Pagliarini S, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/857148
   Polar O, 2017, TURK OFTALMOL DERG, V47, P205, DOI 10.4274/tjo.28003
   Ramakrishnan MS, 2020, JAMA OPHTHALMOL, V138, P237, DOI 10.1001/jamaophthalmol.2019.4577
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Sachs HG, 2016, KLIN MONATSBL AUGENH, V233, P958, DOI 10.1055/s-0041-107672
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Subhi Y, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7194927
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
   Vaze A, 2014, ACTA OPHTHALMOL, V92, pe697, DOI 10.1111/aos.12417
   Vaze A, 2014, RETINA-J RET VIT DIS, V34, P1774, DOI 10.1097/IAE.0000000000000173
   Westborg I, 2018, OPHTHAL EPIDEMIOL, V25, P176, DOI 10.1080/09286586.2017.1397701
   WHO, 2003, ADHERENCE LONG TERM
   Wintergerst MWM, 2018, OPHTHALMOLOGE, V115, P1035, DOI 10.1007/s00347-017-0610-z
NR 40
TC 8
Z9 9
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUL
PY 2021
VL 139
IS 7
BP 769
EP 776
DI 10.1001/jamaophthalmol.2021.1660
EA JUN 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TN1OE
UT WOS:000657800500001
PM 34081099
OA Green Submitted, Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Synowiec, E
   Szaflik, J
   Chmielewska, M
   Wozniak, K
   Sklodowska, A
   Waszczyk, M
   Dorecka, M
   Blasiak, J
   Szaflik, JP
AF Synowiec, Ewelina
   Szaflik, Jerzy
   Chmielewska, Marta
   Wozniak, Katarzyna
   Sklodowska, Anna
   Waszczyk, Maja
   Dorecka, Mariola
   Blasiak, Janusz
   Szaflik, Jacek Pawel
TI An association between polymorphism of the heme oxygenase-1 and-2 genes
   and age-related macular degeneration
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Age-related macular degeneration; AMD; Heme oxygenase-1 and-2; HMOX1,
   HMOX2; Gene; Polymorphism
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; FAMILY-HISTORY;
   DISEASE; IRON; MACULOPATHY; POPULATION; GENETICS; DAMAGE; RISK
AB Iron may be implicated in the generation of oxidative stress by the catalyzing the Haber-Weiss or Fenton reaction. On the other hand, oxidative stress has been implicated in the pathogenesis of age-related macular degeneration (AMD) and heme oxygenase-1 (HO-1), encoded by the HMOX1 gene and heme oxygenase-2 (HO-2), encoded by the HMOX2 gene are important markers of iron-related oxidative stress and its consequences. Therefore, variability of the HMOX1 and HMOX2 genes might be implicated in the pathogenesis of AMD through the modulation of the cellular reaction to oxidative stress. In the present work, we investigated the association between AMD and a G -> C transversion at the 19 position in the HMOX1 gene (the 19G>C-HMOX1 polymorphism, rs2071747) and a A -> G transition at the -42 + 1444 position in the HMOX2 gene (the -42 + 1444A>G-HMOX2 polymorphism, rs2270363) and its modulation by some environmental factors. 279 patients with AMD and 105 controls were recruited in this study and the polymorphisms were typed by restriction fragment length polymorphism and allele-specific polymerase chain reaction (PCR). We observed an association between the occurrence of dry AMD and the G/A genotype of the -42 + 1444A>G-HMOX2 polymorphism (odds ratio (OR) 2.72), whereas the G/G genotype reduced the risk of dry AMD (OR 0.41). The G/C genotype and the C allele of the 19 G>C-HMOX1 polymorphism and the G/G genotype and the G allele of the -42 + 1444A>G-HMOX2 polymorphism were associated with progression of AMD from dry to wet form (OR 4.83, 5.20, 2.55, 1.69, respectively). On the other hand, the G/G genotype and the G allele of the 19 G>C-HMOX1 polymorphism and the A/G genotype and the A allele of the -42 + 1444A>G-HMOX2 polymorphism protected against AMD progression (OR 0.19, 0.19, 0.34, 0.59, respectively). Therefore, the 19G>C-HMOX1 and the -42 + 1444A>G-HMOX2 polymorphisms may be associated with the occurrence and progression of AMD.
C1 [Szaflik, Jerzy; Sklodowska, Anna; Waszczyk, Maja; Szaflik, Jacek Pawel] Med Univ Warsaw, Dept Ophthalmol, PL-03710 Warsaw, Poland.
   [Szaflik, Jerzy; Sklodowska, Anna; Waszczyk, Maja; Szaflik, Jacek Pawel] Samodzielny Publi Klin Szpital Okulisty, PL-03710 Warsaw, Poland.
   [Synowiec, Ewelina; Chmielewska, Marta; Wozniak, Katarzyna; Blasiak, Janusz] Univ Lodz, Dept Mol Genet, PL-90236 Lodz, Poland.
   [Dorecka, Mariola] Med Univ Silesia, Dept Ophthalmol, PL-40514 Katowice, Poland.
C3 Medical University of Warsaw; University of Lodz; Medical University
   Silesia
RP Szaflik, JP (通讯作者)，Med Univ Warsaw, Dept Ophthalmol, Ul Sierakowskiego 13, PL-03710 Warsaw, Poland.
EM szaflik@ophthalmology.pl
RI Wozniak, Katarzyna/R-9226-2018
OI Wozniak, Katarzyna/0000-0001-6666-7973; Blasiak,
   Janusz/0000-0001-9539-9584; Bielska, Marta/0000-0003-1446-532X;
   Synowiec, Ewelina/0000-0002-0730-4491; Dorecka,
   Mariola/0000-0003-1768-9628; Szaflik, Jerzy/0000-0002-7601-1326
FU Ministry of Science and Higher Education [N N402 248336]
FX This study was supported by the grant number N N402 248336 of Ministry
   of Science and Higher Education.
CR Abraham NG, 1996, CELL PHYSIOL BIOCHEM, V6, P129, DOI 10.1159/000154819
   Ayala-Haedo JA, 2010, ANN HUM GENET, V74, P195, DOI 10.1111/j.1469-1809.2010.00570.x
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Centers for Disease Control and Prevention (CDC), 2009, WHY IS VIS LOSS PUBL
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Funke C, 2009, J NEURAL TRANSM, V116, P853, DOI 10.1007/s00702-009-0237-6
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Geirsdottir A, 2007, AM J OPHTHALMOL, V143, P889, DOI 10.1016/j.ajo.2006.11.057
   Green WR, 1996, OPHTHALMIC PATHOLOGY, P676
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776
   Hughes AL, 2003, P NATL ACAD SCI USA, V100, P15754, DOI 10.1073/pnas.2536718100
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klein Michael L, 2003, Ophthalmol Clin North Am, V16, P567, DOI 10.1016/S0896-1549(03)00063-4
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   KUTTY RK, 1994, GENOMICS, V20, P513, DOI 10.1006/geno.1994.1213
   Lee PH, 2008, NUCLEIC ACIDS RES, V36, pD820, DOI 10.1093/nar/gkm904
   Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Miyamura N, 2004, INVEST OPHTH VIS SCI, V45, P1562, DOI 10.1167/iovs.02-0761
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Ng PC, 2006, ANNU REV GENOM HUM G, V7, P61, DOI 10.1146/annurev.genom.7.080505.115630
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Qi SL, 2011, MOL BIOL REP, V38, P2869, DOI 10.1007/s11033-010-9948-x
   Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493
   Reddy MB, 2004, NUTR REV, V62, P120, DOI 10.1301/nr.2004.mar.120-124
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Shibata N, 2009, DEMENT GERIATR COGN, V27, P273, DOI 10.1159/000203891
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Sun MH, 2007, INVEST OPHTH VIS SCI, V48, P5699, DOI 10.1167/iovs.07-0340
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Welch KD, 2002, FREE RADICAL BIO MED, V32, P577, DOI 10.1016/S0891-5849(02)00760-8
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   World Health Organization (WHO), 2009, PRIOR EYE DIS
NR 46
TC 19
Z9 21
U1 0
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD MAR
PY 2012
VL 39
IS 3
BP 2081
EP 2087
DI 10.1007/s11033-011-0955-3
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 903HS
UT WOS:000301107800003
PM 21647550
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Mayr-Sponer, U
   Waldstein, SM
   Kundi, M
   Ritter, M
   Golbaz, I
   Heiling, U
   Papp, A
   Simader, C
   Schmidt-Erfurth, U
AF Mayr-Sponer, Ulrike
   Waldstein, Sebastian M.
   Kundi, Michael
   Ritter, Markus
   Golbaz, Isabelle
   Heiling, Ursula
   Papp, Andrea
   Simader, Christian
   Schmidt-Erfurth, Ursula
TI Influence of the Vitreomacular Interface on Outcomes of Ranibizumab
   Therapy in Neovascular Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; ADHESION; VERTEPORFIN; RISK
AB Purpose: To investigate the influence of the vitreomacular interface (VMI) on the functional and anatomic efficacy of ranibizumab therapy in patients with neovascular age-related macular degeneration (AMD).
   Design: Subanalysis of a prospective, 12-month, multicenter, phase IIIb trial.
   Participants: A total of 353 treatment-naive patients with subfoveal choroidal neovascularization (CNV) receiving quarterly or monthly ranibizumab therapy.
   Methods: On monthly optical coherence tomography (OCT) scan sets, the VMI configuration was graded by a certified reading center into one of the following conditions: continuous posterior vitreoretinal attachment (PVA), vitreomacular adhesion (VMA), partial vitreous detachment without vitreomacular contact, or complete posterior vitreous detachment (PVD). Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) measurements were performed at monthly intervals. Analysis included patients with a minimum of 10 OCT examinations, including baseline and month 12 (n = 251). After integration of the VMI configuration over 12 months, patients were divided into one of the following categories: PVD (n = 162), release of vitreomacular contact (RELEASE; n 48), VMA (n = 37), or PVA (n = 4). General estimation equation analyses were applied to test for noninferiority of quarterly versus monthly treatment.
   Main Outcome Measures: The BCVA and CRT changes at month 12.
   Results: Mean BCVA changes in letters were +4.7 (PVD), +3.2 (RELEASE), and -0.2 (VMA) in the quarterly regimen and +4.9 (PVD), +12.7 (RELEASE), and +7.5 (VMA) in the monthly regimen. No difference in therapeutic efficiency between monthly and quarterly intervention was found in eyes with PVD, and quarterly treatment was noninferior to monthly treatment (P = 0.001). However, monthly treatment was superior to quarterly treatment in the RELEASE (P = 0.008) and VMA (P = 0.043) groups. Mean CRT changes were -98 and -96 mu m (PVD), -117 and -136 mu m (RELEASE), and -93 and -87 mu m (VMA) in the monthly and quarterly regimens, respectively, without statistically significant differences.
   Conclusions: The configuration of the VMI seems to have an important effect on visual outcomes and need for retreatment. In patients with PVD, a lower treatment frequency may be feasible, whereas patients with RELEASE or VMA may benefit from intensive retreatment. These findings may serve as a basis for individualized treatment decisions in anti-angiogenic therapy of neovascular AMD and perhaps other indications. (C) 2013 by the American Academy of Ophthalmology.
C1 [Mayr-Sponer, Ulrike; Waldstein, Sebastian M.; Ritter, Markus; Golbaz, Isabelle; Heiling, Ursula; Papp, Andrea; Simader, Christian; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Vienna Reading Ctr, A-1090 Vienna, Austria.
   [Kundi, Michael] Med Univ Vienna, Inst Environm Hlth, A-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Waldstein, Sebastian/0000-0003-2899-6279; Ritter,
   Markus/0000-0003-1406-8340; Simader, Christian/0000-0002-1784-2883;
   Schmidt-Erfurth, Ursula/0000-0002-7788-7311
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   El Sanharawi M, 2010, PROG RETIN EYE RES, V29, P443, DOI 10.1016/j.preteyeres.2010.04.001
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FOOS RY, 1972, INVEST OPHTH VISUAL, V11, P801
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Johnson Mark W, 2005, Trans Am Ophthalmol Soc, V103, P537
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Le Goff MM, 2008, EYE, V22, P1214, DOI 10.1038/eye.2008.21
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Nomura Y, 2011, OPHTHALMOLOGY, V118, P853, DOI 10.1016/j.ophtha.2010.09.001
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   SEBAG J, 1989, INVEST OPHTH VIS SCI, V30, P1867
   SEBAG J, 1991, ARCH OPHTHALMOL-CHIC, V109, P966, DOI 10.1001/archopht.1991.01080070078039
   SEBAG J, 1987, GRAEF ARCH CLIN EXP, V225, P89, DOI 10.1007/BF02160337
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Uchino E, 2001, ARCH OPHTHALMOL-CHIC, V119, P1475
   Waldstein SM, 2012, RETINA-J RET VIT DIS, V32, P424, DOI 10.1097/IAE.0b013e3182278b80
NR 32
TC 60
Z9 61
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2013
VL 120
IS 12
BP 2620
EP 2629
DI 10.1016/j.ophtha.2013.05.032
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 255OL
UT WOS:000327249600048
PM 23870300
DA 2022-11-30
ER

PT J
AU Zhu, ZT
   Wang, W
   Keel, S
   Zhang, J
   He, MG
AF Zhu, Zhuoting
   Wang, Wei
   Keel, Stuart
   Zhang, Jian
   He, Mingguang
TI Association of Age-Related Macular Degeneration With Risk of All-Cause
   and Specific-Cause Mortality in the National Health and Nutrition
   Examination Survey, 2005 to 2008
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID VISUAL IMPAIRMENT; CARDIOVASCULAR-DISEASE; VISION IMPAIRMENT;
   UNITED-STATES; CATARACT-SURGERY; HIP FRACTURE; EYE DISEASE; MACULOPATHY;
   PREVALENCE; ATHEROSCLEROSIS
AB IMPORTANCE. Age-related macular degeneration (AMD) is the leading cause of irreversible visual impairment and blindness in the United States if subretinal neovascularization is left untreated. Knowledge of the association between AMD and survival is informative for underlying mechanisms of AMD.
   OBJECTIVE To examine the association between AMD and risk of all-cause and specific-cause mortality in a representative US sample.
   DESIGN, SETTING. AND PARTICIPANTS This population-based prospective cohort study included 5603 participants 40 years or older who responded to the National Health and Nutrition Examination Survey (NHANES) in the 2005-2008 phase. Retinal photographs were graded as early, late, or no AMD. All analyses accounted for the complex and stratified design of NHANES with weighted data. Risks of all-cause mortality were assessed with Cox proportional hazards regression models; risks of specific-cause mortality, with Fine and Gray competing risks regression models. Time to death was counted from baseline to date of death or December 31, 2011, whichever came first. Data analysis was conducted from April 1 through 30, 2018.
   EXPOSURES Age-related macular degeneration status as determined by digital fundus images.
   MAIN OUTCOMES AND MEASURES Mortality resulting from all causes and specific causes until December 31, 2011,
   RESULTS Among the 5603 participants (52.6% female [n = 2793] and 77.1% white [n = 3017]; mean [SE] age, 56.4 [0.4] years), weighted prevalence of any AMD was 6.6%, with 386 (5.8%) having early AMD and 55 (0.8%) having late AMD. After a median follow-up of 4.5 years (interquartile range, 3.6-5.6 years), 433 (5.3%) died of all causes, of whom 361(83.1%) had no AMD, 54 (11.5%) had signs of early AMD, 18 (5.4%) had signs of late AMD, and 72 (16.9%) had any AMD at baseline. Overall, unadjusted all-cause and specific-cause mortality rates were higher for those participants who had early, late, or any AMD compared with no AMD. However, after adjusting confounding factors, only late AMD was associated with more than a doubling of all-cause mortality (hazard ratio [HR], 2.01; 95% Cl, 1.00-4.03) and more than a 3-fold higher risk of mortality due to causes other than cardiovascular disease and cancer (HR, 3.42; 95% Cl, 1.38-8.49). No association was identified between AMD presence or early AMD and all-cause or specific-cause mortality.
   CONCLUSIONS AND RELEVANCE In this study's findings, only late AMD was independently associated with all-cause mortality and mortality due to causes other than cardiovascular disease and cancer, indicating that late AMD may be a marker of biological aging. Alternatively, this association may be due to unmeasured or inadequately assessed confounding factors for late AMD.
C1 [Zhu, Zhuoting; Wang, Wei; Zhang, Jian; He, Mingguang] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
   [Keel, Stuart; He, Mingguang] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, East Melbourne, Australia.
C3 Sun Yat Sen University; Centre for Eye Research Australia; Royal
   Victorian Eye & Ear Hospital; University of Melbourne
RP He, MG (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
EM mingguang.he@unimelb.edu.au
RI He, Mingguang/AAY-5239-2020; Wang, Wei/J-4000-2016
OI He, Mingguang/0000-0002-6912-2810; Wang, Wei/0000-0002-5273-3332
FU Fundamental Research Funds of the State Key Laboratory in Ophthalmology;
   University of Melbourne at Research Accelerator Program; CERA Foundation
FX This study was supported by Fundamental Research Funds of the State Key
   Laboratory in Ophthalmology; the University of Melbourne at Research
   Accelerator Program and the CERA Foundation (Dr He); and Operational
   Infrastructure Support from the Victorian State Government (Centre for
   Eye Research Australia).
CR Berry SD, 2010, J AM GERIATR SOC, V58, P783, DOI 10.1111/j.1532-5415.2010.02767.x
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Centers for Disease Control and Prevention [CDC] National Center for Health Statistics, 2005, NATL NUTR HLTH SURVE
   Chiang PPC, 2013, OPHTHALMOLOGY, V120, P415, DOI 10.1016/j.ophtha.2012.07.077
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   FELSON DT, 1989, J AM GERIATR SOC, V37, P495, DOI 10.1111/j.1532-5415.1989.tb05678.x
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Fisher DE, 2015, OPHTHALMOLOGY, V122, P382, DOI 10.1016/j.ophtha.2014.08.006
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   Gopinath B, 2016, MATURITAS, V84, P63, DOI 10.1016/j.maturitas.2015.11.001
   Gupta P, 2016, INVEST OPHTH VIS SCI, V57, P2905, DOI 10.1167/iovs.15-18469
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ivers RQ, 1999, AM J PUBLIC HEALTH, V89, P85, DOI 10.2105/AJPH.89.1.85
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Khanna RC, 2018, BRIT J OPHTHALMOL, V102, P1477, DOI 10.1136/bjophthalmol-2017-311654
   Khanna RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078002
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Klein R, 2005, AM J OPHTHALMOL, V140, P129, DOI 10.1016/j.ajo.2004.12.049
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Knudtson MD, 2009, ARCH GERONTOL GERIAT, V49, P22, DOI 10.1016/j.archger.2008.04.006
   Lamoureux EL, 2008, OPHTHALMOLOGY, V115, P1973, DOI 10.1016/j.ophtha.2008.05.005
   Larson EB, 2004, ANN INTERN MED, V140, P501, DOI 10.7326/0003-4819-140-7-200404060-00008
   Loprinzi PD, 2016, MAYO CLIN PROC, V91, P763, DOI 10.1016/j.mayocp.2016.03.019
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   McGuinness MB, 2017, EYE, V31, P1345, DOI 10.1038/eye.2017.139
   McGuinness MB, 2017, OPHTHAL EPIDEMIOL, V24, P141, DOI 10.1080/09286586.2016.1259422
   NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663
   Papudesu C, 2018, OPHTHALMOLOGY, V125, P512, DOI 10.1016/j.ophtha.2017.10.028
   Pedula KL, 2015, J AM GERIATR SOC, V63, P910, DOI 10.1111/jgs.13405
   Pratt NL, 2014, DRUG SAFETY, V37, P1021, DOI 10.1007/s40264-014-0231-2
   Rajala U, 2000, DIABETES CARE, V23, P957, DOI 10.2337/diacare.23.7.957
   Schlenker MB, 2015, AM J OPHTHALMOL, V160, P569, DOI 10.1016/j.ajo.2015.06.011
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Shim RS, 2011, J AM BOARD FAM MED, V24, P33, DOI 10.3122/jabfm.2011.01.100121
   Siantar RG, 2015, SCI REP-UK, V5, DOI 10.1038/srep16304
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang J, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8212063
   Wang JJ, 1999, INVEST OPHTH VIS SCI, V40, P12
   Wang WY, 2016, INT J HYG ENVIR HEAL, V219, P850, DOI 10.1016/j.ijheh.2016.07.012
   Willis JR, 2017, JAMA OPHTHALMOL, V135, P926, DOI 10.1001/jamaophthalmol.2017.2553
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wooldridge JM, 2007, J ECONOMETRICS, V141, P1281, DOI 10.1016/j.jeconom.2007.02.002
   Xin XL, 2018, RETINA-J RET VIT DIS, V38, P497, DOI 10.1097/IAE.0000000000001741
   Xu L, 2008, OPHTHALMOLOGICA, V222, P378, DOI 10.1159/000151468
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zhu ZT, 2016, INVEST OPHTH VIS SCI, V57, P2290, DOI 10.1167/iovs.15-17673
NR 62
TC 8
Z9 8
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2019
VL 137
IS 3
BP 248
EP 257
DI 10.1001/jamaophthalmol.2018.6150
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA HO8LL
UT WOS:000461203100009
PM 30570662
OA Green Published
DA 2022-11-30
ER

PT J
AU Inoue, M
   Yamane, S
   Sato, S
   Sakamaki, K
   Arakawa, A
   Kadonosono, K
AF Inoue, Maiko
   Yamane, Shin
   Sato, Shimpei
   Sakamaki, Kentaro
   Arakawa, Akira
   Kadonosono, Kazuaki
TI Comparison of Time to Retreatment and Visual Function Between
   Ranibizumab and Aflibercept in Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GROWTH-FACTOR THERAPY; INTRAVITREAL AFLIBERCEPT; GEOGRAPHIC ATROPHY;
   TREATMENTS TRIALS; VEGF-TRAP; BEVACIZUMAB; OUTCOMES; TREAT; EYES
AB PURPOSE: To compare time to retreatment and visual function between patients with treatment-naive neovascular age-related macular degeneration (AMD) treated with either intravitreal ranibizumab (IVR) or intravitreal aflibercept (IVA) in routine clinical practice.
   DESIGN: Retrospective, interventional comparative case series.
   PARTICIPANTS: A total of 200 eyes of 197 patients with neovascular AMD.
   METHODS: A total of 99 patients in the IVR group and 101 patients in the IVA group who met the inclusion criteria with 12 months of follow-up were included in the present study. All patients received 3 consecutive monthly injections of 0.5 mg/0.05 mL ranibizumab or 2.0 mg/0.05 mL aflibercept as loading doses. Retreatment was allowed if evidence of clinical deterioration or the presence of intraretinal edema or subretinal fluid on spectral domain optical coherence tomography examination performed at the 1-month follow-up was noted. The time to retreatment after the third injection during the loading phase to the first recurrence during the maintenance phase was compared between treatments using the Kaplan-Meier analysis. Functional and anatomic outcomes were also compared between the IVR and IVA groups.
   RESULTS: The median time to retreatment after the last induction dose was 5 months in both groups. The proportion of IVR patients who required injection retreatment was not significantly higher than that of IVA patients (67.7% and 63.4%, respectively, at the 12 -month follow up; log -rank test, P = .554). In both groups, significant improvements in postoperative best-corrected visual acuity (BCVA) compared with preoperative visual acuity was observed over the 12 -month follow-up period (P < .05 for both). Central foveal thickness (CFT) decreased from the baseline values in both groups during the follow-up period (P < .001 for both). Although there was a trend toward greater BCVA improvements in the IVA grohp, no significant differences in BCVA or CFT were observed between the treatment groups.
   CONCLUSIONS: Both IVR and IVA were well tolerated and demonstrated efficacy in improving the visual acuity in treatment-naive patients with AMD. Despite a trend toward greater BCVA improvements in the IVA group, a similar injection burden was observed following the loading phases of both ranibizumab and aflibercept. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Inoue, Maiko; Yamane, Shin; Sato, Shimpei; Arakawa, Akira; Kadonosono, Kazuaki] Yokohama City Univ, Med Ctr, Dept Ophthalmol, Yokohama, Kanagawa, Japan.
   [Sakamaki, Kentaro] Yokohama City Univ, Med Ctr, Dept Biostat, Yokohama, Kanagawa, Japan.
C3 Yokohama City University; Yokohama City University
RP Inoue, M (通讯作者)，Yokohama City Univ, Med Ctr, Dept Ophthalmol, Minami Ku, 4-57 Urafune Cho, Yokohama, Kanagawa 2320024, Japan.
EM maicoo@urahp.yokohama-cu.ac.jp
FU NOVARTIS PHARMA K.K., TOKYO, JAPAN
FX THIS WORK WAS SUPPORTED BY NOVARTIS PHARMA K.K., TOKYO, JAPAN. THE
   FUNDING ORGANIZATION had no role in the design or conduct of this
   research.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Kaiser PK, 2007, CORE EVID, V2, P273
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Niwa Y, 2015, INVEST OPHTH VIS SCI, V56, P6501, DOI 10.1167/iovs.15-17279
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 22
TC 23
Z9 23
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2016
VL 169
BP 95
EP 103
DI 10.1016/j.ajo.2016.06.021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DW4UA
UT WOS:000383637300011
PM 27320059
DA 2022-11-30
ER

PT J
AU Kiss, S
   Campbell, J
   Almony, A
   Shih, V
   Serbin, M
   LaPrise, A
   Wykoff, CC
AF Kiss, Szilard
   Campbell, Joanna
   Almony, Arghavan
   Shih, Vanessa
   Serbin, Michael
   LaPrise, Andrew
   Wykoff, Charles C.
TI Management and Outcomes for Neovascular Age-Related Macular Degeneration
   Analysis of United States Electronic Health Records
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; VISUAL-ACUITY OUTCOMES; TREAT-AND-EXTEND;
   DAILY CLINICAL-PRACTICE; 2.0 MG RANIBIZUMAB; ANTI-VEGF AGENTS;
   INTRAVITREAL RANIBIZUMAB; DOSING REGIMEN; FACTOR THERAPY; SAFETY
AB Purpose: To assess anti-vascular endothelial growth factor (VEGF) management patterns and anatomic and visual acuity (VA) outcomes among patients with neovascular age-related macular degeneration (nAMD) in United States clinical practice.
   Design: Retrospective observational cohort study.
   Participants: Patients (N = 30 106) initiating intravitreal anti-VEGF treatment for nAMD between October 2009 and November 2016.
   Methods: Analysis of longitudinal electronic health records from USRetina.
   Main Outcome Measures: Number of intravitreal injections, OCT examinations, and fluorescein angiography (FA) examinations per study eye during the first 12 months; corrected VA and central retinal thickness (CRT) at 12 months; and number of ophthalmologist visits, stratified by index anti-VEGF agent.
   Results: Over the first 12 months, patients made a mean of 8.1 (range, 1-39) ophthalmologist visits, received a mean of 6.0 (range, 1-27) anti-VEGF injections, and underwent 7.2 OCT and 5.3 FA examinations per study eye. For eyes with paired baseline and 12-month readings, mean CRT declined from 320 to 271 tm (mean change, -48 limb and mean VA increased from 60.3 to 61.0 approximate Early Treatment Diabetic Retinopathy Study (ETDRS) letters (mean change, +0.6 letters). Twelve months after initiating index treatment with bevacizumab, ranibizumab, and aflibercept, 19.3%, 15.8%, and 15.5% of eyes, respectively, showed greater than 10-letter gain, whereas 13.2%, 14.7%, and 14.4% of eyes, respectively, showed greater than 10-letter loss. Mean change from baseline VA at 12 months increased linearly with cumulative anti-VEGF injection count: +1.79 versus -0.95 approximate ETDRS letters for eyes receiving 7 or more injections versus fewer than 7 injections. Similarly, the magnitude of the reduction from baseline CRT at 12 months tended to increase linearly with increasing number of anti-VEGF injections. Multivariate linear regression analysis, adjusted for covariates, indicated a significant association between cumulative number of anti-VEGF injections and change from baseline in VA at 12 months, with each unit increase producing an estimated gain of 0.37 approximate ETDRS letters.
   Conclusions: This analysis of combined morphologic and functional outcomes of anti-VEGF therapy, the largest conducted to date in nAMD, identified relatively low anti-VEGF injection frequencies, coupled with moderate anatomic and limited VA improvements, in United States clinical practice. (C) 2020 by the American Academy of Ophthalmology.
C1 [Kiss, Szilard] Weill Cornell Med Coll, Dept Ophthalmol, New York, NY USA.
   [Campbell, Joanna; Shih, Vanessa; Serbin, Michael] Allergan Plc, Global Hlth Econ & Outcomes Res, Irvine, CA USA.
   [Almony, Arghavan] Carolina Eye Associates, Southern Pines, NC USA.
   [Almony, Arghavan] Campbell Univ, Dept Surg, Lillington, NC USA.
   [LaPrise, Andrew] PYA Analyt, Knoxville, TN USA.
   [Wykoff, Charles C.] Retina Consultants Houston, 6650 Fannin St,Suite 750, Houston, TX 77030 USA.
C3 Cornell University; AbbVie; Allergan; Campbell University
RP Wykoff, CC (通讯作者)，Retina Consultants Houston, 6650 Fannin St,Suite 750, Houston, TX 77030 USA.
EM ccwmd@houstonretina.com
OI Kiss, Szilard/0000-0003-3433-8432
FU Allergan plc, Dublin, Ireland
FX Supported by Allergan plc, Dublin, Ireland, including funding for
   writing assistance. The sponsor participated in the design of the study,
   data analysis and data interpretation, and also supervised the
   preparation, review, and approval of the manuscript. All authors met the
   International Committee of Medical Journal Editors authorship criteria.
   Neither honoraria nor payments were made for authorship.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Ablonczy Z, 2014, FASEB J, V28, P2369, DOI 10.1096/fj.13-248021
   Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   American Society of Retina Specialists, 2019, GLOB TRENDS RET
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chavan R, 2014, CLIN OPHTHALMOL, V8, P717, DOI 10.2147/OPTH.S60763
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Eldem B, 2018, GRAEF ARCH CLIN EXP, V256, P963, DOI 10.1007/s00417-017-3890-8
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gabai A, 2014, EUR J OPHTHALMOL, V24, P396, DOI 10.5301/ejo.5000385
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Grisanti S, 2015, RETINA-J RET VIT DIS, V35, P764, DOI 10.1097/IAE.0000000000000385
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Holz FG, 2016, EYE, V30, P1063, DOI 10.1038/eye.2016.90
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Hussain RM, 2017, OSLI RETINA, V48, P780, DOI 10.3928/23258160-20170928-01
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kataja M, 2018, BRIT J OPHTHALMOL, V102, P959, DOI 10.1136/bjophthalmol-2017-311055
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Kiss S, 2014, OSLI RETINA, V45, P285, DOI 10.3928/23258160-20140709-04
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Santarelli M, 2015, EXPERT OPIN PHARMACO, V16, P1769, DOI 10.1517/14656566.2015.1067679
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shona O, 2011, CLIN EXP OPHTHALMOL, V39, P5, DOI 10.1111/j.1442-9071.2010.02424.x
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Stewart MW, 2015, J CLIN MED, V4, P1079, DOI 10.3390/jcm4051079
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   You JY, 2012, CURR EYE RES, V37, P438, DOI 10.3109/02713683.2011.647227
NR 63
TC 18
Z9 19
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2020
VL 127
IS 9
BP 1179
EP 1188
DI 10.1016/j.ophtha.2020.02.027
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OH6OK
UT WOS:000582712500022
PM 32345477
OA hybrid
DA 2022-11-30
ER

PT J
AU Newman, AM
   Gallo, NB
   Hancox, LS
   Miller, NJ
   Radeke, CM
   Maloney, MA
   Cooper, JB
   Hageman, GS
   Anderson, DH
   Johnson, LV
   Radeke, MJ
AF Newman, Aaron M.
   Gallo, Natasha B.
   Hancox, Lisa S.
   Miller, Norma J.
   Radeke, Carolyn M.
   Maloney, Michelle A.
   Cooper, James B.
   Hageman, Gregory S.
   Anderson, Don H.
   Johnson, Lincoln V.
   Radeke, Monte J.
TI Systems-level analysis of age-related macular degeneration reveals
   global biomarkers and phenotype-specific functional networks
SO GENOME MEDICINE
LA English
DT Article
ID COMPLEMENT FACTOR-H; RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL
   GROWTH-FACTOR; C-REACTIVE PROTEIN; S-TRANSFERASE M1; GENE-EXPRESSION;
   APOLIPOPROTEIN-E; RISK-FACTORS; ENRICHMENT ANALYSIS; PROGRESSIVE STAGES
AB Background: Age-related macular degeneration (AMD) is a leading cause of blindness that affects the central region of the retinal pigmented epithelium (RPE), choroid, and neural retina. Initially characterized by an accumulation of sub-RPE deposits, AMD leads to progressive retinal degeneration, and in advanced cases, irreversible vision loss. Although genetic analysis, animal models, and cell culture systems have yielded important insights into AMD, the molecular pathways underlying AMD's onset and progression remain poorly delineated. We sought to better understand the molecular underpinnings of this devastating disease by performing the first comparative transcriptome analysis of AMD and normal human donor eyes.
   Methods: RPE-choroid and retina tissue samples were obtained from a common cohort of 31 normal, 26 AMD, and 11 potential pre-AMD human donor eyes. Transcriptome profiles were generated for macular and extramacular regions, and statistical and bioinformatic methods were employed to identify disease-associated gene signatures and functionally enriched protein association networks. Selected genes of high significance were validated using an independent donor cohort.
   Results: We identified over 50 annotated genes enriched in cell-mediated immune responses that are globally over-expressed in RPE-choroid AMD phenotypes. Using a machine learning model and a second donor cohort, we show that the top 20 global genes are predictive of AMD clinical diagnosis. We also discovered functionally enriched gene sets in the RPE-choroid that delineate the advanced AMD phenotypes, neovascular AMD and geographic atrophy. Moreover, we identified a graded increase of transcript levels in the retina related to wound response, complement cascade, and neurogenesis that strongly correlates with decreased levels of phototransduction transcripts and increased AMD severity. Based on our findings, we assembled protein-protein interactomes that highlight functional networks likely to be involved in AMD pathogenesis.
   Conclusions: We discovered new global biomarkers and gene expression signatures of AMD. These results are consistent with a model whereby cell-based inflammatory responses represent a central feature of AMD etiology, and depending on genetics, environment, or stochastic factors, may give rise to the advanced AMD phenotypes characterized by angiogenesis and/or cell death. Genes regulating these immunological activities, along with numerous other genes identified here, represent promising new targets for AMD-directed therapeutics and diagnostics. Please see related commentary: http://www.biomedcentral.com/1741-7015/10/21/abstract
C1 [Newman, Aaron M.; Gallo, Natasha B.; Radeke, Carolyn M.; Maloney, Michelle A.; Anderson, Don H.; Johnson, Lincoln V.; Radeke, Monte J.] Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.
   [Hancox, Lisa S.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Miller, Norma J.; Hageman, Gregory S.] Univ Utah, Dept Ophthalmol & Visual Sci, John A Moran Eye Ctr, Salt Lake City, UT 84132 USA.
   [Cooper, James B.] Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.
C3 University of California System; University of California Santa Barbara;
   University of Iowa; Utah System of Higher Education; University of Utah;
   University of California System; University of California Santa Barbara
RP Radeke, MJ (通讯作者)，Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Study Macular Degenerat, Biol Sci 2 Bldg, Santa Barbara, CA 93106 USA.
EM monte.radeke@lifesci.ucsb.edu
RI Newman, Aaron M/ABE-1620-2021
OI Newman, Aaron M/0000-0002-1857-8172; Hancox, Lisa/0000-0003-1940-2619
FU National Eye Institute [EY R24 EY017404]; Allergan, Inc.; Alcon Research
   Institute; Research to Prevent Blindness, Inc.; NATIONAL EYE INSTITUTE
   [P30EY014800] Funding Source: NIH RePORTER
FX This work was supported by a grant from the National Eye Institute (EY
   R24 EY017404), benefactors to the UCSB Center for the Study of Macular
   Degeneration, grants from Allergan, Inc. and the Alcon Research
   Institute (GSH), and unrestricted grants to the University of Utah
   Department of Ophthalmology and Visual Sciences and the University of
   Iowa Department of Ophthalmology and Visual Sciences from Research to
   Prevent Blindness, Inc.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Booij Judith C, 2010, PLoS One, V5, pe9341, DOI 10.1371/journal.pone.0009341
   Bossi A, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.17
   CAUX C, 1994, J EXP MED, V180, P1841, DOI 10.1084/jem.180.5.1841
   Chao W, 2008, CYTOKINE GROWTH F R, V19, P111, DOI 10.1016/j.cytogfr.2008.01.005
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chen CC, 2009, INT J BIOCHEM CELL B, V41, P771, DOI 10.1016/j.biocel.2008.07.025
   Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chowers I, 2003, INVEST OPHTH VIS SCI, V44, P3732, DOI 10.1167/iovs.02-1080
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Cohen LH, 1965, BIOCH RETINA, P35
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Day A, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-6-r112
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Edelman LB, 2010, WIRES SYST BIOL MED, V2, P438, DOI 10.1002/wsbm.75
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   Ethen CM, 2005, INVEST OPHTH VIS SCI, V46, P769, DOI 10.1167/iovs.04-0810
   Evereklioglu C, 2003, EYE, V17, P350, DOI 10.1038/sj.eye.6700345
   Ezzat MK, 2008, BRIT J OPHTHALMOL, V92, P976, DOI 10.1136/bjo.2007.129742
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fedarko NS, 2000, J BIOL CHEM, V275, P16666, DOI 10.1074/jbc.M001123200
   Fiotti N, 2005, GENET MED, V7, P272, DOI 10.1097/01.GIM.0000159903.69597.73
   Fisher R.A., 1948, STAT TABLES BIOL AGR
   FOULDS WS, 1990, EYE, V4, P243, DOI 10.1038/eye.1990.35
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Fritsche LG, 2009, HUM MUTAT, V30, P1048, DOI 10.1002/humu.20957
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Gerlini G, 2001, J INVEST DERMATOL, V117, P576, DOI 10.1046/j.0022-202x.2001.01458.x
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Guven M, 2011, OPHTHALMIC RES, V46, P31, DOI 10.1159/000321940
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   He S, 2003, ARCH OPHTHALMOL-CHIC, V121, P1283, DOI 10.1001/archopht.121.9.1283
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760
   Jiang SN, 2008, INVEST OPHTH VIS SCI, V49, P1345, DOI 10.1167/iovs.07-0308
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2007, OPTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Lederman M, 2010, INVEST OPHTH VIS SCI, V51, P53, DOI 10.1167/iovs.08-3019
   Leung KW, 2009, MOL IMMUNOL, V46, P1374, DOI 10.1016/j.molimm.2008.12.001
   Lin JM, 2008, AM J OPHTHALMOL, V145, P716, DOI 10.1016/j.ajo.2007.11.006
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Machalinska A, 2011, INVEST OPHTH VIS SCI, V52, P93, DOI 10.1167/iovs.10-5756
   Maeda A, 2005, BIOCHEMISTRY-US, V44, P480, DOI 10.1021/bi048016f
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Muller M, 2010, NEUROPATH APPL NEURO, V36, P368, DOI 10.1111/j.1365-2990.2010.01089.x
   Munch IC, 2007, INVEST OPHTH VIS SCI, V48, P833, DOI 10.1167/iovs.06-0529
   Munch IC, 2010, INVEST OPHTH VIS SCI, V51, P2317, DOI 10.1167/iovs.09-4482
   Munro KM, 2009, NEUROSIGNALS, V17, P311, DOI 10.1159/000231897
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Newman AM, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-117
   NEWSOME DA, 1986, INVEST OPHTH VIS SCI, V27, P1675
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Olson JK, 2001, J VIROL, V75, P9780, DOI 10.1128/JVI.75.20.9780-9789.2001
   Oz O, 2006, EUR J OPHTHALMOL, V16, P105
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Radeke MJ, 2007, EXP EYE RES, V85, P366, DOI 10.1016/j.exer.2007.05.006
   Radmacher MD, 2002, J COMPUT BIOL, V9, P505, DOI 10.1089/106652702760138592
   Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   Sancho D, 2005, TRENDS IMMUNOL, V26, P136, DOI 10.1016/j.it.2004.12.006
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Shi G, 2008, INVEST OPHTH VIS SCI, V49, P4620, DOI 10.1167/iovs.08-1816
   Shijubo N, 2000, CRIT REV ONCOGENESIS, V11, P135
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tolppanen AM, 2009, MOL VIS, V15, P762
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   van Soest SS, 2007, MOL VIS, V13, P1608
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Viola A, 2008, ANNU REV PHARMACOL, V48, P171, DOI 10.1146/annurev.pharmtox.48.121806.154841
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang ZY, 2009, FREE RADICAL BIO MED, V46, P1032, DOI 10.1016/j.freeradbiomed.2008.11.027
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Watanabe D, 2005, RETINA-J RET VIT DIS, V25, P911, DOI 10.1097/00006982-200510000-00015
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Wysokinski D, 2011, TOHOKU J EXP MED, V223, P253, DOI 10.1620/tjem.223.253
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yasuda Y, 2004, J BIOL CHEM, V279, P36761, DOI 10.1074/jbc.M403986200
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 143
TC 167
Z9 171
U1 2
U2 23
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756-994X
J9 GENOME MED
JI Genome Med.
PD FEB 24
PY 2012
VL 4
AR 16
DI 10.1186/PREACCEPT-1418491035586234
PG 18
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 084VF
UT WOS:000314566500002
PM 22364233
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU De, S
   Rabin, DM
   Salero, E
   Lederman, PL
   Temple, S
   Stern, JH
AF De, Soma
   Rabin, David M.
   Salero, Enrique
   Lederman, Patricia L.
   Temple, Sally
   Stern, Jeffrey H.
TI Human retinal pigment epithelium cell changes and expression of alpha
   B-crystallin - A biomarker for retinal pigment epithelium cell change in
   age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID STRESS-PROTEINS; DRUSEN; APOPTOSIS; PATHOGENESIS; ETIOLOGY; DISEASE
AB Objective: To examine changes in the retinal pigment epithelium (RPE) in eyes with age-related macular degeneration (AMD) and specifically to characterize alpha beta-crystallin expression in RPE cells as a biomarker in this disease.
   Methods: Maculae from human patients diagnosed as having AMD or from age-matched control eyes were isolated, cryosectioned, and analyzed immunohistochemically for alpha beta-crystallin and for cell type-specific markers.
   Results: In eyes with dry and wet AMD, alpha beta-crystallin was heterogeneously expressed by a subpopulation of RPE cells in the macular region (frequently in cells adjacent to drusen) and in areas of RPE hypertrophy associated with wet AMD. In contrast, alpha beta-crystallin was not detected at significant levels in control RPE.
   Conclusion: Accompanying the formation of drusen in early-stage and late-stage AMD, RPE cells undergo change to express alpha beta-crystallin.
   Clinical Relevance: The detection of alpha beta-crystallin in the RPE of patients with early and advanced AMD implicates this as an AMD biomarker. Sporadic expression of alpha beta-crystallin by RPE cells localized adjacent to drusen in early AMD indicates that changes in the gene expression of RPE cells accompany early stages of the disease and introduces novel potential targets for AMD therapy.
C1 Albany Med Coll, Ctr Neuropharmacol & Neurosci, Albany, NY 12208 USA.
   Albany Med Coll, Dept Ophthalmol, Albany, NY 12208 USA.
C3 Albany Medical College; Albany Medical College
RP Temple, S (通讯作者)，Albany Med Coll, Ctr Neuropharmacol & Neurosci, 42 New Scotland Ave, Albany, NY 12208 USA.
EM temples@mail.amc.edu
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Alge CS, 2002, INVEST OPHTH VIS SCI, V43, P3575
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Andley UP, 2000, J BIOL CHEM, V275, P36823, DOI 10.1074/jbc.M004233200
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Graw J, 1997, BIOL CHEM, V378, P1331
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Proulx S, 2003, MOL VIS, V9, P473
   Richter-Landsberg C, 2003, CELL MOL LIFE SCI, V60, P337, DOI 10.1007/s000180300028
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   SHINOHARA H, 1993, J NEUROL SCI, V119, P203, DOI 10.1016/0022-510X(93)90135-L
   van Rijk AF, 2000, OPHTHALMOLOGICA, V214, P7, DOI 10.1159/000027468
NR 18
TC 65
Z9 71
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAY
PY 2007
VL 125
IS 5
BP 641
EP 646
DI 10.1001/archopht.125.5.641
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 165XI
UT WOS:000246340200007
PM 17502503
OA Bronze
DA 2022-11-30
ER

PT J
AU Najeeb, BH
   Deak, GG
   Mylonas, G
   Sacu, S
   Gerendas, BS
   Schmidt-Erfurth, U
AF Najeeb, Bilal Haj
   Deak, Gabor G.
   Mylonas, Georgios
   Sacu, Stefan
   Gerendas, Bianca S.
   Schmidt-Erfurth, Ursula
TI THE RAP STUDY, REPORT 5: REDISCOVERING MACULAR NEOVASCULARIZATION TYPE 3
   Multimodal Imaging of Fellow Eyes over 24 months
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE disciform scar; macular fibrosis; macular neovascularization; multimodal
   imaging; optical coherence tomography; retinal angiomatous
   proliferation; retinal-choroidal anastomosis
ID RETINAL ANGIOMATOUS PROLIFERATION; DEGENERATION; RISK; CLASSIFICATION;
   PROGRESSION
AB Purpose: To explore the condition of fellow eyes of patients with macular neovascularization Type 3 (MNV3) and to verify whether the retinal-choroidal anastomosis (RCA) develops equally in all MNV types. Methods: The contralateral eyes of 94 patients with MNV3, 96 patients with MNV1, and 96 patients with MNV2 were included. Multimodal imaging was performed. The MNV3 stage including the development of fibrosis and RCA over 24 months was determined. Results: In the contralateral eyes of patients of the solitary (one lesion) MNV3 group, 32 eyes (42.1%) showed early/intermediate age-related macular degeneration, 25 eyes (33%) showed MNV3, and 11 eyes (14.5%) experienced fibrosis, of which 4 eyes (5.2%) had a RCA, 7 eyes (9.2%) had atrophy after resolved MNV3, and 1 eye (1.3%) developed MNV1. In the multifocal (more than one lesion) MNV3 group, 2 eyes (11.1%) showed early/intermediate age-related macular degeneration, 9 eyes (50%) showed 15 MNV3 lesions, and 4 eyes (22.2%) showed fibrosis, of which 2 eyes (11.1%) manifested with a RCA and 3 eyes (16.7%) showed atrophy after resolved MNV3. The number of eyes with a RCA accounted for 40% of all eyes with fibrosis. The count of simultaneous bilateral multifocal MNV3 was 5 (55.6%). In the MNV1 and MNV2 groups, no eye developed a RCA. The incidence of RCAs in the scarred eyes in MNV3 was significantly higher (P < 0.0001). Conclusion: Retinal-choroidal anastomosis is an exclusive clinical feature of MNV3. The development of the multifocal MNV3 is usually bilateral and simultaneous. The occurrence of fibrosis in MNV3 has decreased dramatically after the introduction of the antiangiogenic therapy.
C1 [Najeeb, Bilal Haj; Deak, Gabor G.; Mylonas, Georgios; Gerendas, Bianca S.; Schmidt-Erfurth, Ursula] Med Univ Vienna, Vienna Reading Ctr, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
   [Najeeb, Bilal Haj; Deak, Gabor G.; Sacu, Stefan; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Macula Clin, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Najeeb, BH (通讯作者)，Med Univ Vienna, Vienna Reading Ctr, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM bilal.hajnajeeb@meduniwien.ac.at
OI Haj Najeeb, Bilal/0000-0002-8147-1415
CR Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Campa C, 2010, EYE, V24, P1585, DOI 10.1038/eye.2010.88
   Caramoy A, 2014, ACTA OPHTHALMOL, V92, P745, DOI 10.1111/aos.12437
   Cho HJ., 2020, ACTA OPHTHALMOL, V36, P1843
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   GREEN WR, 1971, ARCH OPHTHALMOL-CHIC, V86, P487, DOI 10.1001/archopht.1971.01000010489001
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Haj Najeeb B., ACTA OPHTHALMOL
   Haj Najeeb B., GRAEF ARCH CLIN EXP
   Najeeb BH, 2021, BRIT J OPHTHALMOL, V105, P113, DOI 10.1136/bjophthalmol-2019-315311
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kim JH, 2020, RETINA-J RET VIT DIS, V40, P1124, DOI 10.1097/IAE.0000000000002489
   Kim JH, 2018, RETINA-J RET VIT DIS, V38, P2356, DOI 10.1097/IAE.0000000000001876
   Koizumi H, 2008, GRAEF ARCH CLIN EXP, V246, P515, DOI 10.1007/s00417-007-0705-3
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   Miere A, 2021, RETINA-J RET VIT DIS, V41, P135, DOI 10.1097/IAE.0000000000002815
   Najeeb BH, 2020, RETINA-J RET VIT DIS, V40, P2255, DOI 10.1097/IAE.0000000000002774
   Oeller JN., 1904, ATLAS RARE OPHTHALMO, P15
   Ravera V, 2016, RETINA-J RET VIT DIS, V36, P2274, DOI 10.1097/IAE.0000000000001152
   Scott AW, 2010, EYE, V24, P491, DOI 10.1038/eye.2009.311
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Wong TY, 2020, RETINA-J RET VIT DIS, V40, P599, DOI 10.1097/IAE.0000000000002768
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 31
TC 3
Z9 3
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2022
VL 42
IS 3
BP 485
EP 493
DI 10.1097/IAE.0000000000003330
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZD6KA
UT WOS:000758305500016
PM 35188490
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Gibson, DM
AF Gibson, Diane M.
TI Eye Care Availability and Access Among Individuals With Diabetes,
   Diabetic Retinopathy, or Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID PREVALENCE; TELEMEDICINE; RANIBIZUMAB; REFERRALS; ADULTS
AB IMPORTANCE Understanding whether differences in the local availability of eye care professionals are related to differences in realized access to eye care is important for assessing whether and where public health efforts are needed to increase access to eye care professionals.
   OBJECTIVE To examine whether the county-level availability of ophthalmologists and optometrists is associated with measures of realized access to eye care for individuals with diabetes mellitus, diabetic retinopathy, or age-related macular degeneration (ARMD).
   DESIGN, SETTING, AND PARTICIPANTS We studied a cross-sectional sample of US adults 40 years and older (1098 individuals with diabetes, 345 with diabetic retinopathy, and 498 with ARMD) from the 2005-2008 National Health and Nutrition Examination Survey.
   MAIN OUTCOMES AND MEASURES Outcomes were whether diabetic individuals reported undergoing a dilated eye examination in the past year, whether individuals were unaware they had diabetic retinopathy, whether diabetic individuals had vision-threatening diabetic retinopathy, and whether individuals were unaware they had ARMD.
   RESULTS In logistic regression models that also included individual characteristics, individuals who lived in a county in the highest ophthalmologist availability quartile were less likely to be unaware they had diabetic retinopathy (predictive margin [ PM], 66.1%; 90% CI,. 48.8%-83.4%; vs PM, 84.1%; 90% CI, 78.7%-89.6%) and were less likely to have vision-threatening diabetic retinopathy (PM, 1.4%; 90% CI, 0.9%-1.9%; vs PM, 2.6%; 90% CI, 1.8%-3.4%) than individuals who lived in a county in the lower 3 ophthalmologist availability quartiles. Individuals who lived in a county in the lowest ophthalmologist availability quartile were more likely to be unaware they had ARMD (PM, 93.8%; 90% CI, 90.6%-97.0%; vs PM, 88.3%; 90% CI, 84.7%-91.9%) than individuals who lived a county in the higher 3 ophthalmologist availability quartiles. Optometrist availability quartiles were not significantly related to any of the outcomes.
   CONCLUSIONS AND RELEVANCE The results suggest that efforts to increase access to ophthalmologists to improve outcomes related to diabetic retinopathy or to increase awareness of ARMD should focus on improving access for diabetic individuals who live in counties in the lowest 3 quartiles of ophthalmologist availability and on individuals at risk of ARMD who live in counties in the lowest quartile of ophthalmologist availability.
C1 CUNY Bernard M Baruch Coll, Sch Publ Affairs, New York, NY 10010 USA.
C3 City University of New York (CUNY) System; Baruch College (CUNY)
RP Gibson, DM (通讯作者)，CUNY Bernard M Baruch Coll, Sch Publ Affairs, 17 Lexington Ave,POB D-901, New York, NY 10010 USA.
EM diane.gibson@baruch.cuny.edu
FU City University of New York Professional Staff Congress-City University
   of New York Research Award Program [64099-00 42]
FX This research was supported by grant 64099-00 42 from The City
   University of New York Professional Staff Congress-City University of
   New York Research Award Program (Dr Gibson).
CR Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI 10.2337/dc10-s062
   American Academy of Ophthalmology, 2008, PREF PRACT PATT DIAB
   American Academy of Ophthalmology, 2008, PREF PRACT PATT AG R
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   [Anonymous], 2012, AR HLTH RES FIL AHRF
   Au A, 2011, CURR OPIN OPHTHALMOL, V22, P194, DOI 10.1097/ICU.0b013e3283459508
   AVERY RL, 2006, OPHTHALMOLOGY, V113
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1566, DOI 10.1001/archophthalmol.2009.308
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Centers for Disease Control and Prevention, 2005, AN REP GUID NAT HLTH
   Centers for Disease Control and Prevention, 2011, ED SERV UDOHAH
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gibson DM, 2012, AM J PREV MED, V43, P48, DOI 10.1016/j.amepre.2012.02.028
   Hanson C, 2008, TELEMED J E-HEALTH, V14, P441, DOI [10.1089/tmj.2007.0068, 10.1089/tmj.2008.0068]
   Ioannidis JPA, 2013, J CLIN EPIDEMIOL, V66, P903, DOI 10.1016/j.jclinepi.2013.03.002
   Jones S, 2010, DIABETIC MED, V27, P249, DOI 10.1111/j.1464-5491.2009.02870.x
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kelly SP, 2011, CLIN OPHTHALMOL, V5, P1673, DOI 10.2147/OPTH.S26753
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R., 1995, DIABETES AM, V2nd ed., P293, DOI DOI 10.1063/1.1522643
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Korn EL, 1999, ANAL HLTH SURVEYS
   Lazaridis EN, 1997, DIABETES CARE, V20, P1073, DOI 10.2337/diacare.20.7.1073
   Lee PP, 2007, ARCH OPHTHALMOL-CHIC, V125, P403, DOI 10.1001/archopht.125.3.403
   Lee PP, 2007, ARCH OPHTHALMOL-CHIC, V125, P406, DOI 10.1001/archopht.125.3.406
   Liu L, 2013, CLIN OPTOM, V5, P1, DOI 10.2147/OPTO.S29932
   National Diabetes Data Group, 1995, DIABETES AM
   National Health and Nutrition Examination Survey, 2010, OPHTH RET IM DAT DOC
   Rein DB, 2011, HEALTH SERV RES, V46, P1534, DOI 10.1111/j.1475-6773.2011.01263.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Sloan FA, 2004, HEALTH SERV RES, V39, P1429, DOI 10.1111/j.1475-6773.2004.00297.x
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   Taylor CR, 2007, DIABETES CARE, V30, P574, DOI 10.2337/dc06-1509
   Wang F, 1996, OPHTHALMOLOGY, V103, P1744, DOI 10.1016/S0161-6420(96)30432-6
   White A J, 2000, Optometry, V71, P284
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
   Zhang XZ, 2008, OPHTHAL EPIDEMIOL, V15, P418, DOI 10.1080/09286580802399102
   Zhang XP, 2007, AM J PREV MED, V33, P318, DOI 10.1016/j.amepre.2007.05.002
NR 44
TC 28
Z9 28
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD APR
PY 2014
VL 132
IS 4
BP 471
EP 477
DI 10.1001/jamaophthalmol.2013.7682
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AJ7QF
UT WOS:000337890500014
PM 24458097
DA 2022-11-30
ER

PT J
AU Wen, XF
   Liu, Y
   Yan, Q
   Liang, ML
   Tang, M
   Liu, R
   Pan, JY
   Liu, QH
   Chen, TT
   Guo, SX
   Liang, JR
   Lu, L
   Ding, XY
   Chen, W
   Wei, L
AF Wen, Xiaofeng
   Liu, Yu
   Yan, Qi
   Liang, Minling
   Tang, Miao
   Liu, Ran
   Pan, Jianying
   Liu, Qiuhui
   Chen, Tingting
   Guo, Shixin
   Liang, Juanran
   Lu, Lin
   Ding, Xiaoyan
   Chen, Wei
   Wei, Lai
TI Association of IGFN1 variant with polypoidal choroidal vasculopathy
SO JOURNAL OF GENE MEDICINE
LA English
DT Article
DE age-related macular degeneration; IGFN1; polypoidal choroidal
   vasculopathy
ID GENOME-WIDE ASSOCIATION; DNA-SEQUENCING DATA; MACULAR DEGENERATION;
   GENETIC-VARIATION; PROTEIN; LOCI; POPULATIONS; FRAMEWORK; COMMON; RISK
AB BackgroundPolypoidal choroidal vasculopathy (PCV) and neovascular age-related macular degeneration (nAMD) share a similar phenotype but are different in their clinical manifestations, responses to treatment and prognosis. Whether PCV is a subtype of AMD or a distinct entity from nAMD remains unknown. Therefore, we performed a whole-exome sequencing based association analysis to compare the genetic architecture of PCV and nAMD in Han Chinese.
   MethodsWhole-exome sequencing analysis was performed on 21 nAMD cases, 20 PCV cases and 20 healthy controls. As a follow-up validation, 145 nAMD cases, 160 PCV cases and 193 controls were genotyped using the Sequenom MassARRAY platform (Sequenom, San Diego, CA, USA).
   ResultsA novel variant, c.6196A>G in the IGFN1 gene, was significantly associated with only PCV (combined p = 7.1 x 10(-11), odds ratio = 9.44), but not with nAMD (combined p = 0.683, odds ratio = 1.30). The minor allele G conferred an increased risk of PCV.
   ConclusionsThe findings of the present study indicate that, although some of the susceptibility loci are shared between PCV and nAMD, a unique genetic signature may decide the pathogenesis of PCV.
C1 [Wen, Xiaofeng; Liu, Yu; Liang, Minling; Tang, Miao; Liu, Ran; Pan, Jianying; Liu, Qiuhui; Chen, Tingting; Guo, Shixin; Liang, Juanran; Lu, Lin; Ding, Xiaoyan; Wei, Lai] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 Xianlie South Rd, Guangzhou 510060, Guangdong, Peoples R China.
   [Liu, Yu; Yan, Qi; Chen, Wei] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Liu, Yu; Yan, Qi; Chen, Wei] UPMC, Childrens Hosp Pittsburgh, Div Pulm Med Allergy & Immunol, Pittsburgh, PA 15224 USA.
C3 Sun Yat Sen University; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh
RP Wei, L (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 Xianlie South Rd, Guangzhou 510060, Guangdong, Peoples R China.; Chen, W (通讯作者)，UPMC, Childrens Hosp Pittsburgh, Div Pulm Med Allergy & Immunol, Pittsburgh, PA 15224 USA.
EM wei.chen@chp.edu; weil9@mail.sysu.edu.cn
RI Chen, Wei/AAX-5994-2020
OI Chen, Wei/0000-0001-7196-8703
FU National Natural Science Foundation of China [81570828]; 1000 Young
   Talent Plan China; Li Foundation Heritage Prize; National Basic Research
   Program of China [2015CB964601]
FX National Natural Science Foundation of China, Grant/Award Number:
   81570828; 1000 Young Talent Plan China; Li Foundation Heritage Prize;
   National Basic Research Program of China, Grant/Award Number:
   2015CB964601
CR Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Altshuler DM, 2010, NATURE, V467, P52, DOI 10.1038/nature09298
   Andrews S., 2012, FASTQC
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Danecek P, 2011, BIOINFORMATICS, V27, P2156, DOI 10.1093/bioinformatics/btr330
   DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806
   Freeman DJ, 2003, EUR HEART J, V24, P1833, DOI 10.1016/j.ehj.2003.07.001
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Huang LZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7687
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Khalyfa A, 2001, J BIOL CHEM, V276, P22915, DOI 10.1074/jbc.M101011200
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698
   Mansilla F, 2008, J CELL BIOCHEM, V105, P847, DOI 10.1002/jcb.21880
   Martin M., 2011, EMBNET J, V17, P10, DOI [DOI 10.14806/EJ.17.1.200, 10.14806/ej.17.1.200]
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308
   Ye ZM, 2016, SCI REP-UK, V6, DOI 10.1038/srep20914
NR 25
TC 5
Z9 6
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1099-498X
EI 1521-2254
J9 J GENE MED
JI J. Gene. Med.
PD FEB-MAR
PY 2018
VL 20
IS 2-3
AR e3007
DI 10.1002/jgm.3007
PG 5
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA GA5AQ
UT WOS:000428344900003
PM 29323771
DA 2022-11-30
ER

PT J
AU Schmidt-Erfurth, U
   Vogl, WD
   Jampol, LM
   Bogunovic, H
AF Schmidt-Erfurth, Ursula
   Vogl, Wolf-Dieter
   Jampol, Lee Merrill
   Bogunovic, Hrvoje
TI Application of Automated Quantification of Fluid Volumes to Anti-VEGF
   Therapy of Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIAL DETACHMENT; 2.0 MG
   RANIBIZUMAB; VISUAL-ACUITY; SUBRETINAL FLUID; MORPHOLOGY; EFFICACY;
   OUTCOMES; SAFETY; IMAGES
AB Purpose: Anti-vascular endothelial growth factor (VEGF) treatment of neovascular age-related macular degeneration (AMD) is a highly effective advance in the retinal armentarium. OCT offering 3-dimensional imaging of the retina is widely used to guide treatment. Although poor outcomes reported from clinical practice are multifactorial, availability of reliable, reproducible, and quantitative evaluation tools to accurately measure the fluid response, that is, a "VEGF meter," may be a better means of monitoring and treating than the current purely qualitative evaluation used in clinical practice.
   Design: Post hoc analysis of a phase III, randomized, multicenter study.
   Participants: Study eyes of 1095 treatment-naive subjects receiving pro re nata (PRN) or monthly ranibizumab therapy according to protocol-specified criteria in the HARBOR study.
   Methods: A deep learning method for localization and quantification of fluid in all retinal compartments was applied for automated segmentation of fluid with every voxel classified by a convolutional neural network (CNN). Three-dimensional volumes (nanoliters) for intraretinal fluid (IRF), subretinal fluid (SRF), and pigment epithelial detachment (PED) were determined in 24 362 volume scans obtained from 1095 patients treated over 24 months in a phase III clinical trial with randomization to 2 drug dosages (0.5 mg and 2.0 mg ranibizumab) and 2 regimens (monthly and PRN). A multivariable mixed-effects regression model was used to test for differences in fluid between the arms and for fluid/function correlation.
   Main Outcome Measures: Fluid volume in nanoliters, structure-function as Pearson's correlation coefficient, and as a coefficient of determination (R-2).
   Results: Fluid volumes were quantified in all visits of all patients. Automated segmentation demonstrated characteristic response patterns for each fluid compartment individually: Intraretinal fluid showed the greatest and most rapid resolution, followed by SRF and PED the least. The loading dose treatment achieved resolution of all fluid types close to the lowest levels attainable. Dosage and regimen parameters correlated directly with resulting fluid volumes. Fluid/function correlation showed a volume-dependent negative impact of IRF on vision and weak positive prognostic effect of SRF.
   Conclusions: Automated quantification of the fluid response may improve therapeutic management of neovascular AMD, avoid discrepancies between clinicians/investigators, and establish structure/function correlations. (C) 2020 by the American Academy of Ophthalmology.
C1 [Schmidt-Erfurth, Ursula; Vogl, Wolf-Dieter; Bogunovic, Hrvoje] Med Univ Vienna, Dept Ophthalmol & Optometry, Christian Doppler Lab Ophthalm Image Anal, Vienna, Austria.
   [Jampol, Lee Merrill] Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA.
C3 Medical University of Vienna; Northwestern University; Feinberg School
   of Medicine
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Spitalgasse 23, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
RI Bogunovic, Hrvoje/J-3445-2014
OI Bogunovic, Hrvoje/0000-0002-9168-0894; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311
FU Austrian Federal Ministry for Digital and Economic Affairs
FX Supported by the Austrian Federal Ministry for Digital and Economic
   Affairs.
CR Abramoff MD, 2013, JAMA OPHTHALMOL, V131, P351, DOI 10.1001/jamaophthalmol.2013.1743
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hykin P, 2016, CLIN OPHTHALMOL, V10, P87, DOI 10.2147/OPTH.S92627
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson PCD, 2014, METHODS ECOL EVOL, V5, P944, DOI 10.1111/2041-210X.12225
   Klimscha S, 2017, INVEST OPHTH VIS SCI, V58, P4039, DOI 10.1167/iovs.16-20201
   Kodjikian L, 2018, RETINA-J RET VIT DIS, V38, P1492, DOI 10.1097/IAE.0000000000001736
   Lowry EA, 2018, OPHTHALMOL RETINA, V2, P531, DOI 10.1016/j.oret.2017.10.002
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Obermeyer Z, 2016, NEW ENGL J MED, V375, P1216, DOI 10.1056/NEJMp1606181
   Penha FM, 2013, RETINA-J RET VIT DIS, V33, P459, DOI 10.1097/IAE.0b013e31827d2657
   Ritter M, 2011, BRIT J OPHTHALMOL, V95, P381, DOI 10.1136/bjo.2009.175976
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2018, AM J OPHTHALMOL, V191, P135, DOI 10.1016/j.ajo.2018.04.008
   Rosenfeld PJ, 2016, INVEST OPHTH VIS SCI, V57, pOCT14, DOI 10.1167/iovs.16-19969
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Seebock P, 2019, IEEE T MED IMAGING, V38, P1037, DOI 10.1109/TMI.2018.2877080
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Toth CA, 2015, RETINA-J RET VIT DIS, V35, P1303, DOI 10.1097/IAE.0000000000000483
   Vaze A, 2014, ACTA OPHTHALMOL, V92, pe697, DOI 10.1111/aos.12417
   Vogl WD, 2017, INVEST OPHTH VIS SCI, V58, P4173, DOI 10.1167/iovs.17-21878
   Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Wickremasinghe SS, 2012, OPHTHALMOLOGY, V119, P2413, DOI 10.1016/j.ophtha.2012.06.056
   Windsor MA, 2018, AM J OPHTHALMOL, V185, P115, DOI 10.1016/j.ajo.2017.09.027
   Zhang L, 2014, INVEST OPHTH VIS SCI, V55, P2329, DOI 10.1167/iovs.13-13048
NR 44
TC 51
Z9 53
U1 3
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2020
VL 127
IS 9
BP 1211
EP 1219
DI 10.1016/j.ophtha.2020.03.010
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OH6OK
UT WOS:000582712500026
PM 32327254
OA hybrid
DA 2022-11-30
ER

PT J
AU Yongpeng, Z
   Yaxing, W
   Jinqiong, Z
   Qian, W
   Yanni, Y
   Xuan, Y
   Jingyan, Y
   Wenjia, Z
   Ping, W
   Chang, S
   Ming, Y
   Yanan, L
   Jinyuan, W
   Shouling, W
   Shuohua, C
   Haiwei, W
   Lijian, F
   Qianqian, W
   Jingyuan, Z
   Zihan, N
   Yuning, C
   Ying, X
   Jonas, JB
   Wenbin, W
AF Yongpeng, Zhang
   Yaxing, Wang
   Jinqiong, Zhou
   Qian, Wang
   Yanni, Yan
   Xuan, Yang
   Jingyan, Yang
   Wenjia, Zhou
   Ping, Wang
   Chang, Shen
   Ming, Yang
   Yanan, Luan
   Jinyuan, Wang
   Shouling, Wu
   Shuohua, Chen
   Haiwei, Wang
   Lijian, Fang
   Qianqian, Wan
   Jingyuan, Zhu
   Zihan, Nie
   Yuning, Chen
   Ying, Xie
   Jonas, Jost B.
   Wenbin, Wei
TI The Association Between Diabetic Retinopathy and the Prevalence of
   Age-Related Macular Degeneration-The Kailuan Eye Study
SO FRONTIERS IN PUBLIC HEALTH
LA English
DT Article
DE diabetes mellitus; diabetic retinopathy; age-related macular
   degeneration; prevalence; epidemiology
ID GLYCATION END-PRODUCTS; BLOOD-PRESSURE CONTROL; RISK-FACTORS;
   MACROMOLECULAR DAMAGE; GLOBAL PREVALENCE; MACULOPATHY; POPULATION;
   DISEASE; BLINDNESS; MELLITUS
AB This study aimed to investigate the prevalence of age-related macular degeneration (AMD) in patients with diabetes mellitus (DM) and diabetic retinopathy (DR) and analyze whether DR is a risk factor for AMD. This population-based epidemiological study included 14,440 people from the Kailuan Eye Study in 2016, of whom 1,618 were patients with type 2 DM aged over 50 years, and 409 had DM with DR. We analyzed whether there were differences in the prevalence of AMD between DM with DR and DM without DR, and conducted a hierarchical statistical analysis according to different stages of DR. Using variable regression analysis, we explored whether DR constituted a risk factor for AMD. In the DM population, the prevalence of wet AMD in patients with DM with and without DR was 0. 3 and 0.2%, respectively, with no significant difference (P = 0.607). Meanwhile, the prevalence of dry AMD in patients with DM with and without DR was 20.8 and 16.0%, respectively, with a significant difference. In the subgroup analysis of dry AMD, the prevalence of early, middle, and late dry AMD in DM with DR was 14.4, 5.9, and 0.5%, respectively. In DM without DR, the prevalence of early, middle, and late dry AMD was 10.5, 4.8, and 0.7%, respectively (P = 0.031). In the subgroup analysis of DR staging, statistical analysis could not be performed because of the limited number of patients with PDR. In the variable regression analysis of risk factors for dry AMD, after adjusting for age, sex, body mass index, hypertension, and dyslipidemia, DR constituted the risk factor for dry AMD. In conclusion, DM did not constitute a risk factor for AMD, and the prevalence of wet AMD and dry AMD in patients with DM and DR was higher than that in patients with DM without DR (among which dry AMD was statistically significant). Multivariate regression analysis confirmed that DR is an independent risk factor for dry AMD. Reasonable control of DM and slowing down the occurrence and development of DR may effectively reduce the prevalence of AMD in patients with DM.
C1 [Yongpeng, Zhang; Jinqiong, Zhou; Qian, Wang; Yanni, Yan; Xuan, Yang; Jingyan, Yang; Wenjia, Zhou; Ping, Wang; Chang, Shen; Ming, Yang; Yanan, Luan; Jinyuan, Wang; Jingyuan, Zhu; Zihan, Nie; Yuning, Chen; Wenbin, Wei] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr,Beijing Ophthalmol & Visua, Beijing Key Lab Intraocular Tumor Diag & Treatment, Beijing, Peoples R China.
   [Yaxing, Wang] Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol & Visual Sci, Beijing Tongren Eye Ctr, Beijing, Peoples R China.
   [Shouling, Wu] Kailuan Gen Hosp, Cardiol Dept, Tangshan, Peoples R China.
   [Shuohua, Chen] Hlth Care Ctr, Kailuan Grp, Tangshan, Peoples R China.
   [Haiwei, Wang] Capital Med Univ, Fuxing Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Lijian, Fang] Capital Med Univ, Beijing Liangxiang Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Qianqian, Wan] Second Hosp Anhui Med Univ, Dept Ophthalmol, Hefei, Peoples R China.
   [Ying, Xie] Shanxi Prov Peoples Hosp, Dept Ophthalmol, Taiyuan, Peoples R China.
   [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany.
C3 Capital Medical University; Capital Medical University; Capital Medical
   University; Capital Medical University; Shanxi People's Hospital;
   Ruprecht Karls University Heidelberg
RP Wenbin, W (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr,Beijing Ophthalmol & Visua, Beijing Key Lab Intraocular Tumor Diag & Treatment, Beijing, Peoples R China.
EM weiwenbintr@163.com
OI Chen, Yuning/0000-0002-6626-9403
CR Bandello F, 2020, OPHTHALMOLOGICA, V243, P163, DOI 10.1159/000506312
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bora A, 2021, LANCET DIGIT HEALTH, V3, pE10, DOI 10.1016/S2589-7500(20)30250-8
   Borrone R, 2008, EUR J OPHTHALMOL, V18, P949, DOI 10.1177/112067210801800615
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Cao K, 2021, OPHTHALMIC RES, V64, P983, DOI 10.1159/000512667
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108196
   Cheung N, 2012, AM J OPHTHALMOL, V153, P193, DOI 10.1016/j.ajo.2011.11.022
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Chua J, 2018, ASIA-PAC J OPHTHALMO, V7, P3, DOI 10.22608/APO.2017511
   Claessen H, 2018, DIABETES CARE, V41, P478, DOI 10.2337/dc17-2031
   Estacio RO, 2000, DIABETES CARE, V23, pB54
   GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study, 2021, LANCET GLOB HEALTH, V9, P144
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   He MS, 2018, DIABETES CARE, V41, P2202, DOI 10.2337/dc18-0707
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Jampol LM, 2020, NEW ENGL J MED, V382, P1629, DOI 10.1056/NEJMra1909637
   Jin PY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113359
   Jonas JB, 2014, LANCET GLOB HEALTH, V2, pE65, DOI 10.1016/S2214-109X(13)70163-3
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Lains I, 2018, RETINA-J RET VIT DIS, V38, P173, DOI 10.1097/IAE.0000000000001516
   Leley SP, 2021, CLIN INTERV AGING, V16, P1367, DOI 10.2147/CIA.S297494
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   Matthews DR, 2004, ARCH OPHTHALMOL-CHIC, V122, P1631
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   Mohamed Q, 2007, JAMA-J AM MED ASSOC, V298, P902, DOI 10.1001/jama.298.8.902
   Ogurtsova K, 2017, DIABETES RES CLIN PR, V128, P40, DOI 10.1016/j.diabres.2017.03.024
   Olivares AM, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0913-0
   Peng XY, 2010, OPHTHALMOLOGY, V117, P531, DOI 10.1016/j.ophtha.2009.07.045
   Proctor B, 2007, INVEST OPHTHALMOL VI, V48, P2149
   Rizwan A, 2021, J PAK MED ASSOC, V71, P651, DOI 10.47391/JPMA.897
   Saeedi P, 2019, DIABETES RES CLIN PR, V157, DOI 10.1016/j.diabres.2019.107843
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Singh SR, 2021, EUR J OPHTHALMOL, V31, P584, DOI 10.1177/1120672120902027
   Soulis T, 1997, DIABETOLOGIA, V40, P619, DOI 10.1007/s001250050725
   Stitt AW, 2010, INVEST OPHTH VIS SCI, V51, P4867, DOI 10.1167/iovs.10-5881
   Tam VHK, 2009, J DIABETES COMPLICAT, V23, P185, DOI 10.1016/j.jdiacomp.2008.03.001
   Teo ZL, 2021, OPHTHALMOLOGY, V128, P1580, DOI 10.1016/j.ophtha.2021.04.027
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Venza I, 2012, AGING CLIN EXP RES, V24, P21, DOI 10.3275/7659
   Voutilainen-Kaunisto RM, 2000, DIABETES CARE, V23, P1672, DOI 10.2337/diacare.23.11.1672
   Vujosevic S, 2020, LANCET DIABETES ENDO, V8, P337, DOI 10.1016/S2213-8587(19)30411-5
   Wang FH, 2011, ACTA OPHTHALMOL, V89, pE336, DOI 10.1111/j.1755-3768.2010.02062.x
   Wang FH, 2009, OPHTHALMOLOGY, V116, P461, DOI 10.1016/j.ophtha.2008.10.003
   Wang Q, 2021, ACTA OPHTHALMOL, V99, pE669, DOI 10.1111/aos.14670
   Wang Q, 2019, INVEST OPHTH VIS SCI, V60, P3689, DOI 10.1167/iovs.19-27531
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xie XW, 2009, EUR J OPHTHALMOL, V19, P91, DOI 10.1177/112067210901900114
   Xie YC, 2020, LANCET DIGIT HEALTH, V2, pE240, DOI 10.1016/S2589-7500(20)30060-1
   Xu LA, 2006, AM J OPHTHALMOL, V142, P688, DOI 10.1016/j.ajo.2006.05.028
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Yang MC, 2020, INT J OPHTHALMOL-CHI, V13, P1467, DOI 10.18240/ijo.2020.09.20
   Yang WY, 2010, NEW ENGL J MED, V362, P1090, DOI 10.1056/NEJMoa0908292
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Zhang Wenbo, 2011, J Cardiovasc Dis Res, V2, P96, DOI 10.4103/0975-3583.83035
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
   Zhou WJ, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.2.20
   Zylbermann R, 1997, EYE, V11, P872, DOI 10.1038/eye.1997.224
NR 66
TC 0
Z9 0
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-2565
J9 FRONT PUBLIC HEALTH
JI Front. Public Health
PD JUL 18
PY 2022
VL 10
AR 922289
DI 10.3389/fpubh.2022.922289
PG 9
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA 3M5VU
UT WOS:000835529600001
PM 35923972
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ajana, S
   Cougnard-Gregoire, A
   Colijn, JM
   Merle, BMJ
   Verzijden, T
   de Jong, PTVM
   Hofman, A
   Vingerling, JR
   Hejblum, BP
   Korobelnik, JF
   Meester-Smoor, MA
   Ueffing, M
   Jacqmin-Gadda, H
   Klaver, CCW
   Delcourt, C
AF Ajana, Soufiane
   Cougnard-Gregoire, Audrey
   Colijn, Johanna M.
   Merle, Benedicte M. J.
   Verzijden, Timo
   de Jong, Paulus T. V. M.
   Hofman, Albert
   Vingerling, Johannes R.
   Hejblum, Boris P.
   Korobelnik, Jean-Francois
   Meester-Smoor, Magda A.
   Ueffing, Marius
   Jacqmin-Gadda, Helene
   Klaver, Caroline C. W.
   Delcourt, Cecile
CA EYE-RISK Consortium
TI Predicting Progression to Advanced Age-Related Macular Degeneration from
   Clinical, Genetic, and Lifestyle Factors Using Machine Learning
SO OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Genetics; Lifestyle; Nutrition;
   Personalized medicine; Prediction; Smoking
AB Purpose: Current prediction models for advanced age-related macular degeneration (AMD) are based on a restrictive set of risk factors. The objective of this study was to develop a comprehensive prediction model applying a machine learning algorithm allowing selection of the most predictive risk factors automatically.
   Design: Two population-based cohort studies.
   Participants: The Rotterdam Study I (RS-I; training set) included 3838 participants 55 years of age or older, with a median follow-up period of 10.8 years, and 108 incident cases of advanced AMD. The Antioxydants, Lipids Essentiels, Nutrition et Maladies Oculaires (ALIENOR) study (test set) included 362 participants 73 years of age or older, with a median follow-up period of 6.5 years, and 33 incident cases of advanced AMD.
   Methods: The prediction model used the bootstrap least absolute shrinkage and selection operator (LASSO) method for survival analysis to select the best predictors of incident advanced AMD in the training set. Predictive performance of the model was assessed using the area under the receiver operating characteristic curve (AUC).
   Main Outcome Measures: Incident advanced AMD (atrophic, neovascular, or both), based on standardized interpretation of retinal photographs.
   Results: The prediction model retained (1) age, (2) a combination of phenotypic predictors (based on the presence of intermediate drusen, hyperpigmentation in one or both eyes, and Age-Related Eye Disease Study simplified score), (3) a summary genetic risk score based on 49 single nucleotide polymorphisms, (4) smoking, (5) diet quality, (6) education, and (7) pulse pressure. The cross-validated AUC estimation in RS-I was 0.92 (95% confidence interval [CI], 0.88-0.97) at 5 years, 0.92 (95% CI, 0.90-0.95) at 10 years, and 0.91 (95% CI, 0.88-0.94) at 15 years. In ALIENOR, the AUC reached 0.92 at 5 years (95% CI, 0.87-0.98). In terms of calibration, the model tended to underestimate the cumulative incidence of advanced AMD for the high-risk groups, especially in ALIENOR.
   Conclusions: This prediction model reached high discrimination abilities, paving the way toward making precision medicine for AMD patients a reality in the near future. (C) 2020 by the American Academy of Ophthalmology
C1 [Ajana, Soufiane; Cougnard-Gregoire, Audrey; Merle, Benedicte M. J.; Hejblum, Boris P.; Korobelnik, Jean-Francois; Jacqmin-Gadda, Helene; Delcourt, Cecile] Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, INSERM, Bordeaux, France.
   [Colijn, Johanna M.; Verzijden, Timo; Vingerling, Johannes R.; Meester-Smoor, Magda A.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Colijn, Johanna M.; Verzijden, Timo; Hofman, Albert; Meester-Smoor, Magda A.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Amsterdam Univ MC, KNAW, Dept Retinal Signal Proc, Netherlands Inst Neurosci, Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Amsterdam Univ MC, Dept Ophthalmol, Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Leiden Univ MC, Dept Ophthalmol, Leiden, Netherlands.
   [Hofman, Albert] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Hejblum, Boris P.] Bordeaux Sud Ouest, SISTM, INRIA, Bordeaux, France.
   [Korobelnik, Jean-Francois] Bordeaux Univ Hosp, Dept Ophthalmol, Bordeaux, France.
   [Ueffing, Marius] Univ Tubingen, Dept Ophthalmol, Inst Ophthalm Res, Tubingen, Germany.
   [Klaver, Caroline C. W.] Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   [Klaver, Caroline C. W.] Inst Mol & Clin Ophthalmol Basel, Basel, Switzerland.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; Erasmus
   University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus
   MC; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute
   for Neuroscience (NIN-KNAW); Leiden University; Leiden University
   Medical Center (LUMC); Harvard University; Harvard T.H. Chan School of
   Public Health; Inria; CHU Bordeaux; Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital; Radboud University
   Nijmegen
RP Delcourt, C (通讯作者)，Univ Bordeaux ISPED, Res Ctr, Inserm U1219, Lifelong Exposure Hlth & Aging Team, 146 Rue Leo Saignat,CS61292, F-33076 Bordeaux, France.
EM cecile.delcourt@u-bordeaux.fr
RI Delcourt, Cecile/I-2627-2013; Merle, Benedicte MJ/AAQ-5021-2021; Emri,
   Eszter/ABE-9363-2020; Acar, İlhan Erkin/B-7758-2018; Hejblum, Boris
   P/T-5309-2019; Arango-Gonzalez, Blanca/AAR-7427-2021
OI Delcourt, Cecile/0000-0002-2099-0481; Merle, Benedicte
   MJ/0000-0003-1332-0954; Acar, İlhan Erkin/0000-0002-2078-9905; Hejblum,
   Boris P/0000-0003-0646-452X; Arango-Gonzalez,
   Blanca/0000-0002-9045-182X; Sousa, Jose/0000-0001-9570-6054; Mones,
   Jordi/0000-0003-3685-2160
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bach FR, P 25 INT C MACH LEAR
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blanche P, 2013, STAT MED, V32, P5381, DOI 10.1002/sim.5958
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Breiman L, 1996, ANN STAT, V24, P2350
   Breiman L, 1996, MACH LEARN, V24, P123, DOI 10.1007/bf00058655
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Burlina PM, 2018, JAMA OPHTHALMOL, V136, P1359, DOI 10.1001/jamaophthalmol.2018.4118
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   CATTELL RB, 1966, MULTIVAR BEHAV RES, V1, P245, DOI 10.1207/s15327906mbr0102_10
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chiu CJ, 2014, OPHTHALMOLOGY, V121, P1421, DOI 10.1016/j.ophtha.2014.01.016
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Delcourt C, 2017, INVEST OPHTH VIS SCI, V58, P6399, DOI 10.1167/iovs.17-21819
   Erie JC, 2016, OPHTHALMOLOGY, V123, P1257, DOI 10.1016/j.ophtha.2016.02.015
   Ferrara D, 2017, INVEST OPHTH VIS SCI, V58, P3519, DOI 10.1167/iovs.17-21696
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Hallak JA, 2019, JAMA OPHTHALMOL, V137, P738, DOI 10.1001/jamaophthalmol.2019.0868
   Heinze G, 2018, BIOMETRICAL J, V60, P431, DOI 10.1002/bimj.201700067
   HOLM S, 1979, SCAND J STAT, V6, P65
   Ikram MA, 2017, EUR J EPIDEMIOL, V32, P807, DOI 10.1007/s10654-017-0321-4
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Leffondre K, 2013, INT J EPIDEMIOL, V42, P1177, DOI 10.1093/ije/dyt126
   Mansiaux Y, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-99
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Obermeyer Z, 2016, NEW ENGL J MED, V375, P1216, DOI 10.1056/NEJMp1606181
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Pylypchuk R, 2018, LANCET, V391, P1897, DOI [10.1016/S0140-6736(18)30664-0, 10.1016/s0140-6736(18)30664-0]
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Seddon JM, 2019, AM J OPHTHALMOL, V198, P223, DOI 10.1016/j.ajo.2018.10.022
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sofi F, 2014, PUBLIC HEALTH NUTR, V17, P2769, DOI 10.1017/S1368980013003169
   Tibshirani R, 1997, STAT MED, V16, P385, DOI 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3
   Touraine C, 2017, J STAT SOFTW, V79, P1, DOI 10.18637/jss.v079.i07
   Touraine C, 2016, STAT METHODS MED RES, V25, P1452, DOI 10.1177/0962280213489234
   van Buuren S, 2011, J STAT SOFTW, V45, P1
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x
   Zou H, 2006, J AM STAT ASSOC, V101, P1418, DOI 10.1198/016214506000000735
NR 52
TC 13
Z9 13
U1 1
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2021
VL 128
IS 4
BP 587
EP 597
DI 10.1016/j.ophtha.2020.08.031
EA MAR 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RG3DQ
UT WOS:000635423500021
PM 32890546
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Sadda, SR
   Guymer, R
   Holz, FG
   Schmitz-Valckenberg, S
   Curcio, CA
   Bird, AC
   Blodi, BA
   Bottoni, F
   Chakravarthy, U
   Chew, EY
   Csaky, K
   Danis, RP
   Fleckenstein, M
   Freund, KB
   Grunwald, J
   Hoyng, CB
   Jaffe, GJ
   Liakopoulos, S
   Mones, JM
   Pauleikhoff, D
   Rosenfeld, PJ
   Sarraf, D
   Spaide, RF
   Tadayoni, R
   Tufail, A
   Wolf, S
   Staurenghi, G
AF Sadda, Srinivas R.
   Guymer, Robyn
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
   Curcio, Christine A.
   Bird, Alan C.
   Blodi, Barbara A.
   Bottoni, Ferdinando
   Chakravarthy, Usha
   Chew, Emily Y.
   Csaky, Karl
   Danis, Ronald P.
   Fleckenstein, Monika
   Freund, K. Bailey
   Grunwald, Juan
   Hoyng, Carel B.
   Jaffe, Glenn J.
   Liakopoulos, Sandra
   Mones, Jordi M.
   Pauleikhoff, Daniel
   Rosenfeld, Philip J.
   Sarraf, David
   Spaide, Richard F.
   Tadayoni, Ramin
   Tufail, Adnan
   Wolf, Sebastian
   Staurenghi, Giovanni
TI Consensus Definition for Atrophy Associated with Age-Related Macular
   Degeneration on OCT Classification of Atrophy Report 3
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL DRUSENOID DEPOSITS; GEOGRAPHIC
   ATROPHY; FUNDUS AUTOFLUORESCENCE; PREDICTIVE-VALUE; GRADING SYSTEM;
   END-POINTS; MACULOPATHY; PROGRESSION; GROWTH
AB Purpose: To develop consensus terminology and criteria for defining atrophy based on OCT findings in the setting of age-related macular degeneration (AMD).
   Design: Consensus meeting.
   Participants: Panel of retina specialists, image reading center experts, retinal histologists, and optics engineers.
   Methods: As part of the Classification of Atrophy Meetings (CAM) program, an international group of experts surveyed the existing literature, performed a masked analysis of longitudinal multimodal imaging for a series of eyes with AMD, and reviewed the results of this analysis to define areas of agreement and disagreement. Through consensus discussions at 3 meetings over 12 months, a classification system based on OCT was proposed for atrophy secondary to AMD. Specific criteria were defined to establish the presence of atrophy.
   Main Outcome Measures: A consensus classification system for atrophy and OCT-based criteria to identify atrophy.
   Results: OCT was proposed as the reference standard or base imaging method to diagnose and stage atrophy. Other methods, including fundus autofluorescence, near-infrared reflectance, and color imaging, provided complementary and confirmatory information. Recognizing that photoreceptor atrophy can occur without retinal pigment epithelium (RPE) atrophy and that atrophy can undergo an evolution of different stages, 4 terms and histologic candidates were proposed: complete RPE and outer retinal atrophy (cRORA), incomplete RPE and outer retinal atrophy, complete outer retinal atrophy, and incomplete outer retinal atrophy. Specific OCT criteria to diagnose cRORA were proposed: (1) a region of hypertransmission of at least 250 mu m in diameter, (2) a zone of attenuation or disruption of the RPE of at least 250 mu m in diameter, (3) evidence of overlying photoreceptor degeneration, and (4) absence of scrolled RPE or other signs of an RPE tear.
   Conclusions: A classification system and criteria for OCT-defined atrophy in the setting of AMD has been proposed based on an international consensus. This classification is a more complete representation of changes that occur in AMD than can be detected using color fundus photography alone. Longitudinal information is required to validate the implied risk of vision loss associated with these terms. This system will enable such future studies to be undertaken using consistent definitions. (C) 2017 by the American Academy of Ophthalmology
C1 [Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Doheny Eye Inst, Los Angeles, CA 90095 USA.
   [Guymer, Robyn] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Dept Surg Ophthalmol, Melbourne, Vic, Australia.
   [Holz, Frank G.; Schmitz-Valckenberg, Steffen; Fleckenstein, Monika] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL USA.
   [Bird, Alan C.; Tufail, Adnan] UCL, Inst Ophthalmol, London, England.
   [Blodi, Barbara A.; Danis, Ronald P.] Univ Wisconsin, Fundus Photograph Reading Ctr, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Bottoni, Ferdinando; Staurenghi, Giovanni] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
   [Chakravarthy, Usha] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Chew, Emily Y.] NEI, NIH, Bethesda, MD 20892 USA.
   [Csaky, Karl; Spaide, Richard F.] Texas Retina Associates, Dallas, TX USA.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Grunwald, Juan] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Hoyng, Carel B.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
   [Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Liakopoulos, Sandra] Univ Cologne, Cologne Image Reading Ctr CIRCL, Dept Ophthalmol, Cologne, Germany.
   [Mones, Jordi M.] Inst Macula, 16, Barcelona, Spain.
   [Mones, Jordi M.] Barcelona Macula Fdn, 16, Barcelona, Spain.
   [Pauleikhoff, Daniel] St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
   [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA.
   [Tadayoni, Ramin] Univ Paris 7 Sorbonne Paris Cite, Hop Lariboisiere, AP HP, Dept Ophthalmol, Paris, France.
   [Tufail, Adnan] Moorfields Eye Hosp, NHS Trust, London, England.
   [Wolf, Sebastian] Univ Bern, Univ Hosp Bern, Dept Ophthalmol, Bern, Switzerland.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Centre for Eye Research
   Australia; Royal Victorian Eye & Ear Hospital; University of Melbourne;
   University of Bonn; University of Alabama System; University of Alabama
   Birmingham; University of London; University College London; University
   of Wisconsin System; University of Wisconsin Madison; University of
   Milan; Luigi Sacco Hospital; Queens University Belfast; National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   Vitreous Retina Macula Consultants of New York; University of
   Pennsylvania; Radboud University Nijmegen; Duke University; University
   of Cologne; St. Franziskus-Hospital; Bascom Palmer Eye Institute;
   University of Miami; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Assistance Publique
   Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal
   - APHP; UDICE-French Research Universities; Universite Paris Cite;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of Bern; University Hospital of Bern
RP Sadda, SR (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Doheny Eye Inst, Los Angeles, CA 90095 USA.
EM ssadda@doheny.org
RI Spaide, Richard/ABD-7368-2020; Wolf, Sebastian/B-8782-2008; mones,
   jordi/CAJ-2963-2022; Freund, K. Bailey/V-7488-2018; Staurenghi,
   Giovanni/K-4388-2017
OI Wolf, Sebastian/0000-0002-7467-7028; mones, jordi/0000-0003-3685-2160;
   Freund, K. Bailey/0000-0002-7888-9773; Guymer,
   Robyn/0000-0002-9441-4356; Chakravarthy, Usha/0000-0002-2606-3734;
   Tufail, Adnan/0000-0001-6131-7640; Grunwald, Juan/0000-0002-5973-6616;
   Staurenghi, Giovanni/0000-0002-2299-5251; Fleckenstein,
   Monika/0000-0001-8321-8037; Tadayoni, Ramin/0000-0001-5616-3579
FU Optos; Carl Zeiss Meditec; Allergan; Novartis; Bayer; Genentech;
   Heidelberg Engineering; Zeiss; Bayer Healthcare; Acucela; Boehringer
   Ingelheim; Alcon; Formycon/Bioeq; Hoffman-LaRoche; Regeneron; Unity;
   Janssen Cell Therapy; Santen; Ophthotech; GSK; Roche; Thrombogenics;
   KangHong; Ionis; Genentech/Roche; Eyerisk Consortium 2020; Astellas
   Institute for Regenerative Medicine (AIRM); Tyrogenex; Optovue; Alimera;
   B+L; FCI; Thromgenics; Zeiss Meditec; Centervue; Nidek; National
   Institutes of Health, Bethesda, Maryland [R01EY06019, P30 EY003039];
   EyeSight Foundation of Alabama; International Retinal Research
   Foundation; Edward N. and Della L. Thome Foundation; Arnold and Mabel
   Beckman Initiative for Macular Research; Research to Prevent Blindness,
   Inc, New York, New York; Lowy Research Medical Institute; NATIONAL EYE
   INSTITUTE [P30EY003039] Funding Source: NIH RePORTER
FX The author(s) have made the following disclosure(s): S.R.S.: Consultant
   - Allergan, Iconic Therapeutics, Novartis, Thrombogenics, Genentech,
   Centervue, Heidelberg Engineering; Research support - Optos, Carl Zeiss
   Meditec, Allergan; Research Instruments - Optos, Carl Zeiss Meditec,
   Nidek, Centervue, Heidelberg Engineering; R.G.: Financial support -
   Novartis, Bayer, Genentech; F.G.H.: Financial support - Heidelberg
   Engineering, Optos, Zeiss, Novartis, Bayer Healthcare, Genentech,
   Acucela, Boehringer Ingelheim, Alcon, Allergan; S.S.-V.: Financial
   support - Novartis, Bayer Healthcare, Genentech, Acucela, Alcon,
   Allergan, Heidelberg Engineering, Formycon/Bioeq; Nonfinancial support -
   Optos, Heidelberg Engineering, Carl Zeiss Meditec; C.A.C.: Financial
   support - Hoffman-LaRoche, Heidelberg Engineering, Regeneron, Novartis,
   Unity, Janssen Cell Therapy; K.C.: Financial support - Genentech,
   Regeneron, Heidelberg Engineering, Santen, Ophthotech, Acucela, GSK,
   Roche, Allergan; Other - Ophthotech; R.D.: Financial support - Allergan,
   GSK, Thrombogenics, KangHong, Ionis; Equity owner - EyeKor, Inc;
   Employee - EyeKor, Inc; K.B.F.: Consultant - Heidelberg Engineering,
   Optovue, Optos, Spark Therapeutics; Financial support - Genentech/Roche;
   J.M.M.: Financial support - Eyerisk Consortium 2020, Novartis, Bayer,
   Alcon, Roche, Ophthotech; Consultant - Novartis, Bayer, Alcon, Roche,
   Genentech; Equity owner - Ophthotech, Notalvision; P.J.R.: Research
   support - Astellas Institute for Regenerative Medicine (AIRM), Carl
   Zeiss Meditec, Genentech, Tyrogenex; Consultant - Acucela, Apellis,
   Boehringer-Ingelheim, Carl Zeiss Meditec, Cell Cure Neurosciences,
   Chengdu Kanghong Biotech, Isarna Therapeutics, Genentech, Healios K.K.,
   Hemera Biosciences, F. Hoffmann-La Roche Ltd., Ocudyne, Ocunexus,
   Tyrogenex, Unity Biotechnology; Equity Interest - Apellis, Digisight,
   Ocudyne; D.S.: Consultant - Genentech, Optovue, Bayer, Novartis;
   Financial support - Allergan, Genentech, Heidelberg Engineering,
   Regeneron, Optovue, Optovue; Lecturer - Optovue; R.T.: Financial support
   - Alcon, Allergan, Alimera, Novartis, Bayer, B+L, FCI, Zeiss,
   Thromgenics, Genentech, Roche; Nonfinancial support - Alcon, Allergan,
   Novartis, Bayer, B+L, Zeiss; G.S.: Financial support - Heidelberg
   Engineering, Zeiss Meditec, Optovue, Optos, Centervue, Nidek, Novartis,
   Bayer; Other - Heidelberg Engineering, Zeiss Meditec, Optos, Centervue,
   Novartis, Bayer, Boeheringer, Allergan, Alcon; Acquisition of human
   donor eyes and the Project MACULA web site were supported by the
   National Institutes of Health, Bethesda, Maryland (grant nos.:
   R01EY06019 and P30 EY003039 [C.A.C.]); EyeSight Foundation of Alabama
   (C.A.C.); International Retinal Research Foundation (C.A.C.); the Edward
   N. and Della L. Thome Foundation (C.A.C.); the Arnold and Mabel Beckman
   Initiative for Macular Research (C.A.C.); and Research to Prevent
   Blindness, Inc, New York, New York (C.A.C.). Supported by the Lowy
   Research Medical Institute (travel grant, A.C.B.).
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Behr C, 1920, MONATSBLATTER AUGENH, V65, P465
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Gass JD, 1970, STEREOSCOPIC ATLAS M
   Giocanti-Auregan A, 2015, INVEST OPHTH VIS SCI, V56, P8325, DOI 10.1167/iovs.14-15480
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Haab O, 1885, CENTRALBLAT AUGENHEI, V9, P384
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hu ZH, 2013, INVEST OPHTH VIS SCI, V54, P8375, DOI 10.1167/iovs.13-12552
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLIEN BA, 1950, AM J OPHTHALMOL, V33, P371, DOI 10.1016/0002-9394(50)90335-7
   Lek JJ, 2017, OPHTHALMOL RETINA, V1, P227, DOI 10.1016/j.oret.2016.12.001
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nettleship E, 1884, T OPHTHAL SOC UK, V4, P165
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58
   Pilotto E, MICROPERIMETRY FEATU, P873
   Polyak S. L., 1941, RETINA-J RET VIT DIS
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P98, DOI 10.1136/bjo.57.2.98
   Schaal KB, 2017, AM J OPHTHALMOL, V174, P145, DOI 10.1016/j.ajo.2016.11.002
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Tan ACS, 2017, INVEST OPHTH VIS SCI, V58, P2349, DOI 10.1167/iovs.16-21237
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Wolf-Schnurrbusch UEK, 2011, INVEST OPHTH VIS SCI, V52, P9497, DOI 10.1167/iovs.11-8346
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yehoshua Z, 2015, OSLI RETINA, V46, P413, DOI 10.3928/23258160-20150422-03
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
NR 50
TC 291
Z9 296
U1 2
U2 31
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2018
VL 125
IS 4
BP 537
EP 548
DI 10.1016/j.ophtha.2017.09.028
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FZ9HE
UT WOS:000427920000022
PM 29103793
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Hanna, V
   Oakley, J
   Russakoff, D
   Choudhry, N
AF Hanna, Verina
   Oakley, Jonathan
   Russakoff, Daniel
   Choudhry, Netan
TI Effects of subthreshold nanosecond laser therapy in age-related macular
   degeneration using artificial intelligence (STAR-AI Study)
SO PLOS ONE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; GEOGRAPHIC ATROPHY; SEGMENTATION;
   THICKNESS
AB Purpose To investigate changes in retinal thickness, drusen volume, and visual acuity following subthreshold nanosecond laser (SNL) treatment in patients with age-related macular degeneration (ARMD).
   Design Retrospective chart review.
   Methods Patients with intermediate ARMD treated with a single session of SNL (2RT (R), Ellex R&D Pty Ltd, Adelaide, Australia) were included. Swept-source optical coherence tomography (OCT) imaging (Triton; Topcon Medical Systems, Tokyo, Japan) was performed within 6 months before and after SNL treatment. Retinal layers were segmented using the artificial intelligence-enabled Orion (R) software (Voxeleron LLC, San Francisco, USA). The macular region was analyzed according to the Early Treatment Diabetic Retinopathy Study map. Mean difference and standard deviation in baseline and post-treatment retinal layer thicknesses are reported.
   Results 37 eyes from 25 patients were included in this study (mean age 74.79.2 years). An average of 51 +/- 6 spots were applied around the macula of each study eye, with a mean spot power of 0.33 +/- 0.04mJ. Increases in total retinal thickness were observed within the outer temporal and inferior sectors (P < 0.05). Within the annulus, there was an increase in thickness of the sub-retinal pigment epithelial (RPE) space [0.88 +/- 2.41 mu m, P = 0.03], defined between the RPE and Bruch's membrane. An increase in thickness of 1.13 +/- 2.55 mu m (P = 0.01) was also noted in the inferior sector of the photoreceptor complex, defined from the inner and outer segment junction to the RPE. Decreases in thickness were observed within the superior sector of the inner nuclear layer (INL) [-1.08 +/- 2.55 mu m, P = 0.01], and within the annulus of the outer nuclear layer (ONL) [-1.44 +/- 3.55 mu m, P = 0.02].
   Conclusions At 6 months post-SNL treatment, there were sectoral increases in OPL, photoreceptor complex, and sub-RPE space thicknesses and sectoral decreases in INL and ONL thicknesses. This pilot study demonstrates the utility of OCT combined with artificial intelligence-enabled software to track retinal changes that occur following SNL treatment in intermediate ARMD.
C1 [Hanna, Verina; Choudhry, Netan] Univ Toronto, Fac Med, Toronto, ON ON M5S, Canada.
   [Hanna, Verina; Choudhry, Netan] Vitreous Retina Macula Specialists Toronto, Etobicoke, ON M8X 2X3, Canada.
   [Oakley, Jonathan; Russakoff, Daniel] Voxeleron LLC, Pleasanton, CA USA.
   [Choudhry, Netan] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON ON M5S, Canada.
C3 University of Toronto; University of Toronto
RP Choudhry, N (通讯作者)，Univ Toronto, Fac Med, Toronto, ON ON M5S, Canada.; Choudhry, N (通讯作者)，Vitreous Retina Macula Specialists Toronto, Etobicoke, ON M8X 2X3, Canada.; Choudhry, N (通讯作者)，Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON ON M5S, Canada.
EM netan.choudhry@vrmto.com
OI Hanna, Verina/0000-0001-5777-4005
CR Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Kim M, 2013, INDIAN J OPHTHALMOL, V61, P213, DOI 10.4103/0301-4738.97075
   Lamin A, 2019, EYE, V33, P428, DOI 10.1038/s41433-018-0234-9
   Mandic K, 2016, ACTA CLIN CROAT, V55, P354, DOI 10.20471/acc.2016.55.03.02
   Meyers KJ, 2015, OPHTHALMOLOGY, V122, P2286, DOI 10.1016/j.ophtha.2015.07.029
   Nivison-Smith L, 2018, OPTOMETRY VISION SCI, V95, P648, DOI 10.1097/OPX.0000000000001256
   Oakley JD, 2014, INVEST OPHTH VIS SCI, V55
   Rabiolo A, 2017, CLIN OPHTHALMOL, V11, P1707, DOI 10.2147/OPTH.S130165
   Rosenfeld PJ, 2019, OPHTHALMOLOGY, V126, P839, DOI 10.1016/j.ophtha.2018.12.016
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Theodore Smith R, 2019, Ann Eye Sci, V4, DOI 10.21037/aes.2018.12.04
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Zhang JJ, 2012, INVEST OPHTH VIS SCI, V53, P2928, DOI 10.1167/iovs.11-8585
NR 18
TC 0
Z9 1
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 29
PY 2021
VL 16
IS 4
AR e0250609
DI 10.1371/journal.pone.0250609
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA SW6DA
UT WOS:000664603100052
PM 33914797
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Thompson, AC
   Luhmann, UFO
   Stinnett, SS
   Vajzovic, L
   Horne, A
   Toth, CA
   Cousins, SW
   Lad, EM
AF Thompson, Atalie C.
   Luhmann, Ulrich F. O.
   Stinnett, Sandra S.
   Vajzovic, Lejla
   Horne, Anupama
   Toth, Cynthia A.
   Cousins, Scott W.
   Lad, Eleonora M.
TI Association of Low Luminance Questionnaire With Objective Functional
   Measures in Early and Intermediate Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; low luminance questionnaire;
   patient-centered outcomes; functional metrics; low luminance visual
   acuity; low luminance deficit
ID QUALITY-OF-LIFE; VISUAL-ACUITY; DARK-ADAPTATION; MACULOPATHY; VISION;
   EYES; PREVALENCE
AB PURPOSE: To determine whether Low Luminance Questionnaire (LLQ) scores are associated with objective measures of visual function in early and intermediate age-related macular degeneration (AMD).
   METHODS: Cross-sectional study of subjects with early AMD Age-Related Eye Disease Study (AREDS) stage 2, N = 33), intermediate AMD (AREDS stage 3, N = 47), and age-matched healthy controls (N = 21). Subjects were interviewed with the LLQ. Psychophysical tests performed included best-corrected visual acuity (BCVA), mesopic microperimetry, dark adaptometry (DA), low luminance visual acuity (LLVA), and cone contrast test (CCT). Low luminance deficit (LLD) was the difference in the number of letters read under photopic versus low luminance settings. The relationship between LLQ and visual function test scores was assessed with linear regression.
   RESULTS: Subjects with intermediate AMD had significantly lower LLQ composite scores (mean = 75.8 +/- 16.7; median = 76, range [29, 97]) compared with early AMD (mean = 85.3 +/- 13.3; median = 88, range [50, 100], P = 0.007) or controls (mean = 91.4 +/- 6.5; median = 94, range [79, 99], P < 0.001) in the overall cohort. LLQ composite scores were associated with computerized BCVA (beta = 0.516), computerized LLVA at two background luminance (1.3 cd/m(2), beta = 0.660; 0.5 cd/m(2), beta = 0.489) along with their respective computerized LLDs (beta = -0.531 and -0.467), rod intercept (beta = -0.312), and CCT green (beta = 0.183) (all P < 0.05). Only the computerized LLVAs and computerized LLDs remained statistically significant after adjusting for AMD versus control status (P < 0.05). Among AMD subjects, LLQ composite scores were significantly associated with the computerized LLVAs (beta = 0.622 and 0.441) and LLDs (beta = -0.795 and -0.477) at both the 1.3 and 0.5 cd/m(2) luminance levels, respectively, and these associations remained significant after adjusting for AMD severity (P < 0.05).
   CONCLUSIONS: Among subjects with early and intermediate AMD, LLQ scores were significantly associated with computerized LLVA and LLD. LLQ is a useful patient-centered functional measure of visual impairment in early and intermediate AMD.
C1 [Thompson, Atalie C.; Stinnett, Sandra S.; Vajzovic, Lejla; Horne, Anupama; Toth, Cynthia A.; Cousins, Scott W.; Lad, Eleonora M.] Duke Univ, Dept Ophthalmol, 2351 Erwin Rd,Hudson Room 4527, Durham, NC 27705 USA.
   [Luhmann, Ulrich F. O.] F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Translat Med Ophthalmol, Roche Pharmaceut Res & Early Dev, Basel, Switzerland.
C3 Duke University; Roche Holding
RP Thompson, AC (通讯作者)，Duke Univ, Dept Ophthalmol, 2351 Erwin Rd,Hudson Room 4527, Durham, NC 27705 USA.
EM ataliethompson@gmail.com
RI Toth, Cynthia/L-5534-2019
OI Toth, Cynthia/0000-0002-2324-0854; Luhmann, Ulrich
   F.O./0000-0002-1993-1951; Stinnett, Sandra/0000-0001-7192-0195
FU National Eye Institute (NEI) Clinical Scientist Development award
   National Institutes of Health [NEI 5K12 EY016333-08]; Hoffmann-La Roche
   Ltd. (Basel, Switzerland); Duke University (Durham, NC, USA); NATIONAL
   EYE INSTITUTE [K12EY016333, K23EY026988] Funding Source: NIH RePORTER
FX Supported by grants from the National Eye Institute (NEI) Clinical
   Scientist Development award National Institutes of Health/NEI 5K12
   EY016333-08 (EL; Bethesda, MD, USA) The parent clinical study was funded
   by Hoffmann-La Roche Ltd. (Basel, Switzerland) through a research
   agreement with Duke University (Durham, NC, USA).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Brabyn J, 2001, OPTOMETRY VISION SCI, V78, P264, DOI 10.1097/00006324-200105000-00008
   BRESSLER NM, 1995, OPHTHALMOLOGY, V102, P1206, DOI 10.1016/S0161-6420(95)30889-5
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   ELLWEIN LB, 1994, INT OPHTHALMOL, V18, P263
   Feigl B, 2011, INVEST OPHTH VIS SCI, V52, P1145, DOI 10.1167/iovs.10-5967
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P8241, DOI 10.1167/iovs.11-7858
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujita K, 2013, CLIN EXP OPTOM, V96, P100, DOI 10.1111/j.1444-0938.2012.00796.x
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Holz F G, 1995, Ger J Ophthalmol, V4, P336
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0274-5
   Owsley C, 2016, INVEST OPHTH VIS SCI, V57, P1782, DOI 10.1167/iovs.15-18962
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Rabin J, 2011, INVEST OPHTH VIS SCI, V52, P816, DOI 10.1167/iovs.10-6283
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Yazdanie M, 2017, OPHTHALMOLOGY, V124, P1332, DOI 10.1016/j.ophtha.2017.05.005
NR 32
TC 17
Z9 17
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2018
VL 59
IS 1
BP 289
EP 297
DI 10.1167/iovs.17-22528
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FX1ZL
UT WOS:000425855900034
PM 29340643
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ong, BB
   Ah-Fat, FG
AF Ong, B. B.
   Ah-Fat, F. G.
TI Age-related macular degeneration
SO BRITISH JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
ID RANIBIZUMAB
C1 [Ong, B. B.; Ah-Fat, F. G.] Maidstone Hlth Author, Maidstone & Tunbridge Wells NHS Trust, Dept Ophthalmol, Maidstone ME16 9QQ, Kent, England.
RP Ah-Fat, FG (通讯作者)，Maidstone Hlth Author, Maidstone & Tunbridge Wells NHS Trust, Dept Ophthalmol, Maidstone ME16 9QQ, Kent, England.
EM frankah-fat@nhs.net
FU Novartis; Bayer; Alimera Sciences
FX Dr BB Ong-none; Mr FG Ahfat has received travel grants from Novartis,
   Bayer and Alimera Sciences.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cohen D, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1654
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Hawkes N, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6867
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Orzalesi N, 2007, OPHTHALMOLOGY, V114, P860, DOI 10.1016/j.ophtha.2007.01.005
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singer MA, 2012, CLIN OPHTHALMOL, V6, P33, DOI 10.2147/OPTH.S15028
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Williams D, 2013, 31 ANN M AM SOC RET
NR 16
TC 6
Z9 6
U1 0
U2 4
PU MA HEALTHCARE LTD
PI LONDON
PA ST JUDES CHURCH, DULWICH ROAD, LONDON SE24 0PB, ENGLAND
SN 1750-8460
EI 1759-7390
J9 BRIT J HOSP MED
JI Br. J. Hosp. Med.
PD FEB
PY 2016
VL 77
IS 2
BP C18
EP C21
DI 10.12968/hmed.2016.77.2.C18
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DF3XJ
UT WOS:000371281400021
PM 26875813
DA 2022-11-30
ER

PT J
AU Li, CM
   Presley, B
   Zhang, XM
   Dashti, N
   Chung, BH
   Medeiros, NE
   Guidry, C
   Curcio, CA
AF Li, CM
   Presley, B
   Zhang, XM
   Dashti, N
   Chung, BH
   Medeiros, NE
   Guidry, C
   Curcio, CA
TI Retina expresses microsomal triglyceride transfer protein: implications
   for age-related maculopathy
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE lipoprotein assembly; esterified cholesterol; retinal pigment
   epithelium; Bruch's membrane; abetalipoproteinemia
ID B-CONTAINING LIPOPROTEINS; APOLIPOPROTEIN-B; BRUCHS MEMBRANE; MACULAR
   DEGENERATION; PIGMENT EPITHELIUM; CELL-LINE; ABETALIPOPROTEINEMIA GENE;
   DOCOSAHEXAENOIC ACID; EMBRYONIC LETHALITY; TOTAL CHOLESTEROL
AB The principal extracellular lesions of age-related maculopathy (ARM), the leading cause of vision loss in the elderly, involve Bruch's membrane (BrM), a thin vascular intima between the retinal pigment epithelium (RPE) and its blood supply. With age, 80-100 nm solid particles containing esterified cholesterol (EC) accumulate in normal BrM, and apolipoprotein B (apoB) immunoreactivity is detectable in BrM- and ARM-associated lesions. Yet little evidence indicates that increased plasma cholesterol is a risk factor for ARM. To determine if RPE is capable of assembling its own apoB-containing lipoprotein, we examined RPE for the expression of microsomal triglyceride transfer protein (MTP), which is required for this process. Consistent with previous evidence for apoB expression, MTP is expressed in RPE, the ARPE-19 cell line, and, unexpectedly, retinal ganglion cells, which are neurons of the central nervous system. De novo synthesis and secretion of neutral lipid by ARPE-19 was supported by high levels of radiolabeled EC and triglyceride in medium after supplementation with oleate. Lipoprotein assembly and secretion is implicated as a constitutive retinal function and a plausible candidate mechanism involved in forming extracellular cholesterol-containing lesions in ARM. The pigmentary retinopathy and neuropathy of abetalipoproteinemia (Mendelian Inheritance of Man 200100; Bassen-Kornzwieg disease), which is caused by mutations in the MTP gene, may involve loss of function at the retina.
C1 Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Sch Med, Dept Med, Div Gerontol, Birmingham, AL USA.
   Univ Alabama Birmingham, Sch Med, Dept Med, Atherosclerosis Res Program, Birmingham, AL USA.
   Retina Specialists N Alabama, Huntsville, AL USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
EM curcio@uab.edu
FU NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R01EY013258] Funding Source: NIH RePORTER;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060936, P01HL034343]
   Funding Source: NIH RePORTER
CR Accad M, 2000, J CLIN INVEST, V105, P711, DOI 10.1172/JCI9021
   Al-Shali K, 2003, CLIN GENET, V63, P135, DOI 10.1046/j.0009-9163.2002.00175.x
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   BAKER BN, 1986, EXP EYE RES, V42, P547, DOI 10.1016/0014-4835(86)90045-X
   BAZAN NG, 1992, ADV EXP MED BIOL, V318, P295
   Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   Bjorkegren J, 2001, J BIOL CHEM, V276, P38511, DOI 10.1074/jbc.M106839200
   Blackburn J, 2003, INVEST OPHTH VIS SCI, V44, P4613, DOI 10.1167/iovs.03-0112
   CAMPOCHIARO PA, 1986, INVEST OPHTH VIS SCI, V27, P1615
   CHAN WCW, 2000, P SOC PHOTO-OPT INS, V1, P2
   Chang CCY, 2000, J BIOL CHEM, V275, P28083
   Chowers I, 2001, EYE, V15, P525, DOI 10.1038/eye.2001.167
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   CURCIO CA, 2005, IN PRESS EXP EYE RES
   DASHTI N, 1991, PROG LIPID RES, V30, P219, DOI 10.1016/0163-7827(91)90018-Z
   Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169
   de Turco EBR, 1999, J NEUROSCI RES, V57, P479
   DIXON JL, 1991, J BIOL CHEM, V266, P5080
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774
   FISHER WR, 1986, METHOD ENZYMOL, V128, P247
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   FORTE TM, 1986, METHOD ENZYMOL, V128, P442
   FOSS AJE, 1995, BRIT J BIOMED SCI, V52, P22
   GAMBLE W, 1978, J LIPID RES, V19, P1068
   Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4
   GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628
   GORIN MB, 1994, OPHTHALMIC GENET, V15, P151, DOI 10.3109/13816819409057843
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   HAYES KC, 1989, INVEST OPHTH VIS SCI, V30, P225
   HEWITT AT, 1989, INVEST OPHTH VIS SCI, V30, P478
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   JOHNSON FL, 1986, J LIPID RES, V27, P537
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Koch S, 2001, J LIPID RES, V42, P1143
   Kruth H S, 1997, Subcell Biochem, V28, P319
   LEIPER JM, 1994, J BIOL CHEM, V269, P21951
   Levin LA, 2002, PROG RETIN EYE RES, V21, P465, DOI 10.1016/S1350-9462(02)00012-5
   Levy E, 2002, J BIOL CHEM, V277, P16470, DOI 10.1074/jbc.M102385200
   Li CM, 2002, MECH DEVELOP, V116, P85, DOI 10.1016/S0925-4773(02)00148-X
   Liu W, 2000, DEVELOPMENT, V127, P3237
   Lu S, 2002, J LIPID RES, V43, P1303, DOI 10.1194/jlr.M200035-JLR200
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Mamballikalathil I, 2000, INVEST OPHTH VIS SCI, V41, P529
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nguyen-Legros J, 2000, INT REV CYTOL, V196, P245
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Philp NJ, 2003, INVEST OPHTH VIS SCI, V44, P1716, DOI 10.1167/iovs.02-0287
   Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   RUNGE P, 1986, BRIT J OPHTHALMOL, V70, P166, DOI 10.1136/bjo.70.3.166
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sellers JA, 2001, J LIPID RES, V42, P1897
   Sharon D, 2002, P NATL ACAD SCI USA, V99, P315, DOI 10.1073/pnas.012582799
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   SMITH EB, 1973, NUTR METAB, V15, P17
   Smith JL, 2004, J LIPID RES, V45, P686, DOI 10.1194/jlr.M300365-JLR200
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Swaroop A, 2002, GENOME BIOL, V3
   SWIFT LL, 1982, J LIPID RES, V23, P962
   THRIFT RN, 1986, J LIPID RES, V27, P236
   VERSCHUREN WMM, 1995, JAMA-J AM MED ASSOC, V274, P131, DOI 10.1001/jama.274.2.131
   WANG N, 1993, BIOCHEMISTRY-US, V32, P13703, DOI 10.1021/bi00212a040
   Wang XY, 1998, P NATL ACAD SCI USA, V95, P7643, DOI 10.1073/pnas.95.13.7643
   WETTERAU JR, 1992, SCIENCE, V258, P999
   Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3
   WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zhang YL, 2004, J BIOL CHEM, V279, P19362, DOI 10.1074/jbc.M400220200
NR 80
TC 76
Z9 77
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PD APR
PY 2005
VL 46
IS 4
BP 628
EP 640
DI 10.1194/jlr.M400428-JLR200
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 913BS
UT WOS:000228125800003
PM 15654125
OA hybrid, Green Submitted
DA 2022-11-30
ER

PT J
AU Thomas, CJ
   Mirza, RG
   Gill, MK
AF Thomas, Catherine J.
   Mirza, Rukhsana G.
   Gill, Manjot K.
TI Age-Related Macular Degeneration
SO MEDICAL CLINICS OF NORTH AMERICA
LA English
DT Article
DE Drusen; Choroidal neovascularization (CNV); Vascular endothelial growth
   factor (VEGF); Neovascular (exudative, wet) age-related macular
   degeneration; Nonneovascular (nonexudative, dry) age-related macular
   degeneration; Geographic atrophy
ID RETINAL-PIGMENT EPITHELIUM; EYE DISEASE; CHOROIDAL NEOVASCULARIZATION;
   SYSTEMIC SAFETY; SEVERITY SCALE; RANIBIZUMAB; AREDS; ASSOCIATION;
   PROGRESSION; PREVALENCE
C1 [Thomas, Catherine J.; Mirza, Rukhsana G.; Gill, Manjot K.] Northwestern Univ, Feinberg Sch Med, Dept Ophthalmol, 645 North Michigan Ave,Suite 440, Chicago, IL 60611 USA.
C3 Northwestern University; Feinberg School of Medicine
RP Gill, MK (通讯作者)，Northwestern Univ, Feinberg Sch Med, Dept Ophthalmol, 645 North Michigan Ave,Suite 440, Chicago, IL 60611 USA.
EM mgill@nm.org
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   [Anonymous], 2019, AG REL MAC DEG FACTS
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Brown D., 2017, J VITREORETINAL DIS, V1, P294, DOI [10.1177/2474126417725946, DOI 10.1177/2474126417725946]
   Brown EE, 2019, INVEST OPHTH VIS SCI, V60, P1470, DOI 10.1167/iovs.18-26422
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Csaky K.G., 2017, J VITR DIS, V1, P75, DOI [10.1177/2474126416680671, DOI 10.1177/2474126416680671]
   Csaky KG, 2019, AM AC OPHTH ANN M OC
   Daien V, 2018, OPHTHALMOLOGY, V125, P66, DOI 10.1016/j.ophtha.2017.07.005
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Fallor MA, 2016, J OPHTHALMOL, V1
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fujimoto JG, 2000, NEOPLASIA, V2, P9, DOI 10.1038/sj.neo.7900071
   Gaudreault J., 2012, INVEST OPHTHALMOL VI, V53, P3025
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gess AJ, 2011, SEMIN OPHTHALMOL, V26, P225, DOI 10.3109/08820538.2011.582533
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Hahn P, 2020, RETINA TIMES
   Hanna RM, 2019, KIDNEY INT, V96, P572, DOI 10.1016/j.kint.2019.02.042
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho A, RETINA TODAY
   Homayouni Mansour, 2009, J Ophthalmic Vis Res, V4, P105
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   Kirkner R., RETINA SPECIALIST
   Kitchens JW, 2016, OPHTHALMOLOGY, V123, P1511, DOI 10.1016/j.ophtha.2016.02.046
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lau PET, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/8567912
   Ma J, 2017, OPHTHALMOL EYE DIS, V9, DOI 10.1177/1179172116686075
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Maloney MH, 2021, OPHTHALMOLOGY, V128, P417, DOI 10.1016/j.ophtha.2020.07.062
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Moisseiev E, 2016, JAMA OPHTHALMOL, V134, P748, DOI 10.1001/jamaophthalmol.2016.1000
   Parmet Sharon, 2006, JAMA, V295, P2438, DOI 10.1001/jama.295.20.2438
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pieramici D., 2018, 2018 AM AC OPHTH ANN
   Pieramici D., 2018, RET SOC 2018 ANN M S
   Rush D., 2020, RETIN PHYS, V17, P29
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zarbin M, 2019, STEM CELL TRANSL MED, V8, P466, DOI 10.1002/sctm.18-0282
   Zarbin MA, 2018, OPHTHALMOL RETINA, V2, P1087, DOI 10.1016/j.oret.2018.04.018
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
   Zhou HJ, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-1004-y
NR 58
TC 17
Z9 17
U1 9
U2 17
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0025-7125
EI 1557-9859
J9 MED CLIN N AM
JI Med. Clin. N. Am.
PD MAY
PY 2021
VL 105
IS 3
BP 473
EP 491
DI 10.1016/j.mcna.2021.01.003
EA APR 2021
PG 19
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA RX5SF
UT WOS:000647282800008
PM 33926642
OA hybrid
DA 2022-11-30
ER

PT J
AU Wang, ZY
   Zhao, KK
   Zheng, JW
   Rossmiller, B
   Ildefonso, C
   Biswal, M
   Zhao, PQ
AF Wang, Zhao-Yang
   Zhao, Keke
   Zheng, Jingwei
   Rossmiller, Brian
   Ildefonso, Cristhian
   Biswal, Manas
   Zhao, Pei-quan
TI Systematic Review and Meta-Analysis of the Association between
   Complement Factor H I62V Polymorphism and Risk of Polypoidal Choroidal
   Vasculopathy in Asian Populations
SO PLOS ONE
LA English
DT Review
ID MACULAR DEGENERATION; CFH; VARIANTS; PHENOTYPE; SUBTYPES; ARMS2; GENE
AB Purpose: To investigate whether the polymorphism rs800292 (184G>A, I62V) in the complement factor H gene is associated with polypoidal choroidal vasculopathy (PCV) and the genetic difference between PCV and neovascular age-related macular degeneration (nAMD), in Asian populations.
   Methods: A comprehensive literature search was performed in PubMed, Medline, Web of Science, and reference lists. A system review and meta-analysis of the association between I62V and PCV and/or nAMD were performed from 8 studies involving 5,062 subjects. The following data from individual studies were extracted and analyzed: 1) comparison of I62V polymorphisms between PCV and controls; 2) comparison of I62V polymorphisms between PCV and nAMD. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using fixed-effects models. The Q-statistic test was used to assess heterogeneity, and Egger's test was used to evaluate publication bias. Sensitivity analysis and cumulative meta-analysis were also performed.
   Results: The I62V polymorphism showed a significant summary OR1 for genotype GA+GG versus homozygous genotype AA was 3.18 (95% CI, 2.51-4.04, P<0.00001), the OR2 of heterozygous genotype GA versus AA was 2.29 (95% CI: 1.79-2.94, P<0.00001), the OR3 of homozygous genotype GG versus AA was 4.42 (95% CI: 3.45-5.67, P<0.00001), and the OR4 of allele G versus A was 2.04 (95% CI: 1.85-2.26, P<0.00001). Sensitivity analysis indicated the robustness of our findings, and evidence of publication bias was not observed in our meta-analysis. Cumulative meta-analysis revealed that the summary ORs were stable. There was no significant difference in every genetic model between PCV and nAMD (n = 5, OR1 = 0.92, OR2 = 0.96, OR3 = 0.90, OR4 = 0.94).
   Conclusions: Our analysis provides evidence that the I62V polymorphism is associated with an increased risk of PCV. The variant of I62V could be a promising genetic biomarker of PCV in Asian populations.
C1 [Wang, Zhao-Yang; Zhao, Pei-quan] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Ophthalmol, Shanghai 200030, Peoples R China.
   [Wang, Zhao-Yang; Zhao, Keke; Rossmiller, Brian; Ildefonso, Cristhian; Biswal, Manas] Univ Florida, Dept Mol Genet, Gainesville, FL USA.
   [Zheng, Jingwei] Wenzhou Med Univ, Hosp Eye, Wenzhou, Zhejiang, Peoples R China.
C3 Shanghai Jiao Tong University; State University System of Florida;
   University of Florida; Wenzhou Medical University
RP Zhao, PQ (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Ophthalmol, Shanghai 200030, Peoples R China.
EM zhaokekewzy@hotmail.com
RI Ildefonso, Cristhian/AAC-3576-2021
OI Ildefonso, Cristhian/0000-0001-6179-720X; Biswal,
   Manas/0000-0002-9685-2923
FU National Natural Science Funds of China [81371040, 81070760, 81100677];
   Shanghai Rising-Star Program [12QA1402200]
FX This study was supported by Project of the National Natural Science
   Funds of China (No. 81371040, 81070760 and No. 81100677), and Shanghai
   Rising-Star Program (No. 12QA1402200). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Bessho H, 2011, MOL VIS, V17, P977
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chantaren P, 2012, CLIN OPHTHALMOL, V6, P465, DOI 10.2147/OPTH.S30529
   Chen HY, 2012, MOL VIS, V18, P816
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Ioannidis JPA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000841
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Miki A, 2013, OPHTHALMIC GENET, V34, P146, DOI 10.3109/13816810.2012.749288
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Tanaka K, 2011, MOL VIS, V17, P2751
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864
   Yuan DQ, 2013, MOL VIS, V19, P374
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 33
TC 12
Z9 12
U1 1
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 10
PY 2014
VL 9
IS 2
AR e88324
DI 10.1371/journal.pone.0088324
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AA7CL
UT WOS:000331254600058
PM 24520367
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Kumar, N
   Mrejen, S
   Fung, ATC
   Marsiglia, M
   Loh, BK
   Spaide, RF
AF Kumar, Nishant
   Mrejen, Sarah
   Fung, Adrian Tien-Chin
   Marsiglia, Marcela
   Loh, Boon K.
   Spaide, Richard F.
TI Retinal Pigment Epithelial Cell Loss Assessed by Fundus Autofluorescence
   Imaging in Neovascular Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; GEOGRAPHIC ATROPHY;
   PHOTODYNAMIC THERAPY; IN-VIVO; RANIBIZUMAB; VERTEPORFIN; BEVACIZUMAB;
   MACULOPATHY; PROGRESSION
AB Purpose: To characterize retinal pigment epithelial (RPE) cell loss as evidenced by autofluorescence imaging in patients with neovascular age-related macular degeneration (AMD).
   Design: Retrospective cohort study.
   Participants: There were 162 eyes of 116 consecutive patients with neovascular AMD examined in a retinal practice.
   Methods: Each patient underwent a complete examination including autofluorescence imaging. Areas of confluent absence of autofluorescence signal of at least 0.5 mm in greatest linear diameter were measured within the macular area. Patient demographic and examination data were evaluated in relation to the autofluorescence data.
   Main Outcome Measures: Prevalence and progression of confluent areas of absent autofluorescence and the relationship these areas had with visual acuity.
   Results: The mean age of the patients was 82.9 years, and the mean visual acuity was 20/71 (logarithm minimum angle of resolution [logMAR], 0.55). Confluent loss of autofluorescence was seen in 58.6% of eyes at baseline, and the median area of absent autofluorescence among those was 1.57 mm(2) (interquartile range [IQR], 0.62-4.32 mm(2)). Using generalized estimation equation modeling, the significant predictors for area of confluent absent autofluorescence at baseline were duration of disease and any previous treatment with photodynamic therapy. The significant predictor of baseline visual acuity was baseline area of confluent absent autofluorescence. Follow-up was available for 124 (76.5%) eyes, with a mean follow-up of 2.9 years. By then, the mean visual acuity was 20/90 (logMAR, 0.65), and 79% of eyes had confluent areas of absent autofluorescence, the large majority of which affected the central macula. The median area of absent autofluorescence was 3.61 mm(2) (IQR, 1.16-7.11 mm(2)). The best predictor of final visual acuity was the area of absent autofluorescence at the final follow-up.
   Conclusions: Confluent absence of autofluorescence, a measure signifying RPE loss, was a significant predictor of visual acuity both at baseline and at final follow-up. This is the first study to document the prevalence, rate of progression, and factors associated with measures of confluent RPE loss in patients with neovascular AMD. Application of strategies to limit RPE cell loss may prove useful in eyes with neovascular AMD.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2013;120:334-341 (C) 2013 by the American Academy of Ophthalmology.
C1 [Kumar, Nishant; Mrejen, Sarah; Fung, Adrian Tien-Chin; Marsiglia, Marcela; Loh, Boon K.; Spaide, Richard F.] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
C3 Vitreous Retina Macula Consultants of New York
RP Spaide, RF (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM rickspaide@gmail.com
RI Spaide, Richard/ABD-7368-2020; Mrejen, Sarah/G-2089-2016
FU Macula Foundation, New York, New York
FX Supported by the Macula Foundation, New York, New York.
CR Bakri SJ, 2006, AM J OPHTHALMOL, V142, P162, DOI 10.1016/j.ajo.2006.03.058
   Bearelly S, 2010, ADV EXP MED BIOL, V664, P395, DOI 10.1007/978-1-4419-1399-9_45
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Choudhry N, 2010, SEMIN OPHTHALMOL, V25, P206, DOI 10.3109/08820538.2010.518121
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Feiner L, 2006, RETINA-J RET VIT DIS, V26, P882, DOI 10.1097/01.iae.0000230717.85319.f5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gobel AP, 2011, OPHTHALMOLOGICA, V226, P182, DOI 10.1159/000330420
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Imamura Y, 2011, OPHTHALMOLOGY, V118, P700, DOI 10.1016/j.ophtha.2010.08.017
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kellner U, 2006, INVEST OPHTH VIS SCI, V47, P3531, DOI 10.1167/iovs.05-1290
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Lorenz B, 2004, OPHTHALMOLOGY, V111, P1585, DOI 10.1016/j.ophtha.2004.01.033
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Mustafa MS, 2010, CLIN OPHTHALMOL, V4, P1497, DOI 10.2147/OPTH.S14846
   Robson AG, 2011, RETINA-J RET VIT DIS, V31, P1670, DOI 10.1097/IAE.0b013e318206d155
   Roe RH, 2011, RETINA-J RET VIT DIS, V31, P559, DOI 10.1097/IAE.0b013e3181f0d2c4
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Sarks J, 2006, BRIT J OPHTHALMOL, V90, P442, DOI 10.1136/bjo.2005.083022
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Sunness JS, 2006, RETINA-J RET VIT DIS, V26, P666, DOI 10.1097/00006982-200607000-00013
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   von Ruckmann A, 1999, GRAEF ARCH CLIN EXP, V237, P1, DOI 10.1007/s004170050186
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 45
TC 38
Z9 39
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2013
VL 120
IS 2
BP 334
EP 341
DI 10.1016/j.ophtha.2012.07.076
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 085WX
UT WOS:000314646100018
PM 23137630
DA 2022-11-30
ER

PT J
AU Keane, PA
   Liakopoulos, S
   Chang, KT
   Wang, M
   Dustin, L
   Walsh, AC
   Sadda, SR
AF Keane, Pearse A.
   Liakopoulos, Sandra
   Chang, Karen T.
   Wang, Mingwu
   Dustin, Laurie
   Walsh, Alexander C.
   Sadda, Srinivas R.
TI Relationship Between Optical Coherence Tomography Retinal Parameters and
   Visual Acuity in Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY;
   QUANTITATIVE SUBANALYSIS; EDEMA; RANIBIZUMAB; ATROPHY; VERTEPORFIN;
   DETACHMENT; THICKNESS; SECONDARY
AB Purpose: To investigate the relationship between optical coherence tomography (OCT)-derived measurements of retinal morphology and visual acuity in patients with neovascular age-related macular degeneration (AMD).
   Design: Retrospective cross-sectional study.
   Participants: A total of 216 consecutive patients (216 eyes) newly diagnosed with neovascular AMD who underwent StratusOCT imaging at the time of diagnosis.
   Methods: Best-corrected Snellen visual acuity was recorded for each patient. Raw exported StratusOCT images for each patient were analyzed using publicly available custom software entitled "OCTOR," which allows the precise positioning of prespecified boundaries on individual B-scans. Thickness and volume were calculated for morphologic parameters of interest: neurosensory retina, subretinal fluid, subretinal tissue (SRT), and pigment epithelial detachment.
   Main Outcome Measures: OCT-derived measurements of retinal morphology and visual acuity.
   Results: An increased total volume of SRT was correlated with decreased visual acuity (r = 0.370, P<0.0001). Decreased visual acuity was also modestly correlated with increased thickness of the neurosensory retina at the foveal center point (r = 0.245, P = 0.0004). No statistically significant association was detected between visual acuity and the total volume of subretinal fluid or pigment epithelial detachment. The association between visual acuity and both the neurosensory retina and the SRT was stronger for lesions classified as minimally classic or occult on fluorescein angiography. For occult lesions, 20% of the variation in visual acuity could be predicted by a multiple regression model that incorporated age and SRT volume, whereas, for minimally classic lesions, 62% of the variation in visual acuity could be predicted by a multiple regression model that incorporated age, total neurosensory retinal volume, and total SRT volume.
   Conclusions: The presence of increased SRT thickness and volume on OCT, and to a lesser extent increased neurosensory retinal thickness and volume, is associated with decreased visual acuity in neovascular AMD. However, because of the complex pathophysiology of neovascular AMD and, in part, the limitations of StratusOCT, these factors only account for a small degree of the variation in visual acuity that these patients exhibit. The detection of stronger correlations between retinal anatomy and visual acuity is likely to require the use of more advanced imaging modalities.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2008; 115:2206-2214 (C) 2008 by the American Academy of Ophthalmology.
C1 [Keane, Pearse A.; Liakopoulos, Sandra; Chang, Karen T.; Wang, Mingwu; Walsh, Alexander C.; Sadda, Srinivas R.] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA 90033 USA.
   [Liakopoulos, Sandra] Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, D-5000 Cologne 41, Germany.
   [Dustin, Laurie] Univ So Calif, Keck Sch Med, Dept Prevent Med, Stat Consultat & Res Ctr, Los Angeles, CA 90033 USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Cologne; University of Southern California
RP Sadda, SR (通讯作者)，Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Image Reading Ctr, DEI 3623,1450 San Pablo St, Los Angeles, CA 90033 USA.
RI Keane, Pearse/AAE-5709-2019; Keane, Pearse A/H-1860-2011
OI Keane, Pearse/0000-0002-9239-745X; 
FU National Institutes of Health [EY03040]; National Eye Institute [R01
   EY014375]; NATIONAL EYE INSTITUTE [P30EY003040, R21EY015914,
   R01EY014375] Funding Source: NIH RePORTER
FX Supported in part by National Institutes of Health Grant EY03040 and
   National Eye Institute Grant R01 EY014375.
CR Ahlers C, 2008, BRIT J OPHTHALMOL, V92, P197, DOI 10.1136/bjo.2007.120956
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bolz M, 2007, BRIT J OPHTHALMOL, V91, P785, DOI 10.1136/bjo.2006.102467
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Bringmann A, 2004, OPHTHALMIC RES, V36, P241, DOI 10.1159/000081203
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Browning DJ, 2008, AM J OPHTHALMOL, V145, P149, DOI 10.1016/j.ajo.2007.08.038
   Browning DJ, 2007, OPHTHALMOLOGY, V114, P525, DOI 10.1016/j.ophtha.2006.06.052
   Chen J, 2007, ELECTRON LETT, V43, P2, DOI 10.1049/el:20073431
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GASS JDM, 1997, STEREOSCOPIC ATLAS M, V1, P49
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hussain B, 2006, CLIN EXP OPHTHALMOL, V34, P6, DOI 10.1111/j.1442-9071.2006.01135.x
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Kim BY, 2006, AM J OPHTHALMOL, V142, P405, DOI 10.1016/j.ajo.2006.04.023
   Kniestedt Christoph, 2003, Ophthalmol Clin North Am, V16, P155, DOI 10.1016/S0896-1549(03)00013-0
   Krebs I, 2005, BRIT J OPHTHALMOL, V89, P1184, DOI 10.1136/bjo.2005.067389
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Sahni J, 2005, BRIT J OPHTHALMOL, V89, P316, DOI 10.1136/bjo.2004.043364
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   Sandhu SS, 2007, RETINA-J RET VIT DIS, V27, P13, DOI 10.1097/01.iae.0000256657.64240.a1
   Sarks J, 2006, BRIT J OPHTHALMOL, V90, P442, DOI 10.1136/bjo.2005.083022
   Shah SP, 2006, BRIT J OPHTHALMOL, V90, P33, DOI 10.1136/bjo.2005.072934
   SOUBRANE G, 1990, OPHTHALMOLOGY, V97, P649
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Sunness JS, 2006, BRIT J OPHTHALMOL, V90, P398, DOI 10.1136/bjo.2005.084830
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Voo Irene, 2004, Ophthalmol Clin North Am, V17, P21, DOI 10.1016/j.ohc.2003.12.002
NR 41
TC 79
Z9 82
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2008
VL 115
IS 12
BP 2206
EP 2214
DI 10.1016/j.ophtha.2008.08.016
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 381PK
UT WOS:000261548200013
PM 18930551
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Binder, S
   Krebs, I
   Hilgers, RD
   Abri, A
   Stolba, U
   Assadoulina, A
   Kellner, L
   Stanzel, BV
   Jahn, C
   Feichtinger, H
AF Binder, S
   Krebs, I
   Hilgers, RD
   Abri, A
   Stolba, U
   Assadoulina, A
   Kellner, L
   Stanzel, BV
   Jahn, C
   Feichtinger, H
TI Outcome of transplantation of autologous retinal pigment epithelium in
   age-related macular degeneration: A prospective trial
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; SURGICAL REMOVAL; RPE
   ALLOGRAFTS; MACULOPATHY; MEMBRANES; CLASSIFICATION; TRANSLOCATION;
   PROGRESSION; MANAGEMENT; EXCISION
AB Purpose. To present the outcome of a consecutive series of patients who had foveal choroidal neovascularization (fCNV) in age-related macular degeneration (AMD) and were treated with subretinal surgery combined with simultaneous transplantation of autologous retinal pigment epithelial (RPE) cells.
   Methods. Patients with fCNV who were not eligible for laser or photodynamic therapy were included in the study. They underwent subretinal membrane excision with simultaneous transplantation of autologous RPE cells. Eyes with membrane excision alone served as the control. Tests included best corrected visual acuity for far and near with Early Treatment Diabetic Retinopathy Study (ETDRS) and Jaeger charts, multi-focal (mt)ERG, central visual field analysis, optical coherence tomography (OCT), and angiography, before surgery, and 1 month and 3 months after treatment, and at 3-month intervals thereafter.
   Results. The results of final examinations of 53 eyes are presented. In 39 eyes, RPE transplantation was performed (group 1); 14 eyes had membrane excision alone (group 2). In group 1, visual acuity improved significantly, two or more lines in 21 (53.8%) patients; remained stable in 12 patients (30.8%); and decreased two or more lines in 6 patients (15.4%; P=0.0062). In group 2, the corresponding values were 21.1%, 57.8%, and 21.1% (P=0.5377 NS). Statistical analysis of results in the two groups showed a trend in favor of group 1 (P=0.9714). The difference in reading acuity was significant between the two groups (mean change in group 1: 1.85+/-0.42 vs. 0.43+/-0.47 in group 2; P=0.0001). mfERG response density changes were significantly different between groups 1 and 2 (P=0.0094). No significant decreases in central visual field defects were detected. OCT showed the postoperative median retinal thickness in the lesion area in group I to be higher (242.31+/-12-30 mum) than in group 2 (202.07+/-10.68 mum), showing a trend (P=0.0682).
   Conclusions. Patients undergoing fCNV removal with autologous transplantation of RPE reached significantly better reading acuity and higher mfERG-response density than control subjects. The results provide evidence that autologous transplantation of RPE is a beneficial supplement to membrane excision alone in patients with fCNV in AMD and may be regarded as a reasonable treatment option.
C1 Rudolph Fdn Clin, Dept Ophthalmol, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, A-1030 Vienna, Austria.
   Rudolph Fdn Clin, Dept Pathol & Bacteriol, A-1030 Vienna, Austria.
   Rhein Westfal TH Aachen, Inst Med Stat, D-5100 Aachen, Germany.
C3 Ludwig Boltzmann Institute; RWTH Aachen University
RP Binder, S (通讯作者)，Rudolph Fdn Clin, Dept Ophthalmol, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Juchgasse 25, A-1030 Vienna, Austria.
EM susanne.binder@wienkav.at
RI Stanzel, Boris/AAG-7010-2022; Hilgers, Ralf-Dieter/C-7090-2013; Stanzel,
   Boris/ADP-9221-2022
OI Stanzel, Boris/0000-0002-4316-1539; Hilgers,
   Ralf-Dieter/0000-0002-5945-1119; Stanzel, Boris/0000-0002-4316-1539
CR ABRI A, 2001, SPECTRUM AUGENHEILK, V15, P185
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   [Anonymous], 1994, Arch Ophthalmol, V112, P489
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   ASSADOULLINA A, 2003, SPECTRUM AUGENHEILK, V17, P120
   AWYLARD GW, 1999, 12 ANN M RET SOC REG
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BOK D, 1993, J CELL SCI, P189
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Castellarin AA, 1998, RETINA-J RET VIT DIS, V18, P143, DOI 10.1097/00006982-199818020-00008
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Crafoord S, 2000, ACTA OPHTHALMOL SCAN, V78, P122, DOI 10.1034/j.1600-0420.2000.078002122.x
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   Durlu YK, 1997, CELL TRANSPLANT, V6, P149, DOI 10.1016/S0963-6897(96)00142-X
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   FALKNER C, IN PRESS SURVEY OPHT
   Fang XY, 2001, AM J OPHTHALMOL, V131, P481, DOI 10.1016/S0002-9394(00)00899-0
   Gouras P., 1998, RETINAL PIGMENT EPIT, P492
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   LANE C, 1989, EYE, V3, P27, DOI 10.1038/eye.1989.4
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Majji AB, 2000, GRAEF ARCH CLIN EXP, V238, P779, DOI 10.1007/s004170000132
   Melberg NS, 1996, RETINA-J RET VIT DIS, V16, P190, DOI 10.1097/00006982-199616030-00002
   Nasir MA, 1997, BRIT J OPHTHALMOL, V81, P481, DOI 10.1136/bjo.81.6.481
   ORMEROD LD, 1994, OPHTHALMOLOGY, V101, P1201
   Oshima Y, 1998, RETINA-J RET VIT DIS, V18, P109, DOI 10.1097/00006982-199818020-00003
   Phillips SJ, 2003, CURR EYE RES, V26, P81, DOI 10.1076/ceyr.26.2.81.14508
   Piao CH, 2000, INVEST OPHTH VIS SCI, V41, P513
   Radner T, 1998, KLIN MONATSBL AUGENH, V213, P174, DOI 10.1055/s-2008-1034969
   Scheider A, 1999, GRAEF ARCH CLIN EXP, V237, P10, DOI 10.1007/s004170050187
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
   THOMAS MA, 1991, AM J OPHTHALMOL, V111, P1, DOI 10.1016/S0002-9394(14)76888-6
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang H, 2003, INVEST OPHTH VIS SCI, V44, P2199, DOI 10.1167/iovs.02-0435
   WIEDEMANN P, 2000, SPEKTRUM AUGENHEILKU, V14, P254
   WONGPICHEDCHAI S, 1992, INVEST OPHTH VIS SCI, V33, P3341
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 54
TC 160
Z9 171
U1 1
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2004
VL 45
IS 11
BP 4151
EP 4160
DI 10.1167/iovs.04-0118
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 865BT
UT WOS:000224678200042
PM 15505069
DA 2022-11-30
ER

PT J
AU van Romunde, SHM
   Polito, A
   Deiro, AP
   Bertazzi, L
   Guerriero, M
   Pertile, G
AF van Romunde, Saskia Helena Margaretha
   Polito, Antonio
   Deiro, Antonio Peroglio
   Bertazzi, Laura
   Guerriero, Massimo
   Pertile, Grazia
TI Morphological changes in the diseased retina on a healthy
   choroid-retinal pigment epithelial complex after full macular
   translocation for exudative age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   multimodal imaging; optical coherence tomography; submacular surgery
ID FUNDUS AUTOFLUORESCENCE; VISUAL-ACUITY; SURGERY; CHORIOCAPILLARIS
AB Purpose To describe the change in the retinal morphology after full macular translocation (FMT) for exudative age-related macular degeneration (AMD) and identify predictive factors for the visual outcome. Methods All patients who underwent FMT from December 2008 through July 2013 were selected. Exclusion criteria were FMT for other disease than AMD, age <60 years, <12 months of follow-up or no available images. Spectral domain optical coherence tomography, fundus autofluorescence, fluorangiography and indocyanine green angiography were evaluated. Results In total, 51 patients were included with a mean follow-up of 30 months. The presence of the external limiting membrane (ELM) was a significant predictor for a favourable visual outcome 1 year after FMT (OR = -0.30). Other significant predictive factors were the absence of intraretinal fluid (OR = 0.28) and the mixed choroidal neovascularization type (OR = -0.47), whereas nonresponders (OR = 0.41) and fibrotic lesions (OR = 0.35) were less likely to have a good visual function after surgery. Conclusion Full macular translocation (FMT), that permits to relocate the diseased macula onto an area of unaffected retinal pigment epithelial and choroid, can restore the anatomy and visual function in some patients with AMD when the outer retina layers are not irreversibly damaged. The presence of the ELM seems to be the most reliable factor in predicting the functional outcome.
C1 [van Romunde, Saskia Helena Margaretha; Polito, Antonio; Deiro, Antonio Peroglio; Bertazzi, Laura; Pertile, Grazia] Sacrocuore Hosp, Via Don Sempreboni 5, I-37024 Verona, Italy.
   [Guerriero, Massimo] Univ Verona, Dept Comp Sci, Verona, Italy.
C3 IRCCS Sacro Cuore Don Calabria; University of Verona
RP Polito, A (通讯作者)，Sacrocuore Hosp, Via Don Sempreboni 5, I-37024 Verona, Italy.
EM apolito32@yahoo.it
RI Guerriero, Massimo/AAA-9409-2020; Pertile, Grazia/AAC-4956-2022
OI Guerriero, Massimo/0000-0003-1310-539X; Polito,
   Antonio/0000-0001-6758-6470
FU Hospital Sacro Cuore - Don Calabria (Negrar, Italy)
FX The study was financially supported by the Hospital Sacro Cuore - Don
   Calabria (Negrar, Italy). The funding organization had no role in the
   design or conduct of this research. We did not receive any funding from
   National Institutes of Health (NIH), Wellcome Trust, Howard Hughes
   Medical Institute (HHMI), or others.
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Bertazzi L, 2010, INVEST OPHTH VIS SCI, V51
   Bertolotto M, 2014, BIOMED RES INT, V2014, P6
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Chen FK, 2010, INVEST OPHTH VIS SCI, V51, P4207, DOI 10.1167/iovs.09-4728
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Johnson MW, 2010, AM J OPHTHALMOL, V149, P371, DOI 10.1016/j.ajo.2009.11.022
   Mathew R, 2013, AM J OPHTHALMOL, V155, P720, DOI 10.1016/j.ajo.2012.11.003
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P435, DOI 10.1007/s00417-012-2034-4
   Polito A, 2016, INT J OPHTHALMOL CLI, V123, P1762
   Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477
   Sawa M, 2008, GRAEF ARCH CLIN EXP, V246, P1087, DOI 10.1007/s00417-008-0835-2
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Terasaki H, 2003, OPHTHALMOLOGY, V110, P2403, DOI 10.1016/S0161-6420(03)00829-7
   Uppal G, 2007, CLIN EXP OPHTHALMOL, V35, P448, DOI 10.1111/j.1442-9071.2007.01528.x
   van Romunde SHM, 2015, OPHTHALMOLOGY, V122, P1366, DOI 10.1016/j.ophtha.2015.03.012
   VANSMEURS JC, 2004, BR J OPHTHALMOL, V88, P110
   Wakabayashi T, 2010, OPHTHALMOLOGY, V117, P1815, DOI 10.1016/j.ophtha.2010.01.017
   Wakabayashi T, 2009, OPHTHALMOLOGY, V116, P519, DOI 10.1016/j.ophtha.2008.10.001
   Wong D, 2004, BRIT J OPHTHALMOL, V88, P186, DOI 10.1136/bjo.2003.019273
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 27
TC 2
Z9 2
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2019
VL 97
IS 2
BP E283
EP E289
DI 10.1111/aos.13880
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HM7DQ
UT WOS:000459637900031
PM 30284413
DA 2022-11-30
ER

PT J
AU Gallego-Pinazo, R
   Pina-Marin, B
   Comellas, M
   Aceituno, S
   Gomez-Baldo, L
   Blanch, C
AF Gallego-Pinazo, Roberto
   Pina-Marin, Begona
   Comellas, Marta
   Aceituno, Susana
   Gomez-Baldo, Laia
   Blanch, Carles
CA AMD-Manage Investigators
TI Patient and retina specialists' preferences in neovascular age-related
   macular degeneration treatment. A discrete choice experiment
SO PLOS ONE
LA English
DT Article
ID GLAUCOMA PATIENTS; MANAGEMENT; GUIDELINES; VIEWS
AB Introduction and objective
   Neovascular age-related macular degeneration (nAMD) leads to severe and permanent visual impairment, significantly impacting patients' quality of life and functional independence. Although treatment with anti-vascular endothelial growth factor (VEGF) prevents and, in some cases, reverses visual damage, the need for frequent monitoring visits and intravitreal injections represents a significant burden on patients, caregivers and retina specialists.
   Objective
   To elicit preferences for nAMD treatment characteristics from the perspectives of patients and retina specialists.
   Method
   A discrete choice experiment was conducted. Participants (patients > 50 years with nAMD receiving anti-VEGF drugs for at least 2 years and without previous experience with anti-VEGF and retina specialists working in the Spanish National Healthcare System) were asked to select one of two hypothetical treatments resulting from the combination of five attributes (effects on visual function, effects on retinal fluid, treatment regimen, monitoring frequency, and cost); their levels were identified by reviewing the literature and two focus groups. The relative importance (RI) given to each attribute was estimated using a mixed logit model. The marginal rates of substitution (MRS) were calculated taking cost as the risk attribute.
   Results
   A total of 110 patients (P) [aged 79.0 (SD:7.4) years; 57.3% women; 2.3 (SD:0.7) years with nAMD; 2.1 years (SD:0.1) in treatment] and 66 retina specialists (RS) participated in the study. Participants gave greater RI to improvements in their visual function [60.0% (P); 52.7% (RS)], lower monitoring frequency [20.2% (P); 27.1% (RS)] and reduction in retinal fluid [9.8% (P); 13.0%(RS)]. Patients and retina specialists would agree to an increase in cost by 65.0% and 56.5%, respectively, in exchange for improvements of visual function; and 25.5% and 43.3% on delaying monitoring frequency by one month.
   Conclusions
   Efficacy of treatment, in terms of visual function improvements, is the main driver for treatment election for both patients and retina specialists. Treatment monitoring requirements are also considered, mainly from the retina specialist's perspective. These results suggest that the use of more efficacious anti-VEGF agents with a longer duration of action may contribute to aligning treatment characteristics with patients/specialists' preferences. A better alignment would facilitate better disease management, fulfilling the unmet needs of patients and retina specialists.
C1 [Gallego-Pinazo, Roberto] Oftalvist Clin, Unit Macula, Barcelona, Spain.
   [Pina-Marin, Begona] Hosp Maig, Dept Ophthalmol, Barcelona, Spain.
   [Comellas, Marta; Aceituno, Susana] Outcomes 10, Castellon De La Plana, Spain.
   [Gomez-Baldo, Laia] Novartis Farmaceut SA, Med Dept, Barcelona, Spain.
   [Blanch, Carles] Novartis Farmaceut SA, Hlth Econ & Market Access, Barcelona, Spain.
C3 Novartis; Novartis
RP Blanch, C (通讯作者)，Novartis Farmaceut SA, Hlth Econ & Market Access, Barcelona, Spain.
EM carles.blanch@novartis.com
CR Androudi S, 2016, ADV THER, V33, P715, DOI 10.1007/s12325-016-0332-7
   Arroyo J., 2020, AGE RELATED MACULAR
   Barry MJ, 2012, NEW ENGL J MED, V366, P780, DOI 10.1056/NEJMp1109283
   Baxter JM, 2016, EYE, V30, P698, DOI 10.1038/eye.2016.18
   Bhagat D, 2020, CLIN OPHTHALMOL, V14, P2975, DOI 10.2147/OPTH.S273564
   Bhargava JS, 2008, BRIT J OPHTHALMOL, V92, P1601, DOI 10.1136/bjo.2008.140483
   Bhargava JS, 2006, INVEST OPHTH VIS SCI, V47, P2885, DOI 10.1167/iovs.05-1244
   Bridges JFP, 2011, VALUE HEALTH, V14, P403, DOI 10.1016/j.jval.2010.11.013
   Chakravarthy U, 2020, JAMA-J AM MED ASSOC, V324, P794, DOI 10.1001/jama.2020.5576
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Danner M, 2017, VALUE HEALTH, V20, P1166, DOI 10.1016/j.jval.2017.04.022
   Finger R, 2012, BRIT J OPHTHALMOL, V96, P997, DOI 10.1136/bjophthalmol-2011-301201
   Garcia-Layana A, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/9821509
   Garcia-Layana A, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/595132
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Hauber AB, 2013, OSTEOARTHR CARTILAGE, V21, P289, DOI 10.1016/j.joca.2012.11.007
   Heinemann M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222045
   Jackson Y, 2019, EXPERT REV PHARM OUT, V19, P383, DOI 10.1080/14737167.2019.1612242
   Jaffe DH, 2018, J COMP EFFECT RES, V7, P1125, DOI 10.2217/cer-2018-0058
   Johnson FR, 2013, VALUE HEALTH, V16, P3, DOI 10.1016/j.jval.2012.08.2223
   Joko T, 2020, PATIENT PREFER ADHER, V14, P553, DOI 10.2147/PPA.S228890
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mott DJ, 2020, VALUE HEALTH, V23, P979, DOI 10.1016/j.jval.2020.04.1831
   Mueller S, 2016, OPHTHALMOLOGY, V123, P876, DOI 10.1016/j.ophtha.2015.12.001
   Orme B.K., 2006, GETTING STARTED CONJ
   Marin BP, 2022, EUR J OPHTHALMOL, V32, P385, DOI 10.1177/11206721211001716
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Ruiz-Moreno J., 2014, SOC ESPANOLA RETIN V
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   StataCorp, 2015, STAT STAT SOFTW REL
   van Overbeeke E, 2019, DRUG DISCOV TODAY, V24, P57, DOI 10.1016/j.drudis.2018.09.015
   Varano M, 2016, CLIN OPHTHALMOL, V10, P257, DOI 10.2147/OPTH.S92616
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
   Vennedey V, 2016, PATIENT PREFER ADHER, V10, P993, DOI 10.2147/PPA.S101584
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
NR 36
TC 0
Z9 0
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 31
PY 2021
VL 16
IS 12
AR e0261955
DI 10.1371/journal.pone.0261955
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ZZ9AO
UT WOS:000773555700075
PM 34972174
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chakravarthy, U
   Evans, J
   Rosenfeld, PJ
AF Chakravarthy, Usha
   Evans, Jennifer
   Rosenfeld, Philip J.
TI Age related macular degeneration
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Review
ID COMPLEMENT C3; RISK; RANIBIZUMAB; SAFETY; ANTIOXIDANTS; THERAPY
C1 [Chakravarthy, Usha] Inst Clin Sci, Ctr Vasc & Vis Sci, Belfast BT12 6BA, Antrim, North Ireland.
   [Evans, Jennifer] Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1E 7HT, England.
   [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 University of London; London School of Hygiene & Tropical Medicine;
   Bascom Palmer Eye Institute; University of Miami
RP Chakravarthy, U (通讯作者)，Inst Clin Sci, Ctr Vasc & Vis Sci, Belfast BT12 6BA, Antrim, North Ireland.
EM u.chakravarthy@qub.ac.uk
RI Evans, Jennifer/F-4672-2012
OI Evans, Jennifer/0000-0002-6137-2030; Chakravarthy,
   Usha/0000-0002-2606-3734
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CHAKRAVARTHY U, 2007, BRIT MED J, V10, P269
   ELDEM B, 2009, RET C SCI ABSTR
   Emerich DF, 2008, CURR OPIN MOL THER, V10, P506
   ERFURTH US, 2009, RET C SCI ABSTR
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Landa G, 2008, CURR EYE RES, V33, P1011, DOI 10.1080/02713680802484637
   *NAT I HLTH CLIN E, 2008, PEG RAN TREATM AG RE
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Royal College of Ophthalmologists, 2009, AG REL MAC DEG GUID
   Satia JA, 2009, AM J EPIDEMIOL, V169, P815, DOI 10.1093/aje/kwn409
   Schnatbaum K, 2006, BIOORG MED CHEM LETT, V16, P5088, DOI 10.1016/j.bmcl.2006.07.036
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Witkin AJ, 2009, OPHTHALMOLOGY, V116, P956, DOI 10.1016/j.ophtha.2008.12.018
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Woo JH, 2009, ACTA OPHTHALMOL, V87, P262, DOI 10.1111/j.1755-3768.2008.01376.x
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhou J, 2008, J NEUROCHEM, V106, P2080, DOI 10.1111/j.1471-4159.2008.05558.x
NR 35
TC 53
Z9 56
U1 0
U2 12
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD FEB 26
PY 2010
VL 340
AR c981
DI 10.1136/bmj.c981
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 561TI
UT WOS:000275001400011
PM 20189972
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ayoub, T
   Patel, N
AF Ayoub, Tariq
   Patel, Nishal
TI Age-related macular degeneration
SO JOURNAL OF THE ROYAL SOCIETY OF MEDICINE
LA English
DT Review
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIALS;
   OPTICAL COHERENCE TOMOGRAPHY; FACTOR-H POLYMORPHISM; BODY-MASS INDEX;
   PHOTODYNAMIC THERAPY; UNITED-STATES; VERTEPORFIN; MACULOPATHY;
   RANIBIZUMAB
C1 [Ayoub, Tariq] Guys & St Thomas NHS Trust, London SE1 7EH, England.
   [Patel, Nishal] UCL, Inst Ophthalmol, Dept Cellular Therapy, London, England.
C3 Guy's & St Thomas' NHS Foundation Trust; University of London;
   University College London
RP Ayoub, T (通讯作者)，Guys & St Thomas NHS Trust, Westminster Bridge Rd, London SE1 7EH, England.
EM tariqayoub@gmail.com
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cheng LY, 2001, J OCUL PHARMACOL TH, V17, P295, DOI 10.1089/108076801750295326
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Ciulla TA, 2003, RETINA-J RET VIT DIS, V23, P808, DOI 10.1097/00006982-200312000-00011
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2006, COCHRANE DB SYST REV, V2
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Freeman WR, 2006, RETINA-J RET VIT DIS, V26, P853, DOI 10.1097/01.iae.0000244722.35073.7c
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gohel PS, 2008, AM J MED, V121, P279, DOI 10.1016/j.amjmed.2007.10.020
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Guidetti B., 2008, Current Drug Delivery, V5, P7, DOI 10.2174/156720108783331050
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   HORNTON J, 2005, EYE, V19, P935
   Hughes EH, 2005, AM J OPHTHALMOL, V139, P344, DOI 10.1016/j.ajo.2004.07.058
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Janoria KG, 2007, EXPERT OPIN DRUG DEL, V4, P371, DOI 10.1517/17425247.4.4.371
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   MILLER JW, 1993, OPHTHALMOLOGY, V100, P9
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Saishin Y, 2003, INVEST OPHTH VIS SCI, V44, P4989, DOI 10.1167/iovs.03-0600
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tezel TH, 2004, TRENDS MOL MED, V10, P417, DOI 10.1016/j.molmed.2004.07.004
   Wachter A, 2004, OPHTHALMOLOGE, V101, P50, DOI 10.1007/s00347-003-0868-1
   Wormald R, 2007, COCHRANE DB SYST REV, V3
NR 45
TC 24
Z9 24
U1 0
U2 0
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 0141-0768
J9 J ROY SOC MED
JI J. R. Soc. Med.
PD FEB
PY 2009
VL 102
IS 2
BP 56
EP 61
DI 10.1258/jrsm.2009.080298
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 412DA
UT WOS:000263702500009
PM 19208869
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Toto, L
   Borrelli, E
   Mastropasqua, R
   Di Antonio, L
   Mattel, PA
   Carpineto, P
   Mastropasqua, L
AF Toto, Lisa
   Borrelli, Enrico
   Mastropasqua, Rodolfo
   Di Antonio, Luca
   Mattel, Peter A.
   Carpineto, Paolo
   Mastropasqua, Leonardo
TI ADULT-ONSET FOVEOMACULAR VITELLIFORM DYSTROPHY EVALUATED BY MEANS OF
   OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY A Comparison With Dry
   Age-Related Macular Degeneration and Healthy Eyes
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE adult-onset foveomacular vitelliform dystrophy; age-related macular
   degeneration; vessel density; choroidal thickness; optical coherence
   tomography angiography
ID PIGMENT EPITHELIAL DYSTROPHY; SOURCE OCT ANGIOGRAPHY; CHOROIDAL
   THICKNESS; FEATURES; RETINA
AB Purpose: To investigate alterations of superficial and deep retinal vascular densities, as well as of choroidal thickness, in patients affected by adult-onset foveomacular vitelliform dystrophy (AOFVD).
   Methods: A total of 22 eyes (15 patients) affected by AOFVD were recruited in the study. Furthermore, 20 eyes of 20 healthy subjects and 20 eyes of 18 patients affected by intermediate dry age-related macular degeneration (AMD) were enrolled. All patients underwent a complete ophthalmologic examination, including optical coherence tomography angiography. Outcome measures were superficial vessel density, deep vessel density, and choroidal thickness.
   Results: Parafoveal superficial vessel density was increased in patients with AOFVD compared with the AMD group (50.6 +/- 4.3% and 46.3 +/- 4.3%, respectively, P = 0.016). Parafoveal deep vessel density was 57.9 +/- 6.4% in patients with AOFVD, 52.2 +/- 3.8% in patients with AMD, and 52.7 +/- 6.0% in healthy controls (P = 0.006 and P = 0.035, respectively, after comparison with the AOFVD group).
   Conclusion: We demonstrated that both superficial and deep vessel densities were significantly increased in patients with AOFVD, after the comparison with intermediate patients with AMD. These findings suggest that the pathogenic mechanisms in AOFVD are different from those in AMD and that optical coherence tomography angiography could be useful in differentiate early stages of these two diseases.
C1 [Toto, Lisa; Borrelli, Enrico; Di Antonio, Luca; Mattel, Peter A.; Carpineto, Paolo; Mastropasqua, Leonardo] Univ G dAnnunzio, Dept Med & Sci Ageing, Ophthalmol Clin, Chieti, Italy.
   [Mastropasqua, Rodolfo] Univ Verona, Ophthalmol Unit, Dept Neurol Neuropsychol Morphol & Movement Sci, Verona, Italy.
C3 G d'Annunzio University of Chieti-Pescara; University of Verona
RP Borrelli, E (通讯作者)，Univ G dAnnunzio, Dept Med & Sci Ageing, Via Vestini, I-66100 Chieti, CH, Italy.
EM borrelli.enrico@yahoo.com
RI Toto, Lisa/K-3473-2018; Mastropasqua, Rodolfo/AAC-6453-2022; Borrelli,
   Enrico/AAR-3693-2020; Carpineto, Paolo/AAN-9688-2020
OI Toto, Lisa/0000-0001-5311-5184; Borrelli, Enrico/0000-0003-2815-5031; 
CR Arnold JJ, 2003, EYE, V17, P717, DOI 10.1038/sj.eye.6700460
   Chowers I, 2015, PROG RETIN EYE RES, V47, P64, DOI 10.1016/j.preteyeres.2015.02.001
   Coscas F, 2014, INVEST OPHTH VIS SCI, V55, P64, DOI 10.1167/iovs.13-12931
   Dubovy SR, 2000, RETINA-J RET VIT DIS, V20, P638, DOI 10.1097/00006982-200011000-00009
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gass J D, 1974, Trans Am Ophthalmol Soc, V72, P139
   Harb E, 2015, AM J OPHTHALMOL, V160, P62, DOI 10.1016/j.ajo.2015.04.018
   Huang YP, 2014, OSLI RETINA, V45, P382, DOI 10.3928/23258160-20140909-08
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   JAFFE GJ, 1988, ARCH OPHTHALMOL-CHIC, V106, P958
   Jia YL, 2012, BIOMED OPT EXPRESS, V3, DOI 10.1364/BOE.3.003127
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kaur C, 2006, INVEST OPHTH VIS SCI, V47, P1126, DOI 10.1167/iovs.05-0518
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Mastropasqua L, 2017, RETINA-J RET VIT DIS, V37, P247, DOI 10.1097/IAE.0000000000001145
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   PATRINELY JR, 1985, OPHTHALMOLOGY, V92, P1712
   Puche N, 2010, BRIT J OPHTHALMOL, V94, P1190, DOI 10.1136/bjo.2009.175075
   Querques G, 2016, BR J OPHTHALMOL
   Querques G, 2008, AM J OPHTHALMOL, V146, P501, DOI 10.1016/j.ajo.2008.05.029
   Querques G, 2011, AM J OPHTHALMOL, V152, P304, DOI 10.1016/j.ajo.2011.01.047
   SANYAL S, 1989, CURR EYE RES, V8, P1093, DOI 10.3109/02713688908997402
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Toto L, 2017, BRIT J OPHTHALMOL, V101, P774, DOI 10.1136/bjophthalmol-2016-309160
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Ulas F, 2014, CURR EYE RES, V39, P504, DOI 10.3109/02713683.2013.850099
   Usui S, 2012, INVEST OPHTH VIS SCI, V53, P2300, DOI 10.1167/iovs.11-8383
   VINE AK, 1980, AM J OPHTHALMOL, V89, P680, DOI 10.1016/0002-9394(80)90288-3
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wei E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081343
   Zerbib J, 2014, GRAEF ARCH CLIN EXP, V252, P899, DOI 10.1007/s00417-013-2537-7
NR 32
TC 10
Z9 11
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2018
VL 38
IS 4
BP 731
EP 738
DI 10.1097/IAE.0000000000001615
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP2BD
UT WOS:000440623400018
PM 28338556
DA 2022-11-30
ER

PT J
AU Gocuk, SA
   Lee, JH
   Keller, PR
   Ayton, LN
   Guymer, RH
   McKendrick, AM
   Downie, LE
AF Gocuk, Sena A.
   Lee, Ji-hyun
   Keller, Peter R.
   Ayton, Lauren N.
   Guymer, Robyn H.
   McKendrick, Allison M.
   Downie, Laura E.
TI Clinical audit as an educative tool for optometrists: an intervention
   study in age-related macular degeneration
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE age&#8208; related macular degeneration; clinical audit; clinical
   record; optometry
ID RETICULAR PSEUDODRUSEN; DIABETIC-RETINOPATHY; FUNDUS PHOTOGRAPHY;
   GEOGRAPHIC-ATROPHY; QUALITY IMPROVEMENT; PACK-YEARS; SMOKING;
   ASSOCIATION; MANAGEMENT; RISK
AB Purpose Age-related macular degeneration (AMD) is a major cause of vision loss. This study investigated whether performing clinical audit and receiving analytical performance feedback altered documentation of the AMD care provided by optometrists.
   Methods Australian optometrists were recruited and completed a survey about their demographics and confidence in AMD care, and a three-month audit of their practice records using an AMD audit tool (termed the pre-audit evaluation). After receiving analytical feedback, participants identified areas for improvement and re-audited their practices after three months to analyse changes in performance (termed the post-audit evaluation). Paired t-tests and Wilcoxon signed-rank tests, as appropriate, were used to compare pre- and post-audit data.
   Results Twenty optometrists, most practising in Victoria, Australia, completed the study. Participants primarily worked in corporate practice and/or rural settings and had a range of optometric experience (2-40 years). At baseline, participants felt confident in their: knowledge of AMD risk factors (65%), advice to patients about these factors (55%) and management of earlier stages of AMD (55%). Each clinician completed (median [IQR]): 15 [IQR: 10-19] and 12 [IQR: 8-16] audits of unique patient records, pre- and post-audit, respectively. Post-audit, average record documentation (per optometrist) improved for asking about: AMD family history (94% to 100%, p = 0.03), smoking status (21% to 58%, p < 0.01), diet (11% to 29%, p < 0.01) and nutritional supplementation (20% to 51%, p < 0.01). For clinical examination, compliance with documenting pinhole visual acuity, performing an in-office Amsler grid (upon indication) and using optical coherence tomography improved post-audit (p < 0.05). Accuracy of severity documentation improved for earlier stages of AMD (p < 0.05). For earlier stages of AMD, documentation of counselling about modifiable risk factors significantly improved post-audit (p < 0.05). Aspects well-performed pre-audit that did not change included documenting: medical histories (100% at both time points, p = 0.06) and retinal imaging (77% at both time points, p = 0.97).
   Conclusions Self-audit with analytical feedback improved clinical record documentation of: AMD risk factors, clinical examination, AMD severity classification and management advice. These findings support a role for audit to improve optometric clinical care of AMD, as evidenced by improved documentation of the AMD care delivered.
C1 [Gocuk, Sena A.; Lee, Ji-hyun; Keller, Peter R.; Ayton, Lauren N.; McKendrick, Allison M.; Downie, Laura E.] Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic, Australia.
   [Ayton, Lauren N.; Guymer, Robyn H.] Univ Melbourne, Dept Surg Ophthalmol, Parkville, Vic, Australia.
   [Ayton, Lauren N.; Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 University of Melbourne; University of Melbourne; Centre for Eye
   Research Australia; Royal Victorian Eye & Ear Hospital
RP Downie, LE (通讯作者)，Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic, Australia.
EM ldownie@unimelb.edu.au
RI McKendrick, Allison M/A-2114-2008; Ayton, Lauren/AAV-2977-2021
OI Ayton, Lauren/0000-0001-9907-084X; McKendrick,
   Allison/0000-0003-1972-1222; Downie, Laura/0000-0002-1596-2259
FU Macular Disease Foundation Australia; National Health and Medical
   Research Council (NHMRC) of Australia Translating Research Into Practice
   (TRIP) Fellowship [APP1091833]; NHMRC Medical Research Future Fund Next
   Generation Clinical Researcher Fellowship [APP1151055]; NHMRC Fellowship
   [GNT1103013]
FX This study was funded by a 2015 Blackmores Research Grant from the
   Macular Disease Foundation Australia (awarded to LED, PRK, LNA and RHG),
   a 2015 National Health and Medical Research Council (NHMRC) of Australia
   Translating Research Into Practice (TRIP) Fellowship (awarded to LED,
   APP1091833), a 2019 NHMRC Medical Research Future Fund Next Generation
   Clinical Researcher Fellowship (awarded to LNA, APP1151055) and a 2016
   NHMRC Fellowship (awarded to RHG, GNT1103013).
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Augustin AJ, 2005, RETINA-J RET VIT DIS, V25, P443, DOI 10.1097/00006982-200506000-00008
   Azzolini E, 2019, J Prev Med Hyg, V60, pE250, DOI 10.15167/2421-4248/jpmh2019.60.3.1203
   Bennadi D, 2014, J INT DENT MED RES, V7, P49
   Borbasi S, 2010, USING EVIDENCE GUIDE, P113
   Bott D, 2018, J PUBLIC HEALTH-UK, V40, P614, DOI 10.1093/pubmed/fdx115
   Bowie P, 2012, J EVAL CLIN PRACT, V18, P42, DOI 10.1111/j.1365-2753.2010.01523.x
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   De Koning-Backus APM, 2019, AM J OPHTHALMOL, V198, P70, DOI 10.1016/j.ajo.2018.09.036
   DICKSON WJ, 1966, COUNSELING ORG SEQUE
   Downie LE, 2017, OPHTHAL PHYSL OPT, V37, P202, DOI 10.1111/opo.12353
   Downie LE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124533
   Downie LE, 2014, OPTOMETRY VISION SCI, V91, P821, DOI 10.1097/OPX.0000000000000285
   Esposito Pasquale, 2014, World J Nephrol, V3, P249, DOI 10.5527/wjn.v3.i4.249
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   Farzandipour M, 2013, J ROY COLL PHYS EDIN, V43, P29, DOI 10.4997/JRCPE.2013.106
   Fenner BJ, 2018, OPHTHALMOL THER, V7, P333, DOI 10.1007/s40123-018-0153-7
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fu DJ, 2021, JAMA OPHTHALMOL, V139, P57, DOI 10.1001/jamaophthalmol.2020.5044
   Galor A, 2011, CURR OPIN OPHTHALMOL, V22, P477, DOI 10.1097/ICU.0b013e32834bbe7a
   Garcia GL, 2002, ARCH BRONCONEUMOL, V38, P317, DOI 10.1016/S0300-2896(02)75225-3
   Gopinath B, 2014, BRIT J NUTR, V111, P1673, DOI 10.1017/S000711451300408X
   Govender I, 2012, INT J QUAL HEALTH C, V24, P612, DOI 10.1093/intqhc/mzs063
   Graham WJ, 2009, BEST PRACT RES CL OB, V23, P375, DOI 10.1016/j.bpobgyn.2009.01.017
   Han NgWai, 2018, Malaysian Journal of Nutrition, V24, P627
   Ho KC, 2020, OPHTHAL PHYSL OPT, V40, P433, DOI 10.1111/opo.12699
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Ivers N, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000259.pub3
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kirby CN, 2009, AUST FAM PHYSICIAN, V38, P637
   Kleczka B, 2018, INT J MED INFORM, V114, P121, DOI 10.1016/j.ijmedinf.2017.10.014
   Krebs EE, 2010, J GEN INTERN MED, V25, P194, DOI 10.1007/s11606-009-1194-3
   Ku JJY, 2013, MED J AUSTRALIA, V198, P93, DOI 10.5694/mja12.10607
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Lin DY, 2002, AM J OPHTHALMOL, V134, P204, DOI 10.1016/S0002-9394(02)01522-2
   Lindsay J, 2004, OPHTHAL PHYSL OPT, V24, P360, DOI 10.1111/j.1475-1313.2004.00227.x
   Liu LT, 2013, SCI WORLD J, DOI 10.1155/2013/589675
   Lord J, 1996, INT J QUAL HEALTH C, V8, P527, DOI 10.1093/intqhc/8.6.527
   Mak DB, 2012, MED TEACH, V34, pE251, DOI 10.3109/0142159X.2012.660216
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   McCambridge J, 2014, J CLIN EPIDEMIOL, V67, P267, DOI 10.1016/j.jclinepi.2013.08.015
   McKay-Brown Lisa, 2008, Asia Pac Fam Med, V7, P4, DOI 10.1186/1447-056X-7-4
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mohammadi-Sardo M.R., 2018, ACTA MED IRANICA, V56, P598
   Nebbioso M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071693
   Neuner B, 2009, ADDICT BEHAV, V34, P938, DOI 10.1016/j.addbeh.2009.05.015
   Palmer NAO, 2001, BRIT DENT J, V191, P253, DOI 10.1038/sj.bdj.4801156a
   Pessian F, 2004, BRIT DENT J, V197, P703, DOI 10.1038/sj.bdj.4811866
   PUGH JA, 1993, DIABETES CARE, V16, P889, DOI 10.2337/diacare.16.6.889
   Pullen I, 2018, ADV PSYCHIAT TREAT, V12, P280
   Puvanachandra N, 2008, OPHTHAL PHYSL OPT, V28, P313, DOI 10.1111/j.1475-1313.2008.00574.x
   Royal Australian and New Zealand College of Ophthalmologists (RANZCO), 2018, RANZC REF PATHW AMD
   Salti HI, 2015, OSLI RETINA, V46, P531, DOI 10.3928/23258160-20150521-04
   Sayin N, 2014, CUTAN OCUL TOXICOL, V33, P201, DOI 10.3109/15569527.2013.832688
   Schmidt M, 2005, INT J STD AIDS, V16, P822, DOI 10.1258/095646205774988073
   Sealey C, 1999, BRIT J OCCUP THER, V62, P238
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Sivertsen J, 2017, BMC NURS, V16, DOI 10.1186/s12912-017-0222-6
   Srinivasan S, 2017, CUTAN OCUL TOXICOL, V36, P253, DOI 10.1080/15569527.2016.1265548
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Valikodath NG, 2017, JAMA OPHTHALMOL, V135, P225, DOI 10.1001/jamaophthalmol.2016.5551
   Vijayakumar C, 2016, INT J SURG, V35, P44, DOI 10.1016/j.ijsu.2016.09.011
   Weng JP, 2020, J DIABETES, V12, P66, DOI 10.1111/1753-0407.12963
   Wightman AJ, 2019, CLIN EXP OPTOM, V102, P455, DOI 10.1111/cxo.12842
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
NR 79
TC 4
Z9 4
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD JAN
PY 2021
VL 41
IS 1
BP 53
EP 72
DI 10.1111/opo.12754
EA NOV 2020
PG 20
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA QA8QH
UT WOS:000586020000001
PM 33156555
OA Green Published
DA 2022-11-30
ER

PT J
AU Rohm, M
   Tresp, V
   Muller, M
   Kern, C
   Manakov, I
   Weiss, M
   Sim, DA
   Priglinger, S
   Keane, PA
   Kortuem, K
AF Rohm, Markus
   Tresp, Volker
   Mueller, Michael
   Kern, Christoph
   Manakov, Ilja
   Weiss, Maximilian
   Sim, Dawn A.
   Priglinger, Siegfried
   Keane, Pearse A.
   Kortuem, Karsten
TI Predicting Visual Acuity by Using Machine Learning in Patients Treated
   for Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL AFLIBERCEPT; DIABETIC-RETINOPATHY; RANIBIZUMAB;
   BEVACIZUMAB; OUTCOMES; EDEMA; PROGRESSION; TRIAL; EYE
AB Purpose: To predict, by using machine learning, visual acuity (VA) at 3 and 12 months in patients with neovascular age-related macular degeneration (AMD) after initial upload of 3 anti-vascular endothelial growth factor (VEGF) injections.
   Design: Database study.
   Participants: For the 3-month VA forecast, 653 patients (379 female) with 738 eyes and an average age of 74.1 years were included. The baseline VA before the first injection was 0.54 logarithm of the minimum angle of resolution (logMAR) (+/- 0.39). A total of 456 of these patients (270 female, 508 eyes, average age: 74.2 years) had sufficient follow-up data to be included for a 12-month VA prediction. The baseline VA before the first injection was 0.56 logMAR (+/- 0.42).
   Methods: Five different machine-learning algorithms (AdaBoost.R2, Gradient Boosting, Random Forests, Extremely Randomized Trees, and Lasso) were used to predict VA in patients with neovascular AMD after treatment with 3 anti-VEGF injections. Clinical data features came from a data warehouse (DW) containing electronic medical records (41 features, e.g., VA) and measurement features from OCT (124 features, e.g., central retinal thickness). The VA of patient eyes excluded from machine learning was predicted and compared with the ground truth, namely, the actual VA of these patients as recorded in the DW.
   Main Outcome Measures: Difference in logMAR VA after 3 and 12 months upload phase between prediction and ground truth as defined.
   Results: For the 3-month VA forecast, the difference between the prediction and ground truth was between 0.11 logMAR (5.5 letters) mean absolute error (MAE)/0.14 logMAR (7 letters) root mean square error (RMSE) and 0.18 logMAR (9 letters) MAE/0.2 logMAR (10 letters) RMSE. For the 12-month VA forecast, the difference between the prediction and ground truth was between 0.16 logMAR (8 letters) MAE/0.2 logMAR (10 letters) RMSE and 0.22 logMAR (11 letters) MAE/0.26 logMAR (13 letters) RMSE. The best performing algorithm was the Lasso protocol.
   Conclusions: Machine learning allowed VA to be predicted for 3 months with a comparable result to VA measurement reliability. For a forecast after 12 months of therapy, VA prediction may help to encourage patients adhering to intravitreal therapy. (C) 2018 by the American Academy of Ophthalmology
C1 [Rohm, Markus; Mueller, Michael; Kern, Christoph; Manakov, Ilja; Weiss, Maximilian; Priglinger, Siegfried; Kortuem, Karsten] Ludwig Maximilians Univ Munchen, Dept Ophthalmol, Munich, Germany.
   [Rohm, Markus; Tresp, Volker; Manakov, Ilja] Ludwig Maximilians Univ Munchen, Dept Comp Sci, Munich, Germany.
   [Sim, Dawn A.; Keane, Pearse A.; Kortuem, Karsten] Moorfields Eye Hosp, London, England.
C3 University of Munich; University of Munich; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust
RP Kortuem, K (通讯作者)，Univ Eye Hosp Munich, Mathildenstr 8, D-80336 Munich, Germany.
EM karsten.kortuem@med.uni-muenchen.de
RI Manakov, Ilja/AAC-4633-2019; Keane, Pearse/AAE-5709-2019
OI Keane, Pearse/0000-0002-9239-745X
FU Novartis; Alcon; National Institute for Health Research; Heidelberg
   Engineering; Topcon; Zeiss; Haag-Streit; Allergan; Bayer; National
   Institute for Health Research [CS-2014-14-023] Funding Source:
   researchfish
FX D.A.S.: Lecture fees - Novartis; Stock/stock options - Big Picture Eye
   Health Ltd.; Travel expenses -Bayer, Allergan.; S.P.: Lecture fees -
   Alcon, Novartis.; P.A.K.: Board member - Novartis, Bayer; Consultant -
   DeepMind, Optos; Employee - University College London; Grants/grants
   pending - National Institute for Health Research; Lecture fees -
   Heidelberg Engineering, Topcon, Zeiss, Haag-Streit, Allergan, Novartis,
   Bayer; Stock/stock options - Big Picture Eye Health; Travel expenses -
   Allergan, Bayer.; K.K.: Consultant - Big Picture Eye Health Ltd., Google
   DeepMind; Grants/grants pending - Bayer, Novartis; Lecture fees - Zeiss,
   Bayer; Travel expenses - Allergan, Zeiss, Novartis, Alcon.
CR Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, pBIO141, DOI 10.1167/iovs.17-21789
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   BREIMAN L, 2001, MACH LEARN, V0045
   Bressler NM, 2013, OPHTHALMOLOGY, V120, P160, DOI 10.1016/j.ophtha.2012.07.027
   Brown DM, 2013, AM J OPHTHALMOL, V155, P429, DOI 10.1016/j.ajo.2012.09.026
   Caixinha M, 2017, CURR EYE RES, V42, P1, DOI 10.1080/02713683.2016.1175019
   Chen T., 2016, PROC 22 ACM SIGKDD I, P785, DOI DOI 10.48550/ARXIV.1603.02754
   Chiu CJ, 2014, OPHTHALMOLOGY, V121, P1421, DOI 10.1016/j.ophtha.2014.01.016
   De Fauw Jeffrey, 2016, F1000Res, V5, P1573
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Drucker H., ICML1997, V97
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrucci DA, 2012, IBM J RES DEV, V56, DOI 10.1147/JRD.2012.2184356
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Gesellschaft DO, 2015, OPHTHALMOLOGE, V112, P237
   Geurts P, 2006, MACH LEARN, V63, P3, DOI 10.1007/s10994-006-6226-1
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Haritoglou C, 2014, RETINA-J RET VIT DIS, V34, P157, DOI 10.1097/IAE.0b013e318295f6de
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Kortum KU, 2017, AM J OPHTHALMOL, V178, P84, DOI 10.1016/j.ajo.2017.03.026
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Massin P, 2010, DIABETES CARE, V33, P2399, DOI 10.2337/dc10-0493
   Oliveira CM, 2011, OPHTHALMOLOGICA, V226, P191, DOI 10.1159/000330285
   Parke DW, 2017, OPHTHALMOLOGE, V114, pS1, DOI 10.1007/s00347-016-0265-1
   Pauleikhoff D, 2013, KLIN MONATSBL AUGENH, V230, P170
   Quartilho A, 2016, EYE, V30, P602, DOI 10.1038/eye.2015.288
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rovner BW, 2014, OPHTHALMOLOGY, V121, P2204, DOI 10.1016/j.ophtha.2014.05.002
   SAMUEL AL, 1959, IBM J RES DEV, V3, P211, DOI 10.1147/rd.33.0210
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Senra H, 2016, GRAEF ARCH CLIN EXP, V254, P1873, DOI 10.1007/s00417-016-3384-0
   Siderov J, 1999, ACTA OPHTHALMOL SCAN, V77, P673, DOI 10.1034/j.1600-0420.1999.770613.x
   Sim DA, 2015, CURR DIABETES REP, V15, DOI 10.1007/s11892-015-0577-6
   Thetford C, 2013, BRIT J VISUAL IMPA, V31, P89, DOI 10.1177/0264619613481778
   Thomas RL, 2015, BRIT J OPHTHALMOL, V99, P64, DOI 10.1136/bjophthalmol-2013-304017
   Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 42
TC 52
Z9 54
U1 6
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2018
VL 125
IS 7
BP 1028
EP 1036
DI 10.1016/j.ophtha.2017.12.034
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GL0DD
UT WOS:000436632700020
PM 29454659
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Inoue, M
   Arakawa, A
   Yamane, S
   Kadonosono, K
AF Inoue, Maiko
   Arakawa, Akira
   Yamane, Shin
   Kadonosono, Kazuaki
TI VARIABLE RESPONSE OF VASCULARIZED PIGMENT EPITHELIAL DETACHMENTS TO
   RANIBIZUMAB BASED ON LESION SUBTYPES, INCLUDING POLYPOIDAL CHOROIDAL
   VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   intravitreal injection; pigment epithelial detachment; ranibizumab
ID MACULAR DEGENERATION; INTRAVITREAL BEVACIZUMAB; NEOVASCULARIZATION;
   CLASSIFICATION; THERAPY; TEARS
AB Purpose: The purpose of this study was to evaluate the prognosis and response to intravitreal ranibizumab (IVR) of neovascular age-related macular degeneration, according to the type of pigment epithelial detachment (PED).
   Methods: The authors prospectively studied 57 eyes of 57 consecutive patients with PED associated with exudative age-related macular degeneration, who were treated by IVR. All patients received 3 consecutive monthly injections of 0.5 mg/0.05 mL of ranibizumab as induction treatment. Retreatment was allowed if evidence of clinical deterioration was noted or spectral domain optical coherence tomography at the 1-month follow-up showed intraretinal edema, subretinal fluid, or recurrent PED. The best-corrected visual acuity (BCVA) values measured before and at 3, 6, and 12 months after the first injection were compared according to the type of PED. Changes in the height of PED to treatment with IVR were also investigated.
   Results: Fifty-six eyes were assessed at the 12-month follow-up examination. There were 4 types of PED, including serous PED in 11 patients (19.6%), fibrovascular PED in 28 patients (50.0%), mixed PED with serous and fibrovascular component in 7 patients (12.5%), and hemorrhagic PED in 10 patients (17.9%). Eyes with serous PED showed significant improvement of the mean logarithm of the minimum angle of resolution (logMAR) BCVA as compared with the value at the baseline, which was sustained throughout the 12-month period (P < 0.05). Regarding the eyes with fibrovascular and mixed PED, significant improvement of the mean logMAR BCVA was observed compared with the value at the baseline at 3 months; however, a slight decrease was observed at 6 and 12 months. In the eyes with hemorrhagic PED, no significant difference in the mean BCVA values compared with the value at the baseline was observed at any follow-up time point. In relation to the height of the PED, all eyes in the serous and mixed PED group, 17 eyes in the fibrovascular PED group (60.7%), and 9 eyes in the hemorrhagic PED group (90.0%) showed reduction of the maximum PED height by 100 mu m or more. The PED response to IVR was not correlated with the final BCVA.
   Conclusion: Intravitreal ranibizumab for the treatment of exudative age-related macular degeneration is effective for stabilizing vision in patients with PED, but it may be better tolerated in patients with serous PED. Although it may be important to consider the type of PED to predict the visual acuity in patients treated by IVR, the anatomical response of the PED may not correlate directly with the visual outcome. RETINA 33: 990-997, 2013
C1 [Inoue, Maiko; Arakawa, Akira; Yamane, Shin; Kadonosono, Kazuaki] Yokohama City Univ, Med Ctr, Dept Ophthalmol, Yokohama, Kanagawa 2320024, Japan.
C3 Yokohama City University
RP Inoue, M (通讯作者)，Yokohama City Univ, Med Ctr, Dept Ophthalmol, Minami Ku, 4-57 Urafune Cho, Yokohama, Kanagawa 2320024, Japan.
EM maicoo@urahp.yokohama-cu.ac.jp
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   Arias L, 2010, CLIN OPHTHALMOL, V4, P369
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   CHISHOLM IH, 1982, BRIT J OPHTHALMOL, V66, P1
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Jonas JB, 2006, J OCUL PHARMACOL TH, V22, P370, DOI 10.1089/jop.2006.22.370
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 17
TC 31
Z9 35
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2013
VL 33
IS 5
BP 990
EP 997
DI 10.1097/IAE.0b013e3182755793
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 131QY
UT WOS:000318011100015
PM 23446653
DA 2022-11-30
ER

PT J
AU Dong, L
   Yang, Q
   Zhang, RH
   Wei, WB
AF Dong, Li
   Yang, Qiong
   Zhang, Rui Heng
   Wei, Wen Bin
TI Artificial intelligence for the detection of age-related macular
   degeneration in color fundus photographs: A systematic review and
   meta-analysis
SO ECLINICALMEDICINE
LA English
DT Review
DE Artificial intelligence; Deep learning; Convolutional neural networks;
   Algorithm; Agerelated macular degeneration
ID DIABETIC-RETINOPATHY; VALIDATION; FEATURES; IMAGES; CLASSIFICATION;
   SEVERITY
AB Background: Age-related macular degeneration (AMD) is one of the leading causes of vision loss in the elderly population. The application of artificial intelligence (AI) provides convenience for the diagnosis of AMD. This systematic review and meta-analysis aimed to quantify the performance of AI in detecting AMD in fundus photographs.
   Methods: We searched PubMed, Embase, Web of Science and the Cochrane Library before December 31st, 2020 for studies reporting the application of AI in detecting AMD in color fundus photographs. Then, we pooled the data for analysis. PROSPERO registration number: CRD42020197532.
   Findings: 19 studies were finally selected for systematic review and 13 of them were included in the quantitative synthesis. All studies adopted human graders as reference standard. The pooled area under the receiver operating characteristic curve (AUROC) was 0.983 (95% confidence interval (CI):0.979-0.987). The pooled sensitivity, specificity, and diagnostic odds ratio (DOR) were 0.88 (95% CI:0.88-0.88), 0.90 (95% CI:0.90-0.91), and 275.27 (95% CI:158.43-478.27), respectively. Threshold analysis was performed and a potential threshold effect was detected among the studies (Spearman correlation coefficient: -0.600, P = 0.030), which was the main cause for the heterogeneity. For studies applying convolutional neural networks in the Age-Related Eye Disease Study database, the pooled AUROC, sensitivity, specificity, and DOR were 0.983 (95% CI:0.978-0.988), 0.88 (95% CI:0.88-0.88), 0.91 (95% CI:0.91-0.91), and 273.14 (95% CI:130.79-570.43), respectively.
   Interpretation: Our data indicated that AI was able to detect AMD in color fundus photographs. The application of AI-based automatic tools is beneficial for the diagnosis of AMD. (C) 2021 The Author(s). Published by Elsevier Ltd.
C1 [Dong, Li; Yang, Qiong; Zhang, Rui Heng; Wei, Wen Bin] Capital Med Univ, Beijing Key Lab Intraocular Tumor Diag & Treatmen, Beijing Ophthalmol & Visual Sci Key Lab,Med Artif, Beijing Tongren Hosp,Beijing Tongren Eye Ctr,Mini, 1 Dong Jiao Min Lane, Beijing 100730, Peoples R China.
C3 Capital Medical University
RP Wei, WB (通讯作者)，Capital Med Univ, Beijing Key Lab Intraocular Tumor Diag & Treatmen, Beijing Ophthalmol & Visual Sci Key Lab,Med Artif, Beijing Tongren Hosp,Beijing Tongren Eye Ctr,Mini, 1 Dong Jiao Min Lane, Beijing 100730, Peoples R China.
EM weiwenbintr@163.com
OI Zhang, Ruiheng/0000-0002-1324-4739
FU Capital Health Research and Development of Special [2020-1-2052]
FX This study was supported by the Capital Health Research and Development
   of Special (2020-1-2052).
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Zapata MA, 2020, CLIN OPHTHALMOL, V14, P419, DOI 10.2147/OPTH.S235751
   Anwar SM, 2018, J MED SYST, V42, DOI 10.1007/s10916-018-1088-1
   Bhuiyan A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.25
   Brereton RG, 2010, ANALYST, V135, P230, DOI 10.1039/b918972f
   Brown JM, 2018, JAMA OPHTHALMOL, V136, P803, DOI 10.1001/jamaophthalmol.2018.1934
   Burlina P, 2011, IEEE ENG MED BIO, P3962, DOI 10.1109/IEMBS.2011.6090984
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Carpenter CR, 2016, ACAD EMERG MED, V23, P963, DOI 10.1111/acem.12984
   Castelvecchi D, 2016, NATURE, V537, P20, DOI 10.1038/538020a
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Glas AS, 2003, J CLIN EPIDEMIOL, V56, P1129, DOI 10.1016/S0895-4356(03)00177-X
   Gonzalez-Gonzalo C, 2020, ACTA OPHTHALMOL, V98, P368, DOI 10.1111/aos.14306
   Govindaiah Arun, 2018, Annu Int Conf IEEE Eng Med Biol Soc, V2018, P702, DOI 10.1109/EMBC.2018.8512379
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kankanahalli S, 2013, INVEST OPHTH VIS SCI, V54, P1789, DOI 10.1167/iovs.12-10928
   Keel S, 2019, CLIN EXP OPHTHALMOL, V47, P1009, DOI 10.1111/ceo.13575
   Keenan TD, 2019, OPHTHALMOLOGY, V126, P1533, DOI 10.1016/j.ophtha.2019.06.005
   Kriegeskorte N, 2019, CURR BIOL, V29, pR231, DOI 10.1016/j.cub.2019.02.034
   KUNUMPOL P, 2017, C PROC IEEE ENG MED, V2017, P1469
   Li ZX, 2018, OPHTHALMOLOGY, V125, P1199, DOI 10.1016/j.ophtha.2018.01.023
   Liew G, 2016, OPHTHALMOLOGY, V123, P1874, DOI 10.1016/j.ophtha.2016.05.043
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Milea D, 2020, NEW ENGL J MED, V382, P1687, DOI 10.1056/NEJMoa1917130
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Mookiah MRK, 2015, COMPUT BIOL MED, V63, P208, DOI 10.1016/j.compbiomed.2015.05.019
   Mookiah MRK, 2014, COMPUT BIOL MED, V53, P55, DOI 10.1016/j.compbiomed.2014.07.015
   Mookiah MRK, 2014, MED BIOL ENG COMPUT, V52, P781, DOI 10.1007/s11517-014-1180-8
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Ragab DA, 2019, PEERJ, V7, DOI 10.7717/peerj.6201
   Rahimy E, 2018, CURR OPIN OPHTHALMOL, V29, P254, DOI 10.1097/ICU.0000000000000470
   SAMUEL AL, 1959, IBM J RES DEV, V3, P211, DOI 10.1147/rd.33.0210
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Phan TV, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/5893601
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P2053, DOI 10.1007/s00417-018-4098-2
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Vaghefi E, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/7493419
   Venhuizen FG, 2017, INVEST OPHTH VIS SCI, V58, P2318, DOI 10.1167/iovs.16-20541
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yoo TK, 2019, MED BIOL ENG COMPUT, V57, P677, DOI 10.1007/s11517-018-1915-z
   Zheng YL, 2012, INVEST OPHTH VIS SCI, V53, P8310, DOI 10.1167/iovs.12-9576
NR 49
TC 11
Z9 11
U1 1
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2589-5370
J9 ECLINICALMEDICINE
JI EClinicalMedicine
PD MAY
PY 2021
VL 35
AR 100875
DI 10.1016/j.eclinm.2021.100875
EA MAY 2021
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA SL2WS
UT WOS:000656780900033
PM 34027334
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Schmid, MK
   Thiel, MA
   Lienhard, K
   Schlingemann, RO
   Faes, L
   Bachmann, LM
AF Schmid, Martin K.
   Thiel, Michael A.
   Lienhard, Kenny
   Schlingemann, Reinier O.
   Faes, Livia
   Bachmann, Lucas M.
TI Reliability and diagnostic performance of a novel mobile app for
   hyperacuity self-monitoring in patients with age-related macular
   degeneration
SO EYE
LA English
DT Article
ID SHAPE-DISCRIMINATION; RANDOMIZED-TRIAL; ACCURACY; DEVICE; ACUITY;
   SYSTEM; HOME
AB Purpose To assess the reliability and the diagnostic performance of a novel CE (European Conformity)-marked and FDA (Food and Drug Administration)-cleared dot patient self-monitoring test (Alleye, Oculocare medical Inc.) for the detection and characterization of metamorphopsia in age-related macular degeneration (AMD).
   Methods Three consecutive tests were performed in 63 wet AMD, 26 dry AMD, and 19 age-matched healthy eyes. In addition, the test was performed in 34 young healthy eyes. The mean Alleye score and standard deviations (SDs) were calculated for each eye and group. We compared and tested healthy with dry and wet AMD eyes and assessed the extent to which the test discriminated between healthy subjects and patients with dry and wet AMD using the area under the receiver operating characteristic curve (AUC).
   Results The mean (SD) Alleye score was 49.5 (16.1) in wet AMD eyes, 62.1 (22.5) in dry AMD eyes, 69.8 (10.2) in age-matched healthy eyes, and 85.3 (10.0) in young healthy subjects. Compared to age-matched healthy subjects, the AUC (95% confidence interval) to detect wet AMD was 0.845 (0.759-0.932), and 0.660 (0.520-0.799) to discriminate between dry and wet AMD. Compared to young healthy subjects, the AUC to detect dry AMD was 0.799 (0.675-0.923), and 0.969 (0.940-0.997) to detect wet AMD.
   Conclusions This is the first assessment of Alleye in clinical practice. The test is highly accurate to detect wet AMD and reasonably accurate to classify dry vs. wet AMD. Data from longitudinal monitoring and its role in the therapeutic management of AMD is warranted.
C1 [Schmid, Martin K.; Thiel, Michael A.; Faes, Livia] Cantonal Hosp Lucerne, Dept Ophthalmol, Luzern, Switzerland.
   [Schmid, Martin K.; Thiel, Michael A.; Bachmann, Lucas M.] Univ Zurich, Fac Med, Zurich, Switzerland.
   [Lienhard, Kenny; Bachmann, Lucas M.] Oculocare Med AG, Zurich, Switzerland.
   [Schlingemann, Reinier O.] Acad Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
   [Faes, Livia] Moorfields Eye Hosp NHS Fdn Trust, Med Retina Dept, London, England.
C3 Lucerne Cantonal Hospital; University of Geneva; University of Zurich;
   University of Amsterdam; Academic Medical Center Amsterdam; University
   of London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust
RP Bachmann, LM (通讯作者)，Univ Zurich, Fac Med, Zurich, Switzerland.; Bachmann, LM (通讯作者)，Oculocare Med AG, Zurich, Switzerland.
EM bachmann@oculocare.com
OI , Lucas/0000-0002-9868-154X
CR AMSLER M, 1947, OPHTHALMOLOGICA, V114, P248, DOI 10.1159/000300476
   Chew EY, 2014, CONTEMP CLIN TRIALS, V37, P294, DOI 10.1016/j.cct.2014.02.003
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Crossland M, 2007, BRIT J OPHTHALMOL, V91, P391, DOI 10.1136/bjo.2006.095315
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   GEISLER WS, 1984, J OPT SOC AM A, V1, P775, DOI 10.1364/JOSAA.1.000775
   Kaiser PK, 2013, RETINA-J RET VIT DIS, V33, P1863, DOI 10.1097/IAE.0b013e3182899258
   Keane PA, 2015, CLIN OPHTHALMOL, V9, P353, DOI 10.2147/OPTH.S59012
   Lienhard KR, 2017, P 13 INT C WIRTSCH W
   Schmid MK, 2018, OPEN OPHTHALMOL J, V12, P19, DOI 10.2174/1874364101812010019
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schwartz Roy, 2015, Int J Retina Vitreous, V1, P20, DOI 10.1186/s40942-015-0022-7
   Simunovic MP, 2015, RETINA-J RET VIT DIS, V35, P1285, DOI 10.1097/IAE.0000000000000581
   Wang YZ, 2013, INVEST OPHTH VIS SCI, V54, P5497, DOI 10.1167/iovs.13-12037
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
   WESTHEIMER G, 1975, INVEST OPHTH VISUAL, V14, P570
NR 17
TC 23
Z9 23
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD OCT
PY 2019
VL 33
IS 10
BP 1584
EP 1589
DI 10.1038/s41433-019-0455-6
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JC8VJ
UT WOS:000489553900011
PM 31043690
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Feigl, B
   Morris, CP
   Voisey, J
   Kwan, A
   Zele, AJ
AF Feigl, Beatrix
   Morris, C. Phillip
   Voisey, Joanne
   Kwan, Anthony
   Zele, Andrew J.
TI The Relationship between BCMO1 Gene Variants and Macular Pigment Optical
   Density in Persons with and without Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID HETEROCHROMATIC FLICKER PHOTOMETRY; LUTEIN SUPPLEMENTATION;
   BETA-CAROTENE; BINDING PROTEIN; VISUAL-ACUITY; ZEAXANTHIN; SERUM; EYE;
   ASSOCIATION; MACULOPATHY
AB Background: Recent evidence indicates that gene variants related to carotenoid metabolism play a role in the uptake of macular pigments lutein (L) and zeaxanthin (Z). Moreover, these pigments are proposed to reduce the risk for advanced age-related macular degeneration (AMD). This study provides the initial examination of the relationship between the gene variants related to carotenoid metabolism, macular pigment optical density (MPOD) and their combined expression in healthy humans and patients with AMD.
   Participants and Methods: Forty-four participants were enrolled from a general population and a private practice including 20 healthy participants and 24 patients with advanced (neovascular) AMD. Participants were genotyped for the three single nucleotide polymorphisms (SNPs) upstream from BCMO1, rs11645428, rs6420424 and rs6564851 that have been shown to either up or down regulate beta-carotene conversion efficiency in the plasma. MPOD was determined by heterochromatic flicker photometry.
   Results: Healthy participants with the rs11645428 GG genotype, rs6420424 AA genotype and rs6564851 GG genotype all had on average significantly lower MPOD compared to those with the other genotypes (p, 0.01 for all three comparisons). When combining BCMO1 genotypes reported to have "high" (rs11645428 AA/rs6420424 GG/rs6564851 TT) and "low" (rs11645428 GG/rs6420424 AA/rs6564851 GG) beta-carotene conversion efficiency, we demonstrate clear differences in MPOD values (p < 0.01). In patients with AMD there were no significant differences in MPOD for any of the three BCMO1 gene variants.
   Conclusion: In healthy participants MPOD levels can be related to high and low beta-carotene conversion BCMO1 genotypes. Such relationships were not found in patients with advanced neovascular AMD, indicative of additional processes influencing carotenoid uptake, possibly related to other AMD susceptibility genes. Our findings indicate that specific BCMO1 SNPs should be determined when assessing the effects of carotenoid supplementation on macular pigment and that their expression may be influenced by retinal disease.
C1 [Feigl, Beatrix; Morris, C. Phillip; Voisey, Joanne; Zele, Andrew J.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia.
   [Feigl, Beatrix; Morris, C. Phillip; Voisey, Joanne] Queensland Univ Technol, Sch Biomed Sci, Brisbane, Qld 4001, Australia.
   [Zele, Andrew J.] Queensland Univ Technol, Sch Optometry & Vis Sci, Brisbane, Qld 4001, Australia.
   [Feigl, Beatrix; Kwan, Anthony] Queensland Eye Inst, Brisbane, Qld, Australia.
   [Kwan, Anthony] Univ Queensland, Fac Hlth Sci, Brisbane, Qld, Australia.
C3 Queensland University of Technology (QUT); Queensland University of
   Technology (QUT); Queensland University of Technology (QUT); Queensland
   Eye Institute; University of Queensland
RP Feigl, B (通讯作者)，Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia.
EM b.feigl@qut.edu.au
OI Zele, Andrew/0000-0003-0291-9929; Feigl, Beatrix/0000-0001-7198-7373;
   Voisey, Joanne/0000-0001-6645-6164; Morris, Phillip/0000-0001-8976-619X
FU QUT ECARD grant
FX The project was funded by a QUT ECARD grant. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Berendschot TT, 2005, EXP EYE RES, V81, P602, DOI 10.1016/j.exer.2005.03.019
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Borel P, 2012, MOL NUTR FOOD RES, V56, P228, DOI 10.1002/mnfr.201100322
   Carroll YL, 1999, EUR J CLIN NUTR, V53, P644, DOI 10.1038/sj.ejcn.1600827
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Connolly EE, 2010, CURR EYE RES, V35, P335, DOI 10.3109/02713680903521951
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P3452, DOI 10.1167/iovs.10-6713
   During A, 2002, J LIPID RES, V43, P1086, DOI 10.1194/jlr.M200068-JLR200
   Feeney J, 2013, NEUROBIOL AGING, V34, P2449, DOI 10.1016/j.neurobiolaging.2013.05.007
   Feigl B, 2012, ARCH OPHTHALMOL-CHIC, V130, P1402, DOI 10.1001/archophthalmol.2012.1940
   Feigl B, 2011, INVEST OPHTH VIS SCI, V52, P1145, DOI 10.1167/iovs.10-5967
   Hammond BR, 2013, INVEST OPHTH VIS SCI, V54, P476, DOI 10.1167/iovs.12-10411
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Hammond CJ, 2012, INVEST OPHTH VIS SCI, V53, P4963, DOI 10.1167/iovs.12-9618
   Howells O, 2013, INVEST OPHTH VIS SCI, V54, P2211
   Kaya S, 2012, ACTA OPHTHALMOL, V90, pe399, DOI 10.1111/j.1755-3768.2012.02423.x
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   KOSTIC D, 1995, AM J CLIN NUTR, V62, P604, DOI 10.1093/ajcn/62.3.604
   Kvansakul J, 2006, OPHTHAL PHYSL OPT, V26, P362, DOI 10.1111/j.1475-1313.2006.00387.x
   Li BX, 2011, BIOCHEMISTRY-US, V50, P2541, DOI 10.1021/bi101906y
   Lietz G, 2012, J NUTR, V142, p161S, DOI 10.3945/jn.111.140756
   Liew SHM, 2005, INVEST OPHTH VIS SCI, V46, P4430, DOI 10.1167/iovs.05-0519
   Loane E, 2011, EXP EYE RES, V93, P592, DOI 10.1016/j.exer.2011.07.005
   Loughman J, 2010, VISION RES, V50, P1249, DOI 10.1016/j.visres.2010.04.009
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Meyers KJ, 2013, INVEST OPHTH VIS SCI, DOI [10.1167/iovs.13-13216, DOI 10.1167/I0VS.13-13216.[]
   Meyers KJ, 2013, INVEST OPHTH VIS SCI, V54, P2333, DOI [10.1167/iovs.12-10867, 10.1167/iovs.13-13216]
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Nolan JM, 2011, VISION RES, V51, P459, DOI 10.1016/j.visres.2010.12.016
   Nolan JM, 2010, OPHTHALMIC RES, V44, P131, DOI 10.1159/000315531
   Obana A, 2008, OPHTHALMOLOGY, V115, P147, DOI 10.1016/j.ophtha.2007.02.028
   Ott J., 1988, UTILITY PROGRAMS ANA
   Quaggin SE, 2012, J CLIN INVEST, V122, P3849, DOI 10.1172/JCI65509
   Raman R, 2012, EYE, V26, P950, DOI 10.1038/eye.2012.69
   Renzi LM, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-33
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rodriguez-Carmona M, 2006, OPHTHAL PHYSL OPT, V26, P137, DOI 10.1111/j.1475-1313.2006.00386.x
   Rosenthal JM, 2006, INVEST OPHTH VIS SCI, V47, P5227, DOI 10.1167/iovs.05-1513
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   Stringham JM, 2008, EXP EYE RES, V87, P445, DOI 10.1016/j.exer.2008.08.005
   Thurnham DI, 2007, NUTR RES REV, V20, P163, DOI 10.1017/S0954422407842235
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Vachali PP, 2013, ARCH BIOCHEM BIOPHYS, V539, P181, DOI 10.1016/j.abb.2013.07.008
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   Yonova-Doing E, 2013, EXP EYE RES, V115, P172, DOI 10.1016/j.exer.2013.07.020
NR 56
TC 12
Z9 12
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 19
PY 2014
VL 9
IS 2
AR e89069
DI 10.1371/journal.pone.0089069
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AB3TA
UT WOS:000331711900083
PM 24586510
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Barbosa, BRD
   Barbosa, SF
   Tavares, GD
   Chacra, NAB
   Pinto, TDA
AF Dutra Barbosa, Bruna Renata
   Barbosa, Savio Fujita
   Tavares, Guilherme Diniz
   Bou Chacra, Nadia Araci
   Andreoli Pinto, Terezinha de Jesus
TI Critical evaluation of the off-label indication and of the risks
   associated to the use of multi-dose vials on the treatment of
   age-related macular degeneration
SO BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Age-related macular degeneration/treatment; Ranibizumab/intravitreal
   injection; Bevacizumab/intravitreal injection; Ophthalmic
   therapy/off-label use; Off-label indication/patients risks; Multi-dose
   vials/patients risks
ID INTRAVITREAL BEVACIZUMAB AVASTIN; ANTITUMOR NECROSIS FACTOR; CONCOMITANT
   METHOTREXATE; ACUTE ENDOPHTHALMITIS; RHEUMATOID-ARTHRITIS;
   MONOCLONAL-ANTIBODY; SERRATIA-MARCESCENS; OUTBREAK; RANIBIZUMAB;
   CONTAMINATION
AB Age-related macular degeneration (AMD) is an ocular inflammatory diseases treated mainly by means of a bevacizumab (Avastin (R)) or ranibizumab (Lucentis (R)) intravitreal injection. Among these drugs, only ranibizumab has a specific therapeutic indication for AMD. Considering that, the off-label use on ophthalmic therapy seems to become a rule when it should be an exception. Furthermore, bevacizumab presentation consists of multi-dose vials although it does not contain preservatives in its formula. The current literature review aimed at assessing the risks for the patient related to the use of off-label indication and multi-dose vials on AMD treatment. Considering this, the proposal related to the Brazilian Public Consultation no. 10, dated September 12, 2012, which proposes the Clinical Protocol and Therapeutic Guidelines for AMD treatment, was evaluated. This systematic review allowed to conclude that the bevacizumab off-label indication results in increased risks for the patient when compared to the product with specific therapeutic indication for AMD treatment (ranibizumab), especially referring to the significant raise in the adverse events. The risks for the patient related to the multi-dose vial use, referring to the microbiological stability and dose precision, were also made clear.
C1 [Dutra Barbosa, Bruna Renata] Fac Oswaldo Cruz, Fac Pharmaceut Sci, Sao Paulo, Brazil.
   [Barbosa, Savio Fujita; Tavares, Guilherme Diniz; Bou Chacra, Nadia Araci; Andreoli Pinto, Terezinha de Jesus] Univ Sao Paulo, Fac Pharmaceut Sci, Dept Pharm, BR-05508000 Sao Paulo, Brazil.
C3 Fundacao Oswaldo Cruz; Universidade de Sao Paulo
RP Barbosa, SF (通讯作者)，Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Farm, Av Prof Lineu Prestes 580, BR-05508000 Sao Paulo, Brazil.
EM savio.barbosa@usp.br
RI de Jesus Andreoli Pinto, Terezinha/AAR-2389-2020; Tavares,
   Guilherme/AAQ-7583-2020; Pinto, Terezinha JA/C-4777-2012
OI de Jesus Andreoli Pinto, Terezinha/0000-0002-0238-8227; Tavares,
   Guilherme/0000-0001-6276-0994
CR [Anonymous], 2010, FARMACOPEIA BRASILEI, V5a
   [Anonymous], 2000, REMINGTON SCI PRACTI
   [Anonymous], 2012, B FARMACOVIGILANCIA, V1, P1
   [Anonymous], 2012, CONSULTA PUBLICA
   Artunay O, 2009, EYE, V23, P2187, DOI 10.1038/eye.2009.7
   AVIS K. E., 2000, REMINGTON SCI PRACTI, P780
   Bevacizunabe AVASTIN, 2011, RESP TECN GN FERR
   BRASIL, CONSULTA PUBLICA
   BRASIL. Ministerio da Saude. Agencia Nacional de Vigilancia Sanitaria, 2005, REG MED COM ANV US O
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2004, EXPERT OPIN BIOL TH, V4, P1395, DOI 10.1517/14712598.4.9.1395
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Dade J, 2000, LANCET, V356, P1684, DOI 10.1016/S0140-6736(05)70390-1
   Di Paolo Ermindo R, 2006, Swiss Med Wkly, V136, P218
   dos Santos R.V., 2006, REV BRAS ALERG IMUNO, V29, P77
   Ellis LM, 2006, SEMIN ONCOL, V33, pS1, DOI 10.1053/j.seminoncol.2006.08.002
   GARFINKLE B. D., 2000, REMINGTON SCI PRACTI, P753
   Goldberg RA, 2012, AM J OPHTHALMOL, V153, P204, DOI 10.1016/j.ajo.2011.11.035
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Henry B, 2001, AM J INFECT CONTROL, V29, P312, DOI 10.1067/mic.2001.117043
   Kahook MY, 2010, RETINA-J RET VIT DIS, V30, P887, DOI 10.1097/IAE.0b013e3181d50cea
   Kirschke DL, 2003, CLIN INFECT DIS, V36, P1369, DOI 10.1086/375064
   Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431
   Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, CLIN EXP OPHTHALMOL, V39, P718, DOI 10.1111/j.1442-9071.2011.02703.x
   Mattner F, 2004, AM J INFECT CONTROL, V32, P12, DOI 10.1016/j.ajic.2003.06.004
   MELNYK PS, 1993, ANN PHARMACOTHER, V27, P274, DOI 10.1177/106002809302700302
   Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113
   MORO ML, 1990, INFECT CONT HOSP EP, V11, P27, DOI 10.1086/646075
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   NAKASHIMA AK, 1987, J CLIN MICROBIOL, V25, P1019, DOI 10.1128/JCM.25.6.1019-1021.1987
   Neubert A, 2004, DRUG SAFETY, V27, P1059, DOI 10.2165/00002018-200427130-00006
   PATEL H., 2007, BMC CLIN PHARM, V7, P1
   Radley DC, 2006, ARCH INTERN MED, V166, P1021, DOI 10.1001/archinte.166.9.1021
   Ranibizumabe LUCENTIS, 2011, RESP TECN VIRG SILV
   Ranpura V, 2010, AM J HYPERTENS, V23, P460, DOI 10.1038/ajh.2010.25
   REGATIERI C., 2010, RETINA VITREO, V21, P5
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   Scartozzi M, 2009, ANN ONCOL, V20, P227, DOI 10.1093/annonc/mdn637
   Thomas K., 2012, NY TIMES
   UNITED STATE, US REINST US INTR AV
   UNITED STATES. Department of Justice. Office of Public Affairs, 2012, US PHARM CO MERCK SH
   UNITED STATES. Department of Justice. Office of Public Affairs, 2012, ABB LABS PAY 1 5 BIL
   UNITED States Pharmacopeia, 2012, US PHARM USP35
   Weinblatt ME, 2003, ARTHRITIS RHEUM-US, V48, P35, DOI 10.1002/art.10697
   Wiens A, 2010, PHARMACOTHERAPY, V30, P339, DOI 10.1592/phco.30.4.339
NR 51
TC 1
Z9 1
U1 0
U2 4
PU UNIV SAO PAULO, CONJUNTO QUIMICAS
PI SAO PAULO
PA SERVICO PUBLICACOES E CIRCULACAO, CAIXA POSTAL 66083, SAO PAULO, 00000,
   BRAZIL
SN 1984-8250
EI 2175-9790
J9 BRAZ J PHARM SCI
JI Braz. J. Pharm. Sci.
PD JAN-MAR
PY 2014
VL 50
IS 1
BP 63
EP 72
DI 10.1590/S1984-82502011000100006
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AH5CW
UT WOS:000336147100006
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Arrigo, A
   Aragona, E
   Di Nunzio, C
   Bandello, F
   Parodi, MB
AF Arrigo, Alessandro
   Aragona, Emanuela
   Di Nunzio, Carlo
   Bandello, Francesco
   Parodi, Maurizio Battaglia
TI Quantitative Optical Coherence Tomography Angiography Parameters in Type
   1 Macular Neovascularization Secondary to Age-Related Macular
   Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; optical coherence tomography (OCT);
   optical coherence tomography angiography (OCTA); macular
   neovascularization (MNV); vessel density; vessel tortuosity; vessel
   dispersion
AB Purpose: The purpose of this paper was to study type 1 macular neovascularization (MNV) quantitative optical coherence tomography (OCT) angiography (OCTA) features by means of advanced postprocessing analyses.
   Methods: We recruited patients affected by naive type 1 MNV secondary to agerelated macular degeneration (AMD) and age-matched controls. All patients underwent ophthalmologic examination and multimodal imaging. They were treated with pro-re-nata anti-VEGF injections. The ensuing follow-up lasted 24 months. Quantitative OCT and OCTA parameters were statistically analyzed to obtain cutoff values able to distinguish two clinically different patient subgroups. Main outcome measures were best-corrected visual acuity (BCVA), central macular thickness, vessel density of superficial, deep and choriocapillaris plexa, vessel tortuosity (VT) of MNV, vessel dispersion of MNV, number of injections, blooding, pigment epithelium detachment, subretinal fluid, photoreceptor elongation, subretinal fibrosis, and outer retinal atrophy.
   Results: Ninety-one eyes (91 patients; 49 men; mean age 78 +/- 7 years) and 91 control eyeswere included. Mean logarithm of the minimum angle of resolution (logMAR) BCVA was 0.46 +/- 0.56 at baseline, increasing up to 0.29 +/- 0.30 after 2 years of treatment (P < 0.01). The mean number of intravitreal injections was 7.1 +/- 2.0 during the first year and 4.5 +/- 1.4 during the second year. A baseline VT cutoff of 8.40 detected two patients' subgroups differing significantly in terms of BCVA improvement after 2 years of treatment.
   Conclusions: OCTA-based classification of type 1MNV, performed at baseline, provided useful information in terms of the functional outcome achievable after 24 months of anti-VEGF treatment.
   Translational Relevance: Quantitative OCTA-based classification of type 1 MNV, performed at baseline, provided useful information in terms of the functional outcome achievable after 24 months of anti-VEGF treatment.
C1 [Arrigo, Alessandro; Aragona, Emanuela; Di Nunzio, Carlo; Bandello, Francesco; Parodi, Maurizio Battaglia] Univ Vita Salute San Raffaele, IRCCS San Raffaele Hosp, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Arrigo, A (通讯作者)，Univ Vita Salute San Raffaele, IRCCS San Raffaele Hosp, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
EM alessandro.arrigo@hotmail.com
OI Battaglia Parodi, Maurizio/0000-0002-0385-7961; Di Nunzio,
   Carlo/0000-0003-1280-6856; bandello, francesco/0000-0003-3238-9682
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Arganda-Carreras I, 2010, MICROSC RES TECHNIQ, V73, P1019, DOI 10.1002/jemt.20829
   Arrigo A, 2020, RETINA-J RET VIT DIS, V40, P2263, DOI 10.1097/IAE.0000000000002775
   Arrigo A, 2018, AM J OPHTHALMOL, V195, P233, DOI 10.1016/j.ajo.2018.08.001
   *BRIT STAND I, 1979, 5497 BS BSI 1
   Coscas F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205513
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Goldman D, 2000, J THEOR BIOL, V206, P181, DOI 10.1006/jtbi.2000.2113
   Grisan E, 2008, IEEE T MED IMAGING, V27, P310, DOI 10.1109/TMI.2007.904657
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Konerding MA, 1999, BRIT J CANCER, V80, P724, DOI 10.1038/sj.bjc.6690416
   LIU ZQ, 1991, APPL OPTICS, V30, P1369, DOI 10.1364/AO.30.001369
   Manikandan S, 2011, J PHARMACOL PHARMACO, V2, P315, DOI 10.4103/0976-500X.85931
   Mrejen S, 2019, RETINA-J RET VIT DIS, V39, P1973, DOI 10.1097/IAE.0000000000002244
   Righi M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35788-4
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Tomita Y, 2005, J CEREBR BLOOD F MET, V25, P858, DOI 10.1038/sj.jcbfm.9600077
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
NR 20
TC 10
Z9 10
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD AUG
PY 2020
VL 9
IS 9
AR 48
DI 10.1167/tvst.9.9.48
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OH9SL
UT WOS:000582929100048
PM 32934898
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hoffmann, L
   Hatz, K
AF Hoffmann, Laura
   Hatz, Katja
TI External Limiting Membrane Disruption Predicts Long-Term Outcome in
   Strict Treat-And-Extend Regimen in Neovascular Age-Related Macular
   Degeneration
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE AMD; predictor; treat-and-extend; external limiting membrane; anti-VEGF;
   long-term
ID ANTI-VEGF THERAPY; INTRAVITREAL AFLIBERCEPT; VISUAL OUTCOMES;
   RANIBIZUMAB; ACUITY; EDEMA; EYES
AB The use of anti-vascular-endothelial growth factor agents for neovascular age-related macular degeneration (nAMD) in different treatment schemes is widely common in clinical practice. However, there is currently limited data on the long-term outcomes of a strict treat-and-extend regimen (TER) and imaging biomarkers to predict both functional outcome and the potential for a TER exit due to success. In this retrospective study we followed treatment-naive subjects with nAMD starting treatment with either ranibizumab or aflibercept in a TER without loading dose but with predefined exit criteria for up to 8 years. We evaluated both the functional outcome and several spectral-domain optical coherence tomography parameters in a follow-up mode using a standardized protocol. Within the 211 eyes followed for a mean of 60.3 +/- 20.9 months, follow-up adherence was high with major part of discontinuations of TER being due to success. Mean best-corrected visual acuity (BCVA) increased from initially 63.9 +/- 15.5 ETDRS letters to 70.0 +/- 14.7 after 1 year (+6.1 letters, p < 0.001) and to 68.5 +/- 18.1 (+4.6 letters, p = 0.028) at 5 years. A worse BCVA (p = 0.001) and a better external limiting membrane (ELM) disruption score at baseline predicted (p = 0.019) BCVA gain at 5 years. The probability of reaching the exit criteria was significantly associated with a better ELM disruption score (p = 0.044) and the absence of a central pigment epithelial detachment (PED) (p = 0.05) at baseline. Significant visual gains were sustained in a long-term TER in a real-world setting. Integrity of ELM at baseline predicted BCVA gain at 5 years and the potential for TER exit due to success.
C1 [Hoffmann, Laura; Hatz, Katja] Vista Augenldin Binningen, Dept Ophthalmol, Binningen, Switzerland.
   [Hatz, Katja] Univ Basel, Fac Med, Basel, Switzerland.
C3 University of Basel; University of Geneva
RP Hatz, K (通讯作者)，Vista Augenldin Binningen, Dept Ophthalmol, Binningen, Switzerland.; Hatz, K (通讯作者)，Univ Basel, Fac Med, Basel, Switzerland.
EM katja.hatz@vista.ch
FU Bayer Switzerland AG; Bayer Switzerland; Novartis Switzerland; Alcon;
   Allergan; Roche
FX Publication fee funding was provided by Bayer Switzerland AG. Bayer
   Switzerland had no influence on the study or the content of the
   manuscript. KH has received financial compensation from Novartis
   Switzerland, Bayer Switzerland, Alcon, Allergan and Roche for
   consultancies and contract research.
CR Arendt P, 2019, RETINA-J RET VIT DIS, V39, P27, DOI 10.1097/IAE.0000000000001923
   Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Coscas F, 2015, INVEST OPHTH VIS SCI, V56, P4129, DOI 10.1167/iovs.15-16735
   Eandi CM, 2005, RETINA-J RET VIT DIS, V25, P417, DOI 10.1097/00006982-200506000-00004
   Giannakaki-Zimmermann H, 2021, OPHTHALMIC RES, V64, P465, DOI 10.1159/000514721
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Haddad WM, 2017, RETINA-J RET VIT DIS, V37, P951, DOI 10.1097/IAE.0000000000001282
   Hatz K, 2018, OPHTHALMOLOGICA, V239, P205, DOI 10.1159/000485852
   Hatz K, 2017, RETINA-J RET VIT DIS, V37, P1185, DOI 10.1097/IAE.0000000000001318
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Hatz K, 2016, BRIT J OPHTHALMOL, V100, P1341, DOI 10.1136/bjophthalmol-2015-307299
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jaggi D, 2022, BRIT J OPHTHALMOL, V106, P246, DOI 10.1136/bjophthalmol-2020-316514
   Kaiser PK, 2017, OPHTHALMOL RETINA, V1, P304, DOI 10.1016/j.oret.2017.01.004
   Khanani AM, 2019, CLIN OPHTHALMOL, V13, P347, DOI 10.2147/OPTH.S191170
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mekjavic PJ, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00125
   Mrejen S, 2015, J CLIN MED, V4, P1380, DOI 10.3390/jcm4071380
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P435, DOI 10.1007/s00417-012-2034-4
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Yamaike N, 2008, OPHTHALMOLOGY, V115, P355, DOI 10.1016/j.ophtha.2007.04.052
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zandi S, 2017, OSLI RETINA, V48, P326, DOI 10.3928/23258160-20170329-07
   Zhang XY, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9640131
NR 31
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD SEP 3
PY 2021
VL 8
AR 706084
DI 10.3389/fmed.2021.706084
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA UR1RW
UT WOS:000696533800001
PM 34540863
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Rim, TH
   Yoo, TK
   Kim, SH
   Kim, DW
   Kim, SS
AF Rim, Tyler Hyungtaek
   Yoo, Tae Keun
   Kim, Seo Hee
   Kim, Dong Wook
   Kim, Sung Soo
TI Incidence of exudative age-related macular degeneration and treatment
   load under the Korean national health insurance system in 2010-2015
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RISK; PROGRESSION; STROKE; OCCLUSION
AB Background/Aim The aim of this study was to estimate the nationwide incidence of clinically diagnosed exudative age-related macular degeneration (AMD) and associated use of ranibizumab and aflibercept in South Korea.
   Methods In this retrospective, population-based cohort study, claims data for 2010-2015 were analysed in a randomly selected sample of 519 661 adults aged >= 40 years. The incidence per 10 000 person-years was estimated, along with the 95% CI. Incident exudative AMD was defined based on the registration code for rare intractable diseases. Use of ranibizumab and aflibercept and the incidence of exudative AMD were recorded.
   Results Nine hundred and twelve patients were newly diagnosed with exudative AMD in 2010-2015. The 6-year incidence in the general population aged >= 40 years was 2.9 (95% CI 2.8 to 3.0) per 10 000 person-years. The incidence was highest in individuals aged 75-79 years (12.0, 95% CI 10.3 to 13.8). The incidence was higher in men than in women in all age groups. Six hundred and twenty-five (69%) of the 912 newly diagnosed patients started ranibizumab or aflibercept as a first-line treatment. The average number of injections administered was 6.1 (SD 3.9; minimum of 1 injection and maximum government-supported limit of 14) during 2010-2015; the number increased with increasing government funding support (from 5 to 10 and from 10 to 14 in 2013 and 2014, respectively).
   Conclusions This study describes the incidence of exudative AMD in South Korea and its treatment under the national health insurance system in this country. Its findings could be used for reference purposes and be useful when planning treatment for exudative AMD.
C1 [Rim, Tyler Hyungtaek; Yoo, Tae Keun; Kim, Seo Hee; Kim, Sung Soo] Yonsei Univ, Inst Vis Res, Severance Hosp, Dept Ophthalmol,Coll Med, Seoul 03722, South Korea.
   [Kim, Dong Wook] Natl Hlth Insurance Serv Ilsan Hosp, Dept Policy Res Affairs, Goyang, South Korea.
C3 Yonsei University; Yonsei University Health System; National Health
   Insurance Service
RP Kim, SS (通讯作者)，Yonsei Univ, Inst Vis Res, Severance Hosp, Dept Ophthalmol,Coll Med, Seoul 03722, South Korea.
EM semekim@yuhs.ac
RI Yoo, Tae Keun/Q-3620-2019
OI Yoo, Tae Keun/0000-0003-0890-8614; Rim, Tyler
   Hyungtaek/0000-0001-6465-2620; Kim, Sung Soo/0000-0002-0574-7993
FU Yonsei University College of Medicine [6-2017-0089]
FX This study was supported by a faculty research grant from Yonsei
   University College of Medicine in 2017 (6-2017-0089).
CR Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1305, DOI 10.1016/j.ophtha.2017.03.056
   Fisher DE, 2016, OPHTHALMOLOGY, V123, P1297, DOI 10.1016/j.ophtha.2015.12.026
   Geirsdottir A, 2012, BRIT J OPHTHALMOL, V96, P444, DOI 10.1136/bjophthalmol-2011-300304
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lee AY, 2018, BRIT J OPHTHALMOL, V102, P465, DOI 10.1136/bjophthalmol-2017-310939
   Lee J, 2017, INT J EPIDEMIOL, V46, DOI 10.1093/ije/dyv319
   Park SJ, 2015, OPHTHALMOLOGY, V122, P2063, DOI 10.1016/j.ophtha.2015.06.018
   Rim TH, 2017, BRIT J OPHTHALMOL, V101, P1367, DOI 10.1136/bjophthalmol-2016-309952
   Rim TH, 2016, RETINA-J RET VIT DIS, V36, P2166, DOI 10.1097/IAE.0000000000001084
   Rim TH, 2016, STROKE, V47, P376, DOI 10.1161/STROKEAHA.115.010828
   Rim TH, 2015, OPHTHALMOLOGY, V122, P1187, DOI 10.1016/j.ophtha.2015.01.020
   Varma R, 2010, AM J OPHTHALMOL, V149, P741, DOI 10.1016/j.ajo.2010.01.009
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
NR 16
TC 3
Z9 3
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2019
VL 103
IS 10
BP 19
EP 24
DI 10.1136/bjophthalmol-2018-312693
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JZ5SV
UT WOS:000505163800003
PM 30573498
DA 2022-11-30
ER

PT J
AU Constable, IJ
   Lai, CM
   Magno, AL
   French, MA
   Barone, SB
   Schwartz, SD
   Blumenkranz, MS
   Degli-Esposti, MA
   Rakoczy, EP
AF Constable, Ian J.
   Lai, Chooi-May
   Magno, Aaron L.
   French, Martyn A.
   Barone, Samuel B.
   Schwartz, Steven D.
   Blumenkranz, Mark S.
   Degli-Esposti, Mariapia A.
   Rakoczy, Elizabeth P.
TI Gene Therapy in Neovascular Age-related Macular Degeneration: Three-Year
   Follow-up of a Phase 1 Randomized Dose Escalation Trial
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ANTI-VEGF DRUGS; CHOROIDAL NEOVASCULARIZATION; OCULAR
   NEOVASCULARIZATION; TREATMENT PATTERNS; SYSTEMIC SAFETY; RANIBIZUMAB;
   INHIBITION; OUTCOMES; HORIZON; EVENTS
AB PURPOSE: To assess the safety of rAAV.sFlt-1 subretinal injection in neovascular age-related macular degeneration (wet AMD) over 36 months.
   DESIGN: Phase 1 dose escalation trial.
   METHODS: Eight subjects with advanced, treatment experienced wet AMD were randomly assigned (3:1) to treatment and non gene therapy control groups. Eligible subjects were 65 years, had wet AMD, and had best corrected visual acuity (BCVA) 10/200 to 20/80 in the study eye and 20/200 or better in the other eye. Three of the treatment group subjects received low-dose (1 x 10(10) vector genomes) and 3 high-dose (1 x 10(11) vector genomes) rAAV.sFLT-1 via subretinal injection. Study monitoring was monthly to the primary endpoint at month 12 and then protocol-driven follow-up study visits were conducted at months 18 and 36. All subjects received intravitreal ranibizumab at baseline and at week 4, and retreatment injections at subsequent visits based on prespecified criteria for active wet AMD. The primary endpoint was ocular and systemic safety, but exploratory data including BCVA, retinal center point thickness, and the number of ranibizumab retreatments at and between study visits were also analyzed.
   RESULTS: Six of the 8 subjects completed the 36-month study. Subretinal injection with pars plana vitrectomy was well tolerated in this cohort. No ocular or systemic safety signals were observed during the long-term follow-up period. Exploratory data analysis suggests stability of wet AMD over the 36-month period.
   CONCLUSIONS: Subretinal delivery of rAAV.sFLT-1 was well tolerated and demonstrated a favourable safety profile through month 36. Thus, rAAV.sFLT-1 could be safely considered for future evaluation in the treatment of wet AMD. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Constable, Ian J.; Lai, Chooi-May; Magno, Aaron L.; Degli-Esposti, Mariapia A.; Rakoczy, Elizabeth P.] Lions Eye Inst, Nedlands, WA, Australia.
   [Constable, Ian J.; Lai, Chooi-May; Degli-Esposti, Mariapia A.; Rakoczy, Elizabeth P.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Crawley, WA, Australia.
   [French, Martyn A.] Univ Western Australia, Sch Pathol & Lab Med, Crawley, WA, Australia.
   [Constable, Ian J.] Sir Charles Gairdner Hosp, Nedlands, WA, Australia.
   [French, Martyn A.] Royal Perth Hosp, Dept Clin Immunol, Perth, WA, Australia.
   [French, Martyn A.] PathWest Lab Med, Perth, WA, Australia.
   [Barone, Samuel B.] Adverum Biotechnol Inc, Menlo Pk, CA USA.
   [Schwartz, Steven D.] Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90024 USA.
   [Blumenkranz, Mark S.] Stanford Univ, Sch Med, Byers Eye Inst, Palo Alto, CA 94304 USA.
C3 Lions Eye Institute; University of Western Australia; University of
   Western Australia; University of Western Australia; University of
   Western Australia; Royal Perth Hospital; University of Western
   Australia; University of Western Australia; University of California
   System; University of California Los Angeles; Stanford University
RP Rakoczy, EP (通讯作者)，Lions Eye Inst, Mol Ophthalmol, 2 Verdun St, Nedlands, WA 6009, Australia.
EM Elizabeth.rakoczy@uwa.edu.au
RI Lai, Chooi-May/H-5224-2014
OI Degli-Esposti, Mariapia/0000-0002-7808-5935; French,
   Martyn/0000-0002-4644-1982; constable, ian/0000-0002-2140-6478; Magno,
   Aaron/0000-0001-6099-819X
FU LIONS EYE INSTITUTE (PERTH, AUSTRALIA); National Health and Medical
   Research Council of Australia [AP1010405]
FX FUNDING/SUPPORT: THIS WORK WAS FUNDED BY THE LIONS EYE INSTITUTE (PERTH,
   AUSTRALIA), ADVERUM BIOTECHNOLogies, Inc (Menlo Park, California, USA),
   and the National Health and Medical Research Council of Australia (Grant
   No: AP1010405). Adverum Biotechnologies, Inc has no role in the design
   of trial but participated in the data management and data analysis of
   the manuscript. The contribution of the other 2 funding sources was only
   financial.
CR Asokan A, 2012, MOL THER, V20, P699, DOI 10.1038/mt.2011.287
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Lai CM, 2012, GENE THER, V19, P999, DOI 10.1038/gt.2011.169
   Lai CM, 2009, INVEST OPHTH VIS SCI, V50, P4279, DOI 10.1167/iovs.08-3253
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lai YKY, 2002, GENE THER, V9, P804, DOI 10.1038/sj.gt.3301695
   Lebherz C, 2005, DIABETES, V54, P1141, DOI 10.2337/diabetes.54.4.1141
   Lebherz C, 2008, J GENE MED, V10, P375, DOI 10.1002/jgm.1126
   Lim LS, 2011, AM J OPHTHALMOL, V152, P329, DOI 10.1016/j.ajo.2011.05.040
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Qualls LG, 2013, RETINA-J RET VIT DIS, V33, P854, DOI 10.1097/IAE.0b013e31826f065e
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scott LJ, 2015, EXPERT OPIN DRUG SAF, V14, P379, DOI 10.1517/14740338.2015.991712
   Semeraro F, 2014, EXPERT OPIN DRUG SAF, V13, P785, DOI 10.1517/14740338.2014.911284
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Ueta T, 2014, OPHTHALMOLOGY, V121, P2193, DOI 10.1016/j.ophtha.2014.05.022
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 37
TC 44
Z9 48
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2017
VL 177
BP 150
EP 158
DI 10.1016/j.ajo.2017.02.018
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EU3TS
UT WOS:000400954500021
PM 28245970
DA 2022-11-30
ER

PT J
AU Callaghan, T
   Margrain, TH
   Binns, AM
AF Callaghan, Tamsin
   Margrain, Tom H.
   Binns, Alison M.
TI The Effect of Systemic Hyperoxia and Hypoxia on Scotopic Thresholds in
   People with Early and Intermediate Age-related Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; hyperoxia; hypoxia; scotopic
   thresholds; visual function
ID MEDIATED DARK-ADAPTATION; FELLOW EYE; NEOVASCULAR MEMBRANES; CHROMATIC
   SENSITIVITY; CONTRAST SENSITIVITY; OXIDATIVE STRESS; BRUCHS MEMBRANE;
   RETINAL OXYGEN; GROWTH-FACTORS; IMPAIRMENT
AB Purpose: Morphological retinal changes combined with functional evidence implicate hypoxia in the pathogenesis of age-related macular degeneration (AMD). However, the role of hypoxia in the scotopic threshold deficit reported in AMD has not been investigated. This study compared scotopic thresholds in participants with early and intermediate AMD recorded under conditions of systemic hypoxia, hyperoxia and normoxia. Materials and Methods: Over two sessions scotopic thresholds were measured with participants breathing 21% and 60% oxygen (n = 12 early AMD, n = 11 age-similar controls) or 21% and 14% oxygen (n = 16 early AMD, n = 20 age-similar controls). Thresholds were measured using a 'white', annular 12 degrees stimulus, using a QUEST procedure. Results: There was no statistically significant change in scotopic thresholds within the AMD or control group when breathing the hyperoxic gas mixture (60% oxygen) or the hypoxic gas mixture (14% oxygen) when compared to the normoxic condition (21% oxygen). There was also no statistically significant difference in scotopic thresholds between groups under the hyperoxic or hypoxic gas conditions. The difference between groups under the normoxic condition was not statistically significant for the hyperoxia study (p = .70), but did reach significance in the hypoxia study (p = .05). Conclusion: This study provided no evidence that breathing that breathing 14% or 60% oxygen altered scotopic thresholds in those with early AMD when compared to controls. However, the lack of elevated scotopic thresholds in the AMD group of the hyperoxia study is of note, as it is unlikely that hyperoxia would reduce thresholds which were not significantly raised at baseline, regardless of whether hypoxia was a factor in the disease pathogenesis. The findings of this study do not rule out a role for hypoxia in early AMD, but this needs to be assessed in future experiments using measures that differ significantly between people with AMD and controls.
C1 [Callaghan, Tamsin; Binns, Alison M.] City Univ London, Sch Hlth Sci, Northampton Sq, London EC1V 0HB, England.
   [Margrain, Tom H.] Cardiff Univ, Cardiff Ctr Vis Sci, Cardiff, Wales.
C3 City University London; Cardiff University
RP Binns, AM (通讯作者)，City Univ London, Sch Hlth Sci, Northampton Sq, London EC1V 0HB, England.
EM Alison.binns.1@city.ac.uk
OI Callaghan, Tamsin/0000-0002-9258-8504
FU Cardiff University Endowment Fund
FX This research received no specific grant from any funding agency in the
   public, commercial, or not-for-profit sectors. The project was funded by
   the Cardiff University Endowment Fund.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Anderson AJ, 2003, VISION RES, V43, P165, DOI 10.1016/S0042-6989(02)00396-6
   Arden GB, 2004, BRIT J OPHTHALMOL, V88, P1180, DOI 10.1136/bjo.2003.033480
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   Bunce C, 2015, PUBLIC HEALTH, V129, P138, DOI 10.1016/j.puhe.2014.12.018
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Connolly DM, 2008, VISION RES, V48, P281, DOI 10.1016/j.visres.2007.11.006
   Connolly DM, 2008, INVEST OPHTH VIS SCI, V49, P820, DOI 10.1167/iovs.07-1004
   Connolly DM, 2006, VISION RES, V46, P1784, DOI 10.1016/j.visres.2005.10.027
   Connolly DM, 2010, AVIAT SPACE ENVIR MD, V81, P475, DOI 10.3357/ASEM.2728.2010
   Curcio CA, 2005, VISION RES, V45, P3496, DOI 10.1016/j.visres.2005.07.038
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Dimopoulos IS, 2013, INVEST OPHTH VIS SCI, V54, P5186, DOI 10.1167/iovs.13-12194
   Drasdo N, 2002, LANCET, V359, P2251, DOI 10.1016/S0140-6736(02)09265-6
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   ERNEST JT, 1971, INVEST OPHTH VISUAL, V10, P323
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fukumura D, 2001, CANCER RES, V61, P6020
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Harris A, 1996, BRIT J OPHTHALMOL, V80, P209, DOI 10.1136/bjo.80.3.209
   HECHT S, 1946, J GEN PHYSIOL, V29, P335, DOI 10.1085/jgp.29.5.335
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   KOBRICK JL, 1984, AVIAT SPACE ENVIR MD, V55, P191
   Linsenmeier RA, 2017, PROG RETIN EYE RES, V58, P115, DOI 10.1016/j.preteyeres.2017.01.003
   McDonald R, 1939, ARCH OPHTHALMOL-CHIC, V37, P368
   McFarland RA, 1940, J GEN PHYSIOL, V24, P69, DOI 10.1085/jgp.24.1.69
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   O'Neill-Biba M, 2010, OPHTHAL PHYSL OPT, V30, P705, DOI 10.1111/j.1475-1313.2010.00775.x
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   REDDY VM, 1995, AM J OPHTHALMOL, V120, P291, DOI 10.1016/S0002-9394(14)72158-0
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Wald G, 1942, J GEN PHYSIOL, V25, P891, DOI 10.1085/jgp.25.6.891
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   WATSON AB, 1983, PERCEPT PSYCHOPHYS, V33, P113, DOI 10.3758/BF03202828
   Wei X, 2017, RETINA-J RET VIT DIS, V37, P1120, DOI 10.1097/IAE.0000000000001312
   Willmann G, 2010, BRIT J OPHTHALMOL, V94, P1393, DOI 10.1136/bjo.2009.178491
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 56
TC 0
Z9 0
U1 2
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD OCT 2
PY 2020
VL 45
IS 10
BP 1273
EP 1282
DI 10.1080/02713683.2020.1739315
EA MAR 2020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NR0FX
UT WOS:000524667300001
PM 32155095
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kozak, I
   Gurbaxani, A
   Safar, A
   Rao, P
   Masalmeh, A
   Assaf, H
   Farghaly, M
   Pathak, P
   Natarajan, A
   Saffar, I
AF Kozak, Igor
   Gurbaxani, Avinash
   Safar, Ammar
   Rao, Prasan
   Masalmeh, Amal
   Assaf, Hazar
   Farghaly, Mohamed
   Pathak, Prathamesh
   Natarajan, Ashok
   Saffar, Insaf
TI Treatment patterns in patients with age-related macular degeneration and
   diabetic macular edema: A real-world claims analysis in Dubai
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR THERAPY; RANIBIZUMAB 0.5 MG; ANTI-VEGF; INTRAVITREAL
   AFLIBERCEPT; GLOBAL PREVALENCE; EFFICACY; RESTORE; OUTCOMES; SAFETY;
   BURDEN
AB Objectives To characterize the pattern of approved anti-vascular endothelial growth factor (VEGF) treatments among patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) in the United Arab Emirates (UAE). Method This was a retrospective, nonrandomized, observational cohort analysis of the Dubai Real-world Claims Database with a 360-day follow-up period. Adult patients diagnosed with nAMD or DME treated with ranibizumab or aflibercept for the first time were included. The primary objective was to evaluate anti-VEGF treatment patterns with respect to the proportion of patients receiving ranibizumab and aflibercept for nAMD and DME separately. Results Of the 451 patients included in the final study cohort, 83.6% and 16.4% had a diagnosis of DME (ranibizumab: 48.5%; aflibercept: 51.5%) and nAMD (ranibizumab: 40.5%; aflibercept: 59.5%), respectively, at baseline. Treatment frequency of ranibizumab/aflibercept was similar for nAMD (mean: 2.4/2.9 injections; p = 0.2389) with fewer injections in the ranibizumab cohort for DME (mean: 1.9/2.5 injections; p = 0.0002). Most patients received <= 3 anti-VEGF injections during the 360-day follow-up period. The time between consecutive treatments was large (nAMD: 73.6 days/10.5 weeks; DME: 80.5 days/11.5 weeks). Approximately 10%-13.5% of patients switched their anti-VEGF therapy. Most patients (83.8%) had a diabetes diagnosis during the follow-up period. Conclusions This real-world study provides an initial understanding of anti-VEGF treatment patterns in patients with nAMD and DME in the UAE. Treatment frequency of the 2 anti-VEGF agents assessed was similar in both patient populations. Both treatments were infrequently administered with large dosing intervals.
C1 [Kozak, Igor; Gurbaxani, Avinash; Safar, Ammar] Moorfields Eye Hosp, Abu Dhabi, U Arab Emirates.
   [Rao, Prasan] Medcare Eye Ctr, Dubai, U Arab Emirates.
   [Masalmeh, Amal; Assaf, Hazar] Novartis Middle East FZE, Dept Ophthalmol, Dubai, U Arab Emirates.
   [Farghaly, Mohamed] Dubai Hlth Author, Dubai Hlth Insurance Corp, Dubai, U Arab Emirates.
   [Pathak, Prathamesh; Natarajan, Ashok] IQVIA AG, Dubai, U Arab Emirates.
   [Saffar, Insaf] Novartis Pharma AG, Basel, Switzerland.
C3 Novartis
RP Saffar, I (通讯作者)，Novartis Pharma AG, Basel, Switzerland.
EM insaf.saffar@novartis.com
FU Novartis Middle East FZE, Dubai, United Arab Emirates
FX This study was funded by Novartis Middle East FZE, Dubai, United Arab
   Emirates. The sponsor participated in the design of the study,
   conducting of the study, data collection, data management, data
   analysis, interpretation of the data, preparation, review, and approval
   of the manuscript.
CR Al-Haj Mohd MMM., BMC PUBLIC HEALTH
   AlAlami U., 2017, Arab Journal of Nutrition and Exercise, V2, P118, DOI 10.18502/ajne.v2i2.1250
   Barthelmes D, 2018, GRAEF ARCH CLIN EXP, V256, P1839, DOI 10.1007/s00417-018-4061-2
   Bhandari S, 2020, OPHTHALMOLOGY, V127, P369, DOI 10.1016/j.ophtha.2019.10.006
   Brand C, 2013, INVEST OPHTH VIS SCI, V54
   Carrasco J, 2020, ADV THER, V37, P300, DOI 10.1007/s12325-019-01147-6
   Chen E, 2010, CURR MED RES OPIN, V26, P1587, DOI 10.1185/03007995.2010.482503
   Cheung N, 2014, DIABETES CARE, V37, P900, DOI 10.2337/dc13-1990
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P1179, DOI 10.1016/j.oret.2018.06.004
   Dhoot DS, 2012, EXPERT OPIN BIOL TH, V12, P371, DOI 10.1517/14712598.2012.660523
   EMA, 2015, ASS REP ENTR
   EMA, EYEL SUMM PROD CHARA EYEL SUMM PROD CHARA
   EMA, 2021, LUC SUMM PROD CHAR 2 LUC SUMM PROD CHAR 2
   EMA, 2021, LUC ASS REP 2014 LUC ASS REP 2014
   FDA, 2021, EYEL PRESCR INF 2014 EYEL PRESCR INF 2014
   FDA, 2021, LUC PRESCR INF 2012 LUC PRESCR INF 2012
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Fong DS, 2018, RETINA-J RET VIT DIS, V38, P1830, DOI 10.1097/IAE.0000000000001790
   Gale RP, 2019, EYE, V33, DOI 10.1038/s41433-018-0300-3
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Institute NE, 2021, MAC ED 2019 MAC ED 2019
   International R, 2021, INC PREV DIAB REL EY INC PREV DIAB REL EY
   Johnston SS, 2013, ADV THER, V30, P1111, DOI 10.1007/s12325-013-0078-4
   Kim LA, 2012, AM J PATHOL, V181, P376, DOI 10.1016/j.ajpath.2012.06.006
   Lad E, 2013, INVEST OPHTH VIS SCI, V54
   Lang GE, 2013, OPHTHALMOLOGY, V120, P2004, DOI 10.1016/j.ophtha.2013.02.019
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Lee R, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0026-2
   Massin P, 2010, DIABETES CARE, V33, P2399, DOI 10.2337/dc10-0493
   Mitchell P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233595
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Pikkel J, 2018, INT OPHTHALMOL, V38, P2031, DOI 10.1007/s10792-017-0695-z
   Nguyen QD, 2012, J OCUL PHARMACOL TH, V28, P581, DOI 10.1089/jop.2011.0261
   Reich O, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0617-x
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P1045, DOI 10.1016/j.ophtha.2013.11.041
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
   WHO, 2021, BLINDN VIS IMP 2019 BLINDN VIS IMP 2019
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Zafar S, 2018, CAN J OPHTHALMOL, V53, P94, DOI 10.1016/j.jcjo.2017.07.027
   Ziemssen F, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0401-y
NR 43
TC 1
Z9 1
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 13
PY 2021
VL 16
IS 7
AR e0254569
DI 10.1371/journal.pone.0254569
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA TQ2ME
UT WOS:000678118700016
PM 34255798
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Woronkowicz, M
   Lightman, S
   Tomkins-Netzer, O
AF Woronkowicz, Malgorzata
   Lightman, Sue
   Tomkins-Netzer, Oren
TI The prognostic value of total macular external limiting membrane and
   ellipsoid zone damage for clinical outcome in treatment-resistant
   neovascular age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Ellipsoid zone; External limiting
   membrane; Best corrected visual acuity; Aflibercept
ID OPTICAL COHERENCE TOMOGRAPHY; ANTI-VEGF THERAPY; PREDICTORS; AMD
AB Purpose To examine the prognostic value of the extent of damage to the ellipsoid zone (EZ) and external limiting membrane (ELM) in response to the treatment of age-related macular degeneration (AMD) eyes switched from ranibizumab to aflibercept. Methods This is a retrospective study of patients with neovascular AMD resistant to ranibizumab defined as having persistent intra- or subretinal fluid on OCT scans despite at least 6-month treatment and switched to aflibercept. Clinical data was collected and quantitative measurements of the area of EZ and ELM damage were obtained, on en-face optical coherence tomography images, at the time of switch to aflibercept (baseline) and up to 6 months of follow-up. Results The study included 71 eyes (52.1% right eye) of 71 patients. At baseline, there was a correlation between the size of the EZ and ELM damaged area and BCVA (R = -0.39,p = 0.001 andR = -0.47,p < 0.001, respectively). The EZ and ELM damaged areas maintained correlation with BCVA at 6 months (R = -0.28,p = 0.01 andR = -0.39,p = 0.001, respectively). Central retinal thickness did not correlate with BCVA at the time of switch (p = 0.38) or at 6 months (p = 0.36). Conclusions The extent of damage to the EZ and ELM correlates with BCVA following a switch in treatment.
C1 [Woronkowicz, Malgorzata; Lightman, Sue; Tomkins-Netzer, Oren] Moorfields Eye Hosp, 162 City Rd, London EC1V 2PD, England.
   [Woronkowicz, Malgorzata; Lightman, Sue; Tomkins-Netzer, Oren] UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
   [Tomkins-Netzer, Oren] Technion Israel Inst Technol, Ruth & Bruch Rappaport Fac Med, Haifa, Israel.
   [Tomkins-Netzer, Oren] Lady Davis Carmel Med Ctr, Ophthalmol Dept, Haifa, Israel.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Technion Israel Institute of Technology; Clalit Health Services; Carmel
   Medical Center
RP Tomkins-Netzer, O (通讯作者)，Moorfields Eye Hosp, 162 City Rd, London EC1V 2PD, England.; Tomkins-Netzer, O (通讯作者)，UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.; Tomkins-Netzer, O (通讯作者)，Technion Israel Inst Technol, Ruth & Bruch Rappaport Fac Med, Haifa, Israel.; Tomkins-Netzer, O (通讯作者)，Lady Davis Carmel Med Ctr, Ophthalmol Dept, Haifa, Israel.
EM oren.tomkins@gmail.com
OI Tomkins-Netzer, Oren/0000-0002-1015-1641
CR Chae B, 2015, INVEST OPHTH VIS SCI, V56, P5040, DOI 10.1167/iovs.15-16494
   Chhablani J, 2013, INT J OPHTHALMOL-CHI, V6, P62, DOI 10.3980/j.issn.2222-3959.2013.01.13
   Coscas F, 2015, INVEST OPHTH VIS SCI, V56, P4129, DOI 10.1167/iovs.15-16735
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gamulescu MA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/851648
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Itoh Y, 2016, BRIT J OPHTHALMOL, V100, P295, DOI 10.1136/bjophthalmol-2015-307105
   Keane PA, 2011, SAUDI J OPHTHALMOL, V25, P145, DOI 10.1016/j.sjopt.2011.01.003
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kolb S, 2012, KLIN MONATSBL AUGENH, V229, P343, DOI 10.1055/s-0031-1299250
   Kwon Yoon Hyung, 2014, Korean J Ophthalmol, V28, P386, DOI 10.3341/kjo.2014.28.5.386
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Litts KM, 2018, RETINA-J RET VIT DIS, V38, P445, DOI 10.1097/IAE.0000000000001946
   Marmor MF, 1999, DOC OPHTHALMOL, V97, P239, DOI 10.1023/A:1002192829817
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P435, DOI 10.1007/s00417-012-2034-4
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Roberts P, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14293
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Subhi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091227
   Tsilimbaris MK, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4367631
   Wu MX, 2017, BRIT J OPHTHALMOL, V101, P976, DOI 10.1136/bjophthalmol-2016-309418
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
NR 28
TC 4
Z9 4
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2020
VL 258
IS 11
BP 2373
EP 2378
DI 10.1007/s00417-020-04869-4
EA AUG 2020
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OH1OE
UT WOS:000558149900001
PM 32778909
DA 2022-11-30
ER

PT J
AU Kim, SH
   Kim, H
   Ku, HJ
   Park, JH
   Cha, H
   Lee, S
   Lee, JH
   Park, JW
AF Kim, Sung Hwan
   Kim, Hyunjin
   Ku, Hyeong Jun
   Park, Jung Hyun
   Cha, Hanvit
   Lee, Seoyoon
   Lee, Jin Hyup
   Park, Jeen-Woo
TI Oxalomalate reduces expression and secretion of vascular endothelial
   growth factor in the retinal pigment epithelium and inhibits
   angiogenesis: Implications for age-related macular degeneration
SO REDOX BIOLOGY
LA English
DT Article
DE VEGF; Retinal pigment epithelium; Oxalomalate; Reactive oxygen species
ID NADP(+)-DEPENDENT ISOCITRATE DEHYDROGENASE; COMPETITIVE INHIBITOR;
   OXIDATIVE DAMAGE; LIPID-METABOLISM; MOUSE MODEL; FACTOR VEGF;
   HEAT-SHOCK; RAT-LIVER; MITOCHONDRIAL; GLYOXYLATE
AB Clinical and experimental observations indicate a critical role for vascular endothelial growth factor (VEGF), secreted by the retinal pigment epithelium (RPE), in pathological angiogenesis and the development of choroidal neovascularization (CNV) in age-related macular degeneration (AMD). RPE-mediated VEGF expression, leading to angiogenesis, is a major signaling mechanism underlying ocular neovascular disease. Inhibiting this signaling pathway with a therapeutic molecule is a promising anti-angiogenic strategy to treat this disease with potentially fewer side effects. Oxalomalate (OMA) is a competitive inhibitor of NADP(+)-dependent isocitrate dehydrogenase (IDH), which plays an important role in cellular signaling pathways regulated by reactive oxygen species (ROS). Here, we have investigated the inhibitory effect of OMA on the expression of VEGF, and the associated underlying mechanism of action, using in vitro and in vivo RPE cell models of AMD. We found that OMA reduced the expression and secretion of VEGF in RPE cells, and consequently inhibited CNV formation. This function of OMA was linked to its capacity to activate the pVHL-mediated HIF-1 alpha degradation in these cells, partly via a ROS-dependent ATM signaling axis, through inhibition of IDH enzymes. These findings reveal a novel role for OMA in inhibiting RPE-derived VEGF expression and angiogenesis, and suggest unique therapeutic strategies for treating pathological angiogenesis and AMD development.
C1 [Kim, Sung Hwan; Kim, Hyunjin; Ku, Hyeong Jun; Cha, Hanvit; Lee, Seoyoon; Park, Jeen-Woo] Kyungpook Natl Univ, Sch Life Sci & Biotechnol, Plus RNLI Creat BioResearch Grp BK21, Coll Nat Sci, Daegu, South Korea.
   [Park, Jung Hyun; Lee, Jin Hyup] Korea Univ, Dept Food & Biotechnol, Sejong, South Korea.
   [Lee, Jin Hyup] Korea Univ, Inst Nat Sci, Sejong, South Korea.
C3 Kyungpook National University; Korea University; Korea University
RP Park, JW (通讯作者)，Kyungpook Natl Univ, Sch Life Sci & Biotechnol, Plus RNLI Creat BioResearch Grp BK21, Coll Nat Sci, Daegu, South Korea.; Lee, JH (通讯作者)，Korea Univ, Dept Food & Biotechnol, Sejong, South Korea.
EM jinhyuplee@korea.ac.kr; parkjw@knu.ac.kr
FU National Research Foundation of Korea, South Korea (NRF) grant - Korean
   government (MSIP) [NRF-2015R1A4A1042271, NRF-2015R1C1A1A01053746]; Korea
   University
FX We appreciate the help of our laboratory members, in particular Ye Jin
   Lim and Jeong Ho Kim for critically reading the manuscript and providing
   useful comments. We are grateful to Suk Hee Lee, Jeong Hoon Pan, Jun Ho
   Kim, and Young Jun Kim for critical comments and helpful discussions
   regarding the manuscript. We acknowledge the service of the Biomedical
   Research Imaging Center at Kyungpook National University, Republic of
   Korea. This work was supported by the National Research Foundation of
   Korea, South Korea (NRF) grant funded by the Korean government (MSIP)
   (NRF-2015R1A4A1042271 and NRF-2015R1C1A1A01053746) and granted by Korea
   University. No potential conflicts of interest relevant to this article
   are reported.
CR ADINOLFI A, 1971, BIOCHEM J, V125, P557, DOI 10.1042/bj1250557
   Akerboom T P, 1981, Methods Enzymol, V77, P373
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548
   Andriolo RB, 2009, SAO PAULO MED J, V127, P84, DOI 10.1590/S1516-31802009000200006
   BAIS R, 1991, NEPHRON, V57, P460, DOI 10.1159/000186350
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Choi IY, 2003, FREE RADICAL RES, V37, P1099, DOI 10.1080/10715760310001601047
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   DAVIS WL, 1989, FASEB J, V3, P1651, DOI 10.1096/fasebj.3.5.2537775
   Espada L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051544
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   FUJIWARA S, 1995, BIOCHEM J, V312, P315, DOI 10.1042/bj3120315
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Guo Z, 2010, SCIENCE, V330, P517, DOI 10.1126/science.1192912
   Holmes DIR, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-2-209
   Horie S, 2013, SCI REP-UK, V3, DOI 10.1038/srep03072
   INGEBRETSEN OC, 1976, BIOCHIM BIOPHYS ACTA, V452, P302, DOI 10.1016/0005-2744(76)90180-7
   Irace C, 2007, LIFE SCI, V80, P1282, DOI 10.1016/j.lfs.2006.12.008
   Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0
   Iwasaki K, 2006, MOL CELL BIOL, V26, P2845, DOI 10.1128/MCB.26.7.2845-2856.2006
   Izuta H, 2009, EVID-BASED COMPL ALT, V6, P489, DOI 10.1093/ecam/nem152
   Ji W, 2014, BIOCHEM J, V457, P185, DOI 10.1042/BJ20130793
   Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200
   JOHANSON RA, 1977, BIOCHIM BIOPHYS ACTA, V483, P24, DOI 10.1016/0005-2744(77)90004-3
   Jung UJ, 2003, J BIOCHEM MOL TOXIC, V17, P295, DOI 10.1002/jbt.10092
   Kannan R, 2006, MOL VIS, V12, P1649
   Kim HJ, 2005, BIOCHEM BIOPH RES CO, V337, P685, DOI 10.1016/j.bbrc.2005.09.104
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   KOSHLAND DE, 1985, CURR TOP CELL REGUL, V27, P13
   Kourlas H, 2007, CLIN THER, V29, P1850, DOI 10.1016/j.clinthera.2007.09.008
   KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662
   Lee Ji-Won, 2004, Experimental & Molecular Medicine, V36, P1
   Lee SM, 2002, FREE RADICAL BIO MED, V32, P1185, DOI 10.1016/S0891-5849(02)00815-8
   Lin WC, 2001, GENE DEV, V15, P1833
   Liu B, 2008, FREE RADICAL BIO MED, V44, P1529, DOI 10.1016/j.freeradbiomed.2008.01.011
   Lu Ming, 2006, Ophthalmol Clin North Am, V19, P323
   Lyzogubov VV, 2014, EXP EYE RES, V127, P143, DOI 10.1016/j.exer.2014.07.021
   Lyzogubov VV, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.204701
   Lyzogubov VV, 2010, AM J PATHOL, V177, P1870, DOI 10.2353/ajpath.2010.091168
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Miller DW, 2003, OPHTHALMOLOGE, V100, P92, DOI 10.1007/s00347-002-0760-4
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Park HJ, 2006, STEM CELL REV, V2, P93, DOI 10.1007/s12015-006-0015-x
   Pellegrini L, 2012, CELL DEATH DIFFER, V19, P1815, DOI 10.1038/cdd.2012.62
   Pourgholami MH, 2010, BIOCHEM BIOPH RES CO, V397, P729, DOI 10.1016/j.bbrc.2010.06.019
   Raimundo N, 2012, CELL, V148, P716, DOI 10.1016/j.cell.2011.12.027
   Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008
   RUFFO A, 1974, ITAL J BIOCHEM, V23, P357
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Seo JH, 2005, MOL BIOL CELL, V16, P348, DOI 10.1091/mbc.e04-05-0369
   SIES H, 1986, ANGEW CHEM INT EDIT, V25, P1058, DOI 10.1002/anie.198610581
   Simo R, 2008, DIABETOLOGIA, V51, P1574, DOI 10.1007/s00125-008-0989-9
   Slevin M, 2008, EXPERT OPIN INV DRUG, V17, P1301, DOI [10.1517/13543784.17.9.1301, 10.1517/13543784.17.9.1301 ]
   Smolkova Katarina, 2012, Int J Cell Biol, V2012, P273947, DOI 10.1155/2012/273947
   SPRAGG RG, 1985, J CLIN INVEST, V76, P1471, DOI 10.1172/JCI112126
   Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974
   Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Yang ES, 2005, FREE RADICAL RES, V39, P89, DOI 10.1080/10715760400022996
   ZEREZ CR, 1987, ANAL BIOCHEM, V164, P367, DOI 10.1016/0003-2697(87)90506-9
NR 68
TC 10
Z9 10
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2317
J9 REDOX BIOL
JI Redox Biol.
PD DEC
PY 2016
VL 10
BP 211
EP 220
DI 10.1016/j.redox.2016.10.008
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA EF8SD
UT WOS:000390598800022
PM 27810736
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Chaker, L
   Buitendijk, GHS
   Dehghan, A
   Medici, M
   Hofman, A
   Vingerling, JR
   Franco, OH
   Klaver, CCW
   Peeters, RP
AF Chaker, Layal
   Buitendijk, Gabrielle H. S.
   Dehghan, Abbas
   Medici, Marco
   Hofman, Albert
   Vingerling, Johannes R.
   Franco, Oscar H.
   Klaver, Caroline C. W.
   Peeters, Robin P.
TI Thyroid function and age-related macular degeneration: a prospective
   population-based cohort study - the Rotterdam Study
SO BMC MEDICINE
LA English
DT Article
DE Thyroid hormone; Thyroid function; AMD; Age-related macular degeneration
ID RETINAL-PIGMENT EPITHELIUM; VISION LOSS; RISK-FACTORS; SUBCLINICAL
   HYPOTHYROIDISM; CONE PHOTORECEPTORS; GRADING SYSTEM; ASIA 1990-2010;
   BEAVER DAM; ADULT-RAT; PREVALENCE
AB Background: In animal models, lack of thyroid hormone is associated with cone photoreceptor preservation, while administration of high doses of active thyroid hormone leads to deterioration. The association between thyroid function and age-related macular degeneration (AMD) has not been investigated in the general population.
   Methods: Participants of age >= 55 years from the Rotterdam Study with thyroid-stimulating hormone (TSH) and/or free thyroxine (FT4) measurements and AMD assessment were included. We conducted age- and sex-adjusted Cox proportional hazards models to explore the association of TSH or FT4 with AMD, in the full range and in those with TSH (0.4-4.0 mIU/L) and/or FT4 in normal range (11-25 pmol/L). Cox proportional hazards models were performed for the association of TSH or FT4 with retinal pigment alterations (RPA), as an early marker of retinal changes. Multivariable models additionally included cardiovascular risk factors and thyroid peroxidase antibodies positivity. We also performed stratification by age and sex. A bidirectional look-up in genome-wide association study (GWAS) data for thyroid parameters and AMD was performed. Single nucleotide polymorphisms (SNPs) that are significantly associated with both phenotypes were identified.
   Results: We included 5,573 participants with a median follow-up of 6.9 years (interquartile range 4.4-10.8 years). During follow-up 805 people developed AMD. TSH levels were not associated with increased risk of AMD. Within normal range of FT4, participants in the highest FT4 quintile had a 1.34-fold increased risk of developing AMD, compared to individuals in the middle group (95% confidence interval [CI] 1.07-1.66). Higher FT4 values in the full range were associated with a higher risk of AMD (hazard ratio 1.04, CI, 1.01-1.06 per 1 pmol/L increase). Higher FT4 levels were similarly associated with a higher risk of RPA. Restricting analyses to euthyroid individuals, additional multivariable models, and stratification did not change estimates. We found a SNP (rs943080) in the VEGF-A gene, associated with AMD, to be significant in the TSH GWAS (P = 1.2 x 10(-4)). Adding this SNP to multivariable models did not change estimates.
   Conclusions: Higher FT4 values are associated with increased risk of AMD - even in euthyroid individuals - and increased risk of RPA. Our data suggest an important role of thyroid hormone in pathways leading to AMD.
C1 [Chaker, Layal; Medici, Marco; Peeters, Robin P.] Erasmus Univ, Med Ctr, Rotterdam Thyroid Ctr, NL-3000 CA Rotterdam, Netherlands.
   [Chaker, Layal; Medici, Marco; Peeters, Robin P.] Erasmus Univ, Med Ctr, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands.
   [Buitendijk, Gabrielle H. S.; Dehghan, Abbas; Hofman, Albert; Vingerling, Johannes R.; Franco, Oscar H.; Klaver, Caroline C. W.] Erasmus Univ, Med Ctr, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands.
   [Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus Univ, Med Ctr, Dept Ophthalmol, NL-3000 CA Rotterdam, Netherlands.
   [Peeters, Robin P.] Erasmus Univ, Rotterdam Thyroid Ctr, Dept Internal Med, Endocrinol,Med Ctr Rotterdam,Med Ctr, NL-3000 CA Rotterdam, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University
   Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC
RP Peeters, RP (通讯作者)，Erasmus Univ, Med Ctr, Rotterdam Thyroid Ctr, NL-3000 CA Rotterdam, Netherlands.
EM r.peeters@erasmusmc.nl
RI Franco, Óscar H/ABE-2305-2020; Klaver, Caroline C.W./A-2013-2016;
   Medici, Marco/U-2777-2018; Dehghan, Abbas/ABE-7377-2020; Dehghan,
   Abbas/B-9896-2008
OI Franco, Óscar H/0000-0002-4606-4929; Dehghan, Abbas/0000-0001-6403-016X;
   Peeters, Robin/0000-0001-7732-9371; Klaver, Caroline/0000-0002-2355-5258
FU NWO grant (veni) [916.12.154]; EUR Fellowship; Nestle' Nutrition (Nestec
   Ltd.); Metagenics Inc.; AXA; Zon-MWTOP grant [91212044]; Erasmus MC
   MRACE grant
FX We are grateful to the study participants, the staff from the Rotterdam
   Study, and the participating general practitioners and pharmacists. Dr.
   A. Dehghan is supported by an NWO grant (veni, 916.12.154) and the EUR
   Fellowship. Prof. O. H. Franco works in ErasmusAGE, a center for aging
   research across the life course funded by Nestle' Nutrition (Nestec
   Ltd.), Metagenics Inc., and AXA. Nestle' Nutrition (Nestec Ltd.),
   Metagenics Inc., and AXA had no role in the design and conduct of the
   study; collection, management, analysis, and interpretation of the data;
   and preparation, review and approval of the manuscript. Dr. R.P. Peeters
   is supported by a Zon-MWTOP grant (number 91212044) and an Erasmus MC
   MRACE grant.
CR Aghini-Lombardi F, 1999, J CLIN ENDOCR METAB, V84, P561, DOI 10.1210/jc.84.2.561
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Aoki Y, 2007, THYROID, V17, P1211, DOI 10.1089/thy.2006.0235
   Bauer DC, 1998, AM J MED, V104, P546, DOI 10.1016/S0002-9343(98)00116-8
   Biondi B, 2008, ENDOCR REV, V29, P76, DOI 10.1210/er.2006-0043
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Bromfield S, 2012, CURR EYE RES, V37, P549, DOI 10.3109/02713683.2011.647223
   Canaris GJ, 2000, ARCH INTERN MED, V160, P526, DOI 10.1001/archinte.160.4.526
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Douglas IJ, 2007, OPHTHALMOLOGY, V114, P1164, DOI 10.1016/j.ophtha.2006.09.018
   Duncan KG, 1999, OPHTHALMIC RES, V31, P399, DOI 10.1159/000055564
   Fliers E, 2014, EUR J ENDOCRINOL, V171, pR197, DOI 10.1530/EJE-14-0285
   Fritsche LG, NATURE GENETICS, V45, P433
   Gammage MD, 2007, ARCH INTERN MED, V167, P928, DOI 10.1001/archinte.167.9.928
   Gao N, 2013, ATHEROSCLEROSIS, V227, P18, DOI 10.1016/j.atherosclerosis.2012.10.070
   Madariaga AG, 2014, J CLIN ENDOCR METAB, V99, P923, DOI 10.1210/jc.2013-2409
   Gudmundsson J, 2012, NAT GENET, V44, P319, DOI 10.1038/ng.1046
   Hak AE, 2000, ANN INTERN MED, V132, P270, DOI 10.7326/0003-4819-132-4-200002150-00004
   Hofman A, 2013, EUR J EPIDEMIOL, V28, P889, DOI 10.1007/s10654-013-9866-z
   Ittermann T, 2014, THYROID, V24, P1473, DOI 10.1089/thy.2014.0190
   Jonas JB, 2014, BRIT J OPHTHALMOL, V98, P592, DOI 10.1136/bjophthalmol-2013-303998
   Keeffe J, 2014, BRIT J OPHTHALMOL, V98, P586, DOI 10.1136/bjophthalmol-2013-304050
   Khairallah M, 2014, BRIT J OPHTHALMOL, V98, P605, DOI 10.1136/bjophthalmol-2013-304068
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Leasher JL, 2014, BRIT J OPHTHALMOL, V98, P619, DOI 10.1136/bjophthalmol-2013-304013
   Ma HW, 2014, P NATL ACAD SCI USA, V111, P3602, DOI 10.1073/pnas.1317041111
   MEIER CA, 1993, CLIN ENDOCRINOL, V39, P101, DOI 10.1111/j.1365-2265.1993.tb01758.x
   Naidoo K, 2014, BRIT J OPHTHALMOL, V98, P612, DOI 10.1136/bjophthalmol-2013-304081
   Ng L, 2010, J NEUROSCI, V30, P3347, DOI 10.1523/JNEUROSCI.5267-09.2010
   Nguyen-Legros J, 2000, INT REV CYTOL, V196, P245
   Pearce SHS, 2013, EUR THYROID J, V2, P215, DOI 10.1159/000356507
   Porcu E, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003266
   Takeda M, 1996, LIFE SCI, V58, P631, DOI 10.1016/0024-3205(95)02331-3
   TAKEDA M, 1994, THYROID, V4, P467, DOI 10.1089/thy.1994.4.467
   Waring AC, 2012, J CLIN ENDOCR METAB, V97, P3944, DOI 10.1210/jc.2012-2481
   Wong TY, 2014, BRIT J OPHTHALMOL, V98, P599, DOI 10.1136/bjophthalmol-2013-304047
NR 40
TC 40
Z9 41
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD APR 23
PY 2015
VL 13
AR 94
DI 10.1186/s12916-015-0329-0
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CG4MJ
UT WOS:000353259700001
PM 25903050
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Johnson, LV
   Leitner, WP
   Rivest, AJ
   Staples, MK
   Radeke, MJ
   Anderson, DH
AF Johnson, LV
   Leitner, WP
   Rivest, AJ
   Staples, MK
   Radeke, MJ
   Anderson, DH
TI The Alzheimer's A beta-peptide is deposited at sites of complement
   activation in pathologic deposits associated with aging and age-related
   macular degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID AMYLOID PRECURSOR PROTEIN; RETINAL-PIGMENT EPITHELIUM; MESSENGER-RNA;
   APOLIPOPROTEIN-E; DRUSEN FORMATION; BRUCHS MEMBRANE; DISEASE;
   VITRONECTIN; EXPRESSION; PATHOGENESIS
AB Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss in older individuals worldwide. The disease is characterized by abnormal extracellular deposits, known as drusen, that accumulate along the basal surface of the retinal pigmented epithelium. Although drusen deposition is common in older individuals, large numbers of drusen and/or extensive areas of confluent drusen represent a significant risk factor for AMD. Widespread drusen deposition is associated with retinal pigmented epithelial cell dysfunction and degeneration of the photoreceptor cells of the neural retina. Recent studies have shown that drusen contain a variety of immunomodulatory molecules, suggesting that the process of drusen formation involves local inflammatory events, including activation of the complement cascade. Similar observations in Alzheimer's disease (AD) have lead to the hypothesis that chronic localized inflammation is an important element of AD pathogenesis, with significant neurodegenerative consequences. Accordingly, the amyloid beta (Abeta) pepticle, a major constituent of neuritic plaques in AD, has been implicated as a primary activator of complement in AD. Here we show that Abeta is associated with a substructural vesicular component within drusen. Abeta colocalizes with activated complement components in these "amyloid vesicles," thereby identifying them as potential primary sites of complement activation. Thus, Abeta deposition could be an important component of the local inflammatory events that contribute to atrophy of the retinal pigmented epithelium, drusen biogenesis, and the pathogenesis of AMD.
C1 Univ Calif Santa Barbara, Ctr Study Macular Degenetat, Neurosci Res Inst, Santa Barbara, CA 93106 USA.
C3 University of California System; University of California Santa Barbara
RP Johnson, LV (通讯作者)，Univ Calif Santa Barbara, Ctr Study Macular Degenetat, Neurosci Res Inst, Santa Barbara, CA 93106 USA.
EM l.johnso@lifesci.ucsb.edu
FU NATIONAL EYE INSTITUTE [R01EY011521, R01EY011527] Funding Source: NIH
   RePORTER; NEI NIH HHS [R01 EY011521, EY11521, R01 EY011527, EY11527]
   Funding Source: Medline
CR Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   ANDERSON DH, 1995, J COMP NEUROL, V360, P1, DOI 10.1002/cne.903600102
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   ARONSON JF, 1983, IN VITRO CELL DEV B, V19, P642
   Beckman M, 1997, NEUROSCI LETT, V221, P73, DOI 10.1016/S0304-3940(96)13292-4
   Bradt BM, 1998, J EXP MED, V188, P431, DOI 10.1084/jem.188.3.431
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   EIKELENBOOM P, 1982, ACTA NEUROPATHOL, V57, P239, DOI 10.1007/BF00685397
   ERIKSSON S, 1995, P NATL ACAD SCI USA, V92, P2313, DOI 10.1073/pnas.92.6.2313
   EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763
   GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HAMAZAKI H, 1995, BIOCHEM BIOPH RES CO, V211, P349, DOI 10.1006/bbrc.1995.1819
   HILBICH C, 1993, J BIOL CHEM, V268, P26571
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kim K., 1988, NEUROSCI RES COMMUN, V2, P121
   KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Lin H, 1998, INVEST OPHTH VIS SCI, V39, P1703
   LOFFLER KU, 1995, INVEST OPHTH VIS SCI, V36, P24
   MATSUBARA E, 1995, J BIOL CHEM, V270, P7563, DOI 10.1074/jbc.270.13.7563
   MCGEER PL, 1989, CAN J NEUROL SCI, V16, P516, DOI 10.1017/S0317167100029863
   Morgan BP, 1999, CRIT REV IMMUNOL, V19, P173
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nangaku M, 1998, KIDNEY INT, V54, P1419, DOI 10.1046/j.1523-1755.1998.00130.x
   Ozaki S, 1999, BIOCHEM BIOPH RES CO, V258, P524, DOI 10.1006/bbrc.1999.0672
   ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   SCHWARZMAN AL, 1994, P NATL ACAD SCI USA, V91, P8368, DOI 10.1073/pnas.91.18.8368
   SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.ne.17.030194.002421
   Simpson D, 2000, MOL VIS, V6, P178
   Terai K, 2001, NEUROSCIENCE, V104, P299, DOI 10.1016/S0306-4522(01)00095-1
   Torzewski J, 1997, ATHEROSCLEROSIS, V132, P131, DOI 10.1016/S0021-9150(97)00100-7
   ULSHAFER RJ, 1987, INVEST OPHTH VIS SCI, V28, P683
   Webster S, 1997, NEUROBIOL AGING, V18, P415, DOI 10.1016/S0197-4580(97)00042-0
   Westlind-Danielsson A, 2001, BIOCHEMISTRY-US, V40, P14736, DOI 10.1021/bi010375c
   Wilson CA, 1999, J NEUROPATH EXP NEUR, V58, P787, DOI 10.1097/00005072-199908000-00001
NR 46
TC 355
Z9 386
U1 2
U2 17
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 3
PY 2002
VL 99
IS 18
BP 11830
EP 11835
DI 10.1073/pnas.192203399
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 590UW
UT WOS:000177843100054
PM 12189211
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Yeh, CC
   Wu, MM
   Wu, CM
   Sung, FC
   Muo, CH
   Te, A
   Su, FH
AF Yeh, Chih-Ching
   Wu, Meei-Maan
   Wu, Chia-Min
   Sung, Fung-Chang
   Muo, Chih-Hsin
   Te, Arlene
   Su, Fu-Hsiung
TI Increased Risk of Age-Related Macular Degeneration with Chronic
   Hepatitis C Virus Infection: A Nationwide Population-Based Propensity
   Score-Matched Cohort Study in Taiwan
SO VIRUSES-BASEL
LA English
DT Article
DE hepatitis C virus; aged-related macular degeneration; propensity score
   matching; insurance data; retrospective cohort study
ID VIRAL-HEPATITIS; B-VIRUS; EPIDEMIOLOGY; PREVALENCE; RNA; MANIFESTATIONS;
   COMPLICATIONS; ASSOCIATION; THERAPY
AB Studies evaluating the association between age-related macular degeneration (AMD) risk and HCV infection are scant. In this population-based cohort study, 13,300 patients newly diagnosed as having HCV (HCV cohort) and 26,600 propensity score-matched patients without HCV (non-HCV cohort) were identified from the Taiwan National Health Insurance Research Database between 2000 and 2013. Furthermore, 1,983 patients with HCV who received pegylated interferon and ribavirin treatment (HCV-treated cohort) and propensity score-matched patients with HCV (matched at a ratio of 1:2) who did not receive this treatment (HCV-untreated cohort) were selected from the HCV cohort. Cox proportional hazards regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) associated with the risk of AMD in the HCV and non-HCV cohorts. The adjusted HR (aHR) for AMD in the HCV cohort was 1.22 (95% CI = 1.09-1.35). This significant association was observed only for nonexudative AMD (aHR = 1.22, 95% CI = 1.09-1.37). Compared with the HCV-untreated cohort, the HCV-treated cohort showed no significant association with any type of AMD (aHR = 1.07, 95% CI = 0.81-1.43). Age and sex did not modify AMD development after the exposure and treatment of chronic HCV infection. Our findings revealed that patients with chronic HCV infection had an increased risk of AMD.
C1 [Yeh, Chih-Ching; Wu, Meei-Maan; Wu, Chia-Min] Taipei Med Univ, Sch Publ Hlth, Coll Publ Hlth, Taipei 110, Taiwan.
   [Yeh, Chih-Ching] China Med Univ, Dept Publ Hlth, Coll Publ Hlth, Taichung 404, Taiwan.
   [Yeh, Chih-Ching] Taipei Med Univ, Wan Fang Hosp, Ctr Canc, Taipei 116, Taiwan.
   [Yeh, Chih-Ching; Wu, Meei-Maan] Taipei Med Univ, Coll Publ Hlth, Master Program Appl Mol Epidemiol, Taipei 110, Taiwan.
   [Wu, Meei-Maan] Taipei Med Univ, Sch Med, Dept Publ Hlth, Coll Med, Taipei 110, Taiwan.
   [Wu, Chia-Min] Taipei Med Univ, Shuang Ho Hosp, Dept Ophthalmol, New Taipei 235, Taiwan.
   [Sung, Fung-Chang; Muo, Chih-Hsin] China Med Univ Hosp, Management Off Hlth Data, Taichung 404, Taiwan.
   [Sung, Fung-Chang] China Med Univ, Dept Hlth Serv Adm, Taichung 406, Taiwan.
   [Sung, Fung-Chang] Asia Univ, Dept Food Nutr & Hlth Biotechnol, Taichung 413, Taiwan.
   [Te, Arlene; Su, Fu-Hsiung] Fu Jen Catholic Univ, Cardinal Tien Hosp, Dept Family Med, New Taipei 231, Taiwan.
   [Te, Arlene; Su, Fu-Hsiung] Fu Jen Catholic Univ, Sch Med, Coll Med, New Taipei 242, Taiwan.
C3 Taipei Medical University; China Medical University Taiwan; Taipei
   Medical University; Taipei Municipal WanFang Hospital; Taipei Medical
   University; Taipei Medical University; Taipei Medical University; Shuang
   Ho Hospital; China Medical University Taiwan; China Medical University
   Hospital - Taiwan; China Medical University Taiwan; Asia University
   Taiwan; Fu Jen Catholic University; Fu Jen Catholic University
RP Su, FH (通讯作者)，Fu Jen Catholic Univ, Cardinal Tien Hosp, Dept Family Med, New Taipei 231, Taiwan.; Su, FH (通讯作者)，Fu Jen Catholic Univ, Sch Med, Coll Med, New Taipei 242, Taiwan.
EM ccyeh@tmu.edu.tw; mmwu@tmu.edu.tw; windex034@gmail.com;
   fcsung1008@yahoo.com; b8507006@gmail.com; srarlene@yahoo.com;
   williamsufh1@yahoo.com.tw
OI wu, jia min/0000-0002-4369-1142; Su, Fu-Hsiung/0000-0002-9867-7655; Yeh,
   Chih-Ching/0000-0001-6483-1100
FU Ministry of Health and Welfare, Taiwan [MOHW109-TDUB-212-114004,
   MOHW109-TDU-B-212-134020]; Children's Hospital of China Medical
   University [DMR-108-045]; China Medical University Hospital
   [DMR-109-027, DMR-109-175]; Academia Sinica Stroke Biosignature Project
   [BM10701010021]; MOST Clinical Trial Consortium for Stroke
   [MOST107-2321-B-039-004]
FX This study was funded by the Ministry of Health and Welfare, Taiwan
   (MOHW109-TDUB-212-114004 and MOHW109-TDU-B-212-134020), Children's
   Hospital of China Medical University (DMR-108-045), China Medical
   University Hospital (DMR-109-027 and DMR-109-175), Academia Sinica
   Stroke Biosignature Project (BM10701010021), and MOST Clinical Trial
   Consortium for Stroke (MOST107-2321-B-039-004).
CR Abe T, 1995, JPN J OPHTHALMOL, V39, P411
   Alter MJ, 2007, WORLD J GASTROENTERO, V13, P2436, DOI 10.3748/wjg.v13.i17.2436
   Atas M, 2016, OCUL IMMUNOL INFLAMM, V24, P297, DOI 10.3109/09273948.2014.985386
   Bureau of National Health Insurance Taiwan, NATL HLTH INSURANCE
   Cacoub P, 2016, THER ADV INFECT DIS, V3, P3, DOI 10.1177/2049936115585942
   Bertrand RHC, 2019, ARQ BRAS OFTALMOL, V82, P161, DOI 10.5935/0004-2749.20190027
   Central Health Insurance Agency Ministry of Health and Welfare Taiwan, NATL HLTH INSURANCE
   Chang IC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003284
   Chen CH, 2007, J FORMOS MED ASSOC, V106, P148, DOI 10.1016/S0929-6646(09)60231-X
   Chen JJ, 2020, J FORMOS MED ASSOC, V119, P413, DOI 10.1016/j.jfma.2019.07.021
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Gangadharan B, 2007, CLIN CHEM, V53, P1792, DOI 10.1373/clinchem.2007.089144
   Gower E, 2014, J HEPATOL, V61, pS45, DOI 10.1016/j.jhep.2014.07.027
   Hanafiah KM, 2013, HEPATOLOGY, V57, P1333, DOI 10.1002/hep.26141
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Jabs DA, 2015, AM J OPHTHALMOL, V159, P1115, DOI 10.1016/j.ajo.2015.01.037
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kobayakawa Shinichio, 1993, Nippon Ganka Gakkai Zasshi, V97, P1061
   Lai CH, 2018, PHARMACOEPIDEM DR S, V27, P191, DOI 10.1002/pds.4363
   Lee MH, 2011, GUT, V60, P688, DOI 10.1136/gut.2010.220889
   Levine L.M., 2014, AM ACAD OPHTHALMOLOG, P67
   Mendel I, 1997, J MED VIROL, V51, P231, DOI 10.1002/(SICI)1096-9071(199703)51:3&lt;231::AID-JMV15&gt;3.0.CO;2-N
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Miller MS, 2012, AM J MED SCI, V343, P85, DOI 10.1097/MAJ.0b013e318224a25d
   Ministry of Health and Welfare Taiwan, TAIW HEP C POL GUID
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   National Health Insurance Research Database, DAT LHID2000
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Park S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13283-6
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pazienza V, 2011, BIOMED PHARMACOTHER, V65, P317, DOI 10.1016/j.biopha.2011.04.004
   QUILLEN DA, 1994, AM J OPHTHALMOL, V118, P120, DOI 10.1016/S0002-9394(14)72859-4
   Rajalakshmy AR, 2015, CORNEA, V34, P28, DOI 10.1097/ICO.0000000000000304
   Schubert H.D., 2014, AM ACAD OPHTHALMOLOG, P60
   Sengler U, 2001, GRAEF ARCH CLIN EXP, V239, P783, DOI 10.1007/s004170100359
   SHIMAZAKI J, 1994, AM J OPHTHALMOL, V118, P524, DOI 10.1016/S0002-9394(14)75807-6
   Sievert W, 2011, LIVER INT, V31, P61, DOI 10.1111/j.1478-3231.2011.02540.x
   So Y., ANAL SURVIVAL DATA C
   Su FH, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-495
   Thrift AP, 2017, NAT REV GASTRO HEPAT, V14, P122, DOI 10.1038/nrgastro.2016.176
   Tien PT, 2016, RETINA-J RET VIT DIS, V36, P2391, DOI 10.1097/IAE.0000000000001103
   Tsoumani A, 2013, EUR REV MED PHARMACO, V17, P1123
   Wu CM, 2019, ACTA OPHTHALMOL, V97, pE713, DOI 10.1111/aos.14032
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu ML, 2014, J HEPATOL, V60, P253, DOI 10.1016/j.jhep.2013.09.023
   Yu ML, 2001, J MED VIROL, V65, P58, DOI 10.1002/jmv.2001
   Zegans Michael E, 2002, Curr Opin Ophthalmol, V13, P423, DOI 10.1097/00055735-200212000-00014
NR 47
TC 4
Z9 4
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD MAY
PY 2021
VL 13
IS 5
AR 790
DI 10.3390/v13050790
PG 14
WC Virology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Virology
GA SI3DL
UT WOS:000654705700001
PM 33925141
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Cobos, E
   Recalde, S
   Anter, J
   Hernandez-Sanchez, M
   Barreales, C
   Olavarrieta, L
   Valverde, A
   Suarez-Figueroa, M
   Cruz, F
   Abraldes, M
   Perez-Perez, J
   Fernandez-Robredo, P
   Arias, L
   Garcia-Layana, A
AF Cobos, Estefania
   Recalde, Sergio
   Anter, Jaouad
   Hernandez-Sanchez, Maria
   Barreales, Carla
   Olavarrieta, Leticia
   Valverde, Alicia
   Suarez-Figueroa, Marta
   Cruz, Fernando
   Abraldes, Maximino
   Perez-Perez, Julian
   Fernandez-Robredo, Patricia
   Arias, Luis
   Garcia-Layana, Alfredo
TI Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF
   polymorphisms and anatomical and functional response to ranibizumab
   treatment in neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   pharmacogenetic study; ranibizumab
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; GROWTH-FACTOR TREATMENT;
   INTRAVITREAL RANIBIZUMAB; GENETIC-FACTORS; PHARMACOGENETIC ASSOCIATIONS;
   RISK; VARIANTS; BEVACIZUMAB; AMD
AB PurposeWe sought to determine if specific genetic single nucleotide polymorphisms (SNPs) influence vascular endothelial growth factor inhibition response to ranibizumab in neovascular age-related macular degeneration (AMD).
   MethodsA total of 403 Caucasian patients diagnosed with exudative AMD were included. After a three-injection loading phase, a pro re nata regimen was followed. Nine SNPs from six different genes (CFH, CFB, ARMS2, SERPINF1, VEGFR1, VEGF) were genotyped. Non-genetic risk factors (gender, smoking habit and hypertension) were also assessed. Patients were classified as good or poor responders (GR or PR) according to functional (visual acuity), anatomical (foveal thickness measured by OCT) and fluid criteria (fluid/no fluid measured by OCT).
   ResultsHypertension was the environmental factor with the strongest poor response association with ranibizumab in the anatomical measure after the loading phase (p=0.0004; OR 3.7; 95% CI, 2.4-5.8) and after 12months of treatment (p=10(-5); OR 2.3; 95% CI, 1.5-3.4). The genetic variants rs12614 (CFB), rs699947 (VEGFA) and rs7993418 (VEGFR1) predisposed patients to a good response, while rs12603486 and rs1136287 (SERPINF1) were associated with a poor response. The protective genotype of rs800292 variant (CFH) was also associated with a poor anatomical response (p 0.0048).
   ConclusionAll these data suggest that genetics play an important role in treatment response in AMD patients.
C1 [Cobos, Estefania; Arias, Luis] Bellvitge Univ Hosp, Dept Ophthalmol, Feixa Llarga St, Barcelona 08907, Spain.
   [Recalde, Sergio; Hernandez-Sanchez, Maria; Fernandez-Robredo, Patricia; Garcia-Layana, Alfredo] Univ Navarra, Ophthalmol Expt Lab, Pamplona, Spain.
   [Recalde, Sergio; Hernandez-Sanchez, Maria; Fernandez-Robredo, Patricia; Garcia-Layana, Alfredo] Clin Univ Navarra, Dept Ophthalmol, Pamplona, Spain.
   [Anter, Jaouad] Ctr Invest Biol & Ciber Enfermedades Raras, Dept Celular & Mol Med, Madrid, Spain.
   [Barreales, Carla] Hosp Virgen del Camino, Deparment Ophthalmol, Pamplona, Spain.
   [Olavarrieta, Leticia; Perez-Perez, Julian] Secugen SL, Madrid, Spain.
   [Valverde, Alicia] Hosp Clin Madrid, Deparment Ophthalmol, Madrid, Spain.
   [Suarez-Figueroa, Marta] Hosp Ramon & Cajal, Deparment Ophthalmol, Madrid, Spain.
   [Cruz, Fernando] Complejo Asistencial Univ Salamanca, Deparment Ophthalmol, Salamanca, Spain.
   [Abraldes, Maximino] Hosp Univ Santiago de Compostela, Deparment Ophthalmol, Santiago De Compostela, Spain.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge
   University Hospital; University of Barcelona; University of Navarra;
   University of Navarra; CIBER - Centro de Investigacion Biomedica en Red;
   CIBERER; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC -
   Centro de Investigaciones Biologicas (CIB); Hospital Virgen del Camino;
   Servicio Navarro de Salud - Osasunbidea; Hospital Universitario Ramon y
   Cajal; Complexo Hospitalario Universitario de Santiago de Compostela
RP Cobos, E (通讯作者)，Bellvitge Univ Hosp, Dept Ophthalmol, Feixa Llarga St, Barcelona 08907, Spain.
EM ecobosmartin@gmail.com
RI Recalde, Sergio/D-1815-2017; Olavarrieta, Leticia/GYQ-5751-2022
OI Recalde, Sergio/0000-0002-9328-9725; Perez-Perez,
   Julian/0000-0001-6091-0012
FU Instituto de Salud Carlos III from the Ministerio de Economia y
   Competitividad, Spain [RETICs: RD07-0062, RD12/0034]; FIS [PI15/01374];
   ISCIII-Subdireccion General de Redes y Centros de Investigacion
   Cooperativa; European Program FEDER
FX This work has been developed by members of the Spanish Vitreoretinal
   society (SERV), the RETICs: RD07-0062: "Age-Related Ocular Diseases,
   Quality of Life and Vision," and RETICS OFTARED (RD12/0034) "Prevention,
   Early Detection and Treatment of the Prevalent Degenerative and Chronic
   Ocular Pathology" from the Instituto de Salud Carlos III from the
   Ministerio de Economia y Competitividad, Spain. This work has been
   partly funded by the FIS project PI15/01374, integrated in the National
   Plan of I+D+I 2013-2016; the ISCIII-Subdireccion General de Redes y
   Centros de Investigacion Cooperativa; and the European Program FEDER,
   and the grant PI15/01374.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Almeida LN, 2013, OPHTHALMIC RES, V50, P117, DOI 10.1159/000350549
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Boltz A, 2012, OPHTHALMOLOGY, V119, P1615, DOI 10.1016/j.ophtha.2012.02.001
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cruz-Gonzalez F, 2016, INT J OPHTHALMOL-CHI, V9, P1304, DOI 10.18240/ijo.2016.09.12
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dietzel M, 2014, GRAEF ARCH CLIN EXP, V252, P1273, DOI 10.1007/s00417-014-2690-7
   Dikmetas O, 2013, MOL VIS, V19, P2571
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Fong DS, 2000, OPHTHALMOLOGY, V107, P2314
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hall JB, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0760-4
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Huang H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021411
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Hernandez-Pastor LJ, 2008, CLIN THER, V30, P2436, DOI 10.1016/j.clinthera.2008.12.025
   Kanoff J, 2013, SEMIN OPHTHALMOL, V28, P355, DOI 10.3109/08820538.2013.825292
   Kitchens JW, 2013, CLIN OPHTHALMOL, V7, P1987, DOI 10.2147/OPTH.S39635
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Kume A, 2016, OPHTHALMOLOGY, V123, P1263, DOI 10.1016/j.ophtha.2016.01.042
   Kvannli L, 2017, ACTA OPHTHALMOL
   Lechanteur YTE, 2015, JAMA OPHTHALMOL, V133, P533, DOI 10.1001/jamaophthalmol.2015.18
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Leveziel N, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000328981
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Martinez-Barricarte R, 2012, INVEST OPHTH VIS SCI, V53, P1087, DOI 10.1167/iovs.11-8709
   Matsumiya W, 2014, PHARMACOGENOMICS, V15, P833, DOI [10.2217/PGS.14.51, 10.2217/pgs.14.51]
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Park UC, 2014, MOL VIS, V20, P1680
   Park UC, 2014, RETINA-J RET VIT DIS, V34, P288, DOI 10.1097/IAE.0b013e3182979e1e
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Rasmussen A, 2017, ACTA OPHTHALMOL, V95, P128, DOI 10.1111/aos.13233
   Real JP, 2016, ACTA OPHTHALMOL, V94, pE803, DOI 10.1111/aos.13153
   Recalde S, 2008, OPHTHALMOLOGY, V115, P916, DOI 10.1016/j.ophtha.2007.12.012
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Shah AR, 2016, AM J OPHTHALMOL, V163, P154, DOI 10.1016/j.ajo.2015.11.033
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268
   Teper SJ, 2010, MOL VIS, V16, P2598
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Wu B, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7689862
NR 66
TC 17
Z9 18
U1 1
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2018
VL 96
IS 2
BP e201
EP e212
DI 10.1111/aos.13519
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FW5PL
UT WOS:000425369200016
PM 28926193
DA 2022-11-30
ER

PT J
AU Fletcher, DC
   Schuchard, RA
AF Fletcher, DC
   Schuchard, RA
TI Visual function in patients with choroidal neovascularization resulting
   from age-related macular degeneration: The importance of looking beyond
   visual acuity
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; contrast
   sensitivity; laser photocoagulation; pegaptanib sodium; scotoma;
   verteporfin therapy; visual acuity; visual field
ID PREFERRED RETINAL LOCI; CONTRAST SENSITIVITY; LOW-VISION; PHOTODYNAMIC
   THERAPY; FLICKER SENSITIVITY; VERTEPORFIN THERAPY; FUNDUS APPEARANCE;
   OLDER POPULATION; READING-ABILITY; FELLOW EYE
AB Purpose. A detailed understanding of overall quality of vision may help primary care physicians, optometrists, and general ophthalmologists to improve the care of patients with choroidal neovascularization (CNV) resulting from age-related macular degeneration (AMD).
   Methods. Published literature was reviewed using Medline searches and the authors' knowledge of the field.
   Results. Both visual acuity and contrast sensitivity are strongly associated with the ability to perform vision-related activities of daily living. CNV resulting from AMD often leads to scotoma, which is also strongly associated with the ability to perform everyday activities such as reading and driving. Contrast sensitivity and visual field extent may be better predictors of many abilities than visual acuity. Laser photocoagulation, verteporfin therapy, and pegaptanib sodium have been proven to reduce the risk of visual acuity loss in patients with CNV resulting from AMD. Laser photocoagulation frequently causes scotoma, but data on its effects on other aspects of overall quality of vision are scarce. Verteporfin therapy has been shown to also reduce the risk of contrast sensitivity loss and has been associated with stabilization or reduction of scotoma size. Treatment effects beyond visual acuity have not been investigated for pegaptanib. Detailed assessment of overall quality of vision also aids the design of vision rehabilitation programs tailored to the needs of individual patients.
   Conclusions. Understanding the impact of vision loss on patients with CNV resulting from AMD and assessing treatment benefits requires assessment of overall quality of vision. Primary care physicians and optometrists have an important role in ensuring that patients receive the best possible care, which can be aided by prompt referral to an ophthalmologist or retina specialist and collaboration with low-vision specialists and optometrists who together can make detailed assessments of overall quality of vision, implement appropriate treatment, and design effective rehabilitation strategies.
C1 Calif Pacific Med Ctr, Dept Ophthalmol, San Francisco, CA 94415 USA.
   DCF, Smith Kettlewell Eye Res Inst, San Francisco, CA USA.
   Atlanta VA Rehabil Res & Dev Ctr, Atlanta, GA USA.
C3 California Pacific Medical Center; The Smith-Kettlewell Eye Research
   Institute; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Atlanta VA Health Care System
RP Fletcher, DC (通讯作者)，Calif Pacific Med Ctr, Dept Ophthalmol, 2340 Clay St,5th Floor, San Francisco, CA 94415 USA.
EM floridafletch@msn.com
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arden GB, 2004, BRIT J OPHTHALMOL, V88, P1180, DOI 10.1136/bjo.2003.033480
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Bellmann C, 2003, GRAEF ARCH CLIN EXP, V241, P968, DOI 10.1007/s00417-003-0689-6
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bowers Alex R, 2001, Clin Exp Optom, V84, P139
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P127, DOI 10.1016/S0008-4182(00)80005-8
   Bunse A, 2000, KLIN MONATSBL AUGENH, V216, P158, DOI 10.1055/s-2000-10537
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   COSCAS G, 1991, ARCH OPHTHALMOL-CHIC, V109, P1258, DOI 10.1001/archopht.1991.01080090082028
   Crossland MD, 2005, OPTOMETRY VISION SCI, V82, P11
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   CUMMINGS RW, 1985, AM J OPTOM PHYS OPT, V62, P833
   D'Amico D. J., 2005, INVEST OPHTH VIS SCI, V46, P2309
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   DargentMolina P, 1996, LANCET, V348, P145, DOI 10.1016/S0140-6736(96)01440-7
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   Eperjesi F, 2004, OPHTHAL PHYSL OPT, V24, P17, DOI 10.1046/j.1475-1313.2003.00157.x
   *EY PHARM INC, 2004, DIV ANT INFL AN OPHT
   *EY PHARM INC, 2005, PRESCR INF
   *EY PHARM INC, 2004, CORR MAC BRIEF DOC
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Fasce F, 1997, INT OPHTHALMOL, V20, P251
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Fletcher D. C., 1994, OPHTHALMOLOGY CLIN N, V7, P257
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Fletcher DC, 1999, J REHABIL RES DEV, V36, P356
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Frennesson C, 1995, DOC OPHTHALMOL, V91, P9, DOI 10.1007/BF01204619
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Holz F G, 1995, Ger J Ophthalmol, V4, P336
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Kaiser PK, 2003, INVEST OPHTH VIS SCI, V44, pU297
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   Klein BEK, 1998, OPHTHALMOLOGY, V105, P160, DOI 10.1016/S0161-6420(98)91911-X
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Kniestedt Christoph, 2003, Ophthalmol Clin North Am, V16, P155, DOI 10.1016/S0896-1549(03)00013-0
   Krebs I, 2004, OPHTHALMOLOGICA, V218, P185, DOI 10.1159/000076843
   Kuyk T, 1999, J REHABIL RES DEV, V36, P303
   Laidlaw DAH, 2003, BRIT J OPHTHALMOL, V87, P1232, DOI 10.1136/bjo.87.10.1232
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   Lim L, 2004, CLIN EXP OPHTHALMOL, V32, P341, DOI 10.1111/j.1442-9071.2004.00832.x
   MARRON JA, 1982, AM J OPTOM PHYS OPT, V59, P413
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3150
   MAYER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1138
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MIDENA E, 1994, DOC OPHTHALMOL, V88, P179, DOI 10.1007/BF01204616
   MIELER W, 2005, INVEST OPHTH VIS SCI, V46, P1380
   Mones J, 2005, EYE, V19, P1142, DOI 10.1038/sj.eye.6701717
   MURPHY S, 2001, OPHTHALMIC NURSING, V5, P20
   MUSTONEN J, 1993, VISION RES, V33, P2065, DOI 10.1016/0042-6989(93)90005-H
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Owen J, 1996, OPTOMETRY VISION SCI, V73, P558, DOI 10.1097/00006324-199608000-00007
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   RABIN J, 1994, OPTOMETRY VISION SCI, V71, P685, DOI 10.1097/00006324-199411000-00003
   Riusala A, 2003, AM J OPHTHALMOL, V135, P206, DOI 10.1016/S0002-9394(02)01832-9
   Rosser DA, 2001, BRIT J OPHTHALMOL, V85, P432, DOI 10.1136/bjo.85.4.432
   RUBIN GS, 1988, CLIN VISION SCI, V2, P169
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   Rubin GS, 2001, EYE, V15, P430, DOI 10.1038/eye.2001.148
   SANDBERG MA, 1995, RETINA-J RET VIT DIS, V15, P407, DOI 10.1097/00006982-199515050-00006
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Schuchard RA, 1999, J REHABIL RES DEV, V36, P294
   Scott IU, 2002, AM J OPHTHALMOL, V133, P350, DOI 10.1016/S0002-9394(01)01406-4
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   *TAP VIP STUD GROU, 2004, RETINA, V24, P1
   Tholen AM, 2003, OPHTHALMOLOGE, V100, P28, DOI 10.1007/s00347-002-0681-2
   Varano M, 1998, Semin Ophthalmol, V13, P203, DOI 10.3109/08820539809056054
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wolffsohn JS, 2000, OPTOMETRY VISION SCI, V77, P73, DOI 10.1097/00006324-200002000-00011
   Wolffsohn JS, 2002, OPHTHAL PHYSL OPT, V22, P300, DOI 10.1046/j.1475-1313.2002.00036.x
   Wood JM, 2002, HUM FACTORS, V44, P482, DOI 10.1518/0018720024497664
NR 100
TC 46
Z9 47
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD MAR
PY 2006
VL 83
IS 3
BP 178
EP 189
DI 10.1097/01.opx.0000204510.08026.7f
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 026SI
UT WOS:000236362100008
PM 16534460
DA 2022-11-30
ER

PT J
AU Tan, RS
   Guymer, RH
   Luu, CD
AF Tan, Rose S.
   Guymer, Robyn H.
   Luu, Chi D.
TI Repeatability of Retinal Sensitivity Measurements Using a Medmont
   Dark-Adapted Chromatic Perimeter in Healthy and Age-Related Macular
   Degeneration Cases
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE dark-adapted chromatic perimeter; test-retest repeatability; age-related
   macular degeneration; scotopic perimeter
ID VISUAL FUNCTION; ADAPTATION; ROD; MICROPERIMETRY
AB Purpose: To determine the intrasession and intersession test-retest repeatability of retinal sensitivity measurements using a dark-adapted chromatic perimeter (DACP).
   Methods: For intrasession testing, retinal sensitivity within the central 24 degrees for the 505-nm stimulus was measured after 20, 30, and 40 minutes of dark adaptation (DA) and for the 625-nm stimulus was measured after the first and second 505-nm tests. For intersession testing, retinal sensitivity for both stimuli was measured after 30 minutes of DA at baseline and 1 month. The point-wise sensitivity (PWS) difference and coefficient of repeatability (CoR) of each stimulus and group were determined.
   Results: For intrasession testing, 10 age-related macular degeneration (AMD) and eight control subjects were recruited. The overall CoR for the 505-nm stimulus was 8.4 dB for control subjects and 9.1 dB for AMD cases, and for the 625-nm stimulus was 6.7 dB for control subjects and 9.5 dB for AMD cases. For intersession testing, seven AMD cases and 13 control subjects returned an overall CoR for the 505-nm stimulus of 8.2 dB for the control and 11.7 dB for the AMD group. For the 625-nm stimulus the CoR was 6.2 dB for the control group and 8.4 dB for the AMD group. Approximately 80% of all test points had a PWS difference of +/- 5 dB between the two intrasession or intersession measurements for both stimuli.
   Conclusions: The CoR for the DACP is larger than that reported for scotopic perimeters; however, the majority of test points had a PWS difference of +/- 5 dB between tests.
   Translational Relevance: The DACP offers an opportunity to measure static and dynamic rod function at multiple locations with an acceptable reproducibility level.
C1 [Tan, Rose S.; Guymer, Robyn H.; Luu, Chi D.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia.
   [Tan, Rose S.; Guymer, Robyn H.; Luu, Chi D.] Univ Melbourne, Dept Surg Ophthalmol, East Melbourne, Vic, Australia.
   [Tan, Rose S.] Trisakti Univ, Dept Ophthalmol, Jakarta, Indonesia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Universitas Trisakti
RP Luu, CD (通讯作者)，Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia.; Luu, CD (通讯作者)，Univ Melbourne, Dept Surg Ophthalmol, East Melbourne, Vic, Australia.
EM cluu@unimelb.edu.au
OI Rose, Rose/0000-0002-7351-2774; Guymer, Robyn/0000-0002-9441-4356
FU Ryan Initiative for Macular Research; Macular Disease Foundation
   Australia; Australia Awards Scholarship; National Health and Medical
   Research Council (NHMRC) Principal Research Fellowship [1103013]
FX Supported by grants from the Ryan Initiative for Macular Research, the
   Macular Disease Foundation Australia, the Australia Awards Scholarship
   (RT), and the National Health and Medical Research Council (NHMRC)
   Principal Research Fellowship (#1103013, RHG). The Centre for Eye
   Research Australia (CERA) receives Operational Infrastructure Support
   from the Victorian Government.
CR Crossland MD, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-5
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fraser RG, 2016, INVEST OPHTH VIS SCI, V57, P5436, DOI 10.1167/iovs.16-19295
   Goerdt L, 2017, INVEST OPHTH VIS SCI, V58
   Guymer RH, 1997, ARCH OPHTHALMOL-CHIC, V115, P595, DOI 10.1001/archopht.1997.01100150597004
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   NEBBIOSO M, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/671529
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Pfau M, 2017, OPHTHALMOLOGICA, V237, P42, DOI 10.1159/000453079
   Qiu F, 2009, CLIN EXP OPTOM, V92, P90, DOI 10.1111/j.1444-0938.2008.00343.x
   Steinberg JS, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.7
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
NR 28
TC 12
Z9 12
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD MAY
PY 2018
VL 7
IS 3
AR 3
DI 10.1167/tvst.7.3.3
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GF2HX
UT WOS:000431760300003
PM 29736324
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Prea, SM
   Kong, GYX
   Guymer, RH
   Sharangan, P
   Baglin, EK
   Vingrys, AJ
AF Prea, Selwyn M.
   Kong, George Y. X.
   Guymer, Robyn H.
   Sharangan, Pyrawy
   Baglin, Elizabeth K.
   Vingrys, Algis J.
TI The Short-Term Compliance and Concordance to in Clinic Testing for
   Tablet-Based Home Monitoring in Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL-FIELD; RANIBIZUMAB; MEMBRANES; OUTCOMES; SYSTEM; EYE
AB PURPOSE: The aim of this study was to determine the short-term compliance with regular home monitoring of macular retinal sensitivity (RS) in intermediate age-related macular degeneration (iAMD). Home-based outcomes were compared with in-clinic outcomes determined using (1) the same tablet device under supervision, and (2) the Macular Integrity Assessment (MaIA) microperimeter.
   DESIGN: Single-center longitudinal compliance and reliability study.
   METHODS: A total of 73 participants with iAMD were trained to perform macular field testing with the Melbourne Rapid Fields -macular (MRF-m) iPad application. Volunteers were asked to return 6 weekly tests from home, guided by audio instructions. We determined compliance with weekly testing and surveyed for factors that limited compliance. Test reliability (false positive, false negative) and RS were compared to in-clinic assays (MaIA). Data are given as mean +/- SD or as median [quartile 1-3 range]. Group comparisons were achieved with bootstrap to define the 95% confidence limits.
   RESULTS: A total of 59 participants submitted 6 home examinations with a median intertest interval of 8.0 [7.017] days. Compliance with weekly testing (7 days +/- 24 hours) was 55%. The main barrier to compliance was information technology (IT) logistic reasons. Of 694 home examinations submitted, 96% were reliable (false positive results < 25%). The mean RS returned by the tablet was significantly higher ( + 3.2 dB, P < .05) compared to the MaIA.
   CONCLUSIONS: Home monitoring produces reliable results that differ from in-clinic tests because of test design. This should not affect self-monitoring once an at-home baseline is established, but these differences will affect comparisons with in-clinic outcomes. Reasonable compliance with weekly testing was achieved. Improved IT support might lead to better compliance. (C) 2021 The Authors. Published by Elsevier Inc.
C1 [Prea, Selwyn M.; Vingrys, Algis J.] Univ Melbourne, Dept Optometry & Vis Sci, Melbourne, Vic 3010, Australia.
   [Prea, Selwyn M.; Kong, George Y. X.] Royal Victorian Eye & Ear Hosp, East Melbourne 3002, Australia.
   [Kong, George Y. X.; Guymer, Robyn H.; Sharangan, Pyrawy; Baglin, Elizabeth K.; Vingrys, Algis J.] Ctr Eye Res Australia, East Melbourne 3002, Australia.
   [Kong, George Y. X.; Guymer, Robyn H.] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic 3010, Australia.
C3 University of Melbourne; Royal Victorian Eye & Ear Hospital; Centre for
   Eye Research Australia; University of Melbourne
RP Vingrys, AJ (通讯作者)，Univ Melbourne, Dept Optometry & Vis Sci, 200 Berkeley St, Carlton, Vic 3053, Australia.
EM algis@unimelb.edu.au
OI Kong, George/0000-0003-0522-3046; Vingrys, Algis/0000-0001-5920-4604
FU National Health AMP; Medical Research Council of Australia (NHMRC) [GNT
   1103013]; HealthTech Innovation Challenge Prize; Centre for Eye Research
   Australia
FX This study was supported by the National Health & Medical Research
   Council of Australia (NH&MRC) fellowship grant no. GNT 1103013 (R.H.G.)
   and the HealthTech Innovation Challenge Prize (A.J.V. and G.K., 2017) .
   The Centre for Eye Research Australia (CERA) received operational
   infrastructure support from the Victorian Government. The Web-based
   Research Electronic Data Capture (REDCap) application and open-source
   platform OpenClinica allowed secure electronic data capture. No sponsor
   or funding organization had any role in the design or conduct of this
   research.
CR Adams M, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.32
   Anderson AJ, 2017, OPHTHALMOLOGY, V124, P1735, DOI 10.1016/j.ophtha.2017.06.028
   Aslam TM, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0239
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brucker J, 2019, OPHTHALMOL THER, V8, P461, DOI 10.1007/s40123-019-0203-9
   Cassels NK, 2018, SURV OPHTHALMOL, V63, P40, DOI 10.1016/j.survophthal.2017.05.007
   Celler BG, 2016, HOME MONITORING CHRO
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   EFRON B, 1983, AM STAT, V37, P36, DOI 10.2307/2685844
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   Freundlieb PH, 2020, GRAEF ARCH CLIN EXP, V258, P129, DOI 10.1007/s00417-019-04505-w
   Guigou S, 2021, J FR OPHTALMOL, V44, P873, DOI 10.1016/j.jfo.2020.09.034
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho CYD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.2.2
   Hoerster R, 2011, BRIT J OPHTHALMOL, V95, P1424, DOI 10.1136/bjo.2010.201129
   Kaiser PK, 2013, RETINA-J RET VIT DIS, V33, P1863, DOI 10.1097/IAE.0b013e3182899258
   Kiss S, 2020, OPHTHALMOLOGY, V127, P1179, DOI 10.1016/j.ophtha.2020.02.027
   Kong YXG, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.6.2
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   McKendrick AM, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.59
   Prea SM, 2021, AM J OPHTHALMOL, V223, P286, DOI 10.1016/j.ajo.2020.10.023
   Reiniger JL, 2019, J VISION, V19, DOI 10.1167/19.5.11
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Turpin A, 2014, J VISION, V14, DOI 10.1167/14.3.16
   Vingrys AJ, 2001, VISUAL NEUROSCI, V18, P605, DOI 10.1017/S0952523801184105
   Vingrys AJ, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.4.3
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
   Wang YZ, 2001, OPTOMETRY VISION SCI, V78, P447, DOI 10.1097/00006324-200106000-00019
   Wu ZC, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.13
   Yu HJ, 2021, OPHTHALMOL RETINA, V5, P348, DOI 10.1016/j.oret.2020.08.003
   Zaidi FH, 2004, EYE, V18, P503, DOI 10.1038/sj.eye.6700708
NR 34
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2022
VL 235
BP 280
EP 290
DI 10.1016/j.ajo.2021.09.003
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1Y4LB
UT WOS:000808112700017
PM 34509437
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Pappas, CM
   Zouache, MA
   Matthews, S
   Faust, CD
   Hageman, JL
   Williams, BL
   Richards, BT
   Hageman, GS
AF Pappas, Chris M.
   Zouache, Moussa A.
   Matthews, Stacie
   Faust, Caitlin D.
   Hageman, Jill L.
   Williams, Brandi L.
   Richards, Burt T.
   Hageman, Gregory S.
TI Protective chromosome 1q32 haplotypes mitigate risk for age-related
   macular degeneration associated with the CFH-CFHR5 and ARMS2/HTRA1 loci
SO HUMAN GENOMICS
LA English
DT Article
DE Age-related macular degeneration; CFH-CFHR5; ARMS2; HTRA1; Haplotype;
   Diplotype; Genetic association study
ID COMPLEMENT FACTOR-H; MEDIATED DARK-ADAPTATION; GENOME-WIDE ASSOCIATION;
   CONTRAST SENSITIVITY; CFHR1-CFHR3 DELETION; ALLOTYPIC VARIANT;
   BINDING-AFFINITY; CFH SNP; SUSCEPTIBILITY; GENES
AB Background Single-variant associations with age-related macular degeneration (AMD), one of the most prevalent causes of irreversible vision loss worldwide, have been studied extensively. However, because of a lack of refinement of these associations, there remains considerable ambiguity regarding what constitutes genetic risk and/or protection for this disease, and how genetic combinations affect this risk. In this study, we consider the two most common and strongly AMD-associated loci, the CFH-CFHR5 region on chromosome 1q32 (Chr1 locus) and ARMS2/HTRA1 gene on chromosome 10q26 (Chr10 locus). Results By refining associations within the CFH-CFHR5 locus, we show that all genetic protection against the development of AMD in this region is described by the combination of the amino acid-altering variant CFH I62V (rs800292) and genetic deletion of CFHR3/1. Haplotypes based on CFH I62V, a CFHR3/1 deletion tagging SNP and the risk variant CFH Y402H are associated with either risk, protection or neutrality for AMD and capture more than 99% of control- and case-associated chromosomes. We find that genetic combinations of CFH-CFHR5 haplotypes (diplotypes) strongly influence AMD susceptibility and that individuals with risk/protective diplotypes are substantially protected against the development of disease. Finally, we demonstrate that AMD risk in the ARMS2/HTRA1 locus is also mitigated by combinations of CFH-CFHR5 haplotypes, with Chr10 risk variants essentially neutralized by protective CFH-CFHR5 haplotypes. Conclusions Our study highlights the importance of considering protective CFH-CFHR5 haplotypes when assessing genetic susceptibility for AMD. It establishes a framework that describes the full spectrum of AMD susceptibility using an optimal set of single-nucleotide polymorphisms with known functional consequences. It also indicates that protective or preventive complement-directed therapies targeting AMD driven by CFH-CFHR5 risk haplotypes may also be effective when AMD is driven by ARMS2/HTRA1 risk variants.
C1 [Pappas, Chris M.; Zouache, Moussa A.; Matthews, Stacie; Faust, Caitlin D.; Hageman, Jill L.; Williams, Brandi L.; Richards, Burt T.; Hageman, Gregory S.] Univ Utah, Steele Ctr Translat Med, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
C3 Utah System of Higher Education; University of Utah
RP Zouache, MA; Hageman, GS (通讯作者)，Univ Utah, Steele Ctr Translat Med, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
EM moussa.zouache@hsc.utah.edu; gregory.hageman@hsc.utah.edu
FU National Eye Institute of the National Institutes of Health
   [R24EY017404]; Research to Prevent Blindness, New York, NY
FX This work was supported in part by the National Eye Institute of the
   National Institutes of Health under award numbers R24EY017404 (GSH).
   Additional support from donations to the Steele Center for Translational
   Medicine and an Unrestricted Grant from Research to Prevent Blindness,
   New York, NY, to the Department of Ophthalmology and Visual Sciences,
   University of Utah (GSH and MAZ).
CR Alic L, 2020, P NATL ACAD SCI USA, V117, P9942, DOI 10.1073/pnas.1913970117
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Byun YJ, 2010, JPN J OPHTHALMOL, V54, P571, DOI 10.1007/s10384-010-0866-1
   Cipriani V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14499-3
   Cipriani V, 2019, INVEST OPHTH VIS SCI, V60
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   De Luca A, 2003, J HISTOCHEM CYTOCHEM, V51, P1279, DOI 10.1177/002215540305101004
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   FIRTH D, 1993, BIOMETRIKA, V80, P27, DOI 10.1093/biomet/80.1.27
   Francis PJ, 2008, MOL VIS, V14, P1395
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   de Jorge EG, 2018, MOL IMMUNOL, V102, P42, DOI 10.1016/j.molimm.2018.06.011
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Han XK, 2020, J HUM GENET, V65, P657, DOI 10.1038/s10038-020-0750-x
   Hansen G, 2013, CELL MOL LIFE SCI, V70, P761, DOI 10.1007/s00018-012-1076-4
   Harper AR, 2015, NAT REV GENET, V16, P689, DOI 10.1038/nrg4017
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hughes AE, 2010, NAT GENET, V42, P555, DOI 10.1038/ng0710-555
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Keenan TDL, 2015, INVEST OPHTH VIS SCI, V56, P4870, DOI 10.1167/iovs.15-17009
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kosmidis I, 2020, STAT COMPUT, V30, P43, DOI 10.1007/s11222-019-09860-6
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martinez-Barricarte R, 2012, INVEST OPHTH VIS SCI, V53, P1087, DOI 10.1167/iovs.11-8709
   MIDENA E, 1994, DOC OPHTHALMOL, V88, P179, DOI 10.1007/BF01204616
   Myers TA, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00157
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688
   Schmid-Kubista KE, 2009, INVEST OPHTH VIS SCI, V50, P5070, DOI 10.1167/iovs.09-3975
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Spencer KL, 2007, INVEST OPHTH VIS SCI, V48, P4277, DOI 10.1167/iovs.06-1427
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   Team RC, R LANG ENV STAT COMP
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P162
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Williams BL, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103617118
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YIN L, 2021, GENOM PROTEOM BIOINF
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zouache MA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78059-x
   Zurawa-Janicka D, 2017, ARCH BIOCHEM BIOPHYS, V621, P6, DOI 10.1016/j.abb.2017.04.004
NR 85
TC 8
Z9 8
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1473-9542
EI 1479-7364
J9 HUM GENOMICS
JI Hum. Genomics
PD SEP 25
PY 2021
VL 15
IS 1
AR 60
DI 10.1186/s40246-021-00359-8
PG 15
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA UU8BC
UT WOS:000699018800001
PM 34563268
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Beck, M
   Munk, MR
   Ebneter, A
   Wolf, S
   Zinkernagel, MS
AF Beck, Marco
   Munk, Marion R.
   Ebneter, Andreas
   Wolf, Sebastian
   Zinkernagel, Martin S.
TI Retinal Ganglion Cell Layer Change in Patients Treated With
   Anti-Vascular Endothelial Growth Factor for Neovascular Age-related
   Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID NERVE-FIBER LAYER; INTRAOCULAR-PRESSURE; INTRAVITREAL RANIBIZUMAB;
   INJECTIONS; BEVACIZUMAB; THICKNESS
AB PURPOSE: To evaluate macular retinal ganglion cell thickness in patients with neovascular age-related macular degeneration (AMD) and intravitreal anti vascular endothelial growth factor (VEGF) therapy.
   DESIGN: Retrospective case series with fellow-eye comparison.
   METHODS: Patients with continuous unilateral anti-VEGF treatment for subfoveal and juxtafoveal neovascular AMD and a minimum follow-up of 24 months were included. The retinal nerve fiber (RNFL) and retinal ganglion cell layer (RGCL) in the macula were segmented using an ETDRS grid. RNFL and RGCL thickness of the outer ring of the ETDRS grid were quantified at baseline and after repeated anti-VEGF injections, and compared to the patients' untreated fellow eye. Furthermore, best corrected visual acuity (BCVA), age, and retinal pigment epithelium (RPE) atrophy were recorded and correlated with RNFL and RGCL.
   RESULTS: Sixty eight eyes of 34 patients (23 female and 11 male; mean age 76.7 (SD 8.2) with a mean number of 31.5 (SD +/- 9.8) anti-VEGF injections and a mean follow-up period of 45.3 months (SD +/- 10.5) were included. Whereas the RGCL thickness decreased significantly compared to the noninjected fellow eye (P =.01), the decrease of the RNFL was not significant. Visual acuity gain was significantly correlated with RGCL thickness (r = 0.52, P <.05) at follow-up and negatively correlated (r = -0.41, P <.05) with age. Presence of RPE atrophy correlated negatively with the RGCL thickness at follow-up (r = -0.37, P =.03).
   CONCLUSION: During the course of long-term anti-VEGF therapy there is a significant decrease of the RGCL in patients with neovascular AMD compared to the fellow (untreated) eye. (C) 2016 The Authors. Published. by Elsevier Inc.
C1 [Beck, Marco; Munk, Marion R.; Ebneter, Andreas; Wolf, Sebastian; Zinkernagel, Martin S.] Univ Bern, Univ Hosp Bern, Dept Ophthalmol, Inselspital, Bern, Switzerland.
   [Munk, Marion R.; Wolf, Sebastian; Zinkernagel, Martin S.] Univ Bern, Univ Hosp Bern, Dept Ophthalmol, Bern Photog Reading Ctr,Inselspital, Bern, Switzerland.
   [Ebneter, Andreas; Wolf, Sebastian; Zinkernagel, Martin S.] Univ Bern, Univ Hosp Bern, Dept Clin Res, Inselspital, Bern, Switzerland.
C3 University of Bern; University Hospital of Bern; University of Bern;
   University Hospital of Bern; University of Bern; University Hospital of
   Bern
RP Zinkernagel, MS (通讯作者)，Univ Hosp Bern, CH-3010 Bern, Switzerland.
EM m.zinkernagel@gmail.com
RI Wolf, Sebastian/B-8782-2008; Zinkernagel, Martin/C-3799-2017; Ebneter,
   Andreas/C-5226-2017
OI Wolf, Sebastian/0000-0002-7467-7028; Zinkernagel,
   Martin/0000-0002-5622-114X; Ebneter, Andreas/0000-0001-6666-2558;
   Zinkernagel, Martin S./0000-0003-3447-2359
FU Novartis; Bayer; Allergan; Swiss National Science Foundation (SNSF)
FX MARION R. MUNK: CONSULTANT FEES FROM Novartis, Travel Grant from Bayer;
   Consultant for Lumithera; Andreas Ebneter: Honoraria from Bayer for
   lectures, Travel Grant from Allergan; Sebastian Wolf: grants from Swiss
   National Science Foundation (SNSF); nonfinancial support from Heidelberg
   Engineering; Consultant or Advisory Board: Alcon, Allergan, Bayer
   Healthcare, Novartis Pharma, and Roche; Martin S. Zinkernagel: grants
   from Swiss National Science Foundation (SNSF); nonfinancial support from
   Heidelberg Engineering; Consultant or Advisory Board: Bayer Healthcare,
   Novartis Pharma; Stock or equity interests in Novartis Pharma. The
   following author has no financial disclosures: Marco Beck. All authors
   attest that they meet the current ICMJE criteria for authorship.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Brar VS, 2010, MOL VIS, V16, P1848
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Cheng CK, 2009, RETINA-J RET VIT DIS, V29, P306, DOI 10.1097/IAE.0b013e3181909404
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Demirel S, 2015, CURR EYE RES, V40, P87, DOI 10.3109/02713683.2014.917190
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P1044, DOI 10.1097/IAE.0b013e3180592ba6
   Foxton RH, 2013, AM J PATHOL, V182, P1379, DOI 10.1016/j.ajpath.2012.12.032
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Ohkubo S, 2014, INVEST OPHTH VIS SCI, V55, P5269, DOI 10.1167/iovs.14-14153
   Park HYL, 2014, AM J PATHOL, V184, P1752, DOI 10.1016/j.ajpath.2014.02.016
   Parlak M, 2015, INT OPHTHALMOL, V35, P473, DOI 10.1007/s10792-014-9972-2
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sharei V, 2010, EUR J OPHTHALMOL, V20, P174, DOI 10.1177/112067211002000124
   Shin HY, 2013, INVEST OPHTH VIS SCI, V54, P7344, DOI 10.1167/iovs.13-12667
   Shin HJ, 2014, INVEST OPHTH VIS SCI, V55, P2403, DOI 10.1167/iovs.13-13769
   Sobaci G, 2013, INT J OPHTHALMOL-CHI, V6, P211, DOI 10.3980/j.issn.2222-3959.2013.02.20
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zayit-Soudry S, 2010, RETINA-J RET VIT DIS, V30, P671, DOI 10.1097/IAE.0b013e3181c0858c
   Zeimer R, 1998, OPHTHALMOLOGY, V105, P224, DOI 10.1016/S0161-6420(98)92743-9
   Zinkernagel MS, 2015, INVEST OPHTH VIS SCI, V56, P1894, DOI 10.1167/iovs.14-16204
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 27
TC 49
Z9 52
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2016
VL 167
BP 10
EP 17
DI 10.1016/j.ajo.2016.04.003
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DP9OQ
UT WOS:000378826100002
PM 27084000
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Yip, JLY
   Khawaja, AP
   Chan, MPY
   Broadway, DC
   Peto, T
   Tufail, A
   Luben, R
   Hayat, S
   Bhaniani, A
   Wareham, NJ
   Khaw, KT
   Foster, PJ
AF Yip, Jennifer L. Y.
   Khawaja, Anthony P.
   Chan, Michelle P. Y.
   Broadway, David C.
   Peto, Tunde
   Tufail, Adnan
   Luben, Robert
   Hayat, Shabina
   Bhaniani, Amit
   Wareham, Nicholas J.
   Khaw, Kay-Tee
   Foster, Paul J.
TI Cross Sectional and Longitudinal Associations between Cardiovascular
   Risk Factors and Age Related Macular Degeneration in the EPIC-Norfolk
   Eye Study
SO PLOS ONE
LA English
DT Article
ID C-REACTIVE PROTEIN; POSTINFARCTION PATIENTS; POOLED FINDINGS; TERM
   INCIDENCE; PREVALENCE; DISEASE; MACULOPATHY; HYPERTENSION; POLYMORPHISM;
   CHOLESTEROL
AB Purpose
   To examine the cross sectional and longitudinal relationship between cardiovascular risk factors and age-related macular degeneration (AMD) in a large British cohort study.
   Methods
   The EPIC Norfolk Eye study is nested in a larger prospective cohort study. Data on cardiovascular risk factors were collected at baseline (1993-1997) and follow up (2006-2011) via clinical examination, validated lifestyle questionnaires and serum blood samples. AMD was ascertained using standardised grading of fundus photographs at the follow up. Logistic regression was used to examine associations between baseline and follow up risk factors with AMD.
   Results
   5,344 pairs (62.0% of total 8623) of fundus photographs were of sufficient quality for grading of AMD in participants with mean age of 67.4 years old (range 44-91) at diagnosis. There were 28 cases of late AMD (0.5%, 95% confidence interval (CI)=0.3-0.8%) and 645 cases of early AMD (12.1%, 95%CI=11.2-13.0.%). In multivariable analysis, older people with higher levels of baseline high density lipoprotein-cholesterol (HDL-C) and C-reactive protein (CRP) were more likely to have any signs of AMD, after adjusting for sex, education, smoking, and systolic blood pressure. In cross sectional analysis, only older age and higher HDL were significantly associated with AMD.
   Conclusions
   We have found that older age and higher levels of CRP and HDL-C were associated with increased odds of AMD in this population in the longitudinal analysis, but older age and HDL-C, not CRP was significantly associated with AMD in the cross sectional analysis. The prevalence of AMD in this cohort was low compared to other cohorts in Europe, the US and Australia, and probably reflects the some selection biases in follow up participation as well as the low rate of smoking among our healthy participants.
C1 [Yip, Jennifer L. Y.; Khawaja, Anthony P.; Luben, Robert; Hayat, Shabina; Bhaniani, Amit; Khaw, Kay-Tee] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England.
   [Yip, Jennifer L. Y.; Khawaja, Anthony P.; Chan, Michelle P. Y.; Peto, Tunde; Tufail, Adnan; Foster, Paul J.] Moorfields Eye Hosp, NIHR Biomed Res Ctr, London, England.
   [Yip, Jennifer L. Y.; Khawaja, Anthony P.; Chan, Michelle P. Y.; Peto, Tunde; Tufail, Adnan; Foster, Paul J.] UCL Inst Ophthalmol, London, England.
   [Broadway, David C.] Norfolk & Norwich Univ Hosp, Dept Ophthalmol, Norwich, Norfolk, England.
   [Wareham, Nicholas J.] Univ Cambridge, MRC, Epidemiol Unit, Sch Clin Med, Cambridge, England.
C3 University of Cambridge; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust; University of
   London; University College London; Norfolk & Norwich University
   Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital;
   University of Cambridge
RP Yip, JLY (通讯作者)，Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England.
EM jlyy2@medschl.cam.ac.uk
RI Khaw, Kay-Tee/AAZ-3209-2021; Luben, Robert N/H-5519-2015; Peto,
   Tunde/G-8812-2018; Foster, Paul/V-7288-2019
OI Luben, Robert N/0000-0002-5088-6343; Peto, Tunde/0000-0001-6265-0381;
   Foster, Paul/0000-0002-4755-177X; Yip, Jennifer Lai
   Yee/0000-0003-3788-7170; Khawaja, Anthony/0000-0001-6802-8585; Tufail,
   Adnan/0000-0001-6131-7640
FU Medical Research Council [G0401527]; Cancer Research UK [C864/A8257];
   Age UK Research into Ageing grant [262]; International Glaucoma
   Association; Richard Desmond Charitable Trust (via Fight for Sight);
   Department for Health through the NIHR to Moorfields Eye Hospital;
   University College London (UCL) Institute of Ophthalmology for a
   specialist Biomedical Research Centre for Ophthalmology; MRC [G1001939,
   MC_UU_12015/1] Funding Source: UKRI; Medical Research Council [G1001939,
   MC_U106179471, MC_UU_12015/1, G1000143] Funding Source: researchfish;
   National Institute for Health Research [CL-2010-14-004,
   NF-SI-0512-10114, NF-SI-0512-10135] Funding Source: researchfish
FX EPIC-Norfolk infrastructure and core functions are supported by grants
   from the Medical Research Council (G0401527) and Cancer Research UK
   (C864/A8257). The clinic for the third health examination was funded by
   Age UK Research into Ageing grant (262). Dr. Yip is a National Institute
   for Health Research (NIHR) Clinical Lecturer. Dr. Khawaja is a Wellcome
   Trust Clinical Research Fellow. Michelle Chan is an MRC/RCOphth Clinical
   Training Fellow and has received additional support from the
   International Glaucoma Association. Professor Foster has received
   additional support from the Richard Desmond Charitable Trust (via Fight
   for Sight). Professor Foster and Tunde Peto received funding from the
   Department for Health through the award made by the NIHR to Moorfields
   Eye Hospital and the University College London (UCL) Institute of
   Ophthalmology for a specialist Biomedical Research Centre for
   Ophthalmology. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Corsetti JP, 2006, ATHEROSCLEROSIS, V187, P191, DOI 10.1016/j.atherosclerosis.2005.09.012
   Corsetti JP, 2010, ARTERIOSCL THROM VAS, V30, P1657, DOI 10.1161/ATVBAHA.110.207977
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Day N, 1999, BRIT J CANCER, V80, P95
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayat SA, 2014, INT J EPIDEMIOL, V43, P1063, DOI 10.1093/ije/dyt086
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Khaw KT, 2006, INT J EPIDEMIOL, V35, P1034, DOI 10.1093/ije/dyl079
   Khawaja AP, 2013, BMJ OPEN, V3
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Navab M, 2011, NAT REV CARDIOL, V8, P222, DOI 10.1038/nrcardio.2010.222
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
NR 42
TC 26
Z9 27
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 15
PY 2015
VL 10
IS 7
AR e0132565
DI 10.1371/journal.pone.0132565
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CN1RL
UT WOS:000358197600125
PM 26176222
OA gold, Green Published, Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Resch, MD
   Balogh, A
   Deak, GG
   Nagy, ZZ
   Papp, A
AF Resch, Miklos D.
   Balogh, Aniko
   Deak, Gabor Gy
   Nagy, Zoltan Z.
   Papp, Andras
TI Vascular density in age-related macular degeneration after one year of
   antiVEGF treatment with treat-and-extend and fixed regimens
SO PLOS ONE
LA English
DT Article
ID VEGF TREATMENT; RANIBIZUMAB; THERAPY; AFLIBERCEPT; OUTCOMES; AMD; CNV
AB Treatment of neovascular age-related macular degeneration (nAMD) with VEGF can be performed with several posologies. The purpose of our cross-sectional study was to analyze retinal vessel density by quantitative OCT-angiography (OCT-A) and to compare treat-and-extend (T&E) and fixed treatment protocols to a control group with dry AMD. Altogether 48 patients were enrolled: 13 eyes with T&E protocol ranibizumab treatment (group A) and 17 eyes with fixed regimen aflibercept therapy (group B), the control group comprised 18 eyes with dry AMD (group C). One year after the start of the treatment, quantitative OCT-A (AngioVue-Optovue, Fermont, USA) was performed: superficial and deep retinal vessel densities were analyzed in the foveal and parafoveal regions. Our results show, that the density of retinal superficial vasculature in the fovea was not different between the treatment groups (A: 25.9 +/- 9.1%; B: 24.3%+/- 8.9), neither from group C (25.6 +/- 4.8%). Superficial parafoveal vascular density of the retina, however, was decreased in both treated groups (A: 46.7 +/- 9.1%, B: 42.9 +/- 6.1%, C: 49.7 +/- 4.9%). In the deep retinal plexus, vascular density was lower in both treatment groups compared to that of in controls in both the foveal and parafoveal area (A: 29.8 +/- 6.3%, B: 32.5 +/- 6.9%, C: 36.4 +/- 1.7% and A: 46.3 +/- 3.8%, B: 47.1 +/- 5.3%, C: 49.7 +/- 4.9%, foveal and parafoveal respectively). Our data suggest, that after one year of anti-VEGF treatment, reduced macular vessel density in three of the four examined vascular regions can be found independent of the treatment regimen.
C1 [Resch, Miklos D.; Balogh, Aniko; Nagy, Zoltan Z.; Papp, Andras] Semmelweis Univ, Dept Ophthalmol, Budapest, Hungary.
   [Balogh, Aniko] Uzsoki Hosp, Dept Ophthalmol, Budapest, Hungary.
   [Deak, Gabor Gy] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna, Austria.
C3 Semmelweis University; Medical University of Vienna
RP Resch, MD (通讯作者)，Semmelweis Univ, Dept Ophthalmol, Budapest, Hungary.
EM miklosresch@gmail.com
OI Resch, Miklos/0000-0002-8285-1153
CR Amoaku W, 2018, CLIN OPHTHALMOL, V12, P1731, DOI 10.2147/OPTH.S174560
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cennamo G, 2020, OPHTHALMOL THER, V9, P77, DOI 10.1007/s40123-019-00221-0
   Coscas F, 2019, BRIT J OPHTHALMOL, V103, P1342, DOI 10.1136/bjophthalmol-2018-313065
   Czako C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28994-7
   Faatz H, 2019, EYE, V33, P1466, DOI 10.1038/s41433-019-0429-8
   Hikichi T, 2020, RETINA-J RET VIT DIS, V40, P2158, DOI 10.1097/IAE.0000000000002745
   Ho AC, 2018, OPHTHALMOL RETINA, V2, P676, DOI 10.1016/j.oret.2017.10.017
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Matsumoto H, 2018, OPHTHALMOL RETINA, V2, P462, DOI 10.1016/j.oret.2017.09.002
   McClintic SM, 2018, OPHTHALMOL RETINA, V2, P931, DOI 10.1016/j.oret.2018.01.014
   Miere A, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/3751702
   Mitchell P, 2012, CLIN EXP OPHTHALMOL, V40, P44
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Pilotto E, 2019, BRIT J OPHTHALMOL, V103, P67, DOI 10.1136/bjophthalmol-2017-311752
   Rispoli M, 2018, OSLI RETINA, V49, P918, DOI 10.3928/23258160-20181203-02
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Sorour OA, 2019, INT OPHTHALMOL, V39, P2361, DOI 10.1007/s10792-019-01076-x
   Wylegala A, 2018, J HEALTHC ENG, V2018, DOI 10.1155/2018/8595278
   You QS, 2020, AM J OPHTHALMOL, V209, P206, DOI 10.1016/j.ajo.2019.09.004
NR 28
TC 1
Z9 1
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 26
PY 2020
VL 15
IS 2
AR e0229388
DI 10.1371/journal.pone.0229388
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LQ8FM
UT WOS:000535233700030
PM 32101581
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Gabai, A
   Veritti, D
   Lanzetta, P
AF Gabai, Andrea
   Veritti, Daniele
   Lanzetta, Paolo
TI One-year outcome of ranibizumab for neovascular age-related macular
   degeneration: a thorough analysis in a real-world clinical setting
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization;
   Ranibizumab
ID VERTEPORFIN; BEVACIZUMAB; THERAPY
AB Purpose: To verify the safety and efficacy of ranibizumab in neovascular age-related macular degeneration (nAMD) and factors influencing the outcome in a real-world setting.
   Methods: Retrospective 12-month follow-up analysis of 100 naive nAMD eyes treated with as-needed ranibizumab. Changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), lesion, and leakage size were recorded. Type and characteristics of lesions and indicators of protocol adherence were analyzed.
   Results: Mean BCVA at baseline was 61.6 +/- 14.8 Early Treatment Diabetic Retinopathy Study letters and 59.6 +/- 16 at 12 months. Sixty-three eyes maintained or improved BCVA; the number of injections and follow-up visits were 4.8 and 5.1, respectively. First injection and pro re nata retreatments were administered 22.7 and 20.5 days after prescription, respectively. Seventy-two eyes received 3 initial monthly injections. Patients were not reinjected despite BCVA loss >5 letters one or more times in 37% of cases. No adverse events were reported. The CRT diminished by 26 +/- 101 mu m; choroidal neovascularization size and leakage area increased by 0.53 +/- 1.31 mm(2) and 0.34 +/- 1.33 mm(2), respectively. The BCVA gain was correlated with CRT reduction (rho = 0.24, p = 0.016), mean baseline BCVA (rho = -0.25, p = 0.01), age (rho = -0.25, p = 0.01), and decrease in CNV size and leakage area (p = 0.56 and rho = 0.59, respectively, p<0.001).
   Conclusions: Our results compare unfavorably with those of controlled trials. Treatment and followup regimens in real-world settings seem to have a major role in determining outcome. Lower age and BCVA at baseline were associated with better response to treatment.
C1 [Gabai, Andrea; Veritti, Daniele; Lanzetta, Paolo] Univ Udine, Dept Ophthalmol, I-33100 Udine, Italy.
   [Veritti, Daniele; Lanzetta, Paolo] Ist Europeo Microchirurgia Oculare, Udine, Italy.
C3 University of Udine
RP Lanzetta, P (通讯作者)，Univ Udine, Dept Ophthalmol, Piazza S Maria Misericordia, I-33100 Udine, Italy.
EM paolo.lanzetta@uniud.it
OI VERITTI, Daniele/0000-0003-0148-5348
CR Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rofagha S, 2013, OPHTHALMOLOGY
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 16
TC 19
Z9 19
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY-JUN
PY 2014
VL 24
IS 3
BP 396
EP 401
DI 10.5301/ejo.5000385
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AJ4NH
UT WOS:000337652600018
PM 24242222
DA 2022-11-30
ER

PT J
AU Meyers, KJ
   Mares, JA
   Igo, RP
   Truitt, B
   Liu, Z
   Millen, AE
   Klein, M
   Johnson, EJ
   Engelman, CD
   Karki, CK
   Blodi, B
   Gehrs, K
   Tinker, L
   Wallace, R
   Robinson, J
   LeBlanc, ES
   Sarto, G
   Bernstein, PS
   SanGiovanni, JP
   Iyengar, SK
AF Meyers, Kristin J.
   Mares, Julie A.
   Igo, Robert P., Jr.
   Truitt, Barbara
   Liu, Zhe
   Millen, Amy E.
   Klein, Michael
   Johnson, Elizabeth J.
   Engelman, Corinne D.
   Karki, Chitra K.
   Blodi, Barbara
   Gehrs, Karen
   Tinker, Lesley
   Wallace, Robert
   Robinson, Jennifer
   LeBlanc, Erin S.
   Sarto, Gloria
   Bernstein, Paul S.
   SanGiovanni, John Paul
   Iyengar, Sudha K.
TI Genetic Evidence for Role of Carotenoids in Age-Related Macular
   Degeneration in the Carotenoids in Age-Related Eye Disease Study
   (CAREDS)
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE macular degeneration; carotenoids; genes
ID SINGLE NUCLEOTIDE POLYMORPHISMS; POLYUNSATURATED FATTY-ACIDS;
   GENOME-WIDE ASSOCIATION; RECEPTOR CLASS-B; BETA-CAROTENE; LUTEIN
   SUPPLEMENTATION; DENSITY-LIPOPROTEIN; VITAMIN-A; DOCOSAHEXAENOIC ACID;
   SERUM CONCENTRATIONS
AB PURPOSE. We tested variants in genes related to lutein and zeaxanthin status for association with age-related macular degeneration (AMD) in the Carotenoids in Age-Related Eye Disease Study (CAREDS).
   METHODS. Of 2005 CAREDS participants, 1663 were graded for AMD from fundus photography and genotyped for 424 single nucleotide polymorphisms (SNPs) from 24 candidate genes for carotenoid status. Of 337 AMD cases 91% had early or intermediate AMD. The SNPs were tested individually for association with AMD using logistic regression. A carotenoid-related genetic risk model was built using backward selection and compared to existing AMD risk factors using the area under the receiver operating characteristic curve (AUC).
   RESULTS. A total of 24 variants from five genes (BCMO1, BCO2, NPCL1L1, ABCG8, and FADS2) not previously related to AMD and four genes related to AMD in previous studies (SCARB1, ABCA1, APOE, and ALDH3A2) were associated independently with AMD, after adjusting for age and ancestry. Variants in all genes (not always the identical SNPs) were associated with lutein and zeaxanthin in serum and/or macula, in this or other samples, except for BCO2 and FADS2. A genetic risk score including nine variants significantly (P = 0.002) discriminated between AMD cases and controls beyond age, smoking, CFH Y402H, and ARMS2 A69S. The odds ratio (95% confidence interval) for AMD among women in the highest versus lowest quintile for the risk score was 3.1 (2.0-4.9).
   CONCLUSIONS. Variants in genes related to lutein and zeaxanthin status were associated with AMD in CAREDS, adding to the body of evidence supporting a protective role of lutein and zeaxanthin in risk of AMD.
C1 [Meyers, Kristin J.; Mares, Julie A.; Liu, Zhe; Karki, Chitra K.; Blodi, Barbara] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, McPherson Eye Res Inst, Madison, WI 53726 USA.
   [Igo, Robert P., Jr.; Truitt, Barbara; Iyengar, Sudha K.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Millen, Amy E.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Social & Prevent Med, Buffalo, NY 14260 USA.
   [Klein, Michael] Oregon Hlth & Sci Univ, Dept Ophthalmol, Casey Eye Inst, Portland, OR 97201 USA.
   [Johnson, Elizabeth J.] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
   [Engelman, Corinne D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA.
   [Gehrs, Karen] Univ Iowa, Carver Coll Med, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
   [Tinker, Lesley] Fred Hutchinson Canc Res Ctr, Dept Canc Prevent Res Program, Seattle, WA 98104 USA.
   [Wallace, Robert; Robinson, Jennifer] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA.
   [Robinson, Jennifer] Univ Iowa, Dept Med, Coll Publ Hlth, Iowa City, IA 52242 USA.
   [LeBlanc, Erin S.] Kaiser Ctr Hlth Res, Portland, OR USA.
   [Sarto, Gloria] Univ Wisconsin, Sch Med & Publ Hlth, Dept Obstet & Gynecol, Madison, WI 53726 USA.
   [Bernstein, Paul S.] Univ Utah Hlth Care, Moran Eye Ctr, Salt Lake City, UT USA.
   [SanGiovanni, John Paul] NEI, NIH, Clin Trials Branch, Bethesda, MD 20892 USA.
C3 University of Wisconsin System; University of Wisconsin Madison; Case
   Western Reserve University; State University of New York (SUNY) System;
   State University of New York (SUNY) Buffalo; Oregon Health & Science
   University; Tufts University; United States Department of Agriculture
   (USDA); University of Wisconsin System; University of Wisconsin Madison;
   University of Iowa; Fred Hutchinson Cancer Center; University of Iowa;
   University of Iowa; Kaiser Permanente; University of Wisconsin System;
   University of Wisconsin Madison; Utah System of Higher Education;
   University of Utah; University of Utah Hospital; National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI)
RP Mares, JA (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610 N Walnut St,1063 WARF, Madison, WI 53726 USA.
EM jmarespe@wisc.edu
RI , Jennifer/AAD-8336-2019; SanGiovanni, John Paul/AAU-3895-2020; Igo,
   Rob/P-3438-2019; /S-1190-2019
OI Igo, Rob/0000-0002-0024-1993; /0000-0001-7488-250X
FU National Institutes of Health, National Eye Institute [EY013018,
   EY016886]; Retina Research Foundation and Research; National Heart,
   Lung, and Blood Institute [N01 WH22110, 24152, 32100-2, 32105-6,
   32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32,
   44221]; Women's Health Initiative; NATIONAL EYE INSTITUTE [U10EY013018,
   R01EY016886, R01EY011600, R01EY021532] Funding Source: NIH RePORTER;
   WOMEN&apos;S HEALTH INITIATIVE - OFFICE OF THE DIRECTOR NIH
   [N01WH022110] Funding Source: NIH RePORTER
FX Supported by the National Institutes of Health, National Eye Institute
   (Grants EY013018, EY016886), the Retina Research Foundation and Research
   to Prevent Blindness (CAREDS Study), and by the National Heart, Lung,
   and Blood Institute (Contracts N01 WH22110, 24152, 32100-2, 32105-6,
   32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and
   44221; The Women's Health Initiative, to which CAREDS is ancillary).
CR Adams MKM, 2012, AM J EPIDEMIOL, V175, P511, DOI 10.1093/aje/kwr329
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Albanes D, 1997, AM J CLIN NUTR, V66, P366, DOI 10.1093/ajcn/66.2.366
   Aleman TS, 2007, INVEST OPHTH VIS SCI, V48, P1319, DOI 10.1167/iovs.06-0764
   Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   Amengual J, 2013, J BIOL CHEM, V288, P34081, DOI 10.1074/jbc.M113.501049
   Amengual J, 2011, FASEB J, V25, P948, DOI 10.1096/fj.10-173906
   [Anonymous], 2012, ONLINE MENDELIAN INH
   Attie AD, 2002, J LIPID RES, V43, P1610, DOI 10.1194/jlr.M200223-JLR200
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Bhosale P, 2009, BIOCHEMISTRY-US, V48, P4798, DOI 10.1021/bi9004478
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Bone RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-12
   Borel P, 2012, MOL NUTR FOOD RES, V56, P228, DOI 10.1002/mnfr.201100322
   Borel P, 2011, ANN MED, V43, P47, DOI 10.3109/07853890.2010.531757
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Calder PC, 2006, AM J CLIN NUTR, V83, p1505S, DOI 10.1093/ajcn/83.6.1505S
   Chen HY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019454
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Clifford AJ, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-66
   Connolly EE, 2010, CURR EYE RES, V35, P335, DOI 10.3109/02713680903521951
   Connor WE, 2007, INVEST OPHTH VIS SCI, V48, P4226, DOI 10.1167/iovs.06-1275
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Delyfer MN, 2012, INVEST OPHTH VIS SCI, V53, P1204, DOI 10.1167/iovs.11-8721
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   During A, 2008, J LIPID RES, V49, P1715, DOI 10.1194/jlr.M700580-JLR200
   During A, 2005, J NUTR, V135, P2305, DOI 10.1093/jn/135.10.2305
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Ferrucci L, 2009, AM J HUM GENET, V84, P123, DOI 10.1016/j.ajhg.2008.12.019
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Ford NA, 2013, NUTR RES, V33, P733, DOI 10.1016/j.nutres.2013.07.007
   Foulon T, 1999, SCAND J CLIN LAB INV, V59, P239, DOI 10.1080/00365519950185607
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond CJ, 2012, INVEST OPHTH VIS SCI, V53, P4963, DOI 10.1167/iovs.12-9618
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   He MA, 2010, ARTERIOSCL THROM VAS, V30, P885, DOI 10.1161/ATVBAHA.109.199422
   Herron KL, 2006, J NUTR, V136, P1161, DOI 10.1093/jn/136.5.1161
   Hessel S, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M706763200
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Johnson AR, 2012, IMMUNOL REV, V249, P218, DOI 10.1111/j.1600-065X.2012.01151.x
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   Krinsky Norman I., 2005, Molecular Aspects of Medicine, V26, P459
   Kvansakul J, 2006, OPHTHAL PHYSL OPT, V26, P362, DOI 10.1111/j.1475-1313.2006.00387.x
   Landrum JT, 2004, OXIDAT STRESS DIS, V13, P445
   Laurie CC, 2010, GENET EPIDEMIOL, V34, P591, DOI 10.1002/gepi.20516
   Leung IYF, 2004, INVEST OPHTH VIS SCI, V45, P3244, DOI 10.1167/iovs.02-1233
   Lietz G, 2012, MOL NUTR FOOD RES, V56, P241, DOI 10.1002/mnfr.201100387
   Lietz G, 2012, J NUTR, V142, p161S, DOI 10.3945/jn.111.140756
   Liew SHM, 2005, INVEST OPHTH VIS SCI, V46, P4430, DOI 10.1167/iovs.05-0519
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P2636, DOI 10.1167/iovs.09-4397
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   McKay GJ, 2013, OPHTHALMOLOGY, V120, P1632, DOI 10.1016/j.ophtha.2013.01.030
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Mehta N. R., 2006, ARCH OPHTHALMOL-CHIC, V124, P1
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Meyers KJ, 2013, INVEST OPHTH VIS SCI, V54, P2333, DOI [10.1167/iovs.12-10867, 10.1167/iovs.13-13216]
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nelson GJ, 1997, LIPIDS, V32, P1137, DOI 10.1007/s11745-997-0146-5
   Nolan JM, 2012, EXP EYE RES, V101, P9, DOI 10.1016/j.exer.2012.05.006
   Patterson N, 2006, PLOS GENET, V2, P2074, DOI 10.1371/journal.pgen.0020190
   Peter I, 2011, AM J OPHTHALMOL, V152, P1005, DOI 10.1016/j.ajo.2011.05.016
   Price AL, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0030236
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Provost AC, 2009, INVEST OPHTH VIS SCI, V50, P3931, DOI 10.1167/iovs.08-2527
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Reboul E, 2005, BIOCHEM J, V387, P455, DOI 10.1042/BJ20040554
   Reboul E, 2011, PROG LIPID RES, V50, P388, DOI 10.1016/j.plipres.2011.07.001
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   ROMANCHIK JE, 1995, J NUTR, V125, P2610
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2014, CAROTENOIDS AND RETINAL DISEASE, P93
   SanGiovanni JP, 2012, AM J CLIN NUTR, V96, p1223S, DOI 10.3945/ajcn.112.038240
   Sasaki M, 2009, INVEST OPHTH VIS SCI, V50, P1433, DOI 10.1167/iovs.08-2493
   Sato Y, 2012, J PHARM PHARM SCI, V15, P256, DOI 10.18433/J38K56
   Schaefer EJ, 2010, CURR OPIN LIPIDOL, V21, P289, DOI 10.1097/MOL.0b013e32833c1ef6
   Schalch W, 2007, ARCH BIOCHEM BIOPHYS, V458, P128, DOI 10.1016/j.abb.2006.09.032
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Shaban H, 2002, BIOL CHEM, V383, P537, DOI 10.1515/BC.2002.054
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   Stoffel W, 2008, EMBO J, V27, P2281, DOI 10.1038/emboj.2008.156
   Thomas TR, 2004, METABOLISM, V53, P749, DOI 10.1016/j.metabol.2003.12.019
   Tian R, 2010, ANIM GENET, V41, P253, DOI 10.1111/j.1365-2052.2009.01990.x
   Tian Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073387
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Vage DI, 2010, BMC GENET, V11, DOI 10.1186/1471-2156-11-10
   van der Veen RLP, 2010, OPHTHALMOLOGY, V117, P966, DOI 10.1016/j.ophtha.2009.10.019
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   von Lintig J, 2010, ANNU REV NUTR, V30, P35, DOI 10.1146/annurev-nutr-080508-141027
   Wang MX, 2013, ATHEROSCLEROSIS, V227, P380, DOI 10.1016/j.atherosclerosis.2013.01.021
   Wray NR, 2007, GENOME RES, V17, P1520, DOI 10.1101/gr.6665407
   Yeum KJ, 1996, AM J CLIN NUTR, V64, P594, DOI 10.1093/ajcn/64.4.594
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
   Zhu XW, 2012, ANNU REV NUTR, V32, P161, DOI 10.1146/annurev-nutr-071811-150709
NR 119
TC 68
Z9 72
U1 2
U2 33
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2014
VL 55
IS 1
BP 587
EP 599
DI 10.1167/iovs.13-13216
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AB6DG
UT WOS:000331877200069
OA Green Published
DA 2022-11-30
ER

PT J
AU Yuan, MZ
   Han, RA
   Zhang, CX
   Chen, YX
AF Yuan, Ming-zhen
   Han, Ruo-an
   Zhang, Chen-xi
   Chen, You-xin
TI Association of Genes in the High-Density Lipoprotein Metabolic Pathway
   with Polypoidal Choroidal Vasculopathy in Asian Population: A Systematic
   Review and Meta-Analysis
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID EXUDATIVE HEMORRHAGIC CHORIORETINOPATHY; MACULAR DEGENERATION; CLINICAL
   CHARACTERISTICS; VARIANTS; RISK; POLYMORPHISM; CHINESE; RETINA; ABCA1;
   SUSCEPTIBILITY
AB Purpose. To assess the association of genes in the high-density lipoprotein metabolic pathway (HDLMP) with polypoidal choroidal vasculopathy (PCV) and the genetic difference in the HDLMP between PCV and age-related macular degeneration (AMD). Methods. We performed a literature search in EMBASE, PubMed, and Web of Science for genetic studies on 7 single nucleotide polymorphisms (SNPs) from 5 genes in the HDLMP including cholesteryl ester transfer protein (CETP), hepatic lipase (LIPC), lipoprotein lipase (LPL), ATP-binding cassette transporter A1 (ABCA1), and ATP-binding cassette transporter G1 (ABCG1) in PCV. All studies were published before September 30, 2017, without language restriction. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) of each polymorphism were estimated. We also compared the association profiles between PCV and AMD and performed a sensitivity analysis. Results. Our result is based on 43 articles. After excluding duplicates and articles without complete information, 7 studies were applicable to meta-analysis. 7 polymorphisms were meta-analyzed: CETP rs2303790/rs3764261, LIPC rs10468017/rs493258, LPL rs12678919, ABCA1 rs1883025, and ABCG1 rs57137919. We found that in Asian population, CETP rs3764261 (T allele; OR. 1.46; 95% CI: 1.28-1.665, P < 0.01), CETP rs2303790 (G allele; OR. 1.57; 95% CI: 1.258-1.96, P < 0.01), and ABCG1 rs57137919 (A allele; OR. 1.168; 95% CI: 1.016-1.343, P < 0.01) were significantly associated with PCV, and ABCG1 rs57137919 (A allele; OR. 1.208, 95% CI: 1.035-1.411, P < 0.01) has different effects in PCV and AMD. The other 4 polymorphisms in LIPC/LPL/ABCA1 had no significant association with PCV (P > 0.05). The sensitivity analysis validated the significance of our analysis. Conclusions. Our study revealed 7 polymorphisms in 5 genes. Among them, CETP (rs3764261/rs2303790) and ABCG1 (rs57137919) were the major susceptibility genes for PCV in Asian population and ABCG1 (rs57137919) showed allelic diversity between PCV and AMD. Since the size for PCV and AMD was small, we need to study these genes genotyping in larger samples.
C1 [Chen, You-xin] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   Peking Union Med Coll, Beijing, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Peking Union Medical College
RP Chen, YX (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing, Peoples R China.
EM chenyouxinpumch@163.com
CR Bretillon L, 2008, EXP EYE RES, V87, P521, DOI 10.1016/j.exer.2008.08.010
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Fan Q, 2017, J HUM GENET, V62, P1049, DOI 10.1038/jhg.2017.83
   Goldman DR, 2013, RETINA-J RET VIT DIS, V33, P48, DOI 10.1097/IAE.0b013e31825df12a
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hirami Y, 2009, JPN J OPHTHALMOL, V53, P396, DOI 10.1007/s10384-009-0669-4
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Iwama D, 2008, JPN J OPHTHALMOL, V52, P116, DOI 10.1007/s10384-007-0503-9
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kuo JZ, 2013, EXPERT REV OPHTHALMO, V8, P127, DOI 10.1586/EOP.13.3
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee J, 2013, EYE, V27, P266, DOI 10.1038/eye.2012.276
   Li FT, 2014, OPHTHALMIC RES, V51, P210, DOI 10.1159/000357978
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Liu F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097044
   Liu K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07018
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Liutkeviciene R, 2017, GENE, V636, P30, DOI 10.1016/j.gene.2017.09.022
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P5897, DOI 10.1167/iovs.09-4878
   Ma L, 2016, INVEST OPHTH VIS SCI, V57, P5758, DOI 10.1167/iovs.16-20175
   Mantel I, 2012, AM J OPHTHALMOL, V153, P910, DOI 10.1016/j.ajo.2011.10.017
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mathis T, 2016, OSLI RETINA, V47, P1154, DOI 10.3928/23258160-20161130-12
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   Meng Q., 2015, PLOS ONE, V10
   Nakata I, 2013, INVEST OPHTH VIS SCI, V54, P6068, DOI 10.1167/iovs.13-11605
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Wang D, 2015, OPHTHALMIC GENET, V36, P303, DOI 10.3109/13816810.2014.881506
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yokoyama S, 2006, J ATHEROSCLER THROMB, V13, P1, DOI 10.5551/jat.13.1
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yuan DQ, 2013, OPHTHALMOLOGY, V120, P2051, DOI 10.1016/j.ophtha.2013.03.026
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 57
TC 6
Z9 6
U1 0
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2018
VL 2018
AR 9538671
DI 10.1155/2018/9538671
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GK0EK
UT WOS:000435780100001
PM 29977615
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Ma, HW
   Yang, F
   Ding, XQ
AF Ma Hongwei
   Yang Fan
   Ding Xi-Qin
TI Inhibition of thyroid hormone signaling protects retinal pigment
   epithelium and photoreceptors from cell death in a mouse model of
   age-related macular degeneration
SO CELL DEATH & DISEASE
LA English
DT Article
ID SODIUM IODATE; STRESS; DYSFUNCTION; EXPRESSION; INJECTION; RECEPTOR;
   LEADS
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly. Dry AMD is characterized by a progressive macular degeneration of the retinal pigment epithelium (RPE) and photoreceptors, and the RPE oxidative damage/dystrophy is at the core of the disease. Recent population/patients-based studies have shown an association of high free serum thyroid hormone (TH) levels with increased risk of AMD. This work investigated the effects of TH signaling inhibition on RPE and photoreceptor damage/cell death in an oxidative stress-induced mouse model of AMD. TH signaling inhibition was achieved by anti-thyroid drug treatment and oxidative stress was induced by sodium iodate (NaIO3) administration. Mice treated with NaIO3 showed severe RPE and photoreceptor cell death/necroptosis, destruction, oxidative damage, retinal stress, and reduced retinal function. Treatment with anti-thyroid drug protected RPE and photoreceptors from damage/cell death induced by NaIO3, reduced oxidative damage of RPE and photoreceptors, and preserved retinal function. Gene expression analysis showed that the NaIO3-induced RPE/photoreceptor damage/cell death involves multiple mechanisms, including cellular oxidative stress responses, activation of necroptosis/apoptosis signaling, and inflammatory responses. Treatment with anti-thyroid drug abolished these cellular stress/death responses. The findings of this study demonstrate a role of TH signaling in RPE and photoreceptor cell death after oxidative stress challenge, and support a role of TH signaling in the pathogenesis of AMD.
C1 [Ma Hongwei; Yang Fan; Ding Xi-Qin] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center
RP Ding, XQ (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA.
EM xi-qin-ding@ouhsc.edu
FU BrightFocus Foundation [M2018107]; NIH NEI [P30EY021725]
FX We thank the Imaging Core Facility and the Histology Core Facility of
   the Department of Cell Biology at the University of Oklahoma Health
   Sciences Center for technical assistance. This work was supported by the
   BrightFocus Foundation grant M2018107 and the NIH NEI grant P30EY021725.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Balmer J, 2015, INT J MOL SCI, V16, P15086, DOI 10.3390/ijms160715086
   Ceresini G, 2009, J AM GERIATR SOC, V57, P89, DOI 10.1111/j.1532-5415.2008.02080.x
   Chaker L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0329-0
   Chatziralli I, 2017, BIOMED HUB, V2, P1, DOI [10.1159/000454706, DOI 10.1159/000454706]
   Cho BJ, 2016, JPN J OPHTHALMOL, V60, P226, DOI 10.1007/s10384-016-0429-1
   Chowers G, 2017, INVEST OPHTH VIS SCI, V58, P2239, DOI 10.1167/iovs.16-21255
   Cruz-Guilloty F, 2011, NATURE, V478, P42, DOI 10.1038/478042a
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gopinath B, 2016, INVEST OPHTH VIS SCI, V57, P5273, DOI 10.1167/iovs.16-19735
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   HOSODA L, 1993, ACTA OPHTHALMOL, V71, P616
   Jang KH, 2019, EXP EYE RES, V180, P8, DOI 10.1016/j.exer.2018.11.026
   Kalmijn S, 2000, CLIN ENDOCRINOL, V53, P733, DOI 10.1046/j.1365-2265.2000.01146.x
   Kim GH, 2016, GRAEF ARCH CLIN EXP, V254, P705, DOI 10.1007/s00417-015-3258-x
   KIRYU J, 1992, VISION RES, V32, P2221, DOI 10.1016/0042-6989(92)90086-X
   Kiuchi K, 2002, CURR EYE RES, V25, P373, DOI 10.1076/ceyr.25.6.373.14227
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Kuo LJ, 2008, IN VIVO, V22, P305
   Lin SY, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15050902
   Ma HW, 2017, FASEB J, V31, P3425, DOI 10.1096/fj.201601166RR
   Ma HW, 2015, J BIOL CHEM, V290, P20880, DOI 10.1074/jbc.M115.641159
   Ma HW, 2014, P NATL ACAD SCI USA, V111, P3602, DOI 10.1073/pnas.1317041111
   Ma HW, 2013, HUM MOL GENET, V22, P3906, DOI 10.1093/hmg/ddt245
   Machalinska A, 2010, NEUROCHEM RES, V35, P1819, DOI 10.1007/s11064-010-0248-6
   Mao XY, 2018, BIOMED PHARMACOTHER, V103, P517, DOI 10.1016/j.biopha.2018.04.038
   Mones J, 2016, INVEST OPHTH VIS SCI, V57, P6712, DOI 10.1167/iovs.16-19355a
   Moriguchi M, 2018, INVEST OPHTH VIS SCI, V59, P3476, DOI 10.1167/iovs.17-23532
   Ng L, 2001, NAT GENET, V27, P94, DOI 10.1038/83829
   Ng L, 2010, J NEUROSCI, V30, P3347, DOI 10.1523/JNEUROSCI.5267-09.2010
   NILSSON SEG, 1977, ACTA OPHTHALMOL, V55, P994
   Reisenhofer MH, 2017, CURR MOL MED, V17, P100, DOI 10.2174/1566524017666170331162048
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Roberts MR, 2006, P NATL ACAD SCI USA, V103, P6218, DOI 10.1073/pnas.0509981103
   Wang CXZ, 2012, EXP EYE RES, V102, P1, DOI 10.1016/j.exer.2012.06.003
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Xu JH, 2013, J NEUROSCI, V33, P14939, DOI 10.1523/JNEUROSCI.0909-13.2013
   Xu JH, 2012, INVEST OPHTH VIS SCI, V53, P1117, DOI 10.1167/iovs.11-8168
   Xu JH, 2011, INVEST OPHTH VIS SCI, V52, P3557, DOI 10.1167/iovs.10-6358
   Yang F, 2018, FASEB J, V32, P6316, DOI 10.1096/fj.201800484RR
   Yang F, 2016, FASEB J, V30, P4313, DOI 10.1096/fj.201600715R
   Zhang XY, 2016, SCI REP-UK, V6, DOI 10.1038/srep37279
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
NR 46
TC 16
Z9 16
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JAN 13
PY 2020
VL 11
IS 1
AR 24
DI 10.1038/s41419-019-2216-7
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA LF8RI
UT WOS:000527681400002
PM 31932580
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lu, Y
   Huang, WZ
   Zhang, YH
   Huang, XF
   Zhang, X
   Ma, HZ
   Ren, GL
   Shi, F
   Kuang, LH
   Yan, SG
   Luo, SK
   Zhang, JY
   He, JF
   Yang, WZ
   Gao, ZY
   Leng, YX
AF Lu, Yan
   Huang, Wenzhi
   Zhang, Yuehong
   Huang, Xiongfei
   Zhang, Xu
   Ma, Haizhi
   Ren, Guoliang
   Shi, Feng
   Kuang, Lihui
   Yan, Shigang
   Luo, Shuke
   Zhang, Junyan
   He, Jingfang
   Yang, Weizhong
   Gao, Zongyin
   Leng, Yunxia
TI Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet
   Age-Related Macular Degeneration in China: 12 Months Follow up
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE age-related macular degeneration; ranibizumab; conbercept; polypoidal
   choroidal vasculopathy (PCV); choroidal neovascularization (CNV)
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; ENDOTHELIAL GROWTH-FACTOR;
   INTRAVITREAL INJECTION; 12-MONTH OUTCOMES; RANIBIZUMAB; AFLIBERCEPT;
   CONBERCEPT; THERAPY; BLINDNESS; SAFETY
AB Purpose: To evaluate the treatment solutions and effectiveness of intravitreal ranibizumab (RBZ) or conbercept in patients with wet age-related macular degeneration (wAMD) in a real-life setting in China.Methods: The medical records of 368 patients with wAMD who started RBZ or conbercept treatment between 1 May 2014 and 30 April 2018 were evaluated. All patients were defined on fundus angiography at baseline to determine the subtype of AMD (PCV or CNV). We report visual acuity (VA) and central retinal thickness (CRT) measurements at baseline and 12 months.Results: The average number of anti-VEGF injections was 2.1 +/- 1.2. The BCVA improvement of these two groups was similar with a difference of 1.00 letter (95% CI: -1.4~3.4, p = 0.8505). At the end of the study, a BCVA increase of at least 5 letters was determined to be a satisfactory efficacy endpoint. Several factors were related to the possible improvement in the satisfactory efficacy endpoint, including female sex (OR 2.07, 95% CI 1.22~3.51), number of injections (OR 1.40, 95% CI 1.12~1.75) and VA change at the first month (OR 13.75, 95% CI 7.41~25.51). Additionally, some factors were related to the possible reduction in the satisfactory efficacy endpoint, including diabetes (OR 0.27, 95% CI 0.10~0.73) and disease history (OR 0.75, 95% CI 0.57~0.98).Conclusion: Our study demonstrates that anti-VEGF drugs can effectively improve BCVA and reduce CRT in AMD patients. Sex, number of injections, VA change at the first month, diabetes and disease history are the most important factors affecting visual acuity.
C1 [Lu, Yan; Ma, Haizhi; Yan, Shigang; Luo, Shuke] Foshan Second Peoples Hosp, Dept Ophthalmol, Foshan, Peoples R China.
   [Huang, Wenzhi; Zhang, Yuehong; Huang, Xiongfei; Zhang, Xu; Ren, Guoliang; Shi, Feng; Kuang, Lihui; Yang, Weizhong; Gao, Zongyin; Leng, Yunxia] South China Univ Technol, Dept Ophthalmol, Guangzhou First Peoples Hosp, Guangzhou, Peoples R China.
C3 South China University of Technology
RP Leng, YX (通讯作者)，South China Univ Technol, Dept Ophthalmol, Guangzhou First Peoples Hosp, Guangzhou, Peoples R China.
EM eylengyx@scut.edu.cn
OI ZHANG, JUNYAN/0000-0002-7890-3707
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chavan R, 2014, CLIN OPHTHALMOL, V8, P717, DOI 10.2147/OPTH.S60763
   Chen XL, 2018, GRAEF ARCH CLIN EXP, V256, P1449, DOI 10.1007/s00417-018-4020-y
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Cui J, 2018, EYE, V32, P391, DOI 10.1038/eye.2017.187
   Ding K, 2017, MABS-AUSTIN, V9, P269, DOI 10.1080/19420862.2016.1268305
   Fenner BJ, 2020, OPHTHALMOL RETINA, V4, P403, DOI 10.1016/j.oret.2019.10.019
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fursova A Zh, 2018, Vestn Oftalmol, V134, P59, DOI 10.17116/oftalma201813406159
   Gao L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65000-5
   Gao L, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019007
   Gao Y, 2018, INVEST OPHTH VIS SCI, V59, P4307, DOI 10.1167/iovs.17-23747
   Garweg JG, 2017, J OCUL PHARMACOL TH, V33, P567, DOI 10.1089/jop.2017.0031
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gupta ADSP, 2014, LUMINOUS DET STAT ME
   Hirakata T, 2016, CLIN OPHTHALMOL, V10, P969, DOI 10.2147/OPTH.S101596
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Huang LZ, 2014, INVEST OPHTH VIS SCI, V55, P2534, DOI 10.1167/iovs.13-13437
   Jin EZ, 2017, RETINA-J RET VIT DIS, V37, P971, DOI 10.1097/IAE.0000000000001274
   Johnston RL, 2016, OPHTHALMOLOGY, V123, P2386, DOI 10.1016/j.ophtha.2016.07.037
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Kamenskih T G, 2019, Vestn Oftalmol, V135, P134, DOI 10.17116/oftalma2019135061134
   Kim JH, 2016, GRAEF ARCH CLIN EXP, V254, P2101, DOI 10.1007/s00417-016-3353-7
   Kiss S, 2020, J MANAG CARE SPEC PH, V26, P253, DOI 10.18553/jmcp.2020.19245
   Li X, 2019, RETINA-J RET VIT DIS, V39, P1353, DOI 10.1097/IAE.0000000000002152
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Madhusudhana KC, 2016, BRIT J OPHTHALMOL, V100, P1617, DOI 10.1136/bjophthalmol-2015-308077
   Menon G, 2013, EYE, V27, P959, DOI 10.1038/eye.2013.93
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Minnella AM, 2016, BIODRUGS, V30, P353, DOI 10.1007/s40259-016-0179-0
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Nguyen TT, 2015, EXPERT REV CLIN PHAR, V8, P541, DOI 10.1586/17512433.2015.1075879
   Pieramici DJ, 2006, EXPERT OPIN BIOL TH, V6, P1237, DOI 10.1517/14712598.6.11.1237
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Randolph SA, 2014, WORKPLACE HEALTH SAF, V62, P352, DOI 10.3928/21650799-20140708-06
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shen YS, 2021, EUR J OPHTHALMOL, V31, P1267, DOI 10.1177/1120672120913012
   Song PG, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020703
   Sugiyama A, 2018, OPHTHALMOLOGICA, V239, P52, DOI 10.1159/000480439
   Takahashi Y, 2018, JPN J OPHTHALMOL, V62, P576, DOI 10.1007/s10384-018-0615-4
   Wang FH, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/7530458
   Wang LP, 2018, DRUG DES DEV THER, V12, P3625, DOI 10.2147/DDDT.S176021
   Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070544
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wu B, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7689862
   Zhang JX, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0807-1
   Zhang Y, 2014, VALUE HEALTH, V17, pA782, DOI 10.1016/j.jval.2014.08.381
NR 55
TC 1
Z9 1
U1 4
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD NOV 11
PY 2021
VL 8
AR 735318
DI 10.3389/fmed.2021.735318
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA XH6TF
UT WOS:000725564000001
PM 34859005
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Westborg, I
   Albrecht, S
   Rosso, A
AF Westborg, Inger
   Albrecht, Susanne
   Rosso, Aldana
TI RISK FOR LOW VISUAL ACUITY AFTER 1 AND 2 YEARS OF TREATMENT WITH
   RANIBIZUMAB OR BEVACIZUMAB FOR PATIENTS WITH NEOVASCULAR AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascular age-related macular degeneration; bevacizumab; choroidal
   neovascularization; ETDRS; ranibizumab; register data
ID VERTEPORFIN PHOTODYNAMIC THERAPY; DAILY CLINICAL-PRACTICE; INTRAVITREAL
   RANIBIZUMAB; HORIZON; ANCHOR
AB Purpose: To investigate how patients with neovascular age-related macular degeneration treated with ranibizumab or bevacizumab respond to treatment in daily clinical practice.
   Methods: Data from the Swedish Macula Register on the treatment received by 3,912 patients during 2011 to 2014 is reported. Patients' characteristics at the first visit, visual acuity, number of injections, and reason for terminating the treatment if applicable are discussed. Furthermore, the risk of having poor vision (visual acuity under 60 Early Treatment Diabetes Retinopathy Study letters or approximately 20/60 Snellen) is calculated for the treated eye after 1 year and 2 years.
   Results: The treatment outcome depends on the visual acuity at the first visit. For patients with visual acuity more than 60 letters, the risk of having a visual acuity lower than 60 letters after 1 year or 2 years of treatment is approximately 20%. However, for patients with low visual acuity at diagnosis (fewer than 60 letters), the risk is approximately 60%. The risk of having a visual acuity lower than 60 letters does not depend on the choice of treatment drug.
   Conclusion: Treatment with anti-vascular endothelial growth factor intravitreal injections mainly maintains the visual acuity level, and only approximately 20% and 40% of the patients required vision rehabilitation after 1 year and 2 years, respectively.
C1 [Westborg, Inger] Umea Univ, Dept Clin Sci Ophthalmol, Umea, Sweden.
   [Albrecht, Susanne] Blekinge Hosp, Ctr Registers South, Karlskrona, Sweden.
   [Rosso, Aldana] Skane Univ Hosp, Ctr Registers South, Klin Gatan 22, SE-22185 Lund, Sweden.
   [Rosso, Aldana] Lund Univ, Inst Translat Med, Dept Radiol, Malmo, Sweden.
C3 Umea University; Lund University; Skane University Hospital; Lund
   University
RP Rosso, A (通讯作者)，Skane Univ Hosp, Ctr Registers South, Klin Gatan 22, SE-22185 Lund, Sweden.
EM Aldana.Rosso@med.lu.se
RI Westborg, Inger/AAD-7108-2021
OI Rosso, Aldana/0000-0001-6603-2855
CR Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Levesque LE, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b5087
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Pepe MS, 2004, STAT EVALUATION MED
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
NR 17
TC 10
Z9 10
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2017
VL 37
IS 11
BP 2035
EP 2046
DI 10.1097/IAE.0000000000001431
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FW3LV
UT WOS:000425208800022
PM 28141748
DA 2022-11-30
ER

PT J
AU Heussen, FMA
   Fawzy, NF
   Joeres, S
   Lux, A
   Maaijwee, K
   Meurs, JC
   Kirchhof, B
   Joussen, AM
AF Heussen, F. M. A.
   Fawzy, N. F.
   Joeres, S.
   Lux, A.
   Maaijwee, K.
   Meurs, J. Cv
   Kirchhof, B.
   Joussen, A. M.
TI Autologous translocation of the choroid and RPE in age-related macular
   degeneration: 1-year follow-up in 30 patients and recommendations for
   patient selection
SO EYE
LA English
DT Article
DE age-related macular degeneration; translocation; RPE; choriod
ID RETINAL-PIGMENT EPITHELIUM; OPHTHALMIC FINDINGS; READING CHART; SURGERY;
   NEOVASCULARIZATION; TRANSPLANTATION; VERTEPORFIN; RETINECTOMY;
   RETINOTOMY; SECONDARY
AB Aim To evaluate the long-term ( 1 year) functional and anatomical outcome of autologous translocation of peripheral choroid and retinal pigment epithelium (RPE) in 30 patients with age-related macular degeneration (AMD).
   Methods After the extraction of the neovascular complex, an autologous peripheral full-thickness graft of RPE and choroid was positioned under the macula. Functional tests included ETDRS vision, reading (Radner test), and microperimetry ( scanning laser ophthalmoscope). Fluorescein, indocyanine green angiography, and autofluorescence were monitored.
   Results Preoperative visual acuity ranged from 20/40 to 20/800 (0.3-1.6 log MAR). Vision ranged from 20/25 to LP (0.1-2.1 logMAR) 1 year after surgery, with stabilization in six eyes, an increase in five eyes, and a decrease in 19 eyes. Deterioration mostly occurred within the first 3 months after surgery. In patients who demonstrated vascularization of the graft after 3 months, this persisted up to 12 months as did fixation when initially stable. Autofluorescence decreased significantly from 6 to 12 months postoperatively. Eleven cases showed a recurrence of choroidal neovascularization (CNV) within this period.
   Conclusion Patch translocation results in a viable graft. There is no evidence of graft failure within a 1-year follow-up. Nevertheless, there is risk for late CNV formation originating from the edges of the excision side of the CNV and growing peripheral to the graft.
C1 [Lux, A.; Joussen, A. M.] Univ Dusseldorf, Dept Ophthalmol, D-40225 Dusseldorf, Germany.
   [Heussen, F. M. A.; Fawzy, N. F.; Joeres, S.; Lux, A.; Kirchhof, B.; Joussen, A. M.] Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, Cologne, Germany.
   [Maaijwee, K.; Meurs, J. Cv] Rotterdam Eye Hosp, Rotterdam, Netherlands.
C3 Heinrich Heine University Dusseldorf; University of Cologne; Rotterdam
   Eye Hospital
RP Joussen, AM (通讯作者)，Univ Dusseldorf, Dept Ophthalmol, Moorenstr 5, D-40225 Dusseldorf, Germany.
EM Joussena@googlemail.com
RI Joussen, Antonia/AAA-6901-2022
OI Heussen, Florian Moritz/0000-0003-0536-9870; Fawzy,
   Nader/0000-0002-0916-5667; van Meurs, Joyce/0000-0001-6245-2123
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Aisenbrey S, 2006, ARCH OPHTHALMOL-CHIC, V124, P183, DOI 10.1001/archopht.124.2.183
   Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   [Anonymous], 1994, Arch Ophthalmol, V112, P489
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Cahill MT, 2005, ARCH OPHTHALMOL-CHIC, V123, P935, DOI 10.1001/archopht.123.7.935
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Joussen AM, 2007, OPHTHALMOLOGY, V114, P551, DOI 10.1016/j.ophtha.2006.08.016
   Lappas A, 2004, GRAEF ARCH CLIN EXP, V242, P638, DOI 10.1007/s00417-003-0764-z
   Lappas A, 2000, GRAEF ARCH CLIN EXP, V238, P631, DOI 10.1007/s004170000149
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   Mruthyunjaya P, 2005, RETINA-J RET VIT DIS, V25, P597, DOI 10.1097/00006982-200507000-00010
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Radner T, 1998, KLIN MONATSBL AUGENH, V213, P174, DOI 10.1055/s-2008-1034969
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scheider A, 1999, GRAEF ARCH CLIN EXP, V237, P10, DOI 10.1007/s004170050187
   Semkova I, 2002, P NATL ACAD SCI USA, V99, P13090, DOI 10.1073/pnas.202486199
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   Stifter E, 2004, GRAEF ARCH CLIN EXP, V242, P31, DOI 10.1007/s00417-003-0776-8
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   Wong D, 2004, BRIT J OPHTHALMOL, V88, P186, DOI 10.1136/bjo.2003.019273
NR 30
TC 43
Z9 43
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2008
VL 22
IS 6
BP 799
EP 807
DI 10.1038/sj.eye.6702823
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 312HL
UT WOS:000256659800010
PM 17641681
OA Bronze
DA 2022-11-30
ER

PT J
AU Oner, A
   Gumus, K
   Arda, H
   Yuce, Y
   Karakucuk, S
   Mirza, E
AF Oner, Ayse
   Gumus, Koray
   Arda, Hatice
   Yuce, Yudum
   Karakucuk, Sarper
   Mirza, Ertugrul
TI Pattern electroretinographic results after photodynamic therapy alone
   and photodynamic therapy in combination with intravitreal bevacizumab
   for choroidal neovascularization in age-related macular degeneration
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE Pattern electroretinography; Photodynamic therapy; Intravitreal
   bevacizumab
ID VERTEPORFIN THERAPY; MULTIFOCAL-ERG; AVASTIN; INJECTION; TRIAMCINOLONE;
   EFFICACY; ANTIBODY; SAFETY; EDEMA; OCT
AB Purpose To evaluate the changes in pattern electroretinography (PERG) 1 month after photodynamic therapy alone and photodynamic therapy in combination with intravitreal bevacizumab for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Methods This is a prospective series of 45 eyes with subfoveal CNV secondary to AMD. Twenty eyes were treated with photodynamic therapy (PDT) with verteporfin and 1.25 mg of intravitreal bevacizumab, and 25 patients were treated with PDT alone. Visual acuities and serial PERG recordings were performed both before and 1 month after therapy. Results Following the 1-month therapy period, visual acuity improved in 56% of patients in the PDT group and 76% of patients in the combination group. No significant ocular or systemic adverse effects were observed in either group. According to the PERG results, the mean P50 amplitude was 1.5 +/- A 0.9 mu V before PDT and improved to 2.1 +/- A 1.1 mu V at 1 month after PDT. The mean P50 amplitudes in the combination therapy group before and after therapy were 1.6 +/- A 0.8 mu V and 2.7 +/- A 1.2 mu V, respectively, and the difference was statistically significant between the groups. Conclusions In this small series of eyes with limited follow-up, the combined treatment of PDT with verteporfin and intravitreal bevacizumab seems to be associated with improvement in VA and pattern electroretinographic results when compared to those in the PDT group.
C1 [Oner, Ayse; Gumus, Koray; Arda, Hatice; Yuce, Yudum; Karakucuk, Sarper; Mirza, Ertugrul] Erciyes Univ, Dept Ophthalmol, Fac Med, TR-38039 Kayseri, Turkey.
C3 Erciyes University
RP Oner, A (通讯作者)，Erciyes Univ, Dept Ophthalmol, Fac Med, TR-38039 Kayseri, Turkey.
EM aoner@erciyes.edu.tr
CR Ahmadieh H, 2008, EUR J OPHTHALMOL, V18, P297, DOI 10.1177/112067210801800222
   Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bach Michael, 2000, Documenta Ophthalmologica, V101, P11
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   BASSHHUR ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI DOI 10.1016/J.AJO.2007.09.031
   BERNINGER T, 1991, PRINCIPLES PRACTICE, P291
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Hahn R, 2007, OPHTHALMOLOGE, V104, P588, DOI 10.1007/s00347-007-1547-4
   Heiduschka P, 2008, RETINA-J RET VIT DIS, V28, P46, DOI 10.1097/IAE.0b013e31815e9368
   Holder GE, 2001, PROG RETIN EYE RES, V20, P531, DOI 10.1016/S1350-9462(00)00030-6
   Inan UU, 2007, INVEST OPHTH VIS SCI, V48, P1773, DOI 10.1167/iovs.06-0828
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Maffei L, 1986, FRONTIERS CLIN NEURO, V3, P101
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   Moschos MM, 2008, DOC OPHTHALMOL, V116, P147, DOI 10.1007/s10633-007-9110-9
   Moschos MM, 2007, DOC OPHTHALMOL, V114, P37, DOI 10.1007/s10633-006-9036-7
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Shetty R, 2008, DOC OPHTHALMOL, V116, P129, DOI 10.1007/s10633-007-9090-9
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
NR 28
TC 3
Z9 4
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD AUG
PY 2009
VL 119
IS 1
BP 37
EP 42
DI 10.1007/s10633-009-9167-8
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 461TK
UT WOS:000267294200006
PM 19225818
DA 2022-11-30
ER

PT J
AU Wykoff, CC
   Brown, DM
   Maldonado, ME
   Croft, DE
AF Wykoff, Charles C.
   Brown, David M.
   Maldonado, Maria E.
   Croft, Daniel E.
TI Aflibercept treatment for patients with exudative age-related macular
   degeneration who were incomplete responders to multiple ranibizumab
   injections (TURF trial)
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID 2.0 MG RANIBIZUMAB; INTRAVITREAL AFLIBERCEPT; THERAPY; BEVACIZUMAB;
   RESISTANT; OUTCOMES; FLUID; AMD
AB Aim To determine the efficacy of 2.0 mg aflibercept in the management of patients with recalcitrant exudative age-related macular degeneration (AMD).
   Methods In this prospective, open-label, single-arm clinical trial, patients were seen monthly and given mandatory 2.0 mg aflibercept at baseline, months 1, 2 and 4. Pro re nata (PRN) retreatment at months 3 and 5 was performed upon evidence of disease on spectral domain-optical coherence tomography (SD-OCT). End point at month 6: mean change in Early Treatment Diabetic Retinopathy Study best corrected visual acuity (ETDRS BCVA) and central subfield thickness (CST), mean number of aflibercept injections, percentage of PRN injections required, patients with no fluid on SD-OCT and patients losing >15 letters.
   Results At baseline, 46 patients with a mean of 42 prior antivascular endothelial growth factor-A (anti-VEGF) intravitreal treatments had a mean of 74.2 letters (Snellen equivalent 20/32) and mean CST of 347 mu m. ETDRS letters remained stable throughout the trial; at month 6, mean BCVA change was +0.2 letters (range -10 to +13, p=0.71). Anatomically, mean CST improved significantly from baseline at each study visit including -23.6 mm at month 1 and -27.3 mm at month 6 (p=0.018). Seventy-one of 90 (79%) possible PRN injections were required and a mean of 5.6 aflibercept injections out of the maximum six were administered. Ten of 45 (22%) patients had no retinal fluid on SD-OCT at month 6. No patient lost >15 letters.
   Conclusions Aflibercept 2.0 mg treatment maintained mean visual acuity improvements previously achieved with high-dose 2.0-mg ranibizumab injections in recalcitrant wet AMD patients. Aflibercept 2.0 mg treatment led to significant anatomic improvement and was required monthly in most patients.
C1 [Wykoff, Charles C.; Brown, David M.; Maldonado, Maria E.; Croft, Daniel E.] Houston Methodist Hosp, Retina Consultants Houston, Weill Cornell Med Coll, Houston, TX 77030 USA.
C3 Cornell University; The Methodist Hospital System; The Methodist
   Hospital - Houston
RP Wykoff, CC (通讯作者)，Houston Methodist Hosp, Retina Consultants Houston, Weill Cornell Med Coll, 6560 Fannin,Suite 750, Houston, TX 77030 USA.
EM ccwmd@houstonretina.com
FU Regeneron Pharmaceuticals
FX Research grant from Regeneron Pharmaceuticals. The funding organisation
   had no role in the design or conduct of this research.
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jaffe G, 2013, EFFECT EARLY PERSIST
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schachat AP, 2013, AM J OPHTHALMOL, V156, P1, DOI 10.1016/j.ajo.2013.04.009
   Wykoff CC, 2013, OPHTHALMOLOGY, V120, P1945, DOI 10.1016/j.ophtha.2013.06.030
   Wykoff CC, 2013, OPHTHAL SURG LAS IM, V44, P121, DOI 10.3928/23258160-20130313-04
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 18
TC 65
Z9 73
U1 0
U2 9
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2014
VL 98
IS 7
BP 951
EP 955
DI 10.1136/bjophthalmol-2013-304736
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AJ2NH
UT WOS:000337492500021
PM 24518078
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Foster, WJ
   Tufail, W
   Issa, AM
AF Foster, William J.
   Tufail, Waqas
   Issa, Amalia M.
TI The quality of pharmacoeconomic evaluations of age-related macular
   degeneration therapeutics: a systematic review and quantitative
   appraisal of the evidence
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID COST-EFFECTIVENESS; PHOTODYNAMIC THERAPY; VISUAL IMPAIRMENT;
   CLINICAL-PRACTICE; 5-YEAR INCIDENCE; CHOROIDAL NEOVASCULARIZATION;
   ECONOMIC-EVALUATION; MEDICAL LITERATURE; USERS GUIDES; UTILITY
AB Aim To appraise the quality of published pharmacoeconomic studies of therapeutic interventions for age-related macular degeneration (AMD).
   Methods Systematic review of the literature and evaluation of study quality using the Quality of Health Economic Studies instrument. A systematic search of the English-language literature for economic studies of therapeutic interventions for AMD from 1990 to March 2008 was performed.
   Results A total of 3637 articles were initially identified. Only 24 met eligibility criteria and were rated using the Quality of Health Economic Studies. The mean quality overall rating was 61.6, with quality scores ranging from 18 to 92. There was a higher mean quality score in the studies designed as clinical trials versus observational type designed studies (mean=74.7(11.4), 52.6 (16.5) respectively, p=0.002) and studies in which the statistical analyses were clearly presented versus studies in which the statistical analyses were not so clear (mean=74.3 (12.3), 53.1 (16.1) respectively, p=0.004). Interestingly, government funded studies exhibited a similar mean quality score to studies that were funded by industry (mean=71.0 (15.1), 61.7 (18.5) respectively, p=0.25). A general linear model was fitted using those independent variables which were significantly associated with quality score. The variables 'study design' and 'statistics presented clearly' were found to be jointly significant and explained nearly 70% of the variation in the dependent variable (R-2=0.68).
   Conclusions Our analysis reveals that the methodological quality of the health economic analysis of AMD therapeutic interventions in the literature is suboptimal. There is considerable variation in methodological rigour between the articles, and we have identified several attributes that are predictive of study quality.
C1 [Tufail, Waqas; Issa, Amalia M.] Univ Houston, Dept Clin Sci & Adm, Coll Pharm, Program Personalized Med & Targeted Therapeut, Houston, TX 77030 USA.
   [Foster, William J.; Issa, Amalia M.] Methodist Hosp, Res Inst, Houston, TX 77030 USA.
   [Foster, William J.] Univ Houston, Dept Phys, Ophthalm Res & Nanotechnol Grp, Houston, TX 77030 USA.
   [Foster, William J.] Methodist Hosp, Dept Ophthalmol, Weill Cornell Med Coll, Houston, TX 77030 USA.
C3 University of Houston System; University of Houston; The Methodist
   Hospital System; The Methodist Hospital - Houston; University of Houston
   System; University of Houston; Cornell University; The Methodist
   Hospital System; The Methodist Hospital - Houston
RP Issa, AM (通讯作者)，Univ Houston, Dept Clin Sci & Adm, Coll Pharm, Program Personalized Med & Targeted Therapeut, 1441 Moursund St, Houston, TX 77030 USA.
EM aissa@uh.edu
OI Foster, William/0000-0002-6668-3831
FU National Eye Institute of the National Institutes of Health [EY017112];
   NATIONAL EYE INSTITUTE [K08EY017112] Funding Source: NIH RePORTER
FX WJF acknowledges funding from the National Eye Institute of the National
   Institutes of Health, EY017112.
CR *AM AC OPHTH, 2006, AG REL MAC DEG PREF
   Au F, 2008, VALUE HEALTH, V11, P435, DOI 10.1111/j.1524-4733.2007.00255.x
   Bansback N, 2007, EYE, V21, P1455, DOI 10.1038/sj.eye.6702636
   *BCBSA, 2005, TEC ASS PROGR, V20
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BROWN A, 2008, 43 CAN AG DRUGS TECH
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   BUCKLEY JG, 2006, GERIATRICS AGING, V9, P276
   Buhrmann RHW, 2006, FORECASTING VISION L
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Busbee BG, 2003, RETINA-J RET VIT DIS, V23, P279, DOI 10.1097/00006982-200306000-00001
   Carlson JJ, 2005, GENET MED, V7, P519, DOI 10.1097/01.GIM.0000182467.79495.e2
   Chiou CF, 2003, MED CARE, V41, P32, DOI 10.1097/00005650-200301000-00007
   Coleman AL, 2004, OPHTHALMOLOGY, V111, P857, DOI 10.1016/j.ophtha.2003.09.033
   *DHHS, 2004, PUB DHHS
   Donati G, 2007, J FR OPHTALMOL, V30, P837, DOI 10.1016/S0181-5512(07)92619-4
   Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275
   Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552
   EARNSHAW SR, 2005, ISPOR 8 ANN EUR C FL
   *EUR CENTR BANK, 2006, ECB MONTHLY B    OCT
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gerkens S, 2008, INT J TECHNOL ASSESS, V24, P318, DOI 10.1017/S0266462308080422
   Greiner R A, 2001, Semin Ophthalmol, V16, P218, DOI 10.1076/soph.16.4.218.10302
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P450, DOI 10.1136/bjo.2003.035279
   Ivers RQ, 2000, AM J EPIDEMIOL, V152, P633, DOI 10.1093/aje/152.7.633
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lees M, 2003, VALUE HEALTH, V6, P239, DOI 10.1016/S1098-3015(10)63950-2
   Ligthart S, 2007, CAN MED ASSOC J, V176, P199, DOI 10.1503/cmaj.061020
   Lord SR, 2001, J AM GERIATR SOC, V49, P508, DOI 10.1046/j.1532-5415.2001.49107.x
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Meads C, 2001, 24 WMHTAC U BIRM DEP
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   *MSAC, 2001, PHOT THER VERT PDT V
   Muslera E., 2006, Arch Soc Esp Oftalmol, V81, P199
   *NAT I CLIN EXC, 2003, FIN APPR DET PHOT TH
   *NAT I HLTH CLIN E, 2008, FIN APPR DET RAN PEG
   *NICE, 2003, 68 NICE
   OBrien BJ, 1997, JAMA-J AM MED ASSOC, V277, P1802
   Ofman Joshua J, 2003, J Manag Care Pharm, V9, P53
   PACKO KH, 2008, RETINA TIMES, V26, P18
   Peterson LE, 2009, PHYS THER, V89, P733, DOI 10.2522/ptj.20080326
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rein DB, 2007, OPHTHALMOLOGY, V114, P1319, DOI 10.1016/j.ophtha.2006.10.041
   Sharma S, 2005, CAN J OPHTHALMOL, V40, P369, DOI 10.1016/S0008-4182(05)80079-1
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   SMITH DH, 2002, 187 U YORK CTR HLTH
   Spiegel BMR, 2004, GASTROENTEROLOGY, V127, P403, DOI 10.1053/j.gastro.2004.04.020
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Topouzis F, 2006, AM J OPHTHALMOL, V142, P1076, DOI 10.1016/j.ajo.2006.07.042
   Torrance GW, 1996, PHARMACOECONOMICS, V9, P535, DOI 10.2165/00019053-199609060-00008
   Trevithick JR, 2004, OPHTHAL EPIDEMIOL, V11, P337, DOI 10.1080/09286580490888780
   United States Census Bureau, 2008, NAT POP PROJ
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wolowacz SE, 2007, PHARMACOECONOMICS, V25, P863, DOI 10.2165/00019053-200725100-00005
NR 65
TC 12
Z9 12
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2010
VL 94
IS 9
BP 1118
EP 1126
DI 10.1136/bjo.2009.170282
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 654YF
UT WOS:000282206500003
PM 20813751
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Joo, K
   Mun, YS
   Park, SJ
   Park, KH
   Woo, SJ
AF Joo, Kwangsic
   Mun, Yong Seok
   Park, Sang Jun
   Park, Kyu Hyung
   Woo, Se Joon
TI Ten-Year Progression From Intermediate to Exudative Age-Related Macular
   Degeneration and Risk Factors: Bundang AMD Cohort Study Report 1
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER-DAM-EYE; VISUAL IMPAIRMENT; CIGARETTE-SMOKING; UNITED-STATES;
   HTRA1 GENE; PREVALENCE; MACULOPATHY; AREDS; POLYMORPHISMS; DISEASE
AB PURPOSE: This study investigated the 10-year incidence of progression from intermediate to exudative age-related macular degeneration (AMD) and identified genetic and environmental factors influencing that progression in the Korean population.
   DESIGN: Retrospective, observational cohort study.
   METHODS: In total, 632 eyes of 418 patients (age: >= 50 years) with intermediate AMD were enrolled. The incidence of exudative AMD was assessed from color fundus photographs and optical coherence tomography images obtained at baseline and during annual visits. Data regarding lifestyle variables and dietary habits were acquired through comprehensive questionnaires. Genotyping data concerning 3 single nucleotide polymorphisms (SNPs), rs800292 and rs1061170 in the CFH gene and rs10490924 in ARMS2 were also analyzed. The cumulative incidence of exudative changes was estimated using Kaplan-Meier analysis. Associated influential factors were evaluated using univariate and multivariate Cox regression models.
   RESULTS: The mean follow-up period was 3.99 +/- 2.85 years. The cumulative incidence of progression to exudative AMD was 5.6%, 14.8%, and 28.4% at 2, 5, and 10 years, respectively. Multivariate Cox analysis showed that age (hazard ratio [HR]: 1.041; P = .0393), family history of AMD (HR: 3.175; P= .0184), and preexisting exudative AMD in the fellow eye (HR: 3.186; P = 5.31310L5) were positively associated with exudative changes. Regular intake of green tea (HR: 0.632; P = .0475) was associated with a decrease in exudative changes. The ARMS2 SNP rs10490924 (HR: 1.482; P =.0185) showed a significant association with AMD progression.
   CONCLUSIONS: The annual progression rate from intermediate to exudative AMD in the Korean population is approximately 2.8%, which is comparable with that for whites. Intake of green tea may be a modifiable protective factor against exudative changes. (Am J Ophthalmol (C) 2020 Elsevier Inc. All rights reserved.
C1 [Joo, Kwangsic; Mun, Yong Seok; Park, Sang Jun; Park, Kyu Hyung; Woo, Se Joon] Seoul Natl Univ, Dept Ophthalmol, Coll Med, Bundang Hosp, Seongnam, South Korea.
C3 Seoul National University (SNU)
RP Woo, SJ (通讯作者)，Seoul Natl Univ, Dept Ophthalmol, Coll Med, Bundang Hosp, 82,Gumi Ro 173 Beon Gil, Seongnam Si 13620, Gyeonggi Do, South Korea.
EM sejoon1@snu.ac.kr
RI ; Park, Sang Jun/C-3234-2015
OI Park, Kyu Hyung/0000-0002-5516-8121; Park, Sang Jun/0000-0003-0542-2758;
   Mun, Yongseok/0000-0003-0123-0361
FU National Research Foundation of Korea (NRF) - Korean government (MSIP)
   [2019R1C1C1009345, 2020R1A2C201118911, 2020R1F1A1072795, 14-2018-019];
   SNUBH Research Fund
FX Publication of this article was supported by National Research
   Foundation of Korea (NRF) grants funded by the Korean government (MSIP),
   2019R1C1C1009345, 2020R1A2C201118911, and 2020R1F1A1072795; and by grant
   14-2018-019 from the SNUBH Research Fund. The funding organization had
   no role in the design or conduct of this research. The authors have
   reported that they have no relationships relevant to the contents of
   this paper to disclose.
CR Akkaya S, 2018, INT OPHTHALMOL, V38, P2239, DOI 10.1007/s10792-017-0666-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Chan CM, 2008, MOL VIS, V14, P2528
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1305, DOI 10.1016/j.ophtha.2017.03.056
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Edwards DRV, 2010, INVEST OPHTH VIS SCI, V51, P1873, DOI 10.1167/iovs.09-4000
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fisher DE, 2016, OPHTHALMOLOGY, V123, P1297, DOI 10.1016/j.ophtha.2015.12.026
   Francis PJ, 2008, MOL VIS, V14, P1395
   Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701
   Gunnlaugsdottir E, 2008, ACTA OPHTHALMOL, V86, P778, DOI 10.1111/j.1755-3768.2008.01191.x
   Hashemi R, 2002, LIFETIME DATA ANAL, V8, P335, DOI 10.1023/A:1020514804325
   Iwama D, 2008, JPN J OPHTHALMOL, V52, P116, DOI 10.1007/s10384-007-0503-9
   Jiang H, 2009, RETINA-J RET VIT DIS, V29, P974, DOI 10.1097/IAE.0b013e3181a3b90e
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lim LS, 2013, ASIA-PAC J OPHTHALMO, V2, P32, DOI 10.1097/APO.0b013e31827ff5bc
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Rhone M, 2008, NUTR REV, V66, P465, DOI 10.1111/j.1753-4887.2008.00078.x
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Zhang B, 2006, BRAIN RES, V1124, P176, DOI 10.1016/j.brainres.2006.09.067
NR 51
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2021
VL 224
BP 228
EP 237
DI 10.1016/j.ajo.2020.11.012
EA FEB 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RN7UW
UT WOS:000640559300023
PM 33279454
DA 2022-11-30
ER

PT J
AU McCarty, CA
   Dowrick, A
   Cameron, J
   McGrath, B
   Robman, LD
   Dimitrov, P
   Tikellis, G
   Nicolas, C
   McNeil, J
   Guymer, R
AF McCarty, Catherine A.
   Dowrick, Adam
   Cameron, James
   McGrath, Barry
   Robman, Luba D.
   Dimitrov, Peter
   Tikellis, Gabriella
   Nicolas, Caroline
   McNeil, John
   Guymer, Robyn
TI Novel measures of cardiovascular health and its association with
   prevalence and progression of age-related macular degeneration: the
   CHARM study
SO BMC OPHTHALMOLOGY
LA English
DT Article
AB Background: To determine if novel measures of cardiovascular health are associated with prevalence or progression of age-related macular degeneration (AMD).
   Methods: Measures of the cardiovascular system: included intima media thickness (IMT), pulse wave velocity (PWV), systemic arterial compliance (SAC), carotid augmentation index (AI). For the prevalence study, hospital-based AMD cases and population-based age-and gender-matched controls with no signs of AMD in either eye were enrolled. For the progression component, participants with early AMD were recruited from two previous studies; cases were defined as progression in one or both eyes and controls were defined as no progression in either eye.
   Results: 160 cases and 160 controls were included in the prevalence component. The upper two quartiles of SAC, implying good cardiovascular health, were significantly associated with increased risk of AMD (OR = 2.54, 95% CL = 1.29, 4.99). High PWV was associated with increased prevalent AMD. Progression was observed in 82 (32.3%) of the 254 subjects recruited for the progression component. Higher AI (worse cardiovascular function) was protective for AMD progression (OR = 0.30, 95% CL = 0.13, 0.69). Higher aortic PWV was associated with increased risk of AMD progression; the highest risk was seen with the second lowest velocity (OR = 6.22, 95% CL = 2.35, 16.46).
   Conclusion: The results were unexpected in that better cardiovascular health was associated with increased risk of prevalent AMD and progression. Inconsistent findings between the prevalence and progression components could be due to truly different disease etiologies or to spurious findings, as can occur with inherent biases in case control studies of prevalence. Further investigation of these non-invasive methods of characterizing the cardiovascular system should be undertaken as they may help to further elucidate the role of the cardiovascular system in the etiology of prevalent AMD and progression.
C1 [McCarty, Catherine A.; Dowrick, Adam; Cameron, James] Marshfield Clin Res Fdn, Ctr Human Genet, Marshfield, MA USA.
   [McCarty, Catherine A.; Robman, Luba D.; Dimitrov, Peter; Tikellis, Gabriella; Nicolas, Caroline; Guymer, Robyn] Univ Melbourne, Ctr Eye Res Australia, East Melbourne, Vic, Australia.
   [Dowrick, Adam; McNeil, John] Monash Univ, Dept Epidemiol & Prevent Med, Clayton, SA, Australia.
   [McGrath, Barry] Monash Univ, Dept Vasc Sci, Clayton, SA, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; Monash
   University; Monash University
RP McCarty, CA (通讯作者)，Marshfield Clin Res Fdn, Ctr Human Genet, Marshfield, MA USA.
EM mccarty.catherine@mcrf.mfldclin.edu; Adam.Dowrick@med.monash.edu.au;
   james.cameron@med.monash.edu.au; barry.mcgrath@med.monash.edu.au;
   liubov@unimelb.edu.au; dimitrov@unimelb.edu.au; gtike@unimelb.edu.au;
   Bernard.Nicolas@Tenix.com; John.McNeil@med.monash.edu.au;
   rhg@unimelb.edu.au
RI McNeil, John/L-6440-2019; Cameron, james/GQP-4595-2022
OI McNeil, John/0000-0002-1049-5129; Cameron, james/0000-0003-0589-0367;
   McCarty, Catherine/0000-0003-1089-0142; Guymer,
   Robyn/0000-0002-9441-4356
FU National Health and Medical Research Council [128201]; Ramaciotti
   Foundation; Hugh D. Williamson Foundation; Lions Clubs of Victoria
FX The CHARM Study was funded in large part by project grant number 128201
   from the National Health and Medical Research Council. Support was also
   received from the Ramaciotti Foundation, the Hugh D. Williamson
   Foundation, and the Lions Clubs of Victoria. The authors acknowledge the
   contributions of Sonya Ristevski to training and ongoing quality
   assurance for the arterial structure measurements.
CR [Anonymous], 2002, VIS PROBL US PREV AD
   Asmar R, 2001, AM J HYPERTENS, V14, P183
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Benetos A, 1998, HYPERTENSION, V32, P560, DOI 10.1161/01.HYP.32.3.560
   Benetos A, 1996, CIRCULATION, V94, P698, DOI 10.1161/01.CIR.94.4.698
   Benetos A, 1997, HYPERTENSION, V30, P1410, DOI 10.1161/01.HYP.30.6.1410
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boutouyrie P, 2002, HYPERTENSION, V39, P10, DOI 10.1161/hy0102.099031
   Bulpitt CJ, 1999, J HUM HYPERTENS, V13, P753, DOI 10.1038/sj.jhh.1000879
   Cameron J, 1999, CLIN EXP PHARMACOL P, V26, P285, DOI 10.1046/j.1440-1681.1999.03032.x
   Cameron JD, 1995, J HYPERTENS, V13, P1718
   Cameron JD, 2002, CORONARY ARTERY DIS, V13, P405, DOI 10.1097/00019501-200212000-00004
   Chen W, 2004, AM J HYPERTENS, V17, P553, DOI 10.1016/j.amjhyper.2004.02.021
   Cruickshank K, 2002, CIRCULATION, V106, P2085, DOI 10.1161/01.CIR.0000033824.02722.F7
   de Groot E, 2004, CIRCULATION, V109, P33, DOI 10.1161/01.CIR.0000131516.65699.ba
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Dogru M, 1998, EYE, V12, P929, DOI 10.1038/eye.1998.241
   Eichner JE, 2002, AM J EPIDEMIOL, V155, P487, DOI 10.1093/aje/155.6.487
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Garrett S K, 1999, Ophthalmic Epidemiol, V6, P195, DOI 10.1076/opep.6.3.195.1500
   Hodge A, 2000, AUST NZ J PUBL HEAL, V24, P576, DOI 10.1111/j.1467-842X.2000.tb00520.x
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Kingwell BA, 2002, J HYPERTENS, V20, P2337, DOI 10.1097/00004872-200212000-00006
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Liang YL, 1998, CLIN SCI, V95, P669, DOI 10.1042/cs0950669
   Livingston P M, 1994, Ophthalmic Epidemiol, V1, P139, DOI 10.3109/09286589409047222
   Mattace-Raso FUS, 2004, ATHEROSCLEROSIS, V174, P121, DOI 10.1016/j.atherosclerosis.2004.01.012
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   Medley TL, 2003, CIRC RES, V92, P1254, DOI 10.1161/01.RES.0000076891.24317.CA
   Medley TL, 2002, CIRCULATION, V105, P810, DOI 10.1161/hc0702.104129
   Mitchell P, 1999, MED J AUSTRALIA, V171, P173, DOI 10.5694/j.1326-5377.1999.tb123591.x
   North KE, 2002, ARTERIOSCL THROM VAS, V22, P1698, DOI 10.1161/01.ATV.0000032656.91352.5E
   Nurnberger J, 2002, J HYPERTENS, V20, P2407, DOI 10.1097/00004872-200212000-00020
   O'Leary DH, 2002, AM J CARDIOL, V90, p18L, DOI 10.1016/S0002-9149(02)02957-0
   Robman L, 2004, OPHTHAL EPIDEMIOL, V11, P161, DOI 10.1080/09286580490514469
   Robman LD, 1999, AUST NZ J OPHTHALMOL, V27, P410
   Sambrook J., 1989, MOL CLONING LAB MANU
   Simon A, 2002, J HYPERTENS, V20, P159, DOI 10.1097/00004872-200202000-00001
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Taylor HR, 2002, BRIT MED J, V325, P1
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tikellis G, 2007, EYE, V21, P169, DOI 10.1038/sj.eye.6702151
   Tikellis G, 1999, Ophthalmic Epidemiol, V6, P181, DOI 10.1076/opep.6.3.181.1502
   Tikellis G, 2002, CLIN EXPER OPHTHAL S, V30, pA254
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VERMA D, 1993, MED HYPOTHESES, V41, P205, DOI 10.1016/0306-9877(93)90231-E
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
NR 59
TC 10
Z9 10
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PY 2008
VL 8
AR 25
DI 10.1186/1471-2415-8-25
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA V18OK
UT WOS:000208013900025
PM 19102747
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Menke, MN
   Dabov, S
   Knecht, P
   Sturm, V
AF Menke, Marcel N.
   Dabov, Simeon
   Knecht, Pascal
   Sturm, Veit
TI Reproducibility of retinal thickness measurements in patients with
   age-related macular degeneration using 3D Fourier-domain optical
   coherence tomography (OCT) (Topcon 3D-OCT 1000)
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; imaging; optical coherence tomography;
   retina
ID CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY;
   ULTRAHIGH-RESOLUTION; CLINICAL-APPLICATION; HIGH-SPEED; REPEATABILITY;
   BEVACIZUMAB; ANGIOGRAPHY
AB Purpose: Conventional time-domain optical coherence tomography (OCT) has become an important tool for following dry or exudative age-related macular degeneration (AMD). Fourier-domain three-dimensional (3D) OCT was recently introduced. This study tested the reproducibility of 3D-OCT retinal thickness measurements in patients with dry and exudative AMD.
   Methods: Ten eyes with dry AMD and 12 eyes with exudative AMD were included in the study. Sets of three OCT 6 x 6-mm raster scans were taken by one operator. Mean retinal thickness was calculated for 36 areas. Coefficients of variation (CoV) were calculated for each patient and area. For analysis, two separate areas (central and peripheral) were defined. Generalized estimating equations (GEEs) were applied to all 36 subfields in order to analyse possible differences in CoV and mean retinal thickness between dry and exudative AMD.
   Results: Mean retinal thickness values were significantly larger in the central area in exudative AMD (p < 0.001). Mean CoV for exudative AMD was 3.7% (standard deviation [SD] 1.4%). Mean CoV for dry AMD was 1.8 (SD 0.6%). The reproducibility of retinal thickness measurements was significantly less in exudative AMD (p = 0.009).
   Conclusions: Reproducibility of 3D-OCT retinal thickness measurements was good in both groups. However, reproducibility was significantly better in dry AMD than in exudative AMD.
C1 [Menke, Marcel N.; Knecht, Pascal; Sturm, Veit] Univ Zurich, Dept Ophthalmol, Zurich, Switzerland.
   [Dabov, Simeon] Univ Munster, Sch Med, Munster, Germany.
C3 University of Zurich; University of Munster
RP Menke, MN (通讯作者)，Univ Zurich USZ, Dept Ophthalmol, Frauenklinikstr 24, CH-8091 Zurich, Switzerland.
EM marcel.menke@gmail.com
OI Menke, Marcel/0000-0002-6561-6178
CR Ahlers C, 2008, OPHTHALMOLOGE, V105, P248, DOI 10.1007/s00347-007-1597-7
   Alam S, 2006, OPHTHALMOLOGY, V113, P1425, DOI 10.1016/j.ophtha.2006.03.020
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Baumann M, 1998, OPHTHALMIC SURG LAS, V29, P280
   Choma MA, 2003, OPT EXPRESS, V11, P2183, DOI 10.1364/OE.11.002183
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Costa RA, 2001, AM J OPHTHALMOL, V132, P557, DOI 10.1016/S0002-9394(01)01138-2
   Eriksson U, 2008, ACTA OPHTHALMOL
   Eter N, 2004, OPHTHALMOLOGE, V101, P794, DOI 10.1007/s0034-004-1052-y
   Evans J., 1995, STUDIES MED POPULATI, V57
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Giovannini A, 1999, BRIT J OPHTHALMOL, V83, P438, DOI 10.1136/bjo.83.4.438
   Gurses-Ozden R, 2004, J GLAUCOMA, V13, P238
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Koozekanani D, 2000, INVEST OPHTH VIS SCI, V41, P1486
   Menke MN, 2008, BRIT J OPHTHALMOL, V92, P1492, DOI 10.1136/bjo.2008.141242
   Menke MN, 2005, OPHTHAL SURG LAS IM, V36, P310, DOI 10.3928/1542-8877-20050701-10
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Muscat S, 2002, INVEST OPHTH VIS SCI, V43, P490
   Paunescu LA, 2004, INVEST OPHTH VIS SCI, V45, P1716, DOI 10.1167/iovs.03-0514
   Polito A, 2005, ARCH OPHTHALMOL-CHIC, V123, P1330, DOI 10.1001/archopht.123.10.1330
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Spraul CW, 1998, KLIN MONATSBL AUGENH, V212, P141, DOI 10.1055/s-2008-1034850
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Talks J, 2007, BRIT J OPHTHALMOL, V91, P600, DOI 10.1136/bjo.2006.108043
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Van Kerckhoven W, 2001, Bull Soc Belge Ophtalmol, P75
   Wojtkowski M, 2005, 2005 Conference on Lasers & Electro-Optics (CLEO), Vols 1-3, P2058
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Wojtkowski M, 2004, OPT EXPRESS, V12, P2404, DOI 10.1364/OPEX.12.002404
NR 35
TC 20
Z9 20
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2011
VL 89
IS 4
BP 346
EP 351
DI 10.1111/j.1755-3768.2009.01692.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 769ZQ
UT WOS:000291057200031
PM 20039855
DA 2022-11-30
ER

PT J
AU Lekwuwa, M
   Choudhary, M
   Lad, EM
   Malek, G
AF Lekwuwa, Michael
   Choudhary, Mayur
   Lad, Eleonora M.
   Malek, Goldis
TI Osteopontin accumulates in basal deposits of human eyes with age-related
   macular degeneration and may serve as a biomarker of aging
SO MODERN PATHOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; CHRONIC INFLAMMATION; ALZHEIMERS-DISEASE;
   BRUCHS MEMBRANE; RAT-BRAIN; EXPRESSION; DRUSEN; CELLS; ACTIVATION;
   MECHANISMS
AB A common clinical phenotype of several neurodegenerative and systemic disorders including Alzheimer's disease and atherosclerosis is the abnormal accumulation of extracellular material, which interferes with routine cellular functions. Similarly, patients with age-related macular degeneration (AMD), the leading cause of vision loss among the aged population, present with extracellular lipid- and protein-filled basal deposits in the back of the eye. While the exact mechanism of growth and formation of these deposits is poorly understood, much has been learned from investigating their composition, providing critical insights into AMD pathogenesis, prevention, and therapeutics. We identified human osteopontin (OPN), a phosphoprotein expressed in a variety of tissues in the body, as a newly discovered component of basal deposits in AMD patients, with a distinctive punctate staining pattern. OPN expression within these lesions, which are associated with AMD disease progression, were found to co-localize with abnormal calcium deposition. Additionally, OPN puncta colocalized with an AMD risk-associated complement pathway protein, but not with apolipoprotein E or vitronectin, two other well-established basal deposit components. Mechanistically, we found that retinal pigment epithelial cells, cells vulnerable in AMD, will secrete OPN into the extracellular space, under oxidative stress conditions, supporting OPN biosynthesis locally within the outer retina. Finally, we report that OPN levels in plasma of aged (non-AMD) human donors were significantly higher than levels in young (non-AMD) donors, but were not significantly different from donors with the different clinical subtypes of AMD. Collectively, our study defines the expression pattern of OPN in the posterior pole as a function of disease, and its local expression as a potential histopathologic biomarker of AMD.
C1 [Lekwuwa, Michael; Choudhary, Mayur; Lad, Eleonora M.; Malek, Goldis] Duke Univ, Duke Eye Ctr, Dept Ophthalmol, Sch Med, Durham, NC 27710 USA.
   [Malek, Goldis] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA.
C3 Duke University; Duke University
RP Malek, G (通讯作者)，Duke Univ, Duke Eye Ctr, Dept Ophthalmol, Sch Med, Durham, NC 27710 USA.; Malek, G (通讯作者)，Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA.
EM gmalek@duke.edu
FU National Eye Institute [R01 EY027802, R01 EY028160, K23 EY026988, P30
   EY005722]; Brightfocus Macular Degeneration Award; Research to Prevent
   Blindness, Inc (RPB) Core grant
FX This research was supported by the National Eye Institute grants R01
   EY027802, R01 EY028160 (to G.M.), K23 EY026988 (to E.M.L.), P30 EY005722
   (to the Duke Eye Center), Brightfocus Macular Degeneration Award (G.M.),
   and the Research to Prevent Blindness, Inc (RPB) Core grant (to the Duke
   Eye Center).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Berezin AE, 2013, ATHEROSCLEROSIS, V229, P475, DOI 10.1016/j.atherosclerosis.2013.06.003
   Boskey AL, 2002, CALCIFIED TISSUE INT, V71, P145, DOI 10.1007/s00223-001-1121-z
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BROWN LF, 1992, MOL BIOL CELL, V3, P1169, DOI 10.1091/mbc.3.10.1169
   Carecchio M, 2011, J ALZHEIMERS DIS, V25, P179, DOI 10.3233/JAD-2011-102151
   CARP H, 1978, AM REV RESPIR DIS, V118, P617
   Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chidlow G, 2008, INVEST OPHTH VIS SCI, V49, P762, DOI 10.1167/iovs.07-0726
   Choi JS, 2007, BRAIN RES, V1151, P195, DOI 10.1016/j.brainres.2007.03.016
   Choudhary M, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.131928
   Choudhary M, 2018, BBA-MOL BASIS DIS, V1864, P1583, DOI 10.1016/j.bbadis.2018.02.015
   Choudhary M, 2016, AGING-US, V8, P1952, DOI 10.18632/aging.101031
   Choudhary M, 2015, J PATHOL, V235, P101, DOI 10.1002/path.4433
   Comi C, 2010, J ALZHEIMERS DIS, V19, P1143, DOI 10.3233/JAD-2010-1309
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Curcio CA, 2005, VISION RES, V45, P3496, DOI 10.1016/j.visres.2005.07.038
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2017, JAMA OPHTHALMOL, V135, P843, DOI 10.1001/jamaophthalmol.2017.2008
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Dai J, 2009, ONCOGENE, V28, P3412, DOI 10.1038/onc.2009.189
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980
   Dwyer MA, 2011, MOL ENDOCRINOL, V25, P360, DOI 10.1210/me.2010-0392
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Ellison JA, 1998, STROKE, V29, P1698, DOI 10.1161/01.STR.29.8.1698
   Farnoodian M, 2018, AM J PHYSIOL-CELL PH, V314, pC456, DOI 10.1152/ajpcell.00259.2017
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gamulescu MA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/851648
   Gao CJ, 2007, J IMMUNOL, V178, P1870, DOI 10.4049/jimmunol.178.3.1870
   GASS JDM, 1967, AM J OPHTHALMOL, V63, P573
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   GIACHELLI CM, 1995, TRENDS CARDIOVAS MED, V5, P88, DOI 10.1016/1050-1738(95)00005-T
   GIACHELLI CM, 1995, ANN NY ACAD SCI, V760, P109, DOI 10.1111/j.1749-6632.1995.tb44624.x
   Green W Richard, 2005, Retina, V25, P180, DOI 10.1097/00006982-200507001-00005
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Han XK, 2020, J HUM GENET, V65, P657, DOI 10.1038/s10038-020-0750-x
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Hirose M, 2012, UROL RES, V40, P121, DOI 10.1007/s00240-011-0400-z
   Holekamp NM, 2019, AM J MANAG CARE, V25, pS172
   Hollborn M, 2020, MOL VIS, V26, P188
   Holm E, 2014, BIOCHEM J, V464, P355, DOI 10.1042/BJ20140702
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Hur EM, 2007, NAT IMMUNOL, V8, P74, DOI 10.1038/ni1415
   Icer MA, 2018, CLIN BIOCHEM, V59, P17, DOI 10.1016/j.clinbiochem.2018.07.003
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kim MD, 2004, J NEUROIMMUNOL, V151, P78, DOI 10.1016/j.jneuroim.2004.02.014
   Kothari AN, 2016, J CLIN MED, V5, DOI 10.3390/jcm5040039
   Kwon HM, 2000, J KOREAN MED SCI, V15, P485, DOI 10.3346/jkms.2000.15.5.485
   Lakkaraju A, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100846
   Lee MY, 2001, CELL TISSUE RES, V306, P179, DOI 10.1007/s004410100456
   Lenga Y, 2008, CIRC RES, V102, P319, DOI 10.1161/CIRCRESAHA.107.160408
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Liu K., 2012, ISRN OPHTHALMOL, V2012
   Lok ZSY, 2019, ARTERIOSCL THROM VAS, V39, P613, DOI 10.1161/ATVBAHA.118.311577
   Lund SA, 2009, J CELL COMMUN SIGNAL, V3, P311, DOI 10.1007/s12079-009-0068-0
   Maetzler W, 2007, NEUROBIOL DIS, V25, P473, DOI 10.1016/j.nbd.2006.10.020
   Malek G, 2014, CELL MOL LIFE SCI, V71, P4617, DOI 10.1007/s00018-014-1709-x
   Maziere C, 2010, FREE RADICAL BIO MED, V48, P1382, DOI 10.1016/j.freeradbiomed.2010.02.022
   Meller R, 2005, J CEREBR BLOOD F MET, V25, P217, DOI 10.1038/sj.jcbfm.9600022
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mori R, 2008, J EXP MED, V205, P43, DOI 10.1084/jem.20071412
   OBRIEN ER, 1994, ARTERIOSCLER THROMB, V14, P1648, DOI 10.1161/01.ATV.14.10.1648
   Poggio P, 2011, J CELL PHYSIOL, V226, P2139, DOI 10.1002/jcp.22549
   Rittling SR, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001839
   Rollo EE, 1996, J LEUKOCYTE BIOL, V60, P397, DOI 10.1002/jlb.60.3.397
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Scatena M, 2007, ARTERIOSCL THROM VAS, V27, P2302, DOI 10.1161/ATVBAHA.107.144824
   Schlecht A, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.618598
   Schroeter M, 2006, BRAIN, V129, P1426, DOI 10.1093/brain/awl094
   SENGER DR, 1979, CELL, V16, P885, DOI 10.1016/0092-8674(79)90103-X
   Shin YJ, 2012, J NEUROTRAUM, V29, P1530, DOI 10.1089/neu.2011.2078
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Sura AA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.19
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Tarau IS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143578
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Urtasun R, 2012, HEPATOLOGY, V55, P594, DOI 10.1002/hep.24701
   van Velthoven CTJ, 2011, STROKE, V42, P2294, DOI 10.1161/STROKEAHA.110.608315
   VANDERSCHAFT TL, 1992, ARCH OPHTHALMOL-CHIC, V110, P389, DOI 10.1001/archopht.1992.01080150087034
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wai PY, 2006, SURGERY, V140, P132, DOI 10.1016/j.surg.2006.02.005
   WANG L, 2010, PLOS ONE, V5
   Wang XK, 1998, J NEUROSCI, V18, P2075
   Wirths O, 2010, NEUROBIOL AGING, V31, P747, DOI 10.1016/j.neurobiolaging.2008.06.011
   Wolak T, 2014, ATHEROSCLEROSIS, V236, P327, DOI 10.1016/j.atherosclerosis.2014.07.004
   Wung JK, 2007, CURR ALZHEIMER RES, V4, P67, DOI 10.2174/156720507779939869
   Yu C, 2020, TRENDS NEUROSCI, V43, P433, DOI 10.1016/j.tins.2020.03.012
   Zhang ZX, 2010, J IMMUNOL, V185, P967, DOI 10.4049/jimmunol.0903245
   Zhao HL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0391-6
   Zhou T, 2017, FRONT NEUROANAT, V11, DOI 10.3389/fnana.2017.00077
NR 101
TC 3
Z9 3
U1 0
U2 4
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2022
VL 35
IS 2
BP 165
EP 176
DI 10.1038/s41379-021-00887-7
EA AUG 2021
PG 12
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA YM5TR
UT WOS:000684790400002
PM 34389792
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Seddon, JM
   Widjajahakim, R
   Rosner, B
AF Seddon, Johanna M.
   Widjajahakim, Rafael
   Rosner, Bernard
TI Rare and Common Genetic Variants, Smoking, and Body Mass Index:
   Progression and Earlier Age of Developing Advanced Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; age of progression; genetics;
   lifestyles
ID C-REACTIVE PROTEIN; HIGH-RISK; ASSOCIATION; CFH; SEVERITY; DISEASE;
   ONSET; SIZE
AB PURPOSE. To determine behavioral and genetic factors associated with incidence and age of progression to advanced age-related macular degeneration (AMD), geographic atrophy (GA), and neovascular disease (NV), and to quantify these effects.
   METHODS. Longitudinal analyses were conducted among 5421 eyes with nonadvanced AMD at baseline in 2976 participants in the Age-Related Eye Disease Study (mean age of 68.8 (+/- 5.0), 56.1% female). Progression was confirmed based on two consecutive visits on the AMD severity scale. Separate analyses for progression and age of progression were performed. All analyses adjusted for correlation between eyes, demographic and behavioral covariates, baseline severity scale, and genetic variants.
   RESULTS. A higher genetic risk score (GRS) including eight genetic variants was associated with a higher rate of progression to advanced AMD within each baseline severity scale, especially for the highest risk intermediate level AMD category, and smoking further increased this risk. When assessing age when progression to advanced disease occurred, smoking reduced age of onset by 3.9 years (P < 0.001), and higher body mass index (BMI) led to earlier onset by 1.7 years (P = 0.003), with similar results for GA and NV. Genetic variants associated with earlier age of progression were CFH R1201C (4.3 years), C3 K155Q (2.15 years), and ARMS2/HTRA1 (0.8 years per allele).
   CONCLUSIONS. Rare variants in the complement pathway and a common risk allele in ARMS2/HTRA1, smoking, and higher BMI can lead to as much as 11.5 additional years of disease and treatment burden. Closer adherence to healthy lifestyles could reduce years of visual impairment.
C1 [Seddon, Johanna M.; Widjajahakim, Rafael] Univ Massachusetts, Dept Ophthalmol & Visual Sci, Med Sch, 55 Lake Ave North,S3-119, Worcester, MA 01655 USA.
   [Rosner, Bernard] Harvard Med Sch, Channing Div Network Med, Boston, MA 02115 USA.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; Harvard University; Harvard Medical School
RP Seddon, JM (通讯作者)，Univ Massachusetts, Dept Ophthalmol & Visual Sci, Med Sch, 55 Lake Ave North,S3-119, Worcester, MA 01655 USA.
EM johanna_seddon@yahoo.com
FU NIH [R01-EY011309, R01-EY028602, R01-EY022445]; American Macular
   Degeneration Foundation, Northampton, MA; Macular Degeneration Center of
   Excellence, University of Massachusetts Medical School, Department of
   Ophthalmology and Visual Sciences, Worcester, MA
FX Supported by NIH R01-EY011309, R01-EY028602, R01-EY022445, American
   Macular Degeneration Foundation, Northampton, MA, The Macular
   Degeneration Center of Excellence, University of Massachusetts Medical
   School, Department of Ophthalmology and Visual Sciences, Worcester, MA.
CR [Anonymous], AG REL MAC DEG FACTS
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ferrara D, 2017, INVEST OPHTH VIS SCI, V58, P3519, DOI 10.1167/iovs.17-21696
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lechanteur YTE, 2015, JAMA OPHTHALMOL, V133, P533, DOI 10.1001/jamaophthalmol.2015.18
   Lu ZG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216808
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosner B, 2009, BIOMETRICS, V65, P188, DOI 10.1111/j.1541-0420.2008.01062.x
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Seddon J, 2020, RARE COMMON GENETIC
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2019, AM J OPHTHALMOL, V198, P223, DOI 10.1016/j.ajo.2018.10.022
   Seddon JM, 2017, INVEST OPHTH VIS SCI, V58, P6513, DOI 10.1167/iovs.17-23544
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Widjajahakim R, 2020, INVEST OPHTH VIS SCI, V61
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu Y, 2016, HUM MOL GENET, V25, P5276, DOI 10.1093/hmg/ddw336
NR 28
TC 7
Z9 7
U1 1
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2020
VL 61
IS 14
AR 32
DI 10.1167/iovs.61.14.32
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PN0YS
UT WOS:000604213900026
PM 33369641
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ohayon, A
   De Rosa, I
   Semoun, O
   Jung, C
   Colantuono, D
   El Ameen, A
   Srour, M
   Souied, EH
AF Ohayon, Avi
   De Rosa, Irene
   Semoun, Oudy
   Jung, Camille
   Colantuono, Donato
   El Ameen, Ala'a
   Srour, Mayer
   Souied, Eric H.
TI Subretinal pigment epithelium fibrotic tissue morphological changes
   after a single anti-vascular endothelial growth factor injection in
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE macula; retina; degeneration
ID OPTICAL COHERENCE TOMOGRAPHY; INTRAVITREAL RANIBIZUMAB; CHOROIDAL
   NEOVASCULARIZATION; NATURAL-HISTORY; FACTOR THERAPY; DETACHMENT;
   QUANTIFICATION; AFLIBERCEPT; RISK; AMD
AB Aims
   To demonstrate and evaluate the morphological changes of multilayered fibrovascular pigment epithelial detachment (PED) to a single anti-vascular endothelial growth factor (VEGF) injection in age-related macular degeneration (AMD).
   Methods
   We retrospectively analysed the morphological changes of 30 eyes with exudative AMD showing fibrotic multilayered PED, between two consecutive visits. All patients had one anti-VEGF intravitreal injection at the first visit. We quantitatively analysed the different compartments within the PED and their morphological response.
   Results
   The mean follow-up time interval between the first and the second visit was 32.46 +/- 4.64 days. We defined three optical coherence tomography zones within the PED: a subretinal pigment epithelium inhomogeneous hyporeflective space (layer 1), a hyper-reflective band beneath layer 1 (layer 2), and a hyporeflective space between the Bruch's membrane and layer 2 (layer 3). The mean height of layer 1 was 142 +/- 44.63 and 99.30 +/- 39.79 mu m at visits 1 and 2, respectively. The mean thickness of layer 2 was 101.42 +/- 46.66 and 82.76 +/- 35.24 mu m at visits 1 and 2, respectively. The mean height of layer 3 was 35.77 +/- 32.77 and 5.66 +/- 8.68 mu m at visits 1 and 2, respectively (p=0.009). The mean height change for layer 1 was statistically significantly higher than for layer 2 (p=0.0002).
   Conclusions
   Fibrovascular PED was compartmented into three layers with different reflectivities that morphologically responded differently to a single anti-VEGF injection. Layer 2 had a statistically significantly lower response compared with layer 1, suggesting the hypothesis of a fibrotic component in layer 2.
C1 [Ohayon, Avi; De Rosa, Irene; Semoun, Oudy; Jung, Camille; Colantuono, Donato; El Ameen, Ala'a; Srour, Mayer; Souied, Eric H.] Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
   [Jung, Camille] Ctr Hosp Intercommunal Creteil, Clin Res Ctr, Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Ohayon, A (通讯作者)，Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
EM aviohayonmd@gmail.com
RI Ohayon, Avi/R-2676-2018
OI Ohayon, Avi/0000-0002-4435-8659; De Rosa, Irene/0000-0002-9509-2408
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arora S, 2011, EYE, V25, P1034, DOI 10.1038/eye.2011.115
   Au A, 2017, BRIT J OPHTHALMOL, V101, P970, DOI 10.1136/bjophthalmol-2016-309434
   Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Chen XJ, 2016, RETINA-J RET VIT DIS, V36, pS50, DOI 10.1097/IAE.0000000000001271
   Chevreaud O, 2017, GRAEF ARCH CLIN EXP, V255, P743, DOI 10.1007/s00417-016-3564-y
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Coscas F, 2012, INVEST OPHTH VIS SCI, V53, P4147, DOI 10.1167/iovs.12-9878
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Introini U, 2012, GRAEF ARCH CLIN EXP, V250, P1283, DOI 10.1007/s00417-012-1955-2
   Iordanous Y, 2014, CAN J OPHTHALMOL, V49, P367, DOI 10.1016/j.jcjo.2014.05.010
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kanesa-Thasan A, 2015, OSLI RETINA, V46, P638, DOI 10.3928/23258160-20150610-07
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Khanani AM, 2018, RETINA-J RET VIT DIS, V38, P2103, DOI 10.1097/IAE.0000000000002195
   Kim JH, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/2578349
   Kim JM, 2017, RETINA-J RET VIT DIS, V37, P2047, DOI 10.1097/IAE.0000000000001435
   Mouallem A, 2016, RETINA-J RET VIT DIS, V36, P2197, DOI 10.1097/IAE.0000000000001062
   Mukai R, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-159
   Nagai N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29619
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Or C, 2016, RETINA-J RET VIT DIS, V36, P264, DOI 10.1097/IAE.0000000000000795
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Ritter M, 2010, EYE, V24, P962, DOI 10.1038/eye.2009.265
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
   Zinkernagel MS, 2016, OPHTHALMOLOGICA, V235, P42, DOI 10.1159/000441428
NR 35
TC 2
Z9 2
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2020
VL 104
IS 8
BP 1085
EP 1088
DI 10.1136/bjophthalmol-2019-314923
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PK2OA
UT WOS:000602289600010
PM 31744799
DA 2022-11-30
ER

PT J
AU Salabati, M
   Obeid, A
   Mahmoudzadeh, R
   Gupta, O
   Chiang, A
   Spirn, M
   Klufas, MA
   Hsu, J
AF Salabati, Mirataollah
   Obeid, Anthony
   Mahmoudzadeh, Raziyeh
   Gupta, Omesh
   Chiang, Allen
   Spirn, Marc
   Klufas, Michael A.
   Hsu, Jason
CA Wills Switch Study Grp
TI Outcomes after switching eyes that were stable on aflibercept to
   ranibizumab versus continuing aflibercept in neovascular age-related
   macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Switch; Aflibercept; Ranibizumab
ID INTRAVITREAL AFLIBERCEPT; RESISTANT; RELEVANT; THERAPY
AB Purpose To describe outcomes of neovascular age-related macular degeneration (nAMD) eyes that were stable on aflibercept but switched to ranibizumab compared to eyes maintained on aflibercept over the same period.
   Methods In this retrospective cohort study, eyes switched from aflibercept to ranibizumab due to intraocular inflammation (MI) concerns with aflibercept were identified. Data was gathered from 3 visits pre-switch, switch visit (Sw), and 3 visits post-switch (P1, P2, P3). Similar data was gathered on eyes eligible to switch but continued on aflibercept with the middle visit considered the "presumed switch." Outcome measures included visual acuity (VA) and central foveal thickness (CFT).
   Results A total of 142 eyes were analyzed with 71 in each of the switch and aflibercept groups. In the switch group, mean CFT increased from 165.7 mu m at Sw to 184.7 mu m at P1 (p = 0.009), 180.9 mu m at P2 (p = 0.007), and 183.3 mu m at P3 (p = 0.004). VA changed from logMAR 0.43 (20/54) at Sw to 0.49 (20/61) at P1 (p = 0 .02), 0.54 (20/69) at P2 (p =0 .008), and 0.53 (20/68) at P3 (p = 0.04). In the aflibercept group, no significant change in CFT was found over the same period. VA changed from 1ogMAR 0.56 (20/72) at the "presumed switch" to 0.58 (20/76) at P1 (p = 0.085), 0.62 (20/83) at P2 (p = 0.001), and 0.59 (20/77) at P3 (p = 0.14).
   Conclusions nAMD eyes that were stable or improving on aflibercept but were switched to ranibizumab worsened, while those in a comparable group maintained on aflibercept remained fairly stable, suggesting a potential efficacy difference between the two drugs.
C1 [Salabati, Mirataollah; Obeid, Anthony; Mahmoudzadeh, Raziyeh; Gupta, Omesh; Chiang, Allen; Spirn, Marc; Klufas, Michael A.; Hsu, Jason] Wills Eye Hosp & Res Inst, Mid Atlantic Retina, Retina Serv, Suite 1020,840 Walnut St, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Hsu, J (通讯作者)，Wills Eye Hosp & Res Inst, Mid Atlantic Retina, Retina Serv, Suite 1020,840 Walnut St, Philadelphia, PA 19107 USA.
EM jhsu@midatlanticretina.com
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Despreaux R, 2016, GRAEF ARCH CLIN EXP, V254, P639, DOI 10.1007/s00417-015-3084-1
   Ferris FL, 2017, JAMA OPHTHALMOL, V135, P145, DOI 10.1001/jamaophthalmol.2016.4820
   Gale RP, 2020, BRIT J OPHTHALMOL, V104, P493, DOI 10.1136/bjophthalmol-2019-314251
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Greenberg JP, 2019, OPHTHALMOL RETINA, V3, P753, DOI 10.1016/j.oret.2019.04.006
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Hahn P, 2015, JAMA OPHTHALMOL, V133, P421, DOI 10.1001/jamaophthalmol.2014.5650
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Mantel I, 2018, SURV OPHTHALMOL, V63, P638, DOI 10.1016/j.survophthal.2018.02.004
   Mantel I, 2016, RETINA-J RET VIT DIS, V36, P53, DOI 10.1097/IAE.0000000000000664
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Yannuzzi NA, 2019, CLIN OPHTHALMOL, V13, P1323, DOI 10.2147/OPTH.S184706
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 23
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2022
VL 260
IS 8
BP 2509
EP 2516
DI 10.1007/s00417-022-05601-0
EA MAR 2022
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3F5UF
UT WOS:000762896800003
PM 35230472
DA 2022-11-30
ER

PT J
AU Husum, YS
   Moe, MC
   Bragadottir, R
   Jorstad, OK
AF Husum, Yngvil Solheim
   Moe, Morten Carstens
   Bragadottir, Ragnheidur
   Jorstad, Oystein Kalsnes
TI Switching to aflibercept versus continuing bevacizumab for
   treatment-resistant neovascular age-related macular degeneration: a
   one-year comparative observational study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE neovascular age&#8208; related macular degeneration; treatment
   resistance; switching; anti&#8208; VEGF; aflibercept; bevacizumab
AB Purpose To compare outcomes of a treatment algorithm that allows for switching treatment-resistant neovascular age-related macular degeneration (nAMD) eyes to aflibercept with continuing bevacizumab.
   Methods Retrospective study of nAMD patients who initiated treatment in 2012 (aflibercept unavailable) and 2018 (aflibercept available). Eyes were included in the case of residual macular fluid after a minimum of 4 monthly bevacizumab injections. Only eyes in the 2018 group could then switch to aflibercept.
   Results The study included 40 eyes from 2012 and 88 eyes from 2018. Patient characteristics were similar across the groups at baseline and 4 months. In 2018, 59 eyes (67%) were switched to aflibercept after 4 months. Mean change in BCVA from 4 months to one year was +2.8 letters in 2018 versus -1.7 letters in 2012 (p = 0.043). Mean change in BCVA from baseline to one year was +9.4 letters in 2018 (p < 0.001) and +4.4 letters in 2012 (p = 0.073). Mean change in CRT from 4 months to one year was -36 mu m in 2018 versus -23 mu m in 2012 (p = 0.373). Mean change in CRT from baseline to one year was -100 mu m in 2018 (p < 0.001) and -75 mu m in 2012 (p < 0.001). Mean number of injections given in one year was 11.8 in 2018 versus 10.4 in 2012 (p < 0.001). After one year, a majority of eyes in both groups still received treatment at 4-week intervals.
   Conclusion The study suggests that the possibility of switching eyes with treatment-resistant nAMD to aflibercept leads to a modest visual benefit compared with continuing first-line bevacizumab therapy.
C1 [Husum, Yngvil Solheim; Moe, Morten Carstens; Bragadottir, Ragnheidur; Jorstad, Oystein Kalsnes] Oslo Univ Hosp, Dept Ophthalmol, Postboks 4950 Nydalen, N-0424 Oslo, Norway.
   [Moe, Morten Carstens; Bragadottir, Ragnheidur; Jorstad, Oystein Kalsnes] Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway.
C3 University of Oslo; University of Oslo
RP Husum, YS (通讯作者)，Oslo Univ Hosp, Dept Ophthalmol, Postboks 4950 Nydalen, N-0424 Oslo, Norway.
EM yngvil.husum@gmail.com
OI Jorstad, Oystein Kalsnes/0000-0003-1259-0653; Husum, Yngvil
   Solheim/0000-0002-0039-6186
FU Oslo University Hospital, Norway
FX The study was funded by Oslo University Hospital, Norway. The funding
   organization had no role in the design or conduct of the research.
CR Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   DELAEY JJ, 1983, DOC OPHTHALMOL, V55, P91, DOI 10.1007/BF00140466
   Elshout M, 2018, ACTA OPHTHALMOL, V96, P770, DOI 10.1111/aos.13824
   Empeslidis T, 2019, ADV THER, V36, P1532, DOI 10.1007/s12325-019-00971-0
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Ferris FL, 2017, JAMA OPHTHALMOL, V135, P145, DOI 10.1001/jamaophthalmol.2016.4820
   Freund KB., 2014, CURR OPHTHALMOL REP, V2, P6
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jorstad OK, 2020, ACTA OPHTHALMOL, V98, P774, DOI 10.1111/aos.14177
   Jorstad OK, 2017, ACTA OPHTHALMOL, V95, P460, DOI 10.1111/aos.13480
   Kim LA, 2012, AM J PATHOL, V181, P376, DOI 10.1016/j.ajpath.2012.06.006
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0
   Mantel I, 2018, SURV OPHTHALMOL, V63, P638, DOI 10.1016/j.survophthal.2018.02.004
   Mantel I, 2016, RETINA-J RET VIT DIS, V36, P53, DOI 10.1097/IAE.0000000000000664
   Pikkel J, 2018, INT OPHTHALMOL, V38, P2031, DOI 10.1007/s10792-017-0695-z
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
NR 20
TC 3
Z9 3
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2021
VL 99
IS 8
BP E1354
EP E1359
DI 10.1111/aos.14825
EA FEB 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WW9GS
UT WOS:000622277500001
PM 33638291
OA hybrid
DA 2022-11-30
ER

PT J
AU Gower, EW
   Stein, JD
   Shekhawat, NS
   Mikkilineni, S
   Blachley, TS
   Pajewski, NM
AF Gower, Emily W.
   Stein, Joshua D.
   Shekhawat, Nakul S.
   Mikkilineni, Shravani
   Blachley, Taylor S.
   Pajewski, Nicholas M.
TI Geographic and Demographic Variation in Use of Ranibizumab Versus
   Bevacizumab for Neovascular Age-related Macular Degeneration in the
   United States
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB; EYE CARE; MEDICARE BENEFICIARIES; GLAUCOMA;
   AVASTIN; HEALTH; ENDOPHTHALMITIS; INJECTION; OUTBREAK; DISEASES
AB PURPOSE: To examine demographic and geographic variation in the use of ranibizumab and bevacizumab for the treatment of neovascular age-related macular degeneration (AMD) among Medicare beneficiaries.
   DESIGN: Retrospective cohort study.
   METHODS: Using a100% sample of Medicare claims data, we evaluated Medicare beneficiaries (N = 195 812) with an index claim for neovascular AMD between July 1, 2006, and June 30, 2009, to determine whether beneficiaries first received ranibizumab or bevacizumab following initial diagnosis.
   RESULTS: The overall proportion of beneficiaries that first received ranibizumab for neovascular AMD was 35%, and varied significantly (0.9%-84.6%) across the 306 US hospital referral regions (median = 33%, interquartile range = 17%-49%). Based on hierarchical logistic regression models, the likelihood of receiving ranibizumab declined over time (adjusted odds ratio (aOR) comparing treatment in 2009 vs 2006 = 0.39, P < .001). After we controlled for year of treatment, black beneficiaries were 45% less likely to receive ranibizumab compared to non-blacks (P < .0001). Beneficiaries residing in urban areas (aOR vs isolated rural towns = 1.12, P < .001), in zip codes with higher median incomes, and in the New England and Fast South Central census regions (aOR vs Pacific census region = 5.57, P < .001; aOR = 3.58, P < .001, respectively) had increased odds of receiving ranibizumab.
   CONCLUSIONS: The odds of receiving bevacizumab vs ranibizumab as initial therapy for neovascular AMD among US Medicare beneficiaries varied substantially across geographic and demographic groups. Relatively fewer patients received ranibizumab for initial neovascular AMD treatment in 2009 vs 2006. Future research should study the drivers of variation in utilization of these interventions, the extent this variation indicates differential access to these agents, and whether treatment choice impacts patient outcomes. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Gower, Emily W.] Wake Forest Sch Med, Div Publ Hlth Sci, Dept Epidemiol & Prevent, Winston Salem, NC USA.
   [Pajewski, Nicholas M.] Wake Forest Sch Med, Div Publ Hlth Sci, Dept Biostat Sci, Winston Salem, NC USA.
   [Stein, Joshua D.; Shekhawat, Nakul S.; Mikkilineni, Shravani; Blachley, Taylor S.] Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI USA.
   [Gower, Emily W.] Univ N Carolina, 2104H McGavran Greenberg Hall,CB 7435, Chapel Hill, NC 27599 USA.
C3 Wake Forest University; Wake Forest University; University of Michigan
   System; University of Michigan; University of North Carolina; University
   of North Carolina Chapel Hill
RP Gower, EW (通讯作者)，Univ N Carolina, 2104H McGavran Greenberg Hall,CB 7435, Chapel Hill, NC 27599 USA.
EM egower@unc.edu
RI Pajewski, Nicholas/J-1096-2019; Shekhawat, Nakul/AAJ-4116-2020
OI Shekhawat, Nakul/0000-0003-4472-3852; Stein, Joshua/0000-0003-2937-6987
FU Genentech; National Eye Institute, National Institutes of Health,
   Bethesda, Maryland [1K23-EY019511]; Physician Scientist Award from
   Research to Prevent Blindness, Inc, New York, New York
FX THE MEDICARE CLAIMS DATA USED IN THIS MANUSCRIPT WERE ORIGINALLY
   PURCHASED THROUGH A research grant from Genentech (E.W.G.). Work was
   also supported in part by the National Eye Institute, National
   Institutes of Health, Bethesda, Maryland (1K23-EY019511 to J.D.S.) and a
   Physician Scientist Award from Research to Prevent Blindness, Inc, New
   York, New York (to J.D.S.). The sponsors or funding organizations had no
   role in the design or conduct of this research.
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Baker RS, 2005, OPHTHAL EPIDEMIOL, V12, P1, DOI 10.1080/09286580590921330
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cassard SD, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.032
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   CHIANG YP, 1995, PUBLIC HEALTH REP, V110, P147
   Chou CF, 2012, OPHTHAL EPIDEMIOL, V19, P340, DOI 10.3109/09286586.2012.722244
   Cohen D, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1654
   Coleman AL, 2005, OPHTHALMOLOGY, V112, P401, DOI 10.1016/j.ophtha.2004.09.034
   Coleman AL, 2006, J GLAUCOMA, V15, P486, DOI 10.1097/01.ijg.0000212287.62798.8f
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Devgan U, 2000, ARCH OPHTHALMOL-CHIC, V118, P253
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Goldberg RA, 2013, OPHTHALMOLOGY, V120, P1448, DOI 10.1016/j.ophtha.2012.12.009
   Hutton D, 2014, HEALTH AFFAIR, V33, P931, DOI 10.1377/hlthaff.2013.0832
   Hwang JC, 2012, AM J OPHTHALMOL, V153, P1125, DOI 10.1016/j.ajo.2011.11.034
   Jampel HD, 2014, JAMA OPHTHALMOL, V132, P685, DOI 10.1001/jamaophthalmol.2014.369
   JAVITT JC, 1995, MED CARE, V33, P90, DOI 10.1097/00005650-199501000-00008
   Jeng KW, 2014, RETINA-J RET VIT DIS, V34, P1796, DOI 10.1097/IAE.0000000000000182
   Ko DT, 2008, J AM COLL CARDIOL, V51, P716, DOI 10.1016/j.jacc.2007.10.039
   Larsen K, 2005, AM J EPIDEMIOL, V161, P81, DOI 10.1093/aje/kwi017
   LEAPE LL, 1990, JAMA-J AM MED ASSOC, V263, P669, DOI 10.1001/jama.263.5.669
   Lee PP, 2003, OPHTHALMOLOGY, V110, P1952, DOI 10.1016/S0161-6420(03)00817-0
   Lotery A, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6887
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mikacic I, 2016, DRUG SAFETY, V39, P517, DOI 10.1007/s40264-016-0408-y
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Muir KW, 2013, JAMA OPHTHALMOL, V131, P119, DOI 10.1001/jamaophthalmol.2013.577
   Office of the Inspector General (OIG) US Department of Health and Human Services (HHS), 2012, MED PAYM DRUGS US TR
   Orr P, 1999, OPHTHALMOLOGY, V106, P904, DOI 10.1016/S0161-6420(99)00508-4
   Parikh R, 2017, OPHTHALMOLOGY, V124, P352, DOI 10.1016/j.ophtha.2016.10.036
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   Pollack A., 2010, NY TIMES
   Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83
   Rosenfeld PJ, 2011, NEW ENGL J MED, V364, P1966, DOI 10.1056/NEJMe1103334
   Schein OD, 2012, OPHTHAL EPIDEMIOL, V19, P257, DOI 10.3109/09286586.2012.698692
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Sheyman AT, 2013, JAMA OPHTHALMOL, V131, P864, DOI 10.1001/jamaophthalmol.2013.88
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Stein JD, 2013, AM J OPHTHALMOL, V156, P1169, DOI 10.1016/j.ajo.2013.06.035
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Thilen SR, 2014, JAMA INTERN MED, V174, P380, DOI 10.1001/jamainternmed.2013.13426
   US Census Bureau, AM FACT FIND
   US Office of Government Accountability, 2015, MED B
   Virgili G, 2017, COCHRANE DB SYST REV, V6
   Wang WJ, 2015, INT J OPHTHALMOL-CHI, V8, P138, DOI 10.3980/j.issn.2222-3959.2015.01.26
   WashingtonW Alaska, 2014, RURAL URBAN COMMUTIN
   Zhang XY, 2014, INT J OPHTHALMOL-CHI, V7, P355, DOI 10.3980/j.issn.2222-3959.2014.02.30
NR 55
TC 10
Z9 10
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2017
VL 184
BP 157
EP 166
DI 10.1016/j.ajo.2017.10.010
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FP6ZP
UT WOS:000417776400018
PM 29106914
DA 2022-11-30
ER

PT J
AU Mukkamala, LK
   Mishra, K
   Daftari, I
   Moshiri, A
   Park, SS
AF Mukkamala, Lekha K.
   Mishra, Kavita
   Daftari, Inder
   Moshiri, Ala
   Park, Susanna S.
TI Phase I/II randomized study of proton beam with anti-VEGF for exudative
   age-related macular degeneration: long-term results
SO EYE
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; FOLLOW-UP; IRRADIATION; THERAPY;
   RADIATION; OUTCOMES; MELANOMAS; ATROPHY
AB Background/objective To determine if treatment of exudative age-related macular degeneration (eAMD) using proton beam therapy (PBT) combined with intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is safe and effective long term. Subject/methods Thirty eyes with newly diagnosed eAMD were enrolled in a phase I/II prospective, sham-controlled double-masked university study. Eyes were randomized 1:1:1-24 GyE, 16 GyE or sham radiation, and treated with three initial monthly intravitreal ranibizumab or bevacizumab. Subsequent anti-VEGF reinjection was based on monthly optical coherence tomography and examination for 2 years and standard of care thereafter. Results A total of 23 eyes completed 2-year study follow-up, of which 16 maintained monthly follow-up. Mean best-correct visual acuity (BCVA) at 2 years was similar among treatment groups (p > 0.05). The 24 GyE group required fewer anti-VEGF injections when compared with the sham group at 2 years (4.67 +/- 1.9 vs 9.67 +/- 3.5; p = 0.017). Extended follow-up (mean 4 years) available in 22 eyes showed persistent reduced need for anti-VEGF therapy among eyes treated with 24 GyE compared with sham radiation (2.0 +/- 1.6 vs 4.84 +/- 2.4 per year, p = 0.008). New and increasing geographic atrophy (GA), noted in some eyes in all treatment groups, resulted in decreased mean BCVA from baseline for the 24 GyE group on extended follow-up (p = 0.009). Possible mild radiation retinopathy noted in 15% of eyes was not visually significant. Conclusions Initial treatment combining PBT (24 GyE) with intravitreal anti-VEGF therapy appears to decrease the need for anti-VEGF reinjection in eyes with newly diagnosed eAMD. Radiation retinopathy risk was low and does not appear visually significant. Long-term vision was limited by GA development especially in the 24 GyE group.
C1 [Mukkamala, Lekha K.; Moshiri, Ala; Park, Susanna S.] Univ Calif Davis, Ctr Eye, Dept Ophthalmol & Vis Sci, Vitreoretinal Serv, Sacramento, CA 95817 USA.
   [Mishra, Kavita; Daftari, Inder] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA.
C3 University of California System; University of California Davis;
   University of California System; University of California San Francisco
RP Park, SS (通讯作者)，Univ Calif Davis, Ctr Eye, Dept Ophthalmol & Vis Sci, Vitreoretinal Serv, Sacramento, CA 95817 USA.
EM sscpark@ucdavis.edu
FU Strategic Opportunities Support Award, Clinical and Translational
   Science Institute, University of California San Francisco
FX The study was supported in part by the Strategic Opportunities Support
   Award, Clinical and Translational Science Institute, University of
   California San Francisco.
CR Bensoussan E, 2016, AM J OPHTHALMOL, V165, P78, DOI 10.1016/j.ajo.2016.02.027
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Brand C, 2018, EYE, V32, P1345, DOI 10.1038/s41433-018-0080-9
   Ciulla TA, 2002, AM J OPHTHALMOL, V134, P905, DOI 10.1016/S0002-9394(02)01821-4
   Daftari I., 2016, INT J MED PHYS CLIN, V5, P242, DOI [10.4236/ijmpcero.2016.54025., DOI 10.4236/IJMPCERO.2016.54025]
   Daftari IK, 2010, MED PHYS, V37, P5199, DOI 10.1118/1.3488891
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Flaxel CJ, 2000, EYE, V14, P155, DOI 10.1038/eye.2000.46
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   GOITEIN M, 1983, MED PHYS, V10, P275, DOI 10.1118/1.595258
   Gragoudas ES, 2006, INVEST OPHTH VIS SCI, V47, P4666, DOI 10.1167/iovs.06-0659
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   GUYER DR, 1992, OPHTHALMOLOGY, V99, P1278
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Osmanovic S, 2017, OPHTHALMOL RETINA, V1, P217, DOI 10.1016/j.oret.2016.11.003
   Park SS, 2012, RETINA-J RET VIT DIS, V32, P956, DOI 10.1097/IAE.0b013e31822a8d6a
   Sikuade MJ, 2015, EYE, V29, P1194, DOI 10.1038/eye.2015.109
   Trikha R, 2011, RETINA-J RET VIT DIS, V31, P1303, DOI 10.1097/IAE.0b013e318203ee46
   Yonemoto LT, 1996, INT J RADIAT ONCOL, V36, P867, DOI 10.1016/S0360-3016(96)00339-2
   Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036
NR 22
TC 1
Z9 1
U1 0
U2 1
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2020
VL 34
IS 12
BP 2271
EP 2279
DI 10.1038/s41433-020-0807-2
EA FEB 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QG6KF
UT WOS:000513313500006
PM 32055016
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Chiu, CJ
   Milton, RC
   Klein, R
   Gensler, G
   Taylor, A
AF Chiu, Chung-Jung
   Milton, Roy C.
   Klein, Ronald
   Gensler, Gary
   Taylor, Allen
TI Dietary carbohydrate and the progression of age-related macular
   degeneration: a prospective study from the age-related eye disease study
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE retina; nutrition; carbohydrate; diabetes; sugar; glycation;
   inflammation; aging; stress; epidemiology
ID GLYCEMIC INDEX; REGRESSION-ANALYSIS; VISUAL IMPAIRMENT; ASSOCIATION;
   PREVALENCE; PROTEINS; EXPOSURE; FOODS; LOAD
AB Background: Cross-sectional studies indicate that diets that provide a higher dietary glycemic index (dGI) are associated with a greater risk of age-related macular degeneration (AMD). No prospective studies have addressed this issue.
   Objective: The objective was to prospectively evaluate the effect of baseline dGI on the progression of AMD.
   Design: dGI was calculated as the weighted average of GIs from foods and was evaluated as being above or below the sex median (women: 77.9; men: 79.3) for 3977 participants aged 55-80 y (58% women) in the Age-Related Eye Disease Study. The 7232 eligible eyes without advanced AMD were classified into I of 3 AMD categories: group 1 (nonextensive small drusen), group 2 (intermediate drusen. extensive small drusen, or pigmentary abnormalities), or Group 3 (large drusen or extensive intermediate drusen). With the use of multifailure Cox proportional-hazards regression, we modeled the time to the maximal progression to evaluate the relation between dGI and the risk of AMD.
   Results: Overall, the multivariate-adjusted risk of progression over 8 y of follow-up ((x) over bar: 5.4 y) was significantly higher (risk ratio: 1.10; 95% CI: 1.00, 1.20; P = 0.047) in the high-dGI group than in the low-dGI group. The risk of progression for groups 1, 2, and 3 eyes was 5%, 8%, and 17% greater, respectively (P for trend < 0.001). The latter gives an estimate that 7.8% of new advanced AMD cases would be prevented in 5 y if people consumed the low-dGI diet.
   Conclusion: Persons at risk of AMD progression, especially those at high risk of advanced AMD, may benefit from consuming a smaller amount of refined carbohydrates.
C1 Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
   EMMES Corp, AREDS Coordinat Ctr, Rockville, MD USA.
   Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI USA.
C3 Tufts University; United States Department of Agriculture (USDA); Emmes
   Corporation; University of Wisconsin System; University of Wisconsin
   Madison
RP Taylor, A (通讯作者)，Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.
EM allen.taylor@tufts.edu
FU NEI NIH HHS [R03-EY014183-01A2] Funding Source: Medline; PHS HHS
   [R01-13250] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R03EY014183] Funding Source: NIH RePORTER
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976
   Augustin LS, 2002, EUR J CLIN NUTR, V56, P1049, DOI 10.1038/sj.ejcn.1601454
   Brand-Miller JC, 2005, AM J CLIN NUTR, V82, P350, DOI 10.1093/ajcn/82.2.350
   Chin CJ, 2005, AM J CLIN NUTR, V81, P1411
   Chiu CJ, 2007, EXP EYE RES, V84, P229, DOI 10.1016/j.exer.2006.05.015
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P1177, DOI 10.1093/ajcn/83.5.1177
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Foster-Powell K, 2002, AM J CLIN NUTR, V76, P5, DOI 10.1093/ajcn/76.1.5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hu FB, 2002, JAMA-J AM MED ASSOC, V288, P2569, DOI 10.1001/jama.288.20.2569
   Hu YQ, 2006, AM J CLIN NUTR, V84, P70, DOI 10.1093/ajcn/84.1.70
   JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362
   Jenkins DJA, 2002, AM J CLIN NUTR, V76, p266S, DOI 10.1093/ajcn/76.1.266S
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   McCarty CA, 1996, B WORLD HEALTH ORGAN, V74, P353
   MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617
   Pawlak DB, 2004, LANCET, V364, P778, DOI 10.1016/S0140-6736(04)16937-7
   PRENTICE RL, 1981, BIOMETRIKA, V68, P373, DOI 10.2307/2335582
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Shaw LC, 2004, REV ENDOCR METAB DIS, V5, P199, DOI 10.1023/B:REMD.0000032408.18015.b1
   Stitt AW, 2005, ANN NY ACAD SCI, V1043, P582, DOI 10.1196/annals.1338.066
   Thornalley PJ, 1999, BIOCHEM J, V344, P109, DOI 10.1042/0264-6021:3440109
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   Willett W., 2013, NUTR EPIDEMIOLOGY, V3rd
   WOLEVER TMS, 1994, AM J CLIN NUTR, V59, P1265, DOI 10.1093/ajcn/59.6.1265
NR 33
TC 65
Z9 68
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD OCT
PY 2007
VL 86
IS 4
BP 1210
EP 1218
DI 10.1093/ajcn/86.4.1210
PG 9
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 220CN
UT WOS:000250134600044
PM 17921404
DA 2022-11-30
ER

PT J
AU Marin, BP
   Paniagua, NMG
   Gomez-Baldo, L
   Gallego-Pinazo, R
AF Pina Marin, Begona
   Gajate Paniagua, Nuria Maria
   Gomez-Baldo, Laia
   Gallego-Pinazo, Roberto
CA AMD-Manage investigators
TI Burden of disease assessment in patients with neovascular age-related
   macular degeneration in Spain: Results of the AMD-MANAGE study
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Anti-VEGF; burden of disease; real-world outcomes; Spain; wet macular
   degeneration
ID LIVED EXPERIENCE; RANIBIZUMAB; OUTCOMES; AFLIBERCEPT; THERAPY
AB Background/Aims: The present study evaluates the burden of neovascular age-related macular degeneration (nAMD) to Healthcare System and patients, describing the management and treatment effectiveness in routine clinical practice in Spain. Methods: Observational, non-interventional, cross-sectional, retrospective (24 months), multicentre study including patients who started treatment with licensed vascular endothelial growth factor inhibitors (anti-VEGF) for nAMD with a minimum follow up of 24 months. Results: 126 evaluable patients were included with mean (SD) age of 79.1 (7.5) years. From diagnosis, it took a mean (SD) of 0.5 (0.5) months for the first treatment. Throughout 24 months, mean (SD) number of visits per patient was 16.0 (5.0), 9.4 (4.3) associated intravitreal injection. There were 1186 injection visits, 53.6% of them only with injection and 46.3% with injection and tests. After loading phase, preferred treatment regimens were T&E (46.0%), PRN (44.4%), fixed regimen (4.0%), and others (5.6%). Total number of visits in patients with T&E and PRN were 16.5 (5.7) and 15.5 (4.7), respectively. After complete loading phase, mean (SD) time between two consecutive treatment injections was 2.2 (1.6) months. 27.8% patients underwent a treatment change, being lack of response the most frequent reason to change (43.2%). Mean (SD) best-corrected visual acuity change was 2.1 (15.9) letters at 24 months. Conclusion: This study showed an important burden to Healthcare System and patients related to monitoring visits. More efficacious and longer lasting treatments could be useful to increase treatment intervals, thus reducing the burden of patients and caregivers and the use of healthcare resources.
C1 [Pina Marin, Begona] Hosp Dos de Mayo, Dept Ophthalmol, Barcelona, Spain.
   [Gajate Paniagua, Nuria Maria] Hosp Univ Burgos, Dept Ophthalmol, Burgos, Spain.
   [Gomez-Baldo, Laia] Novartis Farmaceut SA, Med Dept, Barcelona, Spain.
   [Gallego-Pinazo, Roberto] Oftalvist Clin, Unit Macula, Valencia, Spain.
C3 Novartis
RP Gallego-Pinazo, R (通讯作者)，Clin Oftalvist, Calle Ruzafa 19, Valencia 1946004, Spain.
EM rgallego@oftalvist.es
OI Gajate Paniagua, Nuria Maria/0000-0002-9848-7413
FU Novartis Farmaceutica SA
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship and/or publication of this article: This
   research was funded by Novartis Farmaceutica SA. The sponsor or funding
   organisation participated in the design of the study; management,
   analysis and interpretation of the data; preparation, review and
   approval of the manuscript.
CR Araiz J, 2013, Arch Soc Esp Oftalmol, V88, P216, DOI 10.1016/j.oftal.2012.07.003
   Armada-Maresca J, 2014, SOC ESPANOLA RETINA
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2621, DOI 10.1007/s00417-020-04955-7
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Casaroli-Marano R, 2013, Arch Soc Esp Oftalmol, V88, P307, DOI 10.1016/j.oftal.2012.10.009
   Casaroli-Marano R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/346360
   Casaroli-Marano R, 2011, BRIT J OPHTHALMOL, V95, P931, DOI 10.1136/bjo.2010.187773
   Castro-Navarro V, 2016, OPHTHALMOLOGICA, V236, P215, DOI 10.1159/000453281
   Coco RM, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-138
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Damian Javier, 2006, Aten Primaria, V38, P51, DOI 10.1157/13090016
   Escobar J., 22 C SPAN SOC RET VI
   Fasler K, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027441
   Garc?a Layana J, 2016, SOC ESPANOLA RETINA
   Garcia-Layana A, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/9821509
   Holz FG, 2016, EYE, V30, P1063, DOI 10.1038/eye.2016.90
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Hykin P, 2016, CLIN OPHTHALMOL, V10, P87, DOI 10.2147/OPTH.S92627
   Jaffe DH, 2018, J COMP EFFECT RES, V7, P1125, DOI 10.2217/cer-2018-0058
   L?pez-Guajardo R, 2017, ARCH SOC ESP OFTALMO, V92
   Mantel I, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.6
   McCloud C, 2015, EYE, V29, P1561, DOI 10.1038/eye.2015.167
   McCloud C, 2014, OPTOMETRY VISION SCI, V91, P966, DOI 10.1097/OPX.0000000000000320
   Mones J, 2020, OPHTHALMOLOGICA, V243, P1, DOI 10.1159/000502747
   Monje-Fernandez L, 2018, Arch Soc Esp Oftalmol (Engl Ed), V93, P324, DOI 10.1016/j.oftal.2018.02.003
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Udaondo P, 2016, OPHTHALMOLOGICA, V236, P29, DOI 10.1159/000445724
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Yannuzzi NA, 2019, CLIN OPHTHALMOL, V13, P1323, DOI 10.2147/OPTH.S184706
NR 33
TC 3
Z9 3
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN
PY 2022
VL 32
IS 1
BP 385
EP 394
AR 11206721211001716
DI 10.1177/11206721211001716
EA MAR 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YK3MJ
UT WOS:000679143900001
PM 33719641
DA 2022-11-30
ER

PT J
AU Tano, Y
   Ohji, M
AF Tano, Yasuo
   Ohji, Masahito
CA EXTEND-I Study Grp
TI EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with
   subfoveal choroidal neovascularization secondary to age-related macular
   degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; best-corrected visual acuity score;
   choroidal neovascularization; efficacy; Japanese patients; ranibizumab;
   safety; subfoveal; tolerability
ID PHOTODYNAMIC THERAPY; VERTEPORFIN; PREVALENCE; POPULATION; TRIAL; AMD
AB Purpose:
   To evaluate the efficacy and safety of intravitreal ranibizumab for subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in Japanese patients.
   Methods:
   This open-label, multicentre, Phase I/II study enroled patients into Group A (single injection of ranibizumab nonrandomized doses of 0.3 or 0.5 mg followed by 11 monthly injections of the same dose) and Group B (12 monthly injections of ranibizumab randomized to 0.3 or 0.5 mg). The primary efficacy endpoint was the mean change from baseline in best-corrected visual acuity (BCVA) score at Month 6. Safety was evaluated in all patients who received ranibizumab.
   Results:
   Of 88 patients enroled, 12 entered Group A (six per dose) and 76 entered Group B (0.3 mg: n = 35; 0.5 mg: n = 41). Mean change from baseline in BCVA was significantly increased for both doses (Group B) at Month 6 (0.3 mg: +8.1 letters, p = 0.0006; 0.5 mg: +9.0 letters, p < 0.0001) and Month 12 (0.3 mg: +9.5 letters, p = 0.0001; 0.5 mg: +10.5 letters, p < 0.0001). At Month 12, one patient (0.3 mg) and 0 patients (0.5 mg) lost >= 15 letters, while 37.1% (0.3 mg) and 31.7% (0.5 mg) of patients gained >= 15 letters. Ocular serious adverse events (SAEs) of the study eye were reported in 1 and 2 patients in the 0.3- and 0.5-mg groups, respectively. Nonocular SAEs were experienced by 2 and 5 patients in the 0.3- and 0.5-mg groups, respectively. No cases of endophthalmitis were reported.
   Conclusion:
   Ranibizumab was effective and well tolerated in Japanese patients with subfoveal CNV secondary to AMD.
C1 [Ohji, Masahito] Shiga Univ Med Sci, Dept Ophthalmol, Shiga 5202192, Japan.
   [Tano, Yasuo] Osaka Univ Med Sch, Dept Ophthalmol, Osaka, Japan.
C3 Shiga University of Medical Science; Osaka University
RP Ohji, M (通讯作者)，Shiga Univ Med Sci, Dept Ophthalmol, Seta Tsukinowa Cho, Shiga 5202192, Japan.
EM ohji@belle.shiga-med.ac.jp
FU Novartis
FX The authors acknowledge former principal investigator, Dr Shinobu
   Takeuchi (Toho University Ohashi Medical Center), and Dr Takashi Tokoro
   (Tokyo Medical and Dental University) for their contribution to the
   study protocol and clinical study report. The authors acknowledge
   medical writing assistance from Vanessa Cobb from Complete Medical
   Communications. This study was funded unconditionally by Novartis. The
   views and opinions expressed herein are those of the authors.The
   EXTEND-I study was presented at the ARVO 2008 annual meeting as a poster
   presentation.
CR Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Dadgostar H, 2008, EYE, V22, P761, DOI 10.1038/eye.2008.86
   *FDA, 2006, HIGHL LUC PRESCR INF
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   HOGAN MJ, 1959, AM J OPHTHALMOL, V47, P155, DOI 10.1016/S0002-9394(14)78239-X
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Tano Y, 2008, JPN J OPHTHALMOL, V52, P99, DOI 10.1007/s10384-008-0512-3
NR 14
TC 39
Z9 49
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2010
VL 88
IS 3
BP 309
EP 316
DI 10.1111/j.1755-3768.2009.01843.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 589CO
UT WOS:000277122600017
PM 20163368
DA 2022-11-30
ER

PT J
AU Seitsonen, SP
   Onkamo, P
   Peng, G
   Xiong, MM
   Tommila, PV
   Ranta, PH
   Holopainen, JM
   Moilanen, JA
   Palosaari, T
   Kaarniranta, K
   Meri, S
   Immonen, IR
   Jarvela, IE
AF Seitsonen, Sanna P.
   Onkamo, Paivi
   Peng, Gang
   Xiong, Momiao
   Tommila, Petri V.
   Ranta, Paivi H.
   Holopainen, Juha M.
   Moilanen, Jukka A.
   Palosaari, Tapani
   Kaarniranta, Kai
   Meri, Seppo
   Immonen, Ilkka R.
   Jarvela, Irma E.
TI Multifactor Effects and Evidence of Potential Interaction between
   Complement Factor H Y402H and LOC387715 A69S in Age-Related Macular
   Degeneration
SO PLOS ONE
LA English
DT Article
ID HTRA1 PROMOTER POLYMORPHISM; CIGARETTE-SMOKING; GEOGRAPHIC ATROPHY;
   VARIANT INCREASES; 3RD COMPONENT; IN-VITRO; RISK; GENE; SUSCEPTIBILITY;
   ASSOCIATION
AB Background: Variants in the complement cascade genes and the LOC387715/HTRA1, have been widely reported to associate with age-related macular degeneration (AMD), the most common cause of visual impairment in industrialized countries.
   Methods/Principal Findings: We investigated the association between the LOC387715 A69S and complement component C3 R102G risk alleles in the Finnish case-control material and found a significant association with both variants (OR 2.98, p = 3.75x10(-9); non-AMD controls and OR 2.79, p = 2.78x10(-19), blood donor controls and OR 1.83, p = 0.008; non-AMD controls and OR 1.39, p = 0.039; blood donor controls), respectively. Previously, we have shown a strong association between complement factor H (CFH) Y402H and AMD in the Finnish population. A carrier of at least one risk allele in each of the three susceptibility loci (LOC387715, C3, CFH) had an 18-fold risk of AMD when compared to a non-carrier homozygote in all three loci. A tentative gene-gene interaction between the two major AMD-associated loci, LOC387715 and CFH, was found in this study using a multiplicative (logistic regression) model, a synergy index (departure-from-additivity model) and the mutual information method (MI), suggesting that a common causative pathway may exist for these genes. Smoking (ever vs. never) exerted an extra risk for AMD, but somewhat surprisingly, only in connection with other factors such as sex and the C3 genotype. Population attributable risks (PAR) for the CFH, LOC387715 and C3 variants were 58.2%, 51.4% and 5.8%, respectively, the summary PAR for the three variants being 65.4%.
   Conclusions/Significance: Evidence for gene-gene interaction between two major AMD associated loci CFH and LOC387715 was obtained using three methods, logistic regression, a synergy index and the mutual information (MI) index.
C1 [Seitsonen, Sanna P.; Tommila, Petri V.; Ranta, Paivi H.; Holopainen, Juha M.; Moilanen, Jukka A.; Meri, Seppo; Immonen, Ilkka R.] Univ Helsinki, Dept Ophthalmol, Helsinki, Finland.
   [Seitsonen, Sanna P.; Jarvela, Irma E.] Univ Helsinki, Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland.
   [Onkamo, Paivi] Univ Helsinki, Dept Biol & Environm Sci, FIN-00014 Helsinki, Finland.
   [Peng, Gang; Xiong, Momiao] Fudan Univ, Sch Life Sci, Fudan, Peoples R China.
   [Xiong, Momiao] Univ Texas, Sch Publ Hlth, Human Genet Ctr, Houston, TX USA.
   [Palosaari, Tapani] Univ Oulu, Dept Ophthalmol, Helsinki, Finland.
   [Kaarniranta, Kai] Univ Kuopio, Dept Ophthalmol, FIN-70211 Kuopio, Finland.
   Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, FIN-00014 Helsinki, Finland.
   [Jarvela, Irma E.] Univ Helsinki, Cent Hosp, Lab Mol Genet, FIN-00014 Helsinki, Finland.
C3 University of Helsinki; University of Helsinki; University of Helsinki;
   Fudan University; University of Texas System; University of Texas Health
   Science Center Houston; University of Texas School Public Health;
   University of Oulu; University of Eastern Finland; University of
   Helsinki; University of Helsinki; Helsinki University Central Hospital
RP Seitsonen, SP (通讯作者)，Univ Helsinki, Dept Ophthalmol, Helsinki, Finland.
EM sanna.seitsonen@hus.fi
RI Jarvela, Irma E/L-5836-2013; Peng, Gang/AAN-5355-2020
OI Jarvela, Irma E/0000-0002-1770-6187; Peng, Gang/0000-0003-0307-9351;
   Meri, Seppo/0000-0001-9142-501X; Kaarniranta, Kai/0000-0003-2600-8679
FU Eye Foundation, Helsinki, Finland; The Evald and Hilda Nissi Foundation,
   Vaasa, Finland; The Academy of Finland, Hel-sinki, Finland; Helsinki
   University Central Hospital Research Funds, Helsinki, Finland [TYH5117,
   TYH6233]; National Institutes of Health [EY11515]; NATIONAL EYE
   INSTITUTE [R01EY011515] Funding Source: NIH RePORTER
FX This study was funded by grants from the Paivikki and Sakari Sohlberg
   Foundation, Hel-sinki, Finland; The Mary and Georg Ehrnrooth Foundation,
   Helsinki, Finland; The Eye and Tissue Bank Foundation, Helsinki,
   Finland; The Eye Foundation, Helsinki, Finland; The Evald and Hilda
   Nissi Foundation, Vaasa, Finland; The Academy of Finland, Hel-sinki,
   Finland; Helsinki University Central Hospital Research Funds (TYH5117,
   TYH6233), Helsinki, Finland; and National Institutes of Health
   (EY11515). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript. The
   authors do not have any financial interests to disclose.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Andersson T, 2005, EUR J EPIDEMIOL, V20, P575, DOI 10.1007/s10654-005-7835-x
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Cordell HJ, 2002, HUM MOL GENET, V11, P2463, DOI 10.1093/hmg/11.20.2463
   Cover T.M., 2006, ELEMENTS INFORM THEO
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis PJ, 2008, MOL VIS, V14, P1395
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   GICLAS PC, 1979, J IMMUNOL, V122, P146
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   KEW RR, 1987, CLIN IMMUNOL IMMUNOP, V44, P248, DOI 10.1016/0090-1229(87)90069-9
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Liew G, 2007, OPHTHALMOLOGY, V114, P1793, DOI 10.1016/j.ophtha.2007.04.036
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Narayanan R, 2007, OPHTHALMOLOGY, V114, P1327, DOI 10.1016/j.ophtha.2006.10.035
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   North BV, 2005, HUM HERED, V59, P79, DOI 10.1159/000085222
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   ROBBINS RA, 1991, AM J PHYSIOL, V260, pL254, DOI 10.1152/ajplung.1991.260.4.L254
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Rothman K, 2002, EPIDEMIOLOGY INTRO
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Scott WK, 2007, OPHTHALMOLOGY, V114, P1151, DOI 10.1016/j.ophtha.2006.08.054
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seitsonen S, 2006, MOL VIS, V12, P796
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 2005, MOL VIS, V11, P1135
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Thornton-Wells TA, 2004, TRENDS GENET, V20, P640, DOI 10.1016/j.tig.2004.09.007
   TUO J, 2008, OPHTHALMOLO IN PRESS
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Weger M, 2007, MOL VIS, V13, P1274
   Yanbaeva DG, 2007, CHEST, V131, P1557, DOI 10.1378/chest.06-2179
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida T, 2007, MOL VIS, V13, P545
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhao JY, 2006, AM J HUM GENET, V79, P831, DOI 10.1086/508571
NR 62
TC 58
Z9 61
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 2
PY 2008
VL 3
IS 12
AR e3833
DI 10.1371/journal.pone.0003833
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 436YM
UT WOS:000265452000006
PM 19048105
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Udaondo, P
   Salom, D
   Garcia-Delpech, S
   Cisneros-Lanuza, A
AF Udaondo, Patricia
   Salom, David
   Garcia-Delpech, Salvador
   Cisneros-Lanuza, Angel
TI Aflibercept as First-Line Therapy in Patients with Treatment-Naive
   Neovascular Age-Related Macular Degeneration: Prospective Case Series
   Analysis in Real-Life Clinical Practice
SO OPHTHALMOLOGICA
LA English
DT Article
DE Aflibercept; Eylea (R); Macular degeneration; Prospective studies;
   Receptors; Vascular endothelial growth factor
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; SHORT-TERM EFFICACY; INTRAVITREAL
   AFLIBERCEPT; GROWTH-FACTOR; VEGF TRAP; RANIBIZUMAB; BEVACIZUMAB; EYE;
   IMPAIRMENT; PREVALENCE
AB Purpose: To assess the 13-month effectiveness and safety of aflibercept in naive patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting. Methods: Thirty-two treatment-naive patients with nvAMD participated in a prospective two-center study. Patients received intravitreal injections of aflibercept (Eylea (R)), a loading dose of three monthly injections (2 mg/0.05 ml) every 4 weeks for the first 3 months, followed by intravitreal injections every 2 months. Results: At 3 and 13 months, the mean best-corrected visual acuity improved significantly as compared with baseline (logMAR 0.53 +/- 0.30 and 0.55 +/- 0.32 vs. 0.30 +/- 0.24, respectively, p < 0.001). At 3 and 13 months, 46.8% of patients (15/32) gained >= 15 ETDRS letters. The mean decrease in central macular thickness was also significant at 3 months (252 +/- 35 mu m) and at 13 months (249 +/- 38 mu m) as compared with pretreatment values (383 +/- 76 mu m) (p < 0.01). Also, 50% resolution of pigment epithelial detachment (PED) was observed in 8 out of 9 eyes (88.9%) with PED at baseline. Intravitreal injections were well tolerated and no adverse events were recorded. Conclusion: Aflibercept was effective and safe for treating nvAMD in naive patients in routine daily practice. (C) 2016 S. Karger AG, Basel
C1 [Udaondo, Patricia; Garcia-Delpech, Salvador; Cisneros-Lanuza, Angel] Hosp Univ Politecn La Fe Valencia, Dept Ophthalmol, Avinguda Fernando Abril Martorell 106, ES-46026 Valencia, Spain.
   [Salom, David] Hosp Manises, Dept Ophthalmol, Valencia, Spain.
C3 Hospital Universitari i Politecnic La Fe
RP Udaondo, P (通讯作者)，Hosp Univ Politecn La Fe Valencia, Dept Ophthalmol, Avinguda Fernando Abril Martorell 106, ES-46026 Valencia, Spain.
EM draudondo@gmail.com
RI Salom, David/ABH-6567-2020
OI Udaondo, Patricia/0000-0002-5241-0066; Salom, David/0000-0002-6341-2905;
   GARCIA-DELPECH, SALVADOR/0000-0002-6016-9284
FU Bayer Hispania, S.L.
FX The authors thank Marta Pulido, MD, for editing the manuscript and
   editorial assistance. The study was supported by Bayer Hispania, S.L.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Bohni SC, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0101-4
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Buckle M, 2015, EYE, V29, P403, DOI 10.1038/eye.2014.296
   Campa C, 2011, CURR DRUG TARGETS, V12, P173, DOI 10.2174/138945011794182674
   Campochiaro PA, 2007, DRUG TODAY, V43, P529, DOI 10.1358/dot.2007.43.8.1120868
   Casaroli-Marano R, 2011, BRIT J OPHTHALMOL, V95, P931, DOI 10.1136/bjo.2010.187773
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   El-Mollayess GM, 2011, SEMIN OPHTHALMOL, V26, P69, DOI 10.3109/08820538.2010.545100
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Gambon R, 2014, KLIN MONATSBL AUGENH, V231, P423, DOI 10.1055/s-0034-1368292
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Ijiri S, 2015, GRAEF ARCH CLIN EXP, V253, P351, DOI 10.1007/s00417-014-2707-2
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Lai K, 2015, EXPERT REV CLIN PHAR, V8, P135, DOI 10.1586/17512433.2015.990379
   Mazaraki K, 2015, BRIT J OPHTHALMOL, V99, P1341, DOI 10.1136/bjophthalmol-2015-306636
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Seddon JM, 2014, INT OPHTHALMOL CLIN, V44, P17
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Sophie Raafay, 2012, Biol Ther, V2, P3, DOI 10.1007/s13554-012-0003-4
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Triantafylla M, 2014, CLIN OPHTHALMOL, V8, P1187, DOI 10.2147/OPTH.S40350
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Zampros I, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/319728
NR 39
TC 5
Z9 5
U1 1
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2016
VL 236
IS 1
BP 29
EP 35
DI 10.1159/000445724
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DT6KE
UT WOS:000381592300004
PM 27348231
DA 2022-11-30
ER

PT J
AU Lee, TG
   Kim, JH
   Chang, YS
   Kim, CG
   Kim, JW
AF Lee, Tae Gon
   Kim, Jae Hui
   Chang, Young Suk
   Kim, Chul Gu
   Kim, Jong Woo
TI Factors influencing the exudation recurrence after cataract surgery in
   patients previously treated with anti-vascular endothelial growth factor
   for exudative age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Anti-vascular endothelial growth factor; Cataract surgery; Exudative
   age-related macular degeneration; Phacoemulsification
ID RANIBIZUMAB; BEVACIZUMAB; OUTCOMES; FLARE; DELAY
AB Purpose To investigate factors influencing exudation recurrence following cataract surgery in patients already treated with anti-vascular endothelial growth factor (VEGF) agents for exudative age-related macular degeneration (AMD).
   Methods A retrospective review of medical records was performed for patients who underwent cataract surgery and had been previously treated with anti-VEGF for exudative AMD. Visual acuity was examined before surgery and 1 and 6 months after surgery. The time between diagnosis and surgery, and the exudation-free period before surgery were examined and compared between patients who had exudation recurrence and those that did not.
   Results Thirty-nine eyes of 39 patients were included in analyses. The logarithm of the minimum angle of resolution visual acuity was 1.02 +/- 0.58 and had significantly improved 1 month (0.81 +/- 0.62, P < 0.001) and 6 months (0.85 +/- 0.64, P = 0.001) following surgery. Both the diagnosis-to-surgery period (P = 0.001) and the preoperative exudation-free period (P < 0.001) were significantly longer in patients without recurrence than in patients with recurrence.
   Conclusions Cataract surgery was beneficial in patients previously treated with anti-VEGF for exudative AMD. Our data suggests that cataract surgery should be performed after a sufficiently long exudation-free period to minimize exudation recurrence. But larger prospective studies are required to draw definitive clinical guidelines.
C1 [Lee, Tae Gon; Kim, Jae Hui; Chang, Young Suk; Kim, Chul Gu; Kim, Jong Woo] Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, Seoul 150034, South Korea.
   [Lee, Tae Gon] Kyung Hee Univ, Grad Sch Med, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital; Kyung Hee University
RP Kim, JH (通讯作者)，Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4Ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
FU Kim's Eye Hospital Research Center
FX This study is supported by Kim's Eye Hospital Research Center.
CR Alio JL, 1997, J CATARACT REFR SURG, V23, P935, DOI 10.1016/S0886-3350(97)80256-8
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Ersoy L, 2013, BRIT J OPHTHALMOL, V97, P862, DOI 10.1136/bjophthalmol-2012-302995
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Muniraju R, 2013, OPHTHALMOLOGICA, V230, P27, DOI 10.1159/000350238
   Muzyka-Wozniak M, 2011, EUR J OPHTHALMOL, V21, P766, DOI 10.5301/EJO.2011.6389
   Oliver-Fernandez M, 2005, CAN J OPHTHALMOL, V40, P313, DOI 10.1016/S0008-4182(05)80074-2
   Rauch R, 2012, RETINA-J RET VIT DIS, V32, P1260, DOI 10.1097/IAE.0b013e3182018df6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
   Saleh M, 2013, GRAEF ARCH CLIN EXP, V251, P1901, DOI 10.1007/s00417-013-2284-9
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tabandeh H, 2012, J CATARACT REFR SURG, V38, P677, DOI 10.1016/j.jcrs.2011.10.036
NR 19
TC 13
Z9 14
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2014
VL 252
IS 10
BP 1573
EP 1579
DI 10.1007/s00417-014-2624-4
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AT0NB
UT WOS:000344631600008
PM 24723165
DA 2022-11-30
ER

PT J
AU Giansanti, F
   Virgili, G
   Bini, A
   Rapizzi, E
   Giacomelli, G
   Donati, MC
   Verdina, T
   Menchini, U
AF Giansanti, F.
   Virgili, G.
   Bini, A.
   Rapizzi, E.
   Giacomelli, G.
   Donati, M. C.
   Verdina, T.
   Menchini, U.
TI Intravitreal bevacizumab therapy for choroidal neovascularization
   secondary to age-related macular degeneration: 6-month results of an
   open-label uncontrolled clinical study
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; bevacizumab; choroidal
   neovascularization; intravitreal injection
ID AVASTIN; INJECTION
AB PURPOSE. To investigate the 6-month safety and clinical outcomes of intravitreal injections of bevacizumab administered to treat choraidal neovascularization secondary to age-related macular degeneration.
   METHODS. Twenty-seven patients underwent 1.25 mg intravitreal injections of bevacizumab at baseline. A similar intravitreal injection was administered to all eyes at 1 and 2 month follow-up visits. At baseline and at each follow-up visit (1, 2, 3, and 6 months), patients underwent best-corrected visual acuity (BCVA) measurement, fluorescein angiography, indocyanine green angiography, and optical coherence tomography. Laboratory testing, visual field analyses, and endothelial cell counts were performed at baseline and third and sixth months.
   RESULTS. At 3 months, the mean BCVA remained substantially stable at 20/100. Mean central retinal thickness (CRT) decreased from 373 to 279 pm (p<0.0 1). Mean lesion greatest linear dimension (GLD) decreased from 4087 to 3782 microns (p<0.01). At 6 months, mean BCVA slightly decreased from 20/100(-1) to 20/125(-3) (not significant, p=0.40). Mean CRT was still inferior to baseline (305 mu m, p<0.01). Mean lesion GLD was 4186 mu m, not different from baseline values (p=0.59), but superior to 3-month mean GLD (p<0.01). Significant visual field defects or endothelial cell losses were not detected at 3 and 6 months. Laboratory testing did not reveal any clinically significant deviations compared to baseline values.
   CONCLUSIONS. Intravitreal therapy using bevacizumab over 6 months showed stabilization of visual acuity and choroidal neovascularization activity; the safety data were convincing.
C1 Univ Florence, Eye Clin, Dept Otoneuroophthalmol Surg Sci, I-50134 Florence, Italy.
C3 University of Florence
RP Giansanti, F (通讯作者)，Univ Florence, Eye Clin, Dept Otoneuroophthalmol Surg Sci, Viale Morgagni 85, I-50134 Florence, Italy.
EM fabriziogiansanti@interfree.it
RI Verdina, Tommaso/AAL-5724-2020; giacomelli, giovanni/ABC-6173-2020;
   Giansanti, Fabrizio/I-2193-2012; Virgili, Gianni/P-6607-2014
OI Verdina, Tommaso/0000-0001-7877-4485; Giansanti,
   Fabrizio/0000-0002-4107-2807; Virgili, Gianni/0000-0002-9960-2989
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Luthra S, 2006, RETINA-J RET VIT DIS, V26, P512, DOI 10.1097/01.iae.0000222547.35820.52
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Michels S, 2006, AM J OPHTHALMOL, V141, P396, DOI 10.1016/j.ajo.2005.08.046
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Nicolo M, 2006, EUR J OPHTHALMOL, V16, P770, DOI 10.1177/112067210601600521
   Rabe-Hesketh S, 2001, STAT METHODS MED RES, V10, P409, DOI 10.1191/096228001682157634
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Yourey PA, 2000, J NEUROSCI, V20, P6781, DOI 10.1523/JNEUROSCI.20-18-06781.2000
NR 19
TC 32
Z9 32
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR-APR
PY 2007
VL 17
IS 2
BP 230
EP 237
DI 10.1177/112067210701700213
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 177UZ
UT WOS:000247179300013
PM 17415697
DA 2022-11-30
ER

PT J
AU Nishijima, K
   Takahashi, M
   Akita, J
   Katsuta, H
   Tanemura, M
   Aikawa, H
   Mandai, M
   Takagi, H
   Kiryu, J
   Honda, Y
AF Nishijima, K
   Takahashi, M
   Akita, J
   Katsuta, H
   Tanemura, M
   Aikawa, H
   Mandai, M
   Takagi, H
   Kiryu, J
   Honda, Y
TI Laser photocoagulation of indocyanine green angiographically identified
   feeder vessels to idiopathic polypoidal choroidal vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To evaluate the efficacy of laser photocoagulation of indocyanine green angiographically identified feeder vessels to idiopathic polypoidal choroidal vasculo-pathic lesions.
   DESIGN: Interventional case series.
   METHODS: Fifteen eyes of 14 consecutive patients with idiopathic polypoidal choroidal vasculopathy lesions treated by laser photocoagulation of indocyanine green angiographically identified feeder vessels were investigated.
   RESULTS: In 10 of the 15 eyes, serous retinal detachment of sensory retina in the macula disappeared after photo. coagulation of the feeder vessels. The best,corrected visual acuity improved by 2 or more lines in eight of the 15 eyes and worsened in two eyes during the mean follow-up period of 13.6 months.
   CONCLUSIONS: Laser photocoagulation targeted exclusively to the feeder vessels supplying the idiopathic polypoidal choroidal vasculopathy lesions is a safe and effective method and can improve vision in eyes in which a serous retinal detachment is present in the macula. Indocyanine green angiography,guided laser photocoagulation should be considered as an optional treatment for idiopathic polypoidal choroidal vasculopathy. (C) 2004 by Elsevier Inc. All rights reserved.
C1 Kyoto Univ Hosp, Dept Expt Therapeut, Translat Res Ctr, Sakyo Ku, Kyoto 6068507, Japan.
   Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
C3 Kyoto University; Kyoto University
RP Takahashi, M (通讯作者)，Kyoto Univ Hosp, Dept Expt Therapeut, Translat Res Ctr, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.
EM masataka@kuhp.kyoto-u.ac.jp
RI Mandai, Michiko/E-7986-2011
CR BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Mervin K, 1999, AM J OPHTHALMOL, V128, P155, DOI 10.1016/S0002-9394(99)00104-X
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 5
TC 31
Z9 35
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2004
VL 137
IS 4
BP 770
EP 773
DI 10.1016/j.ajo.2003.09.059
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 811HK
UT WOS:000220762800033
PM 15059729
DA 2022-11-30
ER

PT J
AU Kim, HM
   Murakami, Y
   Woo, SJ
AF Kim, Hyeong Min
   Murakami, Yusuke
   Woo, Se Joon
TI Clinical features of red blood cell-coated intraocular lens after
   breakthrough vitreous hemorrhage secondary to neovascular age-related
   macular degeneration
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
ID COMBINED CATARACT-SURGERY; SUBMACULAR HEMORRHAGE; OPTIC OPACIFICATION;
   VITRECTOMY; CALCIFICATION
AB Purpose: To investigate the incidence and clinical features of red blood cell (RBC)-coated intraocular lens (IOL) in breakthrough vitreous hemorrhage (VH) with subretinal hemorrhage (SRH) sec-ondary to neovascular age-related macular degeneration (nAMD). Setting: Seoul National University Bundang Hospital, Seongnam, Korea. Design: Retrospective cohort analysis.
   Methods: A total of 30 patients diagnosed as breakthrough VH with SRH in nAMD who underwent pars plana vitrectomy were included in this study. Demographics and clinical characteristics of the subjects, visual acuities, and SRH sizes measured as disc diameters were analyzed. The correlation analysis between SRH size and absorption duration of RBC-coated IOL were performed.
   Results: Out of 30 eyes in 30 patients, RBC-coated IOLs were observed in 11 patients (37%). Appearance of RBC-coated IOLs was noted 1 month postoperatively, and the mean duration of SRH ab-sorption was 8.6 +/- 2.6 months. SRH sizes were significantly different between eyes with RBC-coated IOL and clear IOL (62.8 +/- 20.7 vs 27.4 +/- 14.2, P < .001). There was definite correlation between SRH size and absorption duration of RBC-coated IOL (correlation coefficient 0.899, P < .001, R-2 = 0.831). There were no statistically significant differences according to age, sex, laterality, underlying medical conditions, pre-operative lens status, history of antivascular endothelial growth factor treatment, and visual acuities. The degenerated RBC on the surface of IOL was confirmed by electron and light microscopy.
   Conclusions: RBC-coated IOL could develop after vitrectomy surgery for breakthrough VH with massive SRH secondary to nAMD, and it can be confused with IOL opacification. Because it spontaneously disappears gradually, observation without IOL re-moval is warranted. Copyright (C) 2021 Published by Wolters Kluwer on behalf of ASCRS and ESCRS
C1 [Kim, Hyeong Min; Woo, Se Joon] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Bundang Hosp, Seongnam, South Korea.
   [Murakami, Yusuke] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka, Japan.
C3 Seoul National University (SNU); Kyushu University
RP Woo, SJ (通讯作者)，Seoul Natl Univ, Dept Ophthalmol, Bundang Hosp, 173-82 Gumi Ro, Seongnam Si 13620, Gyeonggi Do, South Korea.
EM sejoon1@snu.ac.kr
FU National Research Foundation of Korea (NRF) - Korea government (MSIT)
   [2020R1F1A1072795]; Seoul National University Bundang Hospital
   [13-2019-003]
FX Supported by the National Research Foundation of Korea (NRF) grant
   funded by the Korea government (MSIT) (No. 2020R1F1A1072795) and by a
   research grant from Seoul National University Bundang Hospital
   (13-2019-003). The funding organization had no role in the design or
   conduct of this study.
CR Ahad MA, 2014, CORNEA, V33, P1307, DOI 10.1097/ICO.0000000000000279
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Chaudhry NA, 2002, OPHTHALMIC SURG LAS, V33, P16
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P524, DOI 10.1016/j.ajo.2013.04.029
   Cho JH, 2020, RETINA-J RET VIT DIS, V40, P468, DOI 10.1097/IAE.0000000000002384
   Cho JH, 2016, AM J OPHTHALMOL, V169, P79, DOI 10.1016/j.ajo.2016.06.014
   Dhital A, 2012, AM J OPHTHALMOL, V153, P1154, DOI 10.1016/j.ajo.2011.11.017
   Fellman MA, 2013, J CATARACT REFR SURG, V39, P799, DOI 10.1016/j.jcrs.2013.01.028
   Fernandez J, 2020, CLIN EXP OPHTHALMOL, V48, P89, DOI 10.1111/ceo.13650
   GILLIES A, 1983, ANN OPHTHALMOL, V15, P1068
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Groh MJM, 2001, KLIN MONATSBL AUGENH, V218, P645, DOI 10.1055/s-2001-18385
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   Johnson M W, 2000, Curr Opin Ophthalmol, V11, P201, DOI 10.1097/00055735-200006000-00009
   Jung JH, 2010, RETINA-J RET VIT DIS, V30, P865, DOI 10.1097/IAE.0b013e3181c969e9
   Kim JH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57297-8
   Kim Kun Hae, 2015, Korean J Ophthalmol, V29, P315, DOI 10.3341/kjo.2015.29.5.315
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0
   Lee SJ, 2010, J CATARACT REFR SURG, V36, P676, DOI 10.1016/j.jcrs.2009.08.045
   Lim AKE, 2011, J CATARACT REFR SURG, V37, P655, DOI 10.1016/j.jcrs.2010.10.050
   Pandey SK, 2002, OPHTHALMOLOGY, V109, P2042, DOI 10.1016/S0161-6420(02)01265-4
   Park CY, 2012, J CATARACT REFR SURG, V38, P166, DOI 10.1016/j.jcrs.2011.08.027
   Park DI, 2011, JPN J OPHTHALMOL, V55, P595, DOI 10.1007/s10384-011-0074-7
   Park DH, 2010, BRIT J OPHTHALMOL, V94, P1688, DOI 10.1136/bjo.2010.181743
   Patryn E, 2012, CORNEA, V31, P1189, DOI 10.1097/ICO.0b013e31823d1e12
   Roufail E, 2008, CLIN EXP OPHTHALMOL, V36, P36, DOI 10.1111/j.1442-9071.2007.01651.x
   SANDERS D, 1975, A GRAEF ARCH KLIN EX, V197, P255, DOI 10.1007/BF00410870
   Shin YI, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28938-1
   Wu TT, 2011, RETINA-J RET VIT DIS, V31, P2071, DOI 10.1097/IAE.0b013e31822528c8
   Yildirim TM, 2018, AM J OPHTHALMOL, V193, P10, DOI 10.1016/j.ajo.2018.06.002
NR 30
TC 0
Z9 0
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0886-3350
EI 1873-4502
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD JUL
PY 2021
VL 47
IS 7
BP 892
EP 897
DI 10.1097/j.jcrs.0000000000000549
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA TL1FH
UT WOS:000674599400011
PM 33315740
DA 2022-11-30
ER

PT J
AU Seddon, JM
   Reynolds, R
   Rosner, B
AF Seddon, Johanna M.
   Reynolds, Robyn
   Rosner, Bernard
TI Associations of smoking, body mass index, dietary lutein, and the LIPC
   genetic variant rs10468017 with advanced age-related macular
   degeneration
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; VITAMIN-C; ENVIRONMENTAL ASSOCIATIONS; FAMILIAL
   AGGREGATION; RISK-FACTORS; MACULOPATHY; SUSCEPTIBILITY; POLYMORPHISM;
   LIPOPROTEINS; CAROTENOIDS
AB Objective: A novel locus in the hepatic lipase (LIPC) gene was found to be significantly related to advanced age-related macular degeneration (AMD) in our genome-wide association study. We evaluated its association and interaction with previously identified genetic variants and modifiable factors.
   Methods: Participants in the Age-Related Eye Disease Study with advanced AMD (n=545 cases) or no AMD (n=275 controls) were evaluated. AMD status was determined using fundus photography. Covariates included cigarette smoking, body mass index (BMI), and dietary lutein. Individuals were genotyped for the rs10468017 polymorphism in LIPC as well as seven previously identified AMD genetic loci. Unconditional logistic regression analyses were then performed.
   Results: The TT genotype of the LIPC variant was associated with a reduced risk of AMD, with odds ratios (OR) of 0.50 (95% confidence interval (CI) 0.20-0.90) and p=0.014 for the TT genotype versus the CC genotype, controlling for age, gender, smoking, body mass index (BMI), and nutritional factors. Controlling for seven other AMD genetic variants, the OR was 0.50, 95% (CI 0.20-1.1, p=0.077). The magnitude of the effect was similar for both atrophic and neovascular forms of AMD. Cigarette smoking and higher BMI increased the risk, while higher dietary lutein reduced the risk of advanced AMD, adjusting for genetic variants. There were no significant interactions between LIPC and smoking, BMI, or lutein. There was a possible association between LIPC and complement factor H (CFH) rs1410996, and a possible interaction effect between LIPC and both CFH rs10033900 and the complement factor I (CFI) variants in terms of risk of AMD.
   Conclusions: LIPC is associated with reduced risk of advanced AMD, independent of demographic and environmental variables. Both genetic susceptibility and behavioral and lifestyle factors modify the risk of developing AMD.
C1 [Seddon, Johanna M.; Reynolds, Robyn] Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, Dept Ophthalmol, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [Rosner, Bernard] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA.
C3 Tufts Medical Center; Tufts University; Harvard University; Brigham &
   Women's Hospital
RP Seddon, JM (通讯作者)，Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, Dept Ophthalmol, 800 Washington St 450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
FU National Eye Institute, National Institutes of Health, Bethesda, MD
   [R01-EY11309]; Massachusetts Lions Eye Research Fund, Inc., New Bedford,
   MA; Research to Prevent Blindness, Inc., New York, NY; The American
   Macular Degeneration Foundation, Northampton, MA; S. Elizabeth O'Brien
   Trust, Boston, MA; Ophthalmic Epidemiology and Genetics Service, Tufts
   Medical Center, Tufts University School of Medicine, Boston, MA;
   NATIONAL EYE INSTITUTE [R01EY011309] Funding Source: NIH RePORTER
FX We thank the AREDS Research Group; and Marion McPhee, B.Ed., for her
   programming assistance. Tufts Medical Center has filed a patent
   application related to some of this work (J.M.S.). Robyn Reynolds and
   Dr. Rosner declare no conflict of interest. This study was funded by an
   anonymous donor (to the research of J.M.S.); the National Eye Institute,
   National Institutes of Health, Bethesda, MD (R01-EY11309); Massachusetts
   Lions Eye Research Fund, Inc., New Bedford, MA; Research to Prevent
   Blindness, Inc., New York, NY; The American Macular Degeneration
   Foundation, Northampton, MA; S. Elizabeth O'Brien Trust, Boston, MA; and
   the Macular Degeneration Research Fund-Ophthalmic Epidemiology and
   Genetics Service, Tufts Medical Center, Tufts University School of
   Medicine, Boston, MA.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   FREEMAN DJ, 1993, EUR J CLIN INVEST, V23, P630, DOI 10.1111/j.1365-2362.1993.tb00724.x
   Gabriel S., 2004, CURR PROTOC HUM GENE, DOI 10.1002/0471142905.hg0212s42
   HAARBO J, 1990, ATHEROSCLEROSIS, V84, P239, DOI 10.1016/0021-9150(90)90096-2
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosner B., 2000, FUNDAMENTALS BIOSTAT
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Seddon J. M., 1997, Investigative Ophthalmology and Visual Science, V38, pS676
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Souied EH, 2005, MOL VIS, V11, P1135
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 44
TC 54
Z9 56
U1 0
U2 9
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD NOV 17
PY 2010
VL 16
IS 259
BP 2412
EP 2424
PG 13
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 698KF
UT WOS:000285592000001
PM 21139980
DA 2022-11-30
ER

PT J
AU Tounakaki, O
   Tsakou, A
   Malamas, A
   Chrisoula, D
   Ioannis, S
   Elias, Z
AF Tounakaki, Ourania
   Tsakou, Angeliki
   Malamas, Angelakis
   Chrisoula, Doxani
   Ioannis, Stefanidis
   Elias, Zintzaras
TI Assessment of reporting quality of meta-analyses of randomized
   controlled trials in neovascular age-related macular degeneration
   published from April 2014 to May 2018 using prisma statement
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE PRISMA; AMD; Anti-VEGF; Reporting quality; Meta-analysis; Systematic
   reviews
ID SYSTEMATIC REVIEWS; RANIBIZUMAB; PUBLICATION; PREVALENCE; EFFICACY;
   IMPACT
AB Purpose To evaluate the reporting quality of meta-analysis on neovascular age-related macular degeneration treatment and safety profile based on PRISMA statement. Methods Electronic search performed in August 2018 to retrieve meta-analyses published from April 2014 to May 2018. PRISMA evaluation was determined by total scores of individual meta-analyses and items scores. Statistical analysis of parameters affecting the reporting evaluation included subgroup multivariate analysis and regression analysis. Results Twelve meta-analyses were finally included, three being Cochrane systematic reviews. Mean PRISMA score is 23.2/27 (86.1%). Eleven PRISMA ITEMS had significantly higher %score in 12 meta-analyses than in nine non-Cochrane meta-analyses measurements. Positive strong correlation identified between PRISMA %score and journal impact factor (JIF). Multivariate analysis between high-scored and low-scored meta-analyses established difference in means of several parameters (JIF, Publication Year). Conclusions The evaluation of overall reporting quality was favorable. As expected, the key role of several characteristics of meta-analysis affects this quality. Under-reporting of specific items (protocol, search strategy and assessment of risk of bias) indicates the urgency for PRISMA compliance.
C1 [Tounakaki, Ourania; Malamas, Angelakis] Achilopouleio Gen Hosp, Dept Ophthalmol, Polimeri 134, Volos 38222, Greece.
   [Tsakou, Angeliki] Achilopouleio Gen Hosp, Dept Internal Med 2, Polimeri 143, Volos, Greece.
   [Chrisoula, Doxani] Univ Thessaly, Dept Biomath, Sch Med, Mezourlo, Larissa, Greece.
   [Ioannis, Stefanidis] Univ Thessaly, Dept Nephrol, Sch Med, Mezourlo, Larissa, Greece.
   [Elias, Zintzaras] Univ Thessaly, Fac Med, Dept Biostat & Clin Bioinformat, Mezourlo, Larissa, Greece.
C3 University of Thessaly; University of Thessaly; University of Thessaly
RP Malamas, A (通讯作者)，Achilopouleio Gen Hosp, Dept Ophthalmol, Polimeri 134, Volos 38222, Greece.
EM malamasaggelos@gmail.com
OI Tsakou, Angeliki/0000-0002-7915-1500
CR Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Campbell RJ, 2013, CURR OPIN OPHTHALMOL, V24, P197, DOI 10.1097/ICU.0b013e32835f8bbe
   Dwan K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003081
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   Eun Lee Si, 2016, [Journal of Korean Gerontological Nursing, 노인간호학회지], V18, P1, DOI 10.17079/jkgn.2016.18.1.1
   Fleming PS, 2013, ANGLE ORTHOD, V83, P158, DOI 10.2319/032612-251.1
   Frampton JE, 2013, DRUG AGING, V30, P331, DOI 10.1007/s40266-013-0077-9
   Gagnier Joel J, 2013, J Bone Joint Surg Am, V95, pe771, DOI 10.2106/JBJS.L.00597
   Glass G.V., 1976, ED RES, V5, P3, DOI [DOI 10.3102/0013189X005010003, 10.2307/1174772ISSN0536-1036]
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Ioannidis JPA, 1998, JAMA-J AM MED ASSOC, V279, P281, DOI 10.1001/jama.279.4.281
   Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821
   Juni P, 2002, INT J EPIDEMIOL, V31, P115, DOI 10.1093/ije/31.1.115
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kodjikian L, 2014, GRAEF ARCH CLIN EXP, V252, P1529, DOI 10.1007/s00417-014-2764-6
   Lee SY, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0450-1
   Li SS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184998
   Liberati A, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2700, 10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3
   Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Nguyen CL, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0785-3
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Panic N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083138
   Patsopoulos NA, 2005, JAMA-J AM MED ASSOC, V293, P2362, DOI 10.1001/jama.293.19.2362
   Peters JPM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136540
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schmier JK, 2006, PHARMACOECONOMICS, V24, P319, DOI 10.2165/00019053-200624040-00003
   Si JK, 2014, INT J OPHTHALMOL-CHI, V7, P541, DOI 10.3980/j.issn.2222-3959.2014.03.28
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Su YX, 2018, PHOTODIAGN PHOTODYN, V22, P263, DOI 10.1016/j.pdpdt.2018.05.002
   Tong Y, 2016, INT J OPHTHALMOL-CHI, V9, P1028, DOI 10.18240/ijo.2016.07.16
   Tunis AS, 2013, RADIOLOGY, V269, P413, DOI 10.1148/radiol.13130273
   Ueta T, 2014, OPHTHALMOLOGY, V121, P2193, DOI 10.1016/j.ophtha.2014.05.022
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109744
NR 39
TC 3
Z9 3
U1 2
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD MAY
PY 2020
VL 40
IS 5
BP 1163
EP 1180
DI 10.1007/s10792-019-01282-7
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LI7VT
UT WOS:000529689200014
PM 31912405
DA 2022-11-30
ER

PT J
AU Guymer, R
   Wu, ZC
AF Guymer, Robyn
   Wu, Zhichao
TI Age-related macular degeneration (AMD): More than meets the eye. The
   role of multimodal imaging in today's management ofAMD-A review
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration (AMD); clinical tests; multi-modal
   imaging
ID OPTICAL COHERENCE TOMOGRAPHY; RETICULAR PSEUDODRUSEN; FUNDUS
   AUTOFLUORESCENCE; HYPERREFLECTIVE FOCI; GEOGRAPHIC-ATROPHY;
   SWEPT-SOURCE; RISK-FACTOR; FEATURES; DRUSEN; PROGRESSION
AB Multimodal imaging (MMI) allows a more granular grading of age-related macular degeneration (AMD) disease severity, with many novel risk factors having been recently identified. With this imaging information, we are better able to counsel our patients with more accurate and individualized progression scenarios. MMI also allows identification of anatomical features that increase our understanding of disease processes involved in progression to late AMD. Treatment protocols for neovascular AMD (nAMD) depend largely on the optical coherence tomography (OCT) appearance to determine disease activity, which allows us to individualize treatment. In geographic atrophy (GA), new intervention trials require the ability to define the extent of GA, so that GA growth rate can be determined. This is achieved through fundus autofluorescence (FAF) imaging, which allows greater accuracy of border identification, as well as revealing FAF patterns predictive of growth rates. As we strive to bring interventions earlier in the disease course, OCT imaging provides an ability to identify the first signs of atrophy, which may serve as novel surrogate biomarkers for GA, thereby facilitating trials. In the future, the use of artificial intelligence (AI) to automatically identify relevant features on MMI could further enhance our ability to determine disease severity, predict progression and assist in identifying disease activity parameters to support clinical decision making when treating nAMD. Newer developments may allow frequent, remote capturing of images, reducing clinic visits, detecting progression and monitoring neovascular activity in-between clinic visits. Being aware of these new imaging insights in AMD, greatly enhance our clinical management of AMD.
C1 [Guymer, Robyn; Wu, Zhichao] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Guymer, Robyn] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Guymer, R (通讯作者)，Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
EM rhg@unimelb.edu.au
OI Guymer, Robyn/0000-0002-9441-4356
FU National Health and Medical Research Council [GNT1103013]
FX National Health and Medical Research Council, Grant/Award Number:
   GNT1103013
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Bearelly S, 2010, ADV EXP MED BIOL, V664, P395, DOI 10.1007/978-1-4419-1399-9_45
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3456, DOI 10.1167/iovs.17-22339
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   FERCHER AF, 1993, AM J OPHTHALMOL, V116, P113, DOI 10.1016/S0002-9394(14)71762-3
   Ferrara D, 2017, INVEST OPHTH VIS SCI, V58, P3519, DOI 10.1167/iovs.17-21696
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Fragiotta S, 2019, INVEST OPHTH VIS SCI, V60, P3100, DOI 10.1167/iovs.19-26589
   Gil JQ, 2017, EYE, V31, P364, DOI 10.1038/eye.2016.207
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Guymer RH, 2020, OPHTHALMOL RETINA, V4, P249, DOI 10.1016/j.oret.2019.11.016
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Lek JJ, 2018, OPHTHALMOL RETINA, V2, P792, DOI 10.1016/j.oret.2018.01.005
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Maloca P, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.4.8
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Narita C, 2020, OPHTHALMOLOGY, V127, P637, DOI 10.1016/j.ophtha.2019.11.007
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Oishi A, 2017, INVEST OPHTH VIS SCI, V58, P2198, DOI 10.1167/iovs.16-20781
   Pfau M, 2020, OPHTHALMOL RETINA, V4, P238, DOI 10.1016/j.oret.2019.09.016
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Shi YY, 2019, OPHTHALMOL RETINA, V3, P211, DOI 10.1016/j.oret.2018.10.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Wightman AJ, 2019, CLIN EXP OPTOM, V102, P455, DOI 10.1111/cxo.12842
   Wu ZC, 2020, OPHTHALMOL RETINA, V4, P568, DOI 10.1016/j.oret.2019.12.011
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   ZARBIN MA, 2020, INVEST OPHTH VIS SCI, V61
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 57
TC 15
Z9 16
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD SEP
PY 2020
VL 48
IS 7
BP 983
EP 995
DI 10.1111/ceo.13837
EA SEP 2020
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NY9LU
UT WOS:000566390600001
PM 32741052
OA Green Published
DA 2022-11-30
ER

PT J
AU Ramsey, DJ
   McCullum, JC
   Steinberger, EE
   Zhang, YB
   Alwreikat, AM
   Cooper, ML
   Roh, S
   Cotran, PR
AF Ramsey, David J.
   McCullum, James C.
   Steinberger, Elise E.
   Zhang, Yubo
   Alwreikat, Amer Mosa
   Cooper, Michael L.
   Roh, Shiyoung
   Cotran, Paul R.
TI Intraocular pressure decreases in eyes with glaucoma-related diagnoses
   after conversion to aflibercept for treatment-resistant age-related
   macular degeneration
SO EYE
LA English
DT Article
ID INTRAVITREAL AFLIBERCEPT; OCULAR HYPERTENSION; RANIBIZUMAB; BEVACIZUMAB;
   INJECTIONS; COMPLICATIONS; ASSOCIATION; ELEVATION; BLINDNESS; OUTCOMES
AB Objective To understand intraocular pressure (IOP) response after switching from intravitreal bevacizumab (IVB) and/or ranibizumab (IVR) to intravitreal aflibercept (IVA) for treatment-resistant neovascular age-related macular degeneration (nAMD) in patients with and without coexisting glaucoma-related diagnoses. Methods Retrospective, cross-sectional comparative case series of 62 eyes of 58 patients treated with intravitreal injection for nAMD from March 2010 to April 2018. Patients with glaucoma-related diagnoses, defined here as open-angle glaucoma or suspicion of open-angle glaucoma, ocular hypertension, and/or narrow-angle glaucoma, were compared to those without glaucoma. IOP data were collected at baseline, at the three visits where patients received loading doses of IVB/IVR, and at all of the visits following the switch to IVA through the end of follow-up. Results 19 eyes with pre-existing glaucoma-related diagnoses were compared to 43 eyes without such diagnoses. Baseline IOP was similar for glaucoma and non-glaucoma patients. The loading doses of IVB/IVR did not impact IOP; however, a small, sustained rise in IOP was noted among patients with glaucoma-related diagnoses by the final IVB/IVR injections before the switch to IVA ( increment IOP 1.61 +/- 0.52 mmHg, P < 0.002). After conversion to IVA, pre-injection IOP declined in eyes both with (-1.59 +/- 0.54 mmHg, P < 0.001) and without (-0.99 +/- 0.28 mmHg, P < 0.001) glaucoma-related diagnoses. Conclusions IOP in patients with glaucoma-related diagnoses appears to be more sensitive to intravitreal injections than it is in patients without glaucoma-related diagnoses. It rises with IVB/IVR and declines after the switch to IVA. Switching patients with nAMD to IVA may present an opportunity to lower IOP in patients with glaucoma.
C1 [Ramsey, David J.; McCullum, James C.; Alwreikat, Amer Mosa; Roh, Shiyoung; Cotran, Paul R.] Lahey Hosp & Med Ctr, Dept Ophthalmol, Peabody, MA 01960 USA.
   [Ramsey, David J.; McCullum, James C.; Steinberger, Elise E.; Alwreikat, Amer Mosa; Cooper, Michael L.; Roh, Shiyoung; Cotran, Paul R.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Zhang, Yubo] Brandeis Univ, Waltham, MA USA.
C3 Lahey Hospital & Medical Center; Tufts University; Brandeis University
RP Ramsey, DJ (通讯作者)，Lahey Hosp & Med Ctr, Dept Ophthalmol, Peabody, MA 01960 USA.; Ramsey, DJ (通讯作者)，Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
EM David.J.Ramsey@lahey.org
OI McCullum, James/0000-0002-2814-1927; Ramsey, David/0000-0002-5504-812X
FU Harry N. Lee Family Chair in Innovation at the Lahey Hospital & Medical
   Center, Beth Israel Lahey Health; Office of Medical Education, Lahey
   Hospital & Medical Center, Beth Israel Lahey Health
FX DJR: Supported by the Harry N. Lee Family Chair in Innovation at the
   Lahey Hospital & Medical Center, Beth Israel Lahey Health. JCM:
   Supported by a grant from Office of Medical Education, Lahey Hospital &
   Medical Center, Beth Israel Lahey Health.
CR Atchison EA, 2018, OPHTHALMOLOGY, V125, P676, DOI 10.1016/j.ophtha.2017.11.027
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Bakri SJ, 2014, OPHTHALMOLOGY, V121, P1102, DOI 10.1016/j.ophtha.2013.11.029
   Bilgic A, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/7462098
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cui QN, 2019, GRAEF ARCH CLIN EXP, V257, P1931, DOI 10.1007/s00417-019-04362-7
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Eadie BD, 2017, JAMA OPHTHALMOL, V135, P363, DOI 10.1001/jamaophthalmol.2017.0059
   Foss AJE, 2016, BRIT J OPHTHALMOL, V100, P1662, DOI 10.1136/bjophthalmol-2015-307595
   Freund KB, 2015, OPHTHALMOLOGY, V122, P1802, DOI 10.1016/j.ophtha.2015.04.018
   Gabrielle PH, 2020, OPHTHALMOL RETINA, V4, P861, DOI 10.1016/j.oret.2020.06.020
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Haddock LJ, 2014, SEMIN OPHTHALMOL, V29, P257, DOI 10.3109/08820538.2014.959616
   Hahn P, 2013, OPHTHALMOLOGY, V120, P1100, DOI 10.1016/j.ophtha.2012.11.018
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hoang QV, 2013, RETINA-J RET VIT DIS, V33, P179, DOI 10.1097/IAE.0b013e318261a6f7
   Hoang QV, 2012, OPHTHALMOLOGY, V119, P321, DOI 10.1016/j.ophtha.2011.08.011
   Hu CC, 2017, EYE, V31, P872, DOI 10.1038/eye.2016.325
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Leske MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P48
   Mansberger SL, 2012, OPHTHALMOLOGY, V119, P1826, DOI 10.1016/j.ophtha.2012.02.050
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mergen B, 2021, EYE, V35, P3350, DOI 10.1038/s41433-021-01417-0
   Mojica G, 2008, BRIT J OPHTHALMOL, V92, P584, DOI 10.1136/bjo.2007.126193
   Pershing S, 2013, OPHTHAL SURG LAS IM, V44, P460, DOI 10.3928/23258160-20130909-07
   Ramsey DJ, 2014, SEMIN OPHTHALMOL, V29, P263, DOI 10.3109/08820538.2014.959195
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rusu IM, 2014, RETINA-J RET VIT DIS, V34, P2161, DOI 10.1097/IAE.0000000000000264
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shaikh Y, 2014, AM J OPHTHALMOL, V158, P1121, DOI 10.1016/j.ajo.2014.08.023
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Tham Yih-Chung, 2014, Ophthalmology, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
   Unsal E, 2018, J CURR OPHTHALMOL, V30, P337, DOI 10.1016/j.joco.2018.07.002
   Zhou YD, 2016, SCI REP-UK, V6, DOI 10.1038/srep39301
   Zlateva GP, 2007, RETINA-J RET VIT DIS, V27, P1292, DOI 10.1097/01.iae.0000300915.81866.b8
NR 38
TC 1
Z9 1
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2022
VL 36
IS 9
BP 1813
EP 1819
DI 10.1038/s41433-021-01729-1
EA AUG 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3W0KK
UT WOS:000684480200003
PM 34385697
DA 2022-11-30
ER

PT J
AU McKibbin, M
   Ali, M
   Bansal, S
   Baxter, PD
   West, K
   Williams, G
   Cassidy, F
   Inglehearn, CF
AF McKibbin, Martin
   Ali, Manir
   Bansal, Shveta
   Baxter, Paul D.
   West, Kumi
   Williams, Grange
   Cassidy, Frances
   Inglehearn, Chris F.
TI CFH, VEGF and HTRA1 promoter genotype may influence the response to
   intravitreal ranibizumab therapy for neovascular age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; PHOTODYNAMIC THERAPY; LOC387715 GENOTYPES;
   ASSOCIATION; POLYMORPHISM; SUSCEPTIBILITY; VERTEPORFIN; BEVACIZUMAB;
   Y402H
AB Aims To investigate an association between genotype for three single nucleotide polymorphisms strongly associated with the development of age-related macular degeneration (AMD) and the early response to treatment with intravitreal ranibizumab for neovascular AMD.
   Methods Best corrected visual acuity letter score was recorded at baseline and each subsequent visit. Age, sex, smoking history, lesion type and the number of injections were also recorded. Genotypes were obtained for rs11200638 in HTRA1, rs1061170 in CFH and rs1413711 in VEGF. Data were analysed with treatment response at month 6 as both a binary (>5 letter improvement vs <= 5 letter gain) and a linear trait.
   Results This initial study cohort consisted of 104 Caucasian neovascular AMD patients treated with intravitreal ranibizumab. Trends towards a more favourable outcome were seen with the higher AMD risk genotypes in CFH and VEGF in both the linear and binary models and in HTRA1 in the linear model alone. For CFH, mean letter score change after 6 months was +1.6, +5.9 and +7.2 letters for the TT, TC and CC genotypes and a >5 letter gain was seen in 34.6%, 56.6% and 56%, respectively. For VEGF, mean letter score change after 6 months was +1.3, +5.8 and +7.4 letters for the TT, TC and CC genotypes and a > 5 letter gain was seen in 40%, 55.8% and 51.9%, respectively. For HTRA1, mean letter score change was +2.2, +7.5 and +2.9 letters for the GG, GA and AA genotypes.
   Conclusions This study reports preliminary evidence suggesting that the higher AMD risk genotypes in CFH, VEGF and HTRA1 may influence the short-term response to treatment with ranibizumab for neovascular AMD.
C1 [McKibbin, Martin; Bansal, Shveta; West, Kumi; Cassidy, Frances] St James Univ Hosp, Eye Clin, Leeds LS9 7TF, W Yorkshire, England.
   [McKibbin, Martin; Ali, Manir; Bansal, Shveta; Williams, Grange; Inglehearn, Chris F.] Univ Leeds, Sect Ophthalmol & Neurosci, Leeds Inst Mol Med, Leeds, W Yorkshire, England.
   [Baxter, Paul D.] Univ Leeds, Div Biostat, Leeds Inst Genet Hlth & Therapeut, Leeds, W Yorkshire, England.
C3 Saint James's University Hospital; University of Leeds; University of
   Leeds
RP McKibbin, M (通讯作者)，St James Univ Hosp, Eye Clin, Leeds LS9 7TF, W Yorkshire, England.
EM mckibbin@leedsth.nhs.uk
RI Inglehearn, Chris/GYD-9783-2022; Ali, Manir/ABE-5251-2020
OI Ali, Manir/0000-0003-3204-3788; Baxter, Paul/0000-0003-2699-3103
FU Yorkshire Eye Research; Novartis Pharmaceuticals UK
FX This project was supported by a grant from Yorkshire Eye Research and by
   an investigator-initiated research grant from Novartis Pharmaceuticals
   UK. The funding organisations had no role in either the design or the
   conduct of the research.
CR [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Chen W, 2009, EXP EYE RES, V89, P292, DOI 10.1016/j.exer.2008.10.017
   Chowers I, 2008, MOL VIS, V14, P2263
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Mckay GJ, 2009, OPHTHALMOLOGY, V116, P1227, DOI 10.1016/j.ophtha.2009.01.008
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Nelson GW, 2004, J IMMUNOL, V173, P4273, DOI 10.4049/jimmunol.173.7.4273
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
NR 28
TC 85
Z9 92
U1 0
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2012
VL 96
IS 2
BP 208
EP 212
DI 10.1136/bjo.2010.193680
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 879GW
UT WOS:000299318700011
PM 21558292
DA 2022-11-30
ER

PT J
AU Nishimura, T
   Machida, S
AF Nishimura, Tomoharu
   Machida, Shigeki
TI Correlation between macular structure and function in patients with
   age-related macular degeneration treated with intravitreal ranibizumab:
   12-month-results
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Intravitreal ranibizumab; Focal
   macular electroretinogram; Serous retinal detachment; Pigment epithelial
   detachment
ID PIGMENT EPITHELIAL DETACHMENT; PHOTOPIC NEGATIVE RESPONSE; AFLIBERCEPT;
   INJECTIONS; THERAPY; ELECTRORETINOGRAMS; OUTCOMES; EYES; VERTEPORFIN;
   SUBFOVEAL
AB PurposeTo determine the significance of the correlation between optical coherence tomographic (OCT) findings and focal macular electroretinograms (fmERG) at 12 months after beginning intravitreal injections of ranibizumab (IVR) in eyes with age-related macular degeneration (AMD).Study designProspective, clinical study.MethodWe studied 28 eyes of 28 patients with AMD treated with IVR at monthly intervals for the initial three months. Additional IVR was given according to a pro re nata (PRN) regimen. OCT and fmERGs were performed preoperatively and at 3 and 12 months postoperatively. The fmERGs were elicited by a 15 degrees white stimulus spot centered on the fovea. The thickness of the inner, middle, and outer layers of the retina and also of the serous retinal detachment (SRD) and pigment epithelial detachment (PED) in the horizontal and vertical meridians at 1.2 mm from the fovea (parafoveal) were measured in the OCT images.ResultsThe b-wave amplitude at 12 months was significantly correlated with the thicknesses of the outer retinal layer, SRD, and PED (P=0.001-0.02). Multiple regression analyses showed that the outer retinal layer thickness was an independent determinant (P= 0.0001). The changes in the b-wave amplitude between the baseline and 12 months were significantly correlated with the changes in the SRD thickness (P=0.006). The changes in the b-wave amplitude during the PRN period were significantly correlated with the changes in the PED thickness (P=0.02).ConclusionsAt 12 months after beginning treatment, the reduction in the SRD thickness affects macular function recovery. As recurrences of the PED can occur during the PRN period, control of the PED is necessary to obtain good macular function for the long term.
C1 [Nishimura, Tomoharu; Machida, Shigeki] Dokkyo Med Univ, Saitama Med Ctr, Dept Ophthalmol, 2-1-50 Minami Koshigaya, Koshigaya, Saitama 3438555, Japan.
   [Machida, Shigeki] Iwate Med Univ, Sch Med, Dept Ophthalmol, 19-1 Uchimaru, Morioka, Iwate 0208505, Japan.
C3 Dokkyo Medical University; Iwate Medical University
RP Machida, S (通讯作者)，Dokkyo Med Univ, Saitama Med Ctr, Dept Ophthalmol, 2-1-50 Minami Koshigaya, Koshigaya, Saitama 3438555, Japan.; Machida, S (通讯作者)，Iwate Med Univ, Sch Med, Dept Ophthalmol, 19-1 Uchimaru, Morioka, Iwate 0208505, Japan.
EM machidas@dokkyomed.ac.jp
CR Balaskas K, 2017, RETINA-J RET VIT DIS, V37, P1297, DOI 10.1097/IAE.0000000000001342
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   Giansanti F, 2014, EUR J OPHTHALMOL, V24, P402, DOI 10.5301/ejo.5000388
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hibi N, 2013, INVEST OPHTH VIS SCI, V54, P7207, DOI 10.1167/iovs.13-12884
   Iwata E, 2012, INVEST OPHTH VIS SCI, V53, P4185, DOI 10.1167/iovs.11-9335
   Johnston RL, 2016, OPHTHALMOLOGY, V123, P2386, DOI 10.1016/j.ophtha.2016.07.037
   Kizawa J, 2006, JPN J OPHTHALMOL, V50, P367, DOI 10.1007/s10384-006-0326-0
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Machida S, 2008, INVEST OPHTH VIS SCI, V49, P5636, DOI 10.1167/iovs.08-1946
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Miyake Y, 1988, Nippon Ganka Gakkai Zasshi, V92, P1419
   MIYAKE Y, 1981, JPN J OPHTHALMOL, V25, P438
   Nishihara H, 2008, INVEST OPHTH VIS SCI, V49, P3121, DOI 10.1167/iovs.08-1835
   Nishimura T, 2015, GRAEF ARCH CLIN EXP, V253, P1201, DOI 10.1007/s00417-014-2779-z
   Nishimura T, 2012, CLIN OPHTHALMOL, V6, P1073, DOI 10.2147/OPTH.S31674
   Ogino K, 2013, INVEST OPHTH VIS SCI, V54, P3771, DOI 10.1167/iovs.12-11494
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Takayama K, 2017, RETINA-J RET VIT DIS, V37, P553, DOI 10.1097/IAE.0000000000001225
   Tamada K, 2010, CURR EYE RES, V35, P155, DOI 10.3109/02713680903447926
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P1693, DOI 10.1007/s00417-015-3260-3
   Yuzawa M, 2015, OPHTHALMOLOGY, V122, P571, DOI 10.1016/j.ophtha.2014.09.024
   Zinkernagel MS, 2016, OPHTHALMOLOGICA, V235, P42, DOI 10.1159/000441428
NR 36
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JAN
PY 2019
VL 63
IS 1
BP 90
EP 99
DI 10.1007/s10384-018-0642-1
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HH0KB
UT WOS:000455404400011
PM 30470956
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Tao, Y
   Neumaier, M
   Findeisen, P
AF Jonas, Jost B.
   Tao, Yong
   Neumaier, Michael
   Findeisen, Peter
TI Monocyte Chemoattractant Protein 1, Intercellular Adhesion Molecule 1,
   and Vascular Cell Adhesion Molecule 1 in Exudative Age-Related Macular
   Degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PROLIFERATIVE DIABETIC-RETINOPATHY; CHOROIDAL
   NEOVASCULARIZATION; INTRAVITREAL TRIAMCINOLONE; PIGMENT-EPITHELIUM;
   BRUCHS MEMBRANE; MACULOPATHY; PREVALENCE; EXPRESSION; EYE
AB Objective: To examine intraocular concentrations of monocyte chemoattractant protein 1 (MCP-1), soluble intercellular adhesion molecule 1 (sICAM-1), soluble vascular cell adhesion molecule 1 (sVCAM-1), and vascular endothelial growth factor (VEGF) in eyes with exudative age-related macular degeneration (AMD).
   Methods: The investigation included a study group of 28 patients (28 eyes) with exudative AMD and a control group of 25 patients (25 eyes) with cataract. The concentrations of MCP-1, sICAM-1, sVCAM-1, and VEGF in aqueous humor samples obtained during surgery were measured using a solid-phase chemiluminescence immunoassay.
   Results: The study group as compared with the control group had higher aqueous concentrations of sICAM-1 (mean [SD], 844 [2073] vs 246 [206] pg/mL, respectively; P <.001), sVCAM-1 (mean [SD], 7978 [7120] vs 2999 [1426] pg/mL, respectively; P<.001), and MCP-1 (mean [SD], 587 [338] vs 435 [221] pg/mL, respectively; P=.07). The concentration of VEGF did not vary significantly between the groups (P=.76). The MCP-1 concentration was significantly associated with macular thickness (r=0.40; P=.004). It decreased significantly with the type of subfoveal neovascular membrane (classic membrane type, occult membrane, retinal pigment epithelium detachment) (P=.009). The concentrations of sICAM-1, sVCAM-1, and VEGF were not significantly associated with membrane type and macular thickness (P >=.18).
   Conclusions: Concentrations of MCP-1, sICAM-1, and sVCAM-1 are significantly associated with exudative AMD, even in the presence of normal VEGF concentrations. Intraocular MCP-1 concentrations are correlated with the subfoveal neovascular membrane type and the amount of macular edema. One may infer that MCP-1, sICAM-1, and sVCAM-1 could potentially be additional target molecules in therapy for exudative AMD.
C1 [Jonas, Jost B.; Tao, Yong] Univ Heidelberg, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany.
   [Neumaier, Michael; Findeisen, Peter] Univ Heidelberg, Inst Clin Chem, Med Fac Mannheim, Heidelberg, Germany.
   [Tao, Yong] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg; Peking University
RP Jonas, JB (通讯作者)，Univ Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM jost.jonas@augen.ma.uni-heidelberg.de
FU German Academic Exchange Service
FX Dr Tao was supported by the K. C. Wong Fellowship from the German
   Academic Exchange Service.
CR AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Austin BA, 2009, INVEST OPHTH VIS SCI, V50, P2896, DOI 10.1167/iovs.08-2495
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P1308, DOI 10.1097/IAE.0b013e31818358b2
   Crane IJ, 2000, IMMUNOLOGY, V101, P426, DOI 10.1046/j.0019-2805.2000.01105.x
   CRONSTEIN BN, 1993, ARTHRITIS RHEUM-US, V36, P147, DOI 10.1002/art.1780360204
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heidenkummer H.-P., 1995, Ophthalmologe, V92, P631
   Hong KH, 2005, BLOOD, V105, P1405, DOI 10.1182/blood-2004-08-3178
   HUTCHINSON AK, 1993, ARCH OPHTHALMOL-CHIC, V111, P734, DOI 10.1001/archopht.1993.01090060020010
   Ishida S, 2003, NAT MED, V9, P781, DOI 10.1038/nm877
   Jonas JB, 2005, ACTA OPHTHALMOL SCAN, V83, P645, DOI 10.1111/j.1600-0420.2005.00592.x
   Jonas JB, 2007, OPHTHAL RES, V39, P139, DOI 10.1159/000102935
   Jonas JB, 2007, CLIN EXP OPHTHALMOL, V35, P186, DOI 10.1111/j.1442-9071.2006.01437.x
   Katsura Y, 2005, DIABETES CARE, V28, P2252, DOI 10.2337/diacare.28.9.2252
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   MACKAY CR, 1993, IMMUNOL TODAY, V14, P99, DOI 10.1016/0167-5699(93)90205-Y
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Morgan E, 2004, CLIN IMMUNOL, V110, P252, DOI 10.1016/j.clim.2003.11.017
   Mullins RF, 2006, MOL VIS, V12, P224
   Nakao S, 2005, J CLIN INVEST, V115, P2979, DOI 10.1172/JCI23298
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Voskuil M, 2003, AM J PHYSIOL-HEART C, V284, pH1422, DOI 10.1152/ajpheart.00506.2002
   Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Yamada M, 2003, ARTERIOSCL THROM VAS, V23, P1996, DOI 10.1161/01.ATV.0000096208.80992.63
NR 47
TC 113
Z9 119
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD OCT
PY 2010
VL 128
IS 10
BP 1281
EP 1286
DI 10.1001/archophthalmol.2010.227
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 662WC
UT WOS:000282844000006
PM 20937997
OA Bronze
DA 2022-11-30
ER

PT J
AU van Zeeburg, EJT
   Cereda, MG
   Amarakoon, S
   van Meurs, JC
AF van Zeeburg, Elsbeth J. T.
   Cereda, Matteo G.
   Amarakoon, Sankha
   van Meurs, Jan C.
TI Prospective, Randomized Intervention Study Comparing Retinal Pigment
   Epithelium-Choroid Graft Surgery and Anti-VEGF Therapy in Patients with
   Exudative Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Retinal pigment epithelium-choroid graft surgery; Anti-vascular
   endothelial growth factor; Age-related macular degeneration
ID NEOVASCULAR LESIONS; INTRAVITREAL RANIBIZUMAB; SUBRETINAL HEMORRHAGE;
   TRANSPLANTATION; TRANSLOCATION
AB Purpose: To investigate whether patients with exudative age-related macular degeneration and a submacular hemorrhage, retinal pigment epithelium (RPE) tear or nonresponders to anti-vascular endothelial growth factor (VEGF) benefit more from a free RPE-choroid graft transplantation surgery than from (continuation of) anti-VEGF treatment. Procedures: A total of 20 patients were included in this prospective, international, multicenter, randomized intervention study. Results: The change in the mean number of Early Treatment of Diabetic Retinopathy Study (ETDRS) letters in the graft group 1 year postoperatively was -15 (range -54 to +26), whilst 2 patients experienced a gain of >10 letters. The median preoperative visual acuity (VA) was 0.75 logMAR (range 0.46-2.8), and the mean postoperative VA was 1.48 logMAR (range 0.14-2.8). The change in the mean number of ETDRS letters in the anti-VEGF group was -8 (range -26 to +6); no patients experienced a >10 letter gain. The median preoperative VA was 1.36 logMAR (range 0.58-1.6), and the median postoperative VA was 1.42 logMAR (range 0.44-1.66). Conclusions: The included patient group is far too small to draw conclusions. However, both gain and loss of VA may be experienced by patients undergoing either treatment method; more gain might be possible for patients with a graft in the absence of complications. (C) 2015 S. Karger AG, Basel
C1 [van Zeeburg, Elsbeth J. T.; Cereda, Matteo G.; Amarakoon, Sankha; van Meurs, Jan C.] Rotterdam Eye Hosp, NL-3011 BH Rotterdam, Netherlands.
   [van Zeeburg, Elsbeth J. T.; Amarakoon, Sankha] Erasmus Univ, Rotterdam Ophthalm Inst, Rotterdam, Netherlands.
   [van Meurs, Jan C.] Erasmus Univ, Dept Ophthalmol, Rotterdam, Netherlands.
   [Cereda, Matteo G.] Univ Milan, Sacco Hosp, Dept Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
C3 Rotterdam Eye Hospital; Erasmus University Rotterdam; Erasmus University
   Rotterdam; University of Milan; Luigi Sacco Hospital
RP van Zeeburg, EJT (通讯作者)，Rotterdam Eye Hosp, Schiedamse Vest 180, NL-3011 BH Rotterdam, Netherlands.
EM e.vanzeeburg@oogziekenhuis.nl
FU Rotterdam Eye Hospital Flieringa Research Foundation, Rotterdam, the
   Netherlands; Royal Visio, Rotterdam, the Netherlands
FX The authors would like to thank L. Spielberg (REH) for manuscript
   editing. The study was supported by the Rotterdam Eye Hospital Flieringa
   Research Foundation, Rotterdam, the Netherlands, and Royal Visio,
   Rotterdam, the Netherlands. The funding organizations had no role in the
   design or conduct of this research.
CR BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bouwens MD, 2003, GRAEF ARCH CLIN EXP, V241, P89, DOI 10.1007/s00417-002-0613-5
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Crossland MD, 2011, RETINA-J RET VIT DIS, V31, P2109, DOI 10.1097/IAE.0b013e31820d3fba
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Konstantinidis L, 2011, KLIN MONATSBL AUGENH, V228, P288, DOI 10.1055/s-0031-1273214
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Maaijwee K, 2008, BRIT J OPHTHALMOL, V92, P526, DOI 10.1136/bjo.2007.131383
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   Maajwee K, 2008, OPTOMETRY VISION SCI, V85, P353, DOI 10.1097/OPX.0b013e31816bf58b
   Peroglio Deiro A, 2013, ARVO, V2013, P5814
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   van Meurs JC, 2013, RETINA, P2010
   van Zeeburg EJT, 2014, ACTA OPHTHALMOL, V92, P228, DOI 10.1111/aos.12178
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   van Zeeburg EJT, 2011, INVEST OPHTH VIS SCI, V52, P5881, DOI 10.1167/iovs.11-7245
NR 22
TC 10
Z9 10
U1 0
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2015
VL 233
IS 3-4
BP 134
EP 145
DI 10.1159/000380829
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CK3LO
UT WOS:000356117800003
PM 25832909
DA 2022-11-30
ER

PT J
AU Esmaeelpour, M
   Ansari-Shahrezaei, S
   Glittenberg, C
   Nemetz, S
   Kraus, MF
   Hornegger, J
   Fujimoto, JG
   Drexler, W
   Binder, S
AF Esmaeelpour, Marieh
   Ansari-Shahrezaei, Siamak
   Glittenberg, Carl
   Nemetz, Susanne
   Kraus, Martin F.
   Hornegger, Joachim
   Fujimoto, James G.
   Drexler, Wolfgang
   Binder, Susanne
TI Choroid, Haller's, and Sattler's Layer Thickness in Intermediate
   Age-Related Macular Degeneration With and Without Fellow Neovascular
   Eyes
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; optical coherence tomography;
   choroidal thickness maps; retina; choroid; retina
ID OPTICAL COHERENCE TOMOGRAPHY; RETICULAR PSEUDODRUSEN;
   MORPHOMETRIC-ANALYSIS; BRUCHS MEMBRANE; IN-VIVO; PROGRESSION;
   CHORIOCAPILLARIS; MACULOPATHY; PREVALENCE; MAPS
AB PURPOSE. To analyze choroidal, Sattler's, and Haller's layer thickness maps in age-related macular degeneration (AMD) patients having eyes with bilateral large drusen and pigment changes (intermediate AMD), in patients having intermediate AMD eyes with neovascular fellow eyes (nAMD), and in healthy subjects using three-dimensional (3D) 1060-nm optical coherence tomography (OCT).
   METHODS. Automatically generated choroidal thickness (ChT), retinal thickness, and Sattler's and Haller's layer thickness maps were statistically analyzed in 67 subjects consisting of intermediate AMD (n = 21), intermediate AMD (n = 22) with fellow nAMD eyes (n = 22), and healthy eyes (n = 24) with no age and axial eye length difference between groups of eyes (P > 0.05, ANOVA). Eyes were imaged by a prototype high-speed (60,000 A-scans/s) spectral-domain 3D 1060-nm OCT over a 36 degrees x 36 degrees field of view.
   RESULTS. The mean +/- SD (mu m) subfoveal ChT for healthy subjects and for bilateral intermediate AMD, unilateral intermediate AMD, and their nAMD fellow eyes was 259 +/- 95 and 222 +/- 98, 149 +/- 60, and 171 +/- 78, respectively. Choroidal thickness maps demonstrated significant submacular thinning in unilateral intermediate AMD in comparison to healthy and bilateral intermediate AMD eyes (P < 0.001, ANOVA, post hoc P < 0.001 and P < 0.05, respectively). Sattler's and Haller's layers were thinnest in intermediate AMDs that presented with nAMD fellow eyes (Kruskal-Wallis test P < 0.01). For the choroid and its sublayers, there was no difference between the intermediate AMD eyes and their fellow nAMD eyes (paired testing, P < 0.05).
   CONCLUSIONS. The 3D 1060-nm OCT choroidal imaging visualized significant changes in choroidal, Sattler's, and Haller's layer thickness in relation to the progression of AMD. This may be important for understanding the choroidopathy in the pathophysiology of AMD.
C1 [Esmaeelpour, Marieh; Ansari-Shahrezaei, Siamak; Glittenberg, Carl; Binder, Susanne] Rudolf Fdn Clin, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Dept Ophthalmol, A-1030 Vienna, Austria.
   [Esmaeelpour, Marieh; Drexler, Wolfgang] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria.
   [Nemetz, Susanne] Opt Nemetz, Vienna, Austria.
   [Kraus, Martin F.; Hornegger, Joachim] Univ Erlangen Nurnberg, Pattern Recognit Lab, D-91054 Erlangen, Germany.
   [Kraus, Martin F.; Hornegger, Joachim] Univ Erlangen Nurnberg, Sch Adv Opt Technol, D-91054 Erlangen, Germany.
   [Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
C3 Ludwig Boltzmann Institute; Medical University of Vienna; University of
   Erlangen Nuremberg; University of Erlangen Nuremberg; Massachusetts
   Institute of Technology (MIT)
RP Esmaeelpour, M (通讯作者)，Rudolf Fdn Clin, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
EM marieh.esmaeelpour@meduniwien.ac.at
RI Hornegger, Joachim/H-2465-2017
OI Hornegger, Joachim/0000-0002-1834-8844; Drexler,
   Wolfgang/0000-0002-3557-6398
FU Medical University Vienna; Oesterreichische Nationalbank
   (Jubilaeumsfond) [14294]; Macular Vision Research Foundation, United
   States; FAMOS (FP7 ICT) [317744]; FWF-NFN (Photoacoustic Imaging in
   Biology and Medicine); National Institutes of Health [R01-EY011289-27];
   Carl Zeiss Meditec, Inc.; Femtolasers GmbH; Christian Doppler Society;
   German Research Foundation [DFG-HO-1791/11-1]; DFG Training Group
   [1773]; Erlangen Graduate School of Advanced Optical Technologies;
   NATIONAL EYE INSTITUTE [R01EY011289] Funding Source: NIH RePORTER
FX Supported in part by Medical University Vienna; Oesterreichische
   Nationalbank (Jubilaeumsfond, Project 14294); Macular Vision Research
   Foundation, United States; FAMOS (FP7 ICT 317744); FWF-NFN
   (Photoacoustic Imaging in Biology and Medicine); National Institutes of
   Health Grant R01-EY011289-27; Carl Zeiss Meditec, Inc.; Femtolasers
   GmbH; the Christian Doppler Society (Christian Doppler Laboratory [Laser
   Development and Their Application in Medicine]); German Research
   Foundation DFG-HO-1791/11-1, DFG Training Group 1773 (Heterogeneous
   Image Systems); and Erlangen Graduate School of Advanced Optical
   Technologies.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   ANSI, 2000, SAF US LAS SAF US OP, P168
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Coscas F, 2014, INVEST OPHTH VIS SCI, V55, P64, DOI 10.1167/iovs.13-12931
   Esmaeelpour M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099690
   Esmaeelpour M, 2010, INVEST OPHTH VIS SCI, V51, P5260, DOI 10.1167/iovs.10-5196
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   HAYREH SS, 1974, A GRAEF ARCH KLIN EX, V192, P181
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   ICNIRP, 2000, REV GUID LIM EXP LAS, P431
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kajic V, 2013, BIOMED OPT EXPRESS, V4, P134, DOI 10.1364/BOE.4.000134
   Kajic V, 2012, BIOMED OPT EXPRESS, V3, P86, DOI 10.1364/BOE.3.000086
   Kajic V, 2010, OPT EXPRESS, V18, P14730, DOI 10.1364/OE.18.014730
   Kerbs I, 2009, OPHTHAL SURG LAS IM, V40, P285, DOI [10.9999/15428877-20090430-10, 10.3928/15428877-20090430-10]
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Mendrinos E, 2009, ACTA OPHTHALMOL, V87, P290, DOI 10.1111/j.1755-3768.2008.01247.x
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Povazay B, 2009, INVEST OPHTH VIS SCI, V50, P1856, DOI 10.1167/iovs.08-2869
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Sim DA, 2013, INVEST OPHTH VIS SCI, V54, P2893, DOI 10.1167/iovs.12-11085
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Unterhuber A, 2005, OPT EXPRESS, V13, P3252, DOI 10.1364/OPEX.13.003252
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
NR 45
TC 40
Z9 42
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2014
VL 55
IS 8
BP 5074
EP 5080
DI 10.1167/iovs.14-14646
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ9DV
UT WOS:000343145500051
PM 25052997
OA Green Published
DA 2022-11-30
ER

PT J
AU Xia, HK
   Zhang, Q
   Shen, Y
   Bai, YJ
   Ma, XY
   Zhang, B
   Qi, Y
   Zhang, JJ
   Hu, QR
   Du, W
   Zhu, L
   Zhou, P
   Wang, B
   Xu, H
   Huang, LZ
   Li, XX
AF Xia, Huika
   Zhang, Qi
   Shen, Yan
   Bai, Yujing
   Ma, Xiaoyun
   Zhang, Bo
   Qi, Yun
   Zhang, Jingjing
   Hu, Qinrui
   Du, Wei
   Zhu, Li
   Zhou, Peng
   Wang, Bin
   Xu, Hui
   Huang, Lvzhen
   Li, Xiaoxin
TI ube3d, a New Gene Associated with Age-Related Macular Degeneration,
   Induces Functional Changes in Both In Vivo and In Vitro Studies
SO MOLECULAR THERAPY-NUCLEIC ACIDS
LA English
DT Article
ID UBIQUITIN-PROTEASOME PATHWAY; RETINAL-PIGMENT EPITHELIUM; VISUAL
   IMPAIRMENT; PATHOGENESIS; MODEL; PHAGOCYTOSIS; MELANOSOME; EXPRESSION;
   ZEBRAFISH; SYSTEM
AB Neovascular age-related macular degeneration (AMD) is characterized by the formation of choroidal neovascularization, which is responsible for more than 80% of cases of severe vision loss. Ubiquitin protein ligase E3D (UBE3D) gene missense has been proven to be associated with neovascular AMD in the East Asian population based on our previous study. In vivo, we explored the role of ube3d in eye development and the mechanisms underlying the development of neovascular AMD in a zebrafish model. In vitro, we investigated the function and mechanism of ube3d in oxidative damage in human retinal pigment epithelium (hRPE) cells. The ube3d gene was knocked down in zebrafish in our experiments, and rescue of ube3d morphants was also performed. We observed the zebrafish model at the molecular level and functional and morphological changes in vivo. Lentivirus-based gene transfer technology was used to overexpress/knockdown ube3d expression in hRPE cells in vitro. hRPE oxidative damage was induced by tert-butyl hydroperoxide (t-TBH). Cell proliferation and migration were assessed. Quantitative real-time PCR and western blot were used to measure the expression levels of UBE3D and CyclinB1. Abnormal eye development was found in zebrafish in this study, including small eyes, delayed retinal development, delayed retrograde melanosome transport, and reduced dark-induced hyper-locomotor activity under light-off conditions. In addition, increased angiogenesis was observed in ube3d morphants. A negative correlation between UBE3D and CyclinB1 was observed. Low UBE3D expression can promote oxidative damage and inflammatory reactions. UBE3D and autophagy have a synergetic effect on anti-oxidative damage. These findings indicate that ube3d may play an important role in the pathogenesis of AMD by affecting retinal development, oxidative damage, and autophagy.
C1 [Xia, Huika; Zhang, Qi; Bai, Yujing; Qi, Yun; Zhang, Jingjing; Hu, Qinrui; Du, Wei; Zhu, Li; Xu, Hui; Huang, Lvzhen; Li, Xiaoxin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China.
   [Xia, Huika; Zhang, Qi; Bai, Yujing; Qi, Yun; Zhang, Jingjing; Hu, Qinrui; Du, Wei; Zhu, Li; Xu, Hui; Huang, Lvzhen; Li, Xiaoxin] Peking Univ, Peoples Hosp, Beijing Key Lab Diag & Therapy Retinal & Choroid, Beijing 100044, Peoples R China.
   [Xia, Huika] Hebei Gen Hosp, Dept Ophthalmol, Shijiazhuang 050051, Hebei, Peoples R China.
   [Shen, Yan; Zhang, Bo] Peking Univ, Coll Life Sci, Minist Educ, Key Lab Cell Proliferat & Differentiat, Beijing 100871, Peoples R China.
   [Ma, Xiaoyun] Shanghai Univ Med & Hlth Sci, Zhoupu Hosp, Dept Ophthalmol, Shanghai 201318, Peoples R China.
   [Zhou, Peng] Parkway Hlth, Hongqiao Med Ctr, Shanghai 201101, Peoples R China.
   [Wang, Bin; Li, Xiaoxin] Xiamen Univ, Xiamen Eye Ctr, Xiamen 361000, Fujian, Peoples R China.
   [Wang, Bin; Li, Xiaoxin] Xiamen Univ, Eye Inst, Xiamen 361000, Fujian, Peoples R China.
C3 Peking University; Peking University; Peking University; Shanghai
   University of Medicine & Health Sciences; Xiamen University; Xiamen
   University
RP Huang, LZ; Li, XX (通讯作者)，Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China.
EM huanglvzhen@126.com; drlixiaoxin@163.com
OI Hu, Qinrui/0000-0003-0185-4537
FU National Natural Science Foundation of China [81470649, 81670870];
   National Basic Research Program of China (973 Program) [2011CB510200,
   2012CB945101]; Beijing Nova Program [Z161100004916058]; Science and
   Technology Innovation Project of Chinese Academy of Medical Sciences
   [2019-RC-HL-019]; Huaxia Translational Medicine Fund for Young Scholars
   [2017-C-001]
FX This work was supported by the National Natural Science Foundation of
   China (grant number 81470649, 81670870), the National Basic Research
   Program of China (973 Program, grant number 2011CB510200, 2012CB945101),
   the Beijing Nova Program (Z161100004916058), Science and Technology
   Innovation Project of Chinese Academy of Medical Sciences
   (2019-RC-HL-019), and Huaxia Translational Medicine Fund for Young
   Scholars (grant number 2017-C-001). The funders had no role in the study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abedin MJ, 2014, CIRC RES, V114, P1690, DOI 10.1161/CIRCRESAHA.1134303145
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Bai YJ, 2013, INVEST OPHTH VIS SCI, V54, P6628, DOI 10.1167/iovs.13-12625
   Barral DC, 2004, PIGM CELL RES, V17, P111, DOI 10.1111/j.1600-0749.2004.00138.x
   Boulton M, 2004, GRAEF ARCH CLIN EXP, V242, P76, DOI 10.1007/s00417-003-0812-8
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Campello L, 2013, MOL NEUROBIOL, V47, P790, DOI 10.1007/s12035-012-8391-5
   Castro A, 2005, ONCOGENE, V24, P314, DOI 10.1038/sj.onc.1207973
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Doherty FJ, 2002, ESSAYS BIOCHEM, V38, P51, DOI 10.1042/bse0380051
   Drinjakovic J, 2010, NEURON, V65, P341, DOI 10.1016/j.neuron.2010.01.017
   Fernandes AF, 2006, EXP EYE RES, V83, P1472, DOI 10.1016/j.exer.2006.07.024
   Figurska Malgorzata, 2010, Klin Oczna, V112, P147
   Galy A, 2002, DEV BIOL, V248, P251, DOI 10.1006/dbio.2002.0736
   Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012
   Haas AL, 1997, FASEB J, V11, P1257
   Huang LZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7687
   Huang LZ, 2010, INVEST OPHTH VIS SCI, V51, P3193, DOI 10.1167/iovs.09-3779
   Hume AN, 2011, BIOCHEM SOC T, V39, P1191, DOI 10.1042/BST0391191
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kushimoto T, 2003, PIGM CELL RES, V16, P237, DOI 10.1034/j.1600-0749.2003.00034.x
   Lam YA, 2000, P NATL ACAD SCI USA, V97, P9902, DOI 10.1073/pnas.170173897
   Lamb TD, 2007, NAT REV NEUROSCI, V8, P960, DOI 10.1038/nrn2283
   LAVAIL MM, 1983, T OPHTHAL SOC UK, V103, P397
   LENNOX G, 1988, NEUROSCI LETT, V94, P211, DOI 10.1016/0304-3940(88)90297-2
   Li XX, 2012, OPHTHALMOLOGY, V119, P2087, DOI 10.1016/j.ophtha.2012.05.016
   Liu ZZ, 2014, ADV EXP MED BIOL, V801, P237, DOI 10.1007/978-1-4614-3209-8_31
   Marmorstein AD, 1998, ANN NY ACAD SCI, V857, P1, DOI 10.1111/j.1749-6632.1998.tb10102.x
   MURALIDHAR MG, 1993, NEURON, V11, P253, DOI 10.1016/0896-6273(93)90182-Q
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rizzolo LJ, 1997, HISTOL HISTOPATHOL, V12, P1057
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmitt EA, 1999, J COMP NEUROL, V404, P515
   Shang F, 1997, EXP EYE RES, V64, P21, DOI 10.1006/exer.1996.0176
   Shang F, 2012, MOL ASPECTS MED, V33, P446, DOI 10.1016/j.mam.2012.04.001
   Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060
   THISSE C, 1993, DEVELOPMENT, V119, P1203
   van Wijk SJL, 2010, FASEB J, V24, P981, DOI 10.1096/fj.09-136259
   Viiri J, 2010, MOL VIS, V16, P1399
   Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799
   Winkler BS, 1999, MOL VIS, V5
   Xu WD, 2000, EXP CELL RES, V255, P135, DOI 10.1006/excr.2000.4803
   Yen HJ, 2006, HUM MOL GENET, V15, P667, DOI 10.1093/hmg/ddi468
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 49
TC 1
Z9 1
U1 3
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2162-2531
J9 MOL THER-NUCL ACIDS
JI Mol. Ther.-Nucl. Acids
PD JUN 5
PY 2020
VL 20
BP 217
EP 230
DI 10.1016/j.omtn.2020.02.010
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA LW2IL
UT WOS:000538968000020
PM 32200270
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Motulsky, EH
   Zheng, F
   Shi, YY
   Gregori, G
   Rosenfeld, PJ
AF Motulsky, Elie H.
   Zheng, Fang
   Shi, Yingying
   Gregori, Giovanni
   Rosenfeld, Philip J.
TI Anatomic Localization of Type 1 and Type 2 Macular Neovascularization
   Using Swept-Source OCT Angiography
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; SPECTRAL-DOMAIN; CHOROIDAL
   NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAPHY; CLASSIFICATION
AB BACKGROUND AND OBJECTIVE: Swept-source optical coherence tomography angiography (SS-OCTA) and different boundary-specific segmentation strategies were used to distinguish type 1 macular neovascularization (MNV) from type 2 MNV in eyes with exudative age-related macular degeneration (AMD).
   PATIENTS AND METHODS: Eyes with exudative AMD were enrolled in a prospective study. Segmentation strategies included a slab from the outer retina (OR) to the choriocapillaris (CC) for the entire MNV, a slab from the retinal pigment epithelium (RPE) to the CC for the type 1 MNV, and a slab from the. OR to the RPE for the type 2 MNV.
   RESULTS: In 13 eyes, SS-OC-TA B-scans and en face images using different segmentation strategies were able to identify type 1 and type 2 components of the MNV.
   CONCLUSION: In eyes with exudative AMD, SS-OCTA imaging and commercially available boundary-specific segmentation strategies were used to distinguish between type 1 and type 2 MNV.
C1 [Motulsky, Elie H.; Zheng, Fang; Shi, Yingying; Gregori, Giovanni; Rosenfeld, Philip J.] Univ Miami, Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL USA.
   [Zheng, Fang] Tianjin Med Univ, Gen Hosp, Dept Ophthalmol, Tianjin, Peoples R China.
C3 Bascom Palmer Eye Institute; University of Miami; Tianjin Medical
   University
RP Rosenfeld, PJ (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@miami.edu
FU Carl Zeiss Meditec (Dublin, CA); Salah Foundation; Research to Prevent
   Blindness, New York, NY; National Eye Institute Center Core Grant
   [P30EY014801]; Carl Zeiss Meditec; Genentech; Tyrogenex
FX This study was supported by grants from Carl Zeiss Meditec (Dublin, CA);
   the Salah Foundation; an unrestricted grant from the Research to Prevent
   Blindness, New York, NY; and the National Eye Institute Center Core
   Grant (P30EY014801) to the Department of Ophthalmology, University of
   Miami Miller School of Medicine.; Drs. Gregori and Rosenfeld received
   research support from Carl Zeiss Meditec. Dr. Gregori and the University
   of Miami co-own a patent that is licensed to Carl Zeiss Meditec. Dr.
   Rosenfeld received additional research support from Genentech and
   Tyrogenex; is a consultant for Achillion Pharmaceuticals, Acucela,
   Boehringer-Ingelheim, Carl Zeiss Meditec, Cell Cure Neurosciences,
   Chengdu Kanghong Biotech, Ocunexus Therapeutics, Genentech, Healios K.
   K, Hemera Biosciences, F. Hoffmann-La Roche Ltd., Isarna
   Pharmaceuticals, Lin Bioscience, MacRegen Inc., NGM Biopharmaceuticals,
   Ocunexus, Ocudyne, Tyrogenex, and Unity Biotechnology; and has equity
   interest in Apellis, Digisight, and Ocudyne. The remaining authors
   report no relevant financial disclosures.
CR Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Ma J, 2017, OPHTHALMOL EYE DIS, V9, DOI 10.1177/1179172116686075
   Mathew R, 2014, OPHTHALMOLOGICA, V231, P153, DOI 10.1159/000355091
   Miere A, 2017, RETINA-J RET VIT DIS, V37, P1873, DOI 10.1097/IAE.0000000000001447
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Soares M, 2017, BRIT J OPHTHALMOL, V101, P62, DOI 10.1136/bjophthalmol-2016-309424
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
   Zhang QQ, 2015, RETINA-J RET VIT DIS, V35, P2285, DOI 10.1097/IAE.0000000000000840
   Zheng F, 2016, OSLI RETINA, V47, P517, DOI 10.3928/23258160-20160601-02
NR 11
TC 5
Z9 5
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD NOV
PY 2018
VL 49
IS 11
BP 878
EP 886
DI 10.3928/23258160-20181101-09
PG 9
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA HB7FY
UT WOS:000451244100018
PM 30457647
OA Green Published
DA 2022-11-30
ER

PT J
AU Ghosh, S
   Shang, P
   Terasaki, H
   Stepicheva, N
   Hose, S
   Yazdankhah, M
   Weiss, J
   Sakamoto, T
   Bhutto, IA
   Xia, SL
   Zigler, JS
   Kannan, R
   Qian, J
   Handa, JT
   Sinha, D
AF Ghosh, Sayan
   Shang, Peng
   Terasaki, Hiroto
   Stepicheva, Nadezda
   Hose, Stacey
   Yazdankhah, Meysam
   Weiss, Joseph
   Sakamoto, Taiji
   Bhutto, Imran A.
   Xia, Shuli
   Zigler, J. Samuel, Jr.
   Kannan, Ram
   Qian, Jiang
   Handa, James T.
   Sinha, Debasish
TI A Role for beta A3/A1-Crystallin in Type 2 EMT of RPE Cells Occurring in
   Dry Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE crystallin; lysosomes; EMT; dry AMD; autophagy
ID RETINAL-PIGMENT EPITHELIUM; TO-MESENCHYMAL TRANSITION; SUBRETINAL
   FIBROSIS; GEOGRAPHIC ATROPHY; OXIDATIVE STRESS; E-CADHERIN; AUTOPHAGY;
   GROWTH; CANCER; PATHWAY
AB PURPOSE. The RPE cells have a major role in the development of dry age-related macular degeneration (AMD). We present novel evidence that beta A3/A1-crystallin, encoded by the Cryba1 gene, a protein known to be important for lysosomal clearance in the RPE, also has a role in epithelial-to-mesenchymal transition (EMT) of RPE cells.
   METHODS. RPE from dry AMD globes, genetically engineered mice lacking Cryba1 globally or specifically in the RPE, spontaneous mutant rats (Nuc1) with a loss-of-function mutation in Cryba1, and the melanoma OCM3 cell line were used. Spatial localization of proteins was demonstrated with immunofluorescence, gene expression levels were determined by quantitative PCR (qPCR), and protein levels by Western blotting. Cell movement was evaluated using wound healing and cell migration assays. Co-immunoprecipitation was used to identify binding partners of beta A3/A1-crystallin.
   RESULTS. beta A3/A1-crystallin is upregulated in polarized RPE cells compared to undifferentiated cells. Loss of beta A3/A1-crystallin in murine and human RPE cells resulted in upregulation of Snail and vimentin, downregulation of E-cadherin, and increased cell migration. beta A3/A1-crystallin binds to cortactin, and loss of beta A3/A1-crystallin resulted in increased P-cortactin(Y421). The RPE from AMD samples had increased Snail and vimentin, and decreased E-cadherin, compared to age-matched controls.
   CONCLUSIONS. We introduced a novel concept of dry AMD initiation induced by lysosomal clearance defects in the RPE and subsequent attempts by RPE cells to avoid the resulting stress by undergoing EMT. We demonstrate that beta A3/A1-crystallin is a potential therapeutic target for AMD through rejuvenation of lysosomal dysfunction and potentially, reversal of EMT.
C1 [Ghosh, Sayan; Shang, Peng; Stepicheva, Nadezda; Hose, Stacey; Yazdankhah, Meysam; Weiss, Joseph; Bhutto, Imran A.; Sinha, Debasish] Univ Pittsburgh, Dept Ophthalmol, Glia Res Lab, Pittsburgh, PA 15260 USA.
   [Terasaki, Hiroto; Sakamoto, Taiji; Kannan, Ram] Doheny Eye Inst, Arnold & Mabel Beckman Macular Res Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Terasaki, Hiroto; Sakamoto, Taiji] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Kagoshima, Japan.
   [Xia, Shuli] Johns Hopkins Univ, Sch Med, Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD USA.
   [Xia, Shuli] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
   [Zigler, J. Samuel, Jr.; Qian, Jiang; Handa, James T.; Sinha, Debasish] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 400 N Broadway,Smith Bldg Room 3015, Baltimore, MD 21287 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Doheny Eye Institute; Kagoshima University; Johns Hopkins
   University; Johns Hopkins University; Johns Hopkins University; Johns
   Hopkins Medicine
RP Handa, JT (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 400 N Broadway,Smith Bldg Room 3015, Baltimore, MD 21287 USA.; Sinha, D (通讯作者)，Univ Pittsburgh, Sch Med, Dept Ophthalmol, 4401 Penn Ave, Pittsburgh, PA 15224 USA.
EM jthanda@jhmi.edu; Debasish@pitt.edu
RI kannan, ram/ABB-7154-2020; Ghosh, Sayan/ABB-8587-2021
OI kannan, ram/0000-0002-1583-3414; /0000-0002-3780-5641
FU University of Pittsburgh; Jennifer Salvitti Davis, M.D. Chair in
   Ophthalmology; BrightFocus, Inc. Foundation; RPB/IRRF Catalyst Award for
   Innovative Research Approaches for AMD; National Institutes of Health
   (NIH; Bethesda, MD, USA) [EY019037-S]; NIH [R01EY027691]; Macular
   Degeneration Foundation; Research to Prevent Blindness; Wilmer Core
   Grant [EY001765]; NATIONAL EYE INSTITUTE [R01EY027691] Funding Source:
   NIH RePORTER
FX Supported by University of Pittsburgh start-up funds (DS), Jennifer
   Salvitti Davis, M.D. Chair in Ophthalmology (DS), BrightFocus, Inc.
   Foundation (DS), RPB/IRRF Catalyst Award for Innovative Research
   Approaches for AMD (DS), National Institutes of Health (NIH; Bethesda,
   MD, USA) Grants EY019037-S (DS) and NIH R01EY027691 (JTH), Macular
   Degeneration Foundation (JTH), Research to Prevent Blindness (Wilmer Eye
   Institute) and Wilmer Core Grant EY001765. JTH is the Robert Bond Welch
   Professor.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Asnaghi L, 2015, MOL VIS, V21, P919
   Catalano M, 2015, MOL ONCOL, V9, P1612, DOI 10.1016/j.molonc.2015.04.016
   Chang Chi-Wu, 2014, Biomed Res Int, V2014, P141582, DOI 10.1155/2014/141582
   Desai RA, 2009, J CELL SCI, V122, P905, DOI 10.1242/jcs.028183
   Fort PE, 2011, EXP EYE RES, V92, P98, DOI 10.1016/j.exer.2010.11.008
   Ghosh S, 2017, J PATHOL, V241, P583, DOI 10.1002/path.4870
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Grassi G, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.249
   Guha S, 2014, EXP EYE RES, V126, P68, DOI 10.1016/j.exer.2014.05.013
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449
   Iannaccone A, 2015, PLOS ONE, V10
   Ishikawa K, 2016, AM J PATHOL, V186, P859, DOI 10.1016/j.ajpath.2015.11.014
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Katsunuma S, 2016, J CELL BIOL, V212, P561, DOI 10.1083/jcb.201509020
   Khristov V, 2018, METHODS MOL BIOL, V1722, P223, DOI 10.1007/978-1-4939-7553-2_15
   Kim JW, 2008, GENE DEV, V22, P3147, DOI 10.1101/gad.1700108
   Kimura K, 2015, J MOL MED, V93, P749, DOI 10.1007/s00109-015-1289-8
   Krstic J, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/654594
   Lee JY, 2010, AUTOPHAGY, V6, P555, DOI 10.4161/auto.6.4.11812
   Li GB, 2015, CELL PHYSIOL BIOCHEM, V35, P1773, DOI 10.1159/000373989
   Ma B, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.100
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mony S, 2013, EXP EYE RES, V115, P113, DOI 10.1016/j.exer.2013.06.007
   Myong NH, 2012, KOREAN J PATHOL, V46, P341, DOI 10.4132/KoreanJPathol.2012.46.4.341
   Piatigorsky J., 2007, GENE SHARING EVOLUTI
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   Rajaii F, 2014, INVEST OPHTH VIS SCI, V55, P6178, DOI 10.1167/iovs.14-13933
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Shang P, 2017, AGING CELL, V16, P349, DOI 10.1111/acel.12561
   Sinha D, 2008, MOL CELL NEUROSCI, V37, P85, DOI 10.1016/j.mcn.2007.08.016
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Slingsby C, 2014, PROG BIOPHYS MOL BIO, V115, P52, DOI 10.1016/j.pbiomolbio.2014.02.006
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sreekumar PG, 2008, INVEST OPHTH VIS SCI, V49, P1210, DOI 10.1167/iovs.07-0667
   Sun B, 2015, BIOMED REP, V3, P603, DOI 10.3892/br.2015.494
   Tennakoon AH, 2016, J CLIN MED, V5, DOI 10.3390/jcm5010004
   Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113
   Valapala M, 2015, SCI REP-UK, V5, DOI 10.1038/srep08755
   Valapala M, 2014, AGING CELL, V13, P1091, DOI 10.1111/acel.12274
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   Valapala M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2624
   Vilchez D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6659
   Wang J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03856-y
   Wang WQ, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-49
   Wong SHM, 2018, CRIT REV ONCOL HEMAT, V121, P11, DOI 10.1016/j.critrevonc.2017.11.010
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu SW, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.69
   Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480
   Yao Tso-Pang, 2010, Genes Cancer, V1, P779
   Yin M, 2017, ONCOTARGET, V8, P88232, DOI 10.18632/oncotarget.21088
   Yoshihara N, 2017, RETINA-J RET VIT DIS, V37, P179, DOI 10.1097/IAE.0000000000001117
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zhang C, 2011, EUR J CELL BIOL, V90, P440, DOI 10.1016/j.ejcb.2011.01.003
   Zhao Z, 2016, AM J CANCER RES, V6, P2162
   Zigler JS, 2015, PROG RETIN EYE RES, V44, P62, DOI 10.1016/j.preteyeres.2014.11.002
   Zigler JS, 2011, J CELL SCI, V124, P523, DOI 10.1242/jcs.078790
NR 62
TC 40
Z9 42
U1 1
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2018
VL 59
IS 4
SI SI
BP 104
EP 113
DI 10.1167/iovs.18-24132
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GO7KR
UT WOS:000440244300002
PM 30098172
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Bian, W
   Wan, JL
   Smith, G
   Li, SY
   Tan, MQ
   Zhou, FJ
AF Bian, Wei
   Wan, Junli
   Smith, Graeme
   Li, Shiying
   Tan, Mingqiong
   Zhou, Fengjiao
TI Domains of health-related quality of life in age-related macular
   degeneration: a qualitative study in the Chinese cultural context
SO BMJ OPEN
LA English
DT Article
ID SEVERE VISUAL IMPAIRMENT; DEPRESSIVE SYMPTOMS; QUESTIONNAIRE;
   EXPERIENCE; VISION; IMPACT; PREVALENCE; MACDQOL; PEOPLE; ADULTS
AB Objective To explore which areas of health-related quality of life were affected in Chinese patients, and to identify whether the areas are well covered by validated questionnaires.
   Design A qualitative study based on semistructured interviews was conducted. A qualitative thematic analysis following the approach of Colaizzi was used to analyse the interview data for significant statements and phrases. The themes and subthemes organised from the analysis were then compared by using the following current instruments: National Eye Institute Visual Function Questionnaire (NEI-VFQ-25), Macular Disease Quality of life Questionnaire (MacDQoL) and Low-Luminance Questionnaire (LLD).
   Participants and setting Twenty-one patients with age-related macular degeneration were recruited from the eye clinic of Southwest Eye Hospital in Chongqing, mainland China.
   Results The mean age of the participants was 69.8 years (range 57-82 years) and the duration of the disease ranged from 3 months to 6 years. The qualitative analysis revealed nine important domains including symptoms, difficulties with daily activities, depending on others, depression and uncertainty, optimism and hope, social isolation, role change, family support and financial burden. However, all the three questionnaires were insufficient to capture the full extent of quality of life issues of Chinese patients with AMD, and MacDQoL covered more domains when compared with NEI-VFQ-25 and LLD.
   Conclusion The domains of concepts important to people with AMD in the Chinese culture are not fully represented in the three widely used questionnaires. Nine important domains were identified for the assessment of quality of life and should be considered when assessing the impact of AMD on Chinese individuals. Further studies are needed to develop an AMD quality of life questionnaire, better tailored to the needs and culture of Chinese patients.
C1 [Bian, Wei; Wan, Junli; Li, Shiying; Tan, Mingqiong; Zhou, Fengjiao] Army Med Univ, Third Mil Med Univ, Southwest Eye Hosp, Chongqing, Peoples R China.
   [Bian, Wei; Wan, Junli; Li, Shiying; Tan, Mingqiong; Zhou, Fengjiao] Key Lab Visual Damage & Regenerat & Restorat Chon, Chongqing, Peoples R China.
   [Smith, Graeme] Edinburgh Napier Univ, Fac Sch Hlth & Social Care Hlth & Life Sci, Edinburgh, Midlothian, Scotland.
C3 Army Medical University; Edinburgh Napier University
RP Bian, W (通讯作者)，Army Med Univ, Third Mil Med Univ, Southwest Eye Hosp, Chongqing, Peoples R China.; Bian, W (通讯作者)，Key Lab Visual Damage & Regenerat & Restorat Chon, Chongqing, Peoples R China.
EM 664091353@qq.com
RI Smith, Graeme Drummond/AAU-7167-2021
OI Smith, Graeme Drummond/0000-0003-2974-3919
FU Army Medical University of Humanities and Social Science project
   [2017XRW21]; First Affiliated Hospital of Third Military Medical
   University Innovation Research Grants [SWH2015QNO4]
FX This study was funded by the Army Medical University of Humanities and
   Social Science project (2017XRW21) and the First Affiliated Hospital of
   Third Military Medical University Innovation Research Grants
   (SWH2015QNO4).
CR Beaton DE, 2003, CLIN ORTHOP RELAT R, P90, DOI 10.1097/01.blo.0000079772.06654.c8
   Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   Cimarolli VR, 2005, J VISUAL IMPAIR BLIN, V99, P521, DOI 10.1177/0145482X0509900904
   Colaizzi PF., 1978, EXISTENTIAL PHENOMEN, P6
   Coleman AL, 2010, AM J OPHTHALMOL, V150, P683, DOI 10.1016/j.ajo.2010.05.030
   Dixon P, 2016, QUAL LIFE RES, V25, P935, DOI 10.1007/s11136-015-1145-x
   Feely M, 2007, J VISUAL IMPAIR BLIN, V101, P44, DOI 10.1177/0145482X0710100106
   Finger RP, 2012, OPHTHALMOLOGY, V119, P2351, DOI 10.1016/j.ophtha.2012.05.031
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Huang Y. M., 2015, INT J ANTENN PROPAG, V2015, P1, DOI DOI 10.1155/2015/216983
   Ivanoff SD, 1996, DISABIL REHABIL, V18, P515, DOI 10.3109/09638289609166038
   Jivraj J, 2013, CAN J OPHTHALMOL, V48, P269, DOI 10.1016/j.jcjo.2013.03.007
   Khadka J, 2016, OPTOMETRY VISION SCI, V93, P1485, DOI 10.1097/OPX.0000000000000992
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Matamoros E, 2015, OPHTHALMOLOGICA, V234, P151, DOI 10.1159/000433448
   Mathew RS, 2011, OPHTHAL PHYSL OPT, V31, P375, DOI 10.1111/j.1475-1313.2011.00848.x
   McCloud C, 2014, OPTOMETRY VISION SCI, V91, P966, DOI 10.1097/OPX.0000000000000320
   Mitchell Jan, 2005, Health Qual Life Outcomes, V3, P25, DOI 10.1186/1477-7525-3-25
   Mogk M, 2008, J VISUAL IMPAIR BLIN, V102, P581, DOI 10.1177/0145482X0810201002
   Moore LW, 2000, WESTERN J NURS RES, V22, P571, DOI 10.1177/01939450022044601
   Moore LW, 2003, J ADV NURS, V43, P10
   Ord LM, 2015, J CLIN MED, V4, P1841, DOI 10.3390/jcm4091841
   Owsley C, 2006, REHABIL PSYCHOL, V51, P23, DOI 10.1037/0090-5550.51.1.23
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Qiu M, 2014, OPHTHALMOLOGY, V121, P733, DOI 10.1016/j.ophtha.2013.09.043
   Rovner BW, 2013, OPHTHALMOLOGY, V120, P1649, DOI 10.1016/j.ophtha.2013.01.022
   Samsa G, 1999, PHARMACOECONOMICS, V15, P141, DOI 10.2165/00019053-199915020-00003
   Senra H, 2016, GRAEF ARCH CLIN EXP, V254, P1873, DOI 10.1007/s00417-016-3384-0
   Siaudvytyte L, 2012, MEDICINA-LITHUANIA, V48, P109, DOI 10.3390/medicina48020015
   Sorensen S, 2015, CONTEMP CLIN TRIALS, V42, P68, DOI 10.1016/j.cct.2015.03.007
   Stanford P, 2009, BRIT J VISUAL IMPA, V27, P129, DOI 10.1177/0264619609102216
   Sturrock BA, 2015, INVEST OPHTH VIS SCI, V56, P2416, DOI 10.1167/iovs.14-16223
   Wang LL, 2015, CHINESE MED J-PEKING, V128, P1154, DOI 10.4103/0366-6999.156083
   Wong EYH, 2004, J VISUAL IMPAIR BLIN, V98, P629, DOI 10.1177/0145482X0409801007
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhu Wanlu, 2014, Zhonghua Yan Ke Za Zhi, V50, P189
NR 36
TC 9
Z9 10
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD APR
PY 2018
VL 8
IS 4
AR e018756
DI 10.1136/bmjopen-2017-018756
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA GJ3FT
UT WOS:000435176700025
PM 29666126
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chew, EY
   Sperduto, RD
   Milton, RC
   Clemons, TE
   Gensler, GR
   Bressler, SB
   Klein, R
   Klein, BEK
   Ferris, FL
AF Chew, Emily Y.
   Sperduto, Robert. D.
   Milton, Roy C.
   Clemons, Traci E.
   Gensler, Gary R.
   Bressler, Susan B.
   Klein, Ronald
   Klein, Barbara E. K.
   Ferris, Frederick L., III
TI Risk of Advanced Age-Related Macular Degeneration after Cataract Surgery
   in the Age-Related Eye Disease Study AREDS Report 25
SO OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM; MACULOPATHY; ASSOCIATION; EXTRACTION
AB Purpose: To assess the risk of advanced age-related macular degeneration (AMD) developing after cataract surgery.
   Design: Cohort study.
   Participants: Four thousand five hundred seventy-seven participants (8050 eyes) from a multicenter, controlled, randomized clinical trial, the Age-Related Eye Disease Study (AREDS).
   Methods: Development of advanced AMD, either neovascular (NV) AMD or geographic atrophy (GA), was evaluated with annual fundus photographs, and history of cataract surgery was assessed every 6 months. Cox proportional hazard models with time-dependent covariates were conducted for NV AMD and GA separately.
   Main Outcome Measures: Neovascular AMD, GA, and central GA (CGA; involving the center of the macula).
   Results: The Cox proportional hazards model of right eyes showed nonsignificant hazard ratios of 1.20 (95% confidence interval [CI], 0.82-1.75) for NV AMD, 0.80 (95% CI, 0.61-1.06) for GA, and 0.87 (95% CI, 0.64-1.18) for CGA. Similar results were obtained for left eyes: 1.07 (95% CI, 0.72-1.58) for NV AMD, 0.94 (95% CI, 0.71-1.25) for GA, and 0.86 (95% CI, 0.63-1.19) for CGA. For participants with advanced AMD in 1 eye (AREDS category 4), the hazard ratios for fellow eyes were 1.08 (95% CI, 0.65-1.72) for NV AMD and 0.98 (95% CI, 0.64-1.49) for CGA.
   Conclusions. The AREDS results show-ad no clear effect of cataract surgery on the risk of progression to advanced AMD.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009;116:297-303 (C) 2009 by the American Academy of Ophthalmology.
C1 [Chew, Emily Y.; Ferris, Frederick L., III] NEI, Bethesda, MD 20892 USA.
   [Bressler, Susan B.] Johns Hopkins Wilmer Eye Inst, Baltimore, MD USA.
   [Sperduto, Robert. D.; Milton, Roy C.; Clemons, Traci E.; Gensler, Gary R.] EMMES Corp, Rockville, MD USA.
   [Klein, Ronald; Klein, Barbara E. K.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Johns Hopkins University; Johns Hopkins Medicine; Emmes
   Corporation; University of Wisconsin System; University of Wisconsin
   Madison
RP Chew, EY (通讯作者)，NEI, Bethesda, MD 20892 USA.
OI Klein, Ronald/0000-0002-4428-6237; Ferris, Frederick/0000-0002-4933-0639
FU National Eye Institute; National Institutes of Health; Department of
   Health and Human Services, Bethesda, Maryland; NATIONAL EYE INSTITUTE
   [ZIEEY000487, ZIAEY000489] Funding Source: NIH RePORTER
FX Supported by contracts from the National Eye Institute, National
   Institutes of Health, Department of Health and Human Services, Bethesda,
   Maryland.
CR *AG REL EYE DIS ST, 2001, AM J OPHTHALMOL, V12, P668
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   BLAIR CJ, 1979, AM J OPHTHALMOL, V87, P77, DOI 10.1016/0002-9394(79)90195-8
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   De Jong G, 2004, TRANSPORT REV, V24, P103, DOI 10.1080/0144164032000080494
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
NR 22
TC 111
Z9 114
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2009
VL 116
IS 2
BP 297
EP 303
DI 10.1016/j.ophtha.2008.09.019
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 403QW
UT WOS:000263098100020
PM 19091420
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Chen, CX
   Liu, ML
   Cao, K
   Yusufu, M
   Wang, JD
AF Chen, Chang-Xi
   Liu, Mei-Ling
   Cao, Kai
   Yusufu, Mayinuer
   Wang, Jin-Da
TI Diagnostic Value of Optical Coherence Tomography Angiography for
   Choroidal Neovascularization in Age-Related Macular Degeneration: A
   Systematic Review and Meta-Analysis
SO OPHTHALMIC RESEARCH
LA English
DT Review
DE Optical coherence tomography angiography; Age-related macular
   degeneration; Meta-analysis; Diagnosis; Sensitivity; Specificity
ID FLUORESCEIN ANGIOGRAPHY; VISUAL OUTCOMES; OCT ANGIOGRAPHY;
   CLASSIFICATION
AB Objective: This study aims to evaluate the diagnostic value of optical coherence tomography angiography (OCTA) in detecting the choroidal neovascularization (CNV) in age-related macular degeneration (AMD). Methods: A systematic review and meta-analysis was performed by searching Pubmed, Science Direct, Embase, and Web of Science. The pooled sensitivity and specificity with 95% confidence intervals (CIs), area under the summary receiver operator characteristic curve (sROC), and the total accurate classification rate were used to evaluate OCTA's diagnostic value of CNV in AMD patients. Results: Seven studies involving 517 eyes were included in the analysis. The mean age of subjects in each study ranged from 58.5 years to 81.7 years. Fluorescein angiography was applied as the gold standard in 5 studies. There were 350 eyes diagnosed with CNV, OCTA detected 301 eyes correctly, while among the 167 eyes without CNV, OCTA identified 150 correctly. The total accurate classification rate was 87.23%. The Spearman's rank correlation coefficient was 0.5, indicating that there was no significant threshold effect in the current study (S = 8, p = 0.103). The pooled sensitivity and pooled specificity were 0.89 (95% CI: 0.82, 0.94) and 0.96 (95% CI: 0.85, 1.00), respectively. The area under sROC was up to 0.911. Conclusion: The specificity of OCTA for the detection of CNV in AMD patients is extremely high; however, the sensitivity still needs to be improved. In general, the meta-analysis revealed that OCTA had a high diagnostic value for the detection of CNV in AMD patients. (C) 2021 S. Karger AG, Basel
C1 [Chen, Chang-Xi; Cao, Kai; Yusufu, Mayinuer; Wang, Jin-Da] Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R China.
   [Liu, Mei-Ling] Dahongmen Community Healthcare Ctr, Beijing, Peoples R China.
C3 Capital Medical University
RP Cao, K; Wang, JD (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R China.
EM anzhen602@163.com; wjd3636@163.com
CR Ahmed D, 2018, RETINA-J RET VIT DIS, V38, P2143, DOI 10.1097/IAE.0000000000001832
   Baumal CR, 2016, DEV OPHTHALMOL, V56, P122, DOI 10.1159/000442803
   Bonini MA, 2015, JAMA OPHTHALMOL, V133, P899, DOI 10.1001/jamaophthalmol.2015.1320
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Chae B, 2015, INVEST OPHTH VIS SCI, V56, P5040, DOI 10.1167/iovs.15-16494
   Chen FK, 2016, CLIN EXP OPHTHALMOL, V44, P388, DOI 10.1111/ceo.12683
   Cohen SY, 2017, RETINA-J RET VIT DIS, V37, P1625, DOI 10.1097/IAE.0000000000001695
   Coscas G, 2016, DEV OPHTHALMOL, V56, P30, DOI 10.1159/000442774
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Dingerkus VLS, 2019, J OPHTHALMIC INFLAMM, V9, DOI 10.1186/s12348-019-0176-9
   Endersid C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210505
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   Giocanti-Auregan A, 2020, GRAEF ARCH CLIN EXP, V258, P537, DOI 10.1007/s00417-019-04581-y
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   Hollo Gabor, 2017, J Curr Glaucoma Pract, V11, P35, DOI 10.5005/jp-journals-10028-1219
   Hwang TS, 2015, RETINA-J RET VIT DIS, V35, P2371, DOI 10.1097/IAE.0000000000000716
   Jeong SY, 2017, BRIT J OPHTHALMOL, V101, P758, DOI 10.1136/bjophthalmol-2016-309144
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Johannesen SK, 2019, ACTA OPHTHALMOL, V97, P7, DOI 10.1111/aos.13859
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kashani AH, 2015, RETINA-J RET VIT DIS, V35, P2323, DOI 10.1097/IAE.0000000000000811
   Khurana RN., 2020, OPHTHALMOL RETINA
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   KWITEROVICH KA, 1991, OPHTHALMOLOGY, V98, P1139
   Le Rouic JF, 2020, J FR OPHTALMOL, V43, P397, DOI 10.1016/j.jfo.2019.09.013
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Moghimi S, 2019, ASIA-PAC J OPHTHALMO
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Mrejen S, 2019, RETINA-J RET VIT DIS, V39, P1973, DOI 10.1097/IAE.0000000000002244
   Mrejen S, 2015, J CLIN MED, V4, P1380, DOI 10.3390/jcm4071380
   Nakano Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216304
   Nikolopoulou E, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/6724818
   Pakzad-Vaezi K, 2017, BRIT J OPHTHALMOL, V101, P985, DOI 10.1136/bjophthalmol-2016-309200
   Patel R, 2018, INVEST OPHTH VIS SCI, V59, P4285, DOI 10.1167/iovs.18-24624
   Patel RC, 2018, OPHTHALMOL RETINA, V2, P816, DOI 10.1016/j.oret.2017.11.010
   Safi H, 2018, SURV OPHTHALMOL, V63, P601, DOI 10.1016/j.survophthal.2018.04.003
   Sambhav K, 2017, SURV OPHTHALMOL, V62, P838, DOI 10.1016/j.survophthal.2017.05.006
   Shaimova V A, 2013, Vestn Oftalmol, V129, P51
   Soomro T, 2018, EYE, V32, P662, DOI 10.1038/eye.2018.2
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2161, DOI 10.1097/IAE.0000000000000881
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Usman M, 2019, CUREUS, V11, DOI 10.7759/cureus.6485
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   Yarmohammadi A, 2016, INVEST OPHTH VIS SCI, V57, pOCT451, DOI 10.1167/iovs.15-18944
   Yeo JH, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091272
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
NR 48
TC 2
Z9 2
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PD SEP
PY 2021
VL 64
IS 5
BP 704
EP 712
DI 10.1159/000511265
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YY2JO
UT WOS:000754619600003
PM 33342974
OA Bronze
DA 2022-11-30
ER

PT J
AU Cho, BJ
   Heo, JW
   Kim, TW
   Ahn, J
   Chung, H
AF Cho, Bum-Joo
   Heo, Jang Won
   Kim, Tae Wan
   Ahn, Jeeyun
   Chung, Hum
TI Prevalence and Risk Factors of Age-Related Macular Degeneration in
   Korea: The Korea National Health and Nutrition Examination Survey
   2010-2011
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; prevalence; risk factor
ID GAMMA-GLUTAMYL-TRANSFERASE; ANGELES LATINO EYE; BEAVER DAM EYE;
   BEIJING-EYE; CARDIOVASCULAR RISK; ADULT-POPULATION; 5-YEAR INCIDENCE;
   POOLED FINDINGS; 3 CONTINENTS; MACULOPATHY
AB PURPOSE. To investigate the prevalence and risk factors of age-related macular degeneration (AMD) in the general Korean adult population.
   METHODS. The study involved a nationally representative Korean population from the 2010 to 2011 Korea National Health and Nutrition Examination Survey. A total of 7899 subjects >= 40 years old participated in health interviews, physical examinations, and ophthalmologic assessment including fundus photography.
   RESULTS. The overall prevalence of early AMD was estimated at 6.7% (95% confidence interval [CI], 6.1-7.4), and that of late AMD was estimated at 0.7% (95% CI, 0.5-0.9), which included 0.5% prevalence of neovascular AMD and 0.2% prevalence of geographic atrophy. The prevalence rates of early and late AMD among participants aged >= 65 years were 16.9% and 1.8%, respectively. Hyperopia was positively associated with the presence of any AMD type (odds ratio [OR], 1.08 for every 1 diopter increase). In multivariate analyses, significant risk factors for the presence of any AMD type were age, serum high-density lipoprotein (HDL) level, serum gamma-glutamyl transferase (GGT) level, and hepatitis B surface antigen (HBsAg) serum positivity (OR, 2.26). The risk factors for late AMD included age, ever-smoking history (OR, 2.18), serum GGT level, and systolic blood pressure.
   CONCLUSIONS. The prevalence of AMD in Korea was similar to the prevalence of pooled Asian and Western populations. Age and serum GGT level were strongly associated with both the presence of any AMD and late AMD. Additionally, serum HDL level, HBsAg serum positivity, ever-smoking history, and systolic blood pressure were identified as risk factors for AMD.
C1 [Cho, Bum-Joo; Heo, Jang Won; Kim, Tae Wan; Ahn, Jeeyun; Chung, Hum] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 110744, South Korea.
   [Cho, Bum-Joo; Heo, Jang Won; Chung, Hum] Seoul Natl Univ Hosp, Dept Ophthalmol, Seoul 110744, South Korea.
   [Kim, Tae Wan; Ahn, Jeeyun] Seoul Natl Univ, Boramae Med Ctr, Seoul Metropolitan Govt, Dept Ophthalmol, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University Hospital; Seoul National University (SNU); Seoul
   National University Hospital
RP Heo, JW (通讯作者)，Seoul Natl Univ, Coll Med, Dept Ophthalmol, 101 Daehang No, Seoul 110744, South Korea.
EM jangwonheo@gmail.com
OI Cho, Bum-Joo/0000-0002-0244-388X; Ahn, Jeeyun/0000-0001-9017-1652
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Butt AL, 2011, OPHTHALMOLOGY, V118, P1380, DOI 10.1016/j.ophtha.2010.11.007
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   DONNELLY CA, 1995, BRIT J OPHTHALMOL, V79, P1036, DOI 10.1136/bjo.79.11.1036
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   GOLDBERG DM, 1980, CRC CR REV CL LAB SC, V12, P1, DOI 10.3109/10408368009108725
   GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Korea National Statistical Office, PREL RES 2010 POP HO
   Lee DH, 2005, ATHEROSCLEROSIS, V178, P327, DOI 10.1016/j.atherosclerosis.2004.08.027
   Lee DS, 2007, ARTERIOSCL THROM VAS, V27, P127, DOI 10.1161/01.ATV.0000251993.20372.40
   Li YB, 2008, AM J OPHTHALMOL, V146, P329, DOI 10.1016/j.ajo.2008.04.015
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moss SE, 1998, OPHTHALMOLOGY, V105, P789, DOI 10.1016/S0161-6420(98)95016-3
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Piermarocchi S, 2011, OPHTHAL EPIDEMIOL, V18, P129, DOI 10.3109/09286586.2011.574334
   Roh MI, 2008, YONSEI MED J, V49, P931, DOI 10.3349/ymj.2008.49.6.931
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sarli B, 2013, CORONARY ARTERY DIS, V24, P298, DOI 10.1097/MCA.0b013e32835f301d
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Turgut O, 2006, MED HYPOTHESES, V67, P1060, DOI 10.1016/j.mehy.2006.04.010
   Turgut O, 2011, J ATHEROSCLER THROMB, V18, P177, DOI 10.5551/jat.6189
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Yoon Kyung-Chul, 2011, Korean J Ophthalmol, V25, P421, DOI 10.3341/kjo.2011.25.6.421
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
NR 41
TC 44
Z9 45
U1 0
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2014
VL 55
IS 2
BP 1101
EP 1108
DI 10.1167/iovs.13-13096
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AB6IU
UT WOS:000331891700057
PM 24204048
DA 2022-11-30
ER

PT J
AU Wei, TT
   Zhang, MY
   Zheng, XH
   Xie, TH
   Wang, WJ
   Zou, J
   Li, Y
   Li, HY
   Cai, JP
   Wang, XL
   Tan, JX
   Yang, XS
   Yao, Y
   Zhu, LP
AF Wei, Ting-Ting
   Zhang, Meng-Yuan
   Zheng, Xin-Hua
   Xie, Tian-Hua
   Wang, Wenjuan
   Zou, Jian
   Li, Yan
   Li, Hong-Ying
   Cai, Jiping
   Wang, Xiaolu
   Tan, Jianxin
   Yang, Xusheng
   Yao, Yong
   Zhu, Lingpeng
TI Interferon-gamma induces retinal pigment epithelial cell Ferroptosis by
   a JAK1-2/STAT1/SLC7A11 signaling pathway in Age-related Macular
   Degeneration
SO FEBS JOURNAL
LA English
DT Article
DE age-related macular degeneration; ferroptosis; IFN-gamma; SLC40A1;
   SLC7A11
ID IRON ACCUMULATION; DEATH; GLUTATHIONE; METABOLISM; INHIBITOR; DAMAGE
AB Retinal pigment epithelium (RPE) cell damage is implicated in the pathogenesis of age-related macular degeneration (AMD). An increase of interferon-gamma (IFN-gamma) levels was observed in patients with AMD, but whether inflammatory factors are causally related to AMD progression is unclear. Here, we demonstrate a direct causal relationship between IFN-gamma and RPE cell death. IFN-gamma induced human retinal pigment epithelial cell (ARPE-19) death accompanied by increases in Fe2+, reactive oxygen species, lipid peroxidation, and glutathione (GSH) depletion, which are main characteristics of ferroptosis. Mechanistically, IFN-gamma upregulates the level of intracellular Fe2+ through inhibiting Fe2+ efflux protein SLC40A1 and induces GSH depletion by blocking cystine/glutamate antiporter, System xc-. At the same time, treatment with IFN-gamma decreases the level of glutathione peroxidase 4 (GPx4), rendering the cells more sensitive to ferroptosis. JAK1/2 and STAT1 inhibitors could reverse the reduction of SLC7A11, GPx4 and GSH expression induced by IFN-gamma, indicating IFN-gamma induces ARPE-19 cell ferroptosis via activation of the JAK1-2/STAT1/SLC7A11 signaling pathway. The above results were largely confirmed in IFN-gamma-treated mice in vivo. Finally, we used sodium iodate (NaIO3)-induced retinal degeneration to further explore the role of ferroptosis in AMD in vivo. Consistent with the role of IFN-gamma, treatment with NaIO3 decreased SLC7A11, GPx4 and SLC40A1 expressions. NaIO3-induced RPE damage was accompanied by increased iron, lipid peroxidation products (4-hydroxynonenal, malondialdehyde), and GSH depletion, and ferroptosis inhibitors could reverse the above phenomenon. Taken together, our findings suggest that inhibiting ferroptosis or reducing IFN-gamma may serve as a promising target for AMD.
C1 [Wei, Ting-Ting; Wang, Wenjuan; Zou, Jian; Wang, Xiaolu; Tan, Jianxin; Yang, Xusheng; Zhu, Lingpeng] Nanjing Med Univ, Ctr Clin Res, Affiliated Wuxi Peoples Hosp, Wuxi, Jiangsu, Peoples R China.
   [Zhang, Meng-Yuan; Zheng, Xin-Hua; Xie, Tian-Hua; Li, Yan; Li, Hong-Ying; Cai, Jiping; Yao, Yong] Nanjing Med Univ, Dept Ophthalmol, Affiliated Wuxi Peoples Hosp, Wuxi, Jiangsu, Peoples R China.
   [Yao, Yong] Nanjing Med Univ, Dept Ophthalmol, Affiliated Wuxi Peoples Hosp 2, Wuxi, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University
RP Zhu, LP (通讯作者)，Nanjing Med Univ, Ctr Clin Res, Affiliated Wuxi Peoples Hosp, Wuxi, Jiangsu, Peoples R China.; Yao, Y (通讯作者)，Nanjing Med Univ, Dept Ophthalmol, Affiliated Wuxi Peoples Hosp, Wuxi, Jiangsu, Peoples R China.
EM yongyao@njmu.edu.cn; zhulingpeng@njmu.edu.cn
FU National Natural Science Foundation of China [82000912, 81770941];
   Natural Science Foundation of Jiangsu Province [BK20200163, BK20190149];
   Postdoctoral Science Foundation of China [2020M681668, 2020M681669];
   Youth Project of Wuxi Municipal Health Commission [Q202022, Q202042]
FX This project was supported by National Natural Science Foundation of
   China (82000912, 81770941); Natural Science Foundation of Jiangsu
   Province (BK20200163, BK20190149); Postdoctoral Science Foundation of
   China (2020M681668, 2020M681669); Youth Project of Wuxi Municipal Health
   Commission (Q202022, Q202042).
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   An PJ, 2019, ACS APPL MATER INTER, V11, P42988, DOI 10.1021/acsami.9b16124
   Bertrand RL, 2017, MED HYPOTHESES, V101, P69, DOI 10.1016/j.mehy.2017.02.017
   Bian H, 2019, FOOD CHEM, V296, P63, DOI 10.1016/j.foodchem.2019.05.183
   Carbone M, 2019, CELL DEATH DIFFER, V26, P2516, DOI [10.1038/s41418-019-0418, 10.1038/s41418-019-0418-2]
   Chen JJ, 2017, CELL PHYSIOL BIOCHEM, V44, P357, DOI 10.1159/000484907
   Chew Emily Y, 2013, Ophthalmology, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Doll S, 2017, NAT CHEM BIOL, V13, P91, DOI [10.1038/nchembio.2239, 10.1038/NCHEMBIO.2239]
   Fang XX, 2019, P NATL ACAD SCI USA, V116, P2672, DOI 10.1073/pnas.1821022116
   Gao MH, 2016, CELL RES, V26, P1021, DOI 10.1038/cr.2016.95
   Gao MH, 2015, MOL CELL, V59, P298, DOI 10.1016/j.molcel.2015.06.011
   Green DR, 2019, CELL, V177, P1094, DOI 10.1016/j.cell.2019.04.024
   Guellec J, 2019, FASEB J, V33, P14625, DOI 10.1096/fj.201901857R
   Hou W, 2016, AUTOPHAGY, V12, P1425, DOI 10.1080/15548627.2016.1187366
   Liu BH, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03520-2
   Liu Y, 2015, BIOL PHARM BULL, V38, P1234, DOI 10.1248/bpb.b15-00048
   Lu LL, 2009, ANTIOXID REDOX SIGN, V11, P715, DOI 10.1089/ARS.2008.2171
   Luu J, 2018, P NATL ACAD SCI USA, V115, P2866, DOI 10.1073/pnas.1721033115
   Masaldan S, 2018, REDOX BIOL, V14, P100, DOI 10.1016/j.redox.2017.08.015
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moriguchi M, 2018, INVEST OPHTH VIS SCI, V59, P3476, DOI 10.1167/iovs.17-23532
   Nishizawa H, 2020, J BIOL CHEM, V295, P69, DOI 10.1074/jbc.RA119.009548
   Nunez MT, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00048
   Otsuki Y, 2020, CANCER SCI, V111, P127, DOI 10.1111/cas.14224
   Park TJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2061-8
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Shao S, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav7561
   Shintoku R, 2017, CANCER SCI, V108, P2187, DOI 10.1111/cas.13380
   Shu WT, 2019, INVEST OPHTH VIS SCI, V60, P4378, DOI 10.1167/iovs.19-28250
   Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021
   Subramanian P, 2016, INVEST OPHTH VIS SCI, V57, P4581, DOI 10.1167/iovs.15-19039
   Sun Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0794-4
   Tang ZM, 2021, REDOX BIOL, V43, DOI 10.1016/j.redox.2021.101971
   Thulliez M, 2018, JAMA OPHTHALMOL, V136, P557, DOI 10.1001/jamaophthalmol.2018.0002
   Totsuka K, 2019, EXP EYE RES, V181, P316, DOI 10.1016/j.exer.2018.08.019
   Wang WM, 2019, NATURE, V569, P270, DOI 10.1038/s41586-019-1170-y
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang XF, 2020, J CELL PHYSIOL, V235, P3425, DOI 10.1002/jcp.29232
NR 38
TC 11
Z9 11
U1 8
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-464X
EI 1742-4658
J9 FEBS J
JI FEBS J.
PD APR
PY 2022
VL 289
IS 7
BP 1968
EP 1983
DI 10.1111/febs.16272
EA NOV 2021
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 0G5BH
UT WOS:000721021800001
PM 34741776
DA 2022-11-30
ER

PT J
AU Cho, HJ
   Kim, J
   Nah, SK
   Lee, J
   Kim, CG
   Kim, JW
AF Cho, Han Joo
   Kim, Jaemin
   Nah, Seung Kwan
   Lee, Jihyun
   Kim, Chul Gu
   Kim, Jong Woo
TI Nonexudative morphologic changes of neovascularization on optical
   coherence tomography angiography as predictive factors for exudative
   recurrence in age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization; Optical
   coherence tomography angiography; Vascular endothelial growth factor
ID CHOROIDAL NEOVASCULARIZATION; NATURAL-HISTORY; THERAPY; RANIBIZUMAB;
   AFLIBERCEPT
AB Purpose To evaluate morphologic changes of choroidal neovascularization (CNV) on optical coherence tomography angiography (OCTA) during the nonexudative period and to correlate the features and timing of recurrence in neovascular age-related macular degeneration. (AMD). Methods Two hundred thirty-eight eyes with type 1 CNV were retrospectively reviewed. For cases with exudative recurrence, OCTA images were tracked for analysis between the recurrences. Qualitative parameters of morphologic changes of CNV on OCTA, including tiny branching vessels, anastomotic loops, peripheral vascular arcade, and perilesional halo, were correlated with the features of exudative recurrence. Results Exudative recurrence was identified in 163 cases, and among them, nonexudative morphological changes in CNV were identified using OCTA in 45 cases. For the cases with nonexudative changes on OCTA, exudative recurrence eventually developed within 0.5-3.5 months (mean, 2.3 +/- 2.0 months) after identifying morphologic changes OCTA. The following changes in CNV were revealed on OCTA: tiny branching vessels in 53.3% (24/45) of cases, anastomotic loops in 40.0% (18/45), peripheral vascular arcades in 44.4% (20/45), and perilesional halo in 35.6% (16/45). Among the morphologic parameters, development of tiny branching vessels was significantly associated with early exudative recurrence (1.5 +/- 1.2 months, p = 0.019), higher incidence of intraretinal fluid (IRF) (p = 0.016), and subretinal or subretinal pigment epithelial hemorrhage (p = 0.023) at recurrence, compared with other morphologic changes. Conclusion Development of tiny branching vessels of CNV on OCTA during the nonexudative period was associated with early exudative recurrence, including IRF or hemorrhage. Identifying the nonexudative changes of CNV on OCTA might predict exudative recurrence and provide additional parameters for monitoring neovascular AMD.
C1 [Cho, Han Joo; Kim, Jaemin; Nah, Seung Kwan; Lee, Jihyun; Kim, Chul Gu; Kim, Jong Woo] Konyang Univ, Coll Med, Kims Eye Hosp, 156 4Ga Yeongdeungpo Dong, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Cho, HJ (通讯作者)，Konyang Univ, Coll Med, Kims Eye Hosp, 156 4Ga Yeongdeungpo Dong, Seoul, South Korea.
EM chojoo@kimeye.com
OI Cho, Han Joo/0000-0001-7336-5762
CR Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Bae K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55871-8
   Carnevali A, 2018, OPHTHALMOL RETINA, V2, P922, DOI 10.1016/j.oret.2018.02.002
   Chakravarthy U, 2020, EYE, V34, P2249, DOI 10.1038/s41433-020-0799-y
   Choi M, 2020, AM J OPHTHALMOL, V213, P109, DOI 10.1016/j.ajo.2020.01.012
   Coscas F, 2019, BRIT J OPHTHALMOL, V103, P1342, DOI 10.1136/bjophthalmol-2018-313065
   de Massougnes S, 2018, RETINA-J RET VIT DIS, V38, P717, DOI 10.1097/IAE.0000000000001613
   Dervenis N, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S106734
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Fauser S, 2016, BRIT J OPHTHALMOL, V100, P1494, DOI 10.1136/bjophthalmol-2015-308264
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Han JW, 2020, RETINA-J RET VIT DIS, V40, P1245, DOI 10.1097/IAE.0000000000002562
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kim JM, 2019, SEMIN OPHTHALMOL, V34, P168, DOI 10.1080/08820538.2019.1620791
   Madhusudhana KC, 2016, BRIT J OPHTHALMOL, V100, P1617, DOI 10.1136/bjophthalmol-2015-308077
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Miere A, 2019, RETINA-J RET VIT DIS, V39, P548, DOI 10.1097/IAE.0000000000001964
   Nakano Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216304
   Pilotto E, 2019, BRIT J OPHTHALMOL, V103, P67, DOI 10.1136/bjophthalmol-2017-311752
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Stewart MW, 2014, EXPERT REV CLIN PHAR, V7, P167, DOI 10.1586/17512433.2014.884458
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
NR 28
TC 0
Z9 0
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2022
VL 260
IS 3
BP 839
EP 848
DI 10.1007/s00417-021-05405-8
EA SEP 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZB5IP
UT WOS:000695378500001
PM 34515840
DA 2022-11-30
ER

PT J
AU Kaya, S
   Weigert, G
   Pemp, B
   Sacu, S
   Werkmeister, RM
   Dragostinoff, N
   Garhofer, G
   Schmidt-Erfurth, U
   Schmetterer, L
AF Kaya, Semira
   Weigert, Guenther
   Pemp, Berthold
   Sacu, Stefan
   Werkmeister, Rene Marcel
   Dragostinoff, Nikolaus
   Garhoefer, Gerhard
   Schmidt-Erfurth, Ursula
   Schmetterer, Leopold
TI Comparison of macular pigment in patients with age-related macular
   degeneration and healthy control subjects - a study using spectral
   fundus reflectance
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; fundus reflectance; macular pigment
   optical density; objective measurement
ID HETEROCHROMATIC FLICKER PHOTOMETRY; OPTICAL-DENSITY; LUTEIN
   SUPPLEMENTATION; RISK-FACTORS; IN-VIVO; EYE; CAROTENOIDS; POPULATION;
   MACULOPATHY; REFLECTOMETRY
AB Purpose: Previous studies have reported an age-dependent decline of macular pigment optical density (MPOD) as well as a relative lack of MPOD in age-related macular degeneration (AMD). Results are, however, strongly dependent on the technique used. In this study, we investigated the age dependence of MPOD using spectral fundus reflectance. In addition, we hypothesized that patients with AMD have a reduced MPOD as compared to healthy controls. Methods: A total of 85 healthy subjects and 96 patients with AMD were included in this study. The healthy control subjects showed a wide range of ages (mean, 51.6 years; range, 2179 years). Patients with AMD were significantly older (mean, 71.2 years; range, 5089 years). Spectral fundus reflectance of the fovea was measured in a 2.3 degrees detection field with a custom built fundus reflectometer. Calculation of MPOD was based on a previously published fundus reflectance model. Results: Patients with AMD showed a reduced MPOD (0.35 +/- 0.12) as compared to the healthy control group (0.39 +/- 0.12, p = 0.013 between groups). No age dependence of MPOD (r = -0.14, p = 0.19) was found in the healthy control group. In the AMD group, however, MPOD declined with age (r = -0.24, p = 0.019). Conclusions: This study indicates that MPOD is reduced in patients with AMD. In addition, the data of this study indicate that MPOD is age dependent in AMD patients, but not in healthy controls. Taken together with data indicating that lutein supplementation increases MPOD, this provides a rationale for supplementation of the macular pigments in patients with AMD, although long-term clinical outcome data are lacking.
C1 [Kaya, Semira; Pemp, Berthold; Garhoefer, Gerhard; Schmetterer, Leopold] Med Univ Vienna, Dept Clin Pharmacol, A-1090 Vienna, Austria.
   [Weigert, Guenther; Pemp, Berthold; Sacu, Stefan; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
   [Werkmeister, Rene Marcel; Dragostinoff, Nikolaus; Schmetterer, Leopold] Med Univ Vienna, Ctr Med Phys & Biomed Engn, A-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna; Medical
   University of Vienna
RP Schmetterer, L (通讯作者)，Med Univ Vienna, Dept Clin Pharmacol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM leopold.schmetterer@meduniw-ien.ac.at
OI Pemp, Berthold/0000-0002-0569-0229; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311; Dragostinoff, Nikolaus/0000-0001-9372-9084;
   Schmetterer, Leopold/0000-0002-7189-1707
FU Pharmaselect (Vienna, Austria)
FX Financial support from an unrestricted grant from Pharmaselect (Vienna,
   Austria) is gratefully acknowledged.
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Beatty S, 2008, INVEST OPHTH VIS SCI, V49, P843, DOI 10.1167/iovs.07-1276
   Berendschot TTJM, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3523370
   Berendschot TT, 2005, EXP EYE RES, V81, P602, DOI 10.1016/j.exer.2005.03.019
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Berendschot TTJM, 2004, ARCH BIOCHEM BIOPHYS, V430, P149, DOI 10.1016/j.abb.2004.04.029
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bernstein PS, 2010, VISION RES, V50, P716, DOI 10.1016/j.visres.2009.10.014
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Celentano JC, 2002, J NUTR, V132, p535S, DOI 10.1093/jn/132.3.535S
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Ciulla TA, 2004, AM J OPHTHALMOL, V138, P582, DOI 10.1016/j.ajo.2004.05.057
   de Kinkelder R, 2011, EYE, V25, P105, DOI 10.1038/eye.2010.164
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Fletcher AE, 2010, OPHTHALMIC RES, V44, P191, DOI 10.1159/000316476
   Gellermann W, 2004, J BIOMED OPT, V9, P75, DOI 10.1117/1.1628240
   Hagen S, 2010, ACTA OPHTHALMOL, V88, P207, DOI 10.1111/j.1755-3768.2008.01418.x
   Howells O, 2011, GRAEF ARCH CLIN EXP, V249, P315, DOI 10.1007/s00417-010-1577-5
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jahn C, 2005, GRAEF ARCH CLIN EXP, V243, P222, DOI 10.1007/s00417-004-0995-7
   Kanis MJ, 2007, GRAEF ARCH CLIN EXP, V245, P767, DOI 10.1007/s00417-006-0478-0
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Neelam K, 2005, INVEST OPHTH VIS SCI, V46, P1023, DOI 10.1167/iovs.04-1032
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   Nolan JM, 2007, INVEST OPHTH VIS SCI, V48, P571, DOI 10.1167/iovs.06-0864
   Sasamoto Y, 2011, INVEST OPHTH VIS SCI, V52, P927, DOI 10.1167/iovs.10-5664
   Schweitzer D, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3526358
   Solomon SD, 2009, RETINA-J RET VIT DIS, V29, P1080, DOI 10.1097/IAE.0b013e3181b1baeb
   Tsika C, 2011, ACTA OPHTHALMOL, V89, pE573, DOI 10.1111/j.1755-3768.2011.02170.x
   van de Kraats J, 2008, INVEST OPHTH VIS SCI, V49, P5568, DOI 10.1167/iovs.08-1939
   van der Veen RLP, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3275481
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Wenzel AJ, 2007, OPHTHAL PHYSL OPT, V27, P329, DOI 10.1111/j.1475-1313.2007.00495.x
   WERNER JS, 1987, VISION RES, V27, P257, DOI 10.1016/0042-6989(87)90188-X
   Wong TY, 2008, AM J OPHTHALMOL, V146, P656, DOI 10.1016/j.ajo.2008.07.048
   Wustemeyer H, 2003, GRAEF ARCH CLIN EXP, V241, P647, DOI 10.1007/s00417-003-0730-9
   Zagers NPA, 2002, APPL OPTICS, V41, P4686, DOI 10.1364/AO.41.004686
NR 43
TC 30
Z9 31
U1 0
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2012
VL 90
IS 5
BP e399
EP e403
DI 10.1111/j.1755-3768.2012.02423.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 980OV
UT WOS:000306903600012
PM 23035764
OA Bronze
DA 2022-11-30
ER

PT J
AU Chin-Yee, D
   Eck, T
   Fowler, S
   Hardi, A
   Apte, RS
AF Chin-Yee, David
   Eck, Thomas
   Fowler, Susan
   Hardi, Angela
   Apte, Rajendra S.
TI A systematic review of as needed versus treat and extend ranibizumab or
   bevacizumab treatment regimens for neovascular age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID TRIAL
AB Purpose To evaluate the relative efficacy of as needed versus treat and extend regimen for the treatment of neovascular age-related macular degeneration (AMD).
   Methods We conducted a systematic review of studies that evaluated the efficacy of as needed or treat and extend regimen for neovascular AMD by searching multiple databases up to December 2013. Included studies were selected based on study duration of no less than 12 months, availability of outcome data, treatment protocol for as needed groups or pro re nata (PRN) receiving bevacizumab or ranibizumab, and all studies with treat extend protocols following the 'inject and extend' regimen. The outcome data were pooled and analysed.
   Results 1046 peer reviewed articles meeting our initial search criteria were returned. After further review by two independent reviewers, 8 studies meeting treat and extend protocol and 62 studies meeting PRN protocol were included. The mean improvement in visual acuity in the PRN group was 5.4 ETDRS letters compared with 10.4 ETDRS letters in the treat and extend group. The PRN group received an average of 5.60 injections at 1 year compared with 8.09 in the treat and extend group. Central retinal thickness improved on average by 100.32 mu in the PRN group compared with 87.7 mu in the treat and extend group.
   Conclusions Though our study suggests superiority of the treat and extend regimen to PRN treatment in a 12-month period, this review demonstrates the need for randomised clinical trials to confirm our findings and to evaluate long-term efficacy outcomes with these regimens compared with monthly therapy.
C1 [Chin-Yee, David; Eck, Thomas; Apte, Rajendra S.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 South Euclid Ave,Box 8096, St Louis, MO 63110 USA.
   [Fowler, Susan; Hardi, Angela] Washington Univ, Sch Med, Becker Med Lib, St Louis, MO USA.
C3 Washington University (WUSTL); Washington University (WUSTL)
RP Apte, RS (通讯作者)，Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 South Euclid Ave,Box 8096, St Louis, MO 63110 USA.
EM apte@vision.wustl.edu
OI Hardi, Angela/0000-0001-5693-8979
CR Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
NR 12
TC 76
Z9 76
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2016
VL 100
IS 7
BP 914
EP 917
DI 10.1136/bjophthalmol-2015-306987
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DS4JI
UT WOS:000380747000008
PM 26516125
DA 2022-11-30
ER

PT J
AU Hakobyan, S
   Harris, CL
   Tortajada, A
   De Jorge, EG
   Garcia-Layana, A
   Fernandez-Robredo, P
   De Cordoba, SR
   Morgan, BP
AF Hakobyan, Svetlana
   Harris, Claire L.
   Tortajada, Agustin
   De Jorge, Elena Goicochea
   Garcia-Layana, Alfredo
   Fernandez-Robredo, Patricia
   De Cordoba, Santiago Rodriguez
   Morgan, B. Paul
TI Measurement of factor H variants in plasma using variant-specific
   monoclonal antibodies: Application to assessing risk of age-related
   macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; Y402H POLYMORPHISM; GENE
   POLYMORPHISM; NO ASSOCIATION; FACTOR-B; CFH; DRUSEN; MACULOPATHY;
   GENERATION
AB PURPOSE. The Y402H polymorphism in the complement regulator factor H (fH) is strongly associated with age-related macular degeneration (AMD) across diverse populations. Persons homozygous for histidine at this position have up to 12-fold greater risk for AMD than those homozygous for tyrosine. Knowledge of fH-Y402H status is, therefore, valuable in predicting risk and focusing preventive measures in the elderly. This knowledge requires genetic analysis, which is unavailable in most laboratories and which provides no information about the levels of fH protein, a putative linked determinant of disease risk.
   METHODS. The authors describe novel monoclonal antibodies that distinguish the two fH allelic variants in plasma. ELISA with these antibodies not only reliably identifies the fH-Y402H status, confirmed by genotyping, but also quantifies the concentration of total fH and the fH-Y402 and fH-H402 variants.
   RESULTS. In young adult control subjects, mean fH concentration was 233 mg/L. In elderly control subjects, mean fH concentration was 269 mg/L, whereas in a matching AMD cohort, mean fH concentration was 288 mg/L. Total fH concentration was similar in each subgroup of young and elderly control subjects; however, in the AMD group, fH concentration was significantly higher in the heterozygous subgroup. Measurement of the two variants in this subgroup showed that both were elevated to a similar degree.
   CONCLUSIONS. The novel monoclonal antibody MBI-7 was used to develop a robust assay for measurement of fH and the variants in plasma. The simplicity of the assay means that it may be used by any clinical laboratory to identify polymorphic status and to quantify plasma levels in persons at risk for AMD.
C1 [Hakobyan, Svetlana; Harris, Claire L.; Morgan, B. Paul] Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales.
   [Tortajada, Agustin; De Jorge, Elena Goicochea; De Cordoba, Santiago Rodriguez] Ctr Invest Biol, Dept Mol & Cellular Physiopathol, Madrid, Spain.
   [Tortajada, Agustin; De Jorge, Elena Goicochea; De Cordoba, Santiago Rodriguez] Ctr Invest Biomed Red De Enfermedades Raras, Madrid, Spain.
   [Garcia-Layana, Alfredo; Fernandez-Robredo, Patricia] Univ Navarra, Univ Clin, Dept Ophthalmol, E-31080 Pamplona, Spain.
C3 Cardiff University; Consejo Superior de Investigaciones Cientificas
   (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); CIBER -
   Centro de Investigacion Biomedica en Red; CIBERER; University of Navarra
RP Morgan, BP (通讯作者)，Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Henry Wellcome Bldg,Heath Pk Way, Cardiff CF14 4XN, S Glam, Wales.
EM morganbp@cardiff.ac.uk
RI de Cordoba, Santiago Rodriguez/K-6727-2014; Tortajada,
   Agustín/H-2857-2015; Goicoechea De Jorge, Elena/L-4580-2016
OI de Cordoba, Santiago Rodriguez/0000-0001-6401-1874; Tortajada,
   Agustín/0000-0002-2131-2594; Goicoechea De Jorge,
   Elena/0000-0002-4978-2483; Morgan, Paul/0000-0003-4075-7676
FU Multiple Sclerosis Society [884] Funding Source: Medline; Wellcome Trust
   [068590, 068823] Funding Source: Medline
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Biro A, 2007, IMMUNOLOGY, V121, P40, DOI 10.1111/j.1365-2567.2007.02535.x
   Botto M, 1993, Int Rev Immunol, V10, P37, DOI 10.3109/08830189309051170
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   DEVITO LD, 1993, HUM IMMUNOL, V37, P165, DOI 10.1016/0198-8859(93)90182-Z
   DISCIPIO RG, 2000, COMPLEMENT FACTS BOO, P168
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Fernando AN, 2007, J MOL BIOL, V368, P564, DOI 10.1016/j.jmb.2007.02.038
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harris CL, 2003, J BIOL CHEM, V278, P36068, DOI 10.1074/jbc.M306351200
   Harris CL, 2002, CLIN EXP IMMUNOL, V129, P198, DOI 10.1046/j.1365-2249.2002.01924.x
   Harris CL, 2002, J IMMUNOL METHODS, V268, P245, DOI 10.1016/S0022-1759(02)00207-7
   Hayashi Y, 2004, J PHARMACEUT BIOMED, V36, P225, DOI 10.1016/j.jpba.2004.05.017
   Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200
   HOYLAERTS MF, 1991, EUR J BIOCHEM, V202, P605, DOI 10.1111/j.1432-1033.1991.tb16414.x
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   MANI JC, 1994, MOL IMMUNOL, V31, P439, DOI 10.1016/0161-5890(94)90063-9
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Prosser BE, 2007, ACTA CRYSTALLOGR F, V63, P480, DOI 10.1107/S1744309107020052
   Reis ES, 2006, SCAND J IMMUNOL, V63, P155, DOI 10.1111/j.1365-3083.2006.01729.x
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   SIM E, 1983, BIOSCIENCE REP, V3, P1119, DOI 10.1007/BF01120205
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   STANKER LH, 1986, J IMMUNOL, V136, P4174
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
NR 47
TC 72
Z9 74
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2008
VL 49
IS 5
BP 1983
EP 1990
DI 10.1167/iovs.07-1523
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 292UH
UT WOS:000255291100032
PM 18436830
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Michalewski, J
   Nawrocki, J
   Izdebski, B
   Michalewska, Z
AF Michalewski, Janusz
   Nawrocki, Jerzy
   Izdebski, Bartosz
   Michalewska, Zofia
TI Morphological changes in spectral domain optical coherence tomography
   guided bevacizumab injections in wet age-related macular degeneration,
   12-months results
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age- related macular degeneration; anti-Vascular endothelial growth
   factor; Avastin; bevacizumab; neovascular age-related macular
   degeneration; spectral domain optical coherence tomography; spectral
   domain optical coherence tomography; wet age-related macular
   degeneration
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; RETINAL-PIGMENT EPITHELIUM;
   GROWTH-FACTOR THERAPY; ANTI-VEGF THERAPY; TERM-FOLLOW-UP; VISUAL-ACUITY;
   RANIBIZUMAB; EXPRESSION; CELLS
AB Purpose: To describe retinal changes during Spectral Domain Optical Coherence Tomography (SD-OCT) guided bevacizumab treatment for neovascular age-related macular degeneration (AMD). Settings and Design: Single center observational study. Materials and Methods: We confirmed wet AMD in 47 eyes of 45 patients by fluorescein angiography and SD-OCT. After bevacizumab injection, we examined the patients at 4-week intervals. During each follow-up control, we performed SD-OCT and a complete ophthalmic examination. Criteria for reinjection were visual acuity loss of more than five ETDRS letters, and/or increase of central retinal thickness, sub-retinal fluid, intra-retinal fluid, pigment epithelium detachment. If reinjection criteria were not met, we advised the patient to return in 4 weeks' time for the next scheduled follow-up. We used 3-dimensional SD-OCT to measure photoreceptor defects and sub-retinal fibrosis. The main efficacy endpoints were the SD-OCT measurements of the size of photoreceptor defects, the size of external membrane defects and the central retinal thickness. Results: Over the 12 months study period, the percentage of scans in 3-D imaging mode showing visible defects of the junction between inner and outer segments of photoreceptors increased from 38.96 to 53.8%. The percentage of scans in 3-D imaging mode with visible sub-retinal fibrosis increased from 33 to 52% and mean central retinal thickness decreased from 333 mu m (96-900 mu m) to 272 mu m (P = 0.011). Conclusion: In long-term anti-Vascular endothelial growth factor (VEGF) treatment for neovascular AMD, photoreceptor defects and fibrosis progress despite a decrease in central retinal thickness and improvements in visual acuity. We would encourage further discussion as to whether this is the natural course of the disease or a result of the treatment.
C1 [Michalewski, Janusz; Nawrocki, Jerzy; Michalewska, Zofia] Ophthalm Clin Jasne Blonia, Dept Ophthalmol, Lodz, Poland.
   [Michalewski, Janusz; Nawrocki, Jerzy; Izdebski, Bartosz; Michalewska, Zofia] III Municipal Hosp K Jonscher, Lodz, Poland.
RP Michalewska, Z (通讯作者)，Tkacka 28b, PL-90156 Lodz, Poland.
EM zosia_n@yahoo.com
OI Michalewski, Janusz/0000-0002-1516-6703; Nawrocka, Zofia
   Anna/0000-0001-8376-9218
CR Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Dunavoelgyi R, 2012, RETINA-J RET VIT DIS, V32, P1471, DOI 10.1097/IAE.0b013e318236e805
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Helzner J., 2012, RETIN PHYS, V9, P8
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Klettner A, 2010, GRAEF ARCH CLIN EXP, V248, P819, DOI 10.1007/s00417-010-1317-x
   Klettner AK, 2009, GRAEF ARCH CLIN EXP, V247, P1601, DOI 10.1007/s00417-009-1136-0
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P435, DOI 10.1007/s00417-012-2034-4
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P1, DOI 10.1007/s00417-012-2022-8
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Sharma RK, 2009, ACTA OPHTHALMOL, V87, P618, DOI 10.1111/j.1755-3768.2008.01410.x
   Spitzer MS, 2007, GRAEF ARCH CLIN EXP, V245, P1837, DOI 10.1007/s00417-007-0568-7
   Tao Y, 2010, J OCUL PHARMACOL TH, V26, P79, DOI 10.1089/jop.2009.0095
   Thaler S, 2010, ACTA OPHTHALMOL, V88, pE170, DOI 10.1111/j.1755-3768.2010.01927.x
   Witkin AJ, 2009, OPHTHALMOLOGY, V116, P956, DOI 10.1016/j.ophtha.2008.12.018
   Wu L, 2009, JPN J OPHTHALMOL, V53, P125, DOI 10.1007/s10384-008-0622-y
   You JY, 2012, CURR EYE RES, V37, P438, DOI 10.3109/02713683.2011.647227
   Zayit-Soudry S, 2010, RETINA-J RET VIT DIS, V30, P671, DOI 10.1097/IAE.0b013e3181c0858c
NR 33
TC 7
Z9 7
U1 0
U2 5
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD MAY
PY 2014
VL 62
IS 5
BP 554
EP 560
DI 10.4103/0301-4738.133485
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AZ9WG
UT WOS:000348564100006
PM 24881600
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Keenan, TDL
   Kelly, SP
   Sallam, A
   Mohamed, Q
   Tufail, A
   Johnston, RL
AF Keenan, Tiarnan D. L.
   Kelly, Simon P.
   Sallam, Ahmed
   Mohamed, Quresh
   Tufail, Adnan
   Johnston, Robert L.
TI Incidence and baseline clinical characteristics of treated neovascular
   age-related macular degeneration in a well-defined region of the UK
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Macula; Treatment Surgery; Neovascularisation; Epidemiology; Public
   health
ID VISUAL IMPAIRMENT; RANIBIZUMAB TREATMENT; PREVALENCE; BLINDNESS;
   ENGLAND; TRENDS; WALES; TIME
AB Aims
   To analyse the incidence and baseline clinical characteristics of patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal anti-vascular endothelial growth factor (VEGF) injections in a defined UK region.
   Methods
   A standardised dataset was collected prospectively using an electronic medical record (EMR) system from 1 January 2008 to 21 June 2012 for all patients living in Gloucestershire who received intravitreal anti-VEGF injections for nAMD.
   Results
   Over the study period, 1207 eyes from 1033 patients began intravitreal anti-VEGF injections for nAMD. The annual incidence in the years after National Institute for Health and Care Excellence (NICE) technology appraisal 155 implementation was stable at 120 (95% CI 110 to 138) eyes or 100 (89 to 115) people per 100000 population. The most common indication was occult choroidal neovascularisation (51%). Median baseline visual acuity (VA) was significantly higher for second treated than first treated eyes (66 and 56 letters, respectively; p<0.0001). Median baseline VA of fellow eyes increased from 47 (2008) to 67 letters (2012; p<0.005). The proportion of patients with baseline VA in the better eye 70 letters increased from 27.6% (2008) to 51.4% (2012; p<0.0001), while the proportion eligible at baseline for full or partial certificate of visual impairment decreased from 13.8% (2008) to 7.1% (2012; p<0.05).
   Conclusions
   The incidence of patients undergoing anti-VEGF therapy for nAMD increased substantially following NICE approval of ranibizumab (August 2008), and has been stable since 2009. This equates to an annual UK incidence of 26850 (21320 to 32440) eyes, similar to NICE estimates. Patients eligible for blindness certification before treatment decreased by half from 2008-2012. Prospective data collection using an EMR system is invaluable for efficient monitoring of real-world clinical care.
C1 [Keenan, Tiarnan D. L.] Univ Manchester, Inst Human Dev, Manchester, Lancs, England.
   [Keenan, Tiarnan D. L.] Manchester Royal Eye Hosp, Manchester M13 9WH, Lancs, England.
   [Kelly, Simon P.] Royal Bolton Hosp NHS Fdn Trust, Dept Ophthalmol, Bolton, England.
   [Sallam, Ahmed; Mohamed, Quresh; Johnston, Robert L.] Gloucestershire Hosp NHS Fdn Trust, Dept Ophthalmol, Cheltenham GL53 7AN, Glos, England.
   [Tufail, Adnan] Moorfields Eye Hosp NHS Fdn Trust, London, England.
C3 University of Manchester; Manchester Royal Eye Hospital; Royal Bolton
   Hospital; Gloucestershire Hospitals NHS Foundation Trust; University of
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust
RP Johnston, RL (通讯作者)，Gloucestershire Hosp NHS Fdn Trust, Cheltenham Gen Hosp, Dept Ophthalmol, Sandford Rd, Cheltenham GL53 7AN, Glos, England.
EM Rob.Johnston@glos.nhs.uk
RI Sallam, Ahmed/A-4791-2014
OI Sallam, Ahmed/0000-0001-7207-6782; Tufail, Adnan/0000-0001-6131-7640
FU Fight For Sight; Fight for Sight [1865/66] Funding Source: researchfish
FX TDLK is funded by Fight For Sight through a Clinical Fellowship. The
   views expressed are those of the authors and not necessarily the funding
   body. The researchers are independent of the funders, and the
   researchers had access to all of the data.
CR Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Bunce C, 2008, EYE, V22, P905, DOI 10.1038/sj.eye.6702767
   Cackett P, 2013, INVEST OPHTHALMOL VI
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Fletcher A, 2001, LOW VIS SERV PEOPL A
   Javitt J, 2005, EYE, V19, P727, DOI 10.1038/sj.eye.6701645
   Keenan TDL, 2012, BRIT J OPHTHALMOL, V96, P413, DOI 10.1136/bjophthalmol-2011-300338
   Kelly SP, 2011, EYE, V25, P710, DOI 10.1038/eye.2011.89
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   National Institute for Health and Clinical Excellence, 2008, RAN PEG TREATM AG RE
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Ross AH, 2013, EYE, V27, P56, DOI 10.1038/eye.2012.225
   Rostron E, 2012, EYE, V26, P933, DOI 10.1038/eye.2012.61
   Royal College of Ophthalmology statement, 2009, MAX CAP AMD SERV
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   The Royal College of Ophthalmologists, 2007, COMM CONT AMD SERV G
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
NR 22
TC 26
Z9 26
U1 0
U2 12
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2013
VL 97
IS 9
BP 1168
EP 1172
DI 10.1136/bjophthalmol-2013-303233
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 201SO
UT WOS:000323163500018
PM 23813420
DA 2022-11-30
ER

PT J
AU Chen, SJ
   Lin, TB
   Peng, HY
   Liu, HJ
   Lee, AS
   Lin, CH
   Tseng, KW
AF Chen, Shiu-Jau
   Lin, Tzer-Bin
   Peng, Hsien-Yu
   Liu, Hsiang-Jui
   Lee, An-Sheng
   Lin, Cheng-Hsien
   Tseng, Kuang-Wen
TI Cytoprotective Potential of Fucoxanthin in Oxidative Stress-Induced
   Age-Related Macular Degeneration and Retinal Pigment Epithelial Cell
   Senescence In Vivo and In Vitro
SO MARINE DRUGS
LA English
DT Article
DE fucoxanthin; retinal pigment epithelium; premature senescence;
   age-related macular degeneration
ID JUNCTIONS
AB Oxidative stress is identified as a major inducer of retinal pigment epithelium (RPE) cell dysregulation and is associated with age-related macular degeneration (AMD). The protection of RPE disorders plays an essential role in the pathological progress of retinal degeneration diseases. The pharmacological functions of fucoxanthin, a characteristic carotenoid, including anti-inflammatory and antioxidant properties, may ameliorate an outstanding bioactivity against premature senescence and cellular dysfunction. This study demonstrates that fucoxanthin protects RPE cells from oxidative stress-induced premature senescence and decreased photoreceptor cell loss in a sodium iodate-induced AMD animal model. Similarly, oxidative stress induced by hydrogen peroxide, nuclear phosphorylated histone (gamma H2AX) deposition and premature senescence-associated beta-galactosidase staining were inhibited by fucoxanthin pretreatment in a human RPE cell line, ARPE-19 cells. Results reveal that fucoxanthin treatment significantly inhibited reactive oxygen species (ROS) generation, reduced malondialdehyde (MDA) concentrations and increased the mitochondrial metabolic rate in oxidative stress-induced RPE cell damage. Moreover, atrophy of apical microvilli was inhibited in cells treated with fucoxanthin after oxidative stress. During aging, the RPE undergoes well-characterized pathological changes, including amyloid beta (A beta) deposition, beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1) expression and tight junction disruption, which were also reduced in fucoxanthin-treated groups by immunofluorescence. Altogether, pretreatment with fucoxanthin may protect against premature senescence and cellular dysfunction in retinal cells by oxidative stress in experimental AMD animal and human RPE cell models.
C1 [Chen, Shiu-Jau] Mackay Mem Hosp, Dept Neurosurg, Taipei 10449, Taiwan.
   [Chen, Shiu-Jau; Peng, Hsien-Yu; Lee, An-Sheng; Lin, Cheng-Hsien; Tseng, Kuang-Wen] Mackay Med Coll, Dept Med, New Taipei 25245, Taiwan.
   [Lin, Tzer-Bin] Taipei Med Univ, Coll Med, Sch Med, Dept Physiol, Taipei 11049, Taiwan.
   [Liu, Hsiang-Jui] Mackay Jr Coll Med Nursing & Management, Dept Optometry, New Taipei 11260, Taiwan.
C3 Mackay Memorial Hospital; Mackay Medical College; Taipei Medical
   University; Mackay Junior College of Medicine, Nursing & Management
RP Tseng, KW (通讯作者)，Mackay Med Coll, Dept Med, New Taipei 25245, Taiwan.
EM T149@mmc.edu.tw; tblin2@tmu.edu.tw; hypeng@mmc.edu.tw;
   s458@eip.mkc.edu.tw; anshenglee@mmc.edu.tw; davidlin@mmc.edu.tw;
   tseng@mmc.edu.tw
OI Chen, Shiu-Jau/0000-0002-4263-527X; Lee, An-sheng/0000-0001-8176-3269
FU Ministry of Science and Technology, Taiwan [MOST 108-2320-B-715-003-];
   Mackay Medical College, Taiwan [1081H03, 1091B05]; Mackay Memorial
   Hospital, Taiwan [MMH-MM-10903]
FX This work was supported by grants to K.-W.T. (MOST 108-2320-B-715-003-)
   from the Ministry of Science and Technology, Taiwan, and (1081H03 and
   1091B05) from Mackay Medical College, Taiwan, and to S.-J.C.
   (MMH-MM-10903) from Mackay Memorial Hospital, Taiwan.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   ANDERSON DH, 1979, J ULTRA MOL STRUCT R, V67, P23, DOI 10.1016/S0022-5320(79)80014-3
   Aryan Nona, 2016, Open Neurol J, V10, P83, DOI 10.2174/1874205X01610010083
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Chen SJ, 2019, MAR DRUGS, V17, DOI 10.3390/md17030152
   Chen SJ, 2016, MAR DRUGS, V14, DOI 10.3390/md14010013
   Chen WW, 2019, J ENVIRON PATHOL TOX, V38, P239, DOI 10.1615/JEnvironPatholToxicolOncol.2019030301
   Chen YC, 2018, J ETHNOPHARMACOL, V224, P391, DOI 10.1016/j.jep.2018.06.023
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   de Smet MD, 2010, DEV OPHTHALMOL, V47, P136, DOI 10.1159/000320077
   Dentchev T, 2003, MOL VIS, V9, P184
   Di Mambro VM, 2003, J PHARMACEUT BIOMED, V32, P97, DOI 10.1016/S0731-7085(03)00055-4
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gu XR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038673
   Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Imai S, 2010, EUR J PHARMACOL, V642, P77, DOI 10.1016/j.ejphar.2010.05.057
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jones DP, 2015, REDOX BIOL, V5, P71, DOI 10.1016/j.redox.2015.03.004
   Karpinski TM, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8080239
   Li RC, 2019, FREE RADICAL BIO MED, V135, P116, DOI 10.1016/j.freeradbiomed.2019.02.005
   Lu ZG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216808
   Lynn SA, 2017, NEURAL REGEN RES, V12, P538, DOI 10.4103/1673-5374.205083
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Mao YY, 2016, ADV EXP MED BIOL, V854, P717, DOI 10.1007/978-3-319-17121-0_95
   Masuda N, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1076-3
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Miyoshi J, 2008, BBA-BIOMEMBRANES, V1778, P670, DOI 10.1016/j.bbamem.2007.12.014
   Morandi AC, 2014, EUR J NUTR, V53, P779, DOI 10.1007/s00394-013-0582-y
   Nomura T, 1997, BIOCHEM MOL BIOL INT, V42, P361
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Prasad T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03397-2
   Rottenberg H, 2017, AGING CELL, V16, P943, DOI 10.1111/acel.12650
   Shamsi FA, 2007, CURR EYE RES, V32, P575, DOI 10.1080/02713680701363833
   Shen L, 2012, ANN NY ACAD SCI, V1258, P9, DOI 10.1111/j.1749-6632.2012.06613.x
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Sun JR, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.502
   Tan CP, 2014, INFLAMMATION, V37, P443, DOI 10.1007/s10753-013-9757-1
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Vinores SA, 1999, DOC OPHTHALMOL, V97, P217, DOI 10.1023/A:1002136712070
   Wang AL, 2008, MOL VIS, V14, P644
   Wang SB, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.588050
   WEBSTER SH, 1957, J PHARMACOL EXP THER, V120, P171
   Xia CH, 2015, SCI REP-UK, V5, DOI 10.1038/srep09358
   Yang YP, 2014, INVEST OPHTH VIS SCI, V55, P1696, DOI 10.1167/iovs.13-12477
   Yin LL, 2012, AM J PATHOL, V180, P541, DOI 10.1016/j.ajpath.2011.10.015
NR 50
TC 9
Z9 9
U1 4
U2 21
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-3397
J9 MAR DRUGS
JI Mar. Drugs
PD FEB
PY 2021
VL 19
IS 2
AR 114
DI 10.3390/md19020114
PG 15
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA QN8GK
UT WOS:000622690500001
PM 33670685
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Khanani, AM
   Patel, SS
   Ferrone, PJ
   Osborne, A
   Sahni, J
   Grzeschik, S
   Basu, K
   Ehrlich, JS
   Haskova, Z
   Dugel, PU
AF Khanani, Arshad M.
   Patel, Sunil S.
   Ferrone, Philip J.
   Osborne, Aaron
   Sahni, Jayashree
   Grzeschik, Susanna
   Basu, Karen
   Ehrlich, Jason S.
   Haskova, Zdenka
   Dugel, Pravin U.
TI Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs
   Ranibizumab in Neovascular Age-Related Macular Degeneration The STAIRWAY
   Phase 2 Randomized Clinical Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID GROWTH-FACTOR THERAPY; VISUAL-ACUITY; OUTCOMES; AFLIBERCEPT
AB Importance Faricimab neutralizes angiopoietin-2 and vascular endothelial growth factor A via both simultaneous and independent binding.
   Objective To evaluate extended dosing with faricimab, the first bispecific antibody designed for intraocular use, in patients with neovascular age-related macular degeneration.
   Design, Setting, and Participants This phase 2 randomized clinical trial was a 52-week multicenter, active comparator-controlled, parallel-group study. Study participants were enrolled in 25 sites in the US from January and March 2017 with treatment-naive choroidal neovascularization secondary to neovascular age-related macular degeneration and best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study letter score of 73 (approximate Snellen equivalent, 20/40) to 24 (approximate Snellen equivalent, 20/320). Analysis began January 2017 and ended March 2018.
   Interventions Participants were randomized 1:2:2 to receive intravitreal ranibizumab, 0.5 mg, every 4 weeks or faricimab, 6.0 mg, every 12 or 16 weeks. Participants in the faricimab arms initially received 4 monthly injections of faricimab. No rescue injections were allowed. Participants randomized to dosing every 16 weeks were assessed for disease activity at week 24 using prespecified criteria. Those with no active disease continued dosing every 16 weeks through trial end; participants with disease activity continued received dosing every 12 weeks.
   Main Outcomes and Measures Mean change in BCVA from baseline at week 40. Results Of 76 participants enrolled (mean [SD] age, 78.5 [8.5] years; age range, 56-94 years; 41 women [58%]; 69 white [97%]), 16 (21.0%) were randomized to ranibizumab every 4 weeks, 29 (38.2%) to faricimab every 12 weeks, and 31 (40.8%) to faricimab every 16 weeks. At week 24, 12 weeks after their last initiation injection, 65% (36 of 55) of all faricimab-treated participants had no disease activity. At week 40, adjusted mean BCVA gains from baseline (Early Treatment Diabetic Retinopathy Study letters) were +11.4 (80% CI, 7.8-15.0), +9.3 (80% CI, 6.4-12.3), and +12.5 (80% CI, 9.9-15.1) for the ranibizumab every 4 weeks, faricimab every 12 weeks, and faricimab every 16 weeks arms, respectively. Participants received a mean (SD) total of 12.9 (0.25), 6.7 (0.91), and 6.2 (093) injections, for the ranibizumab every 4 weeks, faricimab every 12 weeks, and faricimab every 16 weeks arms, respectively, through week 52. The secondary BCVA and anatomical imaging end points supported the primary end point and were comparable with ranibizumab every 4 weeks. No new or unexpected safety signals were identified.
   Conclusions and Relevance At week 52, faricimab dosing every 16 weeks and every 12 weeks resulted in maintenance of initial vision and anatomic improvements comparable with monthly ranibizumab. These results suggest a role for simultaneous neutralization of angiopoietin-2 and vascular endothelial growth factor A in providing sustained efficacy through extended durability, warranting further investigation.
C1 [Khanani, Arshad M.] Sierra Eye Associates, 950 Ryland St, Reno, NV 89502 USA.
   [Khanani, Arshad M.] Univ Nevada, Reno Sch Med, Reno, NV 89557 USA.
   [Patel, Sunil S.] West Texas Retina Consultants, Abilene, TX USA.
   [Ferrone, Philip J.] Long Isl & Queens Vitreoretinal Consultants PC, Great Neck, NY USA.
   [Osborne, Aaron; Grzeschik, Susanna; Basu, Karen; Ehrlich, Jason S.; Haskova, Zdenka] Genentech Inc, San Francisco, CA 94080 USA.
   [Osborne, Aaron] Adverum Biotechnol Inc, Menlo Pk, CA USA.
   [Sahni, Jayashree] F Hoffmann La Roche, Roche Pharma Res & Early Dev, Roche Innovat Ctr Basel, Basel, Switzerland.
   [Basu, Karen] Roche Prod Ireland, Dublin, Ireland.
   [Ehrlich, Jason S.] Kodiak Sci Inc, Palo Alto, CA USA.
   [Dugel, Pravin U.] Retinal Consultants Arizona, Phoenix, AZ USA.
   [Dugel, Pravin U.] Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, Los Angeles, CA 90007 USA.
   [Dugel, Pravin U.] IVERIC Bio, New York, NY USA.
C3 Nevada System of Higher Education (NSHE); University of Nevada Reno;
   Roche Holding; Genentech; Roche Holding; University of Southern
   California
RP Khanani, AM (通讯作者)，Sierra Eye Associates, 950 Ryland St, Reno, NV 89502 USA.
EM arshad.khanani@gmail.com
FU F. Hoffmann-La Roche
FX F. Hoffmann-La Roche provided financial support for the study.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   American Academy of Ophthalmology, 2019, AG REL MAC DEGR PPP
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Chakravarthy U, 2017, OPHTHALMOL RETINA, V1, P474, DOI 10.1016/j.oret.2017.03.003
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P645, DOI 10.1016/j.oret.2018.01.006
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Foxton RH, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201810204
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Ozturk M, 2018, CLIN EXP OPHTHALMOL, V46, P407, DOI 10.1111/ceo.13085
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Regula JT, 2019, EMBO MOL MED, V11
   Saharinen P, 2017, NAT REV DRUG DISCOV, V16, P635, DOI 10.1038/nrd.2016.278
   Sahni J, 2020, JAMA OPHTHALMOL, V138, P955, DOI 10.1001/jamaophthalmol.2020.2685
   Sahni J, 2019, OPHTHALMOLOGY, V126, P1155, DOI 10.1016/j.ophtha.2019.03.023
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   US Food and Drug Administration, REG GOOD CLIN PRACT
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
   Vukicevic M, 2016, EYE, V30, P413, DOI 10.1038/eye.2015.235
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
NR 29
TC 48
Z9 49
U1 1
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD SEP
PY 2020
VL 138
IS 9
BP 964
EP 972
DI 10.1001/jamaophthalmol.2020.2699
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NS2LN
UT WOS:000572098900006
PM 32729897
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Auer, C
   Tran, VT
   Herbort, CR
AF Auer, C
   Tran, VT
   Herbort, CR
TI Transpupillary thermotherapy for occult subfoveal neovessels in
   age-related macular degeneration: importance of patient pigmentation for
   the determination of laser settings
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE transpupillary thermotherapy; occult subfoveal neovessels; pigmentation;
   chorioretinal atrophy
ID CHOROIDAL NEOVASCULARIZATION
AB Background: Presently the indication for transpupillary thermotherapy (TIT) is the treatment of retrofoveal occult subretinal neovascular membranes (OSRNM) for which PDT (photodynamic therapy) has a limited effect. The diode laser power settings given by the manufacturer (Iridex Co, Mountain View, California) have to be modulated according to several criteria including patient pigmentation. The purpose here was to report on a group of patients that presented chorioretinal atrophy after TTT. Methods: Thirty-eight eyes of 37 patients with OSRNM due to age-related macular degeneration underwent TTT, Indications to treat were diffuse exudative membranes, limited subfoveal OSRNM with a visual acuity of less than 0.4, or a drop of visual acuity of 3 Snellen lines or more since the previous examination. Dual fluorescein and indocyanine green angiography were used for angiographic follow-up. Treatment was performed according to the manufacturer's parameters. The group of patients that presented chorioretinal atrophy after TIT was analysed in this study Results: Five patients presented a limited or spot-size related post-TTT chorioretinal atrophy. Pre-laser visual acuity was 0.34+/-0.13 and post-TTT visual acuity was 0.25+/-0.15. The OSRNM had disappeared in all cases. The common denominator in these patients was that they were white haired but upon questioning all happened to be dark-haired in their youth. Conclusions: Evolution towards atrophy can occur after TTT and probably depends on several factors, We showed that pigmentation is a parameter to be evaluated carefully before TIT and that laser power settings should progressively be diminished with increasing patient pigmentation. In white haired persons the original pigmentary status should be part of the patient history.
C1 La Source Eye Ctr, CH-1004 Lausanne, Switzerland.
   Univ Lausanne, Lausanne, Switzerland.
C3 University of Lausanne
RP Herbort, CR (通讯作者)，La Source Eye Ctr, 2 Ave des Bergieres, CH-1004 Lausanne, Switzerland.
CR Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Buchi ER, 2001, INVEST OPHTH VIS SCI, V42, pS796
   Kaga T, 2001, RETINA-J RET VIT DIS, V21, P172, DOI 10.1097/00006982-200104000-00012
   MAINSTER MA, 1970, J OPT SOC AM, V60, P264, DOI 10.1364/JOSA.60.000264
   Morimura Y, 2001, INVEST OPHTH VIS SCI, V42, pS226
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   OKADA AA, 2000, OPHTHALMOLOGY S, P247
   OOSTERHUIS JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P315, DOI 10.1001/archopht.1995.01100030071024
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Shields CL, 1996, OPHTHALMOLOGY, V103, P1642, DOI 10.1016/S0161-6420(96)30451-X
   Suzuki S, 1999, JPN J OPHTHALMOL, V43, P327, DOI 10.1016/S0021-5155(99)00016-7
   SVAASAND LO, 1985, LASER SURG MED, V5, P589, DOI 10.1002/lsm.1900050607
NR 12
TC 15
Z9 15
U1 0
U2 1
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD APR
PY 2002
VL 219
IS 4
BP 250
EP 253
DI 10.1055/s-2002-30649
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 560UJ
UT WOS:000176099500015
PM 12022011
DA 2022-11-30
ER

PT J
AU Chen, L
   Zhang, XZ
   Gan, YH
   Liu, B
   Zhang, YX
   Wen, F
AF Chen, Ling
   Zhang, Xiongze
   Gan, Yuhong
   Liu, Bing
   Zhang, Yuxin
   Wen, Feng
TI Retinal pigment epithelium hyperplasia overlying pigment epithelial
   detachment in age-related macular degeneration can masquerade as
   neovascularization on optical coherence tomography angiography
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Pigment epithelial detachment; Retinal
   pigment epithelium hyperplasia; Optical coherence tomography
   angiography; Image artifacts
ID OCT ANGIOGRAPHY; IMAGE ARTIFACTS; REDUCTION; DRUSEN
AB PurposeTo report the image artifacts due to retinal pigment epithelium (RPE) hyperplasia overlying retinal pigment epithelial detachment (PED) in age-related macular degeneration (AMD), which can masquerade as neovascularization on optical coherence tomography angiography (OCTA).MethodsA hospital-based, retrospective, and cross-sectional study. Twenty-two eyes from 16 patients with non-vascularized PED related to AMD were included in this study. All patients were examined by OCTA, spectral-domain optical coherence tomography, fluorescence angiography, and indocyanine green angiography. Vascular flow signals (VFS) on both the outer retinal slab of en face OCTA and cross-sectional OCTA and their correspondence with RPE hyperplasia were evaluated.ResultsFifteen eyes (68.2%) showed VFS on both the outer retina slab of en face OCTA and cross-sectional OCTA, all corresponding to the RPE hyperplasia overlying PED. Among them, 12 eyes with lump RPE hyperplasia outside foveal avascular zone (FAZ) all showed obvious VFS on the outer retina slab of OCTA, and 3 eyes with scattered RPE hyperplasia outside FAZ showed VFS fragments. Of note, 4 eyes had accompanied RPE hyperplasia inside FAZ, and 7 eyes without RPE hyperplasia overlying PED showed no corresponding VFS on the outer retina slab of OCTA. Additionally, a round-like dark band at the edge of PED was observed in the outer retina slab on en face OCTA in 17 eyes (77.3%).ConclusionsRPE hyperplasia overlying PED in AMD can masquerade as neovascularization on OCTA. To avoid misdiagnosis and unnecessary treatment, this RPE hyperplasia-related image artifact should be considered when interpreting OCTA images.
C1 [Chen, Ling; Zhang, Xiongze; Gan, Yuhong; Liu, Bing; Zhang, Yuxin; Wen, Feng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@foxmail.com
OI Chen, Ling/0000-0002-5552-4667
FU National Natural Science Foundation of China [81470647]
FX The National Natural Science Foundation of China (grant no. 81470647)
   provided financial support in the form of science funding. The sponsor
   had no role in the design or conduct of this research.
CR Ahmed D, 2018, RETINA-J RET VIT DIS, V38, P2143, DOI 10.1097/IAE.0000000000001832
   Alten F, 2017, GRAEF ARCH CLIN EXP, V255, P2347, DOI 10.1007/s00417-017-3813-8
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   Bonini MA, 2015, JAMA OPHTHALMOL, V133, P899, DOI 10.1001/jamaophthalmol.2015.1320
   Camino A, 2016, BIOMED OPT EXPRESS, V7, P3905, DOI 10.1364/BOE.7.003905
   Chen FK, 2016, CLIN EXP OPHTHALMOL, V44, P388, DOI 10.1111/ceo.12683
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Falavarjani KG, 2017, BRIT J OPHTHALMOL, V101, P564, DOI 10.1136/bjophthalmol-2016-309104
   Ferrara D, 2016, CLIN EXP OPHTHALMOL, V44, P367, DOI 10.1111/ceo.12781
   Flower RW, 1998, RETINA-J RET VIT DIS, V18, P260, DOI 10.1097/00006982-199803000-00012
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kim DY, 2011, BIOMED OPT EXPRESS, V2, P1504, DOI 10.1364/BOE.2.001504
   Kvanta A, 2017, RETINA-J RET VIT DIS, V37, P936, DOI 10.1097/IAE.0000000000001248
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Lu YS, 2018, INVEST OPHTH VIS SCI, V59, P2212, DOI 10.1167/iovs.17-23498
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Matsunaga D, 2014, OSLI RETINA, V45, P510, DOI 10.3928/23258160-20141118-04
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Nesper PL, 2018, RETINA-J RET VIT DIS, V38, P1289, DOI 10.1097/IAE.0000000000001863
   Runkle AP, 2017, INVEST OPHTH VIS SCI, V58, P3683, DOI 10.1167/iovs.16-20976
   Samara WA, 2016, AM J OPHTHALMOL, V166, P76, DOI 10.1016/j.ajo.2016.03.033
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Tan ACS, 2018, RETINA-J RET VIT DIS, V38, P1759, DOI 10.1097/IAE.0000000000002016
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
NR 24
TC 3
Z9 3
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2018
VL 256
IS 12
BP 2283
EP 2291
DI 10.1007/s00417-018-4138-y
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GZ4RZ
UT WOS:000449389300002
PM 30229304
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Jackson, GR
   McGwin, G
   Phillips, JM
   Klein, R
   Owsley, C
AF Jackson, GR
   McGwin, G
   Phillips, JM
   Klein, R
   Owsley, C
TI Impact of aging and age-related maculopathy on activation of the a-wave
   of the rod-mediated electroretinogram
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MACULAR DEGENERATION; RECEPTOR ACTIVITY; DARK-ADAPTATION; CONTRAST
   SENSITIVITY; CLINICAL RESEARCH; GRADING SYSTEM; LEADING-EDGE;
   PHOTOTRANSDUCTION; CONE; PHOTORECEPTORS
AB PURPOSE. To examine the impact of aging and age-related maculopathy ( ARM) on the activation of phototransduction in rod photoreceptors by measuring the a-wave of the flash, full-field electroretinogram ( ERG).
   METHODS. Enrollees consisted of older adults ( greater than or equal to 60 years of age) in normal retinal health ( n = 41) and those with early ( n = 39) or late ARM ( n = 7), in whom disease presence and severity were defined based on grading of stereoscopic color fundus photographs according to the Wisconsin Age-Related Maculopathy grading system. Young adults ( ages 16 - 30 years; n = 27) were enrolled for comparison purposes. Previously established procedures were used to estimate the ERG response to two families of flash intensities. By computer subtraction of responses, the isolated rod response was identified. Each participant's ensemble rod responses were fit with the following equation to describe the response ( R) as function of flash intensity ( I), and time ( t): R( I, t) = [1 - exp{- I . S . (t - t(d))(2)}] . Rm(P3), where S is sensitivity, t(d) is the delay before onset of the a-wave, and Rm(P3) is the maximum amplitude.
   RESULTS. In analyses of older adults, there was no impact of early ARM presence or severity on log S, Rm(P3), or t(d) after adjustment for age and intraocular lens presence. Differences between young and old normal subjects in log S, Rm(P3), and t(d) disappeared when analyses were limited to older adults with intraocular lenses.
   CONCLUSIONS. When the light absorption of the aged lens is taken into account and reliable definitions of normal retinal aging and ARM are used, the activation of the a-wave as measured by the rod-mediated full-field ERG is not affected by early ARM, nor is it impacted by normal retinal aging.
C1 Univ Alabama, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
   Univ Alabama, Sch Med, Dept Surg, Sect Trauma Burn & Crit Care, Birmingham, AL 35294 USA.
   Univ Alabama, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
   Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Wisconsin System; University of Wisconsin Madison
RP Jackson, GR (通讯作者)，Univ Alabama, Sch Med, Dept Ophthalmol, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
EM grjackson@uab.edu
FU NEI NIH HHS [R21-EY14071] Funding Source: Medline; NIA NIH HHS
   [R01-AG04212] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R21EY014071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [R01AG004212] Funding Source: NIH RePORTER
CR Bearse MA, 1996, J OPT SOC AM A, V13, P634
   Birch DG, 2002, ARCH OPHTHALMOL-CHIC, V120, P1045
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624
   BRETON ME, 1994, INVEST OPHTH VIS SCI, V36, P1603
   BROWN KT, 1961, J PHYSIOL-LONDON, V158, P257, DOI 10.1113/jphysiol.1961.sp006768
   Cideciyan AV, 1996, VISION RES, V36, P2609, DOI 10.1016/0042-6989(95)00327-4
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   ELLIOTT DB, 1991, CLIN VISION SCI, V6, P471
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P97, DOI 10.1016/0002-9394(82)90198-2
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   HEYNEN H, 1985, VISION RES, V25, P697, DOI 10.1016/0042-6989(85)90176-2
   Holopigian K, 2002, INVEST OPHTH VIS SCI, V43, P2364
   HOOD DC, 1990, INVEST OPHTH VIS SCI, V31, P2070
   HOOD DC, 1993, VISION RES, V33, P1605, DOI 10.1016/0042-6989(93)90027-T
   HOOD DC, 1990, VISUAL NEUROSCI, V5, P379, DOI 10.1017/S0952523800000468
   Hood DC, 1998, INVEST OPHTH VIS SCI, V39, P1152
   HOOD DC, 1993, VISUAL NEUROSCI, V10, P857, DOI 10.1017/S0952523800006076
   Hood DC, 1996, J OPT SOC AM A, V13, P623, DOI 10.1364/JOSAA.13.000623
   HOOD DC, 1990, CLIN VISION SCI, V5, P293
   HOOD DC, 1993, J OPT SOC AM A, V10, P1624, DOI 10.1364/JOSAA.10.001624
   Hood Donald C., 1996, Documenta Ophthalmologica, V92, P253, DOI 10.1007/BF02584080
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   JACKSON GR, IN PRESS MACULAR DEG
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111
   LEWIS H, 1986, OPHTHALMOLOGY, V93, P1098
   LEWIS H, 1985, OPHTHALMOLOGY, V11, P1485
   Loewenfeld IE., 1979, TOPICS NEUROOPHTHALM, P124
   MARSHALL J, 1979, BRIT J OPHTHALMOL, V63, P181, DOI 10.1136/bjo.63.3.181
   *NAT ADV EYE COUNC, 1999, VIS RES NAT PLAN 199
   Norren D Van, 1974, VISION RES, V14, P1237
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   PENN RD, 1969, NATURE, V223, P201, DOI 10.1038/223201a0
   POKORNY J, 1987, APPL OPTICS, V26, P1437, DOI 10.1364/AO.26.001437
   Polyak S. L., 1941, RETINA-J RET VIT DIS
   PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H
   ROBSON JG, 1995, VISUAL NEUROSCI, V12, P837, DOI 10.1017/S0952523800009408
   SAMPLE PA, 1988, INVEST OPHTH VIS SCI, V29, P1306
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SILLMAN AJ, 1969, VISION RES, V9, P1435, DOI 10.1016/0042-6989(69)90059-5
   Smith NP, 1997, VISION RES, V37, P2943, DOI 10.1016/S0042-6989(97)00094-1
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
NR 55
TC 33
Z9 34
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2004
VL 45
IS 9
BP 3271
EP 3278
DI 10.1167/iovs.04-0019
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 848XH
UT WOS:000223500900056
PM 15326151
DA 2022-11-30
ER

PT J
AU Tyagi, P
   Juma, Z
   Hor, YK
   Scott, NW
   Ionean, A
   Santiago, C
AF Tyagi, Pallavi
   Juma, Zain
   Hor, Yong Keen
   Scott, Neil W.
   Ionean, Andreea
   Santiago, Cynthia
TI Clinical response of pigment epithelial detachment associated with
   neovascular age-related macular degeneration in switching treatment from
   Ranibizumab to Aflibercept
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Pigment epithelial detachment; Neovascular age related
   macular degeneration
ID OCCULT CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL AFLIBERCEPT;
   ANATOMICAL OUTCOMES; VEGF TRAP; EYES; SECONDARY; THERAPY
AB Background: To study the clinical outcomes of pigment epithelial detachment (PED) associated with neovascular age-related macular degeneration (nAMD) in patients switched from Ranibizumab to Aflibercept.
   Methods: Retrospective non-comparative case series. 50 eyes with active nAMD and fovea involving PED of >= 100 mu m measured manually using the caliper on the OCT, initially treated with intravitreal Ranibizumab (0.5 mg/0.05 ml) and later switched to Aflibercept (2.0 mg/0.05 ml). The outcome measures of best corrected visual acuity (BCVA), PED height, PED width and number of injections were measured at baseline and at time point of switch, 4 months, 1 year and at last follow up visit post-switch. Three paired t-tests and Pearson's correlations were calculated to analyze variables at switch and change in variables at 1 year.
   Results: After switch to Aflibercept, the improvement of BCVA was 1.84 (p = 0.11), 1.74 (p = 0.21) and 1.16 (p = 0.45) letters, the change in PED height was -65.6 mu m (p < 0.001), -50.64 mu m (p = 0.007) and -68.48 mu m (p < 0.001) and the change in PED width was -36.6 mu m (p = 0.514), + 29.7 mu m (p = 0.922) and + 118.4 mu m (p = 0.210) at 4 months, 1 year and the last visit respectively. There was a moderate negative correlation between reduction in PED height at 1 year after switch and PED height at the time of switch to Aflibercept (r = -0.474, p < 0.05).
   Conclusion: The improvement in BCVA and change in PED width was not statistically significant however the reduction in PED height was significant after switching treatment to Aflibercept. The change in BCVA at 1 year after switch was not correlated with any of the analyzed anatomical characteristics of PED.
C1 [Tyagi, Pallavi; Juma, Zain; Ionean, Andreea; Santiago, Cynthia] Aberdeen Royal Infirm, Dept Ophthalmol, Forresterhill Rd, Aberdeen AB25 5ZN, Scotland.
   [Hor, Yong Keen] Univ Aberdeen, Sch Med, Aberdeen AB25 2ZD, Scotland.
   [Scott, Neil W.] Univ Aberdeen, Med Stat Team, Aberdeen AB25 2ZD, Scotland.
C3 University of Aberdeen; University of Aberdeen; University of Aberdeen
RP Tyagi, P (通讯作者)，Aberdeen Royal Infirm, Dept Ophthalmol, Forresterhill Rd, Aberdeen AB25 5ZN, Scotland.
EM palv2007@gmail.com
FU BAYER, UK; Novartis, UK; Bayer
FX PT received travel grant from BAYER, UK to attend international meetings
   and AI and CS have received travel grants and speaker fees from Bayer
   and Novartis, UK and acted as consultants for BAYER, UK.
CR Arora S, 2011, EYE, V25, P1034, DOI 10.1038/eye.2011.115
   Au A, 2017, BRIT J OPHTHALMOL, V101, P970, DOI 10.1136/bjophthalmol-2016-309434
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Baba T, 2012, OPHTHALMOLOGICA, V228, P102, DOI 10.1159/000337251
   Balaskas K, 2017, RETINA-J RET VIT DIS, V37, P1297, DOI 10.1097/IAE.0000000000001342
   Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Chan CK, 2015, EYE, V29, P80, DOI 10.1038/eye.2014.233
   Chevreaud O, 2017, GRAEF ARCH CLIN EXP, V255, P743, DOI 10.1007/s00417-016-3564-y
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   De Massougnes S, 2016, RETINA-J RET VIT DIS, V36, P881, DOI 10.1097/IAE.0000000000000813
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Freeman WR, 2011, RETINA-J RET VIT DIS, V31, P1812, DOI 10.1097/IAE.0b013e31821987a4
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Giansanti F, 2014, EUR J OPHTHALMOL, V24, P402, DOI 10.5301/ejo.5000388
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Gross-Jendroska M, 1998, AUST NZ J OPHTHALMOL, V26, P311, DOI 10.1111/j.1442-9071.1998.tb01335.x
   He LM, 2016, RETINA-J RET VIT DIS, V36, P492, DOI 10.1097/IAE.0000000000000749
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Nicolo M, 2005, EUR J OPHTHALMOL, V15, P415, DOI 10.1177/112067210501500318
   Panos GD, 2013, DRUG DES DEV THER, V7, P565, DOI 10.2147/DDDT.S46610
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Punjabi OS, 2013, BRIT J OPHTHALMOL, V97, P1024, DOI 10.1136/bjophthalmol-2013-303155
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 28
TC 7
Z9 8
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUN 22
PY 2018
VL 18
AR 148
DI 10.1186/s12886-018-0824-0
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GK2GC
UT WOS:000435944100003
PM 29929478
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Erdem, B
   Gok, M
AF Erdem, Burak
   Gok, Mustafa
TI Evaluation of the Effects of Intravitreal Aflibercept and Ranibizumab on
   Systemic Inflammatory and Cardiovascular Biomarkers in Patients with
   Neovascular Age-related Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Aflibercept; ranibizumab; age-related macular degeneration;
   inflammation; cardiovascular system
AB Purpose: To investigate the effects of intravitreal ranibizumab (IVR) and intravitreal aflibercept (IVA) on systemic inflammatory and cardiovascular biomarkers in treatment-naive patients with neovascular age-related macular degeneration (nAMD)
   Methods: This study included 24 eyes of 24 patients treated with 0.5 mg ranibizumab (IVR group) and 25 eyes of 25 patients treated with 2.0 mg aflibercept (IVA group). Complete blood count, C-reactive protein (CRP), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), uric acid (UA), albumin, fibrinogen levels were measured in blood samples before and after the three-monthly loading dose treatment. Neutrophil/lymphocyte ratio (NLR), monocyte/HDL-c ratio (MHR), CRP/albumin ratio (CAR), monocyte/lymphocyte ratio (MLR), platelet/lymphocyte ratio (PLR) were also calculated.
   Results: A statistically significant decline was determined in post-treatment CRP (P = .002), LDL-c (P < .001) levels, white blood cell (WBC, P = .001), neutrophil (P < .001), monocyte (P = .019) counts and NLR (P = .020), MHR (P = .042), CAR (P = .010) ratios comparing with pre-treatment values in the IVA group. No statistically significant change was found in any of the parameters evaluated in the study in the IVR group. Also, there was no significant change in fibrinogen, lymphocyte count, MLR, HDL-c, UA, PLR, and platelet count values in both groups.
   Conclusion: Compared to IVR, IVA treatment had a small but significant effect on systemic inflammatory and cardiovascular biomarkers.
C1 [Erdem, Burak] Ordu Univ, Fac Med, Dept Ophthalmol, Ordu, Turkey.
   [Gok, Mustafa] Private Atanur Eye Hosp, Dept Ophthalmol, Isparta, Turkey.
C3 Ordu University
RP Erdem, B (通讯作者)，Ordu Univ Res & Training Hosp, Minist Hlth, TR-52200 Ordu, Turkey.
EM burakerdem89@gmail.com
RI gok, mustafa/V-6690-2017
OI gok, mustafa/0000-0002-7660-6557; Erdem, Burak/0000-0002-8889-6096
CR AVERY R, 2017, RETINA-J RET VIT DIS, V37
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Bisoendial RJ, 2010, EUR HEART J, V31, P2087, DOI 10.1093/eurheartj/ehq238
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Budzianowski J, 2017, DIS MARKERS, V2017, DOI 10.1155/2017/3041565
   Catapano AL, 2017, BRIT J PHARMACOL, V174, P3973, DOI 10.1111/bph.13805
   Costagliola C, 2019, EXPERT OPIN DRUG SAF, V18, P803, DOI 10.1080/14740338.2019.1643838
   Danulescu R, 2013, MED-SURG J, V117, P328
   Fauser S, 2015, ACTA OPHTHALMOL, V93, P734, DOI 10.1111/aos.12770
   Feng F, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003248
   FERRARA N, 2006, RETINA-J RET VIT DIS, V26
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A
   Hirano T, 2018, RETINA-J RET VIT DIS, V38, P1801, DOI 10.1097/IAE.0000000000002004
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Imtiaz Fauzia, 2012, Int Arch Med, V5, P2, DOI 10.1186/1755-7682-5-2
   Kang M, 2018, ENDOCR J, V65, P437, DOI 10.1507/endocrj.EJ17-0363
   Katipoglu Z, 2020, OCUL IMMUNOL INFLAMM, V28, P632, DOI 10.1080/09273948.2019.1611876
   Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237
   Manresa N, 2015, J NUTR HEALTH AGING, V19, P228, DOI 10.1007/s12603-014-0531-3
   Manresa N, 2015, RETINA-J RET VIT DIS, V35, P1765, DOI 10.1097/IAE.0000000000000552
   Papezikova I, 2013, FREE RADICAL RES, V47, P82, DOI 10.3109/10715762.2012.747677
   Ramakrishnan S, 2014, J NEUROIMMUNE PHARM, V9, P142, DOI 10.1007/s11481-014-9531-7
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shibuya M, 2015, ENDOCR METAB IMMUNE, V15, P135, DOI 10.2174/1871530315666150316121956
   Skoda M, 2018, CYTOKINE GROWTH F R, V39, P116, DOI 10.1016/j.cytogfr.2017.12.001
   Sproston NR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00754
   Tanriverdi Z, 2020, ANGIOLOGY, V71, P360, DOI 10.1177/0003319719897490
   Ternant D, 2005, EXPERT OPIN BIOL TH, V5, pS37, DOI 10.1517/14712598.5.1.S37
   Wang XY, 2014, AM J OPHTHALMOL, V158, P738, DOI 10.1016/j.ajo.2014.06.009
   Wong BW, 2009, J HEART LUNG TRANSPL, V28, P950, DOI 10.1016/j.healun.2009.05.005
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Yazar HO, 2020, IRISH J MED SCI, V189, P677, DOI 10.1007/s11845-019-02136-y
NR 34
TC 0
Z9 0
U1 1
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD SEP 2
PY 2021
VL 46
IS 9
BP 1387
EP 1392
DI 10.1080/02713683.2021.1879868
EA JAN 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TY9BU
UT WOS:000611605500001
PM 33471564
DA 2022-11-30
ER

PT J
AU Luu, ST
   Gray, T
   Warrier, SK
   Patel, I
   Muecke, JS
   Casson, R
   Gilhotra, JS
AF Luu, Susie T.
   Gray, Timothy
   Warrier, Sunil K.
   Patel, Ilesh
   Muecke, James S.
   Casson, Robert
   Gilhotra, Jagjit S.
TI Retrospective study of an as required dosing regimen of intravitreal
   bevacizumab in neovascular age-related macular degeneration in an
   Australian population
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; age-related maculopathy; choroidal
   neovascularization
ID OCCULT CHOROIDAL NEOVASCULARIZATION; ARTERIAL THROMBOEMBOLIC EVENTS;
   RETINA STUDY-GROUP; VISUAL IMPAIRMENT; UNITED-STATES; FOLLOW-UP;
   AVASTIN; PREVALENCE; INJECTIONS; SECONDARY
AB P>Purpose:
   To investigate the efficacy of intravitreal bevacizumab for the treatment of neovascular age-related macular degeneration (AMD) using an as required dosing regimen.
   Methods:
   A retrospective study of 210 patients (231 eyes) with choroidal neovascularization resulting from neovasacular AMD. Patients were treated with 1.25 mg intravitreal bevacizumab at a vitreoretinal practice in Adelaide, South Australia. Patients were followed up at 2-4 weeks and then at 1-month intervals; repeat injections were offered in the event of recurrence. Recurrence was defined as either a decrease of best-corrected visual acuity or an increase in macular oedema, subretinal fluid or intraretinal fluid on optical coherence tomography, after complete or partial resolution in previous follow-up visits. Patient data were collected for 12 months of follow up or until the patient's treatment was changed to ranibizumab.
   Results:
   Significant improvement in visual acuity and central retinal thickness was demonstrated at 1 month with an improvement of vision from logMAR equivalent 0.76 to 0.68 (P < 0.001) and a decrease of central retinal thickness from 306 mu m to 244 mu m (P < 0.001). This overall improvement was continued throughout the 12-month follow-up period; however, follow up was poor with 12-month data available for only a small number of patients (7.8%). Ocular and systemic side-effects were rare at 3.5% and 0.4%, respectively.
   Conclusion:
   Eyes with neovascular AMD treated with intravitreal bevacizumab for up to 12 months had significant functional and anatomical improvement. Further studies need to confirm the long-term safety and efficacy of this treatment.
C1 [Luu, Susie T.] Univ Adelaide, Discipline Ophthalmol & Visual Sci, Adelaide, SA 5000, Australia.
   S Australian Inst Ophthalmol, Adelaide, SA 5000, Australia.
C3 University of Adelaide
RP Luu, ST (通讯作者)，Univ Adelaide, Discipline Ophthalmol & Visual Sci, Adelaide, SA 5000, Australia.
EM susie.luu@health.sa.gov.au
OI Warrier, Sunil/0000-0001-6113-5337
CR Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Arevalo JF, 2008, RETINA-J RET VIT DIS, V28, P1387, DOI 10.1097/IAE.0b013e3181884ff4
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Madhusudhana KC, 2007, BRIT J OPHTHALMOL, V91, P1716, DOI 10.1136/bjo.2006.108639
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Reidy A, 1998, BRIT MED J, V316, P1643, DOI 10.1136/bmj.316.7145.1643
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stevenson MR, 2004, BRIT J OPHTHALMOL, V88, P1125, DOI 10.1136/bjo.2003.032383
   Tao Y, 2010, J OCUL PHARMACOL TH, V26, P79, DOI 10.1089/jop.2009.0095
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 24
TC 8
Z9 8
U1 0
U2 10
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1442-6404
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD OCT
PY 2010
VL 38
IS 7
BP 659
EP 663
DI 10.1111/j.1442-9071.2010.02309.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 664RC
UT WOS:000282979200003
PM 20456433
OA Bronze
DA 2022-11-30
ER

PT J
AU Feigl, B
   Brown, B
   Love-Kitchin, J
   Swann, P
AF Feigl, B
   Brown, B
   Love-Kitchin, J
   Swann, P
TI Cone- and rod-mediated multifocal electroretinogram in early age-related
   maculopathy
SO EYE
LA English
DT Article
DE multifocal electroretinogram; MfERG; cones; rods; early age-related
   maculopathy; early ARM
ID OSCILLATORY POTENTIALS; MACULAR DEGENERATION; RETINAL FUNCTION; SYSTEM
   FUNCTION; BLOOD-FLOW; LOCAL CONE; TOPOGRAPHY; ERG; VULNERABILITY;
   COMPONENTS
AB Purpose To investigate the cone- and rod-mediated multifocal electroretinograms (mfERG) in early age-related maculopathy ( early ARM).
   Methods and subjects We investigated the cone- and rod-mediated mfERG in 17 eyes of 17 subjects with early ARM and 16 eyes of 16 age-matched control subjects with normal fundi. All subjects had a visual acuity of 6/12 or better. We divided the ARM subjects into two groups based on drusen size and retinal pigment epithelium abnormalities-a less advanced (ARM1) and a more advanced (ARM2) group. The mfERG data were compared to templates derived from the control group. We analysed the mfERG results for the central and peripheral fields (CP method) and the superior and inferior fields ( SI method).
   Results While the mean cone results showed no statistically significant difference between the groups, the rods showed significantly delayed responses in the ARM1 group for the CP and the SI methods, but not in the ARM2 group, although there was a trend of longer latencies compared to the control group.
   Conclusion Our results show a functional impairment of the rods in early ARM subjects. As there is histopathological evidence showing earlier rod than cone impairment in early ARM, following the rod function with the mfERG might be helpful in diagnosis or for monitoring the progression of early ARM.
C1 Queensland Univ Technol, Sch Optometry, Ctr Hlth Res, Kelvin Grove Q 4059, Australia.
   Graz Univ, Dept Ophthalmol, A-8010 Graz, Austria.
C3 Queensland University of Technology (QUT); University of Graz
RP Feigl, B (通讯作者)，Queensland Univ Technol, Sch Optometry, Ctr Hlth Res, Victoria Pk Rd, Kelvin Grove Q 4059, Australia.
EM b.feigi@qut.edu.au
OI Feigl, Beatrix/0000-0001-7198-7373
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Arden GB, 1998, VISION RES, V38, P1723, DOI 10.1016/S0042-6989(98)00004-2
   Bearse MA, 1996, J OPT SOC AM A, V13, P634
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   ESAKOWITZ L, 1993, EYE, V7, P169, DOI 10.1038/eye.1993.36
   Fortune B, 1999, INVEST OPHTH VIS SCI, V40, P2638
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   GARTNER S, 1981, BRIT J OPHTHALMOL, V65, P23, DOI 10.1136/bjo.65.1.23
   Gerth C, 2002, GRAEF ARCH CLIN EXP, V240, P202, DOI 10.1007/s00417-002-0442-6
   Gordon WC, 2002, INVEST OPHTH VIS SCI, V43, P3511
   GREENSTEIN VC, 1993, OPTOMETRY VISION SCI, V37, P1140
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Hicks D, 1999, INVEST OPHTH VIS SCI, V40, P3071
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   Holopigian K, 2002, INVEST OPHTH VIS SCI, V43, P2364
   Holopigian K, 2001, INVEST OPHTH VIS SCI, V42, P779
   Holopigian K, 1997, OPTOMETRY VISION SCI, V74, P152, DOI 10.1097/00006324-199703000-00026
   Hood DC, 1998, INVEST OPHTH VIS SCI, V39, P1152
   Hood DC, 1997, VISUAL NEUROSCI, V14, P533, DOI 10.1017/S0952523800012190
   Hood DC, 2002, INVEST OPHTH VIS SCI, V43, P1673
   HOOD DC, 1997, NONINVASIVE ASSESSME, V11, P33
   Huang Shizhou, 2000, Documenta Ophthalmologica, V101, P115
   Jackson GR, 2002, J OPT SOC AM A, V19, P185, DOI 10.1364/JOSAA.19.000185
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   JURKLIES B, 2000, INVEST OPHTHALMOL VI, V41
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Keating D, 2002, VISION RES, V42, P2959, DOI 10.1016/S0042-6989(02)00359-0
   KEATING D, 1996, INVEST OPHTHALMOL  S, V37, P346
   Keating David, 2000, Documenta Ophthalmologica, V100, P77, DOI 10.1023/A:1002723501303
   Kretschmann U, 1998, BRIT J OPHTHALMOL, V82, P267, DOI 10.1136/bjo.82.3.267
   Kurtenbach A, 2000, INVEST OPHTH VIS SCI, V41, P3234
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   MARSHALL J, 1979, BRIT J OPHTHALMOL, V63, P181, DOI 10.1136/bjo.63.3.181
   MARTINSON G, 2000, INVEST OPHTHALMOL VI, V42
   Onozu H, 2003, DOC OPHTHALMOL, V106, P327, DOI 10.1023/A:1022903627332
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   PALMOWSKI A, 2001, VIS SCI APPL OSA, P32
   Palmowski AM, 2002, OPHTHALMOLOGY, V109, P1788, DOI 10.1016/S0161-6420(02)01147-8
   Palmowski AM, 1997, INVEST OPHTH VIS SCI, V38, P2586
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Seeliger M, 1998, AM J OPHTHALMOL, V125, P214, DOI 10.1016/S0002-9394(99)80094-4
   Seeliger MW, 1998, INVEST OPHTH VIS SCI, V39, P718
   Seiple W, 2003, INVEST OPHTH VIS SCI, V44, P1783, DOI 10.1167/iovs.02-0518
   SUNNESS JS, 1986, AM J OPTOM PHYS OPT, V63, P7
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Sutter EE, 2001, VISION RES, V41, P1241, DOI 10.1016/S0042-6989(01)00078-5
   Ulbig M. W., 1993, Ophthalmologe, V90, P395
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   WU SA, 1995, VISUAL NEUROSCI, V12, P1013, DOI 10.1017/S0952523800006696
NR 56
TC 36
Z9 38
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD APR
PY 2005
VL 19
IS 4
BP 431
EP 441
DI 10.1038/sj.eye.6701503
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 912PF
UT WOS:000228090900013
PM 15286663
OA Bronze
DA 2022-11-30
ER

PT J
AU Katz, G
   Giavedoni, L
   Muni, R
   Evans, T
   Pezda, M
   Wong, D
   Moffat, A
   Altomare, F
   Boyd, S
   Berger, A
AF Katz, Gabriel
   Giavedoni, Louis
   Muni, Rajeev
   Evans, Teodoro
   Pezda, Matthew
   Wong, David
   Moffat, Ashley
   Altomare, Filiberto
   Boyd, Shelley
   Berger, Alan
TI EFFECTIVENESS AT 1 YEAR OF MONTHLY VERSUS VARIABLE-DOSING INTRAVITREAL
   RANIBIZUMAB IN THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY
   TO AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE ranibizumab; variable dosing; AMD; visual acuity; OCT; 1 year
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL THICKNESS; LUCENTIS; STRATUS
AB Purpose: To evaluate the visual acuity results of monthly ranibizumab injections compared with a variable-dosing schedule for the treatment of neovascular age-related macular degeneration.
   Methods: A retrospective study that compared two cohorts of consecutive patients. All patients were treatment naive, with baseline visual acuity of 20/400 or better, and completed 12 months of therapy. In the first group all patients received monthly injections. In the other group, after 3 monthly loading doses, a variable-dosing schedule was used, based on a monthly clinical assessment and optical coherence tomography.
   Results: Fifty-six consecutive patients (60 eyes) were included. At 12 months the median number of injections were 12 and 8, respectively, and the mean change in Snellen visual acuity was an improvement of 0.27 logarithm of the minimum angle of resolution in the monthly treated group versus 0.21 logarithm of the minimum angle of resolution improvement in the variable-dosing group (P = 0.53). In the monthly treated group 96.8% of eyes lost <0.3 logarithm of the minimum angle of resolution versus 96.6% of eyes in the variable-dosing group (P = 1.0).
   Conclusion: We were able to show that in our clinical setting patients achieved similar visual acuity results with either monthly injections or with a variable-dosing protocol. There was a trend toward better results with monthly treatment. RETINA 32:293-298, 2012
C1 [Katz, Gabriel; Giavedoni, Louis; Muni, Rajeev; Evans, Teodoro; Pezda, Matthew; Wong, David; Moffat, Ashley; Altomare, Filiberto; Boyd, Shelley; Berger, Alan] Univ Toronto, St Michaels Hosp, Dept Ophthalmol, Toronto, ON M5C 2T2, Canada.
C3 University of Toronto; University Toronto Affiliates; Saint Michaels
   Hospital Toronto
RP Katz, G (通讯作者)，Univ Toronto, St Michaels Hosp, Dept Ophthalmol, 61 Queen St E, Toronto, ON M5C 2T2, Canada.
EM gabrielkatz.dr@gmail.com
OI Altomare, Filiberto/0000-0002-2589-6320; Wong, David/0000-0003-1376-845X
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Ernst Benjamin J., 2010, International Ophthalmology, V30, P267, DOI 10.1007/s10792-009-9324-9
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Grover S, 2010, INVEST OPHTH VIS SCI, V51, P2644, DOI 10.1167/iovs.09-4774
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   HOLZ FG, 2008, AAO SOE JOINT ANN M
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   Kiernan DF, 2009, AM J OPHTHALMOL, V147, P267, DOI 10.1016/j.ajo.2008.08.018
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   MEYER CH, 2008, INVEST OPHTHALMOL VI, V49
   Michalova K, 2009, EYE, V23, P1633, DOI 10.1038/eye.2009.175
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 17
TC 9
Z9 10
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2012
VL 32
IS 2
BP 293
EP 298
DI 10.1097/IAE.0b013e31821e20b0
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 890YJ
UT WOS:000300182700012
PM 21926941
DA 2022-11-30
ER

PT J
AU Jeong, YJ
   Hong, IH
   Chung, JK
   Kim, KL
   Kim, HK
   Park, SP
AF Jeong, Y. J.
   Hong, I. H.
   Chung, J. K.
   Kim, K. L.
   Kim, H. K.
   Park, S. P.
TI Predictors for the progression of geographic atrophy in patients with
   age-related macular degeneration: fundus autofluorescence study with
   modified fundus camera
SO EYE
LA English
DT Article
DE fundus autofluorescence; fundus camera; geographic atrophy; progression;
   age-related macular degeneration
ID RETINAL-PIGMENT EPITHELIUM; JUNCTIONAL ZONE; RPE CELLS; LIPOFUSCIN;
   PATTERNS; CLASSIFICATION; FLUORESCENCE; INHIBITION; LASER
AB Purpose We examined the association between abnormal fundus autofluorescence (FAF) features on images obtained by a modified fundus camera (mFC) and geographic atrophy (GA) progression in patients with age-related macular degeneration (AMD).
   Methods Serial FAF images of 131 eyes from 131 patients with GA were included in the study. All FAF images were obtained with an mFC (excitation, similar to 500-610 nm; emission, similar to 675-715 nm). The GA area was quantified at baseline and 1 year later using a customized segmentation program. The yearly GA enlargement rate was then calculated. Abnormal FAF patterns in the junctional zone of GA were classified as None or Minimal change, Focal, Patchy, Banded, or Diffuse according to previously published classification based on confocal scanning laser ophthalmoscopy (cSLO). The relationship between GA enlargement and abnormal FAF was evaluated.
   Results The mean rate of GA enlargement was the fastest in eyes with Diffuse pattern (1.74 mm(2) per year), followed by eyes with the Banded pattern (1.69 mm(2) per year). Binary logistic regression analysis revealed that eyes with the Banded and Diffuse pattern had significantly higher risk for GA enlargement compared with eyes with the other patterns.
   Conclusions FAF image obtained by mFC appears to be acceptable for evaluating GA in accordance with an established cSLO-based classification. Eyes with the Banded or the Diffuse patterns of abnormal FAF at baseline indicate a high risk for GA progression. Identifying patients at high risk for GA progression using an mFC is broadly available method that can provide additional information to help predict disease course.
C1 [Jeong, Y. J.; Hong, I. H.; Chung, J. K.; Kim, K. L.; Kim, H. K.; Park, S. P.] Hallym Univ, Coll Med, Kangdong Sacred Heart Hosp, Dept Ophthalmol, Seoul 134814, South Korea.
   [Park, S. P.] Columbia Univ, Dept Ophthalmol, Med Ctr, New York, NY 10027 USA.
C3 Hallym University; Columbia University
RP Park, SP (通讯作者)，Hallym Univ, Coll Med, Kangdong Sacred Heart Hosp, Dept Ophthalmol, Seongan Ro 150, Seoul 134814, South Korea.
EM sungpyo@hanafos.com
RI Mitchell, Paul/P-1498-2014
CR Bearelly S, 2011, RETINA-J RET VIT DIS, V31, P81, DOI 10.1097/IAE.0b013e3181e0958b
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Biarnes M, 2012, GRAEF ARCH CLIN EXP, V250, P485, DOI 10.1007/s00417-011-1846-y
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Bindewald-Wittich A, 2006, INVEST OPHTH VIS SCI, V47, P4553, DOI 10.1167/iovs.05-1562
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   Hammer M, 2006, MOL VIS, V12, P1348
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Sunness JS, 1999, MOL VIS, V5
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
NR 20
TC 20
Z9 23
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2014
VL 28
IS 2
BP 209
EP 218
DI 10.1038/eye.2013.275
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AB2IN
UT WOS:000331616500014
PM 24458203
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Midena, E
   Frizziero, L
   Torresin, T
   Todaro, PB
   Miglionico, G
   Pilotto, E
AF Midena, Edoardo
   Frizziero, Luisa
   Torresin, Tommaso
   Todaro, Paolo Boscolo
   Miglionico, Giacomo
   Pilotto, Elisabetta
TI Optical coherence tomography and color fundus photography in the
   screening of age-related macular degeneration: A comparative,
   population-based study
SO PLOS ONE
LA English
DT Article
ID RELIABILITY; PREVALENCE; OCT
AB Purpose To analyze the individual value and the contribution of color fundus photography (CFP) and optical coherence tomography (OCT) in the screening of age-related macular degeneration (AMD) of an unselected population. Methods CFP and OCT images of 15957 eyes of 8069 subjects older than 55 years, obtained during a population-based screening for AMD using a single diagnostic non-mydriatic imaging device, were analyzed by a blinded examiner. The two techniques were preliminary evaluated considering the dichotomous parameter "gradable/ungradable", then gradable images were classified. CFP were graded according to the standardized classification of AMD lesions. OCT images were also categorized considering the presence of signs of early/intermediate AMD, late AMD, or other retinal diseases. Another blinded operator re-graded 1978 randomly selected images (for both CFP and OCT), to assess test reproducibility. Results Of the 15957 eyes, 8356 CFP (52.4%) and 15594 (97.7%) OCT scans were gradable. Moreover, most of the eyes with ungradable CFP (7339, 96.6%) were gradable at OCT. AMD signs were revealed in 7.4% of gradable CFP and in 10.4% of gradable OCT images. Moreover, at OCT, AMD signs were found in 1110 (6.9%) eyes whose CFP were ungradable or without AMD (847 and 263 eyes, respectively). The inter-operator agreement was good for the gradable versus ungradable parameter, and optimal for the AMD grading parameter of CFP. The agreement was optimal for all OCT parameters. Conclusions OCT provided gradable images in almost all examined eyes, compared to limited CFP efficiency. Moreover, OCT images allowed to detect more AMD eyes compared to gradable photos. OCT imaging appears to significantly improve the power of AMD screening in a general, unselected population, compared to CFP alone.
C1 [Midena, Edoardo; Torresin, Tommaso; Todaro, Paolo Boscolo; Miglionico, Giacomo; Pilotto, Elisabetta] Univ Padua, Dept Ophthalmol, Padua, Italy.
   [Midena, Edoardo; Frizziero, Luisa] IRCCS Fdn Bietti, Rome, Italy.
C3 University of Padua; IRCCS - Fondazione "G.B. Bietti" per lo Studio e la
   Ricerca in Oftalmologia
RP Midena, E (通讯作者)，Univ Padua, Dept Ophthalmol, Padua, Italy.; Midena, E (通讯作者)，IRCCS Fdn Bietti, Rome, Italy.
EM edoardo.midena@unipd.it
RI Frizziero, Luisa/AAB-3249-2020
OI Torresin, Tommaso/0000-0001-5535-9350; Boscolo Todaro,
   Paolo/0000-0002-9091-7466
FU Fondazione Roma; Ministry of Health
FX The G.B. Bietti Foundation was supported by Fondazione Roma and the
   Ministry of Health. The authors received no specific funding for this
   work.
CR Bennett TJ, 2009, CLIN EXP OPHTHALMOL, V37, P2, DOI 10.1111/j.1442-9071.2008.01812.x
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Cheung CMG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31109-x
   De Bats F, 2014, OPHTHALMOLOGICA, V231, P172, DOI 10.1159/000356695
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   Gwet KL, 2008, BRIT J MATH STAT PSY, V61, P29, DOI 10.1348/000711006X126600
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kandasamy R, 2017, ASIA-PAC J OPHTHALMO, V6, P508, DOI 10.22608/APO.2017262
   Keel S, 2019, CLIN EXP OPHTHALMOL, V47, P1009, DOI 10.1111/ceo.13575
   Kelly SP, 2011, CLIN OPHTHALMOL, V5, P1673, DOI 10.2147/OPTH.S26753
   Krasnik V, 2018, SEMIN OPHTHALMOL, V33, P506, DOI 10.1080/08820538.2017.1316861
   Le Tien V, 2008, AM J OPHTHALMOL, V146, P520, DOI 10.1016/j.ajo.2008.05.031
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maberley DAL, 2005, EYE, V19, P611, DOI 10.1038/sj.eye.6701584
   Miller JW, 2018, AM J OPHTHALMOL, V195, P249
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Motozawa N, 2019, OPHTHALMOL THER, V8, P527, DOI 10.1007/s40123-019-00207-y
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Rein DB, 2007, OPHTHALMOLOGY, V114, P1319, DOI 10.1016/j.ophtha.2006.10.041
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   SAHA S, 2019, SCI REP UK, V0009
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Stevenson W, 2016, CLIN OPHTHALMOL, V10, P527, DOI 10.2147/OPTH.S97722
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zapata MA, 2017, TELEMED E-HEALTH, V23, P31, DOI 10.1089/tmj.2016.0020
NR 33
TC 1
Z9 1
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 14
PY 2020
VL 15
IS 8
AR e0237352
DI 10.1371/journal.pone.0237352
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NE5WK
UT WOS:000562671300025
PM 32797085
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Schadlu, R
   Kymes, SM
   Apte, RS
AF Schadlu, Ramin
   Kymes, Steven M.
   Apte, Rajendra S.
TI Combined photodynamic therapy and intravitreal triamcinolone for
   neovascular age-related macular degeneration: effect of initial visual
   acuity on treatment response
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE AMD; PDT; verteporfin; triamcinolone
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; TRIAL INCLUDING LESIONS;
   VERTEPORFIN THERAPY; ACETONIDE; OCCULT; INJECTION
AB To evaluate visual outcomes in combination therapy with photodynamic therapy (PDT) and intravitreal triamcinolone acetonide (IVTA) for subfoveal choroidal neovascularization (CNV) from age-related macular degeneration (AMD).
   Charts of 39 eyes from 38 patients with exudative AMD treated with PDT and 4 mg of triamcinolone acetate injected intravitreally were reviewed retrospectively. Visual data, angiographic lesion type, prior PDT exposure, number of treatments, and follow-up were recorded. Snellen visual acuities were converted to LogMAR for all calculations. Lines of vision lost or gained pertain to calculated ETDRS lines of vision (via LogMAR).
   Twenty-two of the choroidal neovascular membranes were occult, and 17 were classified as predominantly classic. Mean follow-up was 43 weeks. The average number of treatments was 2.23. At final follow-up, 11 eyes (28.21%) experienced improved visual acuity, 8 eyes (20.51%) were stable, and 20 eyes (51.28%) had worsened. No significant difference in treatment response was found between angiographic subtypes (p > 0.59). Lack of previous PDT exposure did not improve treatment outcomes (p > 0.77). Pre-treatment visual acuity (PTVA) was determined as a strong predictor of treatment outcome in our study cohort. Visual acuity of 20/200 or worse was associated with a 40.9% chance of some improvement and a 35.75% chance of three or more lines of improvement. Visual acuity better than 20/200 was associated with an 89.4% chance of no improvement and a 58.8% chance of three or more lines of visual loss.
   Counter to previously reported results with combination therapy, the majority of our patients (72%) did not demonstrate improved vision and 51% lost vision. When PTVA was accounted for, selected patients benefitted significantly from treatment. PTVA may be a useful and simple patient selection tool for combination treatment with PDT and IVTA.
C1 Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
C3 Washington University (WUSTL)
RP Apte, RS (通讯作者)，Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave,Box 8096, St Louis, MO 63110 USA.
EM apte@vision.wustl.edu
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BLYTH CR, 1983, J AM STAT ASSOC, V78, P108, DOI 10.2307/2287116
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2006, BRIT J OPHTHALMOL, V90, P1188, DOI 10.1136/bjo.2005.082255
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   Ergun E, 2006, AM J OPHTHALMOL, V142, P10, DOI 10.1016/j.ajo.2006.02.048
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Nicolo M, 2006, RETINA-J RET VIT DIS, V26, P58, DOI 10.1097/00006982-200601000-00010
   Pauleikhoff D, 2005, KLIN MONATSBL AUGENH, V222, P381, DOI 10.1055/s-2005-858225
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
NR 20
TC 6
Z9 6
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2007
VL 245
IS 11
BP 1667
EP 1672
DI 10.1007/s00417-007-0619-0
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 215BK
UT WOS:000249782200012
PM 17583819
DA 2022-11-30
ER

PT J
AU Liutkeviciene, R
   Vilkeviciute, A
   Gedvilaite, G
   Kaikaryte, K
   Kriauciuniene, L
AF Liutkeviciene, Rasa
   Vilkeviciute, Alvita
   Gedvilaite, Greta
   Kaikaryte, Kriste
   Kriauciuniene, Loresa
TI Haplotypes of HTRA1 rs1120638, TIMP3 rs9621532, VEGFA rs833068, CFI
   rs10033900, ERCC6 rs3793784, and KCTD10 rs56209061 Gene Polymorphisms in
   Age-Related Macular Degeneration
SO DISEASE MARKERS
LA English
DT Article
ID COMPLEMENT FACTOR-I; GENOME-WIDE ASSOCIATION; SORSBYS FUNDUS DYSTROPHY;
   CELL NUCLEAR ANTIGEN; TISSUE INHIBITOR; METALLOPROTEINASES-3 TIMP3;
   COMMON VARIANT; MYOCARDIAL-INFARCTION; PRECISION MEDICINE; PROTEIN
AB Background. To determine the impact of HTRA1 rs1120638, TIMP3 rs9621532, VEGFA rs833068, CFI rs10033900, ERCC6 rs3793784, and KCTD10 rs56209061 genotypes on the development of age-related macular degeneration (AMD) in the Lithuanian population. Methods. A total of 916 subjects were examined: 309 patients with early AMD, 301 patients with exudative AMD, and 306 healthy controls. The genotyping of HTRA1 rs11200638, TIMP3 rs9621532, VEGFA rs833068, CFI rs10033900, ERCC6 rs3793784, and KCTD10 rs56209061 was carried out using the RT-PCR method. Results. Our study showed that single-nucleotide polymorphisms rs3793784 and rs11200638 were associated with increased odds of early and exudative AMD, and the variant in KCTD10 (rs56209061) was found to be associated with decreased odds of early and exudative AMD development after adjustments for age and gender in early AMD analysis and after adjustments only for age in exudative AMD. The haplotype containing two minor alleles C-A and the G-A haplotype in rs3793784-rs11200638 were statistically significantly associated with an increased risk of exudative AMD development after adjustment for age, while the G-G haplotype showed a protective role against early and exudative AMD and the haplotype C-G in rs3793784-rs11200638 was associated with a decreased risk only of exudative AMD development. Conclusions. Our study identified two markers, rs11200638 and rs3793784, as risk factors for early and exudative AMD, and one marker, rs56209061, as a protective factor for early and exudative AMD development. The haplotypes constructed of rs3793784-rs11200638 were found to be associated with AMD development, as well.
C1 [Liutkeviciene, Rasa; Vilkeviciute, Alvita; Gedvilaite, Greta; Kaikaryte, Kriste; Kriauciuniene, Loresa] Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Eiveniu 2, LT-50161 Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences
RP Liutkeviciene, R (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Eiveniu 2, LT-50161 Kaunas, Lithuania.
EM rliutkeviciene@gmail.com
OI Gedvilaite, Greta/0000-0001-7469-8825
FU Research Council of Lithuania [SEN-11/2015]
FX This work was funded by Grant No. SEN-11/2015 from the Research Council
   of Lithuania.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Akagi-Kurashige Y, 2015, OPHTHALMOLOGY, V122, P2295, DOI 10.1016/j.ophtha.2015.07.032
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Ardeljan D, 2013, EUR J HUM GENET, V21, P1152, DOI 10.1038/ejhg.2013.14
   Baas DC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013786
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Cascella R, 2018, PROG RETIN EYE RES, V63, P132, DOI 10.1016/j.preteyeres.2017.11.004
   Cascella Raffaella, 2018, Oncotarget, V9, P7812, DOI 10.18632/oncotarget.23241
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cimbalas A, 2004, MED LITH, V39, P37
   Cipriani V, 2012, EUR J HUM GENET, V20, P1, DOI 10.1038/ejhg.2011.118
   Claesson-Welsh L, 2013, J INTERN MED, V273, P114, DOI 10.1111/joim.12019
   Colak E, 2011, OPHTHALMIC RES, V46, P125, DOI 10.1159/000323815
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Felbor U, 1996, J MED GENET, V33, P233, DOI 10.1136/jmg.33.3.233
   FELBOR U, 1995, HUM MOL GENET, V4, P2415, DOI 10.1093/hmg/4.12.2415
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Fraczek LA, 2010, MOL IMMUNOL, V48, P9, DOI 10.1016/j.molimm.2010.08.016
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gaedigk A, 2017, GENET MED, V19, P69, DOI 10.1038/gim.2016.80
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Gupta S, 2017, MODERN PATHOL, V30, P998, DOI 10.1038/modpathol.2017.24
   Hadley D, 2010, INVEST OPHTH VIS SCI, V51, P2191, DOI 10.1167/iovs.09-3798
   He H, 2001, P NATL ACAD SCI USA, V98, P11979, DOI 10.1073/pnas.221452098
   Huang Q, 2018, MED SCI MONITOR, V24, P1693, DOI 10.12659/MSM.906298
   Jiang H, 2009, RETINA-J RET VIT DIS, V29, P974, DOI 10.1097/IAE.0b013e3181a3b90e
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Kokki E, 2018, GENES-BASEL, V9, DOI 10.3390/genes9090438
   Kondo N, 2010, EUR J HUM GENET, V18, P634, DOI 10.1038/ejhg.2009.243
   Kubota D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073896
   Liang XY, 2014, EYE, V28, P1502, DOI 10.1038/eye.2014.226
   Liu R, 2009, FEBS J, V276, P1114, DOI 10.1111/j.1742-4658.2008.06855.x
   Liutkeviciene R, 2019, GENE, V686, P8, DOI 10.1016/j.gene.2018.11.004
   Liutkeviciene R, 2017, GENE, V636, P30, DOI 10.1016/j.gene.2017.09.022
   Lores-Motta L, 2018, MOL DIAGN THER, V22, P315, DOI 10.1007/s40291-018-0332-1
   Macgregor AM, 2009, J HISTOCHEM CYTOCHEM, V57, P207, DOI 10.1369/jhc.2008.952531
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Mousavi M., 2013, J OPTOM, V6, P176, DOI [10.1016/j.optom.2013.07.002, DOI 10.1016/j.optom.2013.07.002]
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Neverauskiene J., 2003, INT J OPHTHALMOL-CHI, V3, P225
   Oszajca K, 2018, OPHTHALMIC GENET, V39, P684, DOI 10.1080/13816810.2018.1525752
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Qian DG, 2014, EUR J HUM GENET, V22, P1417, DOI 10.1038/ejhg.2014.37
   Rajendran A, 2018, BRIT J OPHTHALMOL, V102, P1213, DOI 10.1136/bjophthalmol-2017-311384
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Sun J, 2016, LIPIDS HEALTH DIS, V15, DOI 10.1186/s12944-016-0348-7
   Tang NP, 2009, ANN EPIDEMIOL, V19, P740, DOI 10.1016/j.annepidem.2009.03.002
   Tuo JS, 2009, FASEB J, V23
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Vilkeviciute A, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/5631083
   VYSE TJ, 1994, GENOMICS, V24, P90, DOI 10.1006/geno.1994.1585
   Wang JH, 2011, HEART, V97, P1542, DOI 10.1136/heartjnl-2011-300342
   Wang YB, 2009, J CELL BIOCHEM, V106, P409, DOI 10.1002/jcb.22026
   WEBER BHF, 1994, NAT GENET, V7, P158, DOI 10.1038/ng0694-158
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Zhang YW, 2010, EXP EYE RES, V90, P374, DOI 10.1016/j.exer.2009.09.018
   Zhao L, 2013, CURR MOL MED, V13, P929, DOI 10.2174/15665240113139990048
   Zhou JL, 2005, BBA-GENE STRUCT EXPR, V1729, P200, DOI 10.1016/j.bbaexp.2005.05.005
   Zhou JL, 2005, FEBS LETT, V579, P1715, DOI 10.1016/j.febslet.2005.02.027
   Zhou JL, 2005, J EXP ZOOL PART A, V303A, P227, DOI 10.1002/jez.a.150
NR 82
TC 7
Z9 7
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0278-0240
EI 1875-8630
J9 DIS MARKERS
JI Dis. Markers
PD SEP 8
PY 2019
VL 2019
AR 9602949
DI 10.1155/2019/9602949
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine; Pathology
GA JA3TR
UT WOS:000487750800004
PM 31583032
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kar, D
   Clark, ME
   Swain, TA
   McGwin, G
   Crosson, JN
   Owsley, C
   Sloan, KR
   Curcio, CA
AF Kar, Deepayan
   Clark, Mark E.
   Swain, Thomas A.
   McGwin, Gerald, Jr.
   Crosson, Jason N.
   Owsley, Cynthia
   Sloan, Kenneth R.
   Curcio, Christine A.
TI Local Abundance of Macular Xanthophyll Pigment Is Associated with Rod-
   and Cone-Mediated Vision in Aging and Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE autofluorescence; macular xanthophyll pigment; Muller glia; rod-mediated
   dark adaptation; cone-mediated vision; age-related macular degeneration;
   fundus grading
ID OPTICAL-DENSITY; DARK-ADAPTATION; VISUAL PERFORMANCE; RETINAL THICKNESS;
   EYE DISEASE; LUTEIN SUPPLEMENTATION; CONTRAST SENSITIVITY; SPATIAL
   PROFILE; OLDER-ADULTS; DOUBLE-BLIND
AB PURPOSE. We assessed the association between the abundance of macular xanthophyll carotenoid pigment using dual-wavelength autofluorescence and multimodal vision testing including rod-mediated dark adaptation (RMDA), a measure of retinoid re-supply, in adults >= 60 years old with and without age-related macular degeneration (AMD).
   METHODS. AMD severity was determined using the nine-step Age-Related Eye Disease Study grading. Tests probed cones (best-corrected visual acuity, contrast sensitivity), cones and rods (low-luminance visual acuity, low-luminance deficit, mesopic light sensitivity), or rods only (scotopic light sensitivity, RMDA). Signal attenuation by macular pigment optical density (MPOD) was estimated using a ratio of blue and green autofluorescence signal to yield mean MPOD in a 1 degrees-diameter fovea-centered disk, mean MPOD in a 2 degrees-diameter disk centered on a perifoveal RMDA test location, and macular pigment optical volume (MPOV, or integrated MPOD) in a 4 degrees-diameter fovea-centered disk. Age-adjusted associations between vision and imaging measures were determined.
   RESULTS. In 88 eyes of 88 subjects (age, 74.9 +/- 5.8 years) with normal eyes (n = 32), early AMD (n = 23), or intermediate AMD (n = 33), foveal and perifoveal MPOD and MPOV were higher in the AMD eyes than in the normal eyes. At the RMDA test location, higher MPOD was unrelated to AMD severity but was associated with faster RMDA.
   CONCLUSIONS. In older adults with and without AMD, higher macular xanthophyll concentrations are associated with better best-corrected visual acuity and RMDA. Data are consistent with a model of cone resilience and rod vulnerability in aging and AMD and can be further explored in a larger sample study.
C1 [Kar, Deepayan; Clark, Mark E.; Swain, Thomas A.; McGwin, Gerald, Jr.; Crosson, Jason N.; Owsley, Cynthia; Sloan, Kenneth R.; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL USA.
   [Swain, Thomas A.; McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
   [Crosson, Jason N.] Retina Consultants Alabama, Birmingham, AL USA.
   [Sloan, Kenneth R.] Univ Alabama Birmingham, Dept Comp Sci, Sch Arts & Sci, Birmingham, AL USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, EyeSight Fdn Alabama, Dept Ophthalmol & Visual Sci, Vis Res Labs,Sch Med, 1670 Univ Blvd,Room 360, Birmingham, AL 35294 USA.
EM christinecurcio@uabmc.edu
RI Kar, Deepayan/AAX-8374-2020
OI Kar, Deepayan/0000-0003-2176-7430
FU National Institutes of Health [R01AG04212, R01EY029595, R01EY027948];
   EyeSight Foundation of Alabama; Dorsett Davis Discovery Fund; Alfreda J.
   Schueler Trust; Research to Prevent Blindness, Inc.; Heidelberg
   Engineering
FX Supported by National Institutes of Health Grants (R01AG04212,
   R01EY029595, and R01EY027948); EyeSight Foundation of Alabama; Dorsett
   Davis Discovery Fund; Alfreda J. Schueler Trust; Research to Prevent
   Blindness, Inc.; and Heidelberg Engineering.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Ahmad KM, 2003, VISUAL NEUROSCI, V20, P189, DOI 10.1017/S0952523803202091
   Akuffo KO, 2015, EYE, V29, P902, DOI 10.1038/eye.2015.64
   Akuffo KO, 2017, INVEST OPHTH VIS SCI, V58, P5347, DOI 10.1167/iovs.16-21192
   Akuffo KO, 2017, BRIT J OPHTHALMOL, V101, P190, DOI 10.1136/bjophthalmol-2016-308418
   Balaratnasingam C, 2015, INVEST OPHTH VIS SCI, V56, P7859, DOI 10.1167/iovs.15-17532
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Beirne RO, 2019, CLIN EXP OPTOM, V102, P611, DOI 10.1111/cxo.12882
   Bermond K, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.35
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Bovier ER, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108178
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Conrady CD, 2017, INVEST OPHTH VIS SCI, V58, P3616, DOI 10.1167/iovs.17-21818
   Crosson JN, 2019, OPHTHALMOL RETINA, V3, P670, DOI 10.1016/j.oret.2019.03.019
   Ctori I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169520
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01467-0
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Dolz-Marco R, 2018, AM J OPHTHALMOL, V193, P166, DOI 10.1016/j.ajo.2018.06.020
   DRASDO N, 1974, BRIT J OPHTHALMOL, V58, P709, DOI 10.1136/bjo.58.8.709
   Dubis AM, 2012, INVEST OPHTH VIS SCI, V53, P1628, DOI 10.1167/iovs.11-8488
   Edwards MM, 2017, INVEST OPHTH VIS SCI, V58, P1352, DOI 10.1167/iovs.16-21229
   ELLIOTT DB, 1991, CLIN VISION SCI, V6, P471
   Engles M, 2007, INVEST OPHTH VIS SCI, V48, P2922, DOI 10.1167/iovs.06-0883
   Erdman JW, 2015, FOODS, V4, P547, DOI 10.3390/foods4040547
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Freund KB, 2013, JAMA OPHTHALMOL, V131, P1645, DOI 10.1001/jamaophthalmol.2013.5030
   Gambril JA, 2019, INVEST OPHTH VIS SCI, V60, P2481, DOI 10.1167/iovs.19-26949
   Gass JDM, 1999, ARCH OPHTHALMOL-CHIC, V117, P821
   Giani A, 2010, AM J OPHTHALMOL, V150, P815, DOI 10.1016/j.ajo.2010.06.025
   Green-Gomez M, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.41
   Hammond BR, 2014, INVEST OPHTH VIS SCI, V55, P8583, DOI 10.1167/iovs.14-15573
   Hammond BR, 1998, INVEST OPHTH VIS SCI, V39, P397
   Helb HM, 2008, RETINA-J RET VIT DIS, V28, P808, DOI 10.1097/IAE.0b013e31816d81aa
   HIRSCH J, 1989, VISION RES, V29, P1095, DOI 10.1016/0042-6989(89)90058-8
   Hong IH, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e30
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kirby ML, 2009, INVEST OPHTH VIS SCI, V50, P1383, DOI 10.1167/iovs.08-2494
   Kvansakul J, 2006, OPHTHAL PHYSL OPT, V26, P362, DOI 10.1111/j.1475-1313.2006.00387.x
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Li BX, 2020, P NATL ACAD SCI USA, V117, P12352, DOI 10.1073/pnas.1922793117
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Liew SHM, 2006, EXP EYE RES, V82, P915, DOI 10.1016/j.exer.2005.10.014
   Linderman RE, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.20
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   Loughman J, 2012, INVEST OPHTH VIS SCI, V53, P7871, DOI 10.1167/iovs.12-10690
   Loughman J, 2010, VISION RES, V50, P1249, DOI 10.1016/j.visres.2010.04.009
   Mohn ES, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186767
   Muller S, 2018, AM J OPHTHALMOL, V194, P163, DOI 10.1016/j.ajo.2018.07.017
   Nolan JM, 2008, INVEST OPHTH VIS SCI, V49, P2134, DOI 10.1167/iovs.07-0933
   Nolan JM, 2016, INVEST OPHTH VIS SCI, V57, P3429, DOI 10.1167/iovs.16-19520
   Nolan JM, 2011, VISION RES, V51, P459, DOI 10.1016/j.visres.2010.12.016
   Obana A, 2020, JPN J OPHTHALMOL, V64, P160, DOI 10.1007/s10384-020-00716-5
   Obana A, 2017, INVEST OPHTH VIS SCI, V58, P5157, DOI 10.1167/iovs.17-22347
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Pang CE, 2016, RETINA-J RET VIT DIS, V36, P1408, DOI 10.1097/IAE.0000000000001069
   Patryas L, 2014, GRAEF ARCH CLIN EXP, V252, P657, DOI 10.1007/s00417-014-2564-z
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   PERRY VH, 1988, NEUROSCIENCE, V25, P225, DOI 10.1016/0306-4522(88)90021-8
   Powner MB, 2013, OPHTHALMOLOGY, V120, P2344, DOI 10.1016/j.ophtha.2013.04.013
   Powner MB, 2010, OPHTHALMOLOGY, V117, P2407, DOI 10.1016/j.ophtha.2010.04.001
   Puell MC, 2013, ACTA OPHTHALMOL, V91, pE298, DOI 10.1111/aos.12067
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Renzi LM, 2010, OPHTHAL PHYSL OPT, V30, P351, DOI 10.1111/j.1475-1313.2010.00720.x
   Rodriguez-Carmona M, 2006, OPHTHAL PHYSL OPT, V26, P137, DOI 10.1111/j.1475-1313.2006.00386.x
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rossi EA, 2010, NAT NEUROSCI, V13, P156, DOI 10.1038/nn.2465
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schultz R, 2018, INVEST OPHTH VIS SCI, V59
   Schultze M, 1866, ARCH MIKROSK ANAT, V2, P165
   Shi YY, 2019, OPHTHALMOL RETINA, V3, P211, DOI 10.1016/j.oret.2018.10.012
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Steinberg JS, 2016, AM J OPHTHALMOL, V168, P52, DOI 10.1016/j.ajo.2016.04.025
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Stringham JM, 2008, OPTOMETRY VISION SCI, V85, P82, DOI 10.1097/OPX.0b013e318162266e
   Stringham JM, 2015, INVEST OPHTH VIS SCI, V56, P2459, DOI 10.1167/iovs.14-15716
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Theelen T, 2014, ACTA OPHTHALMOL, V92, P138, DOI 10.1111/aos.12092
   Thurnham DI, 2015, GRAEF ARCH CLIN EXP, V253, P1231, DOI 10.1007/s00417-014-2811-3
   Trieschmann M, 2008, EYE, V22, P132, DOI 10.1038/sj.eye.6702780
   van der Made SM, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/9035745
   Van Der Veen RLP, 2009, EUR J OPHTHALMOL, V19, P836, DOI 10.1177/112067210901900524
   Vitale S, 2016, JAMA OPHTHALMOL, V134, P1041, DOI 10.1001/jamaophthalmol.2016.2383
   Wagner-Schuman M, 2011, INVEST OPHTH VIS SCI, V52, P625, DOI 10.1167/iovs.10-5886
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Warburton S, 2007, MOL VIS, V13, P318
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Westrup VMZ, 2014, INVEST OPHTH VIS SCI, V55, P1169, DOI 10.1167/iovs.13-12903
   Yao Y, 2013, NUTRITION, V29, P958, DOI 10.1016/j.nut.2012.10.017
   Zarubina AV, 2018, CURR EYE RES, V43, P913, DOI 10.1080/02713683.2018.1460380
   Zhang TJ, 2015, AM J OPHTHALMOL, V160, P290, DOI 10.1016/j.ajo.2015.04.034
NR 99
TC 4
Z9 4
U1 3
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2020
VL 61
IS 8
AR 46
DI 10.1167/iovs.61.8.46
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MS8BL
UT WOS:000554499000046
PM 32729911
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kenney, MC
   Chwa, M
   Atilano, SR
   Pavlis, JM
   Falatoonzadeh, P
   Ramirez, C
   Malik, D
   Hsu, T
   Woo, G
   Soe, K
   Nesburn, AB
   Boyer, DS
   Kuppermann, BD
   Jazwinski, SM
   Miceli, MV
   Wallace, DC
   Udar, N
AF Kenney, M. Cristina
   Chwa, Marilyn
   Atilano, Shari R.
   Pavlis, Janelle M.
   Falatoonzadeh, Payam
   Ramirez, Claudio
   Malik, Deepika
   Hsu, Tiffany
   Woo, Grace
   Soe, Kyaw
   Nesburn, Anthony B.
   Boyer, David S.
   Kuppermann, Baruch D.
   Jazwinski, S. Michal
   Miceli, Michael V.
   Wallace, Douglas C.
   Udar, Nitin
TI Mitochondrial DNA Variants Mediate Energy Production and Expression
   Levels for CFH, C3 and EFEMP1 Genes: Implications for Age-Related
   Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; MYOSIN VIIA; DRUSEN FORMATION; RISK; HAPLOGROUPS;
   LONGEVITY; GLAUCOMA; DISEASES; CELLS; VARIABILITY
AB Background: Mitochondrial dysfunction is associated with the development and progression of age-related macular degeneration (AMD). Recent studies using populations from the United States and Australia have demonstrated that AMD is associated with mitochondrial (mt) DNA haplogroups (as defined by combinations of mtDNA polymorphisms) that represent Northern European Caucasians. The aim of this study was to use the cytoplasmic hybrid (cybrid) model to investigate the molecular and biological functional consequences that occur when comparing the mtDNA H haplogroup (protective for AMD) versus J haplogroup (high risk for AMD).
   Methodology/Principal Findings: Cybrids were created by introducing mitochondria from individuals with either H or J haplogroups into a human retinal epithelial cell line (ARPE-19) that was devoid of mitochondrial DNA (Rho0). In cybrid lines, all of the cells carry the same nuclear genes but vary in mtDNA content. The J cybrids had significantly lower levels of ATP and reactive oxygen/nitrogen species production, but increased lactate levels and rates of growth. Q-PCR analyses showed J cybrids had decreased expressions for CFH, C3, and EFEMP1 genes, high risk genes for AMD, and higher expression for MYO7A, a gene associated with retinal degeneration in Usher type IB syndrome. The H and J cybrids also have comparatively altered expression of nuclear genes involved in pathways for cell signaling, inflammation, and metabolism.
   Conclusion/Significance: Our findings demonstrate that mtDNA haplogroup variants mediate not only energy production and cell growth, but also cell signaling for major molecular pathways. These data support the hypothesis that mtDNA variants play important roles in numerous cellular functions and disease processes, including AMD.
C1 [Kenney, M. Cristina; Chwa, Marilyn; Atilano, Shari R.; Pavlis, Janelle M.; Falatoonzadeh, Payam; Ramirez, Claudio; Malik, Deepika; Hsu, Tiffany; Woo, Grace; Soe, Kyaw; Nesburn, Anthony B.; Kuppermann, Baruch D.; Udar, Nitin] Univ Calif Irvine, Gavin Herbert Eye Inst, Irvine, CA 92717 USA.
   [Nesburn, Anthony B.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
   [Boyer, David S.] Retina Vitreous Associates Med Grp, Beverly Hills, CA USA.
   [Jazwinski, S. Michal; Miceli, Michael V.] Tulane Univ, Tulane Ctr Aging, New Orleans, LA 70118 USA.
   [Jazwinski, S. Michal; Miceli, Michael V.] Tulane Univ, Dept Med, New Orleans, LA 70118 USA.
   [Wallace, Douglas C.] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA.
C3 University of California System; University of California Irvine; Cedars
   Sinai Medical Center; Retina Vitreous Associates Medical Group; Tulane
   University; Tulane University; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh
RP Kenney, MC (通讯作者)，Univ Calif Irvine, Gavin Herbert Eye Inst, Irvine, CA 92717 USA.
EM mkenney@uci.edu
OI Udar, Nitin/0000-0001-8533-9190; Atilano, Shari/0000-0002-7729-7864
FU Discovery Eye Foundation; Lincy Foundation; Beckman Macular Research
   Initiative; Henry Guenther Foundation; Polly and Michael Smith
   Foundation; Research to Prevent Blindness Foundation; National Institute
   on Aging [AG006168]; NATIONAL INSTITUTE ON AGING [R01AG006168,
   R37AG006168] Funding Source: NIH RePORTER
FX Funding provided by The Discovery Eye Foundation www.discoveryeye.org,
   Lincy Foundation lincyinstitute.unlv.edu/lincy.html, Beckman Macular
   Research Initiative www.beckmanmacular.org, The Henry Guenther
   Foundation, Polly and Michael Smith Foundation, Research to Prevent
   Blindness Foundation www.rpbusa.org, and the National Institute on Aging
   (AG006168). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abu-Amero KK, 2011, MOL VIS, V17, P1468
   Abu-Amero KK, 2011, MOL VIS, V17, P543
   Arning L, 2010, J MOL MED, V88, P431, DOI 10.1007/s00109-010-0589-2
   Bellizzi D, 2009, CELL STRESS CHAPERON, V14, P265, DOI 10.1007/s12192-008-0081-x
   Bellizzi D, 2006, GENES CELLS, V11, P883, DOI 10.1111/j.1365-2443.2006.00986.x
   Bellizzi D, 2012, EPIGENOMICS-UK, V4, P17, DOI [10.2217/EPI.11.109, 10.2217/epi.11.109]
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   BROWN MD, 1992, AM J HUM GENET, V51, P378
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Chomyn A, 1996, PLALTELET MEDIATED T
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Czarnecka AM, 2011, J AGING RES, V2011, DOI DOI 10.4061/2011/136435
   De Benedictis G, 1999, FASEB J, V13, P1532, DOI 10.1096/fasebj.13.12.1532
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fernandez-Moreno M, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00129
   Fernandez-Moreno M, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-264
   Ferraresi R, 2008, CYTOM PART A, V73A, P528, DOI 10.1002/cyto.a.20544
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Gomez-Duran A, 2010, HUM MOL GENET, V19, P3343, DOI 10.1093/hmg/ddq246
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HASSON T, 1995, P NATL ACAD SCI USA, V92, P9815, DOI 10.1073/pnas.92.21.9815
   Jazwinski S. M., 2012, BIOCH BIOPHYS ACTA, DOI 10.1016/j.bbr.2011.03.031
   Jazwinski SM, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00139
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Juel HB, 2011, EXP EYE RES, V92, P180, DOI 10.1016/j.exer.2011.01.003
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kofler B, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-35
   Liu XR, 1998, NAT GENET, V19, P117, DOI 10.1038/470
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Marcuello A, 2009, MITOCHONDRION, V9, P326, DOI 10.1016/j.mito.2009.04.007
   Marcuello A, 2009, MITOCHONDRION, V9, P27, DOI 10.1016/j.mito.2008.10.002
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Martinez-Redondo D, 2010, MITOCHONDRION, V10, P102, DOI 10.1016/j.mito.2009.11.005
   McFarland R, 2009, J INTERN MED, V265, P210, DOI 10.1111/j.1365-2796.2008.02066.x
   Miceli MV, 2005, EXP CELL RES, V302, P270, DOI 10.1016/j.yexcr.2004.09.006
   Miceli MV, 2005, INVEST OPHTH VIS SCI, V46, P1765, DOI 10.1167/iovs.04-1327
   Mueller EE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030874
   Narayanan R, 2007, OPHTHALMOLOGY, V114, P1327, DOI 10.1016/j.ophtha.2006.10.035
   Niemi AK, 2003, HUM GENET, V112, P29, DOI 10.1007/s00439-002-0843-y
   Okamoto H, 2006, MOL VIS, V12, P156
   Pathak D, 2011, MOL VIS, V17, P1514
   Penisson-Besnier I, 2001, REV NEUROL-FRANCE, V157, P537
   Reynier P, 1999, EUR J HUM GENET, V7, P404, DOI 10.1038/sj.ejhg.5200293
   Rodley CDM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030943
   Ross OA, 2001, EXP GERONTOL, V36, P1161, DOI 10.1016/S0531-5565(01)00094-8
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Song EL, 2011, GYNECOL ONCOL, V121, P174, DOI 10.1016/j.ygyno.2010.11.004
   Song EL, 2010, GYNECOL ONCOL, V117, P417, DOI 10.1016/j.ygyno.2009.12.016
   Suissa S, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000474
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   WALLACE DC, 1994, J BIOENERG BIOMEMBR, V26, P241, DOI 10.1007/BF00763096
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Wallace DC, 2007, MITOCHONDRIAL GENES, P194
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Weil D, 1996, P NATL ACAD SCI USA, V93, P3232, DOI 10.1073/pnas.93.8.3232
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0
   Wolf C, 2010, BMC GENET, V11, DOI 10.1186/1471-2156-11-8
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yates JR, 2005, NAT REV MOL CELL BIO, V6, P702, DOI 10.1038/nrm1711
NR 71
TC 71
Z9 72
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 24
PY 2013
VL 8
IS 1
AR e54339
DI 10.1371/journal.pone.0054339
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 077JK
UT WOS:000314023600048
PM 23365660
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pham, TQ
   Wang, JJ
   Maloof, A
   Mitchell, P
AF Pham, TQ
   Wang, JJ
   Maloof, A
   Mitchell, P
TI Cataract surgery in patients with age-related maculopathy: preoperative
   diagnosis and postoperative visual acuity
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related maculopathy; cataract surgery; sensitivity; specificity
ID BLUE MOUNTAINS EYE; QUALITY-OF-LIFE; BEAVER DAM EYE;
   POPULATION-CROSS-SECTIONS; MACULAR DEGENERATION; 5-YEAR INCIDENCE;
   IMPAIRMENT; PREVALENCE; OUTCOMES; PROGRESSION
AB Purpose: To report the reliability in detecting age-related maculopathy (ARM) lesions before cataract surgery and postoperative visual acuity (VA) in cataract surgery patients with ARM.
   Methods: Medical records of surgical patients in a large public hospital, west of Sydney, were reviewed retrospectively Detection of ARM lesions was compared before and after surgery to determine sensitivity and specificity of preoperative diagnoses. Postoperative VA was assessed 4 weeks after surgery.
   Results: Data were available for 721/784 eyes (92.0%) of 656 patients aged 60 years or older. ARM lesions were detected in 98 eyes (13.6%) before and 92 eyes (12.8%) after surgery Sensitivities for detecting late ARM lesions, soft drusen and retinal pigment epithelium abnormalities preoperatively were 100%, 94% and 69%, respectively Corresponding specificities were 100%, 100% and 77%, respectively. Postoperative VA achieved or remained 6/12 or better in 81.6% of eyes.
   Conclusion: A high sensitivity and specificity in detecting late ARM lesions and soft drusen preoperatively, and a good postoperative VA outcome is achievable in patients with preoperative early ARM lesions.
C1 Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Westmead, NSW 2145, Australia.
   Westmead Hosp, Westmead Millennium Inst, Sydney, NSW, Australia.
   Westmead Hosp, Dept Ophthalmol, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; University of Sydney
RP Wang, JJ (通讯作者)，Univ Sydney, Westmead Hosp, Dept Ophthalmol, Ctr Vis Res, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin_wang@wmi.usyd.edu.au
RI wang, jie/GRS-0942-2022; Wang, Jie Jin/P-1499-2014; Mitchell,
   Paul/P-1498-2014
OI Wang, Jie Jin/0000-0001-9491-4898; 
CR Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Desai P, 1999, BRIT J OPHTHALMOL, V83, P1336, DOI 10.1136/bjo.83.12.1336
   Desai P, 1996, BRIT J OPHTHALMOL, V80, P868, DOI 10.1136/bjo.80.10.868
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Keeffe JE, 1996, AUST NZ J OPHTHALMOL, V24, P313, DOI 10.1111/j.1442-9071.1996.tb01601.x
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Lundstrom M, 1999, BRIT J OPHTHALMOL, V83, P1272, DOI 10.1136/bjo.83.11.1272
   Pollack A, 1998, OPHTHALMIC SURG LAS, V29, P286
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   SCHEIN OD, 1995, OPHTHALMOLOGY, V102, P817, DOI 10.1016/S0161-6420(95)30952-9
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   SPERDUTO RD, 1986, AM J EPIDEMIOL, V124, P994, DOI 10.1093/oxfordjournals.aje.a114489
   Tan AG, 2004, CLIN EXP OPHTHALMOL, V32, P284, DOI 10.1111/j.1442-9071.2004.00817.x
   TIELSCH JM, 1995, ARCH OPHTHALMOL-CHIC, V113, P1312, DOI 10.1001/archopht.1995.01100100100038
   Tikellis G, 2000, CLIN EXP OPHTHALMOL, V28, P367, DOI 10.1046/j.1442-9071.2000.00336.x
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wang JJ, 1999, INVEST OPHTH VIS SCI, V40, P12
NR 25
TC 7
Z9 8
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD AUG
PY 2005
VL 33
IS 4
BP 360
EP 363
DI 10.1111/j.1442-9071.2005.01031.x
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 965YP
UT WOS:000231987100007
PM 16033346
DA 2022-11-30
ER

PT J
AU Kim, EK
   Kim, H
   Vijayakumar, A
   Kwon, O
   Chang, N
AF Kim, Eun-kyung
   Kim, Hyesook
   Vijayakumar, Aswathy
   Kwon, Oran
   Chang, Namsoo
TI Associations between fruit and vegetable, and antioxidant nutrient
   intake and age-related macular degeneration by smoking status in elderly
   Korean men
SO NUTRITION JOURNAL
LA English
DT Article
DE Age-related macular degeneration; Fruit and vegetables; Antioxidants;
   Elderly male smokers; KNHANES
ID NUTRITION EXAMINATION SURVEY; RISK-FACTORS; OXIDATIVE STRESS;
   NATIONAL-HEALTH; CIGARETTE-SMOKING; BETA-CAROTENE; HUMAN PLASMA; LUTEIN;
   CONSUMPTION; PREVALENCE
AB Background: Age-related macular degeneration (AMD) is one of the major causes of irreversible blindness. The objective of this study was to determine whether there is any relationship between dietary intake of fruits and vegetables (F&V) and antioxidant nutrients including carotenoids and AMD according to smoking status in elderly men.
   Methods: We performed a cross-sectional analysis using nationally representative samples of elderly aged >= 65 years (n = 1414) from the Korea National Health and Nutrition Examination Survey (KNHANES, 2010-2012).
   Results: The current smokers consumed less food in total, and, in particular, less cereals/potatoes/sugar products, fruits and vegetables than the nonsmokers and former smokers (p < 0.05). Intake of energy, thiamin, vitamin C, vitamin A, and beta-carotene were significantly lower in the current smokers than in the nonsmokers and the former smokers. For current smokers, the ORs of the highest tertile compared with the lowest tertile were 0.36 (95% CI: 0.14-0.96, p for trend = 0. 0576) for F&V, 0.32 (95% CI: 0.12-0.85, p for trend = 0.0561) for vitamin C, 0.23 (95% CI: 0.08-0.67, p for trend = 0.0038) for a-carotene, 0.13 (95% CI: 0.04-0.46, p for trend = 0.0003) for beta-carotene after adjusting for confounding factors. In contrast, there was no association between antioxidant nutrient intake and AMD among the nonsmokers and former smokers.
   Conclusions: These results suggest that increased consumption of fruits and vegetables containing antioxidant components such as vitamin C, a-carotene, and beta-carotene may have a protective effect on AMD. These effects may be more evident among current smokers.
C1 [Kim, Eun-kyung; Kim, Hyesook; Vijayakumar, Aswathy; Kwon, Oran; Chang, Namsoo] Ewha Womans Univ, Dept Nutr Sci & Food Management, Seoul 120750, South Korea.
C3 Ewha Womans University
RP Chang, N (通讯作者)，Ewha Womans Univ, Dept Nutr Sci & Food Management, Seoul 120750, South Korea.
EM nschang@ewha.ac.kr
RI Vijayakumar, Aswathy/AAV-5262-2021
OI Vijayakumar, Aswathy/0000-0003-1111-7354
FU Brain Korea 21 Plus
FX This research was supported by the Brain Korea 21 Plus.
CR Amirul Islam FM, 2014, OPHTHALMOLOGY, V121
   [Anonymous], 2016, KOR NAT HLTH NUTR EX
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Barbosa JM, 2008, REV BRAS FARMACOGN, V18, P135, DOI 10.1590/S0102-695X2008000100023
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benetou V, 2016, J BONE MINER RES, V31, P1743, DOI 10.1002/jbmr.2850
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cheong S, 2017, INT J PUBLIC HLTH CL, V4, P28
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chichili GR, 2006, BRIT J NUTR, V96, P643, DOI 10.1079/BJN20061843
   Cho BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102816
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P4430, DOI 10.1167/iovs.14-14379
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003
   Coleman AL, 2010, AM J OPHTHALMOL, V149, P160, DOI 10.1016/j.ajo.2009.07.025
   DIANA JN, 1993, ANN NY ACAD SCI, V686, P1, DOI 10.1111/j.1749-6632.1993.tb39147.x
   Eisenhauer B, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020120
   Endoh Kaori, 2015, Asian Pac J Cancer Prev, V16, P6527
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   FREI B, 1991, AM J CLIN NUTR, V54, pS1113, DOI 10.1093/ajcn/54.6.1113s
   Gopinath B, 2017, BRIT J OPHTHALMOL, V101, P1027, DOI 10.1136/bjophthalmol-2016-309490
   Gopinath B, 2014, BRIT J NUTR, V111, P1673, DOI 10.1017/S000711451300408X
   Haibach JP, 2013, NICOTINE TOB RES, V15, P355, DOI 10.1093/ntr/nts130
   Hininger I, 1997, EUR J CLIN NUTR, V51, P601, DOI 10.1038/sj.ejcn.1600451
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kaarniranta K, 2015, CURR EYE RES, V40, P226, DOI 10.3109/02713683.2014.925933
   Kellen E, 2006, INT J CANCER, V118, P2572, DOI 10.1002/ijc.21714
   Korea Centers for Disease Control and Prevention, 2013, 5 KOR NAT HLTH NUTR
   [Korea MoHaWo Prevention KCfDCa], 2010, REP PRES KOR NAT HLT
   Koushan K, 2013, NUTRIENTS, V5, P1823, DOI 10.3390/nu5051823
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Masood S, 2015, INT J PUBLIC HEALTH, V60, P891, DOI 10.1007/s00038-015-0730-7
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Michikawa T, 2009, ASIA PAC J CLIN NUTR, V18, P1
   Moriarty SE, 2003, FREE RADICAL BIO MED, V35, P1582, DOI 10.1016/j.freeradbiomed.2003.09.006
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Nidhi B, 2013, INDIAN J OPHTHALMOL, V61, P722, DOI 10.4103/0301-4738.120218
   Ozawa Y., 2014, NEUROPROT NEUROREGEN, P239
   Palaniappan U, 2001, J NUTR, V131, P1952, DOI 10.1093/jn/131.7.1952
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Piermarocchi S, 2016, OPHTHALMIC RES, V55, P111, DOI 10.1159/000441795
   Pisoschi AM, 2015, EUR J MED CHEM, V97, P55, DOI 10.1016/j.ejmech.2015.04.040
   Schleicher M, 2013, NUTRIENTS, V5, P2405, DOI 10.3390/nu5072405
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Sharkey JR, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-32
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Xie HL, 2013, OSTEOPOROSIS INT, V24, P2827, DOI 10.1007/s00198-013-2383-9
   Yao Y, 2013, NUTRITION, V29, P958, DOI 10.1016/j.nut.2012.10.017
   Yoon Kyung-Chul, 2011, Korean J Ophthalmol, V25, P421, DOI 10.3341/kjo.2011.25.6.421
   Zhu W, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110743
NR 59
TC 15
Z9 16
U1 2
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2891
J9 NUTR J
JI Nutr. J.
PD DEC 4
PY 2017
VL 16
AR 77
DI 10.1186/s12937-017-0301-2
PG 9
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA FP3MG
UT WOS:000417521700002
PM 29202844
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Mozaffarieh, M
   Sacu, S
   Wedrich, A
AF Mozaffarieh, Maneli
   Sacu, Stefan
   Wedrich, Andreas
TI The role of the carotenoids, lutein and zeaxanthin, in protecting
   against age-related macular degeneration: A review based on
   controversial evidence
SO NUTRITION JOURNAL
LA English
DT Review
ID 3RD NATIONAL-HEALTH; BETA-CAROTENE; RISK-FACTORS; VITAMIN-A; TISSUE
   DISTRIBUTION; STARGARDT-DISEASE; CIGARETTE-SMOKING; IRIS PIGMENTATION;
   PLASMA; SERUM
AB Purpose: A review of the role of the carotenoids, lutein and zeaxanthin, and their function in altering the pathogenesis of age-related macular degeneration (AMD).
   Methods: Medline and Embase search.
   Results: Recent evidence introduces the possibility that lutein and zeaxanthin, carotenoids found in a variety of fruits and vegetables may protect against the common eye disease of macular degeneration. This potential and the lack to slow the progression of macular degeneration, has fueled high public interest in the health benefits of these carotenoids and prompted their inclusion in various supplements. The body of evidence supporting a role in this disease ranges from basic studies in experimental animals to various other clinical and epidemiological studies. Whilst some epidemiological studies suggest a beneficial role for carotenoids in the prevention of AMD, others are found to be unrelated to it. Results of some clinical studies indicate that the risk for AMD is reduced when levels of the carotenoids are elevated in the serum or diet, but this correlation is not observed in other studies. Published data concerning the toxicity of the carotenoids or the optimum dosage of these supplements is lacking.
   Conclusion: An intake of dietary supplied nutrients rich in the carotenoids, lutein and zeaxanthin, appears to be beneficial in protecting retinal tissues, but this is not proven. Until scientifically sound knowledge is available we recommend for patients judged to be at risk for AMD to: alter their diet to more dark green leafy vegetables, wear UV protective lenses and a hat when outdoors. Future investigations on the role of nutrition, light exposure, genetics, and combinations of photodynamic therapy with intravitreal steroid (triamcinolone-acetonide) injections hold potential for future treatment possibilities.
C1 [Mozaffarieh, Maneli; Sacu, Stefan; Wedrich, Andreas] Univ Vienna, Dept Ophthalmol, A-1010 Vienna, Austria.
C3 University of Vienna
RP Wedrich, A (通讯作者)，Univ Vienna, Dept Ophthalmol, A-1010 Vienna, Austria.
EM m.maneli@utanet.at; stefan.sacu@akh-wien.ac.at;
   andreas.wedrich@akh-wien.ac.at
RI Wedrich, Andreas/AAE-9171-2020
CR Albanes D, 1997, AM J CLIN NUTR, V66, P366, DOI 10.1093/ajcn/66.2.366
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1999, INT J VITAM NUTR RES, V69, P198
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   BENDICH A, 1988, NUTR CANCER, V11, P207, DOI 10.1080/01635588809513989
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bernstein PS, 1997, INVEST OPHTH VIS SCI, V38, P167
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   BONE RA, 1984, VISION RES, V24, P103, DOI 10.1016/0042-6989(84)90094-4
   BORGES J, 1990, ARCH OPHTHALMOL-CHIC, V108, P727, DOI 10.1001/archopht.1990.01070070113047
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Canfield LM, 1997, AM J CLIN NUTR, V66, P52, DOI 10.1093/ajcn/66.1.52
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   CLEVIDENCE BA, 1993, METHOD ENZYMOL, V214, P33
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   DAYHAWBARKER P, 1987, PHOTOCHEM PHOTOBIOL, V46, P1051, DOI 10.1111/j.1751-1097.1987.tb04892.x
   DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497
   DICHTBURN RW, 1973, EYE MOVEMENTS VISUAL
   Faulks RM, 1998, J LAB CLIN MED, V132, P507, DOI 10.1016/S0022-2143(98)90129-9
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   FITE KV, 1989, CURR EYE RES, V8, P1039, DOI 10.3109/02713688908997396
   FOOTE CS, 1970, J AM CHEM SOC, V92, P5216, DOI 10.1021/ja00720a036
   Fotouhi N, 1996, AM J CLIN NUTR, V63, P553, DOI 10.1093/ajcn/63.4.553
   GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209
   GIBSON JM, 1986, T OPHTHAL SOC UK, V105, P463
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   GOLDSMITH TH, 1984, VISION RES, V24, P1661, DOI 10.1016/0042-6989(84)90324-9
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   HOLZ FG, 1994, AM J OPHTHALMOL, V117, P19, DOI 10.1016/S0002-9394(14)73010-7
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   KHACHIK F, 1992, METHOD ENZYMOL, V213, P347
   KHACHIK F, 1992, METHOD ENZYMOL, V213, P205
   KIRSCHFELD K, 1982, PROC R SOC SER B-BIO, V216, P71, DOI 10.1098/rspb.1982.0061
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   LAKSHMAN MR, 1993, METHOD ENZYMOL, V214, P74
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Leung IYF, 1999, INVEST OPHTH VIS SCI, V40, pS608
   Leung IYF, 2001, INVEST OPHTH VIS SCI, V42, P466
   LEUREDUPREE AE, 1982, INVEST OPHTH VIS SCI, V23, P425
   MALINOW MR, 1980, INVEST OPHTH VIS SCI, V19, P857
   MANGELS AR, 1993, J AM DIET ASSOC, V93, P284, DOI 10.1016/0002-8223(93)91553-3
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Mares-Perlman JA, 1999, AM J CLIN NUTR, V70, P431
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   MCCARTY C, 1999, CRC MOD NUT, P135
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   MICOZZI MS, 1992, AM J CLIN NUTR, V55, P1120, DOI 10.1093/ajcn/55.6.1120
   Moeller SM, 2000, J AM COLL NUTR, V19, p522S, DOI 10.1080/07315724.2000.10718975
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Nierenberg DW, 1997, AM J CLIN NUTR, V66, P315, DOI 10.1093/ajcn/66.2.315
   Nussbaum J J, 1981, Retina, V1, P296, DOI 10.1097/00006982-198101040-00007
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   ORGANISCIAK DT, 1985, INVEST OPHTH VIS SCI, V26, P1580
   Peterson K, 1996, SCIENCE, V271, P441
   Pratt S, 1999, J Am Optom Assoc, V70, P39
   READING VM, 1974, J OPT SOC AM, V64, P231, DOI 10.1364/JOSA.64.000231
   REDDY KJ, 1993, METHOD ENZYMOL, V214, P390
   RIBAYAMERCADO JD, 1995, J AM COLL NUTR, V14, P614
   SANDBERG MA, 1994, INVEST OPHTH VIS SCI, V35, P2734
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schalch W., 1992, FREE RADICALS AGEING
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Snodderly DM, 1997, J NUTR, V127, P122, DOI 10.1093/jn/127.1.122
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Toyoda Y, 2002, INVEST OPHTH VIS SCI, V43, P1210
   Toyoda Y, 1996, INVEST OPHTH VIS SCI, V37, P3692
   URSIN G, 1993, AM J EPIDEMIOL, V137, P916, DOI 10.1093/oxfordjournals.aje.a116753
   van den Berg H, 1999, NUTR REV, V57, P1, DOI 10.1111/j.1753-4887.1999.tb01769.x
   Vandenlangenberg GM, 1988, AM J EPIDEMIOL, V148, P204
   Votruba M, 2001, EYE, V15, P424, DOI 10.1038/eye.2001.147
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
   Ziegler RG, 1996, J NATL CANCER I, V88, P612, DOI 10.1093/jnci/88.9.612
NR 105
TC 136
Z9 148
U1 0
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2891
J9 NUTR J
JI Nutr. J.
PY 2003
VL 2
AR 20
DI 10.1186/1475-2891-2-20
PG 8
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA V40MC
UT WOS:000209481700020
PM 14670087
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Karnon, J
   Czoski-Murray, C
   Smith, KJ
   Brand, C
AF Karnon, Jonathan
   Czoski-Murray, Carolyn
   Smith, Kevin J.
   Brand, Christopher
TI A Hybrid Cohort Individual Sampling Natural History Model of Age-Related
   Macular Degeneration: Assessing the Cost-Effectiveness of Screening
   Using Probabilistic Calibration
SO MEDICAL DECISION MAKING
LA English
DT Article
DE screening; age-related macular degeneration; cost-utility; probabilistic
   calibration; hybrid cohort individual sampling model
ID EXTRAFOVEAL CHOROIDAL NEOVASCULARIZATION; GEOGRAPHIC ATROPHY FORM;
   5-YEAR FOLLOW-UP; UNILATERAL EXTRAFOVEAL; LASER PHOTOCOAGULATION;
   UTILITY VALUES; RISK-FACTORS; FELLOW EYES; VITAMIN-E; MACULOPATHY
AB Background. Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness. It is likely that treatment of AMD at earlier stages is more effective than later treatment; thus, screening for AMD should be considered. The aim of this study was to develop a natural history model of AMD to estimate the cost-effectiveness of screening. Methods. A hybrid cohort/individual sampling decision analytic model was developed. Primary data sets, expert elicitation, and data from the literature were used to populate the model. To incorporate joint parameter uncertainty, and to populate unobservable parameters, an innovative form of probabilistic calibration was applied to a range of output parameters. Results. In the reference case, annual screening from age 60 y is the most cost-effective option, although this is subject to high levels of uncertainty. Alternative, age-specific utility values show that screening is predicted to be less cost-effective, assuming interventions that reduce progression to wet AMD moderately improve the cost-effectiveness of screening, whereas the addition of anti-vascular endothelial growth factor therapy for juxtafoveal or subfoveal wet AMD lesions improves the cost-effectiveness of screening significantly. Conclusions. The extent of the uncertainty around the mean results, and the additional resources and possible reorganization of services required to implement screening, indicate that it may be preferable to reduce the level of uncertainty before implementing screening for AMD. Initial actions may be best targeted at assessing how routine data may be used to describe clinical presentation, a screening pilot study, and a secondary costing study.
C1 [Karnon, Jonathan] Univ Adelaide, Sch Populat Hlth & Clin Practice, Adelaide, SA 5005, Australia.
   [Czoski-Murray, Carolyn; Smith, Kevin J.] Univ Sheffield, Sch Hlth & Related Res, Sheffield S10 2TN, S Yorkshire, England.
   [Brand, Christopher] Univ Sheffield, Teaching Hosp, Sheffield S10 2TN, S Yorkshire, England.
C3 University of Adelaide; University of Sheffield; University of Sheffield
RP Karnon, J (通讯作者)，Univ Adelaide, Sch Populat Hlth & Clin Practice, Level 9,10 Pulteney St, Adelaide, SA 5005, Australia.
OI Karnon, Jonathan/0000-0003-3220-2099; Czoski Murray,
   Carolyn/0000-0001-7742-2883
FU UK National Health Service Health Technology Assessment program
FX Received 17 August 2007 from the School of Population Health and
   Clinical Practice, University of Adelaide, Australia (JK); School of
   Health and Related Research, University of Sheffield, United Kingdom
   (CC-M, KJS); and Sheffield University Teaching Hospitals, Sheffield,
   United Kingdom (CB). This work was supported by a research grant from
   the UK National Health Service Health Technology Assessment program. JK
   was based at the School of Health and Related Research, University of
   Sheffield, during the conduct of this research. Revision accepted for
   publication 16 September 2008.
CR Ali F, 2004, ARCH OPHTHALMOL-CHIC, V122, P710, DOI 10.1001/archopht.122.5.710
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Barton Pelham, 2004, J Health Serv Res Policy, V9, P110, DOI 10.1258/135581904322987535
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Busbee BG, 2003, RETINA-J RET VIT DIS, V23, P279, DOI 10.1097/00006982-200306000-00001
   Claxton K, 1999, J HEALTH ECON, V18, P341, DOI 10.1016/S0167-6296(98)00039-3
   *CLIN GOV, OP LAB POST JUXT INJ
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hall NF, 2002, BRIT MED J, V325, P1, DOI 10.1136/bmj.325.7354.1
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Henstock E., 2002, EVALUATION HPV LBC C
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Karnon J, 1998, Health Care Manag Sci, V1, P133, DOI 10.1023/A:1019090401655
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Krumpaszky HG, 1999, OPHTHALMOLOGICA, V213, P48, DOI 10.1159/000027393
   Meads C, 2001, HEALTH TECHNOL ASSES, V7, P1
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   National Institute for Health and Clinical Excellence, 2004, GUID METH TECHN APPR
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Roderick P, 2003, Health Technol Assess, V7, P1
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schachat AP, 2005, OPHTHALMOLOGY, V112, P531, DOI 10.1016/j.ophtha.2005.01.018
   Sharma S, 2005, CAN J OPHTHALMOL, V40, P369, DOI 10.1016/S0008-4182(05)80079-1
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Stevenson MR, 2005, BRIT J OPHTHALMOL, V89, P1045, DOI 10.1136/bjo.2003.030445
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Tomany SC, 2001, AM J OPHTHALMOL, V132, P271, DOI 10.1016/S0002-9394(01)00895-9
   *UK GOV, INT LIF TABL ENG WAL
   Wilkinson CP, 1996, ARCH OPHTHALMOL-CHIC, V114, P677
   1997, ARCH OPHTHAMOL, V115, P741
NR 40
TC 14
Z9 14
U1 0
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0272-989X
J9 MED DECIS MAKING
JI Med. Decis. Mak.
PD MAY
PY 2009
VL 29
IS 3
BP 304
EP 316
DI 10.1177/0272989X08327491
PG 13
WC Health Care Sciences & Services; Health Policy & Services; Medical
   Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; Medical Informatics
GA 455MM
UT WOS:000266764700004
PM 19129156
DA 2022-11-30
ER

PT J
AU Bonyadi, M
   Foruzandeh, Z
   Mohammadian, T
   Fotouhi, N
   Soheilian, M
   Bonyadi, MHJ
   Javadzadeh, A
   Moein, H
   Yaseri, M
AF Bonyadi, Mortaza
   Foruzandeh, Zahra
   Mohammadian, Tahereh
   Fotouhi, Nikou
   Soheilian, Masoud
   Bonyadi, Mohammad Hossein Jabbarpoor
   Javadzadeh, Alireza
   Moein, Hamidreza
   Yaseri, Mehdi
TI Evaluation of CC-cytokine ligand 2 and complementary factor H Y402H
   polymorphisms and their interactional association with age-related
   macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; CC-cytokine ligand 2; complement
   factor H (CFH Y402H) gene; Iranian population; monocyte chemo-attractant
   protein 1; single nucleotide polymorphism
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL
   NEOVASCULARIZATION; GENE POLYMORPHISM; DRUSEN; EYE; INFLAMMATION;
   METAANALYSIS; MACROPHAGES; PROGRESSION
AB PurposeTo evaluate the association of CC-cytokine ligand 2 CCL2-2518 (rs1024611) single nucleotide polymorphism, complement factor H (CFH Y402H) and their possible interaction in developing advanced age-related macular degeneration (AMD).
   MethodsIn this case-control study, DNA samples from 266 patients with advanced AMD and 229 healthy controls were genotyped for CCL2 polymorphism and also 254 patients and 164 healthy controls were genotyped for CFH polymorphism. The possible associations of these polymorphisms with susceptibility to AMD independently and in different joint combinations were evaluated.
   ResultsThe genotype frequency for CFH was found to be significantly different between AMD and normal controls (31.5% versus 20.7%, OR=3.56, p<0.001 for CC and 52.4% versus 41.5%, OR=2.96, p<0.001 for CT genotype). However, no significant association between CCL2 polymorphism and AMD was observed in this cohort (OR=1.15 and OR=0.8, p=0.172). Interestingly, studying the joint effects of two genotypes (TT genotype of CFH Y402H and AG genotype of CCL2-2518) showed more significant protective effect against AMD (p=0.0001), while the risk effect of CC and CT genotypes of CFH was only visible in the presence of AA genotype of CCL2-2518 (p=0.044 and p=0.05).
   ConclusionComplement factor H Y402H polymorphism is strongly associated with advanced type AMD. Although this study revealed no association of CCL2-2518 with AMD, the risk effect of CFH genotypes was only visible in the presence of AA genotype of CCL2-2518. AG genotype of CCL2-2518 in combination with TT genotype of CFH Y402H showed significant protective effect against AMD.
C1 [Bonyadi, Mortaza; Foruzandeh, Zahra; Mohammadian, Tahereh; Fotouhi, Nikou; Bonyadi, Mohammad Hossein Jabbarpoor] Univ Tabriz, Fac Nat Sci, Ctr Excellence Biodivers, Tabriz, Iran.
   [Bonyadi, Mortaza] Tabriz Univ Med Sci, Liver & Gastrointestinal Dis Res Ctr, Tabriz, Iran.
   [Soheilian, Masoud; Bonyadi, Mohammad Hossein Jabbarpoor; Moein, Hamidreza] Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Ocular Tissue Engn Res Ctr, Tehran, Iran.
   [Javadzadeh, Alireza] Tabriz Univ Med Sci, Dept Ophthalmol, Tabriz, Iran.
   [Yaseri, Mehdi] Univ Tehran Med Sci, Dept Biostat & Epidemiol, Tehran, Iran.
C3 University of Tabriz; Tabriz University of Medical Science; Shahid
   Beheshti University Medical Sciences; Tabriz University of Medical
   Science; Tehran University of Medical Sciences
RP Bonyadi, MHJ (通讯作者)，Shahid Beheshti Univ Med Sci, Dept Ophthalmol, Tehran, Iran.
EM mhbonyadi@yahoo.com
RI Soheilian, Masoud/AAW-4743-2020; Yaseri, Mehdi/I-1645-2018; Javadzadeh,
   Alireza/L-6424-2017; Hossein, Jabbarpoor Bonyadi Mohammad/A-1886-2014;
   Javadzadeh, Aliehsadat/J-9830-2017
OI Yaseri, Mehdi/0000-0002-4066-873X; Javadzadeh,
   Alireza/0000-0002-5151-6125; Foruzandeh, Zahra/0000-0002-9131-8940;
   Soheilian, Masoud/0000-0001-7508-426X
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049905
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Babanejad M, 2015, OPHTHALMIC GENET, V23, P1
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bonyadi M, 2016, OPHTHALMIC GENET, V30, P1
   Bonyadi M, 2015, INT J DERMATOL, V54, P1269, DOI 10.1111/ijd.12940
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chowers I, 2008, MOL VIS, V14, P1829
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Crane IJ, 2000, IMMUNOLOGY, V101, P426, DOI 10.1046/j.0019-2805.2000.01105.x
   Csaky K, 2004, ARCH OPHTHALMOL-CHIC, V122, P650, DOI 10.1001/archopht.122.4.650
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fenoglio C, 2004, NEUROBIOL AGING, V25, P1169, DOI 10.1016/j.neurobiolaging.2003.11.008
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Garcia M, 2015, ACTA OPHTHALMOL, V93, pE658, DOI 10.1111/aos.12790
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hautamaki A, 2015, ACTA OPHTHALMOL, V93, P726, DOI 10.1111/aos.12799
   Hong KH, 2005, BLOOD, V105, P1405, DOI 10.1182/blood-2004-08-3178
   Hughes AE, 2016, ACTA OPHTHALMOL, V94, pE247, DOI 10.1111/aos.12822
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Quan YL, 2012, INT J OPHTHALMOL-CHI, V5, P242, DOI 10.3980/j.issn.2222-3959.2012.02.25
   R Core Team, 2014, R LANG ENV STAT COMP
   Rovin BH, 1999, BIOCHEM BIOPH RES CO, V259, P344, DOI 10.1006/bbrc.1999.0796
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Soysal Y, 2012, DNA CELL BIOL, V31, P322, DOI 10.1089/dna.2011.1214
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Wang JCC, 2015, MOL VIS, V21, P264
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yamada M, 2003, ARTERIOSCL THROM VAS, V23, P1996, DOI 10.1161/01.ATV.0000096208.80992.63
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
NR 51
TC 13
Z9 13
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2016
VL 94
IS 8
BP E779
EP E785
DI 10.1111/aos.13143
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ED1AR
UT WOS:000388576400024
PM 27316788
OA Bronze
DA 2022-11-30
ER

PT J
AU Casten, R
   Rovner, BW
   Fontenot, JL
AF Casten, Robin
   Rovner, Barry W.
   Fontenot, Joseph L.
TI Targeted Vision Function Goals and Use of Vision Resources in
   Ophthalmology Patients with Age-Related Macular Degeneration and
   Comorbid Depressive Symptoms
SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS
LA English
DT Article
ID COGNITIVE DECLINE; VISUAL-ACUITY; OLDER-ADULTS; DEVICE USE;
   REHABILITATION; SERVICES; PARTICIPATION; INTERVENTION; OUTCOMES; TRIAL
AB Introduction: This study characterizes self-reported functional vision goals and the use of low vision resources (for example, services and devices) in ophthalmology clinic patients with age-related macular degeneration (AMD) and comorbid depressive symptoms. Methods: From July 2009 to February 2013, we assessed 188 consecutive patients (age 65+; mean 84.0 years; 70.2% female) with AMD (best corrected distance acuity 20/70 or worse) enrolled in a 12-month randomized clinical trial to test the efficacy of a multicomponent intervention that combined low vision optometry and home-based occupational therapy to prevent depression (Low Vision Depression Prevention Trial [VITAL]). A geriatric nurse conducted in-home assessments to measure visual acuity and contrast sensitivity, self-reported functional vision, functional vision goals that were personally important yet difficult to achieve (targeted vision function goals), and the use of low vision resources (defined as services, devices and strategies utilized by low vision patients to compensate for visual deficits). This study reports on baseline data collected prior to randomization. Results: Only 9.6% of the sample had received formal low vision services. The five most common goals were newspaper reading, leisure and entertainment, computer use, personal communication, and correspondence. Participants engaged in targeted vision function goals less frequently since being diagnosed with AMD, despite using low vision resources and reporting low to moderate difficulty in using them. Discussion: Few patients with AMD seen in ophthalmology clinics received low vision rehabilitation. Patients who utilized resources engaged in goals less frequently since being diagnosed with AMD. Implications for practitioners: Patients with AMD are underutilizing low vision rehabilitation resources. Strategies for increasing low vision referrals are suggested.
C1 [Casten, Robin] Thomas Jefferson Univ, Jefferson Hosp Neurosci, Dept Psychiat & Human Behav, 900 Walnut St,2nd Floor, Philadelphia, PA 19107 USA.
   [Rovner, Barry W.] Wills Eye Hosp & Res Inst, Jefferson Hosp Neurosci, 900 Walnut St, Philadelphia, PA 19107 USA.
   [Fontenot, Joseph L.] Community Serv Vis Rehabil, 600 Bel Air Blvd,Suite 110, Mobile, AL 36606 USA.
C3 Jefferson University; Jefferson University
RP Casten, R (通讯作者)，Thomas Jefferson Univ, Jefferson Hosp Neurosci, Dept Psychiat & Human Behav, 900 Walnut St,2nd Floor, Philadelphia, PA 19107 USA.
EM robin.casten@jefferson.edu; barry.rovner@jefferson.edu;
   jlfontenot@bellsouth.net
FU National Eye Institute [U01 EY018819]
FX This work was supported by National Eye Institute grant U01 EY018819.
CR APA, 1994, DIAGNOSTIC STAT MANU
   Binns AM, 2012, SURV OPHTHALMOL, V57, P34, DOI 10.1016/j.survophthal.2011.06.006
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P127, DOI 10.1016/S0008-4182(00)80005-8
   Brown JC, 2014, OPHTHALMOLOGY, V121, P1655, DOI 10.1016/j.ophtha.2014.02.030
   Brunnstrom G, 2004, OPHTHAL PHYSL OPT, V24, P274, DOI 10.1111/j.1475-1313.2004.00192.x
   Casten RJ, 2005, J VISUAL IMPAIR BLIN, V99, P720
   Christ SL, 2014, JAMA OPHTHALMOL, V132, P1400, DOI 10.1001/jamaophthalmol.2014.2847
   Coco-Martin MB, 2013, OPHTHALMOLOGY, V120, P151, DOI 10.1016/j.ophtha.2012.07.035
   Copolillo A, 2005, AM J OCCUP THER, V59, P305, DOI 10.5014/ajot.59.3.305
   Eklund Kajsa, 2006, Can J Occup Ther, V73, P272
   Eklund K, 2007, DISABIL REHABIL-ASSI, V2, P326, DOI 10.1080/17483100701714717
   Evans JR, 2007, OPHTHALMOLOGY, V114, P283, DOI 10.1016/j.ophtha.2006.10.006
   Goldstein JE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1028, DOI 10.1001/archophthalmol.2012.1197
   Hooper P, 2008, CAN J OPHTHALMOL, V43, P180, DOI 10.3129/i08-001
   Horowitz A, 2005, AM J GERIAT PSYCHIAT, V13, P180, DOI 10.1176/appi.ajgp.13.3.180
   Horowitz A, 2006, J GERONTOL B-PSYCHOL, V61, pS274, DOI 10.1093/geronb/61.5.S274
   Jones GC, 2009, REHABIL PSYCHOL, V54, P164, DOI 10.1037/a0015910
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1476, DOI 10.1167/iovs.06-0610
   Markowitz SN, 2008, J VISUAL IMPAIR BLIN, V102, P774, DOI 10.1177/0145482X0810201205
   Massof RW, 2005, ARCH PHYS MED REHAB, V86, P954, DOI 10.1016/j.apmr.2004.09.017
   McCabe P, 2000, Ophthalmic Epidemiol, V7, P259, DOI 10.1076/opep.7.4.259.4173
   Nguyen NX, 2009, NEURO-OPHTHALMOLOGY, V33, P115, DOI 10.1080/01658100902825513
   Overbury O, 2011, INVEST OPHTH VIS SCI, V52, P8933, DOI 10.1167/iovs.11-8116
   Owsley C, 2009, ARCH OPHTHALMOL-CHIC, V127, P681, DOI 10.1001/archophthalmol.2009.55
   Reeves BC, 2004, BRIT J OPHTHALMOL, V88, P1443, DOI 10.1136/bjo.2003.037457
   Reischies FM, 1997, BRIT J PSYCHIAT, V171, P449, DOI 10.1192/bjp.171.5.449
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rovner BW, 2014, OPHTHALMOLOGY, V121, P2204, DOI 10.1016/j.ophtha.2014.05.002
   Rovner BW, 2009, ALZHEIMERS DEMENT, V5, P12, DOI 10.1016/j.jalz.2008.06.001
   Rovner BW, 1998, J AM GERIATR SOC, V46, P617, DOI 10.1111/j.1532-5415.1998.tb01080.x
   Scanlan JM, 2004, J VISUAL IMPAIR BLIN, V98, P601, DOI 10.1177/0145482X0409801005
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   Stelmack JA, 2008, ARCH OPHTHALMOL-CHIC, V126, P608, DOI 10.1001/archopht.126.5.608
   Stelmack JA, 2007, ARCH PHYS MED REHAB, V88, P691, DOI 10.1016/j.apmr.2007.03.025
   Sunness JS, 2009, RETINA-J RET VIT DIS, V29, P1036, DOI 10.1097/IAE.0b013e3181a91da8
   Wahl HW, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/278135
   Watson GR, 1997, OPTOMETRY VISION SCI, V74, P249, DOI 10.1097/00006324-199705000-00019
   Watson GR, 1997, OPTOMETRY VISION SCI, V74, P260, DOI 10.1097/00006324-199705000-00020
NR 40
TC 5
Z9 5
U1 0
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0145-482X
EI 1559-1476
J9 J VISUAL IMPAIR BLIN
JI J. Vis. Impair. Blind.
PD NOV-DEC
PY 2016
VL 110
IS 6
BP 413
EP 424
PG 12
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA EJ3MX
UT WOS:000393117400004
DA 2022-11-30
ER

PT J
AU Neveu, MM
   Tufail, A
   Dowler, JG
   Holder, GE
AF Neveu, Magella M.
   Tufail, Adnan
   Dowler, Jonathan G.
   Holder, Graham E.
TI A comparison of pattern and multifocal electroretinography in the
   evaluation of age-related macular degeneration and its treatment with
   photodynamic therapy
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE pattern ERG; multifocal ERG; age-related macular degeneration;
   fluorescein angiography
ID RETINAL FUNCTION; CHOROIDAL NEOVASCULARIZATION; RETINITIS-PIGMENTOSA;
   ERG; MACULOPATHY; DYSTROPHY
AB This study compares pattern electroretinography (PERG) and multifocal electroretinography (mfERG) measures in 13 patients with predominantly classic choroidal neovascularisation (CNV) associated with age-related macular degeneration (ARMD, 9/13 unilateral, 4/13 bilateral), assesses the usefulness of each test in monitoring disease progression, and identifies electrophysiological predictors of outcome following treatment with photodynamic therapy (PDT). PERG and mfERGs were recorded at presentation, 2 weeks post-treatment, and at 3 monthly intervals for 2 years. The PERG was detectable in 8/13 patients with unilateral disease; the mfERG was detectable in 12/13 patients. P50 and N95 amplitudes increased in 6/8 patients and mfERG p1 increased in 7/13 patients at 2 years. PERG amplitudes correlated strongly with mfERG amplitudes in patients with unilateral disease. PERG P50 and mfERG p1 amplitude correlated with visual acuity at 2 years (R = 0.68, R = 0.82, respectively). The largest PERG P50 and mfERG p1 amplitude difference between treated and fellow eyes of all the groups on initial visit was associated with a poor visual outcome (P50 64% difference; p1 29% difference) whereas those with the smallest P50 and p1 amplitude difference was associated with improved vision at 2 years (P50 30% difference; p1 21% difference). The PERG and mfERG provide an objective measure of central retinal function in the progression of ARMD. A detectable PERG on presentation was the single best indicator of improved function and visual acuity at 2 years. The mfERG demonstrated disease progression from central retina into the paramacular regions over 2 years. Patients with poor visual outcomes had the largest inter-ocular amplitude difference on presentation, suggesting that such patients may have a worse prognosis following treatment.
C1 Moorfields Eye Hosp, Dept Electrophysiol, London EC1V 2PD, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Holder, GE (通讯作者)，Moorfields Eye Hosp, Dept Electrophysiol, 162 City Rd, London EC1V 2PD, England.
EM Graham.Holder@moorfields.nhs.uk
OI Tufail, Adnan/0000-0001-6131-7640
CR Bach Michael, 2000, Documenta Ophthalmologica, V101, P11
   Bearse MA, 1996, J OPT SOC AM A, V13, P634
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Eksandh L, 2001, Ophthalmic Genet, V22, P107, DOI 10.1076/opge.22.2.107.2226
   Gerth C, 2002, GRAEF ARCH CLIN EXP, V240, P202, DOI 10.1007/s00417-002-0442-6
   Heinemann-Vernaleken B, 2001, GRAEF ARCH CLIN EXP, V239, P556, DOI 10.1007/s004170100308
   Holder GE, 2001, PROG RETIN EYE RES, V20, P531, DOI 10.1016/S1350-9462(00)00030-6
   Holopigian K, 2001, INVEST OPHTH VIS SCI, V42, P779
   Hood DC, 2000, PROG RETIN EYE RES, V19, P607, DOI 10.1016/S1350-9462(00)00013-6
   Huang Shizhou, 2000, Documenta Ophthalmologica, V101, P115
   Jurklies B, 2002, GRAEF ARCH CLIN EXP, V240, P244, DOI 10.1007/s00417-002-0439-1
   Kondo M, 2001, INVEST OPHTH VIS SCI, V42, P1342
   Kretschmann U, 1998, BRIT J OPHTHALMOL, V82, P267, DOI 10.1136/bjo.82.3.267
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Marmor MF, 2003, DOC OPHTHALMOL, V106, P105, DOI 10.1023/A:1022591317907
   Palmowski AM, 2002, OPHTHALMOLOGY, V109, P1788, DOI 10.1016/S0161-6420(02)01147-8
   Palmowski AM, 1999, OPHTHALMOLOGE, V96, P166, DOI 10.1007/s003470050389
   Ruther K, 2003, OPHTHALMOLOGE, V100, P459, DOI 10.1007/s00347-002-0757-z
   Scholl HPN, 2002, VISION RES, V42, P1053, DOI 10.1016/S0042-6989(02)00034-2
   Seeliger M, 1998, AM J OPHTHALMOL, V125, P214, DOI 10.1016/S0002-9394(99)80094-4
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Varano M, 2005, INVEST OPHTH VIS SCI, V46, P1453, DOI 10.1167/iovs.04-0903
NR 22
TC 11
Z9 15
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
EI 1573-2622
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD SEP
PY 2006
VL 113
IS 2
BP 71
EP 81
DI 10.1007/s10633-006-9016-y
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 115GD
UT WOS:000242721900001
PM 16972084
DA 2022-11-30
ER

PT J
AU Galvez, MIL
   Barquet, LA
   Figueroa, MS
   Garcia-Layana, A
   Moreno, JMR
AF Galvez, Maria Isabel Lopez
   Barquet, Lluis Arias
   Figueroa, Marta S.
   Garcia-Layana, Alfredo
   Moreno, Jose M. Ruiz
CA Ineye Study Grp
TI Bimonthly, treat-and-extend and as-needed ranibizumab in naive
   neovascular age-related macular degeneration patients: 12-month outcomes
   of a randomized study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE best-corrected visual acuity; fixed bimonthly; intravitreal anti-VEGF;
   neovascular age-related macular degeneration; pro re nata; ranibizumab;
   treat-and-extend
ID DOSING REGIMEN; SAFETY; EFFICACY; VERTEPORFIN; THERAPY
AB Purpose To assess the noninferiority of the treat-and-extend (T&E) and fixed bimonthly regimens of 0.5 mg intravitreal ranibizumab as compared with the pro re nata (PRN) in naive patients with neovascular age-related macular degeneration (nAMD).
   Methods Phase IV, randomized, 12-month, multicentre trial. Patients aged >= 50 years with nAMD and visual impairment [best-corrected visual acuity (BCVA) between 23 and 78 Early Treatment Diabetic Retinopathy Study (ETDRS) letters] were eligible. Patients (one eye per patient) were randomized to bimonthly, n = 103, T&E, n = 99 or PRN, n = 104. Noninferiority was established at five letters ETDRS.
   Results The mean (95% CI) difference in BCVA at 12 months was 7.2 (4.2-10.2), 6.4 (2.9-9.8), and 8.0 (51.1-11.0) in the bimonthly, T&E and PRN, respectively. The bimonthly or T&E regimens were not inferior to the PRN scheme. All regimens were associated with a significant reduction of central subfield thickness and volume. The mean (95% CI) number of injections in the bimonthly regimen (7.6, 7.5-7.7) was similar as compared with the PRN regimen (7.4, 6.7-8.0) (p = 0.159) but lower than in the T&E regimen (9.3, 8.9-9.7) (p < 0.001).
   Conclusion At 12 months, bimonthly and T&E ranibizumab were noninferior to PRN in naive nAMD.
C1 [Galvez, Maria Isabel Lopez] Hosp Clin Univ Valladolid, Dept Ophthalmol, Ave Ramon y Cajal 3, E-47005 Valladolid, Spain.
   [Barquet, Lluis Arias] Hosp Univ Bellvitge, Dept Ophthalmol, Barcelona, Spain.
   [Figueroa, Marta S.] Hosp Univ Ramon y Cajal, Dept Ophthalmol, Madrid, Spain.
   [Garcia-Layana, Alfredo] Clin Univ Navarra, Dept Ophthalmol, Pamplona, Spain.
   [Moreno, Jose M. Ruiz] Hosp Univ Puerta de Hierro Majadahonda, Dept Ophthalmol, Madrid, Spain.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge
   University Hospital; University of Barcelona; Hospital Universitario
   Ramon y Cajal; University of Navarra; Hospital Puerta de
   Hierro-Majadahonda
RP Galvez, MIL (通讯作者)，Hosp Clin Univ Valladolid, Dept Ophthalmol, Ave Ramon y Cajal 3, E-47005 Valladolid, Spain.
EM maribel@ioba.med.uva.es
RI Sanchez, Estanislao Gutierrez/P-7776-2018
OI Sanchez, Estanislao Gutierrez/0000-0003-4851-680X; Ruiz-Moreno, Jose
   M/0000-0001-9636-0788; Lopez, Maria Isabel/0000-0002-7878-287X; CABRERA
   LOPEZ, FRANCISCO/0000-0002-5074-5102; Asencio-Duran,
   Monica/0000-0002-6281-3109; Garcia-Arumi, Jose/0000-0001-8827-1160
FU Spanish Ministry of Health, Institutode SaludCarlos III, Red Tematicade
   Investigacion Cooperativa en Salud: 'Prevencion, deteccion precoz, y
   tratamiento de la patologia ocular prevalente, degenerativa y cronica'
   [RD16/0008/0021]; Novartis Farmaceutica, S.A.
FX This study has been supported in part by a grant of the Spanish Ministry
   of Health, Institutode SaludCarlos III, Red Tematicade Investigacion
   Cooperativa en Salud: 'Prevencion, deteccion precoz, y tratamiento de la
   patologia ocular prevalente, degenerativa y cronica' (RD16/0008/0021).
   The study was promoted by the Spanish Vitreoretinal Society (SERV) and
   supported by Novartis Farmaceutica, S.A. The funding organization had no
   role in the in the design or conduct of this research.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Cohen SY, 2014, OPHTHALMOLOGICA, V231, P80, DOI 10.1159/000356401
   Danyliv A, 2017, ADV THER, V34, P611, DOI 10.1007/s12325-017-0484-0
   Dugel PU, 2018, TREAT AND EXTENT STR
   Feltgen N, 2017, GRAEF ARCH CLIN EXP, V255, P923, DOI 10.1007/s00417-017-3589-x
   Guo MY, 2018, PHARMACOTHERAPY, V38, P197, DOI 10.1002/phar.2079
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Ozkaya Abdullah, 2017, Korean J Ophthalmol, V31, P424, DOI 10.3341/kjo.2016.0125
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rufai SR, 2017, EYE, V31, P1337, DOI 10.1038/eye.2017.67
   Sawada T, 2014, GRAEF ARCH CLIN EXP, V252, P1545, DOI 10.1007/s00417-014-2612-8
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Silva R, 2017, ACTA MEDICA PORT, V30, P449, DOI 10.20344/amp.8217
   Toth CA, 2015, RETINA-J RET VIT DIS, V35, P1303, DOI 10.1097/IAE.0000000000000483
   Vardarinos A, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0451-1
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Yang Y, 2017, OPHTHALMOL THER, V6, P175, DOI 10.1007/s40123-017-0091-9
   Yasukawa T, 2013, EXPERT REV OPHTHALMO, V8, P321, DOI 10.1586/17469899.2013.814960
NR 33
TC 9
Z9 9
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2020
VL 98
IS 7
BP E820
EP E829
DI 10.1111/aos.14399
EA MAR 2020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OC4CH
UT WOS:000520536500001
PM 32190990
DA 2022-11-30
ER

PT J
AU Rivera, A
   Fisher, SA
   Fritsche, LG
   Keilhauer, CN
   Lichtner, P
   Meitinger, T
   Weber, BHF
AF Rivera, A
   Fisher, SA
   Fritsche, LG
   Keilhauer, CN
   Lichtner, P
   Meitinger, T
   Weber, BHF
TI Hypothetical LOC387715 is a second major susceptibility gene for
   age-related macular degeneration, contributing independently of
   complement factor H to disease risk
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID GENOMEWIDE-SCAN; EXTENDED FAMILIES; CHROMOSOME 10Q26; LINKAGE ANALYSIS;
   MACULOPATHY; EYE; VARIANT; LOCUS; POLYMORPHISM; ASSOCIATION
AB Age-related macular degeneration (AMD) is a multifactorial disease and a prevalent cause of visual impairment in developed countries. Risk factors include environmental components and genetic determinants. The complement factor H (CFH) has been the first major susceptibility gene for AMD identified within 1q32. Here, we focused on a second region of interest in 10q26 where a recent meta-analysis revealed strongest evidence for linkage to AMD at a genome-wide significance level. Within an interval of 22 Mb, we have analyzed 93 single nucleotide polymorphisms for allelic association with AMD in two independent case-control cohorts of German origin (AMD(combined) n=1166; controls(combined) n=945). Significant association was found across a 60 kb region of high linkage disequilibrium harboring two genes PLEKHA1 and hypothetical LOC387715. The strongest association (P=10(-34)) centered over a frequent coding polymorphism, Ala69Ser, at LOC387715, strongly implicating this gene in the pathogenesis of AMD. Besides abundant expression in placenta, we demonstrate weak expression of LOC387715 in the human retina. At present, however, there is no functional information on this gene, which appears to have evolved recently within the primate lineage. The joint contribution of the common risk allele at LOC387715, Ala69Ser, and at CFH, Tyr402His, was assessed in our case-control population, which suggests an additive model indicating an independent contribution of the two gene loci to disease risk. Our data show a disease odds ratio of 57.6 (95% CI: 37.2, 89.0) conferred by homozygosity for risk alleles at both CFH and LOC387715 when compared with the baseline non-risk genotype.
C1 Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
   Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Med & Mol Genet, London, England.
   Univ Eye Clin, Dept Ophthalmol, Wurzburg, Germany.
   Tech Univ Munich, Inst Human Genet, D-81675 Munich, Germany.
   GSF Natl Res Ctr Environm & Hlth, Inst Human Genet, D-85764 Neuherberg, Germany.
C3 University of Regensburg; University of London; King's College London;
   University of Wurzburg; Technical University of Munich; Helmholtz
   Association; Helmholtz-Center Munich - German Research Center for
   Environmental Health
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
EM bweb@biozentrum.uni-wuerzburg.de
RI Fritsche, Lars G/AAF-9387-2019; Meitinger, Thomas/O-1318-2015
OI Fritsche, Lars G/0000-0002-2110-1690; Weber, Bernhard
   H.F./0000-0002-8808-7723; Meitinger, Thomas/0000-0002-8838-8403
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Agresti A., 2019, INTRO CATEGORICAL DA
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Comer GM, 2004, DRUG AGING, V21, P967, DOI 10.2165/00002512-200421150-00002
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003
   Dudbridge Frank, 2003, Human Genomics, V1, P63
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LEWONTIN RC, 1964, GENETICS, V49, P49
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Santangelo Susan L, 2005, Ophthalmic Genet, V26, P61, DOI 10.1080/13816810490967944
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-18
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 43
TC 612
Z9 641
U1 0
U2 18
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD NOV 1
PY 2005
VL 14
IS 21
BP 3227
EP 3236
DI 10.1093/hmg/ddi353
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 976QR
UT WOS:000232748800011
PM 16174643
OA Bronze
DA 2022-11-30
ER

PT J
AU Pencak, M
   Veith, M
AF Pencak, Martin
   Veith, Miroslav
TI Asymmetric response to ranibizumab in mixed choroidal neovascularization
   in a neovascular age-related macular degeneration diagnosed on OCT
   angiography - case report
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Anti-VEGF; Mixed CNV; Age-related macular degeneration; Resistance; Case
   report
ID VEGF TRAP; AFLIBERCEPT; THERAPY; TACHYPHYLAXIS; BEVACIZUMAB; PEGAPTANIB
AB Background To present a case report of a patient with a mixed choroidal neovascular membrane (CNV) with an asymmetric response to ranibizumab diagnosed on optical coherence tomography angiography (OCTa). Case presentation A 61-year-old male was referred to our department in September 2017 due to decreased vision in his left eye. Best-corrected visual acuity (BCVA) was 43 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in the left eye. Macular edema was present in the left eye, and a mixed CNV was identified on the OCTa. Therapy with intravitreal ranibizumab was commenced. After 5 ranibizumab injections, the BCVA was 42 ETDRS letters, and considerable intraretinal edema was still present. OCTa showed a resolution of the type 2 lesion of the mixed CNV; however, the type 1 lesion had continued to grow. The patient was then switched to intravitreal aflibercept. After 3 monthly aflibercept injections, the BCVA improved to 53 ETDRS letters, and a reduction of the edema was observed on the optical coherence tomography (OCT). OCTa showed a decrease in both the area and vessel density in the type 1 lesion of the CNV. Therapy with aflibercept was continued; however, while the intraretinal edema continued to improve, atrophy developed in the macula and the BCVA worsened to 43 ETDRS letters. Conclusions Ranibizumab nonresponse in a neovascular age-related macular degeneration is not uncommon. However, to our knowledge, this is the first described case of an asymmetric response to ranibizumab in a mixed CNV. While the type 2 lesion of the CNV reacted swiftly to the ranibizumab therapy, the type 1 lesion continued to grow. As with some other cases of ranibizumab resistance, switching to aflibercept proved effective.
C1 [Pencak, Martin; Veith, Miroslav] Charles Univ Prague, Fac Med 3, Dept Ophthalmol, Srobarova 1150-50, Prague 10034, Czech Republic.
   [Pencak, Martin; Veith, Miroslav] Univ Hosp Kralovske Vinohrady, Srobarova 1150-50, Prague 10034, Czech Republic.
C3 Charles University Prague; University Hospital Vinohrady
RP Pencak, M (通讯作者)，Charles Univ Prague, Fac Med 3, Dept Ophthalmol, Srobarova 1150-50, Prague 10034, Czech Republic.
EM pencak@volny.cz
OI Pencak, Martin/0000-0002-9090-0998
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bressler NM, 2013, RETINA, P1183
   Doguizi S, 2015, INT J OPHTHALMOL-CHI, V8, P846, DOI 10.3980/j.issn.2222-3959.2015.04.37
   Forooghian F, 2011, ACTA OPHTHALMOL, V89, pE206, DOI 10.1111/j.1755-3768.2009.01773.x
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Kim JM, 2019, SEMIN OPHTHALMOL, V34, P168, DOI 10.1080/08820538.2019.1620791
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shiragami C, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000116
   Stepanov A, 2021, EUR J OPHTHALMOL, V31, P2488, DOI 10.1177/1120672120971190
NR 17
TC 0
Z9 0
U1 1
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JAN 15
PY 2021
VL 21
IS 1
AR 42
DI 10.1186/s12886-021-01810-z
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PU7SN
UT WOS:000609501100002
PM 33451290
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Detaram, HD
   Liew, G
   Russell, J
   Vu, KV
   Burlutsky, G
   Mitchell, P
   Gopinath, B
AF Detaram, Harshil Dharamdasani
   Liew, Gerald
   Russell, Joanna
   Kim Van Vu
   Burlutsky, George
   Mitchell, Paul
   Gopinath, Bamini
TI Dietary antioxidants are associated with presence of intra- and
   sub-retinal fluid in neovascular age-related macular degeneration after
   1 year
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE antioxidants; beta-carotene; neovascular age-related macular
   degeneration; retinal fluid; zinc
ID BETA-CAROTENE; VISUAL-ACUITY; RISK; ZINC; SUPPLEMENTATION; COPPER;
   TRIAL; TREAT
AB Purpose To assess whether dietary intake of antioxidants, fruits, vegetables and fish is associated with 12-month treatment outcomes in neovascular age-related macular degeneration (nAMD) patients. Methods A total of 547 participants were diagnosed with nAMD at baseline, of whom 494 were followed up after 12 months of antivascular endothelial growth factor therapy. Dietary intakes were determined using a validated food frequency questionnaire. Presence of intra-retinal and sub-retinal fluid (IRF, SRF), pigment epithelial detachment (PED) and central macular thickness (CMT) were recorded from optical coherence tomography images. Best-corrected visual acuity was recorded using log of the Minimum Angle of Resolution (LogMAR) charts. Results Participants in the upper three quartiles combined compared to those in the first quartile of baseline dietary zinc intake had 49% reduced odds of SRF 12 months later, multivariable-adjusted odds ratio (OR) 0.51 [95% confidence interval (CI) 0.30-0.89]. The upper three quartiles combined compared to the first quartile of beta-carotene intake had 90% greater odds of IRF presence at 12-month follow-up, multivariable-adjusted OR 1.90 (95% CI 1.04-3.46). The highest versus lowest quartile of dietary beta-carotene intake had a nearly twofold greater odds of PED presence, multivariable-adjusted OR 1.99 (95% CI 1.03-3.84). Conclusion A higher intake of dietary zinc was associated with a reduced likelihood of SRF at 1 year. Conversely, a higher intake of dietary beta-carotene was associated with an increased risk of IRF and PED. These findings underscore the importance of ongoing nutritional advice for nAMD patients presenting for treatment.
C1 [Detaram, Harshil Dharamdasani; Liew, Gerald; Kim Van Vu; Burlutsky, George; Mitchell, Paul; Gopinath, Bamini] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW, Australia.
   [Detaram, Harshil Dharamdasani; Liew, Gerald; Kim Van Vu; Burlutsky, George; Mitchell, Paul; Gopinath, Bamini] Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Russell, Joanna] Univ Wollongong, Fac Social Sci, Sch Hlth & Soc, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; University of Wollongong
RP Gopinath, B (通讯作者)，Univ Sydney, Westmead Hosp, Westmead Inst Med Res, Ctr Vis Res, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM bamini.gopinath@sydney.edu.au
RI Liew, Gerald/AAB-6870-2022
OI Dharamdasani Detaram, Harshil/0000-0002-6095-5963
FU Macular Disease Foundation Australia (MDFA)
FX The study received funding or support from Macular Disease Foundation
   Australia (MDFA).
CR [Anonymous], 2006, FOOD AUST, V58, P298
   BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Christen WG, 2007, ARCH OPHTHALMOL-CHIC, V125, P333, DOI 10.1001/archopht.125.3.333
   Detaram HD, 2020, CLIN EXP OPHTHALMOL, V48, P61, DOI 10.1111/ceo.13644
   Erie JC, 2009, AM J OPHTHALMOL, V147, P276, DOI 10.1016/j.ajo.2008.08.014
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   Gemenetzi M, 2017, OPHTHALMOL THER, V6, P79, DOI 10.1007/s40123-017-0087-5
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Johnson AR, 2007, J UROLOGY, V177, P639, DOI 10.1016/j.juro.2006.09.047
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khanani AM, 2018, RETINA-J RET VIT DIS, V38, P2103, DOI 10.1097/IAE.0000000000002195
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   NUTTAB, 2010, NUTTAB
   Smailhodzic D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112682
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Ugarte M, 2013, SURV OPHTHALMOL, V58, P585, DOI 10.1016/j.survophthal.2012.12.002
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
   Zhou HY, 2011, INVEST OPHTH VIS SCI, V52, P4338, DOI 10.1167/iovs.10-6519
   Zhu W, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110743
NR 30
TC 1
Z9 1
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2020
VL 98
IS 7
BP E814
EP E819
DI 10.1111/aos.14394
EA MAR 2020
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OC4CH
UT WOS:000563889300001
PM 32162461
DA 2022-11-30
ER

PT J
AU Begum, R
   Powner, MB
   Hudson, N
   Hogg, C
   Jeffery, G
AF Begum, Rana
   Powner, Michael B.
   Hudson, Natalie
   Hogg, Chris
   Jeffery, Glen
TI Treatment with 670 nm Light Up Regulates Cytochrome C Oxidase Expression
   and Reduces Inflammation in an Age-Related Macular Degeneration Model
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT FACTOR-H; EMITTING DIODE TREATMENT; NEAR-INFRARED LIGHT;
   AMYLOID-BETA; PHOTOBIOMODULATION; POLYMORPHISM; DYSFUNCTION; RADIATION;
   LESIONS; RETINA
AB Inflammation is an umbrella feature of ageing. It is present in the aged retina and many retinal diseases including age-related macular degeneration (AMD). In ageing and in AMD mitochondrial function declines. In normal ageing this can be manipulated by brief exposure to 670 nm light on the retina, which increases mitochondrial membrane potential and reduces inflammation. Here we ask if 670 nm exposure has the same ability in an aged mouse model of AMD, the complement factor H knockout (CFH-/-) where inflammation is a key feature. Further, we ask whether this occurs when 670 nm is delivered briefly in environmental lighting rather than directly focussed on the retina. Mice were exposed to 670 nm for 6 minutes twice a day for 14 days in the form of supplemented environmental light. Exposed animals had significant increase in cytochrome c oxidase (COX), which is a mitochondrial enzyme regulating oxidative phosphorylation. There was a significant reduction in complement component C3, an inflammatory marker in the outer retina. Vimetin and glial fibrillary acidic protein (GFAP) expression, which reflect retinal stress in Muller glia, were also significantly down regulated. There were also significant changes in outer retinal macrophage morphology. However, amyloid beta (A beta) load, which also increases with age in the outer retina and is pro-inflammatory, did not change. Hence, 670 nm is effective in reducing inflammation probably via COX activation in mice with a genotype similar to that in 50% of AMD patients even when brief exposures are delivered via environmental lighting. Further, inflammation can be reduced independent of A beta. The efficacy revealed here supports current early stage clinical trials of 670 nm in AMD patients.
C1 [Begum, Rana; Powner, Michael B.; Hudson, Natalie; Hogg, Chris; Jeffery, Glen] UCL, Inst Ophthalmol, London, England.
   [Hogg, Chris] Moorfields Eye Hosp, London, England.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust
RP Jeffery, G (通讯作者)，UCL, Inst Ophthalmol, London, England.
EM g.jeffery@ucl.ac.uk
RI Powner, Michael/CAG-7455-2022
OI Powner, Michael/0000-0003-4913-1004
FU Rosetrees Trust
FX This study was funded by the Rosetrees Trust. The funder had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Albarracin R, 2012, PHOTOCHEM PHOTOBIOL, V88, P1418, DOI 10.1111/j.1751-1097.2012.01130.x
   Albarracin R, 2011, INVEST OPHTH VIS SCI, V52, P3582, DOI 10.1167/iovs.10-6664
   Alonso-Fernandez Patricia, 2011, Curr Aging Sci, V4, P78
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Catchpole IR, 2011, ARVO M 2011, V262, P1778
   Chiang PK, 2008, CURR MOL MED, V8, P580, DOI 10.2174/156652408785747951
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Cunea A, 2007, VISUAL NEUROSCI, V24, P151, DOI 10.1017/S0952523807070204
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Fitzgerald M, 2010, J NEUROTRAUM, V27, P2107, DOI 10.1089/neu.2010.1426
   Freund PR, 2011, DOC OPHTHALMOL, V122, P177, DOI 10.1007/s10633-011-9273-2
   GRAYMORE CN, 1969, EXP EYE RES, V8, P375, DOI 10.1016/S0014-4835(69)80001-1
   Hageman G.S., 2008, WEBVISION ORG RETINA
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kokkinopoulos I, 2013, NEUROBIOL AGING, V34, P602, DOI 10.1016/j.neurobiolaging.2012.04.014
   Lane N, 2006, NATURE, V443, P901, DOI 10.1038/443901a
   Lee V, 2012, NEUROBIOL AGING, V33, P2382, DOI 10.1016/j.neurobiolaging.2011.12.002
   Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liang HL, 2008, NEUROSCIENCE, V153, P963, DOI 10.1016/j.neuroscience.2008.03.042
   Lim J, 2010, J PHOTOCH PHOTOBIO B, V99, P105, DOI 10.1016/j.jphotobiol.2010.03.002
   Lim J, 2009, J BIOCHEM MOL TOXIC, V23, P1, DOI 10.1002/jbt.20257
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lutty G, 1999, MOL VIS, V5
   Merry G., 2012, INVESTIG OPHTHALMOL, V53, P2049
   Parihar MS, 2010, J ALZHEIMERS DIS, V22, P741, DOI 10.3233/JAD-2010-101020
   PASSARELLA S, 1984, FEBS LETT, V175, P95, DOI 10.1016/0014-5793(84)80577-3
   Pastore D, 2000, FEBS LETT, V470, P88, DOI 10.1016/S0014-5793(00)01292-8
   Peirson SN, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng073
   Puzzo D, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.12.020
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Shaw VE, 2010, J COMP NEUROL, V518, P25, DOI 10.1002/cne.22207
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   von Leithner PL, 2009, AM J PATHOL, V175, P412, DOI 10.2353/ajpath.2009.080927
   Whelan HT, 2001, J CLIN LASER MED SUR, V19, P305, DOI 10.1089/104454701753342758
   Wong-Riley MTT, 2001, NEUROREPORT, V12, P3033, DOI 10.1097/00001756-200110080-00011
   Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200
   Yeh S, 2008, J AUTOIMMUN, V31, P91, DOI 10.1016/j.jaut.2008.05.001
NR 53
TC 89
Z9 100
U1 1
U2 26
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 28
PY 2013
VL 8
IS 2
AR e57828
DI 10.1371/journal.pone.0057828
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 098DA
UT WOS:000315524900174
PM 23469078
OA gold, Green Published, Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Wang, XY
   Sawada, T
   Kakinoki, M
   Miyake, T
   Kawamura, H
   Saishin, Y
   Liu, P
   Ohji, M
AF Wang, Xiying
   Sawada, Tomoko
   Kakinoki, Masashi
   Miyake, Taichiro
   Kawamura, Hajime
   Saishin, Yoshitsugu
   Liu, Ping
   Ohji, Masahito
TI Aqueous vascular endothelial growth factor and ranibizumab
   concentrations after monthly and bimonthly intravitreal injections of
   ranibizumab for age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Aqueous humor; Ranibizumab; Bimonthly
   intravitreal injection; Vascular endothelial growth factor
ID VISUAL IMPAIRMENT; HUMOR LEVELS; VEGF-TRAP; PHARMACOKINETICS; EYE;
   NEOVASCULARIZATION; PREVALENCE
AB To evaluate vascular endothelial growth factor (VEGF) and ranibizumab concentrations in eyes with age-related macular degeneration (AMD) after monthly and bimonthly intravitreal ranibizumab (IVR) injections.
   Aqueous humor samples were obtained from 26 eyes with AMD before and after IVR injections. Nine eyes received three monthly injections and 17 eyes received two bimonthly injections. The VEGF and ranibizumab concentrations were measured by enzyme-linked immunosorbent assay.
   The aqueous VEGF concentrations in the monthly injection group decreased below the lowest detectable limit in eight of nine eyes 1 month after the first injection and seven of nine eyes 1 month after the second injection (P < 0.001, mean baseline value, 94.7 pg/ml); the aqueous VEGF concentrations in the bimonthly injection group decreased below the lowest detectable limit in two of 17 eyes 2 months after the first injection (P < 0.001, mean baseline value, 152.4 pg/ml). The mean aqueous ranibizumab concentrations with monthly injections were 71.2 ng/ml 1 month after the first injection, and 96.3 ng/ml 1 month after the second injection. The mean aqueous ranibizumab concentrations in the bimonthly injection group were 2.5 ng/ml in 15 of 17 eyes, and below the lowest detectable limit in two of 17 eyes 2 months after the first injection.
   In this pilot study with limited follow-up, intravitreal injection of ranibizumab can suppress aqueous VEGF completely for 1 month in most cases. Its effect does not last for 2 months enough to suppress VEGF completely in most cases, although aqueous VEGF at 2 months after intravitreal injection of ranibizumab is less than that before injection in most cases.
C1 [Wang, Xiying; Sawada, Tomoko; Kakinoki, Masashi; Miyake, Taichiro; Kawamura, Hajime; Saishin, Yoshitsugu; Ohji, Masahito] Shiga Univ Med Sci, Dept Ophthalmol, Otsu, Shiga 5202192, Japan.
   [Wang, Xiying; Liu, Ping] Harbin Med Univ, Key Lab, Ctr Eye, Eye Hosp,Affiliated Hosp 1, Harbin, Peoples R China.
C3 Shiga University of Medical Science; Harbin Medical University
RP Sawada, T (通讯作者)，Shiga Univ Med Sci, Dept Ophthalmol, Otsu, Shiga 5202192, Japan.
EM tsawada@belle.shiga-med.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [24592668]; Ministry of Health, Labour and Welfare; Grants-in-Aid for
   Scientific Research [24592668] Funding Source: KAKEN
FX Supported in part by a grant from the Ministry of Education, Culture,
   Sports, Science and Technology of Japan (#24592668) and a grant from the
   Ministry of Health, Labour and Welfare.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Ahn JK, 2009, AM J OPHTHALMOL, V148, P718, DOI 10.1016/j.ajo.2009.06.012
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Hoerster R, 2011, BRIT J OPHTHALMOL, V95, P1424, DOI 10.1136/bjo.2010.201129
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Jonas JB, 2007, OPHTHAL RES, V39, P139, DOI 10.1159/000102935
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sawada O, 2010, RETINA-J RET VIT DIS, V30, P1034, DOI 10.1097/IAE.0b013e3181ce74c8
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   US Food and Drug Administration, 2011, FDA LAB INF EYL
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 33
TC 11
Z9 11
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2014
VL 252
IS 7
BP 1033
EP 1039
DI 10.1007/s00417-013-2505-2
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AK5US
UT WOS:000338492500002
PM 24196779
DA 2022-11-30
ER

PT J
AU Nicolo, M
   Ghiglione, D
   Lai, S
   Nasciuti, F
   Cicinelli, S
   Calabria, G
AF Nicolo, M
   Ghiglione, D
   Lai, S
   Nasciuti, F
   Cicinelli, S
   Calabria, G
TI Occult with no classic choroidal neovascularization secondary to
   age-related macular degeneration treated by intravitreal triamcinolone
   and photodynamic therapy with verteporfin
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE triamcinolone; occult with no classic choroidal neovascularization;
   chorioretinal anastomoses; photodynamic therapy
ID RETINAL ANGIOMATOUS PROLIFERATION; BRUCHS MEMBRANE; EXPRESSION;
   ACETONIDE; PERMEABILITY; MACULOPATHY; MACROPHAGES; PREVALENCE;
   CLEARANCE; STEROIDS
AB Purpose: To examine combined treatment with intravitreal triamcinolone acetonide (IVT) and photodynamic therapy (PDT) for occult with no classic choroidal neovascularization (CNV) secondary to age-related macular degeneration.
   Methods: In this prospective, interventional case series, 11 eyes of 10 consecutive patients with occult with no classic CNV underwent a single injection (25 mg) of IVT followed 1 month later by PDT. Best-corrected visual acuity was measured by Early Treatment Diabetic Retinopathy Study (ETDRS) protocol refraction.
   Results: Median best-corrected visual acuity was 20/160, 20/80, 20/80, 20/50, and 20/80 at baseline and 1, 3, 6, and 12 months, respectively. Best-corrected visual acuity at baseline was statistically different (P < 0.05) than best-corrected visual acuity at 1, 3, and 6 months. Of 11 eyes, 5 (45.5%), 7 (63.6%), 7 (63.6%), and 4 (36.3%) had improved best-corrected visual acuity of at least 3 ETDRS lines at 1, 3, 6, and 12 months, respectively, while 6 (54.5%), 9 (81.8%), 10 (91%), and 8 (73%) had improved best-corrected visual acuity of at least 2 ETDRS lines at 1, 3, 6, and 12 months, respectively. Two eyes (18%) lost > 3 lines at 12 months. One eye had intraocular hypertension at 3 months and was treated with a combination of topical antiglaucomatous drugs. One eye developed a dense cataract at the last follow-up visit. No endophthalmitis, retinal detachment, or vitreous hemorrhage developed. Fluorescein leakage and retinal thickness reduced significantly after treatment.
   Conclusions: Improvement of best-corrected visual acuity and lack of fluorescein leakage suggest combination treatment with IVT and PDT for occult with no classic CNV merits further investigation.
C1 Univ Genoa, Sez Clin Oculist, Dipartimento Neurosci Oftalmol & Genet, I-16132 Genoa, Italy.
   Ist Biosanitas, Genoa, Italy.
C3 University of Genoa
RP Nicolo, M (通讯作者)，Univ Genoa, Clin Oculist, Osp San Martino, Pad 9, Piano Terra Stanza 13,Largo R Benzi 10, I-16132 Genoa, Italy.
EM massimo.nicolo@hsanmartino.it
OI Nicolo, Massimo/0000-0002-7824-3091
CR Antonetti DA, 2002, J NEUROCHEM, V80, P667, DOI 10.1046/j.0022-3042.2001.00740.x
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Axer-Siegel R, 1999, AM J OPHTHALMOL, V128, P331, DOI 10.1016/S0002-9394(99)00176-2
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boscia F, 2004, AM J OPHTHALMOL, V138, P1077, DOI 10.1016/j.ajo.2004.06.072
   Brancato R, 2002, EUR J OPHTHALMOL, V12, P467, DOI 10.5301/EJO.2008.2283
   Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CANTRILL HL, 1983, ARCH OPHTHALMOL-CHIC, V101, P1074
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   CHISHOLM IH, 1982, BRIT J OPHTHALMOL, V66, P1
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Halaby IA, 2002, MOL THER, V5, P300, DOI 10.1006/mthe.2002.0539
   Hori Y, 1996, BRIT J PHARMACOL, V118, P1584, DOI 10.1111/j.1476-5381.1996.tb15578.x
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   MCCUEN BW, 1981, AM J OPHTHALMOL, V91, P785, DOI 10.1016/0002-9394(81)90013-1
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nauck M, 1997, AM J RESP CELL MOL, V16, P398, DOI 10.1165/ajrcmb.16.4.9115750
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Perretti M, 2000, MICROCIRCULATION, V7, P147, DOI 10.1038/sj.mn.7300108
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   SCHINDLER RH, 1982, AM J OPHTHALMOL, V93, P415, DOI 10.1016/0002-9394(82)90130-1
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   SCHOLES GN, 1985, ARCH OPHTHALMOL-CHIC, V103, P1567
   Silva RM, 2004, GRAEF ARCH CLIN EXP, V242, P368, DOI 10.1007/s00417-003-0844-0
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WILSON CA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1155, DOI 10.1001/archopht.1992.01080200135041
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 42
TC 26
Z9 30
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2006
VL 26
IS 1
BP 58
EP 64
DI 10.1097/00006982-200601000-00010
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 004YO
UT WOS:000234788800010
PM 16395140
DA 2022-11-30
ER

PT J
AU Albarrak, A
   Coenen, F
   Zheng, Y
AF Albarrak, Abdulrahman
   Coenen, Frans
   Zheng, Yalin
TI Volumetric image classification using homogeneous decomposition and
   dictionary learning: A study using retinal optical coherence tomography
   for detecting age-related macular degeneration
SO COMPUTERIZED MEDICAL IMAGING AND GRAPHICS
LA English
DT Article
DE Feature selection; Image classification; Dictionary learning;
   Homogeneous decomposition; Optical Coherence Tomography (OCT);
   Age-related Macular Degeneration (AMD)
ID LOCAL BINARY PATTERNS; TEXTURE; DIAGNOSIS; SHAPE
AB Three-dimensional (3D) (volumetric) diagnostic imaging techniques are indispensable with respect to the diagnosis and management of many medical conditions. However there is a lack of automated diagnosis techniques to facilitate such 3D image analysis (although some support tools do exist). This paper proposes a novel framework for volumetric medical image classification founded on homogeneous decomposition and dictionary learning. In the proposed framework each image (volume) is recursively decomposed until homogeneous regions are arrived at. Each region is represented using a Histogram of Oriented Gradients (HOG) which is transformed into a set of feature vectors. The Gaussian Mixture Model (GMM) is then used to generate a "dictionary" and the Improved Fisher Kernel (IFK) approach is used to encode feature vectors so as to generate a single feature vector for each volume, which can then be fed into a classifier generator. The principal advantage offered by the framework is that it does not require the detection (segmentation) of specific objects within the input data. The nature of the framework is fully described. A wide range of experiments was conducted with which to analyse the operation of the proposed framework and these are also reported fully in the paper. Although the proposed approach is generally applicable to 3D volumetric images, the focus for the work is 3D retinal Optical Coherence Tomography (OCT) images in the context of the diagnosis of Age-related Macular Degeneration (AMD). The results indicate that excellent diagnostic predictions can be produced using the proposed framework. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Albarrak, Abdulrahman] Al Imam Mohammad Ibn Saud Islamic Univ IMSIU, Coll Comp & Informat Sci, Dept Comp Sci, Riyadh, Saudi Arabia.
   [Coenen, Frans] Univ Liverpool, Dept Comp Sci, Ashton Bldg,Ashton St, Liverpool L69 3BX, Merseyside, England.
   [Zheng, Yalin] Univ Liverpool, Dept Eye & Vis Sci, Apex Bldg,6 West Derby St, Liverpool L7 87X, Merseyside, England.
C3 Imam Mohammad Ibn Saud Islamic University (IMSIU); University of
   Liverpool; University of Liverpool
RP Albarrak, A (通讯作者)，Al Imam Mohammad Ibn Saud Islamic Univ IMSIU, Coll Comp & Informat Sci, Dept Comp Sci, Riyadh, Saudi Arabia.
EM aabkb@yahoo.com
RI Zheng, Yalin/N-6432-2017
OI Zheng, Yalin/0000-0002-7873-0922
CR Albarrak A, 2013, COMP MED SY, P11, DOI 10.1109/CBMS.2013.6627757
   Albarrak A, 2014, LECT NOTES ARTIF INT, V8556, P272, DOI 10.1007/978-3-319-08979-9_21
   Albarrak A, 2012, INT SYMP COMP INTELL, P263, DOI 10.1109/CINTI.2012.6496771
   Bruzzone L, 2006, IEEE T GEOSCI REMOTE, V44, P2587, DOI 10.1109/TGRS.2006.875360
   Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199
   Chen M., 2003, P WORKSH VOL GRAPH, P35, DOI DOI 10.1145/827051.827056
   Csurka G., 2004, P WORKSHOP STAT LEAR, P1, DOI DOI 10.1234/12345678
   Dalal N., 2005, CVPR
   DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x
   Demsar J, 2006, J MACH LEARN RES, V7, P1
   Frisken SF, 2000, COMP GRAPH, P249
   Gossage KW, 2003, J BIOMED OPT, V8, P570, DOI 10.1117/1.1577575
   Hijazi MHA, 2011, LECT NOTES ARTIF INT, V6912, P65, DOI 10.1007/978-3-642-23783-6_5
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huang YZ, 2014, IEEE T PATTERN ANAL, V36, P493, DOI 10.1109/TPAMI.2013.113
   Johnson DonH., 2001, IEEE T INFORM THEORY, V1, P1
   Lazebnik S., 2009, OBJECT CATEGORIZATIO, V3, P4
   Lazebnik S., 2006, 2006 IEEE COMPUTER S, V2, P2169, DOI DOI 10.1109/CVPR.2006.68
   Lin Z, 2010, IEEE T PATTERN ANAL, V32, P604, DOI 10.1109/TPAMI.2009.204
   Liu YY, 2011, MED IMAGE ANAL, V15, P748, DOI 10.1016/j.media.2011.06.005
   Lowe D. G., 1999, Proceedings of the Seventh IEEE International Conference on Computer Vision, P1150, DOI 10.1109/ICCV.1999.790410
   Marszalek M., 2007, VIS REC CHALL WORKSH
   Ojansivu V, 2008, LECT NOTES COMPUT SC, V5099, P236, DOI 10.1007/978-3-540-69905-7_27
   Paivarinta J, 2011, LECT NOTES COMPUT SC, V6688, P360, DOI 10.1007/978-3-642-21227-7_34
   Perronnin F, 2010, LECT NOTES COMPUT SC, V6314, P143, DOI 10.1007/978-3-642-15561-1_11
   Quellec G, 2010, IEEE T MED IMAGING, V29, P1321, DOI 10.1109/TMI.2010.2047023
   Schneider J, 2003, IEEE VISUALIZATION 2003, PROCEEDINGS, P293, DOI 10.1109/VISUAL.2003.1250385
   Scovanner P., 2007, P 15 ACM INT C MULT, P357, DOI DOI 10.1145/1291233.1291311
   Sivic J, 2003, NINTH IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION, VOLS I AND II, PROCEEDINGS, P1470, DOI 10.1109/iccv.2003.1238663
   Sundar H., 2007, P INT C HIGH PERF CO, DOI DOI 10.1145/1362622.1362656
   Tuytelaars T, 2007, FOUND TRENDS COMPUT, V3, P177, DOI 10.1561/0600000017
   Vlachos M., 2003, P 9 ACM SIGKDD INT C, P216, DOI DOI 10.1145/956750.956777
   Voisin A, 2013, IEEE GEOSCI REMOTE S, V10, P96, DOI 10.1109/LGRS.2012.2193869
   WANG JJ, 2010, PROC CVPR IEEE, P3360, DOI DOI 10.1109/CVPR.2010.5540018
   Yang Jun, 2009, Proceedings of the 2009 2nd International Congress on Image and Signal Processing (CISP), DOI 10.1109/CISP.2009.5304123
   Zang YF, 2004, NEUROIMAGE, V22, P394, DOI 10.1016/j.neuroimage.2003.12.030
   Zhao GY, 2007, IEEE T PATTERN ANAL, V29, P915, DOI 10.1109/TPAMI.2007.1110
   Zheng YL, 2012, INVEST OPHTH VIS SCI, V53, P8310, DOI 10.1167/iovs.12-9576
   Zhou X, 2010, LECT NOTES COMPUT SC, V6315, P141, DOI 10.1007/978-3-642-15555-0_11
NR 39
TC 5
Z9 5
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0895-6111
EI 1879-0771
J9 COMPUT MED IMAG GRAP
JI Comput. Med. Imaging Graph.
PD JAN
PY 2017
VL 55
SI SI
BP 113
EP 123
DI 10.1016/j.compmedimag.2016.07.007
PG 11
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA EI7NW
UT WOS:000392685900012
PM 27507326
DA 2022-11-30
ER

PT J
AU Ozkaya, A
   Alkin, Z
   Agca, A
   Satici, T
   Karakucuk, Y
   Yazici, AT
   Demirok, A
AF Ozkaya, Abdullah
   Alkin, Zeynep
   Agca, Alper
   Satici, Turgay
   Karakucuk, Yalcin
   Yazici, Ahmet Taylan
   Demirok, Ahmet
TI One-Year Results of Treatment with Bevacizumab Alone or Ranibizumab
   Alone for Low Visual Acuity Due to Neovascular Age-Related Macular
   Degeneration
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB; INJECTION
AB Purpose: To investigate treatment with bevacizumab alone or ranibizumab alone in neovascular age-related macular degeneration (nAMD) patients with low visual acuity. Methods: Data were analyzed retrospectively. Inclusion criteria were (1) pretreatment visual acuity of LogMAR 1.3 or worse and (2) treatment duration of at least 12 months. Injections were given monthly for the first 3 months and thereafter as needed. Data collected for each patient included best corrected visual acuity and central retinal thickness measured before treatment, at months 3, 6, 9, and 12 during treatment, and at the last follow-up visit. Results: In the bevacizumab patients, mean visual acuity was initially 1.70 LogMAR; at months 3, 6, 9, and 12 during treatment it was 1.20, 1.11, 1.14, and 1.10 LogMAR, respectively, and at the last follow-up it was 1.12 LogMAR (P<0.01 for all differences with respect to the initial value). Mean injection number in the first 12 months was 5.3. In the ranibizumab patients, mean visual acuity was initially 1.53 LogMAR; at months 3, 6, 9, and 12 during treatment it was 1.18, 1.17, 1.17, and 1.28 LogMAR, respectively, and at the last follow-up it was 1.21 LogMAR (P<0.01 for all differences with respect to the initial value). Mean injection number in the first 12 months was 4.2. Conclusion: Patients with nAMD and low pretreatment visual acuities can benefit from treatment with bevacizumab or ranibizumab.
C1 [Ozkaya, Abdullah; Alkin, Zeynep; Agca, Alper; Satici, Turgay; Karakucuk, Yalcin; Yazici, Ahmet Taylan] Beyoglu Eye Training & Res Hosp, TR-34000 Istanbul, Turkey.
   [Demirok, Ahmet] Medeniyet Univ, Dept Ophthalmol, Beyoglu Eye Training & Res Hosp, Istanbul, Turkey.
C3 Istanbul Prof Dr N Resat Belger Beyoglu Eye Training & Research
   Hospital; Istanbul Medeniyet University; Istanbul Prof Dr N Resat Belger
   Beyoglu Eye Training & Research Hospital
RP Ozkaya, A (通讯作者)，Beyoglu Eye Training & Res Hosp, Bereketzade Camii Sok, TR-34000 Istanbul, Turkey.
EM abdozkaya@gmail.com
RI Agca, Alper/E-2166-2013; Demirok, Ahmet/AAE-1713-2020; Alkin,
   Zeynep/V-7252-2017; Ozkaya, Abdullah/L-5745-2013
OI Agca, Alper/0000-0001-5435-075X; Demirok, Ahmet/0000-0001-8197-2458;
   Alkin, Zeynep/0000-0002-5363-1944; Ozkaya, Abdullah/0000-0002-1940-8669;
   karakucuk, Yalcin/0000-0001-6430-2233
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Ehrlich R, 2008, RETINA-J RET VIT DIS, V28, P1302, DOI 10.1097/IAE.0b013e3181803c2a
   El Matri L, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/861384
   Galbinur T, 2009, BRIT J OPHTHALMOL, V93, P1351, DOI 10.1136/bjo.2009.158931
   Jonas JB, 2011, J OCUL PHARMACOL TH, V27, P467, DOI 10.1089/jop.2011.0038
   Jonas JB, 2011, J OCUL PHARMACOL TH, V27, P401, DOI 10.1089/jop.2011.0080
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Sorensen TL, 2011, ACTA OPHTHALMOL, V89, pE97, DOI 10.1111/j.1755-3768.2010.01899.x
   Tao Y, 2010, J OCUL PHARMACOL TH, V26, P79, DOI 10.1089/jop.2009.0095
NR 12
TC 4
Z9 4
U1 0
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD DEC 1
PY 2013
VL 29
IS 10
BP 865
EP 869
DI 10.1089/jop.2013.0106
PG 5
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 262ZS
UT WOS:000327777000004
PM 24053539
DA 2022-11-30
ER

PT J
AU Ozcaliskan, S
   Artunay, O
   Balci, S
   Perente, I
   Yenerel, NM
AF Ozcaliskan, Sehnaz
   Artunay, Ozgur
   Balci, Sevcan
   Perente, Irfan
   Yenerel, Nursal Melda
TI Quantitative analysis of inner retinal structural and microvascular
   alterations in intermediate age-related macular degeneration: A
   swept-source OCT angiography study
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Age-related macular degeneration; Ganglion cell complex; Vessel density,
   OCT
ID NERVE-FIBER LAYER; PLEXIFORM LAYER; CLASSIFICATION; MACULOPATHY
AB Purpose: To investigate the structural and microvascular alterations of the inner retinal layers in patients with intermediate age-related macular degeneration (iAMD), and determine an association between structural and microvascular parameters.
   Methods: In this prospective study, 58 eyes of iAMD patients and 64 age and sex-matched control eyes were enrolled. Participants underwent spectral-domain optical coherence tomography (OCT) and swept-source OCT angiography (OCTA) imaging. Retinal layer segmentation was performed automatically using the built-in software of the OCT device. Retinal nerve fiber layer (RNFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), and outer plexiform layer (OPL) thicknesses were analyzed in the central and parafoveal region. Foveal avascular zone (FAZ) area and vessel density of the superficial and deep capillary plexuses (SCP and DCP) in the fovea and parafoveal region were obtained.
   Results: In iAMD eyes, the RNFL, GCL, and IPL were significantly thinner compared to control eyes in the parafovea (p < 0.05 all). The overall parafoveal SCP vessel density significantly decreased in iAMD eyes compared to the controls (p = 0.022). There was also a non-significant reduction in DCP vessel density measurements in iAMD eyes compared to controls (p > 0.05 all). The ganglion cell complex was significantly correlated with SCP vessel density measurements in iAMD eyes (r = 0.224, p = 0.043).
   Conclusion: This study demonstrates that the inner retina is effected in iAMD in terms of structural and microvascular components. Inner retinal thinning is significantly correlated with vessel density reduction, suggesting a cause and effect relationship between these parameters. Further longitudinal studies may aid in characterizing these alterations to better understand AMD pathogenesis.
C1 [Ozcaliskan, Sehnaz; Artunay, Ozgur; Perente, Irfan] Univ Hlth Sci, Beyoglu Eye Training & Res Hosp, Istanbul, Turkey.
   [Balci, Sevcan; Yenerel, Nursal Melda] Univ Hlth Sci, Haydarpasa Numune Training & Res Hosp, Istanbul, Turkey.
C3 University of Health Sciences Turkey; Istanbul Haydarpasa Numune
   Training & Research Hospital; University of Health Sciences Turkey
RP Ozcaliskan, S (通讯作者)，Univ Hlth Sci, Beyoglu Eye Training & Res Hosp, Istanbul, Turkey.
EM drsehnaz@yahoo.com
RI Ozcaliskan, Sehnaz/ABC-9911-2020; Balci, Sevcan/CAF-6805-2022;
   Ozcaliskan, Sehnaz/AAA-1305-2021; Balci, Sevcan Yildiz/AAW-9338-2020
OI Balci, Sevcan/0000-0002-1695-0583; Ozcaliskan,
   Sehnaz/0000-0002-3783-3570; Balci, Sevcan Yildiz/0000-0002-1695-0583;
   Yenerel, Nursal Melda/0000-0001-9940-8599
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Campbell JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42201
   Cicinelli MV, 2018, BRIT J OPHTHALMOL, V102, P1192, DOI 10.1136/bjophthalmol-2017-311317
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Giani A, 2010, RETINA-J RET VIT DIS, V30, P607, DOI 10.1097/IAE.0b013e3181c2e09d
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Lamin A, 2019, EYE, V33, P428, DOI 10.1038/s41433-018-0234-9
   Lavia C, 2019, RETINA-J RET VIT DIS, V39, P247, DOI 10.1097/IAE.0000000000002413
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P1478, DOI 10.1097/IAE.0000000000001759
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Savastano MC, 2014, INVEST OPHTH VIS SCI, V55, P560, DOI 10.1167/iovs.13-12172
   Shin IH, 2018, RETINA-J RET VIT DIS, V38, P253, DOI 10.1097/IAE.0000000000001535
   SNODDERLY DM, 1992, J NEUROSCI, V12, P1169
   Sullivan R, 2003, INVEST OPHTH VIS SCI, V44, P856, DOI 10.1167/iovs.02-0416
   Tan CS, 2016, AM J OPHTHALMOL, V165, P201, DOI 10.1016/j.ajo.2016.02.035
   Tomita R, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.27
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Trinh M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.2
   Trinh M, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.4.20
   Wakabayashi T, 2010, OPTICAL COHERENCE TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION: OCT IN AMD, SECOND EDITION, P67
NR 29
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD DEC
PY 2020
VL 32
AR 102030
DI 10.1016/j.pdpdt.2020.102030
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA PH4AO
UT WOS:000600357900011
PM 33011396
DA 2022-11-30
ER

PT J
AU Zinkernagel, MS
   Wolf, S
   Ebneter, A
AF Zinkernagel, Martin Sebastian
   Wolf, Sebastian
   Ebneter, Andreas
TI Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a
   Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related
   Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Retina; Anti-VEGF; Intravitreal injections; Pigment epithelial
   detachment; Spectral domain optical coherence tomography; Atrophy
ID INTRAVITREAL AFLIBERCEPT; VEGF TRAP; RANIBIZUMAB; BEVACIZUMAB; OUTCOMES;
   EYE
AB Purpose: To assess the effect of a bimonthly treatment regimen with intravitreal aflibercept on retinal fluid and pigment epithelial detachment (PED) in patients with neovascular age-related macular degeneration (AMD).
   Methods: Twenty- six treatment-naive eyes of 26 patients with choroidal neovascularisation secondary to AMD were included. The patients received three initial monthly (mean 30 days) intravitreal injections of aflibercept followed by a bimonthly (mean 62 days) fixed regimen for a total of 1 year. Best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) measurements were recorded at monthly intervals. In addition, the presence of intraretinal fluid (IRF) or subretinal fluid (SRF) or a combination of both as well as serous and fibrovascular PEDs were assessed.
   Results: The mean patient age was 80 years (range 54-93). There were 14 male and 12 female patients. The mean gain in BCVA at 1 year was 9.3 letters (SEM +/- 3) with a mean reduction of the central retinal thickness of 154 mu m (SEM +/- 50). After 3 monthly injections of aflibercept, there was resolution of IRF and SRF in 80% of the treated eyes; the amount of fluid increased at months 4, 6 and 8 with troughs in between. Whereas fibrovascular PEDs remained stable after the loading phase, serous PEDs displayed a seesaw pattern. Patients without retinal pigment epithelium (RPE) atrophy at the end of the 1-year period had significantly better BCVA compared to patients with RPE atrophy (p = 0.03).
   Conclusion: Despite significant overall BCVA gain, bimonthly intervals seem insufficient to maintain the morphological improvements after the initial loading dose with intravitreal aflibercept. (C) 2015 S. Karger AG, Basel
C1 [Zinkernagel, Martin Sebastian; Wolf, Sebastian; Ebneter, Andreas] Univ Hosp Bern, Dept Ophthalmol, CH-3010 Bern, Switzerland.
C3 University of Bern; University Hospital of Bern
RP Zinkernagel, MS (通讯作者)，Univ Hosp Bern, Inselspital, Dept Ophthalmol, CH-3010 Bern, Switzerland.
EM m.zinkernagel@gmail.com
RI Zinkernagel, Martin/C-3799-2017; Wolf, Sebastian/B-8782-2008; Ebneter,
   Andreas/C-5226-2017
OI Zinkernagel, Martin/0000-0002-5622-114X; Wolf,
   Sebastian/0000-0002-7467-7028; Ebneter, Andreas/0000-0001-6666-2558;
   Zinkernagel, Martin S./0000-0003-3447-2359
FU Allergan; Swiss National Science Foundation (SNSF); Bayer
FX A.E. reports honoraria from Bayer for lectures and a travel grant from
   Allergan. S.W. reports grants from Swiss National Science Foundation
   (SNSF), non-financial support from Heidelberg Engineering; other from
   Alcon, Allergan, Bayer Healthcare, Novartis Pharma and Roche, outside
   the submitted work. M.S.Z. reports grants from Swiss National Science
   Foundation (SNSF), a grant from Bayer and non-financial support from
   Heidelberg Engineering; he is a consultant for Allergan, consultant for
   Bayer Healthcare and stock holder in Novartis Pharma.
CR Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Economides AN, 2003, NAT MED, V9, P47, DOI 10.1038/nm811
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
NR 13
TC 17
Z9 17
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2016
VL 235
IS 1
BP 42
EP 48
DI 10.1159/000441428
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB0FS
UT WOS:000368184600006
PM 26540259
OA Green Published
DA 2022-11-30
ER

PT J
AU Wang, XL
   Ma, W
   Han, S
   Meng, ZY
   Zhao, L
   Yin, Y
   Wang, YL
   Li, JF
AF Wang, Xiaolei
   Ma, Wei
   Han, Song
   Meng, Zhaoyang
   Zhao, Lu
   Yin, Yi
   Wang, Yanling
   Li, Junfa
TI TGF-beta participates choroid neovascularization through
   Smad2/3-VEGF/TNF-alpha signaling in mice with Laser-induced wet
   age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; PHOTODYNAMIC
   THERAPY; VEGF; BEVACIZUMAB; EXPRESSION; ANGIOGENESIS; PREVENTION;
   TGF-BETA-1; MEMBRANE
AB Choroidal neovascularization(CNV) is the most severe complication in Age-related macular degeneration(AMD) and the most common cause of irreversible blindness in the elderly in developed world. The aim of this study was to identify the effect of transforming growth factor-beta(TGF-beta) and Smad2/3-VEGF/TNF-alpha signaling on CNV angiopoiesis, and to explore TGF-beta inhibitors on the development of CNV in a CNV mouse model. Fundus fluorescein angiography(FFA) was used to evaluate the laser-induced CNV formation. The histology of CNV lesions stained with hematoxylin-eosin(HE) was obtained. The immunofluorescent staining was performed to determine TGF-beta protein expression. The expressions of TGF-beta, phosphorylated Smad2/3, VEGF and TNF-alpha were determined by using Western blot analysis. The CNV areas were analyzed by using fluorescein stain on RPE/choroid-sclera flat mounts. We found the levels of TGF-beta protein expression increasingly reached the peak till 3rd week during the CNV development. The protein levels of VEGF and TNF-alpha also increased significantly in CNV mice, which were inhibited by a synthetic TGF-beta inhibitor LY2157299 or a natural TGF-beta inhibitor Decorin. The phosphorylated Smad2/3 levels increased significantly in CNV mice, but this response was profoundly suppressed by the TGF-beta inhibitors. Here we have demonstrated that TGF-beta/Smad signaling plays an important role in Laser-induced CNV formation through down-regulation of VEGF and TNF-alpha expressions, suggesting TGF-beta inhibitors may provide an alternative to traditional methods in wet AMD treatment.
C1 [Wang, Xiaolei; Meng, Zhaoyang; Zhao, Lu; Yin, Yi; Wang, Yanling] Capital Med Univ, Beijing Friendship Hosp, Dept Ophthalmol, Beijing 100050, Peoples R China.
   [Wang, Xiaolei; Ma, Wei; Han, Song; Li, Junfa] Capital Med Univ, Dept Neurobiol, Beijing 100069, Peoples R China.
   [Wang, Xiaolei; Ma, Wei; Han, Song; Li, Junfa] Capital Med Univ, Ctr Stroke, Beijing Inst Brain Disorders, Beijing 100069, Peoples R China.
   [Ma, Wei] Capital Med Univ, Beijing Stomatol Hosp, Beijing 100050, Peoples R China.
C3 Capital Medical University; Capital Medical University; Capital Medical
   University; Capital Medical University
RP Wang, XL (通讯作者)，Capital Med Univ, Beijing Friendship Hosp, Dept Ophthalmol, Beijing 100050, Peoples R China.; Wang, XL (通讯作者)，Capital Med Univ, Dept Neurobiol, Beijing 100069, Peoples R China.; Wang, XL (通讯作者)，Capital Med Univ, Ctr Stroke, Beijing Inst Brain Disorders, Beijing 100069, Peoples R China.
EM wangxleye@ccmu.edu.cn; junfali@ccmu.edu.cn
RI ; Li, Junfa/H-8707-2013
OI WANG, Xiaolei/0000-0003-0528-2265; Li, Junfa/0000-0002-1930-9724
FU Seed Grant of International Alliance of Translational Neuroscience
   [PXM2014-014226-000006]; Beijing Natural Science Foundation [7141001];
   National Natural Science Foundation of China [31171147, 31471142];
   Beijing Ophthalmology & Visual Sciences Key Laboratory [2015YKSJ02]
FX This work was supported by the grants from the Seed Grant of
   International Alliance of Translational Neuroscience
   (PXM2014-014226-000006), Beijing Natural Science Foundation (7141001),
   National Natural Science Foundation of China (31171147 and 31471142),
   and Beijing Ophthalmology & Visual Sciences Key Laboratory (2015YKSJ02).
CR Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bian ZM, 2007, EXP EYE RES, V84, P812, DOI 10.1016/j.exer.2006.12.016
   Birke K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076766
   Brand CS, 2012, EYE, V26, pS1, DOI 10.1038/eye.2012.32
   Bueno L, 2008, EUR J CANCER, V44, P142, DOI 10.1016/j.ejca.2007.10.008
   Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7
   Fan YC, 2010, ADV EXP MED BIOL, V664, P71, DOI 10.1007/978-1-4419-1399-9_9
   Ferrari G, 2009, J CELL PHYSIOL, V219, P449, DOI 10.1002/jcp.21706
   Freund KB, 2013, EXPERT OPIN PHARMACO, V14, P1017, DOI 10.1517/14656566.2013.787410
   Holderfield MT, 2008, CIRC RES, V102, P637, DOI 10.1161/CIRCRESAHA.107.167171
   Keane PA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/483034
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Loukovaara S, 2013, ACTA OPHTHALMOL, V91, P531, DOI 10.1111/j.1755-3768.2012.02473.x
   Lu HY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087530
   Lu Ming, 2006, Ophthalmol Clin North Am, V19, P323
   Lyzogubov V, 2014, AM J PATHOL, V184, P2537, DOI 10.1016/j.ajpath.2014.06.001
   Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5
   Nagineni CN, 2014, AGING DIS, V5, P88, DOI 10.14366/AD.2014.050088
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Nassar K, 2011, GRAEF ARCH CLIN EXP, V249, P1649, DOI 10.1007/s00417-011-1730-9
   Nunes I, 1998, J Am Optom Assoc, V69, P643
   Parodi MB, 2010, ARCH OPHTHALMOL-CHIC, V128, P437, DOI 10.1001/archophthalmol.2009.408
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Ruiz-Moreno JM, 2007, RETINA-J RET VIT DIS, V27, P458, DOI 10.1097/IAE.0b013e318030c77c
   Ryskulova A, 2008, AM J PUBLIC HEALTH, V98, P454, DOI 10.2105/AJPH.2006.098202
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Semkova I, 2014, EXP EYE RES, V118, P80, DOI 10.1016/j.exer.2013.11.006
   Seuntjens E, 2009, CYTOKINE GROWTH F R, V20, P449, DOI 10.1016/j.cytogfr.2009.10.005
   Shi X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.282
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   Simo R, 2006, CURR DIABETES REV, V2, P71, DOI 10.2174/157339906775473671
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   van Royen N, 2002, FASEB J, V16, P432, DOI 10.1096/fj.01-0563fje
   Wang XM, 2013, NATURE, V499, P306, DOI 10.1038/nature12345
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Xie P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053329
   Zarranz-Ventura J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065434
   Zhang J, 2014, PROTEIN CELL, V5, P503, DOI 10.1007/s13238-014-0058-8
   Zhang PP, 2014, ONCOTARGETS THER, V7, P263, DOI 10.2147/OTT.S56909
NR 41
TC 41
Z9 42
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 29
PY 2017
VL 7
AR 9672
DI 10.1038/s41598-017-10124-4
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FE9PN
UT WOS:000408535700017
PM 28852052
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Mendrinos, E
   Mangioris, G
   Papadopoulou, DN
   Donati, G
   Pournaras, CJ
AF Mendrinos, Efstratios
   Mangioris, Georgios
   Papadopoulou, Domniki N.
   Donati, Guy
   Pournaras, Constantin J.
TI Long-term results of the effect of intravitreal ranibizumab on the
   retinal arteriolar diameter in patients with neovascular age-related
   macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; ranibizumab; retinal arteriolar
   diameter; retinal vessel analyzer
ID ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; BLOOD-FLOW;
   BEVACIZUMAB AVASTIN(R); VISUAL IMPAIRMENT; VEGF; INJECTION; MACULOPATHY;
   PREVALENCE; ACTIVATION
AB Purpose: To study the effect of intravitreal (IVT) ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration (AMD).
   Methods: Ten eyes of 10 patients with previously untreated neovascular AMD were included. All eyes had three monthly IVT injections of ranibizumab and then were retreated as needed, based on visual acuity and optical coherence tomography (OCT) criteria. The diameter of the retinal arterioles was measured in vivo with a retinal vessel analyser (RVA) before the first IVT injection, 7 and 30 days after the first, the second and the third injection, and at month 12 of follow-up.
   Results: A significant vasoconstriction of the retinal arterioles was observed following each one of the first three IVT injections of ranibizumab. Thirty days following the first, second and third injection, there was a mean decrease of 8.4 +/- 3.2%, 11.9 +/- 4.5% and 18.5 +/- 7.2%, respectively, of the retinal arteriolar diameter compared with baseline (p < 0.01). At month 12, the vasoconstriction was still present with a mean decrease of 19.1 +/- 8.3% of the retinal arteriolar diameter compared with baseline (p < 0.01). Median number of ranibizumab injections was 4 (range 3-10). There was no correlation between the number of injections and percentage diameter decrease at month 12 (r = -0.54, p > 0.1). There was no significant change in mean arterial pressure (MAP) during the period of follow-up (p > 0.05).
   Conclusions: These results suggest that IVT ranibizumab induces sustained retinal arteriolar vasoconstriction in eyes with neovascular AMD.
C1 [Mendrinos, Efstratios; Mangioris, Georgios; Papadopoulou, Domniki N.; Donati, Guy; Pournaras, Constantin J.] Univ Geneva, Univ Hosp Geneva, Fac Med, Vitreo Retinal Unit,Dept Ophthalmol, Geneva, Switzerland.
C3 University of Geneva
RP Pournaras, CJ (通讯作者)，Dept Ophthalmol, 22 Rue Alcide Jentzer, CH-1211 Geneva 14, Switzerland.
EM constantin.pournaras@hcuge.ch
CR Ameri H, 2007, INVEST OPHTH VIS SCI, V48, P5708, DOI 10.1167/iovs.07-0731
   [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Babiak A, 2004, CARDIOVASC RES, V61, P789, DOI 10.1016/j.cardiores.2003.12.014
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Blum M, 2006, OPHTHALMOLOGE, V103, P209, DOI 10.1007/s00347-005-1280-9
   Bonnin P, 2010, ACTA OPHTHALMOL, V88, P641, DOI 10.1111/j.1755-3768.2009.01526.x
   Bouloumie A, 1999, CARDIOVASC RES, V41, P773, DOI 10.1016/S0008-6363(98)00228-4
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2008, MOL THER, V16, P791, DOI 10.1038/mt.2008.10
   Chen E, 2009, OPHTHAL SURG LAS IM, V40, P68, DOI 10.3928/15428877-20090101-04
   Chun DW, 2006, OPHTHALMOLOGY, V113, P1706, DOI 10.1016/j.ophtha.2006.04.033
   Clayton JA, 2008, CIRC RES, V103, P1027, DOI 10.1161/CIRCRESAHA.108.181115
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DONATI G, 1995, INVEST OPHTH VIS SCI, V36, P2228
   FEKE GT, 1989, INVEST OPHTH VIS SCI, V30, P58
   Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358
   Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198
   Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054
   Ikram MK, 2005, OPHTHALMOLOGY, V112, P548, DOI 10.1016/j.ophtha.2004.10.038
   Jeganathan VSE, 2008, AM J OPHTHALMOL, V146, P954, DOI 10.1016/j.ajo.2008.07.006
   Jeppesen P, 2007, INVEST OPHTH VIS SCI, V48, P328, DOI 10.1167/iovs.06-0360
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kim KS, 2008, ACTA OPHTHALMOL, V86, DOI 10.1111/j.1755-3768.2008.01175.x
   Klein R, 2004, AM J OPHTHALMOL, V137, P435, DOI 10.1016/j.ajo.2003.10.020
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Kook D, 2008, RETINA-J RET VIT DIS, V28, P1053, DOI 10.1097/IAE.0b013e318176de48
   KU DD, 1993, AM J PHYSIOL, V265, pH586, DOI 10.1152/ajpheart.1993.265.2.H586
   Lakshminarayanan S, 2000, INVEST OPHTH VIS SCI, V41, P4256
   Lee CS, 2008, ACTA OPHTHALMOL, V86, P812, DOI 10.1111/j.1600-0420.2007.01111.x
   Liew G, 2006, OPHTHALMOLOGY, V113, P1481, DOI 10.1016/j.ophtha.2006.03.051
   MAYROVITZ HN, 1983, AM J PHYSIOL, V245, P1031, DOI 10.1152/ajpheart.1983.245.6.H1031
   Micieli JA, 2012, ACTA OPHTHALMOL, V90, pE13, DOI 10.1111/j.1755-3768.2011.02209.x
   Moncada S, 2006, BRIT J PHARMACOL, V147, pS193, DOI 10.1038/sj.bjp.0706458
   Neubauer AS, 2007, OPHTHALMOLOGY, V114, P2096, DOI 10.1016/j.ophtha.2007.05.057
   Papadopoulou DN, 2012, ACTA OPHTHALMOL, V90, pE269, DOI 10.1111/j.1755-3768.2011.02374.x
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   PFITZNER J, 1976, ANAESTHESIA, V31, P273, DOI 10.1111/j.1365-2044.1976.tb11804.x
   Pieramici Dante J, 2008, Ophthalmology, V115, pe47, DOI 10.1016/j.ophtha.2008.06.021
   Polak K, 2000, BRIT J OPHTHALMOL, V84, P1285, DOI 10.1136/bjo.84.11.1285
   Pournaras CJ, 2008, PROG RETIN EYE RES, V27, P284, DOI 10.1016/j.preteyeres.2008.02.002
   RIVA CE, 1985, INVEST OPHTH VIS SCI, V26, P1124
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2008, GRAEF ARCH CLIN EXP, V246, P315, DOI 10.1007/s00417-007-0669-3
   Sacu S, 2011, INVEST OPHTH VIS SCI, V52, P3046, DOI 10.1167/iovs.10-5842
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   SCHEINER AJ, 1994, INVEST OPHTH VIS SCI, V35, P3436
   Seifertl B U, 2002, Biomed Tech (Berl), V47 Suppl 1 Pt 2, P678, DOI 10.1515/bmte.2002.47.s1b.678
   SKINNER HB, 1979, MED INFORM, V4, P243, DOI 10.3109/14639237909017762
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P298, DOI 10.1016/j.ajo.2008.08.016
   Tilton RG, 1999, INVEST OPHTH VIS SCI, V40, P689
   Uhlmann S, 2001, MICROVASC RES, V62, P179, DOI 10.1006/mvre.2001.2334
   Vilser W, 2002, Biomed Tech (Berl), V47 Suppl 1 Pt 2, P682, DOI 10.1515/bmte.2002.47.s1b.682
   Yokoyama K, 2008, ACTA OPHTHALMOL, V86, P927, DOI 10.1111/j.1755-3768.2008.01187.x
NR 55
TC 25
Z9 27
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2013
VL 91
IS 3
BP E184
EP E190
DI 10.1111/aos.12008
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 131HH
UT WOS:000317983000003
PM 23590391
OA Bronze
DA 2022-11-30
ER

PT J
AU Murad, N
   Kokkinaki, M
   Gunawardena, N
   Gunawan, MS
   Hathout, Y
   Janczura, KJ
   Theos, AC
   Golestaneh, N
AF Murad, Najiba
   Kokkinaki, Maria
   Gunawardena, Nishantha
   Gunawan, Mia S.
   Hathout, Yetrib
   Janczura, Karolina J.
   Theos, Alexander C.
   Golestaneh, Nady
TI miR-184 regulates ezrin, LAMP-1 expression, affects phagocytosis in
   human retinal pigment epithelium and is downregulated in age-related
   macular degeneration
SO FEBS JOURNAL
LA English
DT Article
DE AMD; ezrin; LAMP-1; miR-184; RPE
ID ENDOTHELIAL GROWTH-FACTOR; SEED REGION; CELLS; MEMBRANE; GENE;
   SECRETION; MICRORNAS; PROTEIN; TISSUE; ROLES
AB MicroRNA 184 (miR-184) is known to play a key role in neurological development and apoptosis and is highly expressed in mouse brain, mouse corneal epithelium, zebrafish lens and human retinal pigment epithelium (RPE). However, the role of miR-184 in RPE is largely unknown. We investigated the role of miR-184 in RPE and its possible implication in age-related macular degeneration (AMD). Proteomic analysis identified the ezrin (EZR) gene as a target of miR-184 in human RPE. EZR is a membrane cytoskeleton crosslinker that is also known to bind to lysosomal-associated membrane protein 1 (LAMP-1) during the formation of phagocytic vacuoles. In adult retinal pigment epithelium 19 (ARPE19) cells, inhibition of miR-184 resulted in upregulation of EZR mRNA and EZR protein, and induced downregulation of LAMP-1. The inhibition of miR-184 decreased EZR-bound LAMP-1 protein levels and affected phagocytic activity in ARPE19 cells. In primary culture of human RPE isolated from eyes of AMD donors (AMD RPE), miR-184 was significantly downregulated compared with control (normal) RPE. Downregulation of miR-184 was consistent with significantly lower levels of LAMP-1 protein in AMD RPE, and overexpression of MIR-184 in AMD RPE was able to rescue LAMP-1 protein expression to normal levels. Altogether, these observations suggest a novel role for miR-184 in RPE health and support a model proposing that downregulation of miR-184 expression during aging may result in dysregulation of RPE function, contributing to retinal degeneration.
C1 [Murad, Najiba; Gunawardena, Nishantha; Gunawan, Mia S.; Golestaneh, Nady] Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, Washington, DC 20057 USA.
   [Kokkinaki, Maria; Golestaneh, Nady] Georgetown Univ, Med Ctr, Dept Ophthalmol, Washington, DC 20057 USA.
   [Hathout, Yetrib] Childrens Natl Med Ctr, Med Genet Res Ctr, Washington, DC 20010 USA.
   [Janczura, Karolina J.; Theos, Alexander C.] Georgetown Univ, Med Ctr, Dept Human Sci, Washington, DC 20057 USA.
   [Golestaneh, Nady] Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20057 USA.
C3 Georgetown University; Georgetown University; Children's National Health
   System; Georgetown University; Georgetown University
RP Golestaneh, N (通讯作者)，Georgetown Univ, Med Ctr, Dept Ophthalmol, 3900 Reservoir Rd NW,Med Dent Bldg,Room NE203, Washington, DC 20057 USA.
EM ncg8@georgetown.edu
OI Theos, Alexander/0000-0002-1826-8705
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   Baehr W, 2003, VISION RES, V43, P2957, DOI 10.1016/j.visres.2003.10.001
   Becerra SP, 2004, EXP EYE RES, V78, P223, DOI 10.1016/j.exer.2003.10.013
   Besch D, 2003, VISION RES, V43, P3095, DOI 10.1016/j.visres.2003.09.020
   BOK D, 1993, J CELL SCI, P189
   Bonilha VL, 1999, J CELL BIOL, V147, P1533, DOI 10.1083/jcb.147.7.1533
   Bonilha VL, 2006, EXP EYE RES, V82, P720, DOI 10.1016/j.exer.2005.09.013
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Cook NR, 2004, TRAFFIC, V5, P685, DOI 10.1111/j.1600-0854.2004.00212.x
   Dornonville de la Cour M, 1993, Acta Ophthalmol Suppl, P1
   Erwig LP, 2006, P NATL ACAD SCI USA, V103, P12825, DOI 10.1073/pnas.0605331103
   Eskelinen Eeva-Liisa, 2006, Molecular Aspects of Medicine, V27, P495, DOI 10.1016/j.mam.2006.08.005
   Federici C, 2009, INT J CANCER, V124, P2804, DOI 10.1002/ijc.24255
   Finnemann SC, 2003, EMBO J, V22, P4143, DOI 10.1093/emboj/cdg416
   Foley NH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-83
   Gehrke S, 2010, NATURE, V466, P637, DOI 10.1038/nature09191
   Gimeno L, 2004, GENE EXPR PATTERNS, V4, P749, DOI 10.1016/j.modgep.2004.03.007
   Gordiyenko NV, 2010, INVEST OPHTH VIS SCI, V51, P1143, DOI 10.1167/iovs.09-4117
   GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x
   Hoffmann A, 2012, MOL MED, V18, P528, DOI 10.2119/molmed.2011.00463
   Huang T, 2003, J CELL SCI, V116, P4935, DOI 10.1242/jcs.00830
   Hughes AE, 2011, AM J HUM GENET, V89, P628, DOI 10.1016/j.ajhg.2011.09.014
   Huynh KK, 2007, EMBO J, V26, P313, DOI 10.1038/sj.emboj.7601511
   Iliff BW, 2012, INVEST OPHTH VIS SCI, V53, P348, DOI 10.1167/iovs.11-8783
   Iovino N, 2009, DEV CELL, V17, P123, DOI 10.1016/j.devcel.2009.06.008
   Ishida K, 2003, OCUL IMMUNOL INFLAMM, V11, P91, DOI 10.1076/ocii.11.2.91.15914
   Karali M, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-715
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5
   Li P, 2011, MOL BIOL REP, V38, P355, DOI 10.1007/s11033-010-0115-1
   Li W, 2013, AGEING RES REV, V12, P1005, DOI 10.1016/j.arr.2013.05.006
   Liu CM, 2010, CELL STEM CELL, V6, P433, DOI 10.1016/j.stem.2010.02.017
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma LF, 2013, ONCOL REP, V30, P1899, DOI 10.3892/or.2013.2641
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marion S, 2011, TRAFFIC, V12, P421, DOI 10.1111/j.1600-0854.2011.01158.x
   Mata NL, 1998, BBA-LIPID LIPID MET, V1394, P16, DOI 10.1016/S0005-2760(98)00078-2
   McKiernan RC, 2012, EXP NEUROL, V237, P346, DOI 10.1016/j.expneurol.2012.06.029
   Nomura T, 2008, HUM MOL GENET, V17, P1192, DOI 10.1093/hmg/ddn011
   Olivieri F, 2013, AGEING RES REV, V56, P154
   Osawa H, 2009, NEURO-ONCOLOGY, V11, P381, DOI 10.1215/15228517-2008-110
   Ren L, 2012, CANCER RES, V72, P1001, DOI 10.1158/0008-5472.CAN-11-0210
   Rizzolo LJ, 1997, HISTOL HISTOPATHOL, V12, P1057
   Ryan D, 2006, MOL VIS, V12, P1175
   Schertler GFX, 2000, METHOD ENZYMOL, V315, P91
   Shalom-Feuerstein R, 2012, STEM CELLS, V30, P898, DOI 10.1002/stem.1068
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Soifer HS, 2007, MOL THER, V15, P2070, DOI 10.1038/sj.mt.6300311
   STEINBERG RH, 1985, DOC OPHTHALMOL, V60, P327, DOI 10.1007/BF00158922
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun K, 2007, MOL VIS, V13, P2310
   Tivnan A, 2010, ANTICANCER RES, V30, P4391
   Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8
   Wang FE, 2010, FASEB J, V24, P1552, DOI 10.1096/fj.08-125856
   Wang GF, 2008, FEBS LETT, V582, P3663, DOI 10.1016/j.febslet.2008.09.051
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   Weitzel RP, 2011, LEUKEMIA, V25, P169, DOI 10.1038/leu.2010.227
   Yu J, 2008, P NATL ACAD SCI USA, V105, P19300, DOI 10.1073/pnas.0803992105
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 60
TC 52
Z9 58
U1 1
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-464X
EI 1742-4658
J9 FEBS J
JI FEBS J.
PD DEC
PY 2014
VL 281
IS 23
BP 5251
EP 5264
DI 10.1111/febs.13066
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AU6EJ
UT WOS:000345695700007
PM 25251993
OA Bronze
DA 2022-11-30
ER

PT J
AU Quellec, G
   Kowal, J
   Hasler, PW
   Scholl, HPN
   Zweifel, S
   Konstantinos, B
   de Carvalho, JER
   Heeren, T
   Egan, C
   Tufail, A
   Maloca, PM
AF Quellec, Gwenole
   Kowal, Jens
   Hasler, Pascal W.
   Scholl, Hendrik P. N.
   Zweifel, Sandrine
   Konstantinos, Balaskas
   de Carvalho, Joao Emanuel Ramos
   Heeren, Tjebo
   Egan, Catherine
   Tufail, Adnan
   Maloca, Peter M.
TI Feasibility of support vector machine learning in age-related macular
   degeneration using small sample yielding sparse optical coherence
   tomography data
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE artificial intelligence; machine learning; monitoring; neovascular
   age-related macular degeneration; optical coherence tomography; support
   vector machine
ID ANTI-VEGF TREATMENT; TREAT-AND-EXTEND; SD-OCT IMAGES; AUTOMATED
   SEGMENTATION; INTRAVITREAL RANIBIZUMAB; DOSING REGIMEN; REPRODUCIBILITY;
   EDEMA; CLASSIFICATION; LAYERS
AB Purpose A retrospective pilot study is conducted to demonstrate the utility of a novel support vector machine learning (SVML) algorithm in a small three-dimensional (3D) sample yielding sparse optical coherence tomography (spOCT) data for the automatic monitoring of neovascular (wet) age-related macular degeneration (wAMD). Methods From the anti-vascular endothelial growth factor injection database, 588 consecutive pairs of OCT volumes (57.624 B-scans) were selected in 70 randomly chosen wAMD patients treated with ranibizumab. The SVML algorithm was applied to 183 OCT volume pairs (17.934 B-scans) in 30 patients. Four independent, diagnosis-blinded retina specialists indicated whether wAMD activity was present between 100 pairs of consecutive OCT volumes (9800 B-scans) in the remaining 40 patients for comparison with the SVML algorithm and a non-complex baseline algorithm using only retinal thickness. The SVML algorithm was assessed using inter-observer variability and receiver operating characteristic (ROC) analyses. Results The retina specialists showed an average Cohen's kappa of 0.57 +/- 0.13 (minimum: 0.41, maximum: 0.83). The average kappa between the proposed algorithm and the retina specialists was 0.62 +/- 0.05 and 0.43 +/- 0.14 between the baseline algorithm and the retina specialists. Using each of the four retina specialists as the reference, the proposed method showed a superior area under the ROC curve of 0.91 +/- 0.03 compared to the ROC 0.81 +/- 0.05 shown by the baseline algorithm. Conclusion The SVML algorithm was as effective as the retina specialists were in detecting activity in wAMD. Support vector machine learning (SVML) may be a useful monitoring tool in wAMD suited for small samples that yield sparse OCT data possibly derived from self-measuring OCT-robots.
C1 [Quellec, Gwenole; Kowal, Jens] Univ Bern, ARTORG Ctr Biomed Engn Res, Bern, Switzerland.
   [Quellec, Gwenole] INSERM, UMR 1101, Brest, France.
   [Hasler, Pascal W.; Maloca, Peter M.] Univ Basel, Dept Ophthalmol, OCTlab, Basel, Switzerland.
   [Hasler, Pascal W.; Scholl, Hendrik P. N.; Maloca, Peter M.] Univ Basel, Dept Ophthalmol, Basel, Switzerland.
   [Scholl, Hendrik P. N.; Maloca, Peter M.] Inst Mol & Clin Ophthalmol Basel IOB, Basel, Switzerland.
   [Scholl, Hendrik P. N.] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Zweifel, Sandrine] Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
   [Konstantinos, Balaskas; Heeren, Tjebo] Moorfields Ophthalm Reading Ctr, London, England.
   [de Carvalho, Joao Emanuel Ramos; Egan, Catherine; Tufail, Adnan; Maloca, Peter M.] Moorfields Eye Hosp NHS Trust, Inst Ophthalmol UCL, London, England.
C3 University of Bern; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universite de Bretagne Occidentale; University of
   Basel; University of Basel; Johns Hopkins University; Johns Hopkins
   Medicine; University of Zurich; University Zurich Hospital; University
   of London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust
RP Maloca, PM (通讯作者)，Moorfields Eye Hosp, 162 City Rd, London EC1V 2PD, England.
EM peter.maloca@moorfields.nhs.uk
RI Zweifel, Sandrine/AAX-5045-2020; Heeren, Tjebo/R-5055-2019; Quellec,
   Gwenole/L-9946-2015; Maloca, Peter/AAG-6214-2020; Maloca,
   Peter/N-4908-2018
OI Heeren, Tjebo/0000-0001-5297-2301; Quellec, Gwenole/0000-0003-1669-7140;
   Maloca, Peter/0000-0002-4794-5859; Egan, Catherine/0000-0001-5593-1169;
   Tufail, Adnan/0000-0001-6131-7640
FU Swiss Commission for Technology and Innovation (CTI, Berne,
   Switzerland); MIMO AG, Berne, Switzerland; Integrated Science Services
   AG, Biel, Switzerland
FX This work was supported in part by the Swiss Commission for Technology
   and Innovation (CTI, Berne, Switzerland) and MIMO AG, Berne,
   Switzerland. The authors thank the University of Bern and Inselspital
   Bern, Berne, Switzerland, for their valuable contribution of data and
   research assistance. The authors also thank Integrated Science Services
   AG, Biel, Switzerland, for their programming and support of this study.
   We would also like to thank Christina Fasser, Retina International,
   Zurich Switzerland, and Stephan Huesler, Retina Suisse, Zurich,
   Switzerland, for their advice. We thank Susanne Suter, Beat Hoermann,
   Pascal Kaiser and Christof Buehler, Supercomputing Systems AG, Zurich,
   Switzerland, for their excellent comments to the manuscript. The authors
   would like to dedicate this study in warm memory to Michael Loretan and
   his family, esteemed co-founder of the MIMOAG, and thank him for his
   great commitment to realise the visionary MIMO-OCT system and to make
   the world a better place.
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Akiyama Miki, 2016, J Prev Med Public Health, V49, P183, DOI 10.3961/jpmph.16.043
   Alsaih K, 2017, BIOMED ENG ONLINE, V16, DOI 10.1186/s12938-017-0352-9
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Bakas T, 2018, GERIATR NURS, V39, P566, DOI 10.1016/j.gerinurse.2018.04.002
   Bisenius S, 2017, NEUROIMAGE-CLIN, V14, P334, DOI 10.1016/j.nicl.2017.02.003
   Bogunovic H., 2017, INVEST OPHTH VIS SCI, V58, pO141
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Churchill NW, 2014, HUM BRAIN MAPP, V35, P4499, DOI 10.1002/hbm.22490
   COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018
   Cruz J, 2014, INT J CLIN PRACT, V68, P369, DOI 10.1111/ijcp.12345
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Dufour PA, 2013, IEEE T MED IMAGING, V32, P531, DOI 10.1109/TMI.2012.2225152
   ELLENBERG JH, 1994, STAT MED, V13, P557, DOI 10.1002/sim.4780130518
   Faulkner L, 2003, BEHAV RES METH INS C, V35, P379, DOI 10.3758/BF03195514
   Feeny AK, 2015, COMPUT BIOL MED, V65, P124, DOI 10.1016/j.compbiomed.2015.06.018
   Framme C, 2012, ACTA OPHTHALMOL, V90, P49, DOI 10.1111/j.1755-3768.2010.01940.x
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujimoto J, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.16-20269
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Geary R., 1954, ICORPORPORATED STAT, V5, P115, DOI [DOI 10.2307/2986645, 10.2307/2986645]
   Haga A, 2018, ACTA OPHTHALMOL, V96, pE393, DOI 10.1111/aos.13607
   Hassan B, 2016, J OPT SOC AM A, V33, P455, DOI 10.1364/JOSAA.33.000455
   Hassan T, 2016, APPL OPTICS, V55, P454, DOI 10.1364/AO.55.000454
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holekamp NM, 2018, AM J OPHTHALMOL, V187, pXXVIII, DOI 10.1016/j.ajo.2017.11.003
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Karri SPK, 2017, BIOMED OPT EXPRESS, V8, P579, DOI 10.1364/BOE.8.000579
   Khalid S, 2018, J DIGIT IMAGING, V31, P464, DOI 10.1007/s10278-017-0038-7
   Krebs I, 2011, INVEST OPHTH VIS SCI, V52, P6925, DOI 10.1167/iovs.10-6612
   Kvannli L, 2017, ACTA OPHTHALMOL, V95, P678, DOI 10.1111/aos.13356
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee AY, 2017, BRIT J OPHTHALMOL, V101, P1683, DOI 10.1136/bjophthalmol-2016-309818
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Maloca P, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.4.8
   Mantyh WG, 2018, NEUROL-CLIN PRACT, V8, P62, DOI 10.1212/CPJ.0000000000000426
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   MORAN PAP, 1950, BIOMETRIKA, V37, P17, DOI 10.2307/2332142
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Orozco-Beltran D, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.7677
   Ouyang YL, 2010, INVEST OPHTH VIS SCI, V51, P5213, DOI 10.1167/iovs.09-4635
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P5405, DOI 10.1167/iovs.09-3505
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Ritter M, 2011, BRIT J OPHTHALMOL, V95, P381, DOI 10.1136/bjo.2009.175976
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rufai SR, 2017, EYE, V31, P1337, DOI 10.1038/eye.2017.67
   SAKOE H, 1978, IEEE T ACOUST SPEECH, V26, P43, DOI 10.1109/TASSP.1978.1163055
   Scholkopf B, 2000, NEURAL COMPUT, V12, P1207, DOI 10.1162/089976600300015565
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Song HH, 1997, BIOMETRICS, V53, P370, DOI 10.2307/2533123
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P348, DOI 10.1364/BOE.5.000348
   Sun YK, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.1.016012
   Syed AM, 2016, COMPUT METH PROG BIO, V137, P1, DOI 10.1016/j.cmpb.2016.09.004
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wang Y, 2016, BIOMED OPT EXPRESS, V7, P4928, DOI 10.1364/BOE.7.004928
   Wu ML, 2015, OPT EXPRESS, V23, P31216, DOI 10.1364/OE.23.031216
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 63
TC 5
Z9 6
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2019
VL 97
IS 5
BP E719
EP E728
DI 10.1111/aos.14055
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IH9DK
UT WOS:000474806400020
PM 30839157
OA Bronze
DA 2022-11-30
ER

PT J
AU Sugino, IK
   Rapista, A
   Sun, Q
   Wang, JQ
   Nunes, CF
   Cheewatrakoolpong, N
   Zarbin, MA
AF Sugino, Ilene K.
   Rapista, Aprille
   Sun, Qian
   Wang, Jianqiu
   Nunes, Celia F.
   Cheewatrakoolpong, Noounanong
   Zarbin, Marco A.
TI A Method to Enhance Cell Survival on Bruch's Membrane in Eyes Affected
   by Age and Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; EXTRACELLULAR-MATRIX MOLECULES; IN-VITRO;
   RPE TRANSPLANTATION; VISUAL FUNCTION; RCS RATS; PRESERVATION;
   RANIBIZUMAB; ATTACHMENT; BEHAVIOR
AB PURPOSE. To determine whether conditioned medium (CM) derived from bovine corneal endothelial cells (BCECs) can support transplanted cells on aged and age-related macular degeneration (AMD) Bruch's membrane (BM).
   METHODS. Retinal pigment epithelium (RPE) cells derived from human embryonic stem cells (hES-RPE) and cultured fetal and aged adult RPE were seeded onto the inner collagenous layer of submacular BM-choroid-sclera explants generated from aged and AMD human donor eyes. Paired explants were cultured in BCEC-CM or CM vehicle. To assess cell behavior after attachment to BM was established, explants were harvested after 21 days in culture. To assess whether sustained exposure to BCEC-CM was necessary for improved cell survival on BM, short exposure to BCEC-CM (3, 7, 14 days) was compared with 21-day exposure. Explants were harvested and evaluated by scanning electron and light microscopy. Extracellular matrix (ECM) deposition after exposure to BCEC-CM was evaluated following RPE cell removal after day 21 on tissue culture dishes or on BM.
   RESULTS. BCEC-CM significantly enhanced hES-RPE, fetal RPE, and aged adult RPE survival on BM, regardless of submacular pathology. Although shorter BCEC-CM exposure times showed significant improvement in cell survival compared with culture in CM vehicle, longer BCEC-CM exposure times were more effective. BCEC-CM increased RPE ECM deposition on tissue culture plastic and on BM.
   CONCLUSIONS. The results of this study indicate that RPE survival is possible on AMD BM and offer a method that could be developed for enhancing transplanted cell survival on AMD BM. Increased ECM deposition may account for improved cell survival after culture in BCEC-CM. (Invest Ophthalmol Vis Sci. 2011; 52:9598-9609) DOI: 10.1167/iovs.11-8400
C1 [Sugino, Ilene K.; Rapista, Aprille; Sun, Qian; Wang, Jianqiu; Nunes, Celia F.; Cheewatrakoolpong, Noounanong; Zarbin, Marco A.] Univ Med & Dent New Jersey, New Jersey Med Sch, Inst Ophthalmol & Visual Sci, Newark, NJ 07101 USA.
C3 Rutgers State University New Brunswick; Rutgers State University Medical
   Center
RP Zarbin, MA (通讯作者)，Univ Med & Dent New Jersey, New Jersey Med Sch, Inst Ophthalmol & Visual Sci, 90 Bergen St, Newark, NJ 07101 USA.
EM zarbin@umdnj.edu
OI Zarbin, Marco/0000-0002-7811-7132
FU Lincy Foundation; Foundation Fighting Blindness; Research to Prevent
   Blindness; Eye Institute of New Jersey; Janice Mitchell Vassar and Ashby
   John Mitchell Fellowship; Joseph J. and Marguerite DiSepio Retina
   Research Fund; Foundation of UMDNJ; New Jersey Lions Eye Research
   Foundation
FX Supported by the Lincy Foundation, the Foundation Fighting Blindness, an
   unrestricted grant from Research to Prevent Blindness, the Eye Institute
   of New Jersey, the Janice Mitchell Vassar and Ashby John Mitchell
   Fellowship, the Joseph J. and Marguerite DiSepio Retina Research Fund,
   the Foundation of UMDNJ, and the New Jersey Lions Eye Research
   Foundation.
CR Baker SE, 1996, EXP CELL RES, V228, P262, DOI 10.1006/excr.1996.0325
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Castellarin AA, 1998, EXP EYE RES, V66, P49, DOI 10.1006/exer.1997.0404
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Del Priore LV, 2002, CURR EYE RES, V25, P79
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Gias C, 2007, EUR J NEUROSCI, V25, P1940, DOI 10.1111/j.1460-9568.2007.05459.x
   Girman SV, 2003, VISION RES, V43, P1817, DOI 10.1016/S0042-6989(03)00276-1
   Gospodarowicz D J, 1984, Prog Clin Biol Res, V145, P103
   Gullapalli Vamsi K, 2004, Trans Am Ophthalmol Soc, V102, P123
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   GULLAPALLI VK, 2006, RETINA, P2597
   GULLAPALLI VK, 2004, T AM OPHTHAL SOC, V102, P137
   KATZ A, 1994, INVEST OPHTH VIS SCI, V35, P495
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   NEWSOME DA, 1988, EXP EYE RES, V46, P305, DOI 10.1016/S0014-4835(88)80022-8
   ROBINSON J, 1983, J CELL PHYSIOL, V117, P368, DOI 10.1002/jcp.1041170312
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SONG MK, 1990, J CELL PHYSIOL, V143, P196, DOI 10.1002/jcp.1041430127
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P4979, DOI 10.1167/iovs.10-5386
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P1345, DOI 10.1167/iovs.10-6112
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tian J, 2004, PHYSIOL GENOMICS, V17, P170, DOI 10.1152/physiolgenomics.00179.2003
   TSENG SCG, 1981, J BIOL CHEM, V256, P3361
   Tsukahara I, 2002, EXP EYE RES, V74, P255, DOI 10.1006/exer.2001.1123
   TURKSEN K, 1989, OPHTHALMIC RES, V21, P56, DOI 10.1159/000266768
   UNDERWOOD PA, 1993, EXP CELL RES, V205, P311, DOI 10.1006/excr.1993.1091
   Wang H, 2006, J REHABIL RES DEV, V43, P713, DOI 10.1682/JRRD.2005.06.0114
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P416, DOI 10.1167/iovs.07-0992
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zarbin MA, WIRES NANOM IN PRESS
   Zarbin Marco A, 2003, Trans Am Ophthalmol Soc, V101, P499
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
NR 38
TC 30
Z9 31
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2011
VL 52
IS 13
BP 9598
EP 9609
DI 10.1167/iovs.11-8400
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 869WC
UT WOS:000298628200046
PM 22039244
DA 2022-11-30
ER

PT J
AU Rosenfeld, PJ
   Shapiro, H
   Ehrlich, JS
   Wong, P
AF Rosenfeld, Philip J.
   Shapiro, Howard
   Ehrlich, Jason S.
   Wong, Pamela
CA MARINA Study Grp
   ANCHOR Study Grp
TI Cataract Surgery in Ranibizumab-Treated Patients With Neovascular
   Age-Related Macular Degeneration From the Phase 3 ANCHOR and MARINA
   Trials
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; INTRAOCULAR-LENS; BEAVER DAM; MACULOPATHY;
   EXTRACTION; PROGRESSION; RISK; IMPLANTATION; ASSOCIATION
AB PURPOSE: To investigate whether cataract surgery was beneficial in patients with neovascular age-related macular degeneration (AMD) receiving monthly ranibizumab injections in the ANCHOR (Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD) and MARINA (Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD) phase 3 trials.
   DESIGN: Retrospective analysis.
   METHODS: Patients were identified who underwent cataract surgery during the 2 pivotal trials. For this analysis, the best-corrected visual acuity (VA) just prior to cataract surgery was referred to as the redefined baseline VA. For the period after cataract surgery, endpoints included change in VA, time to first postsurgery injection, and total number of injections. Monthly follow-up visits after surgery were defined at 30-day intervals +/- 15 days.
   RESULTS: Three subgroups were identified: study eyes of ranibizumab-treated patients (758 eyes [23 undergoing surgery]), fellow eyes of ranibizumab-treated patients (758 eyes [28 undergoing surgery]), and eyes of non-ranibizumab patients (762 [16 undergoing surgery]). Three months postsurgery, the VA of ranibizumab-treated eyes improved by a mean of 10.4 (+/- 3.4) letters compared to the redefined baseline (n = 20; 95% confidence interval +3.3 letters to +17.5 letters). The mean VA change from redefined baseline VA was not significantly different between the 3 groups at any of the evaluated time points postsurgery (P > .44 for all comparisons between each pair of the 3 groups at 1, 2, 3, and 4 months following surgery).
   CONCLUSIONS: In the phase 3 trials, cataract surgery appeared to be safe and beneficial for all eyes with AMD, including ranibizumab-treated eyes with neovascular AMD. An average VA improvement of more than 2 lines was typically observed. (Am J Ophthalmol 2011;152: 793-798. (C) 2011 by Elsevier Inc. All rights reserved.)
C1 [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Shapiro, Howard; Ehrlich, Jason S.; Wong, Pamela] Genentech Inc, San Francisco, CA 94080 USA.
C3 Bascom Palmer Eye Institute; University of Miami; Roche Holding;
   Genentech
RP Rosenfeld, PJ (通讯作者)，Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@med.miami.edu
CR Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   BLAIR CJ, 1979, AM J OPHTHALMOL, V87, P77, DOI 10.1016/0002-9394(79)90195-8
   Bockelbrink A, 2008, SURV OPHTHALMOL, V53, P359, DOI 10.1016/j.survophthal.2008.04.001
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Casparis H, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub2
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   de Jong PTVM, 2004, GRAEF ARCH CLIN EXP, V242, P103, DOI 10.1007/s00417-003-0833-3
   Dong LM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1412, DOI 10.1001/archophthalmol.2009.152
   Forooghian F, 2009, OPHTHALMOLOGY, V116, P2093, DOI 10.1016/j.ophtha.2009.04.033
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Furino C, 2009, J CATARACT REFR SURG, V35, P1518, DOI 10.1016/j.jcrs.2009.04.032
   Hooper CY, 2009, CLIN EXP OPHTHALMOL, V37, P570, DOI 10.1111/j.1442-9071.2009.02095.x
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
NR 23
TC 36
Z9 37
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2011
VL 152
IS 5
BP 793
EP 798
DI 10.1016/j.ajo.2011.04.025
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 840BK
UT WOS:000296413100014
PM 21794843
DA 2022-11-30
ER

PT J
AU Wang, WQ
   Wang, FH
   Qin, WX
   Liu, HY
   Lu, B
   Chung, C
   Zhu, J
   Gu, Q
   Shi, W
   Wen, C
   Wu, F
   Zhang, K
   Sun, XD
AF Wang, Wen-Qiu
   Wang, Feng-Hua
   Qin, Wen-xin
   Liu, Hai-Yun
   Lu, Bing
   Chung, Christopher
   Zhu, Jie
   Gu, Qing
   Shi, William
   Wen, Cindy
   Wu, Frances
   Zhang, Kang
   Sun, Xiao-Dong
TI Joint Antiangiogenic Effect of ATN-161 and Anti-VEGF Antibody in a Rat
   Model of Early Wet Age-Related Macular Degeneration
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE choroidal neovascularization; integrin; VEGF; extracellular matrix;
   age-related macular degeneration
ID ENDOTHELIAL-CELL PROLIFERATION; INTEGRIN ALPHA-5-BETA-1; RANIBIZUMAB;
   NEOVASCULARIZATION; ANGIOGENESIS; PREVALENCE; MODULATION; EXPRESSION;
   ADHESION; SEQUENCE
AB The wet form of age-related macular degeneration (AMD) is a leading cause of blindness among elderly Americans and is characterized by abnormal vessel growth, termed choroidal neovascularization (CNV). Integrin alpha 5 beta 1 is a transmembrane receptor that binds matrix macromolecules and proteinases to stimulate angiogenesis. We recently demonstrated that integrin alpha 5 beta 1 plays a critical role in the development of choroidal neovascularization. In this study, we determined the role and underlying mechanisms of integrin alpha 5 beta 1 in angiogenesis in human choroidal endothelial cells and evaluated the antiangiogenic effects of delivering a combination therapy of ATN-161, an integrin alpha 5 beta 1 inhibitor, and an anti-VEGF monoclonal antibody to rats with laser induced CNV. Vascular endothelial growth factor (VEGF) is a signaling protein that stimulates vasculogenesis and angiogenesis through a pathway that is distinct from the integrin alpha 5 beta 1 signaling pathway. Our results indicate that fibronectin binds to integrin alpha 5 beta 1 and synergizes VEGF-induced angiogenesis via two independent signaling pathways, FN/integrin alpha 5 beta 1/FAK/ERK1/2 and FN/integrin alpha 5 beta 1/FAK/AKT. Integrin alpha 5 knockdown by shRNA inhibits endothelial cell migration, tube formation, and proliferation, while ATN-161 only partially decreases integrin a5 function. Treatment with ATN-161 combined with anti-VEGF antibody showed joint effects in attenuating angiogenesis. In summary, our results provide the first evidence for the mechanisms by which integrin alpha 5 beta 1 is involved in ocular pathological neovascularization in vivo, suggesting that dual inhibition of integrin alpha 5 beta 1 and VEGF may be a promising novel therapeutic strategy for CNV in wet AMD.
C1 [Wang, Wen-Qiu; Wang, Feng-Hua; Liu, Hai-Yun; Lu, Bing; Sun, Xiao-Dong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Ophthalmol, Shanghai 20080, Peoples R China.
   [Wang, Wen-Qiu; Chung, Christopher; Zhu, Jie; Shi, William; Wen, Cindy; Wu, Frances; Zhang, Kang] Univ Calif San Diego, Dept Ophthalmol, Biomat & Tissue Engn Ctr, Inst Engn Med, La Jolla, CA 92093 USA.
   [Wang, Wen-Qiu; Chung, Christopher; Zhu, Jie; Shi, William; Wen, Cindy; Wu, Frances; Zhang, Kang] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA.
   [Shi, William; Wen, Cindy; Zhang, Kang] Sichuan Univ, Mol Med Res Ctr, State Key Lab Biotherapy, West China Hosp, Chengdu 610041, Sichuan, Peoples R China.
   [Zhang, Kang] Vet Adm Healthcare Syst, San Diego, CA 92161 USA.
   [Qin, Wen-xin] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst,Renji Hosp, Shanghai 200032, Peoples R China.
   [Gu, Qing; Sun, Xiao-Dong] Shanghai Jiao Tong Univ, Shanghai Key Lab Fundus Dis, Shanghai 200080, Peoples R China.
   [Gu, Qing; Sun, Xiao-Dong] Shanghai Jiao Tong Univ, Eye Res Inst, Shanghai 200080, Peoples R China.
C3 Shanghai Jiao Tong University; University of California System;
   University of California San Diego; University of California System;
   University of California San Diego; Sichuan University; Shanghai Jiao
   Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong
   University
RP Sun, XD (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Ophthalmol, Shanghai 20080, Peoples R China.; Zhang, K (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, Biomat & Tissue Engn Ctr, Inst Engn Med, La Jolla, CA 92093 USA.; Zhang, K (通讯作者)，Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA.
EM kang.zhang@gmail.com; xdsun@sjtu.edu.cn
RI Zhu, Jie/AAD-1330-2022; Zhang, Kang/Y-2740-2019
OI Zhu, Jie/0000-0001-6862-9022; Zhang, Kang/0000-0002-4549-1697; Shi,
   William/0000-0001-5452-2902
FU National Natural Science Foundation of China Grant [81300778, 81425006];
   Shanghai Key Basic Research Grant [11JC141601]; 863 Program
   [2014AA021604]; 973 Program [2012CB917304]; International Cooperation
   Project from Science and Technology Commission of Shanghai Municipality
   [14430721600]
FX We thank Emily Yeh and Maryam Janferi for the help on the experiment.
   This study was supported by the National Natural Science Foundation of
   China Grant (81300778, 81425006) and Shanghai Key Basic Research Grant
   (11JC141601), 863 Program (2014AA021604), and 973 Program
   (2012CB917304), International Cooperation Project from Science and
   Technology Commission of Shanghai Municipality (14430721600).
CR Adair T. H., 2010, ANGIOGENESIS
   Anfosso F, 1998, J BIOL CHEM, V273, P26852, DOI 10.1074/jbc.273.41.26852
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Bennani-Baiti IM, 2011, J PATHOL, V225, P353, DOI 10.1002/path.2966
   Braren R, 2006, J CELL BIOL, V172, P151, DOI 10.1083/jcb.200506184
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Collier MEW, 2010, ARTERIOSCL THROM VAS, V30, P1810, DOI 10.1161/ATVBAHA.110.211854
   Donate F, 2008, CLIN CANCER RES, V14, P2137, DOI 10.1158/1078-0432.CCR-07-4530
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Huber G, 2009, INVEST OPHTH VIS SCI, V50, P5888, DOI 10.1167/iovs.09-3724
   Kim H, 2010, J CONTROL RELEASE, V142, P286, DOI 10.1016/j.jconrel.2009.10.031
   Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Li LX, 2012, EXP NEUROL, V237, P46, DOI 10.1016/j.expneurol.2012.06.005
   Livant DL, 2000, CANCER RES, V60, P309
   Maier AKB, 2007, CURR EYE RES, V32, P801, DOI 10.1080/02713680701553052
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   Parravano M, 2010, INVEST OPHTH VIS SCI, V51, P4788, DOI 10.1167/iovs.09-4976
   Rahman S, 1998, BIOCHEM J, V335, P247, DOI 10.1042/bj3350247
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Soares Raquel, 2003, Angiogenesis, V6, P271, DOI 10.1023/B:AGEN.0000029413.32882.dd
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Takehana Y, 1999, INVEST OPHTH VIS SCI, V40, P459
   Telci D, 2008, J BIOL CHEM, V283, P20937, DOI 10.1074/jbc.M801763200
   Tschan MP, 2003, J BIOL CHEM, V278, P42750, DOI 10.1074/jbc.M307067200
   van der Flier A, 2010, DEVELOPMENT, V137, P2439, DOI 10.1242/dev.049551
   Wang FH, 2007, CHINESE MED J-PEKING, V120, P1534, DOI 10.1097/00029330-200709010-00013
   Wang WQ, 2011, INVEST OPHTH VIS SCI, V52, P7213, DOI 10.1167/iovs.10-7097
   Wolf S, 2011, BRIT J OPHTHALMOL, V95, P1713, DOI 10.1136/bjophthalmol-2011-300471
   Yao HR, 2011, BREAST CANCER RES TR, V125, P363, DOI 10.1007/s10549-010-0826-y
   Zahn G, 2009, ARCH OPHTHALMOL-CHIC, V127, P1329, DOI 10.1001/archophthalmol.2009.265
   Zhu J, 2009, EXP EYE RES, V88, P910, DOI 10.1016/j.exer.2008.11.034
NR 36
TC 11
Z9 11
U1 2
U2 15
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD SEP
PY 2016
VL 13
IS 9
BP 2881
EP 2890
DI 10.1021/acs.molpharmaceut.6b00056
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA DV1WV
UT WOS:000382713700003
PM 27089240
DA 2022-11-30
ER

PT J
AU Risimic, D
   Milenkovic, S
   Nikolic, D
   Simeunovic, D
   Jaksic, V
   Stojkovic, M
   Stefanovic, I
   Jakovic, N
   Prostran, M
AF Risimic, Dijana
   Milenkovic, Svetislav
   Nikolic, Dejan
   Simeunovic, Dejan
   Jaksic, Vesna
   Stojkovic, Milenko
   Stefanovic, Ivan
   Jakovic, Natasa
   Prostran, Milica
TI Influence of Intravitreal Injection of Bevacizumab on Systemic Blood
   Pressure Changes in Patients with Exudative Form of Age-Related Macular
   Degeneration
SO HELLENIC JOURNAL OF CARDIOLOGY
LA English
DT Article
DE Bevacizumab; age-related macular degeneration; hypertension; gender
ID COHERENCE TOMOGRAPHY FINDINGS; AVASTIN(R); THERAPY; SAFETY
AB Introduction: The aim of our study was to examine blood pressure (BP) changes in hypertensive and non-hypertensive patients after intravitreal bevacizumab injections and to assess whether intravitreal bevacizumab carries an associated vascular risk in patients with exudative ocular disease. We also aimed to estimate the influence of gender.
   Methods: The study included 57 patients with age-related macular degeneration who received an intravitreal injection of 1.25 mg (0.1 mL) of bevacizumab. We analyzed systolic and diastolic BP values separately. Patients were divided into males and females, and into hypertensives and normotensives based on their BP values. BP was measured before bevacizumab administration, and 10 minutes, 1 hour, 2 days, 7 days and 6 weeks after the injection.
   Results: Males had a statistically significant decline in systolic BP values 1 hour and 6 weeks after drug administration (p<0.05). The most notable significant decline in diastolic BP values was for males and for normotensive participants 1 hour after drug administration (p<0.05), while the most notable decline in diastolic BP values for females and for hypertensive participants was 7 days after drug administration, with statistical significance only for hypertensive patients (p<0.01). For males it was noticed that a statistically significant decline in diastolic BP persisted after 6 weeks (p<0.05).
   Conclusions: An intravitreal bevacizumab injection is safe as regards BP changes over 6 weeks post administration. Regular follow up for 6 weeks should be mandatory in order to promptly recognize individuals who have changes in BP values and include them in BP treatment in order to prevent complications.
C1 [Risimic, Dijana; Milenkovic, Svetislav; Simeunovic, Dejan; Jaksic, Vesna; Stojkovic, Milenko; Stefanovic, Ivan; Jakovic, Natasa; Prostran, Milica] Univ Belgrade, Fac Med, Belgrade, Serbia.
   [Risimic, Dijana; Milenkovic, Svetislav; Stojkovic, Milenko; Stefanovic, Ivan; Jakovic, Natasa] Clin Ctr Serbia, Clin Eye Dis, Belgrade, Serbia.
   [Nikolic, Dejan] Univ Childrens Hosp, Dept Phys Med & Rehabil, Belgrade, Serbia.
   [Simeunovic, Dejan] Clin Ctr Serbia, Clin Cardiol, Belgrade, Serbia.
   [Jaksic, Vesna] Univ Eye Clin Zvezdara, Belgrade, Serbia.
C3 University of Belgrade; Clinical Centre of Serbia; University of
   Belgrade; Clinical Centre of Serbia
RP Risimic, D (通讯作者)，Leskovacka 6, Belgrade 11000, Serbia.
EM risimic@gmail.com
RI Nikolic, Dejan/L-1136-2019
OI Nikolic, Dejan/0000-0002-0609-9916; Risimic, Dijana/0000-0001-9918-4302;
   Jaksic, Vesna/0000-0001-9941-7305
CR BARRON H, IMPORTANT DRUG WARNI
   Felmeden DC, 2003, AM J HYPERTENS, V16, P11, DOI 10.1016/S0895-7061(02)03149-7
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Kernt M, 2007, ACTA OPHTHALMOL SCAN, V85, P119, DOI 10.1111/j.1600-0420.2006.00819.x
   Lee K, 2009, RETINA-J RET VIT DIS, V29, P1409, DOI 10.1097/IAE.0b013e3181b21056
   Mancia G, 2013, EUR HEART J, V34, P2159, DOI 10.1093/eurheartj/eht151
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Palatini P, 2004, BLOOD PRESS MONIT, V9, P297, DOI 10.1097/00126097-200412000-00005
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sane David C., 2004, Angiogenesis, V7, P193, DOI 10.1007/s10456-004-2699-3
   U.S. Food and Drug Administration, OFF LAB INV US MARK
   Ventola C Lee, 2009, P T, V34, P428
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Ziemssen Focke, 2009, International Ophthalmology, V29, P213, DOI 10.1007/s10792-008-9221-7
NR 16
TC 10
Z9 10
U1 0
U2 1
PU HELLENIC CARDIOLOGICAL SOC
PI ATHENS
PA 6 POTAMIANOU ST, ATHENS, 11528, GREECE
SN 1109-9666
EI 2241-5955
J9 HELL J CARDIOL
JI Hell. J. Cardiol.
PD NOV-DEC
PY 2013
VL 54
IS 6
BP 435
EP 440
PG 6
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA AS1JN
UT WOS:000344037600004
PM 24305579
DA 2022-11-30
ER

PT J
AU Okada, AA
   Takahashi, K
   Ohji, M
   Moon, SC
   Machewitz, T
   Sasaki, K
AF Okada, Annabelle A.
   Takahashi, Kanji
   Ohji, Masahito
   Moon, SungChul Charles
   Machewitz, Tobias
   Sasaki, Koji
CA ALTAIR Study Investigators
TI Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend
   Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal
   Choroidal Vasculopathy Subgroup
SO ADVANCES IN THERAPY
LA English
DT Article
DE Anatomic outcomes; Exudative age-related macular degeneration;
   Functional outcomes; Intravitreal aflibercept; Polypoidal choroidal
   vasculopathy; Treat-and-extend; Treatment interval
ID MACULAR DEGENERATION; 2-YEAR OUTCOMES; JAPANESE PATIENTS; THERAPY;
   INJECTIONS
AB Introduction To explore the efficacy and safety of intravitreal aflibercept (IVT-AFL) proactive, individualized treat-and-extend (T&E) regimens in exudative age-related macular degeneration (AMD) in the subgroup of patients with polypoidal choroidal vasculopathy (PCV) enrolled in the ALTAIR study. Methods This was a PCV subgroup analysis of ALTAIR, a 96-week, randomized, open-label, phase 4 study in treatment-naive patients with exudative AMD in Japan. Following three initial monthly doses, patients received IVT-AFL at week 16 and were randomized 1:1 to T&E regimens with either 2-week (IVT-AFL-2W) or 4-week (IVT-AFL-4W) adjustments. The primary endpoint of ALTAIR was the mean change in best-corrected visual acuity (BCVA) from baseline to week 52. Endpoints were assessed at weeks 52 and 96. Safety analyses were conducted. Results A total of 90 patients with PCV were included within the full analysis set. From baseline to week 52, mean [standard deviation (SD)] change in BCVA was + 7.5 (14.7) letters and + 8.2 (11.6) letters in the IVT-AFL-2W and IVT-AFL-4W groups, respectively. From baseline to week 96, 91.3% and 90.9% of patients maintained vision in the IVT-AFL-2W and IVT-AFL-4W groups, respectively. From baseline to week 52, mean (SD) change in central retinal thickness was - 153 (177) mu m and -112 (122) mu m in the IVT-AFL-2W and IVT-AFL-4W groups, respectively. Overall, 51.1% of patients (IVT-AFL-2W, 43.5%; IVT-AFL-4W, 59.1%) achieved a treatment interval of 16 weeks between weeks 16 and 96. The safety profile of IVT-AFL was consistent with previous studies. Conclusion In treatment-naive patients with PCV, IVT-AFL administered using two different T&E regimens improved and maintained functional and anatomic outcomes over 96 weeks while minimizing treatment burden.
C1 [Okada, Annabelle A.] Kyorin Univ, Dept Ophthalmol, Sch Med, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.
   [Takahashi, Kanji] Kansai Med Univ, Dept Ophthalmol, Osaka, Japan.
   [Ohji, Masahito] Shiga Univ Med Sci, Dept Ophthalmol, Otsu, Shiga, Japan.
   [Moon, SungChul Charles] Bayer AG, Dept Med Affairs & Pharmacovigilance, Berlin, Germany.
   [Machewitz, Tobias] Bayer AG, Dept Res & Dev, Berlin, Germany.
   [Sasaki, Koji] Bayer Yakuhin Ltd, Dept Med Affairs & Pharmacovigilance, Osaka, Japan.
C3 Kyorin University; Kansai Medical University; Shiga University of
   Medical Science; Bayer AG; Bayer AG; Bayer AG
RP Okada, AA (通讯作者)，Kyorin Univ, Dept Ophthalmol, Sch Med, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.
EM aokada@e23.jp
OI Okada, Annabelle/0000-0002-8850-8962
FU Bayer Yakuhin Ltd.; Bayer Consumer Care AG, Pharmaceuticals, Basel,
   Switzerland; Bayer Consumer Care AG
FX The ALTAIR study was sponsored by Bayer Yakuhin Ltd. This post hoc
   analysis was funded by Bayer Consumer Care AG, Pharmaceuticals, Basel,
   Switzerland. The journal's Rapid Service and Open Access Fees were
   funded by Bayer Consumer Care AG.
CR Arakawa A, 2017, CLIN OPHTHALMOL, V11, P797, DOI 10.2147/OPTH.S129164
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Kokame GT, 2019, OPHTHALMOL RETINA, V3, P744, DOI 10.1016/j.oret.2019.04.018
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Maruko I, 2020, OPHTHALMOL RETINA, V4, P767, DOI 10.1016/j.oret.2020.03.010
   Matsumoto H, 2018, OPHTHALMOL RETINA, V2, P462, DOI 10.1016/j.oret.2017.09.002
   Matsunaga DR, 2021, OPHTHALMOL RETINA, V5, P342, DOI 10.1016/j.oret.2020.07.028
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Morizane-Hosokawa M, 2018, ACTA MED OKAYAMA, V72, P379, DOI 10.18926/AMO/56175
   Ogura Y, 2021, JPN J OPHTHALMOL, V65, P344, DOI 10.1007/s10384-020-00805-5
   Ohji M, 2018, AS PAC VITR SOC APVR
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oshima Y, 2017, OPHTHALMOLOGICA, V238, P163, DOI 10.1159/000477448
   Sakamoto S, 2018, CLIN OPHTHALMOL, V12, P1137, DOI 10.2147/OPTH.S160961
   Tamachi T, 2020, OPHTHALMOL THER, V9, P1069, DOI 10.1007/s40123-020-00312-3
   Teo KYC, 2022, BRIT J OPHTHALMOL, V106, P987, DOI 10.1136/bjophthalmol-2020-318354
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Yamamoto A, 2017, OPHTHALMOLOGICA, V237, P139, DOI 10.1159/000458538
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 31
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0741-238X
EI 1865-8652
J9 ADV THER
JI Adv. Ther.
PD JUN
PY 2022
VL 39
IS 6
BP 2984
EP 2998
DI 10.1007/s12325-022-02162-w
EA MAY 2022
PG 15
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 1J9XW
UT WOS:000790224000002
PM 35503499
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Flinn, JM
   Kakalec, P
   Tappero, R
   Jones, B
   Lengyel, I
AF Flinn, Jane M.
   Kakalec, Peter
   Tappero, Ryan
   Jones, Blair
   Lengyel, Imre
TI Correlations in distribution and concentration of calcium, copper and
   iron with zinc in isolated extracellular deposits associated with
   age-related macular degeneration
SO METALLOMICS
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; FACTOR-H; X-RAY; COMPLEMENT ACTIVATION;
   DRUSEN FORMATION; BRUCHS MEMBRANE; BASAL DEPOSITS; ACCUMULATION;
   PROTEIN; INFLAMMATION
AB Zinc (Zn) is abundantly enriched in sub-retinal pigment epithelial (RPE) deposits, the hallmarks of age-related macular degeneration (AMD), and is thought to play a role in the formation of these deposits. However, it is not known whether Zn is the only metal relevant for sub-RPE deposit formation. Because of their involvement in the pathogenesis of AMD, we determined the concentration and distribution of calcium (Ca), iron (Fe) and copper (Cu) and compared these with Zn in isolated and sectioned macular (MSD), equatorial (PHD) and far peripheral (FPD) sub-RPE deposits from an 86 year old donor eye with post mortem diagnosis of early AMD. The sections were mounted on Zn free microscopy slides and analyzed by microprobe synchrotron X-ray fluorescence (mu SXRF). Metal concentrations were determined using spiked sectioned sheep brain matrix standards, prepared the same way as the samples. The heterogeneity of metal distributions was examined using pixel by pixel comparison. The orders of metal concentrations were Ca >>> Zn > Fe in all three types of deposits but Cu levels were not distinguishable from background values. Zinc and Ca were consistently present in all deposits but reached highest concentration in MSD. Iron was present in some but not all deposits and was especially enriched in FPD. Correlation analysis indicated considerable variation in metal distribution within and between sub-RPE deposits. The results suggest that Zn and Ca are the most likely contributors to deposit formation especially in MSD, the characteristic risk factor for the development of AMD in the human eye.
C1 [Flinn, Jane M.; Kakalec, Peter] George Mason Univ, Fairfax, VA 22030 USA.
   [Tappero, Ryan] Brookhaven Natl Lab, Natl Synchrotron Light Source, Upton, NY 11973 USA.
   [Jones, Blair] US Geol Survey, Reston, VA 22092 USA.
   [Lengyel, Imre] UCL, UCL Inst Ophthalmol, London EC1V 9EL, England.
C3 George Mason University; State University of New York (SUNY) System;
   United States Department of Energy (DOE); Brookhaven National
   Laboratory; United States Department of the Interior; United States
   Geological Survey; University of London; University College London
RP Lengyel, I (通讯作者)，UCL, UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM i.lengyel@ucl.ac.uk
RI Lengyel, Imre/B-5217-2009
OI Lengyel, Imre/0000-0001-7467-2174
FU Bill Brown Charitable Trust Senior Research Fellowship; Moorfields Eye
   Hospital Special Trustees; Mercer Fund from Fight for Sight; DOE, Office
   of Science, Office of Basic Energy Sciences [DE-AC02-98CH10886]; NIHR;
   U.S. Department of Energy (DOE) - Geosciences [DE-FG02-92ER14244, X27A]
FX We thank Professors Alan C Bird, Richard Thompson and Erinn Gideon for
   their generous help and Dr David Sterratt for reconstructing the flat
   mounted samples. The research was supported by the Bill Brown Charitable
   Trust Senior Research Fellowship, Moorfields Eye Hospital Special
   Trustees and Mercer Fund from Fight for Sight (I.L). Portions of this
   work were performed at Beamline X27A, National Synchrotron Light Source
   (NSLS), Brookhaven National Laboratory, under a General user grant to
   JMF. X27A is supported in part by the U.S. Department of Energy (DOE) -
   Geosciences (DE-FG02-92ER14244 to The University of Chicago - CARS). Use
   of the NSLS was supported by the DOE, Office of Science, Office of Basic
   Energy Sciences, under Contract No. DE-AC02-98CH10886. Tissue for this
   project was provided by the UCL Institute of Ophthalmology and
   Moor-fields Eye Hospital Eye Tissue Repository supported by NIHR
   funding.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 1999, INVEST OPHTH VIS SCI, V40, P3305
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Blom AM, 2003, ARCH BIOCHEM BIOPHYS, V418, P108, DOI 10.1016/j.abb.2003.08.018
   Bush AI, 2002, NEUROBIOL AGING, V23, P1031, DOI 10.1016/S0197-4580(02)00120-3
   Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Erie JC, 2009, AM J OPHTHALMOL, V147, P276, DOI 10.1016/j.ajo.2008.08.014
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1196, DOI 10.1016/0002-9394(71)90963-9
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   Flinn JM, 2005, PHYSIOL BEHAV, V83, P793, DOI 10.1016/j.physbeh.2004.10.009
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Lengyel I, 2008, EXPERT REV OPHTHALMO, V3, P1, DOI 10.1586/17469899.3.1.1
   Levenson CW, 2003, NUTR REV, V61, P311, DOI 10.1301/nr.2003.sept.311-313
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Miller LM, 2006, J STRUCT BIOL, V155, P30, DOI 10.1016/j.jsb.2005.09.004
   Molnar Z, 2004, J NEUROCHEM, V89, P1215, DOI 10.1111/j.1471-4159.2004.02427.x
   Nan R, 2013, J BIOL CHEM, V288, P19197, DOI 10.1074/jbc.M113.476143
   Nan R, 2011, J MOL BIOL, V408, P714, DOI 10.1016/j.jmb.2011.03.006
   Nan R, 2008, J MOL BIOL, V384, P1341, DOI 10.1016/j.jmb.2008.10.030
   Neubauer AS, 2005, ACTA OPHTHALMOL SCAN, V83, P759, DOI 10.1111/j.1600-0420.2005.00532.x
   OLIN KL, 1995, P SOC EXP BIOL MED, V208, P370, DOI 10.3181/00379727-208-43864
   Panorgias A, 2013, INVEST OPHTH VIS SCI, V54, P4372, DOI 10.1167/iovs.12-11525
   PERKINS SJ, 1991, BIOCHEMISTRY-US, V30, P2847, DOI 10.1021/bi00225a017
   Rao DV, 2010, J X-RAY SCI TECHNOL, V18, P327, DOI 10.3233/XST-2010-0255
   Ritchie CW, 2004, EXPERT OPIN INV DRUG, V13, P1585, DOI 10.1517/13543784.13.12.1585
   Ritchie CW., 2011, INVEST OPHTH VIS SCI, V52, P6683
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Sterratt DC, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002921
   ULSHAFER RJ, 1990, ARCH OPHTHALMOL-CHIC, V108, P113, DOI 10.1001/archopht.1990.01070030119041
   ULSHAFER RJ, 1987, INVEST OPHTH VIS SCI, V28, P683
   VANDERSCHAFT TL, 1992, ARCH OPHTHALMOL-CHIC, V110, P389, DOI 10.1001/archopht.1992.01080150087034
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Wills NK, 2008, EXP EYE RES, V87, P80, DOI 10.1016/j.exer.2008.04.013
NR 48
TC 28
Z9 28
U1 0
U2 17
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1756-5901
EI 1756-591X
J9 METALLOMICS
JI Metallomics
PY 2014
VL 6
IS 7
BP 1223
EP 1228
DI 10.1039/c4mt00058g
PG 6
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AK7WI
UT WOS:000338638000007
PM 24740686
DA 2022-11-30
ER

PT J
AU Bonnin, P
   Pournaras, JAC
   Lazrak, Z
   Cohen, SY
   Legargasson, JF
   Gaudric, A
   Levy, BI
   Massin, P
AF Bonnin, Philippe
   Pournaras, Jean-Antoine C.
   Lazrak, Zineb
   Cohen, Salomon Yves
   Legargasson, Jean-Francois
   Gaudric, Alain
   Levy, Bernard I.
   Massin, Pascale
TI Ultrasound assessment of short-term ocular vascular effects of
   intravitreal injection of bevacizumab (Avastin (R)) in neovascular
   age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE antiangiogenic therapy; age-related macular degeneration (AMD); central
   retinal artery; ciliary artery; ophthalmic artery; ultrasound imaging
ID CAROTID-ARTERY-DISEASE; BLOOD-FLOW-VELOCITY; CHOROIDAL
   NEOVASCULARIZATION; RETROBULBAR CIRCULATION; EYE; REPRODUCIBILITY;
   INHIBITION; HUMANS
AB Purpose:
   Angiogenic inhibitors, alone or combined with other therapies, are believed to represent a promising treatment for neovascularization in age-related macular degeneration (wet AMD). They can maintain or improve visual acuity (VA), at least for the first 2 years. However, evolution to retinal atrophy cannot be ruled out and it may be useful to assess the effects of antiangiogenic therapy on retinal and choroidal circulation.
   Methods:
   We carried out a pilot study in 15 patients with wet AMD. Time-averaged mean blood flow velocities (BFVs) in the central retinal, temporal posterior ciliary and ophthalmic arteries (CRA, TPCA and OA) were measured by ultrasound imaging before and 4 weeks after a single intravitreal injection of 1.25 mg bevacizumab in 0.05 ml. Patients underwent two ophthalmic examinations, before and 4 weeks after injection, including VA measurement and optical coherence tomography (OCT3) examination.
   Results:
   In treated eyes, bevacizumab injection was followed by a significant improvement in VA (from 20/125 to 20/80; p = 0.0214), and a decrease in mean central macular thickness (from 392 +/- 96 mu m to 271 +/- 50 mu m; p = 0.0038). Mean BFV decreased by 10% in the CRA (p = 0.0226), 20% in the TPCA (p = 0.0026) and 20% in the OA (p = 0.0003). No effect was observed in fellow eyes.
   Conclusions:
   Intravitreal bevacizumab acutely improved VA and reduced central macular thickness in wet AMD. Ultrasound imaging revealed that BFVs decreased in all retrobulbar arteries, suggesting that after local diffusion, bevacizumab exerts a short-term regional effect. Bevacizumab might therefore induce hypoperfusion of the whole eye, which may correspond to a vascular side-effect.
C1 [Bonnin, Philippe; Pournaras, Jean-Antoine C.; Lazrak, Zineb; Cohen, Salomon Yves; Legargasson, Jean-Francois; Gaudric, Alain; Levy, Bernard I.; Massin, Pascale] Univ Paris, Lariboisiere Hosp, AP HP, F-75252 Paris, France.
   [Bonnin, Philippe] Lariboisiere Hosp, INSERM, U965, Paris, France.
   [Legargasson, Jean-Francois] INSERM, UMR 592, Lab Cellular & Mol Pathophysiol Retina, Paris, France.
   [Gaudric, Alain; Levy, Bernard I.; Massin, Pascale] INSERM, Lariboisiere U689, Cardiovasc Res Ctr, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities;
   Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Universite Paris Cite; Institut National de la
   Sante et de la Recherche Medicale (Inserm); Institut National de la
   Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Universite Paris Cite
RP Bonnin, P (通讯作者)，Univ Paris 07, Hop Lariboisiere, 2 Rue Ambroise Pare, F-75475 Paris 10, France.
EM philippe.bonnin@lrb.aphp.fr
RI Bonnin, Philippe/Y-5872-2019
OI Bonnin, Philippe/0000-0003-3184-3740; Gaudric, Alain/0000-0002-2486-4722
CR AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   BAXTER GM, 1995, J ULTRAS MED, V14, P91, DOI 10.7863/jum.1995.14.2.91
   BILL A, 1968, ACTA PHYSIOL SCAND, V73, P204, DOI 10.1111/j.1748-1716.1968.tb04097.x
   Bonnin P, 2008, ULTRASOUND MED BIOL, V34, P1076, DOI 10.1016/j.ultrasmedbio.2007.12.003
   Bonnin P, 2007, ULTRASOUND MED BIOL, V33, P561, DOI 10.1016/j.ultrasmedbio.2006.09.010
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Costa VP, 1999, OPHTHALMOLOGY, V106, P306, DOI 10.1016/S0161-6420(99)90086-6
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Furino C, 2009, ACTA OPHTHALMOL, V87, P404, DOI 10.1111/j.1755-3768.2008.01262.x
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hosal BM, 1998, EUR J OPHTHALMOL, V8, P234, DOI 10.1177/112067219800800406
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Kim KS, 2008, ACTA OPHTHALMOL, V86, DOI 10.1111/j.1755-3768.2008.01175.x
   Kitamoto Y, 2000, Rinsho Byori, V48, P485
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   LIEB WE, 1991, ARCH OPHTHALMOL-CHIC, V109, P527, DOI 10.1001/archopht.1991.01080040095036
   LIEB WE, 1991, OPHTHALMOLOGY, V98, P548
   Matthiessen ET, 2004, EYE, V18, P400, DOI 10.1038/sj.eye.6700651
   Mourad JJ, 2008, ANN ONCOL, V19, P927, DOI 10.1093/annonc/mdm550
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Plange N, 2003, BRIT J OPHTHALMOL, V87, P731, DOI 10.1136/bjo.87.6.731
   Rensch F, 2008, ACTA OPHTHALMOL, V86, P696, DOI 10.1111/j.1600-0420.2007.01131.x
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sabaa N, 2008, J CLIN INVEST, V118, P1924, DOI 10.1172/JCI33308
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   Soliman W, 2008, ACTA OPHTHALMOL, V86, P365, DOI 10.1111/j.1600-0420.2007.01057.x
   Sugimoto H, 2005, LIVER INT, V25, P282, DOI 10.1111/j.1478-3231.2005.01023.x
   Uretmen O, 2003, OPHTHALMOLOGICA, V217, P137, DOI 10.1159/000068559
NR 33
TC 45
Z9 46
U1 0
U2 6
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2010
VL 88
IS 6
BP 641
EP 645
DI 10.1111/j.1755-3768.2009.01526.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 643PI
UT WOS:000281310000014
PM 19563370
DA 2022-11-30
ER

PT J
AU Zhang, YP
   Wang, YX
   Zhou, JQ
   Wang, Q
   Yan, YN
   Yang, X
   Yang, JY
   Zhou, WJ
   Wang, P
   Shen, C
   Yang, M
   Luan, YN
   Wang, JY
   Wu, SL
   Chen, SH
   Wang, HW
   Fang, LJ
   Wan, QQ
   Zhu, JY
   Nie, ZH
   Chen, YN
   Xie, Y
   Jonas, JB
   Wei, WB
AF Zhang Yong Peng
   Wang Ya Xing
   Zhou Jin Qiong
   Wang Qian
   Yan Yan Ni
   Yang Xuan
   Yang Jing Yan
   Zhou Wen Jia
   Wang Ping
   Shen Chang
   Yang Ming
   Luan Ya Nan
   Wang Jin Yuan
   Wu Shou Ling
   Chen Shuo Hua
   Wang Hai Wei
   Fang Li Jian
   Wan Qian Qian
   Zhu Jing Yuan
   Nie Zi Han
   Chen Yu Ning
   Xie Ying
   Jonas, J. B.
   Wei Wen Bin
TI The Influence of Diabetes, Hypertension, and Hyperlipidemia on the Onset
   of Age-Related Macular Degeneration in North China: The Kailuan Eye
   Study
SO BIOMEDICAL AND ENVIRONMENTAL SCIENCES
LA English
DT Article
DE Diabetes; Hypertension; Hyperlipidemia; Age-related macular
   degeneration; Prevalence; Risk factor
ID RISK-FACTORS; MACULOPATHY; RETINOPATHY; PREVALENCE; CLASSIFICATION;
   ASSOCIATION; DISEASE
AB Objective To analyze the prevalence of dry and wet age-related macular degeneration (AMD) in patients with diabetes, hypertension and hyperlipidemia, and to analyze the risk factors for AMD.
   Methods A population-based cross-sectional epidemiologic study was conducted involving 14,440 individuals. We assessed the prevalence of dry and wet AMD in diabetic and non-diabetic subjects and analyzed the risk factors for AMD.
   Results The prevalence of wet AMD in diabetic and non-diabetic patients was 0.3% and 0.5%, respectively, and the prevalence of dry AMD was 17% and 16.4%, respectively. The prevalence of wet AMD in healthy, hypertensive, hyperlipidemic, and hypertensive/hyperlipidemic populations was 0.5%, 0.3%, 0.2%, and 0.7%, respectively. The prevalence of dry AMD in healthy, hypertensive, hyperlipidemic, and hypertensive/hyperlipidemic populations was 16.6%, 16.2%, 15.2%, and 17.2%, respectively. Age, sex, body mass index, and use of hypoglycemic drugs or lowering blood pressure drugs were corrected in the risk factor analysis of AMD. Diabetes, diabetes/hypertension, diabetes/hyperlipidemia, and diabetes/hypertension/hyperlipidemia were analyzed. None of the factors analyzed in the current study increased the risk for the onset of AMD.
   Conclusion There was no significant difference in the prevalence of wet and dry AMD among diabetic and non-diabetic subjects. Similarly, there was no significant difference in the prevalence of wet and dry AMD among subjects with hypertension and hyperlipidemia. Diabetes co-existing with hypertension and hyperlipidemia were not shown to be risk factors for the onset of dry AMD.
C1 [Zhang Yong Peng; Zhou Jin Qiong; Wang Qian; Yan Yan Ni; Yang Xuan; Yang Jing Yan; Zhou Wen Jia; Wang Ping; Shen Chang; Yang Ming; Luan Ya Nan; Wang Jin Yuan; Zhu Jing Yuan; Nie Zi Han; Chen Yu Ning; Wei Wen Bin] Capital Med Univ, Beijing Tongren Hosp,Med Artificial Intelligence, Beijing Tongren Eye Ctr,Beijing Ophthalmol & Visu, Minist Ind & Informat Technol,Beijing Key Lab Int, Beijing 100730, Peoples R China.
   [Wang Ya Xing] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Inst Ophthalmol,Beijing Key Lab Ophthalmo, Beijing 100730, Peoples R China.
   [Wu Shou Ling] Kailuan Gen Hosp, Cardiol Dept, Tangshan 063000, Hebei, Peoples R China.
   [Chen Shuo Hua] Kailuan Grp, Hlth Care Ctr, Tangshan 063000, Hebei, Peoples R China.
   [Wang Hai Wei] Capital Med Univ, Fuxing Hosp, Dept Opthalmol, Beijing 100038, Peoples R China.
   [Fang Li Jian] Capital Med Univ, Beijing Liangxiang Hosp, Dept Ophthalmol, Beijing 102401, Peoples R China.
   [Wan Qian Qian] Anhui Med Univ, Dept Ophthalmol, Hosp 2, Hefei 230000, Anhui, Peoples R China.
   [Xie Ying] Shanxi Prov Peoples Hosp, Dept Opthalmol, Taiyuan 030012, Shanxi, Peoples R China.
   [Jonas, J. B.] Heidelberg Univ, Dept Ophthalmol, Med Fac Mannheim, Heidelberg, Germany.
C3 Capital Medical University; Capital Medical University; Capital Medical
   University; Capital Medical University; Anhui Medical University; Shanxi
   People's Hospital; Ruprecht Karls University Heidelberg
RP Wei, WB (通讯作者)，Capital Med Univ, Beijing Tongren Hosp,Med Artificial Intelligence, Beijing Tongren Eye Ctr,Beijing Ophthalmol & Visu, Minist Ind & Informat Technol,Beijing Key Lab Int, Beijing 100730, Peoples R China.
EM weiwenbintr@163.com
CR [Anonymous], 2004, SIN, V26, P1
   Benson WE, 1988, DIABETES ITS OCULAR
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Borrone R, 2008, EUR J OPHTHALMOL, V18, P949, DOI 10.1177/112067210801800615
   Cao JT, 1998, ARCH OPHTHALMOL-CHIC, V116, P589, DOI 10.1001/archopht.116.5.589
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen Chunming, 2004, Biomed Environ Sci, V17 Suppl, P1
   Chen X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108196
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fukushima I, 1997, AM J OPHTHALMOL, V124, P473, DOI 10.1016/S0002-9394(14)70863-3
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   He MS, 2018, DIABETES CARE, V41, P2202, DOI 10.2337/dc18-0707
   HIDAYAT AA, 1985, OPHTHALMOLOGY, V92, P512
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Joint committee issued Chinese guideline for the management of dyslipidemia in adults, 2016, Zhonghua Xin Xue Guan Bing Za Zhi, V44, P833, DOI 10.3760/cma.j.issn.0253-3758.2016.10.005
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Kananen F, 2021, ACTA OPHTHALMOL, V99, pE1063, DOI 10.1111/aos.14774
   Katsi VK, 2015, J HYPERTENS, V33, P2382, DOI 10.1097/HJH.0000000000000766
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   Nagaoka T, 2004, BRIT J OPHTHALMOL, V88, P1060, DOI 10.1136/bjo.2003.035345
   Proctor B, 2007, INVEST OPHTHALMOL VI, V48, P2149
   Srinivasan S, 2017, EYE, V31, P1176, DOI 10.1038/eye.2017.47
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   VINORES SA, 1988, EXP EYE RES, V46, P545, DOI 10.1016/S0014-4835(88)80011-3
   Voutilainen-Kaunisto RM, 2000, DIABETES CARE, V23, P1672, DOI 10.2337/diacare.23.11.1672
   Wang FH, 2009, OPHTHALMOLOGY, V116, P461, DOI 10.1016/j.ophtha.2008.10.003
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
   Xie XW, 2009, EUR J OPHTHALMOL, V19, P91, DOI 10.1177/112067210901900114
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Zhang SJ, 2022, BIOMED ENVIRON SCI, V35, P107, DOI 10.3967/bes2022.015
   Zhang YC, 2021, J GLOB HEALTH, V11, DOI 10.7189/jogh.11.08009
   Zhang YP, 2022, FRONT PUBLIC HEALTH
   Zylbermann R, 1997, EYE, V11, P872, DOI 10.1038/eye.1997.224
NR 44
TC 0
Z9 0
U1 0
U2 0
PU CHINESE CENTER DISEASE CONTROL & PREVENTION
PI BEIJING
PA 155 CHANGBAI RD, CHANGPING DISTRICT, BEIJING, 102206, PEOPLES R CHINA
SN 0895-3988
EI 2214-0190
J9 BIOMED ENVIRON SCI
JI Biomed. Environ. Sci.
PD JUL
PY 2022
VL 35
IS 7
BP 613
EP 621
DI 10.3967/bes2022.081
PG 9
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA 5A3CE
UT WOS:000862767000003
PM 35945176
DA 2022-11-30
ER

PT J
AU Schnabolk, G
   Obert, E
   Banda, NK
   Rohrer, B
AF Schnabolk, Gloriane
   Obert, Elisabeth
   Banda, Nirmal K.
   Rohrer, Barbel
TI Systemic Inflammation by Collagen-Induced Arthritis Affects the
   Progression of Age-Related Macular Degeneration Differently in Two Mouse
   Models of the Disease
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; rheumatoid arthritis; choroidal
   neovascularization; optical coherence tomography
ID RETINAL ANGIOMATOUS PROLIFERATION; COMPLEMENT COMPONENT 2; FACTOR-H
   POLYMORPHISM; RHEUMATOID-ARTHRITIS; THERAPEUTIC RESPONSE; INDUCIBLE
   PROTEIN-10; SEX-DIFFERENCES; OPTIC NEURITIS; SODIUM IODATE; INHIBITION
AB PURPOSE. Age-related macular degeneration (AMD) shares similar risk factors and inflammatory responses with rheumatoid arthritis (RA). Previously, we identified increased risk for dry AMD among patients with RA compared to control subjects, using retrospective data analysis. In this current study, we investigate the role of systemic inflammation triggered in a murine model of arthritis on choroidal neovascularization and retinal pigment epithelium (RPE) degeneration mouse models.
   METHODS. Collagen-induced arthritis (CIA) was induced in C57BL/6J mice prior to laserinduced choroidal neovascularization (CNV; wet AMD model) or sodium iodate-induced retinal degeneration (NaIO3; dry AMD model). CNV lesion size and retinal thickness were quantified by optical coherence photography (OCT), visual function was analyzed using optokinetic response and electroretinography, RPE morphology was examined by immunohistochemistry, and inflammatory gene expression was analyzed by quantitative PCR.
   RESULTS. CIA mice demonstrated decreased spatial acuity and contrast sensitivity, whereas no difference was observed in the RPE-generated c-wave. CNV lesion size was decreased in CIA mice. NaIO3 decreased c-wave amplitude, as well as retinal thickness, which was augmented by CIA. NaIO3 treatment resulted in loss of normal RPE hexagonal shape, which was further aggravated by CIA. Increased Cxcl9 expression was observed in the presence of CIA and CIA combined with AMD. Disease severity differences were observed between sexes.
   CONCLUSIONS. Our data suggest systemic inflammation by CIA results in increased pathology in a dry AMD model, whereas it reduces lesions in a wet AMD model. These findings highlight the need for additional investigation into the role of secondary inflammation and sex-based differences on AMD.
C1 [Schnabolk, Gloriane; Obert, Elisabeth; Rohrer, Barbel] Med Univ South Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
   [Banda, Nirmal K.] Univ Colorado, Dept Med, Div Rheumatol, Anschutz Med Campus, Aurora, CO USA.
   [Rohrer, Barbel] Ralph H Johnson VA Med Ctr, Div Res, Charleston, SC USA.
C3 Medical University of South Carolina; University of Colorado System;
   University of Colorado Anschutz Medical Campus; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson
   VA Medical Center
RP Schnabolk, G (通讯作者)，Med Univ South Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
EM faith@musc.edu
FU National Institutes of Health (NIH) [K12HD055885]; Building
   Interdisciplinary Research Careers in Women's Health (BIRCWH)
   fellowship; NIH [2R56 AR051749-15, R01EY024581]; Department of Veterans
   Affairs [I01RX000444, I01BX003050, IK6BX004858]; South Carolina
   SmartState Endowment
FX Supported by National Institutes of Health (NIH) K12HD055885 Building
   Interdisciplinary Research Careers in Women's Health (BIRCWH) fellowship
   and the Medical University of South Carolina College of Medicine
   institutional support (GS), NIH 2R56 AR051749-15 (NKB-CoI), and NIH
   (R01EY024581), the Department of Veterans Affairs (I01RX000444,
   I01BX003050, and IK6BX004858), and the South Carolina SmartState
   Endowment (BR).
CR Ablonczy Z, 2007, EXP EYE RES, V85, P762, DOI 10.1016/j.exer.2007.08.010
   Agildere AM, 1999, BRIT J RADIOL, V72, P404
   Akamine R, 2007, J BIOCHEM BIOPH METH, V70, P481, DOI 10.1016/j.jbbm.2006.11.008
   Al-Louzi OA, 2016, MULT SCLER J, V22, P362, DOI 10.1177/1352458515590646
   Amatschek S, 2011, BRIT J CANCER, V104, P469, DOI 10.1038/sj.bjc.6606056
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155
   Bak M, 2017, JAMA OPHTHALMOL, V135, P835, DOI 10.1001/jamaophthalmol.2017.2011
   Banda NK, 2003, J IMMUNOL, V171, P2109, DOI 10.4049/jimmunol.171.4.2109
   Banda NK, 2003, J IMMUNOL, V170, P2100, DOI 10.4049/jimmunol.170.4.2100
   Banda NK, 2002, ARTHRITIS RHEUM-US, V46, P3065, DOI 10.1002/art.10591
   Bresnihan B, 2009, J RHEUMATOL, V36, P1800, DOI 10.3899/jrheum.090348
   Cahill H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002055
   Chen X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108196
   Chen YH, 2008, J NEURO-OPHTHALMOL, V28, P237, DOI 10.1097/WNO.0b013e318183ca13
   Chowers G, 2017, INVEST OPHTH VIS SCI, V58, P2239, DOI 10.1167/iovs.16-21255
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Coughlin B, 2016, SCI REP-UK, V6, DOI 10.1038/srep23794
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Divo MJ, 2014, EUR RESPIR J, V44, P1055, DOI 10.1183/09031936.00059814
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Franceschi C, 2007, NUTR REV, V65, pS173, DOI [10.1111/j.1753-4887.2007.tb00358.x, 10.1301/nr.2007.dec.S173-S176]
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Generali E, 2015, CLIN REV ALLERG IMMU, V49, P263, DOI 10.1007/s12016-015-8518-3
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P3880, DOI 10.1167/iovs.10-6266
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   He LZ, 2014, J BIOL CHEM, V289, P8019, DOI 10.1074/jbc.M113.535765
   Hunter TM, 2017, RHEUMATOL INT, V37, P1551, DOI 10.1007/s00296-017-3726-1
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kimura M, 2007, J IMMUNOL, V178, P3316, DOI 10.4049/jimmunol.178.5.3316
   Kiuchi K, 2002, CURR EYE RES, V25, P373, DOI 10.1076/ceyr.25.6.373.14227
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Klein SL, 2004, PARASITE IMMUNOL, V26, P247, DOI 10.1111/j.0141-9838.2004.00710.x
   Kokona D, 2017, EXP EYE RES, V154, P159, DOI 10.1016/j.exer.2016.11.020
   Li ZL, 2018, ONCOL REP, V39, P1356, DOI 10.3892/or.2017.6169
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   Massacesi AL, 2008, GRAEF ARCH CLIN EXP, V246, P89, DOI 10.1007/s00417-007-0638-x
   Mausset-Bonnefont AL, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-2047-z
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   MORGAN BP, 1988, CLIN EXP IMMUNOL, V73, P473
   MOXLEY G, 1985, ARTHRITIS RHEUM, V28, P1089, DOI 10.1002/art.1780281003
   National Eye Institute, AG REL MAC DEG AMD D
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Obert E, 2017, J MOL MED, V95, P535, DOI 10.1007/s00109-017-1506-8
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Okamoto Hiroshi, 2008, Inflamm Allergy Drug Targets, V7, P53, DOI 10.2174/187152808784165199
   OLMEZ U, 1991, SCAND J RHEUMATOL, V20, P183
   Oto Y, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-2071-z
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Prusky GT, 2004, INVEST OPHTH VIS SCI, V45, P4611, DOI 10.1167/iovs.04-0541
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   RUDDY S, 1974, NEW ENGL J MED, V290, P1284, DOI 10.1056/NEJM197406062902304
   Samtani S, 2009, INVEST OPHTH VIS SCI, V50, P5098, DOI 10.1167/iovs.08-3174
   Sayo A, 2018, INVEST OPHTH VIS SCI, V59, P3469, DOI 10.1167/iovs.18-24635
   Schnabolk G, 2020, RETINAL PIGMENT EPITHELIUM IN HEALTH AND DISEASE, P185, DOI 10.1007/978-3-030-28384-1_11
   Schnabolk G, 2019, INVEST OPHTH VIS SCI, V60, P3520, DOI 10.1167/iovs.18-26444
   Schnabolk G, 2018, MOL THER-METH CLIN D, V9, P1, DOI 10.1016/j.omtm.2017.11.003
   Schnabolk G, 2014, EXP EYE RES, V129, P18, DOI 10.1016/j.exer.2014.10.005
   Schwinge D, 2015, J IMMUNOL, V194, P2522, DOI 10.4049/jimmunol.1400076
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Singh JA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199562
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Sousa K, 2019, GRAEF ARCH CLIN EXP, V257, P265, DOI 10.1007/s00417-018-4185-4
   STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626
   Szekanecz Z, 2009, VASC PHARMACOL, V51, P1, DOI 10.1016/j.vph.2009.02.002
   Wang J, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8212063
   Won JY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005441
   Woodell A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067894
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 82
TC 4
Z9 4
U1 1
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2020
VL 61
IS 14
AR 11
DI 10.1167/iovs.61.14.11
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PN0YS
UT WOS:000604213900003
PM 33289791
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sharma, A
   Cheung, CMG
   Arias-Barquet, L
   Ozdek, S
   Parachuri, N
   Kumar, N
   Hilely, A
   Zur, D
   Loewenstein, A
   Vella, G
   Bandello, F
   Querques, G
AF Sharma, Ashish
   Cheung, Chui Ming Gemmy
   Arias-Barquet, Luis
   Ozdek, Sengul
   Parachuri, Nikulaa
   Kumar, Nilesh
   Hilely, Assaf
   Zur, Dinah
   Loewenstein, Anat
   Vella, Giovanna
   Bandello, Francesco
   Querques, Giuseppe
TI FLUID-BASED VISUAL PROGNOSTICATION IN TYPE 3 MACULAR
   NEOVASCULARIZATION-FLIP-3 STUDY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE type 3 MNV; fluid; IRF; prognosis; anti-VEGF
ID RETINAL ANGIOMATOUS PROLIFERATION; PIGMENT EPITHELIAL DETACHMENT;
   INTRAVITREAL BEVACIZUMAB; GEOGRAPHIC ATROPHY; DEGENERATION; RISK;
   ASSOCIATION; SUBTYPES
AB Purpose: To analyze the effect of fluid on visual acuity in cases of Type 3 macular neovascularization.
   Methods: This multicentric, retrospective cohort study included eyes with treatment-naive Type 3 macular neovascularization. Analysis of fluid in different compartments was performed. Group A included eyes with isolated intraretinal fluid, whereas Group B included eyes with intraretinal fluid in conjunction with subretinal fluid and/or sub retinal pigment epithelial fluid.
   Results: Eyes in Group A (31, 55.3%) had better best-corrected visual acuity of 20/50 snellen equivalent (0.42 +/- 0.31 logarithm of the minimum angle of resolution) at baseline and 20/50 snellen equivalent (0.40 +/- 0.28 logarithm of the minimum angle of resolution) at complete resolution compared with Group B with visual acuity of 20/80 snellen equivalent (0.64 +/- 0.35 logarithm of the minimum angle of resolution) (P = 0.0181) at baseline and 20/100 snellen equivalent (0.70 +/- 0.40 logarithm of the minimum angle of resolution) (P = 0.0021) at complete resolution. Subfoveal atrophy was more in Group B (82.6% 19/23) at complete resolution in comparison to Group A (16/31, 51.6%). Eyes in Group B needed more anti-vascular endothelial growth factor injections (10.3 +/- 9.0) for complete resolution compared with Group A (5.7 +/- 4.8).
   Conclusion: Intraretinal fluid may be associated with good visual acuity in Type 3 macular neovascularization in contrast to other forms of neovascular age related macular degeneration. Furthermore, intraretinal fluid in isolation may need fewer injections and could probably be associated with less subfoveal atrophy.
C1 [Sharma, Ashish; Parachuri, Nikulaa; Kumar, Nilesh] Lotus Eye Hosp & Inst, Dept Vitreoretina, Coimbatore, Tamil Nadu, India.
   [Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Arias-Barquet, Luis] Bellvitge Univ Hosp, Dept Ophthalmol, Barcelona, Spain.
   [Ozdek, Sengul] Gazi Univ, Sch Med, Ophthalmol Dept, Ankara, Turkey.
   [Hilely, Assaf; Zur, Dinah; Loewenstein, Anat] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Div Ophthalmol, Tel Aviv, Israel.
   [Hilely, Assaf; Zur, Dinah; Loewenstein, Anat] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
   [Vella, Giovanna; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute, Sci Inst San Raffaele, Dept Ophthalmol, Milan, Italy.
C3 Singapore National Eye Center; Institut d'Investigacio Biomedica de
   Bellvitge (IDIBELL); Bellvitge University Hospital; University of
   Barcelona; Gazi University; Tel Aviv University; Sackler Faculty of
   Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler
   Faculty of Medicine; Vita-Salute San Raffaele University; IRCCS Ospedale
   San Raffaele
RP Sharma, A (通讯作者)，Lotus Eye Hosp & Inst, Avinashi Rd, Coimbatore 641014, Tamil Nadu, India.
EM drashish79@hot-mail.com
RI Özdek, Şengül/CAF-5314-2022
OI Özdek, Şengül/0000-0002-7494-4106
CR Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Costagliola C, 2007, AM J OPHTHALMOL, V144, P449, DOI 10.1016/j.ajo.2007.05.025
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Hirami Y, 2009, JPN J OPHTHALMOL, V53, P396, DOI 10.1007/s10384-009-0669-4
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Montero JA, 2009, EUR J OPHTHALMOL, V19, P448, DOI 10.1177/112067210901900320
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Sacconi R, 2018, OPHTHALMOL RETINA, V2, P1097, DOI 10.1016/j.oret.2018.04.016
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Sharma A, 2021, BRIT J OPHTHALMOL, V105, P297, DOI 10.1136/bjophthalmol-2020-318128
   Sharma A, 2021, BRIT J OPHTHALMOL, V105, P149, DOI 10.1136/bjophthalmol-2020-317933
   Sharma A, 2020, RETINA-J RET VIT DIS, V40, P1451, DOI 10.1097/IAE.0000000000002870
   Shin JY, 2014, RETINA-J RET VIT DIS, V34, P2359, DOI 10.1097/IAE.0000000000000225
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 23
TC 5
Z9 5
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2022
VL 42
IS 1
BP 107
EP 113
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XS3RA
UT WOS:000732829100023
PM 34255761
DA 2022-11-30
ER

PT J
AU Krilis, M
   Qi, M
   Madigan, MC
   Wong, JWH
   Abdelatti, M
   Guymer, RH
   Whitelock, J
   McCluskey, P
   Zhang, P
   Qi, J
   Hunyor, AP
   Krilis, SA
   Giannakopoulos, B
AF Krilis, Matthew
   Qi, Miao
   Madigan, Michele C.
   Wong, Jason W. H.
   Abdelatti, Mahmoud
   Guymer, Robyn H.
   Whitelock, John
   McCluskey, Peter
   Zhang, Peng
   Qi, Jian
   Hunyor, Alex P.
   Krilis, Steven A.
   Giannakopoulos, Bill
TI Nitration of tyrosines in complement factor H domains alters its
   immunological activity and mediates a pathogenic role in age related
   macular degeneration
SO ONCOTARGET
LA English
DT Article
DE macular degeneration; complement factor H; nitrosative stress; retina
ID HUMAN BRUCHS MEMBRANE; HEPARAN-SULFATE; HUMAN RETINA; POLYMORPHISM;
   SURVIVAL; SYSTEM; RISK
AB Nitrosative stress has been implicated in the pathogenesis of age related macular degeneration (AMD). Tyrosine nitration is a unique type of post translational modification that occurs in the setting of inflammation and nitrosative stress. To date, the significance and functional implications of tyrosine nitration of complement factor H (CFH), a key complement regulator in the eye has not been explored, and is examined in this study in the context of AMD pathogenesis.
   Sections of eyes from deceased individuals with AMD (n = 5) demonstrated the presence of immunoreactive nitrotyrosine CFH. We purified nitrated CFH from retinae from 2 AMD patients. Mass spectrometry of CFH isolated from AMD eyes revealed nitrated residues in domains critical for binding to heparan sulphate glycosaminoglycans (GAGs), lipid peroxidation by-products and complement (C) 3b.
   Functional studies revealed that nitrated CFH did not bind to lipid peroxidation products, nor to the GAG of perlecan nor to C3b. There was loss of cofactor activity for Factor I mediated cleavage of C3b with nitrated CFH compared to non-nitrated CFH. CFH inhibits, but nitrated CFH significantly potentiates, the secretion of the proinflammatory and angiogenic cytokine IL-8 from monocytes that have been stimulated with lipid peroxidation by-products. AMD patients (n = 30) and controls (n = 30) were used to measure plasma nitrated CFH using a novel ELISA. AMD patients had significantly elevated nitrated CFH levels compared to controls (p = 0.0117). These findings strongly suggest that nitrated CFH contributes to AMD progression, and is a target for therapeutic intervention.
C1 [Krilis, Matthew; Madigan, Michele C.; McCluskey, Peter; Hunyor, Alex P.] Univ Sydney, Save Sight Inst, Sydney, NSW, Australia.
   [Krilis, Matthew; Madigan, Michele C.; McCluskey, Peter; Hunyor, Alex P.] Sydney Eye Hosp, Sydney, NSW, Australia.
   [Qi, Miao; Abdelatti, Mahmoud; Zhang, Peng; Qi, Jian; Krilis, Steven A.; Giannakopoulos, Bill] Univ New South Wales, St George Hosp, Dept Infect Dis Immunol & Sexual Hlth, Sydney, NSW, Australia.
   [Qi, Miao; Abdelatti, Mahmoud; Zhang, Peng; Qi, Jian; Krilis, Steven A.; Giannakopoulos, Bill] Univ New South Wales, St George Hosp, Dept Med, Sydney, NSW, Australia.
   [Madigan, Michele C.] Univ New South Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
   [Wong, Jason W. H.] Univ New South Wales, Prince Wales Clin Sch, Lowy Canc Res Ctr, Sydney, NSW, Australia.
   [Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Whitelock, John] Univ New South Wales, Grad Sch Biomed Engn, Sydney, NSW, Australia.
   [Zhang, Peng] Tianjin Med Univ, Gen Hosp, Dept Cardiothorac Surg, Tianjin, Peoples R China.
   [Giannakopoulos, Bill] St George Hosp, Dept Rheumatol, Sydney, NSW, Australia.
C3 University of Sydney; St George Hospital; University of New South Wales
   Sydney; St George Hospital; University of New South Wales Sydney;
   University of New South Wales Sydney; University of New South Wales
   Sydney; Centre for Eye Research Australia; Royal Victorian Eye & Ear
   Hospital; University of Melbourne; University of New South Wales Sydney;
   Tianjin Medical University; St George Hospital
RP Giannakopoulos, B (通讯作者)，Univ New South Wales, St George Hosp, Dept Infect Dis Immunol & Sexual Hlth, Sydney, NSW, Australia.; Giannakopoulos, B (通讯作者)，Univ New South Wales, St George Hosp, Dept Med, Sydney, NSW, Australia.; Giannakopoulos, B (通讯作者)，St George Hosp, Dept Rheumatol, Sydney, NSW, Australia.
EM bill.giannakopoulos@unsw.edu.au
RI McCluskey, Peter J/H-7607-2013; Hunyor, Alex/AAT-8205-2021; Wong,
   Jason/A-9466-2008
OI McCluskey, Peter J/0000-0002-8177-1637; Hunyor,
   Alex/0000-0002-8182-6167; Guymer, Robyn/0000-0002-9441-4356; Wong,
   Jason/0000-0003-2953-7728; Whitelock, John/0000-0003-1835-802X
FU National Health and Medical Research Council Project grant, Canberra
   [ID1060323]; Macular Disease Foundation Australia; Blackmores Research
   Grant
FX National Health and Medical Research Council Project grant, Canberra
   ID1060323, Macular Disease Foundation Australia and Blackmores Research
   Grant. The sponsor or funding organisation had no role in the design or
   conduct of this research.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ali TK, 2008, DIABETES, V57, P889, DOI 10.2337/db07-1669
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feeney MB, 2012, ANTIOXID REDOX SIGN, V17, P1571, DOI 10.1089/ars.2012.4595
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Gropp K, 2011, BLOOD, V118, P2774, DOI 10.1182/blood-2011-02-339564
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Keenan TDL, 2012, INVEST OPHTH VIS SCI, V53, P7528, DOI 10.1167/iovs.12-10797
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369
   Murdaugh LS, 2010, EXP EYE RES, V90, P564, DOI 10.1016/j.exer.2010.01.014
   Ng JY, 2013, BIOCHEM BIOPH RES CO, V440, P37, DOI 10.1016/j.bbrc.2013.09.035
   Nicolis S, 2006, CHEM-EUR J, V12, P749, DOI 10.1002/chem.200500361
   Perkins SJ, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00126
   Radi R, 2013, ACCOUNTS CHEM RES, V46, P550, DOI 10.1021/ar300234c
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Vizcaino JA, 2016, NUCLEIC ACIDS RES, V44, pD447, DOI 10.1093/nar/gkv1145
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Whitelock JM, 1999, MATRIX BIOL, V18, P163, DOI 10.1016/S0945-053X(99)00014-1
NR 30
TC 12
Z9 12
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUL 25
PY 2017
VL 8
IS 30
BP 49016
EP 49032
DI 10.18632/oncotarget.14940
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FB6DV
UT WOS:000406232400044
PM 28159936
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Ong, SY
   Cheung, CY
   Li, X
   Lamoureux, EL
   Ikram, MK
   Ding, J
   Cheng, CY
   Haaland, BA
   Saw, SM
   Venketasubramanian, N
   Chen, CPL
   Wong, TY
AF Ong, Shin Yeu
   Cheung, Carol Y.
   Li, Xiang
   Lamoureux, Ecosse L.
   Ikram, M. Kamran
   Ding, Jie
   Cheng, Ching Yu
   Haaland, Benjamin Adam
   Saw, Seang Mei
   Venketasubramanian, Narayanaswamy
   Chen, Christopher P. L.
   Wong, Tien Yin
TI Visual Impairment, Age-Related Eye Diseases, and Cognitive Function The
   Singapore Malay Eye Study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL MICROVASCULAR ABNORMALITIES; ATHEROSCLEROSIS RISK;
   DIABETIC-RETINOPATHY; MACULAR DEGENERATION; VISION IMPAIRMENT;
   ALZHEIMER-DISEASE; OLDER PERSONS; PREVALENCE; DECLINE; PEOPLE
AB Objective: To describe the associations of visual impairment and major age-related eye diseases with cognitive function in an older Asian population.
   Methods: A population-based, cross-sectional study of 1179 participants aged 60 to 80 years from the Singapore Malay Eye study was conducted. Visual acuity was measured using the logMAR vision chart. Cataract and age-related macular degeneration were graded using the Wisconsin Cataract Grading System and the Wisconsin Age-Related Maculopathy Grading System, respectively. Glaucoma was diagnosed using the International Society Geographical and Epidemiological Ophthalmology criteria. Diabetic retinopathy was graded using the modified Airlie House classification system. Cognitive dysfunction was defined as a locally validated Abbreviated Mental Test using education-based cutoff scores.
   Results: After adjusting for age, sex, education level, income, and type of housing, persons with visual impairment before refractive correction (odds ratio [OR] = 2.59; 95% CI, 1.89-3.56) or after refractive correction (OR = 1.96; 95% CI, 1.27-3.02) and those with visual impairment due to cataract (OR = 2.75; 95% CI, 1.35-5.63) were more likely to have cognitive dysfunction. Only moderate to severe diabetic retinopathy was independently associated with cognitive dysfunction (OR = 5.57; 95% CI, 1.56-19.91) after controlling for concurrent age-related eye diseases. No significant independent associations were observed between cataract, age-related macular degeneration, or glaucoma and cognitive dysfunction.
   Conclusions: Older persons with visual impairment, particularly those with visual impairment due to cataract, were more likely to have cognitive dysfunction. Furthermore, among the major age-related eye diseases, only diabetic retinopathy was associated with cognitive dysfunction.
C1 [Ong, Shin Yeu; Cheung, Carol Y.; Li, Xiang; Lamoureux, Ecosse L.; Ikram, M. Kamran; Ding, Jie; Cheng, Ching Yu; Saw, Seang Mei; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 168751, Singapore.
   [Ong, Shin Yeu; Cheung, Carol Y.; Lamoureux, Ecosse L.; Ikram, M. Kamran; Cheng, Ching Yu; Haaland, Benjamin Adam; Wong, Tien Yin] Duke NUS Grad Med Sch, Singapore, Singapore.
   [Ikram, M. Kamran; Cheng, Ching Yu; Saw, Seang Mei] Natl Univ Singapore Hosp, Dept Epidemiol & Publ Hlth, Singapore, Singapore.
   [Haaland, Benjamin Adam] Natl Univ Singapore Hosp, Dept Stat & Appl Probabil, Singapore, Singapore.
   [Chen, Christopher P. L.] Natl Univ Singapore Hosp, Dept Pharmacol, Singapore, Singapore.
   [Ikram, M. Kamran; Venketasubramanian, Narayanaswamy] Natl Univ Singapore Hosp, Div Neurol, Singapore, Singapore.
   [Cheung, Carol Y.; Cheng, Ching Yu; Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Lamoureux, Ecosse L.; Wong, Tien Yin] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Ikram, M. Kamran] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore;
   National University of Singapore; National University of Singapore;
   National University of Singapore; National University of Singapore;
   Centre for Eye Research Australia; University of Melbourne; Erasmus
   University Rotterdam; Erasmus MC
RP Cheung, CY (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 3rd Hosp Ave,05-00,SNEC Bldg, Singapore 168751, Singapore.
EM carol.cheung.y.l@seri.com.sg
RI Chen, Christopher/E-7023-2013; Cheng, Ching-Yu/K-7017-2013; Ding,
   Jie/K-9943-2015; Wong, Tien Yin/AAC-9724-2020; Lamoureux,
   Ecosse/Z-5482-2019; Cheung, Carol/AAF-1101-2020; Cheung, Carol
   Y./G-7895-2016; Venketasubramanian, Narayanaswamy/GPP-5948-2022; Cheng,
   Ching-Yu/Y-2229-2019
OI Chen, Christopher/0000-0002-1047-9225; Cheng,
   Ching-Yu/0000-0003-0655-885X; Wong, Tien Yin/0000-0002-8448-1264;
   Cheung, Carol/0000-0002-9672-1819; Cheng, Ching-Yu/0000-0003-0655-885X;
   Cheung, Carol/0000-0003-0869-859X; Ikram, Mohammad
   Kamran/0000-0003-0173-9571
FU National Medical Research Council [0796/2003]
FX This work was supported by grant 0796/2003 from the National Medical
   Research Council.
CR Baker ML, 2007, STROKE, V38, P2041, DOI 10.1161/STROKEAHA.107.483586
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Baltes PB, 1997, PSYCHOL AGING, V12, P12, DOI 10.1037/0882-7974.12.1.12
   Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330
   Cheung N, 2010, BRAIN, V133, P1987, DOI 10.1093/brain/awq127
   Cigolle CT, 2007, ANN INTERN MED, V147, P156, DOI 10.7326/0003-4819-147-3-200708070-00004
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Ding J, 2010, DIABETES, V59, P2883, DOI 10.2337/db10-0752
   Elliott AF, 2009, J AM GERIATR SOC, V57, P202, DOI 10.1111/j.1532-5415.2008.02099.x
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Graham JE, 1997, LANCET, V349, P1793, DOI 10.1016/S0140-6736(97)01007-6
   Hall CB, 2009, NEUROLOGY, V73, P356, DOI 10.1212/WNL.0b013e3181b04ae3
   HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233
   Jefferis JM, 2011, BRIT J OPHTHALMOL, V95, P17, DOI 10.1136/bjo.2009.165902
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2010, STROKE, V41, P1826, DOI 10.1161/STROKEAHA.110.585042
   Kessing LV, 2007, J GLAUCOMA, V16, P47, DOI 10.1097/IJG.0b013e31802b3527
   Klein BEK, 2007, AM J OPHTHALMOL, V144, P961, DOI 10.1016/j.ajo.2007.08.016
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   Lautenschlager NT, 2008, JAMA-J AM MED ASSOC, V300, P1027, DOI 10.1001/jama.300.9.1027
   Li L, 2009, EYE, V23, P1464, DOI 10.1038/eye.2008.281
   Lin MY, 2004, J AM GERIATR SOC, V52, P1996, DOI 10.1111/j.1532-5415.2004.52554.x
   Lindenberger U, 1997, PSYCHOL AGING, V12, P410, DOI 10.1037/0882-7974.12.3.410
   Machin D, 2009, SAMPLE SIZE TABLES C, P237
   McGwin G, 2005, J AM GERIATR SOC, V53, P1260, DOI 10.1111/j.1532-5415.2005.53384_2.x
   Mitchell AJ, 2010, AM J GERIAT PSYCHIAT, V18, P759, DOI 10.1097/JGP.0b013e3181cdecb8
   Reijmer YD, 2011, DIABETES-METAB RES, V27, P195, DOI 10.1002/dmrr.1163
   Reyes-Ortiz CA, 2005, J AM GERIATR SOC, V53, P681, DOI 10.1111/j.1532-5415.2005.53219.x
   Rogers MAM, 2010, AM J EPIDEMIOL, V171, P728, DOI 10.1093/aje/kwp453
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Sahadevan S, 1997, AGE AGEING, V26, P481, DOI 10.1093/ageing/26.6.481
   Schneider J, 2010, SURV OPHTHALMOL, V55, P539, DOI 10.1016/j.survophthal.2010.02.004
   Schultz-Larsen K, 2008, J CLIN EPIDEMIOL, V61, P1227, DOI 10.1016/j.jclinepi.2007.12.007
   Shen SY, 2008, INVEST OPHTH VIS SCI, V49, P3846, DOI 10.1167/iovs.08-1759
   Tamura H, 2006, J NEUROL SCI, V246, P79, DOI 10.1016/j.jns.2006.02.009
   Tay T, 2006, GERONTOLOGY, V52, P386, DOI 10.1159/000095129
   Whitson HE, 2007, J AM GERIATR SOC, V55, P885, DOI 10.1111/j.1532-5415.2007.01093.x
   Wong TY, 2008, OPHTHALMOLOGY, V115, P1869, DOI 10.1016/j.ophtha.2008.05.014
   Wong TY, 2008, ARCH OPHTHALMOL-CHIC, V126, P1091, DOI 10.1001/archopht.126.8.1091
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Wong TY, 2002, STROKE, V33, P1487, DOI 10.1161/01.STR.0000016789.56668.43
   Yoneda S, 2005, JPN J OPHTHALMOL, V49, P106, DOI 10.1007/s10384-004-0156-x
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
NR 44
TC 94
Z9 95
U1 0
U2 15
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUL
PY 2012
VL 130
IS 7
BP 895
EP 900
DI 10.1001/archophthalmol.2012.152
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 974FR
UT WOS:000306416900013
PM 22410630
OA Bronze
DA 2022-11-30
ER

PT J
AU Yu, JS
   Carlton, R
   Agashivala, N
   Hassan, T
   Wykoff, CC
AF Yu, Justin S.
   Carlton, Rashad
   Agashivala, Neetu
   Hassan, Tarek
   Wykoff, Charles C.
TI Brolucizumab vs aflibercept and ranibizumab for neovascular age-related
   macular degeneration: a cost-effectiveness analysis
SO JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY
LA English
DT Article
ID TREAT-AND-EXTEND; INTRAVITREAL AFLIBERCEPT; TREATMENT OUTCOMES;
   TRAP-EYE; TRIAL; EFFICACY; SAFETY; MANAGEMENT; REGIMEN
AB BACKGROUND: Age-related macular degeneration (AMD) is a leading cause of blindness worldwide and is the most common cause of blindness in developed countries. Despite antivascular endothelial growth factor (anti-VEGF) therapy demonstrating improvements in visual and anatomical outcomes, unmet needs remain. Brolucizumab-dbll (ie, brolucizumab), a VEGF inhibitor for treatment of neovascular (wet) AMD and recently approved by the FDA for its treatment of wet AMD, attempts to mitigate treatment burden through less frequent injections.
   OBJECTIVE: To assess the incremental cost-effectiveness of brolucizumab compared with aflibercept and ranibizumab, given similar costs per injection and the potential for longer dosing intervals based on phase 3 clinical trial data.
   METHODS: A Markov model was developed to model the treatment of wet AMD patients with brolucizumab vs aflibercept and vs ranibizumab over a lifetime time horizon (base case) and 5-year time horizon (scenario analysis). The Markov model consisted of 3 primary health states: on treatment, off treatment, and death. Markov substates (5 total) described visual acuity (VA) ranging from no vision impairment to blindness. These VA-based substates were defined by best-corrected visual acuity (BCVA) values measured using Early Treatment Diabetic Retinopathy Study letters. Fixed-dosing regimens for each therapy were included in the model: dosing every 4 weeks (q4w) for the first 3 months followed by dosing q8w/q12w for brolucizumab, dosing q4w for the first 3 months followed by dosing q8w for aflibercept, and q4w for ranibizumab.
   RESULTS: In the base case, brolucizumab was less costly than aflibercept ($63,614 vs $72,189), and brolucizumab generated 0.0079 more quality-adjusted life-years (QALYs) than aflibercept (4.580 vs 4.572). Lower total costs with brolucizumab were driven by reduced drug costs ($56,432 vs $64,057), reduced administration costs ($6,013 vs $6,825), and reduced monitoring costs ($1,168 vs $1,306). When evaluating the cost-effectiveness of brolucizumab over a 5-year time horizon, brolucizumab was less costly than aflibercept ($44,644 vs $50,772) and generated an additional 0.0049 QALYs (2.953 vs 2.948). Additionally, brolucizumab was less costly than ranibizumab ($ 63,614 vs $128,163) and generated 0.0078 more QALYs than ranibizumab (4.580 vs 4.572) in the base case. Lower total costs with brolucizumab were driven by reduced drug costs ($56,432 vs $ 114,516), reduced administration costs ($6,013 vs $11,541), and reduced monitoring costs ($1,168 vs $2,107). When evaluating the cost-effectiveness of brolucizumab over a 5-year time horizon, brolucizumab was less costly than ranibizumab ($44,644 vs $ 89,665), and brolucizumab generated an additional 0.0046 QALYs (2.953 vs 2.948).
   CONCLUSIONS: Brolucizumab can be cost saving and cost-effective compared with aflibercept and ranibizumab in the treatment of wet AMD.
C1 [Yu, Justin S.; Agashivala, Neetu] Novartis Pharmaceut, E Hanover, NJ 07936 USA.
   [Carlton, Rashad] Xcenda LLC, Palm Harbor, FL USA.
   [Hassan, Tarek] Oakland Univ, William Beaumont Sch Med, Royal Oak, MI USA.
   [Hassan, Tarek] Associated Retinal Consultants, Royal Oak, MI USA.
   [Wykoff, Charles C.] Retina Consultants Amer, Retina Consultants Houston, Houston, TX USA.
   [Wykoff, Charles C.] Blanton Eye Inst, Houston, TX USA.
   [Wykoff, Charles C.] Houston Methodist Hosp, Houston, TX 77030 USA.
C3 Novartis; AmerisourceBergen Corporation; Xcenda, LLC; Oakland
   University; The Methodist Hospital System; The Methodist Hospital -
   Houston
RP Agashivala, N (通讯作者)，Novartis Pharmaceut, E Hanover, NJ 07936 USA.
EM neetu.agashivala@novartis.com
CR American Academy of Ophthalmology, 2019, AGE RELATED MACULAR
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Beovu, 2019, PRESCRIBING INFORM
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Brown MM, 2016, RETINA-J RET VIT DIS, V36, P285, DOI 10.1097/IAE.0000000000000717
   Brown MM, 2003, OPHTHALMOLOGY, V110, P1076, DOI 10.1016/S0161-6420(03)00254-9
   Center for Medicare & Medicaid Services, PHYS FEE SCHED SEARC
   Chavan R, 2014, CLIN OPHTHALMOL, V8, P717, DOI 10.2147/OPTH.S60763
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Eldem BM, 2015, ACTA OPHTHALMOL, V93, pE458, DOI 10.1111/aos.12540
   Eylea, 2021, PRESCRIBING INFORM
   Feltgen N, 2017, GRAEF ARCH CLIN EXP, V255, P923, DOI 10.1007/s00417-017-3589-x
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Hernandez L, 2018, J MANAG CARE SPEC PH, V24, P608, DOI 10.18553/jmcp.2018.24.7.608
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   IBM Watson Health, IBM MICR RED BOOK
   Institute for Clinical and Economic Review, OV ICER VAL ASS FRAM
   Kataja M, 2018, BRIT J OPHTHALMOL, V102, P959, DOI 10.1136/bjophthalmol-2017-311055
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kiss S, 2018, AM ACAD OPHTHALMOLOG
   Lucentis, 2018, PRESCRIBING INFORM
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mogk LG, DIFFERENCE WET DRY A
   NORC at the University of Chicago, EC BURD VIS LOSS EYE
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Regnier SA, 2015, CLINICOECONOMIC OUTC, V7, P235, DOI 10.2147/CEOR.S82556
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Singh RP, 2018, ASRS GLOBAL TRENDS R
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Wang HB, 2016, MOL VIS, V22, P189
   Wang PP, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3489603
   Wittenborn J, 2013, COST VISION PROBLEMS
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Yuzawa M, 2015, OPHTHALMOLOGY, V122, P571, DOI 10.1016/j.ophtha.2014.09.024
NR 53
TC 4
Z9 4
U1 0
U2 3
PU ACAD MANAGED CARE PHARMACY
PI ALEXANDRIA
PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314-3134 USA
SN 2376-0540
EI 2376-1032
J9 J MANAG CARE SPEC PH
JI J. Manag. Care Spec. Pharm.
PD JUN
PY 2021
VL 27
IS 6
BP 743
EP 752
DI 10.18553/jmcp.2021.27.6.743
PG 10
WC Health Care Sciences & Services; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; Pharmacology & Pharmacy
GA SM5EQ
UT WOS:000657629000006
PM 34057392
DA 2022-11-30
ER

PT J
AU Amarasekera, S
   Samanta, A
   Jhingan, M
   Arora, S
   Singh, S
   Tucci, D
   Lupidi, M
   Chhablani, J
AF Amarasekera, Sohani
   Samanta, Anindya
   Jhingan, Mahima
   Arora, Supriya
   Singh, Sumit
   Tucci, Davide
   Lupidi, Marco
   Chhablani, Jay
CA Age Related Macular Degeneration S
TI Optical coherence tomography predictors of progression of non-exudative
   age-related macular degeneration to advanced atrophic and exudative
   disease
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Optical coherence tomography;
   Incomplete retinal pigment epithelium and outer retinal atrophy;
   Complete retinal pigment epithelium and outer retinal atrophy
ID CLASSIFICATION
AB Purpose To study the natural history of optical coherence tomography (OCT) imaging-based findings seen in non-exudative age-related macular degeneration (neAMD) and model their relative likelihood in predicting development of incomplete retinal pigment epithelium and outer retinal atrophy (iRORA), complete retinal pigment epithelium and outer retinal atrophy (cRORA), and neovascular AMD (nAMD). Methods Retrospective chart review was performed at two academic practices. Patients diagnosed with neAMD for whom yearly OCT scans were obtained for at least 4 consecutive years were included. Baseline demographic, visual acuity, AREDS staging, and OCT data were collected. OCTs were assessed for the presence or absence of eleven features previously individually associated with progression of neAMD, both at baseline, and on all subsequent follow-up scans. Likewise, charts were reviewed to assess visual acuity and staging of NEAMD at all follow-up visits. A multivariate regression analysis was constructed to determine predictors of iRORA, cRORA, and nAMD. Results A total of 107 eyes of 88 patients were evaluated. Follow-up included yearly OCTs obtained over at least 4 consecutive years follow-up (range: 50-94 months). During the follow-up period, 17 eyes progressed to iRORA while 25 progressed to cRORA and 16 underwent conversion to nAMD. Predictors of conversion to iRORA and cRORA included integrity of the external limiting membrane (p = 0.02), the ellipsoid zone (p = 0.01), and the cone outer segment line (p = 0.003) and the presence of intraretinal hyporeflective spaces (p = 0.009), drusen ooze (p = 0.05), and drusen collapse (p = 0.001). OCT features predictive of conversion to nAMD included outer nuclear layer (ONL) loss (p = 0.01), presence of intraretinal (p = 0.001) and subretinal (p = 0.005) hyporeflective spaces, and drusen collapse (p = 0.003). Conclusion Of these multiple factors predictive of progression of neAMD, the OCT feature most strongly correlated to progression to iRORA/cRORA was drusen collapse, and the feature most predictive of conversion to nAMD was the presence of intraretinal hyporeflective spaces.
C1 [Amarasekera, Sohani; Chhablani, Jay] Univ Pittsburgh, Med Ctr, 203 Lothrop St, Pittsburgh, PA 15213 USA.
   [Samanta, Anindya] Texas Tech Univ, Hlth Sci Ctr, Sch Med, Lubbock, TX 79430 USA.
   [Jhingan, Mahima; Singh, Sumit] Joan & Irwin Jacobs Retina Ctr, La Jolla, CA USA.
   [Arora, Supriya] Princess Margaret Hosp, Nassau, Bahamas.
   [Tucci, Davide; Lupidi, Marco] Univ Perugia, Fac Med & Chirurg, Perugia, Umbria, Italy.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Texas Tech University System; Texas Tech University;
   Texas Tech University Health Science Center; University of Perugia
RP Chhablani, J (通讯作者)，Univ Pittsburgh, Med Ctr, 203 Lothrop St, Pittsburgh, PA 15213 USA.
EM jay.chhablani@gmail.com
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fragiotta S, 2019, INVEST OPHTH VIS SCI, V60, P3100, DOI 10.1167/iovs.19-26589
   Freund, 2020, OPHTHALMOL RETINA, V20, P30490
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Holmen IC, 2019, OPHTHALMOL RETINA, V3, P724, DOI 10.1016/j.oret.2019.04.011
   Jhingan M, 2021, GRAEF ARCH CLIN EXP, V259, P2687, DOI 10.1007/s00417-021-05147-7
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Kumar JB, 2019, BRIT J OPHTHALMOL, V103, P918, DOI 10.1136/bjophthalmol-2018-312625
   Mones J, 2017, OPHTHALMOL RETINA, V1, P461, DOI 10.1016/j.oret.2017.02.006
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Spaide RF, 2019, RETINA-J RET VIT DIS, V39, P12, DOI 10.1097/IAE.0000000000002362
NR 16
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2022
VL 260
IS 3
BP 737
EP 746
DI 10.1007/s00417-021-05419-2
EA OCT 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZB5IP
UT WOS:000704176800002
PM 34605954
DA 2022-11-30
ER

PT J
AU Told, R
   Reiter, GS
   Mittermuller, TJ
   Schranz, M
   Reumueller, A
   Schlanitz, FG
   Weigert, G
   Pollreisz, A
   Sacu, S
   Schmidt-Erfurth, U
AF Told, Reinhard
   Reiter, Gregor S.
   Mittermueller, Tamara J.
   Schranz, Markus
   Reumueller, Adrian
   Schlanitz, Ferdinand G.
   Weigert, Guenther
   Pollreisz, Andreas
   Sacu, Stefan
   Schmidt-Erfurth, Ursula
TI Profiling neovascular age-related macular degeneration choroidal
   neovascularization lesion response to anti-vascular endothelial growth
   factor therapy using SSOCTA
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE biomarker; choroidal neovascularization; loading phase; neovascular
   age-related macular degeneration; SSOCTA
ID COHERENCE TOMOGRAPHY-ANGIOGRAPHY; ANTI-VEGF TREATMENT; SPECTRAL-DOMAIN;
   TYPE-1 NEOVASCULARIZATION; RANIBIZUMAB; GUIDELINES
AB Purpose To identify the changes in distinct vascular parameters of choroidal neovascularization (CNV) in eyes with treatment-naive neovascular age-related macular degeneration (nAMD) during the primary response to anti-VEGF therapy using aflibercept. Methods Patients were prospectively followed during the first 3 months according to a standardized protocol with mandatory visits at days 7 and 14 after each anti-VEGF treatment up to day 90. Fourteen eyes were seen in addition at days 1 and 3 post-initial injection. Aflibercept was administered at baseline (BL), day 30 and 60. 6 x 6mm SSOCTA (PlexElite, Zeiss) images were acquired. Using the semi-automated AngioTool, CNV area, vessel area, vessel density (VD), the number of junctions, junctions density, total vessel length, average vessel length, total number of endpoints and lacunarity were assessed. Results Thirty-two consecutive patients presenting with treatment-naive, SSOCTA-positive CNV lesions were included. Close follow-up showed a characteristic neovascular response curve with a dynamic decrease in lesion size within days and a reactive increase following 2 weeks after initial treatment. An undulating pattern was seen for all neovascular parameters except for vascular density, with variable statistical significance. Due to a flattening of the therapeutic response as early as after the second treatment, CNV lesion size and most of the related parameters had an increase in activity above baseline values at the end of the loading phase. Lesion size was the leading feature of reactivation by a mean increase of 19.3% after three monthly aflibercept injections. Subgroup analysis based on lesion size revealed a significant correlation between best-corrected visual acuity and quantitative change in lesion size over time, but not baseline size. Conclusions Using SSOCTA, a morphologic neovascular response pattern can be identified in anti-VEGF treatment of CNV. A synchronized early decrease and consecutive reactivation in a large spectrum of neovascular biomarkers including size and internal structure are visualized in a qualitative and quantitative manner. SSOCTA analyses allow new insights in CNV morphology changes and therapeutic response.
C1 [Told, Reinhard; Reiter, Gregor S.; Mittermueller, Tamara J.; Schranz, Markus; Reumueller, Adrian; Schlanitz, Ferdinand G.; Weigert, Guenther; Pollreisz, Andreas; Sacu, Stefan; Schmidt-Erfurth, Ursula] Med Univ Vienna, Vienna Clin Trial Ctr VTC, Dept Ophthalmol & Optometry, Vienna, Austria.
C3 Medical University of Vienna
RP Told, R (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM reinhard.told@meduniwien.ac.at
RI Pollreisz, Andreas/AAJ-1538-2021
OI Schmidt-Erfurth, Ursula/0000-0002-7788-7311; Told,
   Reinhard/0000-0003-2046-7081; Reiter, Gregor/0000-0001-7661-4015;
   Reumueller, Adrian/0000-0003-4344-4624
CR Babiuch AS, 2019, RETINA, V40, P672
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carnevali A, 2018, OPHTHALMOL RETINA, V2, P922, DOI 10.1016/j.oret.2018.02.002
   Chakravarthy U, 2013, EYE, V27, P1429, DOI 10.1038/eye.2013.233
   Cicinelli MV, 2019, RETINA, V40, P499
   Coscas F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205513
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M
   Fayed AE, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217109
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Khoshnood B, 2010, OPHTHAL PHYSL OPT, V30, P816, DOI 10.1111/j.1475-1313.2010.00766.x
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lassota N, 2010, ACTA OPHTHALMOL, V88, P300, DOI 10.1111/j.1755-3768.2008.01439.x
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Roberts PK, 2017, RETINA-J RET VIT DIS, V37, P1492, DOI 10.1097/IAE.0000000000001400
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2016, INVEST OPHTH VIS SCI, V57, pOCT14, DOI 10.1167/iovs.16-19969
   Sacu S, 2011, INVEST OPHTH VIS SCI, V52, P3046, DOI 10.1167/iovs.10-5842
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Sustronck P, 2019, LONG TERM FOLLOW MAC, P124
   Takeuchi J, 2018, OPHTHALMOLOGICA, V240, P90, DOI 10.1159/000487611
   Told R, 2016, SCI REP-UK, V6, DOI 10.1038/srep38132
   Told R, 2013, OPHTHALMOLOGE, V110, P960, DOI 10.1007/s00347-013-2813-2
   Told R, 2020, RETINA-J RET VIT DIS, V40, P2010, DOI 10.1097/IAE.0000000000002695
   Told R, 2018, INVEST OPHTH VIS SCI, V59, P2393, DOI 10.1167/iovs.17-22902
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
   Zotter S, 2011, OPT EXPRESS, V19, P1217, DOI 10.1364/OE.19.001217
   Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385
NR 42
TC 5
Z9 5
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2021
VL 99
IS 2
BP E240
EP E246
DI 10.1111/aos.14554
EA JUL 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QT2FQ
UT WOS:000551492400001
PM 32706171
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Corominas, J
   Colijn, JM
   Geerlings, MJ
   Pauper, M
   Bakker, B
   Amin, N
   Motta, LL
   Kersten, E
   Garanto, A
   Verlouw, JAM
   van Rooij, JGJ
   Kraaij, R
   de Jong, PTVM
   Hofman, A
   Vingerling, JR
   Schick, T
   Fauser, S
   de Jong, EK
   van Duijn, CM
   Hoyng, CB
   Klaver, CCW
   den Hollander, AI
AF Corominas, Jordi
   Colijn, Johanna M.
   Geerlings, Maartje J.
   Pauper, Marc
   Bakker, Bjorn
   Amin, Najaf
   Motta, Laura Lores
   Kersten, Eveline
   Garanto, Alejandro
   Verlouw, Joost A. M.
   van Rooij, Jeroen G. J.
   Kraaij, Robert
   de Jong, Paulus T. V. M.
   Hofman, Albert
   Vingerling, Johannes R.
   Schick, Tina
   Fauser, Sascha
   de Jong, Eiko K.
   van Duijn, Cornelia M.
   Hoyng, Carel B.
   Klaver, Caroline C. W.
   den Hollander, Anneke I.
TI Whole-Exome Sequencing in Age-Related Macular Degeneration Identifies
   Rare Variants in COL8A1, a Component of Bruch's Membrane
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; HIGH-RISK; ASSOCIATION ANALYSIS; CRYSTAL-STRUCTURE;
   GENETIC-VARIANTS; CODING VARIANTS; GRADING SYSTEM; VIII COLLAGEN; DESIGN
   UPDATE; CFI GENE
AB Purpose: Genome-wide association studies and targeted sequencing studies of candidate genes have identified common and rare variants that are associated with age-related macular degeneration (AMD). Whole-exome sequencing (WES) studies allow a more comprehensive analysis of rare coding variants across all genes of the genome and will contribute to a better understanding of the underlying disease mechanisms. To date, the number of WES studies in AMD case-control cohorts remains scarce and sample sizes are limited. To scrutinize the role of rare protein-altering variants in AMD cause, we performed the largest WES study in AMD to date in a large European cohort consisting of 1125 AMD patients and 1361 control participants.
   Design: Genome-wide case-control association study of WES data.
   Participants: One thousand one hundred twenty-five AMD patients and 1361 control participants.
   Methods: A single variant association test of WES data was performed to detect variants that are associated individually with AMD. The cumulative effect of multiple rare variants with 1 gene was analyzed using a gene-based CMC burden test. Immunohistochemistry was performed to determine the localization of the Col8a1 protein in mouse eyes.
   Main Outcome Measures: Genetic variants associated with AMD.
   Results: We detected significantly more rare protein-altering variants in the COL8A1 gene in patients (22/2250 alleles [1.0%]) than in control participants (11/2722 alleles [0.4%]; P = 7.07 x 10(-5)). The association of rare variants in the COL8A1 gene is independent of the common intergenic variant (rs140647181) near the COL8A1 gene previously associated with AMD. We demonstrated that the Col8a1 protein localizes at Bruch's membrane.
   Conclusions: This study supported a role for protein-altering variants in the COL8A1 gene in AMD pathogenesis. We demonstrated the presence of Col8a1 in Bruch's membrane, further supporting the role of COL8A1 variants in AMD pathogenesis. Protein-altering variants in COL8A1 may alter the integrity of Bruch's membrane, contributing to the accumulation of drusen and the development of AMD. (C) 2018 by the American Academy of Ophthalmology.
C1 [Corominas, Jordi; Geerlings, Maartje J.; Pauper, Marc; Bakker, Bjorn; Motta, Laura Lores; Kersten, Eveline; de Jong, Eiko K.; Hoyng, Carel B.; Klaver, Caroline C. W.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands.
   [Corominas, Jordi; Pauper, Marc; Garanto, Alejandro; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Human Genet, Nijmegen, Netherlands.
   [Colijn, Johanna M.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Colijn, Johanna M.; Kraaij, Robert; Hofman, Albert; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Amin, Najaf; van Duijn, Cornelia M.] Erasmus MC, Dept Epidemiol, Unit Genet Epidemiol, Rotterdam, Netherlands.
   [Verlouw, Joost A. M.; van Rooij, Jeroen G. J.; Kraaij, Robert] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
   [Kraaij, Robert] NCHA, Rotterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Inst Royal Netherlands Acad Arts & Sci KNAW, Amsterdam Med Ctr, NIN, Dept Ophthalmol, Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Leiden Univ, Med Ctr, Leiden, Netherlands.
   [Schick, Tina; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Fauser, Sascha] F Hoffmann La Roche Ltd, Roche Pharma Res & Early Dev, Basel, Switzerland.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Erasmus
   University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus
   MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University
   Rotterdam; Erasmus MC; Royal Netherlands Academy of Arts & Sciences;
   Netherlands Institute for Neuroscience (NIN-KNAW); University of
   Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden
   University Medical Center (LUMC); Leiden University - Excl LUMC;
   University of Cologne; Roche Holding
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM anneke.denhollander@radboudumc.nl
RI Garanto, Alejandro/D-5022-2014; Kersten, Eveline/P-8173-2015; Hollander,
   Anneke den/N-4911-2014; Pauper, Marc/AGZ-0438-2022; Klaver, Caroline
   C.W./A-2013-2016; Geerlings, Maartje/P-3338-2019; Pauper,
   Marc/B-6342-2018; Bakker, Bjorn/E-2842-2016
OI Garanto, Alejandro/0000-0001-5721-1560; Pauper,
   Marc/0000-0001-6274-9891; Geerlings, Maartje/0000-0003-1164-3573;
   Pauper, Marc/0000-0001-6274-9891; Lores-Motta,
   Laura/0000-0002-2423-9126; Verlouw, Joost/0000-0003-2373-0981; Amin,
   Najaf/0000-0002-8944-1771; Van Duijn, Cornelia/0000-0002-2374-9204
FU European Research Council under the European Union's Seventh Framework
   Programme (FP/2007-2013)/ERC grant [310644]; European Union's Horizon
   2020 research and innovation programme [634479]; Oogfonds; MaculaFonds;
   Landelijke Stiching voor Blinden en Slechtzienden; Novartis Fonds
   [201536]; Erasmus Medical Center; Erasmus University, Rotterdam, The
   Netherlands; Netherlands Organization for the Health Research and
   Development (ZonMw); Research Institute for Diseases in the Elderly
   (RIDE); Ministry of Education, Culture and Science; Ministry for Health,
   Welfare and Sports; European Commission (DG XII); Municipality of
   Rotterdam, Rotterdam, The Netherlands; Netherlands Genomics Initiative
   (NGI)/ Netherlands Organisation for Scientific Research (NWO) -
   [050-060810]; Genetic Laboratory of the Department of Internal Medicine,
   Erasmus MC; Complementation Project of the Biobanking and Biomolecular
   Research Infrastructure Netherlands (BBMRI-NL) [CP2010-41]
FX Supported by the European Research Council under the European Union's
   Seventh Framework Programme (FP/2007-2013)/ERC grant agreement no.
   310644 (MACULA). This project has received funding from the European
   Union's Horizon 2020 research and innovation programme under grant
   agreement no. 634479 (EYE-RISK). Financial support for the study was
   provided by the Oogfonds; MaculaFonds; Landelijke Stiching voor Blinden
   en Slechtzienden; and Novartis Fonds (Uitzicht grant no.: 201536). The
   Rotterdam Study is funded by Erasmus Medical Center and Erasmus
   University, Rotterdam, The Netherlands; Netherlands Organization for the
   Health Research and Development (ZonMw); the Research Institute for
   Diseases in the Elderly (RIDE); the Ministry of Education, Culture and
   Science; the Ministry for Health, Welfare and Sports; the European
   Commission (DG XII); and the Municipality of Rotterdam, Rotterdam, The
   Netherlands. The exome sequencing data set of the Rotterdam Study was
   funded by the Netherlands Genomics Initiative (NGI)/ Netherlands
   Organisation for Scientific Research (NWO) sponsored Netherlands
   Consortium for Healthy Aging (NCHA; project no. 050-060810), by the
   Genetic Laboratory of the Department of Internal Medicine, Erasmus MC,
   and by the Complementation Project of the Biobanking and Biomolecular
   Research Infrastructure Netherlands (BBMRI-NL; v ww.hbrnri.n1; project
   number CP2010-41). The sponsors and funding organization had no role in
   the design or conduct of this research.
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Aisenbrey S, 2006, INVEST OPHTH VIS SCI, V47, P5537, DOI 10.1167/iovs.05-1590
   Asimit J, 2010, ANNU REV GENET, V44, P293, DOI 10.1146/annurev-genet-102209-163421
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bogin O, 2002, STRUCTURE, V10, P165, DOI 10.1016/S0969-2126(02)00697-4
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   de Ligt J, 2012, NEW ENGL J MED, V367, P1921, DOI 10.1056/NEJMoa1206524
   Desronvil T, 2010, MOL VIS, V16, P2185
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hofman A, 2015, EUR J EPIDEMIOL, V30, P661, DOI 10.1007/s10654-015-0082-x
   Hofman A, 2013, EUR J EPIDEMIOL, V28, P889, DOI 10.1007/s10654-013-9866-z
   Hoon M, 2014, PROG RETIN EYE RES, V42, P44, DOI 10.1016/j.preteyeres.2014.06.003
   Hopfer U, 2005, FASEB J, V19, P1232, DOI 10.1096/fj.04-3019com
   Huang LZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7687
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Kiezun A, 2012, NAT GENET, V44, P623, DOI 10.1038/ng.2303
   Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kvansakul M, 2003, MATRIX BIOL, V22, P145, DOI 10.1016/S0945-053X(02)00119-1
   Lee S, 2014, AM J HUM GENET, V95, P5, DOI 10.1016/j.ajhg.2014.06.009
   Leveziel N, 2012, INVEST OPHTH VIS SCI, V53, P5004, DOI 10.1167/iovs.12-9538
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Liu DJJ, 2014, NAT GENET, V46, P200, DOI 10.1038/ng.2852
   Lohmueller KE, 2013, AM J HUM GENET, V93, P1072, DOI 10.1016/j.ajhg.2013.11.005
   Moutsianas L, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005165
   Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Sardell RJ, 2016, MOL VIS, V22, P1062
   SAWADA H, 1990, J CELL BIOL, V110, P219, DOI 10.1083/jcb.110.1.219
   Schick T, 2016, RETINA-J RET VIT DIS, V36, P787, DOI 10.1097/IAE.0000000000000756
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stitziel NO, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-227
   TAMURA Y, 1991, INVEST OPHTH VIS SCI, V32, P2636
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Velazquez-Villoria A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162296
   Volland S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125631
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 52
TC 25
Z9 25
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2018
VL 125
IS 9
BP 1433
EP 1443
DI 10.1016/j.ophtha.2018.03.040
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GR1IE
UT WOS:000442285800032
PM 29706360
OA Green Published, hybrid, Green Submitted
DA 2022-11-30
ER

PT J
AU Eong, KGA
   Chan, EW
   Luo, N
   Wong, SH
   Tan, NWH
   Lim, TH
   Wagle, AM
AF Eong, K. G. Au
   Chan, E. W.
   Luo, N.
   Wong, S. H.
   Tan, N. W. H.
   Lim, T. H.
   Wagle, A. M.
TI Validity of EuroQOL-5D, time trade-off, and standard gamble for
   age-related macular degeneration in the Singapore population
SO EYE
LA English
DT Article
DE age-related macular degeneration; quality of life; utility values
ID UTILITY VALUES; DIABETIC-RETINOPATHY; VISUAL IMPAIRMENT; RESOURCE
   UTILIZATION; EYE DISEASE; LIFE; IMPACT; GLAUCOMA; VISION; BURDEN
AB Background/aims Utility values of age-related macular degeneration (AMD) in Asian patients are unknown. This study aims to assess utility values and construct validity of the EuroQOL-5D (EQ-5D), time trade-off (TTO), and standard gamble (SG) instruments in the Singapore multi-ethnic AMD population.
   Methods Cross-sectional, two-centre, institution-based study. Visual acuity (VA), clinical AMD severity, and utility scores on the EQ-5D, TTO, and SG were obtained from 338 AMD patients. VA was analysed in terms of the better-seeing eye (BEVA), worse-seeing eye (WEVA), and weighted average of both eyes (WVA). We evaluated SG on the perfect health-death (SG(death)) and binocular perfect vision-binocular blindness (SG(blindness)) scales. Construct validity was determined by testing a priori hypotheses relating the EQ-5D, TTO, and SG utility scores to VA and clinical AMD severity.
   Results The mean utilities on the EQ-5D, TTO, SG(death), and SG(blindness) were 0.89, 0.81, 0.86, and 0.90, respectively. EQ-5D scores correlated weakly with BEVA, WEVA, and WVA (Pearson's correlation coefficients -0.291, -0.247, and -0.305 respectively, P<0.001 for all). SG(death) and SG(blindness) demonstrated no correlation with BEVA, WEVA, or WVA (Pearson's correlation coefficients, range -0.06 to -0.125). TTO showed weak association only with WEVA and WVA (correlation coefficients -0.237, -0.228, P<0.0001), but not with BEVA (correlation coefficient -0.161). Clinical AMD severity correlated with EQ-5D and SG(death), but not with TTO and SG(blindness) (P=0.004, 0.002, 0.235, and 0.069, respectively).
   Conclusions AMD has a negative impact on utilities, although utility scores were high compared with Western cohorts. EQ-5D, TTO, and SG showed suboptimal construct validity, suggesting that health status utilities may not be sufficiently robust for cost-utility analyses in this population. Eye (2012) 26, 379-388; doi: 10.1038/eye.2011.218; published online 6 January 2012
C1 [Eong, K. G. Au] Mt Elizabeth Med Ctr, Singapore Int Eye Cataract Retina Ctr, Singapore 228510, Singapore.
   [Eong, K. G. Au; Wagle, A. M.] Khoo Teck Puat Hosp, Dept Ophthalmol & Visual Sci, Singapore, Singapore.
   [Eong, K. G. Au; Chan, E. W.; Wong, S. H.; Wagle, A. M.] Alexandra Hosp, Dept Ophthalmol & Visual Sci, Singapore, Singapore.
   [Chan, E. W.] Natl Univ Hlth Syst, Dept Ophthalmol, Natl Univ Hosp, Singapore, Singapore.
   [Luo, N.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Epidemiol & Publ Hlth, Singapore 117595, Singapore.
   [Tan, N. W. H.; Lim, T. H.] Natl Healthcare Grp, Inst Eye, Singapore, Singapore.
   [Tan, N. W. H.; Lim, T. H.] Tan Tock Seng Hosp, Dept Ophthalmol, Singapore, Singapore.
C3 Mount Elizabeth Medical Centre; National University of Singapore;
   National University of Singapore; Tan Tock Seng Hospital
RP Eong, KGA (通讯作者)，Mt Elizabeth Med Ctr, Singapore Int Eye Cataract Retina Ctr, 3 Mt Elizabeth 07-04, Singapore 228510, Singapore.
EM aekg@eyecataractretina.com
RI Luo, Nan/G-1419-2014; Tan, Nikolle/GXH-5775-2022
CR Aspinall PA, 2008, INVEST OPHTH VIS SCI, V49, P1907, DOI 10.1167/iovs.07-0559
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Broman AT, 2002, INVEST OPHTH VIS SCI, V43, P3393
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   BROWN GC, 1999, T AM OPHTHAL SOC, V92, P474
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Brown MM, 1999, AM J OPHTHALMOL, V128, P324, DOI 10.1016/S0002-9394(99)00146-4
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Brown MM, 2008, OPHTHALMOLOGY, V115
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Clark A, 2008, CLIN EXP OPHTHALMOL, V36, P526, DOI 10.1111/j.1442-9071.2008.01827.x
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Datta S, 2008, INVEST OPHTH VIS SCI, V49, P1, DOI 10.1167/iovs.06-1073
   Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   Gupta V, 2005, BRIT J OPHTHALMOL, V89, P1241, DOI 10.1136/bjo.2005.068858
   Kobelt G, 2006, ACTA OPHTHALMOL SCAN, V84, P363, DOI 10.1111/j.1600-0420.2005.00621.x
   KRAMAROW EA, 1995, DEMOGRAPHY, V32, P335, DOI 10.2307/2061684
   Langelaan M, 2007, OPHTHAL EPIDEMIOL, V14, P119, DOI 10.1080/09286580601139212
   Lee BS, 2008, OPHTHALMOLOGY, V115, P898, DOI 10.1016/j.ophtha.2007.06.008
   Lee JE, 2003, OPHTHALMIC EPIDEMIOL, V10, P177, DOI 10.1076/opep.10.3.177.15084
   Lim WY, 2005, CLIN EXP OPHTHALMOL, V33, P598, DOI 10.1111/j.1442-9071.2005.01102.x
   Linder M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1611
   Lloyd A, 2008, DIABETIC MED, V25, P618, DOI 10.1111/j.1464-5491.2008.02430.x
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Luo N, 2003, QUAL LIFE RES, V12, P87, DOI 10.1023/A:1022063721237
   Luo N, 2009, ANN ACAD MED SINGAP, V38, P521
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mitchell J, 2005, INT C SER, V1282, P654
   NICE, 2004, GUID METH TECHN APPR
   Nutheti R, 2006, INVEST OPHTH VIS SCI, V47, P4742, DOI 10.1167/iovs.06-0020
   Polack S, 2008, BRIT J OPHTHALMOL, V92, P1026, DOI 10.1136/bjo.2007.134791
   Polack S, 2007, BRIT J OPHTHALMOL, V91, P927, DOI 10.1136/bjo.2006.110973
   Rajagopalan K, 2005, VALUE HEALTH, V8, P168, DOI 10.1111/j.1524-4733.2005.03074.x
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sahel JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P945, DOI 10.1001/archopht.125.7.945
   Saw SM, 2005, J GLAUCOMA, V14, P455, DOI 10.1097/01.ijg.0000185434.08051.82
   SCOTT IU, 1994, ARCH OPHTHALMOL-CHIC, V112, P329, DOI 10.1001/archopht.1994.01090150059023
   Shah VA, 2004, OPHTHAL EPIDEMIOL, V11, P43, DOI 10.1076/opep.11.1.43.26436
   Sharma S, 2006, BR J OPHTHALMOL, V86, P493
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Tung TH, 2005, DIABETES RES CLIN PR, V68, P265, DOI 10.1016/j.diabres.2004.10.003
NR 44
TC 32
Z9 32
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2012
VL 26
IS 3
BP 379
EP 388
DI 10.1038/eye.2011.218
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 907PD
UT WOS:000301428900004
PM 22222257
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Wu, J
   Zhang, CY
   Yang, Q
   Xie, H
   Zhang, JT
   Qiu, QH
   Liu, K
   Luo, DW
   Liu, F
   Zhang, JF
AF Wu, Jing
   Zhang, Chaoyang
   Yang, Qian
   Xie, Hai
   Zhang, Jingting
   Qiu, Qinghua
   Liu, Kun
   Luo, Dawei
   Liu, Fang
   Zhang, Jingfa
TI Imaging Hyperreflective Foci as an Inflammatory Biomarker after
   Anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration
   Patients with Optical Coherence Tomography Angiography
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
AB Purpose. To investigate the hyperreflective foci (HRF) as an inflammatory biomarker using optical coherence tomography angiography (OCTA) in neovascular age-related macular degeneration (AMD) patients after antivascular endothelial growth factor (anti-VEGF) treatment and its association with the retinal microcapillary density. Methods. Twenty-five eyes from 25 patients with neovascular AMD were included in the study. All eyes were imaged with OCTA at baseline (M0) and after 3 consecutive injections (M3; injection performed each month) of anti-VEGF. The number of HRF in the superficial capillary plexus (SCP), deep capillary plexus (DCP), and outer retina was counted. The vascular density of the fovea, parafovea, and the whole macula, as well as the area of the foveal avascular zone (FAZ), was measured. Results. The mean interval between baseline and follow-up with OCTA was 93.08 +/- 5.00 (range, 85-101) days. Compared with the baseline, the number of HRF significantly decreased in DCP (7.52 +/- 3.06 vs. 3.76 +/- 1.48, P<0.01) and outer retina (12.04 +/- 4.91 vs. 5.88 +/- 3.32, P<0.01) after treatment. There was no significant difference for HRF number in the SCP, the vascular density (containing foveal, parafoveal, and whole macular), and FAZ area before and after treatments. Conclusion. The number of HRF in DCP and outer retina might serve as an inflammatory biomarker in patients with neovascular AMD. The reduced HRF possibly represents the alleviation of inflammation after anti-VEGF treatment in patients with AMD.
C1 [Wu, Jing; Liu, Fang; Zhang, Jingfa] Tongji Univ Sch Med, Shanghai Peoples Hosp 10, Dept Ophthalmol, Shanghai, Peoples R China.
   [Zhang, Chaoyang; Zhang, Jingting; Qiu, Qinghua; Liu, Kun; Luo, Dawei; Zhang, Jingfa] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Ophthalmol, Shanghai Peoples Hosp 1, Shanghai, Peoples R China.
   [Zhang, Chaoyang; Zhang, Jingting; Qiu, Qinghua; Liu, Kun; Luo, Dawei; Zhang, Jingfa] Natl Clin Res Ctr Eye Dis, Shanghai Engn Ctr Visual Sci & Photomed, Shanghai Engn Ctr Precise Diag & Treatment Eye Di, Shanghai Key Lab Ocular Fundus Dis, Shanghai, Peoples R China.
   [Yang, Qian; Xie, Hai; Zhang, Jingfa] Tongji Univ, Tongji Eye Inst, Sch Med, Shanghai, Peoples R China.
C3 Tongji University; Shanghai Jiao Tong University; Tongji University
RP Liu, F; Zhang, JF (通讯作者)，Tongji Univ Sch Med, Shanghai Peoples Hosp 10, Dept Ophthalmol, Shanghai, Peoples R China.; Zhang, JF (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Ophthalmol, Shanghai Peoples Hosp 1, Shanghai, Peoples R China.; Zhang, JF (通讯作者)，Natl Clin Res Ctr Eye Dis, Shanghai Engn Ctr Visual Sci & Photomed, Shanghai Engn Ctr Precise Diag & Treatment Eye Di, Shanghai Key Lab Ocular Fundus Dis, Shanghai, Peoples R China.; Zhang, JF (通讯作者)，Tongji Univ, Tongji Eye Inst, Sch Med, Shanghai, Peoples R China.
EM fangliu_2004@yahoo.com; 13917311571@139.com
OI Zhang, Jingting/0000-0003-3378-2363; Xie, Hai/0000-0001-5950-6573; Wu,
   Jing/0000-0002-7829-944X; Zhang, Jingfa/0000-0003-0601-4342; Liu,
   Kun/0000-0002-0115-7160
FU National Natural Science Foundation of China [81570852, 81870667,
   81970810, 81970811]; Science and Technology Commission of Shanghai
   Municipality [20142203200]; Clinical Research and Cultivation Project of
   Shanghai Municipal Hospital, China [SHDC12019X30]
FX This research was supported by the National Natural Science Foundation
   of China (81570852, 81870667, 81970810, 81970811), the Science and
   Technology Commission of Shanghai Municipality (19495800700), the
   Clinical Research and Cultivation Project of Shanghai Municipal
   Hospital, China (SHDC12019X30), and Science and Technology Commission of
   Shanghai Municipality (20142203200).
CR Altay L, 2016, INVEST OPHTH VIS SCI, V57, P4315, DOI 10.1167/iovs.15-18855
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Cunningham F, 2019, CURR EYE RES, V44, P813, DOI 10.1080/02713683.2019.1614197
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fletcher EL, 2020, OPHTHAL PHYSL OPT, V40, P128, DOI 10.1111/opo.12671
   Hsia Y, 2020, GRAEF ARCH CLIN EXP, V258, P273, DOI 10.1007/s00417-019-04546-1
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Lazzara F, 2019, BIOCHEM PHARMACOL, V168, P341, DOI 10.1016/j.bcp.2019.07.021
   Lee H, 2018, INVEST OPHTH VIS SCI, V59, P715, DOI 10.1167/iovs.17-23042
   Lee H, 2016, RETINA-J RET VIT DIS, V36, P465, DOI 10.1097/IAE.0000000000000645
   Liu DD, 2020, LIFE SCI, V259, DOI 10.1016/j.lfs.2020.118273
   Ma WX, 2019, ELIFE, V8, DOI 10.7554/eLife.42049
   Midena E, 2018, INVEST OPHTH VIS SCI, V59, P5366, DOI 10.1167/iovs.18-25611
   Minaker SA, 2021, ACTA OPHTHALMOL, V99, P134, DOI 10.1111/aos.14537
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Natoli R, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0175-y
   Ogino K, 2012, RETINA-J RET VIT DIS, V32, P77, DOI 10.1097/IAE.0b013e318217ffc7
   Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17
   Pilotto E, 2020, OPHTHALMOLOGY, V127, P1774, DOI 10.1016/j.ophtha.2020.03.024
   Romano F, 2020, RETINA-J RET VIT DIS, V40, P1634, DOI 10.1097/IAE.0000000000002645
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Sitnilska V, 2021, GRAEF ARCH CLIN EXP, V259, P623, DOI 10.1007/s00417-020-04910-6
   Sun YA, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/7532306
   Tiosano L, 2020, GRAEF ARCH CLIN EXP, V258, P2353, DOI 10.1007/s00417-020-04837-y
   Van Bergen T, 2019, PROG RETIN EYE RES, V69, P116, DOI 10.1016/j.preteyeres.2018.10.006
   Vujosevic S, 2017, ACTA OPHTHALMOL, V95, P464, DOI 10.1111/aos.13294
   Vujosevic S, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/491835
   Vujosevic S, 2016, RETINA-J RET VIT DIS, V36, P1298, DOI 10.1097/IAE.0000000000000912
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2020, ACTA OPHTHALMOL, V98, pE781, DOI 10.1111/aos.14381
NR 31
TC 7
Z9 7
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD FEB 4
PY 2021
VL 2021
AR 6648191
DI 10.1155/2021/6648191
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA QK1QD
UT WOS:000620154800002
PM 33614783
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chew, H
   Maberley, DAL
   Ma, P
   Chang, A
   Maberley, A
AF Chew, H
   Maberley, DAL
   Ma, P
   Chang, A
   Maberley, A
TI Socioeconomic status and clinical features of patients undergoing
   photodynamic therapy or transpupillary thermotherapy for subfoveal
   choroidal neovascularization due to age-related macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE age factor; choroidal neovascularization; macular degeneration;
   photodynamic therapy; socioeconomic factors; transpupillary
   thermotherapy
ID BEAVER DAM EYE; DISEASE RISK-FACTORS; CARDIOVASCULAR-DISEASE;
   DIABETIC-PATIENTS; MACULOPATHY; SMOKING; VERTEPORFIN; MORTALITY;
   DEPRIVATION; POPULATION
AB Background: The purpose of this study was to compare baseline clinical and socioeconomic features of patients undergoing self-funded photodynamic therapy (PDT) or government-funded subthreshold transpupillary thermotherapy (TTT) with a diode laser for subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
   Methods: Between July 2000 and August 2001, 115 patients with subfoveal choroidal neovascularization secondary to AMD were offered PDT as an initial intervention. If individuals believed that they could not afford or did not want PDT, then TTT was offered. In masked fashion, leakage pattern and lesion size were determined retrospectively from pretreatment angiograms. Baseline visual acuity was determined with autorefraction and subsequent Snellen testing. The mean income of each treatment group was estimated from the average sex-specific income for each subject's postal code, based on the 1996 Canadian census data. The average education level for each subject's postal code was also determined.
   Results: The patients who were not willing to pay for PDT had significantly worse macular disease before treatment (larger lesions and poorer visual acuity) and a significantly lower mean income than the patients who were willing to pay for PDT had significantly worse macular disease before treatment (larger lesions and poorer visual acuity) and a significantly lower mean income than the patients who were willing to pay for PDT.
   Interpretation: The severity of exudative choroidal neovascularization appears to be associated with lower socioeconomic status.
C1 Univ Toronto, Dept Ophthalmol, Toronto, ON M5S 1A1, Canada.
   Univ British Columbia, Dept Ophthalmol, Vancouver, BC, Canada.
C3 University of Toronto; University of British Columbia
RP Maberley, DAL (通讯作者)，2550 Willow St, Vancouver, BC V5Z 3N9, Canada.
EM crtg_vancouver@hotmail.com
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cabrera C, 2001, EPIDEMIOLOGY, V12, P532, DOI 10.1097/00001648-200109000-00012
   Connolly VM, 1996, DIABETES CARE, V19, P419, DOI 10.2337/diacare.19.5.419
   Fraser S, 2001, BMJ-BRIT MED J, V322, P639, DOI 10.1136/bmj.322.7287.639
   Frost A, 2001, EYE, V15, P739, DOI 10.1038/eye.2001.241
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hennekens CH, 1987, EPIDEMIOLOGY MED, P39
   Hudak D T, 1997, J AAPOS, V1, P214, DOI 10.1016/S1091-8531(97)90040-9
   Iribarren C, 1997, ARCH INTERN MED, V157, P873, DOI 10.1001/archinte.157.8.873
   JAGAL SB, 1994, CAN J CARDIOL, V10, P439
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2001, AM J OPHTHALMOL, V132, P128, DOI 10.1016/S0002-9394(00)00931-4
   Lynch JW, 1996, AM J EPIDEMIOL, V144, P934, DOI 10.1093/oxfordjournals.aje.a008863
   Reijneveld SA, 1998, INT J EPIDEMIOL, V27, P33, DOI 10.1093/ije/27.1.33
   RYAN VC, 1989, J AM DIET ASSOC, V89, P1805
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   *STAT CAN, 1996 CENS
   *TREATM AG REL MAC, 1999, ARCH OPHTHALMOL-CHIC, V118, P488
   Vogels EA, 1999, BRIT J GEN PRACT, V49, P963
   Weng C, 2000, DIABETIC MED, V17, P612, DOI 10.1046/j.1464-5491.2000.00352.x
   Whitlock G, 1997, NEW ZEAL MED J, V110, P327
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 27
TC 6
Z9 6
U1 0
U2 0
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2005
VL 40
IS 3
BP 384
EP 388
DI 10.1016/S0008-4182(05)80081-X
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 941RH
UT WOS:000230231400014
PM 15947808
DA 2022-11-30
ER

PT J
AU Yip, PP
   Woo, CF
   Tang, HHY
   Ho, CK
AF Yip, P. P.
   Woo, C. F.
   Tang, H. H. Y.
   Ho, C. K.
TI Triple therapy for neovascular age-related macular degeneration using
   single-session photodynamic therapy combined with intravitreal
   bevacizumab and triamcinolone
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN THERAPY; ACETONIDE;
   RANIBIZUMAB; INJECTION; AVASTIN; OCCULT; CELLS; TAP; PDT
AB Aim: To evaluate the efficacy and safety of triple therapy consisting single-session photodynamic therapy (PDT), intravitreal bevacizumab (IVB) and intravitreal triamcinolone (IVTA) for treatment of neovascular age-related macular degeneration (AMD)
   Methods: Consecutive patients with subfoveal choroidal neovascularisation (CNV) secondary to AMD were treated with PDT using a standard protocol immediately followed by 1.25 mg of IVB and 4 mg of IVTA. 1.25 mg of IVB was given at 3 months for residual leakage. Best-corrected Snellen visual acuity (BCVA) and fluorescein angiography (FA) were performed prior to treatment. BCVA, intraocular pressure (IOP) and presence of vitritis were documented at 1 and 6 weeks, 3 and 6 months. FA was repeated at 3 and 6 months. Outcome measures included visual improvement measured by logMAR equivalent, angio-graphic evident of leakage and safety profile.
   Results: 36 eyes of 33 patients, aged 76.4 (SD 10.5) years with mean follow-up of 14.7 (6.9-19.2) months were analysed. Baseline logMAR acuity was 1.22 (0.71). The mean logMAR acuity was 1.14 (0.62) and 1.18 (0.63) at 3 and 6 months respectively. At 6 months, 61.1% (22/36) showed stable or gaining vision, and 27.8% (10/36) gained three or more lines. Twenty-eight eyes (77.8%) achieved CNV resolution by single session of triple therapy. One eye lost more than six lines due to retinal pigment epithelium rip, three eyes showed a significant cataract requiring surgery, and two showed persistent raised IOP at 6 months. None resulted in endophthalmitis or reported thromboembolic event.
   Conclusions: Short-term results of single session triple therapy suggested that it might be a useful treatment option for neovascular AMD based on its low retreatment rates, sustainable CNV eradication result and visual gain achievement. However, the risk and benefits of using intravitreal triamcinolone in addition to combined PDT and IVB warrant further evaluation.
C1 [Yip, P. P.; Tang, H. H. Y.; Ho, C. K.] Tuen Mun Hosp, Dept Ophthalmol, Cluster, Hong Kong, Peoples R China.
   [Woo, C. F.] Hong Kong Ophthalm Associates, Hong Kong, Hong Kong, Peoples R China.
C3 Tuen Mun Hospital
RP Yip, PP (通讯作者)，Tuen Mun Hosp, Dept Ophthalmol, Tsing Chung Koon Rd, Tuen Mun, Hong Kong, Peoples R China.
EM terriyip2000@yahoo.com.hk
CR Ahmad K, 2007, LANCET INFECT DIS, V7, P10, DOI 10.1016/S1473-3099(06)70670-3
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Jonas JB, 2005, EUR J OPHTHALMOL, V15, P462, DOI 10.1177/112067210501500407
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Obata R, 2007, BRIT J OPHTHALMOL, V91, P100, DOI 10.1136/bjo.2006.098004
   Peyman GA, 2000, OPHTHALMOLOGY, V107, P29, DOI 10.1016/S0161-6420(99)00012-3
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Rhee DJ, 2006, BRIT J OPHTHALMOL, V90, P999, DOI 10.1136/bjo.2006.090340
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz-Moreno JM, 2006, EUR J OPHTHALMOL, V16, P426, DOI 10.1177/112067210601600311
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
NR 25
TC 35
Z9 37
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2009
VL 93
IS 6
BP 754
EP 758
DI 10.1136/bjo.2008.150987
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 450LI
UT WOS:000266401600013
PM 19273471
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Bansback, N
   Czoski-Murray, C
   Carlton, J
   Lewis, G
   Hughes, L
   Espallargues, M
   Brand, C
   Brazier, J
AF Bansback, N.
   Czoski-Murray, C.
   Carlton, J.
   Lewis, G.
   Hughes, L.
   Espallargues, M.
   Brand, C.
   Brazier, J.
TI Determinants of health related quality of life and health state utility
   in patients with age related macular degeneration: the association of
   contrast sensitivity and visual acuity
SO QUALITY OF LIFE RESEARCH
LA English
DT Article
DE age related macular degeneration; contrast sensitivity; health status;
   visual acuity
ID VISION; DISABILITY; PERFORMANCE; IMPAIRMENT; VALUES; INDEX
AB Background: There has been increasing interest in the use of measures of health related quality of life (HRQoL) and health state utility values in Age Related Macular Degeneration (ARMD). Visual acuity has been found to be an important determinant of such measures in previous studies. More recently, another measure of visual impairment, contrast sensitivity has received considerable attention. We designed a study to examine whether the contribution of contrast sensitivity in explaining HRQoL and health utilities over and above that of visual acuity. Methods: 209 patients with unilateral or bilateral ARMD were recruited into a cross-sectional study of patients from a large teaching hospital. Patients underwent visual tests (near and distant visual acuity, contrast sensitivity) and completed a vision function questionnaire, the VF-14, HUI3, and time trade-off. Results: Using multivariate regression analysis, the study revealed that contrast sensitivity remained a statistically significant predictor of all outcome measures even when visual acuity was included. This result was supported by the correlation coefficients between measures. Conclusions: The measurement of contrast sensitivity appears to be better related to a person's HRQoL and health utility. Future studies should consider incorporating contrast sensitivity in addition to visual acuity. Studies, in particular economic evaluations, may underestimate the effect of treatment unless contrast sensitivity is considered.
C1 Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England.
   Catalan Hlth Serv, Catalan Agcy Hlth Technol Assessment & Res, Catalan, Spain.
   Sheffield Teaching Hosp, Dept Orthopt, Sheffield, S Yorkshire, England.
   Sheffield Teaching Hosp NHS Trust, Dept Ophthalmol, Sheffield, S Yorkshire, England.
C3 University of Sheffield; University of Sheffield; University of
   Sheffield
RP Bansback, N (通讯作者)，Univ Sheffield, Sch Hlth & Related Res, Regent Court,30 Regnet St, Sheffield S1 4DA, S Yorkshire, England.
EM n.j.bansback@sheffield.ac.uk
RI Carlton, Jill/N-3225-2019; Carlton, Jill/E-6673-2010; brazier, john
   e/B-1936-2008
OI Carlton, Jill/0000-0002-9373-7663; Carlton, Jill/0000-0002-9373-7663;
   Brazier, John/0000-0001-8645-4780; Bansback, Nick/0000-0002-1510-3462
FU Medical Research Council [MC_U145080960] Funding Source: researchfish;
   MRC [MC_U145080960] Funding Source: UKRI
CR ALEXANDER MF, 1988, ARCH OPHTHALMOL-CHIC, V106, P1543, DOI 10.1001/archopht.1988.01060140711040
   BAILEY IL, 1980, AM J OPTOM PHYS OPT, V57, P378
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   CASSARD SD, 1995, ARCH OPHTHALMOL-CHIC, V113, P1508, DOI 10.1001/archopht.1995.01100120038005
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Dolan P, 2002, SOC SCI MED, V54, P919, DOI 10.1016/S0277-9536(01)00066-1
   Dolan P, 1996, J HEALTH ECON, V15, P209, DOI 10.1016/0167-6296(95)00038-0
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Feeny D, 2002, MED CARE, V40, P113, DOI 10.1097/00005650-200202000-00006
   LEAT SJ, 1993, OPHTHAL PHYSL OPT, V13, P9, DOI 10.1111/j.1475-1313.1993.tb00420.x
   LEGGE GE, 1992, INVEST OPHTH VIS SCI, V33, P677
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   MONES J, 2004, EYE, P1
   OWSLEY C, 1981, INVEST OPHTH VIS SCI, V21, P362
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Rubin, 1989, OPHTHALMOL CLIN N AM, V2, P357
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   WILLIAMS A, 1995, 130 CTR HLTH EC
NR 25
TC 59
Z9 60
U1 0
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0962-9343
EI 1573-2649
J9 QUAL LIFE RES
JI Qual. Life Res.
PD APR
PY 2007
VL 16
IS 3
BP 533
EP 543
DI 10.1007/s11136-006-9126-8
PG 11
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA 143AQ
UT WOS:000244692800015
PM 17119846
DA 2022-11-30
ER

PT J
AU Sreekumar, PG
   Li, Z
   Wang, W
   Spee, C
   Hinton, DR
   Kannan, R
   MacKay, JA
AF Sreekumar, Parameswaran G.
   Li, Zhe
   Wang, Wan
   Spee, Christine
   Hinton, David R.
   Kannan, Ram
   MacKay, J. Andrew
TI Intra-vitreal alpha B crystallin fused to elastin-like polypeptide
   provides neuroprotection in a mouse model of age-related macular
   degeneration
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Elastin-like polypeptides; Geographic atrophy; alpha B crystallin; RPE
   cell death; Retinal degeneration; NaIO3
ID RETINAL-PIGMENT EPITHELIUM; PROTEIN POLYMER NANOPARTICLES;
   IODATE-INDUCED MODEL; HEAT-SHOCK-PROTEIN; SODIUM-IODATE;
   THERAPEUTIC-EFFICACY; CHAPERONE ACTIVITY; OXIDATIVE STRESS; RPE CELLS;
   IN-VIVO
AB Age-related macular degeneration (AMD) is the leading cause of severe and irreversible central vision loss, and the primary site of AMD pathology is the retinal pigment epithelium (RPE). Geographic atrophy (GA) is an advanced form of AMD characterized by extensive RPE cell loss, subsequent degeneration of photoreceptors, and thinning of retina. This report describes the protective potential of a peptide derived from the alpha B crystallin protein using a sodium iodate (NaIO3) induced mouse model of GA. Systemic NaIO3 challenge causes degeneration of the RPE and neighboring photoreceptors, which have similarities to retinas of GA patients. alpha B crystallin is an abundant ocular protein that maintains ocular clarity and retinal homeostasis, and a small peptide from this protein (mini cry) displays neuroprotective properties. To retain this peptide for longer in the vitreous, mini cry was fused to an elastin-like polypeptide (ELP). A single intra-vitreal treatment by this crySI fusion significantly inhibits retinal degeneration in comparison to free mini cry. While mini cry is cleared from the eye with a mean residence time of 0.4 days, crySI is retained with a mean residence time of 3.0 days; furthermore, fundus photography reveals evidence of retention at two weeks. Unlike the free mini cry, crySI protects the RPE against NaIO3 challenge for at least two weeks after administration. CrySI also inhibits RPE apoptosis and caspase-3 activation and protects the retina from cell death up to 1-month post NaIO3 challenge. These results show that intra-ocular ELP-linked peptides such as crySI hold promise as protective agents to prevent RPE atrophy and progressive retinal degeneration in AMD.
C1 [Sreekumar, Parameswaran G.; Kannan, Ram] Doheny Eye Inst, Arnold & Mabel Beckman Macular Res Ctr, Los Angeles, CA 90033 USA.
   [Li, Zhe; Wang, Wan; MacKay, J. Andrew] Univ Southern Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, 1985 Zonal Ave, Los Angeles, CA 90089 USA.
   [Spee, Christine; Hinton, David R.; MacKay, J. Andrew] Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Hinton, David R.] Univ Southern Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
   [MacKay, J. Andrew] Univ Southern Calif, Viterbi Sch Engn, Dept Biomed Engn, Los Angeles, CA 90033 USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California; University of Southern California; University of
   Southern California
RP MacKay, JA (通讯作者)，Univ Southern Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, 1985 Zonal Ave, Los Angeles, CA 90089 USA.
EM jamackay@usc.edu
RI kannan, ram/ABB-7154-2020
OI kannan, ram/0000-0002-1583-3414; /0000-0002-9425-3986
FU L.K. Whittier foundation [RO1EY01545]; Gavin S. Herbert Endowed Chair of
   Pharmaceutical Sciences; Arnold and Mabel Beckman Foundation; USC
   Clinical and Translational Science Institute SC CTSI (NIH/NCRR/NCATS)
   Grant [UL1TR000130]; NATIONAL CANCER INSTITUTE [P30CA014089] Funding
   Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCES [UL1TR001855] Funding Source: NIH RePORTER; NATIONAL EYE
   INSTITUTE [R01EY001545] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   OF GENERAL MEDICAL SCIENCES [R01GM114839] Funding Source: NIH RePORTER
FX This work was supported by RO1EY01545, the L.K. Whittier foundation, the
   Gavin S. Herbert Endowed Chair of Pharmaceutical Sciences, the Arnold
   and Mabel Beckman Foundation, and USC Clinical and Translational Science
   Institute SC CTSI (NIH/NCRR/NCATS) Grant # UL1TR000130.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Arac A, 2011, P NATL ACAD SCI USA, V108, P13287, DOI 10.1073/pnas.1107368108
   Bhattacharyya J, 2006, BIOCHEMISTRY-US, V45, P3069, DOI 10.1021/bi0518141
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Bisht R., 2016, CHARACTERIZATION TOX, P1
   BORHANI H, 1995, INT OPHTHALMOL, V19, P43, DOI 10.1007/BF00156419
   Burgess A, 2010, P NATL ACAD SCI USA, V107, P12564, DOI 10.1073/pnas.0914191107
   Cappello J, 1998, J CONTROL RELEASE, V53, P105, DOI 10.1016/S0168-3659(97)00243-5
   Cho S, 2016, J DRUG TARGET, V24, P328, DOI 10.3109/1061186X.2015.1077847
   Clark JI, 2016, BBA-GEN SUBJECTS, V1860, P240, DOI 10.1016/j.bbagen.2015.08.014
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   Despanie J, 2016, J CONTROL RELEASE, V240, P93, DOI 10.1016/j.jconrel.2015.11.010
   Enzmann V, 2006, EXP EYE RES, V82, P441, DOI 10.1016/j.exer.2005.08.002
   Fosgerau K, 2015, DRUG DISCOV TODAY, V20, P122, DOI 10.1016/j.drudis.2014.10.003
   Franco LM, 2009, INVEST OPHTH VIS SCI, V50, P4004, DOI 10.1167/iovs.08-2898
   Ghosh JG, 2005, BIOCHEMISTRY-US, V44, P14854, DOI 10.1021/bi0503910
   Ghosh JG, 2007, INT J BIOCHEM CELL B, V39, P1804, DOI 10.1016/j.biocel.2007.04.027
   Ghosh JG, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14837
   Gilroy CA, 2018, J CONTROL RELEASE, V277, P154, DOI 10.1016/j.jconrel.2018.03.015
   Gilroy CA, 2016, J CONTROL RELEASE, V240, P151, DOI 10.1016/j.jconrel.2015.12.002
   Janib SM, 2014, POLYM CHEM-UK, V5, P1614, DOI 10.1039/c3py00537b
   Kannan R, 2014, NEURAL REGEN RES, V9, P2044, DOI 10.4103/1673-5374.147927
   Kannan R, 2012, PROG RETIN EYE RES, V31, P576, DOI 10.1016/j.preteyeres.2012.06.001
   Kim H, 2010, J CONTROL RELEASE, V142, P286, DOI 10.1016/j.jconrel.2009.10.031
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klopstein A, 2012, J NEUROSCI, V32, P14478, DOI 10.1523/JNEUROSCI.0923-12.2012
   Kurnellas MP, 2012, J BIOL CHEM, V287, P36423, DOI 10.1074/jbc.M112.371229
   Li H, 2006, EXP EYE RES, V83, P824, DOI 10.1016/j.exer.2006.04.014
   Masilamoni JG, 2006, BBA-MOL BASIS DIS, V1762, P284, DOI 10.1016/j.bbadis.2005.11.007
   McGowan JWD, 2016, DRUG DES DEV THER, V10, P2803, DOI 10.2147/DDDT.S106216
   Megeed Z, 2002, ADV DRUG DELIVER REV, V54, P1075, DOI 10.1016/S0169-409X(02)00063-7
   Moktan S, 2012, MOL CANCER THER, V11, P1547, DOI 10.1158/1535-7163.MCT-11-0998
   NILSSON SEG, 1977, ACTA OPHTHALMOL, V55, P1007
   Obata R, 2005, EYE, V19, P464, DOI 10.1038/sj.eye.6701531
   Ousman SS, 2007, NATURE, V448, P474, DOI 10.1038/nature05935
   Pangratz-Fuehrer S, 2011, EYE, V25, P809, DOI 10.1038/eye.2011.42
   Raju M, 2016, BBA-GEN SUBJECTS, V1860, P246, DOI 10.1016/j.bbagen.2015.06.010
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Roberts S, 2015, FEBS LETT, V589, P2477, DOI 10.1016/j.febslet.2015.08.029
   Rothbard JB, 2012, J BIOL CHEM, V287, P9708, DOI 10.1074/jbc.M111.337691
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sreekumar PG, 2008, INVEST OPHTH VIS SCI, V49, P1210, DOI 10.1167/iovs.07-0667
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   Sreekumar PG, 2013, INVEST OPHTH VIS SCI, V54, P2787, DOI 10.1167/iovs.12-11571
   Sreekumar PG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033420
   Sreekumar PG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012578
   Tang XAN, 2010, J NEUROSCI METH, V190, P240, DOI 10.1016/j.jneumeth.2010.05.004
   Ulery BD, 2011, J POLYM SCI POL PHYS, V49, P832, DOI 10.1002/polb.22259
   van Noort JM, 2013, BIOMATERIALS, V34, P831, DOI 10.1016/j.biomaterials.2012.10.028
   Velotta JB, 2011, ANN THORAC SURG, V91, P1907, DOI 10.1016/j.athoracsur.2011.02.072
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Wang W, 2014, J CONTROL RELEASE, V191, P4, DOI 10.1016/j.jconrel.2014.04.028
   Wright C.B., 2016, DRY AGE RELATED MACU, P321
   Yang YP, 2016, SCI REP-UK, V6, DOI 10.1038/srep29546
   Yaung J, 2008, EXP EYE RES, V86, P355, DOI 10.1016/j.exer.2007.11.007
   Yaung J, 2007, MOL VIS, V13, P566
   Zhang XY, 2016, SCI REP-UK, V6, DOI 10.1038/srep37279
   Zhou P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098275
   Zhu DH, 2010, VISION RES, V50, P643, DOI 10.1016/j.visres.2009.09.002
NR 60
TC 22
Z9 22
U1 0
U2 25
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD AUG 10
PY 2018
VL 283
BP 94
EP 104
DI 10.1016/j.jconrel.2018.05.014
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA GM4HZ
UT WOS:000438079900008
PM 29778783
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Mowatt, G
   Hernandez, R
   Castillo, M
   Lois, N
   Elders, A
   Fraser, C
   Aremu, O
   Amoaku, W
   Burr, J
   Lotery, A
   Ramsay, C
   Azuara-Blanco, A
AF Mowatt, Graham
   Hernandez, Rodolfo
   Castillo, Mayret
   Lois, Noemi
   Elders, Andrew
   Fraser, Cynthia
   Aremu, Olatunde
   Amoaku, Winfried
   Burr, Jennifer
   Lotery, Andrew
   Ramsay, Craig
   Azuara-Blanco, Augusto
TI Optical coherence tomography for the diagnosis, monitoring and guiding
   of treatment for neovascular age-related macular degeneration: a
   systematic review and economic evaluation
SO HEALTH TECHNOLOGY ASSESSMENT
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; INDOCYANINE GREEN ANGIOGRAPHY; FUNDUS
   FLUORESCEIN ANGIOGRAPHY; PHOTODYNAMIC THERAPY; FELLOW EYE; FOLLOW-UP;
   MACULOPATHY; LEAKAGE; DOMAIN; METAANALYSIS
AB Background: Age-related macular degeneration is the most common cause of sight impairment in the UK. In neovascular age-related macular degeneration (nAMD), vision worsens rapidly (over weeks) due to abnormal blood vessels developing that leak fluid and blood at the macula.
   Objectives: To determine the optimal role of optical coherence tomography (OCT) in diagnosing people newly presenting with suspected nAMD and monitoring those previously diagnosed with the disease.
   Data sources: Databases searched: MEDLINE (1946 to March 2013), MEDLINE In-Process & Other Non-Indexed Citations (March 2013), EMBASE (1988 to March 2013), Biosciences Information Service (1995 to March 2013), Science Citation Index (1995 to March 2013), The Cochrane Library (Issue 2 2013), Database of Abstracts of Reviews of Effects (inception to March 2013), Medion (inception to March 2013), Health Technology Assessment database (inception to March 2013).
   Review methods: Types of studies: direct/indirect studies reporting diagnostic outcomes. Index test: time domain optical coherence tomography (TD-OCT) or spectral domain optical coherence tomography (SD-OCT). Comparators: clinical evaluation, visual acuity, Amsler grid, colour fundus photographs, infrared reflectance, red-free images/blue reflectance, fundus autofluorescence imaging, indocyanine green angiography, preferential hyperacuity perimetry, microperimetry. Reference standard: fundus fluorescein angiography (FFA). Risk of bias was assessed using quality assessment of diagnostic accuracy studies, version 2. Meta-analysis models were fitted using hierarchical summary receiver operating characteristic curves. A Markov model was developed (65-year-old cohort, nAMD prevalence 70%), with nine strategies for diagnosis and/or monitoring, and cost-utility analysis conducted. NHS and Personal Social Services perspective was adopted. Costs (2011/12 prices) and quality-adjusted life-years (QALYs) were discounted (3.5%). Deterministic and probabilistic sensitivity analyses were performed.
   Results: In pooled estimates of diagnostic studies (all TD-OCT), sensitivity and specificity [95% confidence interval (CI)] was 88% (46% to 98%) and 78% (64% to 88%) respectively. For monitoring, the pooled sensitivity and specificity (95% CI) was 85% (72% to 93%) and 48% (30% to 67%) respectively. The FFA for diagnosis and nurse-technician-led monitoring strategy had the lowest cost (39,769; pound QALYs 10.473) and dominated all others except FFA for diagnosis and ophthalmologist-led monitoring (44,649; pound QALYs 10.575; incremental cost-effectiveness ratio 47,768) pound. The least costly strategy had a 46.4% probability of being cost-effective at 30,000 pound willingness-to-pay threshold.
   Limitations: Very few studies provided sufficient information for inclusion in meta-analyses. Only a few studies reported other tests; for some tests no studies were identified. The modelling was hampered by a lack of data on the diagnostic accuracy of strategies involving several tests.
   Conclusions: Based on a small body of evidence of variable quality, OCT had high sensitivity and moderate specificity for diagnosis, and relatively high sensitivity but low specificity for monitoring. Strategies involving OCT alone for diagnosis and/or monitoring were unlikely to be cost-effective. Further research is required on (i) the performance of SD-OCT compared with FFA, especially for monitoring but also for diagnosis; (ii) the performance of strategies involving combinations/sequences of tests, for diagnosis and monitoring; (iii) the likelihood of active and inactive nAMD becoming inactive or active respectively; and (iv) assessment of treatment-associated utility weights (e.g. decrements), through a preference-based study.
C1 [Mowatt, Graham; Hernandez, Rodolfo; Castillo, Mayret; Elders, Andrew; Fraser, Cynthia; Ramsay, Craig] Univ Aberdeen, Hlth Serv Res Unit, Aberdeen, Scotland.
   [Hernandez, Rodolfo; Aremu, Olatunde] Univ Aberdeen, Hlth Econ Res Unit, Aberdeen, Scotland.
   [Lois, Noemi; Azuara-Blanco, Augusto] Queens Univ Belfast, Ctr Med Expt, Belfast, Antrim, North Ireland.
   [Amoaku, Winfried] Univ Nottingham, Fac Med & Hlth Sci, Dept Ophthalmol, Nottingham NG7 2RD, England.
   [Burr, Jennifer] Univ St Andrews, Sch Med, St Andrews, Fife, Scotland.
   [Lotery, Andrew] Univ Southampton, Fac Med, Clin Neurosci Res Grp, Southampton SO9 5NH, Hants, England.
C3 University of Aberdeen; University of Aberdeen; Queens University
   Belfast; University of Nottingham; University of St Andrews; University
   of Southampton
RP Azuara-Blanco, A (通讯作者)，Queens Univ Belfast, Ctr Med Expt, Belfast, Antrim, North Ireland.
EM a.azuara-blanco@qub.ac.uk
RI Ramsay, Craig/AAD-8249-2021; Elders, Andrew/N-4195-2015; Aremu,
   Olatunde/AAD-1995-2019
OI Ramsay, Craig/0000-0003-4043-7349; Elders, Andrew/0000-0003-4172-4702;
   Aremu, Olatunde/0000-0002-5832-2403; Burr, Jennifer/0000-0002-9478-738X;
   Azuara-Blanco, Augusto/0000-0002-4805-9322; Hernandez,
   Rodolfo/0000-0003-2619-8230; Amoaku, Winfried/0000-0001-5028-7984;
   Lotery, Andrew/0000-0001-5541-4305
FU National Institute for Health Research Health Technology Assessment
   programme; National Institute for Health Research [10/57/22] Funding
   Source: researchfish; Chief Scientist Office [HSRU1, HERU1] Funding
   Source: researchfish
FX The National Institute for Health Research Health Technology Assessment
   programme.
CR Alster Y, 2005, OPHTHALMOLOGY, V112, P1758, DOI 10.1016/j.ophtha.2005.06.008
   Amoaku W, 2012, EYE, V26, pS2, DOI 10.1038/eye.2011.343
   [Anonymous], 2013, BRIT NATL FORMULARY
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Barton Pelham, 2004, J Health Serv Res Policy, V9, P110, DOI 10.1258/135581904322987535
   Brennan A, 2006, HEALTH ECON, V15, P1295, DOI 10.1002/hec.1148
   Briggs A., 2006, DECISION MODELLING H
   Briggs AH, 2012, VALUE HEALTH, V15, P835, DOI 10.1016/j.jval.2012.04.014
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Cachulo L, 2011, OPHTHALMOLOGICA, V225, P144, DOI 10.1159/000321064
   [陈松 Chen Song], 2003, [眼科研究, Ophthalmic Research], V21, P428
   *COCHR COLL, 2013, GLOSS COCHR TERMS
   Colquitt JL, 2008, HLTH TECHNOL ASSESS, V12
   Curtis L., 2012, UNIT COSTS HLTH SOCI
   Czoski-Murray C, 2009, VALUE HEALTH, V12, P793, DOI 10.1111/j.1524-4733.2009.00527.x
   Deeks JJ, 2001, BRIT MED J, V323, P157, DOI 10.1136/bmj.323.7305.157
   Department of Health, 2012, NHS REF COSTS 2011 1
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Drummond MF, 2005, METHODS EC EVALUATIO
   Eter N, 2005, RETINA-J RET VIT DIS, V25, P691, DOI 10.1097/00006982-200509000-00002
   Fenwick E, 2004, HEALTH ECON, V13, P405, DOI 10.1002/hec.903
   Fujii C, 1996, FOLIA OPHTHALMOL JPN, V47, P300
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   Glasziou P, 2008, ANN INTERN MED, V149, P816, DOI 10.7326/0003-4819-149-11-200812020-00009
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hassenstein A, 2001, KLIN MONATSBL AUGENH, V218, P503, DOI 10.1055/s-2001-16293
   HASSENSTEIN A, 2000, SPEKTRUM AUGENHEILKD, V14, P209
   Henschel A, 2009, EUR J OPHTHALMOL, V19, P831, DOI 10.1177/112067210901900523
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Horster R, 2011, GRAEF ARCH CLIN EXP, V249, P645, DOI 10.1007/s00417-010-1588-2
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Hughes EH, 2005, AM J OPHTHALMOL, V139, P344, DOI 10.1016/j.ajo.2004.07.058
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Ivan SI, 2012, OPHTHALMOLOGY, V119, P1399, DOI DOI 10.1016/J.0PHTHA.2012.04.015
   JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389
   Khondkaryan A, 2009, INVEST OPHTHALMOL VI, V50
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Kim SG, 2003, YONSEI MED J, V44, P821, DOI 10.3349/ymj.2003.44.5.821
   Kozak I, 2008, RETINA-J RET VIT DIS, V28, P538, DOI 10.1097/IAE.0b013e318167270b
   Krebs I, 2007, SPEKTRUM AUGENHEILKD, V21, P33, DOI 10.1007/s00717-006-0169-6
   Leeflang MMG, 2008, ANN INTERN MED, V149, P889, DOI 10.7326/0003-4819-149-12-200812160-00008
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Loewenstein A, 2010, RETINA-J RET VIT DIS, V30, P1058, DOI 10.1097/IAE.0b013e3181d1a75e
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McGuire A, 2001, EC EVALUATION HLTH C, P172
   Meads C, 2003, BRIT J OPHTHALMOL, V87, P1201, DOI 10.1136/bjo.87.10.1201
   Medical Advisory Secretariat, 2009, ONT HLTH TECHNOL ASS, V9
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   *MSAC, 2009, 1116 MSAC
   National Institute for Health and Care Excellence (NICE), 2013, GUID METH TECHN APPR
   *NHS, 2013, GEN OPHTH SERV CONTR
   *NHS ENGL, 2013, GEN OPHTH SERV INCR
   NICE, 2008, PEG RAN TREATM AG RE
   Obata R, 2006, JPN J OPHTHALMOL, V50, P354, DOI 10.1007/s10384-005-0337-2
   Office for National Statistics, 2013, INT LIF TABL
   Office for National Statistics, 2011, STAT B 2011 CENS POP
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Padnick-Silver L, 2012, RETINA-J RET VIT DIS, V32, P1045, DOI 10.1097/IAE.0b03e31823fb82b
   Park SS, 2010, INVEST OPHTH VIS SCI, V51, P4200, DOI 10.1167/iovs.09-4256
   Parravano M, 2012, ACTA OPHTHALMOL COPE, V90
   Petrou S, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1766
   Rechel B, 2013, LANCET, V381, P1312, DOI 10.1016/S0140-6736(12)62087-X
   Regillo CD, 1998, OPHTHALMOLOGY, V105, P1821, DOI 10.1016/S0161-6420(98)91022-3
   Reichel E, 1995, OPHTHALMOLOGY, V102, P1871, DOI 10.1016/S0161-6420(95)30781-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   *ROYAL COLL OPHT, 2013, AGE RELATED MACULAR
   Rutter CM, 2001, STAT MED, V20, P2865, DOI 10.1002/sim.942
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   Sandhu SS, 2005, BRIT J OPHTHALMOL, V89, P967, DOI 10.1136/bjo.2004.060863
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   Siebert U, 2012, VALUE HEALTH, V15, P812, DOI 10.1016/j.jval.2012.06.014
   Silva R, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329473
   SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409
   Sturzlinger H, 2007, EVALUATION OPTICAL C
   Sulzbacher F, 2011, AM J OPHTHALMOL, V152, P799, DOI 10.1016/j.ajo.2011.04.011
   Talks J, 2007, BRIT J OPHTHALMOL, V91, P600, DOI 10.1136/bjo.2006.108043
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Torron FB, 2002, ARCH SOC ESP OFTALMO, V77, P353
   Torron FB, 2001, ARCH SOC ESP OFTALMO, V76, P221
   Usha Chakravarthy J.E., 2010, BMJ-BRIT MED J, V340, P526
   Van de Moere A, 2006, BRIT J OPHTHALMOL, V90, P304, DOI 10.1136/bjo.2005.079947
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   van Velthoven MEJ, 2006, GRAEF ARCH CLIN EXP, V244, P1119, DOI 10.1007/s00417-005-0209-y
   VANDENBRUEL A, 2008, GUIDANCE USE 5 OPH C
   VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
   Xu L, 2009, OPHTHALMOLOGY, V116, P732, DOI 10.1016/j.ophtha.2008.11.003
NR 93
TC 15
Z9 15
U1 0
U2 22
PU NIHR JOURNALS LIBRARY
PI SOUTHAMPTON
PA UNIV SOUTHAMPTON, EVALUATION, TRIALS & STUDIES COORDINATING CENTRE,
   ALPHA HOUSE, ENTERPRISE RD, SOUTHAMPTON, SO16 7NS, ENGLAND
SN 1366-5278
EI 2046-4924
J9 HEALTH TECHNOL ASSES
JI Health Technol. Assess.
PD DEC
PY 2014
VL 18
IS 69
BP 1
EP +
DI 10.3310/hta18690
PG 255
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA AX1KO
UT WOS:000346706300001
PM 25436855
OA Green Accepted, Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Seguin-Greenstein, S
   Lightman, S
   Tomkins-Netzer, O
AF Seguin-Greenstein, Sophie
   Lightman, Sue
   Tomkins-Netzer, Oren
TI A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in
   Patients with Treatment Resistant Neovascular Age-Related Macular
   Degeneration following Switching to Treatment with Aflibercept
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL AFLIBERCEPT; GEOGRAPHIC ATROPHY; RANIBIZUMAB; BEVACIZUMAB;
   TACHYPHYLAXIS; VEGF; EYES; GROWTH; FLUID; AMD
AB With the introduction of aflibercept, eyes with neovascular age-related macular degeneration (AMD) not responding well to injections of ranibizumab or bevacizumab can be switched to treatment with aflibercept. We carried out a meta-analysis to analyze all available evidence of visual and anatomical outcomes of eyes with resistant neovascular AMD switched to aflibercept at six months. Data from seven retrospective and prospective studies looking at change in best corrected visual acuity (BCVA) and central retinal thickness (CRT) were included. Weighted mean difference (WMD) and 95% CI were estimated using the standardized mean change method. The overall results of the meta-analysis showed a small but statistically significant improvement in BCVA six months following treatment switch to aflibercept (WMD 0.142, 95% CI 0.006 to 0.28; p = 0.04), and the effect was more significant in data gathered from prospective studies (WMD 0.407, 95% CI 0.023 to 0.791, p = 0.038). There was a significant improvement in CRT following treatment switch to aflibercept (WMD -0.36, 95% CI -0.485 to -0.235; p < 0.0001). Our meta-analysis indicates that following treatment switch to aflibercept patients may have a significant improvement in CRT with stabilization or even some improvement in their visual acuity.
C1 [Seguin-Greenstein, Sophie; Lightman, Sue; Tomkins-Netzer, Oren] Moorfields Eye Hosp, 162 City Rd, London EC1V 2PD, England.
   [Seguin-Greenstein, Sophie; Lightman, Sue; Tomkins-Netzer, Oren] UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
   [Lightman, Sue; Tomkins-Netzer, Oren] Royal Surrey Cty Hosp, Egerton Rd, Guildford GU2 7XX, Surrey, England.
   [Tomkins-Netzer, Oren] Bnai Zion Med Ctr, 47 Golomb Rd, IL-31048 Haifa, Israel.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Royal Surrey County Hospital; Bnai Zion Medical Center
RP Tomkins-Netzer, O (通讯作者)，Moorfields Eye Hosp, 162 City Rd, London EC1V 2PD, England.; Tomkins-Netzer, O (通讯作者)，UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.; Tomkins-Netzer, O (通讯作者)，Royal Surrey Cty Hosp, Egerton Rd, Guildford GU2 7XX, Surrey, England.; Tomkins-Netzer, O (通讯作者)，Bnai Zion Med Ctr, 47 Golomb Rd, IL-31048 Haifa, Israel.
EM o.tomkins-netzer@ucl.ac.uk
OI Tomkins-Netzer, Oren/0000-0002-1015-1641
FU Bayer AG
FX This study was supported by an educational grant from Bayer AG. All
   authors had no other financial support for this study.
CR Arcinue C. A., 2015, AM J OPHTHALMOL, V159
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bawor M, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-45
   BECKER BJ, 1988, BRIT J MATH STAT PSY, V41, P257, DOI 10.1111/j.2044-8317.1988.tb00901.x
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Borenstein M., 2009, INTRO METAANALYSIS
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan Clement K, 2014, Trans Am Ophthalmol Soc, V112, P160
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferrone PJ, 2014, BRIT J OPHTHALMOL, V98, P17, DOI 10.1136/bjophthalmol-2013-304474
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Liberati A, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2700, 10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lipsey M. W., 2001, PRACTICAL META ANAL
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Thorell MR, 2014, OSLI RETINA, V45, P526, DOI 10.3928/23258160-20141118-07
   Wells G., 2003, P 11 COCHR C EV HLTH
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
NR 38
TC 41
Z9 43
U1 0
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2016
VL 2016
AR 4095852
DI 10.1155/2016/4095852
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DJ7KT
UT WOS:000374391000001
PM 27042342
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU SanGiovanni, JP
   Chew, EY
   Clemons, TE
   Ferris, FL
   Gensler, G
   Linblad, AS
   Milton, RC
   Seddon, JM
   Sperduto, RD
AF SanGiovanni, John Paul
   Chew, Emily Y.
   Clemons, Traci E.
   Ferris, Frederick L., III
   Gensler, Gary
   Linblad, Anne S.
   Milton, Roy C.
   Seddon, Johanna M.
   Sperduto, Robert D.
CA Age Related Eye Dis Study Res Grp
TI The relationship of dietary carotenoid and vitamin A, E, and C intake
   with age-related macular degeneration in a case-control study - AREDS
   Report no. 22
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; MACULOPATHY; ZEAXANTHIN; LUTEIN;
   ANTIOXIDANTS; PATHOGENESIS; PREVALENCE; HEALTH; SERUM
AB Objective: To evaluate the relationship of dietary carotenoids, vitamin A, alpha-tocopherol, and vitamin C with prevalent age-related macular degeneration (AMD) in the Age-Related Eye Disease Study (AREDS).
   Methods: Demographic, lifestyle, and medical characteristics were ascertained on 4519 AREDS participants aged 60 to 80 years at enrollment. Stereoscopic color fundus photographs were used to categorize participants into 4 AMD severity groups and a control group ( participants with < 15 small drusen). Nutrient intake was estimated from a self-administered semiquantitative food frequency questionnaire at enrollment. Intake values were energy adjusted and classified by quintiles. The relationship between diet and AMD status was assessed using logistic regression analyses.
   Results: Dietary lutein/zeaxanthin intake was inversely associated with neovascular AMD (odds ratio [OR], 0.65; 95% confidence interval [CI], 0.45-0.93), geographic atrophy (OR, 0.45; 95% CI, 0.24-0.86), and large or extensive intermediate drusen (OR, 0.73; 95% CI, 0.56-0.96), comparing the highest vs lowest quintiles of intake, after adjustment for total energy intake and non-nutrient-based covariates. Other nutrients were not independently related to AMD.
   Conclusion: Higher dietary intake of lutein/zeaxanthin was independently associated with decreased likelihood of having neovascular AMD, geographic atrophy, and large or extensive intermediate drusen.
C1 EMMES Corp, AREDS Coordinating Ctr, Rockville, MD 20850 USA.
C3 Emmes Corporation
RP SanGiovanni, JP (通讯作者)，EMMES Corp, AREDS Coordinating Ctr, 401 N washington St,Ste 700, Rockville, MD 20850 USA.
RI SanGiovanni, John Paul/A-7605-2008; SanGiovanni, John Paul/AAU-3895-2020
OI Ferris, Frederick/0000-0002-4933-0639
FU Intramural NIH HHS [Z99 EY999999] Funding Source: Medline
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Boulton M, 2004, GRAEF ARCH CLIN EXP, V242, P76, DOI 10.1007/s00417-003-0812-8
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   KURINIJ N, 1998, INT C DIET ASS METH
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   ROSNER B, 1988, AM J EPIDEMIOL, V127, P377, DOI 10.1093/oxfordjournals.aje.a114811
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1366
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1228
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1499
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Van de Kerkhof PCM, 2002, DERMATOLOGY, V204, P214, DOI 10.1159/000057884
   Winkler BS, 1999, MOL VIS, V5
NR 35
TC 309
Z9 319
U1 0
U2 39
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD SEP
PY 2007
VL 125
IS 9
BP 1225
EP 1232
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 208TM
UT WOS:000249342100011
PM 17846363
DA 2022-11-30
ER

PT J
AU Inoda, S
   Takahashi, H
   Inoue, Y
   Tan, X
   Tampo, H
   Arai, Y
   Yanagi, Y
   Kawashima, H
AF Inoda, Satoru
   Takahashi, Hidenori
   Inoue, Yuji
   Tan, Xue
   Tampo, Hironobu
   Arai, Yusuke
   Yanagi, Yasuo
   Kawashima, Hidetoshi
TI Cytokine profiles of macular neovascularization in the elderly based on
   a classification from a pachychoroid/drusen perspective
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization; Drusen;
   Inflammatory cytokines; Pachychoroid
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; C-REACTIVE PROTEIN; AQUEOUS-HUMOR;
   GROWTH-FACTOR; DEGENERATION; ASSOCIATION; EXCAVATION; NEOVASCULOPATHY;
   PREVALENCE; DISEASE
AB Purpose To classify macular neovascularization (MNV) based on pachychoroid and drusen features and to examine the aqueous humor cytokine signatures of each group.
   Methods In total, 106 consecutive eyes with treatment-naive MNV and 104 control eyes were examined. The aqueous humor concentrations of 15 cytokines were compared among the MNV groups classified based on the presence of drusen and/or pachychoroid features. Multidimensional scaling analysis was used to visualize the similarity level of the MNV subtypes according to their cytokine profiles.
   Results Thirty-one, 18, 43, and 10 eyes were classified into the pachychoroid-associated, drusen-associated, pachychoroid/drusen-associated, and non-drusen/non-pachychoroid MNV groups, respectively. Compared with the control group, cytokines were differently upregulated among the MNV groups. CRP and CXCL12 were significantly upregulated in all MNV groups, whereas CXCL13 and IL-8 were significantly upregulated in three MNV groups, excluding the non-pachychoroid/non-drusen-associated MNV group. Ang-2 was significantly upregulated in three MNV groups except the drusen-associated MNV group. PlGF was significantly upregulated in the pachychoroid-associated and drusen-associated MNV groups. CCL-2 was significantly upregulated in the pachychoroid-associated and pachychoroid/drusen-associated MNV groups. VEGF was downregulated in the pachychoroid-associated and drusen-associated MNV groups, respectively. Multidimensional scaling analysis showed a distinct cytokine profile for each MNV group.
   Conclusion All MNV groups showed distinct cytokine profiles. Eyes with "neovascular age-related macular degeneration with drusen and concomitant pachychoroid" may share a similar etiology to those with "pachychoroid neovasculopathy" and "choroidal neovascularization with drusen," but have a distinct etiology to those without these. These findings suggest the importance of evaluating drusen and the choroid during the diagnosis of neovascular age-related macular degeneration.
C1 [Inoda, Satoru; Takahashi, Hidenori; Inoue, Yuji; Tampo, Hironobu; Arai, Yusuke; Yanagi, Yasuo; Kawashima, Hidetoshi] Jichi Med Univ, Dept Ophthalmol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290431, Japan.
   [Takahashi, Hidenori; Tan, Xue] Japan Community Healthcare Org, Tokyo Shinjuku Med Ctr, Dept Ophthalmol, Shinjuku Ku, Tokyo, Japan.
   [Yanagi, Yasuo] Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore, Singapore.
C3 Jichi Medical University; National University of Singapore; Singapore
   National Eye Center
RP Takahashi, H (通讯作者)，Jichi Med Univ, Dept Ophthalmol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290431, Japan.; Takahashi, H (通讯作者)，Japan Community Healthcare Org, Tokyo Shinjuku Med Ctr, Dept Ophthalmol, Shinjuku Ku, Tokyo, Japan.
EM takahah-tky@umin.ac.jp
RI Yanagi, Yasuo/AAA-5441-2022
OI Takahashi, Hidenori/0000-0001-5331-4730
FU KAKENHI grant from the Japan Society for the Promotion of Science
   [15K10899]
FX This work was supported by a KAKENHI grant from the Japan Society for
   the Promotion of Science, Grant Number 15K10899.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Agrawal R, 2019, INVEST OPHTH VIS SCI, V60, P376, DOI 10.1167/iovs.18-24387
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Chung HW, 2017, RETINA-J RET VIT DIS, V37, P199, DOI 10.1097/IAE.0000000000001345
   Dansingani KK, 2016, OPHTHALMOLOGY, V123, P2628, DOI 10.1016/j.ophtha.2016.06.060
   Dong A, 2014, ANGIOGENESIS, V17, P553, DOI 10.1007/s10456-013-9402-5
   Fukuda Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48494-6
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Khan M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9081869
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Lee J, 2019, RETINA-J RET VIT DIS, V39, P670, DOI 10.1097/IAE.0000000000002019
   Lim FPM, 2016, BRIT J OPHTHALMOL, V100, P918, DOI 10.1136/bjophthalmol-2015-307055
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pongsachareonnont P, 2018, CLIN OPHTHALMOL, V12, P1877, DOI 10.2147/OPTH.S171636
   Nguyen QD, 2018, ACTA OPHTHALMOL, V96, pE1, DOI 10.1111/aos.13325
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Sakamoto S, 2018, BRIT J OPHTHALMOL, V102, P448, DOI 10.1136/bjophthalmol-2017-310284
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Spindler J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203337
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Takahashi A, 2018, OPHTHALMOL RETINA, V2, P295, DOI 10.1016/j.oret.2017.08.016
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Xu HF, 2014, OPHTHALMOLOGY, V121, P246, DOI 10.1016/j.ophtha.2013.08.014
   Yanagi Y, 2020, JPN J OPHTHALMOL, V64, P323, DOI 10.1007/s10384-020-00740-5
   Zhang ZX, 2011, CURR EYE RES, V36, P838, DOI 10.3109/02713683.2011.593107
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 43
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2022
VL 260
IS 3
BP 747
EP 758
DI 10.1007/s00417-021-05445-0
EA OCT 2021
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZB5IP
UT WOS:000712749700001
PM 34714383
DA 2022-11-30
ER

PT J
AU Angermann, R
   Huber, AL
   Nowosielski, Y
   Salcher, S
   Gasser, T
   Seifarth, C
   Kralinger, MT
   Zehetner, C
AF Angermann, Reinhard
   Huber, Anna Lena
   Nowosielski, Yvonne
   Salcher, Stefan
   Gasser, Thomas
   Seifarth, Christof
   Kralinger, Martina T.
   Zehetner, Claus
TI CHANGES IN SYSTEMIC LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER
   INTRAVITREAL INJECTION OF AFLIBERCEPT OR BROLUCIZUMAB FOR NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aflibercept; age-related macular degeneration; brolucizumab; VEGF levels
ID VEGF; RANIBIZUMAB; MANAGEMENT; SAFETY
AB Purpose: To analyze and compare the effects of intravitreal brolucizumab versus aflibercept on systemic vascular endothelial growth factor (VEGF)-A levels in patients with neovascular age-related macular degeneration. Methods: In this prospective interventional case series study, brolucizumab (6.0 mg/50 mu L) or aflibercept (2.0 mg/50 mu L) was injected intravitreally in 30 patients each. Blood samples were drawn at baseline and 7 days and 28 days after the first injection. Systemic VEGF-A levels were measured using enzyme-linked immunosorbent assay. Thirty healthy individuals served as controls. Results: The median baseline systemic VEGF-A levels in the brolucizumab, aflibercept, and control groups were 10.8 (8.0-13.2), 12.0 (8.0-18.5), and 10.0 (8.0-15.1) pg/mL, respectively (P = 0.315). In the brolucizumab group, VEGF-A levels significantly decreased to 8.0 (8.0-11.5) pg/mL on Day 7 (P = 0.0254) and to 8.0 (8.0-8.0) pg/mL on Day 28 (P < 0.001). In the aflibercept group, VEGF-A levels significantly decreased to 8.0 (8.0-8.0) pg/mL on Day 7 (P < 0.001) but returned to the baseline level, 12.5 (8.5-14.6) pg/mL, on Day 28 (P = 0.120). Vascular endothelial growth factor-A levels were significantly different between the treatment groups after 28 days (P < 0.001). Conclusion: Intravitreal brolucizumab resulted in a sustained reduction of systemic VEGF-A levels until 28 days posttreatment, which raises concerns regarding its safety and long-term effects.
C1 [Angermann, Reinhard; Huber, Anna Lena; Nowosielski, Yvonne; Gasser, Thomas; Seifarth, Christof; Kralinger, Martina T.; Zehetner, Claus] Med Univ Innsbruck, Dept Ophthalmol, Anichstr 35, A-6020 Innsbruck, Austria.
   [Angermann, Reinhard] Paracelsus Med Univ Salzburg, Dept Ophthalmol, Salzburg, Austria.
   [Salcher, Stefan] Med Univ Innsbruck, Dept Hematol & Oncol, Innsbruck, Austria.
C3 Medical University of Innsbruck; Paracelsus Private Medical University;
   Medical University of Innsbruck
RP Zehetner, C (通讯作者)，Med Univ Innsbruck, Dept Ophthalmol, Anichstr 35, A-6020 Innsbruck, Austria.
EM claus.zehetner@i-med.ac.at
OI Salcher, Stefan/0000-0003-2391-6954
CR Angermann R, 2021, ACTA OPHTHALMOL, V99, pE869, DOI 10.1111/aos.14691
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Bagley RG, 2011, CLIN CANCER RES, V17, P976, DOI 10.1158/1078-0432.CCR-10-2687
   Berlin JA, 2008, AM J PUBLIC HEALTH, V98, P1366, DOI 10.2105/AJPH.2007.124537
   Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Gaudreault J., 2012, INVEST OPHTHALMOL VI, V53, P3025
   Haug Sara J, 2020, Am J Ophthalmol Case Rep, V18, P100680, DOI 10.1016/j.ajoc.2020.100680
   Kaiser PK, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2018-000185
   Kim H, 2009, MOL VIS, V15
   Leclaire MD, 2022, OPHTHALMOLOGE, V119, P296, DOI 10.1007/s00347-021-01341-4
   Mor F, 2004, J IMMUNOL, V172, P4618, DOI 10.4049/jimmunol.172.7.4618
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Reinders MEJ, 2003, J CLIN INVEST, V112, P1655, DOI 10.1172/JCI17712
   Riedel AM, 2022, OPHTHALMOLOGE, V119, P75, DOI 10.1007/s00347-021-01323-6
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Sennino B, 2012, NAT REV CANCER, V12, P699, DOI 10.1038/nrc3366
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Tietz J, 2015, INVEST OPHTH VIS SCI, V56
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Touzani F, 2019, Case Rep Nephrol, V2019, P2919080, DOI 10.1155/2019/2919080
   Walz JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145375
   Witkin Andre J, 2020, J Vitreoretin Dis, V4, P269, DOI 10.1177/2474126420930863
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Zachary I, 2000, ARTERIOSCL THROM VAS, V20, P1512, DOI 10.1161/01.ATV.20.6.1512
   Zehetner C, 2015, INVEST OPHTH VIS SCI, V56, P3279, DOI 10.1167/iovs.15-16686
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
   Zhang JS, 2010, CIRC RES, V107, P408, DOI 10.1161/CIRCRESAHA.109.210963
NR 34
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2022
VL 42
IS 3
BP 503
EP 510
DI 10.1097/IAE.0000000000003344
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZD6KA
UT WOS:000758305500018
PM 34731094
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Hernandez, M
   Recalde, S
   Gonzalez-Zamora, J
   Bilbao-Malave, V
   de Viteri, MS
   Bezunartea, J
   Moreno-Orduna, M
   Belza, I
   Barrio-Barrio, J
   Fernandez-Robredo, P
   Garcia-Layana, A
AF Hernandez, Maria
   Recalde, Sergio
   Gonzalez-Zamora, Jorge
   Bilbao-Malave, Valentina
   Saenz de Viteri, Manuel
   Bezunartea, Jaione
   Moreno-Orduna, Maite
   Belza, Idoia
   Barrio-Barrio, Jesus
   Fernandez-Robredo, Patricia
   Garcia-Layana, Alfredo
TI Anti-Inflammatory and Anti-Oxidative Synergistic Effect of Vitamin D and
   Nutritional Complex on Retinal Pigment Epithelial and Endothelial Cell
   Lines against Age-Related Macular Degeneration
SO NUTRIENTS
LA English
DT Article
DE vitamin D; nutritional complex; AMD; inflammation; oxidative stress;
   retina
ID OXIDATIVE STRESS AFFECTS; HYDROGEN-PEROXIDE; ATHEROSCLEROSIS RISK;
   DIABETIC-RETINOPATHY; 25-HYDROXYVITAMIN D; D SUPPLEMENTATION; PROTECTIVE
   ROLE; D DEFICIENCY; DIETARY-FAT; INFLAMMATION
AB Age-related macular degeneration (AMD) is a multifactorial disease of the retina featured by dysfunction of retinal pigmented epithelial (RPE) and loss of photoreceptor cells under oxidative stress and inflammatory conditions. Vitamin D and antioxidants have beneficial effects against retinal degenerative diseases, such as AMD. We investigated the impact of associating vitamin D (ND) with a nutritional antioxidant complex (Nutrof Total(R); N) on oxidative stress and inflammation-like induced conditions by H2O2 and LPS, respectively, in human retinal epithelial (ARPE-19) and human retinal endothelial (HREC) cells. Application of either N or ND treatments to H2O2-induced media in ARPE-19 cells counteracted late apoptosis, attenuated oxidative DNA damage, and increased cell proliferation. Significant reduction in the expression levels of MCP1, IL-8, and IL6 cytokines was observed following application of either N or ND treatments under LPS-induced conditions in ARPE-19 cells and in MCP-1 and IL12p70 cytokine levels in HREC cells. ND and not N revealed significant downregulation of IFN gamma in ARPE-19 cells, and of IL-6 and IL-18 in HREC cells. In conclusion, adding vitamin D to Nutrof Total(R) protects in a synergistic way against oxidative and inflammatory stress-induced conditions in retinal epithelial and endothelial cells.
C1 [Hernandez, Maria; Recalde, Sergio; Gonzalez-Zamora, Jorge; Bilbao-Malave, Valentina; Saenz de Viteri, Manuel; Bezunartea, Jaione; Moreno-Orduna, Maite; Belza, Idoia; Barrio-Barrio, Jesus; Fernandez-Robredo, Patricia; Garcia-Layana, Alfredo] Clin Univ Navarra, Dept Ophthalmol, Retinal Pathol & New Therapies Grp, Expt Ophthalmol Lab, Pamplona 31008, Spain.
   [Hernandez, Maria; Recalde, Sergio; Saenz de Viteri, Manuel; Bezunartea, Jaione; Moreno-Orduna, Maite; Fernandez-Robredo, Patricia; Garcia-Layana, Alfredo] Navarra Inst Hlth Res, IdiSNA, Pamplona 31008, Spain.
   [Hernandez, Maria; Recalde, Sergio; Saenz de Viteri, Manuel; Barrio-Barrio, Jesus; Fernandez-Robredo, Patricia; Garcia-Layana, Alfredo] Red Temat Invest Cooperat Sanitaria Enfermedades, Pamplona 31008, Spain.
C3 University of Navarra
RP Hernandez, M (通讯作者)，Clin Univ Navarra, Dept Ophthalmol, Retinal Pathol & New Therapies Grp, Expt Ophthalmol Lab, Pamplona 31008, Spain.; Hernandez, M (通讯作者)，Navarra Inst Hlth Res, IdiSNA, Pamplona 31008, Spain.; Hernandez, M (通讯作者)，Red Temat Invest Cooperat Sanitaria Enfermedades, Pamplona 31008, Spain.
EM mahersan@unav.es; srecalde@unav.es; jgzamora@unav.es; vbilbao@unav.es;
   msaenzdevit@unav.es; jbezunartea@unav.es; maimoreno@unav.es;
   idoiabelza@unav.es; jbarrio@unav.es; pfrobredo@unav.es; aglayana@unav.es
RI Barrio-Barrio, Jesus/AAW-5511-2021; Recalde, Sergio/D-1815-2017
OI Barrio-Barrio, Jesus/0000-0002-0654-0249; Saenz-de-Viteri,
   Manuel/0000-0002-9375-4535; Gonzalez Zamora, Jorge/0000-0002-2826-6842;
   Recalde, Sergio/0000-0002-9328-9725
FU Thea Laboratories (Clermont-Ferrand, France)
FX This study has been sponsored by Thea Laboratories (Clermont-Ferrand,
   France). The funding sponsors had no role in the interpretation of data
   or the writing of the manuscript.
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Albert DM, 2007, INVEST OPHTH VIS SCI, V48, P2327, DOI 10.1167/iovs.06-1210
   Alizadeh E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123846
   Alsalem JA, 2014, INVEST OPHTH VIS SCI, V55, P2140, DOI 10.1167/iovs.13-13019
   An EY, 2008, MOL VIS, V14, P2292
   Annweiler C, 2016, MATURITAS, V88, P101, DOI 10.1016/j.maturitas.2016.04.002
   Antunes F, 2017, REDOX BIOL, V13, P1, DOI 10.1016/j.redox.2017.04.039
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Aranow C, 2011, J INVEST MED, V59, P881, DOI 10.2310/JIM.0b013e31821b8755
   Aryan Nona, 2016, Open Neurol J, V10, P83, DOI 10.2174/1874205X01610010083
   Bae SH, 2016, SCI REP-UK, V6, DOI 10.1038/srep33083
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Barbour M, 2014, EUR J IMMUNOL, V44, P3320, DOI 10.1002/eji.201444671
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blasiak J, 2019, ACTA OPHTHALMOL, V97, DOI 10.1111/j.1755-3768.2019.5425
   Canning MO, 2001, EUR J ENDOCRINOL, V145, P351, DOI 10.1530/eje.0.1450351
   Carmeliet P, 2009, NAT REV CLIN ONCOL, V6, P315, DOI 10.1038/nrclinonc.2009.64
   Cascella R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/582842
   Chen XD, 2017, INT J OPHTHALMOL-CHI, V10, P507, DOI 10.18240/ijo.2017.04.02
   Cougnard-Greoire A, 2015, J NUTR, V145, P1865, DOI 10.3945/jn.115.214387
   Damghanian P, 2019, PROG NUTR, V21, P138, DOI 10.23751/pn.v21i1-S.5831
   Day S, 2012, ARCH OPHTHALMOL-CHIC, V130, P1070, DOI 10.1001/archophthalmol.2012.439
   Detrick B., 2020, RETINAL PIGMENT EPIT
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dwyer MA, 2011, MOL ENDOCRINOL, V25, P360, DOI 10.1210/me.2010-0392
   Fernandez-Robredo P, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9090838
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Layana AG, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101120
   Gee Katrina, 2009, Inflammation & Allergy Drug Targets, V8, P40
   Gheorghe Andreea, 2015, Rom J Ophthalmol, V59, P74
   Golan S, 2011, EYE, V25, P1122, DOI 10.1038/eye.2011.174
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Groeger G, 2009, ANTIOXID REDOX SIGN, V11, P2655, DOI [10.1089/ars.2009.2728, 10.1089/ARS.2009.2728]
   Guillot X, 2010, JOINT BONE SPINE, V77, P552, DOI 10.1016/j.jbspin.2010.09.018
   Hewison M, 2010, ENDOCRIN METAB CLIN, V39, P365, DOI 10.1016/j.ecl.2010.02.010
   Jamali N, 2018, AM J PHYSIOL-HEART C, V314, pH753, DOI 10.1152/ajpheart.00319.2017
   Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517
   JOHNSON JA, 1995, CURR EYE RES, V14, P101, DOI 10.3109/02713689508999921
   Kan Emrah, 2020, Oman Med J, V35, pe83, DOI 10.5001/omj.2020.01
   Karaca EE, 2020, ARQ BRAS OFTALMOL, V83, P312, DOI 10.5935/0004-2749.20200043
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P4823, DOI 10.1167/iovs.14-14763
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kutty RK, 2016, MOL VIS, V22, P1156
   Lightman S, 2006, PLOS MED, V3, P1218, DOI 10.1371/journal.pmed.0030364
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Longo-Mbenza B, 2014, INT J OPHTHALMOL-CHI, V7, P293, DOI 10.3980/j.issn.2222-3959.2014.02.18
   Lu L, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/8193523
   Ma ZX, 2022, OCUL IMMUNOL INFLAMM, V30, P630, DOI 10.1080/09273948.2020.1828488
   Mares J., 2004, KRINSKY NI MAYNE ST
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Marinho HS, 2014, REDOX BIOL, V2, P535, DOI 10.1016/j.redox.2014.02.006
   MARRS JA, 1995, J CELL BIOL, V129, P507, DOI 10.1083/jcb.129.2.507
   Merle BMJ, 2017, INVEST OPHTH VIS SCI, V58, P4569, DOI 10.1167/iovs.17-21673
   Millen AE, 2017, J NUTR HEALTH AGING, V21, P772, DOI 10.1007/s12603-016-0827-6
   Millen AE, 2019, INVEST OPHTH VIS SCI, V60, P1362, DOI 10.1167/iovs.18-25945
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Murugeswari P, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.4
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Nielsen MK, 2019, INVEST OPHTH VIS SCI, V60, P202, DOI 10.1167/iovs.18-25878
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Redza-Dutordoir M, 2016, BBA-MOL CELL RES, V1863, P2977, DOI 10.1016/j.bbamcr.2016.09.012
   Reins RY, 2015, EXP EYE RES, V134, P101, DOI 10.1016/j.exer.2015.02.019
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Sommer A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130395
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Theodoropoulou S, 2017, J PATHOL, V241, P45, DOI 10.1002/path.4816
   Tohari AM, 2020, EXP CELL RES, V392, DOI 10.1016/j.yexcr.2020.112023
   Tohari AM, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090341
   Tohari AM, 2016, CELL BIOCHEM FUNCT, V34, P82, DOI 10.1002/cbf.3167
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Valavanidis A, 2009, J ENVIRON SCI HEAL C, V27, P120, DOI 10.1080/10590500902885684
   Vilema-Enriquez G, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1908164
   Wang W, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061816
   Wang YJ, 2012, APOPTOSIS, V17, P1144, DOI 10.1007/s10495-012-0750-1
   Wooff Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01618
   Yerramothu P, 2018, EYE, V32, P491, DOI 10.1038/eye.2017.241
   Yildirim Z, 2012, INT J GERONTOL, V6, P101, DOI 10.1016/j.ijge.2012.01.018
   Zeisel SH, 2004, J NUTR, V134, p3179S, DOI 10.1093/jn/134.11.3179S
   Zhao M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125150
   Zhao QQ, 2018, MOL MED REP, V17, P7301, DOI 10.3892/mmr.2018.8787
   Zou XL, 2018, INT J OPHTHALMOL-CHI, V11, P1594, DOI 10.18240/ijo.2018.10.04
NR 91
TC 5
Z9 5
U1 6
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD MAY
PY 2021
VL 13
IS 5
AR 1423
DI 10.3390/nu13051423
PG 15
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA ST4IV
UT WOS:000662410200001
PM 33922669
OA gold, Green Published
DA 2022-11-30
ER

EF